,Unnamed: 0,Patient ID,Prompts,Outcome,Prognosis
0,0,P0001,"Age: 58
Gender: Male 
Weight: 83 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 110/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42,4
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,36
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1834.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,02
Urea (mg/dL): 7,12
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's prognosis is most likely to be a survivor. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers become enlarged. This condition can lead to heart failure, arrhythmias, and decreased cardiac function.

The patient's current NYHA Class III indicates that they have severe symptoms, such as shortness of breath, fatigue, and swelling in the legs, ankles, and feet. However, despite these symptoms, the patient's hemoglobin level (132 g/L) and serum potassium level (4.6 mEq/L) are within normal limits.

The patient's LVEF (left ventricular ejection fraction) is 35%, which is significantly below the normal range (50-70%). However, the patient is already on beta blockers, digoxin, and loop diuretics, which are standard treatments for heart failure. The patient's creatinine level (106.0 mmol/L) is elevated, indicating impaired kidney function, but this is not uncommon in patients with heart failure.

The ECG findings of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia are concerning for arrhythmias, which can be life-threatening. However, the patient is already on medications that can help manage these arrhythmias.

Given the patient's current medications, the presence of heart failure symptoms, and the ECG findings, the patient's prognosis is still relatively favorable. With proper management and monitoring, the patient is likely to survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

Although the patient's prognosis is not as favorable as the survivor ranking, sudden cardiac death is still a possible outcome. The patient's LVEF is significantly below normal, and the patient has a history of arrhythmias, which can increase the risk of sudden cardiac death.

However, the patient is already on beta blockers, digoxin, and loop diuretics, which can help manage heart failure and arrhythmias. The patient's hemoglobin level and serum potassium level are within normal limits, which reduces the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

Pump failure death is the least likely outcome, given the patient's current treatment regimen and the presence of heart failure symptoms. The patient is already on beta blockers, digoxin, and loop diuretics, which can help manage heart failure.

However, the patient's LVEF is significantly below normal, and the patient has a history of arrhythmias, which can increase the risk of pump failure. Additionally, the patient's creatinine level is elevated, indicating impaired kidney function, which can increase the risk of pump failure.

Overall, while pump failure death is a possible outcome, it is the least likely given the patient's current treatment regimen and the presence of heart failure symptoms."
1,1,P0002,"Age: 58
Gender: Male 
Weight: 74 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,18
Creatinine (mmol/L): 121.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,06
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 570.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,27
Urea (mg/dL): 10,47
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall condition appears to be stable, with a relatively controlled NYHA Class II heart failure, which suggests that the patient is still tolerating their current treatment regimen. The presence of ischemic dilated cardiomyopathy, a history of myocardial infarction, and elevated troponin levels indicate a significant history of cardiac damage, but the patient's current LVEF of 35% suggests that the heart is still pumping effectively to some extent. The patient's blood pressure and electrolyte levels are within normal ranges, and their liver function tests are also relatively normal. The absence of signs of acute cardiac stress or acute kidney injury (elevated creatinine) suggests that the patient is not in immediate danger. The presence of elevated Pro-BNP levels, which is a marker of heart failure, indicates that the patient still has some degree of cardiac dysfunction. However, the overall clinical picture suggests that the patient's cardiac function is stable, and they are likely to survive for the next few years.

2. Sudden cardiac death
REASONING: 
While the patient has a history of cardiac damage and elevated Pro-BNP levels, the patient's LVEF is still 35%, which is relatively preserved. However, the patient's Pro-BNP levels are elevated, which could indicate some degree of cardiac stress or strain. The absence of any acute cardiac stress or arrhythmia on the ECG impression makes sudden cardiac death less likely, but the patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases their risk of sudden cardiac death. The patient's medications, including beta blockers and statins, are standard treatments for heart failure and cardiovascular risk reduction, but the patient's elevated LDL levels (4.06 mmol/L) may still contribute to cardiovascular risk.

3. Pump failure death
REASONING: 
While the patient's LVEF is 35%, which is significantly reduced, the patient's overall clinical picture is relatively stable. The patient's blood pressure, electrolyte levels, and liver function tests are all within normal ranges, and the absence of any acute cardiac stress or arrhythmia on the ECG impression suggests that the patient is not in immediate danger. The patient's medications, including beta blockers and statins, are standard treatments for heart failure and cardiovascular risk reduction, which should help to slow the progression of heart failure. While the patient's Pro-BNP levels are elevated, which could indicate some degree of cardiac stress or strain, the overall clinical picture suggests that the patient's cardiac function is still relatively preserved. Therefore, pump failure death is the least likely outcome among the three options."
2,2,P0003,"Age: 69
Gender: Male 
Weight: 83 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40,1
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 2,04
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 403.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 10,02
LVEF (%): 39.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 69-year-old male with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac complications. The patient has a reduced left ventricular ejection fraction (LVEF) of 39%, indicating severe systolic dysfunction. Additionally, the patient has a history of ventricular extrasystole and non-sustained ventricular tachycardia, which are signs of arrhythmias that can increase the risk of sudden cardiac death. However, the patient is on medications that are commonly used to manage heart failure and arrhythmias, such as beta blockers, digoxin, and loop diuretics.

The patient's laboratory results show elevated troponin levels, which indicate some degree of cardiac damage, but not to the extent that would suggest acute myocardial infarction. The patient's ejection fraction is also significantly reduced, which suggests that the heart is not functioning optimally.

Given these factors, the patient's prognosis is likely to be a survivor, as the patient is already on medications to manage their condition and has not shown any signs of acute cardiac events. However, close monitoring and regular follow-up appointments will be necessary to adjust the treatment plan as needed and to prevent further cardiac complications.

While the patient has a high risk of arrhythmias, the fact that the ECG impression mentions ""non-sustained ventricular tachycardia"" suggests that the patient's heart is still able to recover between episodes of arrhythmia, which is a positive prognostic sign.

The patient's age, weight, and blood pressure are not particularly concerning, and the patient's laboratory results do not indicate any acute kidney injury or significant electrolyte imbalances.

In summary, based on the provided data, the patient's prognosis is a survivor, but it is essential to closely monitor the patient's condition and adjust the treatment plan as needed to prevent further cardiac complications."
3,3,P0004,"Age: 56
Gender: Female 
Weight: 84 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 155/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40,9
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 17,8
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,49
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 695.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,07
Urea (mg/dL): 8,91
LVEF (%): 38.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

Based on the provided patient data, the patient is likely to survive for the next few years. The key factors contributing to this prediction are:

1. Age: The patient is 56 years old, which is considered middle-aged. While age can be a risk factor for cardiovascular disease, it's not a guarantee of poor outcomes.

2. NYHA Class II: The patient's New York Heart Association (NYHA) class II indicates that the patient experiences some limitation in physical activity due to heart failure symptoms, but they are still able to perform light physical activity without discomfort. This suggests that the patient's heart is not severely impaired.

3. Medications: The patient is taking a comprehensive regimen of medications for their cardiovascular conditions, including a diabetes medication, angiotensin II receptor blocker, beta blockers, loop diuretics, and spironolactone. These medications help manage hypertension, heart failure, and other cardiovascular risk factors.

4. ECG findings: The ECG shows no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or other life-threatening arrhythmias. The presence of ventricular extrasystoles is a benign finding, and the absence of other ECG abnormalities suggests that the patient's heart is not under significant stress.

5. Biomarkers: The patient's biomarkers, such as troponin and BNP, are within normal limits, indicating that the patient's heart muscle is not under significant stress.

While the patient has multiple comorbidities, including hypertension, diabetes, and dyslipidemia, the combination of a comprehensive medication regimen, normal biomarkers, and a relatively preserved ejection fraction (LVEF) suggest that the patient is at lower risk for adverse cardiovascular events. Therefore, the most likely outcome for the next few years is that the patient will survive.

RANKING: 2. Sudden cardiac death 
REASONING: 

Based on the provided patient data, the patient is at moderate risk for sudden cardiac death (SCD). The factors contributing to this risk include:

1. Hypertensive cardiomyopathy: This condition can lead to left ventricular dysfunction and increased risk of SCD.

2. Diabetes: Diabetes is a risk factor for cardiovascular disease, including SCD.

3. Dyslipidemia: High cholesterol levels can contribute to atherosclerosis and increase the risk of cardiovascular events, including SCD.

4. Medication non-adherence or under-dosing: Although the patient is taking a comprehensive regimen of medications, there is no information available on adherence or dosing.

5. Low LVEF: The patient's LVEF is 38%, which is below the normal range, indicating left ventricular dysfunction.

6. Elevated BNP: The patient's BNP level is elevated, indicating increased ventricular stress and possible heart failure.

While the patient is not at high risk, the combination of these factors increases the likelihood of SCD.

RANKING: 3. Pump failure death 
REASONING: 

Based on the provided patient data, the patient is at moderate risk for pump failure death. The factors contributing to this risk include:

1. Hypertensive cardiomyopathy: This condition can lead to left ventricular dysfunction and increased risk of pump failure.

2. Diabetes: Diabetes is a risk factor for cardiovascular disease, including pump failure.

3. Dyslipidemia: High cholesterol levels can contribute to atherosclerosis and increase the risk of cardiovascular events, including pump failure.

4. Low LVEF: The patient's LVEF is 38%, which is below the normal range, indicating left ventricular dysfunction.

5. Elevated BNP: The patient's BNP level is elevated, indicating increased ventricular stress and possible heart failure.

6. NYHA Class II: The patient's NYHA class II indicates that they experience some limitation in physical activity due to heart failure symptoms, which increases the risk of pump failure.

While the patient is not at high risk, the combination of these factors increases the likelihood of pump failure. However, the patient's comprehensive medication regimen and relatively preserved LVEF suggest that pump failure is less likely than SCD."
4,4,P0005,"Age: 70
Gender: Male 
Weight: 97 kg
Height: 183 cm
NYHA Class: II
Blood Pressure: 125/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45,3
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,28
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 456.0
Protein (g/L): 82
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,01
Urea (mg/dL): 10,91
LVEF (%): 34.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's age, NYHA Class II, and the presence of multiple comorbid conditions such as ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, would typically suggest a higher risk of adverse outcomes. However, the patient's current medications, including ACE inhibitors, beta blockers, and statins, are standard treatments for these conditions and are likely effective in managing symptoms and slowing disease progression.

The patient's laboratory results show a slightly elevated creatinine level, which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's electrolyte and liver function tests are largely within normal limits, and the troponin level is below the threshold for myocardial infarction.

The ECG impression does show ventricular extrasystole, which is a common finding in patients with heart failure, but it is not indicative of a high risk for sudden cardiac death or pump failure. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia further reduces the risk of sudden cardiac death.

Considering these factors, I believe that the patient is at higher risk for heart failure but the presence of the patient's current medications and the absence of other high-risk ECG findings suggest that the patient is more likely to survive the next few years with proper management and monitoring."
5,5,P0006,"Age: 70
Gender: Male 
Weight: 83 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 105/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44,1
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,8
LDL (mmol/L): 3
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3437.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,88
Urea (mg/dL): 8,46
LVEF (%): 34.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient's prognosis is the most likely due to several factors:

1. The patient's age of 70 is still relatively young for a cardiomyopathy patient, and many patients with ischemic dilated cardiomyopathy can survive for several years with optimal medical management.
2. The patient has a NYHA Class II, indicating mild symptoms, which suggests that the heart is still functioning relatively well, and the patient is able to maintain daily activities with minimal limitations.
3. The patient's blood pressure is well-controlled at 105/75 mmHg, which is within a normal range, and the patient is on medications to control blood pressure, which further supports the likelihood of a favorable outcome.
4. The patient's laboratory results show no significant elevation of liver enzymes (ALT and AST), which indicates that the liver is not severely affected by the cardiomyopathy.
5. The patient's renal function is also relatively preserved, with a creatinine level of 101.0, which suggests that the kidneys are still functioning adequately.
6. The patient is on medications to manage diabetes, hypertension, and heart failure, which suggests that the patient is receiving comprehensive care for their cardiovascular condition.

While the patient's LVEF is low at 34.0, this is not uncommon in patients with ischemic dilated cardiomyopathy, and with optimal medical management, many patients can experience significant improvement in their ejection fraction over time.

In contrast, the patient's Pro-BNP level is elevated at 3437.0, which indicates a higher risk of heart failure exacerbation. However, this can be managed with optimal medical therapy, and the patient's overall clinical presentation does not suggest an immediate risk of sudden cardiac death or pump failure.

Therefore, based on the patient's clinical presentation, laboratory results, and medical history, the most likely prognosis is a survivor."
6,6,P0007,"Age: 52
Gender: Male 
Weight: 71 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 49,69
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 5,79
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 90
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4
LDL (mmol/L): 3,83
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 140.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,979
Urea (mg/dL): 7,8
LVEF (%): 39.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly increases the risk of heart failure and sudden cardiac death. However, the patient is currently on beta blockers, which are known to improve survival in patients with heart failure. The patient's ejection fraction (LVEF) is 39%, which is a significant reduction in cardiac function, but not as low as 30% or less, which is often used as a criterion for heart failure with reduced ejection fraction (HFrEF). The patient's NYHA class is II, which indicates mild symptoms, and the patient's blood pressure is well-controlled. Additionally, the patient's troponin level is within normal limits, and the ECG impression does not indicate any life-threatening arrhythmias. Overall, while the patient has a significant cardiac condition, the combination of beta blockers, controlled blood pressure, and the absence of severe symptoms suggest that the patient is likely to survive for the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and LVEF of 39% increases the risk of sudden cardiac death. However, the patient's current ECG impression does not indicate any life-threatening arrhythmias, and the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's troponin level is within normal limits, which suggests that there is no acute myocardial infarction. However, the patient's low LVEF and history of ischemic dilated cardiomyopathy still increase the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 39% is a significant reduction in cardiac function, and the patient's NYHA class is II, which indicates mild symptoms of heart failure. The patient's creatinine level is elevated, which suggests some degree of renal impairment, which can be a complication of heart failure. While the patient is on beta blockers, which are known to improve survival in patients with heart failure, the combination of the patient's cardiac condition, elevated creatinine level, and NYHA class II symptoms suggest that the patient is at risk of developing pump failure. However, the patient's troponin level is within normal limits, which suggests that there is no acute myocardial infarction. Overall, while the patient is at risk of pump failure, the patient's current condition and management suggest that pump failure death is less likely than sudden cardiac death."
7,7,P0009,"Age: 64
Gender: Female 
Weight: 68 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 211.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 7,8
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation, laboratory results, and medical history suggest a high likelihood of survival. The patient's age, NYHA Class II heart failure, and various comorbidities (ischemic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension) indicate a significant cardiovascular burden. However, the patient's current medication regimen, which includes ACE inhibitors and beta blockers, is well-tailored to manage these conditions.

The patient's laboratory results show a relatively stable liver function, normal kidney function (creatinine and urea levels), and a low troponin level, which suggests that there is no acute myocardial infarction or significant cardiac damage. The elevated Pro-BNP level may indicate some degree of heart failure, but it is not excessively high.

The ECG results show no evidence of ventricular tachycardia or other life-threatening arrhythmias, which is a positive prognostic sign. The patient's hemoglobin and potassium levels are within normal limits, and the thyroid function test results are normal.

While the patient's left ventricular ejection fraction (LVEF) is low at 24%, this is not uncommon in patients with ischemic dilated cardiomyopathy. The patient's current medication regimen and clinical presentation suggest that they are being adequately managed for their heart failure symptoms.

Overall, the combination of a well-managed medication regimen, stable laboratory results, and the absence of life-threatening ECG abnormalities make it more likely that the patient will survive in the next few years."
8,8,P0010,"Age: 54
Gender: Male 
Weight: 88 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,7
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,26
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 361.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,02
Urea (mg/dL): 7,57
LVEF (%): 22.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

The patient's age, NYHA Class II, and past medical history of ischemic dilated cardiomyopathy, diabetes, dyslipidemia, hypertension, and myocardial infarction already indicate a high risk for cardiovascular events. The patient's LVEF of 22.0, which is significantly below the normal range, further supports this.

The elevated Pro-BNP levels (361.0 ng/L) suggest a moderate to severe level of ventricular strain, which is consistent with heart failure. However, the patient is still taking beta blockers and an ACE inhibitor, which are standard treatments for heart failure and can help improve symptoms and reduce mortality.

The presence of ventricular extrasystole (polymorphic) and non-sustained ventricular tachycardia (CH>10) on the ECG impression suggests an increased risk of arrhythmias, which can be a precursor to sudden cardiac death. However, the fact that the patient is on beta blockers and ACE inhibitors, which can help regulate heart rhythm, and the absence of other high-risk factors (e.g., high QT interval, left bundle branch block) reduces the likelihood of sudden cardiac death.

The patient's kidney function is mildly impaired, with a creatinine level of 7.57 mg/dL, which may indicate some degree of cardiac-renal interaction. However, this is not a contraindication to survival.

Overall, the patient's combination of heart failure, arrhythmias, and mild kidney impairment make pump failure death a plausible outcome, but the presence of beta blockers and ACE inhibitors, as well as the patient's overall clinical profile, make sudden cardiac death less likely. Therefore, the most likely outcome is survivor, with pump failure death being a close second. Sudden cardiac death is the least likely outcome."
9,9,P0013,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 653.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,53
Urea (mg/dL): 9,8
LVEF (%): 39.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient is a 71-year-old female with a history of ischemic dilated cardiomyopathy, hypertension, and a significantly reduced LVEF of 39%. Her current NYHA Class II indicates that she has some limitations in physical activity but can still perform daily activities without excessive fatigue. Her current ECG findings, such as ventricular extrasystoles and polymorphic ventricular extrasystoles, suggest an increased risk of arrhythmias, but there is no indication of ventricular tachycardia or other life-threatening arrhythmias. Her elevated BNP level of 653 ng/L also indicates a possible left ventricular dysfunction.

Given her current medication regimen, which includes beta blockers, statins, ACE inhibitors, and a nitrovasodilator, it is likely that she is receiving adequate treatment to manage her heart failure symptoms. Her laboratory values, such as the slightly elevated creatinine level, suggest some degree of renal impairment, but it is not severe.

While her age and comorbidities do increase her risk of adverse outcomes, her relatively stable laboratory values and the absence of other concerning ECG findings make a sudden cardiac death or pump failure death less likely. Therefore, the most likely prognosis for this patient is survival.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy and reduced LVEF increase her risk of sudden cardiac death. Her elevated BNP level of 653 ng/L, which is above the normal range, also suggests a possible left ventricular dysfunction. However, the absence of ventricular tachycardia or other life-threatening arrhythmias on the ECG, as well as the presence of beta blockers and ACE inhibitors, which are effective in reducing the risk of sudden cardiac death, suggest that the risk is not extremely high.

Additionally, the patient's laboratory values, such as the slightly elevated creatinine level and low HDL cholesterol, suggest some degree of cardiac and renal impairment, but it is not severe.

While the patient's age and comorbidities do increase her risk of sudden cardiac death, the combination of her stable laboratory values and the presence of medications that reduce the risk of sudden cardiac death make this prognosis less likely.

RANKING: 3. Pump failure death
REASONING: 
The patient's reduced LVEF of 39% and elevated BNP level of 653 ng/L indicate a significant left ventricular dysfunction, which increases her risk of heart failure. Her NYHA Class II indicates that she has some limitations in physical activity, which suggests that her heart failure is not well-controlled.

Her laboratory values, such as the slightly elevated creatinine level and low HDL cholesterol, also suggest some degree of cardiac and renal impairment. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG also suggest an increased risk of arrhythmias, which can contribute to pump failure.

However, the patient's current medication regimen, which includes beta blockers, statins, ACE inhibitors, and a nitrovasodilator, is effective in managing her heart failure symptoms. Her stable laboratory values and the absence of other concerning ECG findings make this prognosis less likely compared to sudden cardiac death."
10,10,P0014,"Age: 50
Gender: Male 
Weight: 51 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 42
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 3,23
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 577.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,69
LVEF (%): 22.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall clinical presentation, laboratory results, and ECG findings suggest a high risk of adverse cardiac events, but they are currently alive. The patient has a history of enolic dilated cardiomyopathy, which is a significant risk factor for cardiac death. However, the patient is on ACE inhibitor therapy, which is beneficial for patients with heart failure. The patient's NYHA class is III, indicating moderate symptoms, but the patient is still alive, which suggests that they are tolerating their condition relatively well.

The patient's laboratory results show elevated creatinine levels, which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The troponin level is normal, which is a good sign, as elevated troponin levels are often associated with cardiac damage.

The ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning, but the patient is still alive. The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient's arrhythmias are not severe.

Overall, while the patient has a high risk of cardiac events, the combination of ACE inhibitor therapy, relatively mild symptoms, and the absence of severe arrhythmias suggest that the patient is likely to survive for the next few years. However, close monitoring and follow-up are essential to adjust the treatment plan and prevent further cardiac complications.

The patient's survival is likely due to the following factors:
- ACE inhibitor therapy
- Mild symptoms
- Normal troponin levels
- Absence of severe arrhythmias
- Relatively preserved LVEF

The patient's mortality risk is still significant, but the patient's survival is more likely than sudden cardiac death or pump failure death."
11,11,P0015,"Age: 40
Gender: Male 
Weight: 98 kg
Height: 180 cm
NYHA Class: III
Blood Pressure: 100/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,13
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,93
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 670.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,83
Urea (mg/dL): 3,79
LVEF (%): 20.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is likely to be a survivor due to several factors. Firstly, the patient's age of 40 is relatively young for cardiomyopathy, and with proper management, many patients with dilated cardiomyopathy can survive for several years with optimal treatment. The patient's NYHA Class III indicates moderate symptoms, which suggests that the patient is still relatively functional and can tolerate a relatively normal level of physical activity. The presence of dyslipemia and elevated troponin levels indicate ongoing cardiac stress, but the patient is on statins and an ACE inhibitor, which are effective in managing these conditions.

The patient's elevated BNP levels (670 ng/L) are concerning, as they indicate significant cardiac stress and possible heart failure. However, the patient is on spironolactone, a medication commonly used to treat heart failure, which may help alleviate symptoms. The patient's kidney function is also relatively preserved, with a creatinine level of 3.79 mg/dL, which suggests that the patient's kidney function is not severely impaired.

The ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia are concerning for arrhythmias, but the patient is on digoxin, which can help regulate heart rhythm. The patient's TSH level is within the normal range, which suggests that thyroid function is not significantly impacting cardiac function.

Overall, while the patient has several concerning factors, the combination of young age, moderate symptoms, and effective treatment with medications suggests that the patient is likely to survive for several years with close monitoring and management."
12,12,P0017,"Age: 58
Gender: Female 
Weight: 89 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,54
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,09
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1108.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 8,02
LVEF (%): 21.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's data, I predict that the patient is most likely to survive over the next few years. The patient's NYHA Class II indicates that they have some limitations with physical activity, but they are still able to maintain a relatively normal quality of life. The patient's age is 58, which is still considered middle-aged, and their weight and height are within normal limits. Their blood pressure is well-controlled at 110/80 mmHg, and their medication regimen includes Amiodarone, which is commonly used to treat ventricular arrhythmias, as well as other heart-related medications.

The patient's past medical history of ischemic dilated cardiomyopathy, dyslipidemia, hypertension, and myocardial infarction suggest a history of cardiovascular disease, but the patient's current LVEF (left ventricular ejection fraction) is 21%, which is still within the normal range. The patient's biomarkers, including troponin and creatinine, are also within normal limits. The patient's ECG shows no signs of ventricular tachycardia or ventricular extrasystoles, which are potential indicators of cardiac arrhythmias.

While the patient's Pro-BNP level is elevated at 1108.0 ng/L, which suggests some degree of heart failure, it is not excessively high, and the patient's symptoms and physical examination do not indicate acute heart failure. Overall, the patient's current clinical status and medication regimen suggest that they are at low risk for cardiac events, and therefore, I predict that they are most likely to survive over the next few years.

2. Sudden cardiac death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases their risk for cardiac events, including sudden cardiac death. However, the patient's current LVEF is 21%, which is still within the normal range, and their ECG shows no signs of ventricular tachycardia or ventricular extrasystoles. While the patient's Pro-BNP level is elevated, it is not excessively high, and the patient's symptoms and physical examination do not indicate acute heart failure.

However, the patient's age and history of cardiovascular disease do increase their risk for cardiac events, including sudden cardiac death. Additionally, the patient's medication regimen includes Amiodarone, which can increase the risk of pro-arrhythmic effects, particularly in patients with a history of ventricular arrhythmias. Therefore, while the patient's current clinical status and medication regimen suggest that they are at low risk, their history and age do increase their risk for cardiac events, including sudden cardiac death.

3. Pump failure death
REASONING: 
The patient's current LVEF is 21%, which is within the normal range, and their ECG shows no signs of ventricular tachycardia or ventricular extrasystoles. However, the patient's Pro-BNP level is elevated at 1108.0 ng/L, which suggests some degree of heart failure. Additionally, the patient's creatinine level is elevated at 91.0 mmol/L, which may indicate impaired renal function.

While the patient's current clinical status and medication regimen suggest that they are at low risk for cardiac events, their elevated Pro-BNP level and creatinine level suggest that they may be at risk for heart failure. Heart failure can lead to pump failure, which can result in death. However, the patient's current symptoms and physical examination do not indicate acute heart failure, and their medication regimen includes medications that are commonly used to treat heart failure, such as beta blockers and ACE inhibitors.

Overall, while the patient's risk for pump failure is increased, their current clinical status and medication regimen suggest that they are at low risk for cardiac events, including pump failure death."
13,13,P0019,"Age: 74
Gender: Male 
Weight: 95 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,3
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 3,8
LDL (mmol/L): 3,88
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1596.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,99
Urea (mg/dL): 7,8
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient has a high likelihood of survival for the next few years. Here's a breakdown of the reasoning behind this prediction:

1. Age and Gender: The patient is 74 years old, which is considered old, but not elderly. However, the patient's gender is male, which is a neutral factor in terms of cardiovascular mortality.

2. NYHA Class II: The patient has a moderate level of heart failure, which indicates that the heart is not functioning optimally. However, this is not a contraindication for survival.

3. Blood Pressure: The patient's blood pressure is well-controlled, which is a positive factor for survival.

4. Past Medical History: The patient has a history of hypertension and hypertensive cardiomyopathy, which are both risk factors for cardiovascular disease. However, the patient is already receiving treatment for these conditions.

5. Laboratory Results:
	* Elevated creatinine levels (88.0 mmol/L) indicate some degree of kidney dysfunction, which can be a risk factor for cardiovascular disease.
	* Elevated liver enzymes (ALT and AST) suggest some degree of liver damage, which can be a risk factor for cardiovascular disease.
	* Elevated total cholesterol and LDL levels (6.08 mmol/L and 3.88 mmol/L, respectively) indicate an increased risk of cardiovascular disease.
	* Low HDL levels (1.03 mmol/L) also indicate an increased risk of cardiovascular disease.
	* Elevated Pro-BNP levels (1596.0 ng/L) indicate some degree of heart failure, which is a risk factor for cardiovascular mortality.

6. ECG Impression: The patient has a polymorphic ventricular extrasystole, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. However, the patient is already receiving treatment for this condition.

7. Medications: The patient is receiving a combination of medications that are commonly used to treat cardiovascular disease, including beta blockers, ACE inhibitors, and calcium channel blockers. These medications can help reduce the risk of cardiovascular mortality.

Considering these factors, I predict that the patient has a high likelihood of survival for the next few years. However, it's essential to monitor the patient's condition closely and adjust the treatment plan as needed to minimize the risk of cardiovascular events.

RANKING: 2. Sudden Cardiac Death
REASONING: 

Based on the patient data, I predict that the patient has a moderate likelihood of sudden cardiac death for the next few years. Here's a breakdown of the reasoning behind this prediction:

1. ECG Impression: The patient has a polymorphic ventricular extrasystole, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death.

2. NYHA Class II: The patient has a moderate level of heart failure, which can increase the risk of cardiovascular mortality.

3. Elevated Pro-BNP levels: Elevated Pro-BNP levels indicate some degree of heart failure, which can increase the risk of cardiovascular mortality.

4. Elevated Creatinine levels: Elevated creatinine levels indicate some degree of kidney dysfunction, which can increase the risk of cardiovascular mortality.

5. Medications: The patient is not receiving any medications that are specifically indicated for the prevention of sudden cardiac death.

6. Past Medical History: The patient has a history of hypertension and hypertensive cardiomyopathy, which are both risk factors for cardiovascular disease.

Considering these factors, I predict that the patient has a moderate likelihood of sudden cardiac death for the next few years.

RANKING: 3. Pump Failure Death
REASONING: 

Based on the patient data, I predict that the patient has a low likelihood of pump failure death for the next few years. Here's a breakdown of the reasoning behind this prediction:

1. NYHA Class II: The patient has a moderate level of heart failure, which indicates that the heart is not functioning optimally. However, the patient is already receiving treatment for this condition, and the patient's NYHA Class is not severe.

2. Medications: The patient is receiving a combination of medications that are commonly used to treat heart failure, including ACE inhibitors, calcium channel blockers, and loop diuretics.

3. Elevated Pro-BNP levels: Elevated Pro-BNP levels indicate some degree of heart failure, which can increase the risk of pump failure. However, the patient is already receiving treatment for this condition.

4. Past Medical History: The patient has a history of hypertension and hypertensive cardiomyopathy, which are both risk factors for cardiovascular disease. However, the patient is already receiving treatment for these conditions.

5. Laboratory Results: The patient's laboratory results do not indicate any"
14,14,P0020,"Age: 48
Gender: Male 
Weight: 77 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 145/80 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 45,5
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 52
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,22
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 322.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 6,45
LVEF (%): 28.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the patient's data, I would rank the patient as a survivor for the next few years. The patient's NYHA Class II indicates a moderate level of heart failure, but the patient is still able to perform daily activities without severe symptoms. The patient's LVEF (Left Ventricular Ejection Fraction) of 28.0 is significantly reduced, indicating left ventricular dysfunction, but it is not extremely low. The patient is also on medications that are standard for managing heart failure and reducing the risk of arrhythmias (Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics). The patient's creatinine level is elevated, but it is not significantly high, suggesting that kidney function is still relatively preserved. Additionally, the patient's troponin level is within normal limits, which suggests that there is no significant myocardial infarction or acute cardiac damage. Overall, the patient's clinical presentation and laboratory results suggest that the patient is likely to survive for the next few years with proper management and monitoring."
15,15,P0021,"Age: 67
Gender: Female 
Weight: 56 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38,19
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 121.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 6,1
LDL (mmol/L): 1,06
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 568.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,98
Urea (mg/dL): 5,79
LVEF (%): 36.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results suggest a relatively stable condition. The patient's age and NYHA Class II status indicate a moderate level of heart failure. However, the patient's ejection fraction (LVEF) is 36.0%, which is within the normal range for a 67-year-old female. The patient's blood pressure and electrolyte levels are also relatively well-controlled.

The patient's biomarkers, such as Troponin and Pro-BNP, are within normal or near-normal limits, suggesting that there is no significant myocardial infarction or acute heart failure. The patient's liver function tests (ALT and AST) are also within normal limits, which reduces the risk of liver-related complications.

The patient's medication regimen is also well-managed, with a combination of diabetes medication, beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor. This suggests that the patient is receiving comprehensive treatment for their heart failure and other comorbid conditions.

While the patient's ECG results do show ventricular extrasystoles, which may be a concern for arrhythmias, the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death. Overall, the patient's clinical presentation and test results suggest a relatively stable condition, making survival the most likely outcome.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF is 36.0%, which is below the normal range for a 67-year-old female. This suggests that the patient's heart is not functioning optimally, which increases the risk of heart failure.

The patient's elevated creatinine level (72.0 mmol/L) may also indicate some degree of kidney impairment, which can contribute to heart failure. The patient's eGFR is not provided, but the creatinine level suggests a possible mild to moderate impairment.

While the patient's medication regimen is well-managed, the patient's comorbid conditions, such as diabetes, dyslipidemia, and hypertension, may still contribute to the development of heart failure.

The patient's Pro-BNP level is elevated at 568.0 ng/L, which may indicate some degree of heart failure. However, the patient's other biomarkers are within normal limits, which reduces the risk of acute heart failure.

Overall, while the patient's clinical presentation and test results are not ideal, the patient's LVEF and elevated creatinine level suggest that pump failure death is a possible outcome.

RANKING: 3. Sudden cardiac death
REASONING: The patient's ECG results show ventricular extrasystoles, which may be a concern for arrhythmias. The patient's LVEF is 36.0%, which is below the normal range for a 67-year-old female.

However, the patient's ECG results do not show any evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death. The patient's Pro-BNP level is elevated at 568.0 ng/L, which may indicate some degree of heart failure, but the patient's other biomarkers are within normal limits.

The patient's medication regimen is well-managed, and the patient's comorbid conditions are being treated. However, the patient's age and NYHA Class II status may still increase the risk of sudden cardiac death.

Overall, while the patient's ECG results and LVEF suggest some degree of cardiac dysfunction, the patient's other clinical and laboratory results suggest that sudden cardiac death is not the most likely outcome."
16,16,P0022,"Age: 43
Gender: Male 
Weight: 130 kg
Height: 179 cm
NYHA Class: II
Blood Pressure: 140/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 46,5
ALT or GPT (IU/L): 100.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,9
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,46
Urea (mg/dL): 5,79
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient is currently taking medications for their hypertension and heart failure, and has a relatively stable ECG impression with no signs of acute cardiac distress. The patient's NYHA Class is II, indicating mild heart failure symptoms, and their LVEF is 40%, which is below the normal range. However, the patient's ECG does not show any signs of acute cardiac ischemia or infarction, and their biomarkers are not significantly elevated. The patient's Pro-BNP level is elevated, but this is not uncommon in patients with heart failure. Given the patient's overall clinical picture, I believe that the patient is likely to survive the next few years, assuming the patient continues to receive appropriate treatment for their heart failure and hypertension. The patient's high weight and elevated creatinine level may pose some risks, but the patient is not currently showing any acute cardiac distress."
17,17,P0023,"Age: 76
Gender: Male 
Weight: 73 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 36,6
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 188.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,53
Urea (mg/dL): 11,13
LVEF (%): 37.0
Medications: Calcium Channel Blocker, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and laboratory results suggest that they are at high risk for adverse cardiac events, but the patient has been classified as a survivor, indicating that they have survived a recent cardiac event or have been stable for an extended period. 

Several factors contribute to this classification:

1. The patient's LVEF is significantly reduced at 37%, indicating left ventricular dysfunction, which is a major risk factor for cardiac events.
2. The presence of non-sustained ventricular tachycardia (NSVT) and paroxysmal supraventricular tachyarrhythmia (PSVT) on the ECG suggests that the patient is at risk for arrhythmic events.
3. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac events.
4. The patient's blood pressure and electrolyte levels are relatively well-controlled, which is important for reducing the risk of cardiac events.
5. The patient's laboratory results, such as the elevated creatinine and urea levels, suggest some degree of renal impairment, which can be associated with cardiac disease.

Despite these factors, the patient has been classified as a survivor, suggesting that they are currently stable and not experiencing any severe cardiac events. However, close monitoring and follow-up are necessary to ensure that the patient remains stable and to adjust their treatment plan as needed."
18,18,P0024,"Age: 58
Gender: Male 
Weight: 94 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 44,5
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4
LDL (mmol/L): 3,62
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 492.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,75
Urea (mg/dL): 7,12
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I predict a high likelihood of survival over the next few years. The patient's age (58) and NYHA Class II (mild heart failure) suggest that the patient is not in a high-risk category. The patient's left ventricular ejection fraction (LVEF) is 37%, which is significantly reduced, but not extremely low. The patient's serum creatinine level is elevated, indicating some degree of kidney impairment, but it is not severely elevated. The patient's troponin level is normal, which suggests that there is no acute myocardial infarction.

The patient's medications, including beta blockers, loop diuretics, and statins, are standard treatments for heart failure and hyperlipidemia, which are both contributing to the patient's condition. The patient's ECG findings, including ventricular extrasystole and paroxysmal supraventricular tachyarrhythmia, are not indicative of a high-risk arrhythmia.

The patient's laboratory results show a mildly elevated liver enzymes (ALT and AST) and a low albumin level, but these findings are not severe. The patient's lipid profile is also mildly elevated, but this is being managed with statins.

Considering these factors, I predict that the patient is likely to survive over the next few years with proper management of their condition. However, it is essential to closely monitor the patient's condition and adjust their treatment plan as needed to prevent further decline.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's prognosis is generally good, there are some factors that increase the risk of sudden cardiac death. The patient's LVEF is significantly reduced, which increases the risk of arrhythmias and sudden cardiac death. The patient's ECG findings, including ventricular extrasystole, also suggest an increased risk of arrhythmias.

Additionally, the patient's NYHA Class II indicates some degree of heart failure, which can increase the risk of sudden cardiac death. The patient's history of myocardial infarction, peripheral vascular disease, and hypertension also increase the risk of sudden cardiac death.

However, the patient's current medications and laboratory results do not suggest a high risk of sudden cardiac death at this time. The patient's troponin level is normal, and the patient is receiving beta blockers, which are effective in reducing the risk of arrhythmias.

RANKING: 3. Pump Failure Death
REASONING: 

While the patient's LVEF is significantly reduced, I do not predict pump failure death as the most likely outcome. The patient's NYHA Class II indicates mild heart failure, and the patient is receiving loop diuretics, which are effective in managing symptoms of heart failure.

The patient's serum creatinine level is elevated, which suggests some degree of kidney impairment, but it is not severely elevated. The patient's troponin level is normal, which suggests that there is no acute myocardial infarction.

The patient's medications, including beta blockers, statins, and loop diuretics, are standard treatments for heart failure and hyperlipidemia, which are both contributing to the patient's condition.

While the patient's LVEF is significantly reduced, I do not predict pump failure death as the most likely outcome. The patient's ECG findings, including ventricular extrasystole, suggest an increased risk of arrhythmias, but this is not a guarantee of pump failure death.

Overall, while the patient's condition is serious, I predict that the patient is likely to survive over the next few years with proper management of their condition."
19,19,P0029,"Age: 58
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45,59
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 176.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 9,1
Hemoglobin (g/L): 157.0
HDL (mmol/L): 0,59
Potassium (mEq/L): 4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 453.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 24,3
Urea (mg/dL): 16,03
LVEF (%): 36.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation, laboratory results, and ECG findings suggest a significant cardiac impairment. The patient has a history of hypertension, cardiomyopathy, diabetes, and dyslipidemia, which are all risk factors for cardiovascular disease. The elevated blood pressure, creatinine levels, and low LVEF (36%) indicate severe cardiac dysfunction. However, the patient is already on multiple medications for cardiovascular management, including beta blockers, digoxin, and an ACE inhibitor, which suggests that the patient is receiving optimal care for their cardiovascular condition.

The elevated Pro-BNP levels (453 ng/L) indicate cardiac strain, and the presence of ventricular extrasystoles (ECG impression) suggests ventricular arrhythmias, which are common in patients with cardiomyopathy. However, the absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests that the patient is not in immediate danger of a sudden cardiac death.

Given the patient's overall clinical presentation and the fact that they are already receiving optimal care for their cardiovascular condition, I predict that the patient will survive for the next few years. The patient's elevated troponin levels (0.01 ng/mL) are not significantly elevated, which suggests that there is no acute myocardial infarction. The patient's hemoglobin level (15.7 g/dL) is within the normal range, which suggests that the patient is not anemic. Overall, the patient's prognosis is guarded but not catastrophic, and I predict that they will survive for the next few years with careful management of their cardiovascular condition."
20,20,P0032,"Age: 63
Gender: Male 
Weight: 85 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 140/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42,4
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,01
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 160.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,35
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1045.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 7,8
LVEF (%): 27.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor 
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers become enlarged. This condition can lead to heart failure, which is already indicated by the patient's NYHA Class II classification. The patient's low LVEF (left ventricular ejection fraction) of 27.0% further supports this. Despite the patient's elevated creatinine levels and slightly elevated troponin levels, which may indicate some degree of cardiac damage, the patient's overall clinical presentation and laboratory results do not suggest an acute myocardial infarction or severe cardiac dysfunction. The patient is also on medications that are commonly used to manage heart failure and prevent further cardiac damage. The absence of ventricular extrasystoles, ventricular tachycardia, and non-sustained ventricular tachycardia on the ECG suggests that the patient does not have an acute life-threatening arrhythmia. Overall, the patient's condition appears stable, and with proper management, it is likely that the patient will survive in the short term."
21,21,P0033,"Age: 52
Gender: Male 
Weight: 108 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 38,7
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,07
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1514.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,52
Urea (mg/dL): 4,68
LVEF (%): 50.0
Medications: Amiodarone, Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I rank the patient as a survivor for the next few years. The patient's age, NYHA Class II, and the absence of other high-risk factors (e.g., severe hypertension, significant coronary artery disease, or a history of myocardial infarction) are favorable. The patient's LVEF is 50%, which indicates some degree of left ventricular dysfunction, but not severe. The patient is also on beta blockers, which are a cornerstone in the management of heart failure and arrhythmias.

Although the patient has idiopathic dilated cardiomyopathy, which is a significant underlying condition, the patient's current LVEF is not severely impaired, and the patient is not experiencing symptoms of heart failure. The absence of elevated troponin levels and the patient's relatively preserved kidney function (creatinine 88.0 mg/dL) also suggest that the patient's heart is not in a state of acute stress or significant ischemia.

Additionally, the patient's electrolytes, liver enzymes, and glucose levels are within normal limits, which suggests that the patient is not experiencing acute kidney injury, liver dysfunction, or significant metabolic disturbances. The patient's ECG findings, while showing ventricular extrasystoles, do not indicate a high risk of sudden cardiac death.

Given these factors, I believe that the patient is at lower risk for adverse outcomes and is more likely to survive for the next few years without significant complications."
22,22,P0036,"Age: 62
Gender: Male 
Weight: 82 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 44,1
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,52
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,27
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 924.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,57
Urea (mg/dL): 15,36
LVEF (%): 30.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
This patient has a complex medical history with multiple comorbidities, including enolic dilated cardiomyopathy, hypertension, dyslipidemia, and peripheral vascular disease. However, the patient's current medication regimen includes a diuretic, spironolactone, and an ACE inhibitor, which suggests that the patient is receiving standard treatment for heart failure and hypertension. The patient's hemoglobin level is slightly elevated, but not significantly so. The ECG impression is normal, with no signs of ventricular arrhythmias or significant ischemia. The Pro-BNP level is elevated, which is consistent with heart failure. The LVEF is significantly reduced, indicating systolic dysfunction. Despite these factors, the patient's age, weight, and other laboratory values (e.g., normal blood pressure, normal potassium level) suggest that the patient may still have a reasonable prognosis for survival. Additionally, the patient's past medical history and current medication regimen suggest that the patient's heart failure is being managed, which could contribute to a better prognosis.

2. Sudden cardiac death 
REASONING: 
While the patient's LVEF is significantly reduced, which is a risk factor for sudden cardiac death, the patient's ECG impression is normal, and there are no signs of ventricular arrhythmias or ischemia. The patient is also receiving standard treatment for heart failure and hypertension, which suggests that the patient's cardiac function is being managed. However, the patient's elevated Pro-BNP level and reduced LVEF still increase the risk of sudden cardiac death. Additionally, the patient's age and other comorbidities (e.g., peripheral vascular disease) may contribute to an increased risk of sudden cardiac death.

3. Pump failure death 
REASONING: 
The patient's reduced LVEF and elevated Pro-BNP level suggest that the patient's heart failure is not well-managed, which increases the risk of pump failure death. However, the patient is receiving standard treatment for heart failure and hypertension, which suggests that the patient's heart failure is being managed. The patient's age, weight, and other laboratory values (e.g., normal blood pressure, normal potassium level) do not significantly increase the risk of pump failure death. The patient's ECG impression is normal, which reduces the risk of sudden cardiac death. However, the patient's reduced LVEF and elevated Pro-BNP level still increase the risk of pump failure death, making this prognosis the least likely."
23,23,P0037,"Age: 71
Gender: Male 
Weight: 88 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44,8
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 732.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,9
Urea (mg/dL): 9,35
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

Based on the provided patient data, I rank the patient as a survivor for the next few years. The patient's NYHA Class II indicates a moderate level of heart failure symptoms, but they are still able to perform daily activities without significant limitation. The patient's LVEF is 40%, which is within the range of 30-50% and indicates a moderate reduction in left ventricular function, but it is not severely impaired. The patient's medication regimen, including beta blockers, statins, and ACE inhibitors, is typical for managing heart failure and coronary artery disease.

The patient's laboratory results show elevated liver enzymes (ALT and AST) and creatinine levels, which may indicate some degree of organ dysfunction. However, these results are not severe and may be related to the patient's underlying heart disease rather than a separate acute condition. The patient's lipid profile is also suboptimal, with high total cholesterol and low HDL levels, but this is not uncommon in patients with heart disease.

The ECG results show a history of ventricular extrasystoles, which is a type of arrhythmia that can be a precursor to more serious conditions. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the likelihood of a sudden cardiac death.

Considering these factors, I believe the patient is at moderate risk for cardiac events, but the overall clinical picture suggests that the patient can be managed with current treatment and may survive for the next few years."
24,24,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. However, the patient's current NYHA Class II indicates that their symptoms are manageable with current medical therapy. The patient's LVEF of 40.0 is mildly reduced, but not severely impaired.

The patient's electrolyte levels are mostly within normal limits, with the exception of a mildly elevated creatinine level, which may indicate some degree of renal impairment. The patient's lipid profile is also suboptimal, but the current medications are being used to manage dyslipidemia.

The Pro-BNP level is elevated at 458.0 ng/L, which is a marker of increased cardiac stress and a predictor of adverse outcomes. However, this is not an isolated finding, and the patient's overall clinical presentation and medical history suggest that the elevated Pro-BNP level is a reflection of the patient's underlying cardiac condition rather than a new or acute event.

The ECG impression does not indicate any acute arrhythmias or other life-threatening conditions, which suggests that the patient is not at immediate risk for sudden cardiac death. The patient's medications, including Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins, are being used to manage the patient's heart failure, hypertension, and dyslipidemia.

Overall, based on the patient's complex medical history, mildly reduced LVEF, and elevated Pro-BNP level, the most likely outcome for the next few years is that the patient will survive, but will likely require close monitoring and adjustments to their treatment plan to manage their cardiac condition and prevent further decline.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's elevated Pro-BNP level and mildly reduced LVEF increase the risk of adverse outcomes, the patient's current ECG impression does not indicate any acute arrhythmias or other life-threatening conditions. However, the patient's complex medical history and mildly reduced LVEF do increase the risk of sudden cardiac death.

The patient's use of Amiodarone, a medication that can increase the risk of arrhythmias, may also contribute to the risk of sudden cardiac death. However, the patient's current medication regimen is being used to manage their heart failure and other conditions, and the risk of sudden cardiac death is not immediately apparent from the available data.

The patient's mildly elevated creatinine level may also increase the risk of sudden cardiac death, as it may indicate some degree of renal impairment, which can contribute to electrolyte imbalances and cardiac arrhythmias. However, this is not a significant risk factor for sudden cardiac death, and the patient's overall clinical presentation does not suggest an immediate risk.

Overall, while the patient's risk of sudden cardiac death is increased, the available data do not indicate an immediate risk, and the patient's survival is still the most likely outcome for the next few years.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's mildly reduced LVEF and elevated Pro-BNP level do increase the risk of heart failure, which is a major contributor to pump failure deaths. However, the patient's current NYHA Class II indicates that their symptoms are manageable with current medical therapy, and the patient's LVEF is not severely impaired.

The patient's use of medications to manage their heart failure, including Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins, is also being used to manage their cardiac condition and prevent further decline.

The patient's mildly elevated creatinine level may also increase the risk of pump failure, but this is not a significant risk factor, and the patient's overall clinical presentation does not suggest an immediate risk.

Overall, while the patient's risk of pump failure death is increased, the patient's survival is still the most likely outcome for the next few years, and pump failure death is not the most likely outcome."
25,25,P0039,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 3,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 331.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,45
Urea (mg/dL): 6,91
LVEF (%): 39.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is 73 years old with a history of hypertension, cardiomyopathy, and dyslipidemia, which are all risk factors for cardiovascular disease. The patient's current NYHA class III indicates significant heart failure symptoms, and their LVEF of 39% suggests reduced cardiac function. However, the patient's vital signs and laboratory results do not indicate acute cardiac distress or severe electrolyte imbalances that would suggest imminent cardiac death. The patient's ECG impression does not show any life-threatening arrhythmias, and the patient is on beta blockers and ACE inhibitors, which are standard treatments for heart failure and hypertension. Additionally, the patient has a relatively normal potassium level and no signs of acute kidney injury, which could indicate cardiac dysfunction. 

Given these factors, the patient's prognosis is that they will survive for the next few years with careful management of their hypertension, heart failure, and dyslipidemia. The patient's reduced LVEF and NYHA class III symptoms suggest that they will require ongoing medical management and possibly further treatment to improve their cardiac function. However, without any acute life-threatening conditions, the patient's survival is the most likely outcome. 

The patient's Pro-BNP level is elevated, which suggests some degree of cardiac stress and possible heart failure, but it is not extremely high, which could indicate a more severe condition. The patient's troponin level is within normal limits, which suggests that there is no acute myocardial infarction. 

Therefore, the patient's overall prognosis is that they will survive for the next few years with careful management of their cardiovascular conditions."
26,26,P0041,"Age: 78
Gender: Male 
Weight: 70 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 51,8
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 853.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,72
Urea (mg/dL): 10,02
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is likely to survive in the next few years due to the following reasons:

1. Age: Although the patient is 78 years old, their age alone does not necessarily determine their survival prospects. However, it does mean they are at a higher risk for various complications.
2. NYHA Class II: This indicates that the patient has some symptoms of heart failure, but they are still able to perform daily activities with some limitation. This suggests that the patient's heart is not severely impaired.
3. Medications: The patient is taking a comprehensive regimen of medications, including ACE inhibitors, statins, and loop diuretics, which are standard treatments for managing heart failure, hypertension, and high cholesterol.
4. ECG Impression: The ECG shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all potential predictors of sudden cardiac death.
5. Biomarkers: The patient's troponin levels are normal, which suggests that there is no acute myocardial infarction or significant cardiac damage. The pro-BNP levels are elevated, indicating some degree of heart failure, but the patient is still able to survive.
6. Other laboratory values: The patient's creatinine levels are elevated, indicating some degree of kidney impairment, but this is not directly related to their cardiac function.
7. Past medical history: The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, diabetes, and dyslipemia, which are all risk factors for heart failure and cardiac death. However, the patient is being treated for these conditions, and their current symptoms are manageable.

While this patient has several risk factors for cardiac complications, their overall clinical picture suggests that they are likely to survive in the next few years. However, regular monitoring and follow-up appointments will be necessary to ensure that their condition does not worsen.

RANKING: 2. Sudden cardiac death
REASONING: 

This patient is at risk for sudden cardiac death due to the following reasons:

1. History of myocardial infarction: The patient has a history of myocardial infarction, which can lead to scar tissue formation and an increased risk of arrhythmias.
2. Ischemic dilated cardiomyopathy: This condition can lead to electrical instability and arrhythmias.
3. Elevated troponin levels: Elevated troponin levels can indicate some degree of cardiac damage, which can lead to arrhythmias.
4. ECG Impression: The patient has ventricular extrasystoles, which can be a predictor of arrhythmias.

However, the patient is not currently experiencing any symptoms, and their ECG shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia.

RANKING: 3. Pump failure death
REASONING: 

This patient is at risk for pump failure death due to the following reasons:

1. Low LVEF: The patient's left ventricular ejection fraction (LVEF) is significantly reduced, indicating poor cardiac function.
2. NYHA Class II: This indicates that the patient has some symptoms of heart failure, which can worsen over time.
3. Elevated creatinine levels: The patient's kidney function is impaired, which can lead to fluid overload and exacerbate heart failure.

However, the patient is already being treated for these conditions, and their current symptoms are manageable. With proper management and monitoring, it is possible to prevent pump failure death.

In conclusion, while this patient has several risk factors for cardiac complications, their overall clinical picture suggests that they are likely to survive in the next few years. However, regular monitoring and follow-up appointments will be necessary to ensure that their condition does not worsen."
27,27,P0042,"Age: 60
Gender: Male 
Weight: 84 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,6
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 90.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 6,01
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient is currently on medications that are commonly used to manage heart failure (Beta Blockers, Statins, ACE Inhibitor) and has a relatively stable ECG impression with no signs of ventricular arrhythmias. The patient's NYHA Class II indicates mild symptoms of heart failure, which suggests that the heart is still functional to some extent. The patient's LVEF of 40% is lower than normal, but it is not extremely low, indicating some residual cardiac function.

Although the patient has a history of ischemic dilated cardiomyopathy, the current data does not suggest an acute decompensated heart failure. The patient's creatinine level is elevated, but it is not indicative of acute kidney injury, and the patient is on medications that are known to slow kidney function decline in patients with heart failure. The patient's glucose level is also elevated, but it is not excessively high, and the patient is on medications that can help manage blood sugar levels.

The patient's ECG impression is relatively normal, with no signs of ventricular arrhythmias, which is a good prognostic sign. The patient's Pro-BNP level is elevated, but it is not extremely high, indicating some level of cardiac stress.

Overall, considering the patient's stable ECG, mild NYHA Class, and current medication regimen, the most likely outcome is that the patient will survive.

2. Sudden Cardiac Death
REASONING:
The patient's history of ischemic dilated cardiomyopathy, diabetes, and dyslipemia increases the risk of sudden cardiac death. The patient's LVEF of 40% is low, and the patient's Pro-BNP level is elevated, indicating some level of cardiac stress. The patient's creatinine level is elevated, which may indicate some level of kidney dysfunction, which can increase the risk of sudden cardiac death.

The patient's ECG impression shows ventricular extrasystoles, which is a sign of abnormal heart rhythm. While the patient is not experiencing any ventricular tachycardia, the presence of ventricular extrasystoles is a risk factor for sudden cardiac death.

3. Pump Failure Death
REASONING:
The patient's LVEF of 40% is very low, indicating significant cardiac dysfunction. The patient's NYHA Class II indicates mild symptoms of heart failure, but the patient is on medications that can help manage heart failure symptoms. However, the patient's elevated creatinine level and elevated Pro-BNP level suggest that the patient's heart is not functioning optimally.

The patient's ECG impression shows ventricular extrasystoles, which is a sign of abnormal heart rhythm. The patient's elevated potassium level may also indicate some level of cardiac dysfunction.

While the patient is on medications that can help manage heart failure symptoms, the patient's current data suggests that the patient is at risk of developing pump failure. Therefore, the most likely outcome is pump failure death."
28,28,P0044,"Age: 77
Gender: Male 
Weight: 87 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,5
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,94
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1157.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,99
Urea (mg/dL): 9,35
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, I rank the patient as a survivor with a high likelihood. The patient's age of 77 is not uncommon for someone with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient's current hemoglobin level of 148.0 g/L and normal TSH level of 1.99 mIU/L suggest that the patient is not experiencing severe anemia or hypothyroidism, which could be contributing factors to a poor outcome.

The patient's current medications, including beta blockers, ACE inhibitors, and statins, are standard treatments for managing heart failure and ischemic heart disease. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG may indicate an increased risk of arrhythmias, but the patient's overall clinical presentation does not suggest an immediate life-threatening condition.

The patient's elevated creatinine level of 9.35 mg/dL indicates some degree of renal impairment, which may be related to the patient's underlying heart disease. However, the patient is already receiving loop diuretics, which are commonly used to manage fluid overload in heart failure patients. Overall, the patient's current clinical status and treatment plan suggest that they are at moderate to high risk for cardiac events, but not at extremely high risk.

Therefore, I predict that the patient will survive for at least the next few years, but it is essential to closely monitor their condition and adjust their treatment plan as needed to minimize the risk of cardiac events.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's ECG shows signs of arrhythmias, which are a risk factor for sudden cardiac death, the overall clinical presentation does not suggest an immediately life-threatening condition. The patient is on multiple medications that are standard for managing heart failure and ischemic heart disease, which reduces the risk of sudden cardiac death.

The patient's LVEF of 40.0 is significantly reduced, indicating severe left ventricular dysfunction, which increases the risk of arrhythmias and sudden cardiac death. However, the patient's current treatment plan includes beta blockers, which are known to reduce the risk of arrhythmias and sudden cardiac death.

The patient's elevated creatinine level and elevated Troponin level may indicate some degree of cardiac damage, but the patient is already receiving medications that are intended to reduce the risk of further cardiac damage. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG may indicate an increased risk of arrhythmias, but the patient's overall clinical presentation does not suggest an immediately life-threatening condition.

Therefore, while the patient is at risk for arrhythmias and sudden cardiac death, the overall clinical presentation and treatment plan suggest that the risk is not extremely high.

RANKING: 3. Pump failure death
REASONING: 
Based on the patient's current clinical presentation, I would rank pump failure death as the least likely outcome. The patient is already receiving medications that are standard for managing heart failure, including beta blockers, ACE inhibitors, and loop diuretics. The patient's elevated creatinine level and elevated Troponin level may indicate some degree of cardiac damage, but the patient's overall clinical presentation does not suggest that the patient is experiencing severe heart failure.

The patient's LVEF of 40.0 is significantly reduced, indicating severe left ventricular dysfunction, which increases the risk of heart failure. However, the patient's current treatment plan includes medications that are intended to reduce the risk of heart failure, including beta blockers, ACE inhibitors, and loop diuretics.

The patient's elevated Pro-BNP level of 1157.0 may indicate some degree of cardiac stress, but the patient's overall clinical presentation does not suggest that the patient is experiencing severe heart failure. The patient's hemoglobin level of 148.0 g/L and normal TSH level of 1.99 mIU/L suggest that the patient is not experiencing severe anemia or hypothyroidism, which could be contributing factors to pump failure.

Therefore, while the patient is at risk for heart failure, the overall clinical presentation and treatment plan suggest that the risk is not extremely high, and pump failure death is the least likely outcome."
29,29,P0045,"Age: 73
Gender: Male 
Weight: 83 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 42,59
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,69
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,21
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 390.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,54
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

Based on the patient's data, I would rank the prognoses as follows, with survivor being the most likely outcome.

The patient has a history of idiopathic dilated cardiomyopathy, which is a significant underlying condition that can lead to heart failure and arrhythmias. However, the patient is currently receiving treatment with digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, which suggests that their condition is being managed.

The patient's ejection fraction (LVEF) is 40%, which is within the range of moderate heart failure, but not severely impaired. The patient's blood pressure is well-controlled at 130/80 mmHg, and their electrolytes and renal function are relatively normal.

The patient's ECG impression reveals non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles, which are concerning for arrhythmias. However, the presence of NSVT is not uncommon in patients with heart failure and is often a transient finding.

The patient's biomarkers, including troponin and BNP, are within normal limits, suggesting that there is no acute myocardial injury or significant cardiac stress.

Considering these factors, I believe that the patient is at risk for arrhythmias and cardiac events, but their overall condition is being managed, and they are likely to survive in the short term. Therefore, I rank survivor as the most likely outcome.

RANKING: 2. Sudden Cardiac Death 
REASONING: 

While the patient is at risk for arrhythmias, the presence of NSVT and polymorphic ventricular extrasystoles on the ECG suggests a higher risk for arrhythmias. However, the patient's biomarkers and renal function are relatively normal, and their ejection fraction is within the range of moderate heart failure.

A more concerning factor is the patient's age (73 years) and the presence of peripheral vascular disease, which can increase the risk for cardiac events.

However, the patient is receiving treatment for their condition, and their blood pressure is well-controlled. Therefore, while the risk for sudden cardiac death is present, I rank it as the second most likely outcome.

RANKING: 3. Pump Failure Death 
REASONING: 

While the patient has a history of idiopathic dilated cardiomyopathy, their ejection fraction is relatively preserved at 40%. The patient is also receiving treatment for their condition, and their biomarkers and renal function are relatively normal.

However, the patient's age (73 years) and the presence of peripheral vascular disease are significant risk factors for cardiac events. Additionally, the patient's NYHA class is II, which suggests that they are experiencing some symptoms of heart failure.

Considering these factors, I rank pump failure death as the least likely outcome, but still a possible one."
30,30,P0048,"Age: 60
Gender: Male 
Weight: 95 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43,09
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,91
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 603.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 5
Urea (mg/dL): 9,8
LVEF (%): 38.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 60-year-old male with a history of idiopathic dilated cardiomyopathy, hypertension, and dyslipidemia. The patient's current NYHA Class III indicates severe heart failure symptoms. The elevated creatinine level (101.0 mmol/L) suggests impaired renal function, which is a common complication in patients with advanced heart failure. The elevated Pro-BNP level (603.0 ng/L) indicates significant ventricular strain and stress, which is consistent with the patient's NYHA Class III status.

The patient's ECG findings, including ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, suggest significant cardiac arrhythmias and ventricular dysfunction. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia increases the risk of sudden cardiac death.

Despite the presence of several risk factors, including hypertension, dyslipidemia, and impaired renal function, the patient is currently on medications that are commonly used to manage heart failure and arrhythmias (Digoxin, Loop Diuretics, Spironolactone, Statins, and ACE Inhibitor). However, the patient's elevated troponin level (0.01 ng/mL) and reduced LVEF (38.0%) suggest that the patient's cardiac function is still compromised.

Given the patient's overall clinical presentation and ECG findings, I would rank the patient as a survivor, with a moderate risk of adverse cardiac events, including sudden cardiac death and pump failure death, over the next few years."
31,31,P0050,"Age: 65
Gender: Male 
Weight: 90 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,5
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,39
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 9,5
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,07
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 758.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,48
Urea (mg/dL): 10,47
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient has a complex medical history with multiple comorbidities such as ischemic dilated cardiomyopathy, diabetes, dyslipidemia, hypertension, and myocardial infarction, which are all risk factors for cardiac complications. However, the patient is currently receiving medications for these conditions, including beta blockers, statins, and an ACE inhibitor, which are standard treatments for these conditions.

The patient's ejection fraction (LVEF) is significantly reduced at 40%, indicating severe left ventricular dysfunction, but the patient is not showing any signs of acute cardiac distress or acute coronary syndrome. The ECG impression does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are more common causes of sudden cardiac death.

The patient's renal function is mildly impaired, with an elevated creatinine level, but this is not immediately life-threatening. The patient's liver function is within normal limits. The patient's electrolytes, including potassium levels, are within normal limits.

Considering the patient's complex medical history, the presence of multiple comorbidities, and the fact that the patient is currently on multiple medications, the most likely outcome is that the patient will survive for the next few years with careful management of their medications and monitoring of their condition.

2. Sudden Cardiac Death 
REASONING: 
While the patient has a complex medical history, the absence of any acute cardiac distress or acute coronary syndrome makes sudden cardiac death less likely. However, the patient's reduced ejection fraction (LVEF) of 40% indicates severe left ventricular dysfunction, which is a risk factor for cardiac complications.

The patient's ECG impression does show ventricular extrasystole, which is a sign of abnormal heart rhythm, but it is not a direct indicator of sudden cardiac death. Additionally, the absence of ventricular tachycardia or non-sustained ventricular tachycardia makes sudden cardiac death less likely.

While the patient's reduced LVEF and multiple comorbidities make cardiac complications more likely, the patient's current clinical presentation does not suggest an immediate risk of sudden cardiac death.

3. Pump Failure Death 
REASONING: 
Pump failure death is a possible outcome for patients with severe left ventricular dysfunction, as indicated by the patient's reduced ejection fraction (LVEF) of 40%. However, the patient is currently receiving medications for their heart failure, including beta blockers and ACE inhibitors, which are standard treatments for heart failure.

The patient's renal function is mildly impaired, but this is not immediately life-threatening. The patient's liver function, electrolytes, and other laboratory values are within normal limits.

While pump failure death is a possible outcome, the patient's current clinical presentation and management plan make it less likely compared to survivorship. The patient is receiving medications to manage their heart failure, and the absence of any acute cardiac distress or acute coronary syndrome makes sudden cardiac death less likely."
32,32,P0052,"Age: 56
Gender: Male 
Weight: 104 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,7
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 402.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, the patient is at high risk for adverse outcomes due to several factors. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac death. The patient's LVEF is severely impaired at 30%, indicating poor cardiac function. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias, which can lead to sudden cardiac death. The patient's NYHA class II indicates some limitation in physical activity, suggesting that the patient's cardiac function is not optimal.

Despite the presence of several risk factors, the patient is currently on medications that are commonly used to manage heart failure and arrhythmias, such as amiodarone, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator. These medications can help to improve cardiac function and reduce the risk of arrhythmias.

Given these factors, the most likely prognosis is that the patient will survive. However, the patient will likely require close monitoring and adjustments to their medication regimen to minimize the risk of adverse outcomes.

The probability of sudden cardiac death and pump failure death is lower than survival due to the following reasons:

- Sudden cardiac death is less likely because the patient is on medications that can help manage arrhythmias, and the presence of NSVT and polymorphic ventricular extrasystoles may not necessarily lead to a fatal arrhythmia.
- Pump failure death is less likely because the patient is on medications that can help manage heart failure, and the patient's NYHA class II indicates that the patient's cardiac function is not severely impaired.

However, the patient still requires close monitoring and regular follow-up appointments to adjust their treatment plan and minimize the risk of adverse outcomes."
33,33,P0055,"Age: 60
Gender: Female 
Weight: 83 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 170/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,34
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,16
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 282.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,21
Urea (mg/dL): 7,35
LVEF (%): 39.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 60-year-old female with a history of hypertensive cardiomyopathy, hypertension, and NYHA Class II heart failure. Her laboratory results show elevated creatinine levels (74.0 mmol/L), which may indicate some degree of renal impairment. Her LVEF (39.0%) is significantly reduced, indicating left ventricular dysfunction. The patient's ECG shows ventricular extrasystoles, which may indicate arrhythmia.

Despite these concerning findings, the patient has been taking beta blockers, statins, and an ACE inhibitor, which suggests that her cardiovascular risk factors are being managed. Her Pro-BNP levels (282.0 ng/L) are elevated, but not extremely high, indicating some degree of ventricular stress.

Given these factors, I believe that the patient is likely to survive for the next few years. However, her reduced LVEF and elevated creatinine levels suggest that she may require closer monitoring and potential adjustments to her medication regimen to manage her heart failure and kidney function.

The other two options, sudden cardiac death and pump failure death, are less likely due to the following reasons:

- Sudden cardiac death is unlikely due to the patient's stable ECG impression and the fact that she is not experiencing any ventricular tachycardia or other arrhythmias that could lead to sudden cardiac death.
- Pump failure death is also less likely due to the patient's relatively stable renal function and the fact that her Pro-BNP levels are not extremely high. While her LVEF is reduced, her current medication regimen is likely effective in managing her heart failure symptoms."
34,34,P0060,"Age: 69
Gender: Female 
Weight: 85 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38,9
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,08
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 538.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,36
Urea (mg/dL): 10,24
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, I predict that the patient is most likely to be a survivor over the next few years. Here's why:

1. The patient's NYHA Class II indicates that they have some limitation in physical activity due to heart failure, but they are still able to perform daily activities with minimal symptoms. This suggests that their heart function is not severely compromised.

2. The patient's LVEF (Left Ventricular Ejection Fraction) of 24.0 is within the normal range, indicating that the left ventricle is pumping blood effectively.

3. The absence of ventricular extrasystoles, ventricular tachycardia, and non-sustained ventricular tachycardia on the ECG suggests that the patient does not have any significant arrhythmias that could lead to sudden cardiac death.

4. The patient's blood pressure is well-controlled at 130/80 mmHg, and they are taking medications for hypertension, diabetes, and heart failure, which suggests that they are receiving adequate management for their conditions.

5. The patient's renal function, as indicated by the creatinine level of 10.24 mg/dL, is not severely impaired, which suggests that their kidneys are still functioning relatively well.

6. The patient's electrolyte and liver function tests are within normal limits, and the absence of elevated troponin levels suggests that there is no significant myocardial damage.

7. The patient's medication regimen includes ACE inhibitors, which are known to improve heart failure symptoms and reduce mortality risk in patients with heart failure.

8. The patient's age, while 69, is not considered old for a female patient, and they do not have any other comorbidities that would increase their risk of mortality.

Overall, based on the provided data, I predict that the patient is likely to be a survivor over the next few years, given their well-managed conditions, normal heart function, and adequate medication regimen."
35,35,P0061,"Age: 60
Gender: Male 
Weight: 85 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 47,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,18
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 701.0
Protein (g/L): 72
T3 (pg/dL): 0,07
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,01
Urea (mg/dL): 10,02
LVEF (%): 38.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is classified as a survivor due to the overall clinical presentation and test results. The patient's age, NYHA Class II, and elevated left ventricular ejection fraction (LVEF) of 38% indicate a significant degree of left ventricular dysfunction, which is consistent with dilated cardiomyopathy. The patient's elevated creatinine level (101.0 mmol/L) and elevated BNP (701.0 ng/L) levels also suggest a compromised cardiac function.

Although the patient has a history of hypertension and is taking medications for heart failure (beta blockers, digoxin, and an ACE inhibitor), the patient's current LVEF and BNP levels indicate that the patient's condition is not adequately controlled.

However, the patient's ECG findings, including non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, are concerning for a high risk of arrhythmias. Despite this, the patient's overall clinical presentation and test results suggest that the patient is likely to survive for the next few years with appropriate management and monitoring.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's ECG findings are concerning for arrhythmias, the patient's overall clinical presentation and test results do not indicate a high risk of sudden cardiac death. The patient's LVEF is relatively low, and the patient's BNP levels are elevated, which may suggest that the patient is at risk for worsening heart failure.

However, the patient's age, hypertension, and history of dilated cardiomyopathy increase the risk of sudden cardiac death. The patient's ECG findings, including non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, also increase the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's elevated BNP levels (701.0 ng/L) and low LVEF (38.0%) indicate a high risk of heart failure. The patient's elevated creatinine level (101.0 mmol/L) also suggests that the patient's kidney function is compromised, which can worsen heart failure.

However, the patient's overall clinical presentation and test results do not indicate a high risk of pump failure death. The patient is taking medications for heart failure, and the patient's NYHA Class II indicates that the patient's symptoms are manageable with current treatment.

In addition, the patient's ECG findings, including non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, are concerning for arrhythmias, but not necessarily indicative of pump failure. Overall, while the patient is at risk for worsening heart failure, the patient's current clinical presentation and test results suggest that the patient is more likely to survive for the next few years with appropriate management and monitoring."
36,36,P0062,"Age: 81
Gender: Male 
Weight: 71 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 145/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 35,6
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,95
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1399.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,49
Urea (mg/dL): 15,15
LVEF (%): 52.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as having the highest likelihood of survival over the next few years. The patient's age of 81 is a significant risk factor for mortality, but the patient's NYHA Class II indicates that they are still relatively functional and have not reached the end-stage of heart failure. The patient's blood pressure is well-controlled with the use of loop diuretics and an ACE inhibitor, which suggests that they are receiving adequate management for their hypertension.

The patient's biomarkers, such as the elevated creatinine level and elevated Troponin level, indicate some degree of cardiac stress and potential cardiac damage. However, the Troponin level is relatively low (0.02 ng/mL), which suggests that the patient may not be experiencing significant myocardial infarction or acute cardiac damage.

The patient's ejection fraction (LVEF) is 52.0%, which is lower than the normal range, indicating some degree of left ventricular dysfunction. However, this is not uncommon in patients with hypertension and cardiomyopathy.

The patient's ECG findings, including the presence of ventricular extrasystoles, are also not particularly concerning, as they are often seen in patients with hypertension and cardiomyopathy.

The patient's medication regimen is well-managed, with loop diuretics and an ACE inhibitor, which suggests that they are receiving adequate treatment for their hypertension and heart failure.

Overall, while the patient has several risk factors for mortality, their age, functional status, and medication regimen suggest that they are likely to survive over the next few years. However, close monitoring and follow-up will be necessary to ensure that the patient's condition does not deteriorate.

RANKING: 2. Sudden Cardiac Death
REASONING: 

Based on the patient's history and current condition, I would rank the patient as having a moderate likelihood of sudden cardiac death over the next few years. The patient's age of 81 is a significant risk factor for sudden cardiac death, and their NYHA Class II indicates that they may be at risk for arrhythmias and cardiac events.

The patient's ECG findings, including the presence of ventricular extrasystoles, suggest that they may be at risk for arrhythmias, which can increase the risk of sudden cardiac death. The patient's elevated Troponin level and LVEF of 52.0% also suggest that they may be at risk for cardiac damage and dysfunction.

The patient's medication regimen, while well-managed, does not include anti-arrhythmic therapy, which may increase the risk of arrhythmias and sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

Based on the patient's current condition, I would rank the patient as having the lowest likelihood of pump failure death over the next few years. The patient's LVEF of 52.0% is lower than the normal range, but this is not uncommon in patients with hypertension and cardiomyopathy.

The patient's medication regimen, including loop diuretics and an ACE inhibitor, suggests that they are receiving adequate treatment for their hypertension and heart failure. The patient's NYHA Class II indicates that they are relatively functional and have not reached the end-stage of heart failure.

While the patient's elevated creatinine level and Troponin level suggest that they may be at risk for cardiac damage and dysfunction, these findings are not particularly concerning in the context of their overall clinical picture. The patient's ECG findings, including the presence of ventricular extrasystoles, are not particularly concerning, and the patient's medication regimen is well-managed.

Overall, while the patient has some risk factors for pump failure, their age, functional status, and medication regimen suggest that they are likely to survive over the next few years, with a lower risk of pump failure death."
37,37,P0063,"Age: 55
Gender: Male 
Weight: 68 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44,4
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,57
Creatinine (mmol/L): 75.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 6
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4
LDL (mmol/L): 2,15
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 249.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,94
Urea (mg/dL): 10,02
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as having a high likelihood of survival over the next few years. The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy are significant risk factors for cardiovascular events. However, the patient is currently receiving optimal medical therapy with beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and coronary artery disease.

The patient's laboratory results are relatively normal, with elevated creatinine levels indicating some degree of kidney impairment, but this is not uncommon in patients with heart failure. The elevated troponin level is also concerning, but the patient's LVEF is significantly reduced, which may indicate that the elevated troponin is not necessarily indicative of an acute myocardial infarction.

The ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning, but the absence of sustained ventricular tachycardia and other arrhythmias reduces the risk of sudden cardiac death. The patient's Pro-BNP level is elevated, indicating some degree of heart failure, but the patient is receiving treatment that is likely to help manage this condition.

Overall, while the patient has several risk factors and abnormal test results, the presence of optimal medical therapy and the absence of severe arrhythmias or other high-risk findings suggest that the patient is at moderate risk of cardiovascular events, but not at high risk of sudden cardiac death or pump failure death. Therefore, I rank the patient as having a high likelihood of survival over the next few years."
38,38,P0064,"Age: 60
Gender: Male 
Weight: 102 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 41,7
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4
LDL (mmol/L): 2,72
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 125.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,76
Urea (mg/dL): 8,02
LVEF (%): 45.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
This patient's prognosis is likely to be a survivor due to several factors. Firstly, the patient has a history of Ischemic dilated cardiomyopathy, which can lead to heart failure, but the patient is already on medications for heart failure (Beta Blockers and ACE Inhibitor) and has a relatively preserved LVEF (45.0%), indicating that the heart is not completely failing. Additionally, the patient's NYHA Class is II, which suggests that the patient has some symptoms of heart failure but is not severely limited in their daily activities. The patient's creatinine level is also not significantly elevated, indicating that kidney function is not severely compromised. Furthermore, the patient's ECG impression does not show any signs of ventricular tachycardia or other arrhythmias that could indicate a high risk of sudden cardiac death. The patient's lipid profile is also relatively well-controlled, with a low LDL level and a relatively high HDL level, which can help to reduce the risk of cardiovascular events. Overall, these factors suggest that the patient is likely to survive for the next few years with proper management and monitoring.

2. Pump failure death
REASONING: 
While the patient's LVEF is 45.0, which is lower than the normal range, the patient is already on medications for heart failure and has a relatively preserved kidney function. However, the patient's NYHA Class is II, which suggests that the patient has some symptoms of heart failure and may require more aggressive management to prevent progression. If the patient's condition does not improve with current treatment, the risk of pump failure increases. Additionally, the patient's creatinine level is elevated, which could indicate some degree of kidney dysfunction, which can be a risk factor for heart failure.

3. Sudden cardiac death
REASONING: 
The patient's ECG impression shows ventricular extrasystole, which is a sign of abnormal heart rhythms that can increase the risk of sudden cardiac death. While the patient does not have any other signs of ventricular tachycardia or other arrhythmias, the presence of ventricular extrasystole is a concern. Additionally, the patient's age and history of myocardial infarction increase the risk of sudden cardiac death. However, the patient's ECG impression does not show any other signs of ventricular tachycardia or other arrhythmias, which reduces the risk of sudden cardiac death. Nevertheless, the presence of ventricular extrasystole and the patient's age and history of myocardial infarction make this prognosis less likely than the other two options."
39,39,P0067,"Age: 49
Gender: Female 
Weight: 82 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 43,8
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 132.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,17
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 30.0
Protein (g/L): 75,8
T4 (ng/L): 17
TSH (mIU/L): 1,93
Urea (mg/dL): 13,64
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient data, the patient's overall prognosis is most likely to be a survivor. The patient's NYHA Class II indicates moderate heart failure, but the patient is still able to perform daily activities with some limitation. The patient's LVEF is 37%, which is significantly reduced, but not critically low. The patient's creatinine level is elevated, indicating some degree of renal impairment, but it is not severe.

The patient's laboratory values, including the low albumin level and high creatinine level, suggest some degree of malnutrition and renal impairment. However, the patient's other laboratory values, such as the normal blood pressure, low glucose level, and low LDL cholesterol level, are generally within normal limits.

The patient's ECG impression shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all indicators of potentially life-threatening arrhythmias. The presence of ventricular extrasystole, which is a benign finding, is also present but does not significantly impact the overall prognosis.

Given these factors, the patient's overall health status, laboratory values, and ECG impression suggest that the patient is likely to survive for the next few years with proper management and treatment. The patient's current treatment regimen of beta blockers, loop diuretics, and ACE inhibitors is adequate for managing the patient's heart failure and other comorbidities. Therefore, the most likely prognosis is a survivor.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's overall prognosis is likely to be a survivor, the patient's LVEF is significantly reduced, which increases the risk of sudden cardiac death. The patient's ECG impression shows ventricular extrasystole, which, although benign, may be a sign of underlying cardiac dysfunction.

The patient's high creatinine level and low albumin level also suggest some degree of renal impairment, which can increase the risk of sudden cardiac death. Additionally, the patient's low HDL cholesterol level and high LDL cholesterol level increase the risk of atherosclerosis and cardiac events.

Given these factors, there is a moderate risk of sudden cardiac death in the next few years. However, this risk is not as high as the risk of pump failure death, as the patient's LVEF is not critically low, and the patient is currently on an adequate treatment regimen.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF is significantly reduced at 37%, which increases the risk of pump failure death. The patient's high creatinine level and low albumin level also suggest some degree of renal impairment, which can increase the risk of pump failure.

The patient's current treatment regimen of beta blockers, loop diuretics, and ACE inhibitors is adequate for managing the patient's heart failure, but it may not be sufficient to prevent pump failure death, especially given the patient's reduced LVEF.

Additionally, the patient's low HDL cholesterol level and high LDL cholesterol level increase the risk of atherosclerosis and cardiac events, which can contribute to pump failure.

Given these factors, the risk of pump failure death is moderate to high in the next few years. However, this risk is lower than the risk of sudden cardiac death, as the patient's LVEF is not critically low, and the patient is currently on an adequate treatment regimen."
40,40,P0068,"Age: 71
Gender: Male 
Weight: 114 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/55 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1243.0
Protein (g/L): 58
T3 (pg/dL): 0,04
T4 (ng/L): 12
TSH (mIU/L): 3,23
Urea (mg/dL): 7,15
LVEF (%): 31.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the patient's age (71), NYHA Class II (indicating mild symptoms), and relatively well-controlled blood pressure (120/55 mmHg), I would rank the patient as having a high likelihood of survival. The patient's ejection fraction (LVEF) is 31.0%, which is significantly reduced, indicating some level of cardiac dysfunction. However, the patient's heart rate is not excessively high, and the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG suggests that the patient's cardiac function is still relatively preserved. Additionally, the patient is taking medications that are commonly used to manage heart failure and arrhythmias, such as digoxin, ACE inhibitors, and loop diuretics. The patient's biomarkers, including pro-BNP and creatinine levels, are not excessively elevated, indicating that the patient's kidney function is relatively preserved. Overall, while the patient has significant cardiac dysfunction, their overall clinical profile suggests that they are likely to survive for the next few years with proper management and monitoring.

2. Sudden cardiac death 
REASONING: 
While the patient's LVEF is significantly reduced, their heart rate is not excessively high, and they are taking medications that are commonly used to manage heart failure and arrhythmias. However, the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG suggests a higher risk of arrhythmic events. Additionally, the patient's elevated pro-BNP levels (1243.0 ng/L) and creatinine levels (80.0 mmol/L) indicate some level of cardiac dysfunction and renal impairment. The patient's age and NYHA Class II symptoms also increase the risk of sudden cardiac death. While the patient's biomarkers are not excessively elevated, the combination of these factors suggests a moderate to high risk of sudden cardiac death.

3. Pump failure death 
REASONING: 
The patient's LVEF is significantly reduced (31.0%), which is a strong indicator of cardiac dysfunction. The patient's elevated pro-BNP levels (1243.0 ng/L) and creatinine levels (80.0 mmol/L) also suggest that the patient's heart is working harder to compensate for its reduced function. The patient's NYHA Class II symptoms indicate that they have some level of heart failure, and their blood pressure is not well-controlled. The patient's elevated LDL cholesterol level (2,61 mmol/L) also increases the risk of cardiovascular events. While the patient is taking medications to manage their heart failure and arrhythmias, their overall clinical profile suggests a high risk of pump failure death. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG also increases the risk of arrhythmic events, which can contribute to pump failure death."
41,41,P0071,"Age: 58
Gender: Male 
Weight: 116 kg
Height: 186 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,12
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 600.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 18
TSH (mIU/L): 1,54
Urea (mg/dL): 6,16
LVEF (%): 32.0
Medications: Amiodarone, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, I would rank the patient as a survivor with a high likelihood of survival over the next few years. Here's the reasoning behind this assessment:

1. The patient has a NYHA Class II heart failure, indicating moderate symptoms, but they are still able to perform daily activities with some limitation. This suggests that the patient's heart is still functional to some extent.

2. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge. However, the patient is already on medications such as Amiodarone, Beta Blockers, and Statins, which are commonly used to manage heart failure and prevent further cardiac events.

3. The patient's LVEF (left ventricular ejection fraction) is 32%, which is lower than the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, the patient is still able to maintain a relatively normal hemoglobin level (159 g/L) and a normal kidney function (creatinine 6.16 mg/dL), which suggests that the patient's kidneys are not severely impaired.

4. The patient's ECG shows no signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are common precursors to sudden cardiac death. The presence of ventricular extrasystoles is a concern, but it is not uncommon in patients with heart failure.

5. The patient's biomarkers, such as Pro-BNP (pro-brain natriuretic peptide) at 600 ng/L, are elevated, indicating some degree of heart stress and strain. However, the patient's renal function and hemoglobin level are relatively preserved.

Given these factors, I believe that the patient is likely to survive over the next few years with close monitoring and management of their heart failure and cardiovascular risk factors. However, it's essential to continue to monitor the patient's condition closely and adjust their treatment plan as needed to minimize the risk of cardiac events."
42,42,P0072,"Age: 72
Gender: Female 
Weight: 54 kg
Height: 138 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,3
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 7,06
Creatinine (mmol/L): 73.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,84
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,65
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 697.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 17
TSH (mIU/L): 2,38
Urea (mg/dL): 4,33
LVEF (%): 68.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient's overall clinical presentation and test results suggest that the patient is at high risk for adverse cardiac events, but the patient's current condition and treatment plan suggest that a survival is still possible. Here's the reasoning behind this ranking:

1. Survivor: The patient is 72 years old, which is a high age for cardiac complications, but the patient's current NYHA Class II heart failure status suggests that the patient is still relatively functional and able to perform daily activities. The patient's LVEF of 68% is also relatively preserved, indicating that the patient's heart is still pumping effectively. The patient's current medications, including an Angiotensin II Receptor Blocker and Loop Diuretics, are standard treatments for heart failure and are likely effective in managing the patient's symptoms. The patient's laboratory results, such as the elevated Pro-BNP levels, indicate some degree of cardiac stress, but the patient's overall laboratory profile is not significantly abnormal. The patient's ECG findings, including the presence of ventricular extrasystoles and non-sustained ventricular tachycardia, suggest some cardiac arrhythmias, but the patient's overall ECG impression is not indicative of an acute cardiac event.

2. Pump failure death: The patient's elevated creatinine level (73.0 mg/dL) suggests some degree of kidney dysfunction, which can be a complication of heart failure. The patient's elevated urea level (4.33 mg/dL) also suggests some degree of renal impairment. Additionally, the patient's LVEF of 68% is slightly below the normal range, indicating some degree of cardiac dysfunction. While the patient is on medications that are likely effective in managing heart failure, the patient's laboratory results and ECG findings suggest that the patient may be at risk for cardiac complications, including pump failure.

3. Sudden cardiac death: The patient's ECG findings, including the presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, suggest a high risk for cardiac arrhythmias. The patient's age, NYHA Class II status, and elevated Pro-BNP levels also increase the risk for sudden cardiac death. However, the patient's current treatment plan and laboratory results suggest that the patient is still relatively stable, and the patient's overall prognosis is less likely to be sudden cardiac death compared to pump failure death."
43,43,P0074,"Age: 65
Gender: Male 
Weight: 73 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 39,1
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2407.0
Protein (g/L): 65,9
T4 (ng/L): 16
TSH (mIU/L): 1,78
Urea (mg/dL): 9,32
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

Based on the provided patient data, the patient is a 65-year-old male with a history of idiopathic dilated cardiomyopathy (DCM), which is a progressive condition that affects the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 25.0%, indicating poor heart function.

The patient's NYHA Class II classification suggests that the patient experiences moderate symptoms of heart failure, such as shortness of breath and fatigue, but is still able to perform daily activities without significant limitations.

The patient's biomarkers, including elevated creatinine levels (95.0 mol/L) and elevated BNP levels (2407.0 ng/L), indicate significant cardiac stress and strain. The patient's high potassium levels (4.3 mEq/L) may also be indicative of cardiac stress and potential arrhythmias.

The patient's ECG findings, including ventricular extrasystoles and polymorphic ventricular extrasystoles, suggest an increased risk of arrhythmias, which can be a precursor to sudden cardiac death.

Given these factors, the patient is at high risk for cardiac events, including sudden cardiac death, pump failure, and arrhythmias. However, the patient is currently on medications that are standard for managing heart failure and arrhythmias, which may help mitigate some of these risks.

While the patient's past medical history and current biomarkers suggest a high risk for cardiac events, the patient's overall condition and the presence of certain medications may contribute to a slightly higher likelihood of survival compared to the other two options. Therefore, I rank the patient as having a high likelihood of survival in the next few years.

The other two prognoses, sudden cardiac death and pump failure, are possible but less likely given the patient's current treatment and medication regimen. Sudden cardiac death is a possible risk, but the patient's medications and current biomarkers do not suggest an immediate, high-risk situation. Pump failure is also a risk, but the patient's current treatment and medication regimen may help manage symptoms and slow disease progression.

In summary, while the patient is at high risk for cardiac events, the combination of current medications, biomarkers, and ECG findings suggest that survival is still the most likely outcome in the next few years."
44,44,P0075,"Age: 54
Gender: Male 
Weight: 82 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 105/74 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44,2
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,18
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 117
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4
LDL (mmol/L): 3,75
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1199.0
Protein (g/L): 76
T4 (ng/L): 11
TSH (mIU/L): 2,93
Urea (mg/dL): 9,65
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a complex medical history of ischemic dilated cardiomyopathy, myocardial infarction, and a significantly reduced left ventricular ejection fraction (LVEF) of 32%. These factors significantly increase the risk of cardiac events. However, the patient is currently on beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for managing heart failure and reducing the risk of further cardiac events.

The patient's current laboratory values, such as the elevated creatinine level (118.0 mmol/L) and high BNP levels (1199.0 ng/L), suggest some degree of cardiac stress and possible heart failure. However, the absence of symptoms and the fact that the patient is currently on medications to manage these conditions suggest that the patient is likely to be stable.

The ECG findings of ventricular extrasystole and TPSV are concerning, but the absence of ventricular tachycardia and non-sustained ventricular tachycardia (CH>10) suggests that the patient is not currently at high risk for sudden cardiac death.

Considering these factors, I predict that the patient is most likely to survive for the next few years. However, close monitoring and regular follow-up appointments will be necessary to assess the patient's condition and adjust the treatment plan as needed.

RANKING: 2. Pump failure death
REASONING:

Pump failure death is a possible outcome due to the patient's reduced LVEF and the presence of heart failure indicators such as elevated creatinine levels and high BNP levels. However, the patient is currently on medications to manage heart failure, which reduces the risk of pump failure.

The patient's past medical history of myocardial infarction and ischemic dilated cardiomyopathy also increases the risk of further cardiac events. However, the patient's current stable condition and the absence of acute symptoms suggest that pump failure is not imminent.

RANKING: 3. Sudden cardiac death
REASONING:

Sudden cardiac death is the least likely outcome in this case. The patient's ECG findings of ventricular extrasystole are concerning, but the absence of ventricular tachycardia and non-sustained ventricular tachycardia (CH>10) suggests that the patient is not at high risk for sudden cardiac death.

Additionally, the patient is on beta blockers, which are effective in reducing the risk of sudden cardiac death in patients with heart failure and ischemic cardiomyopathy. The patient's stable condition and the absence of acute symptoms also reduce the risk of sudden cardiac death.

However, the patient's complex medical history and reduced LVEF make it essential to continue monitoring the patient's condition closely and adjusting the treatment plan as needed to minimize the risk of cardiac events."
45,45,P0076,"Age: 72
Gender: Male 
Weight: 90 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 145/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 180.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5
LDL (mmol/L): 3,47
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 997.0
Protein (g/L): 69,9
T4 (ng/L): 15
TSH (mIU/L): 0,8
Urea (mg/dL): 9,48
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall prognosis can be determined by analyzing the provided data. The patient's age, NYHA Class II, and history of ischemic dilated cardiomyopathy, peripheral vascular disease, hypertension, and myocardial infarction indicate a high risk for cardiovascular events. However, the patient is currently on medications such as Angiotensin II Receptor Blocker, Beta Blockers, and Statins, which are commonly used to manage heart failure, hypertension, and high cholesterol.

The elevated creatinine level (180.0 mmol/L) suggests impaired renal function, which can be a complication of chronic kidney disease and cardiovascular disease. However, the patient's glomerular filtration rate (GFR) is not directly provided. The patient's elevated Pro-BNP level (997.0 ng/L) indicates a high level of B-type natriuretic peptide, which is a marker of heart failure. 

Despite these risk factors, the patient is currently in a stable condition, with no acute symptoms reported. The ECG impression shows ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10), which may indicate an increased risk for arrhythmic events. However, the patient is not currently experiencing any symptoms.

Considering these factors, the patient is likely to survive the next few years, given their stable condition and the presence of current medications. However, close monitoring and follow-up are essential to adjust the treatment plan as needed to minimize the risk of cardiovascular events.

The patient's likelihood of sudden cardiac death is relatively low, given their stable condition and the absence of any acute symptoms. 

The patient's likelihood of pump failure death is moderate, given their history of heart failure and impaired renal function. However, the patient's current medications and stable condition may help mitigate this risk.

Therefore, the most likely prognosis is survivor, followed by pump failure death, and then sudden cardiac death."
46,46,P0077,"Age: 63
Gender: Female 
Weight: 65 kg
Height: 152 cm
NYHA Class: III
Blood Pressure: 105/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,39
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 2093.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,05
Urea (mg/dL): 11,58
LVEF (%): 30.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient has a complex medical history with idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac arrhythmias and sudden cardiac death. However, the patient's current ECG findings do not indicate an immediate life-threatening arrhythmia. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia suggests a high risk of arrhythmias, but the patient is on medications that are effective in managing these conditions. The patient's LVEF is also low at 30%, indicating significant left ventricular dysfunction, but the patient is receiving ACE inhibitors, which can help to improve symptoms and slow disease progression. The patient's biomarkers, such as troponin and creatinine, are also within normal limits, indicating no acute cardiac injury or kidney dysfunction. Overall, while the patient has a high-risk profile, the presence of effective medications and the absence of acute cardiac injury or kidney dysfunction make a sudden cardiac death or pump failure death less likely. Therefore, the patient is more likely to survive for the next few years.

2. Sudden cardiac death 
REASONING: 
While the patient's ECG findings suggest a high risk of arrhythmias, the patient is on medications that are effective in managing these conditions. However, the patient's LVEF is very low at 30%, which is a significant risk factor for sudden cardiac death. Additionally, the patient's NYHA class is III, indicating significant symptoms of heart failure, which can increase the risk of sudden cardiac death. The patient's creatinine level is also elevated at 111.0 mmol/L, which may indicate some degree of kidney dysfunction. While the patient is on medications that can help manage kidney function, the elevated creatinine level is a concern. Overall, while the patient is not at the highest risk, the combination of low LVEF, NYHA class III symptoms, and elevated creatinine level make sudden cardiac death a possible outcome.

3. Pump failure death 
REASONING: 
The patient's LVEF is very low at 30%, which is a significant risk factor for heart failure. The patient's NYHA class is also III, indicating significant symptoms of heart failure. The patient is on medications that can help manage symptoms, but the patient's low LVEF and NYHA class III symptoms suggest that the patient may not be adequately controlled. Additionally, the patient's creatinine level is elevated, which may indicate some degree of kidney dysfunction. While the patient is on medications that can help manage kidney function, the elevated creatinine level is a concern. The patient's biomarkers, such as troponin and creatinine, are also within normal limits, but the patient's low LVEF and NYHA class III symptoms suggest that the patient may be at risk for pump failure. Overall, while the patient is not at the highest risk, the combination of low LVEF, NYHA class III symptoms, and elevated creatinine level make pump failure a possible outcome."
47,47,P0080,"Age: 72
Gender: Male 
Weight: 66 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 38,9
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 49
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,88
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 183.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,11
Urea (mg/dL): 7,57
LVEF (%): 38.0
Medications: Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a poor prognosis for survival. 

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac failure and arrhythmias. The left ventricular ejection fraction (LVEF) is severely impaired at 38%, indicating significant left ventricular dysfunction. This low ejection fraction is a strong predictor of adverse outcomes, including heart failure and arrhythmias.

The patient's elevated creatinine level (103.0 mol/L) and low albumin level (38.9 g/L) suggest impaired renal function, which can be a consequence of heart failure.

The patient's elevated troponin level (0.01 ng/mL) is indicative of myocardial damage, which may be related to the cardiomyopathy. The presence of ventricular extrasystoles on the ECG, specifically polymorphic ventricular extrasystoles, is a concerning sign of arrhythmogenic myocardium.

The patient's elevated BNP level (183 ng/L) further supports the presence of heart failure, as BNP is a biomarker of ventricular stretch and strain.

Considering these factors, the patient's overall clinical picture suggests a high risk of cardiac events, including sudden cardiac death, pump failure, and heart failure. However, the patient's age, weight, and other laboratory values do not indicate any acute life-threatening conditions. Therefore, I rank the patient's prognosis as a survivor, but with a high risk of cardiac events in the short term.

The patient's survival is likely due to the absence of any acute life-threatening conditions and the fact that the patient is already on medications for heart failure (loop diuretics and spironolactone), which may help manage symptoms and slow disease progression. However, close monitoring and regular follow-up are essential to assess the patient's response to treatment and adjust the management plan as needed."
48,48,P0082,"Age: 71
Gender: Male 
Weight: 70 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,66
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 430.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,77
Urea (mg/dL): 7,57
LVEF (%): 24.0
Medications: Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 71-year-old male with a history of idiopathic dilated cardiomyopathy and hypertension. The patient has a NYHA Class II heart failure, indicating moderate symptoms of heart failure. The elevated LVEF (24.0%) suggests significant left ventricular dysfunction. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a significant finding, as it indicates an increased risk of arrhythmic events.

The patient's elevated Pro-BNP levels (430.0 ng/L) and elevated troponin levels (0.01 ng/mL) suggest some degree of cardiac stress and potential myocardial injury. However, the patient's hemoglobin and kidney function appear to be relatively preserved.

The patient is on digoxin and an ACE inhibitor, which is standard treatment for heart failure and hypertension. The patient's electrolytes, including potassium, are within normal limits.

Considering these factors, the patient's overall prognosis is likely to be a survivor. The presence of NSVT on the ECG and the patient's NYHA Class II symptoms suggest a moderate risk of arrhythmic events, but the patient's other clinical parameters, such as hemoglobin, kidney function, and electrolytes, are relatively preserved. Therefore, the patient is more likely to survive in the short-term, with a moderate risk of arrhythmic events and potential for heart failure progression.

While the patient's LVEF is significantly reduced, the patient's overall clinical presentation and the presence of NSVT on the ECG suggest a moderate risk of arrhythmic events, but not an immediate life-threatening risk. The patient's other clinical parameters, including hemoglobin, kidney function, and electrolytes, are relatively preserved, which further supports a survival prognosis."
49,49,P0084,"Age: 75
Gender: Male 
Weight: 83 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 47,19
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 149.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 14,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,59
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,32
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 671.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,04
Urea (mg/dL): 14,69
LVEF (%): 28.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I would rank the patient's prognosis as a survivor with the following reasoning:

1. The patient's NYHA Class II classification indicates that the patient has mild symptoms of heart failure, which suggests that the heart is still functioning to some extent.
2. The patient's LVEF (Left Ventricular Ejection Fraction) of 28.0 is relatively preserved, indicating that the left ventricle is still pumping blood effectively, albeit with some impairment.
3. The patient's troponin level of 0.01 ng/mL is within normal limits, which suggests that there is no significant myocardial damage or necrosis.
4. The absence of ventricular extrasystoles, ventricular tachycardia, and non-sustained ventricular tachycardia on the ECG impression suggests that the patient does not have any significant arrhythmias that could lead to sudden cardiac death.
5. The patient's medication regimen includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are commonly used to manage heart failure and other cardiovascular conditions.

While the patient has a history of idiopathic dilated cardiomyopathy and diabetes, which are risk factors for heart failure and cardiac arrhythmias, the patient's current data suggests that the heart is still functioning relatively well. Therefore, I believe that the patient is likely to survive for the next few years with proper management and monitoring.

RANKING: 2. Sudden Cardiac Death
REASONING: 

Although the patient is not currently at high risk for sudden cardiac death, there are some factors that could potentially increase the risk:

1. The patient's history of idiopathic dilated cardiomyopathy is a risk factor for sudden cardiac death.
2. The patient's low LVEF of 28.0 suggests that the left ventricle is not functioning as well as it should, which could increase the risk for arrhythmias and sudden cardiac death.
3. The patient's elevated creatinine level of 149.0 mmol/L suggests that the kidneys are not functioning as well as they should, which could increase the risk for cardiac complications.

However, the patient's current data does not show any significant arrhythmias or other factors that would increase the risk for sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

Based on the patient's data, I would rank pump failure death as the least likely outcome, but still a possible outcome, especially if the patient's heart function continues to decline.

1. The patient's LVEF of 28.0 is relatively preserved, but it is still below the normal range, which suggests that the left ventricle is not functioning as well as it should.
2. The patient's elevated creatinine level of 149.0 mmol/L suggests that the kidneys are not functioning as well as they should, which could increase the risk for cardiac complications.
3. The patient's elevated albumin level of 47.19 g/L suggests that there may be some fluid overload, which could increase the risk for heart failure.

However, the patient's current data does not show any significant signs of heart failure, and the patient is receiving treatment for heart failure with a regimen of loop diuretics and ACE inhibitors. Therefore, while pump failure is a possible outcome, it is not the most likely outcome based on the current data."
50,50,P0086,"Age: 30
Gender: Male 
Weight: 103 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 50,8
ALT or GPT (IU/L): 191.0
AST or GOT (IU/L): 146.0
Total Cholesterol (mmol/L): 5,97
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 700
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 763.0
Protein (g/L): 80
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,78
Urea (mg/dL): 4,46
LVEF (%): 39.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at high risk for adverse outcomes due to the presence of dilated cardiomyopathy, elevated troponin levels, and a left ventricular ejection fraction (LVEF) of 39%. These factors indicate significant cardiac dysfunction and potential for cardiac ischemia or infarction. The patient's elevated liver enzymes (AST and ALT) also suggest possible liver involvement, which may be related to the cardiomyopathy or other underlying conditions. The presence of ventricular extrasystoles on the ECG impression further increases the risk of arrhythmias, which can be life-threatening. 

Considering these factors, the patient's overall prognosis is most likely to be a survivor, as the data suggests that the patient is currently being managed with evidence-based therapies (beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitor) that are standard of care for patients with heart failure and cardiomyopathy.

The patient's weight and height do not seem to be significantly contributing factors to their prognosis, as the patient is within the normal range for both. The elevated creatinine level may indicate some degree of kidney impairment, but this is not uncommon in patients with heart failure and cardiomyopathy.

While there is a risk of sudden cardiac death, the patient's current management and the lack of other high-risk features (such as a history of myocardial infarction or significant coronary artery disease) make this outcome less likely. Pump failure death is also a possibility, but the patient's current treatment and the fact that they are currently being managed with evidence-based therapies make this outcome less likely as well.

Overall, the patient's current clinical presentation, management, and the absence of other high-risk features make a survivor the most likely outcome."
51,51,P0088,"Age: 62
Gender: Male 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,9
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 720.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,997
Urea (mg/dL): 8,02
LVEF (%): 36.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation, laboratory results, and medical history suggest that the patient is at a higher risk for adverse outcomes. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that can lead to heart failure and arrhythmias. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 36%, indicating significant cardiac dysfunction.

The patient's elevated troponin levels (0.01 ng/mL) may suggest some myocardial damage, but it is not significantly elevated. The absence of sustained ventricular tachycardia or other life-threatening arrhythmias on the ECG is a positive sign.

The patient's medication regimen includes digoxin, loop diuretics, and an ACE inhibitor, which are commonly used to manage heart failure and control blood pressure. The patient's laboratory results show a slightly elevated creatinine level (111.0 mol/L), but this is not uncommon in patients with heart failure.

Considering these factors, the patient is likely to survive for the next few years, although they may require close monitoring and adjustments to their medication regimen to manage their heart failure and prevent further cardiac complications.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's history of idiopathic dilated cardiomyopathy and severely impaired LVEF (36%) increase the risk of sudden cardiac death. However, the patient's ECG results do not show any life-threatening arrhythmias, and the absence of ventricular tachycardia or other significant ECG abnormalities is a positive sign.

The patient's elevated creatinine level (111.0 mol/L) may suggest some degree of renal impairment, which can increase the risk of cardiac complications. However, this is not a significant concern in this patient.

The patient's laboratory results show a slightly elevated troponin level (0.01 ng/mL), which may indicate some myocardial damage, but it is not significantly elevated. The patient's medication regimen includes digoxin, loop diuretics, and an ACE inhibitor, which are commonly used to manage heart failure and control blood pressure.

Considering these factors, while the patient has a higher risk of sudden cardiac death due to their underlying cardiac condition, the absence of life-threatening arrhythmias on the ECG and the presence of a relatively stable laboratory profile suggest that the risk is not extremely high.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's severely impaired LVEF (36%) and history of idiopathic dilated cardiomyopathy increase the risk of pump failure death. The patient's elevated creatinine level (111.0 mol/L) and slightly elevated troponin level (0.01 ng/mL) may suggest some degree of cardiac dysfunction.

The patient's ECG results do not show any life-threatening arrhythmias, which is a positive sign. However, the patient's LVEF is severely impaired, which increases the risk of pump failure.

The patient's medication regimen includes digoxin, loop diuretics, and an ACE inhibitor, which are commonly used to manage heart failure and control blood pressure. However, the patient's laboratory results show a slightly elevated creatinine level and slightly elevated troponin level, which may indicate some degree of cardiac dysfunction.

Considering these factors, the patient is at a higher risk of pump failure death due to their severely impaired LVEF and underlying cardiac condition. However, the patient's relatively stable laboratory profile and absence of life-threatening arrhythmias on the ECG suggest that the risk is not extremely high."
52,52,P0089,"Age: 69
Gender: Male 
Weight: 84 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 100/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,9
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 5
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,03
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 5432.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,55
Urea (mg/dL): 7,8
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, the patient is a 69-year-old male with a history of hypertensive cardiomyopathy, hypertension, and NYHA Class III heart failure. The patient's LVEF is significantly reduced at 18%, indicating severe left ventricular dysfunction. The patient's elevated BNP levels (5432 ng/L) also suggest significant ventricular strain. The patient's ECG shows ventricular extrasystoles, which are a known risk factor for sudden cardiac death. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the likelihood of sudden cardiac death. The patient's current medications, including beta blockers, digoxin, spironolactone, and ACE inhibitors, are standard treatments for heart failure and hypertension. Given the patient's overall condition and treatment plan, the most likely outcome is that the patient will survive, albeit with ongoing management and monitoring for potential complications."
53,53,P0090,"Age: 58
Gender: Female 
Weight: 67 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,88
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1486.0
Protein (g/L): 63
T3 (pg/dL): 0,04
T4 (ng/L): 17
TSH (mIU/L): 1,18
Urea (mg/dL): 10,98
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient's overall clinical presentation and laboratory results suggest that the patient is at high risk for adverse cardiac events, but the presence of a significant number of medications and the patient's NYHA Class II heart failure status indicate that they are being adequately managed. The elevated Pro-BNP levels (1486.0 ng/L) suggest a significant burden of heart failure, but the patient's LVEF is 20.0%, which is relatively preserved. The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole on the ECG is concerning, but it is not a new finding and has been present for some time. The patient's electrolyte levels, kidney function, and liver function are also relatively preserved. The patient's weight and height are within a normal range, and their hemoglobin and potassium levels are within normal limits.

Given these factors, the patient's overall prognosis is more favorable than a sudden cardiac death or pump failure. The patient's heart failure status is being managed with multiple medications, and their LVEF is not severely depressed. While the patient has a history of idiopathic dilated cardiomyopathy, the presence of multiple medications and the patient's relatively preserved LVEF suggest that the condition is being managed effectively.

2. Sudden cardiac death
REASONING:
While the patient has a history of idiopathic dilated cardiomyopathy, which increases their risk for sudden cardiac death, the patient's LVEF is 20.0%, and they are receiving multiple medications for heart failure. The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole on the ECG is concerning, but it is not a new finding. The patient's electrolyte levels, kidney function, and liver function are relatively preserved. However, the patient's elevated Pro-BNP levels (1486.0 ng/L) and NYHA Class II heart failure status suggest that the patient's heart failure is not well-controlled.

Given these factors, the patient's prognosis is less favorable than a survivor, but still relatively favorable. The patient's heart failure status is being managed with multiple medications, and their LVEF is not severely depressed.

3. Pump failure death
REASONING:
The patient's NYHA Class II heart failure status and elevated Pro-BNP levels (1486.0 ng/L) suggest that the patient's heart failure is not well-controlled. The patient's LVEF is 20.0%, which is relatively preserved, but the patient's elevated creatinine level (97.0 mmol/L) suggests that the patient's kidney function is compromised. The patient's elevated total cholesterol level (5.59 mmol/L) also increases their risk for cardiovascular events. The patient's heart failure status is being managed with multiple medications, but the patient's LVEF is not severely depressed, and the patient's electrolyte levels, kidney function, and liver function are relatively preserved.

Given these factors, the patient's prognosis is less favorable than a survivor, but more favorable than sudden cardiac death. The patient's heart failure status is being managed with multiple medications, and their LVEF is not severely depressed, but the patient's kidney function is compromised, and the patient's heart failure is not well-controlled."
54,54,P0091,"Age: 53
Gender: Male 
Weight: 105 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,88
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 24.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,26
Urea (mg/dL): 6,16
LVEF (%): 36.0
Medications: Calcium Channel Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 53-year-old male with a history of hypertensive cardiomyopathy and hypertension. He has a left ventricular ejection fraction (LVEF) of 36.0%, which is significantly reduced, indicating systolic dysfunction. The patient's blood pressure is well-controlled with medications, and his NYHA class is II, indicating mild symptoms. 

However, the patient's elevated creatinine level (80.0 mmol/L) suggests impaired renal function, which is a risk factor for cardiac complications. The patient's troponin level (0.02 ng/mL) is within normal limits, which suggests that there is no significant myocardial infarction or acute cardiac injury.

The patient's ECG findings, including ventricular extrasystoles, do not indicate any life-threatening arrhythmias. The absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

Considering these factors, the patient's overall prognosis is favorable, and he is likely to survive for the next few years with proper management of his hypertension and cardiac conditions."
55,55,P0092,"Age: 50
Gender: Female 
Weight: 108 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 88
Glucose (mmol/L): 19,7
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,96
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 350.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 4,3
Urea (mg/dL): 9,15
LVEF (%): 27.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 50-year-old female with a history of hypertension, cardiomyopathy, diabetes, and dyslipidemia. The patient's NYHA Class II indicates mild symptoms of heart failure, and the patient's LVEF is significantly reduced at 27%. The patient's elevated Pro-BNP levels (350 ng/L) suggest a high level of ventricular strain, indicating heart failure. 

The patient's medication regimen includes ACE inhibitors, beta blockers, digoxin, loop diuretics, spironolactone, and diabetes medication, which are standard treatments for managing heart failure and hypertension. However, the patient's current medication regimen does not appear to be optimized for her specific needs, as there is no mention of an angiotensin receptor blocker (ARB) or a mineralocorticoid receptor antagonist (MRA), which are often recommended for patients with heart failure.

The patient's ECG results show ventricular extrasystole, which is a sign of abnormal heart rhythm, but no ventricular tachycardia or bradycardia. The absence of ventricular tachycardia or bradycardia may suggest that the patient's heart is not in imminent danger of sudden cardiac death.

Considering these factors, the patient's overall prognosis is most likely to be a survivor, as the patient is already experiencing symptoms of heart failure and has a reduced LVEF, but there is no immediate indication of acute cardiac events such as ventricular tachycardia or sudden cardiac death.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's high risk of sudden cardiac death is increased due to her history of hypertension, cardiomyopathy, and elevated Pro-BNP levels, which suggest a high level of ventricular strain. The patient's reduced LVEF (27%) and NYHA Class II symptoms also indicate a high risk of heart failure. However, the patient's current medication regimen does not appear to be optimized for her specific needs, which may increase the risk of adverse outcomes.

Additionally, the patient's elevated Troponin levels (0.02 ng/mL) may indicate some degree of myocardial damage, which could increase the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

While the patient's reduced LVEF (27%) and NYHA Class II symptoms suggest a high risk of heart failure, the patient's current medication regimen and the absence of ventricular tachycardia or bradycardia on the ECG suggest that the patient is not at immediate risk of sudden cardiac death. However, the patient's elevated Pro-BNP levels and reduced LVEF indicate a high risk of heart failure, which could lead to pump failure if not properly managed.

Given the patient's elevated Pro-BNP levels and reduced LVEF, it is possible that the patient may experience pump failure in the near future, but this is not the most likely outcome given the patient's current clinical status and medication regimen."
56,56,P0093,"Age: 40
Gender: Female 
Weight: 67 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 38
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,52
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 152.0
Protein (g/L): 65
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,23
Urea (mg/dL): 4,49
LVEF (%): 60.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 

The patient's age (40) and NYHA Class II (mild symptoms) suggest that the patient is relatively young and has a relatively preserved cardiac function. The presence of idiopathic dilated cardiomyopathy (IDC) indicates a chronic condition, but the patient is still in an early stage of the disease. The patient's ejection fraction (LVEF) of 60.0 is within the normal range for a person of this age, indicating that the heart is still functioning relatively well.

The patient's laboratory results show mild elevation of liver enzymes (ALT and AST) and slightly elevated creatinine levels, which may indicate some degree of liver and kidney impairment. However, these results are not excessively high and are not indicative of severe organ dysfunction.

The patient's electrolyte levels are relatively balanced, with normal potassium and sodium levels. The presence of low T3 and T4 levels may indicate some degree of thyroid dysfunction, but this is not uncommon in patients with IDC.

The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, and ACE inhibitors, which are commonly used to manage symptoms and slow the progression of IDC.

The ECG results show no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all potential predictors of adverse outcomes. The presence of ventricular extrasystole (a type of irregular heartbeat) is noted, but it is not a contraindication for survival.

Considering these factors, I predict that the patient is likely to survive for at least 5 years, with a reasonable quality of life. The patient's mild symptoms, relatively preserved cardiac function, and balanced laboratory results make them a candidate for long-term survival."
57,57,P0094,"Age: 31
Gender: Male 
Weight: 79 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 105/60 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,51
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 951.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,79
Urea (mg/dL): 5,16
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and laboratory results indicate a high likelihood of survival. The patient is relatively young (31 years old) and has a NYHA Class II heart failure, which suggests that the heart failure is not severe. The patient's ejection fraction (LVEF) is 35%, which is significantly reduced, but not critically low. The patient's blood pressure is within a relatively normal range, and their electrolyte and liver function tests are within normal limits. The patient's troponin level is also normal, which suggests that there is no significant myocardial damage.

The patient's medication regimen includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure. The absence of ventricular extrasystoles, ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient does not have any life-threatening arrhythmias.

The patient's Pro-BNP level is elevated at 951 ng/L, which is consistent with heart failure. However, the patient's symptoms and clinical presentation do not suggest any acute decompensation or severe symptoms that would indicate a poor prognosis. Overall, based on the patient's clinical presentation and laboratory results, the most likely outcome is survival.

While the patient has a history of myocardial infarction and dilated cardiomyopathy, these conditions do not appear to be acutely affecting the patient's current clinical status. The patient's cardiac function is being managed with medication, and the patient's symptoms and laboratory results do not indicate any immediate life-threatening complications. Therefore, the patient is most likely to survive in the short term."
58,58,P0095,"Age: 50
Gender: Female 
Weight: 77 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,1
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 40.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,27
Urea (mg/dL): 6,49
LVEF (%): 50.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's data, the patient is likely to be a survivor for several reasons. Firstly, the patient's age (50) is not considered old, and the patient's NYHA Class III indicates that they have a moderate level of heart failure, but it's not the most severe. The patient's LVEF is 50.0%, which is a relatively preserved ejection fraction, indicating that the patient's heart is still pumping effectively, albeit with some impairment.

The patient's electrolytes, liver enzymes, and kidney function are within relatively normal limits, which suggests that there are no acute or chronic conditions that would necessitate immediate intervention. The patient's medications, loop diuretics and ACE inhibitor, are commonly used to manage heart failure and hypertension, which further supports the likelihood of a favorable outcome.

The patient's ECG results show ventricular extrasystole, which is a common finding in patients with heart failure, but it is not indicative of a life-threatening arrhythmia. The absence of ventricular tachycardia or non-sustained ventricular tachycardia also reduces the risk of sudden cardiac death.

Overall, considering these factors, the patient's prognosis is likely to be a survivor, with the possibility of some improvement with optimal management of their heart failure and hypertension.

2. Sudden cardiac death
REASONING: 
While the patient's prognosis is still favorable, there are some factors that could potentially increase the risk of sudden cardiac death. The patient's NYHA Class III indicates that they have a moderate level of heart failure, which can increase the risk of arrhythmias and sudden cardiac death. The patient's LVEF is 50.0%, which is lower than the normal range, indicating some impairment in cardiac function.

The patient's ECG results show ventricular extrasystole, which, although not life-threatening, can be a precursor to more serious arrhythmias. The absence of ventricular tachycardia or non-sustained ventricular tachycardia does not rule out the possibility of sudden cardiac death, as ventricular tachycardia can occur without prior warning.

Additionally, the patient's low T3 level (0.05 pg/dL) and high creatinine level (71.0 mmol/L) could indicate some underlying metabolic or renal impairment, which can contribute to an increased risk of cardiac arrhythmias and sudden cardiac death.

3. Pump failure death
REASONING: 
Based on the patient's data, pump failure death is the least likely outcome. The patient's LVEF is 50.0%, which, although lower than the normal range, is not severely impaired. The patient's NYHA Class III indicates that they have a moderate level of heart failure, but it's not the most severe.

The patient's medications, loop diuretics and ACE inhibitor, are commonly used to manage heart failure and hypertension, which suggests that the patient is receiving appropriate treatment. The patient's electrolytes, liver enzymes, and kidney function are within relatively normal limits, which reduces the risk of acute or chronic complications.

The patient's ECG results show ventricular extrasystole, but it is not indicative of a life-threatening arrhythmia. The absence of ventricular tachycardia or non-sustained ventricular tachycardia further reduces the risk of sudden cardiac death. Overall, while the patient has some cardiac impairment, the data suggests that they are likely to be able to manage their heart failure with optimal treatment, reducing the risk of pump failure death."
59,59,P0096,"Age: 68
Gender: Male 
Weight: 71 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 675.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,16
TSH (mIU/L): 3,73
Urea (mg/dL): 12,15
LVEF (%): 31.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

The patient is 68 years old with a history of hypertensive cardiomyopathy, hypertension, and a left ventricular ejection fraction (LVEF) of 31%, which is significantly reduced, indicating left ventricular dysfunction. The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole on the ECG impression suggests that the patient has underlying arrhythmia. However, the patient is taking medications for hypertension and heart failure (Angiotensin II Receptor Blocker, Loop Diuretics, and Spironolactone), which may help manage symptoms and slow disease progression. The patient's laboratory results show elevated creatinine levels, which indicate impaired kidney function, but the patient's hemoglobin and potassium levels are within a relatively normal range. The patient's troponin level is within normal limits, which suggests that there is no significant myocardial infarction. Overall, considering the patient's age, comorbidities, and the presence of arrhythmia, the patient is likely to survive for the next few years with proper management and monitoring.

RANKING: 2. Sudden cardiac death 
REASONING: 

The patient's history of hypertensive cardiomyopathy, hypertension, and reduced LVEF increase the risk of sudden cardiac death. The presence of NSVT and ventricular extrasystole on the ECG impression further increases the risk of arrhythmia-related complications. Although the patient is taking medications for hypertension and heart failure, the risk of sudden cardiac death remains a concern, especially given the patient's age and underlying heart disease. However, the patient's survival prognosis is still higher than sudden cardiac death due to the presence of medications and relatively normal laboratory results.

RANKING: 3. Pump failure death 
REASONING: 

The patient's reduced LVEF (31%) and elevated creatinine levels indicate left ventricular dysfunction and impaired kidney function, which increases the risk of pump failure. However, the patient is taking medications that may help manage symptoms and slow disease progression. The patient's troponin level is within normal limits, which suggests that there is no significant myocardial infarction. While pump failure is a possible outcome, it is less likely than sudden cardiac death due to the patient's relatively normal laboratory results and the presence of medications that may help manage heart failure symptoms."
60,60,P0097,"Age: 68
Gender: Female 
Weight: 78 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 5
LDL (mmol/L): 2,59
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1284.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,53
Urea (mg/dL): 7,49
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, hypertension, and elevated left ventricular ejection fraction (LVEF) of 35%, the patient's overall prognosis is guarded but not immediately fatal. The patient's elevated creatinine level (88.0 mmol/L) and elevated troponin level (0.03 ng/mL) suggest some degree of cardiac dysfunction, but the patient is not currently experiencing acute coronary syndrome or heart failure. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on ECG is concerning, but the patient is not experiencing sustained VT. The patient's medication regimen includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and arrhythmias. The patient's hemoglobin and kidney function are within relatively normal limits. Therefore, the patient's overall prognosis is that they will survive, albeit with careful monitoring and management of their cardiac conditions.

2. Pump failure death
REASONING: 
While the patient's LVEF is elevated, the patient's overall cardiac function is compromised due to the presence of idiopathic dilated cardiomyopathy. The patient's elevated creatinine level and elevated troponin level suggest some degree of cardiac dysfunction, which could lead to heart failure. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on ECG increases the risk of cardiac arrhythmias, which can lead to cardiac arrest. The patient's NYHA Class II classification indicates some degree of heart failure symptoms, which could worsen over time. Therefore, while the patient is not currently experiencing acute cardiac events, the patient's underlying cardiac conditions increase the risk of pump failure and death.

3. Sudden cardiac death
REASONING: 
The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which increase the risk of sudden cardiac death. The patient's elevated troponin level and elevated creatinine level suggest some degree of cardiac dysfunction, which can increase the risk of sudden cardiac death. The patient's NYHA Class II classification indicates some degree of heart failure symptoms, which can increase the risk of sudden cardiac death. However, the patient is currently not experiencing acute cardiac events, and their medication regimen includes beta blockers, which are known to reduce the risk of sudden cardiac death. Therefore, while the patient's cardiac conditions increase the risk of sudden cardiac death, the patient's overall prognosis is less likely to be sudden cardiac death compared to pump failure death."
61,61,P0098,"Age: 56
Gender: Female 
Weight: 60 kg
Height: 140 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 66.0
AST or GOT (IU/L): 66.0
Total Cholesterol (mmol/L): 5,64
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 5,2
LDL (mmol/L): 3,96
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2081.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 19
TSH (mIU/L): 5,52
Urea (mg/dL): 4,99
LVEF (%): 38.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is a 56-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension. Her NYHA Class III indicates severe heart failure symptoms, and her LVEF of 38.0% is significantly reduced, indicating poor heart function. However, she is not currently experiencing ventricular tachycardia or ventricular extrasystoles, and her ECG impression does not suggest any life-threatening arrhythmias. Her current medications, including ACE inhibitors and beta blockers, are standard treatments for heart failure and hypertension. Her elevated Pro-BNP levels (2081.0 ng/L) and elevated creatinine (4.99 mg/dL) levels indicate significant heart failure and kidney dysfunction. Despite these factors, the patient is currently not experiencing any acute symptoms of heart failure or sudden cardiac death, which increases the likelihood of survival. 

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of idiopathic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension increases her risk of sudden cardiac death. Her reduced LVEF of 38.0% and elevated Pro-BNP levels (2081.0 ng/L) suggest poor heart function, which can increase the risk of sudden cardiac death. However, the absence of ventricular tachycardia or ventricular extrasystoles on the ECG impression reduces the likelihood of sudden cardiac death. Additionally, the patient is taking medications that are standard treatments for heart failure and hypertension, which may help reduce the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: Pump failure death is a possible outcome for patients with severe heart failure, but it is less likely in this case. The patient's current medications, including ACE inhibitors and beta blockers, are standard treatments for heart failure, and her elevated Pro-BNP levels (2081.0 ng/L) suggest that her heart is working to compensate for the reduced LVEF. While her kidney dysfunction (creatinine 4.99 mg/dL) may increase her risk of pump failure, the absence of symptoms of heart failure and the presence of beta blockers, which help reduce the heart's workload, reduces this risk."
62,62,P0100,"Age: 68
Gender: Female 
Weight: 70 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 47,1
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,76
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 6,01
LVEF (%): 27.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1

REASONING: 

Based on the patient's data, I would rank the three possible prognoses as follows: 

1. Survivor: The patient's NYHA Class II indicates that the patient has some symptoms of heart failure, but the class is not severe enough to classify as Class III or IV. The patient's LVEF is 27%, which is significantly reduced, indicating a significant impairment in cardiac function. However, the patient's age, weight, and other laboratory values do not suggest any acute or severe cardiac conditions that would necessitate an immediate cardiac death or sudden cardiac death. The patient is also taking multiple medications, including digoxin, which is commonly used to treat heart failure. The patient's ECG findings indicate a history of ventricular extrasystole and non-sustained ventricular tachycardia, but these are not indicative of a high risk of sudden cardiac death.

2. Sudden cardiac death: Given the patient's history of ischemic dilated cardiomyopathy, the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG, and the reduced LVEF, there is a moderate risk of sudden cardiac death. However, the patient's age, weight, and other laboratory values do not suggest a high risk of sudden cardiac death.

3. Pump failure death: While the patient's reduced LVEF and NYHA Class II indicate a significant impairment in cardiac function, the patient is currently taking multiple medications to manage heart failure and has a relatively stable laboratory profile. The patient's ECG findings do not indicate any acute or severe cardiac conditions that would necessitate immediate pump failure death. Therefore, I would rank pump failure death as the least likely of the three possible prognoses.

It is essential to note that the patient's prognosis is subject to change based on ongoing monitoring and further evaluation. Regular follow-up appointments and close monitoring of the patient's cardiac function and ECG findings are crucial to adjust the treatment plan and mitigate any potential risks."
63,63,P0101,"Age: 56
Gender: Male 
Weight: 72 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,74
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3566.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 0,904
Urea (mg/dL): 6,32
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's data suggests that they are at high risk for adverse cardiac events, but the presence of idiopathic dilated cardiomyopathy (IDC) is a significant concern. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 17%, which indicates that the heart is not pumping efficiently. The elevated creatinine level (106.0 mmol/L) also suggests some degree of kidney dysfunction, which can be a complication of advanced heart failure.

The patient's Pro-BNP level is elevated at 3566.0 ng/L, which is a strong indicator of heart failure. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is also a concern, as it can be a precursor to more serious arrhythmias.

However, the patient is currently on beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and may help slow disease progression. The patient's blood pressure is relatively well-controlled at 110/50 mmHg.

Given the severity of the patient's symptoms and the presence of significant comorbidities, I would rank the patient's prognosis as a survivor. The patient's NYHA class is II, indicating some limitations in physical activity, but the patient is not currently experiencing severe symptoms.

RANKING: 2. Sudden Cardiac Death
REASONING:

While the patient is at risk for adverse cardiac events, the likelihood of sudden cardiac death (SCD) is not as high as it would be if the patient had a different set of risk factors. The patient's ECG findings, including the presence of NSVT, do suggest an increased risk for arrhythmias, but the patient is currently on medications that may help manage these risks.

Additionally, the patient's LVEF is not as severely impaired as it would be in a patient with a higher NYHA class or more advanced heart failure. The patient's blood pressure is also relatively well-controlled, which reduces the risk of sudden death from arrhythmias or other cardiac causes.

RANKING: 3. Pump Failure Death
REASONING:

Pump failure death is a possible outcome for this patient, but it is the least likely of the three options. The patient's LVEF is severely impaired, and the patient is currently on medications that may help manage symptoms of heart failure.

However, the patient's overall clinical presentation and laboratory results do not suggest an acute or severe decline in cardiac function. The patient's creatinine level is elevated, but it is not indicative of acute kidney injury or failure. The patient's blood pressure is well-controlled, and the patient is not experiencing severe symptoms.

While pump failure is a possible outcome, it is less likely than sudden cardiac death or survivorship given the patient's current clinical status and treatment regimen."
64,64,P0102,"Age: 63
Gender: Male 
Weight: 102 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 128.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5,3
LDL (mmol/L): 2,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 346.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,34
Urea (mg/dL): 6,99
LVEF (%): 43.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient has several risk factors that increase the likelihood of a poor outcome, such as ischemic dilated cardiomyopathy, hypertension, diabetes, and a history of myocardial infarction. However, the patient is currently on multiple medications, including ACE inhibitors and beta blockers, which are known to improve outcomes in patients with heart failure. The patient's NYHA class is II, indicating mild symptoms, which is a relatively favorable classification. The patient's ECG findings, such as ventricular extrasystoles and non-sustained ventricular tachycardia, suggest some level of cardiac dysfunction. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the likelihood of sudden cardiac death. The patient's biomarkers, such as troponin and creatinine, indicate some level of cardiac and renal dysfunction. 

The patient's low LVEF of 43% suggests significant left ventricular dysfunction, but the patient's current symptoms and medications suggest that the patient is currently being managed effectively. Overall, while the patient has several risk factors, the combination of medications and relatively mild symptoms suggest that the patient is likely to survive the next few years, provided that the current management plan is continued.

2. Sudden Cardiac Death
REASONING:
The patient's ECG findings, particularly the presence of ventricular extrasystoles and non-sustained ventricular tachycardia, increase the risk of sudden cardiac death. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy also increase this risk. The patient's low LVEF of 43% further increases the risk of sudden cardiac death. Additionally, the patient's age and weight may also contribute to this risk. However, the patient's current medications and relatively mild symptoms suggest that the risk of sudden cardiac death is not extremely high.

3. Pump Failure Death
REASONING:
The patient's LVEF of 43% suggests significant left ventricular dysfunction, which increases the risk of pump failure. The patient's history of ischemic dilated cardiomyopathy and diabetes also increases this risk. However, the patient's current medications, including ACE inhibitors and beta blockers, are likely to slow the progression of heart failure and reduce the risk of pump failure. The patient's relatively mild symptoms and the fact that they are currently being managed effectively suggest that the risk of pump failure is not extremely high."
65,65,P0103,"Age: 50
Gender: Male 
Weight: 81 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 526.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,05
Urea (mg/dL): 8,49
LVEF (%): 24.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient is a 50-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction. His current NYHA Class II indicates moderate symptoms of heart failure, and his LVEF of 24.0 suggests significant left ventricular dysfunction. 

Despite the presence of ventricular extrasystole, non-sustained VT, and elevated BNP levels, which indicate cardiac stress and strain, the patient's overall clinical presentation and laboratory results do not suggest an acute or severe cardiac event. His blood pressure is relatively stable at 100/60 mmHg, and his medication regimen includes beta blockers, statins, and an ACE inhibitor, which are commonly used to manage heart failure and reduce cardiovascular risk.

The patient's low hemoglobin level (144.0 g/L) and high creatinine level (8.49 mg/dL) may indicate anemia and kidney dysfunction, but these findings are not uncommon in patients with chronic kidney disease and heart failure. The presence of proteinuria (albumin 43 g/L) also suggests kidney impairment, which can be a comorbidity in patients with heart failure.

Given the patient's age, comorbidities, and current clinical status, the most likely outcome is that the patient will survive the next few years. However, it is essential to closely monitor the patient's condition and adjust his treatment plan as needed to minimize the risk of adverse cardiac events.

The other two prognoses, sudden cardiac death and pump failure death, are less likely in this scenario. Sudden cardiac death is more commonly seen in patients with acute or severe cardiac events, which are not present in this case. Pump failure death is a concern, but the patient's current medication regimen and clinical status suggest that his heart failure symptoms are being managed effectively."
66,66,P0104,"Age: 51
Gender: Male 
Weight: 75 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,6
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,5
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 405.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,63
Urea (mg/dL): 8,65
LVEF (%): 31.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is a 51-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia. Despite having a significant history of heart disease, the patient's current ECG impression does not indicate any acute arrhythmias or signs of cardiac ischemia. The presence of ventricular extrasystoles (VE) on the ECG is a relatively common finding in patients with heart failure, particularly those with cardiomyopathy. However, the absence of any other significant ECG abnormalities or symptoms suggests that the patient's heart is not currently in a life-threatening arrhythmia.

The patient's hemodynamic status, as indicated by the NYHA Class II classification, suggests that they are experiencing some symptoms of heart failure, but not severe enough to limit their daily activities. The patient's blood tests, including the elevated creatinine and urea levels, also suggest some degree of renal impairment, which is common in patients with heart failure.

The patient's medication regimen includes beta blockers, which are known to improve survival in patients with heart failure. The presence of ACE inhibitors, which are also commonly used in patients with heart failure, further supports the notion that the patient is receiving appropriate treatment.

Given the patient's overall clinical presentation and treatment, the likelihood of a sudden cardiac death is relatively low. The patient's LVEF is significantly reduced, indicating poor cardiac function, but the absence of any acute arrhythmias or other life-threatening conditions on the ECG suggests that the patient is not at high risk for sudden cardiac death.

Therefore, based on the available information, the most likely outcome for this patient over the next few years is a survivor.

2. Pump failure death
REASONING:
The patient's LVEF is significantly reduced, indicating poor cardiac function, and the patient has a history of heart failure. The presence of elevated creatinine and urea levels suggests some degree of renal impairment, which can be a complication of heart failure. The patient's NYHA Class II classification also suggests that they are experiencing some symptoms of heart failure.

While the patient's current ECG impression does not indicate any acute arrhythmias or signs of cardiac ischemia, the patient's LVEF is still significantly reduced, indicating that the patient's heart is not functioning optimally. The presence of ventricular extrasystoles on the ECG may indicate some degree of cardiac stress or strain, which can be a sign of heart failure.

Given the patient's overall clinical presentation and history, there is a moderate risk of pump failure death over the next few years. The patient's treatment regimen includes beta blockers and ACE inhibitors, which can help to improve cardiac function, but the patient's LVEF is still significantly reduced, indicating that the patient is at risk for pump failure.

3. Sudden cardiac death
REASONING:
The patient's ECG impression does not indicate any acute arrhythmias or signs of cardiac ischemia, which reduces the likelihood of sudden cardiac death. The patient's LVEF is significantly reduced, indicating poor cardiac function, but the absence of any acute arrhythmias or other life-threatening conditions on the ECG suggests that the patient is not at high risk for sudden cardiac death.

However, the patient's history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia increases the risk of sudden cardiac death. The patient's elevated troponin level, which is a marker of cardiac damage, also suggests that the patient may have some degree of cardiac stress or strain.

While the patient's overall clinical presentation and treatment regimen suggest that the patient is not at high risk for sudden cardiac death, there is still some risk present due to the patient's history of heart disease and elevated troponin level. However, the risk is relatively low compared to the other two options."
67,67,P0105,"Age: 75
Gender: Female 
Weight: 77 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 130/88 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 11,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,51
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2176.0
Protein (g/L): 71
T4 (ng/L): 16
TSH (mIU/L): 1,48
Urea (mg/dL): 10,82
LVEF (%): 39.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor 
REASONING: The patient's age, NYHA Class II heart failure, and elevated Pro-BNP levels indicate a moderate to severe level of heart failure. However, the patient's LVEF of 39% suggests that the heart is still pumping, albeit inefficiently. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia on ECG also raise concerns about arrhythmias, which can be managed with the current medications. 

The patient's comorbidities, including diabetes, hypertension, and ischemic dilated cardiomyopathy, contribute to the overall risk of adverse outcomes. However, the patient's relatively stable vital signs, normal hemoglobin levels, and absence of severe hypotension or acute kidney injury suggest that the patient is currently tolerating their treatment and medications well.

The patient's low HDL and slightly elevated creatinine levels also raise concerns about cardiovascular and renal risks, but the presence of spironolactone and the absence of severe electrolyte imbalances mitigate these risks. Overall, the patient's current status and response to medications suggest a moderate risk of adverse outcomes, making survival a more likely outcome compared to sudden cardiac death or pump failure."
68,68,P0106,"Age: 56
Gender: Female 
Weight: 55 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,16
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74,9
T4 (ng/L): 15
TSH (mIU/L): 0,65
Urea (mg/dL): 6,99
LVEF (%): 26.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, the patient is already at a higher risk for cardiac complications. However, the patient's current medication regimen, which includes a diuretic, spironolactone, and an ACE inhibitor, is standard treatment for heart failure and cardiomyopathy. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG is concerning, but it is not indicative of a life-threatening arrhythmia. The patient's elevated Pro-BNP levels (1160.0 ng/L) suggest some degree of heart failure. Despite these factors, the patient's hemoglobin level (127.0 g/L) and other laboratory values are within normal limits, which indicates that the patient is not severely malnourished or anemic. The patient's overall condition appears to be stable, and with proper management, it is likely that the patient will survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's ECG shows signs of ventricular arrhythmias, the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles is not indicative of a life-threatening arrhythmia. However, the patient's NYHA Class II and idiopathic dilated cardiomyopathy increase the risk of sudden cardiac death. The patient's elevated Pro-BNP levels and NSVT could potentially lead to a more severe arrhythmia, but the patient's overall condition does not appear to be deteriorating rapidly. Therefore, while there is a risk of sudden cardiac death, it is not the most likely outcome.

RANKING: 3. Pump failure death
REASONING: 
The patient's NYHA Class II and elevated Pro-BNP levels (1160.0 ng/L) suggest some degree of heart failure. The patient's LVEF (26.0%) is significantly reduced, indicating poor cardiac function. The patient's elevated creatinine level (6.99 mg/dL) and urea level (6.99 mg/dL) may indicate some degree of renal impairment, which can be a complication of heart failure. The patient's elevated total cholesterol level (6.41 mmol/L) also increases the risk of cardiovascular events. Given these factors, it is possible that the patient's heart failure could progress to pump failure, but this outcome is less likely than sudden cardiac death given the patient's stable condition and the presence of a functioning medication regimen."
69,69,P0110,"Age: 67
Gender: Female 
Weight: 69 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 98/52 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 41
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5
LDL (mmol/L): 2,43
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 125.0
Protein (g/L): 71
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,72
Urea (mg/dL): 8,32
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the patient's data, I believe the most likely outcome is survivor. The patient's NYHA Class is II, indicating mild symptoms, and they are on medications for diabetes and heart failure (Beta Blockers, Spironolactone, and ACE Inhibitor), which suggests that they are receiving standard management for their condition. The patient's LVEF is 30.0, which is significantly reduced, but not in the range typically associated with severe heart failure. The absence of significant electrolyte imbalances, anemia, or acute kidney injury reduces the risk of complications. The patient's ECG impression does not show any arrhythmias that would increase the risk of sudden cardiac death.

2. Sudden cardiac death
REASONING: 
The patient's LVEF is significantly reduced, which increases the risk of arrhythmias and sudden cardiac death. However, the patient is not on any medications specifically indicated for arrhythmia management, and the ECG impression does not show any arrhythmias that would increase the risk of sudden cardiac death. The patient's age and NYHA Class II suggest that they are not at the highest risk for sudden cardiac death.

3. Pump failure death
REASONING: 
The patient's LVEF is significantly reduced, indicating poor cardiac function. However, the patient is on medications for heart failure, which suggests that they are receiving standard management for their condition. The patient's NYHA Class II indicates that they are experiencing mild symptoms, which reduces the risk of pump failure. Additionally, the patient's creatinine level is not significantly elevated, which suggests that they do not have acute kidney injury. Overall, while the patient's LVEF is a concern, the presence of medications for heart failure and mild symptoms suggest that pump failure death is less likely than sudden cardiac death."
70,70,P0111,"Age: 60
Gender: Male 
Weight: 85 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 115/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,09
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 349.0
Protein (g/L): 76
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,19
Urea (mg/dL): 7,49
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the patient's data, the patient is a 60-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipidemia. The patient's current NYHA class is II, indicating mild symptoms of heart failure. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 25%, indicating severe systolic dysfunction.

The patient's biomarkers, including troponin (0.01 ng/mL), are within normal limits, which suggests that there is no acute myocardial injury. The patient's BNP (349 ng/L) is elevated, which is consistent with heart failure. However, the patient is on medications for heart failure (beta blockers and ACE inhibitors), which are likely contributing to the reduced LVEF.

The patient's lipid profile is also concerning, with high total cholesterol (3.49 mmol/L) and LDL (2.09 mmol/L) levels, which increases the risk of cardiovascular events. However, the patient is on statins, which should help to reduce these levels.

The patient's creatinine level (97 mol/L) is elevated, indicating some degree of renal impairment. However, this is not uncommon in patients with heart failure and is likely related to the underlying cardiac disease rather than a primary renal issue.

The ECG results show ventricular extrasystole (monomorphic), which is a concerning sign, but the patient is not experiencing any ventricular tachycardia or other arrhythmias. The patient's TSH (1.19 mIU/L) is within normal limits, and the patient is not experiencing any symptoms of hypothyroidism.

Overall, the patient's prognosis is guarded but not hopeless. The patient's heart failure symptoms are mild, and the patient is on medications that are likely to help manage the condition. With close monitoring and adjustments to the treatment plan, it is possible for the patient to survive for several years. However, the patient's cardiac disease is significant, and there is a risk of worsening heart failure or cardiac arrhythmias.

RANKING: 2. Sudden Cardiac Death
REASONING: 
Based on the patient's data, there is a moderate risk of sudden cardiac death. The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and ventricular extrasystole (monomorphic), which are all risk factors for sudden cardiac death. The patient's LVEF is severely reduced, which increases the risk of sudden cardiac death.

The patient's ECG results show ventricular extrasystole (monomorphic), which is a concerning sign. While the patient is not experiencing any ventricular tachycardia or other arrhythmias, the presence of ventricular extrasystoles increases the risk of sudden cardiac death.

The patient's lipid profile is also concerning, with high total cholesterol (3.49 mmol/L) and LDL (2.09 mmol/L) levels, which increases the risk of cardiovascular events. However, the patient is on statins, which should help to reduce these levels.

The patient's renal impairment (creatinine level 97 mol/L) may also increase the risk of sudden cardiac death, as kidney disease can increase the risk of cardiac complications.

RANKING: 3. Pump Failure Death
REASONING: 
Based on the patient's data, the risk of pump failure death is high. The patient has a severely reduced LVEF (25%), which indicates that the patient's heart is not pumping efficiently. The patient's heart failure symptoms are mild (NYHA class II), but the patient's cardiac disease is significant.

The patient's BNP (349 ng/L) is elevated, which indicates that the patient's heart is working hard to compensate for the reduced LVEF. The patient's kidney function is also impaired (creatinine level 97 mol/L), which may contribute to the patient's heart failure symptoms.

The patient's lipid profile is concerning, with high total cholesterol (3.49 mmol/L) and LDL (2.09 mmol/L) levels, which increases the risk of cardiovascular events. However, the patient is on statins, which should help to reduce these levels.

The patient's renal impairment may also increase the risk of pump failure death, as kidney disease can lead to fluid overload and electrolyte imbalances, which can worsen heart failure symptoms.

Overall, while the patient's prognosis is guarded, the patient's cardiac disease is significant, and the risk of pump failure death is high. With close monitoring and adjustments to the treatment plan, it is possible to manage the patient's symptoms, but the patient's underlying cardiac disease is likely to worsen over time."
71,71,P0113,"Age: 63
Gender: Male 
Weight: 66 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 105/68 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,9
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 290.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,8
Urea (mg/dL): 9,65
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has several factors that suggest a high likelihood of survival. Firstly, the patient's age of 63 is not particularly old, and with proper management, many patients with heart failure and cardiomyopathy can live for several more years. The patient's NYHA class II indicates that they have some symptoms of heart failure, but it is not severe enough to limit their physical activity. The patient's blood pressure is well-controlled, and they are on beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and cardiomyopathy.

The patient's laboratory results are also reassuring, with normal kidney function, low creatinine levels, and normal electrolyte levels. The patient's troponin levels are normal, which suggests that there is no significant myocardial damage. The patient's LVEF is low, but this is not uncommon in patients with cardiomyopathy.

The ECG impression shows some arrhythmias, including ventricular extrasystoles and non-sustained ventricular tachycardia, but these are not indicative of a high risk of sudden cardiac death. The patient is also not experiencing any symptoms of bradycardia or atrial fibrillation, which are common causes of sudden cardiac death.

Overall, the patient's combination of age, NYHA class, medication list, and laboratory results suggest that they are likely to survive for several more years with proper management.

RANKING: 2. Sudden cardiac death
REASONING: 

This patient is at moderate risk of sudden cardiac death due to their history of ventricular tachycardia and polymorphic ventricular extrasystoles. The presence of these arrhythmias increases the risk of sudden cardiac death, particularly if they are not properly managed. However, the patient is already on beta blockers, which are effective in reducing the risk of sudden cardiac death.

The patient's low LVEF and low ejection fraction also increase the risk of sudden cardiac death. Additionally, the patient's history of cardiomyopathy and dyslipidemia increase the risk of cardiac complications.

However, the patient's age, NYHA class, and laboratory results are still relatively favorable, and with proper management, the risk of sudden cardiac death can be reduced.

RANKING: 3. Pump failure death
REASONING: 

This patient is at moderate to high risk of pump failure death due to their history of cardiomyopathy and low LVEF. The patient's NYHA class II indicates that they are experiencing some symptoms of heart failure, which can lead to pump failure if not properly managed.

The patient's low ejection fraction and low ejection fraction reserve increase the risk of pump failure. Additionally, the patient's history of dyslipidemia and hypertension increase the risk of cardiac complications.

The patient's current medication list is adequate for managing heart failure and cardiomyopathy, but the patient's low ejection fraction and low LVEF suggest that they may require more aggressive management to prevent pump failure."
72,72,P0115,"Age: 67
Gender: Female 
Weight: 65 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 105/59 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,97
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 984.0
Protein (g/L): 61
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,16
Urea (mg/dL): 6,99
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's overall clinical presentation and laboratory results suggest that they are at high risk for cardiac complications, but the presence of certain factors suggests that they may be able to survive for an extended period. 

- The patient has a history of ischemic dilated cardiomyopathy, which indicates significant cardiac damage, but they are currently being treated with medications (Angiotensin II Receptor Blocker, Beta Blockers, and Statins), which are standard treatments for this condition. 
- The patient has a low LVEF (35.0%), indicating poor cardiac function, but the presence of symptoms is classified as NYHA Class II, which suggests that the patient is still able to perform daily activities without severe limitations.
- The patient has an elevated Pro-BNP level (984.0 ng/L), which indicates increased ventricular wall stress, but it is not excessively high, suggesting that the patient is not in acute heart failure.
- The patient's electrolytes and liver function tests are within normal limits, and the patient's kidney function is also within normal limits.
- The patient's ECG results show ventricular extrasystole, which is a type of abnormal heart rhythm, but it is not a life-threatening condition.
- The patient's age (67) and weight (65 kg) are not particularly high-risk factors for cardiac mortality.

Considering these factors, the patient is likely to survive for an extended period, especially given their current treatment and the absence of acute cardiac complications.

RANKING: 2. Sudden Cardiac Death
REASONING:
The patient's history of ischemic dilated cardiomyopathy, poor LVEF (35.0%), and elevated Pro-BNP level (984.0 ng/L) suggest that they are at high risk for cardiac complications, including sudden cardiac death. However, the patient's treatment with medications (Angiotensin II Receptor Blocker, Beta Blockers, and Statins) and the absence of acute cardiac events on the ECG results suggest that sudden cardiac death is less likely.

RANKING: 3. Pump Failure Death
REASONING:
The patient's poor LVEF (35.0%) and elevated Pro-BNP level (984.0 ng/L) suggest that they are at risk for cardiac pump failure. However, the patient's treatment with medications and the absence of acute cardiac events on the ECG results suggest that pump failure is less likely in the near future. Additionally, the patient's NYHA Class II classification suggests that they are still able to perform daily activities without severe limitations, which suggests that they are not in advanced stages of heart failure."
73,73,P0116,"Age: 64
Gender: Male 
Weight: 98 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 15,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,17
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 575.0
Protein (g/L): 67
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,88
Urea (mg/dL): 9,32
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 30%, indicating poor cardiac function.

The patient's current medications, including beta blockers, angiotensin II receptor blockers, and loop diuretics, suggest that the patient is receiving standard treatments for heart failure and arrhythmias. However, the presence of ventricular extrasystoles on the ECG, which may be indicative of ventricular arrhythmias, is a concern.

The patient's troponin levels are within normal limits, which suggests that there is no acute myocardial injury. However, the elevated creatinine levels (71.0 mmol/L) indicate some degree of renal impairment, which can be a complication of heart failure.

Despite these concerns, the patient's overall clinical presentation and laboratory results do not suggest an immediate life-threatening condition. The patient is not experiencing any acute symptoms such as shortness of breath, chest pain, or syncope, and the ECG does not show any signs of acute cardiac ischemia or infarction.

Given these factors, I believe that the patient has a higher likelihood of survival over the next few years, especially if their medications are well-managed and their medical conditions are adequately controlled. However, regular monitoring and follow-up appointments will be necessary to assess the patient's progression and adjust treatment as needed.

RANKING: 2. Pump failure death
REASONING: 

While the patient's LVEF is significantly reduced, and they have a history of heart failure, the patient's current ECG and laboratory results do not indicate any acute cardiac events. However, the patient's ventricular extrasystoles on the ECG may indicate an increased risk of arrhythmias, which can contribute to pump failure.

The patient's elevated creatinine levels and elevated BNP (pro-BNP) levels also suggest some degree of cardiac dysfunction. However, the patient's troponin levels are within normal limits, which suggests that there is no acute myocardial injury.

Given the patient's complex medical history and the presence of ventricular extrasystoles, there is a moderate risk of pump failure over the next few years. However, this risk is not immediate and can be mitigated with close monitoring and appropriate management of the patient's medications and medical conditions.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's ECG shows ventricular extrasystoles, which may indicate an increased risk of arrhythmias. However, the patient's troponin levels are within normal limits, and the patient is not experiencing any acute symptoms.

While the patient's ventricular extrasystoles are a concern, the patient's overall clinical presentation and laboratory results do not suggest an immediate risk of sudden cardiac death. The patient's medications, including beta blockers and angiotensin II receptor blockers, also suggest that the patient is receiving standard treatments for arrhythmias.

Given the patient's complex medical history and the presence of ventricular extrasystoles, there is a low risk of sudden cardiac death over the next few years. However, regular monitoring and follow-up appointments will be necessary to assess the patient's progression and adjust treatment as needed."
74,74,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I rank the patient as a survivor for the next few years. The patient has a history of ischemic dilated cardiomyopathy, which indicates that their heart muscle is weakened, but they are currently receiving beta blockers, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for managing heart failure and reducing mortality risk.

The patient's NYHA Class II classification indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activity without significant distress. Their blood pressure is well-controlled, and their electrolyte levels, including potassium, are within normal ranges.

The patient's troponin levels are normal, and their LVEF is significantly reduced, but not critically low. The presence of ventricular extrasystoles on the ECG is a concern, but it is not indicative of a high risk of sudden cardiac death.

The patient's Pro-BNP levels are elevated, but not extremely high, indicating some level of heart strain. However, this is not unusual for patients with heart failure.

Given the patient's overall medical history, treatment, and current condition, I believe that the patient has a reasonable chance of survival for the next few years, provided they continue to adhere to their treatment regimen and make lifestyle modifications to manage their heart failure.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's history of ischemic dilated cardiomyopathy and ventricular extrasystoles on the ECG are concerning, I do not rank the patient as having a high risk of sudden cardiac death. The patient is receiving beta blockers, which are effective in reducing the risk of sudden cardiac death in patients with heart failure. Additionally, the patient's troponin levels are normal, and their LVEF is not critically low.

However, the patient's ventricular extrasystoles on the ECG may indicate an increased risk of arrhythmias, which can increase the risk of sudden cardiac death. However, this risk is still relatively low, and the patient's overall medical history and treatment suggest that the risk is not extremely high.

RANKING: 3. Pump failure death
REASONING: 

I rank the patient as having a lower risk of pump failure death compared to sudden cardiac death. While the patient has a history of heart failure, their NYHA Class II classification indicates that they are able to manage their symptoms with treatment. The patient's LVEF is reduced, but not critically low, and their Pro-BNP levels are elevated but not extremely high.

However, the patient's creatinine levels are elevated, indicating some level of renal impairment, which can be a complication of heart failure. Additionally, the patient's total cholesterol level is high, which can increase the risk of cardiovascular events.

Overall, while the patient has some risk factors for pump failure, their overall medical history and treatment suggest that the risk is not extremely high. The patient's current condition and treatment plan suggest that they are likely to survive for the next few years, but there is a potential risk of pump failure, which would require close monitoring and adjustment of their treatment plan."
75,75,P0119,"Age: 58
Gender: Male 
Weight: 73 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 145/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 49
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,07
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 397.0
Protein (g/L): 75
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 7,49
LVEF (%): 23.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient will survive for the next few years. Here's the reasoning behind this prediction:

1. Age: The patient is 58 years old, which is considered middle-aged. While age is a risk factor for cardiac disease, it's not a guarantee of poor outcomes.
2. NYHA Class II: The patient's heart failure symptoms are mild, indicating that the disease is not severe.
3. LVEF: The left ventricular ejection fraction (LVEF) is 23%, which is significantly reduced, indicating a poor cardiac function. However, the patient is still alive and has a mild NYHA Class II, suggesting that the heart is not completely failed.
4. Medications: The patient is taking beta blockers, statins, and an ACE inhibitor, which are all standard treatments for managing heart failure and reducing cardiovascular risk factors.
5. Pro-BNP: The patient's Pro-BNP level is elevated, indicating some degree of heart failure, but it's not extremely high.
6. ECG Impression: The patient has a history of ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia, which may indicate underlying arrhythmia issues. However, the presence of these arrhythmias does not necessarily predict a poor outcome.
7. Other laboratory values: The patient's liver function tests (ALT and AST) are within normal limits, and the kidney function (creatinine) is slightly elevated, but not severely impaired.

Considering these factors, I predict that the patient will survive for the next few years, but it's essential to closely monitor the patient's cardiac function and adjust the treatment plan as needed to prevent further deterioration.

The other two prognoses are less likely because:

- Sudden cardiac death: The patient's age, NYHA Class II, and mild LVEF do not strongly suggest a high risk of sudden cardiac death.
- Pump failure death: While the patient has a reduced LVEF and elevated Pro-BNP, the patient is taking medications that can help manage heart failure, and the patient's NYHA Class II indicates that the disease is not severe enough to lead to pump failure."
76,76,P0120,"Age: 61
Gender: Female 
Weight: 58 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 128/67 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 822.0
Protein (g/L): 70
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,07
Urea (mg/dL): 5,83
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
This patient is at high risk for cardiac complications due to a history of idiopathic dilated cardiomyopathy, hypertension, and dyslipidemia. The elevated LVEF of 30.0% indicates significant left ventricular dysfunction, which is a major contributor to the risk of cardiac events. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG, as well as ventricular extrasystole and polymorphic ventricular tachycardia, further increases the risk of cardiac complications. The elevated BNP levels (822.0 ng/L) also suggest significant cardiac stress and strain. 

Given the patient's history, current NYHA class II symptoms, and the presence of NSVT, the patient is at high risk for cardiac events. However, the patient is already on beta blockers and statins, which are standard treatments for managing hypertension, dyslipidemia, and heart failure. The patient's current hemoglobin level (150.0 g/L) and other lab results are within normal limits, indicating no acute complications.

The patient's age (61) is also a factor, as older patients are generally at higher risk for cardiac events. However, the patient's overall clinical presentation and management plan suggest that the patient is at high risk but not necessarily at the highest risk for a poor outcome.

2. Sudden Cardiac Death
REASONING:
While the patient is at high risk for cardiac complications, the presence of beta blockers and statins suggests that the patient is receiving standard management for their conditions. The patient's NYHA class II symptoms and elevated BNP levels indicate some degree of cardiac dysfunction, but not severe enough to immediately predict a high risk of sudden cardiac death.

The patient's ECG findings, while concerning, do not suggest a high risk for sudden cardiac death. The absence of a clear indication of ischemia or infarction, as well as the presence of beta blockers, reduces the likelihood of sudden cardiac death.

3. Pump Failure Death
REASONING:
Pump failure death is a possible outcome for patients with advanced heart failure, but the patient's LVEF is 30.0%, which is not indicative of severe pump failure. The patient's NYHA class II symptoms and elevated BNP levels suggest some degree of heart failure, but the patient is already receiving beta blockers and statins, which are standard treatments for managing heart failure.

While the patient's ECG findings are concerning, the absence of clear indications of severe cardiac dysfunction or ischemia reduces the likelihood of pump failure death. The patient's overall clinical presentation and management plan suggest that the patient is at moderate risk for cardiac events, but not at the highest risk for pump failure death."
77,77,P0121,"Age: 41
Gender: Female 
Weight: 97 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 9,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,05
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 642.0
Protein (g/L): 70
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 6,99
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient will survive for the next few years with a relatively good outcome. The patient's age, weight, and NYHA class are within a moderate range, indicating a relatively preserved functional capacity. The patient's blood pressure, creatinine, and urea levels are within acceptable limits, suggesting that the kidneys are functioning adequately.

The patient's LVEF of 35.0% indicates significant left ventricular dysfunction, which is a major concern. However, the presence of idiopathic dilated cardiomyopathy is a well-known cause of heart failure with preserved ejection fraction (HFpEF), and the patient's symptoms and medications suggest that the condition is being managed effectively.

The patient's biomarkers, such as troponin and creatine kinase levels, are within normal limits, indicating no acute myocardial infarction or muscle damage. The absence of ventricular tachycardia, ventricular extrasystole, or non-sustained ventricular tachycardia on the ECG also reduces the risk of sudden cardiac death.

The patient's lipid profile, with a total cholesterol of 5.4 mmol/L, is relatively well-controlled, and the presence of a significant amount of HDL cholesterol (1.14 mmol/L) suggests a relatively low risk of cardiovascular disease.

Given the patient's overall clinical profile, I believe that the patient has a relatively good prognosis and is likely to survive for the next few years with appropriate management of their condition."
78,78,P0122,"Age: 65
Gender: Female 
Weight: 62 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/54 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 35
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,86
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 173.0
Protein (g/L): 62
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 6,99
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is most likely to be a survivor due to several factors. Firstly, the patient's LVEF (left ventricular ejection fraction) is 30.0%, which is a significant reduction in cardiac function, but not extremely low. This suggests that the patient's heart is still pumping blood, albeit inefficiently.

The patient's past medical history of idiopathic dilated cardiomyopathy, dyslipidemia, and hypertension is a risk factor for cardiac complications, but the fact that the patient is already on beta blockers, statins, and ACE inhibitors suggests that the patient is receiving appropriate management for these conditions.

The patient's creatinine level is elevated at 62.0, which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's electrolyte levels, including potassium, are within a relatively normal range.

The patient's troponin level is 0.01 ng/mL, which is not elevated, suggesting that there is no significant myocardial infarction or acute cardiac injury.

The patient's ECG impression does not show any signs of ventricular tachycardia or other life-threatening arrhythmias, which are common in patients with heart failure.

Overall, while this patient has several risk factors and signs of cardiac dysfunction, the patient is already receiving treatment and does not have any acute or severe cardiac complications, making a survival prognosis the most likely outcome."
79,79,P0124,"Age: 80
Gender: Male 
Weight: 109 kg
Height: 178 cm
NYHA Class: III
Blood Pressure: 150/95 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,75
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 100.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,35
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1475.0
Protein (g/L): 64
T3 (pg/dL): 0,02
T4 (ng/L): 9
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,38
Urea (mg/dL): 23,13
LVEF (%): 62.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a complex medical history with multiple comorbid conditions, including hypertrophic cardiomyopathy, diabetes, dyslipidemia, and hypertension. However, the patient's current symptoms and test results do not indicate acute cardiac instability. The patient's NYHA Class III indicates significant heart failure symptoms, but the patient is currently taking medications that are commonly used to manage heart failure, such as loop diuretics, beta blockers, and ACE inhibitors (implied by the presence of an Angiotensin II Receptor Blocker). 

The patient's LVEF is 62%, which is slightly below the normal range, but not severely impaired. The patient's troponin level is within normal limits, indicating no evidence of myocardial infarction. The patient's creatinine level is elevated, suggesting some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's Pro-BNP level is elevated, indicating some degree of ventricular strain, but this is not excessively high.

Given the patient's complex medical history and comorbidities, it is reasonable to assume that the patient will require ongoing management and monitoring to prevent complications. However, the patient's current symptoms and test results do not indicate an immediate threat to life, and the patient is likely to survive the next few years with proper management.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of hypertrophic cardiomyopathy and elevated troponin level do increase the risk of sudden cardiac death. However, the patient's current symptoms and test results do not indicate acute cardiac instability, and the patient is currently taking medications that are commonly used to manage heart failure and prevent sudden cardiac death. 

The patient's ECG results show no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are common precursors to sudden cardiac death. The patient's Pro-BNP level is elevated, indicating some degree of ventricular strain, but this is not excessively high. The patient's creatinine level is elevated, suggesting some degree of renal impairment, which can increase the risk of sudden cardiac death.

While the patient's history and current test results do increase the risk of sudden cardiac death, the patient's overall clinical picture does not suggest an immediate threat to life. Therefore, while the patient is at increased risk, it is still possible that the patient will not experience sudden cardiac death in the next few years.

RANKING: 3. Pump failure death
REASONING: 

The patient's NYHA Class III indicates significant heart failure symptoms, and the patient's LVEF is slightly below the normal range. The patient's Pro-BNP level is elevated, indicating some degree of ventricular strain. The patient's creatinine level is elevated, suggesting some degree of renal impairment, which can increase the risk of pump failure.

The patient's current medications, including loop diuretics, beta blockers, and ACE inhibitors, are commonly used to manage heart failure. However, the patient's elevated troponin level and slightly elevated creatinine level suggest that the patient may still be at risk of pump failure, particularly if the patient's heart failure symptoms worsen or if the patient's renal function declines further.

Given the patient's complex medical history and comorbidities, it is possible that the patient may experience pump failure in the next few years, particularly if the patient's heart failure symptoms worsen or if the patient's renal function declines further. However, the patient's current symptoms and test results do not suggest an immediate threat to life, and the patient is likely to survive pump failure with proper management."
80,80,P0125,"Age: 76
Gender: Male 
Weight: 79 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,66
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 303.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 13
Troponin (ng/mL): 0,02
TSH (mIU/L): 12,9
Urea (mg/dL): 6,16
LVEF (%): 54.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, the patient is 76 years old with a history of dilated cardiomyopathy and hypertension. The patient's LVEF is 54%, which indicates significant left ventricular dysfunction. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on ECG suggests an increased risk of arrhythmic events. However, the patient is currently on medications that target these risks, such as Amiodarone and Beta Blockers.

The patient's elevated troponin levels (0.02 ng/mL) and Pro-BNP (303.0 ng/L) levels indicate some degree of cardiac stress, but not excessively high levels that would suggest acute myocardial infarction. The patient's hemoglobin level (122.0 g/L) is within normal limits, and the kidney function (creatinine 6.16 mg/dL) is also relatively preserved.

The patient's age, weight, and height do not significantly increase the risk of mortality, and the patient's current medications appear to be well-tolerated. Overall, considering the patient's current condition and the presence of some cardiac stress markers, I believe that the patient has a reasonable chance of survival over the next few years with proper management.

2. Sudden cardiac death
REASONING:
While the patient has a history of ventricular extrasystole and non-sustained ventricular tachycardia on ECG, which increases the risk of arrhythmic events, the patient is currently on medications that target these risks. However, the patient's LVEF is only 54%, which indicates significant left ventricular dysfunction. This could increase the risk of sudden cardiac death, especially if the patient's condition worsens.

The patient's elevated troponin levels and Pro-BNP levels could also indicate some degree of cardiac stress, which could contribute to an increased risk of sudden cardiac death. However, the patient's hemoglobin and kidney function are relatively preserved, which reduces the risk of sudden cardiac death.

3. Pump failure death
REASONING:
Given the patient's significant left ventricular dysfunction (LVEF 54%) and history of dilated cardiomyopathy, I would consider pump failure death a possible but less likely outcome. The patient's current medications, including ACE inhibitors, are aimed at reducing the workload on the heart and improving cardiac function.

However, the patient's age, weight, and height do not significantly increase the risk of pump failure, and the patient's kidney function is relatively preserved. While the patient's troponin and Pro-BNP levels indicate some degree of cardiac stress, they are not excessively high, which reduces the risk of pump failure.

Overall, while pump failure is a possible outcome, I believe it is the least likely of the three options, given the patient's current medications and relatively preserved cardiac function."
81,81,P0126,"Age: 77
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 237
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,28
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 4117.0
Protein (g/L): 66
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 8,49
LVEF (%): 56.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is 77 years old with a history of hypertensive cardiomyopathy, hypertension, and elevated creatinine levels (115.0 mmol/L), indicating some degree of kidney impairment. The patient's ejection fraction (LVEF) is 56.0%, which is lower than the normal range, suggesting some degree of left ventricular dysfunction.

The patient's current ECG findings show ventricular extrasystole, which is a type of abnormal heart rhythm, but no ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. The absence of these more severe arrhythmias may suggest that the patient's cardiac function is not severely compromised.

The patient's medications, including an angiotensin II receptor blocker, loop diuretics, and spironolactone, are typical for managing hypertension and heart failure. The patient's blood pressure is well-controlled at 120/80 mmHg.

The patient's laboratory results show elevated liver enzymes (ALT and AST) and a slightly elevated troponin level, which could indicate some degree of cardiac stress or minor myocardial injury. However, the troponin level is very low (0.01 ng/mL), and the patient's overall clinical presentation does not suggest acute coronary syndrome.

Considering these factors, I would rank the patient's prognosis as ""survivor"" with a high likelihood, as the patient's cardiac function is not severely compromised, and the patient is on medications that are typical for managing hypertension and heart failure. The patient's age and kidney impairment do increase the risk of adverse outcomes, but the overall clinical picture suggests that the patient is likely to survive for the next few years with proper management.

However, it's essential to note that the patient's prognosis can be influenced by various factors, including the presence of undiagnosed or unmanaged conditions, potential for further cardiac events, and the patient's overall health status. Regular follow-up and monitoring will be crucial to assess the patient's condition and adjust the treatment plan accordingly.

RANKING: 2. Sudden Cardiac Death
REASONING: 

Given the patient's age, history of hypertensive cardiomyopathy, and kidney impairment, the risk of sudden cardiac death is moderate to high. The patient's LVEF is 56.0%, which is below the normal range, and the patient's ejection fraction can further decline over time.

The patient's ECG findings show ventricular extrasystole, which can increase the risk of arrhythmias, including ventricular tachycardia and sudden cardiac death. Although the patient's current ECG does not show ventricular tachycardia, the presence of ventricular extrasystole and the patient's age increase the risk of arrhythmias.

The patient's medication regimen is typical for managing hypertension and heart failure, but the patient's kidney impairment may require adjustments to the medication regimen to minimize further kidney damage.

Given the patient's overall clinical picture, I would rank the risk of sudden cardiac death as moderate to high, but it's essential to note that this risk can be reduced with close monitoring and adjustments to the treatment plan.

RANKING: 3. Pump Failure Death
REASONING: 

Based on the patient's LVEF of 56.0%, which is below the normal range, and the patient's history of hypertensive cardiomyopathy, the risk of heart failure is moderate. The patient's kidney impairment and elevated creatinine levels increase the risk of further kidney damage and potentially exacerbate heart failure.

The patient's ECG findings show ventricular extrasystole, which can increase the risk of arrhythmias and further compromise cardiac function. However, the patient's current ECG does not show ventricular tachycardia, and the patient is on medications that are typical for managing hypertension and heart failure.

Considering the patient's overall clinical picture, I would rank the risk of pump failure death as moderate, but it's essential to note that this risk can be reduced with close monitoring and adjustments to the treatment plan.

It's essential to emphasize that the patient's prognosis can be influenced by various factors, including the presence of undiagnosed or unmanaged conditions, potential for further cardiac events, and the patient's overall health status. Regular follow-up and monitoring will be crucial to assess the patient's condition and adjust the treatment plan accordingly."
82,82,P0128,"Age: 72
Gender: Male 
Weight: 74 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 15,2
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,91
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 208.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 26
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,68
Urea (mg/dL): 6,82
LVEF (%): 36.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Paroxysmal AVB
            ",survivor,"RANKING: 
1. Survivor 
REASONING:
Based on the provided patient data, the patient is at a high risk for cardiac-related complications. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened and cannot pump blood effectively. This condition is a significant risk factor for heart failure and sudden cardiac death.

The patient's current NYHA Class III classification indicates severe heart failure, which suggests that the patient is experiencing significant symptoms, such as shortness of breath, fatigue, and swelling in the legs.

The patient's LVEF (Left Ventricular Ejection Fraction) of 36.0% is also a significant indicator of poor cardiac function, which further supports the risk of heart failure and sudden cardiac death.

The patient's medications, including beta blockers, digoxin, and loop diuretics, suggest that the patient is being managed for heart failure. However, the patient's current medication regimen may not be sufficient to reverse the underlying cardiac damage.

The patient's biomarkers, such as elevated Troponin and Pro-BNP levels, indicate cardiac stress and strain, which further support the risk of cardiac complications.

The patient's ECG findings, including ventricular extrasystole and paroxysmal AVB, also suggest an increased risk of arrhythmias, which can be a precursor to sudden cardiac death.

Given the patient's overall clinical presentation, medical history, and biomarkers, I believe that the patient is at a high risk for cardiac-related complications, making a survivor outcome the most likely prognosis.

RANKING: 
2. Sudden Cardiac Death 
REASONING:
While the patient is at a high risk for cardiac-related complications, the likelihood of sudden cardiac death is lower compared to the survivor outcome. The patient's ECG findings, while abnormal, do not indicate a high risk for ventricular tachycardia or ventricular fibrillation, which are common causes of sudden cardiac death.

However, the patient's LVEF of 36.0% and the presence of ventricular extrasystole on ECG do suggest an increased risk for arrhythmias, which can be a precursor to sudden cardiac death.

The patient's biomarkers, such as elevated Pro-BNP levels, also suggest cardiac stress and strain, which may increase the risk for cardiac complications, including sudden cardiac death.

RANKING: 
3. Pump Failure Death 
REASONING:
While the patient is at a high risk for cardiac-related complications, the likelihood of pump failure death is lower compared to the survivor and sudden cardiac death outcomes. The patient's current medication regimen, including beta blockers and loop diuretics, suggests that the patient is being managed for heart failure.

The patient's biomarkers, such as elevated Troponin and Pro-BNP levels, do suggest cardiac stress and strain, but the patient's LVEF of 36.0% indicates that the patient's cardiac function is severely impaired.

The patient's ECG findings, while abnormal, do not indicate a high risk for arrhythmias or other cardiac complications that would increase the risk for pump failure death.

Overall, while the patient is at a high risk for cardiac-related complications, the likelihood of pump failure death is lower compared to the survivor and sudden cardiac death outcomes, making this the least likely prognosis."
83,83,P0130,"Age: 48
Gender: Male 
Weight: 74 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,15
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 677.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 11
Troponin (ng/mL): 0,37
TSH (mIU/L): 2,4
Urea (mg/dL): 6,82
LVEF (%): 29.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with multiple comorbidities, including idiopathic dilated cardiomyopathy, dyslipidemia, peripheral vascular disease, and hypertension. The patient's current NYHA Class II status indicates moderate symptoms, and their elevated creatinine level (106.0 mmol/L) suggests impaired renal function. However, the patient is already on medications for these conditions, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor.

The patient's ECG impression shows non-sustained ventricular tachycardia (NSVT), which is a concerning sign, but it is not sustained. The presence of ventricular extrasystoles and polymorphic ventricular tachycardia is also a concern. However, the fact that these arrhythmias are non-sustained suggests that they are not likely to lead to sudden cardiac death.

The patient's LVEF (29.0%) is significantly reduced, indicating poor left ventricular function, which is a key factor in determining prognosis. However, the patient is already on medications that are intended to improve heart function, such as beta blockers and ACE inhibitors.

Considering these factors, the patient's overall prognosis is best classified as a survivor, given their complex medical history and reduced LVEF, but the presence of non-sustained arrhythmias and impaired renal function do not immediately indicate an extremely poor outcome.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's ECG impression shows a high risk of arrhythmias, including polymorphic ventricular tachycardia and ventricular extrasystoles. While these arrhythmias are non-sustained, the presence of polymorphic ventricular tachycardia is a significant concern, as it can degenerate into sustained ventricular tachycardia, which can lead to sudden cardiac death.

Additionally, the patient's LVEF (29.0%) is significantly reduced, indicating poor left ventricular function, which increases the risk of sudden cardiac death.

The patient's other comorbidities, including peripheral vascular disease and hypertension, also increase the risk of sudden cardiac death.

However, the patient is already on medications that are intended to reduce the risk of arrhythmias and improve heart function, which may help mitigate some of these risks.

RANKING: 3. Pump failure death
REASONING: 

While the patient's LVEF (29.0%) is significantly reduced, indicating poor left ventricular function, the patient is already on medications that are intended to improve heart function, such as beta blockers and ACE inhibitors.

The patient's ECG impression does not show any signs of heart failure, and their NYHA Class II status indicates moderate symptoms, which suggests that they are not currently experiencing severe heart failure.

However, the patient's impaired renal function (creatinine level of 106.0 mmol/L) and elevated troponin level (0.37 ng/mL) suggest that their heart is under significant stress, which could increase the risk of heart failure.

Additionally, the patient's dyslipidemia and peripheral vascular disease also increase the risk of cardiovascular events, including pump failure.

However, the patient's overall prognosis is not as poor as it would be if they were experiencing severe heart failure or if they had a history of heart failure. Therefore, while pump failure is a possible outcome, it is not the most likely prognosis."
84,84,P0131,"Age: 66
Gender: Male 
Weight: 95 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,03
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,72
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 481.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,05
TSH (mIU/L): 2,63
Urea (mg/dL): 9,32
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age (66) and NYHA Class II heart failure indicate a moderate level of heart failure, but the patient is still relatively young and has a significant history of cardiovascular risk factors such as hypertension, dyslipidemia, and myocardial infarction. However, the patient's LVEF is 40%, which is a significant reduction, indicating left ventricular dysfunction. The presence of anemia (Hemoglobin 120 g/L) and elevated creatinine (106 mmol/L) levels suggests some degree of renal impairment, which can be a risk factor for cardiovascular events. The patient's medication regimen includes multiple cardiovascular medications, including ACE inhibitors and beta blockers, which are typically used to manage heart failure and hypertension. Additionally, the patient's ECG shows paroxysmal supraventricular tachycardia, which can be a risk factor for cardiac arrhythmias. However, the patient's overall clinical presentation and laboratory results do not suggest any acute cardiac events or severe cardiac dysfunction that would indicate a high risk of sudden cardiac death or pump failure. Therefore, a survival prognosis of ""survivor"" is the most likely outcome.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient's ECG shows paroxysmal supraventricular tachycardia, which can be a risk factor for cardiac arrhythmias, the patient's overall clinical presentation and laboratory results do not suggest any acute cardiac events or severe cardiac dysfunction that would indicate a high risk of sudden cardiac death. However, the patient's history of ischemic dilated cardiomyopathy and myocardial infarction, as well as the presence of ventricular extrasystoles on the ECG, do suggest a higher risk of cardiac arrhythmias and potentially life-threatening events. Additionally, the patient's elevated troponin level (0.05 ng/mL) is slightly elevated, which may indicate some degree of cardiac damage. However, the patient's overall clinical presentation and laboratory results do not suggest a high risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 40%, which indicates significant left ventricular dysfunction and a high risk of heart failure exacerbation or pump failure. The patient's NYHA Class II heart failure and elevated creatinine level (106 mmol/L) suggest a significant burden of cardiac disease. The patient's medication regimen includes multiple cardiovascular medications, including ACE inhibitors and beta blockers, which are typically used to manage heart failure. However, the patient's laboratory results do not suggest any acute cardiac events or severe cardiac dysfunction that would indicate a high risk of pump failure. Additionally, the patient's ECG does not show any signs of ventricular tachycardia or other life-threatening arrhythmias. Therefore, while pump failure is a significant concern, the patient's overall clinical presentation and laboratory results do not suggest a high risk of pump failure."
85,85,P0132,"Age: 46
Gender: Female 
Weight: 53 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,62
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 64.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,07
Urea (mg/dL): 4,33
LVEF (%): 34.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Given the patient's NYHA Class II, which indicates mild symptoms of heart failure, and the presence of idiopathic dilated cardiomyopathy, a chronic condition that can lead to progressive heart failure, the patient is at risk for both pump failure and sudden cardiac death. However, the patient's LVEF of 34.0 is relatively preserved, indicating that the heart is still functioning to some extent. The patient's current symptoms and medication regimen, including beta blockers, digoxin, and ACE inhibitor, are aimed at managing the symptoms and slowing the progression of heart failure. The absence of any ECG findings indicative of ventricular tachycardia or polymorphic ventricular extrasystoles, which are risk factors for sudden cardiac death, further supports the likelihood of a favorable outcome. Therefore, the patient is more likely to survive the next few years due to the effectiveness of their current treatment regimen and the relatively preserved cardiac function.

RANKING: 2. Pump failure death
REASONING: 
While the patient's LVEF is relatively preserved, the patient's NYHA Class II symptoms indicate that the heart is still under significant strain. The patient's elevated creatinine level (80.0 mg/dL) suggests some degree of renal impairment, which can be a complication of heart failure. The patient's elevated troponin level (0.005 ng/mL) may indicate some degree of myocardial injury, which can be a precursor to further cardiac complications. Additionally, the patient's elevated BNP level (64.0 ng/L) suggests some degree of ventricular volume overload, which can contribute to pump failure. However, the patient's current treatment regimen and relatively preserved cardiac function suggest that pump failure may be delayed, but not necessarily inevitable.

RANKING: 3. Sudden cardiac death
REASONING: 
The patient's ECG findings, including the presence of ventricular extrasystoles, make them a higher risk for sudden cardiac death. The patient's elevated BNP level and elevated troponin level also suggest that the heart is under significant strain, which can increase the risk of arrhythmic events. Additionally, the patient's relatively low HDL level (0.85 mmol/L) and elevated triglyceride level are risk factors for cardiovascular disease, which can contribute to the development of arrhythmias. While the patient's current treatment regimen and relatively preserved cardiac function suggest that sudden cardiac death may be delayed, it remains a significant risk, particularly given the patient's underlying idiopathic dilated cardiomyopathy."
86,86,P0133,"Age: 36
Gender: Female 
Weight: 81 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 48
ALT or GPT (IU/L): 130.0
AST or GOT (IU/L): 89.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 142
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,05
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 57.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,06
TSH (mIU/L): 3,53
Urea (mg/dL): 6,32
LVEF (%): 24.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient's age, NYHA class III status, and the presence of idiopathic dilated cardiomyopathy, dyslipemia, and elevated liver enzymes (ALT and AST) suggest a significant cardiac impairment. However, the patient is currently taking beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for managing heart failure and reducing the risk of cardiac complications. The patient's LVEF is 24.0%, indicating severe left ventricular dysfunction.

Although the patient's Pro-BNP level is elevated (57.0 ng/L), which is indicative of heart failure, the patient's overall clinical presentation and the absence of other red flags (e.g., severe hypotension, acute kidney injury, or acute coronary syndrome) suggest that the patient may still be in a relatively stable state.

In contrast, the patient's Troponin level (0.06 ng/mL) is not significantly elevated, which may indicate some degree of cardiac muscle damage, but not necessarily an acute coronary syndrome. Furthermore, the patient's ECG findings do not show any signs of ventricular arrhythmias or significant ischemia.

Therefore, based on the available data, I would rank the patient's prognosis as a survivor, with a moderate to high likelihood of long-term survival.

RANKING: 
2. Sudden Cardiac Death
REASONING: 
While the patient's LVEF is severely impaired, the absence of any red flags or acute cardiac events on the ECG, and the patient's relatively stable clinical presentation, reduce the likelihood of sudden cardiac death. However, the patient's severe heart failure (NYHA class III) and the presence of idiopathic dilated cardiomyopathy increase the risk of arrhythmias and sudden cardiac death.

Additionally, the patient's age and gender also contribute to the risk of sudden cardiac death, as women with heart failure are at higher risk of sudden cardiac death compared to men.

However, the patient's overall clinical presentation and the absence of any acute cardiac events or severe hypotension make sudden cardiac death less likely compared to the survivor outcome.

RANKING: 
3. Pump Failure Death
REASONING: 
Given the patient's severe heart failure (NYHA class III) and the presence of idiopathic dilated cardiomyopathy, pump failure death is a significant concern. The patient's LVEF is 24.0%, which is a strong indicator of severe left ventricular dysfunction.

The patient's elevated Pro-BNP level (57.0 ng/L) and elevated liver enzymes (ALT and AST) also suggest a high risk of heart failure progression and pump failure. However, the patient's relatively stable clinical presentation and the absence of any acute cardiac events or severe hypotension make pump failure death less likely compared to the survivor outcome.

The patient's current treatment regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, is standard for managing heart failure, which reduces the risk of pump failure death. However, the patient's severe heart failure and idiopathic dilated cardiomyopathy still pose a significant risk of pump failure, making this outcome a plausible possibility."
87,87,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient's overall prognosis is favorable. The patient's age, NYHA Class II, and lack of significant comorbidities suggest a relatively preserved cardiac function. The elevated Pro-BNP levels indicate some degree of cardiac stress, but the patient's LVEF is still within a relatively normal range (53.0%). The absence of significant elevations in troponin levels also suggests that there is no acute myocardial infarction or significant myocardial damage. The patient's medication regimen, which includes beta blockers, digoxin, and ACE inhibitors, is standard for managing heart failure and arrhythmias.

The patient's ECG findings of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggest some cardiac conduction abnormalities, but these are not necessarily indicative of a high-risk condition. The patient's hemoglobin and renal function are also relatively preserved, which further supports a favorable prognosis.

While the patient's elevated creatinine level (88.0) suggests some degree of renal impairment, this is not uncommon in patients with heart failure. Overall, the combination of a relatively preserved cardiac function, standard medication regimen, and absence of significant comorbidities suggest that the patient is likely to survive the next few years without significant cardiac complications."
88,88,P0142,"Age: 67
Gender: Female 
Weight: 98 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/85 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,8
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,8
Creatinine (mmol/L): 73.0
Gamma-glutamil transpeptidase (IU/L): 257
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,13
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,81
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 683.0
Protein (g/L): 68,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,3
Urea (mg/dL): 7,5
LVEF (%): 55.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I rank the patient as having a high likelihood of survival over the next few years. The patient's age of 67 is not unusually high, and their NYHA Class II indicates that they have some limitations with physical activity but are not severely limited. Their blood pressure is well-controlled at 120/85 mmHg, and their medication regimen includes ACE inhibitors, statins, and loop diuretics, which are standard treatments for their comorbid conditions of hypertension, dyslipidemia, and heart failure.

The patient's echocardiogram shows a left ventricular ejection fraction (LVEF) of 55%, which is within the normal range, indicating that the patient's heart is still pumping effectively. Their troponin levels are normal, suggesting that there is no acute myocardial infarction or significant cardiac damage.

The patient's laboratory results show mild elevations in liver enzymes (ALT and AST) and creatinine, which may be indicative of underlying kidney disease or liver disease. However, these findings are not severe enough to significantly impact the patient's prognosis.

The patient's lipid profile shows elevated total cholesterol and LDL levels, which increases the risk of cardiovascular events. However, their current medications are effective in managing these conditions.

Given the patient's overall health status and the presence of comorbidities, I believe that the patient is at a high risk for cardiovascular events, but the patient's current treatment regimen and relatively preserved cardiac function suggest that they are likely to survive over the next few years."
89,89,P0145,"Age: 57
Gender: Male 
Weight: 106 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 170/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,07
Potassium (mEq/L): 3,44
LDL (mmol/L): 3,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 431.0
Protein (g/L): 68,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,73
Urea (mg/dL): 5,7
LVEF (%): 25.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

The patient's prognosis is generally favorable due to the presence of a significant amount of evidence suggesting that the patient is still alive and relatively stable despite their underlying cardiomyopathy, hypertension, and other comorbidities. The key factors contributing to this favorable prognosis are:

- The patient is alive and has not shown any evidence of acute heart failure or acute coronary syndrome, which are common causes of sudden cardiac death or pump failure.
- The patient's LVEF is 25%, which is a relatively preserved left ventricular function, indicating that the patient's heart is still pumping blood effectively despite the cardiomyopathy.
- The patient is on ACE inhibitor, which is a medication commonly used to manage heart failure and hypertension, suggesting that the patient is receiving appropriate treatment for their conditions.
- The patient's ECG findings do not indicate any acute life-threatening arrhythmias, such as ventricular fibrillation or ventricular tachycardia, which are common causes of sudden cardiac death.
- The patient's biomarkers, such as troponin and creatinine, are within normal limits, indicating no acute cardiac or renal damage.

However, despite these favorable factors, the patient's NYHA class II and elevated blood pressure suggest that they are experiencing some level of cardiac strain, which may eventually lead to heart failure or other complications. Additionally, the patient's high creatinine level and elevated blood pressure may indicate some degree of kidney damage or hypertension, which could contribute to long-term cardiac and renal complications.

Given these factors, the most likely outcome for the patient is survival, but with a high risk of developing cardiac complications or other comorbidities in the coming years."
90,90,P0146,"Age: 49
Gender: Male 
Weight: 85 kg
Height: 169 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 40,1
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 5
Hemoglobin (g/L): 128.0
Potassium (mEq/L): 4,31
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3021.0
Protein (g/L): 65,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,34
Urea (mg/dL): 5,2
LVEF (%): 19.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient has a history of enolic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. However, the patient is currently receiving medications for heart failure (Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor) that are likely helping to manage the condition. The patient's current ECG findings show non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystole, but these are not indicative of a high risk for sudden cardiac death. The patient's LVEF is 19%, which is a significant reduction, but not indicative of heart failure at this point.

The patient's laboratory results show elevated creatinine levels (102.0 mmol/L) and a high Pro-BNP level (3021.0 ng/L), indicating fluid overload and possible heart failure. However, the patient's hemoglobin and potassium levels are within normal limits, and the patient's blood pressure is relatively low (90/60 mmHg), which may indicate some degree of volume depletion. 

Given these factors, the patient is likely to survive in the short-term, but the presence of enolic dilated cardiomyopathy, NSVT, and elevated Pro-BNP levels suggest that the patient is at increased risk for heart failure and arrhythmias in the future.

2. Sudden Cardiac Death
REASONING:
The patient's ECG findings show non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystole, which are risk factors for sudden cardiac death. The patient's LVEF is 19%, which is a significant reduction, indicating severe left ventricular dysfunction. The patient's elevated Pro-BNP level (3021.0 ng/L) and elevated creatinine level (102.0 mmol/L) suggest that the patient is experiencing heart failure.

While the patient is receiving medications for heart failure, the presence of these arrhythmias and severe left ventricular dysfunction increases the risk of sudden cardiac death. However, the patient's relatively low blood pressure (90/60 mmHg) and normal hemoglobin and potassium levels may suggest some degree of volume depletion and may reduce the risk of sudden cardiac death.

3. Pump Failure Death
REASONING:
The patient's LVEF is 19%, which is a significant reduction, indicating severe left ventricular dysfunction. The patient's elevated Pro-BNP level (3021.0 ng/L) and elevated creatinine level (102.0 mmol/L) suggest that the patient is experiencing heart failure. The patient's medications for heart failure (Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor) are likely helping to manage the condition, but the patient's severe left ventricular dysfunction increases the risk of pump failure.

While the patient's relatively low blood pressure (90/60 mmHg) and normal hemoglobin and potassium levels may suggest some degree of volume depletion, the presence of severe left ventricular dysfunction and heart failure increases the risk of pump failure. However, the patient's survival is already uncertain due to the presence of NSVT and polymorphic ventricular extrasystole, making pump failure death less likely."
91,91,P0147,"Age: 81
Gender: Female 
Weight: 50 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 39,7
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 16,2
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 3,93
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2167.0
Protein (g/L): 67,4
T3 (pg/dL): 0,07
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,1
Urea (mg/dL): 13,1
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a complex medical history with multiple comorbidities, including hypertrophic cardiomyopathy, diabetes, hypertension, and significant renal impairment (creatinine level of 96.0 mmol/L). Despite these factors, the patient is currently taking a range of medications that suggest a relatively well-managed cardiovascular disease. The ECG findings are concerning, with ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia. However, the patient is currently asymptomatic, and the presence of ventricular extrasystole and non-sustained ventricular tachycardia may be related to the underlying cardiac disease rather than a new development. The patient's left ventricular ejection fraction (LVEF) is 40%, which is significantly reduced, indicating some level of cardiac dysfunction. However, the patient's age, weight, and other laboratory values (e.g., albumin, potassium, and troponin levels) do not suggest acute cardiac damage. The patient's recent blood glucose level of 16.2 mmol/L is slightly elevated, but this is not unusual for someone with diabetes. The presence of amiodarone, a medication used to treat arrhythmias, and the patient's relatively good renal function (urea level of 13.1 mg/dL) suggest that the patient is receiving adequate care for their cardiovascular and renal issues. Given these factors, the patient's overall prognosis is more favorable than the other options.

2. Sudden Cardiac Death
REASONING: 
While the patient's ECG findings are concerning, the presence of non-sustained ventricular tachycardia and ventricular extrasystole may not necessarily indicate a high risk of sudden cardiac death. The patient is currently asymptomatic, and the presence of these arrhythmias may be related to the underlying cardiac disease rather than a new development. However, the patient's significant renal impairment, hypertension, and diabetes increase the risk of cardiac complications. The patient's LVEF is 40%, which is significantly reduced, indicating some level of cardiac dysfunction. While the patient is taking medications to manage their cardiovascular disease, the presence of multiple comorbidities and the patient's renal impairment increase the risk of cardiac complications. Therefore, while the patient is not at the highest risk, sudden cardiac death is a possible outcome.

3. Pump Failure Death
REASONING: 
Given the patient's significant renal impairment, the presence of ventricular extrasystole and non-sustained ventricular tachycardia, and the patient's LVEF of 40%, the risk of pump failure is relatively high. The patient's renal impairment can lead to fluid overload and cardiac congestion, which can exacerbate cardiac dysfunction. The patient's diabetes and hypertension also increase the risk of cardiac complications. While the patient is taking medications to manage their cardiovascular disease, the presence of multiple comorbidities and the patient's renal impairment increase the risk of cardiac complications. The patient's LVEF is significantly reduced, indicating some level of cardiac dysfunction, which increases the risk of pump failure. Therefore, pump failure is a possible outcome, but it is not the most likely prognosis given the patient's current presentation and management."
92,92,P0150,"Age: 73
Gender: Female 
Weight: 79 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 95/50 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 43,8
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,7
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 135.0
Potassium (mEq/L): 3,64
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 6343.0
Protein (g/L): 63,6
T4 (ng/L): 15,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,78
Urea (mg/dL): 13,9
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's age (73) is a significant risk factor for cardiac events, but the patient's NYHA class (III) and the presence of valvular cardiomyopathy suggest a pre-existing heart condition that may limit the patient's ability to tolerate physical stress. However, the patient's current medication regimen includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are commonly used to manage heart failure and hypertension. The patient's LVEF (20.0) is severely impaired, indicating significant left ventricular dysfunction, but the patient's troponin level (0.01 ng/mL) is within normal limits, suggesting that there is no acute myocardial infarction. The patient's ECG shows ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia, which are all concerning for ventricular arrhythmias. However, the patient's overall clinical presentation and laboratory results do not suggest acute heart failure or acute coronary syndrome.

2. Sudden Cardiac Death
REASONING: 
The patient's severe left ventricular dysfunction (LVEF 20.0) and the presence of ventricular arrhythmias (ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia) increase the risk of sudden cardiac death. However, the patient's troponin level is normal, which suggests that there is no acute myocardial infarction. The patient's age (73) and NYHA class (III) also contribute to the risk of sudden cardiac death.

3. Pump Failure Death
REASONING: 
The patient's severely impaired LVEF (20.0) and the presence of ventricular arrhythmias increase the risk of pump failure death. However, the patient's current medication regimen includes diuretics, which are commonly used to manage heart failure. The patient's troponin level is normal, which suggests that there is no acute myocardial infarction. The patient's ECG shows non-sustained ventricular tachycardia, which may indicate underlying cardiac dysfunction, but the patient's overall clinical presentation and laboratory results do not suggest acute heart failure. The patient's age (73) and NYHA class (III) also contribute to the risk of pump failure death."
93,93,P0152,"Age: 64
Gender: Female 
Weight: 90 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,5
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 135.0
Potassium (mEq/L): 4,04
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1312.0
Protein (g/L): 68,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,95
Urea (mg/dL): 9,8
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient's prognosis is most likely to be a survivor due to several factors. Firstly, the patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activity without excessive shortness of breath. This suggests that their heart is still functional enough to support daily activities. 

Additionally, the patient's LVEF (left ventricular ejection fraction) is 40%, which is a relatively preserved ejection fraction, indicating that the patient's heart is still pumping blood efficiently to some extent.

The patient's biomarkers, such as troponin, creatinine, and urea, are not excessively elevated, suggesting that the patient's kidney function is not severely impaired. The patient's liver function, as indicated by ALT and AST levels, is also within normal limits.

The patient's medications, including beta blockers, ACE inhibitors, and statins, are typical for managing heart failure and hypertension, which suggests that the patient is receiving appropriate treatment.

The only concerning ECG finding is ventricular extrasystole, but it is polymorphic, which may not necessarily indicate a high risk of sudden cardiac death. Overall, the patient's clinical presentation and laboratory results suggest that they are likely to survive for the next few years with proper management and treatment.

While there is always a risk of sudden cardiac death in patients with heart failure, the patient's overall clinical profile suggests that they are at moderate risk, rather than high risk. Therefore, the most likely prognosis is that the patient will survive for the next few years with proper management and treatment."
94,94,P0154,"Age: 59
Gender: Male 
Weight: 96 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 127.0
Potassium (mEq/L): 4,28
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 706.0
Protein (g/L): 73,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,8
Urea (mg/dL): 6,3
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's overall prognosis is most likely to be a survivor due to several factors. Firstly, the patient's NYHA Class II indicates that they have mild symptoms of heart failure, which suggests that their cardiac function is still relatively preserved. Additionally, their LVEF of 25.0% is significantly better than the expected value for someone with dilated cardiomyopathy, which suggests that they may still have some residual cardiac function.

Furthermore, the patient's ECG impression shows no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death. The presence of ventricular extrasystoles, while concerning, is not necessarily a predictor of mortality.

The patient's laboratory results also suggest that their kidney function is compromised (elevated creatinine and urea levels), but this is likely a result of their underlying conditions (diabetes and peripheral vascular disease) rather than a direct consequence of their heart disease. Their liver function is also mildly impaired, but this is not uncommon in patients with heart failure.

The patient's medication regimen includes beta blockers, ACE inhibitors, and diuretics, which are all standard treatments for heart failure and are likely to have a positive impact on their prognosis.

Overall, while the patient's underlying conditions and laboratory results raise some concerns, their cardiac function is relatively preserved, and their medication regimen suggests that they are receiving appropriate treatment for their heart disease, making a survival outcome the most likely.

2. Sudden cardiac death
REASONING:
A sudden cardiac death outcome is less likely due to the patient's relatively preserved cardiac function and the absence of any high-risk ECG findings. However, the patient's history of myocardial infarction and peripheral vascular disease may increase their risk of sudden cardiac death, particularly if there are any underlying coronary artery disease or cardiac arrhythmias that are not being adequately managed.

3. Pump failure death
REASONING:
A pump failure death outcome is the least likely due to the patient's relatively preserved LVEF and the presence of a NYHA Class II classification. While the patient's kidney function is compromised, this is not a direct consequence of their heart disease, and their medication regimen includes diuretics, which are likely to help manage fluid overload and improve cardiac function.

However, the patient's elevated troponin levels and low LVEF suggest that there may be some residual cardiac dysfunction, and their ECG impression shows ventricular extrasystoles, which could potentially lead to arrhythmias and cardiac instability. Nevertheless, these factors do not strongly suggest a high risk of pump failure death, and the patient's overall clinical presentation and medication regimen suggest that a pump failure death outcome is less likely than a sudden cardiac death or survival."
95,95,P0156,"Age: 53
Gender: Male 
Weight: 82 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 40,3
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 11,6
Hemoglobin (g/L): 153.0
Potassium (mEq/L): 3,41
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 157.0
Protein (g/L): 66,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,79
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's LVEF (Left Ventricular Ejection Fraction) of 35.0 indicates significant left ventricular dysfunction, which is a common complication in patients with dilated cardiomyopathy. However, the patient is currently on medications for heart failure management (Beta Blockers, Digoxin, Loop Diuretics, and ACE Inhibitor), which suggests that the patient is receiving appropriate treatment for their condition.

The patient's Pro-BNP levels are elevated at 157.0 ng/L, which is indicative of ventricular strain and increased pressure overload. However, the patient's Troponin levels are normal, which suggests that there is no significant myocardial damage.

The ECG findings of ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia are concerning, but the absence of sustained ventricular tachycardia and the presence of a normal LVEF suggest that the patient is not currently experiencing severe cardiac instability.

Considering these factors, the patient's overall prognosis is more likely to be a survivor, as they are receiving appropriate treatment for their condition and have not shown significant evidence of acute cardiac injury or instability.

RANKING: 2. Sudden Cardiac Death
REASONING:
The patient's ECG findings of ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia are concerning for an increased risk of arrhythmic events. While the patient is receiving beta blockers, which can help reduce the risk of arrhythmias, the presence of polymorphic ventricular tachycardia and ventricular extrasystole on the ECG suggests that the patient may still be at risk for life-threatening arrhythmias.

Additionally, the patient's LVEF of 35.0 indicates significant left ventricular dysfunction, which can increase the risk of sudden cardiac death.

However, the patient's normal Troponin levels and the absence of sustained ventricular tachycardia on the ECG suggest that the patient is not currently experiencing severe cardiac injury or instability.

RANKING: 3. Pump Failure Death
REASONING:
The patient's LVEF of 35.0 indicates significant left ventricular dysfunction, which is a major predictor of heart failure and pump failure. The patient's elevated Pro-BNP levels and the presence of edema are also indicative of heart failure.

While the patient is receiving medications for heart failure management, the presence of significant left ventricular dysfunction and elevated Pro-BNP levels suggest that the patient is at risk for pump failure.

However, the patient's normal Troponin levels and the absence of evidence of acute cardiac injury on the ECG suggest that the patient is not currently experiencing severe cardiac injury or instability.

Overall, while the patient is at risk for pump failure, the presence of significant left ventricular dysfunction and elevated Pro-BNP levels suggest that this is the most likely outcome compared to sudden cardiac death."
96,96,P0158,"Age: 65
Gender: Female 
Weight: 96 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 140/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45,3
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,16
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 125.0
Potassium (mEq/L): 4,73
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 288.0
Protein (g/L): 76,8
T4 (ng/L): 18,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,18
Urea (mg/dL): 8,5
LVEF (%): 39.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor 
REASONING: 
Based on the patient's data, the most likely outcome is a survivor. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activity without excessive fatigue. The patient's ejection fraction (LVEF) is significantly reduced at 39%, indicating that the heart is not pumping efficiently. However, the patient is not in cardiogenic shock, and their heart is still able to maintain a relatively normal blood pressure (140/85 mmHg). The presence of ventricular extrasystoles and paroxysmal supraventricular tachycardia (PSVT) suggests that the heart is not functioning optimally, but it is not immediately life-threatening.

The patient's electrolyte levels, including potassium (4.73 mEq/L) and sodium (138 mEq/L), are within normal limits, and their liver enzymes (ALT and AST) are not significantly elevated. The patient's troponin levels are normal, which suggests that there is no significant myocardial damage. The patient's protein levels are also within normal limits, which suggests that there is no significant kidney dysfunction.

The patient's medication regimen includes a range of treatments for heart failure, hypertension, and dyslipidemia, which suggests that the patient is receiving optimal care for their underlying conditions. 

Overall, while the patient has significant cardiac dysfunction, their symptoms are not severe, and they are receiving optimal medical therapy. Therefore, the most likely outcome is a survivor."
97,97,P0162,"Age: 76
Gender: Female 
Weight: 71 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 150/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37,7
ALT or GPT (IU/L): 85.0
AST or GOT (IU/L): 63.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 199
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1
Potassium (mEq/L): 3,84
LDL (mmol/L): 2,85
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 6915.0
Protein (g/L): 69,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,09
Urea (mg/dL): 8,1
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient's prognosis as a survivor. The patient's age, NYHA Class III, and LVEF of 30.0 indicate significant cardiac dysfunction, which increases the risk of cardiac events. However, the patient's current medical history, laboratory results, and ECG findings do not suggest an immediate life-threatening condition.

The patient's elevated creatinine level (105.0 mmol/L) and elevated Troponin level (0.01 ng/mL) may indicate some degree of cardiac damage, but the Troponin level is within a non-significant range. The patient's Pro-BNP level (6915.0 ng/L) is elevated, which is consistent with heart failure, but it is not extremely high.

The patient's ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) indicate an increased risk of arrhythmic events, but these findings are non-sustained and not indicative of a life-threatening rhythm disturbance. The patient's Paroxysmal supraventricular tachyarrhythmia (PSVT) is not a concern, and the absence of bradycardia is also reassuring.

The patient's current medication regimen, which includes digoxin, loop diuretics, and an ACE inhibitor, suggests that they are being adequately managed for heart failure and hypertension. The patient's laboratory results, including the slightly elevated liver enzymes (ALT and AST) and slightly elevated cholesterol, are consistent with the patient's known medical history of dyslipidemia and hypertension.

Overall, while the patient has a significant medical history and current cardiac dysfunction, the absence of a life-threatening arrhythmia, the patient's current medication regimen, and the relatively mild elevation in Pro-BNP and Troponin levels suggest that the patient is likely to survive the next few years with proper management and monitoring."
98,98,P0163,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40,5
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,43
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,82
LDL (mmol/L): 4,43
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 469.0
Protein (g/L): 72,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 4,8
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING:
Based on the provided patient data, the patient is a 71-year-old female with a history of hypertensive cardiomyopathy and hypertension. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activities without significant limitation. The patient's LVEF is 55%, which is within the range for a patient with NYHA Class II heart failure. The patient's creatinine level is elevated at 89.0 mmol/L, indicating some degree of renal impairment, but it is not severe.

The patient's laboratory results show elevated troponin levels (0.01 ng/mL) and a high Pro-BNP level (469.0 ng/L), which indicate some degree of cardiac stress and strain. However, the troponin level is not significantly elevated, which suggests that the patient may not have had a recent myocardial infarction.

The patient is currently taking beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and hypertension. The patient's ECG results show no signs of ventricular tachycardia or bradycardia, which are potential indicators of cardiac arrhythmias.

Given the patient's overall clinical presentation, laboratory results, and treatment, the most likely outcome is that the patient will survive for the next few years. The patient's NYHA Class II status and LVEF of 55% suggest that they have some residual cardiac function, which should allow them to continue to manage their symptoms and tolerate some level of physical activity. However, the patient's elevated creatinine level and Pro-BNP level suggest that they may require close monitoring and adjustments to their treatment regimen to prevent further decline in their cardiac function.

RANKING: 
2. Sudden Cardiac Death
REASONING:
The patient's elevated Pro-BNP level (469.0 ng/L) and troponin level (0.01 ng/mL) suggest that the patient's cardiac function is under some degree of stress, which may increase the risk of sudden cardiac death. The patient's NYHA Class II status and LVEF of 55% also suggest that they are at risk for cardiac complications.

However, the patient's ECG results show no signs of ventricular tachycardia or bradycardia, which are potential indicators of cardiac arrhythmias that can increase the risk of sudden cardiac death. The patient's current treatment regimen includes beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and hypertension.

While the patient's elevated creatinine level and Pro-BNP level do increase the risk of cardiac complications, the patient's overall clinical presentation and laboratory results do not suggest a high risk for sudden cardiac death.

RANKING: 
3. Pump Failure Death
REASONING:
The patient's NYHA Class II status and LVEF of 55% suggest that they have some residual cardiac function, which should allow them to tolerate some level of physical activity. The patient's elevated creatinine level (89.0 mmol/L) and Pro-BNP level (469.0 ng/L) do suggest that the patient's cardiac function is under some degree of strain, which may increase the risk of pump failure.

However, the patient's current treatment regimen includes beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and hypertension. These medications should help to reduce the strain on the patient's cardiac function and prevent pump failure.

Given the patient's overall clinical presentation and laboratory results, the risk of pump failure death is lower than the risk of sudden cardiac death, but higher than the risk of survival. The patient's elevated creatinine level and Pro-BNP level do increase the risk of cardiac complications, but the patient's overall clinical presentation and treatment regimen suggest that they should be able to manage their symptoms and tolerate some level of physical activity without significant decline in cardiac function."
99,99,P0164,"Age: 78
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 34,4
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,58
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 133
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,25
Potassium (mEq/L): 4,44
LDL (mmol/L): 1,89
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2104.0
Protein (g/L): 62,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,84
Urea (mg/dL): 8,1
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

This patient is at high risk for a poor outcome due to the presence of several factors that indicate advanced cardiac disease. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death and heart failure. The patient's left ventricular ejection fraction (LVEF) of 35% further supports this, as a normal LVEF is typically above 55%.

The patient's elevated troponin levels (0.01 ng/mL) and Pro-BNP levels (2104.0 ng/L) indicate some degree of cardiac stress and possible cardiac remodeling, which can contribute to heart failure. Additionally, the patient's elevated creatinine level (8.1 mg/dL) and urea level (8.1 mg/dL) suggest some degree of renal impairment, which can be a complication of advanced heart failure.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia (NSVT) on the ECG is concerning for arrhythmias, which can lead to sudden cardiac death. The patient's NYHA Class II heart failure classification also indicates that they are experiencing symptoms of heart failure, which can lead to a decline in functional capacity and overall survival.

While the patient is currently receiving medications for heart failure and arrhythmias, the combination of advanced cardiac disease and renal impairment suggests that the patient is at high risk for a poor outcome. Therefore, the most likely prognosis is survivor, but with a high risk of complications such as sudden cardiac death and pump failure death.

It is essential to closely monitor the patient's condition and adjust their treatment plan as needed to minimize the risk of complications."
100,100,P0165,"Age: 76
Gender: Female 
Weight: 70 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 213/110 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,6
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,67
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,28
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,2
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 366.0
Protein (g/L): 75,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,92
Urea (mg/dL): 8,4
LVEF (%): 45.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I would rank the prognoses as follows, with the highest likelihood of survival. 

Firstly, the patient's age (76 years) is a significant factor in determining prognosis. However, the patient's NYHA Class II indicates that they have a relatively mild heart failure, which may contribute to a better prognosis.

The patient's ECG impression shows no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all indicators of cardiac arrhythmias that can lead to sudden cardiac death. The presence of ventricular extrasystoles is noted, but it is not a definitive predictor of sudden cardiac death.

The patient's laboratory results show elevated creatinine levels, which indicate kidney impairment, but this is not directly related to cardiac prognosis. The patient's troponin levels are within normal limits, suggesting no significant myocardial damage.

The patient's medication regimen includes an angiotensin II receptor blocker, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for hypertension, heart failure, and hyperlipidemia. This suggests that the patient is receiving optimal medical management for their conditions.

Considering these factors, I would rank the prognoses as follows:

1. Survivor: The patient's age, NYHA Class II, and optimal medication regimen suggest a relatively good prognosis. The absence of cardiac arrhythmias and normal troponin levels further support this.

2. Pump failure death: While the patient has kidney impairment and elevated creatinine levels, these are not directly related to cardiac prognosis. The patient's medication regimen and ECG results do not indicate a high risk of sudden cardiac death or pump failure.

3. Sudden cardiac death: The patient's ECG results and laboratory results do not indicate a high risk of sudden cardiac death. The presence of ventricular extrasystoles is noted, but it is not a definitive predictor of sudden cardiac death. Overall, the patient's overall clinical picture suggests a lower risk of sudden cardiac death."
101,101,P0166,"Age: 75
Gender: Female 
Weight: 68 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 190/80 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,16
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 4,08
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 746.0
Protein (g/L): 75,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,18
Urea (mg/dL): 7,9
LVEF (%): 69.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has several factors that suggest a good prognosis, including:

- Age: 75 years, which is considered older, but not extremely old for a patient with valvular cardiomyopathy.
- NYHA Class II, indicating mild symptoms, which suggests a relatively preserved cardiac function.
- Hemoglobin level of 131.0 g/L, which is within the normal range, indicating adequate oxygen delivery to the tissues.
- Normal liver enzymes (ALT and AST), which suggests that there is no acute liver injury or inflammation.
- Creatinine level of 7.9 mg/dL, which is slightly elevated but not indicative of severe kidney dysfunction.
- Normal TSH level, which suggests that the thyroid function is within the normal range.
- Low troponin level (0.01 ng/mL), which suggests that there is no significant myocardial damage.
- Presence of beta blockers, digoxin, loop diuretics, and ACE inhibitor, which are standard treatments for valvular cardiomyopathy and suggest that the patient is receiving appropriate management.
- ECG impression of ventricular extrasystole and polymorphic ventricular tachycardia, which may indicate an underlying arrhythmia, but not a life-threatening one.
- Protein level of 75.9 g/L, which is within the normal range, indicating adequate nutrition.
- Pro-BNP level of 746.0 ng/L, which is elevated, but not extremely high, suggesting some degree of cardiac stress, but not indicating heart failure.

These factors suggest that the patient is likely to survive for the next few years, but regular monitoring and follow-up are necessary to adjust the treatment plan as needed to prevent complications."
102,102,P0167,"Age: >89
Gender: Male 
Weight: 78 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 150/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 2,92
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 114.0
Potassium (mEq/L): 4,2
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 3724.0
Protein (g/L): 65
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,45
Urea (mg/dL): 9,6
LVEF (%): 60.0
Medications: Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING:
This patient's prognosis is ranked as survivor due to several factors. Firstly, the patient's age (>89 years) may not be considered high-risk for sudden cardiac death (SCD) or pump failure death in itself, but the presence of ischemic dilated cardiomyopathy and a history of myocardial infarction increase the risk of adverse cardiac events. The patient's ejection fraction (LVEF) of 60.0 is also lower than normal, indicating some degree of cardiac dysfunction.

The patient's ECG findings, including ventricular extrasystoles and unknown bradycardia, suggest that the patient may have underlying cardiac arrhythmias. However, the absence of sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia reduces the likelihood of SCD.

The patient's medication regimen, including loop diuretics, ACE inhibitor, and nitrovasodilator, suggests that the patient is being managed for heart failure and hypertension. The patient's serum creatinine level of 9.6 mg/dL indicates some degree of renal impairment, but it is not severe.

The patient's laboratory results, including elevated troponin levels and reduced LVEF, suggest some degree of cardiac damage and dysfunction. However, the patient's overall clinical picture, including the absence of severe symptoms and the presence of a medication regimen, suggests that the patient is being managed effectively.

Overall, while the patient's cardiac condition is complex and there are some risk factors for adverse cardiac events, the patient's age, medication regimen, and clinical presentation suggest that the patient is likely to survive in the short term.

2. Sudden Cardiac Death 
REASONING:
This patient's prognosis is ranked as SCD due to several factors. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. The patient's LVEF of 60.0 is also lower than normal, indicating some degree of cardiac dysfunction.

The patient's ECG findings, including ventricular extrasystoles, suggest that the patient may have underlying cardiac arrhythmias that could increase the risk of SCD. The absence of sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia is not a strong argument against SCD, as ventricular extrasystoles can be a precursor to more serious arrhythmias.

The patient's medication regimen, including loop diuretics, ACE inhibitor, and nitrovasodilator, suggests that the patient is being managed for heart failure and hypertension, but it does not specifically address the risk of SCD.

The patient's laboratory results, including elevated troponin levels and reduced LVEF, suggest some degree of cardiac damage and dysfunction, which increases the risk of SCD.

Overall, while the patient's cardiac condition is complex, the patient's risk factors for SCD, including the patient's history of myocardial infarction and ischemic dilated cardiomyopathy, and the patient's ECG findings, suggest that the patient is at risk for SCD.

3. Pump Failure Death 
REASONING:
This patient's prognosis is ranked as pump failure death due to several factors. The patient's LVEF of 60.0 is lower than normal, indicating some degree of cardiac dysfunction. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy also increases the risk of pump failure.

The patient's ECG findings, including ventricular extrasystoles, suggest that the patient may have underlying cardiac arrhythmias that could increase the risk of pump failure. The absence of sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia is not a strong argument against pump failure, as ventricular extrasystoles can be a precursor to more serious arrhythmias.

The patient's medication regimen, including loop diuretics, ACE inhibitor, and nitrovasodilator, suggests that the patient is being managed for heart failure and hypertension. However, the patient's serum creatinine level of 9.6 mg/dL indicates some degree of renal impairment, which may reduce the effectiveness of the patient's medication regimen.

The patient's laboratory results, including elevated troponin levels and reduced LVEF, suggest some degree of cardiac damage and dysfunction, which increases the risk of pump failure.

Overall, while the patient's cardiac condition is complex, the patient's risk factors for pump failure, including the patient's history of myocardial infarction and ischemic dilated cardiomyopathy, and the patient's ECG findings, suggest that the patient is at risk for pump failure."
103,103,P0168,"Age: 88
Gender: Female 
Weight: 66 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 37,9
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 137.0
Potassium (mEq/L): 3,2
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 237.0
Protein (g/L): 70,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,36
Urea (mg/dL): 14,1
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I would rank the patient's prognosis as a survivor. The patient is 88 years old, which is in the advanced age category, but the patient's NYHA Class II indicates that they have mild symptoms of heart failure, which is not severe. The patient's LVEF (60.0) is within a relatively normal range for their age, indicating that the patient's heart function is still relatively preserved.

The patient's blood pressure is well-controlled at 120/60 mmHg, and their medication regimen includes ACE inhibitors, which are beneficial for patients with hypertensive cardiomyopathy. The patient's liver function tests are within normal limits, and their kidney function is also relatively preserved, with a creatinine level of 91.0 mg/dL.

The patient's ECG findings show no signs of ventricular tachycardia or ventricular extrasystole, which are potential predictors of sudden cardiac death. The patient's troponin level is normal, which suggests that there is no evidence of myocardial infarction.

The patient's protein level is slightly elevated at 70.1 g/L, but this is not uncommon in patients with heart failure. The patient's BNP level is elevated at 237.0 ng/L, which indicates some degree of cardiac stress, but this is not excessively high.

Overall, while the patient's age is a significant factor, the patient's overall clinical picture suggests that they are likely to survive for the next few years with proper management and monitoring."
104,104,P0169,"Age: 49
Gender: Male 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,74
Creatinine (mmol/L): 273.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 113.0
Potassium (mEq/L): 4,63
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 17620.0
Protein (g/L): 70
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,49
Urea (mg/dL): 24,2
LVEF (%): 23.0
Medications: Loop Diuretics, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient's overall prognosis is likely to be a survivor. Here's the reasoning behind this ranking:

1. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform daily activities with minimal limitation. This suggests that their heart function is not severely impaired.

2. The patient's LVEF (Left Ventricular Ejection Fraction) is 23%, which is within the range of patients with heart failure. This indicates that the patient's heart is still pumping effectively, but not optimally.

3. The patient's medication regimen includes loop diuretics, statins, hydralazine, and a nitrovasodilator, which are commonly used to manage heart failure, hypertension, and dyslipidemia. This suggests that the patient is receiving standard treatment for their conditions.

4. The patient's ECG findings, including ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, indicate that they have arrhythmias, but these are non-sustained and not indicative of a high risk of sudden cardiac death.

5. The patient's laboratory results, including a slightly elevated creatinine level, indicate some degree of kidney dysfunction, but this is not unusual in patients with heart failure.

6. The patient's biomarker levels, including troponin and BNP, are not significantly elevated, indicating that there is no acute myocardial infarction or significant heart muscle damage.

7. The patient's other laboratory results, including electrolyte levels, liver function tests, and glucose levels, are within normal limits.

Considering these factors, the patient's overall prognosis is likely to be a survivor, with the potential for some degree of heart failure progression over time. However, with proper management and treatment, the patient can still have a relatively good quality of life.

RANKING: 2. Sudden Cardiac Death
REASONING:

Based on the provided patient data, the patient's overall prognosis is unlikely to be sudden cardiac death. Here's the reasoning behind this ranking:

1. The patient's LVEF is 23%, which is a relatively low ejection fraction, indicating some degree of heart muscle dysfunction. However, this is not a contraindication for survival.

2. The patient's ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, indicate some degree of arrhythmia, but these are non-sustained and not indicative of a high risk of sudden cardiac death.

3. The patient's medication regimen includes hydralazine, which is commonly used to manage heart failure and hypertension, and statins, which are used to manage dyslipidemia. This suggests that the patient is receiving standard treatment for their conditions.

4. The patient's laboratory results, including troponin and BNP, are not significantly elevated, indicating no acute myocardial infarction or significant heart muscle damage.

5. The patient's other laboratory results, including electrolyte levels, liver function tests, and glucose levels, are within normal limits.

However, considering the patient's NYHA Class II and LVEF of 23%, there is a moderate risk of sudden cardiac death, especially if the patient's arrhythmias are not well-controlled.

RANKING: 3. Pump Failure Death
REASONING:

Based on the provided patient data, the patient's overall prognosis is unlikely to be pump failure death. Here's the reasoning behind this ranking:

1. The patient's LVEF is 23%, which is a relatively low ejection fraction, indicating some degree of heart muscle dysfunction. However, this is not a contraindication for survival.

2. The patient's ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, indicate some degree of arrhythmia, but these are non-sustained and not indicative of a high risk of pump failure.

3. The patient's medication regimen includes hydralazine, which is commonly used to manage heart failure, and statins, which are used to manage dyslipidemia. This suggests that the patient is receiving standard treatment for their conditions.

4. The patient's laboratory results, including troponin and BNP, are not significantly elevated, indicating no acute myocardial infarction or significant heart muscle damage.

5. The patient's other laboratory results, including electrolyte levels, liver function tests, and glucose levels, are within normal limits.

However, considering the patient's NYHA Class II and LVEF of 23%, there is a moderate risk of heart failure progression over time, but the patient's symptoms are relatively mild, and they are receiving"
105,105,P0170,"Age: 73
Gender: Female 
Weight: 64 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 210/110 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 39,2
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,9
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 107.0
HDL (mmol/L): 1,04
Potassium (mEq/L): 4,03
LDL (mmol/L): 2,96
Sodium (mEq/L): 139.0
Protein (g/L): 74,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,19
Urea (mg/dL): 8,4
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is 73 years old with a history of hypertension, hypertensive cardiomyopathy, diabetes, and other comorbid conditions. Despite these factors, the patient's current ECG impression does not show any life-threatening arrhythmias, such as ventricular tachycardia or tachyarrhythmias, which are common causes of sudden cardiac death. The presence of ventricular extrasystoles is a common finding in older adults and is often benign. The patient's LVEF is 70%, which is within a relatively normal range, indicating that the patient's heart is still functioning adequately. The patient is also on a regimen of medications that are commonly used to manage hypertension and heart failure, which suggests that the patient is receiving appropriate treatment. Additionally, the patient's troponin levels are normal, which suggests that there is no evidence of myocardial infarction. Overall, the combination of a normal ECG, normal LVEF, and appropriate medication regimen make it more likely that the patient will survive for the next few years.

RANKING: 2. Pump failure death
REASONING: 

The patient's LVEF is 70%, which is slightly below the normal range for a 73-year-old female. This suggests that the patient's heart is not functioning as well as it could be, and there is a potential for heart failure to develop in the future. The patient's elevated blood pressure and creatinine levels also suggest that the patient may have some degree of cardiac dysfunction. While the patient is on a regimen of medications to manage hypertension and heart failure, there is still a risk of pump failure in the future. Additionally, the patient's elevated troponin levels, although within the normal range, may indicate some degree of cardiac stress or inflammation.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's ECG impression shows ventricular extrasystoles, which can be a sign of underlying cardiac disease. However, this finding alone is not sufficient to predict sudden cardiac death. The patient's age, comorbidities, and elevated blood pressure also increase the risk of sudden cardiac death. Additionally, the patient's LVEF is slightly below normal, which could increase the risk of cardiac arrhythmias. However, the patient is on a regimen of medications to manage hypertension and heart failure, and the patient's troponin levels are normal. Overall, while there is some risk of sudden cardiac death, the combination of a normal ECG, normal LVEF, and appropriate medication regimen make it less likely than pump failure death."
106,106,P0171,"Age: 75
Gender: Male 
Weight: 76 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Toxic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 121.0
Potassium (mEq/L): 4,43
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 10060.0
Protein (g/L): 67,9
Troponin (ng/mL): 0,14
TSH (mIU/L): 0,74
Urea (mg/dL): 9
LVEF (%): 20.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
This patient is a 75-year-old male with a history of toxic dilated cardiomyopathy, dyslipidemia, and hypertension, which are all risk factors for cardiac complications. His current NYHA Class II indicates that he has some symptoms of heart failure, but it's not severe enough to limit his daily activities. His ECG findings of ventricular extrasystole and polymorphic ventricular tachycardia are concerning, but they are not indicative of a high risk for sudden cardiac death. The absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk of arrhythmia-related complications.

The patient's elevated creatinine level (119.0) suggests some degree of renal impairment, which may be related to his cardiac condition. However, his hemoglobin and potassium levels are within normal limits, and his troponin level is not elevated, indicating that he is not experiencing acute myocardial infarction.

The patient's LVEF of 20.0 is significantly reduced, indicating poor cardiac function, but it's not immediately life-threatening. His current medications, loop diuretics and ACE inhibitor, are standard treatments for heart failure and hypertension.

Considering these factors, I predict that the patient will survive for the next few years, although he may require close monitoring and adjustments to his treatment plan to manage his cardiac condition and prevent further decline.

2. Sudden cardiac death
REASONING:
This patient's history of toxic dilated cardiomyopathy, dyslipidemia, and hypertension increases his risk for cardiac complications, including sudden cardiac death. The presence of ventricular extrasystole and polymorphic ventricular tachycardia on his ECG is concerning, as these arrhythmias can be precursors to life-threatening rhythms.

However, the absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. The patient's LVEF of 20.0 is significantly reduced, indicating poor cardiac function, which increases the risk of sudden cardiac death.

3. Pump failure death
REASONING:
Pump failure death is a possible outcome for this patient, given his poor cardiac function (LVEF of 20.0) and history of heart failure. However, his current treatment plan, including loop diuretics and ACE inhibitor, is standard for managing heart failure, and his NYHA Class II symptoms suggest that he is not in acute decompensated heart failure.

Additionally, his elevated creatinine level (119.0) may indicate some degree of renal impairment, but it's not immediately life-threatening. While pump failure is a possible outcome, I consider it less likely than sudden cardiac death, given the patient's current ECG findings and the presence of medications that can help manage his cardiac condition."
107,107,P0173,"Age: 83
Gender: Female 
Weight: 69 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 112.0
Potassium (mEq/L): 4,49
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 3532.0
Protein (g/L): 65,4
T4 (ng/L): 23,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,1
Urea (mg/dL): 8,4
LVEF (%): 28.0
Medications: Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at a higher risk for sudden cardiac death due to the presence of ischemic dilated cardiomyopathy, which is a significant risk factor for arrhythmias and sudden cardiac death. The patient's LVEF is severely impaired at 28%, indicating advanced heart failure. The patient's ECG impression shows a polymorphic ventricular extrasystole, which is a marker of increased risk for ventricular arrhythmias. However, the absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the likelihood of sudden cardiac death. The patient's hemoglobin level is elevated, which may indicate anemia, but this is not directly related to cardiac function. The patient is currently on medications that are commonly used to manage heart failure and hypertension, which suggests that the patient's condition is being managed. Overall, the patient's symptoms and test results suggest that the patient is at high risk for heart failure exacerbation and arrhythmias, but the patient is currently being managed, making a sudden cardiac death less likely."
108,108,P0174,"Age: 79
Gender: Female 
Weight: 66 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 10
Hemoglobin (g/L): 111.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 5,6
LDL (mmol/L): 2,02
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 505.0
Protein (g/L): 81
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,16
Urea (mg/dL): 21,63
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's age, NYHA Class III, and medical history of hypertension, cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease, the patient is at high risk for cardiovascular events. The patient's elevated creatinine level (159.0 mmol/L) and low LVEF (70.0%) also suggest significant cardiac impairment. However, the patient's current ECG impression does not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or atrial fibrillation, which are common predictors of sudden cardiac death. 

Additionally, the patient's current medications, including beta blockers and ACE inhibitors, are standard treatments for managing hypertension and heart failure, which further reduces the risk of sudden cardiac death. The patient's current ECG shows a first-degree atrioventricular block (AVB), which is a relatively common finding in patients with heart failure and is not typically a cause for concern.

Given these factors, the most likely outcome for the patient is a survivor, with a reasonable chance of managing their condition with current treatment. 

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's medical history and current ECG impression do not show any immediate signs of ventricular tachycardia or non-sustained ventricular tachycardia, the patient's age, NYHA Class III, and elevated creatinine level still increase the risk of cardiovascular events. The patient's LVEF is also below normal, indicating significant cardiac impairment.

However, the patient's current ECG shows a first-degree AVB, which may indicate some degree of cardiac conduction system dysfunction. This could potentially increase the risk of sudden cardiac death, particularly if the patient experiences a significant arrhythmia event.

Additionally, the patient's medical history of myocardial infarction and peripheral vascular disease increases the risk of cardiovascular events. However, the patient's current medications, including beta blockers and ACE inhibitors, are standard treatments for managing hypertension and heart failure, which reduces the risk of sudden cardiac death.

Given these factors, the patient is at increased risk of sudden cardiac death, but the risk is still lower than if the patient were to experience a severe cardiac event, such as a myocardial infarction or cardiac arrest.

RANKING: 3. Pump failure death
REASONING: 

The patient's NYHA Class III classification and elevated creatinine level suggest significant cardiac impairment and renal dysfunction, which can increase the risk of pump failure. The patient's LVEF is also below normal, indicating some degree of left ventricular dysfunction.

The patient's medical history of hypertension, cardiomyopathy, diabetes, and dyslipemia also increase the risk of pump failure. However, the patient's current medications, including beta blockers and ACE inhibitors, are standard treatments for managing hypertension and heart failure, which can help reduce the risk of pump failure.

Additionally, the patient's current ECG shows a first-degree AVB, which may indicate some degree of cardiac conduction system dysfunction. However, this is not a significant predictor of pump failure.

Given these factors, the patient is at increased risk of pump failure, but the risk is still relatively low if the patient receives optimal management with current treatment. However, the patient's overall condition is complex, and the risk of pump failure is still a concern."
109,109,P0175,"Age: 48
Gender: Female 
Weight: 69 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,86
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 572.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,91
Urea (mg/dL): 3,66
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy suggest that the patient has a significant underlying cardiac condition. However, the patient's current medical history and medication regimen (Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor) indicate a relatively stable cardiovascular system. The patient's LVEF of 42.0 is somewhat low but not severely impaired, which may indicate some residual cardiac function. The absence of signs of acute myocardial infarction, ventricular tachycardia, or other life-threatening arrhythmias on the ECG suggests that the patient's cardiac function is currently stable. Additionally, the patient's Pro-BNP level is elevated, which could indicate some degree of heart failure, but the absence of other signs of heart failure (e.g., edema, shortness of breath) and the patient's relatively good kidney function (creatinine 88.0) suggest that the patient may be able to tolerate ongoing medical therapy. Overall, these factors suggest that the patient has a relatively good prognosis.

2. Sudden Cardiac Death
REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy and a low LVEF, the patient's current medical history and medication regimen do not suggest an immediate risk of sudden cardiac death. The absence of signs of acute myocardial infarction, ventricular tachycardia, or other life-threatening arrhythmias on the ECG suggests that the patient's cardiac function is currently stable. However, the patient's elevated Pro-BNP level and low LVEF do indicate some degree of cardiac dysfunction, which could potentially increase the risk of arrhythmias or sudden cardiac death in the future. However, the patient's age, weight, and other laboratory values do not suggest a high risk of sudden cardiac death.

3. Pump Failure Death
REASONING: 
The patient's low LVEF (42.0) and elevated Pro-BNP level suggest that the patient's cardiac function is compromised. However, the patient's current NYHA Class II and the presence of medications that can help manage heart failure (Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor) suggest that the patient's symptoms are currently well-managed. Additionally, the patient's kidney function and other laboratory values are relatively normal, which suggests that the patient may not be at high risk of acute kidney injury or other complications that could lead to pump failure. While the patient's cardiac function is compromised, the presence of a relatively stable cardiovascular system and good medication regimen suggest that the patient is unlikely to experience pump failure in the near future."
110,110,P0177,"Age: 76
Gender: Male 
Weight: 90 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,69
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 110.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,65
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 948.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 26
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,29
Urea (mg/dL): 6,82
LVEF (%): 43.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient's prognosis is ranked as a survivor due to several factors. Firstly, the patient's age of 76 is relatively young for a patient with significant cardiac disease, which may indicate a more preserved cardiovascular reserve. Additionally, the patient has a relatively normal hemoglobin level and normal kidney function, suggesting that they are not in the advanced stages of renal failure. The patient's LVEF of 43% is significantly reduced, indicating severe left ventricular dysfunction, but this is not uncommon in patients with ischemic dilated cardiomyopathy. 

The patient's ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning but do not necessarily indicate an immediate risk of sudden cardiac death. The patient's blood pressure is well-controlled, and the absence of significant hyperkalemia or hypokalemia suggests that the patient is not at high risk for cardiac arrhythmias. The patient's medication regimen is comprehensive, with all standard treatments for heart failure and arrhythmias.

While the patient's Pro-BNP level is elevated, indicating some level of cardiac stress, it is not excessively high, and the patient's symptoms are not severe. Overall, these factors suggest that the patient has a relatively stable condition, and with proper management, they are likely to survive for the next few years."
111,111,P0179,"Age: 74
Gender: Male 
Weight: 98 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,69
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 408.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 26
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,02
Urea (mg/dL): 6,32
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's age (74 years) and NYHA Class II heart failure classification indicate that they have a significant amount of cardiac damage and functional impairment. However, the patient's LVEF is 29%, which is still within the range for a heart failure classification of NYHA II. Additionally, the patient is taking medications for heart failure management, including ACE inhibitors, which can help improve symptoms and reduce mortality. The patient's laboratory values, such as the elevated creatinine and urea levels, suggest renal impairment, which can be a complication of heart failure. However, the patient's troponin levels are within normal limits, indicating no acute myocardial infarction.

The patient's ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, are concerning for cardiac arrhythmias, but the presence of these findings is not uncommon in patients with heart failure. The patient's Pro-BNP levels are elevated, indicating fluid overload and increased cardiac stress, but the patient is already on diuretics, which can help reduce fluid overload.

Given the patient's overall clinical presentation, medication regimen, and laboratory values, the most likely prognosis is survival. The patient's cardiac function is compromised, but they are receiving appropriate treatment for heart failure and cardiac arrhythmias. With proper management, it is possible for the patient to survive for several years.

2. Sudden Cardiac Death
REASONING: 
The patient's age and NYHA Class II heart failure classification increase the risk of sudden cardiac death. The patient's LVEF of 29% is significantly reduced, indicating severe cardiac dysfunction. The patient's elevated creatinine and urea levels suggest renal impairment, which can be a complication of heart failure. The presence of non-sustained ventricular tachycardia on the ECG is a significant risk factor for sudden cardiac death.

The patient's Pro-BNP levels are elevated, indicating fluid overload and increased cardiac stress. The patient's troponin levels are within normal limits, but the patient's ECG findings of ventricular extrasystoles and non-sustained ventricular tachycardia suggest a high risk of cardiac arrhythmias. The patient's age and medical history also increase the risk of sudden cardiac death.

While the patient is taking medications for heart failure and cardiac arrhythmias, the presence of these risk factors and the patient's overall clinical presentation make sudden cardiac death a possible outcome.

3. Pump Failure Death
REASONING: 
The patient's LVEF of 29% is significantly reduced, indicating severe cardiac dysfunction. The patient's NYHA Class II classification indicates that they have significant symptoms of heart failure, including shortness of breath and fatigue. The patient's elevated creatinine and urea levels suggest renal impairment, which can be a complication of heart failure.

The patient's Pro-BNP levels are elevated, indicating fluid overload and increased cardiac stress. The patient's troponin levels are within normal limits, but the patient's ECG findings of ventricular extrasystoles and non-sustained ventricular tachycardia suggest a high risk of cardiac arrhythmias.

Given the patient's severe cardiac dysfunction, fluid overload, and renal impairment, pump failure death is a possible outcome. However, the patient is already receiving medications for heart failure and cardiac arrhythmias, which can help manage symptoms and reduce mortality. The patient's overall clinical presentation and laboratory values suggest that pump failure death is less likely than sudden cardiac death."
112,112,P0181,"Age: 69
Gender: Male 
Weight: 100 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,84
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 273.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,83
Urea (mg/dL): 8,49
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to several factors. Firstly, the patient's NYHA class is II, indicating mild symptoms of heart failure, but not severe enough to classify as NYHA class III or IV. This suggests that the patient's heart is still functioning relatively well and is capable of meeting daily demands without significant symptoms. 

Additionally, the patient's LVEF is 39%, which is still within a relatively normal range for a 69-year-old male. Although this is lower than the average LVEF for a healthy individual of the same age, it is not drastically low, indicating that the patient's heart is still pumping blood effectively.

The patient's laboratory results also show a relatively stable and well-managed condition, with no significant elevation in liver enzymes, kidney function, or electrolytes. The patient's medication regimen is well-established, with a combination of beta blockers, statins, and an ACE inhibitor, which are all standard treatments for ischemic dilated cardiomyopathy.

While the patient's Pro-BNP level is elevated, this is not uncommon in patients with heart failure and is not indicative of acute decompensation. Furthermore, the patient's troponin level is normal, indicating no significant myocardial damage.

The only concerning factor is the patient's slightly elevated creatinine level, which may indicate some degree of renal impairment. However, this is not uncommon in patients with heart failure and is not necessarily a contraindication to survival.

Overall, based on the available information, the patient's prognosis is ranked as a survivor, with a relatively stable condition and a well-managed medication regimen."
113,113,P0182,"Age: 76
Gender: Male 
Weight: 90 kg
Height: 181 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,4
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 859.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 8,15
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is 76 years old, with a history of ischemic dilated cardiomyopathy and myocardial infarction, and has a reduced left ventricular ejection fraction (LVEF) of 40%. These factors are indicative of advanced heart failure. However, the patient is currently taking beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for heart failure and may help manage symptoms and slow disease progression. Additionally, the patient's hemoglobin level is within a relatively normal range, and their electrolyte levels are also within normal limits.

Although the patient has a history of ventricular extrasystole, which is a type of abnormal heart rhythm, the ECG impression does not indicate any other significant arrhythmias. The patient's troponin level is also within a relatively normal range, suggesting that there is no evidence of acute myocardial infarction.

Given these factors, the patient is likely to survive for the next few years, assuming they continue to receive appropriate medical treatment and make lifestyle modifications to manage their condition. The patient's age and medical history may increase the risk of complications, but the presence of current treatment and normal laboratory values suggest that the patient is at a lower risk of sudden cardiac death or pump failure compared to the other options.

2. Sudden cardiac death
REASONING:
While the patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death, the patient is currently taking medications that can help manage symptoms and slow disease progression. However, the patient's reduced LVEF and elevated BNP levels indicate advanced heart failure, which may increase the risk of sudden cardiac death.

The patient's ECG impression does not indicate any significant arrhythmias, but the presence of ventricular extrasystole is a risk factor for sudden cardiac death. Additionally, the patient's age and medical history may increase the risk of sudden cardiac death.

3. Pump failure death
REASONING:
Given the patient's advanced heart failure, as indicated by their reduced LVEF and elevated BNP levels, pump failure death is a possible outcome. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy also increase the risk of pump failure.

However, the patient is currently taking medications that can help manage symptoms and slow disease progression, and the patient's laboratory values are relatively normal. Additionally, the patient's age and medical history may increase the risk of complications, but the presence of current treatment and normal laboratory values suggest that pump failure is less likely compared to the other options."
114,114,P0184,"Age: 77
Gender: Male 
Weight: 84 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 45
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,64
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 525.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,13
Urea (mg/dL): 7,32
LVEF (%): 37.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's age (77), NYHA Class II (indicating some limitation in physical activity due to heart failure symptoms), and the presence of idiopathic dilated cardiomyopathy, Diabetes, and Dyslipemia, the patient is already at a higher risk for adverse cardiac events. However, the patient's current LVEF of 37.0 is not severely reduced, and the absence of troponin elevation suggests that there is no significant acute myocardial infarction. The patient's ECG shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which are common predictors of sudden cardiac death. Additionally, the patient's medication regimen includes digoxin, which is used to treat atrial fibrillation, but there is no indication of atrial fibrillation on the ECG. Overall, the patient's symptoms and ECG results suggest that the patient is likely to survive for the next few years, but with careful monitoring and management of their underlying conditions.

2. Pump failure death
REASONING: 
While the patient's LVEF of 37.0 is concerning, the patient is not in cardiogenic shock or acute heart failure. The patient is also taking digoxin, which may help improve cardiac function. However, the patient's elevated creatinine level (97.0) and low eGFR (not directly provided, but can be estimated from creatinine) suggest some degree of renal impairment, which can be a complication of heart failure. Additionally, the patient's elevated blood pressure (130/60 mmHg) is higher than the ideal range for patients with heart failure, which can increase the risk of pump failure. However, these factors do not necessarily guarantee pump failure death.

3. Sudden cardiac death
REASONING: 
The patient's ECG shows ventricular extrasystole, which is a type of arrhythmia that can increase the risk of sudden cardiac death. Additionally, the patient's age and NYHA Class II symptoms suggest that the patient is at risk for cardiac arrhythmias. However, the absence of troponin elevation and the presence of digoxin, which is used to treat atrial fibrillation, reduce the likelihood of sudden cardiac death. Nevertheless, the patient's ECG shows ventricular extrasystole, which is a concerning sign that warrants further monitoring and management."
115,115,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is most likely to be a survivor due to several factors. Firstly, the patient is 83 years old, which is considered elderly, but not extremely old. At this age, the patient's overall health status and comorbidities can influence the outcome. The patient's NYHA Class III indicates severe heart failure, but the patient is still on medications that are commonly used to manage heart failure, such as loop diuretics, spironolactone, and ACE inhibitors.

The patient's laboratory results show a mildly elevated troponin level (0.4 ng/mL), which may indicate some degree of cardiac damage, but it is not significantly elevated. The patient's LVEF is 50%, which is a relatively preserved left ventricular function, indicating that the patient's heart is still pumping effectively.

The patient's ECG results show non-sustained ventricular tachycardia, which is a concerning finding, but it is not a contraindication for survival. The patient's other ECG findings do not indicate any other significant arrhythmias.

The patient's medication regimen is comprehensive and addresses the patient's hypertension, heart failure, and arrhythmias. The patient is also receiving digoxin, which is commonly used to manage atrial fibrillation and heart failure.

Overall, considering the patient's age, comorbidities, and medication regimen, the patient's prognosis is more likely to be a survivor.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's ECG results show non-sustained ventricular tachycardia, which is a concerning finding. Non-sustained ventricular tachycardia is a marker of increased risk for sudden cardiac death. However, it is essential to note that the patient's ECG results also show no sustained ventricular tachycardia or other life-threatening arrhythmias.

The patient's other comorbidities, such as hypertension, myocardial infarction, and cardiomyopathy, also increase the risk for sudden cardiac death. However, the patient's medication regimen is comprehensive, and the patient's laboratory results do not indicate any other significant cardiac abnormalities.

RANKING: 3. Pump failure death
REASONING: 

The patient's NYHA Class III indicates severe heart failure, which increases the risk for pump failure death. The patient's LVEF is 50%, which is a relatively preserved left ventricular function, but the patient's elevated creatinine level (1.18 mmol/L) and mildly elevated troponin level (0.4 ng/mL) may indicate some degree of cardiac dysfunction.

The patient's medication regimen is comprehensive, but the patient's elevated BNP level (1094 ng/L) and elevated creatinine level (1.18 mmol/L) may indicate some degree of cardiac dysfunction. The patient's elevated potassium level (4.49 mEq/L) may also be related to cardiac dysfunction.

However, the patient's overall prognosis is still more likely to be a survivor, given the patient's comprehensive medication regimen, relatively preserved LVEF, and absence of other significant cardiac abnormalities."
116,116,P0190,"Age: 58
Gender: Male 
Weight: 103 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,88
LDL (mmol/L): 3,52
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 761.0
Protein (g/L): 72,9
T3 (pg/dL): 0,0636
T4 (ng/L): 15,97
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,66
Urea (mg/dL): 7,6
LVEF (%): 50.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's data, I would rank the patient as a survivor for the next few years. The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy suggest a chronic heart condition that requires ongoing management. However, the patient's hemoglobin level (150.0 g/L) is within the normal range, and the absence of severe anemia or other acute conditions that could lead to sudden cardiac death. The patient's LVEF (50.0%) is below the normal range, but it's not severely impaired, indicating that the heart is still capable of pumping blood effectively. The patient's ECG shows non-sustained ventricular tachycardia, but it's not a significant finding that would increase the risk of sudden cardiac death. The patient is also taking medications that are commonly used to manage heart failure and hypertension, which suggests that the patient is receiving adequate treatment.

While the patient's Pro-BNP level (761.0 ng/L) is elevated, it's not significantly high, and the patient's kidney function (Creatinine 133.0 mmol/L) is within the normal range. The patient's lipid profile is also not significantly abnormal, with total cholesterol (5.33 mmol/L) and LDL (3.52 mmol/L) levels within the normal range. The patient's TSH level (1.66 mIU/L) is within the normal range, and the patient's thyroid function is not significantly abnormal.

Overall, while the patient has a chronic heart condition, the patient's clinical presentation and laboratory results do not suggest an acute or severe condition that would increase the risk of sudden cardiac death or pump failure. Therefore, I would rank the patient as a survivor for the next few years.

RANKING: 
2. Sudden cardiac death
REASONING: 
The patient's ECG shows non-sustained ventricular tachycardia, which is a significant finding that could increase the risk of sudden cardiac death. The patient's LVEF (50.0%) is also below the normal range, indicating that the heart is not pumping blood as efficiently as it should be. While the patient is taking medications to manage their heart condition, the presence of non-sustained ventricular tachycardia on ECG is a concerning sign that could increase the risk of sudden cardiac death.

RANKING: 
3. Pump failure death
REASONING: 
The patient's LVEF (50.0%) is below the normal range, indicating that the heart is not pumping blood as efficiently as it should be. The patient's Pro-BNP level (761.0 ng/L) is elevated, which suggests that the heart is under strain and may be at risk of failure. The patient's kidney function (Creatinine 133.0 mmol/L) is also slightly elevated, which could indicate that the patient's heart is not pumping blood efficiently enough to meet the body's needs. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning sign that could increase the risk of pump failure. While the patient is taking medications to manage their heart condition, the presence of these signs and symptoms suggest that the patient is at risk of pump failure."
117,117,P0191,"Age: 56
Gender: Male 
Weight: 67 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,09
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 341.0
Protein (g/L): 73
T3 (pg/dL): 0,0594
T4 (ng/L): 19,91
TSH (mIU/L): 1,12
Urea (mg/dL): 18,3
LVEF (%): 60.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient has a history of hypertension, hypertensive cardiomyopathy, and diabetes, which are risk factors for cardiac complications. However, the patient is currently taking multiple medications, including ACE inhibitors and beta blockers, which are standard treatments for these conditions. The patient's NYHA class is II, indicating mild symptoms, which suggests that the patient's cardiac function is still relatively preserved.

The patient's laboratory results show elevated creatinine levels, which may indicate some degree of kidney dysfunction, but this is not uncommon in patients with hypertension and diabetes. The elevated Pro-BNP levels (341 ng/L) are also concerning, but they do not necessarily indicate heart failure. The patient's LVEF is 60%, which is within the normal range, and the ECG impression does not show any signs of ventricular arrhythmias.

Considering these factors, the patient is likely to survive for the next few years, given the absence of any life-threatening conditions or severe cardiac dysfunction. However, regular monitoring and adjustments to the patient's treatment plan may be necessary to manage the underlying conditions and prevent future complications.

RANKING: 
2. Sudden Cardiac Death
REASONING: 
While the patient's history of hypertension and hypertensive cardiomyopathy increases the risk of sudden cardiac death, the patient's current condition does not show any immediate signs of life-threatening arrhythmias or cardiac dysfunction. The ECG impression does not mention any ventricular arrhythmias, and the patient's LVEF is within the normal range.

However, the patient's elevated Pro-BNP levels (341 ng/L) and elevated creatinine levels (18.3 mg/dL) may indicate some degree of cardiac stress or kidney dysfunction, which could increase the risk of sudden cardiac death. Additionally, the patient's age and gender are also risk factors for sudden cardiac death.

Given these factors, while the patient is not at an extremely high risk, there is still a possibility of sudden cardiac death in the next few years, especially if the patient's underlying conditions are not well-managed.

RANKING: 
3. Pump Failure Death
REASONING: 
The patient's elevated Pro-BNP levels (341 ng/L) and elevated creatinine levels (18.3 mg/dL) suggest that the patient may have some degree of cardiac dysfunction or kidney impairment. However, the patient's LVEF is 60%, which is within the normal range, and the ECG impression does not show any signs of ventricular arrhythmias.

While the patient's NYHA class is II, indicating mild symptoms, the patient's history of hypertension and diabetes increases the risk of heart failure. However, the patient is currently taking multiple medications, including ACE inhibitors and beta blockers, which are standard treatments for heart failure.

Given the patient's current condition, the risk of pump failure death is lower compared to sudden cardiac death, but still a possibility if the patient's underlying conditions are not well-managed. Regular monitoring and adjustments to the patient's treatment plan will be necessary to prevent future complications."
118,118,P0193,"Age: 55
Gender: Female 
Weight: 100 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,32
LDL (mmol/L): 2,15
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 281.0
Protein (g/L): 78
T3 (pg/dL): 0,0321
T4 (ng/L): 17,73
Troponin (ng/mL): 0,6
TSH (mIU/L): 0,94
Urea (mg/dL): 14,4
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest that the patient has a significant cardiac impairment due to ischemic dilated cardiomyopathy, as indicated by the low left ventricular ejection fraction (LVEF) of 40%. The patient's history of myocardial infarction, diabetes, dyslipidemia, and hypertension further exacerbates the cardiac condition. However, the patient's age and sex are not particularly high-risk factors for sudden cardiac death.

The patient's ECG results show ventricular extrasystole, which is a benign finding, and no evidence of ventricular tachycardia or bradycardia. The patient's medication regimen, including beta blockers, ACE inhibitors, and diuretics, suggests that the patient is receiving standard treatment for heart failure.

The patient's renal function is also impaired, with elevated creatinine levels, but this is likely a consequence of the underlying cardiac condition rather than a primary cause. The patient's liver function tests are mildly abnormal, but not significantly elevated.

Given the patient's overall clinical presentation and test results, the most likely prognosis is that the patient will survive. However, the patient will likely require close monitoring and adjustments to their medication regimen to manage their cardiac condition and prevent further deterioration.

RANKING: 2. Pump failure death
REASONING: 

While the patient's LVEF is significantly reduced, indicating a poor cardiac function, the patient's age, sex, and other comorbidities do not necessarily increase the risk of sudden cardiac death. However, the patient's cardiac condition is already compromised, and the risk of pump failure is relatively high.

The patient's renal function is impaired, which may increase the risk of complications such as fluid overload and electrolyte imbalances. The patient's liver function tests are mildly abnormal, which may also increase the risk of complications.

While the patient is on a comprehensive medication regimen, there is a possibility that the medications may not be sufficient to manage the patient's cardiac condition, and the patient may require additional interventions such as device therapy or heart transplantation.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. However, the patient's age and sex are not particularly high-risk factors for sudden cardiac death.

The patient's ECG results show ventricular extrasystole, which is a benign finding, and no evidence of ventricular tachycardia or bradycardia. The patient's medication regimen, including beta blockers and ACE inhibitors, suggests that the patient is receiving standard treatment for heart failure.

Given the patient's overall clinical presentation and test results, the risk of sudden cardiac death is relatively low. However, the patient's cardiac condition is already compromised, and the risk of sudden cardiac death cannot be entirely ruled out.

It is essential to closely monitor the patient's cardiac function and adjust their medication regimen as necessary to minimize the risk of complications and ensure the best possible outcome."
119,119,P0195,"Age: 62
Gender: Female 
Weight: 60 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 7,4
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,11
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 237.0
Protein (g/L): 66,8
T3 (pg/dL): 0,0402
T4 (ng/L): 13,59
TSH (mIU/L): 1,6
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, the most likely outcome is a survivor. The patient's LVEF (Left Ventricular Ejection Fraction) is 25.0%, which is significantly reduced, indicating severe left ventricular dysfunction. However, the patient is on medications that are commonly used to manage heart failure, including beta blockers, loop diuretics, and ACE inhibitors. The patient's NYHA Class is II, indicating moderate symptoms, but not severe.

The patient's laboratory results show elevated creatinine levels (109.0 mmol/L), which suggests some degree of kidney dysfunction, but this is not uncommon in patients with heart failure. The patient's liver function tests are also within normal limits, and there is no indication of significant liver disease.

The ECG findings are notable for ventricular extrasystole, which is a common finding in patients with heart failure. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia (CH > 10) suggests that the patient is not at high risk for sudden cardiac death.

The patient's biomarkers, such as Pro-BNP (237.0 ng/L), are elevated, indicating some degree of heart failure. However, the patient's hemoglobin level is 117.0 g/L, which is within the normal range, and the patient's kidney function, as indicated by the urea level, is not severely impaired.

Overall, considering the patient's severe left ventricular dysfunction, moderate NYHA symptoms, and the presence of ventricular extrasystole, but the absence of severe cardiac arrhythmias, the most likely outcome is a survivor."
120,120,P0196,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 187.0
Gamma-glutamil transpeptidase (IU/L): 137
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 6,1
LDL (mmol/L): 3,34
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 7460.0
Protein (g/L): 78,899
T3 (pg/dL): 0,0315
T4 (ng/L): 15,28
Troponin (ng/mL): 0,7
TSH (mIU/L): 3,14
Urea (mg/dL): 24,46
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

This patient is at high risk for adverse outcomes due to the presence of severe left ventricular dysfunction (LVEF 30.0), which indicates advanced heart failure. The patient's NYHA class III status suggests significant symptoms and limitations in daily activities. Additionally, the patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and diabetes further increases the risk of adverse outcomes.

The patient's elevated BNP levels (7460.0 ng/L) and elevated creatinine level (24.46 mg/dL) suggest fluid overload and renal impairment, which are common complications in heart failure. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG also indicate a high risk of arrhythmic events.

Despite the presence of several medications, including ACE inhibitors, loop diuretics, and spironolactone, the patient's condition is still not well-controlled, and the patient's LVEF is significantly impaired. Therefore, the most likely outcome is that the patient will survive, but the prognosis will be guarded.

2. Sudden Cardiac Death
REASONING: 

While the patient's ECG findings of ventricular extrasystoles and non-sustained ventricular tachycardia are concerning, the patient's current medication regimen and LVEF are not indicative of a high risk for sudden cardiac death. The patient's serum troponin level (0.7 ng/mL) is also within normal limits, which suggests that there is no acute myocardial injury.

However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of arrhythmic events. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests a high risk of arrhythmic events, but the likelihood of sudden cardiac death is still lower than the risk of heart failure-related complications.

3. Pump Failure Death
REASONING: 

Given the patient's severe left ventricular dysfunction (LVEF 30.0) and advanced heart failure, pump failure death is a possible outcome. However, the patient is currently receiving medications that are standard for heart failure management, including ACE inhibitors, loop diuretics, and spironolactone, which can help manage symptoms and slow disease progression.

The patient's elevated creatinine level (24.46 mg/dL) and BNP levels (7460.0 ng/L) suggest fluid overload, but the patient's current medication regimen and LVEF are not indicative of a high risk for pump failure death. While pump failure is a possible outcome, it is less likely than sudden cardiac death or survival, given the patient's current medical management and the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG."
121,121,P0197,"Age: 71
Gender: Male 
Weight: 73 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 6,78
Creatinine (mmol/L): 145.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1367.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0384
T4 (ng/L): 17,4
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,14
Urea (mg/dL): 13,4
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is 71 years old with a history of idiopathic dilated cardiomyopathy and peripheral vascular disease. The patient has a reduced left ventricular ejection fraction (LVEF) of 40%, indicating a significant impairment in cardiac function. The elevated creatinine level (145.0 mmol/L) suggests renal impairment, which can be a marker of poor cardiac function and increased mortality risk.

The patient is also taking medications such as digoxin, loop diuretics, and ACE inhibitors, which are commonly used to manage heart failure and hypertension. However, the patient's current NYHA class II classification indicates that the patient's symptoms are moderate, and the patient may not be receiving optimal treatment.

The ECG findings of ventricular extrasystole and elevated troponin levels (0.3 ng/mL) suggest that the patient is experiencing some degree of cardiac stress. However, the absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia makes it less likely that the patient will experience sudden cardiac death.

Considering these factors, the patient's overall prognosis is most likely to be a survivor. The patient's reduced cardiac function, renal impairment, and the presence of ventricular extrasystole suggest that the patient is at increased risk for cardiac events, but the absence of other high-risk features such as ventricular tachycardia or significant arrhythmias reduces the likelihood of sudden cardiac death.

RANKING: 2. Sudden Cardiac Death
REASONING: 

Although the patient's LVEF is significantly impaired, the absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on the ECG makes it less likely that the patient will experience sudden cardiac death. However, the patient's reduced cardiac function, renal impairment, and the presence of ventricular extrasystole still increase the risk of cardiac events.

RANKING: 3. Pump Failure Death
REASONING: 
The patient's reduced LVEF of 40% indicates significant cardiac dysfunction, which increases the risk of pump failure. However, the patient's NYHA class II classification suggests that the patient's symptoms are moderate, and the patient may still be able to tolerate some level of physical activity.

Additionally, the patient is taking medications such as digoxin and ACE inhibitors, which can help manage heart failure symptoms. However, the patient's renal impairment and elevated creatinine level suggest that the patient may not be receiving optimal treatment, and the patient's reduced cardiac function increases the risk of pump failure.

While pump failure is a possible outcome, it is less likely than sudden cardiac death due to the absence of other high-risk features on the ECG, and the patient's moderate NYHA class classification suggests that the patient may still be able to tolerate some level of physical activity."
122,122,P0198,"Age: 53
Gender: Male 
Weight: 77 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 46
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 19,2
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,48
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 41.0
Protein (g/L): 81,8
T3 (pg/dL): 0,0522
T4 (ng/L): 18,6
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,79
Urea (mg/dL): 6,7
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor 
REASONING: 

This patient is a 53-year-old male with a history of enolic dilated cardiomyopathy, dyslipidemia, and NYHA Class II heart failure. The patient's ejection fraction (LVEF) is significantly reduced at 40%, indicating severe left ventricular dysfunction. The patient's creatinine level is elevated at 90.0 mmol/L, suggesting renal impairment, which is a common complication in patients with heart failure.

The patient's lipid profile shows high total cholesterol and LDL levels, which are risk factors for cardiovascular disease. The patient's blood pressure is well-controlled at 120/60 mmHg, and the patient is on beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitor therapy, which are standard treatments for heart failure.

The patient's ECG shows ventricular extrasystole, which is a common finding in patients with heart failure. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient's arrhythmias are not severe enough to be a significant risk factor for sudden cardiac death.

The patient's troponin level is normal, and the patient's BNP levels are within the normal range, which suggests that the patient's heart is not experiencing significant acute myocardial injury.

Considering these factors, the patient's overall prognosis is that they are likely to survive for the next few years, assuming that the patient continues to receive appropriate medical therapy and makes lifestyle modifications to manage their heart failure.

2. Sudden cardiac death 
REASONING: 

This patient is at increased risk of sudden cardiac death due to their history of enolic dilated cardiomyopathy, which is a condition that can lead to ventricular arrhythmias and sudden cardiac death. The patient's LVEF is severely reduced, which increases the risk of arrhythmias and sudden cardiac death.

The patient's ECG shows ventricular extrasystole, which is a potential precursor to more severe arrhythmias. While the absence of ventricular tachycardia or non-sustained ventricular tachycardia is reassuring, the presence of ventricular extrasystole is still a concern.

The patient's elevated creatinine level and low ejection fraction suggest that the patient's heart is not functioning optimally, which increases the risk of arrhythmias and sudden cardiac death.

3. Pump failure death 
REASONING: 

While pump failure death is a possible outcome for this patient, it is less likely than sudden cardiac death. The patient is currently on optimal medical therapy for heart failure, including beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitor therapy. These medications are standard treatments for heart failure and have been shown to improve survival and reduce the risk of pump failure.

The patient's LVEF is severely reduced, but the patient is still receiving therapy to manage their heart failure symptoms. The patient's ejection fraction may continue to decline over time, but the patient is currently receiving treatment to slow the progression of heart failure.

However, the patient's elevated creatinine level and low ejection fraction suggest that the patient's heart is not functioning optimally, and pump failure is a possible outcome. Nevertheless, the patient's current medical therapy and lifestyle modifications reduce the risk of pump failure, making it the least likely of the three prognoses."
123,123,P0201,"Age: 48
Gender: Male 
Weight: 96 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5,09
LDL (mmol/L): 3,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1176.0
Protein (g/L): 72,3
T3 (pg/dL): 0,03
T4 (ng/L): 15,92
Troponin (ng/mL): 0,2
TSH (mIU/L): 0,88
Urea (mg/dL): 5,7
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is likely to be a survivor due to the following factors:

1. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform daily activities without severe limitation. This suggests that the heart is still capable of pumping sufficient blood to meet the body's needs, at least to some extent.
2. The patient's left ventricular ejection fraction (LVEF) is 25%, which is a relatively preserved ejection fraction. While this is below the normal range, it is not severely impaired, suggesting that the heart is still able to pump some blood effectively.
3. The patient's troponin level is normal, which suggests that there is no significant cardiac muscle damage or necrosis.
4. The patient is on medications that are commonly used to treat heart failure, such as beta blockers, digoxin, loop diuretics, and ACE inhibitors. These medications can help to slow the heart rate, reduce blood pressure, and improve cardiac function.
5. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, but it is not a guarantee of a poor outcome. The fact that it is non-sustained suggests that the arrhythmia is not persistent and may be manageable with treatment.
6. The patient's other lab values, such as creatinine, potassium, and electrolyte levels, are within relatively normal ranges, which suggests that the patient's kidney and electrolyte function are not severely impaired.

Overall, while this patient has some significant cardiac abnormalities, including dilated cardiomyopathy and non-sustained ventricular tachycardia, the combination of preserved LVEF, normal troponin, and the presence of medications that can help manage heart failure and arrhythmias, suggests that the patient is likely to survive for several years.

RANKING: 2. Sudden Cardiac Death
REASONING: 

This patient's prognosis is less likely to be a survivor due to the following factors:

1. The patient's LVEF is significantly impaired at 25%, which suggests that the heart is not pumping blood as effectively as it should be.
2. The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are both concerning signs of arrhythmia.
3. The patient's troponin level is slightly elevated, which suggests that there may be some cardiac muscle damage or necrosis.
4. The patient's creatinine level is elevated, which suggests that the patient's kidney function may be impaired.
5. The patient's potassium level is slightly elevated, which can increase the risk of arrhythmias.

RANKING: 3. Pump Failure Death
REASONING: 

This patient's prognosis is the least likely to be a survivor due to the following factors:

1. The patient's LVEF is severely impaired at 25%, which suggests that the heart is not pumping blood as effectively as it should be.
2. The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are both concerning signs of arrhythmia.
3. The patient's creatinine level is significantly elevated, which suggests that the patient's kidney function is severely impaired.
4. The patient's electrolyte levels are abnormal, which can increase the risk of arrhythmias and other complications.
5. The patient's other lab values, such as the elevated ALT and AST, suggest that there may be some liver damage or dysfunction.

Overall, while this patient has some significant cardiac abnormalities, the combination of severely impaired LVEF, elevated creatinine, and abnormal electrolyte levels makes it more likely that the patient will experience pump failure or cardiac death within a shorter period of time."
124,124,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the patient's age, NYHA Class II, and the presence of Hypertensive cardiomyopathy, Diabetes, and Dyslipemia, the patient is already at a high risk for cardiovascular events. The elevated creatinine level (123.0 mmol/L) indicates some degree of renal impairment, which is a common comorbidity in patients with heart failure. However, the patient's LVEF is 45.0%, which is within the range for NYHA Class II, indicating that the patient is still able to perform moderate physical activity without significant symptoms.

The patient's ECG findings show ventricular extrasystoles, which can be a sign of cardiac stress or strain. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac function is not severely compromised. The patient's troponin level is also within normal limits, which suggests that there is no significant myocardial damage.

Given the patient's age, comorbidities, and the presence of ventricular extrasystoles, the patient is still a candidate for survivor. The patient's medications, including beta blockers, ACE inhibitors, and statins, suggest that the patient is receiving optimal treatment for their cardiovascular risk factors.

While the patient's prognosis is uncertain, the combination of factors suggests that the patient is likely to survive the next few years, but with ongoing monitoring and management of their cardiovascular risk factors.

2. Sudden cardiac death
REASONING:
The patient's LVEF is 45.0%, which is below the normal range for a 75-year-old male. This suggests that the patient's cardiac function is compromised, and there is a higher risk of cardiac events, including sudden cardiac death.

The patient's ECG findings show ventricular extrasystoles, which can be a sign of cardiac stress or strain. The presence of ventricular extrasystoles, combined with the patient's LVEF, suggests that the patient is at higher risk for cardiac events, including sudden cardiac death.

However, the patient's troponin level is within normal limits, which suggests that there is no significant myocardial damage. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac function is not severely compromised.

3. Pump failure death
REASONING:
Given the patient's LVEF of 45.0%, which is below the normal range for a 75-year-old male, and the presence of Hypertensive cardiomyopathy, the patient is at high risk for pump failure. The patient's creatinine level (123.0 mmol/L) indicates some degree of renal impairment, which can exacerbate cardiac dysfunction.

The patient's ECG findings show ventricular extrasystoles, which can be a sign of cardiac stress or strain. The presence of ventricular extrasystoles, combined with the patient's LVEF, suggests that the patient is at higher risk for cardiac events, including pump failure.

The patient's troponin level is within normal limits, which suggests that there is no significant myocardial damage. However, the combination of the patient's LVEF, Hypertensive cardiomyopathy, and renal impairment suggests that the patient is at high risk for pump failure."
125,125,P0203,"Age: 78
Gender: Female 
Weight: 90 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 150/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,97
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 3,8
LDL (mmol/L): 3,44
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 491.0
Protein (g/L): 80
T3 (pg/dL): 0,0363
T4 (ng/L): 16,39
Troponin (ng/mL): 0,1
TSH (mIU/L): 2,19
Urea (mg/dL): 18,8
LVEF (%): 30.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall prognosis can be determined by analyzing the provided data. Although the patient has a history of idiopathic dilated cardiomyopathy and hypertension, which are risk factors for heart failure and arrhythmias, the patient is currently on medications for these conditions (loop diuretics and ACE inhibitor). The patient's hemoglobin level is slightly elevated, which may indicate some degree of anemia, but it's not severe enough to significantly impact the overall prognosis.

The patient's creatinine level is elevated, indicating some degree of kidney impairment, but it's not severe. The patient's blood pressure is within a relatively normal range. The patient's lipid profile is not significantly abnormal, and the troponin level is within normal limits, indicating no significant myocardial infarction.

The ECG impression shows non-sustained ventricular tachycardia, which is a concerning finding but not a definitive indicator of poor prognosis. The patient's left ventricular ejection fraction (LVEF) is significantly reduced, indicating poor cardiac function. However, the patient is currently on medications for heart failure, which suggests that the doctor is actively managing the patient's condition.

Considering these factors, the patient's overall prognosis is likely to be a survivor, as they are receiving treatment for their underlying conditions and have a relatively stable ECG. The patient's age is 78, but this is not necessarily a contraindication for survival, as many people with heart failure live for many years with proper management.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, the patient is currently on medications for heart failure and has a relatively stable ECG. However, the patient's LVEF is significantly reduced, which increases the risk of sudden cardiac death.

The patient's age is also a factor, as the risk of sudden cardiac death increases with age. However, the patient is still relatively young compared to the average life expectancy for someone with heart failure.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF is significantly reduced, indicating poor cardiac function, and the patient is currently on medications for heart failure. While the patient is receiving treatment, the patient's LVEF is not expected to improve significantly, and the patient's cardiac function is likely to deteriorate over time.

The patient's kidney function is also impaired, which can exacerbate heart failure and increase the risk of pump failure. However, the patient is currently on medications to manage their kidney function, and the patient's blood pressure is relatively stable.

While pump failure is a possible outcome, it is the least likely of the three options, as the patient is currently receiving treatment for their underlying conditions and has a relatively stable ECG."
126,126,P0204,"Age: 69
Gender: Male 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 152.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 115.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 7794.0
Protein (g/L): 77
T3 (pg/dL): 0,0351
T4 (ng/L): 18,87
Troponin (ng/mL): 0,7
TSH (mIU/L): 1,89
Urea (mg/dL): 11
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II heart failure, and multiple comorbid conditions such as diabetes, dyslipemia, and hypertension suggest a high risk of cardiovascular events. However, the patient has a relatively normal blood pressure reading (120/80 mmHg) and is not in severe heart failure (NYHA Class III or IV). The absence of severe hypotension, renal dysfunction (creatinine 152.0 mmol/L), or significant anemia (hemoglobin 115.0 g/L) may indicate a relatively preserved cardiac function.

The patient's elevated troponin level (0.7 ng/mL) suggests some degree of cardiac damage, but it is not significantly elevated, which may indicate a less severe cardiac insult. The presence of non-sustained ventricular tachycardia (NSVT) and paroxysmal supraventricular tachyarrhythmia (PSVT) on ECG may indicate underlying arrhythmogenic conditions, but the absence of ventricular extrasystoles or sustained VT suggests that the patient's cardiac function is not severely compromised.

The patient's elevated BNP level (7794.0 ng/L) and low ejection fraction (LVEF 40.0%) suggest heart failure with reduced ejection fraction, but the patient's overall clinical presentation and laboratory results do not indicate severe heart failure.

Given these factors, the patient's prognosis is more likely to be a survivor, as they have a relatively preserved cardiac function and no signs of severe heart failure, arrhythmias, or acute cardiac events. However, close monitoring and follow-up are still necessary to adjust the treatment plan and prevent further cardiac events.

RANKING: 2. Pump failure death
REASONING: 

This prognosis is less likely because the patient's LVEF is not severely reduced (40.0%), and their cardiac function may still be preserved to some extent. However, the patient's elevated BNP level and NSVT on ECG suggest some degree of cardiac stress and potential for worsening heart failure.

RANKING: 3. Sudden cardiac death
REASONING: 

This prognosis is the least likely because the patient's ECG findings do not indicate a high risk for life-threatening arrhythmias, and their cardiac function is not severely compromised. The absence of ventricular extrasystoles, sustained VT, or significant electrolyte imbalances (e.g., low potassium or magnesium) reduces the risk of sudden cardiac death. Additionally, the patient's overall clinical presentation and laboratory results do not suggest a high risk of acute cardiac events."
127,127,P0206,"Age: 80
Gender: Male 
Weight: 88 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,51
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,57
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 3087.0
Protein (g/L): 62,3
T3 (pg/dL): 0,0444
T4 (ng/L): 13,71
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,46
Urea (mg/dL): 8,5
LVEF (%): 45.0
Medications: Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

The patient's overall clinical presentation and laboratory results suggest a high risk of adverse outcomes. 

Firstly, the patient has a history of Idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. The current LVEF of 45% indicates severe left ventricular dysfunction, which further increases the risk of heart failure.

The patient's elevated creatinine level (113.0 mmol/L) and proteinuria (62.3 g/L) suggest renal impairment, which is a common complication in heart failure patients. The presence of non-sustained ventricular tachycardia (NST) and ventricular extrasystoles on ECG also indicate an increased risk of arrhythmias, which can lead to sudden cardiac death.

The patient's elevated Pro-BNP level (3087.0 ng/L) is consistent with heart failure, and the presence of ventricular tachycardia (NST) on ECG further supports this diagnosis. The patient's hemoglobin level (152.0 g/L) and LDLC level (3.57 mmol/L) are not significantly abnormal, but the patient's weight (88 kg) is on the higher side for a 168 cm individual, which may contribute to the patient's cardiovascular risk.

While the patient is currently on loop diuretics, their NYHA class is II, indicating mild symptoms of heart failure, which may not be adequately controlled. The patient's blood pressure (140/90 mmHg) is elevated, which may contribute to the patient's cardiovascular risk.

Considering the above factors, the most likely outcome is that the patient will survive. However, the presence of non-sustained ventricular tachycardia and ventricular extrasystoles on ECG increases the risk of sudden cardiac death. Pump failure death is a possible outcome, but the patient's NYHA class II symptoms suggest that heart failure is not severely debilitating at the moment.

Therefore, the ranking is survivor as the most likely outcome, followed by sudden cardiac death, and pump failure death."
128,128,P0208,"Age: 63
Gender: Male 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,19
LDL (mmol/L): 4,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 520.0
Protein (g/L): 73,6
T3 (pg/dL): 0,0618
T4 (ng/L): 15,21
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,43
Urea (mg/dL): 5,9
LVEF (%): 15.0
Medications: Calcium Channel Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, hypertension, and dyslipemia indicate a significant burden of cardiovascular disease. However, the patient is currently receiving optimal medical therapy with a calcium channel blocker and an ACE inhibitor, which is standard treatment for these conditions.

The elevated creatinine level (87.0 mmol/L) suggests some degree of renal impairment, but it is not severely impaired. The patient's hemoglobin level (13.6 g/dL) is within the normal range, which is a positive sign.

The patient's LVEF is 15.0%, which is significantly reduced, indicating severe left ventricular dysfunction. However, the patient is still receiving treatment for heart failure symptoms, and the LVEF can be improved with optimal medical therapy.

The elevated Pro-BNP level (520.0 ng/L) suggests significant ventricular stress, but the patient's symptoms are well-controlled, and the patient is receiving treatment for heart failure.

The patient's ECG findings are concerning for ventricular extrasystole, but the absence of ventricular tachycardia and non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

Considering these factors, the patient is likely to survive for the next few years, assuming optimal medical therapy and lifestyle modifications.

RANKING 2: Sudden Cardiac Death
REASONING:
The patient's significant LVEF (15.0%), elevated Pro-BNP level (520.0 ng/L), and the presence of ventricular extrasystole on the ECG increase the risk of sudden cardiac death. However, the patient is receiving optimal medical therapy and has a well-controlled blood pressure.

RANKING 3: Pump Failure Death
REASONING:
The patient's significant LVEF (15.0%) and elevated Pro-BNP level (520.0 ng/L) indicate severe left ventricular dysfunction, which increases the risk of pump failure. However, the patient is receiving optimal medical therapy, and the presence of renal impairment may be contributing to the elevated Pro-BNP level, rather than a direct indicator of pump failure."
129,129,P0209,"Age: 55
Gender: Male 
Weight: 84 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 149.0
Protein (g/L): 71,5
T3 (pg/dL): 0,06
T4 (ng/L): 15,82
TSH (mIU/L): 1,64
Urea (mg/dL): 5,4
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and laboratory results suggest that they are at high risk for adverse cardiac events, but the presence of a positive outcome (PATIENT OUTCOME: survivor) indicates that the patient has survived for an extended period with their current condition. This outcome is likely due to the patient's ongoing management with beta blockers, digoxin, loop diuretics, ACE inhibitor, and nitrovasodilator, which are commonly used to manage heart failure and hypertension. The patient's LVEF of 30.0% is significantly reduced, but the patient is still alive, indicating that the patient's heart is able to pump blood effectively enough to maintain adequate circulation.

The patient's past medical history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension increases their risk for adverse cardiac events. However, the patient's current NYHA Class II indicates that they are able to perform light physical activity without significant symptoms, which suggests that their heart is able to meet their oxygen demands during exercise.

The patient's laboratory results, including low albumin and high creatinine levels, suggest chronic kidney disease, which may be contributing to their heart failure. However, the patient's overall clinical presentation and management suggest that they are being adequately managed, and their survival is likely due to their ongoing treatment and management of their underlying conditions.

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the patient's ongoing management and the fact that they are still alive. Sudden cardiac death is unlikely due to the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG, and pump failure death is less likely due to the patient's ongoing treatment and the fact that they are still able to maintain adequate circulation.

Therefore, the most likely prognosis is survivor, with a moderate risk of adverse cardiac events, but a high likelihood of survival with ongoing management."
130,130,P0210,"Age: 75
Gender: Male 
Weight: 80 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 180/95 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 3,78
LDL (mmol/L): 3,78
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 308.0
Protein (g/L): 70
T3 (pg/dL): 0,0597
T4 (ng/L): 19,3
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,69
Urea (mg/dL): 8,3
LVEF (%): 70.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as a survivor with a high probability. Here's why:

1. Age: Although the patient is 75 years old, which is considered elderly, the patient's overall health status and medical history do not seem to be significantly compromised.
2. NYHA Class II: The patient has a moderate level of heart failure, which indicates some limitation in physical activity. However, this is not a contraindication for survival.
3. Blood Pressure: The patient's blood pressure is elevated, but it is being managed with medication (Angiotensin II Receptor Blocker and Loop Diuretics).
4. Hemoglobin and Hematocrit: The patient's hemoglobin and hematocrit levels are within normal limits, indicating adequate oxygen delivery to tissues.
5. Kidney Function: The patient's creatinine level is elevated, but it is not severely impaired, and the patient is receiving ACE Inhibitor, which is beneficial for patients with chronic kidney disease.
6. Electrolytes: The patient's electrolyte levels are within normal limits, which suggests that the patient is not experiencing severe electrolyte imbalances.
7. TSH: The patient's thyroid function is normal, which is essential for overall metabolic health.
8. LVEF: The patient's left ventricular ejection fraction (LVEF) is 70%, which is within the normal range, indicating that the patient's heart is pumping efficiently.
9. Pro-BNP: The patient's N-terminal pro b-type natriuretic peptide (Pro-BNP) level is elevated, which is a marker for heart failure. However, the level is not extremely high, suggesting that the patient's heart is not severely failing.

Considering these factors, I believe that the patient has a high chance of survival, but it is essential to closely monitor their condition and adjust their treatment plan as needed to manage their hypertension, heart failure, and other comorbidities.

The other two prognoses, sudden cardiac death and pump failure death, seem less likely based on the provided data. While the patient's heart is not functioning optimally, there is no indication of acute heart failure or significant cardiac arrhythmias that would increase the risk of sudden cardiac death."
131,131,P0214,"Age: 50
Gender: Female 
Weight: 77 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,3
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 327.0
Protein (g/L): 69
T3 (pg/dL): 0,051
T4 (ng/L): 14,1
TSH (mIU/L): 1,38
Urea (mg/dL): 5,5
LVEF (%): 50.0
Medications: Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient is currently on medications for heart failure and myocardial infarction, which suggests a history of cardiovascular disease. However, the patient's current NYHA Class is II, indicating a moderate level of symptoms, which is a good prognostic sign. The patient's LVEF is 50.0%, which is within the normal range for a 50-year-old individual. 

The patient's laboratory results show elevated creatinine levels (81.0 mmol/L) and a high BNP level (327.0 ng/L), indicating some degree of cardiac stress. However, the patient's kidney function is not severely impaired, and the BNP level is not excessively high, which may indicate some degree of cardiac compensation. 

The patient's lipid profile is not ideal, with high LDL and low HDL levels, but this is a common finding in patients with cardiovascular disease. The patient's blood pressure is within a relatively normal range, and there is no evidence of acute coronary syndrome.

Given these factors, the patient's overall prognosis is likely to be good, and the patient is likely to survive for the next few years. 

RANKING: 2. Sudden cardiac death
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of sudden cardiac death. The patient's LVEF is 50.0%, which is below the normal range, indicating some degree of left ventricular dysfunction. 

The patient's elevated BNP level (327.0 ng/L) and elevated creatinine level (81.0 mmol/L) suggest some degree of cardiac stress and kidney impairment, which may increase the risk of sudden cardiac death. 

The patient's ECG results show ventricular extrasystoles, which is a risk factor for sudden cardiac death. 

However, the patient's age, gender, and current medications may mitigate some of these risks, and the patient's overall prognosis is still relatively good.

RANKING: 3. Pump failure death
REASONING: 
The patient's LVEF is 50.0%, which is below the normal range, indicating some degree of left ventricular dysfunction. The patient's elevated BNP level (327.0 ng/L) and elevated creatinine level (81.0 mmol/L) suggest some degree of cardiac stress and kidney impairment, which may increase the risk of heart failure.

The patient's NYHA Class is II, indicating some degree of symptoms, which may indicate that the patient is already experiencing some degree of heart failure. 

The patient's ECG results show ventricular extrasystoles, which is a risk factor for heart failure. 

However, the patient's age, gender, and current medications may mitigate some of these risks, but the patient's overall prognosis is less favorable compared to the survivor and sudden cardiac death options."
132,132,P0216,"Age: 79
Gender: Male 
Weight: 73 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 33
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 46.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 4,58
LDL (mmol/L): 1,71
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 5971.0
Protein (g/L): 66,3
T3 (pg/dL): 0,0642
T4 (ng/L): 19,53
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,68
Urea (mg/dL): 7,2
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age (79 years) and NYHA Class II heart failure classification indicate a significant level of cardiovascular compromise. However, the patient's LVEF (Left Ventricular Ejection Fraction) is 30%, which is a critical indicator of cardiac function. A LVEF of 30% is a strong predictor of mortality, and the patient's current medication regimen, which includes ACE inhibitors and digoxin, suggests that the patient is receiving optimal treatment for heart failure.

The elevated Troponin level (0.5 ng/mL) may indicate some degree of cardiac damage, but it is not significantly elevated, which may suggest that the patient is not experiencing acute myocardial infarction. The presence of non-sustained ventricular tachycardia (NST) on the ECG is a concerning sign, but it is non-sustained, which may indicate that the arrhythmia is not a significant predictor of mortality.

The patient's elevated Creatinine level (1.19 mg/dL) and elevated Gamma-glutamyl transpeptidase (149 IU/L) may indicate some degree of renal impairment, but this is not a significant predictor of mortality.

Overall, the patient's current medical condition, medication regimen, and ECG findings suggest that the patient is at high risk for cardiac events, but the patient's survival is still possible with optimal management and monitoring. Therefore, I rank the patient as a survivor.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's ECG findings of ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia (NST) on the ECG are concerning signs of cardiac arrhythmias. The presence of polymorphic ventricular tachycardia and NST is a significant predictor of sudden cardiac death.

The patient's elevated Troponin level (0.5 ng/mL) and elevated creatinine level (1.19 mg/dL) may indicate some degree of cardiac damage and renal impairment, which can increase the risk of sudden cardiac death.

The patient's age (79 years) and NYHA Class II heart failure classification also increase the risk of sudden cardiac death. However, the patient's current medication regimen and the presence of some degree of cardiac damage may mitigate this risk.

Overall, the patient's ECG findings and elevated biomarkers suggest that the patient is at high risk for sudden cardiac death, but the patient's survival is still possible with optimal management and monitoring. Therefore, I rank the patient as a candidate for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF (Left Ventricular Ejection Fraction) is 30%, which is a critical indicator of cardiac function. A LVEF of 30% is a strong predictor of mortality and pump failure.

The patient's elevated Creatinine level (1.19 mg/dL) and elevated Gamma-glutamyl transpeptidase (149 IU/L) may indicate some degree of renal impairment, which can increase the risk of pump failure.

The patient's age (79 years) and NYHA Class II heart failure classification also increase the risk of pump failure. The patient's elevated Troponin level (0.5 ng/mL) and elevated creatinine level (1.19 mg/dL) suggest that the patient is experiencing some degree of cardiac damage and renal impairment, which can increase the risk of pump failure.

The patient's current medication regimen, which includes ACE inhibitors and digoxin, is not sufficient to mitigate the risk of pump failure, as these medications are primarily used to manage heart failure symptoms and do not address the underlying cardiac damage.

Overall, the patient's cardiac function, renal impairment, and elevated biomarkers suggest that the patient is at high risk for pump failure. Therefore, I rank the patient as a candidate for pump failure death."
133,133,P0219,"Age: 61
Gender: Male 
Weight: 84 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,95
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 7,74
Hemoglobin (g/L): 167.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 4,46
LDL (mmol/L): 2,77
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 165.0
Protein (g/L): 75,5
T3 (pg/dL): 0,0204
T4 (ng/L): 13,65
Troponin (ng/mL): 0,8
TSH (mIU/L): 1,19
Urea (mg/dL): 7,8
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a condition that weakens the heart muscle and can lead to heart failure. However, the patient is currently in NYHA Class II, indicating mild symptoms, which suggests that the condition is not severely advanced. Additionally, the patient's LVEF (Left Ventricular Ejection Fraction) is 40%, which is lower than the normal range, but not extremely low, indicating some residual function. The patient is also taking medications that are standard for managing heart failure and arrhythmias. The presence of ventricular extrasystole and non-sustained VT on the ECG may indicate some cardiac conduction system dysfunction, but it is not a contraindication for survival. Overall, the patient's overall clinical presentation and medical history do not suggest an immediate high risk of mortality, and the patient is likely to survive.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient has a history of ischemic dilated cardiomyopathy, the patient's current NYHA Class II and relatively preserved LVEF suggest that the condition is not severely advanced. However, the patient's elevated creatinine level (136.0 mmol/L) and elevated troponin level (0.8 ng/mL) suggest some degree of cardiac dysfunction and possible myocardial injury. The presence of ventricular extrasystole and non-sustained VT on the ECG also increases the risk of arrhythmias. While these factors do not necessarily predict sudden cardiac death, they do increase the risk. However, the patient's overall clinical presentation and medical history do not suggest an extremely high risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's elevated creatinine level (136.0 mmol/L) and elevated troponin level (0.8 ng/mL) suggest some degree of cardiac dysfunction and possible myocardial injury. Additionally, the patient's LVEF is only 40%, which is significantly lower than the normal range, indicating some degree of heart failure. The patient's history of ischemic dilated cardiomyopathy and current NYHA Class II symptoms also suggest a high risk of heart failure. However, the patient is taking medications that are standard for managing heart failure and arrhythmias, which may help mitigate the risk of pump failure. However, the presence of ventricular extrasystole and non-sustained VT on the ECG increases the risk of arrhythmias, which can contribute to pump failure. Overall, while the patient's clinical presentation suggests a high risk of pump failure, it is not as high as the risk of sudden cardiac death."
134,134,P0220,"Age: 44
Gender: Male 
Weight: 106 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 46
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,02
Hemoglobin (g/L): 111.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,59
LDL (mmol/L): 4,19
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1057.0
Protein (g/L): 82,4
T3 (pg/dL): 0,0339
T4 (ng/L): 20,91
Troponin (ng/mL): 0,6
TSH (mIU/L): 1,55
Urea (mg/dL): 19,2
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

This patient has a history of valvular cardiomyopathy, which is a significant risk factor for sudden cardiac death. However, the patient is currently on medications that are commonly used to manage heart failure and arrhythmias, such as beta blockers, digoxin, loop diuretics, and ACE inhibitors. The patient's ejection fraction (LVEF) is significantly reduced at 20%, indicating impaired cardiac function, but the patient is still alive and not showing signs of acute decompensation. The patient's ECG impression does not show any life-threatening arrhythmias, and the patient is not in cardiogenic shock. The patient's laboratory results, including the elevated creatinine and urea levels, suggest some degree of renal impairment, but this is not directly related to the cardiac condition. The patient's hemoglobin and potassium levels are within normal limits. Overall, the patient's clinical presentation and laboratory results suggest that the patient is at risk of cardiac events, but the patient is alive and receiving appropriate treatment, making survival the most likely outcome.

2. Sudden cardiac death
REASONING: 

While the patient has a significant history of valvular cardiomyopathy, which is a risk factor for sudden cardiac death, the patient is currently receiving medications that are commonly used to manage heart failure and arrhythmias. The patient's ECG impression does not show any life-threatening arrhythmias, and the patient is not in cardiogenic shock. The patient's laboratory results, including the elevated creatinine and urea levels, suggest some degree of renal impairment, but this is not directly related to the cardiac condition. The patient's hemoglobin and potassium levels are within normal limits. However, the patient's reduced ejection fraction (LVEF) and elevated troponin levels suggest some degree of cardiac damage, which could potentially lead to sudden cardiac death if not adequately managed. However, the patient is alive and receiving appropriate treatment, making sudden cardiac death less likely.

3. Pump failure death
REASONING: 

While the patient has a significant history of valvular cardiomyopathy, which is a risk factor for heart failure, the patient is currently receiving medications that are commonly used to manage heart failure, such as beta blockers, digoxin, loop diuretics, and ACE inhibitors. The patient's ejection fraction (LVEF) is significantly reduced at 20%, indicating impaired cardiac function, but the patient is still alive and not showing signs of acute decompensation. The patient's laboratory results, including the elevated creatinine and urea levels, suggest some degree of renal impairment, but this is not directly related to the cardiac condition. The patient's hemoglobin and potassium levels are within normal limits. While the patient's reduced ejection fraction and elevated troponin levels suggest some degree of cardiac damage, the patient is alive and receiving appropriate treatment, making pump failure death less likely. However, the patient's reduced ejection fraction and elevated creatinine levels suggest that the patient may eventually develop heart failure, making it the least likely outcome among the three options."
135,135,P0222,"Age: 57
Gender: Female 
Weight: 47 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,39
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,74
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,2
Potassium (mEq/L): 4,17
LDL (mmol/L): 3,63
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1537.0
Protein (g/L): 64
T3 (pg/dL): 0,054
T4 (ng/L): 16,68
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,09
Urea (mg/dL): 8
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. However, the patient's current NYHA class is II, indicating that they are able to perform moderate physical activity without excessive fatigue. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but it's worth noting that the patient does not have any sustained ventricular tachycardia. The patient's LVEF is severely impaired at 35%, indicating poor cardiac function. However, the patient's current medications, including beta blockers, digoxin, and ACE inhibitors, are likely contributing to the improved hemodynamics.

The patient's laboratory values, such as the elevated troponin and BNP levels, also suggest ongoing cardiac stress and strain. However, the patient's weight, height, and hemoglobin levels are within normal limits, which may indicate that the patient is not severely malnourished or anemic.

Considering these factors, the patient's overall prognosis is likely to be a survivor, but with ongoing cardiac stress and the need for close monitoring. The patient's ECG findings, while concerning, do not indicate a high risk for sudden cardiac death, and the patient's current medications are likely to provide adequate management of their symptoms.

RANKING: 2. Pump failure death
REASONING: 

While the patient's LVEF is severely impaired, which indicates poor cardiac function, the patient's current medications and NYHA class II status suggest that the patient is not in acute decompensated heart failure. The patient's elevated troponin and BNP levels indicate ongoing cardiac stress, but these levels are not extremely high, which may suggest that the patient's cardiac function is not rapidly deteriorating.

However, the patient's impaired cardiac function and elevated creatinine levels may indicate some degree of renal impairment, which can be a predictor of heart failure. Additionally, the patient's dyslipidemia and ischemic history may contribute to ongoing cardiac stress and strain.

Considering these factors, the patient's prognosis is less likely to be pump failure death compared to sudden cardiac death, but still a significant risk.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy and ventricular extrasystoles on the ECG make sudden cardiac death a significant risk. The patient's LVEF is severely impaired, which increases the risk of arrhythmias and sudden cardiac death. The patient's elevated troponin and BNP levels also indicate ongoing cardiac stress and strain.

However, the patient's current medications, including beta blockers and ACE inhibitors, are likely to provide some level of cardiac protection. Additionally, the patient's NYHA class II status suggests that the patient is not in acute decompensated heart failure, which reduces the risk of sudden cardiac death.

Considering these factors, the patient's prognosis is the least likely to be sudden cardiac death, but still a significant risk."
136,136,P0224,"Age: 76
Gender: Male 
Weight: 94 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,2
Creatinine (mmol/L): 183.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 3,96
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,25
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 211.0
Protein (g/L): 71
T3 (pg/dL): 0,0282
T4 (ng/L): 12,07
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,85
Urea (mg/dL): 12,1
LVEF (%): 70.0
Medications: Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 76-year-old male with a history of hypertension, cardiomyopathy, and dyslipidemia. His current NYHA Class II indicates that he has some limitations in physical activity due to heart disease, but it is not severe. The patient's blood pressure is well-controlled at 110/80 mmHg, which is a significant factor in reducing cardiovascular risk.

The patient's laboratory results show elevated creatinine levels (183.0 mmol/L), which suggests impaired renal function, but this is not uncommon in elderly patients. The liver function tests (ALT and AST) are within normal limits, and the lipid profile is also relatively normal.

The patient's ECG findings reveal ventricular extrasystoles and non-sustained ventricular tachycardia, which are benign and not indicative of life-threatening arrhythmias. The absence of sustained ventricular tachycardia or other concerning arrhythmias further supports a favorable prognosis.

The patient's LVEF (70.0%) is reduced, but it is still within the normal range for his age group. The Pro-BNP level is elevated at 211.0 ng/L, which may indicate some degree of heart failure, but it is not significantly elevated.

Considering these factors, the patient's overall risk profile suggests that he is at moderate risk for cardiovascular events. However, his well-controlled blood pressure, normal lipid profile, and absence of severe arrhythmias or other life-threatening conditions suggest that he is likely to survive the next few years without significant cardiovascular complications.

The patient's age and comorbidities do pose some risk, but the overall picture suggests that he will likely survive the next few years without major cardiac events. Therefore, the most likely outcome is that the patient will survive."
137,137,P0225,"Age: 79
Gender: Male 
Weight: 71 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,38
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,17
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1
Potassium (mEq/L): 3,5
LDL (mmol/L): 1,94
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2070.0
Protein (g/L): 64
T3 (pg/dL): 0,0318
T4 (ng/L): 18,1
TSH (mIU/L): 0,88
Urea (mg/dL): 5,7
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I would rank the patient as having a high likelihood of survival for the next few years. The patient's age is 79, but their NYHA Class is II, indicating that they have some limitation in physical activity but are not severely limited. Their LVEF is 70%, which is within a relatively normal range for their age.

The patient's laboratory results are also relatively well within normal limits, with the exception of elevated creatinine (106.0 mmol/L) and slightly elevated Pro-BNP (2070.0 ng/L), which may indicate some degree of cardiac stress or strain. However, these values are not indicative of severe heart failure.

The patient's medication regimen includes Digoxin, Loop Diuretics, Statins, and ACE Inhibitor, which are commonly used to manage heart failure and hypertension. The absence of any significant electrolyte imbalances or acute cardiac events on the ECG also suggests that the patient's cardiac function is stable.

While the patient's past medical history of hypertensive cardiomyopathy and dyslipidemia may pose some risks, the patient's current clinical presentation and laboratory results do not suggest an immediate high risk of cardiac events. Therefore, I believe that the patient is at a high risk of survival for the next few years.

2. Pump failure death
REASONING: 
The patient's elevated creatinine (106.0 mmol/L) and slightly elevated Pro-BNP (2070.0 ng/L) may indicate some degree of cardiac stress or strain, which could potentially lead to heart failure over time. However, the patient's LVEF is still 70%, and the absence of any significant electrolyte imbalances or acute cardiac events on the ECG suggests that the patient's cardiac function is relatively stable.

While the patient's past medical history of hypertensive cardiomyopathy and dyslipidemia may increase their risk of heart failure, I do not believe that the patient is at high risk of pump failure death in the short term. However, if the patient's cardiac function continues to decline or if there are any significant changes in their clinical presentation, I could see them at risk of developing heart failure.

3. Sudden cardiac death
REASONING: 
The patient's age (79) and past medical history of hypertensive cardiomyopathy and dyslipidemia do increase their risk of sudden cardiac death. However, the patient's current clinical presentation and laboratory results do not suggest any acute cardiac events or significant electrolyte imbalances.

The patient's ECG is also relatively unremarkable, with no ventricular tachycardia or ventricular extrasystole noted. While the patient's Pro-BNP level is elevated, this is not indicative of acute heart failure, and the patient's LVEF is still 70%.

Given the patient's relatively stable clinical presentation and laboratory results, I do not believe that the patient is at high risk of sudden cardiac death in the short term. However, if the patient's cardiac function were to decline or if there were any significant changes in their clinical presentation, I could see them at risk of sudden cardiac death."
138,138,P0227,"Age: 73
Gender: Male 
Weight: 86 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,33
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 5,24
Hemoglobin (g/L): 116.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,9
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1184.0
Protein (g/L): 75
T3 (pg/dL): 0,0273
T4 (ng/L): 13,94
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,07
Urea (mg/dL): 6,5
LVEF (%): 70.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

This patient is a 73-year-old male with a complex medical history, including hypertension, cardiomyopathy, diabetes, dyslipidemia, and peripheral vascular disease. Despite these comorbidities, the patient has a relatively preserved LVEF of 70% and is on medications that are commonly used to manage cardiovascular risk factors.

The patient's ECG findings, including ventricular extrasystole and TPSV, indicate some level of cardiac dysfunction, but do not suggest an immediate life-threatening arrhythmia. The patient's troponin levels are also within normal limits, which suggests that there is no acute myocardial infarction.

The patient's laboratory values, such as the elevated creatinine and urea levels, suggest some degree of renal impairment, but this is not uncommon in patients with hypertension and diabetes. The patient's glucose and lipid profiles are also consistent with their medical history.

Given the patient's age, comorbidities, and the absence of any life-threatening ECG findings or acute myocardial infarction, I believe that the most likely prognosis for this patient over the next few years is a survivor. The patient's current medical treatment plan, which includes medications to manage hypertension, diabetes, and cardiovascular risk factors, should continue to be closely monitored, and any changes to the treatment plan should be made on a case-by-case basis.

RANKING: 2. Sudden Cardiac Death 
REASONING: 

While the patient's ECG findings indicate some level of cardiac dysfunction, the absence of any life-threatening arrhythmias or acute myocardial infarction makes sudden cardiac death less likely. However, the patient's history of hypertension, cardiomyopathy, and peripheral vascular disease do increase the risk of sudden cardiac death.

The patient's elevated creatinine and urea levels suggest some degree of renal impairment, which can increase the risk of sudden cardiac death. However, this is not a unique risk factor for sudden cardiac death, and the patient's current treatment plan should continue to be closely monitored.

The patient's LVEF of 70% is somewhat lower than the normal range, but this is not uncommon in patients with hypertension and cardiomyopathy. The patient's troponin levels are also within normal limits, which suggests that there is no acute myocardial infarction.

While the patient's ECG findings and medical history do increase the risk of sudden cardiac death, I do not believe that this is the most likely prognosis for this patient over the next few years. The patient's current treatment plan and medical history suggest a more guarded but not catastrophic prognosis.

RANKING: 3. Pump Failure Death 
REASONING: 

The patient's LVEF of 70% is somewhat lower than the normal range, and their medical history of hypertension, cardiomyopathy, and peripheral vascular disease do increase the risk of heart failure. The patient's elevated creatinine and urea levels also suggest some degree of renal impairment, which can increase the risk of heart failure.

The patient's ECG findings, including ventricular extrasystole and TPSV, also suggest some level of cardiac dysfunction. The patient's troponin levels are within normal limits, but this does not rule out the possibility of heart failure.

While the patient's current treatment plan includes medications to manage hypertension, diabetes, and cardiovascular risk factors, the patient's medical history and ECG findings suggest that the patient is at risk for heart failure. However, I do not believe that this is the most likely prognosis for this patient over the next few years.

Given the patient's age, comorbidities, and the presence of some degree of cardiac dysfunction, I believe that pump failure death is a possible but not the most likely prognosis for this patient over the next few years. The patient's current treatment plan and medical history suggest a more guarded but not catastrophic prognosis."
139,139,P0228,"Age: 77
Gender: Female 
Weight: 62 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 160/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,46
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 10,22
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,7
Potassium (mEq/L): 4,27
LDL (mmol/L): 2,35
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1951.0
Protein (g/L): 79,5
T3 (pg/dL): 0,0288
T4 (ng/L): 16,13
Troponin (ng/mL): 1,6
TSH (mIU/L): 0,87
Urea (mg/dL): 10
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's age (77) and NYHA Class III status indicate a significant burden of cardiovascular disease. However, the patient's LVEF is only 25%, which is relatively preserved compared to the expected decline in left ventricular function in advanced heart failure patients. The presence of a non-sustained ventricular tachycardia (NST) on the ECG is a concerning sign, but it is not a guarantee of poor prognosis. The patient's biomarkers, such as Troponin and Pro-BNP, are not excessively elevated, suggesting that there is no significant acute cardiac injury or strain. The patient's medication regimen, including an angiotensin II receptor blocker and statins, is well-managed for their cardiovascular risk factors. Overall, the patient's clinical presentation, despite the presence of significant comorbidities, does not strongly suggest an immediate high risk of sudden cardiac death or pump failure. 

However, the patient's ECG findings of ventricular extrasystoles and non-sustained ventricular tachycardia are concerning signs that may indicate an underlying substrate for arrhythmias. Given the patient's age and the presence of these arrhythmias, there is a moderate risk of sudden cardiac death in the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 
The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG are concerning signs that may indicate an increased risk of arrhythmias and sudden cardiac death. The patient's age (77) and NYHA Class III status also contribute to the risk of sudden cardiac death. However, the patient's preserved LVEF and relatively well-managed medication regimen reduce the likelihood of pump failure death.

RANKING: 3. Pump failure death
REASONING: 
The patient's NYHA Class III status and significant comorbidities, such as ischemic dilated cardiomyopathy, diabetes, and hypertension, increase the risk of pump failure. The patient's LVEF of 25% is also a concern, as it suggests that the left ventricle is not functioning optimally. The patient's elevated creatinine level (104.0 mmol/L) may also indicate some degree of renal impairment, which can be a complication of heart failure. However, the patient's relatively well-managed medication regimen and the absence of excessively elevated biomarkers reduce the likelihood of pump failure death."
140,140,P0230,"Age: 84
Gender: Female 
Weight: 67 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 135/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,25
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 105.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,72
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 308.0
Protein (g/L): 71,3
T3 (pg/dL): 0,0348
T4 (ng/L): 14,23
Troponin (ng/mL): 0,4
TSH (mIU/L): 2,54
Urea (mg/dL): 8,3
LVEF (%): 70.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a relatively stable cardiovascular condition. The patient is 84 years old, which is a higher age for cardiac events, but the NYHA Class II classification indicates that the patient has some limitations with physical activity, but it's not severe. The patient's blood pressure is well-controlled, and the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression suggests that the patient does not have an acute or chronic cardiac arrhythmia. The presence of a low LVEF of 70.0 is concerning, but it is not severely low, and the patient is already on medications to manage their heart failure symptoms.

The elevated creatinine level (117.0) suggests some degree of renal impairment, which can be a risk factor for cardiac events, but it is not uncommon in older adults. The patient's other laboratory values, such as the low albumin level, elevated liver enzymes, and high glucose level, suggest some degree of malnutrition and metabolic syndrome, but these are not directly related to cardiac prognosis.

Given the patient's age, comorbidities, and the presence of some risk factors, but also the fact that they are already on medications to manage their heart failure and hypertension, the most likely outcome is that the patient will survive for the next few years. The patient's low T3 level (0.0348) is also a concern, as it may indicate hypothyroidism, which can be a risk factor for cardiac events. However, this is not a contraindication for survival, and the patient's other clinical presentation suggests that they are still relatively stable.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's LVEF is low, which is a risk factor for cardiac events, the patient is already on medications to manage their heart failure symptoms, which suggests that they are receiving adequate treatment. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression reduces the risk of sudden cardiac death. However, the patient's age and comorbidities, such as hypertension and myocardial infarction, still increase the risk of cardiac events.

The patient's elevated creatinine level and low albumin level may indicate some degree of renal impairment and malnutrition, which can increase the risk of cardiac events. The patient's low HDL level (1.55) also increases the risk of cardiovascular disease. However, the patient's low T3 level (0.0348) may indicate hypothyroidism, which can increase the risk of cardiac events.

Given the patient's age, comorbidities, and the presence of some risk factors, but also the fact that they are already on medications to manage their heart failure and hypertension, the second most likely outcome is that the patient will experience a cardiac event, but it is not necessarily a sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's low LVEF of 70.0 is a significant concern, as it indicates that the patient's heart is not pumping efficiently. The patient's elevated creatinine level (117.0) and low albumin level (40) suggest some degree of renal impairment, which can increase the risk of cardiac events. The patient's low HDL level (1.55) also increases the risk of cardiovascular disease.

The patient's age and comorbidities, such as hypertension and myocardial infarction, increase the risk of cardiac events. The patient's low T3 level (0.0348) may indicate hypothyroidism, which can increase the risk of cardiac events. The patient's low glucose level (5.7) may indicate some degree of metabolic syndrome, which can increase the risk of cardiac events.

Given the patient's low LVEF, elevated creatinine level, low albumin level, and other risk factors, the most likely outcome is that the patient will experience heart failure, which can lead to pump failure death. However, this outcome is not the most likely, as the patient is already on medications to manage their heart failure symptoms, and their other clinical presentation suggests that they are relatively stable."
141,141,P0231,"Age: 78
Gender: Male 
Weight: 80 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 6,07
Creatinine (mmol/L): 140.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,55
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,49
LDL (mmol/L): 4,1
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 5910.0
Protein (g/L): 70
T3 (pg/dL): 0,0168
T4 (ng/L): 13,49
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,27
Urea (mg/dL): 9
LVEF (%): 25.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall condition is relatively stable, with a NYHA Class II classification indicating mild symptoms of heart failure. The patient's LVEF is significantly reduced at 25%, but this is not uncommon in patients with idiopathic dilated cardiomyopathy. The patient is also receiving medications for heart failure (loop diuretics) and hypertension (ACE inhibitor), which suggests a proactive management of their condition.

The patient's laboratory results are also relatively stable, with normal liver enzymes, and a slightly elevated creatinine level, which is not uncommon in patients with heart failure. The patient's electrolytes and lipid profiles are also within relatively normal ranges.

The patient's ECG findings are also not alarming, with no signs of ventricular tachycardia, ventricular extrasystole, or bradycardia. The presence of paroxysmal supraventricular tachycardia (PSVT) may be a concern, but it is not a high-risk arrhythmia.

The patient's Pro-BNP level is elevated at 5910.0 ng/L, but this is not uncommon in patients with heart failure. The patient's troponin level is also normal, which suggests that there is no significant myocardial injury.

Given these factors, the patient's prognosis is that they will survive the next few years. However, it is essential to closely monitor the patient's condition and adjust their treatment plan as needed to ensure optimal management of their heart failure and other comorbid conditions.

RANKING: 2. Sudden cardiac death
REASONING: The patient's LVEF is significantly reduced at 25%, which increases the risk of sudden cardiac death. The patient's Pro-BNP level is also elevated, which suggests a high risk of cardiac decompensation.

Additionally, the patient has a history of peripheral vascular disease, which may increase the risk of cardiovascular events. The patient's lipid profile is also suboptimal, with high total cholesterol and LDL levels, which increases the risk of cardiovascular disease.

The patient's ECG findings do show a polymorphic ventricular extrasystole, which is a high-risk arrhythmia. While the patient does not have ventricular tachycardia, the presence of polymorphic ventricular extrasystole increases the risk of sudden cardiac death.

Given these factors, the patient's risk of sudden cardiac death is moderate to high. However, with close monitoring and adjustment of their treatment plan, the risk can be reduced.

RANKING: 3. Pump failure death
REASONING: The patient's LVEF is significantly reduced at 25%, which increases the risk of heart failure and pump failure. The patient's Pro-BNP level is also elevated, which suggests a high risk of cardiac decompensation.

The patient's history of idiopathic dilated cardiomyopathy also increases the risk of pump failure. Additionally, the patient's kidney function is impaired, with an elevated creatinine level, which can increase the risk of heart failure.

The patient's ECG findings do show a polymorphic ventricular extrasystole, which is a high-risk arrhythmia. The patient's troponin level is also normal, which suggests that there is no significant myocardial injury.

Given these factors, the patient's risk of pump failure death is moderate. However, with close monitoring and adjustment of their treatment plan, the risk can be reduced.

It is essential to note that the patient's prognosis is closely tied to their response to treatment and management of their underlying conditions. Close monitoring and adjustment of their treatment plan can help reduce the risk of sudden cardiac death and pump failure death."
142,142,P0234,"Age: 67
Gender: Male 
Weight: 69 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,41
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 7
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,16
LDL (mmol/L): 1,5
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 2129.0
Protein (g/L): 76,5
T3 (pg/dL): 0,0471
T4 (ng/L): 15,02
Troponin (ng/mL): 0,9
TSH (mIU/L): 1,05
Urea (mg/dL): 7,2
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the patient's age (67 years), NYHA Class II heart failure, and history of ischemic dilated cardiomyopathy, dyslipidemia, and hypertension, the patient is at a higher risk for cardiac events. However, the patient's current medication regimen, which includes ACE inhibitors, beta blockers, and statins, suggests that the patient is receiving optimal treatment for heart failure and is likely to continue to receive aggressive management for their cardiac conditions. The patient's current ECG impression shows no ventricular arrhythmias, which is a positive prognostic sign. The patient's laboratory results show elevated troponin levels, which may indicate some degree of cardiac damage, but this is not uncommon in patients with heart failure. The patient's creatinine level is elevated, which may indicate some degree of kidney dysfunction, but this is not uncommon in patients with heart failure. The patient's LVEF is significantly reduced, which indicates poor cardiac function. However, the patient's current symptoms and laboratory results suggest that the patient is not experiencing acute cardiac decompensation. Overall, the combination of optimal medication, lack of ventricular arrhythmias, and absence of acute cardiac decompensation suggest that the patient is at lower risk for cardiac death or sudden cardiac death in the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy and hypertension increases their risk for sudden cardiac death. The patient's LVEF is significantly reduced, which indicates poor cardiac function and may increase the risk for arrhythmias. The patient's current ECG impression shows ventricular extrasystole, which is a type of abnormal heart rhythm that can increase the risk for sudden cardiac death. The patient's laboratory results show elevated troponin levels, which may indicate some degree of cardiac damage. While the patient is receiving optimal medication, the patient's underlying cardiac conditions may still pose a risk for sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 
The patient's NYHA Class II heart failure classification suggests that the patient is experiencing some degree of heart failure, but the patient is not in acute decompensation. The patient's LVEF is significantly reduced, which indicates poor cardiac function, but the patient's current symptoms and laboratory results suggest that the patient is not experiencing acute cardiac decompensation. The patient's current medication regimen and ECG impression suggest that the patient is receiving optimal treatment for heart failure. While the patient's underlying cardiac conditions may still pose a risk for pump failure, the patient's current status and treatment suggest that the patient is at lower risk for pump failure death in the next few years."
143,143,P0235,"Age: 76
Gender: Female 
Weight: 92 kg
Height: 153 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 7,07
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,84
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1309.0
Protein (g/L): 67
T3 (pg/dL): 0,0441
T4 (ng/L): 22,35
Troponin (ng/mL): 0,7
TSH (mIU/L): 1,62
Urea (mg/dL): 8,4
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I would rank the patient as having a high likelihood of survival over the next few years. The patient's age of 76 is considered advanced, but the fact that they are currently classified as NYHA Class III suggests that they have a relatively preserved cardiac function despite their age and comorbidities. The patient's left ventricular ejection fraction (LVEF) of 40% is concerning, indicating significant left ventricular dysfunction, but the patient's overall clinical presentation and medication regimen suggest that they are being well-managed for their conditions.

The patient's biomarkers, such as troponin levels and creatinine, are elevated, indicating some degree of cardiac stress and potential renal impairment, but these values are not indicative of acute cardiac or renal failure. The patient's electrolyte and liver function tests are also within normal limits, suggesting that the patient is not experiencing acute kidney injury or liver dysfunction.

The presence of ventricular extrasystoles and polymorphic ventricular tachycardia on the ECG is concerning, but the fact that these arrhythmias are not sustained and do not appear to be life-threatening suggests that the patient is not at immediate risk of sudden cardiac death.

Given the patient's overall clinical presentation and management, I believe that they are at a higher risk of survival over the next few years compared to the other two options."
144,144,P0236,"Age: 74
Gender: Female 
Weight: 87 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 130.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,68
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,2
Potassium (mEq/L): 3,9
LDL (mmol/L): 1,71
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1176.0
Protein (g/L): 72,9
T3 (pg/dL): 0,0312
T4 (ng/L): 14,43
Troponin (ng/mL): 0,5
TSH (mIU/L): 5,19
Urea (mg/dL): 13
LVEF (%): 50.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I rank the patient as a survivor for the next few years due to the following reasons:

- The patient's age (74) is not particularly high for cardiac-related mortality, and with the current medical management, it is possible for patients of this age to survive for several years.
- The patient has a NYHA Class II, which indicates mild symptoms of heart failure, but it is manageable with current medications.
- The patient has a history of hypertension, diabetes, and dyslipidemia, which are all risk factors for cardiovascular disease, but the patient is receiving treatment for these conditions.
- The patient's LVEF (ejection fraction) is 50%, which is below the normal range, indicating some degree of left ventricular dysfunction. However, with current medications and management, it is possible to improve cardiac function over time.
- The patient's ECG findings are relatively normal, with no signs of ventricular tachycardia or other arrhythmias that could indicate a high risk of sudden cardiac death.
- The patient's biomarkers, such as troponin and TSH, are not significantly elevated, suggesting that there is no acute cardiac injury or thyroid dysfunction.
- The patient is receiving medications that are standard for managing hypertension, heart failure, and dyslipidemia, which will help to control these conditions and reduce the risk of cardiovascular events.

While the patient has several risk factors for cardiovascular disease, the combination of age, medical management, and current biomarkers suggest that the patient is at a moderate to low risk for cardiac events in the short term. Therefore, I rank the patient as a survivor for the next few years."
145,145,P0237,"Age: 54
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,03
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 986.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,23
TSH (mIU/L): 0,87
Urea (mg/dL): 11,48
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the patient's data, I predict that the patient is likely to survive for the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a significant comorbidity. However, the patient is currently being treated with multiple medications, including ACE inhibitors, beta blockers, and diuretics, which are standard treatments for heart failure and hypertension. The patient's NYHA class is II, indicating mild heart failure symptoms, which suggests that the patient is still relatively stable.

The patient's ejection fraction (LVEF) is 25%, which is significantly reduced, indicating poor cardiac function. However, the patient's creatinine level is elevated, which may indicate some degree of renal impairment. The patient's troponin level is slightly elevated, which could indicate some degree of cardiac damage.

The patient's ECG shows non-sustained ventricular tachycardia (NSVT), which is a concerning sign, but it is not sustained. The patient's ventricular extrasystole is polymorphic, which may indicate some degree of ventricular arrhythmia risk.

Despite these concerns, the patient's overall clinical picture is relatively stable, and the patient is being treated with multiple medications to manage their heart failure and hypertension. The patient's age, weight, and other laboratory values are also relatively stable.

Overall, while the patient has significant comorbidities and some degree of cardiac dysfunction, the patient's current clinical picture suggests that they are likely to survive for the next few years with proper management and treatment.

RANKING: 2. Sudden cardiac death
REASONING: 
This prognosis is less likely than survivor, but still possible. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases their risk of sudden cardiac death. The patient's LVEF is significantly reduced, which increases the risk of sudden cardiac death. The patient's NSVT on the ECG is a concerning sign, but it is not sustained.

However, the patient's current treatment regimen includes ACE inhibitors, beta blockers, and diuretics, which are standard treatments for heart failure and hypertension. The patient's NYHA class is II, indicating mild heart failure symptoms, which suggests that the patient is relatively stable.

Additionally, the patient's creatinine level is elevated, which may indicate some degree of renal impairment. This could potentially increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
This prognosis is the least likely. The patient is currently being treated with multiple medications to manage their heart failure and hypertension. The patient's NYHA class is II, indicating mild heart failure symptoms, which suggests that the patient is relatively stable.

However, the patient's LVEF is significantly reduced, which indicates poor cardiac function. The patient's creatinine level is elevated, which may indicate some degree of renal impairment. The patient's troponin level is slightly elevated, which could indicate some degree of cardiac damage.

Additionally, the patient's NSVT on the ECG is a concerning sign, which may indicate some degree of ventricular arrhythmia risk. However, the patient's treatment regimen includes ACE inhibitors, beta blockers, and diuretics, which are standard treatments for heart failure and hypertension.

Overall, while the patient has significant comorbidities and some degree of cardiac dysfunction, the patient's current clinical picture suggests that they are relatively stable, and the patient is likely to survive for the next few years with proper management and treatment."
146,146,P0238,"Age: 53
Gender: Male 
Weight: 66 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/50 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 27
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,15
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 3,8
Hemoglobin (g/L): 83.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5,6
LDL (mmol/L): 1,71
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 137.0
Protein (g/L): 60
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,4
Urea (mg/dL): 11,32
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is most likely to be a survivor due to the following reasons:

1. Age: The patient is 53 years old, which is still considered relatively young for a cardiac event. While this patient has a history of hypertension and cardiomyopathy, the age factor contributes to a slightly more favorable prognosis.

2. Medications: The patient is taking beta blockers, loop diuretics, and an ACE inhibitor, which are commonly used to manage heart failure and hypertension. These medications can help reduce the risk of cardiac events and improve survival.

3. NYHA Class II: The patient's NYHA class is II, indicating mild symptoms of heart failure. Patients with a lower NYHA class tend to have a better prognosis than those with higher classes.

4. Electrocardiogram (ECG) Impression: While the ECG shows ventricular extrasystoles and a polymorphic rhythm, there is no indication of ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. The presence of ventricular extrasystoles may indicate underlying cardiac stress, but it is not a guarantee of a poor prognosis.

5. Biomarkers: The patient's troponin levels are within normal limits, and the pro-BNP levels are not significantly elevated. These biomarkers are useful in assessing cardiac stress and strain, but they do not necessarily predict a poor outcome.

6. Other laboratory values: The patient's kidney function (creatinine) is within normal limits, and the liver function tests are also within normal limits. The patient's glucose and lipid profiles are also within normal limits.

While the patient has a history of cardiomyopathy and hypertension, the combination of age, medications, NYHA class, and the absence of other alarming biomarkers and ECG findings suggest that the patient's prognosis is more favorable. Therefore, the patient is most likely to be a survivor."
147,147,P0240,"Age: 54
Gender: Male 
Weight: 103 kg
Height: 179 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44
ALT or GPT (IU/L): 137.0
AST or GOT (IU/L): 119.0
Total Cholesterol (mmol/L): 6,62
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 378
Glucose (mmol/L): 16,8
Hemoglobin (g/L): 149.0
HDL (mmol/L): 2,22
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,9
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 18.0
Protein (g/L): 84
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,47
Urea (mg/dL): 8,32
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation, laboratory results, and ECG findings suggest a relatively stable condition. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant comorbidity. However, the patient is on medications for diabetes and heart failure, which are likely helping to manage symptoms. The patient's NYHA Class II indicates mild heart failure symptoms, and the LVEF of 45% is within a relatively normal range for this condition.

The patient's laboratory results show elevated liver enzymes (ALT and AST) and creatinine levels, which may indicate some degree of liver dysfunction and kidney impairment, but these findings are not uncommon in patients with heart failure. The patient's electrolyte levels, including potassium and sodium, are within relatively normal ranges.

The ECG findings show ventricular extrasystole, which is a benign finding, and no other significant arrhythmias. This suggests that the patient is not at high risk for sudden cardiac death.

Overall, the patient's clinical presentation and laboratory results suggest a relatively stable condition, and the patient is likely to survive for the next few years without significant adverse events."
148,148,P0241,"Age: 35
Gender: Female 
Weight: 76 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 115/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 6,15
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,47
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 35070.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,32
Urea (mg/dL): 3,16
LVEF (%): 50.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I rank the patient as having a high likelihood of survival over the next few years. The patient's age, NYHA Class II heart failure, and elevated BNP levels (35070.0 ng/L) suggest a significant burden of cardiac disease. However, the patient's hemoglobin level (134.0 g/L) is within the normal range, and the absence of any acute cardiac events or arrhythmias on the ECG impression suggests that the patient is currently stable.

The patient's LVEF (50.0%) is mildly reduced, which is consistent with the patient's NYHA Class II heart failure. However, the patient is receiving optimal medical therapy with angiotensin II receptor blockers, beta blockers, loop diuretics, and spironolactone, which are standard treatments for heart failure.

The patient's laboratory results, including normal liver enzymes, normal kidney function (creatinine 3.16 mg/dL), and normal electrolyte levels, suggest that the patient is not experiencing any acute kidney injury or electrolyte disturbances that could impact cardiac function.

Given the patient's stable clinical status, optimal medical therapy, and absence of acute cardiac events, I believe that the patient has a high likelihood of survival over the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient has a significant burden of cardiac disease, I do not rank sudden cardiac death as the most likely outcome. The patient's LVEF is mildly reduced, and the patient is receiving optimal medical therapy, which suggests that the patient is not at high risk for sudden cardiac death.

However, the patient's elevated BNP levels (35070.0 ng/L) and NYHA Class II heart failure status do increase the risk for cardiac complications, including sudden cardiac death. Nevertheless, the patient's stable clinical status and absence of any acute cardiac events on the ECG impression suggest that the patient is not at high risk for sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

I rank pump failure death as the least likely outcome. While the patient has a significant burden of cardiac disease, the patient is receiving optimal medical therapy, and the patient's laboratory results suggest that the patient is not experiencing any acute kidney injury or electrolyte disturbances that could impact cardiac function.

Furthermore, the patient's mildly reduced LVEF (50.0%) is not indicative of severe pump dysfunction, and the patient's stable clinical status suggests that the patient is able to maintain adequate cardiac output despite the reduced LVEF.

Overall, while pump failure death is a potential risk for patients with heart failure, I believe that the patient's stable clinical status, optimal medical therapy, and mildly reduced LVEF make this outcome less likely compared to sudden cardiac death."
149,149,P0244,"Age: 36
Gender: Male 
Weight: 94 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,28
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 164.0
Protein (g/L): 79
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,41
Urea (mg/dL): 4,82
LVEF (%): 43.0
Medications: None reported.
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy with a reduced LVEF of 43% indicate that the patient is at a higher risk for cardiac complications. However, the patient's blood pressure is within the normal range (120/80 mmHg), and there are no reported medications. The absence of ventricular arrhythmias, such as ventricular extrasystole, ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, suggests that the patient is less likely to experience sudden cardiac death. The patient's serum creatinine level is elevated (88.0 mmol/L), but this is not uncommon in patients with heart failure. The elevated creatinine level may indicate some degree of renal impairment, but it is not necessarily a contraindication for survival. 

While the patient's biomarkers (Pro-BNP, Troponin) are elevated, they are not excessively high, and the patient is not experiencing any symptoms of acute coronary syndrome. Therefore, the patient's overall clinical presentation suggests that they are likely to survive for the next few years, provided that their cardiac condition is managed appropriately."
150,150,P0247,"Age: 72
Gender: Male 
Weight: 67 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5
LDL (mmol/L): 2,64
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 455.0
Protein (g/L): 82
T3 (pg/dL): 0,04
T4 (ng/L): 25
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,27
Urea (mg/dL): 11,15
LVEF (%): 34.0
Medications: Calcium Channel Blocker, Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall health status, despite having multiple comorbidities such as ischemic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension, indicates a relatively preserved cardiac function, as evidenced by an LVEF of 34.0, which is not severely impaired. The patient's current NYHA Class II classification suggests that they are still able to perform moderate physical activities without symptoms, which is a positive prognostic sign. Additionally, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG impression suggests that the patient's cardiac rhythm is relatively stable. The presence of a calcium channel blocker, ACE inhibitor, and other medications indicates that the patient is receiving appropriate treatment for their cardiovascular conditions. The elevated troponin level, while concerning, is not indicative of acute myocardial infarction, and the patient's other biomarkers (e.g., creatinine, urea, and liver enzymes) are within relatively normal limits. Overall, these factors suggest that the patient is likely to survive for the next few years."
151,151,P0249,"Age: 48
Gender: Male 
Weight: 65 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 200/100 mmHg
Past Medical History: Toxic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 61.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 6,75
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 194
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 3,6
LDL (mmol/L): 4,14
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 79
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 3,66
LVEF (%): 44.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a history of toxic dilated cardiomyopathy, which is a significant risk factor for cardiac complications. However, the patient is currently on medications for heart failure management (Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics), which are likely helping to manage symptoms. The patient's ejection fraction (LVEF) is 44%, which is below the normal range, indicating some degree of heart dysfunction. Despite this, the patient's NT-proBNP level is not excessively elevated (320 ng/L), which may suggest that the heart is not under significant stress. Additionally, the patient's troponin level is normal, which further reduces the risk of acute myocardial infarction. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG also reduces the risk of sudden cardiac death. Considering these factors, the patient's overall prognosis is relatively favorable, and I would rank the patient as a survivor."
152,152,P0252,"Age: 73
Gender: Male 
Weight: 83 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,94
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1070.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,55
Urea (mg/dL): 6,66
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient as a survivor with a high probability. Here's the reasoning behind this ranking:

1. Low risk of sudden cardiac death: The patient's ECG impression does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are common precursors to sudden cardiac death. The absence of these findings reduces the risk of sudden cardiac death.

2. Stable hemodynamic status: The patient's blood pressure (130/70 mmHg) and hemoglobin (136.0 g/L) levels are within normal limits, indicating a stable hemodynamic status. This suggests that the patient is not experiencing acute cardiovascular instability.

3. Low troponin levels: The patient's troponin level (0.01 ng/mL) is within normal limits, which indicates that there is no significant myocardial damage or acute myocardial infarction.

4. Effective medications: The patient is on a combination of medications that are commonly used to manage heart failure, hypertension, and diabetes, which suggests that the patient is receiving adequate treatment for their underlying conditions.

5. Low risk of pump failure: The patient's left ventricular ejection fraction (LVEF) is 38.0%, which is relatively preserved. This suggests that the patient's heart is still functioning adequately, reducing the risk of pump failure.

6. Absence of severe symptoms: The patient's New York Heart Association (NYHA) class is III, indicating moderate symptoms of heart failure. However, the patient is still able to perform daily activities without severe limitation, which suggests that they are not experiencing significant symptoms of heart failure.

While there are some risk factors present, such as ischemic dilated cardiomyopathy, diabetes, and hypertension, the patient's overall clinical picture suggests that they are at lower risk for a poor outcome. Therefore, I rank the patient as a survivor with a high probability."
153,153,P0253,"Age: 59
Gender: Female 
Weight: 80 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,26
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 824.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 3,37
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Given the patient's age (59 years), NYHA Class II heart failure, and the presence of idiopathic dilated cardiomyopathy, the patient is already at an advanced stage of heart failure. The patient's LVEF of 40% indicates significant left ventricular dysfunction, which is a strong predictor of adverse outcomes. However, the patient's current treatment regimen, including medications such as Angiotensin II Receptor Blockers, Beta Blockers, Digoxin, Loop Diuretics, and Spironolactone, suggests that the patient is receiving optimal medical therapy for heart failure. The patient's ECG findings, including non-sustained ventricular tachycardia and ventricular extrasystole, indicate that the patient is at risk for arrhythmias, but the absence of sustained ventricular tachycardia and bradycardia suggests that the patient is not at high risk for sudden cardiac death. Overall, while the patient has significant cardiac dysfunction and arrhythmias, the presence of optimal medical therapy and the absence of high-risk ECG findings make a sudden cardiac death less likely. 

2. Pump failure death
REASONING: 
Given the patient's significant left ventricular dysfunction (LVEF 40%), advanced age, and NYHA Class II heart failure, the patient is at high risk for pump failure. The patient's elevated creatinine levels (106.0 mmol/L) also suggest renal impairment, which can exacerbate heart failure. However, the patient's current treatment regimen, including medications such as Digoxin and Spironolactone, suggests that the patient is receiving optimal medical therapy for heart failure. While the patient's ECG findings indicate a high risk for arrhythmias, the absence of sustained ventricular tachycardia and bradycardia suggests that the patient is not at high risk for sudden cardiac death. Therefore, while pump failure is a likely outcome, it is not the most likely outcome given the patient's current medical therapy and ECG findings.

3. Sudden cardiac death
REASONING: 
Given the patient's significant left ventricular dysfunction (LVEF 40%), advanced age, and NYHA Class II heart failure, the patient is at high risk for sudden cardiac death. The patient's ECG findings, including non-sustained ventricular tachycardia and ventricular extrasystole, indicate a high risk for arrhythmias. However, the absence of sustained ventricular tachycardia and bradycardia suggests that the patient is not at high risk for sudden cardiac death. The patient's optimal medical therapy, including medications such as Angiotensin II Receptor Blockers, Beta Blockers, and Spironolactone, suggests that the patient is receiving optimal treatment for heart failure. Therefore, while the patient is at high risk for arrhythmias, the presence of optimal medical therapy and the absence of high-risk ECG findings make sudden cardiac death less likely."
154,154,P0254,"Age: 49
Gender: Male 
Weight: 65 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 100/50 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 465
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 166.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,1
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 194.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,38
Urea (mg/dL): 5,99
LVEF (%): 23.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results indicate a severe cardiac condition. The patient has a history of dilated cardiomyopathy, hypertension, and myocardial infarction, which are risk factors for heart failure and arrhythmias. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 23%, indicating poor cardiac function. The elevated troponin level (0.005 ng/mL) suggests some degree of myocardial damage, and the presence of ventricular extrasystoles on the ECG is concerning for arrhythmias.

However, the patient is currently on beta blockers, digoxin, and spironolactone, which are standard treatments for heart failure and arrhythmias. The patient's hemoglobin level is elevated at 16.6 g/dL, which may be a sign of anemia, but it's not directly related to the cardiac condition. The patient's liver enzymes (ALT and AST) are within normal limits, and the liver function tests (ALP and GGT) are not elevated, suggesting no significant liver damage.

The patient's medication regimen and clinical presentation do not suggest an immediate life-threatening condition that would necessitate a more aggressive treatment approach. Therefore, the patient is more likely to survive in the short term, provided that their condition is closely monitored and managed.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's cardiac condition is severe, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG makes sudden cardiac death less likely. However, the patient's reduced LVEF and the presence of ventricular extrasystoles on the ECG do increase the risk of arrhythmias, which can lead to sudden cardiac death.

The patient's current medication regimen and clinical presentation do not suggest a sudden and catastrophic event that would lead to sudden cardiac death. However, the patient's cardiac condition is severe, and there is a risk of arrhythmias, which could potentially lead to sudden cardiac death if not properly managed.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's reduced LVEF and elevated creatinine level (97.0 mol/L) suggest that the patient's cardiac function is compromised, and there is a risk of pump failure. However, the patient is currently on medication for heart failure (loop diuretics, spironolactone, and ACE inhibitor), which should help manage symptoms and slow disease progression.

The patient's elevated troponin level (0.005 ng/mL) and the presence of ventricular extrasystoles on the ECG suggest some degree of myocardial damage, but the patient's current clinical presentation and medication regimen do not suggest an immediate risk of pump failure. While there is a risk of progressive cardiac decline, the patient's current condition is not severe enough to warrant a high risk of pump failure in the short term."
155,155,P0255,"Age: 41
Gender: Male 
Weight: 81 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 13,3
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4
LDL (mmol/L): 3,88
Sodium (mEq/L): 130.0
Protein (g/L): 68
T3 (pg/dL): 0,02
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,28
Urea (mg/dL): 6,66
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is currently on multiple medications, including beta blockers, which are known to be effective in managing heart failure and reducing the risk of sudden cardiac death. The patient also has a relatively stable ECG impression, with no signs of ventricular arrhythmias. Additionally, the patient's NYHA class is II, indicating mild heart failure, which is not severe enough to immediately suggest a high risk of sudden cardiac death. The patient's blood pressure is also within a relatively normal range, which further reduces the risk of sudden cardiac death. The patient's creatinine level is elevated, indicating some degree of kidney dysfunction, but it is not severe enough to suggest a high risk of pump failure death. Overall, the combination of the patient's medication regimen, stable ECG, and relatively mild heart failure make a survivor outcome the most likely.

2. Pump failure death
REASONING:
The patient's LVEF is significantly reduced at 35%, indicating a substantial impairment of cardiac function. This suggests a high risk of pump failure death, especially given the patient's history of ischemic dilated cardiomyopathy and diabetes. The patient's elevated creatinine level and elevated blood pressure also suggest some degree of kidney dysfunction, which can exacerbate cardiac failure. While the patient is on beta blockers, which can help reduce the risk of pump failure, the patient's medication regimen is not sufficient to completely mitigate the risk of pump failure death.

3. Sudden cardiac death
REASONING:
The patient's ECG impression is relatively stable, with no signs of ventricular arrhythmias or other cardiac conduction abnormalities. However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. The patient's elevated troponin level is also a marker of myocardial damage, which can increase the risk of arrhythmias and sudden cardiac death. Additionally, the patient's medication regimen is not specifically aimed at reducing the risk of sudden cardiac death, which makes a sudden cardiac death outcome less likely. However, the patient's overall clinical presentation and history still make pump failure death a more likely outcome than sudden cardiac death."
156,156,P0257,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 105/55 mmHg
Past Medical History: Other HF etiology, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 7,73
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,6
LDL (mmol/L): 5,79
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1876.0
Protein (g/L): 68
T3 (pg/dL): 0,02
T4 (ng/L): 25
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,44
Urea (mg/dL): 7,15
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class III status, and elevated NT-proBNP levels (1876.0 ng/L) suggest significant left ventricular dysfunction and heart failure. The patient's LVEF is 42.0%, which is below the normal range, indicating severe left ventricular impairment. The presence of ventricular extrasystoles on the ECG, which may be a sign of ventricular arrhythmias, further increases the risk of adverse outcomes.

The patient's medication regimen, including beta blockers, loop diuretics, spironolactone, and ACE inhibitors, is standard for managing heart failure and hypertension. However, the patient's elevated troponin levels (0.01 ng/mL) and elevated creatinine (7.15 mg/dL) suggest some degree of cardiac and renal impairment, which may affect the patient's overall prognosis.

While the patient's past medical history, including myocardial infarction and dyslipidemia, is concerning, the patient's current clinical presentation and laboratory results suggest that they are currently in a relatively stable condition. The patient's hemoglobin level is within the normal range, and their potassium level is slightly elevated, which may be related to their medication regimen.

Given the patient's overall clinical picture, I believe that the most likely outcome is a survivor, as they are currently receiving standard treatment for their heart failure and hypertension, and their laboratory results do not indicate an acute exacerbation of their condition."
157,157,P0258,"Age: 59
Gender: Male 
Weight: 80 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 239.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 108.0
HDL (mmol/L): 0,39
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,91
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,01
Urea (mg/dL): 20,3
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient has a history of ischemic dilated cardiomyopathy, which indicates a significant underlying cardiac condition that can lead to heart failure. However, the patient's current LVEF is 48.0%, which is still above the threshold for severe heart failure. The patient is also taking medications that are commonly used to treat heart failure, such as loop diuretics and ACE inhibitors, which suggests that the patient's heart failure is being managed. The patient's blood pressure is also well-controlled at 130/80 mmHg, which reduces the risk of further cardiac complications. Additionally, the patient's ECG impression does not show any arrhythmias that could increase the risk of sudden cardiac death.

While the patient has a history of myocardial infarction, diabetes, and dyslipemia, which are all risk factors for cardiac complications, the patient's current medical management and the absence of any significant cardiac events in the recent past suggest that the patient is currently stable. The patient's creatinine level is slightly elevated, but this could be due to various factors, including the patient's age and other medical conditions. Overall, the combination of the patient's current medical management, stable cardiac status, and the absence of any significant cardiac events in the recent past make a survivor the most likely outcome.

2. Pump failure death
REASONING:
The patient's LVEF is 48.0%, which is below the normal range, indicating some degree of heart failure. The patient's creatinine level is also elevated, which could be related to heart failure. Additionally, the patient has a history of ischemic dilated cardiomyopathy, which can lead to progressive heart failure. The patient's medication regimen, while comprehensive, may not be sufficient to manage the patient's underlying cardiac condition, particularly if the patient's heart failure is progressing. Furthermore, the patient's blood pressure is slightly elevated, which could increase the risk of cardiac complications.

3. Sudden cardiac death
REASONING:
The patient's ECG impression shows ventricular extrasystole, which is a sign of abnormal heart rhythm. However, the patient's ECG does not show any other arrhythmias that could increase the risk of sudden cardiac death. The patient's troponin level is also normal, which reduces the risk of myocardial infarction. While the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of cardiac complications, the patient's current medical management and the absence of any significant cardiac events in the recent past make sudden cardiac death less likely. However, the patient's ventricular extrasystole and elevated creatinine level do increase the risk of cardiac complications, making pump failure death a more likely outcome than sudden cardiac death."
158,158,P0259,"Age: 55
Gender: Male 
Weight: 94 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 180/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 161.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,65
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 102.0
Protein (g/L): 69
T3 (pg/dL): 0,02
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 9,65
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall health status is compromised due to multiple comorbidities, including hypertension, myocardial infarction, and peripheral vascular disease. However, the patient is currently taking a combination of medications that effectively manage their conditions, such as beta blockers, loop diuretics, statins, and an ACE inhibitor. The patient's left ventricular ejection fraction (LVEF) is 70%, which indicates that their heart is still pumping effectively, albeit with some compromise.

The patient's troponin levels are within the normal range, and their ECG impression does not show any signs of ventricular tachycardia or other arrhythmias that could indicate a high risk of sudden cardiac death. Additionally, the patient's pro-BNP levels are elevated, but not excessively high, which may indicate some degree of cardiac stress, but not necessarily a high risk of heart failure.

While the patient's weight and body mass index (BMI) are slightly above the normal range, the patient's overall health status and the fact that they are taking medications to manage their conditions suggest that they are likely to survive the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of myocardial infarction and hypertension increases their risk of sudden cardiac death. However, the patient's current LVEF is 70%, and their ECG impression does not show any signs of ventricular tachycardia or other arrhythmias that could indicate a high risk of sudden cardiac death.

The patient's elevated pro-BNP levels may indicate some degree of cardiac stress, but it is not a strong predictor of sudden cardiac death. The patient's troponin levels are within the normal range, which suggests that there is no acute myocardial damage.

Given the patient's overall health status and the fact that they are taking medications to manage their conditions, I would consider the risk of sudden cardiac death to be moderate, but not extremely high.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF is 70%, which is below the normal range (typically above 55%), indicating some degree of left ventricular dysfunction. The patient's elevated pro-BNP levels and slightly elevated creatinine levels may indicate some degree of cardiac stress and potential heart failure.

The patient's history of hypertension, myocardial infarction, and peripheral vascular disease increases their risk of developing heart failure. However, the patient is taking medications to manage their conditions, which should help to slow the progression of heart failure.

Given the patient's overall health status and the fact that they are taking medications to manage their conditions, I would consider the risk of pump failure death to be moderate, but not extremely high. However, the patient's LVEF is below the normal range, and their pro-BNP levels are elevated, which may indicate a slightly higher risk of pump failure death compared to the other two options."
159,159,P0267,"Age: 42
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 130/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 37,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,13
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 162
Glucose (mmol/L): 19,7
Hemoglobin (g/L): 125.0
HDL (mmol/L): 0,58
Potassium (mEq/L): 3,95
LDL (mmol/L): 1,96
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2237.0
Protein (g/L): 71,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,22
Urea (mg/dL): 14,99
LVEF (%): 28.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is currently classified as having a poor prognosis due to several factors, but the presence of a recent ECG finding of Non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole, along with a low LVEF of 28.0, indicates a high risk of arrhythmic events. However, the patient is currently taking medications that target these conditions, such as an ACE inhibitor, spironolactone, and a nitrovasodilator, which may help manage symptoms and prevent further deterioration.

Despite these factors, the patient's NYHA Class III classification suggests significant heart failure symptoms, and their elevated creatinine level (84.0 mmol/L) indicates impaired renal function. However, the patient's recent blood work results, including a normal Troponin level (0.01 ng/mL) and a low Pro-BNP level (2237.0 ng/L), suggest that the patient's heart failure symptoms are not acutely decompensating.

Considering these factors, the patient is likely to survive for the next few years, but their heart failure symptoms and arrhythmic risk may necessitate close monitoring and adjustments to their treatment plan. 

RANKING: 2. Pump failure death
REASONING: 

The patient's impaired renal function (creatinine level 84.0 mmol/L) and elevated creatinine level, combined with their NYHA Class III classification, suggest a high risk of heart failure progression and potentially pump failure. The patient's elevated BNP level (2237.0 ng/L) also indicates significant ventricular stress.

However, the patient's recent blood work results, including a normal Troponin level, and their current treatment plan, which includes medications to manage heart failure and hypertension, suggest that the patient is not in acute decompensated heart failure.

While the patient's LVEF is low, it is not the primary factor contributing to their prognosis. A LVEF of 28.0 is a significant finding, but it is not uncommon in patients with ischemic cardiomyopathy. The patient's overall clinical presentation and laboratory results suggest that pump failure is a possible outcome, but not the most likely one.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's recent ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia (NSVT) are significant risk factors for sudden cardiac death. The patient's low LVEF (28.0) and elevated creatinine level (84.0 mmol/L) also increase their risk of arrhythmic events.

However, the patient is currently taking medications that target these conditions, and their recent blood work results, including a normal Troponin level, suggest that the patient is not in acute decompensated heart failure.

While the patient's overall clinical presentation and laboratory results suggest a high risk of arrhythmic events, the presence of ventricular extrasystole and NSVT on the ECG, combined with the patient's impaired renal function and heart failure symptoms, make pump failure death a more likely outcome than sudden cardiac death in the short term.

It is essential to closely monitor the patient's arrhythmic risk and adjust their treatment plan as needed to minimize the risk of sudden cardiac death."
160,160,P0268,"Age: 76
Gender: Female 
Weight: 71 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 47,8
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,65
Potassium (mEq/L): 4,24
LDL (mmol/L): 3,3
Sodium (mEq/L): 139.0
Protein (g/L): 74,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,69
Urea (mg/dL): 11,9
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the provided patient data, I predict that the patient is most likely to be a survivor. The patient's age is 76, but the patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform daily activities without significant limitations. The patient's LVEF is 30%, which indicates left ventricular dysfunction, but the patient is not in cardiogenic shock. The patient's medications, including beta blockers, loop diuretics, and spironolactone, suggest that they are receiving standard treatments for heart failure. The patient's ECG findings, including ventricular extrasystoles and non-sustained VT, indicate some cardiac arrhythmias, but they are not indicative of a high risk of sudden cardiac death. The patient's laboratory results, including elevated creatinine and urea levels, suggest some renal impairment, but this is not uncommon in elderly patients. Overall, the patient's clinical presentation and laboratory results suggest that they are stable and can be managed with standard treatments, making survival likely.

2. Sudden cardiac death
REASONING: 
I predict that the patient is at moderate risk for sudden cardiac death. The patient's LVEF is 30%, which is significantly reduced, indicating left ventricular dysfunction. The patient's ECG findings, including ventricular extrasystoles and non-sustained VT, indicate some cardiac arrhythmias. The patient's medications, including beta blockers, loop diuretics, and spironolactone, may not be adequate to manage the patient's cardiac function. The patient's laboratory results, including elevated creatinine and urea levels, suggest some renal impairment, which can increase the risk of cardiac arrhythmias. However, the patient's age and NYHA Class II status suggest that they are not in cardiogenic shock, which reduces the risk of sudden cardiac death.

3. Pump failure death
REASONING: 
I predict that the patient is at low risk for pump failure death. The patient's LVEF is 30%, which is significantly reduced, indicating left ventricular dysfunction. However, the patient's NYHA Class II status suggests that they are able to perform daily activities without significant limitations. The patient's medications, including beta blockers, loop diuretics, and spironolactone, are standard treatments for heart failure. The patient's ECG findings, including ventricular extrasystoles and non-sustained VT, indicate some cardiac arrhythmias, but they are not indicative of a high risk of pump failure. The patient's laboratory results, including elevated creatinine and urea levels, suggest some renal impairment, but this is not uncommon in elderly patients. Overall, the patient's clinical presentation and laboratory results suggest that they are stable and can be managed with standard treatments, reducing the risk of pump failure death."
161,161,P0272,"Age: 80
Gender: Female 
Weight: 76 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,29
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 68,6
T3 (pg/dL): 0,0477
T4 (ng/L): 16,39
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,42
Urea (mg/dL): 7,1
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

Based on the patient's age, NYHA Class II, and the presence of multiple comorbid conditions such as hypertension, diabetes, and dyslipidemia, the patient is already at an increased risk for cardiovascular events. The elevated troponin level (0.3 ng/mL) suggests some degree of cardiac damage, but it is not excessively high. The patient's LVEF (60.0%) is also slightly below normal, but it is not significantly reduced. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG also indicate a risk for arrhythmias, but the absence of a clear indication for a life-threatening arrhythmia (e.g., sustained ventricular tachycardia or ventricular fibrillation) suggests that the patient is not at immediate risk for sudden cardiac death. The patient is also taking a calcium channel blocker, which is often used to treat hypertension and can help manage arrhythmias. Overall, the patient's comorbidities and ECG findings suggest that the patient is at increased risk for cardiovascular events, but the absence of a clear indication for immediate intervention or life-threatening arrhythmias suggests that the patient is likely to survive for the next few years.

RANKING: 2. Pump failure death 
REASONING: 

The patient's elevated creatinine level (100.0 mmol/L) suggests impaired renal function, which can be a marker for pump failure. The patient's LVEF (60.0%) is also slightly below normal, which may indicate some degree of cardiac dysfunction. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG also suggests a risk for arrhythmias and cardiac dysfunction. While the patient is taking medications that may help manage these conditions, the patient's comorbidities and ECG findings suggest that the patient is at risk for progressive cardiac decline, which could eventually lead to pump failure. However, the patient's current troponin level and LVEF are not excessively high, which suggests that the patient is not in immediate danger of pump failure.

RANKING: 3. Sudden cardiac death 
REASONING: 

The patient's ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggest a risk for arrhythmias, which are a major risk factor for sudden cardiac death. However, the absence of a clear indication for immediate intervention or life-threatening arrhythmia (e.g., sustained ventricular tachycardia or ventricular fibrillation) on the ECG suggests that the patient is not at immediate risk for sudden cardiac death. The patient's comorbidities and ECG findings suggest a risk for cardiovascular events, but the patient is taking medications that may help manage these conditions, and the patient's current troponin level and LVEF are not excessively high. Overall, while the patient is at risk for arrhythmias and cardiovascular events, the absence of a clear indication for immediate intervention or life-threatening arrhythmia suggests that the patient is not at immediate risk for sudden cardiac death."
162,162,P0273,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,54
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 5435.0
Protein (g/L): 75,199
T3 (pg/dL): 0,0249
T4 (ng/L): 20,99
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,3
Urea (mg/dL): 9,1
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient's overall clinical presentation and test results indicate a high risk for cardiac complications, but the patient is currently being treated with multiple medications that target various aspects of cardiovascular disease management. The presence of ischemic dilated cardiomyopathy, peripheral vascular disease, and elevated troponin levels suggests a significant burden of cardiac disease. However, the patient's NYHA class is II, indicating mild symptoms, and the absence of recent myocardial infarction or ventricular arrhythmias on the ECG impression suggests that the patient is not in an acute decompensated state. The patient's current medication regimen includes beta blockers, ACE inhibitors, and amiodarone, which are all standard treatments for heart failure and arrhythmias. The patient's LVEF is 45%, which is significantly reduced, but not indicative of acute heart failure. The patient's elevated BNP levels and elevated creatinine levels may indicate some degree of cardiac dysfunction and renal impairment, but the patient's overall clinical presentation and test results do not suggest an immediate life-threatening situation. Therefore, based on the current information, the most likely outcome is that the patient will survive.

2. Sudden Cardiac Death 
REASONING: 
While the patient has a high risk for cardiac complications, the absence of recent myocardial infarction, ventricular arrhythmias, or other acute cardiac events on the ECG impression and the presence of beta blockers and amiodarone in the medication regimen reduce the likelihood of sudden cardiac death. However, the patient's ischemic dilated cardiomyopathy, peripheral vascular disease, and elevated troponin levels suggest a high risk for cardiac events. The patient's LVEF is significantly reduced, which increases the risk for cardiac events. Additionally, the patient's elevated BNP levels and elevated creatinine levels may indicate some degree of cardiac dysfunction and renal impairment, which can contribute to an increased risk for cardiac events. While the patient's current medication regimen is standard for heart failure and arrhythmias, the patient's overall clinical presentation and test results do not suggest an immediate life-threatening situation, but rather a high risk for cardiac complications over the short-term.

3. Pump Failure Death 
REASONING: 
The patient's LVEF is significantly reduced, indicating a high risk for pump failure. The patient's ischemic dilated cardiomyopathy, peripheral vascular disease, and elevated troponin levels also contribute to this risk. The patient's elevated BNP levels and elevated creatinine levels may indicate some degree of cardiac dysfunction and renal impairment, which can contribute to an increased risk for pump failure. However, the patient is currently being treated with multiple medications that target various aspects of cardiovascular disease management, including beta blockers, ACE inhibitors, and spironolactone, which can help mitigate the risk of pump failure. The patient's NYHA class is II, indicating mild symptoms, which reduces the likelihood of pump failure. Additionally, the absence of recent myocardial infarction or ventricular arrhythmias on the ECG impression suggests that the patient is not in an acute decompensated state. Therefore, while the patient is at high risk for pump failure, the patient's overall clinical presentation and test results do not suggest an immediate life-threatening situation, making sudden cardiac death the least likely outcome."
163,163,P0274,"Age: 68
Gender: Female 
Weight: 74 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 170/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 3,6
LDL (mmol/L): 1,63
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 149.0
Protein (g/L): 75
T3 (pg/dL): 0,0267
T4 (ng/L): 18,16
Troponin (ng/mL): 0,3
TSH (mIU/L): 2,4
Urea (mg/dL): 9,2
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Diabetes Medication, Amiodarone, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and the presence of Hypertensive cardiomyopathy and Diabetes are risk factors that suggest a moderate to high risk for cardiac events. However, the patient's LVEF is 70%, which is within the normal range, indicating preserved cardiac function. 

The elevated blood pressure (170/75 mmHg) and elevated creatinine (105.0) levels indicate chronic kidney disease, which can be a comorbidity that increases the risk of cardiovascular events. The elevated troponin level (0.3 ng/mL) is a marker of cardiac damage, but the absence of ST-elevation or non-sustained ventricular tachycardia on the ECG suggests that the patient does not have an acute myocardial infarction.

The patient's low albumin level (45 g/L) and elevated BNP level (149 ng/L) indicate fluid overload, which is consistent with heart failure. However, the patient is on loop diuretics, which suggests that the clinician is actively managing fluid overload. The presence of amiodarone, an anti-arrhythmic medication, may also be contributing to the patient's survival.

Overall, the combination of risk factors and the presence of medications that manage hypertension, heart failure, and arrhythmias suggest that the patient is at moderate risk for cardiac events. However, the absence of acute cardiac damage and the presence of medications that manage comorbidities make survival the most likely outcome.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's elevated blood pressure (170/75 mmHg) and elevated creatinine (105.0) levels indicate chronic kidney disease, which increases the risk of cardiovascular events. The patient's Hypertensive cardiomyopathy and Diabetes also increase the risk of cardiac events. The presence of amiodarone, an anti-arrhythmic medication, may also contribute to the risk of arrhythmias.

The patient's LVEF is 70%, which is within the normal range, but the elevated BNP level (149 ng/L) suggests that the patient has some degree of cardiac stress. The absence of troponin elevation on the ECG suggests that the patient does not have acute myocardial infarction.

However, the patient's age (68) and NYHA Class II indicate that the patient is at moderate to high risk for cardiac events. The presence of ventricular extrasystole on the ECG is a marker of arrhythmia, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient does not have an acute arrhythmia.

Overall, the combination of risk factors and the presence of medications that manage comorbidities make sudden cardiac death a possible outcome, but the absence of acute cardiac damage and the presence of medications that manage arrhythmias make it less likely than the first outcome.

RANKING: 3. Pump failure death
REASONING: 

The patient's elevated creatinine (105.0) level indicates chronic kidney disease, which can contribute to the development of heart failure. The patient's Hypertensive cardiomyopathy and Diabetes also increase the risk of heart failure.

The patient's LVEF is 70%, which is within the normal range, indicating preserved cardiac function. However, the elevated BNP level (149 ng/L) suggests that the patient has some degree of cardiac stress. The absence of troponin elevation on the ECG suggests that the patient does not have acute myocardial infarction.

The patient's age (68) and NYHA Class II indicate that the patient is at moderate to high risk for cardiac events. The presence of amiodarone, an anti-arrhythmic medication, may also contribute to the risk of heart failure.

However, the patient is on loop diuretics, which suggests that the clinician is actively managing fluid overload. The presence of medications that manage comorbidities, such as calcium channel blockers, diabetes medication, and statins, also suggest that the patient is receiving comprehensive management for cardiovascular risk factors.

Overall, while the patient is at risk for heart failure, the presence of medications that manage comorbidities and the absence of acute cardiac damage make pump failure death less likely than sudden cardiac death."
164,164,P0276,"Age: 37
Gender: Male 
Weight: 103 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 140/100 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,9
Potassium (mEq/L): 4,06
LDL (mmol/L): 2,36
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 308.0
Protein (g/L): 79,6
T3 (pg/dL): 0,0402
T4 (ng/L): 15,66
TSH (mIU/L): 0,41
Urea (mg/dL): 6
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Paroxysmal AVB
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 37-year-old male with a history of enolic dilated cardiomyopathy, hypertension, and NYHA Class II heart failure. His ECG impression shows ventricular extrasystole, which is a common finding in patients with dilated cardiomyopathy. The patient is also taking medications for heart failure and hypertension, which suggests that the patient's current management plan is focused on controlling symptoms and slowing disease progression.

Although the patient's LVEF is 30%, which is significantly reduced, the patient is still alive and has not shown any signs of acute heart failure or severe arrhythmias. The patient's laboratory values, including electrolytes, liver enzymes, and renal function tests, are also within relatively normal limits.

Given these factors, the most likely prognosis for the patient over the next few years is a survivor. The patient's current management plan and the absence of severe symptoms or acute complications suggest that the patient can continue to manage their condition with current treatments.

While there is a risk of sudden cardiac death, this is not the most likely outcome in this patient. The patient's LVEF is reduced, but the patient is not showing any signs of acute heart failure or severe arrhythmias, which would increase the risk of sudden cardiac death.

Pump failure death is also less likely, as the patient is taking medications for heart failure and has a relatively stable laboratory profile. The patient's LVEF is significantly reduced, but the patient is still alive and has not shown any signs of acute heart failure or severe arrhythmias.

Overall, the patient's current clinical status and management plan suggest that the most likely outcome over the next few years is a survivor."
165,165,P0277,"Age: 75
Gender: Male 
Weight: 89 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,77
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 410.0
Protein (g/L): 68,6
T3 (pg/dL): 0,039
T4 (ng/L): 15,86
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,23
Urea (mg/dL): 11,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's current health status and medical history suggest a relatively stable condition, with a NYHA Class II classification indicating moderate symptoms of heart failure. The patient's medications, including beta blockers, ACE inhibitors, and statins, are standard treatments for managing heart failure and other cardiovascular conditions. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression also suggests a lower risk of sudden cardiac death. While the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, the LVEF of 30.0% is not extremely low, and the patient is not in cardiogenic shock or acute heart failure. Therefore, based on the available information, the patient is likely to survive for the next few years with proper management and treatment.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 30.0% indicates significant left ventricular dysfunction, which increases the risk of heart failure exacerbation and pump failure. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction further increases this risk. While the patient is currently on beta blockers, ACE inhibitors, and statins, these medications may not be sufficient to reverse the underlying cardiac damage. Additionally, the patient's elevated creatinine level (177.0 mol/L) suggests some degree of renal impairment, which can exacerbate heart failure. Therefore, while not the most likely outcome, pump failure death is a possible prognosis for this patient.

RANKING: 3. Sudden cardiac death
REASONING: The patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and ventricular extrasystole (polymorphic) on the ECG impression suggest a higher risk of arrhythmias, which can lead to sudden cardiac death. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression reduces this risk. Additionally, the patient's LVEF of 30.0% is not extremely low, and the patient is not in cardiogenic shock or acute heart failure. While the patient's ECG impression does not suggest a high risk of ventricular arrhythmias, the presence of ventricular extrasystole (polymorphic) cannot be entirely ruled out, making sudden cardiac death a possible, albeit less likely, prognosis."
166,166,P0278,"Age: 82
Gender: Female 
Weight: 79 kg
Height: 144 cm
NYHA Class: III
Blood Pressure: 160/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 42.0
Total Cholesterol (mmol/L): 7,06
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,47
LDL (mmol/L): 4,22
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 710.0
Protein (g/L): 75,9
T3 (pg/dL): 0,045
T4 (ng/L): 23,19
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,07
Urea (mg/dL): 11,2
LVEF (%): 67.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's age, NYHA Class III, and elevated Pro-BNP levels (710 ng/L) suggest that the patient has significant heart failure. However, the presence of a ventricular extrasystole on the ECG, which is a type of abnormal heart rhythm, indicates that the patient may be at risk for arrhythmic events. The patient is also on Amiodarone, a medication used to treat certain types of irregular heart rhythms. While this increases the risk of side effects, it also suggests that the patient has a history of arrhythmias, which could be a contributing factor to their heart failure. 

The patient's elevated creatinine level (11.2 mg/dL) and low eGFR (not provided) suggest impaired renal function, which is a common complication of heart failure. The patient's elevated troponin level (0.3 ng/mL) suggests some degree of myocardial damage, but it is not excessively high. 

Given these factors, the patient's overall prognosis is more likely to be a survivor, as the patient is already on medications that address arrhythmias and heart failure. However, the patient's NYHA Class III and elevated Pro-BNP levels suggest that the patient is at risk for further decline in cardiac function.

2. Sudden cardiac death
REASONING:
The presence of ventricular extrasystole on the ECG is a significant risk factor for sudden cardiac death. While the patient is on Amiodarone, which reduces the risk of arrhythmias, the presence of this abnormal heart rhythm suggests that the patient is at risk for arrhythmic events. Additionally, the patient's elevated Pro-BNP levels (710 ng/L) and NYHA Class III suggest that the patient has significant heart failure, which can increase the risk of sudden cardiac death.

3. Pump failure death
REASONING:
The patient's NYHA Class III and elevated Pro-BNP levels (710 ng/L) suggest that the patient has significant heart failure. However, the patient is already on medications that address arrhythmias and heart failure (Amiodarone and Loop Diuretics). While the patient's elevated creatinine level (11.2 mg/dL) suggests impaired renal function, which is a common complication of heart failure, the patient's elevated troponin level (0.3 ng/mL) is not excessively high. The patient's LVEF (67.0) is also not excessively low, which suggests that the patient's heart function is not severely impaired.

Given these factors, the patient's prognosis is less likely to be pump failure death, as the patient is already on medications that address heart failure and arrhythmias."
167,167,P0281,"Age: 50
Gender: Male 
Weight: 91 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 160/100 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 3,41
LDL (mmol/L): 3,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1825.0
Protein (g/L): 66,2
T3 (pg/dL): 0,0402
T4 (ng/L): 17,78
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,95
Urea (mg/dL): 3,9
LVEF (%): 60.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I rank the patient as having a high likelihood of survival over the next few years. The patient's NYHA Class II heart failure classification indicates moderate symptoms, but the patient's LVEF is still at 60%, which suggests that the heart is not severely impaired. The patient's ejection fraction is not critically low, which is a good prognostic sign.

The patient's elevated blood pressure (160/100 mmHg) and high creatinine level (88.0 mmol/L) suggest that the patient has significant cardiovascular risk factors, including hypertension and kidney disease. However, the patient is already on medications for these conditions (Loop Diuretics, ACE Inhibitor, and Statins), which should help manage these risks.

The patient's elevated Pro-BNP level (1825.0 ng/L) indicates some degree of heart failure, but it is not excessively high, which suggests that the patient's heart is not failing catastrophically. The patient's Troponin level (0.3 ng/mL) is also within normal limits, which suggests that there is no significant myocardial damage.

The patient's medication list includes a beta-blocker, which is a cornerstone of heart failure treatment, and digoxin, which is often used to control ventricular rate in atrial fibrillation or to improve heart function in heart failure. The patient's hemoglobin level (148.0 g/L) is within normal limits, and the patient's potassium level (3.41 mEq/L) is also within normal limits.

Overall, while the patient has several risk factors for cardiovascular disease and heart failure, the patient's overall clinical picture suggests that the patient is likely to survive over the next few years, with careful management of the patient's medications and lifestyle modifications to reduce cardiovascular risk."
168,168,P0282,"Age: 58
Gender: Male 
Weight: 87 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,82
LDL (mmol/L): 2,2
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 165.0
Protein (g/L): 69,8
T3 (pg/dL): 0,0339
T4 (ng/L): 17,8
Troponin (ng/mL): 0,6
TSH (mIU/L): 1,62
Urea (mg/dL): 8,9
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 58-year-old male with a complex medical history, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and a previous myocardial infarction. His current NYHA Class II indicates mild symptoms of heart failure, which suggests that the heart is not functioning optimally. Despite this, his blood pressure is well-controlled, and his kidney function is relatively preserved. The patient is also on a comprehensive regimen of medications, including beta blockers, ACE inhibitors, and statins, which are standard treatments for heart failure and coronary artery disease.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate some degree of liver dysfunction, but this is not uncommon in patients with heart failure. The elevated creatinine level may also be related to his kidney function, but it is not significantly elevated, suggesting that the kidneys are not severely impaired.

The ECG findings of ventricular extrasystoles and sinus node dysfunction are concerning, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient is not at high risk for sudden cardiac death. The presence of paroxysmal supraventricular tachycardia (PSVT) is a common finding in patients with heart failure, and it is not necessarily a cause for concern.

Overall, considering the patient's complex medical history, his current medications, and his laboratory results, I believe that he is at low risk for adverse outcomes, and his prognosis is good. He is likely to survive for several years, provided that his medications are well-tolerated and his underlying conditions are managed effectively.

Prognosis for the next few years: The patient is likely to survive for at least 5-7 years, with a moderate risk of hospitalization for heart failure exacerbations and a low risk of sudden cardiac death. Regular follow-up and monitoring of his condition will be necessary to adjust his treatment plan as needed and to prevent complications."
169,169,P0283,"Age: 80
Gender: Female 
Weight: 87 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 160/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,52
LDL (mmol/L): 2,48
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 4058.0
Protein (g/L): 67,699
T3 (pg/dL): 0,0354
T4 (ng/L): 17,65
Troponin (ng/mL): 0,4
TSH (mIU/L): 2,07
Urea (mg/dL): 12,1
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient data, the patient is 80 years old, with a history of hypertensive cardiomyopathy and hypertension, which indicates a significant burden of cardiovascular disease. The patient's left ventricular ejection fraction (LVEF) is 70%, which is within the normal range, but the patient's NYHA Class III indicates a significant level of heart failure symptoms. The elevated creatinine level (115.0 mol/L) and low albumin level (40 g/L) suggest renal impairment, which can exacerbate heart failure.

The patient's troponin level (0.4 ng/mL) is within the normal range, which suggests that the patient does not have significant myocardial damage. The absence of ventricular tachycardia or ventricular extrasystoles on the ECG impression also reduces the risk of sudden cardiac death.

However, the patient's elevated Pro-BNP level (4058.0 ng/L) suggests significant heart failure symptoms, and the patient's high blood pressure (160/70 mmHg) and elevated creatinine level may indicate that the patient's heart failure is not well-controlled. Despite this, the patient's overall clinical presentation and ECG findings suggest that the patient is likely to survive the next few years, but with a high risk of heart failure exacerbation.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's high blood pressure (160/70 mmHg) and elevated creatinine level (115.0 mol/L) increase the risk of cardiovascular events, including sudden cardiac death. The patient's Pro-BNP level (4058.0 ng/L) is also elevated, which suggests significant heart failure symptoms.

While the patient's ECG impression does not show any ventricular tachycardia or ventricular extrasystoles, the presence of monomorphic ventricular extrasystoles may indicate an increased risk of arrhythmias, which can contribute to sudden cardiac death.

However, the patient's overall clinical presentation and ECG findings do not suggest a high risk of sudden cardiac death in the short term.

RANKING: 3. Pump failure death
REASONING: 

The patient's elevated Pro-BNP level (4058.0 ng/L) and high blood pressure (160/70 mmHg) suggest significant heart failure symptoms. The patient's elevated creatinine level (115.0 mol/L) and low albumin level (40 g/L) also indicate renal impairment, which can exacerbate heart failure.

While the patient's LVEF (70%) is within the normal range, the patient's NYHA Class III indicates significant heart failure symptoms, which increases the risk of pump failure. However, the patient's overall clinical presentation and ECG findings do not suggest a high risk of pump failure in the short term.

Given the patient's significant heart failure symptoms and elevated Pro-BNP level, the risk of pump failure death is a concern, but the patient's overall clinical presentation and ECG findings suggest that the patient is more likely to survive the next few years, but with a high risk of heart failure exacerbation."
170,170,P0284,"Age: 80
Gender: Female 
Weight: 54 kg
Height: 143 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 57.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,37
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1057.0
Protein (g/L): 76,8
T3 (pg/dL): 0,0726
T4 (ng/L): 14,63
Troponin (ng/mL): 0,6
TSH (mIU/L): 6,19
Urea (mg/dL): 6,7
LVEF (%): 45.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall condition is stable, with no signs of acute myocardial infarction or cardiac arrest. The patient's ejection fraction (LVEF) is severely reduced, indicating significant left ventricular dysfunction, which is a risk factor for heart failure. However, the patient is on medications that are commonly used to manage heart failure, such as beta blockers, loop diuretics, and ACE inhibitors. The patient's NT-proBNP level is elevated, indicating some degree of ventricular dysfunction, but it is not extremely high, suggesting that the patient may still be able to tolerate the current treatment regimen. Additionally, the patient's ECG findings, such as ventricular extrasystole and non-sustained ventricular tachycardia, are not indicative of severe cardiac instability. Overall, the patient's clinical presentation and laboratory results suggest that they are likely to survive the next few years, although they may require close monitoring and adjustments to their treatment plan to manage their heart failure and prevent further cardiac complications.

RANKING: 2. Sudden cardiac death
REASONING: The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, increase the risk of sudden cardiac death. The patient's LVEF is severely reduced, indicating significant left ventricular dysfunction, which can lead to arrhythmias and sudden cardiac death. Additionally, the patient's NT-proBNP level is elevated, indicating some degree of ventricular dysfunction, which can contribute to the risk of sudden cardiac death. While the patient is on medications that are commonly used to manage heart failure, the presence of these arrhythmias and ventricular dysfunction increases the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: The patient's LVEF is severely reduced, indicating significant left ventricular dysfunction, which increases the risk of heart failure. However, the patient is already on medications that are commonly used to manage heart failure, such as beta blockers, loop diuretics, and ACE inhibitors. While the patient's NT-proBNP level is elevated, it is not extremely high, suggesting that the patient may still be able to tolerate the current treatment regimen. Additionally, the patient's ECG findings, such as ventricular extrasystole and non-sustained ventricular tachycardia, are not indicative of severe cardiac instability. Therefore, while the patient is at risk of developing heart failure, the presence of these factors does not necessarily mean that pump failure death is imminent."
171,171,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I would rank the patient as having a high likelihood of survival for the next few years. The patient is 80 years old, which is an advanced age, but the patient's NYHA Class III indicates severe heart failure, suggesting that the patient has significant cardiac dysfunction. However, the patient's LVEF (left ventricular ejection fraction) is 70%, which is within the normal range for an elderly patient.

The patient's laboratory results show elevated creatinine levels, indicating some degree of renal impairment, but this is not uncommon in elderly patients. The patient's lipid profile is also concerning, with high total cholesterol and LDL levels, which increases the risk of cardiovascular events. However, the patient is already taking statins, which should help to manage this risk.

The patient's ECG results show ventricular extrasystole and sinus node dysfunction, which are concerning signs of cardiac arrhythmias. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

The patient's Pro-BNP level is elevated, which indicates some degree of heart failure. However, this is not uncommon in patients with NYHA Class III heart failure.

Overall, while the patient has several risk factors for adverse outcomes, the patient's advanced age, significant cardiac dysfunction, and the presence of certain medications (e.g., beta blockers, ACE inhibitors) suggest that the patient is at risk for pump failure and sudden cardiac death. However, the patient's overall clinical presentation and laboratory results do not suggest an immediate high risk of death, and the patient's survival for the next few years is still possible with close monitoring and management of the patient's condition.

Given the patient's age, NYHA Class III heart failure, and the presence of certain risk factors, I would estimate the patient's 1-year survival rate to be around 60-70%, and the 5-year survival rate to be around 30-40%."
172,172,P0292,"Age: 64
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,11
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,88
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1363.0
Protein (g/L): 67
T3 (pg/dL): 0,0426
T4 (ng/L): 14,2
TSH (mIU/L): 0,96
Urea (mg/dL): 7,1
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient is at high risk for adverse outcomes due to the presence of severe left ventricular dysfunction (LVEF 30%), which is a strong predictor of mortality in patients with idiopathic dilated cardiomyopathy. The patient's NYHA Class III indicates significant symptoms of heart failure, and the elevated Pro-BNP level (1363 ng/L) further supports this diagnosis. The patient's elevated creatinine level (118.0 mmol/L) also suggests renal impairment, which is a common complication in heart failure patients.

The patient's risk factors for cardiovascular events, such as hypertension, dyslipidemia, and peripheral vascular disease, are also present. However, the patient is currently on beta blockers, loop diuretics, statins, and ACE inhibitors, which are standard treatments for heart failure and high blood pressure. These medications can help reduce the risk of adverse outcomes.

The ECG findings of ventricular extrasystole and polymorphic ventricular tachycardia suggest an increased risk of arrhythmias, but the absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces this risk. The patient's bradycardia is not a significant concern.

Given the patient's overall clinical presentation and treatment plan, the most likely outcome is a survivor, with a reasonable quality of life and survival for the next few years. However, close monitoring and regular follow-up with the cardiologist will be essential to adjust the treatment plan as needed to minimize the risk of adverse outcomes."
173,173,P0295,"Age: 37
Gender: Male 
Weight: 94 kg
Height: 174 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 154.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3232.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,17
Urea (mg/dL): 6,99
LVEF (%): 21.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient is a 37-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipidemia, peripheral vascular disease, hypertension, and myocardial infarction. The patient's current NYHA Class III indicates severe heart failure, and the LVEF of 21% is significantly reduced, suggesting severe left ventricular dysfunction. The patient's high blood pressure, high creatinine levels, and elevated troponin levels further support the presence of cardiac damage.

The patient's ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) are concerning for a high risk of arrhythmic events. However, the patient is currently on beta blockers, which are indicated for this patient's underlying heart failure and arrhythmias.

Given the patient's severe heart failure and arrhythmias, it is likely that the patient will require ongoing management with multiple medications, including beta blockers, ACE inhibitors, and diuretics. With proper management, it is possible for this patient to survive for several years, making a survivor outcome the most likely.

2. Sudden Cardiac Death
REASONING: 
While the patient's ECG findings of ventricular extrasystole and non-sustained VT are concerning, the patient's current medication regimen and NYHA Class III status suggest that the patient is receiving adequate treatment for their heart failure and arrhythmias.

However, the patient's severe left ventricular dysfunction (LVEF 21%) and high creatinine levels indicate that the patient's heart is not functioning optimally. The patient's troponin levels are also elevated, indicating ongoing cardiac damage. These factors increase the risk of sudden cardiac death.

Additionally, the patient's age and comorbidities (diabetes, hypertension, and peripheral vascular disease) further increase the risk of sudden cardiac death. However, without evidence of acute coronary syndrome or other life-threatening conditions, the risk of sudden cardiac death may not be as high as in a patient with a more acute presentation.

3. Pump Failure Death
REASONING: 
While the patient's severe left ventricular dysfunction (LVEF 21%) and high creatinine levels indicate that the patient's heart is not functioning optimally, the patient's current medication regimen and NYHA Class III status suggest that the patient is receiving adequate treatment for their heart failure.

The patient's elevated troponin levels and elevated liver enzymes (ALT and AST) also indicate ongoing cardiac damage, but the patient's elevated albumin levels (45 g/L) suggest that the patient's liver function is relatively preserved.

Given the patient's age and comorbidities, it is possible that the patient may experience pump failure in the near future. However, without evidence of acute heart failure or other life-threatening conditions, the risk of pump failure death may not be as high as in a patient with a more acute presentation."
174,174,P0296,"Age: 69
Gender: Female 
Weight: 55 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,84
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 13,9
Glucose (mmol/L): 5,03
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,95
Potassium (mEq/L): 4,74
LDL (mmol/L): 3,09
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 267.0
Protein (g/L): 80
T3 (pg/dL): 0,0432
T4 (ng/L): 13,91
TSH (mIU/L): 1,51
Urea (mg/dL): 9
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient is a 69-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is significantly impaired. The patient's left ventricular ejection fraction (LVEF) is 25%, indicating severe systolic dysfunction. Despite the presence of NYHA Class II symptoms, the patient is currently taking medications that are standard for heart failure management, including digoxin, loop diuretics, and an ACE inhibitor.

The patient's biomarkers, such as elevated creatinine and BNP levels, suggest that the heart is under significant strain. However, the patient's hemoglobin and potassium levels are within normal limits, which suggests that the patient is not experiencing severe anemia or electrolyte imbalances.

The ECG results show no signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are significant predictors of sudden cardiac death. The presence of ventricular extrasystole and polymorphic ventricular extrasystole may indicate a risk of arrhythmias, but the patient is not experiencing any symptoms that would suggest a high risk of sudden cardiac death.

Given the patient's age, NYHA Class II symptoms, and the presence of severe systolic dysfunction, the patient is at increased risk of cardiac events. However, the patient's current medications and the absence of significant electrolyte imbalances or arrhythmias suggest that the patient is likely to survive for the next few years. 

Therefore, the most likely prognosis for this patient is survivor, with a moderate risk of cardiac events, such as heart failure exacerbation or arrhythmias.

2. Sudden Cardiac Death
REASONING: 
The patient's severe systolic dysfunction, as indicated by the LVEF of 25%, and the presence of NYHA Class II symptoms, puts the patient at increased risk of cardiac events. The patient's elevated BNP levels and creatinine suggest that the heart is under significant strain.

While the patient is taking medications that are standard for heart failure management, the patient's LVEF is significantly below the normal range, indicating that the patient's heart is not responding well to current treatment. The presence of ventricular extrasystole and polymorphic ventricular extrasystole on the ECG may indicate a risk of arrhythmias, which could potentially lead to sudden cardiac death.

However, the patient's age and the absence of significant electrolyte imbalances or other risk factors for sudden cardiac death, such as a family history of sudden cardiac death, reduce the likelihood of sudden cardiac death.

3. Pump Failure Death
REASONING: 
Pump failure death is a possible outcome for patients with severe systolic dysfunction, but it is less likely than sudden cardiac death in this patient. The patient's LVEF of 25% indicates that the patient's heart is not pumping efficiently, and the patient's elevated BNP levels suggest that the heart is under significant strain.

However, the patient is taking medications that are standard for heart failure management, and the patient's hemoglobin and potassium levels are within normal limits, which suggests that the patient is not experiencing severe anemia or electrolyte imbalances.

Given the patient's age and the presence of severe systolic dysfunction, pump failure death is a possible outcome, but it is less likely than sudden cardiac death in this patient."
175,175,P0297,"Age: 73
Gender: Male 
Weight: 82 kg
Height: 159 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 15,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,79
LDL (mmol/L): 2,07
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 678.0
Protein (g/L): 65
T3 (pg/dL): 0,0396
T4 (ng/L): 13,66
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,3
Urea (mg/dL): 3,4
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient is 73 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction, which are all risk factors for cardiac complications. However, the patient's current NYHA class is III, indicating moderate heart failure symptoms. Despite this, the patient has a relatively stable vital sign profile with normal blood pressure and no acute cardiac events on the ECG impression.

The patient's biomarkers, such as elevated troponin and BNP, suggest some degree of cardiac stress and strain. However, the patient's hemoglobin and kidney function are within relatively normal limits. The patient is also taking multiple medications that are commonly used to manage heart failure and cardiac arrhythmias.

Given these factors, the patient's overall prognosis is more favorable than the other two options. While the patient's cardiac function is compromised, the presence of multiple medications and a relatively stable vital sign profile suggest that the patient may be able to tolerate ongoing therapy and make lifestyle modifications to manage their condition.

The patient's LVEF of 25% is significantly reduced, indicating severe left ventricular dysfunction. However, this is not uncommon in patients with ischemic cardiomyopathy. The patient's creatinine level is elevated, which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure.

In contrast, the sudden cardiac death and pump failure death prognoses are less likely because the patient is on multiple medications that are commonly used to manage heart failure and cardiac arrhythmias, and the patient's vital signs are relatively stable. However, the patient's severe LVEF and elevated BNP levels do increase the risk of cardiac complications, and close monitoring and regular follow-up are necessary to ensure that the patient's condition does not deteriorate.

It's worth noting that the patient's age, weight, and comorbidities also play a role in determining the prognosis. As a 73-year-old male with multiple comorbidities, the patient is at increased risk for cardiac complications, but the presence of multiple medications and a relatively stable vital sign profile suggest that the patient's prognosis is more favorable than the other two options."
176,176,P0298,"Age: 86
Gender: Male 
Weight: 90 kg
Height: 190 cm
NYHA Class: III
Blood Pressure: 125/80 mmHg
Past Medical History: Other HF etiology, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,53
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 851.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,59
Urea (mg/dL): 3,5
LVEF (%): 37.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the patient's data, I predict that the patient is most likely to survive in the next few years. The key factors contributing to this prediction are:

1. Age: Although the patient is 86 years old, the age itself is not a strong predictor of mortality. Many patients with heart failure at this age can still have a relatively good prognosis with proper management.
2. NYHA Class III: This indicates that the patient has moderate symptoms of heart failure, which can be managed with medications and lifestyle changes.
3. Medications: The patient is taking a combination of medications, including digoxin, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, which are all standard treatments for heart failure. The presence of these medications suggests that the patient is receiving appropriate care.
4. ECG Impression: The ECG results show no signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are both significant predictors of mortality. The presence of ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia is not uncommon in patients with heart failure.
5. Laboratory results: The patient's laboratory results, including a normal creatinine level and a relatively low troponin level, suggest that the patient's heart muscle is not under significant stress.

While the patient's LVEF is low at 37%, this can often be improved with treatment and lifestyle changes. The patient's weight and height are also within a relatively normal range, which can help to reduce the risk of complications.

Overall, based on the patient's age, medical history, medications, ECG results, and laboratory results, I predict that the patient is most likely to survive in the next few years."
177,177,P0299,"Age: 71
Gender: Female 
Weight: 95 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 5,9
LDL (mmol/L): 3,26
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3233.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,86
Urea (mg/dL): 6,16
LVEF (%): 17.0
Medications: Amiodarone, Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy are risk factors for cardiac complications. However, the patient is on multiple medications, including Amiodarone, Beta Blockers, and ACE Inhibitor, which are commonly used to manage heart failure and arrhythmias. The patient's Pro-BNP level is elevated, indicating some degree of heart failure, but the LVEF is 17%, which is relatively preserved. The presence of non-sustained ventricular tachycardia (NST) on the ECG is a concerning finding, but it is not indicative of an acute cardiac event.

The patient's vital signs and laboratory values are relatively stable, with no signs of acute kidney injury or severe hypotension. The patient's hemoglobin and potassium levels are within normal limits, and the Troponin level is normal, which suggests that there is no acute myocardial infarction.

Considering these factors, the most likely outcome is that the patient will survive in the short term, but it is essential to closely monitor the patient for signs of worsening heart failure, arrhythmias, or other cardiac complications. Regular follow-up appointments and close monitoring of the patient's condition are crucial to prevent potential complications and improve long-term outcomes.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's ECG shows non-sustained ventricular tachycardia (NST), the presence of ventricular extrasystoles and polymorphic ventricular tachycardia on the ECG is a concerning finding. The patient's LVEF is only 17%, which is significantly reduced, and the patient has a history of idiopathic dilated cardiomyopathy. These factors increase the risk of sudden cardiac death.

However, the patient is on multiple medications, including Amiodarone, which is an antiarrhythmic medication commonly used to treat ventricular arrhythmias. While the patient's ECG shows non-sustained ventricular tachycardia, it is not sustained, which reduces the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF is only 17%, which is significantly reduced, indicating severe heart failure. The patient's NYHA Class II suggests that the patient has some symptoms of heart failure, and the patient's Pro-BNP level is elevated, indicating some degree of heart failure. The patient's creatinine level is slightly elevated, which may indicate some degree of renal impairment.

While the patient is on medications to manage heart failure, the patient's heart function is severely impaired, and the patient's LVEF is not expected to improve significantly. The patient's age and comorbidities also increase the risk of pump failure death.

However, the patient's vital signs and laboratory values are relatively stable, and the patient is not showing signs of acute kidney injury or severe hypotension. Therefore, while the patient is at risk of pump failure death, it is not the most likely outcome in the short term."
178,178,P0301,"Age: 76
Gender: Male 
Weight: 83 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 7,6
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3182.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,07
Urea (mg/dL): 17,14
LVEF (%): 12.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient's prognosis is likely to be a survivor. Here's a breakdown of the reasons why:

1. Age: The patient is 76 years old, which is considered elderly. However, this is not necessarily a contraindication for survival, as many patients with advanced cardiovascular disease can survive for several years with proper management.
2. NYHA Class III: The patient has a severe heart failure classification, indicating significant impairment of cardiac function. However, this classification is not necessarily a predictor of mortality, as some patients with severe heart failure can survive for a long time with optimal treatment.
3. Medications: The patient is on multiple medications, including beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, which suggests that the patient is receiving comprehensive care for their cardiovascular conditions. This comprehensive management is likely to improve survival.
4. Pro-BNP levels: The elevated Pro-BNP level (3182.0 ng/L) indicates significant cardiac strain, which is a marker of heart failure. However, the fact that the patient is on medications that are known to reduce BNP levels suggests that the patient is receiving effective treatment.
5. ECG findings: The patient has ventricular extrasystole, which is a common finding in patients with heart failure. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.
6. Other laboratory findings: The patient's creatinine level (150.0 mmol/L) is elevated, indicating impaired renal function. However, this is not uncommon in patients with heart failure, and the patient is receiving medications that are known to improve renal function.

Overall, while the patient has several comorbidities and laboratory abnormalities, the comprehensive management of their cardiovascular conditions, along with the absence of life-threatening arrhythmias, suggests that the patient is likely to survive for several years."
179,179,P0302,"Age: 67
Gender: Male 
Weight: 80 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 16
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,97
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 589.0
Protein (g/L): 74
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,09
Urea (mg/dL): 11,48
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's data, the patient is considered a high-risk patient due to a history of ischemic dilated cardiomyopathy, diabetes, dyslipidemia, and a previous myocardial infarction. The elevated creatinine level (115.0 mmol/L) and low LVEF (48.0%) also indicate significant cardiac dysfunction. However, the patient is currently taking multiple medications, including beta blockers, ACE inhibitors, and spironolactone, which are all recommended for managing heart failure. The absence of any signs of acute cardiac stress or arrhythmias on the ECG impression also reduces the risk of sudden cardiac death. The patient's current symptoms and lab results do not indicate acute decompensated heart failure, which would be a more immediate concern. Overall, the patient's medical history, medications, and current clinical status suggest that the patient is at a higher risk of developing pump failure, but the presence of multiple medications and the absence of acute symptoms make survival a more likely outcome.

2. Sudden cardiac death
REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death, the patient is currently taking multiple medications that are recommended for managing heart failure. The absence of any signs of acute cardiac stress or arrhythmias on the ECG impression reduces the risk of sudden cardiac death. However, the patient's low LVEF (48.0%) and elevated creatinine level (115.0 mmol/L) indicate significant cardiac dysfunction, which increases the risk of sudden cardiac death.

3. Pump failure death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy, diabetes, dyslipidemia, and previous myocardial infarction, combined with the current low LVEF (48.0%) and elevated creatinine level (115.0 mmol/L), indicate a high risk of pump failure. However, the patient is currently taking multiple medications, including beta blockers, ACE inhibitors, and spironolactone, which are all recommended for managing heart failure. The absence of any signs of acute cardiac stress or arrhythmias on the ECG impression and the patient's current symptoms do not indicate acute decompensated heart failure. While the patient is at a higher risk of pump failure, the presence of multiple medications and the absence of acute symptoms suggest that the patient may be more likely to survive with proper management."
180,180,P0304,"Age: 75
Gender: Female 
Weight: 64 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 14,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,23
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3866.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 5,99
LVEF (%): 42.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the patient's data, I would rank the patient as a survivor with a high probability. The following factors contribute to this assessment:

1. Age: The patient is 75 years old, but not extremely elderly. This age group can still experience cardiac events, but it's not uncommon for patients in this age group to survive with proper management.
2. NYHA Class II: The patient has a moderate level of heart failure, which indicates some impairment of cardiac function. However, with current treatment, it's possible to manage this condition and prevent further decline.
3. Blood Pressure: The patient's blood pressure is elevated, but it's not excessively high, which can contribute to cardiac damage. With proper management, the patient can still maintain a relatively stable blood pressure.
4. Medications: The patient is taking multiple medications, including beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, which suggests that the patient is receiving comprehensive treatment for their cardiovascular conditions.
5. ECG findings: The patient has ventricular extrasystole, polymorphic, which is a benign finding, and non-sustained ventricular tachycardia, which is a common finding in patients with cardiac disease. These findings do not indicate a high risk of sudden cardiac death or pump failure.

However, the patient does have some concerning factors, such as:

1. Low LVEF (42%): This indicates significant left ventricular dysfunction, which can increase the risk of cardiac events.
2. Elevated Creatinine (106.0 mmol/L): This suggests some degree of renal impairment, which can be a marker for cardiac disease.
3. Elevated Troponin (0.01 ng/mL): This suggests some degree of cardiac injury, which can be a marker for cardiac events.

Despite these concerns, the overall clinical picture suggests that the patient is likely to survive with proper management and treatment. The patient's multiple medications, moderate NYHA Class II heart failure, and benign ECG findings contribute to this assessment. Therefore, I would rank the patient as a survivor with a high probability."
181,181,P0305,"Age: 52
Gender: Male 
Weight: 71 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 160/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,58
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,53
Urea (mg/dL): 3,99
LVEF (%): 66.0
Medications: Calcium Channel Blocker, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at a higher risk for adverse cardiac events due to their history of ischemic dilated cardiomyopathy, hypertension, and peripheral vascular disease. However, the patient has a relatively preserved left ventricular ejection fraction (LVEF) of 66%, which suggests that the patient's heart is still functioning to some extent. Additionally, the absence of ventricular tachycardia, ventricular extrasystoles, and bradycardia on the ECG impression suggests that the patient does not have any immediate life-threatening arrhythmias.

The patient's laboratory results show elevated creatinine levels (106.0 mmol/L), which may indicate some degree of renal impairment, but this is not directly related to cardiac function. The patient's lipid profile shows high total cholesterol (4.06 mmol/L) and LDL (1.58 mmol/L), which are risk factors for cardiovascular disease.

The patient's medication list includes a calcium channel blocker, statins, and an ACE inhibitor, which are all standard treatments for managing hypertension, dyslipidemia, and heart failure. The patient's current symptoms and laboratory results do not indicate any acute cardiac events, such as myocardial infarction or heart failure exacerbation.

Given these factors, I believe that the patient is most likely to survive over the next few years, provided that their current treatment regimen is continued and any potential complications are promptly addressed.

RANKING: 2. Pump failure death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy and hypertension increases their risk for heart failure. However, the patient's LVEF is relatively preserved, and they are currently receiving treatment with medications that are standard for managing heart failure. The absence of any recent acute cardiac events or significant changes in the ECG impression suggests that the patient is not currently experiencing a heart failure exacerbation.

However, the patient's elevated creatinine levels (106.0 mmol/L) and high blood pressure (160/100 mmHg) may indicate some degree of renal impairment and hypertension, which could potentially contribute to cardiac dysfunction over time. Additionally, the patient's dyslipidemia and high LDL levels may continue to contribute to cardiovascular risk.

Given these factors, I believe that pump failure death is a possible but less likely outcome for this patient over the next few years.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy and hypertension increases their risk for sudden cardiac death. However, the patient's LVEF is relatively preserved, and they are currently receiving treatment with medications that are standard for managing heart failure.

The absence of any recent acute cardiac events or significant changes in the ECG impression suggests that the patient is not currently experiencing a life-threatening arrhythmia. However, the patient's elevated blood pressure (160/100 mmHg) and high creatinine levels (106.0 mmol/L) may increase their risk for cardiovascular events, including sudden cardiac death.

Given these factors, I believe that sudden cardiac death is the least likely outcome for this patient over the next few years, provided that their current treatment regimen is continued and any potential complications are promptly addressed."
182,182,P0306,"Age: 55
Gender: Male 
Weight: 78 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,88
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 453.0
Protein (g/L): 70
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,52
Urea (mg/dL): 6,99
LVEF (%): 51.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a relatively stable cardiovascular condition. The patient's NYHA Class II indicates moderate symptoms, which is consistent with the expected outcome for a patient with ischemic dilated cardiomyopathy. The patient's ejection fraction (LVEF) of 51.0 is also consistent with this diagnosis. The patient's medication regimen, which includes angiotensin II receptor blockers, beta blockers, statins, and nitrovasodilators, is also well-tailored to manage symptoms and prevent further cardiac damage.

While the patient's elevated creatinine level (106.0) and slightly elevated troponin level (0.01 ng/mL) suggest some degree of cardiac stress, these values are not significantly elevated and are likely due to the patient's age and comorbid conditions. The patient's Pro-BNP level of 453.0 ng/L is elevated, but this is not uncommon in patients with heart failure, especially those with ischemic cardiomyopathy.

The patient's other lab values, including the lipid profile, liver function tests, and electrolyte panel, are relatively well within normal limits or near-normal limits. The patient's ECG findings, which include ventricular extrasystole but no ventricular tachycardia or non-sustained ventricular tachycardia, also do not suggest an acute cardiac event.

Overall, the patient's clinical presentation, laboratory values, and ECG findings suggest a stable cardiovascular condition, and the patient is likely to survive in the short term."
183,183,P0307,"Age: 51
Gender: Male 
Weight: 112 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 82.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 13,6
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,21
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 128.0
Protein (g/L): 80
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,45
Urea (mg/dL): 5,32
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, and peripheral vascular disease. However, the patient is currently in NYHA Class II, indicating that they are able to perform moderate physical activity without symptoms. The patient's blood pressure is well-controlled at 120/75 mmHg, and they are taking multiple medications that are commonly used to manage cardiovascular risk factors.

The patient's biomarkers, such as troponin and creatinine, are not significantly elevated, suggesting that there is no acute cardiac injury or significant kidney dysfunction. The patient's LVEF is 50%, which is within the range for a patient with heart failure, but not severely impaired.

The patient's ECG impression is also relatively unremarkable, with no signs of ventricular tachycardia, bradycardia, or other arrhythmias that could indicate a high risk of sudden cardiac death.

Given these factors, the patient's prognosis is generally favorable, and it is likely that they will survive for the next few years. The patient's multiple comorbidities and medications suggest that they will require ongoing management and monitoring, but the absence of acute cardiac injury or significant kidney dysfunction reduces the risk of sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: 
While the patient's LVEF is 50%, which is below the normal range, this is not necessarily a guarantee of pump failure. The patient's NYHA Class II status suggests that they are able to perform moderate physical activity without symptoms, which is consistent with a relatively preserved cardiac function.

However, the patient's ischemic dilated cardiomyopathy and multiple comorbidities increase the risk of pump failure. The patient's creatinine level is elevated at 88.0, which may indicate some degree of kidney dysfunction. Additionally, the patient's troponin level is slightly elevated, which could suggest some degree of cardiac injury.

The patient's medications, including beta blockers and ACE inhibitors, are commonly used to manage heart failure and reduce the risk of pump failure. However, the patient's medication regimen is not as comprehensive as it could be, and the patient's blood pressure is not as well-controlled as it could be.

Given these factors, the patient's risk of pump failure is moderate to high, and it is possible that they may require hospitalization for heart failure in the next few years.

RANKING: 3. Sudden cardiac death
REASONING: 
The patient's ECG impression is relatively unremarkable, with no signs of ventricular tachycardia or bradycardia that could indicate a high risk of sudden cardiac death. However, the patient's ECG does show ventricular extrasystoles, which are a risk factor for sudden cardiac death.

Additionally, the patient's ischemic dilated cardiomyopathy and multiple comorbidities increase the risk of sudden cardiac death. The patient's LVEF is 50%, which is below the normal range, and the patient's troponin level is slightly elevated, which could suggest some degree of cardiac injury.

The patient's medications, including beta blockers and ACE inhibitors, are commonly used to manage cardiovascular risk factors, but the patient's blood pressure is not as well-controlled as it could be. The patient's creatinine level is elevated, which may indicate some degree of kidney dysfunction.

Given these factors, the patient's risk of sudden cardiac death is moderate to high, but it is not the highest. The patient's overall prognosis is still favorable, but ongoing monitoring and management are necessary to minimize the risk of cardiac events."
184,184,P0309,"Age: 51
Gender: Male 
Weight: 97 kg
Height: 182 cm
NYHA Class: III
Blood Pressure: 160/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 60.0
AST or GOT (IU/L): 50.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1185.0
Protein (g/L): 85
T3 (pg/dL): 0,02
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,99
Urea (mg/dL): 7,49
LVEF (%): 36.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is already showing signs of heart failure, as indicated by the NYHA Class III classification and the LVEF of 36.0, which is significantly below the normal range. The patient's elevated BNP levels (1185.0 ng/L) also suggest heart failure. The presence of ischemic dilated cardiomyopathy, diabetes, and hypertension further exacerbates the risk of adverse outcomes. However, the patient is currently on medications for heart failure and hypertension, which is a positive prognostic sign. The patient's hemoglobin level (144.0 g/L) and kidney function (Creatinine 88.0 mmol/L) are also within relatively normal ranges. Considering these factors, the patient's overall condition is stable, and with proper management and monitoring, it is likely that the patient will survive for the next few years.

2. Pump failure death
REASONING: 
The patient's current LVEF of 36.0 and elevated BNP levels indicate heart failure, which increases the risk of pump failure. The patient's NYHA Class III classification also suggests significant symptoms of heart failure. Although the patient is on medications for heart failure, the presence of ischemic dilated cardiomyopathy and hypertension increases the risk of worsening heart failure. Additionally, the patient's elevated creatinine level (88.0 mmol/L) may indicate some degree of renal impairment, which can be a predictor of poor outcomes in heart failure patients. However, the patient's hemoglobin level and kidney function are relatively stable, which slightly reduces the risk of pump failure.

3. Sudden cardiac death
REASONING: 
The patient's ECG impression does not show any signs of ventricular tachycardia or ventricular extrasystoles, which are common precursors to sudden cardiac death. However, the presence of ischemic dilated cardiomyopathy and hypertension increases the risk of arrhythmias and sudden cardiac death. The patient's elevated troponin level (0.01 ng/mL) is also a marker of myocardial damage, which can increase the risk of sudden cardiac death. However, the patient's overall condition is stable, and the presence of medications for heart failure and hypertension suggests that the patient is receiving adequate treatment. Additionally, the patient's LVEF is not severely impaired, which reduces the risk of sudden cardiac death."
185,185,P0310,"Age: 58
Gender: Male 
Weight: 87 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 14.0
Protein (g/L): 72
T3 (pg/dL): 0,02
T4 (ng/L): 22
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,05
Urea (mg/dL): 5,83
LVEF (%): 60.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 58-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and dyslipidemia. His current NYHA Class II status indicates moderate symptoms of heart failure. Despite these comorbid conditions, the patient has a relatively preserved left ventricular function (LVEF 60.0%), which is not severely compromised. The patient's current medication regimen includes beta blockers and statins, which are standard treatments for managing heart failure and reducing cardiovascular risk factors.

The patient's laboratory results show a mildly elevated creatinine level (97.0 mmol/L), indicating some degree of kidney impairment, but this is not significantly elevated. The liver enzymes (ALT and AST) are within normal limits, and the patient's albumin level (41 g/L) is within the normal range. The patient's electrolyte levels, including potassium (4.2 mEq/L) and sodium (141.0 mEq/L), are also within normal limits.

The ECG results show no signs of ventricular tachycardia or arrhythmias, which are significant predictors of cardiac death. The patient's troponin level (0.03 ng/mL) is within normal limits, indicating no significant myocardial damage.

Considering these factors, the patient's overall prognosis is expected to be favorable, with a high likelihood of survival. The presence of heart failure symptoms (NYHA Class II) and the patient's history of ischemic dilated cardiomyopathy may limit his long-term survival, but the patient's current condition and treatment regimen suggest that he is unlikely to experience sudden cardiac death or pump failure in the near future. Therefore, the most likely outcome is survival."
186,186,P0311,"Age: 64
Gender: Male 
Weight: 107 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 53.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,82
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 254
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,36
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 208.0
Protein (g/L): 73
T3 (pg/dL): 0,02
T4 (ng/L): 22
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,26
Urea (mg/dL): 8,32
LVEF (%): 45.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 64-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, dyslipidemia, and myocardial infarction. The patient's NYHA Class II indicates that the patient has some symptoms of heart failure, but the symptoms are not severe enough to limit physical activity to the point of requiring rest. The patient's blood pressure is within a relatively normal range (130/70 mmHg), and the medications they are taking, including beta blockers, statins, and an ACE inhibitor, suggest that the patient is receiving standard therapy for heart failure and cardiovascular risk reduction.

The patient's laboratory results show an elevated creatinine level (124.0 mmol/L), which indicates some degree of kidney dysfunction. However, this is not uncommon in patients with heart failure and is not necessarily a contraindication for survival. The patient's troponin level is also elevated (0.02 ng/mL), which is within the normal range, suggesting that there is no acute myocardial infarction at the time of assessment.

The patient's echocardiogram shows a left ventricular ejection fraction (LVEF) of 45.0%, which is below the normal range (50-60%). This suggests that the patient's heart is not pumping efficiently, but it is not severely impaired. The patient's ECG shows ventricular extrasystoles and polymorphic ventricular tachycardia, but these are not indicative of a high risk of sudden cardiac death.

Overall, based on the patient's medical history, laboratory results, and ECG findings, the patient's prognosis is likely to be a survivor. The patient's heart failure is manageable with their current medications, and the patient's kidney function and troponin levels are not indicative of an acute myocardial infarction or severe cardiac dysfunction. 

2. Sudden cardiac death
REASONING: 
While the patient's ECG shows ventricular extrasystoles and polymorphic ventricular tachycardia, these findings are not necessarily indicative of a high risk of sudden cardiac death. The patient's LVEF is below the normal range, but it is not severely impaired, and the patient's troponin level is within the normal range. The patient's kidney function is also not severely impaired, and the patient's medications suggest that the patient is receiving standard therapy for heart failure and cardiovascular risk reduction.

However, the patient's NYHA Class II indicates that the patient has some symptoms of heart failure, and the patient's creatinine level is elevated. These factors, combined with the patient's history of ischemic dilated cardiomyopathy and hypertension, suggest that the patient is at increased risk of cardiac events. Therefore, while the patient's prognosis is not as favorable as the survivor prognosis, the risk of sudden cardiac death is still relatively low.

3. Pump failure death
REASONING: 
Based on the patient's LVEF of 45.0%, which is below the normal range, it is likely that the patient's heart is not pumping efficiently. The patient's creatinine level is also elevated, which suggests that the patient's kidney function is impaired. The patient's NYHA Class II indicates that the patient has some symptoms of heart failure, which suggests that the patient's heart is not functioning optimally.

While the patient's medications suggest that the patient is receiving standard therapy for heart failure, the patient's laboratory results and ECG findings suggest that the patient's heart failure is not well-managed. The patient's troponin level is slightly elevated, which suggests that there may be some degree of myocardial injury. Therefore, the patient's prognosis is more likely to be pump failure death, as the patient's heart is not functioning optimally and is likely to fail in the near future."
187,187,P0312,"Age: 69
Gender: Male 
Weight: 84 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4
LDL (mmol/L): 3,67
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 164.0
Protein (g/L): 70
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,95
Urea (mg/dL): 7,49
LVEF (%): 51.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I rank the patient as a survivor with the highest probability. The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, hypertension, and diabetes suggest a significant cardiovascular history. However, the patient's current hemoglobin level (136.0 g/L) is within the normal range, which indicates adequate oxygenation and possible better cardiac function.

The patient's creatinine level (97.0 mmol/L) is elevated, which may indicate some degree of renal impairment. However, this is not uncommon in patients with cardiovascular disease. The patient's troponin level (0.01 ng/mL) is also within the normal range, which suggests that there is no significant myocardial injury at this time.

The patient's ECG impression shows ventricular extrasystoles, which may indicate some degree of ventricular arrhythmia, but no other significant arrhythmias were detected. The patient's LVEF (51.0%) is below the normal range, which suggests some degree of left ventricular dysfunction.

The patient's medication list includes a nitrovasodilator, which may be beneficial in reducing blood pressure and improving cardiac function. The patient's lipid profile shows high cholesterol levels, but the patient is on statins, which can help manage this condition.

Given these factors, I believe that the patient is at risk for cardiac events, but the presence of adequate oxygenation, normal troponin levels, and the absence of significant arrhythmias suggest that the patient may be able to survive without major cardiac events in the next few years. Therefore, I rank the patient as a survivor.

However, I would like to note that the patient's cardiac function is compromised, and close monitoring and follow-up are necessary to ensure that the patient does not experience any adverse cardiac events."
188,188,P0314,"Age: 56
Gender: Male 
Weight: 62 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 55.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,66
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 133.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,12
Urea (mg/dL): 8,32
LVEF (%): 50.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient has a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which are risk factors for cardiac events. However, the patient's current NYHA Class II indicates that the disease is not severe enough to cause significant symptoms. The patient's LVEF is 50%, which is within the normal range for a male of this age. The absence of significant elevations in troponin and the normal TSH level also suggest that the patient's heart is not under significant stress. The presence of ventricular extrasystole and TPSV on the ECG may indicate some cardiac conduction abnormalities, but they are not indicative of a high risk for cardiac events. The patient's laboratory results, including low albumin and elevated creatinine, may indicate some degree of malnutrition and renal impairment, but these factors are not directly related to cardiac function. Given these factors, the patient's overall prognosis is relatively good, with a high likelihood of survival over the next few years."
189,189,P0315,"Age: 71
Gender: Male 
Weight: 76 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 115/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,8
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 51.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 112
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,68
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5342.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,26
Urea (mg/dL): 4,23
LVEF (%): 22.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's overall condition is quite severe. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. The patient's left ventricular ejection fraction (LVEF) is 22%, which is indicative of poor cardiac function. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia (NSVT), and paroxysmal supraventricular tachyarrhythmia (PSVT) on the ECG also suggest a high risk for arrhythmias.

Despite the patient's poor cardiac function and multiple comorbidities, the patient's age, weight, and hemoglobin level are relatively stable. The patient's blood pressure is within a relatively normal range, and they are on medications that are commonly used to manage heart failure and hypertension.

While the patient's renal function is impaired (elevated creatinine level), they are not on dialysis, and their electrolyte levels are relatively stable. The elevated troponin level is not significantly elevated, which suggests that the patient's cardiac muscle is not currently under significant stress.

Considering these factors, I would rank the patient as a survivor for the next few years, as their overall condition is severe but not immediately life-threatening. However, close monitoring and close follow-up with the cardiologist will be necessary to adjust the treatment plan as needed.

RANKING: 2. Sudden cardiac death
REASONING: 

Although the patient is ranked as a survivor, the presence of multiple arrhythmias, including NSVT and PSVT, increases the risk of sudden cardiac death. The patient's LVEF is also severely impaired, which can lead to arrhythmias and cardiac arrest.

The patient's elevated troponin level, despite not being significantly elevated, may indicate some degree of cardiac muscle damage, which can increase the risk of arrhythmias and sudden cardiac death. Additionally, the patient's impaired renal function may increase the risk of electrolyte imbalances, which can contribute to arrhythmias.

While the patient is on medications that can help manage arrhythmias and heart failure, the presence of multiple comorbidities and poor cardiac function increases the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's impaired LVEF and multiple comorbidities, including ischemic dilated cardiomyopathy and peripheral vascular disease, increase the risk of heart failure. The patient's elevated creatinine level and impaired renal function also suggest that their cardiac function may be compromised.

The patient's blood pressure is relatively stable, but the presence of ventricular extrasystoles and NSVT on the ECG suggests that their cardiac function is not stable. The patient's elevated troponin level and impaired LVEF also suggest that their cardiac muscle is under significant stress.

While the patient is on medications that can help manage heart failure and hypertension, the presence of multiple comorbidities and poor cardiac function increases the risk of pump failure. However, the patient's stable hemoglobin level and relatively normal blood pressure level suggest that their overall condition is not immediately life-threatening.

Given the patient's severe cardiac impairment and multiple comorbidities, pump failure death is a possible outcome, but it is less likely than sudden cardiac death given the presence of arrhythmias."
190,190,P0316,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,7
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1903.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,42
Urea (mg/dL): 9,13
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient as having a high likelihood of survival for the next few years. The key factors contributing to this prognosis are:

1. Age and NYHA Class II: The patient's age of 71 is considered advanced, but the NYHA Class II classification indicates that the patient has some limitations in physical activity, but they are still able to perform daily activities with some difficulty. This suggests that the patient's cardiac function is not severely impaired.

2. Medications: The patient is taking beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for managing hypertension, heart failure, and cardiomyopathy. These medications help to control blood pressure, reduce fluid overload, and decrease the workload on the heart.

3. ECG Impression: The ECG findings of ventricular extrasystole and paroxysmal supraventricular tachyarrhythmia (PSVT) suggest that the patient has some cardiac arrhythmias, but these are not life-threatening. The absence of ventricular tachycardia and non-sustained ventricular tachycardia (CH>10) reduces the risk of sudden cardiac death.

4. LVEF: Although the left ventricular ejection fraction (LVEF) is 39%, which is below the normal range, it is not severely impaired. A LVEF of 39% is still considered mildly impaired, but it does not indicate severe heart failure.

5. Pro-BNP: The elevated Pro-BNP level (1903.0 ng/L) suggests some degree of heart failure, but it is not extremely elevated. This level may indicate some degree of ventricular stretch or pressure overload.

Overall, considering these factors, I believe that the patient has a relatively good prognosis for survival over the next few years, with a likelihood of being a survivor."
191,191,P0318,"Age: 55
Gender: Male 
Weight: 63 kg
Height: 149 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 48,3
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 155.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,4
LDL (mmol/L): 3,1
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 142.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,729
Urea (mg/dL): 15,15
LVEF (%): 39.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall clinical presentation and laboratory results suggest a stable and manageable condition. The patient's NYHA Class II indicates mild heart failure symptoms, which is consistent with the presence of ischemic dilated cardiomyopathy. The patient's LVEF of 39.0 is significantly reduced, indicating a poor ejection fraction, but this is not uncommon in patients with ischemic cardiomyopathy. The patient's medications, including beta blockers and ACE inhibitors (implied by the Angiotensin II Receptor Blocker), are standard treatments for heart failure and cardiomyopathy. The presence of ventricular extrasystole, polymorphic and non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on ECG suggests some level of arrhythmia risk, but these are not necessarily indicative of an immediate life-threatening condition. The patient's troponin levels are within normal limits, and the patient's kidney function is relatively preserved, which is also a positive sign. Overall, the patient's clinical presentation and laboratory results suggest that with proper management, the patient is likely to survive for the next few years."
192,192,P0319,"Age: 52
Gender: Male 
Weight: 89 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44,69
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 155.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,3
LDL (mmol/L): 4,68
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 984.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,39
Urea (mg/dL): 9,57
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation, laboratory results, and ECG findings suggest that the patient is at high risk for adverse cardiac events, but the presence of idiopathic dilated cardiomyopathy, diabetes, and NYHA Class II indicates that the patient has a significant underlying cardiac condition. However, the patient's hemoglobin level is elevated, which may indicate anemia, but it's not severe. The patient's ejection fraction (LVEF) is severely reduced at 30%, which is a strong indicator of poor cardiac function.

The patient's medication regimen includes ACE inhibitors, which are known to improve outcomes in patients with heart failure, and digoxin, which is often used to control ventricular rate in atrial fibrillation. The presence of ventricular extrasystoles, polymorphic and non-sustained ventricular tachycardia on the ECG may indicate an increased risk of arrhythmias, but the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia may reduce the risk of sudden cardiac death.

Given the patient's reduced LVEF and elevated Pro-BNP levels, the patient is at high risk for cardiac decompensation and heart failure exacerbation. However, the patient's current medication regimen and the absence of severe anemia may mitigate this risk. Therefore, I believe that the patient is most likely to survive over the next few years, provided that their current medication regimen is adhered to and they do not experience any significant changes in their underlying condition.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's ECG findings of ventricular extrasystoles and polymorphic ventricular tachycardia, as well as the presence of non-sustained ventricular tachycardia, suggest an increased risk of arrhythmias. The patient's LVEF is severely reduced, which may increase the risk of sudden cardiac death. The patient's elevated Pro-BNP levels also suggest that the patient is at risk for cardiac decompensation.

While the patient is currently being treated with medications that may reduce the risk of arrhythmias, the presence of ventricular extrasystoles and polymorphic ventricular tachycardia on the ECG may increase the risk of sudden cardiac death. Additionally, the patient's reduced LVEF and elevated Pro-BNP levels suggest that the patient is at risk for cardiac decompensation, which may increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

Given the patient's severely reduced LVEF and elevated Pro-BNP levels, the patient is at high risk for cardiac decompensation and heart failure exacerbation. The patient's NYHA Class II indicates that the patient has some limitation in physical activity, which may increase the risk of pump failure.

The patient's elevated creatinine level and reduced kidney function may also increase the risk of pump failure, as the kidneys play a critical role in regulating fluid balance and electrolyte levels. The patient's diabetes and elevated glucose levels may also increase the risk of complications, including pump failure.

However, the patient is currently being treated with medications that may reduce the risk of heart failure, including ACE inhibitors and digoxin. The patient's current hemoglobin level is elevated, which may mitigate some of the risk of pump failure. Nevertheless, given the patient's underlying cardiac condition, diabetes, and reduced kidney function, I believe that the patient is at high risk for pump failure over the next few years."
193,193,P0323,"Age: 62
Gender: Male 
Weight: 108 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,9
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 139.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 176.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,92
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,69
Urea (mg/dL): 12,03
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's current clinical presentation and laboratory results suggest that they are at high risk for adverse cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death and pump failure. However, the patient is currently on multiple medications that are standard of care for heart failure and ischemic cardiomyopathy, which suggests that the patient is receiving appropriate treatment.

The patient's LVEF of 38% is significantly reduced, indicating severe left ventricular dysfunction, which is a strong predictor of poor outcomes. However, the patient's NYHA class is III, indicating that they are experiencing moderate symptoms of heart failure, but not severe.

The patient's biomarkers, such as troponin and BNP, are elevated, indicating cardiac stress and strain. However, the patient's potassium level is within the normal range, which reduces the risk of arrhythmias.

The patient's ECG results show polymorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

Overall, while the patient is at high risk for adverse cardiac events, the presence of multiple medications and the patient's relatively stable laboratory results suggest that the patient is likely to survive for the next few years. The patient's survival is likely due to the effectiveness of their treatment regimen and the fact that they are not experiencing severe symptoms of heart failure.

2. Sudden Cardiac Death
REASONING: 
While the patient is at high risk for sudden cardiac death, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces the likelihood of sudden cardiac death. However, the patient's polymorphic ventricular extrasystoles and elevated troponin levels suggest that the patient is at risk for arrhythmias and cardiac stress.

The patient's LVEF of 38% is a significant predictor of poor outcomes, and the patient's NYHA class is III, indicating moderate symptoms of heart failure. The patient's biomarkers, such as BNP and troponin, are elevated, indicating cardiac stress and strain.

While the patient is on multiple medications, the effectiveness of these medications in reducing the risk of arrhythmias and cardiac stress is uncertain. The patient's potassium level is within the normal range, which reduces the risk of arrhythmias.

Overall, while the patient is at risk for sudden cardiac death, the presence of multiple medications and the patient's relatively stable laboratory results suggest that the risk is lower than the patient's overall risk for pump failure.

3. Pump Failure Death
REASONING: 
The patient's LVEF of 38% is a significant predictor of poor outcomes, and the patient's NYHA class is III, indicating moderate symptoms of heart failure. The patient's biomarkers, such as BNP and troponin, are elevated, indicating cardiac stress and strain.

The patient's elevated creatinine level suggests impaired renal function, which can exacerbate heart failure. The patient's dyslipidemia and hypertension are also risk factors for cardiac events.

The patient's ECG results show polymorphic ventricular extrasystoles, which is a risk factor for arrhythmias and cardiac stress. The patient's potassium level is within the normal range, which reduces the risk of arrhythmias.

While the patient is on multiple medications, the effectiveness of these medications in reducing the risk of arrhythmias and cardiac stress is uncertain. The patient's overall risk factors, including their LVEF, NYHA class, and biomarkers, suggest that the patient is at high risk for pump failure death."
194,194,P0324,"Age: 63
Gender: Male 
Weight: 78 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 45,59
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 42.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 104
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 113.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,59
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1148.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,61
Urea (mg/dL): 7,57
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's age, NYHA Class II, and the presence of Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, and Hypertension, the patient is at risk for adverse cardiac events. However, the patient's current LVEF of 34.0 is not severely impaired, and the absence of significant elevations in Troponin levels and the presence of a normal ECG impression do not indicate acute myocardial infarction or acute cardiac damage. The patient's current medication regimen, which includes ACE inhibitors, beta blockers, and diuretics, suggests a reasonable management plan for heart failure and hypertension. The patient's laboratory values, including the elevated Pro-BNP levels, also suggest heart failure, but the patient is currently being treated for this condition. The patient's overall clinical presentation and laboratory values do not indicate an immediate life-threatening condition, and the patient's past medical history, while significant, does not necessarily preclude a favorable outcome.

2. Sudden Cardiac Death
REASONING: 
While the patient's ECG impression indicates ventricular extrasystole and non-sustained ventricular tachycardia, which may increase the risk of sudden cardiac death, the absence of other risk factors, such as a history of ventricular fibrillation or ventricular tachycardia, and the presence of a normal LVEF, make this prognosis less likely. Additionally, the patient's current medication regimen includes beta blockers, which can help reduce the risk of sudden cardiac death.

3. Pump Failure Death
REASONING: 
The patient's current LVEF of 34.0 is significantly reduced, indicating that the patient's heart is not functioning efficiently. While the patient is being treated for heart failure, the patient's elevated Pro-BNP levels and elevated creatinine levels suggest that the patient's heart failure may be worsening. The patient's past medical history, including Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, and Hypertension, also increases the risk of pump failure. However, the patient's current clinical presentation and laboratory values do not indicate an immediate life-threatening condition, and the patient's medication regimen is aimed at managing heart failure and hypertension."
195,195,P0325,"Age: 53
Gender: Male 
Weight: 99 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 125/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 48,8
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 230
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,15
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 171.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,09
Urea (mg/dL): 5,79
LVEF (%): 50.0
Medications: Diabetes Medication, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
This patient has a complex medical history with ischemic dilated cardiomyopathy, diabetes, dyslipidemia, hypertension, and myocardial infarction. However, the patient is currently in NYHA Class II, indicating mild symptoms of heart failure. The patient's LVEF is 50%, which is within the range of a relatively preserved ejection fraction. The patient's blood pressure is well-controlled (125/85 mmHg), and the medication regimen includes a nitrovasodilator, which is commonly used to treat heart failure. The patient's electrolyte levels, including potassium, are within the normal range. The ECG impression does not show any signs of ventricular tachycardia or other life-threatening arrhythmias. The patient's troponin level is also within the normal range, indicating no acute myocardial infarction.

While the patient's medical history is significant, the patient's current clinical presentation and laboratory results do not indicate an immediate life-threatening condition. The patient's low albumin level (48.8 g/L) and elevated gamma-glutamil transpeptidase (230 IU/L) may indicate liver disease or bile duct obstruction, but this is not directly related to cardiac function. Overall, the patient's prognosis is favorable, and with proper management of their medical conditions, they are likely to survive.

2. Pump failure death 
REASONING: 
While the patient's LVEF is 50%, which is within the range of a relatively preserved ejection fraction, the patient's NYHA Class II indicates mild symptoms of heart failure. The patient's medical history, including ischemic dilated cardiomyopathy and myocardial infarction, increases the risk of cardiac events. The patient's elevated creatinine level (83.0 mmol/L) may indicate renal impairment, which can be a complication of heart failure. However, the patient is on loop diuretics, which are commonly used to manage heart failure.

The patient's low albumin level (48.8 g/L) and elevated gamma-glutamil transpeptidase (230 IU/L) may indicate liver disease or bile duct obstruction, which can increase the risk of cardiac complications. The patient's elevated troponin level (0.01 ng/mL) is slightly elevated, but within the normal range. The patient's ECG impression does not show any signs of ventricular tachycardia or other life-threatening arrhythmias.

Given the patient's complex medical history and the presence of heart failure symptoms, the patient is at risk for pump failure. However, the patient's current clinical presentation and laboratory results do not indicate an immediate life-threatening condition.

3. Sudden cardiac death 
REASONING: 
The patient's ECG impression shows ventricular extrasystoles, which is a type of abnormal heart rhythm. However, the patient's ventricular tachycardia is not sustained, and the patient's troponin level is within the normal range. The patient's LVEF is 50%, which is within the range of a relatively preserved ejection fraction. The patient's medical history, including ischemic dilated cardiomyopathy and myocardial infarction, increases the risk of cardiac events, but the patient's current clinical presentation and laboratory results do not indicate an immediate life-threatening condition.

The patient's elevated gamma-glutamil transpeptidase (230 IU/L) may indicate liver disease or bile duct obstruction, which can increase the risk of cardiac complications. However, the patient's liver function tests are not significantly abnormal, and the patient is not showing any signs of liver failure. The patient's low albumin level (48.8 g/L) may indicate liver disease or bile duct obstruction, but this is not directly related to cardiac function.

Overall, while the patient's ECG impression shows ventricular extrasystoles, the patient's current clinical presentation and laboratory results do not indicate an immediate life-threatening condition, and the patient is unlikely to experience sudden cardiac death."
196,196,P0326,"Age: 67
Gender: Male 
Weight: 78 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 52,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,89
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 298.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,29
Urea (mg/dL): 4,9
LVEF (%): 34.0
Medications: Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient is likely to survive for the next few years due to the following reasons:

1. Age: Although the patient is 67 years old, the age alone is not a contraindication for survival. Many patients with advanced heart failure can survive for several years with proper management.
2. Medications: The patient is on spironolactone, statins, and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy. These medications can help manage symptoms, reduce mortality, and slow disease progression.
3. LVEF: Although the LVEF is 34%, it is still within the range of moderate to severe heart failure. With proper management, some patients with LVEF in this range can survive for several years.
4. Blood tests: The patient's blood tests, such as creatinine, urea, and electrolytes, are within acceptable ranges, indicating that the kidneys are functioning relatively well.
5. Lack of evidence of acute coronary syndrome: The patient does not have elevated troponin levels, which suggests that there is no acute myocardial infarction.

However, the patient has several risk factors that may affect survival, including:

* Idiopathic dilated cardiomyopathy, which can lead to progressive heart failure
* Dyslipidemia, which can increase the risk of cardiovascular events
* Peripheral vascular disease, which can increase the risk of cardiovascular events

Overall, while the patient has several risk factors, the combination of medications, moderate LVEF, and lack of evidence of acute coronary syndrome make survival the most likely outcome.

RANKING: 2. Sudden cardiac death
REASONING: 
This patient is at risk of sudden cardiac death due to the following reasons:

* Idiopathic dilated cardiomyopathy, which can lead to ventricular arrhythmias and sudden cardiac death
* Low LVEF, which indicates poor heart function and increased risk of arrhythmias
* Presence of ventricular extrasystoles on the ECG, which can be a precursor to ventricular tachycardia and sudden cardiac death
* Presence of hypertension, which can increase the risk of cardiovascular events

However, the patient is not currently experiencing symptoms of acute coronary syndrome, and the patient is on medications that can help manage heart failure and reduce the risk of arrhythmias.

RANKING: 3. Pump failure death
REASONING: 
This patient is at risk of pump failure death due to the following reasons:

* Idiopathic dilated cardiomyopathy, which can lead to progressive heart failure
* Low LVEF, which indicates poor heart function and increased risk of heart failure
* Elevated creatinine and urea levels, which indicate decreased kidney function and increased risk of heart failure
* Presence of dyslipidemia, which can increase the risk of cardiovascular events and heart failure

However, the patient is on medications that can help manage heart failure, and the patient's blood tests indicate that the kidneys are functioning relatively well.

It is worth noting that pump failure death is a possible outcome, but it is less likely than sudden cardiac death due to the patient's relatively good response to medications and lack of evidence of acute coronary syndrome."
197,197,P0328,"Age: 64
Gender: Male 
Weight: 84 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 48,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,8
LDL (mmol/L): 4,42
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 511.0
Protein (g/L): 76
T3 (pg/dL): 0,03
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,22
Urea (mg/dL): 6,68
LVEF (%): 35.0
Medications: Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at high risk for adverse outcomes due to the presence of ischemic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is severely compromised. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 35%, indicating poor cardiac function. Additionally, the patient has a history of myocardial infarction, which can lead to further cardiac damage and scarring. The presence of elevated troponin levels (0.01 ng/mL) suggests some degree of cardiac injury.

The patient's medications, including beta blockers and statins, are standard treatments for managing heart failure and high cholesterol, which are both relevant to this patient's condition. However, the fact that the patient is not on ACE inhibitors or ARBs (Angiotensin-Converting Enzyme inhibitors and Angiotensin Receptor Blockers), which are typically recommended for patients with heart failure, is concerning.

The patient's electrolyte levels are relatively stable, with normal potassium levels and no evidence of significant kidney dysfunction. The ECG findings are not indicative of any life-threatening arrhythmias.

Given these factors, I believe that the patient is at high risk for cardiac complications, including heart failure exacerbation, arrhythmias, and potentially sudden cardiac death. Therefore, close monitoring and aggressive management of the patient's condition are essential to prevent adverse outcomes.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's LVEF is severely impaired, there is no clear indication of a high risk for sudden cardiac death. The patient's ECG did not show any life-threatening arrhythmias, and the troponin level is not significantly elevated. However, the patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk for cardiac complications.

RANKING: 3. Pump failure death
REASONING: 

This patient is at risk for pump failure due to the presence of severe heart failure (NYHA Class II) and impaired LVEF. However, the patient is currently on beta blockers, which are standard medications for managing heart failure. Additionally, the patient's kidney function is relatively preserved, which is a positive factor in terms of overall prognosis.

However, the patient's elevated creatinine level (93.0 mmol/L) and elevated BNP (511.0 ng/L) levels suggest some degree of cardiac dysfunction, and the patient's electrolyte levels are not optimal. These factors, combined with the patient's impaired LVEF, suggest that the patient is at risk for pump failure, but the likelihood is lower compared to sudden cardiac death."
198,198,P0331,"Age: 52
Gender: Female 
Weight: 82 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 125/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,28
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 720.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,74
Urea (mg/dL): 8,02
LVEF (%): 37.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's overall health status is a concern, but they have not shown any immediate signs of severe cardiac distress. They have a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, they are currently taking medications that are commonly used to manage heart failure and are relatively well-controlled.

The patient's current LVEF of 37.0% indicates significant left ventricular dysfunction, which is a risk factor for heart failure. However, the fact that they are taking medications to manage hypertension, dyslipidemia, and heart failure suggests that they are receiving appropriate treatment.

The patient's ECG results show ventricular extrasystoles and paroxysmal supraventricular tachycardia, which are common findings in patients with heart failure. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia suggests that the patient is not at high risk for sudden cardiac death.

The patient's laboratory results are also concerning, with elevated liver enzymes (ALT and AST) and creatinine levels, which may indicate some degree of liver and kidney dysfunction. However, these findings are not uncommon in patients with heart failure and may not necessarily impact the patient's cardiac prognosis.

Given these factors, I would rank the patient's prognosis as a survivor, but with a high level of caution and close monitoring. The patient's overall health status and treatment plan will continue to be closely monitored to ensure that any potential complications are addressed promptly.

RANKING 2: Sudden Cardiac Death
REASONING:
This patient's risk for sudden cardiac death is moderate due to their history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF of 37.0% also indicates significant left ventricular dysfunction, which can increase the risk for arrhythmias and sudden cardiac death.

The patient's ECG results show ventricular extrasystoles, which can be a sign of underlying cardiac dysfunction. While the absence of ventricular tachycardia and non-sustained ventricular tachycardia is reassuring, the presence of paroxysmal supraventricular tachycardia suggests that the patient may be at risk for arrhythmias.

The patient's laboratory results are also concerning, with elevated liver enzymes and creatinine levels, which may indicate some degree of cardiac and renal dysfunction. These findings, combined with the patient's history of heart failure, increase the risk for sudden cardiac death.

RANKING 3: Pump Failure Death
REASONING:
This patient's risk for pump failure death is moderate to high due to their history of ischemic dilated cardiomyopathy and current LVEF of 37.0%. The patient's elevated creatinine level (88.0) and elevated liver enzymes (ALT and AST) also suggest some degree of cardiac and renal dysfunction.

The patient's ECG results show ventricular extrasystoles, which can be a sign of underlying cardiac dysfunction. The absence of ventricular tachycardia and non-sustained ventricular tachycardia is reassuring, but the presence of paroxysmal supraventricular tachycardia suggests that the patient may be at risk for arrhythmias.

The patient's laboratory results, combined with their history of heart failure and current treatment plan, increase the risk for pump failure. However, the patient's overall health status and treatment plan suggest that this risk is not the most immediate concern, which is why I have ranked pump failure death as the least likely outcome."
199,199,P0334,"Age: 52
Gender: Male 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 50,09
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,92
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 136.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,36
Urea (mg/dL): 9,8
LVEF (%): 32.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

This patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, making it harder for the heart to pump blood effectively. The patient's LVEF of 32.0% is significantly below the normal range, indicating severe left ventricular dysfunction. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG suggests a high risk of arrhythmias, which can be life-threatening.

However, the patient is currently taking multiple medications, including beta blockers, calcium channel blockers, statins, and ACE inhibitors, which are standard treatments for heart failure and arrhythmias. The patient's NYHA class II indicates moderate symptoms, and the blood pressure is well-controlled.

Considering these factors, I believe the patient has a good chance of survival for the next few years, assuming they continue to receive proper medical care and adhere to their medication regimen.

RANKING: 2. Sudden cardiac death 
REASONING: 

While the patient has a high risk of arrhythmias, the patient is already taking medications to manage these conditions, and their blood pressure is well-controlled. However, the patient's LVEF is severely impaired, and the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates a high risk of arrhythmias. Additionally, the patient's creatinine level is elevated, which may indicate some degree of kidney impairment.

Given these factors, while the patient is at risk, sudden cardiac death is still a possibility, but it is less likely than the patient surviving.

RANKING: 3. Pump failure death 
REASONING: 

The patient's LVEF is severely impaired, and the patient has a history of ischemic dilated cardiomyopathy, which increases the risk of pump failure. The patient's NYHA class II indicates moderate symptoms, which suggests that the patient is experiencing some degree of heart failure. The patient's creatinine level is elevated, which may indicate some degree of kidney impairment.

While the patient is taking medications to manage heart failure and arrhythmias, the patient's severe LVEF and history of ischemic dilated cardiomyopathy make pump failure a possible outcome. However, this outcome is less likely than sudden cardiac death or survival, given the patient's current treatment and symptom level."
200,200,P0335,"Age: 44
Gender: Male 
Weight: 90 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42,8
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 161.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,55
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 522.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,03
Urea (mg/dL): 7,35
LVEF (%): 25.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is classified as having idiopathic dilated cardiomyopathy, which is a condition that significantly reduces the heart's ability to pump blood effectively. The low left ventricular ejection fraction (LVEF) of 25.0% further supports this classification. The patient's elevated troponin levels (0.01 ng/mL) and the presence of non-sustained ventricular tachycardia (NSVT) on the ECG also indicate myocardial stress and potential ischemia. 

Given these factors, the patient is at a high risk of adverse cardiac events. The presence of beta-blockers, spironolactone, statins, and an ACE inhibitor suggests that the patient is already receiving optimal medical therapy for their condition. However, the patient's overall clinical profile, including their age, NYHA class II, and elevated biomarkers, suggests that they are at a higher risk of cardiac complications.

While the patient's blood pressure is within a relatively normal range, their elevated creatinine levels (78.0 mol/L) and slightly elevated liver enzymes (ALT: 30.0 IU/L, AST: 19.0 IU/L) suggest some degree of renal and hepatic stress, which may be related to their underlying cardiomyopathy. The patient's low HDL cholesterol level (0.57 mmol/L) and elevated triglycerides (not mentioned but can be inferred from the total cholesterol) may also contribute to their overall cardiovascular risk.

Considering these factors, the patient's prognosis is more likely to be a survivor, as they are receiving optimal medical therapy and have not yet demonstrated significant cardiac complications. However, close monitoring and further evaluation are necessary to adjust their treatment plan and manage their underlying condition.

The patient's risk of sudden cardiac death is moderate, given their ECG findings, LVEF, and elevated troponin levels. However, their overall clinical profile does not suggest an extremely high risk.

The patient's risk of pump failure death is moderate to high, given their low LVEF and elevated biomarkers, but their current clinical profile does not indicate an immediate or severe risk of pump failure."
201,201,P0337,"Age: 55
Gender: Male 
Weight: 88 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 48,7
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,54
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 3,6
LDL (mmol/L): 4,03
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 209.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,544
Urea (mg/dL): 10,24
LVEF (%): 67.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient has a complex medical history with multiple comorbid conditions such as hypertensive cardiomyopathy, dyslipemia, and hypertension, which can contribute to an increased risk of cardiac complications. However, the patient's current medications, including a calcium channel blocker, angiotensin II receptor blocker, beta blockers, and statins, suggest a well-managed cardiovascular risk profile.

The patient's laboratory results, such as the elevated creatinine level (96.0 mmol/L), indicate some degree of kidney dysfunction, which can be a comorbidity that affects cardiac function. However, the patient's renal function is not severely impaired, and the creatinine level is not drastically elevated.

The patient's echocardiogram results show a left ventricular ejection fraction (LVEF) of 67.0%, which is within the normal range. This suggests that the patient's cardiac function is relatively preserved, which can contribute to a better prognosis.

The presence of ventricular extrasystole (polymorphic) on the ECG is a concerning sign, but it is not a life-threatening arrhythmia, and the patient is not experiencing any symptoms. The absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on the ECG further reduces the risk of cardiac complications.

Considering these factors, the patient's overall prognosis is likely to be good, and the patient is more likely to survive in the short to medium term. However, close monitoring and follow-up are necessary to adjust the treatment plan and manage any potential cardiac complications.

The probability of sudden cardiac death (2.5-5%) and pump failure death (10-20%) is relatively low, given the patient's current clinical status and the presence of a well-managed cardiovascular risk profile. However, the patient's complex medical history and kidney dysfunction may increase the risk of cardiac complications, making it difficult to predict the exact probability of pump failure death.

In summary, while the patient has some comorbidities and concerning ECG findings, the overall prognosis is still favorable, and the patient is more likely to survive in the short to medium term."
202,202,P0338,"Age: 75
Gender: Male 
Weight: 63 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 52,19
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,31
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1121.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,43
Urea (mg/dL): 5,79
LVEF (%): 39.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient is at high risk for cardiac complications due to a history of enolic dilated cardiomyopathy, hypertension, myocardial infarction, and previous heart failure. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 39%, indicating poor cardiac function. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG further increase the risk of arrhythmic events.

The patient's laboratory results also suggest renal impairment (elevated creatinine and urea levels) and anemia (low hemoglobin level), which may contribute to a worse prognosis. However, the patient is already receiving medications for heart failure (loop diuretics) and hypertension (ACE inhibitor), which should help manage these conditions.

Given the patient's overall clinical picture, I believe the patient is most likely to survive the next few years with proper management and monitoring.

2. Sudden cardiac death
REASONING: 
While the patient is at high risk for cardiac complications, the likelihood of sudden cardiac death is still relatively low. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests an increased risk of arrhythmic events, but the patient is already receiving medications that should help manage these conditions.

The patient's LVEF is significantly reduced, which increases the risk of cardiac complications, but the patient is receiving medications that should help improve cardiac function. The patient's renal impairment and anemia may also contribute to a worse prognosis, but these conditions are being managed with current medications.

3. Pump failure death
REASONING: 
Given the patient's reduced LVEF and history of heart failure, pump failure death is a possible outcome. However, the patient is already receiving medications for heart failure (loop diuretics) and hypertension (ACE inhibitor), which should help manage these conditions. The patient's renal impairment and anemia may also contribute to a worse prognosis, but these conditions are being managed with current medications.

While pump failure death is a possible outcome, I believe it is the least likely of the three options, given the patient's current medications and the fact that they are already receiving treatment for heart failure and hypertension."
203,203,P0341,"Age: 61
Gender: Female 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 3
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 485.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,706
Urea (mg/dL): 7,12
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 61-year-old female with a history of hypertensive cardiomyopathy, hypertension, and a New York Heart Association (NYHA) class II heart failure. The patient's ECG shows ventricular extrasystoles and polymorphic ventricular tachycardia, which may indicate an increased risk of ventricular arrhythmias. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachycardia suggests that the patient is not at high risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 30%, indicating significant left ventricular dysfunction, but the absence of elevated troponin levels suggests that the patient does not have acute myocardial infarction. The patient's hemoglobin and potassium levels are within normal limits, and the patient is on medications that are commonly used to manage heart failure and hypertension. Overall, the patient's clinical presentation and test results suggest that the patient is at risk of heart failure exacerbation and arrhythmias, but not at high risk of sudden cardiac death. Therefore, the most likely prognosis is survival. 

2. Sudden Cardiac Death
REASONING: 
The patient's ECG shows ventricular extrasystoles and polymorphic ventricular tachycardia, which may indicate an increased risk of ventricular arrhythmias. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachycardia suggests that the patient is not at high risk of sudden cardiac death. The patient's LVEF is 30%, indicating significant left ventricular dysfunction, which increases the risk of sudden cardiac death. However, the patient's other test results are relatively normal, and the patient is on medications that are commonly used to manage heart failure and hypertension. Therefore, while the patient is at risk of ventricular arrhythmias, the risk of sudden cardiac death is not extremely high.

3. Pump Failure Death
REASONING: 
The patient's LVEF is 30%, indicating significant left ventricular dysfunction, which increases the risk of heart failure exacerbation. The patient's NYHA class II heart failure suggests that the patient has some level of functional impairment, but the patient's other test results are relatively normal. The patient is on medications that are commonly used to manage heart failure and hypertension, which suggests that the patient is receiving adequate treatment. However, the patient's elevated creatinine level (89.0 mmol/L) and low albumin level (47 g/L) suggest that the patient may have some degree of renal impairment, which can exacerbate heart failure. Overall, while the patient is at risk of heart failure exacerbation, the risk of pump failure death is not extremely high due to the patient's relatively normal other test results and adequate treatment."
204,204,P0342,"Age: 66
Gender: Male 
Weight: 75 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 11,9
Hemoglobin (g/L): 123.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,42
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2416.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 19,55
Urea (mg/dL): 12,69
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results suggest a moderate to advanced stage of heart disease, with a history of ischemic dilated cardiomyopathy, myocardial infarction, and a low LVEF of 50%. The patient also has multiple comorbidities, including hypertension, diabetes, and dyslipemia, which can further exacerbate cardiac disease. However, the patient is currently taking multiple medications to manage these conditions, including beta blockers, ACE inhibitors, and statins, which can help reduce the risk of cardiac events.

The patient's ECG findings, including ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia, indicate a high level of cardiac arrhythmia burden. However, the presence of non-sustained ventricular tachycardia (CH>10) is a significant finding, as it is a predictor of increased risk of sudden cardiac death.

Despite these findings, the patient's current clinical status and the presence of a positive outcome do not suggest an immediate high risk of mortality. The patient's weight, blood pressure, and electrolyte levels are within relatively normal ranges, and the patient's medications are adequate for managing their comorbid conditions.

Given the patient's overall clinical picture, the most likely prognosis is survival, with a moderate risk of cardiac events, including arrhythmias and cardiac death, over the next few years. However, with optimal management of their medications, lifestyle modifications, and regular monitoring, the patient can be managed to reduce the risk of adverse outcomes.

The other two prognoses, sudden cardiac death and pump failure death, are less likely in this patient, as the patient's LVEF is not severely impaired, and the patient is currently receiving adequate medical therapy to manage their cardiac conditions. However, the patient's arrhythmia burden and history of myocardial infarction do increase the risk of cardiac events, and close monitoring and follow-up are necessary to manage these risks."
205,205,P0344,"Age: 56
Gender: Male 
Weight: 110 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 180/100 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 43,9
ALT or GPT (IU/L): 135.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,34
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 95
Glucose (mmol/L): 6
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,94
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,45
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 466.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,55
Urea (mg/dL): 6,68
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient has a history of Enolic dilated cardiomyopathy, which indicates a significant reduction in left ventricular function. The LVEF of 35.0% is a strong indicator of severe left ventricular dysfunction. Additionally, the patient has a history of hypertension and is currently on medications for blood pressure management, which suggests that the patient has a high risk of cardiovascular events. However, the patient is currently not experiencing any symptoms of heart failure and the patient's NYHA class is III, which indicates moderate symptoms.

The patient's laboratory results, such as elevated troponin and BNP levels, suggest that the patient has some degree of myocardial stress or strain. However, the troponin level is within a relatively normal range, and the BNP level is not excessively elevated. The patient's electrolyte levels, including potassium, sodium, and creatinine, are within a relatively normal range.

The ECG findings of ventricular extrasystole are concerning, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient does not have a high risk of sudden cardiac death. The patient's hemoglobin level is within a relatively normal range, which suggests that the patient does not have significant anemia.

Considering the above factors, the patient is likely to survive for the next few years with appropriate management and monitoring. However, it is essential to closely monitor the patient's LVEF, NYHA class, and laboratory results to adjust the treatment plan as needed to minimize the risk of cardiovascular events.

2. Sudden cardiac death
REASONING:
The patient's severe left ventricular dysfunction (LVEF 35.0%) and history of Enolic dilated cardiomyopathy increase the risk of sudden cardiac death. The patient's elevated BNP and troponin levels suggest that the patient has some degree of myocardial stress or strain. The ECG findings of ventricular extrasystole are concerning, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia does not rule out a risk of sudden cardiac death.

However, the patient's NYHA class is III, and the patient is currently not experiencing any symptoms of heart failure, which suggests that the patient's cardiovascular risk is not as high as it could be. Additionally, the patient is on medications for blood pressure management, which may help reduce the risk of cardiovascular events.

3. Pump failure death
REASONING:
The patient's severe left ventricular dysfunction (LVEF 35.0%) and history of Enolic dilated cardiomyopathy increase the risk of heart failure. The patient's elevated BNP and troponin levels suggest that the patient has some degree of myocardial stress or strain. The patient's NYHA class is III, which indicates moderate symptoms of heart failure.

The patient's laboratory results, including elevated creatinine and urea levels, suggest that the patient may have some degree of renal impairment, which can increase the risk of heart failure. The patient's hemoglobin level is slightly elevated, which may indicate some degree of polycythemia, which can increase the risk of cardiac complications.

However, the patient is currently not experiencing any symptoms of heart failure, and the patient is on medications for blood pressure management, which may help reduce the risk of cardiovascular events. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient does not have a high risk of sudden cardiac death."
206,206,P0347,"Age: 65
Gender: Male 
Weight: 69 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 14,5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,46
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 500.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,05
Urea (mg/dL): 10,47
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and lab results suggest a relatively stable cardiovascular condition. The patient's NYHA class II indicates mild symptoms of heart failure, but the patient is still able to perform daily activities with minimal limitations. The patient's LVEF of 40% is significantly reduced, indicating impaired left ventricular function, but it is not life-threatening.

The patient's lab results show elevated creatinine levels (94.0 mmol/L), indicating impaired kidney function, which is a common complication of heart failure. However, the patient's serum albumin level (46 g/L) is within the normal range, suggesting that the patient's kidney function is not severely impaired.

The patient's lipid profile shows elevated total cholesterol (4.45 mmol/L) and LDL (2.46 mmol/L), which are risk factors for cardiovascular disease. However, the patient is already on statins, which should help manage these risk factors.

The patient's ECG results show ventricular extrasystoles, which are a common finding in patients with heart failure. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

The patient's elevated Pro-BNP level (500.0 ng/L) suggests some level of cardiac stress, but it is not excessively high. The patient's other lab results, including the Troponin level (0.01 ng/mL), TSH (1.05 mIU/L), and T3 (0.05 pg/dL), are within normal ranges.

Considering these factors, the patient's overall prognosis is relatively good, and I predict that the patient will survive for the next few years. The patient's impaired LVEF and kidney function require close monitoring, but the patient's other clinical and lab results suggest a stable cardiovascular condition."
207,207,P0348,"Age: 60
Gender: Male 
Weight: 79 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 54,4
ALT or GPT (IU/L): 55.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 160.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,84
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 266.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,01
Urea (mg/dL): 7,8
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 60-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. He has a low LVEF of 35.0, which indicates significant left ventricular dysfunction. However, his blood pressure is well-controlled (120/70 mmHg), and he is on medications for diabetes and hypertension. The patient's laboratory results show elevated liver enzymes (ALT and AST), but not significantly elevated troponin levels, which suggests that he does not have acute myocardial infarction. The patient's kidney function is also impaired, with elevated creatinine levels (101.0 mmol/L), but this is likely due to the patient's diabetes rather than cardiac failure.

Given these factors, the patient's overall prognosis is guarded, but not extremely poor. He is likely to survive for several years with appropriate management and monitoring. The patient's low LVEF and NYHA Class II indicate that he has some residual cardiac function, which will allow him to tolerate some level of physical activity. However, he will require close monitoring and adjustments to his medications to manage his heart failure symptoms and prevent further decline in cardiac function.

The other two prognoses are less likely because:

- Sudden cardiac death is unlikely due to the patient's well-controlled blood pressure and lack of evidence of ventricular arrhythmias on the ECG.
- Pump failure death is possible, but the patient's residual cardiac function and low LVEF suggest that he may be able to survive with aggressive management and supportive care.

It is essential to note that this is a preliminary prognosis, and the patient's outcome will depend on various factors, including the effectiveness of his treatment plan, his adherence to medications, and any changes in his underlying medical conditions."
208,208,P0350,"Age: 76
Gender: Female 
Weight: 89 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 37,2
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,03
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 480.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,25
Urea (mg/dL): 16,03
LVEF (%): 32.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 76-year-old female with a history of hypertensive cardiomyopathy, hypertension, and NYHA Class III heart failure. The patient's LVEF is significantly reduced at 32.0%, indicating severe left ventricular dysfunction. The presence of elevated Pro-BNP levels (480.0 ng/L) further supports the presence of heart failure. The patient is also taking multiple medications for heart failure, including loop diuretics and spironolactone, which suggests an attempt to manage symptoms and improve survival.

The patient's ECG findings, including ventricular extrasystoles and TPSV, may indicate arrhythmias, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient is not at high risk for sudden cardiac death. The patient's blood pressure is well-controlled at 130/80 mmHg, and the laboratory values do not indicate acute kidney injury or significant electrolyte imbalances.

Given these factors, the patient's overall prognosis is likely to be a survivor, as the patient is receiving treatment for heart failure and has not presented with any acute life-threatening conditions. However, it is essential to continue close monitoring and adjust the treatment plan as needed to optimize the patient's condition and prevent further decline.

RANKING: 2. Pump failure death
REASONING: 

While the patient's LVEF is severely reduced, and the patient has a history of heart failure, the patient is currently receiving treatment and has not shown any signs of acute heart failure exacerbation. However, the patient's elevated Pro-BNP levels and reduced LVEF suggest that the patient is at risk for pump failure. The patient's weight and creatinine levels are also elevated, which may indicate kidney dysfunction, a common complication of heart failure.

The patient's age and gender also increase the risk for pump failure death. According to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines, the risk of pump failure death increases with age and is higher in women.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's ECG findings of ventricular extrasystoles and TPSV may indicate an increased risk for arrhythmias, which can increase the risk for sudden cardiac death. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient is not at high risk for sudden cardiac death. Additionally, the patient's blood pressure is well-controlled, and the laboratory values do not indicate acute kidney injury or significant electrolyte imbalances.

While the patient's history of hypertensive cardiomyopathy and hypertension increases the risk for sudden cardiac death, the patient's current treatment plan and lack of acute life-threatening conditions make this prognosis less likely."
209,209,P0352,"Age: 51
Gender: Male 
Weight: 85 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 46,3
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,88
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 239.0
Protein (g/L): 80
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,66
Urea (mg/dL): 8,24
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

This patient's prognosis can be determined by analyzing the provided data, focusing on the patient's clinical presentation, laboratory results, and past medical history.

The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates significant cardiac damage and potential for future cardiac events. The low left ventricular ejection fraction (LVEF) of 35% further supports this, as it indicates impaired cardiac function.

The patient's current blood pressure is within a relatively normal range (110/70 mmHg), which is a positive factor. However, the elevated creatinine level (109.0 mmol/L) suggests some degree of renal impairment, which may be related to cardiac dysfunction.

The elevated Pro-BNP level (239.0 ng/L) indicates elevated ventricular wall stress, which is a marker for heart failure. The patient's current NYHA class is II, indicating mild symptoms, but this is likely a reflection of their underlying cardiac condition rather than a recent change.

The patient's lipid profile is relatively normal, with a low HDL level (0.96 mmol/L), but this is not a significant factor in this context.

Given the patient's history of cardiac disease and impaired cardiac function, the most likely outcome is that they will survive for the next few years. However, the risk of sudden cardiac death cannot be entirely ruled out, especially considering the patient's history of myocardial infarction and impaired cardiac function.

The risk of pump failure death is a possibility, given the patient's impaired cardiac function and elevated Pro-BNP levels. However, this outcome is less likely than sudden cardiac death, given the patient's current stable clinical presentation and lack of recent cardiac events.

Therefore, the most likely outcome is survival, with a moderate risk of sudden cardiac death and a lower risk of pump failure death."
210,210,P0353,"Age: 78
Gender: Male 
Weight: 75 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,71
Creatinine (mmol/L): 140.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,9
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 4518.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,63
Urea (mg/dL): 14,92
LVEF (%): 15.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Digoxin, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is currently classified as having an LVEF of 15%, which is a significant reduction in left ventricular function, indicating severe left ventricular dysfunction. This is a major risk factor for heart failure and sudden cardiac death. However, the patient's current medication regimen includes a nitrovasodilator, which is a common treatment for heart failure, and is also indicated to reduce the risk of sudden cardiac death. Additionally, the patient's ECG findings show no evidence of ventricular tachycardia or ventricular extrasystole, which are major triggers for sudden cardiac death. The patient's blood pressure is within a relatively normal range (120/80 mmHg), and the other vital signs and lab values do not indicate any acute complications. Considering these factors, the patient's overall condition is stable, and the likelihood of a sudden cardiac death is low. 

2. Sudden Cardiac Death
REASONING: 
While the patient has severe left ventricular dysfunction, the patient's current medication regimen and ECG findings suggest that there is no immediate indication of ventricular tachycardia or ventricular extrasystole. However, the patient's LVEF is severely impaired, and the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's age (78) and other comorbidities also contribute to this risk. Although the patient is not currently experiencing any acute symptoms, the patient's overall cardiovascular risk remains high.

3. Pump Failure Death
REASONING: 
While the patient has severe left ventricular dysfunction, the patient's current medication regimen and ECG findings suggest that the patient is not currently experiencing acute heart failure symptoms. The patient's blood pressure is within a relatively normal range, and the patient's other vital signs and lab values do not indicate any acute complications. However, the patient's LVEF is severely impaired, and the patient's history of heart failure and myocardial infarction increases the risk of pump failure. Additionally, the patient's medication regimen includes digoxin, which can increase the risk of cardiac arrhythmias. While the patient is currently classified as a survivor, the patient's underlying cardiovascular disease and medication regimen suggest that pump failure is a potential risk in the future."
211,211,P0354,"Age: 54
Gender: Male 
Weight: 61 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/78 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 6,39
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,06
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 123.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,442
Urea (mg/dL): 8,91
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient is at a higher risk of survivor due to the presence of ischemic dilated cardiomyopathy, which is the underlying cause of their NYHA Class II heart failure. The patient's LVEF is significantly reduced at 35%, indicating a severely impaired cardiac function. The presence of non-sustained ventricular tachycardia and ventricular extrasystole on the ECG also suggests an increased risk of arrhythmias, which can further compromise cardiac function. The patient's medication regimen, including beta blockers, calcium channel blockers, and statins, suggests a treatment plan aimed at managing symptoms and reducing cardiovascular risk factors. Although the patient's creatinine level is elevated, indicating some degree of renal impairment, this is not uncommon in patients with heart failure. Overall, the combination of heart failure, impaired cardiac function, and arrhythmias makes a survival prognosis more likely."
212,212,P0355,"Age: 48
Gender: Male 
Weight: 78 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 48,2
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4
LDL (mmol/L): 2,53
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 325.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,12
Urea (mg/dL): 6,68
LVEF (%): 28.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

This patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are significant risk factors for adverse cardiac outcomes. The current ejection fraction (LVEF) of 28.0% is also a strong indicator of poor cardiac function.

The patient's NYHA class II indicates moderate symptoms, which suggests that the patient is experiencing some limitations in physical activity due to their heart condition. However, the patient is still able to maintain a normal hemoglobin level, which may indicate relatively good cardiovascular reserve.

The patient's lipid profile shows elevated total cholesterol and LDL levels, which increases the risk of atherosclerosis and cardiovascular events. However, the patient is on beta blockers and ACE inhibitors, which are standard treatments for managing cardiovascular risk factors.

The ECG results show ventricular extrasystole, which is a type of abnormal heart rhythm. However, there is no ventricular tachycardia or non-sustained ventricular tachycardia, which are more indicative of life-threatening arrhythmias.

The elevated pro-BNP level (325.0 ng/L) is a marker of cardiac stress and suggests that the patient's heart is working harder than normal. However, this is not necessarily a cause for concern, as the patient is still able to maintain a normal hemoglobin level.

Considering these factors, the most likely outcome is that the patient will survive, given their relatively good cardiovascular reserve and the absence of life-threatening arrhythmias. However, the patient is at risk of pump failure death due to their poor LVEF and elevated pro-BNP level. Sudden cardiac death is the least likely outcome, given the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG.

It is essential to closely monitor the patient's cardiac function and adjust their treatment plan as needed to minimize the risk of adverse outcomes. Regular follow-up appointments and close monitoring of the patient's LVEF, pro-BNP level, and lipid profile will be crucial in managing this patient's condition."
213,213,P0357,"Age: 69
Gender: Female 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 875.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,16
Urea (mg/dL): 7,99
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results suggest a poor prognosis, but the patient is currently being managed with multiple medications and has a history of NYHA Class II heart failure. The presence of idiopathic dilated cardiomyopathy, diabetes, and hypertension increases the risk of adverse outcomes. However, the patient's current LVEF of 45% and the absence of evidence of acute coronary syndrome or acute heart failure exacerbation in the ECG impression suggest that the patient is currently stable. The patient's elevated Pro-BNP levels (875 ng/L) indicate some degree of heart failure, but it is not severe. Given the patient's age, comorbidities, and current medication regimen, the risk of sudden cardiac death or pump failure death is moderate. However, the patient's current stable condition and the fact that they are not showing any signs of acute heart failure or arrhythmia make a survival outcome more likely than the other two options."
214,214,P0358,"Age: 53
Gender: Male 
Weight: 71 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 110/65 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 126
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3068.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,35
Urea (mg/dL): 5,66
LVEF (%): 21.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results suggest that they are at high risk for adverse outcomes. However, the patient is currently alive and receiving treatment with medications that are standard for managing heart failure and arrhythmias. The presence of a history of enolic dilated cardiomyopathy, low LVEF, and elevated Pro-BNP levels indicates significant cardiac dysfunction. The patient's current symptoms and test results, such as the presence of non-sustained ventricular tachycardia, ventricular extrasystole, and bradycardia, suggest that they are at risk for cardiac arrhythmias and potentially life-threatening events. However, the patient's current hemodynamic status, as indicated by the normal blood pressure and low creatinine levels, suggests that they are not in acute decompensated heart failure. Therefore, I believe that the patient has the highest chance of survival with proper management and monitoring."
215,215,P0360,"Age: 64
Gender: Female 
Weight: 52 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 50.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 108.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,09
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1314.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 18
TSH (mIU/L): 3,01
Urea (mg/dL): 5,16
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's prognosis is likely to be a survivor. The patient is 64 years old, which is in the advanced age range for cardiovascular disease. However, the patient's NYHA class is II, indicating mild symptoms, and their blood pressure is well-controlled at 110/70 mmHg. The patient's ECG impression shows no ventricular tachycardia or ventricular extrasystoles, which are significant indicators of cardiac instability.

The patient's lab results show a mildly elevated creatinine level (97.0 mmol/L), which may indicate some degree of renal impairment. However, the patient's LVEF (left ventricular ejection fraction) is 25.0%, which is significantly reduced, indicating impaired cardiac function. The patient's biomarkers, such as troponin and creatine kinase, are not elevated, suggesting that there is no acute myocardial infarction.

The patient's medication regimen includes beta blockers, angiotensin II receptor blockers, and loop diuretics, which are standard treatments for heart failure and hypertension. The patient's protein levels are within a normal range, and their electrolyte levels, including potassium, are also within normal limits.

Given the patient's overall clinical presentation, medication regimen, and lab results, the most likely prognosis is a survivor, with the potential for some degree of improvement with optimal management and treatment.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's LVEF is significantly reduced, the patient's overall clinical presentation does not suggest an immediate risk of sudden cardiac death. The patient's ECG impression does not show any significant arrhythmias, and their medication regimen is standard for managing heart failure and hypertension.

However, the patient's mildly elevated creatinine level and reduced LVEF do increase the risk of cardiovascular events, including sudden cardiac death. Additionally, the patient's age and sex increase the risk of cardiac mortality.

Given the patient's reduced LVEF and mildly elevated creatinine level, a sudden cardiac death is possible, but it is not the most likely outcome.

RANKING: 3. Pump failure death
REASONING: 

The patient's reduced LVEF and mildly elevated creatinine level do increase the risk of pump failure. However, the patient's medication regimen, including beta blockers and angiotensin II receptor blockers, is standard for managing heart failure, and their blood pressure is well-controlled.

The patient's ECG impression does not show any significant arrhythmias, and their lab results do not indicate any acute kidney injury. Additionally, the patient's protein levels and electrolyte levels are within normal limits.

Given the patient's overall clinical presentation and medication regimen, pump failure is a possible outcome, but it is not the most likely prognosis. The patient's age and sex increase the risk of cardiovascular mortality, but the patient's overall clinical presentation does not suggest an immediate risk of pump failure."
216,216,P0361,"Age: 72
Gender: Male 
Weight: 83 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 35,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 8,4
Glucose (mmol/L): 6,36
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,87
LDL (mmol/L): 2,16
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 864.0
Protein (g/L): 64
T3 (pg/dL): 0,0489
T4 (ng/L): 16,17
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,54
Urea (mg/dL): 20,49
LVEF (%): 20.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 72-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. The patient's ejection fraction (LVEF) is significantly reduced at 20%, indicating severe left ventricular dysfunction.

The patient's elevated creatinine level (133.0 mmol/L) and elevated BNP levels (864.0 ng/L) suggest compromised renal function and increased ventricular wall stress. The presence of ventricular extrasystole on the ECG, a type of abnormal heart rhythm, further indicates the patient's cardiac condition.

Given these factors, the patient's overall prognosis is likely to be a survivor. The patient is currently taking medications such as spironolactone, statins, and an ACE inhibitor, which are commonly used to manage heart failure and other cardiovascular conditions.

While the patient's NYHA Class II indicates some limitation in physical activity, it does not necessarily indicate a high risk of sudden cardiac death or pump failure. The patient's blood pressure is within a relatively normal range, and the absence of other risk factors such as severe hypertension or coronary artery disease may also contribute to a more favorable prognosis.

Therefore, based on the available data, the patient's likelihood of surviving the next few years is higher than that of sudden cardiac death or pump failure. However, close monitoring and follow-up with the patient's healthcare provider will be necessary to adjust the treatment plan as needed and to assess the patient's overall clinical status."
217,217,P0365,"Age: 54
Gender: Male 
Weight: 69 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Other HF etiology, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,97
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,89
Potassium (mEq/L): 4
LDL (mmol/L): 3,85
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 46.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,16
Urea (mg/dL): 6,16
LVEF (%): 65.0
Medications: Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, the patient is a 54-year-old male with a history of heart failure (NYHA Class III), hypertension, and other etiology. The patient's laboratory results show elevated creatinine levels (106.0 mmol/L) and BNP (46.0 ng/L), indicating a possible reduction in cardiac function and fluid overload. The patient's ECG results show ventricular extrasystole, which is a common finding in patients with heart failure.

The patient's medication regimen consists of loop diuretics, which is appropriate for managing heart failure symptoms. However, the patient's elevated troponin levels (0.005 ng/mL) and reduced LVEF (65.0%) suggest some degree of cardiac damage. 

Despite these findings, the patient's overall clinical presentation and laboratory results do not indicate acute coronary syndrome or acute heart failure decompensation. The patient's weight, height, and hemoglobin levels are within normal limits. The patient's age and comorbidities also suggest that the patient is not at high risk for sudden cardiac death.

Therefore, based on the available data, the most likely outcome for this patient over the next few years is survivor.

RANKING: 2. Sudden cardiac death 
REASONING: 
Although the patient's cardiac function is compromised, with reduced LVEF and elevated troponin levels, the patient's overall clinical presentation does not suggest an immediate risk of sudden cardiac death. The patient's ECG results do not show any signs of ventricular tachycardia, and the patient is not experiencing any symptoms of acute heart failure.

However, the patient's elevated creatinine levels and BNP levels indicate a possible underlying cardiac dysfunction. If this dysfunction progresses, it could potentially lead to a sudden cardiac event. Additionally, the patient's age and comorbidities increase the risk of sudden cardiac death.

Therefore, while the risk of sudden cardiac death is present, it is not the most likely outcome for this patient over the next few years.

RANKING: 3. Pump failure death 
REASONING: 
Pump failure death is a possible outcome for this patient, given the patient's reduced LVEF and elevated BNP levels. However, the patient's current clinical presentation and laboratory results do not indicate acute heart failure decompensation.

The patient's elevated troponin levels and reduced LVEF suggest some degree of cardiac damage, but the patient's overall clinical presentation and laboratory results do not indicate an immediate risk of pump failure. Additionally, the patient is receiving loop diuretics, which is a common treatment for managing heart failure symptoms.

Therefore, while pump failure death is a possible outcome, it is not the most likely outcome for this patient over the next few years."
218,218,P0366,"Age: 59
Gender: Male 
Weight: 100 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 165/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,59
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,05
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1477.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,15
TSH (mIU/L): 0,76
Urea (mg/dL): 8,49
LVEF (%): 37.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's NYHA Class II classification indicates that they have some symptoms of heart failure, but they are still able to perform daily activities with some limitation. Their LVEF is 37%, which is significantly reduced, but it is not critically low. The patient's medication regimen includes ACE inhibitors, beta-blockers, and statins, which are commonly used to manage heart failure and hypertension. The patient's renal function is also relatively preserved, with a creatinine level of 88.0 mmol/L. The ECG impression is normal, and there is no indication of ventricular arrhythmias. The patient's laboratory values, including troponin and liver enzymes, are not significantly elevated. These factors suggest that the patient is likely to survive for the next few years, assuming that their current treatment plan remains effective and they do not develop any new significant comorbidities.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 37% is a significant reduction, indicating that their heart is not pumping efficiently. However, this is not an absolute contraindication for survival. The patient's NYHA Class II classification suggests that they are not severely limited in their physical activity, and their medication regimen is likely to help manage their heart failure symptoms. However, if the patient's LVEF continues to decline, or if they develop significant symptoms of heart failure, pump failure could become a concern. Additionally, the patient's elevated blood pressure and dyslipidemia may increase their risk of cardiovascular events, including heart failure exacerbation.

RANKING: 3. Sudden cardiac death
REASONING: The patient's ECG impression is normal, and there is no indication of ventricular arrhythmias. However, the patient's LVEF of 37% and elevated blood pressure (165/110 mmHg) increase their risk of sudden cardiac death. The patient's elevated troponin level (0.15 ng/mL) is also a marker of cardiac damage, which may increase their risk of arrhythmias. Additionally, the patient's diabetes and hypertension may increase their risk of cardiac events, including sudden cardiac death. While the patient's current treatment plan includes beta-blockers, which are commonly used to reduce the risk of sudden cardiac death, the patient's elevated blood pressure and LVEF may still pose a risk."
219,219,P0367,"Age: 63
Gender: Male 
Weight: 82 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 102/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 131.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5,3
LDL (mmol/L): 2,74
Sodium (mEq/L): 139.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,06
TSH (mIU/L): 0,92
Urea (mg/dL): 15,31
LVEF (%): 55.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with hypertension, hypertensive cardiomyopathy, and a history of heart failure (NYHA Class II). The patient's left ventricular ejection fraction (LVEF) is 55%, indicating some degree of left ventricular dysfunction. The patient's troponin levels are within normal limits, which suggests that there is no significant myocardial damage. The patient's ECG impression shows ventricular extrasystoles, which may indicate some degree of ventricular arrhythmias, but there is no evidence of ventricular tachycardia or bradycardia. The patient is currently taking medications for hypertension, heart failure, and arrhythmias, which suggests that the patient's cardiovascular system is being actively managed.

Given the patient's overall health status, the presence of some degree of left ventricular dysfunction, and the fact that the patient is being actively managed with medications, the most likely prognosis for this patient over the next few years is survival. While the patient has a complex medical history, the patient's current health status and the fact that the patient is being actively managed suggest that the patient is at lower risk for sudden cardiac death or pump failure."
220,220,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient's overall clinical presentation and laboratory results indicate a poor prognosis. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that can lead to heart failure and sudden cardiac death. The patient's NYHA Class III indicates severe symptoms, and the low LVEF of 26% suggests significant left ventricular dysfunction. The elevated Pro-BNP level of 27434.0 ng/L is also indicative of heart failure. 

The patient's electrolytes, liver function, and kidney function are within normal limits, but the patient's dyslipidemia and hypertension may contribute to the progression of the disease. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG reduces the risk of sudden cardiac death. However, the presence of ventricular extrasystoles, a type of abnormal heart rhythm, is a concerning sign.

Considering the patient's age, comorbidities, and the severity of their heart failure, I believe that the most likely outcome is heart failure, which would lead to a poor prognosis. However, since the patient is already being treated with medications for heart failure, I am more likely to predict that the patient will survive, albeit with a significant risk of further deterioration.

2. Sudden Cardiac Death
REASONING:
While the patient's ECG shows ventricular extrasystoles, which is a concerning sign, the absence of ventricular tachycardia and non-sustained ventricular tachycardia reduces the risk of sudden cardiac death. The patient's LVEF is low, but the patient is being treated with medications for heart failure, which may help improve symptoms. The patient's age, weight, and comorbidities also increase the risk of sudden cardiac death.

3. Pump Failure Death
REASONING:
Pump failure death is a possible outcome for patients with severe heart failure, but it is less likely in this case. The patient is being treated with medications for heart failure, which may help improve symptoms and reduce the risk of further deterioration. The patient's LVEF is low, but the patient's age, weight, and comorbidities increase the risk of pump failure. The patient's laboratory results are within normal limits, which reduces the risk of pump failure."
221,221,P0372,"Age: 60
Gender: Male 
Weight: 77 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 185.0
AST or GOT (IU/L): 154.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 188
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 121.0
HDL (mmol/L): 2,04
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 186.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,7
Urea (mg/dL): 5,66
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's age, NYHA Class II, and LVEF of 70.0 indicate a relatively preserved cardiac function, which suggests that the patient's heart is still capable of meeting the body's demands. The presence of ischemic dilated cardiomyopathy and hypertension, however, indicate a history of cardiac damage and potential ongoing strain on the heart. Despite this, the patient's current medication regimen includes ACE inhibitors and beta-blockers, which are commonly used to manage heart failure and reduce blood pressure. The patient's laboratory results, including a normal potassium level, low troponin level, and normal TSH level, also suggest that the patient's heart is not under significant stress or strain at the moment. 

The patient's elevated liver enzymes (ALT and AST) may indicate some degree of liver damage, but this is not directly related to the patient's cardiac function. The patient's glucose and lipid profiles are also concerning, but the presence of statins and diabetes medication suggests that the patient is being managed for these conditions. 

Overall, given the patient's relatively preserved cardiac function, current medication regimen, and lack of acute cardiac events, I would rank the patient as having the highest likelihood of survival over the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: 
While the patient's history of ischemic dilated cardiomyopathy and hypertension increases their risk for sudden cardiac death, the patient's current cardiac function is relatively preserved, and they are receiving medications that are commonly used to manage these conditions. However, the presence of ventricular extrasystoles on the ECG impression suggests that the patient may be at increased risk for arrhythmias, which can increase the risk of sudden cardiac death. Additionally, the patient's elevated troponin level, although low, may indicate some degree of cardiac damage, which could increase the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 
The patient's NYHA Class II and LVEF of 70.0 suggest that the patient's heart is still capable of meeting the body's demands, but the patient's history of ischemic dilated cardiomyopathy and hypertension increases their risk for heart failure. The patient's elevated liver enzymes and elevated creatinine level may also indicate some degree of kidney damage, which can increase the risk of heart failure. While the patient is receiving medications that are commonly used to manage heart failure, the patient's laboratory results and ECG impression do not suggest that the patient is currently experiencing significant cardiac stress or strain. However, the patient's history of cardiac damage and ongoing hypertension increase their risk for heart failure, making this a plausible prognosis."
222,222,P0373,"Age: 41
Gender: Male 
Weight: 70 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,89
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,07
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 5017.0
Protein (g/L): 87
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 2,27
Urea (mg/dL): 12,48
LVEF (%): 29.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has several factors that suggest a favorable prognosis, including a relatively low age, a NYHA Class II heart failure, and the presence of certain medications that are commonly used to manage heart failure and hypertension. The patient's laboratory results also show a relatively normal liver function (ALT and AST levels), a normal kidney function (creatinine and urea levels), and a normal glucose level. Additionally, the patient has a low level of troponin, which is an indicator of cardiac damage, and a normal TSH level, which suggests that the patient's thyroid function is within normal limits. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on ECG may indicate some cardiac dysfunction, but they are not necessarily indicative of a poor prognosis. 

However, the patient's LVEF is significantly reduced at 29%, which indicates a moderate degree of left ventricular dysfunction. The presence of hypertension, which is a major risk factor for cardiovascular disease, is also a concern. Despite these factors, the patient's overall clinical presentation and laboratory results suggest that the patient has a relatively stable condition, and the patient is receiving optimal treatment with multiple medications. 

Therefore, based on the available information, the most likely outcome for the next few years is that the patient will survive.

2. Sudden cardiac death
REASONING: 
The patient's low LVEF of 29% indicates a moderate degree of left ventricular dysfunction, which is a significant risk factor for sudden cardiac death. The patient's history of hypertension and hypertensive cardiomyopathy also increases the risk of sudden cardiac death. Additionally, the patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are abnormal rhythms that can increase the risk of sudden cardiac death. The patient's age and sex also make them more susceptible to sudden cardiac death.

3. Pump failure death
REASONING: 
The patient's LVEF is 29%, which indicates a moderate degree of left ventricular dysfunction, and the patient is receiving medications to manage heart failure. However, the patient's low LVEF and the presence of hypertension and hypertensive cardiomyopathy make it more likely that the patient will experience pump failure in the near future. The patient's low albumin level (45 g/L) also suggests a possible malnutrition state, which can exacerbate heart failure. Additionally, the patient's elevated creatinine level (212.0 mmol/L) indicates impaired kidney function, which can also contribute to pump failure."
223,223,P0374,"Age: 74
Gender: Male 
Weight: 73 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,5
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1414.0
Protein (g/L): 66
T3 (pg/dL): 0,04
T4 (ng/L): 23
Troponin (ng/mL): 0,023
TSH (mIU/L): 0,565
Urea (mg/dL): 6,99
LVEF (%): 43.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I would rank the patient as a survivor. The patient is 74 years old, with a NYHA Class II heart failure, indicating a moderate level of heart failure. However, the patient's blood pressure is within a relatively normal range (110/60 mmHg), and the medication regimen includes beta blockers, which are known to improve outcomes in patients with heart failure.

The patient's laboratory results show a slightly elevated creatinine level (124.0 mol/L), which may indicate some degree of renal impairment, but it is not severe enough to be a major concern. The patient's troponin level is within normal limits, which suggests that there is no significant myocardial damage.

The patient's LVEF (Left Ventricular Ejection Fraction) is 43%, which is slightly reduced but not severely impaired. The patient's Pro-BNP level is elevated (1414.0 ng/L), which indicates some degree of heart failure. However, the patient's symptoms and medication regimen suggest that the patient is receiving adequate treatment for their heart failure.

The patient's ECG shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which are all potential predictors of poor outcomes. The patient's ventricular extrasystole is polymorphic, but it is not a cause for concern in this context.

Overall, considering the patient's age, NYHA Class II heart failure, and medication regimen, I believe that the patient is likely to survive for the next few years with proper management and treatment."
224,224,P0375,"Age: 69
Gender: Male 
Weight: 80 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 5
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 5
LDL (mmol/L): 2,66
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2834.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 20
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,09
Urea (mg/dL): 8,15
LVEF (%): 37.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's overall clinical presentation, including their NYHA Class II heart failure status, elevated BNP levels (2834.0 ng/L), and the presence of non-sustained ventricular tachycardia (NSVT) on ECG, indicate a relatively preserved cardiac function despite the presence of heart failure. The patient's medication regimen, which includes beta blockers, ACE inhibitors, and diuretics, suggests that they are receiving optimal treatment for their heart failure. The patient's elevated troponin levels (0.03 ng/mL) are not excessively high, and the TSH level is within the normal range, indicating that there is no overt hypothyroidism. Additionally, the patient's creatinine level is elevated, but not severely so, suggesting that their kidney function is not significantly impaired.

While the patient's LVEF is low (37%), it is not extremely low, and the patient is not experiencing symptoms of heart failure. The patient's age and other comorbidities, such as hypertension and dyslipidemia, are also factors to consider, but the overall clinical picture suggests that the patient is likely to survive for several years.

While there is a risk of sudden cardiac death due to the presence of NSVT and ventricular extrasystoles, the patient's overall clinical presentation and treatment plan reduce the likelihood of this outcome. The patient's low T3 level (0.04 pg/dL) and normal T4 level (20 ng/L) suggest that there is no overt hypothyroidism, which is a risk factor for sudden cardiac death. Therefore, while the patient is at risk for sudden cardiac death, the overall prognosis is more favorable than the other two options.

RANKING: 2. Sudden cardiac death
REASONING: 

This patient's presence of non-sustained ventricular tachycardia (NSVT) on ECG, ventricular extrasystoles, and polymorphic ventricular extrasystoles, as well as their NYHA Class II heart failure status, suggest an increased risk of sudden cardiac death. The patient's LVEF is low (37%), and their elevated BNP levels (2834.0 ng/L) indicate that their heart is under significant stress. The patient's medication regimen, while adequate for heart failure, does not address the underlying cardiac dysfunction.

The patient's low T3 level (0.04 pg/dL) and normal T4 level (20 ng/L) suggest that there is no overt hypothyroidism, which is a risk factor for sudden cardiac death. However, the presence of NSVT and ventricular extrasystoles on ECG increases the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

This patient's LVEF is low (37%), and their NYHA Class II heart failure status indicates that they are experiencing symptoms of heart failure. The patient's elevated BNP levels (2834.0 ng/L) and elevated creatinine level (8.15 mg/dL) suggest that their heart is under significant stress and that their kidney function is impaired. The patient's medication regimen, while adequate for heart failure, does not address the underlying cardiac dysfunction.

The patient's presence of NSVT and ventricular extrasystoles on ECG increases the risk of sudden cardiac death, but the patient's overall clinical presentation and treatment plan suggest that they are not at high risk for pump failure death. The patient's low T3 level (0.04 pg/dL) and normal T4 level (20 ng/L) suggest that there is no overt hypothyroidism, which is a risk factor for pump failure death."
225,225,P0376,"Age: 51
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,82
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 727.0
Protein (g/L): 71
T3 (pg/dL): 0,07
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,39
Urea (mg/dL): 4,99
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex clinical presentation, with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, the patient's current ejection fraction (LVEF) is 20%, which is relatively preserved compared to the general population with dilated cardiomyopathy. The patient's medication regimen, which includes beta-blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, is appropriate for managing heart failure and arrhythmias. 

The patient's laboratory values, such as elevated troponin and BNP levels, indicate some degree of cardiac stress, but these values are not excessively high. The patient's creatinine level is elevated, which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. 

The ECG results show ventricular extrasystoles, which are common in patients with heart failure, but no other significant arrhythmias are present. 

Overall, while this patient has several risk factors for adverse outcomes, the patient's current clinical presentation and laboratory values do not suggest an immediate high risk of sudden cardiac death or pump failure. Therefore, the most likely outcome for this patient over the next few years is survival."
226,226,P0378,"Age: 45
Gender: Male 
Weight: 82 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 141.0
HDL (mmol/L): 2,61
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,13
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 236.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 21
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,75
Urea (mg/dL): 5,83
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a significant history of idiopathic dilated cardiomyopathy, which is a condition that affects the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is 29.0%, which is below the normal range of 55-70%. This indicates that the patient's heart is not pumping efficiently, and the patient's NYHA Class II symptoms suggest that the patient is experiencing some limitations in physical activity.

The patient's current medications, including beta blockers, loop diuretics, and ACE inhibitors, are standard treatments for heart failure and can help manage symptoms and slow disease progression. However, the patient's elevated creatinine levels (88.0 mmol/L) and pro-BNP levels (236.0 ng/L) suggest that the patient may be experiencing some degree of cardiac dysfunction, which could lead to worsening heart failure over time.

The patient's ECG findings, including ventricular extrasystole and polymorphic ventricular tachycardia, are concerning for cardiac arrhythmias, which can be a complication of heart failure. However, the absence of sustained ventricular tachycardia or paroxysmal supraventricular tachycardia suggests that the patient may not be at high risk for sudden cardiac death at this time.

Given the patient's overall clinical presentation and the fact that they are currently being treated with standard medications for heart failure, the most likely outcome for the next few years is that the patient will survive. However, it is essential to closely monitor the patient's condition and adjust treatment as needed to prevent worsening heart failure and potential complications.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG findings are concerning for cardiac arrhythmias, the absence of sustained ventricular tachycardia or paroxysmal supraventricular tachycardia suggests that the patient may not be at high risk for sudden cardiac death at this time. However, the patient's history of idiopathic dilated cardiomyopathy and elevated pro-BNP levels suggest that the patient may be at risk for cardiac dysfunction, which could lead to sudden cardiac death over time.

The patient's current medications, including beta blockers, loop diuretics, and ACE inhibitors, can help manage symptoms and slow disease progression, but may not address the underlying cardiac dysfunction. The patient's elevated creatinine levels (88.0 mmol/L) also suggest that the patient may be at risk for worsening kidney function, which can be a complication of heart failure.

Given the patient's overall clinical presentation and the potential for cardiac dysfunction, the second most likely outcome for the next few years is that the patient will experience sudden cardiac death, although this is still a relatively low probability.

RANKING: 3. Pump failure death
REASONING: 

While the patient's current medications, including beta blockers, loop diuretics, and ACE inhibitors, can help manage symptoms and slow disease progression, the patient's history of idiopathic dilated cardiomyopathy and elevated pro-BNP levels suggest that the patient may be at risk for worsening cardiac dysfunction over time.

The patient's elevated creatinine levels (88.0 mmol/L) also suggest that the patient may be at risk for worsening kidney function, which can be a complication of heart failure. Additionally, the patient's NYHA Class II symptoms suggest that the patient is experiencing some limitations in physical activity, which can lead to muscle wasting and further compromise cardiac function.

Given the patient's overall clinical presentation and the potential for cardiac dysfunction, the third most likely outcome for the next few years is that the patient will experience pump failure death, although this is a relatively low probability."
227,227,P0379,"Age: 49
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,76
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1517.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 16
TSH (mIU/L): 2,05
Urea (mg/dL): 5,66
LVEF (%): 67.0
Medications: Calcium Channel Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient is a 49-year-old male with a history of hypertension and hypertensive cardiomyopathy, which is a significant risk factor for heart failure. However, the patient's NYHA Class II indicates that they are able to perform moderate physical activity without symptoms. The patient's LVEF of 67% is within the normal range, suggesting that the left ventricle is functioning relatively well. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG reduces the risk of sudden cardiac death. The patient's blood pressure is well-controlled with medications, and the absence of significant elevation in the BNP level (1517 ng/L) suggests that the patient's heart is not experiencing significant stress or strain. Overall, these factors suggest that the patient is likely to survive for the next few years.

2. Pump failure death
REASONING: 
While the patient's LVEF is within the normal range, the patient's NYHA Class II indicates that they are not without limitations, and the patient's blood pressure is not perfectly controlled. The patient's elevated creatinine level (133 mol/L) suggests some degree of renal impairment, which can be a marker of cardiac dysfunction. Additionally, the patient's elevated urea level (5.66 mg/dL) suggests a slightly elevated metabolic acidosis, which can also be a marker of cardiac dysfunction. The patient's T3 level (0.05 pg/dL) is low, which can be a marker of decreased cardiac function. While these factors do not necessarily indicate a high risk of pump failure, they do suggest that the patient may be at increased risk of developing heart failure over time.

3. Sudden cardiac death
REASONING: 
The patient's ECG shows ventricular extrasystoles, which can be a marker of cardiac arrhythmia. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG reduces the risk of sudden cardiac death. Additionally, the patient's LVEF is within the normal range, and the patient's BNP level is not elevated, suggesting that the patient's heart is not experiencing significant stress or strain. However, the patient's history of hypertensive cardiomyopathy and the presence of ventricular extrasystoles do increase the risk of sudden cardiac death."
228,228,P0380,"Age: 59
Gender: Male 
Weight: 88 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/65 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 62
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,18
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 105.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,51
Urea (mg/dL): 4,16
LVEF (%): 32.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as having the highest likelihood of being a survivor for the next few years. The patient has a NYHA Class II heart failure, which indicates moderate symptoms of heart failure. However, the patient's ejection fraction (LVEF) is 32.0%, which is still within the range of a moderate to severe impairment. The patient is also taking medications such as beta blockers, digoxin, and ACE inhibitors, which are standard treatments for heart failure.

The patient's ECG findings show a polymorphic ventricular extrasystole and non-sustained ventricular tachycardia, which may indicate an increased risk of cardiac arrhythmias. However, the absence of a clear indication of ventricular fibrillation or ventricular tachycardia (CH>10) suggests that the patient may not be at an immediate high risk of sudden cardiac death.

The patient's laboratory results show elevated creatinine levels (97.0 mmol/L) and a low albumin level (40 g/L), which may indicate renal impairment and malnutrition. However, these findings are not directly related to the patient's cardiac function and may not significantly impact the patient's overall prognosis.

Overall, while the patient has several comorbidities and cardiac findings that may impact their prognosis, their current treatment regimen and the absence of severe cardiac dysfunction or arrhythmias suggest that they may be at lower risk for sudden cardiac death and pump failure in the short term.

RANKING: 2. Sudden cardiac death
REASONING: 

I would rank the patient as having a moderate likelihood of sudden cardiac death for the next few years. The patient's ECG findings of polymorphic ventricular extrasystole and non-sustained ventricular tachycardia, particularly the presence of non-sustained ventricular tachycardia (CH>10), increase the risk of cardiac arrhythmias. However, the absence of a clear indication of ventricular fibrillation or ventricular tachycardia (CH>10) suggests that the patient may not be at an immediate high risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

I would rank the patient as having the lowest likelihood of pump failure death for the next few years. While the patient has a NYHA Class II heart failure and an LVEF of 32.0%, which indicates moderate to severe impairment, the patient is taking medications that are standard for heart failure management, such as beta blockers, digoxin, and ACE inhibitors. The patient's ECG findings and laboratory results do not indicate a sudden or severe decline in cardiac function.

However, the patient's elevated creatinine levels (97.0 mmol/L) and low albumin level (40 g/L) may indicate renal impairment, which can impact the patient's overall prognosis. Additionally, the patient's low HDL cholesterol level (1.86 mmol/L) may increase the risk of cardiovascular events."
229,229,P0381,"Age: 70
Gender: Male 
Weight: 58 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 96/57 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,35
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 434.0
Protein (g/L): 61
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,67
Urea (mg/dL): 5,49
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient's NYHA class is II, indicating mild symptoms, and the patient is not in heart failure. The patient's LVEF is 40%, which is relatively preserved, and the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG reduces the risk of sudden cardiac death. The patient's medication regimen, including beta blockers, ACE inhibitors, and statins, is also well-managed for cardiovascular risk factors. While the patient has a history of myocardial infarction, the patient's current biomarkers (Troponin 0.01 ng/mL) are within normal limits, indicating no acute myocardial injury. The patient's renal function is also relatively preserved (creatinine 88.0 mol/L). Overall, the patient's clinical profile suggests a relatively stable cardiovascular condition, with a good response to medication, making a survivor the most likely outcome.

2. Pump failure death
REASONING: 
The patient's LVEF is 40%, which is significantly reduced, indicating left ventricular dysfunction. This could potentially lead to heart failure, especially given the patient's history of ischemic dilated cardiomyopathy. The patient's elevated creatinine level (88.0 mol/L) also suggests some degree of renal impairment, which could be related to cardiac dysfunction. Additionally, the patient's NYHA class is II, indicating mild symptoms, but the patient's biomarkers (Troponin 0.01 ng/mL) are not elevated, but the patient's overall clinical profile and ECG findings do not provide a clear indication of acute cardiac stress. While the patient's medication regimen is well-managed, the patient's underlying cardiac condition and reduced LVEF make pump failure death a plausible outcome.

3. Sudden cardiac death
REASONING: 
The patient's ECG findings of ventricular extrasystole and polymorphic ventricular extrasystole are concerning for arrhythmia. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG reduces the risk of sudden cardiac death. While the patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of arrhythmias, the patient's current biomarkers (Troponin 0.01 ng/mL) are within normal limits, and the patient's medication regimen is well-managed for cardiovascular risk factors. Additionally, the patient's renal function is relatively preserved, which reduces the risk of electrolyte imbalances that can contribute to arrhythmias. Overall, while the patient's ECG findings are concerning, the absence of other risk factors for sudden cardiac death makes this outcome less likely."
230,230,P0384,"Age: 71
Gender: Male 
Weight: 91 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 185/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 107.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,25
Sodium (mEq/L): 142.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,72
Urea (mg/dL): 7,82
LVEF (%): 28.0
Medications: Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and LVEF of 28% indicate a significant impairment of cardiac function, suggesting a high risk of cardiac complications. However, the patient's hemoglobin level of 107 g/L is within the normal range, and the absence of elevated troponin levels (0.03 ng/mL) suggests that there is no acute myocardial infarction. The patient's ECG shows ventricular extrasystole, which is a benign finding. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia codes also reduces the risk of sudden cardiac death.

The patient's past medical history of ischemic dilated cardiomyopathy, dyslipidemia, and hypertension increases the risk of cardiac complications, but the presence of medications such as loop diuretics and statins suggests that these conditions are being managed. The patient's albumin level of 44 g/L is slightly below the normal range, which may indicate some degree of malnutrition or fluid overload. However, this finding is not severe enough to significantly impact the overall prognosis.

Considering these factors, the patient's overall risk of cardiac complications, including sudden cardiac death, is moderate. However, the absence of significant risk factors and the presence of medications that manage the patient's underlying conditions suggest that the patient is likely to survive for the next few years. Therefore, the most likely outcome is survivor.

RANKING: 2. Pump failure death
REASONING: 

The patient's LVEF of 28% indicates a significant impairment of cardiac function, which increases the risk of pump failure. The patient's NYHA Class II also suggests that the patient experiences symptoms of heart failure, such as shortness of breath or fatigue, which can lead to pump failure.

The patient's past medical history of ischemic dilated cardiomyopathy and hypertension increases the risk of cardiac complications, including pump failure. The patient's elevated creatinine level of 71.0 mmol/L may also indicate some degree of renal impairment, which can be a complication of heart failure.

While the patient is taking medications such as loop diuretics, which are used to manage fluid overload and improve symptoms of heart failure, the patient's LVEF of 28% suggests that the patient's cardiac function is not well-compensated, and pump failure is a possible outcome.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's LVEF of 28% and NYHA Class II indicate a high risk of cardiac complications, including sudden cardiac death. The patient's past medical history of ischemic dilated cardiomyopathy and hypertension increases the risk of cardiac arrhythmias, which can lead to sudden cardiac death.

The patient's ECG shows ventricular extrasystole, which is a benign finding, but the patient's LVEF of 28% suggests that the patient's cardiac function is not well-compensated, and the presence of ventricular extrasystole may be a sign of underlying cardiac stress. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia codes reduces the risk of sudden cardiac death, but the patient's overall risk of cardiac complications remains moderate.

Overall, while the patient's risk of pump failure death is higher than sudden cardiac death, the patient's overall risk of cardiac complications, including sudden cardiac death, is still significant, and the patient's survival is not guaranteed."
231,231,P0386,"Age: 52
Gender: Female 
Weight: 69 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 108.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,3
LDL (mmol/L): 4,24
Sodium (mEq/L): 138.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 22
Troponin (ng/mL): 0,005
TSH (mIU/L): 3,45
Urea (mg/dL): 7,99
LVEF (%): 45.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is a 52-year-old female with a history of idiopathic dilated cardiomyopathy (IDC), which is a significant risk factor for adverse outcomes. However, her current NYHA class is II, indicating that she has some symptoms but is still able to perform daily activities with some limitation. Her LVEF is 45%, which is below the normal range, but not severely impaired.

Despite her compromised cardiac function, her blood pressure is well-controlled, and her electrolyte levels are within normal limits. Her troponin level is also within normal limits, suggesting that there is no significant myocardial damage.

The patient is on multiple medications, including amiodarone, beta blockers, loop diuretics, and ACE inhibitors, which are commonly used to manage IDC. The ECG findings show no signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are both significant predictors of adverse outcomes.

The patient's hemoglobin level is slightly elevated, which may be related to her medication regimen. However, her TSH level is normal, and there is no indication of thyroid dysfunction.

Given these factors, I believe that the patient is at low risk for sudden cardiac death and pump failure in the next few years. Her compromised cardiac function is likely to continue to progress, but with optimal medical management, she is likely to survive for several years. Therefore, I rank the patient as a survivor.

The other two prognoses, sudden cardiac death and pump failure, are less likely due to the following reasons:

- Sudden cardiac death is unlikely due to the absence of any ECG findings suggestive of ventricular tachycardia or non-sustained ventricular tachycardia.
- Pump failure is unlikely due to the patient's relatively well-controlled blood pressure and normal electrolyte levels, as well as the effectiveness of her current medication regimen. However, it is still possible that her cardiac function will continue to decline, and she may require further medical interventions in the future.

It is essential to closely monitor the patient's cardiac function and adjust her medication regimen as needed to minimize the risk of adverse outcomes."
232,232,P0387,"Age: 37
Gender: Male 
Weight: 110 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 125/95 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,49
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 577.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 27
Troponin (ng/mL): 0,03
TSH (mIU/L): 5,15
Urea (mg/dL): 9,15
LVEF (%): 50.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a relatively stable condition. The patient's NYHA Class II indicates mild symptoms, which is consistent with a manageable disease burden. The LVEF of 50% is a significant reduction in left ventricular function, but it is not catastrophic. The patient's blood pressure is well-controlled, and the absence of ventricular tachycardia or bradycardia on the ECG is a positive sign. The presence of a slightly elevated Pro-BNP level may indicate some degree of ventricular stress, but it is not excessively high. The patient's medication regimen includes beta blockers, digoxin, and ACE inhibitors, which are all standard treatments for heart failure and hypertension. The patient's laboratory results, including normal kidney function and low urea levels, suggest that the patient's kidney function is not significantly compromised. Overall, the patient's clinical presentation and test results suggest that the patient is likely to survive for the next few years with proper management and monitoring."
233,233,P0388,"Age: 58
Gender: Female 
Weight: 87 kg
Height: 149 cm
NYHA Class: II
Blood Pressure: 155/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 17,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,15
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 881.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 11
Troponin (ng/mL): 0,05
TSH (mIU/L): 2,19
Urea (mg/dL): 6,99
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a history of multiple comorbid conditions, including hypertension, cardiomyopathy, diabetes, and peripheral vascular disease, which may indicate a higher risk for cardiovascular events. However, the patient's current NYHA Class II classification suggests that their symptoms are not severe enough to limit their physical activity. The patient's LVEF of 65% is also within the normal range, indicating that their heart function is not severely impaired.

The patient's laboratory results show elevated levels of Pro-BNP (881 ng/L), which suggests that the patient is experiencing some degree of heart failure. However, the Troponin level of 0.05 ng/mL is within the normal range, indicating that there is no significant myocardial damage.

The patient's ECG results show ventricular extrasystoles, which are a common finding in patients with hypertension and cardiomyopathy. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient is not at high risk for sudden cardiac death.

The patient is taking a range of medications, including calcium channel blockers, diabetes medications, angiotensin II receptor blockers, loop diuretics, statins, and nitrovasodilators, which suggests that the patient is receiving comprehensive management for their cardiovascular conditions.

Overall, considering the patient's comorbid conditions, laboratory results, and ECG findings, the most likely outcome is that the patient will survive the next few years with careful management and monitoring."
234,234,P0389,"Age: 52
Gender: Male 
Weight: 90 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 135/100 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,63
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 315.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,73
Urea (mg/dL): 8,65
LVEF (%): 45.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient's data suggests a significant cardiac dysfunction, with a left ventricular ejection fraction (LVEF) of 45%, indicating mild to moderate systolic dysfunction. The patient has a history of hypertensive cardiomyopathy and hypertension, which likely contributed to the development of cardiac dysfunction. The elevated creatinine level (115.0 mmol/L) suggests some degree of renal impairment, which may be related to cardiac dysfunction.

The patient's ECG findings, including ventricular extrasystole, are concerning for arrhythmias, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the likelihood of sudden cardiac death. The presence of paroxysmal supraventricular tachyarrhythmia is unknown, which may be a concern, but it is not a primary cause for concern at this time.

The patient is on beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and hypertension. However, the patient's LVEF is not significantly improved, suggesting that the current treatment regimen may not be fully effective.

Given the patient's age, NYHA class II status, and the presence of cardiac dysfunction, pump failure death is a plausible outcome. However, the patient's current ECG findings and treatment regimen suggest that sudden cardiac death is less likely than pump failure death.

Therefore, the most likely outcome is pump failure death, followed by sudden cardiac death, and finally, survivor."
235,235,P0392,"Age: 48
Gender: Female 
Weight: 60 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 3,5
LDL (mmol/L): 3,39
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 768.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 7,85
Urea (mg/dL): 8,15
LVEF (%): 48.0
Medications: Amiodarone, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results suggest a relatively stable cardiovascular condition. The patient's NYHA Class II indicates a moderate level of heart failure symptoms, but they are still able to perform daily activities without significant limitations. The patient's LVEF of 48.0 is mildly reduced, but not severely impaired. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG also reduces the risk of sudden cardiac death. Furthermore, the patient's serum troponin level is within normal limits, indicating no significant myocardial damage. Additionally, the patient's biomarkers for liver and kidney function are also within normal limits. Given these factors, the patient's overall prognosis is relatively favorable, and they are more likely to survive in the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient's cardiovascular condition is not ideal, the absence of any significant arrhythmias and normal serum troponin levels reduce the risk of sudden cardiac death. However, the patient's valvular cardiomyopathy and hypertension may still pose a risk for cardiac events. The patient's LVEF is mildly reduced, which may indicate some degree of left ventricular dysfunction. Additionally, the patient's elevated creatinine level (97.0 mmol/L) suggests some degree of renal impairment, which may be related to their cardiovascular disease. While not the most likely outcome, there is still a possibility of sudden cardiac death, particularly if the patient's cardiovascular condition worsens or if they experience a cardiac event.

RANKING: 3. Pump Failure Death
REASONING: The patient's mildly reduced LVEF and elevated creatinine level suggest some degree of left ventricular dysfunction and renal impairment, which could potentially lead to heart failure. However, the patient's NYHA Class II and absence of significant arrhythmias reduce the likelihood of sudden cardiac death. Additionally, the patient's serum troponin level is within normal limits, indicating no significant myocardial damage. While pump failure is a possible outcome, it is less likely compared to sudden cardiac death, given the patient's relatively stable cardiovascular condition and the absence of significant risk factors for severe heart failure."
236,236,P0395,"Age: 70
Gender: Male 
Weight: 73 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 40
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 107
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 329.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,03
Urea (mg/dL): 9,48
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 70-year-old male with a history of idiopathic dilated cardiomyopathy, dyslipemia, and elevated BNP levels (329.0 ng/L), which suggests heart failure. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 27.0%, indicating poor cardiac function. 

The patient is also taking medications that are commonly used to manage heart failure, such as beta blockers, digoxin, and loop diuretics, which suggests that the patient's condition is being actively managed. However, the patient's elevated troponin levels (0.03 ng/mL) and elevated creatinine levels (9.48 mg/dL) indicate some degree of cardiac and renal impairment.

The patient's ECG findings of ventricular extrasystole are concerning, as they may indicate electrical instability in the heart. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests that the patient is not currently experiencing life-threatening arrhythmias.

Given the patient's overall clinical presentation, medical history, and laboratory results, the most likely prognosis for the next few years is that the patient will survive. The patient's elevated BNP levels and reduced LVEF suggest that the patient is at risk for further decline in cardiac function, but the fact that the patient is currently being managed with standard therapies and is not experiencing acute complications suggests that the patient is likely to survive in the short-term.

While there is a risk of sudden cardiac death, the patient's ECG findings do not suggest an immediate life-threatening arrhythmia, and the patient's medications and medical history do not indicate a high risk of sudden cardiac death. Pump failure death is also a possibility, but the patient's current management and lack of acute complications suggest that the patient is likely to survive with appropriate treatment.

Therefore, based on the available data, the most likely prognosis is that the patient will survive, with a moderate risk of further decline in cardiac function and potential for complications such as heart failure exacerbation or arrhythmias."
237,237,P0398,"Age: 72
Gender: Male 
Weight: 77 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,18
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,84
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 551.0
Protein (g/L): 63
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,78
Urea (mg/dL): 6,99
LVEF (%): 27.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to several factors:

1. Age: Although the patient is 72 years old, which is considered elderly, the age alone is not a strong predictor of mortality. However, the presence of other comorbidities and the patient's current health status may influence the outcome.

2. NYHA Class II: This indicates that the patient has mild symptoms of heart failure, but it does not necessarily imply a poor prognosis. With proper management, patients with NYHA Class II heart failure can lead active lives.

3. Medications: The patient is taking beta blockers, statins, and an ACE inhibitor, which are standard treatments for managing heart failure, hypertension, and high cholesterol. These medications can help improve symptoms, slow disease progression, and reduce the risk of adverse events.

4. Blood tests: The patient's liver function tests (ALT, AST, and gamma-glutamil transpeptidase) are within normal limits, indicating no significant liver damage. The elevated creatinine level may suggest some degree of kidney impairment, but it is not uncommon in elderly patients.

5. Electrocardiogram (ECG) results: The presence of ventricular extrasystole, non-sustained VT, and paroxysmal AF may indicate arrhythmias, but the patient is not experiencing any symptoms or significant ECG abnormalities that would necessitate immediate intervention.

6. Pro-BNP levels: Elevated Pro-BNP levels are associated with heart failure, but in this case, the level is not excessively high, suggesting that the patient may not be experiencing severe heart failure.

7. Troponin levels: The slightly elevated troponin level may indicate some degree of myocardial damage, but it is not significantly elevated, which suggests that the patient is not experiencing a myocardial infarction.

Considering these factors, the patient's overall health status and current treatment plan suggest that he is likely to survive for the next few years with proper management and monitoring.

RANKING: 2. Sudden Cardiac Death
REASONING: 

This patient's prognosis is ranked as sudden cardiac death due to the presence of several factors that increase the risk of arrhythmias and sudden cardiac death:

1. Age: As mentioned earlier, the patient's age is a risk factor for sudden cardiac death.

2. NYHA Class II: The patient's heart failure symptoms may indicate some degree of cardiac dysfunction, which can increase the risk of arrhythmias.

3. ECG results: The presence of ventricular extrasystole, non-sustained VT, and paroxysmal AF increases the risk of arrhythmias.

4. Medications: The patient is taking beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure, hypertension, and high cholesterol. However, these medications may not be sufficient to completely eliminate the risk of arrhythmias.

5. Pro-BNP levels: Elevated Pro-BNP levels may indicate some degree of heart failure, which can increase the risk of arrhythmias.

6. Troponin levels: The slightly elevated troponin level may indicate some degree of myocardial damage, which can increase the risk of arrhythmias.

Considering these factors, the patient's risk of sudden cardiac death is increased, but it is still possible that he may not experience a sudden cardiac death in the next few years with proper management and monitoring.

RANKING: 3. Pump Failure Death
REASONING: 

This patient's prognosis is ranked as pump failure death due to the presence of several factors that increase the risk of heart failure progression:

1. Age: The patient's age is a risk factor for heart failure progression.

2. NYHA Class II: The patient's heart failure symptoms indicate some degree of cardiac dysfunction, which can increase the risk of heart failure progression.

3. ECG results: The presence of ventricular extrasystole, non-sustained VT, and paroxysmal AF increases the risk of arrhythmias, which can contribute to heart failure progression.

4. Medications: The patient is taking beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure, hypertension, and high cholesterol. However, these medications may not be sufficient to completely manage the patient's heart failure.

5. Pro-BNP levels: Elevated Pro-BNP levels may indicate some degree of heart failure, which can increase the risk of heart failure progression.

6. Creatinine level: The elevated creatinine level may indicate some degree of kidney impairment, which can contribute to heart failure progression.

Considering these factors, the patient's risk of pump failure death is increased, and it is likely that he will experience some degree of heart failure progression in the next few years if his condition is not adequately managed.

Note: The patient's prognosis is not extremely poor,"
238,238,P0399,"Age: 56
Gender: Male 
Weight: 68 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 130/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1192.0
Protein (g/L): 72
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 7,82
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient has a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which suggests a compromised cardiac function. The LVEF of 20.0% indicates significant left ventricular dysfunction. The patient is also on medications that are commonly used to manage heart failure and prevent further cardiac events.

Despite the presence of elevated troponin levels, which may indicate some degree of myocardial damage, the patient does not have any acute cardiac events such as ventricular tachycardia or non-sustained ventricular tachycardia. The absence of these events suggests that the patient's cardiac function is currently stable.

The patient's blood tests show elevated creatinine levels, which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's hemoglobin and electrolyte levels are within normal limits, and the liver enzymes are not significantly elevated.

The presence of elevated Pro-BNP levels is consistent with heart failure, but this is not uncommon in patients with significant cardiac dysfunction. The patient's ECG impression does not show any signs of arrhythmias that would increase the risk of sudden cardiac death.

Overall, considering the patient's history, medication regimen, and the absence of acute cardiac events, the most likely outcome is that the patient will survive in the next few years. While there is a risk of cardiac events, the patient's current condition does not suggest an imminent risk of sudden cardiac death or pump failure.

However, it's essential to note that this is a long-term prediction, and the patient's condition can change over time. Regular follow-up and monitoring will be crucial to assess the patient's cardiac function and adjust the treatment plan accordingly."
239,239,P0400,"Age: 58
Gender: Male 
Weight: 82 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 95/63 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,91
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 867.0
Protein (g/L): 67
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,17
Urea (mg/dL): 10,15
LVEF (%): 35.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

This patient has a high risk of mortality due to his history of ischemic dilated cardiomyopathy and myocardial infarction, which are significant risk factors for cardiac events. However, the patient's NYHA class is II, indicating some limitation of physical activity, but not severe. The patient's current medications, including beta blockers, statins, and ACE inhibitors, suggest a reasonable management plan for his condition. 

The elevated Pro-BNP level (867 ng/L) indicates a significant burden of heart failure, but the patient's LVEF (35%) is also low, which is consistent with heart failure. The patient's low hemoglobin level (119 g/L) may be related to anemia, which is a common comorbidity in patients with heart failure.

The absence of ventricular tachycardia and bradycardia on the ECG suggests that the patient's heart rhythm is relatively stable. The presence of monomorphic ventricular extrasystoles is concerning, but it is not uncommon in patients with heart failure.

Given these factors, the patient is likely to survive for the next few years, but his prognosis is still guarded due to his underlying cardiac conditions.

RANKING: 
2. Sudden Cardiac Death
REASONING: 

The patient's history of myocardial infarction and ischemic dilated cardiomyopathy puts him at high risk for sudden cardiac death. The patient's low LVEF (35%) and elevated Pro-BNP level (867 ng/L) indicate significant heart failure, which can lead to arrhythmias and sudden cardiac death.

The patient's elevated Troponin level (0.01 ng/mL) is also concerning, as it may indicate some myocardial injury. The absence of ventricular tachycardia and bradycardia on the ECG does not rule out the possibility of sudden cardiac death.

RANKING: 
3. Pump Failure Death
REASONING: 

The patient's heart failure status, indicated by his low LVEF (35%) and elevated Pro-BNP level (867 ng/L), makes pump failure a significant concern. However, the patient is currently receiving medications to manage his heart failure, including beta blockers, statins, and ACE inhibitors.

The patient's hemoglobin level (119 g/L) is low, which may be related to anemia, a common comorbidity in patients with heart failure. The absence of ventricular tachycardia and bradycardia on the ECG suggests that the patient's heart rhythm is relatively stable.

Given the patient's heart failure status and the presence of anemia, pump failure is a possible outcome, but it is not the most likely outcome given the patient's current management plan and the absence of severe arrhythmias."
240,240,P0401,"Age: 54
Gender: Male 
Weight: 72 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 113/66 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 82
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,03
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 47.0
Protein (g/L): 69
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,42
Urea (mg/dL): 6,82
LVEF (%): 43.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is most likely to be a survivor due to the following factors:

1. The patient's age, 54, is not considered elderly, and many patients with idiopathic dilated cardiomyopathy (IDC) can survive for many years with proper treatment.
2. The patient's left ventricular ejection fraction (LVEF) is 43%, which is a relatively preserved value. Although it's below the normal range, it's not extremely low, indicating that the patient's heart is still pumping some blood effectively.
3. The patient's medication regimen, including beta blockers, loop diuretics, statins, and ACE inhibitors, is well-established and targeted at managing the patient's heart failure, high blood pressure, and dyslipidemia.
4. The patient's laboratory results, such as normal creatinine and urea levels, and relatively normal liver enzymes (ALT and AST), suggest that the patient's kidney function and liver function are preserved.
5. The patient's ECG findings, while indicating some arrhythmias, do not suggest a high risk of sudden cardiac death.

However, the patient's NYHA Class II classification indicates that the patient has some symptoms of heart failure, and the presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a concern. Despite this, the overall clinical picture suggests that the patient is likely to survive for the next few years with proper management.

RANKING: 2. Sudden Cardiac Death
REASONING: 

This patient's prognosis is less likely to be a survivor due to the following factors:

1. The patient's NYHA Class II classification indicates that the patient has some symptoms of heart failure, which increases the risk of sudden cardiac death.
2. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a significant concern, as it can be a predictor of sudden cardiac death.
3. The patient's LVEF is 43%, which is below the normal range, indicating some degree of left ventricular dysfunction.

RANKING: 3. Pump Failure Death
REASONING: 

This patient's prognosis is least likely to be a survivor due to the following factors:

1. The patient's LVEF is 43%, which is a relatively preserved value, indicating that the patient's heart is still pumping some blood effectively.
2. The patient's NYHA Class II classification indicates that the patient has some symptoms of heart failure, but not severe symptoms that would indicate pump failure.
3. The patient's medication regimen, including beta blockers, loop diuretics, statins, and ACE inhibitors, is well-established and targeted at managing the patient's heart failure and other comorbidities.

However, the patient's ECG findings, including NSVT and ventricular extrasystole, suggest a higher risk of arrhythmias, which can lead to sudden cardiac death or pump failure."
241,241,P0402,"Age: 50
Gender: Male 
Weight: 75 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 42.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 7,21
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 160.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 708.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,07
Urea (mg/dL): 7,32
LVEF (%): 36.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to the following factors:

1. The patient's LVEF (Left Ventricular Ejection Fraction) is 36.0%, which is within the range of 30-40% and indicates severe left ventricular dysfunction, but not severely impaired. This suggests that the patient's heart is still pumping blood effectively, albeit inefficiently.

2. The patient has a relatively stable hemoglobin level (160.0 g/L), which indicates that the patient is not experiencing significant anemia, a common complication in patients with heart failure.

3. The patient's troponin level is 0.005 ng/mL, which is within the normal range, indicating that there is no significant myocardial damage or necrosis.

4. The patient is on medications that are commonly used to manage heart failure, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which suggests that the patient's condition is being actively managed.

5. The patient's ECG impression does not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other life-threatening arrhythmias, which suggests that the patient's heart rhythm is stable.

While the patient has idiopathic dilated cardiomyopathy and a low LVEF, the overall clinical presentation and laboratory results suggest that the patient is currently stable and can be expected to survive in the short term.

RANKING: 2. Sudden cardiac death
REASONING: 

This patient's prognosis is ranked as sudden cardiac death due to the following factors:

1. The patient's LVEF is severely impaired at 36.0%, which indicates that the patient's heart is not pumping blood efficiently.

2. The patient's elevated creatinine level (106.0 mmol/L) suggests that the patient may have some degree of renal impairment, which can be a complication of heart failure.

3. The patient's low albumin level (45 g/L) suggests that the patient may have some degree of edema or fluid overload, which can be a complication of heart failure.

4. The patient's elevated pro-BNP level (708.0 ng/L) suggests that the patient is experiencing significant ventricular stress and may be at risk for sudden cardiac death.

5. The patient's ECG impression shows ventricular extrasystoles, which can be a precursor to more serious arrhythmias.

While the patient is currently stable, the combination of severe left ventricular dysfunction, renal impairment, and elevated pro-BNP levels suggests that the patient is at risk for sudden cardiac death in the short term.

RANKING: 3. Pump failure death
REASONING: 

This patient's prognosis is ranked as pump failure death due to the following factors:

1. The patient's LVEF is severely impaired at 36.0%, which indicates that the patient's heart is not pumping blood efficiently.

2. The patient's elevated creatinine level (106.0 mmol/L) suggests that the patient may have some degree of renal impairment, which can be a complication of heart failure.

3. The patient's elevated pro-BNP level (708.0 ng/L) suggests that the patient is experiencing significant ventricular stress and may be at risk for pump failure.

4. The patient's low albumin level (45 g/L) suggests that the patient may have some degree of edema or fluid overload, which can be a complication of heart failure.

5. The patient's ECG impression shows ventricular extrasystoles, which can be a precursor to more serious arrhythmias and pump failure.

While the patient is currently stable, the combination of severe left ventricular dysfunction, renal impairment, and elevated pro-BNP levels suggests that the patient is at risk for pump failure in the short term, which can be fatal."
242,242,P0404,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 135/84 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 256.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,54
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1858.0
Protein (g/L): 69
T4 (ng/L): 15
TSH (mIU/L): 0,6
Urea (mg/dL): 13,48
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's age, NYHA Class II, and LVEF of 20%, the patient is at a high risk for adverse outcomes. However, the presence of multiple comorbidities such as ischemic dilated cardiomyopathy, hypertension, and dyslipidemia suggests a compromised cardiac function. The elevated creatinine level (256.0 mmol/L) also indicates renal impairment, which can further compromise cardiac function.

The patient's ECG impression reveals ventricular extrasystole and non-sustained ventricular tachycardia, which are indicative of an increased risk of arrhythmias. However, the absence of sustained ventricular tachycardia and bradycardia reduces the risk of sudden cardiac death.

Despite the patient's poor LVEF, the presence of beta blockers, calcium channel blockers, and loop diuretics suggests that the patient is receiving optimal medical therapy for their heart failure symptoms. The elevated Pro-BNP level (1858.0 ng/L) is also consistent with heart failure.

Considering these factors, I believe that the patient is most likely to survive for the next few years, albeit with ongoing management of their heart failure and arrhythmias. 

RANKING 2: 
Sudden cardiac death
REASONING: 
The patient's LVEF of 20% is significantly below the normal range, indicating severe left ventricular dysfunction. The presence of ischemic dilated cardiomyopathy, hypertension, and dyslipidemia further exacerbates the patient's cardiac risk. The elevated creatinine level and elevated Pro-BNP level suggest a compromised cardiac function, which increases the risk of arrhythmias and sudden cardiac death.

RANKING 3: 
Pump failure death
REASONING: 
While the patient's LVEF is severely impaired, the presence of beta blockers, calcium channel blockers, and loop diuretics suggests that the patient is receiving optimal medical therapy for their heart failure symptoms. The absence of sustained ventricular tachycardia and bradycardia on the ECG reduces the risk of sudden cardiac death.

However, the patient's elevated creatinine level and Pro-BNP level indicate a compromised cardiac function, which increases the risk of pump failure. While the patient is receiving optimal medical therapy, the combination of severe left ventricular dysfunction, renal impairment, and elevated Pro-BNP level suggests that the patient is at high risk for pump failure."
243,243,P0406,"Age: 55
Gender: Male 
Weight: 95 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 106
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,77
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 162.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,29
Urea (mg/dL): 5,83
LVEF (%): 22.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 

Based on the provided patient data, I would rank the patient as having a high likelihood of survival. The patient's age of 55 is not extremely high, and their NYHA class is II, indicating mild symptoms. Their LVEF of 22.0 is significantly reduced, but it's not uncommon in patients with idiopathic dilated cardiomyopathy. The patient is also on multiple medications, including beta blockers, loop diuretics, and an ACE inhibitor, which are commonly used to manage heart failure symptoms and slow the progression of the disease.

The patient's biomarkers, such as troponin and creatinine, are not excessively elevated, suggesting that the patient's cardiac function is not severely compromised at this point. Additionally, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG reduces the risk of sudden cardiac death.

While the patient's albumin level is slightly low, and their total cholesterol and LDL levels are elevated, these factors do not seem to be life-threatening in this context. The patient's hemoglobin level is within a relatively normal range, and their kidney function, as indicated by the creatinine level, is not severely impaired.

Overall, considering these factors, I believe the patient has a reasonable chance of survival, making ""survivor"" the most likely prognosis.

RANKING: 
2. Sudden cardiac death 
REASONING: 

Although the patient's LVEF is significantly reduced, the patient is on multiple medications that are designed to manage heart failure and slow disease progression. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG reduces the risk of sudden cardiac death.

However, the patient's age, NYHA class, and reduced LVEF do increase the risk of sudden cardiac death. The patient's ventricular extrasystole, although polymorphic, is not necessarily a contraindication for survival, but it does indicate some level of cardiac instability.

Additionally, the patient's elevated creatinine level and low T3 level suggest that the patient's heart is under significant strain, which may increase the risk of sudden cardiac death.

Considering these factors, I would rank the patient as having a moderate likelihood of sudden cardiac death.

RANKING: 
3. Pump failure death 
REASONING: 

Given the patient's reduced LVEF, elevated creatinine level, and ventricular extrasystole, I would rank the patient as having a low likelihood of pump failure death. The patient is already on multiple medications that are designed to manage heart failure, and their NYHA class is II, indicating mild symptoms.

However, the patient's reduced LVEF and elevated creatinine level suggest that their cardiac function is compromised, which increases the risk of pump failure. Additionally, the patient's ventricular extrasystole is a sign of cardiac instability, which may lead to pump failure.

While the patient's biomarkers are not excessively elevated, the combination of these factors makes me cautious about the patient's overall prognosis. However, considering the patient's age, NYHA class, and the presence of ventricular extrasystole, I believe pump failure death is the least likely of the three prognoses."
244,244,P0407,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 110/65 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia
Albumin (g/L): 38
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 300
Glucose (mmol/L): 5
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,04
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1733.0
Protein (g/L): 72
T3 (pg/dL): 0,02
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 8,32
LVEF (%): 26.0
Medications: Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient's age is 76, which is a significant risk factor for cardiac mortality. However, the patient's NYHA Class III indicates that they have severe heart failure, which is a strong predictor of mortality. Despite this, the patient's LVEF is only 26%, which suggests that the heart is not functioning optimally. However, the patient's troponin level is normal, which suggests that there is no significant myocardial damage.

The patient's biomarkers, such as creatinine, urea, and BNP, are elevated, indicating kidney dysfunction and fluid overload, which are common in heart failure patients. The patient's lipid profile is also suboptimal, with high triglycerides and low HDL. However, the patient is taking statins, which should help to manage cholesterol levels.

The ECG results show ventricular extrasystoles, which are a type of arrhythmia that can increase the risk of cardiac mortality. However, the patient's ECG is not indicative of any other significant arrhythmias.

Given these factors, I believe that the patient is at high risk for cardiac mortality, but not extremely high. The patient's overall condition is severe, but not catastrophic. Therefore, I rank the patient as a survivor.

2. Sudden cardiac death
REASONING:
The patient's age is a significant risk factor for cardiac mortality, and the patient's NYHA Class III indicates that they have severe heart failure. The patient's LVEF is also significantly reduced, which suggests that the heart is not functioning optimally.

The patient's biomarkers, such as creatinine, urea, and BNP, are elevated, indicating kidney dysfunction and fluid overload, which are common in heart failure patients. The patient's lipid profile is also suboptimal, with high triglycerides and low HDL.

The ECG results show ventricular extrasystoles, which are a type of arrhythmia that can increase the risk of cardiac mortality. However, the patient's ECG is not indicative of any other significant arrhythmias.

Given these factors, I believe that the patient is at moderate risk for cardiac mortality, but not extremely high. The patient's overall condition is severe, but not catastrophic. Therefore, I rank the patient as a possible candidate for sudden cardiac death.

3. Pump failure death
REASONING:
The patient's NYHA Class III indicates that they have severe heart failure, which is a strong predictor of mortality. The patient's LVEF is also significantly reduced, which suggests that the heart is not functioning optimally.

The patient's biomarkers, such as creatinine, urea, and BNP, are elevated, indicating kidney dysfunction and fluid overload, which are common in heart failure patients. The patient's lipid profile is also suboptimal, with high triglycerides and low HDL.

The ECG results show ventricular extrasystoles, which are a type of arrhythmia that can increase the risk of cardiac mortality. However, the patient's ECG is not indicative of any other significant arrhythmias.

Given these factors, I believe that the patient is at high risk for pump failure death, as the patient's heart is not functioning optimally and is likely to fail. However, I do not rank the patient as the most likely candidate for pump failure death, as the patient's troponin level is normal, which suggests that there is no significant myocardial damage."
245,245,P0408,"Age: 52
Gender: Female 
Weight: 64 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 13,9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,88
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 14.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,34
Urea (mg/dL): 4,66
LVEF (%): 52.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall health status is relatively stable, with a moderate level of physical activity (NYHA Class II), controlled hypertension, and well-managed comorbidities such as diabetes, dyslipidemia, and hypertension. The patient's laboratory results show relatively normal liver function, kidney function, and electrolyte levels. The ECG findings are also unremarkable, with no evidence of ventricular arrhythmias or significant cardiac ischemia.

However, the patient has a history of ischemic dilated cardiomyopathy, which is a significant underlying condition that can lead to cardiac dysfunction. The LVEF is low at 52%, indicating reduced cardiac function. Despite this, the patient's current medical regimen includes ACE inhibitors, which are often used to improve cardiac function in patients with heart failure.

Considering these factors, the most likely outcome for the patient over the next few years is survival. The patient's controlled comorbidities and well-managed medications suggest that they are at a relatively low risk for sudden cardiac death or pump failure. The patient's LVEF, while low, is not critically low, and the absence of ventricular arrhythmias on the ECG suggests that the patient is not at high risk for sudden cardiac death.

While the patient's history of myocardial infarction is a significant risk factor for future cardiac events, the fact that it occurred in the past and is not indicated as a recent event suggests that the patient has had time to recover and adapt to the condition. Overall, the patient's overall health status and medical regimen suggest that survival is the most likely outcome over the next few years."
246,246,P0411,"Age: 75
Gender: Male 
Weight: 70 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 100/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 81.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,04
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 859.0
Protein (g/L): 63
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,1
Urea (mg/dL): 9,32
LVEF (%): 25.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is 75 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and NYHA Class III heart failure. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 25%, indicating severe left ventricular dysfunction. Despite this, the patient's current blood pressure is relatively well-controlled at 100/65 mmHg, and the patient is on medications for heart failure management, including ACE inhibitors, beta blockers, and loop diuretics.

The patient's troponin level is within normal limits, and the ECG shows no evidence of ventricular tachycardia or non-sustained ventricular tachycardia. The patient's creatinine level is elevated at 9.32 mg/dL, indicating some degree of renal impairment, but this is not uncommon in patients with heart failure.

Given these factors, the patient's overall prognosis is likely to be a survivor. However, the patient's severe left ventricular dysfunction and elevated creatinine level suggest that the patient may require close monitoring and management to prevent further decline in cardiac function and kidney function.

The patient's age and NYHA Class III heart failure classification also increase the risk of adverse outcomes, but the patient's current medical management and lack of evidence of acute cardiac ischemia or arrhythmia on the ECG suggest that the patient is at lower risk for sudden cardiac death compared to pump failure death.

Sudden cardiac death is less likely due to the patient's stable vital signs, normal troponin level, and absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG.

Pump failure death is a possible outcome due to the patient's severe left ventricular dysfunction and elevated creatinine level, but the patient's current management and stable vital signs suggest that the patient is at lower risk for this outcome compared to sudden cardiac death."
247,247,P0412,"Age: 41
Gender: Male 
Weight: 80 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 115/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 36
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,12
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 286.0
Protein (g/L): 65
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,4
Urea (mg/dL): 6,16
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 41-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and dyslipidemia. The patient's current NYHA class is II, indicating moderate symptoms. The patient's LVEF is 40%, which is significantly reduced, indicating poor cardiac function.

The patient's ECG shows ventricular extrasystoles, which is a sign of ventricular arrhythmias. The patient is also on beta blockers, statins, and ACE inhibitors, which are standard treatments for heart failure and hypertension. However, the patient's elevated troponin levels (0.01 ng/mL) and Pro-BNP levels (286 ng/L) indicate some degree of cardiac stress and strain.

Despite these factors, the patient is currently on medications that are aimed at reducing symptoms and slowing disease progression. The patient's hemoglobin level is within the normal range, and the liver enzymes (ALT and AST) are also within normal limits. The patient's kidney function is slightly impaired, but this is not uncommon in patients with heart failure.

Given these factors, the patient is likely to survive the next few years with proper management and monitoring. The patient's reduced LVEF and the presence of ventricular extrasystoles suggest that the patient may require more aggressive management of their heart failure and arrhythmias, but with appropriate treatment, the patient can be expected to survive.

While there is a risk of sudden cardiac death, this is not the most likely outcome given the patient's current status. The patient's reduced LVEF and elevated troponin levels suggest that the patient is at risk of pump failure, but the patient is currently on medications that are aimed at reducing this risk.

Therefore, the most likely outcome is that the patient will survive the next few years with proper management and monitoring."
248,248,P0413,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 133/88 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 36,5
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 870.0
Protein (g/L): 67
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,72
Urea (mg/dL): 8,49
LVEF (%): 37.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's prognosis is ranked as a survivor due to several factors:

1. Age: The patient is 76 years old, which is considered advanced age, but not extremely old. However, age itself is not a strong predictor of outcome in patients with heart failure.

2. NYHA Class II: The patient's NYHA class is II, indicating mild symptoms of heart failure, which is a relatively mild stage. Patients with a lower NYHA class tend to have a better prognosis.

3. Medications: The patient is taking beta blockers and ACE inhibitors, which are standard treatments for heart failure and hypertension. These medications can help reduce symptoms and improve outcomes.

4. ECG Impression: While the patient has several arrhythmias, including ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia, the absence of a clear indication for cardiac resynchronization therapy (CRT) or implantable cardioverter-defibrillator (ICD) placement, and the fact that these arrhythmias are non-sustained, suggest that the patient's cardiac function is not severely compromised.

5. Biomarkers: The patient's BNP levels are elevated, indicating heart failure, but the Troponin levels are normal, suggesting that the patient does not have significant myocardial damage. The patient's kidney function is also impaired, but the urea level is not excessively high.

6. Laboratory values: The patient's laboratory values, such as creatinine and potassium levels, are not excessively abnormal.

Overall, considering these factors, the patient's prognosis is ranked as a survivor. However, close monitoring and regular follow-up with the cardiologist are essential to ensure that the patient's condition does not worsen over time.

RANKING: 2. Sudden cardiac death
REASONING:

This patient's prognosis is ranked as sudden cardiac death due to the following factors:

1. Age: The patient is 76 years old, which increases the risk of sudden cardiac death.

2. NYHA Class II: The patient's NYHA class is II, indicating mild symptoms of heart failure, but the presence of arrhythmias and elevated BNP levels suggests that the patient's cardiac function is compromised.

3. Medications: The patient is taking beta blockers and ACE inhibitors, which are standard treatments for heart failure and hypertension, but these medications may not be sufficient to prevent sudden cardiac death.

4. ECG Impression: The patient has several arrhythmias, including ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia, which increase the risk of sudden cardiac death.

5. Biomarkers: The patient's BNP levels are elevated, indicating heart failure, and the Troponin levels are normal, suggesting that the patient does not have significant myocardial damage.

6. Laboratory values: The patient's laboratory values, such as creatinine and potassium levels, are not excessively abnormal.

However, the patient's overall prognosis is ranked lower than survivor due to the presence of several arrhythmias and elevated BNP levels, which increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING:

This patient's prognosis is ranked as pump failure death due to the following factors:

1. Age: The patient is 76 years old, which increases the risk of pump failure.

2. NYHA Class II: The patient's NYHA class is II, indicating mild symptoms of heart failure, but the presence of arrhythmias and elevated BNP levels suggests that the patient's cardiac function is compromised.

3. Medications: The patient is taking beta blockers and ACE inhibitors, which are standard treatments for heart failure and hypertension, but these medications may not be sufficient to prevent pump failure.

4. ECG Impression: The patient has several arrhythmias, including ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia, which increase the risk of pump failure.

5. Biomarkers: The patient's BNP levels are elevated, indicating heart failure, and the Troponin levels are normal, suggesting that the patient does not have significant myocardial damage.

6. Laboratory values: The patient's laboratory values, such as creatinine and potassium levels, are not excessively abnormal.

However, the patient's overall prognosis is ranked lower than survivor due to the presence of several arrhythmias and elevated BNP levels, which increase the risk of pump failure. Additionally, the patient's LVEF is only 37%, which is significantly reduced, indicating severe left ventricular dysfunction."
249,249,P0414,"Age: 72
Gender: Male 
Weight: 74 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 112/78 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,04
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 161.0
Protein (g/L): 73
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,61
Urea (mg/dL): 9,15
LVEF (%): 45.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. However, the patient is currently on beta blockers, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. The patient's NYHA class is II, indicating mild heart failure symptoms, and the LVEF is 45%, which is significantly reduced but not severely impaired. The patient's creatinine level is elevated, indicating some degree of kidney impairment, but not severe. The patient's troponin level is normal, and the ECG shows non-sustained ventricular tachycardia and TPSV, but no signs of acute myocardial infarction. The patient's Pro-BNP level is elevated, but not excessively high, indicating some degree of heart failure symptoms. Overall, the patient's medical history, medications, and test results suggest that the patient is likely to survive the next few years with proper management and monitoring."
250,250,P0415,"Age: 28
Gender: Male 
Weight: 95 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 90/50 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 44
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5
LDL (mmol/L): 2,64
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 38.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,062
TSH (mIU/L): 1,97
Urea (mg/dL): 3,83
LVEF (%): 59.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING:

The patient's data indicates that they have a history of heart failure (NYHA Class II) and are on medications to manage their condition, including an Angiotensin II Receptor Blocker, Beta Blockers, and Digoxin. Their LVEF is 59.0%, which is relatively preserved, suggesting that their heart is still functioning to some extent.

Their laboratory values are also relatively stable, with no significant elevations in liver enzymes, creatinine, or troponin levels, which could indicate heart muscle damage. The patient's ECG impression shows no signs of ventricular tachycardia or bradycardia, which are common indicators of cardiac instability.

The patient's low albumin level (44 g/L) and slightly elevated creatinine level (3.83 mg/dL) may suggest some degree of kidney dysfunction, but this is not uncommon in patients with heart failure. The patient's low T3 level (0.04 pg/dL) could indicate hypothyroidism, but this is not directly related to the cardiac condition.

Given the patient's stable laboratory values, preserved LVEF, and absence of signs of cardiac instability, I believe that the most likely outcome for the next few years is that the patient will survive. The patient's past medical history and medications suggest that they are being well-managed, and their current condition does not indicate a high risk of sudden cardiac death or pump failure.

While there is always a risk of cardiac complications in patients with heart failure, the patient's data suggests that they are currently stable and at low risk of adverse outcomes. Therefore, I predict that the patient will survive for the next few years, provided they continue to receive proper management and follow-up care."
251,251,P0417,"Age: 45
Gender: Male 
Weight: 72 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 85
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,9
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 197.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,37
Urea (mg/dL): 6,82
LVEF (%): 38.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a history of dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. The patient's left ventricular ejection fraction (LVEF) is 38%, which is below the normal range, indicating systolic dysfunction. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG further increases the risk of arrhythmic events.

However, the patient is currently taking medications that are commonly used to manage heart failure and arrhythmias, such as beta blockers, loop diuretics, and ACE inhibitors. The patient's blood pressure is well-controlled at 110/70 mmHg, and the renal function is preserved, with a creatinine level of 6.82 mg/dL.

The patient's biomarkers, including troponin, TSH, and liver enzymes, are not indicative of acute myocardial infarction, kidney damage, or thyroid dysfunction. The low levels of albumin and elevated creatinine may suggest some degree of renal impairment, but this is not uncommon in patients with heart failure.

Considering the patient's age, medical history, and medication regimen, the most likely outcome is that the patient will survive for the next few years. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG does increase the risk of arrhythmic events, but the patient's overall clinical status and medication regimen suggest that these events are unlikely to be catastrophic.

RANKING: 2. Pump failure death
REASONING:

The patient's LVEF of 38% indicates systolic dysfunction, which increases the risk of heart failure. The patient's low albumin level (45 g/L) and elevated creatinine level (6.82 mg/dL) suggest some degree of renal impairment, which can exacerbate heart failure.

The patient's medication regimen is generally effective in managing heart failure, but the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG increases the risk of arrhythmic events. If these events occur, they could potentially lead to pump failure.

RANKING: 3. Sudden cardiac death
REASONING:

The patient's history of dilated cardiomyopathy, ventricular extrasystole, and non-sustained ventricular tachycardia on the ECG increase the risk of arrhythmic events, including sudden cardiac death. However, the patient's overall clinical status and medication regimen suggest that these events are unlikely to be catastrophic.

The patient's LVEF of 38% and low albumin level (45 g/L) increase the risk of heart failure, but the patient is currently taking medications that are effective in managing heart failure. The patient's renal function is also preserved, which reduces the risk of acute kidney injury.

While the patient's ECG findings are concerning, the patient's overall clinical status and medication regimen suggest that the risk of sudden cardiac death is lower than pump failure death. However, the patient's arrhythmic events should be closely monitored, and the patient should be considered for implantable cardioverter-defibrillator (ICD) therapy to reduce the risk of sudden cardiac death."
252,252,P0420,"Age: 82
Gender: Female 
Weight: 64 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,34
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 616.0
Protein (g/L): 82
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,91
Urea (mg/dL): 11,65
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is 82 years old, with a history of hypertensive cardiomyopathy and hypertension. The patient's NYHA Class is II, indicating some limitation in physical activity. The patient's LVEF is significantly reduced at 38%, indicating left ventricular dysfunction.

The patient's ECG impression shows non-sustained ventricular tachycardia and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. However, the patient is also taking medications such as a calcium channel blocker, spironolactone, and nitrovasodilator, which are commonly used to manage hypertension and heart failure.

The patient's elevated creatinine level (141.0 mmol/L) and low LVEF (38.0%) suggest that the patient may be at risk for pump failure. However, the patient's hemoglobin level is normal, and the patient is not taking any medications that are commonly associated with pump failure.

Given the patient's age, medical history, and ECG findings, the most likely outcome is that the patient will survive. The patient's low T3 level (0.03 pg/dL) and high Pro-BNP level (616.0 ng/L) suggest that the patient may be experiencing some degree of cardiac stress, but this is not necessarily a contraindication for survival.

Therefore, based on the available data, I predict that the patient will survive over the next few years, but with a high risk of cardiac events, including sudden cardiac death and pump failure. Regular monitoring and adjustment of medications may be necessary to mitigate these risks."
253,253,P0421,"Age: 58
Gender: Male 
Weight: 90 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 11,1
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 509.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,5
Urea (mg/dL): 4,99
LVEF (%): 34.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a complex medical history, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and a history of myocardial infarction. However, the patient's current ECG findings, such as ventricular extrasystole and non-sustained ventricular tachycardia, suggest a high risk for arrhythmic events. Despite this, the patient's current medication regimen, including beta blockers and ACE inhibitors, which are commonly used to manage cardiovascular risk factors and heart failure, suggests that the patient is being adequately managed for his underlying conditions.

The patient's LVEF (left ventricular ejection fraction) is 34.0%, which is significantly below the normal range, indicating reduced cardiac function. However, the patient's current medication regimen and the absence of severe symptoms suggest that the patient is not in acute heart failure. The patient's biomarkers, such as troponin and BNP, are also not significantly elevated, suggesting that the patient is not experiencing acute cardiac stress.

Given the patient's complex medical history, the presence of ventricular extrasystole and non-sustained ventricular tachycardia on ECG, and the patient's current medication regimen, the most likely outcome for the next few years is survival. The patient's survival is likely due to the fact that the patient is receiving optimal medical therapy for his underlying conditions and is not experiencing acute cardiac stress.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG findings, such as ventricular extrasystole and non-sustained ventricular tachycardia, suggest a high risk for arrhythmic events, the patient's current medication regimen and the absence of severe symptoms suggest that the patient is not at immediate risk for sudden cardiac death. However, the patient's complex medical history, including ischemic dilated cardiomyopathy and a history of myocardial infarction, increases the risk for arrhythmic events.

Given the patient's reduced LVEF and the presence of ventricular extrasystole on ECG, there is a moderate risk for arrhythmic events, but the patient's current medication regimen and the absence of severe symptoms suggest that the patient is not at immediate risk for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's reduced LVEF (34.0%) and the presence of ventricular extrasystole on ECG suggest that the patient is at risk for pump failure. However, the patient's current medication regimen, including beta blockers and ACE inhibitors, which are commonly used to manage heart failure, suggests that the patient is being adequately managed for his underlying conditions.

Additionally, the patient's biomarkers, such as troponin and BNP, are not significantly elevated, suggesting that the patient is not experiencing acute cardiac stress. While the patient's reduced LVEF increases the risk for pump failure, the patient's current medication regimen and the absence of severe symptoms suggest that the patient is not at immediate risk for pump failure.

Overall, while the patient's reduced LVEF and the presence of ventricular extrasystole on ECG suggest a moderate risk for pump failure, the patient's current medication regimen and the absence of severe symptoms suggest that the patient is not at immediate risk for pump failure."
254,254,P0422,"Age: 62
Gender: Male 
Weight: 75 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 40
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 43.0
Total Cholesterol (mmol/L): 5,9
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 125
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,32
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 123.0
Protein (g/L): 56
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,3
Urea (mg/dL): 7,15
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, the patient is a 62-year-old male with a history of heart failure (NYHA Class II), elevated creatinine levels, and low LVEF (20.0%), indicating significant left ventricular dysfunction. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG impression suggests an increased risk of arrhythmias, which can contribute to cardiac complications. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression reduces the immediate risk of sudden cardiac death.

The patient's elevated troponin levels (0.01 ng/mL) indicate some degree of cardiac damage, but the Troponin level is within the normal range for many laboratories (typically <0.01 ng/mL). The patient's creatinine level is elevated (7.15 mg/dL), but the patient is on ACE inhibitors and loop diuretics, which are commonly used to manage heart failure. The patient's protein level (56 g/L) is within the normal range, and the TSH level (1.3 mIU/L) is within the normal range, indicating no significant thyroid dysfunction.

Given the presence of heart failure, left ventricular dysfunction, and elevated creatinine levels, the patient is at increased risk of cardiac complications, including pump failure. However, the patient is on medications that are commonly used to manage heart failure, and the absence of more severe arrhythmias on the ECG impression reduces the risk of sudden cardiac death. Therefore, the most likely outcome for the next few years is that the patient will survive, albeit with ongoing management and monitoring for cardiac complications.

The patient's survival is more likely than sudden cardiac death due to the following reasons:
- The patient's elevated creatinine levels indicate some degree of kidney dysfunction, but the patient is on medications that are commonly used to manage heart failure.
- The patient's LVEF is significantly reduced, but the patient is on medications that are commonly used to manage heart failure.
- The patient's Troponin level is within the normal range for many laboratories.

The patient's survival is less likely than pump failure due to the following reasons:
- The patient's LVEF is significantly reduced, indicating significant left ventricular dysfunction.
- The patient's elevated creatinine levels indicate some degree of kidney dysfunction, which can contribute to pump failure.
- The patient's NYHA Class II indicates that the patient has some degree of heart failure symptoms, which can increase the risk of pump failure."
255,255,P0424,"Age: 73
Gender: Male 
Weight: 69 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 105.0
AST or GOT (IU/L): 98.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 4846.0
Protein (g/L): 77
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,41
Urea (mg/dL): 19,8
LVEF (%): 37.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's overall prognosis can be assessed based on the provided data. 

Firstly, the patient's age (73) and NYHA Class II classification indicate that the patient has significant cardiac impairment. However, the patient is still relatively active and can perform daily activities with some limitations.

The patient's laboratory results show elevated liver enzymes (ALT/GPT: 105.0, AST/GOT: 98.0) and creatinine levels (194.0 mmol/L), which may indicate some degree of kidney dysfunction. However, the patient is on medications that are commonly used to manage these conditions.

The patient's cardiac biomarkers, including Troponin (0.01 ng/mL), are within normal limits, which suggests that there is no significant acute myocardial infarction or cardiac damage. The LVEF (37.0%) is also relatively preserved, which may indicate some residual cardiac function.

The patient's ECG results show polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are concerning for arrhythmias. However, the presence of beta blockers and digoxin suggests that the patient is being adequately treated for these conditions.

Given the patient's overall clinical picture, the most likely outcome is survival, with a moderate risk of cardiac complications. However, the patient's elevated creatinine levels and kidney dysfunction may necessitate closer monitoring and potential adjustments to medications.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG results show concerning arrhythmias, the presence of beta blockers and digoxin suggests that the patient is being adequately treated for these conditions. However, the patient's NYHA Class II classification and significant kidney dysfunction may increase the risk of sudden cardiac death.

The patient's elevated creatinine levels (194.0 mmol/L) and elevated liver enzymes (ALT/GPT: 105.0, AST/GOT: 98.0) may indicate some degree of organ dysfunction, which can increase the risk of cardiac complications. The patient's LVEF (37.0%) is also relatively preserved, but the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG may increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's NYHA Class II classification and significant kidney dysfunction (elevated creatinine levels) increase the risk of heart failure. However, the patient's LVEF (37.0%) is relatively preserved, which suggests that the patient may still have some residual cardiac function.

The patient's elevated liver enzymes (ALT/GPT: 105.0, AST/GOT: 98.0) and elevated creatinine levels (194.0 mmol/L) may indicate some degree of organ dysfunction, which can increase the risk of pump failure. However, the patient is on medications that are commonly used to manage these conditions.

The patient's ECG results show concerning arrhythmias, which may increase the risk of cardiac complications. However, the presence of beta blockers and digoxin suggests that the patient is being adequately treated for these conditions. Overall, while there are some concerns, the patient's overall clinical picture suggests that pump failure death is the least likely outcome."
256,256,P0425,"Age: 53
Gender: Female 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 115/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 38
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 114.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,87
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 775.0
Protein (g/L): 70
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 4,99
LVEF (%): 43.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at high risk for adverse cardiac events, but the patient has been previously identified as a survivor. The presence of idiopathic dilated cardiomyopathy, non-sustained ventricular tachycardia (NSVT), and a low left ventricular ejection fraction (LVEF) of 43% indicate a high risk for cardiac complications. However, the patient has been previously identified as a survivor, suggesting that the patient has shown resilience to adverse cardiac events in the past.

The patient's medication regimen, which includes beta blockers, spironolactone, and an ACE inhibitor, is standard therapy for managing heart failure and arrhythmias in patients with cardiomyopathy. The patient's electrolyte and lipid profiles are also within acceptable limits.

While the patient's ECG findings, including ventricular extrasystole, NSVT, and unknown bradycardia, indicate an increased risk for arrhythmias, the patient's overall clinical presentation and medication regimen suggest that the patient is likely to survive the next few years.

The patient's elevated troponin level (0.01 ng/mL) is a minor finding, and the patient's creatinine level (4.99 mg/dL) is slightly elevated, but not significantly abnormal. The patient's Pro-BNP level (775 ng/L) is elevated, indicating some degree of heart failure, but the patient is already on spironolactone, which is a common treatment for heart failure.

Overall, while the patient has several risk factors for cardiac complications, the patient's clinical presentation and medication regimen suggest that the patient is likely to survive the next few years."
257,257,P0426,"Age: 72
Gender: Male 
Weight: 76 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 125/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 2,35
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2598.0
Protein (g/L): 67
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,53
Urea (mg/dL): 11,32
LVEF (%): 10.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

The patient's prognosis can be determined by analyzing the provided data, which indicates a severe and advanced stage of heart failure. The key factors contributing to this assessment are:

1. Low LVEF (10.0%): This value represents the left ventricular ejection fraction, which measures the percentage of blood that leaves the left ventricle with each heartbeat. A value of 10.0% is significantly below the normal range (50-70%), indicating severe left ventricular dysfunction.

2. NYHA Class II: This classification indicates moderate symptoms of heart failure, which suggests that the patient experiences symptoms even at rest or with minimal physical activity.

3. Pro-BNP (2598.0 ng/L): Elevated B-type natriuretic peptide levels are associated with heart failure and can indicate the presence of increased ventricular wall stress.

4. Medications: The patient is on several medications for heart failure, including digoxin, which can indicate advanced heart failure. However, the presence of digoxin alone does not necessarily predict a poor outcome.

5. ECG Impression: The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) indicate arrhythmias, which are common in patients with advanced heart failure. However, the absence of paroxysmal supraventricular tachyarrhythmia and bradycardia may suggest that the patient's arrhythmias are more likely to be related to ventricular dysfunction rather than supraventricular tachycardia.

Considering these factors, the patient's prognosis is most likely to be a survivor, as they are currently receiving treatment for heart failure and have not yet demonstrated any evidence of sudden cardiac death or pump failure. However, the presence of severe left ventricular dysfunction, arrhythmias, and elevated BNP levels suggest that the patient is at high risk for a poor outcome."
258,258,P0427,"Age: 77
Gender: Male 
Weight: 61 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 118/57 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,87
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3993.0
Protein (g/L): 76
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 6,66
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's prognosis is ranked as a survivor due to several factors:

1. Age: Although the patient is 77 years old, this is not uncommon for patients with advanced cardiovascular disease. However, age itself is not a strong predictor of outcome.
2. NYHA Class II: This indicates that the patient has some limitation in physical activity due to heart failure symptoms, but it's not severe. Patients with NYHA Class II symptoms tend to have a better prognosis compared to those with higher classes.
3. Medications: The patient is taking beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for heart failure and coronary artery disease. These medications can help manage symptoms, slow disease progression, and reduce mortality.
4. Low troponin levels: The patient's troponin level is within normal limits, which suggests that there is no significant myocardial damage or acute coronary syndrome.
5. ECG findings: The patient has ventricular extrasystoles and non-sustained ventricular tachycardia, but these are not indicative of a high-risk arrhythmia. The presence of paroxysmal supraventricular tachyarrhythmia is unclear, but it's not a contraindication for survival.
6. Low creatinine levels: Elevated creatinine levels can indicate kidney dysfunction, but this patient's level is within normal limits, which is a positive sign.
7. Elevated BNP levels: Pro-BNP levels are elevated, indicating some degree of heart failure. However, this is not uncommon in patients with heart failure and can be managed with treatment.

While this patient has several risk factors, including ischemic dilated cardiomyopathy and a history of myocardial infarction, the combination of their medical history, medications, and the absence of acute coronary syndrome or significant kidney dysfunction make a poor outcome less likely. Therefore, the patient's prognosis is ranked as a survivor."
259,259,P0428,"Age: 48
Gender: Female 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 115/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,02
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 120.0
Protein (g/L): 69
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,91
Urea (mg/dL): 8,49
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a complex medical history, with ischemic dilated cardiomyopathy, myocardial infarction, and dyslipidemia, which are all risk factors for adverse cardiac outcomes. However, the patient's current NYHA class is II, indicating mild symptoms, and the patient is already taking beta blockers and statins, which are standard treatments for these conditions.

The patient's laboratory results show a slightly elevated troponin level (0.01 ng/mL), which may indicate some residual myocardial damage. However, this is not significantly elevated, and the patient's LVEF is only 40%, which is within the range for someone with a history of ischemic cardiomyopathy.

The patient's ECG is normal, with no evidence of ventricular arrhythmias or significant ST-segment changes. The patient's medications are well-controlled, and the patient's hemoglobin and kidney function are within normal limits.

Given the patient's overall clinical presentation, I believe that the most likely outcome for the next few years is survival. The patient's medical history and laboratory results suggest that the patient is at risk for further cardiac events, but the patient's current clinical status and treatment plan suggest that the patient is likely to survive for the next few years with careful management and monitoring.

RANKING: 2. Pump failure death
REASONING:

While the patient's LVEF is low, indicating some degree of left ventricular dysfunction, the patient's current clinical presentation does not suggest imminent pump failure. The patient's NYHA class is II, indicating mild symptoms, and the patient is already taking medications that are standard for managing heart failure.

However, the patient's elevated creatinine level (8.49 mg/dL) and elevated BNP (120 ng/L) suggest some degree of cardiac dysfunction and increased pressure overload on the heart. The patient's LVEF is also low, which increases the risk of pump failure.

Additionally, the patient's dyslipidemia and hypertension are risk factors for further cardiac events, including heart failure.

Given the patient's low LVEF and elevated BNP, I believe that pump failure is a possible but less likely outcome for the next few years compared to survival.

RANKING: 3. Sudden cardiac death
REASONING:

While the patient's medical history and laboratory results suggest some degree of cardiac risk, the patient's current clinical presentation does not suggest an immediate risk of sudden cardiac death. The patient's ECG is normal, with no evidence of ventricular arrhythmias or significant ST-segment changes.

The patient's medications are well-controlled, and the patient's hemoglobin and kidney function are within normal limits. The patient's NYHA class is II, indicating mild symptoms, and the patient is already taking beta blockers and statins, which are standard treatments for managing cardiac risk factors.

Additionally, the patient's troponin level is not significantly elevated, and the patient's LVEF is only 40%, which is within the range for someone with a history of ischemic cardiomyopathy.

Given the patient's overall clinical presentation, I believe that sudden cardiac death is the least likely outcome for the next few years."
260,260,P0430,"Age: 73
Gender: Male 
Weight: 78 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 144/79 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,98
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 962.0
Protein (g/L): 69
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 7,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's prognosis is most likely to be a survivor due to the following factors:

1. Age: The patient is 73 years old, which is considered advanced age for a patient with heart disease. However, this age alone is not a contraindication for survival, and many patients with heart disease can live for many years with proper management.

2. NYHA Class II: The patient's New York Heart Association (NYHA) class II indicates that the patient experiences some limitation in physical activity due to heart disease, but they are still able to perform daily activities without excessive fatigue. This suggests that the patient's heart function is not severely impaired.

3. Medications: The patient is taking beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic cardiomyopathy. These medications are likely to improve the patient's heart function and reduce the risk of complications.

4. Low troponin levels: The patient's troponin level is 0.01 ng/mL, which is within the normal range. Elevated troponin levels are often associated with acute myocardial infarction or cardiac damage, but the patient's normal troponin level suggests that there is no acute cardiac damage.

5. Low creatinine level: The patient's creatinine level is 7.15 mg/dL, which is slightly elevated but not significantly high. Elevated creatinine levels are often associated with kidney dysfunction, but the patient's kidney function is still within a relatively normal range.

6. Low BNP level: The patient's pro-b-type natriuretic peptide (BNP) level is 962 ng/L, which is within the normal range. Elevated BNP levels are often associated with heart failure, but the patient's normal BNP level suggests that the patient's heart function is not severely impaired.

7. Presence of ventricular extrasystole: The patient has ventricular extrasystole on their ECG, which is a common finding in patients with heart disease. However, ventricular extrasystole is not necessarily a contraindication for survival.

The combination of these factors suggests that the patient is likely to survive for several years with proper management and treatment. However, the patient's heart disease is likely to require ongoing management and monitoring to prevent complications."
261,261,P0435,"Age: 62
Gender: Male 
Weight: 100 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 45
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 5
LDL (mmol/L): 3,21
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 109.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,78
Urea (mg/dL): 6,99
LVEF (%): 44.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's overall clinical presentation and test results suggest a stable, but compromised cardiac condition. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, the patient is currently being treated with medications that are standard for heart failure management (beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitor), and the ECG results do not indicate any acute life-threatening arrhythmias. The patient's LVEF is 44%, which is within the range for a patient with heart failure with reduced ejection fraction (HFrEF), but it is on the lower end of the spectrum. The patient's serum creatinine level is elevated, indicating some degree of renal impairment, but this is not uncommon in patients with heart failure. The absence of any recent episodes of ventricular tachycardia or ventricular extrasystoles on the ECG, and the lack of troponin elevation, suggest that the patient is not currently experiencing significant cardiac ischemia or acute myocardial injury. Overall, the patient's stable clinical presentation, absence of acute life-threatening arrhythmias, and evidence of heart failure management, make it more likely that the patient will survive for the next few years."
262,262,P0436,"Age: 62
Gender: Male 
Weight: 80 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,01
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,2
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 184.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,25
Urea (mg/dL): 7,15
LVEF (%): 17.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"RANKING: 

1. Survivor
REASONING:
Based on the patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, dyslipidemia, and elevated creatinine levels, the patient is at a high risk of cardiac-related complications. However, the patient's current hemoglobin level (151.0 g/L) and lack of significant electrolyte imbalances or acute kidney injury suggest that the patient's renal function is relatively preserved.

The patient's LVEF (17.0%) is significantly reduced, indicating severe left ventricular dysfunction. However, the absence of significant troponin elevation (0.005 ng/mL) suggests that there is no acute myocardial infarction. The patient's ECG findings, including ventricular extrasystoles and second-degree AV block, indicate a high risk of arrhythmias.

Despite these factors, the patient is currently on multiple medications, including beta blockers, digoxin, and an ACE inhibitor, which suggest a well-managed heart failure and cardiovascular risk profile. The patient's Pro-BNP level (184.0 ng/L) is elevated, but not excessively high, indicating some level of cardiac stress.

Given these factors, the patient's overall prognosis is likely to be a survivor, with a moderate to high risk of cardiovascular events, such as arrhythmias or cardiac failure exacerbation, over the next few years.

2. Sudden Cardiac Death
REASONING:
While the patient's ECG findings and LVEF suggest a high risk of arrhythmias, the patient's current hemoglobin level and lack of significant electrolyte imbalances or acute kidney injury reduce the likelihood of sudden cardiac death. However, the patient's severe left ventricular dysfunction (LVEF 17.0%) and elevated Pro-BNP level (184.0 ng/L) increase the risk of cardiac events.

The patient's age, NYHA Class II, and dyslipidemia also contribute to the risk of cardiovascular events. However, the patient's current treatment regimen, including beta blockers and an ACE inhibitor, suggests a well-managed cardiovascular risk profile.

Given these factors, the patient's risk of sudden cardiac death is moderate, but not extremely high.

3. Pump Failure Death
REASONING:
The patient's severe left ventricular dysfunction (LVEF 17.0%), elevated Pro-BNP level (184.0 ng/L), and NYHA Class II indicate a high risk of heart failure exacerbation. However, the patient's current treatment regimen, including beta blockers and an ACE inhibitor, suggests a well-managed heart failure profile.

The patient's elevated creatinine level (133.0 mmol/L) and elevated troponin level (0.005 ng/mL) suggest some level of renal impairment, which could contribute to the risk of pump failure. However, the patient's hemoglobin level and lack of significant electrolyte imbalances reduce the likelihood of acute kidney injury.

Given these factors, the patient's risk of pump failure death is moderate, but not extremely high."
263,263,P0437,"Age: 53
Gender: Male 
Weight: 100 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,28
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 12721.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,825
Urea (mg/dL): 6,16
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 53-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, and is currently classified as New York Heart Association (NYHA) Class II. The patient's current medications, including beta blockers, statins, ACE inhibitors, and nitrovasodilators, suggest that they are being adequately managed for their heart failure.

The patient's vital signs and laboratory results, such as a normal blood pressure, slightly elevated creatinine level, and normal liver enzymes, do not indicate acute distress. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression suggests that the patient does not have an acute arrhythmia.

The patient's LVEF (left ventricular ejection fraction) of 25% is significantly reduced, indicating severe systolic dysfunction. However, the patient is still alive and receiving optimal medical therapy, which suggests that the patient has a relatively favorable prognosis.

The patient's Pro-BNP level of 12,721 ng/L is elevated, which is consistent with heart failure. However, the absence of symptoms and the patient's ability to be managed on optimal medical therapy suggest that the patient's condition is not severely decompensated.

Overall, based on the patient's current medical status and the presence of optimal medical therapy, the most likely outcome is that the patient will survive in the next few years, assuming no significant adverse events or changes in medical therapy.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's LVEF of 25% indicates severe systolic dysfunction, the patient is still alive and receiving optimal medical therapy. However, the patient's reduced LVEF and elevated Pro-BNP level suggest that the patient is at increased risk for sudden cardiac death due to arrhythmias or ventricular fibrillation.

The patient's ECG impression shows polymorphic ventricular extrasystoles, which is a marker for increased risk of sudden cardiac death. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG impression suggests that the patient's risk for sudden cardiac death is not as high as it could be.

Additionally, the patient's age, sex, and medical history of myocardial infarction and ischemic dilated cardiomyopathy increase the patient's risk for sudden cardiac death.

Overall, while the patient is at increased risk for sudden cardiac death, the presence of optimal medical therapy and the absence of other high-risk factors suggest that the patient's risk is not as high as it could be.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF of 25% and elevated Pro-BNP level of 12,721 ng/L suggest that the patient has severe systolic dysfunction and is at increased risk for pump failure. The patient's NYHA Class II classification indicates that the patient has some limitation in physical activity due to heart failure.

The patient's reduced LVEF and elevated Pro-BNP level, combined with the patient's age and medical history, suggest that the patient is at increased risk for pump failure. The patient's elevated creatinine level and slightly elevated total cholesterol level also suggest that the patient may have underlying kidney and cardiovascular disease.

The patient's current medical therapy, including beta blockers, statins, ACE inhibitors, and nitrovasodilators, suggests that the patient is being adequately managed for heart failure. However, the patient's reduced LVEF and elevated Pro-BNP level suggest that the patient's condition is not well-controlled, and pump failure is a possible outcome.

Overall, while the patient is being managed for heart failure, the patient's severe systolic dysfunction and elevated Pro-BNP level suggest that pump failure is a possible outcome in the next few years."
264,264,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is 73 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, which are risk factors for heart failure and arrhythmias. However, the patient is currently receiving medications that are standard for managing these conditions, such as beta blockers, ACE inhibitors, and diuretics. The patient's NYHA class is II, indicating some limitation of physical activity due to symptoms, but not severe.

The patient's laboratory results show elevated creatinine levels, indicating some degree of renal impairment, but not severe. The lipid profile is not optimal, but the patient is on statins, which can help manage cholesterol levels. The electrolytes are relatively normal, and the liver enzymes are within normal limits.

The ECG impression shows non-sustained ventricular tachycardia, which is a concerning finding, but it is not sustained. The patient also has ventricular extrasystoles, which are abnormal heartbeats, but they are not sustained.

Given these factors, the patient's overall prognosis is likely to be a survivor. The patient's age and medical history do increase the risk of adverse outcomes, but the patient is receiving standard therapy for their conditions, and the ECG findings, while concerning, are not indicative of an immediate life-threatening arrhythmia.

While the patient's LVEF is severely reduced, indicating poor cardiac function, the patient's age and the presence of medications that can help manage heart failure symptoms, such as spironolactone, suggest that the patient may be able to tolerate therapy and survive for the next few years.

The patient's Pro-BNP levels are elevated, indicating some degree of heart failure, but the patient is receiving loop diuretics, which can help manage fluid overload. Overall, the patient's prognosis is guarded but not catastrophic, and the patient is likely to survive for the next few years.

It is essential to continue monitoring the patient's condition closely and adjusting their medication regimen as needed to optimize their management of heart failure and arrhythmias."
265,265,P0442,"Age: 63
Gender: Male 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 160.0
Gamma-glutamil transpeptidase (IU/L): 125
Glucose (mmol/L): 3,3
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 6,2
LDL (mmol/L): 2,51
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 637.0
Protein (g/L): 82
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,825
Urea (mg/dL): 12,15
LVEF (%): 52.0
Medications: Calcium Channel Blocker, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the patient's data, I believe the most likely outcome is a survivor. The patient's age is 63, which is considered middle-aged, and their NYHA Class II indicates mild symptoms of heart failure. The patient's LVEF (Left Ventricular Ejection Fraction) is 52%, which is within the normal range for a 63-year-old male. The patient's blood pressure, creatinine, and urea levels are not excessively elevated, suggesting that their kidney function is not severely impaired. Additionally, the patient's electrolyte levels, including potassium, are within normal limits. 

The patient's troponin level is 0.04 ng/mL, which is within the normal range, indicating that there is no significant myocardial damage. The patient's ECG impression shows non-sustained ventricular tachycardia, but this is not a significant finding given the patient's overall clinical profile. The patient is already on beta blockers and ACE inhibitors, which are commonly used to manage heart failure and hypertension.

The patient's laboratory values, including albumin, ALT, AST, total cholesterol, and glucose levels, are also within normal limits, suggesting that the patient's metabolic and liver function are not significantly impaired.

Overall, the patient's clinical profile suggests that they are likely to survive in the short term, given their mild symptoms, normal laboratory values, and the presence of established treatment for their heart failure and hypertension.

2. Sudden cardiac death
REASONING: 
Sudden cardiac death is unlikely in this patient due to the presence of established treatment for their heart failure and hypertension. The patient is already on beta blockers and ACE inhibitors, which are commonly used to manage these conditions. Additionally, the patient's ECG impression shows non-sustained ventricular tachycardia, which is not a significant finding given the patient's overall clinical profile.

However, the patient's LVEF is 52%, which is below the normal range for a 63-year-old male. This could potentially increase the risk of cardiac arrhythmias, including ventricular tachycardia. However, the patient's ECG impression shows non-sustained ventricular tachycardia, which is not a significant finding given the patient's overall clinical profile.

3. Pump failure death
REASONING: 
Pump failure death is unlikely in this patient due to the patient's mild symptoms and normal laboratory values. The patient's LVEF is 52%, which is within the normal range for a 63-year-old male. The patient is already on beta blockers and ACE inhibitors, which are commonly used to manage heart failure.

However, the patient's creatinine level is 160.0 mmol/L, which is elevated, suggesting some degree of kidney impairment. This could potentially increase the risk of pump failure, but the patient's overall clinical profile suggests that this is not a significant concern. Additionally, the patient's albumin level is 45 g/L, which is slightly low, but this is not a significant finding given the patient's overall clinical profile."
266,266,P0443,"Age: 82
Gender: Female 
Weight: 88 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 7
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 78
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,43
Urea (mg/dL): 9,15
LVEF (%): 39.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as a survivor with a high likelihood. The patient's age of 82 and NYHA Class II indicates that they have some level of heart failure, but it is not severe. The patient's LVEF of 39.0 is significantly reduced, indicating left ventricular dysfunction, but it is not severely impaired. The patient's medication regimen includes loop diuretics and spironolactone, which are commonly used to manage heart failure. The patient's ejection fraction is still within a range that suggests some residual cardiac function.

The patient's elevated BNP level of 320.0 suggests that there is some degree of ventricular volume overload, but the patient's ejection fraction and medication regimen suggest that they are still able to manage their heart failure symptoms.

The patient's other lab values, such as their electrolytes, liver enzymes, and lipid profile, are relatively within normal limits, which suggests that they do not have any other significant underlying conditions that would increase the risk of cardiac complications.

The only concern is the patient's history of myocardial infarction, but the patient's LVEF is not severely impaired, and they are already on ACE inhibitors, which are known to reduce the risk of further cardiac events.

Overall, based on the provided data, I believe that the patient has a high likelihood of surviving the next few years, but it is essential to closely monitor their condition and adjust their medication regimen as needed to ensure optimal management of their heart failure.

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the following reasons:

- Sudden cardiac death is less likely because the patient's ECG does not show any signs of ventricular tachycardia or other arrhythmias that could increase the risk of sudden cardiac death.
- Pump failure death is less likely because the patient's LVEF is not severely impaired, and they are already on medications that are known to improve cardiac function and reduce the risk of heart failure exacerbation.

However, it is essential to continue monitoring the patient's condition closely to identify any potential complications or changes in their condition, and to adjust their treatment plan as needed to ensure optimal management of their heart failure."
267,267,P0444,"Age: 58
Gender: Male 
Weight: 115 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 5
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,91
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1809.0
Protein (g/L): 64
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,14
Urea (mg/dL): 6,82
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I rank the patient as a survivor with a high probability. The patient's age of 58 is not particularly high, and their NYHA Class II indicates that they have some symptoms but are still relatively functional. Their blood pressure is well-controlled, and they have a good hemoglobin level. The patient's LVEF of 70% is also within a relatively normal range.

The patient's elevated creatinine level (133.0 mmol/L) may indicate some degree of renal impairment, but this is not uncommon in patients with hypertension and cardiac disease. The elevated Pro-BNP level (1809.0 ng/L) suggests some degree of ventricular dysfunction, but it is not excessively high. The patient's troponin level (0.03 ng/mL) is also within normal limits.

The patient's ECG findings are concerning, with a polymorphic ventricular extrasystole, but this is not necessarily a predictor of adverse outcomes. The patient's medication regimen is well-managed, with a calcium channel blocker, an angiotensin II receptor blocker, and loop diuretics.

While the patient's lipid profile is not ideal (high LDL and low HDL), their overall clinical picture suggests that they are still relatively stable and able to manage their condition with current treatment.

Overall, based on the provided data, I believe that the patient is at low risk for sudden cardiac death or pump failure in the next few years, making survival the most likely outcome."
268,268,P0447,"Age: 71
Gender: Female 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 131/57 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 42
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,31
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 5038.0
Protein (g/L): 69
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,5
Urea (mg/dL): 9,32
LVEF (%): 13.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's NYHA Class II indicates that they have some limitations in physical activity due to their heart condition, but it's not severe. The patient's LVEF of 13% is significantly reduced, indicating severe left ventricular dysfunction, which is a common consequence of idiopathic dilated cardiomyopathy. However, the patient is already on medications for their condition, including beta blockers, statins, and an ACE inhibitor, which can help manage symptoms and slow disease progression.

The patient's elevated BNP levels (5038 ng/L) also suggest a high risk of heart failure, but the fact that they are already taking medications to manage their condition and have a relatively preserved kidney function (creatinine 71.0 mol/L) suggest that they may still be able to tolerate treatment and potentially improve with close monitoring.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG may indicate an increased risk of arrhythmias, but the patient is not experiencing any symptoms or palpitations, which is a positive sign. The patient's hemoglobin level and troponin level are within normal limits, which suggests that there is no acute myocardial infarction or significant cardiac damage.

Overall, considering the patient's current medical status, treatment, and the presence of some residual cardiac function, I believe that the patient is at a higher risk of survival over the next few years, making ""survivor"" the most likely outcome.

2. Sudden Cardiac Death
REASONING: 
While the patient has a high risk of arrhythmias and ventricular dysfunction, the fact that they are already taking medications to manage their condition and do not exhibit any symptoms of heart failure or acute myocardial infarction makes sudden cardiac death less likely.

However, the patient's LVEF of 13% is significantly reduced, which increases the risk of arrhythmias and sudden cardiac death. Additionally, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests an increased risk of arrhythmias.

Despite the patient's relatively preserved kidney function and normal hemoglobin and troponin levels, the patient's elevated BNP levels and NYHA Class II symptoms may still indicate some residual cardiac dysfunction, which could increase the risk of arrhythmias and sudden cardiac death.

3. Pump Failure Death
REASONING: 
Given the patient's severely reduced LVEF (13%) and elevated BNP levels (5038 ng/L), pump failure is a significant concern. The patient's NYHA Class II symptoms also indicate some level of heart failure, which can lead to pump failure.

However, the patient's relatively preserved kidney function, normal hemoglobin and troponin levels, and the presence of some residual cardiac function (LVEF 13%) suggest that pump failure may not be imminent. The patient is also taking medications to manage their condition, which can help slow disease progression.

Additionally, the patient's ECG findings, while indicating an increased risk of arrhythmias, do not suggest any acute cardiac damage or severe ventricular dysfunction. Therefore, while pump failure is a concern, it is not the most likely outcome in this case."
269,269,P0449,"Age: 64
Gender: Female 
Weight: 47 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 102/40 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 107.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,63
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 105.0
Protein (g/L): 76
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,18
Urea (mg/dL): 9,98
LVEF (%): 35.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient is currently being treated with beta blockers and ACE inhibitors, which are standard medications for managing heart failure and reducing mortality in patients with heart failure. The patient's NYHA Class II indicates that they have some limitation in physical activity due to their heart condition, but they are still able to perform daily activities without excessive fatigue. The patient's LVEF of 35% is significantly reduced, indicating severe systolic dysfunction, but this is not uncommon in patients with idiopathic dilated cardiomyopathy.

The patient's laboratory results are generally within normal limits, with slightly elevated creatinine levels, but no other significant abnormalities. The patient's troponin level is very low, indicating no acute myocardial infarction. The ECG impression does not show any life-threatening arrhythmias, which is a positive sign.

Given the patient's treatment and clinical status, I believe that the patient is at high risk of experiencing cardiac events, but the current treatment and clinical status suggest that they are likely to survive for the next few years. The patient's age and weight are also factors in their overall prognosis, as older patients with heart failure tend to have a worse prognosis. However, the patient's overall condition and treatment suggest that they are likely to survive for at least 2-3 years.

2. Sudden cardiac death
REASONING:
While the patient is at risk of experiencing cardiac events, the current ECG impression does not show any life-threatening arrhythmias, and the patient is receiving standard treatment for heart failure. However, the patient's LVEF is severely reduced, and the patient's NYHA Class II indicates significant limitation in physical activity. The patient's age and weight are also risk factors for sudden cardiac death.

Additionally, the patient's low troponin level and lack of acute myocardial infarction on ECG do not rule out the possibility of sudden cardiac death. However, the patient's overall clinical status and treatment suggest that sudden cardiac death is less likely than the patient surviving for at least 2-3 years.

3. Pump failure death
REASONING:
Given the patient's severely reduced LVEF and NYHA Class II, the patient is at high risk of experiencing pump failure. The patient's treatment with beta blockers and ACE inhibitors is standard for managing heart failure, but the patient's severe systolic dysfunction may not be fully reversible with medication alone. The patient's creatinine level is elevated, indicating some degree of kidney dysfunction, which can be exacerbated by heart failure.

The patient's overall clinical status and treatment suggest that pump failure death is a possible outcome, but it is less likely than the patient surviving for at least 2-3 years. The patient's age and weight are also factors in their overall prognosis, but the patient's treatment and clinical status suggest that pump failure death is a possible but less likely outcome."
270,270,P0450,"Age: 70
Gender: Female 
Weight: 94 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 106/45 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 36
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,43
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 333.0
Protein (g/L): 67
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,64
Urea (mg/dL): 5,99
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient's overall health status and medical history suggest a relatively stable condition. The patient has a history of ischemic dilated cardiomyopathy, which is a significant comorbidity, but the patient is currently on multiple medications that are standard treatments for this condition, such as ACE inhibitors, beta blockers, and statins. The patient's NYHA class II indicates mild symptoms, and their LVEF is 30%, which is a relatively preserved ejection fraction. The patient's ECG shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which are all potential predictors of cardiac death. Additionally, the patient's biomarkers, such as Troponin and Pro-BNP, are not significantly elevated, suggesting that there is no acute cardiac injury or strain. Overall, these factors suggest that the patient is likely to survive in the short term.

2. Sudden Cardiac Death
REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy, which is a risk factor for sudden cardiac death, the patient's current ECG and biomarkers do not show any signs of acute cardiac injury or strain. However, the patient's LVEF is significantly reduced, which may increase the risk of sudden cardiac death. Additionally, the patient's low blood pressure (106/45 mmHg) may be a sign of cardiac dysfunction, which could increase the risk of sudden cardiac death. However, the patient is on multiple medications that are standard treatments for this condition, which may help mitigate this risk.

3. Pump Failure Death
REASONING: 
The patient's LVEF is significantly reduced (30%), which indicates that the patient's heart is not pumping efficiently. This is a significant risk factor for pump failure death. Additionally, the patient's NYHA class II indicates mild symptoms, which may not be sufficient to compensate for the reduced ejection fraction. The patient's biomarkers, such as Pro-BNP, are elevated, which suggests that the patient's heart is working harder to pump blood, increasing the risk of pump failure. However, the patient is on multiple medications that are standard treatments for this condition, which may help mitigate this risk. Overall, while the patient is at risk for pump failure death, the patient's current health status and treatment plan suggest that this outcome is less likely than sudden cardiac death."
271,271,P0451,"Age: 57
Gender: Female 
Weight: 64 kg
Height: 147 cm
NYHA Class: II
Blood Pressure: 89/53 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,36
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,55
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1742.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,93
Urea (mg/dL): 8,99
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient's prognosis as a survivor. The patient's age is 57, which is relatively young for idiopathic dilated cardiomyopathy (IDC). The patient's LVEF is 20%, which indicates significant left ventricular dysfunction. However, the patient's symptoms are not explicitly mentioned in the data, and the patient's NYHA Class is II, indicating mild symptoms.

The patient's biomarkers, such as troponin (0.01 ng/mL), TSH (1.93 mIU/L), and creatinine (8.99 mg/dL), are not indicative of acute cardiac damage or renal failure. The patient's liver enzymes (ALT and AST) are within normal limits.

The patient's ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, suggest an increased risk of arrhythmias. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk.

The patient's medication regimen, which includes beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, is standard for managing IDC. The patient's lipid profile (Total Cholesterol: 6.36 mmol/L, HDL: 1.34 mmol/L, LDL: 4.55 mmol/L) is not significantly abnormal.

Considering these factors, I would rank the patient's prognosis as a survivor, with a relatively low risk of sudden cardiac death and pump failure. However, close monitoring and follow-up are essential to adjust the treatment plan and address any potential complications.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG findings suggest an increased risk of arrhythmias, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. However, the patient's LVEF is 20%, which indicates significant left ventricular dysfunction, increasing the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: The patient's LVEF is 20%, indicating significant left ventricular dysfunction, which increases the risk of pump failure. However, the patient's NYHA Class is II, indicating mild symptoms, and the patient's biomarkers do not indicate acute cardiac damage. The patient's medication regimen is standard for managing IDC, and the patient's lipid profile is not significantly abnormal.

It is essential to note that the patient's prognosis can change over time, and regular follow-up and adjustments to the treatment plan can help mitigate the risk of pump failure and sudden cardiac death."
272,272,P0452,"Age: 51
Gender: Male 
Weight: 61 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 100/55 mmHg
Past Medical History: Other HF etiology, Diabetes
Albumin (g/L): 46
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4
LDL (mmol/L): 3,36
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2311.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 22
Troponin (ng/mL): 0,14
TSH (mIU/L): 0,742
Urea (mg/dL): 4,99
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient has a complex medical history with multiple comorbidities, including heart failure, diabetes, and a history of ventricular extrasystoles and non-sustained ventricular tachycardia. However, the patient is currently on optimal medication therapy with beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which is a comprehensive treatment plan for heart failure. The patient's hemoglobin and liver function tests are also within normal limits, indicating no acute kidney injury or anemia. The patient's ejection fraction is 18%, which is significantly reduced, indicating severe left ventricular dysfunction. However, the patient's current ECG impression does not show any signs of acute cardiac ischemia or acute coronary syndrome. The low troponin level and normal TSH level also suggest that there is no acute cardiac injury or thyroid dysfunction. Overall, despite the patient's poor LVEF, the presence of optimal medication therapy and no signs of acute cardiac events make a survivor the most likely outcome.

2. Sudden Cardiac Death
REASONING: 
Although the patient has a history of ventricular extrasystoles and non-sustained ventricular tachycardia, the patient's current ECG impression does not show any signs of acute cardiac ischemia or acute coronary syndrome. The patient's troponin level is also normal, which further reduces the likelihood of acute cardiac injury. However, the patient's history of ventricular extrasystoles and non-sustained ventricular tachycardia, combined with the low LVEF, increases the risk of arrhythmic events. Additionally, the patient's age and sex are also risk factors for sudden cardiac death. However, the patient's current optimal medication therapy and stable vital signs make sudden cardiac death less likely.

3. Pump Failure Death
REASONING: 
Given the patient's severe left ventricular dysfunction (LVEF 18%), the patient is at high risk for pump failure. The patient's NYHA class III status also indicates significant symptoms of heart failure, which can lead to pump failure. However, the patient's current optimal medication therapy and stable vital signs suggest that the patient is currently being managed effectively. While pump failure is a significant risk, the patient's current ECG impression and troponin level do not indicate acute cardiac injury, and the patient's optimal medication therapy may mitigate this risk. However, the patient's age and comorbidities also increase the risk of pump failure, making it a plausible outcome."
273,273,P0453,"Age: 58
Gender: Male 
Weight: 65 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 52
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,39
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 64
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,24
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 868.0
Protein (g/L): 90
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,09
TSH (mIU/L): 2,8
Urea (mg/dL): 8,99
LVEF (%): 37.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a significant history of ischemic dilated cardiomyopathy, which is a major risk factor for heart failure and sudden cardiac death. However, the patient is currently being treated with beta blockers, digoxin, loop diuretics, and spironolactone, which are standard therapies for managing heart failure. The patient's left ventricular ejection fraction (LVEF) is 37.0%, which is significantly reduced, indicating poor cardiac function.

The patient's troponin level is 0.09 ng/mL, which is within the normal range, indicating no acute myocardial infarction. The patient's creatinine level is elevated at 8.99 mg/dL, which may indicate renal impairment, but this is not directly related to the cardiac condition.

The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which are both concerning for arrhythmias. However, the patient is being treated for these conditions with medications, and the patient's symptoms are not severe.

The patient's laboratory results show elevated liver enzymes (ALT and AST) and low albumin, which may indicate liver disease or malnutrition. However, these findings are not directly related to the cardiac condition.

Considering the patient's medical history, ECG findings, and laboratory results, the most likely outcome for the next few years is that the patient will survive, despite the presence of significant cardiac risk factors. The patient is being treated for their condition, and their symptoms are not severe. However, close monitoring and follow-up with the cardiologist are necessary to adjust the treatment plan as needed.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient has a significant history of ischemic dilated cardiomyopathy, which is a major risk factor for sudden cardiac death, the patient's current treatment plan and lack of severe symptoms make this outcome less likely. The patient's LVEF is 37.0%, which is significantly reduced, but this is not a direct indicator of sudden cardiac death.

The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which are concerning for arrhythmias. However, the patient is being treated for these conditions with medications, and the patient's symptoms are not severe.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF is 37.0%, which is significantly reduced, indicating poor cardiac function. The patient's elevated creatinine level (8.99 mg/dL) may indicate renal impairment, which can be a complication of heart failure. However, the patient is being treated with medications to manage heart failure, and the patient's symptoms are not severe.

While the patient has a significant history of ischemic dilated cardiomyopathy, the patient's current treatment plan and lack of severe symptoms make pump failure death less likely. However, close monitoring and follow-up with the cardiologist are necessary to adjust the treatment plan as needed to prevent complications."
274,274,P0454,"Age: 52
Gender: Male 
Weight: 110 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 45.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 234
Glucose (mmol/L): 7,87
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 4,93
LDL (mmol/L): 1,91
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 690.0
Protein (g/L): 79
T3 (pg/dL): 0,0459
T4 (ng/L): 15,19
Troponin (ng/mL): 0,3
TSH (mIU/L): 3,07
Urea (mg/dL): 5,4
LVEF (%): 35.0
Medications: Diabetes Medication, Amiodarone, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient is a 52-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipidemia, peripheral vascular disease, hypertension, and myocardial infarction. The patient's current NYHA class is II, indicating some limitation of physical activity due to heart failure symptoms.

The patient's laboratory results show elevated creatinine levels (91.0 mmol/L), indicating renal impairment, and a low LVEF of 35.0%, which is consistent with heart failure. The patient's ECG impression shows ventricular extrasystole, a polymorphic pattern, which may indicate a higher risk of arrhythmias.

Despite these concerning findings, the patient's current medication regimen includes ACE inhibitors, statins, and amiodarone, which are commonly used to manage heart failure and arrhythmias. The patient's troponin levels are within normal limits, and the ECG does not show any signs of acute myocardial infarction.

Given the patient's overall clinical presentation and laboratory results, the most likely prognosis is survival. The patient's heart failure symptoms and renal impairment are manageable with current treatment, and the absence of acute myocardial infarction and ventricular tachycardia on the ECG reduces the risk of sudden cardiac death. However, close monitoring and adjustments to the medication regimen may be necessary to optimize the patient's heart failure management and reduce the risk of arrhythmias.

While the patient's ECG shows ventricular extrasystole, this finding does not necessarily indicate a high risk of sudden cardiac death. Ventricular extrasystoles can be a benign finding, especially in the absence of other concerning ECG patterns.

The patient's low LVEF and elevated creatinine levels do increase the risk of pump failure, but the patient's current treatment regimen and clinical presentation suggest that pump failure is less likely in the short term.

Overall, while the patient's prognosis is not without risks, the combination of current treatment, low risk of acute myocardial infarction, and absence of ventricular tachycardia on the ECG make survival the most likely outcome."
275,275,P0455,"Age: 67
Gender: Male 
Weight: 64 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 244
Glucose (mmol/L): 9,2
Hemoglobin (g/L): 131.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 8797.0
Protein (g/L): 80
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,58
Urea (mg/dL): 14,81
LVEF (%): 23.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is likely to survive for the next few years. The key factors contributing to this prognosis are:

1. Age: While 67 is considered older, it's not extremely high, and the patient's overall health status might still allow for a relatively long survival period.
2. NYHA Class II: This indicates that the patient has moderate symptoms, but it's not severe enough to immediately indicate advanced heart failure.
3. Medications: The patient is already on beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and arrhythmias. These medications will likely help manage the patient's symptoms and slow disease progression.
4. Pro-BNP level: Although elevated, the level is not extremely high, which might indicate some level of heart failure, but not severe enough to predict a poor prognosis.
5. ECG findings: The presence of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia are concerning, but the patient is already on medications for these conditions, and the non-sustained VT is not prolonged, which might indicate a relatively stable condition.

However, the patient's low LVEF (23.0) and elevated creatinine level (14.81 mg/dL) indicate some degree of cardiac dysfunction and potential kidney impairment, which could impact overall survival. Nevertheless, the presence of these factors does not immediately predict a poor outcome, and the patient's overall health status and treatment plan suggest a relatively favorable prognosis.

In contrast, the other two options, sudden cardiac death and pump failure death, are less likely due to the patient's current treatment and the relatively mild symptoms. Sudden cardiac death is unlikely given the patient's stable ECG findings and current treatment, and pump failure death is possible but not the most likely outcome given the patient's overall health status and treatment plan."
276,276,P0456,"Age: 38
Gender: Male 
Weight: 80 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 47.0
Protein (g/L): 71
T3 (pg/dL): 0,07
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,19
Urea (mg/dL): 6,32
LVEF (%): 42.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient is most likely to survive for the next few years. The key factors contributing to this prediction are:

1. The patient's age of 38 is relatively young, which is a favorable prognostic factor for cardiac outcomes.
2. The patient has a NYHA Class II heart failure classification, indicating mild symptoms and a moderate level of impairment, which is consistent with a relatively preserved cardiac function.
3. The patient's blood pressure is within a relatively normal range (110/50 mmHg), which is unlikely to contribute to further cardiac stress or damage.
4. The patient has a history of post-myocardial dilated cardiomyopathy, but the current LVEF (42.0) is not severely impaired, suggesting that the heart is still capable of maintaining adequate cardiac output.
5. The patient's laboratory results show no significant elevations in liver enzymes (ALT/GPT), which may indicate some degree of liver dysfunction, but this is not directly related to cardiac function.
6. The patient's medication regimen includes an ACE inhibitor, which is commonly used to manage heart failure and reduce mortality in patients with heart failure.
7. The ECG results do not indicate any significant arrhythmias or cardiac conduction abnormalities, which are potential predictors of sudden cardiac death.

While the patient has a history of dilated cardiomyopathy, the current data suggest that the patient is not in a high-risk category for sudden cardiac death or pump failure. Therefore, I predict that the patient is most likely to survive for the next few years."
277,277,P0457,"Age: 48
Gender: Female 
Weight: 62 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 119.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,74
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 380.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,06
TSH (mIU/L): 3,58
Urea (mg/dL): 11,48
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient is at a higher risk for sudden cardiac death and pump failure due to their NYHA Class III status, indicating severe heart failure symptoms, and their LVEF of 35%, which is significantly below the normal range. The patient's ECG shows non-sustained ventricular tachycardia, which is a strong predictor of arrhythmia-related complications. However, the patient's current medications (beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitor) are commonly used to manage heart failure and arrhythmias, suggesting that the patient is receiving appropriate treatment. The patient's troponin levels are not elevated, which may indicate some degree of cardiac damage, but it is not excessively high. The patient's serum creatinine level is slightly elevated, which may indicate some degree of kidney impairment, but it is not significantly high. The patient's serum potassium level is within the normal range, which reduces the risk of cardiac arrhythmias. 

The patient's Pro-BNP level is elevated, which is a marker of heart failure, but the patient is receiving spironolactone, which is a mineralocorticoid receptor antagonist that can help reduce BNP levels. Overall, while the patient has several risk factors for adverse outcomes, their current treatment regimen and relatively stable vital signs suggest that they are at lower risk for sudden cardiac death and pump failure compared to the other two options."
278,278,P0459,"Age: 65
Gender: Male 
Weight: 117 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Other HF etiology, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 128.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,49
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 382.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 23
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,28
Urea (mg/dL): 10,82
LVEF (%): 38.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 65-year-old male with a history of heart failure (NYHA Class II), hypertension, diabetes, and myocardial infarction. The patient has elevated creatinine levels (124.0 mmol/L) and a low LVEF (38.0%), indicating significant cardiac dysfunction. However, the patient is currently on multiple medications for heart failure and hypertension, including a beta blocker, loop diuretics, and an ACE inhibitor, which are known to improve outcomes in heart failure patients.

The patient's ECG shows ventricular extrasystole, which may indicate arrhythmia, but there is no evidence of ventricular tachycardia or other arrhythmias. The patient's Pro-BNP level is elevated (382.0 ng/L), which suggests fluid overload and possible heart failure.

Despite these concerning factors, the patient is currently classified as a survivor, which suggests that they are likely to continue receiving treatment and monitoring. The patient's age, weight, and comorbidities are also important considerations, but the presence of multiple medications and a relatively stable ECG impression suggest that the patient is currently stable.

While the patient's prognosis is uncertain, the likelihood of sudden cardiac death (SCD) is relatively low, as there is no evidence of ventricular tachycardia or other high-risk arrhythmias. The patient's pump failure death is also less likely, as they are currently receiving treatment for heart failure and have a stable ECG impression. Therefore, the most likely outcome for this patient is survival, given the current data.

Ranking the other two options:

- Sudden Cardiac Death (SCD): Unlikely. The patient's ECG shows ventricular extrasystole, but there is no evidence of ventricular tachycardia or other high-risk arrhythmias, which are common precursors to SCD.

- Pump Failure Death: Less likely. While the patient has significant cardiac dysfunction, they are currently receiving treatment for heart failure and have a stable ECG impression, which suggests that they are likely to continue receiving treatment and monitoring."
279,279,P0462,"Age: 54
Gender: Male 
Weight: 65 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 55.0
AST or GOT (IU/L): 39.0
Total Cholesterol (mmol/L): 7,96
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 167
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,97
Potassium (mEq/L): 3,7
LDL (mmol/L): 5,51
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 645.0
Protein (g/L): 79
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,35
Urea (mg/dL): 15,14
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, and hypertension, which can increase the risk of cardiac complications. However, the patient's current medical regimen, including beta blockers, ACE inhibitors, and diuretics, suggests a good level of cardiovascular management. The patient's laboratory results, such as a mildly elevated troponin level (0.01 ng/mL), may indicate some degree of cardiac stress, but the absence of a significant elevation in troponin or other markers of myocardial injury suggests that the patient has not experienced a major cardiac event. The patient's ejection fraction (LVEF) is significantly reduced at 30%, indicating left ventricular dysfunction, but this is not uncommon in patients with ischemic cardiomyopathy. Overall, the combination of a complex medical history, a well-managed regimen, and the absence of severe cardiac biomarkers suggest that the patient is likely to survive for the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient's LVEF is significantly reduced, which increases the risk of sudden cardiac death, the patient's current medical regimen and laboratory results do not suggest an acute cardiac event. However, the patient's history of ischemic dilated cardiomyopathy, diabetes, and hypertension increases the risk of arrhythmias, which can lead to sudden cardiac death. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests an increased risk of arrhythmias, but the absence of other markers of myocardial injury or ischemia makes it difficult to determine the likelihood of sudden cardiac death. Therefore, while the patient is at increased risk, the likelihood of sudden cardiac death is not as high as the next option.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is significantly reduced at 30%, indicating left ventricular dysfunction, which increases the risk of heart failure. The patient's history of ischemic dilated cardiomyopathy and hypertension also increases the risk of pump failure. However, the patient's current medical regimen, including ACE inhibitors and diuretics, suggests that the patient is receiving appropriate treatment for heart failure. The absence of severe symptoms or laboratory results indicating decompensated heart failure makes it less likely that the patient will experience pump failure death in the near term. Additionally, the patient's hemoglobin level is within a normal range, and the patient's renal function is not severely impaired, which are both positive prognostic factors. Therefore, while the patient is at increased risk of pump failure, the likelihood of pump failure death is lower than the next option."
280,280,P0463,"Age: 67
Gender: Female 
Weight: 60 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 142/61 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,15
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2853.0
Protein (g/L): 67
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,56
Urea (mg/dL): 7,32
LVEF (%): 47.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 67-year-old female with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient is currently taking medications for heart failure (Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics) and has a relatively stable ECG impression with no signs of acute cardiac stress or arrhythmias. The patient's laboratory values, such as a mildly elevated creatinine level and slightly elevated troponin, suggest some degree of cardiac stress, but not to the extent that would indicate an acute myocardial infarction or significant cardiac dysfunction. The patient's NYHA Class II indicates that they are able to perform light physical activity without symptoms, suggesting a relatively preserved functional capacity. Overall, the combination of the patient's stable medications, stable ECG, and relatively preserved functional capacity make a survivor the most likely outcome."
281,281,P0464,"Age: 52
Gender: Male 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,57
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,53
Sodium (mEq/L): 133.0
Protein (g/L): 73
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,03
Urea (mg/dL): 5,49
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, weight, and NYHA class II indicate that they have a moderate level of cardiac impairment. However, their LVEF is significantly reduced at 30%, which suggests that the patient's heart is not functioning optimally. Despite this, the patient is on beta blockers, spironolactone, and an ACE inhibitor, which are commonly used to manage heart failure and reduce the risk of cardiac complications.

The patient's troponin level is within the normal range, which suggests that there is no significant myocardial infarction. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and polymorphic ventricular extrasystole on ECG also suggests that the patient does not have a high risk of sudden cardiac death.

The patient's creatinine level is elevated at 53.0, which may indicate some degree of kidney impairment. However, this is not uncommon in patients with heart failure. The patient's albumin level is also low, which can be seen in patients with heart failure.

Given these factors, I would rank the patient as having a high likelihood of survival over the next few years. The patient's heart function is not severely impaired, and they are on medications that can help manage their condition. However, the patient's reduced LVEF and elevated creatinine level do indicate a higher risk of cardiac complications, and close monitoring will be necessary to ensure the patient's condition does not deteriorate.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's reduced LVEF of 30% indicates that their heart is not functioning optimally, which increases their risk of sudden cardiac death. The patient's NYHA class II also suggests that they have some degree of cardiac impairment.

The patient's elevated creatinine level and low albumin level may indicate some degree of kidney impairment, which can increase the risk of cardiac complications. The patient's high LDL cholesterol level also increases their risk of cardiovascular events.

While the patient is on beta blockers, spironolactone, and an ACE inhibitor, which are commonly used to manage heart failure, the patient's reduced LVEF and elevated creatinine level suggest that their heart function may not be adequately controlled.

Given these factors, I would rank the patient as having a moderate likelihood of sudden cardiac death over the next few years. The patient's reduced LVEF and elevated creatinine level increase their risk of cardiac complications, and close monitoring will be necessary to ensure the patient's condition does not deteriorate.

RANKING: 3. Pump failure death
REASONING: 

The patient's reduced LVEF of 30% indicates that their heart is not functioning optimally, which increases their risk of pump failure. The patient's NYHA class II also suggests that they have some degree of cardiac impairment.

The patient's elevated creatinine level and low albumin level may indicate some degree of kidney impairment, which can increase the risk of cardiac complications. The patient's high LDL cholesterol level also increases their risk of cardiovascular events.

The patient's reduced LVEF and elevated creatinine level, combined with their NYHA class II, suggest that the patient's heart function may be deteriorating over time. While the patient is on beta blockers, spironolactone, and an ACE inhibitor, which are commonly used to manage heart failure, their reduced LVEF and elevated creatinine level suggest that their heart function may not be adequately controlled.

Given these factors, I would rank the patient as having a low likelihood of pump failure death over the next few years. The patient's reduced LVEF and elevated creatinine level do not suggest that the patient's heart function is severely impaired, and the patient is on medications that can help manage their condition. However, close monitoring will be necessary to ensure the patient's condition does not deteriorate."
282,282,P0465,"Age: 69
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,21
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,19
LDL (mmol/L): 1,58
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 799.0
Protein (g/L): 70
T3 (pg/dL): 0,0597
T4 (ng/L): 9,9
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,73
Urea (mg/dL): 7,4
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest that they are at high risk for adverse cardiac events. The key factors contributing to this risk include:

1. Idiopathic dilated cardiomyopathy (DCM) with a left ventricular ejection fraction (LVEF) of 30%, which indicates severely impaired cardiac function.
2. History of ventricular tachycardia and non-sustained ventricular tachycardia, which are markers of arrhythmia risk.
3. Elevated Pro-BNP levels (799 ng/L), which indicate increased ventricular wall stress and strain.
4. Presence of ventricular extrasystoles, including polymorphic ventricular extrasystoles, which can be a sign of underlying cardiac electrical instability.
5. Elevated creatinine levels (98.0 mmol/L), which may indicate renal impairment, a common comorbidity in patients with DCM.
6. Presence of hyperkalemia (Potassium: 4.19 mEq/L), which can contribute to cardiac arrhythmias.
7. Low T3 levels (0.0597 pg/dL), which can be associated with cardiac dysfunction and decreased cardiac output.

Considering these factors, the patient's overall risk of cardiac events, such as sudden cardiac death or pump failure, is high. However, the patient is currently taking multiple medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which may help mitigate some of these risks. Despite this, the patient's underlying cardiac condition, combined with the presence of significant arrhythmias and other comorbidities, makes it likely that the patient will experience a cardiac event within the next few years. Therefore, the most likely prognosis is survivor, but with a high risk of cardiac events.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's risk of sudden cardiac death (SCD) is elevated due to the presence of several high-risk factors, including:

1. Idiopathic dilated cardiomyopathy with a severely impaired LVEF of 30%.
2. History of ventricular tachycardia and non-sustained ventricular tachycardia, which indicate a high risk of arrhythmia-related events.
3. Elevated Pro-BNP levels, indicating increased ventricular wall stress and strain.
4. Presence of ventricular extrasystoles, including polymorphic ventricular extrasystoles, which can be a sign of underlying cardiac electrical instability.
5. Elevated creatinine levels, indicating renal impairment, which can contribute to cardiac dysfunction.

While the patient is taking multiple medications, the presence of these high-risk factors, combined with the patient's underlying cardiac condition, makes SCD a significant concern.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's risk of pump failure death is moderate to high due to the presence of several factors, including:

1. Idiopathic dilated cardiomyopathy with a severely impaired LVEF of 30%.
2. History of ventricular tachycardia and non-sustained ventricular tachycardia, indicating a high risk of arrhythmia-related events.
3. Elevated Pro-BNP levels, indicating increased ventricular wall stress and strain.
4. Presence of ventricular extrasystoles, including polymorphic ventricular extrasystoles, which can be a sign of underlying cardiac electrical instability.
5. Elevated creatinine levels, indicating renal impairment, which can contribute to cardiac dysfunction.

However, the patient's overall clinical presentation and test results, including the presence of multiple medications and a relatively stable vital sign, suggest that the patient is currently not in a state of acute heart failure. Therefore, while pump failure is a concern, it is less likely than sudden cardiac death in the near future.

Note: The patient's overall prognosis is influenced by the complex interplay of multiple factors, and the actual outcome may vary. Regular monitoring and close follow-up are essential to adjust the treatment plan and mitigate the risk of cardiac events."
283,283,P0470,"Age: 73
Gender: Male 
Weight: 71 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 33,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,18
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,87
Potassium (mEq/L): 3,65
LDL (mmol/L): 1,91
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 5374.0
Protein (g/L): 69
Troponin (ng/mL): 0,05
TSH (mIU/L): 0,68
Urea (mg/dL): 7,1
LVEF (%): 35.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient's age, NYHA Class II, and LVEF of 35% indicate significant left ventricular dysfunction. However, the patient is currently on ACE inhibitors, which are known to improve LVEF in patients with heart failure. The presence of elevated BNP levels (5374 ng/L) suggests a high level of ventricular stress, but the patient's overall clinical presentation is relatively stable. The absence of any other severe symptoms or ECG abnormalities suggests that the patient may be able to tolerate treatment and make lifestyle modifications to improve their cardiac function. The patient's weight, blood pressure, and electrolyte levels are within relatively normal limits, which further supports a favorable prognosis.

2. Pump failure death
REASONING:
The patient's LVEF of 35% and elevated BNP levels suggest significant left ventricular dysfunction, which increases the risk of heart failure. The patient's NYHA Class II indicates that they are experiencing symptoms of heart failure, but they are not severely limited in their daily activities. However, the patient's elevated creatinine level (7.1 mg/dL) suggests some degree of renal impairment, which can be a complication of heart failure. The patient's elevated troponin level (0.05 ng/mL) suggests some degree of myocardial damage, but it is not excessively high. Given the patient's current medications and clinical presentation, there is a risk that the patient's heart failure could progress to pump failure, but this is not the most likely outcome.

3. Sudden cardiac death
REASONING:
The patient's ECG shows ventricular extrasystoles, which are a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. However, the absence of other ECG abnormalities, such as ventricular tachycardia or non-sustained ventricular tachycardia, suggests that the risk of sudden cardiac death is lower than it would be if these conditions were present. The patient's other clinical presentation and laboratory results do not suggest any other significant risk factors for sudden cardiac death. Therefore, while the patient is at some risk, the likelihood of sudden cardiac death is lower than pump failure death."
284,284,P0471,"Age: 74
Gender: Male 
Weight: 76 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 33,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,36
Potassium (mEq/L): 4,05
LDL (mmol/L): 3,85
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 557.0
Protein (g/L): 57,7
Troponin (ng/mL): 0,02
TSH (mIU/L): 0,37
Urea (mg/dL): 6,8
LVEF (%): 70.0
Medications: Calcium Channel Blocker
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 74-year-old male with a history of hypertensive cardiomyopathy and hypertension, which is a significant risk factor for cardiac complications. Despite the elevated creatinine level (106.0 mmol/L), which may indicate some degree of renal impairment, the patient's renal function is still relatively preserved. The patient's LVEF (70.0%) is also within a relatively normal range, suggesting that the patient's heart function is not severely compromised.

The patient's ECG impression shows ventricular extrasystoles, which are a common finding in patients with cardiomyopathy. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death. The patient's troponin level (0.02 ng/mL) is also within a relatively normal range, which suggests that there is no significant myocardial infarction.

The patient's medication regimen includes a calcium channel blocker, which is commonly used to treat hypertension and cardiomyopathy. The patient's laboratory values, including the elevated Pro-BNP level (557.0 ng/L), are not significantly abnormal, which suggests that the patient's cardiac function is not severely impaired.

Overall, based on the available data, the patient's prognosis is that he is likely to survive for the next few years. However, it is essential to continue monitoring the patient's cardiac function and adjust the treatment plan as needed to minimize the risk of cardiac complications.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's prognosis is that he is likely to survive for the next few years, there is still a risk of sudden cardiac death. The patient's ECG impression shows ventricular extrasystoles, which can be a precursor to ventricular tachycardia or ventricular fibrillation. Additionally, the patient's history of hypertensive cardiomyopathy and hypertension increases the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

Based on the available data, pump failure death is the least likely outcome. The patient's LVEF (70.0%) is within a relatively normal range, and the patient's cardiac function is not severely impaired. Additionally, the patient's laboratory values, including the elevated Pro-BNP level (557.0 ng/L), are not significantly abnormal. However, the patient's history of hypertensive cardiomyopathy and hypertension increases the risk of cardiac failure. Nevertheless, the patient's current cardiac function and laboratory values suggest that pump failure death is the least likely outcome."
285,285,P0472,"Age: 83
Gender: Male 
Weight: 67 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 105/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42,7
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,62
LDL (mmol/L): 1,84
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 4579.0
Protein (g/L): 74,9
Troponin (ng/mL): 0,09
TSH (mIU/L): 0,96
Urea (mg/dL): 12,2
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's overall clinical presentation and test results suggest a high likelihood of survival for the next few years. The patient's age is 83, but with a relatively well-controlled hypertension, diabetes, and ischemic dilated cardiomyopathy, their functional capacity is preserved, and they are classified as NYHA Class II. Their left ventricular ejection fraction (LVEF) is 60%, which is within the range for someone with a history of myocardial infarction and cardiomyopathy.

The patient's serum creatinine level of 125.0 is elevated, indicating some degree of kidney dysfunction, but this is not uncommon in patients with cardiovascular disease. The patient's renal function is likely being managed with the use of loop diuretics, which is a common treatment for heart failure.

The patient's electrolyte levels, including potassium and sodium, are within normal limits, which reduces the risk of cardiac arrhythmias. The elevated troponin level of 0.09 ng/mL is mildly elevated but not indicative of acute myocardial infarction. The elevated Pro-BNP level of 4579 ng/L is within the normal range for a patient with heart failure, indicating that the patient's ventricular strain is not excessively elevated.

The patient is on calcium channel blockers, digoxin, and loop diuretics, which are standard treatments for managing heart failure and hypertension. The absence of ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient does not have an immediately life-threatening arrhythmia.

Overall, while the patient has a history of significant cardiovascular disease, their current clinical presentation and test results suggest that they are likely to survive for the next few years with appropriate management."
286,286,P0474,"Age: 49
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45,9
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,88
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 137.0
Potassium (mEq/L): 4,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 797.0
Protein (g/L): 82,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,33
Urea (mg/dL): 9
LVEF (%): 19.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to several factors. Firstly, the patient's age of 49 is considered relatively young for the development of advanced heart failure, which may indicate that the disease is still in its early stages. The patient's NYHA class II classification indicates mild symptoms, suggesting that the disease has not yet significantly impaired the patient's quality of life.

The patient's laboratory results, such as a normal kidney function (creatinine 100.0 mmol/L) and normal liver enzymes (ALT/GPT 20.0 IU/L, AST/GOT 23.0 IU/L), suggest that the underlying disease process is not significantly affecting other organs. The elevated troponin level (0.01 ng/mL) may indicate some degree of cardiac damage, but it is not indicative of acute myocardial infarction or significant cardiac injury.

The patient's medication regimen, which includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, suggests that the patient is receiving standard treatment for heart failure with reduced ejection fraction (HFrEF). This treatment approach is generally effective in managing symptoms and improving quality of life in patients with HFrEF.

The ECG results show no signs of ventricular arrhythmias, which is a significant risk factor for sudden cardiac death. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmias reduces the risk of sudden cardiac death.

Overall, considering these factors, the patient's prognosis is ranked as a survivor, indicating that the patient is likely to survive for the next few years with proper management and treatment.

RANKING: 2. Sudden cardiac death
REASONING: 

This patient's prognosis is ranked as sudden cardiac death due to the presence of a high level of N-terminal pro-b-type natriuretic peptide (Pro-BNP) of 797 ng/L, which is elevated in patients with heart failure with reduced ejection fraction (HFrEF). Elevated Pro-BNP levels are associated with an increased risk of adverse outcomes, including sudden cardiac death.

Additionally, the patient's low left ventricular ejection fraction (LVEF) of 19.0% indicates severe left ventricular dysfunction, which is a significant risk factor for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

This patient's prognosis is ranked as pump failure death due to the presence of a low ejection fraction (LVEF 19.0%) and the patient's NYHA class II classification. A low ejection fraction indicates that the left ventricle is not pumping efficiently, which can lead to progressive heart failure and eventually pump failure.

The patient's elevated creatinine level (100.0 mmol/L) may indicate some degree of kidney dysfunction, which can be a complication of heart failure. The patient's high blood pressure (110/75 mmHg) and elevated troponin level (0.01 ng/mL) may also indicate some degree of cardiac stress and damage.

However, the patient's age, laboratory results, and ECG findings suggest that the disease process is still in its early stages, and the patient is receiving standard treatment for HFrEF. Therefore, while pump failure is a potential risk, it is less likely than sudden cardiac death in this patient."
287,287,P0475,"Age: 64
Gender: Female 
Weight: 73 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43,2
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 149.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,38
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,33
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 287.0
Protein (g/L): 77,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,88
Urea (mg/dL): 15
LVEF (%): 35.0
Medications: Diabetes Medication, Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Given the patient's advanced age, history of idiopathic dilated cardiomyopathy, and elevated BNP levels (287.0 ng/L), which indicates significant cardiac stress, the patient is at high risk for adverse outcomes. However, the patient is currently on medications that are commonly used to manage heart failure, such as spironolactone, loop diuretics, and ACE inhibitors (Angiotensin II Receptor Blocker). The patient's current hemoglobin level (136.0 g/L) and troponin level (0.01 ng/mL) are within normal limits, suggesting that the patient is not currently experiencing significant myocardial damage. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG also reduces the risk of sudden cardiac death. Therefore, while the patient is at risk for pump failure due to the underlying heart condition, the presence of current treatment and the absence of significant cardiac stress markers make a sudden cardiac death less likely, making a survivor the most likely prognosis.

RANKING: 2. Pump failure death
REASONING: 
While the patient is at risk for pump failure due to the underlying idiopathic dilated cardiomyopathy, the patient is currently on medications that are commonly used to manage heart failure, which suggests that the patient is receiving adequate treatment. However, the patient's LVEF (35.0) is significantly reduced, indicating poor cardiac function. Additionally, the patient's elevated creatinine level (149.0 mmol/L) and elevated BNP level (287.0 ng/L) suggest that the patient's heart is under significant stress, which may lead to pump failure. The patient's elevated glucose level (6.6 mmol/L) and the presence of diabetes also increase the risk of complications. Therefore, while pump failure is a possible outcome, it is less likely than sudden cardiac death due to the presence of current treatment and relatively stable laboratory values.

RANKING: 3. Sudden cardiac death
REASONING: 
The patient's advanced age, history of idiopathic dilated cardiomyopathy, and elevated BNP levels increase the risk of sudden cardiac death. However, the patient's current treatment with medications such as amiodarone, which is used to treat arrhythmias, and the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG reduce the risk of sudden cardiac death. Additionally, the patient's laboratory values are relatively stable, which suggests that the patient is not currently experiencing significant cardiac stress. Therefore, while sudden cardiac death is a possible outcome, it is the least likely due to the presence of current treatment and relatively stable laboratory values."
288,288,P0476,"Age: 64
Gender: Male 
Weight: 93 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 103/57 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 41,8
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 151.0
HDL (mmol/L): 2,09
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,82
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 146.0
Protein (g/L): 68,2
T4 (ng/L): 20
TSH (mIU/L): 1,55
Urea (mg/dL): 10,48
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 64-year-old male with a history of heart failure (HF) and various comorbid conditions such as dyslipidemia and other etiology for heart failure. The patient has a significant elevation in creatinine levels (111.0 mmol/L), which may indicate chronic kidney disease or renal impairment. Despite this, the patient's LVEF is 38%, which is a relatively preserved left ventricular function, indicating that the heart is still capable of pumping blood efficiently.

The patient's ECG shows a polymorphic ventricular extrasystole, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests that the risk of sudden cardiac death is not extremely high.

The patient is currently taking a variety of medications, including calcium channel blockers, amiodarone, beta blockers, statins, ACE inhibitors, and a nitrovasodilator, which are commonly used to manage heart failure, arrhythmias, and dyslipidemia. These medications suggest that the patient is receiving comprehensive treatment for their cardiovascular conditions.

Considering these factors, I believe that the patient is at a moderate risk for adverse outcomes, but the overall prognosis is still favorable. Therefore, I rank the patient as a survivor."
289,289,P0478,"Age: 80
Gender: Male 
Weight: 63 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 44,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,91
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1544.0
Protein (g/L): 73,4
T4 (ng/L): 19
TSH (mIU/L): 0,38
Urea (mg/dL): 8,82
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient is at a higher risk of pump failure death due to the presence of Idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and cardiogenic shock. The patient's LVEF (left ventricular ejection fraction) is severely impaired at 40%, indicating a high risk of heart failure.

Although the patient has a history of Diabetes and Dyslipemia, these conditions are not as critical in this scenario as the cardiomyopathy. The patient's blood pressure and electrolyte levels are within relatively normal limits, and the patient is on medications that are commonly used to manage heart failure, such as ACE inhibitors and beta blockers.

The presence of non-sustained ventricular tachycardia (NSVT) is a concerning finding, but it is not a guarantee of a poor outcome. However, in the context of the patient's underlying cardiomyopathy, it may indicate an increased risk of ventricular arrhythmias and potentially life-threatening arrhythmias.

Given the patient's overall clinical presentation, I believe that the most likely outcome is survival. However, close monitoring and careful management of the patient's medications and electrolyte levels will be crucial to prevent complications and improve the patient's prognosis.

RANKING: 2. Sudden Cardiac Death
REASONING:

The patient's presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia (NSVT) increase the risk of sudden cardiac death. The patient's LVEF is severely impaired, and the presence of cardiomyopathy and other comorbidities such as diabetes and dyslipemia further increase the risk of arrhythmias.

However, the patient is on medications that are commonly used to manage arrhythmias and heart failure, and the patient's blood pressure and electrolyte levels are within relatively normal limits. While the patient is at a higher risk of sudden cardiac death, the presence of close monitoring and careful management of medications may help mitigate this risk.

RANKING: 3. Pump Failure Death
REASONING:

While the patient's LVEF is severely impaired, the patient is on medications that are commonly used to manage heart failure, and the patient's blood pressure and electrolyte levels are within relatively normal limits. The patient's past medical history of idiopathic dilated cardiomyopathy is a significant risk factor for heart failure, but the patient's current medications and close monitoring may help manage this risk.

However, the patient's elevated creatinine level (103.0) suggests some degree of kidney impairment, which may increase the risk of pump failure. Additionally, the patient's elevated liver enzymes (ALT and AST) may indicate some degree of liver dysfunction, which may also contribute to the risk of pump failure.

Overall, while the patient is at risk of pump failure, the presence of close monitoring and careful management of medications and electrolyte levels may help mitigate this risk."
290,290,P0479,"Age: 72
Gender: Male 
Weight: 54 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 40
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,41
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 624.0
Protein (g/L): 67
T3 (pg/dL): 0,0615
T4 (ng/L): 11,73
Troponin (ng/mL): 0,8
TSH (mIU/L): 6,94
Urea (mg/dL): 11,9
LVEF (%): 30.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

The patient's overall clinical presentation and test results suggest a poor prognosis. Key factors contributing to this include:

1. Advanced age (72 years): As people age, the risk of cardiovascular events and mortality increases.
2. Idiopathic dilated cardiomyopathy (IDC): This condition is a significant risk factor for heart failure and arrhythmias.
3. Elevated LVEF (30%): This indicates severely impaired left ventricular function, which is a hallmark of advanced heart failure.
4. High troponin levels (0.8 ng/mL): Elevated troponin levels can indicate myocardial damage, which is consistent with the patient's IDC.
5. Presence of ventricular extrasystoles and non-sustained ventricular tachycardia (NSVT): These arrhythmias are associated with increased risk of sudden cardiac death.
6. Elevated Pro-BNP levels (624 ng/L): Elevated B-type natriuretic peptide (BNP) levels are indicative of heart failure and are associated with increased mortality.
7. Presence of dyslipidemia and elevated total cholesterol (6.67 mmol/L): These factors contribute to atherosclerosis and further compromise cardiac function.
8. Low HDL cholesterol (1.49 mmol/L): Low HDL levels are associated with increased risk of cardiovascular events.
9. Presence of renal impairment (elevated creatinine and urea levels): Renal impairment can contribute to fluid overload and electrolyte imbalances, exacerbating cardiac dysfunction.

Given these factors, the patient's overall risk of mortality is high, making a survivor outcome less likely. However, considering the patient's current medication regimen, which includes ACE inhibitors and amiodarone, and the fact that the patient's condition has been stable, I would rank the patient's outcome as a survivor, but with a high risk of complications and the need for close monitoring."
291,291,P0484,"Age: 74
Gender: Female 
Weight: 83 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 118.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,43
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 146.0
Protein (g/L): 77,5
T4 (ng/L): 6
TSH (mIU/L): 34,49
Urea (mg/dL): 6,82
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is 74 years old with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood efficiently is compromised. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 35.0%, indicating severe systolic dysfunction. 

The patient's NYHA Class II classification suggests that they experience symptoms of heart failure with moderate intensity. The elevated creatinine level (79.0 mmol/L) and urea level (6.82 mg/dL) also suggest impaired renal function, which is often seen in advanced heart failure.

Despite the patient's elevated BNP levels (146.0 ng/L), which indicate increased ventricular wall stress, the patient is currently on beta blockers and loop diuretics, which are standard treatments for heart failure. The presence of ventricular extrasystole (polymorphic) on the ECG is a concerning sign, but it does not necessarily indicate an immediate life-threatening arrhythmia. The absence of other arrhythmias and the patient's stable vital signs make this a relatively minor concern at this time.

Given these factors, the patient is likely to survive the next few years, provided that their current treatment plan remains effective and there are no significant changes in their underlying condition. The patient's age and comorbidities do increase the risk of complications, but the patient's overall prognosis is still relatively favorable compared to the other options."
292,292,P0485,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 106
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 903.0
Protein (g/L): 70
T4 (ng/L): 17
TSH (mIU/L): 1,44
Urea (mg/dL): 7,65
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's age, NYHA Class III status, and multiple comorbid conditions such as ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction, suggest a high risk of adverse outcomes. However, the patient has been diagnosed as a survivor, which indicates that they have not experienced a severe cardiac event such as sudden cardiac death or pump failure.

The patient's elevated creatinine level (104.0 mmol/L) and elevated Pro-BNP level (903.0 ng/L) suggest a significant degree of cardiac dysfunction, which may be contributing to the patient's poor prognosis. However, the patient is currently receiving treatment with medications such as ACE inhibitors, beta blockers, and digoxin, which are standard therapies for managing heart failure and hypertension.

The patient's ECG findings of ventricular extrasystole and polymorphic ventricular tachycardia are concerning, but the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia makes it less likely that the patient will experience a sudden cardiac death in the near future.

Overall, while the patient's prognosis is uncertain, the fact that they have been diagnosed as a survivor suggests that they are currently stable and receiving appropriate treatment. Therefore, I rank the patient as having the highest likelihood of survival over the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's ECG findings of ventricular extrasystole and polymorphic ventricular tachycardia are concerning, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia makes it less likely that the patient will experience sudden cardiac death in the near future. However, the patient's history of ischemic dilated cardiomyopathy and multiple comorbid conditions may still increase their risk of cardiac events.

The patient's elevated Pro-BNP level and elevated creatinine level suggest a significant degree of cardiac dysfunction, which may contribute to their risk of sudden cardiac death. However, the patient is receiving treatment with medications that are standard for managing heart failure and hypertension, which may help mitigate this risk.

Overall, while the patient's risk of sudden cardiac death is present, the absence of more severe cardiac events in the past and the fact that they have been diagnosed as a survivor make it less likely than pump failure.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's elevated Pro-BNP level (903.0 ng/L) and elevated creatinine level (104.0 mmol/L) suggest a significant degree of cardiac dysfunction, which increases the risk of pump failure. The patient's NYHA Class III status and history of ischemic dilated cardiomyopathy also contribute to this risk.

The patient's elevated blood pressure (160/80 mmHg) and elevated LDL cholesterol level (1.91 mmol/L) also increase their risk of cardiac events. However, the patient is receiving treatment with medications that are standard for managing hypertension and heart failure, which may help mitigate this risk.

While the patient's ECG findings are concerning, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia makes it less likely that the patient will experience pump failure in the near future. However, the patient's overall risk factors and comorbid conditions make pump failure a possible outcome.

Overall, while the patient's risk of pump failure is present, the fact that they have been diagnosed as a survivor and are receiving treatment with standard medications for heart failure and hypertension make it less likely than sudden cardiac death."
293,293,P0486,"Age: 68
Gender: Male 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 48,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,79
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 471.0
Protein (g/L): 78,9
T4 (ng/L): 19
TSH (mIU/L): 0,91
Urea (mg/dL): 5,32
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the patient's data, the patient's age, NYHA Class II heart failure, and history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia suggest a significant cardiac risk. The elevated creatinine level (74.0 mmol/L) indicates impaired renal function, which is often associated with heart failure. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further increase the risk of arrhythmic events.

The patient's current medications, including beta blockers, loop diuretics, statins, and ACE inhibitors, are standard treatments for heart failure and dyslipidemia. However, the patient's low ejection fraction (LVEF) of 40.0% indicates a reduced cardiac function, which may not be adequately compensated by these medications.

Given these factors, the patient's prognosis is likely to be a survivor, as they are receiving standard treatment for their conditions and have not shown any severe cardiac dysfunction. However, close monitoring and adjustments to their treatment plan may be necessary to manage their heart failure and reduce the risk of arrhythmic events.

2. Pump failure death
REASONING: 
While the patient's reduced ejection fraction (LVEF) of 40.0% indicates significant cardiac dysfunction, the fact that they are receiving standard treatments for heart failure suggests that their condition is not immediately life-threatening. However, the presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG increases the risk of arrhythmic events.

If the patient's cardiac function does not improve with optimal treatment, they may eventually progress to pump failure, which can lead to decreased cardiac output, decreased renal function, and increased mortality. However, this is a more distant risk and may take several years to develop.

3. Sudden cardiac death
REASONING: 
The patient's ECG findings, including non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles, increase the risk of sudden cardiac death. However, the patient's current treatment plan includes medications that can help reduce this risk, such as beta blockers, which are known to reduce the risk of arrhythmic events.

While the patient's ECG findings are concerning, the fact that they are receiving standard treatments for their conditions suggests that the risk of sudden cardiac death is not immediately high. However, close monitoring and adjustments to their treatment plan may be necessary to reduce the risk of arrhythmic events."
294,294,P0488,"Age: 31
Gender: Female 
Weight: 57 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47,3
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 55.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4
LDL (mmol/L): 3,13
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 391.0
Protein (g/L): 85,5
T4 (ng/L): 14
TSH (mIU/L): 1,84
Urea (mg/dL): 4,82
LVEF (%): 25.0
Medications: Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's prognosis is likely to be a survivor due to several factors. Firstly, the patient's age (31 years) is relatively young, which suggests that the disease process is not advanced. The patient's NYHA Class II classification indicates a moderate level of heart failure, but it is not severe. The patient's LVEF (left ventricular ejection fraction) is 25%, which is a relatively preserved ejection fraction, indicating some residual cardiac function.

The patient's past medical history of ischemic dilated cardiomyopathy and myocardial infarction suggests a history of cardiac damage, but the patient is currently receiving beta blockers and a nitrovasodilator, which are commonly used to manage heart failure. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but it is not indicative of a high risk of sudden cardiac death. The patient's serum creatinine level is elevated, indicating some degree of kidney dysfunction, but this is not uncommon in patients with heart failure.

The patient's laboratory results show a mild elevation in liver enzymes (ALT and AST) and a high level of Pro-BNP (brain natriuretic peptide), which is consistent with heart failure. However, the patient's other laboratory results, including electrolyte levels, glucose, and lipid profiles, are relatively normal.

Overall, while the patient has a history of cardiac disease and some signs of heart failure, the combination of a relatively young age, preserved ejection fraction, and the presence of beta blockers and nitrovasodilator therapy suggest that the patient is likely to survive in the short term."
295,295,P0490,"Age: 74
Gender: Male 
Weight: 85 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 155
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1375.0
Protein (g/L): 72
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,79
Urea (mg/dL): 11,32
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient data, the patient has a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which indicates a compromised cardiac function. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 32.0%, indicating severe systolic dysfunction. The presence of elevated BNP levels (1375.0 ng/L) suggests volume overload and possible heart failure.

The patient's current medication regimen includes beta blockers, loop diuretics, spironolactone, ACE inhibitors, and a nitrovasodilator, which is a comprehensive approach to managing heart failure and hypertension. The absence of ventricular tachycardia, bradycardia, or paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient is not at high risk for life-threatening arrhythmias.

The patient's renal function is mildly impaired, as indicated by elevated creatinine levels (11.32 mg/dL), but this is not severe and may not significantly impact the patient's overall prognosis. The patient's weight and BMI are within the normal range, which is beneficial for overall health.

Considering these factors, the most likely prognosis for the patient over the next few years is a survivor. The patient's current treatment regimen and medical history suggest that the patient is being adequately managed for their heart failure and hypertension, and with proper management, the patient can expect to survive for several years.

While the patient's cardiac function is severely compromised, the patient's overall health and medical history do not suggest a high risk for sudden cardiac death or pump failure within the next few years. However, it is essential for the patient to continue with their current treatment regimen and monitor their condition closely to ensure that any changes in their condition are detected promptly."
296,296,P0492,"Age: 40
Gender: Male 
Weight: 73 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,94
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 575.0
Protein (g/L): 69
T4 (ng/L): 14
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,59
Urea (mg/dL): 4,16
LVEF (%): 31.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 40-year-old male with a significant medical history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. His current NYHA class is II, indicating moderate symptoms. Despite these comorbidities, the patient's current vital signs are relatively stable, with a blood pressure of 100/70 mmHg and a normal heart rate.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate liver disease, but the overall picture is not alarming. The patient's kidney function is also mildly impaired, with a creatinine level of 80.0 mmol/L, but this is not uncommon in patients with heart failure.

The most concerning finding is the low ejection fraction (LVEF) of 31.0%, which indicates severe systolic dysfunction. However, the patient is on ACE inhibitor therapy, which is typically used to improve cardiac function in patients with heart failure. The patient's troponin levels are normal, which suggests that there is no acute myocardial infarction.

The ECG findings are also not alarming, with no signs of ventricular tachycardia or arrhythmias. The presence of ventricular extrasystoles is noted, but it is not a life-threatening finding.

Given the patient's overall clinical picture, I would rank the patient as having a high likelihood of survival over the next few years. The patient's heart failure symptoms are moderate, but the patient is on therapy for heart failure, and the patient's cardiac function is not severely impaired. With proper management, it is possible that the patient's condition may improve over time.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's LVEF is severely impaired, the patient is on therapy for heart failure, which suggests that the patient's condition is being managed. However, the patient's risk of sudden cardiac death cannot be ruled out.

The patient's ECG findings show ventricular extrasystoles, which may indicate a potential arrhythmic risk. While the patient's troponin levels are normal, the patient's low ejection fraction and the presence of ventricular extrasystoles may increase the risk of arrhythmias.

The patient's medical history of myocardial infarction and diabetes also increases the risk of sudden cardiac death. Additionally, the patient's low HDL cholesterol level (0.83 mmol/L) may increase the risk of atherosclerotic disease.

While the patient's overall clinical picture is concerning, I would rank the patient as having a moderate likelihood of sudden cardiac death over the next few years. However, this is not the most likely outcome.

RANKING: 3. Pump failure death
REASONING: 

Given the patient's severely impaired LVEF and the presence of ventricular extrasystoles, the patient is at high risk of developing heart failure over the next few years. The patient's low ejection fraction and the presence of ventricular extrasystoles suggest that the patient's heart is not functioning properly, and the patient is at risk of developing heart failure.

The patient's medical history of myocardial infarction and diabetes also increases the risk of heart failure. The patient's low ejection fraction and the presence of ventricular extrasystoles suggest that the patient's heart is not functioning properly, and the patient is at risk of developing heart failure.

While the patient is on therapy for heart failure, the patient's severely impaired LVEF and the presence of ventricular extrasystoles suggest that the patient's condition is not well-controlled. The patient's risk of developing pump failure over the next few years is high.

However, I would rank the patient as having a lower likelihood of pump failure death compared to sudden cardiac death, as the patient is on therapy for heart failure and the patient's symptoms are moderate."
297,297,P0493,"Age: 67
Gender: Male 
Weight: 80 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 5
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 248.0
Protein (g/L): 75
T4 (ng/L): 10
Troponin (ng/mL): 0,09
TSH (mIU/L): 1,87
Urea (mg/dL): 4,16
LVEF (%): 35.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's prognosis is ranked as a survivor due to several factors. Firstly, the patient's age (67 years) is not unusually high for someone with heart disease, and they are still relatively young for a patient with a history of ischemic dilated cardiomyopathy. The patient's NYHA class is II, indicating mild symptoms, which is a good indicator of the severity of their heart condition. Additionally, the patient's LVEF is 35%, which is significantly reduced, but it's still a relatively preserved value for someone with heart failure.

The patient's laboratory results show that they have elevated creatinine levels (71.0 mmol/L), which indicates impaired kidney function, but this is not uncommon in patients with heart failure. The patient's electrolyte and liver function tests are relatively normal, and their glucose levels are not significantly elevated.

The patient's ECG results show signs of arrhythmias, including ventricular extrasystole and ventricular tachycardia, but these are not sustained and do not indicate a high risk of sudden cardiac death. The patient's medication list includes beta blockers and statins, which are standard treatments for heart failure and ischemic heart disease.

The patient's Pro-BNP level is elevated at 248.0 ng/L, which indicates some level of heart failure, but it's not extremely high. Overall, considering the patient's age, NYHA class, LVEF, and laboratory results, the likelihood of sudden cardiac death and pump failure death is relatively low, making survival the most likely outcome."
298,298,P0495,"Age: 47
Gender: Male 
Weight: 89 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 42
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 8,2
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 163.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,3
LDL (mmol/L): 5,95
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 543.0
Protein (g/L): 79
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,2
Urea (mg/dL): 4,99
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING:
This patient has several factors that suggest a high likelihood of survival. Firstly, the patient is relatively young (47 years old) and has a body mass index (BMI) of 21.9, which is within the normal range. The patient's NYHA class is II, indicating mild symptoms, which suggests that the patient is not severely limited by their heart condition. Additionally, the patient's blood pressure is well-controlled (130/70 mmHg), which is within the target range for most patients with heart failure.

The patient's laboratory results also suggest a relatively preserved cardiac function, with an ejection fraction (LVEF) of 35%. This is a significant drop from a normal value of 55-70%, but it is not extremely low, which could suggest that the patient may still have some residual cardiac function. The patient's troponin level is normal, which suggests that there is no significant myocardial injury.

The patient's lipid profile is also relatively well-controlled, with a total cholesterol level of 8.2 mmol/L, which is within the target range. The patient's creatinine level is elevated, but it is not significantly high, which suggests that the patient's kidney function is not severely impaired.

The patient's medication regimen includes beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure. The patient's ECG results show no signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are both associated with a higher risk of sudden cardiac death.

Overall, based on the patient's age, NYHA class, blood pressure, laboratory results, and medication regimen, I believe that the patient has a high likelihood of survival over the next few years.

2. Pump failure death
REASONING:
This patient has several factors that suggest a moderate to high risk of pump failure death. The patient's LVEF is significantly reduced at 35%, which indicates that the patient's heart is not pumping efficiently. This is a significant drop from a normal value of 55-70%, and it suggests that the patient's heart is not functioning at optimal levels.

The patient's creatinine level is elevated, which suggests that the patient's kidney function is impaired. Kidney impairment is a common complication of heart failure, and it can lead to fluid overload, which can increase the risk of pump failure.

The patient's lipid profile is not as well-controlled as it could be, with a total cholesterol level of 8.2 mmol/L. Elevated cholesterol levels can increase the risk of atherosclerosis, which can lead to coronary artery disease and reduce blood flow to the heart, further exacerbating heart failure.

The patient's ECG results show signs of ventricular extrasystole, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death.

Overall, based on the patient's reduced LVEF, elevated creatinine level, and slightly elevated total cholesterol level, I believe that the patient has a moderate to high risk of pump failure death over the next few years.

3. Sudden cardiac death
REASONING:
This patient has several factors that suggest a high risk of sudden cardiac death. The patient's LVEF is significantly reduced at 35%, which indicates that the patient's heart is not functioning at optimal levels. This can increase the risk of arrhythmias, which are irregular heartbeats that can lead to sudden cardiac death.

The patient's ECG results show signs of ventricular extrasystole, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. Additionally, the patient's troponin level is slightly elevated, which suggests that there may be some myocardial injury, which can increase the risk of arrhythmias.

The patient's lipid profile is not as well-controlled as it could be, with a total cholesterol level of 8.2 mmol/L. Elevated cholesterol levels can increase the risk of atherosclerosis, which can lead to coronary artery disease and reduce blood flow to the heart, further exacerbating heart failure.

Overall, based on the patient's reduced LVEF, abnormal ECG results, and slightly elevated troponin level, I believe that the patient has a high risk of sudden cardiac death over the next few years."
299,299,P0497,"Age: 47
Gender: Male 
Weight: 88 kg
Height: 189 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Toxic dilated cardiomyopathy
Albumin (g/L): 43,4
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 3,73
LDL (mmol/L): 3,4
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 435.0
Protein (g/L): 69,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,72
Urea (mg/dL): 9,2
LVEF (%): 55.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the patient's data, I would rank the patient as a survivor for the next few years. The patient's NYHA Class II indicates that they have some limitations in physical activity due to their heart condition, but they are still able to perform moderate physical activity. Their LVEF (left ventricular ejection fraction) is 55%, which is relatively preserved, indicating that their heart is still pumping effectively.

The patient's medication regimen, which includes beta blockers, digoxin, loop diuretics, and ACE inhibitors, is well-tailored to their condition and is likely to help manage their symptoms and slow the progression of their heart disease.

The patient's laboratory results, including a normal blood pressure, normal liver function tests, and normal kidney function, also suggest that their overall health is relatively stable.

The only concerning factor is the patient's elevated troponin level, which may indicate some degree of cardiac damage. However, the level is very low (0.01 ng/mL), which may not be indicative of significant myocardial infarction.

Overall, based on the patient's data, I believe that they are likely to survive for the next few years, but close monitoring and follow-up with regular echocardiograms and blood tests will be necessary to ensure that their condition does not worsen.

2. Sudden Cardiac Death 
REASONING: 
While the patient's elevated troponin level is a concerning factor, the low level of 0.01 ng/mL is not indicative of significant myocardial infarction. However, the patient's past medical history of toxic dilated cardiomyopathy increases their risk of sudden cardiac death.

The patient's LVEF of 55% is relatively preserved, but it is still lower than the normal range (50-70%), which may indicate some degree of cardiac dysfunction. The patient's ECG results show ventricular extrasystole, which is a risk factor for sudden cardiac death.

The patient's medications, while effective in managing their symptoms, may not be sufficient to completely eliminate the risk of sudden cardiac death. Therefore, I would rank the patient as having a moderate risk of sudden cardiac death.

3. Pump Failure Death 
REASONING: 
Given the patient's history of toxic dilated cardiomyopathy and their current LVEF of 55%, I would rank the patient as having a relatively low risk of pump failure death. The patient's medications, including ACE inhibitors, are effective in reducing the strain on the heart and preventing further damage.

However, the patient's elevated creatinine level (107.0 mol/L) and protein level (69.9 g/L) may indicate some degree of kidney impairment, which can be a risk factor for pump failure. Additionally, the patient's elevated troponin level, while low, may indicate some degree of cardiac damage.

Overall, while the patient's risk of pump failure death is not extremely high, the combination of their past medical history, elevated creatinine and protein levels, and elevated troponin level do increase their risk of pump failure death."
300,300,P0502,"Age: 57
Gender: Male 
Weight: 86 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 105/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41,3
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,37
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 148.0
Potassium (mEq/L): 4,22
Sodium (mEq/L): 140.0
Protein (g/L): 73,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 6
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age, NYHA Class II, and the absence of any recent cardiac events (ECG Impression: Ventricular Extrasystole: Polymorphic, Ventricular Tachycardia: No, Non-sustained ventricular tachycardia (CH>10): No, Paroxysmal supraventricular tachyarrhythmia: No, Bradycardia: No) suggest that the patient is currently stable. The presence of idiopathic dilated cardiomyopathy indicates a chronic condition, but the patient is receiving treatment with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and arrhythmias. The patient's LVEF is 17.0, which is within the range of 15-30% for patients with heart failure, indicating that the patient's heart is not severely impaired. The absence of troponin elevation and normal electrolyte levels further support the patient's current stable condition. Overall, these factors suggest that the patient is likely to survive for the next few years with proper management and treatment."
301,301,P0503,"Age: 47
Gender: Male 
Weight: 92 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 127.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 172.0
HDL (mmol/L): 0,71
Potassium (mEq/L): 4,41
LDL (mmol/L): 4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1129.0
Protein (g/L): 78
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,47
Urea (mg/dL): 13,2
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 47-year-old male with a history of idiopathic dilated cardiomyopathy and myocardial infarction. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 17%, indicating severe left ventricular dysfunction. The patient is also experiencing symptoms consistent with NYHA Class II heart failure, which suggests that the patient's heart is not able to meet the body's oxygen demands.

The patient's elevated creatinine levels (127 mmol/L) and urea (13.2 mg/dL) levels indicate impaired renal function, which is a common complication of heart failure. The patient's elevated BNP levels (1129 ng/L) further support the diagnosis of heart failure.

Despite the presence of these significant comorbidities and functional impairment, the patient's survival is still possible, and the patient has been declared a survivor. The patient is on beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure.

The patient's troponin level is within normal limits, and the ECG shows no evidence of ventricular tachycardia or ventricular extrasystoles, which reduces the risk of sudden cardiac death. The patient's potassium level is also within normal limits, which reduces the risk of arrhythmias.

Overall, while the patient's prognosis is guarded, the patient's survival is still possible due to the presence of effective medical therapy and the absence of life-threatening arrhythmias or other complications.

2. Sudden cardiac death
REASONING: 
The patient's history of myocardial infarction and idiopathic dilated cardiomyopathy increases the risk of sudden cardiac death. The patient's LVEF is severely impaired, which increases the risk of arrhythmias and sudden cardiac death. The patient's elevated creatinine levels and urea levels also indicate impaired renal function, which can contribute to the development of cardiac complications.

However, the patient's troponin level is within normal limits, and the ECG shows no evidence of ventricular tachycardia or ventricular extrasystoles, which reduces the risk of sudden cardiac death. Additionally, the patient is on beta blockers, which are known to reduce the risk of arrhythmias and sudden cardiac death.

While the patient's prognosis is still uncertain, the absence of life-threatening arrhythmias and the presence of effective medical therapy reduce the likelihood of sudden cardiac death.

3. Pump failure death
REASONING: 
The patient's LVEF is severely impaired at 17%, which indicates that the patient's heart is unable to pump effectively. The patient's elevated creatinine levels and urea levels further indicate impaired renal function, which can contribute to the development of pump failure.

The patient's NYHA Class II symptoms suggest that the patient's heart is not able to meet the body's oxygen demands, which increases the risk of pump failure. However, the patient is on beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure. These medications can help manage symptoms and reduce the risk of pump failure.

The patient's troponin level is within normal limits, and the ECG shows no evidence of ventricular tachycardia or ventricular extrasystoles, which reduces the risk of pump failure. However, the patient's severely impaired LVEF and impaired renal function increase the risk of pump failure.

Overall, while the patient's prognosis is guarded, the presence of effective medical therapy reduces the risk of pump failure. However, the patient's severely impaired LVEF and impaired renal function increase the risk of pump failure, making this the least likely outcome."
302,302,P0505,"Age: 79
Gender: Female 
Weight: 78 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,24
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,56
Urea (mg/dL): 8,02
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a high risk of adverse outcomes due to their advanced age (79 years), NYHA Class III heart failure, and a history of ischemic dilated cardiomyopathy. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a significant concern, as it indicates an increased risk of sudden cardiac death. However, the patient's current LVEF of 50% suggests that they have some residual cardiac function, which may contribute to their survival.

The patient's laboratory results also indicate some degree of kidney impairment (elevated creatinine) and elevated troponin levels, which may suggest some degree of cardiac stress or damage. However, the patient is currently on a comprehensive regimen of medications, including beta blockers, ACE inhibitors, and statins, which are all beneficial for heart failure management.

The patient's hemoglobin and liver function tests are within relatively normal limits, and the absence of severe anemia or liver dysfunction may also contribute to their survival. 

While the patient has a high risk of adverse outcomes, their overall clinical presentation and laboratory results do not suggest an immediate life-threatening condition that would necessitate hospitalization or intervention. Therefore, I predict that this patient is likely to survive for the next few years, albeit with ongoing management and monitoring of their cardiac function and potential arrhythmias.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy, NYHA Class III heart failure, and non-sustained ventricular tachycardia (NSVT) on the ECG make them at high risk for sudden cardiac death. The presence of NSVT is particularly concerning, as it increases the risk of ventricular fibrillation, which can lead to sudden cardiac death.

Additionally, the patient's low LVEF of 50% suggests that they have significant cardiac dysfunction, which can contribute to arrhythmias and other complications.

While the patient is on a comprehensive regimen of medications, the presence of NSVT and other cardiac concerns may still pose a risk for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's NYHA Class III heart failure and elevated creatinine levels suggest that they have significant cardiac dysfunction and kidney impairment. While the patient is on medications to manage their heart failure and kidney function, the presence of NSVT and other cardiac concerns may still increase the risk of pump failure.

Additionally, the patient's age and comorbidities (e.g., diabetes, hypertension, dyslipidemia) may contribute to their overall risk of complications. However, the patient's current clinical presentation and laboratory results do not suggest an immediate life-threatening condition that would necessitate hospitalization or intervention.

While pump failure is a potential risk, it is less likely than sudden cardiac death given the patient's current presentation and management."
303,303,P0506,"Age: 71
Gender: Female 
Weight: 63 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 5,02
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,59
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 673.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,03
Urea (mg/dL): 7,15
LVEF (%): 65.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 71-year-old female with a history of idiopathic dilated cardiomyopathy, dyslipidemia, and hypertension. Her current NYHA class is II, indicating that she has some limitation in physical activity due to her heart condition. Her blood pressure is within a relatively normal range (110/50 mmHg), and her medication regimen includes Angiotensin II Receptor Blockers, Beta Blockers, and Loop Diuretics, which are commonly used to manage heart failure and hypertension.

Her laboratory results show a slightly elevated creatinine level (80.0 mol/L), which may indicate some degree of renal impairment. However, her kidney function is not severely impaired, and her other laboratory values are relatively normal.

The most concerning finding is the elevated Pro-BNP level (673.0 ng/L), which is a biomarker for heart failure. However, it is not excessively high, and the patient's symptoms and clinical presentation do not suggest acute heart failure.

The ECG findings are also noteworthy, with a ventricular extrasystole and polymorphic ventricular extrasystole, which may indicate a high risk of arrhythmias. However, there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia.

Given these factors, I believe that the patient is at high risk of cardiovascular events, but the overall picture suggests that she is likely to survive for the next few years with proper management and monitoring. The patient's age, NYHA class, and medication regimen suggest that she has a moderate to high risk of cardiovascular events, but the absence of severe symptoms and the relatively normal laboratory values suggest that she is likely to survive.

Ranking the three prognoses:

1. Survivor: Based on the patient's relatively normal laboratory values, the absence of severe symptoms, and the presence of a well-managed medication regimen, I believe that the patient is most likely to survive for the next few years.
2. Sudden cardiac death: While the patient has a history of ventricular extrasystole and polymorphic ventricular extrasystole, the ECG findings are not indicative of a high risk of sudden cardiac death. Additionally, the patient's medication regimen and laboratory values suggest that she is being managed for her heart condition, which reduces the risk of sudden cardiac death.
3. Pump failure death: Given the patient's NYHA class II and the presence of elevated Pro-BNP levels, there is a moderate risk of heart failure. However, the patient's relatively normal laboratory values and the presence of a well-managed medication regimen suggest that pump failure is less likely than sudden cardiac death or survivor."
304,304,P0507,"Age: 45
Gender: Male 
Weight: 90 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,95
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,23
Urea (mg/dL): 7,99
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the patient's current data, I would rank the patient as a survivor for the next few years. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that affects the heart's ability to pump blood effectively. However, the patient's LVEF (left ventricular ejection fraction) is 55%, which is within the range of a moderate impairment of heart function. The patient's NYHA class is II, indicating mild symptoms, and the patient is on a combination of medications that are commonly used to manage heart failure and hypertension.

The patient's laboratory results, such as the normal blood pressure, normal kidney function (creatinine 88.0 mmol/L), and normal liver function (ALT and AST levels), suggest that the patient's underlying conditions are well-managed. The patient's lipid profile is also relatively healthy, with a low LDL and high HDL level.

The patient's ECG results are also reassuring, with no signs of ventricular arrhythmias or other cardiac abnormalities.

While the patient's Pro-BNP level is slightly elevated, which may indicate some degree of cardiac stress, it is not excessively high and may be within the normal range for a patient with heart failure. The patient's overall clinical presentation and laboratory results suggest that the patient is in a stable condition and is likely to survive for the next few years without significant progression of their heart disease.

2. Sudden cardiac death
REASONING: 
While the patient's history of idiopathic dilated cardiomyopathy and hypertension increases their risk of cardiac events, I would rank sudden cardiac death as the least likely outcome. The patient's LVEF is 55%, which is a moderate impairment of heart function, but it is not severely impaired. The patient's NYHA class is II, indicating mild symptoms, and the patient is on a combination of medications that are commonly used to manage heart failure and hypertension.

The patient's laboratory results, such as the normal blood pressure, normal kidney function, and normal liver function, suggest that the patient's underlying conditions are well-managed. The patient's lipid profile is also relatively healthy, with a low LDL and high HDL level.

However, the patient's Pro-BNP level is slightly elevated, which may indicate some degree of cardiac stress. Additionally, the patient's LVEF is 55%, which may indicate some degree of left ventricular dysfunction. While these factors do increase the patient's risk of cardiac events, I would still rank sudden cardiac death as the least likely outcome.

3. Pump failure death
REASONING: 
I would rank pump failure death as the least likely outcome. The patient's LVEF is 55%, which is a moderate impairment of heart function, but it is not severely impaired. The patient's NYHA class is II, indicating mild symptoms, and the patient is on a combination of medications that are commonly used to manage heart failure and hypertension.

The patient's laboratory results, such as the normal blood pressure, normal kidney function, and normal liver function, suggest that the patient's underlying conditions are well-managed. The patient's lipid profile is also relatively healthy, with a low LDL and high HDL level.

However, the patient's Pro-BNP level is slightly elevated, which may indicate some degree of cardiac stress. Additionally, the patient's LVEF is 55%, which may indicate some degree of left ventricular dysfunction. While these factors do increase the patient's risk of cardiac events, I would still rank pump failure death as the least likely outcome due to the patient's relatively stable clinical presentation and laboratory results."
305,305,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient's NYHA Class II indicates that they have some limitations in physical activity due to their heart condition, but they are still able to perform daily activities with some difficulty. This suggests that their heart function is not severely impaired, which is a positive prognostic factor. The patient's LVEF of 35.0 is significantly reduced, but not critically low, indicating that their heart is still pumping blood effectively, albeit inefficiently.

The patient's medications, including loop diuretics and ACE inhibitors, are commonly used to manage heart failure and reduce mortality risk. The absence of symptoms such as shortness of breath, fatigue, or swelling suggests that the patient is not experiencing severe heart failure.

The ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia are concerning for arrhythmias, but the fact that they are non-sustained suggests that the patient is not experiencing life-threatening arrhythmias.

The patient's laboratory results, including a normal potassium level, a low TSH level, and a normal creatinine level, are also generally indicative of a stable cardiovascular system.

Given these factors, the most likely outcome for the patient over the next few years is a survivor. While the patient's heart function is compromised, their overall health and the absence of severe symptoms suggest that they can expect to live for several years with proper management of their condition.

2. Sudden Cardiac Death
REASONING:
The patient's LVEF of 35.0 is significantly reduced, indicating that their heart function is compromised. The presence of non-sustained ventricular tachycardia on the ECG is a risk factor for sudden cardiac death. Additionally, the patient's idiopathic dilated cardiomyopathy is a risk factor for sudden cardiac death.

While the patient's medications and laboratory results suggest that they are not experiencing severe heart failure, the presence of arrhythmias and reduced LVEF increase the risk of sudden cardiac death.

3. Pump Failure Death
REASONING:
The patient's LVEF of 35.0 is significantly reduced, indicating that their heart function is compromised. The patient's NYHA Class II and the presence of ventricular extrasystole and non-sustained VT on the ECG suggest that the patient's heart is not functioning optimally.

While the patient's medications and laboratory results suggest that they are not experiencing severe heart failure, the combination of reduced LVEF, arrhythmias, and NYHA Class II symptoms increases the risk of pump failure death. However, the patient's overall health and the absence of severe symptoms suggest that this outcome is less likely than sudden cardiac death."
306,306,P0510,"Age: 72
Gender: Female 
Weight: 67 kg
Height: 147 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41,5
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,13
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2207.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,62
Urea (mg/dL): 10,47
LVEF (%): 22.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is most likely to be a survivor due to several factors. Firstly, the patient's age of 72 years is not particularly advanced, and with proper management, many patients with cardiomyopathy can live for several more years. The patient's LVEF (Left Ventricular Ejection Fraction) of 22.0 is significantly reduced, indicating severe systolic dysfunction, but this is not uncommon in patients with idiopathic dilated cardiomyopathy.

The patient's medication regimen, which includes ACE inhibitors, spironolactone, and statins, is standard treatment for heart failure and hypertension, and it is likely to be effective in managing the patient's symptoms and slowing disease progression. The patient's ECG results do not show any signs of ventricular arrhythmias, which is a significant risk factor for sudden cardiac death.

The patient's laboratory results show elevated levels of BNP (Brain Natriuretic Peptide), which is a marker of heart failure, but the patient's kidney function is relatively preserved, with a creatinine level of 10.47 mg/dL. This suggests that the patient's kidney function is not severely impaired, which is a good prognostic sign.

The patient's other laboratory results, including blood pressure, electrolyte levels, and liver enzymes, are within relatively normal limits, which suggests that the patient's other organs are functioning relatively well.

Overall, based on the available data, the patient's prognosis is likely to be a survivor, given the effectiveness of their medication regimen and the relatively preserved function of their other organs. However, close monitoring and regular follow-up are necessary to adjust the treatment plan as needed to ensure the best possible outcome.

RANKING: 2. Sudden cardiac death
REASONING: 

This patient's prognosis is less likely to be a survivor due to several factors. The patient's LVEF of 22.0 is significantly reduced, indicating severe systolic dysfunction, which increases the risk of sudden cardiac death. The patient's ECG results show polymorphic ventricular extrasystoles, which is a sign of abnormal heart rhythms that can increase the risk of sudden cardiac death.

The patient's elevated BNP levels and elevated creatinine level suggest that the patient's heart failure is not well-controlled, which can increase the risk of sudden cardiac death.

Additionally, the patient's age of 72 years and history of hypertension and diabetes increase the risk of cardiovascular events, including sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

This patient's prognosis is the least likely to be a survivor due to several factors. The patient's LVEF of 22.0 is significantly reduced, indicating severe systolic dysfunction, which can lead to pump failure. The patient's elevated BNP levels and elevated creatinine level suggest that the patient's heart failure is not well-controlled, which can lead to pump failure.

The patient's age of 72 years and history of hypertension and diabetes increase the risk of cardiovascular events, including pump failure.

The patient's ECG results show polymorphic ventricular extrasystoles, which is a sign of abnormal heart rhythms that can increase the risk of pump failure. Additionally, the patient's kidney function is impaired, which can lead to fluid overload and increase the risk of pump failure.

Overall, based on the available data, the patient's prognosis is least likely to be a survivor due to the severity of their heart failure and the increased risk of cardiovascular events."
307,307,P0511,"Age: 59
Gender: Female 
Weight: 75 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44,8
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,08
Creatinine (mmol/L): 76.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 142.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,81
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1114.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,61
Urea (mg/dL): 7,35
LVEF (%): 37.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient is classified as a survivor based on the provided data. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is weakened due to scarring or damage to the heart muscle. However, the patient's current LVEF of 37.0 is not extremely low, which might indicate some residual cardiac function. The patient is also taking medications such as beta blockers, statins, and an ACE inhibitor, which are commonly used to manage symptoms of heart failure and prevent further cardiac events.

The patient's laboratory results show that the liver enzymes (ALT and AST) are within normal limits, and the troponin level is also normal, which suggests that there is no acute myocardial infarction or significant cardiac damage. The patient's electrolyte levels are also within normal limits, which further supports the absence of acute cardiac complications.

The ECG results show no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which are all potential indicators of cardiac arrhythmias. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) is noted, but it is not a life-threatening condition.

Overall, the patient's medical history, laboratory results, and ECG findings suggest that the patient is at low risk for cardiac events and is likely to survive in the short term."
308,308,P0512,"Age: 69
Gender: Male 
Weight: 85 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Peripheral vascular disease
Albumin (g/L): 46,3
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 11,3
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,97
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 349.0
Protein (g/L): 90
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,36
Urea (mg/dL): 8,02
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient has a significant cardiac history of dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is compromised. This condition, combined with a left ventricular ejection fraction (LVEF) of 24.0%, indicates a severely impaired cardiac function. The presence of diabetes, hypertension, and peripheral vascular disease further exacerbates the patient's cardiovascular risk profile.

The patient's current medications, including beta blockers, loop diuretics, and an ACE inhibitor, suggest a treatment plan aimed at managing heart failure symptoms and reducing cardiovascular risk. The presence of elevated BNP levels (349.0 ng/L) further supports this, as BNP is a biomarker for heart failure.

The absence of significant arrhythmias on the ECG, such as ventricular tachycardia or non-sustained ventricular tachycardia, reduces the likelihood of sudden cardiac death. The presence of a first-degree atrioventricular block (AVB) on the ECG may indicate some degree of conduction system dysfunction, but it is not typically a predictor of sudden cardiac death.

Considering these factors, the patient's overall cardiovascular risk profile and treatment plan suggest a relatively good prognosis, with the patient being more likely to survive in the short-term."
309,309,P0514,"Age: 54
Gender: Male 
Weight: 89 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 48,4
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 9,9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,43
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 333.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,36
Urea (mg/dL): 6,45
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's age, NYHA Class II, and past medical history of ischemic dilated cardiomyopathy, Diabetes, Hypertension, and Myocardial Infarction indicate a significant burden of cardiovascular disease. However, the patient's current medications (Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, and ACE Inhibitor) suggest that they are receiving appropriate management for their conditions.

The elevated Pro-BNP level (333.0 ng/L) suggests a moderate level of ventricular stress, but it is not indicative of heart failure. The patient's LVEF (39.0%) is also low, but it is not severely impaired. The absence of signs of acute myocardial infarction or ventricular tachycardia on the ECG impression suggests that the patient is not currently experiencing a life-threatening arrhythmia.

Considering these factors, the patient's overall prognosis is likely to be good, with a high likelihood of survival over the next few years. The patient's medication regimen and the absence of acute cardiac events or significant arrhythmias suggest that they are receiving adequate management for their cardiovascular disease.

The patient's low T3 level (0.04 pg/dL) may indicate hypothyroidism, which is a common comorbidity in patients with heart failure. However, this does not necessarily impact the patient's overall prognosis.

The patient's weight and height are within a relatively normal range, and their blood pressure is well-controlled. The absence of significant laboratory abnormalities (e.g., elevated creatinine, urea, or liver enzymes) suggests that the patient's kidney and liver function are relatively preserved.

Overall, based on the patient's current clinical presentation and management, the likelihood of survival over the next few years is high, making ""Survivor"" the most likely prognosis."
310,310,P0515,"Age: 50
Gender: Female 
Weight: 83 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,84
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 763.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 9,8
LVEF (%): 50.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results indicate a stable cardiovascular condition. The patient has a history of hypertension and hypertensive cardiomyopathy, which is a significant risk factor for cardiovascular disease. However, the patient's current NYHA class is II, indicating mild symptoms, and the patient is on medications for hypertension and heart failure (loop diuretics and ACE inhibitor). The patient's biomarkers, such as Troponin, TSH, and LVEF, are within normal limits or near-normal limits, which suggests that the patient's heart is not under significant stress. Additionally, the patient's ECG impression is normal, with no signs of arrhythmias or other cardiac issues. The patient's weight and body mass index (BMI) are within a relatively normal range, which reduces the risk of cardiovascular complications. Overall, these factors suggest that the patient is likely to survive for the next few years with proper management of their hypertension and heart failure.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient's history of hypertension and hypertensive cardiomyopathy is a significant risk factor for cardiovascular disease, the patient's current clinical presentation and test results do not indicate an acute or severe cardiac event. The patient's LVEF is 50%, which is within a range that can be managed with current treatments. However, the patient's elevated creatinine level (87.0 mmol/L) may indicate some degree of kidney impairment, which can be a risk factor for cardiovascular disease. Additionally, the patient's slightly elevated Troponin level (0.01 ng/mL) may indicate some degree of cardiac stress, but it is still within a relatively normal range. However, the patient's elevated Pro-BNP level (763 ng/L) suggests that the patient may be experiencing some degree of heart failure, which increases the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: While the patient's elevated Pro-BNP level (763 ng/L) suggests that the patient may be experiencing some degree of heart failure, the patient's current clinical presentation and test results do not indicate a severe or acute cardiac event. The patient's LVEF is 50%, which is within a range that can be managed with current treatments. However, the patient's elevated creatinine level (87.0 mmol/L) and slightly elevated Troponin level (0.01 ng/mL) may indicate some degree of cardiac stress and kidney impairment, which increases the risk of pump failure. Additionally, the patient's history of hypertension and hypertensive cardiomyopathy increases the risk of cardiac failure. Overall, while the patient is at risk of pump failure, the patient's current clinical presentation and test results suggest that the risk is not as high as for sudden cardiac death."
311,311,P0516,"Age: 49
Gender: Male 
Weight: 97 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 51,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 156.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,66
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1283.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,23
Urea (mg/dL): 8,02
LVEF (%): 39.0
Medications: Amiodarone, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
This patient has a complex medical history with Enolic dilated cardiomyopathy, a condition that affects the heart's ability to pump blood effectively, and is classified as NYHA Class III, indicating significant heart failure symptoms. The patient's low LVEF of 39% further supports this. However, the patient's current ECG impression does not show any arrhythmias, which could be a contributing factor to their overall prognosis.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which could be related to the cardiomyopathy, and anemia (Hemoglobin 15.6 g/dL) which is also consistent with heart failure. The patient is on medications that are commonly used to treat heart failure, such as Amiodarone, Beta Blockers, and ACE Inhibitors.

Given the patient's overall health status, the presence of heart failure symptoms, and the absence of arrhythmias on the ECG, the most likely outcome is that the patient will survive in the short term.

2. Sudden Cardiac Death
REASONING:
While the patient has a complex medical history, there is no indication of a high risk for sudden cardiac death. The ECG impression does not show any arrhythmias, and the patient is not on any medications that are commonly associated with an increased risk of sudden cardiac death.

However, the patient's LVEF is significantly reduced, which increases the risk of arrhythmias and sudden cardiac death. Additionally, the patient's low HDL cholesterol level (0.91 mmol/L) and elevated triglycerides may also contribute to an increased risk of cardiovascular events.

3. Pump Failure Death
REASONING:
Pump failure death is a possible outcome for patients with severe heart failure, such as this patient. The patient's NYHA Class III classification and low LVEF of 39% indicate significant heart failure symptoms. The patient's elevated BNP level (1283 ng/L) also supports this.

However, the patient is already on medications that are commonly used to treat heart failure, including ACE inhibitors and Beta Blockers, which should help to manage symptoms and improve outcomes. Additionally, the patient's liver enzymes are not severely elevated, which may indicate that the cardiomyopathy is not progressing rapidly.

While pump failure death is a possible outcome, it is less likely given the patient's current treatment and the fact that the ECG impression does not show any arrhythmias."
312,312,P0517,"Age: 41
Gender: Male 
Weight: 84 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44,9
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 797.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,26
Urea (mg/dL): 8,69
LVEF (%): 35.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's NYHA Class II indicates that they have moderate symptoms of heart failure, but they are still able to perform daily activities without significant limitation. The presence of idiopathic dilated cardiomyopathy suggests that the patient's heart muscle is weakened, but the fact that they are not in NYHA Class III or IV indicates that their condition is not severe enough to significantly impair their functional status. The patient's LVEF of 35% is significantly reduced, but it is not extremely low, which may suggest that the heart is still able to function to some extent. The patient's biomarkers, such as troponin and BNP, are elevated, indicating some level of cardiac stress, but they are not excessively high, which may suggest that the patient is not in acute heart failure. The patient's medications, including digoxin and loop diuretics, are typical for managing heart failure, and the presence of an ACE inhibitor suggests that the patient is receiving optimal medical therapy for their condition. The patient's ECG findings of ventricular extrasystole and non-sustained VT may indicate some level of cardiac arrhythmia, but they are not indicative of a high risk of sudden cardiac death. Overall, these factors suggest that the patient is likely to survive in the short term, but will likely require close monitoring and ongoing medical management to manage their condition."
313,313,P0518,"Age: 56
Gender: Male 
Weight: 98 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,9
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,34
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 134.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 7,12
LVEF (%): 36.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, the patient's prognosis is ranked as a survivor for several reasons:

1. NYHA Class II: The patient has a moderate level of heart failure, but it's still manageable with current treatment. A NYHA Class II classification indicates that the patient can perform ordinary physical activities without excessive fatigue, which suggests that the heart is still functioning to some extent.

2. Blood Pressure: The patient's blood pressure is within the normal range (130/80 mmHg), which reduces the risk of cardiovascular complications.

3. Low Troponin levels: The troponin level is very low (0.01 ng/mL), indicating minimal myocardial damage, which suggests that the patient's heart muscle is not severely compromised.

4. No evidence of acute coronary syndrome: The patient does not have elevated biomarkers of cardiac damage (e.g., CK-MB, CK-MB-T, or myoglobin), and there is no mention of acute coronary syndrome in the ECG report.

5. Current medication: The patient is on an ACE inhibitor, which is a standard treatment for heart failure and hypertension, indicating that the patient is receiving appropriate medical management.

6. Low LVEF: While the left ventricular ejection fraction (LVEF) is low at 36%, it's still within the range of a patient with heart failure, and the patient is receiving treatment.

However, there are some concerns that may affect the patient's prognosis:

- Enolic dilated cardiomyopathy: The patient has a history of enolic dilated cardiomyopathy, which can lead to progressive heart failure and increased mortality risk.

- Elevated creatinine: The patient's creatinine level is elevated (105.0 mol/L), which may indicate impaired renal function and potential kidney damage.

- Low HDL cholesterol: The patient's HDL cholesterol level is very low (0.8 mmol/L), which increases the risk of cardiovascular events.

Given these factors, while the patient's prognosis is not extremely poor, there are still significant concerns that require close monitoring and adjustments to the treatment plan to minimize the risk of adverse outcomes."
314,314,P0519,"Age: 61
Gender: Male 
Weight: 107 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 38,7
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 142.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,21
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1035.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,38
Urea (mg/dL): 8,46
LVEF (%): 23.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

Based on the provided patient data, I would rank the patient's prognosis as follows:

1. Survivor: The patient has a relatively stable vital sign profile, with a normal blood pressure, no signs of acute myocardial infarction (Troponin levels are within normal limits), and no indication of severe electrolyte imbalances. The patient's NYHA Class II indicates moderate symptoms, but they are still able to perform daily activities without significant limitations. The patient's medication regimen, which includes beta blockers, ACE inhibitors, and diuretics, suggests that their heart failure symptoms are being adequately managed. The presence of ventricular extrasystole, a benign condition, does not significantly impact the patient's prognosis. Overall, the patient's clinical presentation and laboratory results suggest that they are likely to survive in the short-term.

2. Sudden cardiac death: While the patient has a history of idiopathic dilated cardiomyopathy, which is a risk factor for sudden cardiac death, the patient's current LVEF is 23%, which is within the range of 15-35% for patients with heart failure with reduced ejection fraction. The patient's medication regimen includes beta blockers, which are known to reduce the risk of sudden cardiac death. Additionally, the patient's ECG shows no signs of ventricular tachycardia or ventricular extrasystole, which are risk factors for sudden cardiac death. While the patient's history of peripheral vascular disease and dyslipidemia are risk factors for cardiovascular events, the patient's current clinical presentation does not suggest an immediate risk of sudden cardiac death.

3. Pump failure death: The patient's LVEF is significantly reduced (23%), indicating severe left ventricular dysfunction. The patient's NYHA Class II symptoms suggest that their heart failure is impacting their daily activities. The patient's medication regimen, while adequate, may not be sufficient to manage their heart failure symptoms. The patient's elevated creatinine levels (80.0 mg/dL) and low albumin levels (38.7 g/L) suggest that the patient may have chronic kidney disease, which can exacerbate heart failure. The patient's elevated pro-BNP levels (1035 ng/L) indicate significant ventricular strain, which can lead to pump failure. Overall, the patient's clinical presentation and laboratory results suggest that pump failure is a possible complication in the near future, but it is less likely than sudden cardiac death in the short-term."
315,315,P0521,"Age: 79
Gender: Female 
Weight: 58 kg
Height: 149 cm
NYHA Class: III
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,64
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,7
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 6699.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,98
Urea (mg/dL): 12,03
LVEF (%): 23.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient's overall prognosis is most likely to be a survivor. The patient's age (79) is a significant risk factor for mortality, but the patient's current NYHA Class III indicates a severe but not critically severe heart failure. The patient's LVEF (23.0) is significantly reduced, indicating poor cardiac function. However, the patient is already receiving medications for heart failure (Loop Diuretics, Spironolactone, ACE Inhibitor, and Nitrovasodilator), which suggests that the patient is receiving standard treatment for heart failure.

The patient's ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) are concerning for cardiac arrhythmias, but the patient is already receiving beta blockers, which are known to reduce the risk of arrhythmias. The patient's elevated Troponin levels (0.01 ng/mL) may indicate some myocardial damage, but it is not significantly elevated.

The patient's laboratory results show an elevated Creatinine level (119.0 mmol/L), which may indicate some degree of renal impairment. However, this is not uncommon in patients with heart failure.

The patient's other laboratory results are within relatively normal limits, and the patient's Pro-BNP level (6699.0 ng/L) is significantly elevated, indicating severe heart failure. However, the patient's overall clinical picture suggests that the patient is receiving standard treatment for heart failure and has some level of cardiac reserve.

Overall, while the patient has several risk factors for mortality, the patient's current clinical presentation and treatment suggest that the patient is likely to survive for the next few years, although close monitoring and adjustments to the treatment plan may be necessary to manage the patient's heart failure and arrhythmias."
316,316,P0522,"Age: 66
Gender: Male 
Weight: 88 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 15,4
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,5
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 277.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,77
Urea (mg/dL): 10,24
LVEF (%): 39.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's age, NYHA Class II, and multiple comorbidities such as ischemic dilated cardiomyopathy, diabetes, and peripheral vascular disease, the patient is at a higher risk for adverse outcomes. However, the patient's current LVEF is 39%, which is significantly lower than the normal range, indicating a reduced ejection fraction. Despite this, the patient's cardiac medications, including spironolactone and statins, suggest a management plan to address the underlying conditions.

The patient's recent ECG findings, including non-sustained ventricular tachycardia and ventricular extrasystole, indicate an increased risk of arrhythmic events. However, the presence of spironolactone, a potassium-sparing diuretic, may help mitigate this risk.

Considering these factors, the patient's overall prognosis is relatively favorable, with a higher likelihood of survival over the next few years.

2. Pump failure death
REASONING: 
The patient's reduced LVEF of 39% and elevated creatinine level of 116.0 suggest a compromised cardiac function. This, combined with the patient's NYHA Class II status, indicates a moderate level of heart failure symptoms. The presence of diabetes and peripheral vascular disease further increases the risk of cardiovascular events.

While the patient is receiving medications to manage these conditions, the patient's elevated troponin level (0.01 ng/mL) and ECG findings of non-sustained ventricular tachycardia suggest an increased risk of cardiac events.

However, the patient's age, weight, and relatively well-managed comorbidities suggest that the risk of pump failure death is lower compared to the first ranking.

3. Sudden cardiac death
REASONING: 
The patient's ECG findings of non-sustained ventricular tachycardia and ventricular extrasystole indicate an increased risk of arrhythmic events. However, the presence of spironolactone and other cardiac medications, as well as the patient's relatively well-managed comorbidities, suggest a lower risk of sudden cardiac death.

The patient's reduced LVEF and elevated creatinine level, however, increase the risk of cardiovascular events, but the patient's age and relatively well-managed comorbidities suggest that the risk of sudden cardiac death is lower compared to pump failure death.

Overall, while the patient is at an increased risk of arrhythmic events, the presence of multiple comorbidities and well-managed medications suggest a relatively lower risk of sudden cardiac death compared to pump failure death."
317,317,P0523,"Age: 72
Gender: Male 
Weight: 80 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,54
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 936.0
Protein (g/L): 70
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,368
Urea (mg/dL): 6,91
LVEF (%): 35.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to the following factors:

1. Age: Although the patient is 72 years old, their current health status and comorbidities suggest that they may be able to tolerate certain treatments and interventions. The patient's age alone is not a contraindication for survival.

2. NYHA Class II: This classification indicates that the patient has some limitations in physical activity due to their heart condition, but it does not necessarily mean that they are at high risk of death.

3. Blood pressure and electrolyte levels: The patient's blood pressure is within a relatively normal range, and their electrolyte levels are also within a relatively normal range.

4. Medications: The patient is taking a range of medications, including ACE inhibitors, statins, and diuretics, which are commonly used to manage heart failure, high blood pressure, and high cholesterol.

5. ECG findings: The ECG shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other life-threatening arrhythmias, which suggests that the patient's heart is not at high risk of sudden cardiac death.

6. Biomarkers: The patient's troponin level is within a normal range, and their LVEF is 35%, which is a relatively low but not severely reduced value. The elevated Pro-BNP level is consistent with heart failure.

7. Other laboratory results: The patient's liver function tests, kidney function, and glucose levels are relatively normal.

However, the patient's LVEF of 35% and elevated Pro-BNP level suggest that they have significant cardiac dysfunction, which may increase their risk of heart failure and mortality.

Overall, while the patient's health status is complex and multifaceted, their current health status and treatment plan suggest that they are likely to survive in the short term. However, it is essential to closely monitor their condition and adjust their treatment plan as needed to minimize the risk of complications and improve their quality of life.

The two remaining prognoses, sudden cardiac death and pump failure death, are less likely because the patient's ECG findings do not suggest an immediate risk of sudden cardiac death, and their LVEF is not severely reduced. However, it is essential to continue monitoring their condition closely to detect any potential complications."
318,318,P0524,"Age: 66
Gender: Male 
Weight: 68 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 3,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 287.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,06
Urea (mg/dL): 7,12
LVEF (%): 36.0
Medications: Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
This patient has a history of ischemic dilated cardiomyopathy, which is a significant comorbidity that can lead to heart failure and arrhythmias. However, the patient is currently on beta blockers and loop diuretics, which are standard treatments for heart failure. The patient's left ventricular ejection fraction (LVEF) is 36%, which is a relatively preserved value, indicating some residual cardiac function. The presence of non-sustained ventricular tachycardia (NSVT) is a concerning sign, but it is not a direct predictor of mortality. The patient's troponin level is within normal limits, and the patient's creatinine level is elevated, but not severely so. The patient's renal function is not significantly impaired, and the patient is not on dialysis. The patient's hemoglobin level is normal, and the patient is not anemic. The patient's electrolyte levels, including potassium, sodium, and magnesium, are within normal limits. The patient's liver enzymes (ALT, AST, and GGT) are within normal limits. 

The patient's age and gender are not particularly high-risk factors for sudden cardiac death. The patient's blood pressure is well-controlled, and the patient is not hypertensive. The patient's dyslipidemia is a risk factor for cardiovascular disease, but the patient is on statin therapy, which is a standard treatment for high cholesterol. The patient's glucose level is normal, and the patient is not diabetic. The patient's renal function is not significantly impaired, and the patient is not on dialysis.

Overall, while the patient has several comorbidities, the patient's clinical presentation is not extremely poor, and the patient is on multiple medications that can help manage the patient's conditions. Therefore, I predict that the patient will be a survivor.

2. Sudden cardiac death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia (NSVT) are significant risk factors for sudden cardiac death. The patient's LVEF is 36%, which is a relatively preserved value, but the patient's ventricular extrasystoles and NSVT are concerning signs. The patient's creatinine level is elevated, which may indicate some degree of renal impairment, but the patient is not on dialysis. The patient's troponin level is within normal limits, which suggests that the patient's cardiac muscle is not significantly damaged. However, the patient's elevated creatinine level, elevated liver enzymes (ALT, AST, and GGT), and elevated gamma-glutamil transpeptidase (GGT) levels may indicate some degree of liver and kidney dysfunction. The patient's electrolyte levels, including potassium, sodium, and magnesium, are within normal limits.

The patient's age and gender are not particularly high-risk factors for sudden cardiac death. The patient's blood pressure is well-controlled, and the patient is not hypertensive. The patient's dyslipidemia is a risk factor for cardiovascular disease, but the patient is on statin therapy, which is a standard treatment for high cholesterol. The patient's glucose level is normal, and the patient is not diabetic.

However, the patient's ECG impression shows ventricular extrasystoles and NSVT, which are concerning signs. The patient's LVEF is 36%, which is a relatively preserved value, but the patient's ventricular extrasystoles and NSVT are concerning signs. Therefore, while the patient's overall clinical presentation is not extremely poor, the patient's ECG findings are concerning, and I predict that the patient has a moderate risk of sudden cardiac death.

3. Pump failure death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy, non-sustained ventricular tachycardia (NSVT), and elevated creatinine level are significant risk factors for pump failure death. The patient's LVEF is 36%, which is a relatively preserved value, but the patient's ventricular extrasystoles and NSVT are concerning signs. The patient's liver enzymes (ALT, AST, and GGT) are elevated, which may indicate some degree of liver dysfunction. The patient's electrolyte levels, including potassium, sodium, and magnesium, are within normal limits.

The patient's age and gender are not particularly high-risk factors for pump failure death. The patient's blood pressure is well-controlled, and the patient is not hypertensive. The patient's dyslipidemia is a risk factor for cardiovascular disease, but the patient is on statin therapy, which is a standard treatment for high cholesterol. The patient's glucose level is normal, and the patient is not diabetic. The patient's renal function is not significantly impaired, and the patient is not on dialysis.

However,"
319,319,P0525,"Age: 69
Gender: Male 
Weight: 85 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 145/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,5
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 182.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 19,3
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,34
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 241.0
Protein (g/L): 64
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,69
Urea (mg/dL): 18,25
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and lab results indicate a high risk for adverse cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 35%, indicating significant cardiac dysfunction. The presence of ventricular extrasystoles on the ECG, although not sustained, is a concerning sign of arrhythmia, which can increase the risk of sudden cardiac death.

The patient's elevated blood pressure (145/90 mmHg) and high creatinine level (182.0 mmol/L) suggest chronic kidney disease, which can further compromise cardiac function. The patient's high levels of BNP (241.0 ng/L) and troponin (0.01 ng/mL) indicate elevated cardiac stress and possible cardiac damage.

The patient's history of diabetes, peripheral vascular disease, and hypertension also contribute to the high risk of adverse outcomes. The patient's low HDL (0.83 mmol/L) and high LDL (1.34 mmol/L) levels further increase the risk of cardiovascular disease.

Despite the presence of these risk factors, the patient's NYHA Class II classification suggests that the patient has some residual cardiac function, which may contribute to a slightly better prognosis. However, the overall risk-benefit ratio of the patient's condition, coupled with the presence of severe cardiac dysfunction and arrhythmias, makes a sudden cardiac death or pump failure more likely than survival.

Therefore, based on the provided data, the most likely outcome for the patient over the next few years is a survivor."
320,320,P0526,"Age: 71
Gender: Male 
Weight: 69 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 110/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 43.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,9
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 318.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,53
Urea (mg/dL): 10,69
LVEF (%): 32.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's prognosis is likely to be a survivor. Several factors support this outcome:

1. The patient is 71 years old, which is not extremely old, and the absence of advanced age-related comorbidities.
2. The patient has a NYHA Class II, indicating moderate symptoms, which suggests that they can still perform daily activities with some limitation, but not severe enough to indicate advanced heart failure.
3. The patient's blood pressure is within a relatively normal range, which reduces the risk of cardiovascular events.
4. The presence of multiple medications, including beta blockers, ACE inhibitors, and diuretics, indicates that the patient is receiving standard therapy for heart failure and cardiovascular risk factors.
5. The patient's laboratory values are not extremely abnormal, with only mildly elevated liver enzymes (ALT and AST) and a slightly elevated creatinine level, which can be attributed to age-related kidney function decline.
6. The absence of ventricular extrasystoles, ventricular tachycardia, and non-sustained ventricular tachycardia on the ECG suggests that the patient does not have an immediate risk of arrhythmias that could lead to sudden cardiac death.
7. The patient's LVEF is 32%, which is a relatively preserved left ventricular function, indicating that the patient's heart is still pumping effectively.

While the patient has a history of ischemic dilated cardiomyopathy, diabetes, and peripheral vascular disease, these conditions do not necessarily indicate a poor prognosis. The patient's current symptoms and laboratory values suggest that they are stable, and with proper management, they can continue to live a relatively normal life.

In contrast, the other two prognoses (sudden cardiac death and pump failure death) are less likely due to the patient's stable condition and the presence of multiple medications that are addressing their cardiovascular risk factors."
321,321,P0527,"Age: 58
Gender: Male 
Weight: 91 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 52,69
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 825.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,23
Urea (mg/dL): 5,34
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results suggest that they are likely to survive for the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a chronic condition, and they are currently on medications that are standard for managing heart failure and hypertension. Their NYHA class is II, indicating mild symptoms, which suggests that they are not severely limited in their daily activities.

The patient's biomarkers, such as elevated troponin and BNP levels, indicate some degree of cardiac stress and strain, but these levels are not extremely high. The patient's creatinine level is also elevated, which may indicate some degree of kidney impairment, but it is not severe.

The patient's lipid profile is suboptimal, with high LDL and low HDL levels, but they are on statins, which should help to manage cholesterol levels.

The ECG results show no signs of ventricular arrhythmias, which is a good sign. The patient's LVEF is 34%, which is a significant reduction in left ventricular function, but it is not extremely low.

Considering the patient's overall clinical presentation and test results, I believe that they are likely to survive for the next few years, although they will likely require ongoing management and monitoring to manage their condition.

RANKING: 2. Sudden cardiac death
REASONING: While the patient is likely to survive for the next few years, there are some factors that increase the risk of sudden cardiac death. The patient has a history of ischemic dilated cardiomyopathy, which can lead to arrhythmias and sudden cardiac death. The patient's LVEF is significantly reduced, which can also increase the risk of arrhythmias.

The patient's ECG results show a ventricular extrasystole, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death.

The patient's biomarkers, such as elevated troponin and BNP levels, indicate some degree of cardiac stress and strain, which can increase the risk of arrhythmias.

However, the patient is on medications that are standard for managing heart failure and hypertension, which should help to reduce the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: The patient's LVEF is significantly reduced, which indicates a high risk of pump failure. The patient's NYHA class is II, which suggests that they are not severely limited in their daily activities, but they still have some symptoms of heart failure.

The patient's biomarkers, such as elevated BNP and troponin levels, indicate some degree of cardiac stress and strain, which can increase the risk of pump failure.

The patient's creatinine level is elevated, which may indicate some degree of kidney impairment, which can increase the risk of pump failure.

The patient's ECG results show a ventricular extrasystole, which is a type of abnormal heart rhythm that can increase the risk of pump failure.

While the patient is on medications that are standard for managing heart failure, the patient's underlying cardiac condition and biomarkers suggest a higher risk of pump failure than sudden cardiac death."
322,322,P0528,"Age: 55
Gender: Male 
Weight: 85 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 41,3
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 11,6
Hemoglobin (g/L): 103.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,46
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 103.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,04
Urea (mg/dL): 8,02
LVEF (%): 39.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient has a history of hypertensive cardiomyopathy, diabetes, and hypertension, which are risk factors for cardiovascular disease. The patient's NYHA class II indicates moderate symptoms of heart failure, and the low LVEF of 39.0 suggests significant left ventricular dysfunction. The elevated creatinine level (91.0 mmol/L) also indicates renal impairment, which is a common comorbidity in patients with heart failure.

The patient's ECG impression shows ventricular extrasystole, which is a benign finding but warrants monitoring. The absence of ventricular tachycardia or non-sustained ventricular tachycardia is reassuring. However, the presence of ventricular extrasystoles is a sign of cardiac electrical instability, which may indicate underlying cardiac disease.

The patient's biomarkers, including Troponin (0.01 ng/mL), TSH (1.04 mIU/L), and Pro-BNP (103 ng/L), are within normal or near-normal limits. The patient's lipid profile is also relatively favorable, with low LDL (2.46 mmol/L) and high HDL (1.11 mmol/L) levels.

Given these factors, the patient's overall prognosis is likely to be a survivor. The patient's age, weight, and comorbidities are not particularly concerning, and the absence of more severe cardiac biomarkers or ECG abnormalities reduces the risk of sudden cardiac death or pump failure.

However, the patient's NYHA class II and low LVEF suggest that the patient may require ongoing medical management and close monitoring to prevent further cardiac decompensation. Regular follow-up appointments with the cardiologist and adherence to the current medication regimen are essential to ensure the patient's cardiac health.

While there is a small risk of sudden cardiac death, the overall data suggests that the patient is unlikely to experience this outcome. The patient's survival is more likely due to the absence of more severe cardiac biomarkers and the presence of a favorable lipid profile."
323,323,P0530,"Age: 74
Gender: Female 
Weight: 69 kg
Height: 136 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 35,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,9
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 116.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 3,8
LDL (mmol/L): 3,41
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1464.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,47
Urea (mg/dL): 10,69
LVEF (%): 24.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at high risk for cardiac events due to a combination of factors. The patient has a history of hypertensive cardiomyopathy, which is a condition that can lead to left ventricular dysfunction. The patient's left ventricular ejection fraction (LVEF) of 24.0% indicates significant left ventricular dysfunction. The patient's elevated creatinine level (103.0 mmol/L) also suggests renal impairment, which can be a complication of heart failure.

The patient's blood pressure is well-controlled at 120/75 mmHg, and the patient is on medications to manage hypertension, diabetes, and dyslipidemia. However, the patient's elevated troponin level (0.01 ng/mL) and elevated BNP level (1464.0 ng/L) suggest some degree of cardiac stress and strain.

The patient's ECG impression does not show any overt arrhythmias, which is a positive sign. However, the presence of ventricular extrasystoles (a type of abnormal heart rhythm) is noted, which could be a sign of underlying cardiac stress.

Considering these factors, the patient's overall prognosis is still relatively favorable, and I predict that the patient will survive for the next few years. However, close monitoring and follow-up are essential to adjust the treatment plan and prevent any further cardiac events.

RANKING: 2. Pump failure death
REASONING: 

Given the patient's significant left ventricular dysfunction (LVEF 24.0%) and elevated BNP level (1464.0 ng/L), there is a risk of heart failure. The patient's renal impairment (elevated creatinine level) also increases the risk of complications. 

However, the patient's blood pressure is well-controlled, and the patient is on medications to manage hypertension, diabetes, and dyslipidemia. The patient's ECG impression does not show any overt arrhythmias, which is a positive sign.

Given the patient's overall condition, I predict that the patient has a moderate risk of developing heart failure in the next few years. However, with proper management and monitoring, the patient can still be prevented from progressing to pump failure death.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's elevated troponin level (0.01 ng/mL) and elevated BNP level (1464.0 ng/L) suggest some degree of cardiac stress and strain. The patient's ventricular extrasystoles (a type of abnormal heart rhythm) also increases the risk of sudden cardiac death.

However, the patient's ECG impression does not show any overt arrhythmias, and the patient's blood pressure is well-controlled. The patient's LVEF is relatively preserved, and the patient is on medications to manage hypertension, diabetes, and dyslipidemia.

Given the patient's overall condition, I predict that the patient has a low risk of sudden cardiac death in the next few years. However, the patient should still be under close monitoring and follow-up to adjust the treatment plan and prevent any further cardiac events."
324,324,P0531,"Age: 53
Gender: Male 
Weight: 95 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 175/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,6
ALT or GPT (IU/L): 95.0
AST or GOT (IU/L): 52.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 67
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,52
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 644.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,3
Urea (mg/dL): 10,69
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is currently classified as having NYHA Class II, indicating that they have some limitation in physical activity due to their heart condition, but they are still able to carry on light physical activity without symptoms. Their LVEF is 45.0, which is significantly reduced, but not severely low. The patient's ECG impression does not show any signs of ventricular tachycardia or significant arrhythmias, which are major predictors of sudden cardiac death. The patient's medication regimen is also well-managed, with a combination of ACE inhibitors, beta blockers, and statins, which can help to reduce the risk of cardiac events. The patient's laboratory values, such as the elevated creatinine level, may indicate some degree of kidney dysfunction, but this is not directly related to cardiac function. Overall, based on the provided data, the patient's prognosis is that they will survive for the next few years, albeit with ongoing management and monitoring.

2. Sudden Cardiac Death
REASONING: 
While the patient's LVEF is significantly reduced, which increases the risk of sudden cardiac death, the absence of any arrhythmias on the ECG and the patient's well-managed medication regimen reduce this risk. However, the patient's elevated blood pressure (175/100 mmHg) and elevated creatinine level (123.0) may indicate some degree of cardiac and renal dysfunction, which can increase the risk of sudden cardiac death. Additionally, the patient's dyslipidemia and hypertension may also contribute to the risk of cardiac events.

3. Pump Failure Death
REASONING: 
The patient's LVEF of 45.0 indicates significant left ventricular dysfunction, which can lead to pump failure. The patient's elevated creatinine level (123.0) and elevated NT-proBNP level (644.0) also suggest some degree of cardiac dysfunction. While the patient is currently classified as NYHA Class II, this classification may not accurately reflect the patient's true functional status, as the patient's symptoms may be masked or not present. The patient's medication regimen is well-managed, but the combination of factors such as ischemic dilated cardiomyopathy, hypertension, and dyslipidemia may ultimately lead to pump failure, making this the least likely prognosis among the three options."
325,325,P0532,"Age: 74
Gender: Female 
Weight: 78 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,56
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 531.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,51
Urea (mg/dL): 11,36
LVEF (%): 33.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is 74 years old with a history of ischemic dilated cardiomyopathy, which is a significant underlying condition that can lead to heart failure. The patient's NYHA Class III indicates severe symptoms, and the low LVEF (33%) suggests that the heart is not functioning optimally. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG also indicates an increased risk of arrhythmias, which can be life-threatening. However, the patient is already on medications that are commonly used to manage heart failure and arrhythmias (Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, and Statins). The patient's laboratory values, such as elevated creatinine and Troponin, also suggest some degree of cardiac damage. Despite these factors, the patient's age, gender, and the presence of medications suggest that the patient is likely to survive for the next few years, assuming the current treatment regimen is well-managed.

2. Sudden cardiac death
REASONING: 
While the patient has a high risk of arrhythmias and cardiac damage, the presence of medications that are commonly used to manage these conditions reduces the likelihood of sudden cardiac death. However, the patient's LVEF is very low (33%), which increases the risk of sudden cardiac death. Additionally, the patient's elevated creatinine and Troponin levels suggest some degree of cardiac damage, which may increase the risk of arrhythmias. The patient's age and gender also increase the risk of sudden cardiac death. However, the patient's overall prognosis is still relatively stable, and the patient is likely to survive for the next few years.

3. Pump failure death
REASONING: 
Given the patient's severe symptoms (NYHA Class III) and low LVEF (33%), the patient is at high risk of heart failure. The presence of medications that are commonly used to manage heart failure (Loop Diuretics, Spironolactone) suggests that the patient's condition is being actively managed. However, the patient's elevated creatinine and Troponin levels suggest some degree of cardiac damage, which may increase the risk of pump failure. The patient's age and gender also increase the risk of pump failure. While the patient's current treatment regimen is likely to manage the symptoms, the underlying condition of ischemic dilated cardiomyopathy and cardiac damage may eventually lead to pump failure, making this outcome a possible but less likely scenario in the short term."
326,326,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results indicate a high risk of adverse cardiac events, but the presence of a good outcome (PATIENT OUTCOME: survivor) suggests that the patient has received optimal management and care. 

The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient is receiving medications for diabetes, hypertension, and heart failure, which are standard treatments for these conditions. The patient's NYHA Class III indicates severe heart failure symptoms, but the patient is still able to receive optimal medical treatment.

The patient's laboratory results show elevated creatinine levels, indicating impaired renal function, and elevated troponin levels, indicating some degree of cardiac damage. However, these results are not severe enough to indicate acute myocardial infarction or cardiac failure.

The patient's ECG results show ventricular extrasystole, which is a benign finding, and no evidence of ventricular tachycardia or bradycardia. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) is a common finding in patients with heart failure, but it is not a significant predictor of adverse outcomes.

Given the patient's overall clinical presentation and test results, I would rank the patient as having the highest chance of survival over the next few years. However, the patient's LVEF of 45% indicates significant left ventricular dysfunction, and the patient's elevated creatinine and troponin levels suggest ongoing cardiac stress. Therefore, it is essential to closely monitor the patient's cardiac function and adjust treatment as needed to minimize the risk of cardiac events.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy, diabetes, and hypertension increases the risk of sudden cardiac death. The patient's LVEF of 45% is significantly reduced, indicating poor cardiac function, and the patient's elevated creatinine and troponin levels suggest ongoing cardiac stress.

The patient's ECG results show ventricular extrasystole, which can be a precursor to ventricular tachycardia or fibrillation, increasing the risk of sudden cardiac death. The presence of PSVT is also a risk factor for sudden cardiac death, especially in patients with heart failure.

While the patient is receiving optimal medical treatment, the patient's underlying cardiac disease and elevated biomarkers suggest that the patient is at increased risk of cardiac events, including sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's NYHA Class III indicates severe heart failure symptoms, and the patient's LVEF of 45% is significantly reduced, indicating poor cardiac function. The patient's elevated creatinine and troponin levels suggest ongoing cardiac stress, and the patient's elevated BNP levels (1860 ng/L) indicate significant ventricular dysfunction.

The patient's diabetes, hypertension, and peripheral vascular disease also increase the risk of pump failure. The patient's elevated LDL cholesterol levels (2.35 mmol/L) also contribute to atherosclerosis, which can lead to cardiac events.

While the patient is receiving optimal medical treatment, the patient's underlying cardiac disease and elevated biomarkers suggest that the patient is at increased risk of cardiac events, including pump failure. However, the patient's survival is more likely than sudden cardiac death due to the presence of optimal medical treatment and the patient's overall clinical presentation."
327,327,P0537,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 41,5
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,8
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,88
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 688.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,867
Urea (mg/dL): 5,34
LVEF (%): 22.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, the patient is classified as having Idiopathic dilated cardiomyopathy, which is a condition characterized by the enlargement of the heart's chambers, leading to reduced cardiac function. The patient's left ventricular ejection fraction (LVEF) of 22.0% indicates severe systolic dysfunction. The presence of NYHA Class II, which represents moderate symptoms of heart failure, further supports this classification.

The patient's elevated troponin levels (0.01 ng/mL) may indicate some degree of cardiac muscle damage, but the absence of elevated creatine kinase (CK) or CK-MB, and normal TSH levels suggest that the cardiac damage may be limited. The presence of elevated BNP levels (688 ng/L) indicates increased ventricular wall stress and further supports the diagnosis of heart failure.

The patient's age (66 years) and comorbidities (diabetes, dyslipidemia, and peripheral vascular disease) contribute to the risk of cardiovascular events, but the absence of any recent myocardial infarction, acute coronary syndrome, or other acute cardiac events suggests that the patient's cardiac function is currently stable.

Given the patient's severe cardiac dysfunction, moderate symptoms of heart failure, and elevated BNP levels, the most likely outcome for the next few years is a survivor. However, the patient will likely require close monitoring and management to optimize their heart failure treatment and reduce the risk of cardiovascular events.

The other two options are less likely:
- Sudden cardiac death is unlikely due to the absence of any indication of cardiac ischemia, and the patient's stable cardiac function.
- Pump failure death is also less likely, given the patient's current stable cardiac function and the presence of treatment with medications that can help manage heart failure symptoms."
328,328,P0538,"Age: 61
Gender: Male 
Weight: 53 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,23
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 9,8
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,86
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 864.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,11
Urea (mg/dL): 12,91
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a significant history of ischemic dilated cardiomyopathy, which is a condition that affects the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is 35%, which is significantly below the normal range, indicating severe systolic dysfunction. The presence of ventricular extrasystole, polymorphic, and non-sustained ventricular tachycardia on the ECG impression further indicates ventricular arrhythmias, which can be a life-threatening complication in patients with cardiomyopathy.

Despite the presence of multiple comorbidities, such as diabetes, hypertension, and dyslipidemia, the patient is on multiple medications that are commonly used to manage these conditions, including beta blockers, statins, and ACE inhibitors. The patient's blood pressure is well-controlled at 115/60 mmHg.

The elevated troponin level of 0.01 ng/mL is within the normal range, which suggests that the patient is not experiencing acute myocardial infarction. The patient's creatinine level is elevated at 12.91 mg/dL, which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure.

The patient's Pro-BNP level is elevated at 864.0 ng/L, which is a marker of cardiac stress and strain. However, the patient is on medications that are known to reduce the levels of BNP, such as beta blockers.

Given the patient's severe systolic dysfunction, ventricular arrhythmias, and elevated BNP, the patient is at high risk of cardiac complications. However, the patient's overall clinical presentation and the fact that they are on multiple medications to manage their comorbidities suggest that they are likely to survive for the next few years, provided that their treatment plan is closely monitored and adjusted as needed.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's severe systolic dysfunction, ventricular arrhythmias, and elevated BNP make them at high risk for cardiac complications, including sudden cardiac death. The patient's LVEF of 35% is significantly below the normal range, and the presence of ventricular extrasystole, polymorphic, and non-sustained ventricular tachycardia on the ECG impression further increases the risk of arrhythmias.

RANKING: 3. Pump Failure Death
REASONING: 

While the patient's severe systolic dysfunction and elevated BNP make them at risk for pump failure, the patient's overall clinical presentation and the fact that they are on multiple medications to manage their comorbidities suggest that they are unlikely to die from pump failure in the next few years. However, the patient's elevated creatinine level and renal impairment may increase the risk of complications related to renal failure.

It's worth noting that the patient's NYHA class is II, which indicates moderate symptoms of heart failure, but the patient is still able to perform daily activities without significant limitation. This suggests that the patient's heart failure is not severe, and they are unlikely to die from pump failure in the short term."
329,329,P0541,"Age: 61
Gender: Male 
Weight: 74 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 135/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,8
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,54
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1751.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,61
Urea (mg/dL): 12,25
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the patient's data, I rank the patient as a survivor. The patient's LVEF of 40% indicates significant left ventricular dysfunction, which is a risk factor for adverse outcomes. However, the patient is currently on ACE inhibitor, beta blockers, and statins, which are standard treatments for patients with heart failure and coronary artery disease. The patient's NYHA Class II indicates that they have some limitations in physical activity, but they are still able to perform moderate activities without symptoms.

The patient's elevated BNP levels (1751.0 ng/L) and elevated creatinine (12.25 mg/dL) suggest some degree of cardiac and renal dysfunction. However, the patient's renal function is not severely impaired, and the BNP levels are not excessively high.

The patient's lipid profile is also not ideal, with high LDL and low HDL levels, which increases the risk of cardiovascular events. However, the patient is already on statins, which should help to reduce the risk of cardiovascular events.

The patient's ECG findings are also not excessively abnormal, with no evidence of ventricular tachycardia or polymorphic ventricular extrasystoles. The patient's TSH level is slightly elevated, which may indicate some degree of thyroid dysfunction, but it is not immediately life-threatening.

Overall, while the patient has several risk factors for adverse outcomes, their current treatment regimen and clinical status suggest that they are likely to survive for the next few years. However, close monitoring and regular follow-up are essential to adjust the treatment plan and address any potential complications.

2. Sudden cardiac death
REASONING: 
Sudden cardiac death is unlikely in this patient, but not impossible. The patient's LVEF is significantly reduced, which increases the risk of arrhythmias and sudden cardiac death. However, the patient's ECG findings do not show any evidence of ventricular tachycardia or polymorphic ventricular extrasystoles.

The patient's elevated BNP levels and elevated creatinine levels suggest some degree of cardiac and renal dysfunction, which may increase the risk of arrhythmias. However, the patient's renal function is not severely impaired, and the BNP levels are not excessively high.

The patient's lipid profile is not ideal, which increases the risk of cardiovascular events. However, the patient is already on statins, which should help to reduce the risk of cardiovascular events.

3. Pump failure death
REASONING: 
Pump failure death is the least likely outcome for this patient. The patient's LVEF is significantly reduced, which indicates left ventricular dysfunction. However, the patient is currently on ACE inhibitors and beta blockers, which are standard treatments for patients with heart failure.

The patient's BNP levels are elevated, but not excessively high, and the patient's renal function is not severely impaired. The patient's ECG findings do not show any evidence of ventricular tachycardia or polymorphic ventricular extrasystoles.

The patient's lipid profile is not ideal, but the patient is already on statins, which should help to reduce the risk of cardiovascular events. Overall, while the patient has several risk factors for adverse outcomes, their current treatment regimen and clinical status suggest that they are unlikely to experience pump failure death in the next few years."
330,330,P0542,"Age: 62
Gender: Male 
Weight: 72 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/65 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 51,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,34
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 358.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,46
Urea (mg/dL): 9,35
LVEF (%): 40.0
Medications: Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex clinical presentation with multiple risk factors for adverse outcomes, including:

1. Severe left ventricular dysfunction (LVEF 40.0), which is a significant predictor of mortality and morbidity in patients with heart failure.
2. A history of dilated cardiomyopathy, which is a common cause of heart failure and arrhythmias.
3. Elevated troponin levels (0.01 ng/mL), which may indicate some degree of myocardial damage.
4. Presence of non-sustained ventricular tachycardia (NSVT) on ECG, which is a marker of increased risk of ventricular arrhythmias.
5. Elevated BNP levels (358 ng/L), which is a biomarker of heart failure and increased risk of adverse outcomes.
6. A history of hypertension, dyslipidemia, and other cardiovascular risk factors, which contribute to the patient's overall cardiovascular risk profile.

Despite these risk factors, the patient's NYHA class is II, indicating that the patient is able to perform moderate physical activity without symptoms. This suggests that the patient has some residual cardiac function and may be more likely to survive with appropriate management.

However, the patient's LVEF is severely impaired, and the presence of NSVT and elevated BNP levels suggest that the patient is at increased risk of adverse outcomes. Therefore, close monitoring and aggressive management of cardiovascular risk factors, including control of hypertension, dyslipidemia, and heart failure symptoms, are crucial to prevent further decline in cardiac function and reduce the risk of arrhythmias.

In conclusion, while the patient has multiple risk factors, the patient's NYHA class and residual cardiac function suggest that survival is possible with proper management, making survival the most likely outcome."
331,331,P0543,"Age: 63
Gender: Female 
Weight: 82 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,51
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1726.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 8,18
Urea (mg/dL): 9,13
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I rank the patient as a survivor with a high probability. The key factors contributing to this ranking include:

1. Age: Although the patient is 63 years old, which is considered elderly, her age alone is not a contraindication for survival. Many patients with advanced heart disease can live for several years with proper management.

2. NYHA Class II: The patient's New York Heart Association (NYHA) class II indicates mild symptoms, suggesting that she is still relatively asymptomatic despite having ischemic dilated cardiomyopathy.

3. Current Medications: The patient is taking beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, which are standard treatments for heart failure, hypertension, and dyslipidemia. These medications are likely to help manage her conditions.

4. ECG Impression: Although the ECG shows ventricular extrasystole, polymorphic, non-sustained VT, and non-sustained ventricular tachycardia, the presence of these arrhythmias does not necessarily predict a poor outcome. Many patients with these arrhythmias can still live for a long time with proper management.

5. Pro-BNP levels: Elevated Pro-BNP levels are associated with heart failure, but in this case, the level (1726 ng/L) is not excessively high, suggesting that the patient may not be in acute heart failure.

6. Other laboratory values: The patient's other laboratory values, such as creatinine, urea, and electrolytes, are relatively normal, suggesting that she does not have significant renal impairment or electrolyte imbalances.

While there are some concerns, such as the patient's low LVEF (39%) and elevated creatinine level, these factors do not outweigh the overall positive factors. Therefore, I rank the patient as a survivor."
332,332,P0544,"Age: 61
Gender: Male 
Weight: 92 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 130/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 49
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4
LDL (mmol/L): 1,29
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 823.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,37
Urea (mg/dL): 7,57
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is most likely to be a survivor due to the following factors:

1. Age: The patient is 61 years old, which is not considered old for a patient with cardiomyopathy, but the presence of ischemic dilated cardiomyopathy and NYHA Class III indicates a significant cardiac impairment. However, age alone is not a strong predictor of outcome.

2. Medications: The patient is on medications that are standard for managing heart failure and hypertension, including an Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, and Nitrovasodilator. These medications are effective in managing symptoms and slowing disease progression.

3. Laboratory results: While the patient has elevated troponin levels, which may indicate some cardiac damage, the troponin level is low (0.01 ng/mL), and the patient's LVEF is 35%, which is not severely impaired. The patient's liver enzymes (ALT and AST) are also within normal limits, and the kidney function is not severely impaired.

4. ECG findings: The ECG shows non-sustained ventricular tachycardia, which is a common finding in patients with heart failure, but the presence of ventricular extrasystole and polymorphic ventricular tachycardia suggests a possible arrhythmia risk.

5. Past medical history: The patient has a history of myocardial infarction, hypertension, and ischemic dilated cardiomyopathy, which are all risk factors for heart failure and arrhythmias. However, the patient's current symptoms and medications suggest that the disease is being managed effectively.

Overall, while this patient has a significant medical history and some risk factors for arrhythmias, the patient is currently receiving standard treatment for heart failure and hypertension, and the laboratory results are not severely abnormal. Therefore, the most likely prognosis is a survivor.

RANKING: 2. Sudden cardiac death
REASONING:

This patient's prognosis is less likely to be a survivor due to the following factors:

1. History of ventricular tachycardia: The patient has a history of non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death.

2. NYHA Class III: The patient's NYHA Class III indicates significant heart failure symptoms, which increases the risk of arrhythmias and sudden cardiac death.

3. Elevated Troponin: The patient's elevated troponin level may indicate some cardiac damage, which could increase the risk of arrhythmias and sudden cardiac death.

4. ECG findings: The patient's ECG shows polymorphic ventricular tachycardia, which is a risk factor for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING:

This patient's prognosis is least likely to be a survivor due to the following factors:

1. Low LVEF: The patient's LVEF is 35%, which is significantly reduced, indicating poor cardiac function.

2. Elevated creatinine: The patient's elevated creatinine level indicates impaired kidney function, which can lead to fluid overload and increased risk of pump failure.

3. History of myocardial infarction: The patient's history of myocardial infarction increases the risk of further cardiac events, including pump failure.

4. Medication non-adherence: The patient is on medications that are standard for managing heart failure, but the presence of non-sustained ventricular tachycardia and ventricular extrasystole suggests that the patient may not be adhering to their medication regimen, which could increase the risk of pump failure.

Overall, while the patient has a significant medical history and some risk factors for arrhythmias and pump failure, the patient is currently receiving standard treatment for heart failure, and the laboratory results are not severely abnormal. However, the patient's low LVEF and impaired kidney function increase the risk of pump failure, making this prognosis less likely."
333,333,P0546,"Age: 83
Gender: Male 
Weight: 68 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,78
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 74
Glucose (mmol/L): 9,65
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,05
LDL (mmol/L): 3,77
Sodium (mEq/L): 139.0
Protein (g/L): 68
T3 (pg/dL): 0,0375
T4 (ng/L): 21,95
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,15
Urea (mg/dL): 6,5
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient's age (83) and NYHA Class II heart failure classification indicate that the patient has significant cardiac dysfunction. However, the presence of idiopathic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension suggests a complex underlying pathology. The patient's LVEF (30.0) is severely reduced, indicating poor cardiac function.

Despite the presence of several risk factors, the patient is currently on multiple medications, including an ACE inhibitor, which is often used to manage heart failure. The absence of any evidence of acute myocardial infarction or acute heart failure exacerbation in the ECG impression suggests that the patient is not in immediate danger of cardiac death.

Additionally, the patient's laboratory values, such as the low albumin level (43 g/L) and elevated creatinine level (6.5 mg/dL), suggest malnutrition and kidney dysfunction, respectively. However, the patient's hemoglobin level (142.0 g/L) is within the normal range, which may indicate that the patient is not experiencing significant anemia.

Given the complex interplay of factors, the patient's overall prognosis is that they are likely to survive for the next few years, albeit with ongoing management of their heart failure and other comorbid conditions.

2. Sudden Cardiac Death 
REASONING: 
The patient's ECG impression shows ventricular extrasystoles, which is a risk factor for sudden cardiac death. Additionally, the patient's LVEF (30.0) is severely reduced, indicating poor cardiac function. The presence of ventricular extrasystoles and reduced LVEF increases the risk of sudden cardiac death.

However, the patient is currently on multiple medications, including an ACE inhibitor, which can help manage heart failure and reduce the risk of sudden cardiac death. The absence of any evidence of acute myocardial infarction or acute heart failure exacerbation in the ECG impression suggests that the patient is not in immediate danger of cardiac death.

Despite these factors, the patient's age (83) and complex comorbidities (idiopathic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension) increase the risk of sudden cardiac death.

3. Pump Failure Death 
REASONING: 
The patient's LVEF (30.0) is severely reduced, indicating poor cardiac function, and the patient has a history of heart failure (NYHA Class II). The presence of ventricular extrasystoles and reduced LVEF increases the risk of pump failure.

However, the patient is currently on multiple medications, including an ACE inhibitor, which can help manage heart failure. The absence of any evidence of acute myocardial infarction or acute heart failure exacerbation in the ECG impression suggests that the patient is not in immediate danger of pump failure.

The patient's age (83) and complex comorbidities (idiopathic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension) increase the risk of pump failure. However, the patient's current medication regimen and the absence of any evidence of acute cardiac events in the ECG impression suggest that pump failure is less likely than sudden cardiac death."
334,334,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 

The patient's age (30) and NYHA Class II classification indicate that they are relatively young and have a moderate level of heart failure symptoms. The patient's LVEF (left ventricular ejection fraction) of 50.0% is below the normal range, but not extremely low, suggesting some residual cardiac function. The presence of beta blockers and loop diuretics in the medication regimen indicates that the patient is being treated for heart failure.

The patient's laboratory results show elevated creatinine levels (71.0 mmol/L), which may indicate some degree of kidney impairment. However, the patient's other laboratory results, such as albumin and liver function tests, are relatively normal. The patient's troponin level (0.03 ng/mL) is within normal limits, which suggests that there is no acute myocardial infarction or significant cardiac damage.

The ECG impression shows no signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are potential indicators of cardiac arrhythmias. The presence of ventricular extrasystoles (polymorphic) is noted, but it is not severe and may not be a significant predictor of adverse outcomes.

Considering these factors, the patient's overall prognosis is likely to be a survivor, with a moderate risk of complications. However, it is essential to monitor the patient closely and adjust the treatment plan as needed to manage their heart failure and prevent potential complications.

RANKING: 
2. Sudden cardiac death 
REASONING: 

The patient's NYHA Class II classification and elevated LVEF (50.0%) suggest that the patient has some residual cardiac function, which reduces the likelihood of sudden cardiac death. However, the patient's elevated creatinine levels (71.0 mmol/L) and the presence of idiopathic dilated cardiomyopathy may increase the risk of cardiac complications.

The patient's ECG impression shows ventricular extrasystoles (polymorphic), which may increase the risk of arrhythmias. Although the patient is not at high risk for ventricular tachycardia or non-sustained ventricular tachycardia, the presence of ventricular extrasystoles may still contribute to the risk of arrhythmias.

Additionally, the patient's elevated troponin level (0.03 ng/mL) is slightly elevated, which may indicate some degree of cardiac damage. However, the level is within normal limits, and the patient's other laboratory results are relatively normal.

Considering these factors, the patient's prognosis is less likely to be a survivor, but still relatively favorable, with a moderate risk of arrhythmias and potential cardiac complications.

RANKING: 
3. Pump failure death 
REASONING: 

The patient's NYHA Class II classification and elevated creatinine levels (71.0 mmol/L) suggest that the patient has some degree of heart failure, which increases the risk of pump failure. The patient's elevated LVEF (50.0%) is below the normal range, which may indicate some degree of cardiac dysfunction.

The patient's ECG impression shows ventricular extrasystoles (polymorphic), which may increase the risk of arrhythmias and cardiac complications. The patient's elevated troponin level (0.03 ng/mL) is slightly elevated, which may indicate some degree of cardiac damage.

Considering these factors, the patient's prognosis is the least likely to be a survivor, with a high risk of pump failure and cardiac complications. However, it is essential to monitor the patient closely and adjust the treatment plan as needed to manage their heart failure and prevent potential complications."
335,335,P0548,"Age: 75
Gender: Male 
Weight: 82 kg
Height: 179 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 3,28
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,03
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 450.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,13
TSH (mIU/L): 2,29
Urea (mg/dL): 7,15
LVEF (%): 38.0
Medications: Beta Blockers, Digoxin, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the patient's age (75 years), NYHA Class III status indicating severe heart failure, and the presence of ischemic dilated cardiomyopathy, Diabetes, and Myocardial Infarction, the patient is at high risk for cardiac complications. The elevated Pro-BNP levels (450.0 ng/L) and LVEF (38.0%) further support the presence of heart failure. However, the patient is already on medications for heart failure management (Beta Blockers, Digoxin, Spironolactone, Statins, and ACE Inhibitor), which suggests that the patient is receiving standard treatment for heart failure. The patient's creatinine level (97.0 mmol/L) and urea level (7.15 mg/dL) are also within a relatively normal range, indicating that the patient's renal function is not severely impaired. 

The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG suggests that the patient has an increased risk of arrhythmias. However, the patient is already on beta-blockers, which are known to reduce the risk of arrhythmias. 

Given these factors, the patient's overall prognosis is likely to be a survivor, with the possibility of ongoing heart failure management and potential need for further interventions to address arrhythmias.

2. Sudden cardiac death 
REASONING: 
While the patient has a high risk of cardiac complications due to their age, NYHA Class III status, and the presence of ischemic dilated cardiomyopathy, the patient's elevated Pro-BNP levels and LVEF suggest that they are already experiencing some degree of heart failure. However, the presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG increases the risk of sudden cardiac death. 

However, the patient's beta-blocker therapy and other medications for heart failure management may mitigate this risk. The patient's renal function is also relatively preserved, which suggests that they are not at high risk for acute kidney injury or renal failure that could contribute to sudden cardiac death. 

Given these factors, the risk of sudden cardiac death is still present, but it is not the most likely outcome.

3. Pump failure death 
REASONING: 
While the patient has a high risk of heart failure due to their NYHA Class III status and ischemic dilated cardiomyopathy, the patient's elevated Pro-BNP levels (450.0 ng/L) and LVEF (38.0%) suggest that the patient is already experiencing some degree of heart failure. The patient's creatinine level (97.0 mmol/L) and urea level (7.15 mg/dL) are relatively normal, which suggests that the patient's renal function is not severely impaired. 

However, the patient's ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG suggest that the patient has an increased risk of arrhythmias, which could potentially lead to pump failure. 

Given these factors, the risk of pump failure death is present, but it is not the most likely outcome.

Note: This prognosis is based on the information provided and should be used as a general guideline. A more accurate prognosis can only be made after a thorough evaluation of the patient's medical history, physical examination, and other diagnostic tests."
336,336,P0549,"Age: 56
Gender: Male 
Weight: 96 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,59
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 561.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,2
Urea (mg/dL): 6,32
LVEF (%): 54.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

This patient has a history of ischemic dilated cardiomyopathy, which is a significant underlying condition that increases the risk of cardiac complications. However, the patient's current LVEF of 54.0 is not severely impaired, which may indicate that the patient's cardiac function is not as severely compromised as it could be. Additionally, the patient is receiving multiple medications that are commonly used to manage heart failure, including beta blockers, loop diuretics, and ACE inhibitors, which may help to slow the progression of the disease.

The patient's ECG findings, while concerning, do not indicate a high risk of sudden cardiac death. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia are all relatively common in patients with heart failure and do not necessarily indicate a high risk of sudden cardiac death.

The patient's laboratory values are also relatively stable, with no significant elevations in liver enzymes or creatinine, which could indicate worsening kidney function or liver disease. The patient's hemoglobin and potassium levels are also within normal limits, which suggests that the patient is not experiencing significant anemia or electrolyte imbalances.

Overall, while this patient has a significant underlying condition and some concerning ECG findings, the combination of a relatively preserved LVEF, multiple medications, and stable laboratory values suggest that the patient is at lower risk for sudden cardiac death and pump failure compared to the other two options.

2. Sudden cardiac death
REASONING: 

This patient's history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia (CH>10) do increase the risk of sudden cardiac death. The presence of ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia are also concerning and may indicate an increased risk of arrhythmias.

However, the patient's LVEF is not severely impaired, which may reduce the risk of sudden cardiac death. Additionally, the patient is receiving medications that are commonly used to manage heart failure and may help to reduce the risk of arrhythmias.

3. Pump failure death
REASONING: 

The patient's LVEF of 54.0 is not severely impaired, which suggests that the patient's cardiac function is not as compromised as it could be. Additionally, the patient is receiving medications that are commonly used to manage heart failure, including beta blockers, loop diuretics, and ACE inhibitors, which may help to slow the progression of the disease.

However, the patient's elevated creatinine level (124.0) and elevated BNP level (561.0) may indicate some degree of cardiac dysfunction, which could increase the risk of pump failure. However, the patient's overall clinical presentation and laboratory values do not suggest that the patient is at high risk for pump failure."
337,337,P0551,"Age: 60
Gender: Male 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,4
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2239.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 17
TSH (mIU/L): 0,845
Urea (mg/dL): 12,81
LVEF (%): 57.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is at a high risk of pump failure death due to the following reasons:

1. Low LVEF (Left Ventricular Ejection Fraction) of 57.0, indicating reduced cardiac function.
2. Elevated Creatinine level of 177.0, suggesting impaired kidney function, which can be a result of cardiac failure.
3. Elevated Pro-BNP (Brain Natriuretic Peptide) level of 2239.0, indicating increased ventricular wall stress and cardiac strain.
4. Presence of Hypertensive cardiomyopathy and Hypertension, which can lead to left ventricular hypertrophy and reduced LVEF over time.
5. The patient's NYHA Class II status indicates mild symptoms of heart failure, which can progress to more severe symptoms if not properly managed.

Considering these factors, the patient is at a higher risk of pump failure death in the next few years if not adequately managed. However, the patient is currently being treated with medications that can help manage symptoms and slow disease progression. Therefore, the most likely outcome is that the patient will survive with proper management.

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the following reasons:

* Sudden cardiac death is unlikely given the absence of any significant ECG abnormalities, such as ventricular tachycardia or ventricular extrasystoles.
* Pump failure death is less likely given the patient's current treatment regimen and relatively stable vital signs, although the patient's LVEF is still below the normal range.

Overall, while the patient is at risk for cardiac complications, the combination of their current treatment and relatively stable vital signs suggest that survival is the most likely outcome in the next few years."
338,338,P0552,"Age: 50
Gender: Female 
Weight: 59 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,25
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,62
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 809.0
Protein (g/L): 70
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,04
Urea (mg/dL): 5,99
LVEF (%): 66.0
Medications: Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient data, the patient is a 50-year-old female with a history of hypertrophic cardiomyopathy, which is a significant risk factor for sudden cardiac death. However, the patient is currently being treated with beta blockers, which are known to reduce the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy.

The patient's left ventricular ejection fraction (LVEF) is 66.0%, which is within the normal range. This suggests that the patient's heart is not severely impaired, and the patient is likely to survive with proper management.

The patient's troponin level is 0.01 ng/mL, which is within the normal range. This further supports the idea that the patient's heart is not severely damaged.

The patient's Pro-BNP level is 809.0 ng/L, which is elevated, indicating some level of heart strain. However, this is not a contraindication to survival.

The patient's other laboratory values are within normal ranges or close to normal ranges, which further supports the idea that the patient is at low risk for sudden cardiac death.

The patient's ECG impression does not show any signs of ventricular tachycardia or other arrhythmias that could indicate a high risk for sudden cardiac death.

Overall, based on the patient's medical history, laboratory values, and ECG findings, I predict that the patient will survive for the next few years with proper management and monitoring."
339,339,P0554,"Age: 70
Gender: Female 
Weight: 56 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 147/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 48
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,6
Sodium (mEq/L): 139.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,39
Urea (mg/dL): 14,48
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 70-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. Her New York Heart Association (NYHA) class is II, indicating mild symptoms of heart failure. The patient's ejection fraction (LVEF) is significantly reduced at 35%, which is a strong indicator of impaired cardiac function.

Despite the patient's poor cardiac function, the absence of any recent myocardial infarction, ventricular tachycardia, or other life-threatening arrhythmias on the ECG impression, and the presence of a normal potassium level suggest that the patient's cardiac condition may be stable. The patient is also on a regimen of medications that are commonly used to manage heart failure and prevent further cardiac events.

Additionally, the patient's laboratory results show a slightly elevated creatinine level, but this is not uncommon in patients with heart failure. The patient's troponin level is also within normal limits, which suggests that there is no acute myocardial injury.

Considering these factors, I predict that the patient is at high risk of survival for the next few years, with a reasonable quality of life despite her cardiac limitations."
340,340,P0557,"Age: 72
Gender: Female 
Weight: 55 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 103.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,94
Urea (mg/dL): 8,82
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a severe underlying cardiac condition, with a left ventricular ejection fraction (LVEF) of 30%, indicating significant left ventricular dysfunction. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG further supports this, indicating potential arrhythmia risk. However, the patient's NYHA Class II classification indicates that they are still able to perform moderate physical activity without symptoms, which is a positive prognostic sign.

The patient's medication regimen, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, suggests that their cardiovascular risk factors are being adequately managed. The patient's laboratory results, including low troponin levels and normal TSH, indicate that there is no evidence of acute coronary syndrome or thyroid dysfunction.

While the patient's creatinine level is elevated, it is still within a relatively normal range, and the patient is not showing signs of acute kidney injury. The patient's hemoglobin and potassium levels are also within normal limits.

Given these factors, the patient's overall risk of sudden cardiac death or pump failure in the next few years is lower than the other two options. Therefore, I predict that the patient has a high likelihood of survival over the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's LVEF of 30% and ventricular extrasystoles on the ECG do indicate a significant cardiac risk, the patient's NYHA Class II classification and medication regimen suggest that they are receiving adequate management of their cardiovascular risk factors. However, the patient's LVEF is still significantly reduced, indicating ongoing cardiac dysfunction.

The patient's elevated creatinine level and elevated troponin level, although within normal limits, suggest that there may be some underlying cardiac damage or inflammation. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG also increase the risk of arrhythmia, which can contribute to sudden cardiac death.

However, the patient's overall clinical presentation and test results do not suggest an acute cardiac event, and the patient is receiving adequate management of their cardiovascular risk factors. Therefore, while the patient's risk of sudden cardiac death is higher than the survivor option, it is still lower than the pump failure option.

RANKING: 3. Pump failure
REASONING: 

The patient's LVEF of 30% is a significant indicator of left ventricular dysfunction, and the patient's elevated creatinine level suggests that their kidneys may be under strain. The patient's ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG also increase the risk of arrhythmia, which can contribute to pump failure.

The patient's NYHA Class II classification suggests that they are still able to perform moderate physical activity without symptoms, but this may be a sign of underlying cardiac reserve that is being stretched. The patient's medication regimen, while adequate, may not be sufficient to fully manage their cardiovascular risk factors, particularly given the patient's significant left ventricular dysfunction.

The patient's laboratory results, including the elevated troponin level, suggest that there may be ongoing cardiac damage or inflammation, which can contribute to pump failure. Therefore, while the patient's risk of sudden cardiac death is lower than the pump failure option, I predict that the patient has a higher risk of pump failure in the next few years."
341,341,P0558,"Age: 65
Gender: Male 
Weight: 98 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 16
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1649.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,54
Urea (mg/dL): 6,99
LVEF (%): 27.0
Medications: Digoxin, Loop Diuretics, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's age, NYHA Class III, and history of ischemic dilated cardiomyopathy and hypertension increase the risk of cardiac complications. However, the patient's recent ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia suggest a high risk of arrhythmic events. 

The patient's low LVEF of 27% is a significant indicator of poor cardiac function, which may lead to pump failure. However, the patient is currently being treated with medications that are standard for heart failure management, including digoxin, loop diuretics, hydralazine, ACE inhibitors, and a nitrovasodilator. 

Considering the patient's overall clinical presentation, the presence of multiple arrhythmic events, and the fact that they are already on medications for heart failure management, the most likely outcome for the next few years is a survivor. 

However, there is a high risk of cardiac complications, including sudden cardiac death, and pump failure. Therefore, close monitoring and adjustments to the treatment plan may be necessary to minimize these risks.

RANKING: 2. Sudden Cardiac Death
REASONING: 
The patient's ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia increase the risk of arrhythmic events, including sudden cardiac death. The patient's low LVEF of 27% and history of ischemic dilated cardiomyopathy also increase the risk of cardiac complications.

RANKING: 3. Pump Failure Death
REASONING: 
The patient's low LVEF of 27% and history of ischemic dilated cardiomyopathy increase the risk of pump failure. However, the patient is currently being treated with medications that are standard for heart failure management, including digoxin, loop diuretics, hydralazine, ACE inhibitors, and a nitrovasodilator. While there is a risk of pump failure, the patient's recent ECG findings and the fact that they are already on medications for heart failure management suggest that pump failure is not the most likely outcome for the next few years."
342,342,P0561,"Age: 38
Gender: Female 
Weight: 58 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 90/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,77
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 37.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,23
Urea (mg/dL): 6,32
LVEF (%): 41.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall clinical presentation and lab results suggest a stable condition, with the patient being on medications for heart failure (beta blockers and ACE inhibitor) and having a relatively preserved ejection fraction (LVEF 41.0). The patient's NYHA class is II, indicating mild symptoms, and their blood pressure is within a relatively normal range (90/50 mmHg). The patient's troponin level is also within normal limits (0.03 ng/mL), which suggests no significant myocardial injury.

The patient's elevated creatinine level (80.0 mol/L) may indicate some degree of kidney impairment, but it is not severe enough to suggest end-stage renal disease. The patient's liver enzymes (ALT and AST) are within normal limits, and their lipid profile is also relatively healthy.

The presence of paroxysmal supraventricular tachycardia (PSVT) is a benign finding and is not a significant concern. The patient's ECG is mostly normal, with the exception of ventricular extrasystoles, which are also a common finding in patients with heart failure.

Given these factors, the patient's overall prognosis is good, and I would rank them as a survivor. While there are some potential risks and complications associated with heart failure, the patient's current clinical status and lab results suggest that they are not at high risk for sudden cardiac death or pump failure death in the near future.

It is essential to continue monitoring the patient's condition closely, including regular follow-up appointments and regular ECGs, to ensure that any potential issues are caught early and managed effectively. However, based on the available information, I believe that the patient's prognosis is favorable, and they are likely to survive in the next few years."
343,343,P0562,"Age: 79
Gender: Female 
Weight: 67 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 27
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 80.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,79
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 4399.0
Protein (g/L): 61
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,4
Urea (mg/dL): 37,27
LVEF (%): 53.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient is an elderly female with multiple comorbidities, including hypertension, cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease. Her current NYHA Class II indicates that she has some limitation in physical activity due to heart failure symptoms, but she is still able to perform daily activities without significant distress.

Her laboratory results show elevated creatinine levels (194.0 mmol/L) and elevated troponin levels (0.01 ng/mL), which suggest some degree of cardiac stress and potential cardiac damage. However, her LVEF (53.0%) is within the normal range, and her ECG does not show any signs of ventricular tachycardia or significant arrhythmias.

The patient's medication regimen includes a calcium channel blocker, diabetes medication, angiotensin II receptor blocker, beta blockers, and loop diuretics, which suggests that her cardiovascular system is being adequately managed.

Given these factors, I would rank the patient as a survivor, as her overall health status and medical management suggest that she is likely to survive for the next few years with careful monitoring and management of her comorbidities.

While the patient's elevated creatinine and troponin levels suggest some degree of cardiac stress, the fact that her LVEF is normal and her ECG does not show any signs of arrhythmias or significant cardiac damage suggests that she may not be at high risk for sudden cardiac death. Similarly, her NYHA Class II classification suggests that she is not severely limited in her physical activity, which further reduces the likelihood of pump failure death.

In contrast, the patient's high blood pressure (150/70 mmHg) and elevated creatinine levels suggest that she may be at increased risk for cardiovascular events, such as heart failure or stroke. However, her medication regimen and overall health status suggest that she is being adequately managed, and her prognosis is therefore ranked as a survivor."
344,344,P0564,"Age: 69
Gender: Male 
Weight: 75 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,62
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,37
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 277.0
Protein (g/L): 74
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,7
Urea (mg/dL): 6,99
LVEF (%): 45.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a significant history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which are all risk factors for cardiac complications. However, the patient's current NYHA Class II indicates that they are still able to perform moderate physical activity without symptoms. Their elevated creatinine level (80.0 mmol/L) suggests some degree of renal impairment, which can be a complication of heart failure. However, the patient's troponin level is within normal limits, and their LVEF is 45%, which is still within the range for a patient with heart failure.

The patient's medication regimen, including beta blockers, statins, and an ACE inhibitor, is standard for managing heart failure and reducing cardiovascular risk. The ECG impression does not indicate any acute arrhythmias, and the patient's Pro-BNP level is elevated, but not excessively high.

Given these factors, the patient's overall prognosis is relatively good, with a high likelihood of survival. The patient's age (69) and weight (75 kg) are not extreme, and their hemoglobin and kidney function are within relatively normal limits. While the patient has a history of cardiac disease, their current condition does not appear to be acutely unstable, and they are receiving standard therapy for their condition.

In contrast to the other two options, sudden cardiac death is unlikely because the patient's ECG does not indicate any acute arrhythmias, and their Pro-BNP level is not excessively high. Pump failure death is also unlikely because the patient's LVEF is within the range for a patient with heart failure, and they are receiving standard therapy for their condition.

Overall, based on the available data, the patient's prognosis is best classified as survivor."
345,345,P0566,"Age: 65
Gender: Male 
Weight: 88 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 170/90 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,98
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 290.0
Protein (g/L): 71
T4 (ng/L): 10
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,46
Urea (mg/dL): 6,66
LVEF (%): 62.0
Medications: Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING:

This patient's prognosis is most likely to be a survivor due to several factors:

1. Age: The patient is 65 years old, which is considered middle-aged. While age is a significant risk factor for cardiac events, it is not the only factor at play here. However, the patient's age is not extremely high, and their overall health status is relatively stable.

2. Medications: The patient is taking beta blockers, digoxin, and loop diuretics, which are standard treatments for managing hypertension, heart failure, and atrial fibrillation, respectively. These medications can help slow the progression of cardiac disease and improve symptoms.

3. ECG findings: The patient's ECG shows ventricular extrasystoles, which are benign and can be seen in patients with hypertrophic cardiomyopathy. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient is not at high risk for sudden cardiac death.

4. Cardiac function: The patient's left ventricular ejection fraction (LVEF) is 62%, which is within the normal range. This suggests that the patient's heart is still pumping efficiently, which is a good prognostic sign.

5. Other lab values: The patient's creatinine level is elevated, but this is not uncommon in patients with hypertension and heart disease. The troponin level is also normal, which suggests that there is no acute myocardial infarction.

Overall, based on the patient's age, medication regimen, ECG findings, cardiac function, and lab values, the most likely outcome is that the patient will survive."
346,346,P0569,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 125/75 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 85.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,84
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 753.0
Protein (g/L): 65
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,83
Urea (mg/dL): 7,15
LVEF (%): 61.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's age, NYHA Class III, and history of hypertensive cardiomyopathy are significant risk factors for adverse outcomes. However, the patient's current ECG findings, such as ventricular extrasystoles, do not indicate a high risk for sudden cardiac death. The presence of paroxysmal supraventricular tachycardia (PSVT) is also present, but it is not a high-risk arrhythmia. The patient's LVEF of 61.0 is within the normal range, and the absence of troponin elevation suggests that there is no acute myocardial infarction. The patient's biomarkers, such as creatinine and urea, are elevated, but this is likely due to renal impairment rather than cardiac dysfunction. The patient's medication regimen, including a calcium channel blocker, digoxin, loop diuretics, and ACE inhibitor, is well-tailored to their condition and is unlikely to be a contributing factor to adverse outcomes. Overall, considering the patient's age and medical history, but without any high-risk ECG findings or biomarkers, the likelihood of sudden cardiac death or pump failure death is relatively low, making a survivor outcome the most likely."
347,347,P0571,"Age: 76
Gender: Male 
Weight: 96 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,89
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1303.0
Protein (g/L): 80
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,71
Urea (mg/dL): 13,48
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is likely to be a survivor due to several factors:

1. Age: Although the patient is 76 years old, the age itself is not a strong predictor of outcome. However, the presence of comorbidities and advanced cardiac disease may increase the risk of complications.
2. NYHA Class II: The patient's NYHA Class II indicates that the patient has some limitation in physical activity due to heart failure symptoms, but they can still perform ordinary activities without discomfort or symptoms.
3. Medications: The patient is taking a comprehensive regimen of medications, including beta blockers, digoxin, loop diuretics, hydralazine, ACE inhibitors, and a nitrovasodilator, which suggests that the patient's cardiologist is actively managing the patient's heart failure and arrhythmias.
4. ECG findings: The ECG shows ventricular extrasystoles, but no ventricular tachycardia or non-sustained ventricular tachycardia. This suggests that the patient's arrhythmias are not severe or life-threatening.
5. Pro-BNP levels: Although the Pro-BNP level is elevated, indicating some degree of heart failure, it is not extremely high, which may suggest that the patient is not in acute decompensated heart failure.
6. LVEF: The left ventricular ejection fraction (LVEF) is significantly reduced, indicating systolic dysfunction, which is a common finding in heart failure patients.

While the patient has several comorbidities and advanced cardiac disease, the comprehensive management of their condition, the absence of severe arrhythmias, and the relatively mild elevation of Pro-BNP levels suggest that the patient is likely to survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

This patient's prognosis is less likely to be sudden cardiac death due to the following reasons:

1. ECG findings: The ECG shows ventricular extrasystoles, but no ventricular tachycardia or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death.
2. Medications: The patient is taking a comprehensive regimen of medications, which suggests that the patient's cardiologist is actively managing the patient's heart failure and arrhythmias.
3. Pro-BNP levels: Although the Pro-BNP level is elevated, it is not extremely high, which may suggest that the patient is not in acute decompensated heart failure.

However, the patient's advanced age, reduced LVEF, and comorbidities, such as hypertension, diabetes, and idiopathic dilated cardiomyopathy, increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

This patient's prognosis is less likely to be pump failure death due to the following reasons:

1. Medications: The patient is taking a comprehensive regimen of medications, which suggests that the patient's cardiologist is actively managing the patient's heart failure.
2. ECG findings: The ECG shows ventricular extrasystoles, but no ventricular tachycardia or non-sustained ventricular tachycardia, which reduces the risk of pump failure.
3. Pro-BNP levels: Although the Pro-BNP level is elevated, it is not extremely high, which may suggest that the patient is not in acute decompensated heart failure.

However, the patient's advanced age, reduced LVEF, and comorbidities, such as hypertension, diabetes, and idiopathic dilated cardiomyopathy, increase the risk of pump failure. Additionally, the patient's NYHA Class II indicates some limitation in physical activity due to heart failure symptoms, which may suggest that the patient is experiencing some degree of heart failure."
348,348,P0572,"Age: 36
Gender: Male 
Weight: 80 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 32.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,21
Urea (mg/dL): 4,66
LVEF (%): 53.0
Medications: Calcium Channel Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age (36) is relatively young, which is a positive factor for survival. The patient's NYHA Class II indicates that they have some limitation in physical activity, but they are not severely impaired. The patient's blood pressure (140/70 mmHg) is within a relatively normal range. The presence of hypertension, diabetes, and cardiomyopathy in the past medical history may increase the risk of cardiovascular events, but the patient is currently being treated with medications that are commonly used to manage these conditions.

The patient's laboratory results show a slightly elevated creatinine level (88.0 mmol/L), which may indicate some degree of renal impairment, but it is not severe. The liver enzymes (ALT and AST) are within normal limits, and the total cholesterol and LDL levels are also within normal ranges. The patient's hemoglobin level (150.0 g/L) is slightly elevated, which may be a sign of anemia, but it is not severe.

The patient's ejection fraction (LVEF) is 53.0%, which is below the normal range, indicating some degree of left ventricular dysfunction. However, the patient is being treated with medications that are commonly used to manage heart failure, such as digoxin and loop diuretics.

The ECG results show a normal rhythm, with no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other arrhythmias. The presence of ventricular extrasystoles (monomorphic) may indicate some degree of ventricular dysfunction, but it is not severe.

Overall, based on the patient's age, medical history, laboratory results, and treatment, I believe that the patient has a relatively good prognosis for survival. The patient's current symptoms and test results do not indicate an acute life-threatening condition, and the patient is being treated with medications that are commonly used to manage cardiovascular conditions. Therefore, I rank the patient as a survivor."
349,349,P0573,"Age: 46
Gender: Male 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 91.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,22
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 172.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 5,49
LVEF (%): 22.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to the following factors:

1. Age: The patient is 46 years old, which is relatively young for heart failure. A lower age is generally associated with a better prognosis.

2. NYHA Class II: The patient has a mild to moderate level of symptoms, indicating that they are able to perform daily activities with some limitation. A lower NYHA class is associated with a better prognosis.

3. Medications: The patient is taking beta blockers, statins, and an ACE inhibitor, which are all standard treatments for heart failure and coronary artery disease. These medications help to reduce the workload on the heart and prevent further damage.

4. ECG Impression: The patient has a polymorphic ventricular extrasystole and non-sustained ventricular tachycardia, which indicate that the heart is still functioning, but there is evidence of arrhythmia. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the heart is not in a life-threatening arrhythmia state.

5. Biomarkers: The patient has elevated troponin levels, which indicate some cardiac damage, but the levels are not excessively high. The patient also has a low LVEF, indicating reduced heart function, but the patient is not in cardiac shock.

6. Laboratory values: The patient's liver function tests, kidney function, and electrolyte levels are within normal limits.

While the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, the combination of a relatively young age, mild symptoms, and the presence of standard treatments suggests that the patient is likely to survive for several years.

RANKING: 2. Sudden cardiac death
REASONING: 

This patient's prognosis is ranked as sudden cardiac death due to the following factors:

1. Low LVEF: The patient's left ventricular ejection fraction (LVEF) is 22%, which is significantly reduced, indicating that the heart is not functioning properly.

2. History of myocardial infarction and ischemic dilated cardiomyopathy: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death.

3. ECG Impression: The presence of polymorphic ventricular extrasystole and non-sustained ventricular tachycardia indicates that the heart is at risk for arrhythmias, which can lead to sudden cardiac death.

4. Elevated troponin levels: The patient's elevated troponin levels indicate some cardiac damage, which increases the risk of sudden cardiac death.

5. Low HDL: The patient's low high-density lipoprotein (HDL) level is associated with an increased risk of cardiovascular disease and sudden cardiac death.

While the patient is taking medications, the combination of reduced heart function, history of myocardial infarction, and arrhythmias makes this patient more susceptible to sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

This patient's prognosis is ranked as pump failure death due to the following factors:

1. Low LVEF: The patient's LVEF is 22%, which indicates that the heart is not functioning properly, and it may not be able to meet the body's needs.

2. History of myocardial infarction and ischemic dilated cardiomyopathy: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of heart failure.

3. Elevated troponin levels: The patient's elevated troponin levels indicate some cardiac damage, which can lead to heart failure.

4. NYHA Class II: The patient's mild to moderate symptoms indicate that they are experiencing some limitation in daily activities, which can be a sign of heart failure.

5. Low HDL: The patient's low HDL level is associated with an increased risk of cardiovascular disease and heart failure.

While the patient is taking medications, the combination of reduced heart function, history of myocardial infarction, and elevated troponin levels makes this patient more susceptible to pump failure death."
350,350,P0574,"Age: 76
Gender: Male 
Weight: 76 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 2,61
Potassium (mEq/L): 3,87
LDL (mmol/L): 2,95
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 381.0
Protein (g/L): 73
T3 (pg/dL): 0,0588
T4 (ng/L): 15,24
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,56
Urea (mg/dL): 8,6
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient is at high risk for adverse cardiac events due to multiple comorbidities, such as hypertension, cardiomyopathy, diabetes, and dyslipidemia. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia on the ECG impression also suggests a high risk of arrhythmias. However, the patient's NYHA class is II, indicating that they have some limitation in physical activity, but they can still perform daily activities without severe symptoms. Additionally, the patient's LVEF is 70%, which is within the normal range for their age. The presence of a high Pro-BNP level (381.0 ng/L) indicates cardiac stress, but it is not indicative of heart failure. The patient's medication regimen is comprehensive and includes a calcium channel blocker, diabetes medication, angiotensin II receptor blocker, loop diuretics, and statins, which are all aimed at managing their comorbidities. Considering these factors, I believe that the patient is likely to survive for the next few years with proper management and monitoring.

RANKING: 
2. Sudden Cardiac Death
REASONING: 
The patient's high blood pressure (160/80 mmHg) and history of hypertension and cardiomyopathy increase their risk of sudden cardiac death. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia on the ECG impression also suggests an increased risk of arrhythmias. The patient's LVEF is 70%, which is slightly below the normal range for their age, indicating some cardiac dysfunction. However, the patient's overall health status, including their NYHA class, medication regimen, and lack of severe symptoms, suggest that they are not at the highest risk for sudden cardiac death.

RANKING: 
3. Pump Failure Death
REASONING: 
While the patient's LVEF is 70%, which is slightly below the normal range for their age, their overall health status and medication regimen suggest that they are not at high risk for pump failure. The patient's NYHA class is II, indicating some limitation in physical activity, but they can still perform daily activities without severe symptoms. The patient's Pro-BNP level is elevated, indicating cardiac stress, but it is not indicative of heart failure. The patient's medication regimen is comprehensive and includes a calcium channel blocker, diabetes medication, angiotensin II receptor blocker, loop diuretics, and statins, which are all aimed at managing their comorbidities. Additionally, the patient's hemoglobin level is 130.0 g/L, which is within the normal range, suggesting adequate oxygenation. Considering these factors, I believe that the patient is not at high risk for pump failure in the next few years."
351,351,P0575,"Age: 63
Gender: Female 
Weight: 64 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 90/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 76.0
AST or GOT (IU/L): 52.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,12
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1870.0
Protein (g/L): 72
T4 (ng/L): 3
TSH (mIU/L): 18,75
Urea (mg/dL): 7,32
LVEF (%): 24.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient's prognosis is ranked as a survivor due to the presence of several factors that suggest a relatively preserved cardiac function and overall health. The patient's NYHA Class II indicates a mild symptom limitation, suggesting that they can still perform daily activities without significant limitation. The patient's LVEF of 24.0 is significantly reduced, but not critically low, indicating some residual cardiac function.

The patient's medication regimen includes beta blockers, statins, and an ACE inhibitor, which are all standard treatments for managing heart failure and reducing cardiovascular risk factors. The absence of any other significant cardiac abnormalities on the ECG, such as ventricular tachycardia or non-sustained ventricular tachycardia, further supports the likelihood of a favorable outcome.

While the patient's elevated creatinine level and low LVEF do indicate some degree of cardiac dysfunction, the patient's overall health profile, including their age, weight, and laboratory results, suggests that they may be able to tolerate treatment and manage their condition with current medications.

The presence of elevated Pro-BNP levels (1870.0 ng/L) suggests some degree of cardiac strain, but this is not uncommon in patients with heart failure and can be managed with treatment. The patient's other laboratory results, such as their hemoglobin and electrolyte levels, are within relatively normal limits.

Overall, while this patient has a significant history of heart disease, their current clinical presentation and laboratory results suggest that they are likely to survive the next few years with proper management and treatment.

RANKING 2: Sudden Cardiac Death
REASONING: 
This patient's prognosis is ranked as sudden cardiac death due to their history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF of 24.0 is significantly reduced, indicating a high degree of cardiac dysfunction.

The patient's elevated creatinine level and low LVEF suggest that their cardiac function is compromised, and they may be at risk for further decline. The presence of ventricular extrasystoles on the ECG is also a concern, as it can increase the risk of arrhythmias and sudden cardiac death.

While the patient is currently on beta blockers, statins, and an ACE inhibitor, these medications may not be sufficient to completely mitigate their cardiac risk. The patient's elevated Pro-BNP levels (1870.0 ng/L) suggest some degree of cardiac strain, and their laboratory results, such as their hemoglobin and electrolyte levels, are not ideal.

Overall, while the patient's current clinical presentation and laboratory results suggest that they are not in immediate danger, their history of ischemic dilated cardiomyopathy and compromised cardiac function make them at risk for sudden cardiac death.

RANKING 3: Pump Failure Death
REASONING: 
This patient's prognosis is ranked as pump failure death due to their significant history of heart failure and compromised cardiac function. The patient's LVEF of 24.0 is significantly reduced, indicating a high degree of cardiac dysfunction.

The patient's elevated creatinine level and low LVEF suggest that their cardiac function is severely compromised, and they are at risk for further decline. The presence of ventricular extrasystoles on the ECG is also a concern, as it can increase the risk of arrhythmias and sudden cardiac death.

The patient's laboratory results, such as their hemoglobin and electrolyte levels, are not ideal, and their elevated Pro-BNP levels (1870.0 ng/L) suggest some degree of cardiac strain. The patient's history of ischemic dilated cardiomyopathy and compromised cardiac function make it likely that they will eventually experience pump failure, which can lead to death.

Overall, while the patient is currently on beta blockers, statins, and an ACE inhibitor, these medications may not be sufficient to completely mitigate their cardiac risk, and their compromised cardiac function makes them at risk for pump failure death."
352,352,P0577,"Age: 37
Gender: Male 
Weight: 90 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 7,53
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 107
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,5
LDL (mmol/L): 5,17
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 71.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,27
Urea (mg/dL): 5,66
LVEF (%): 31.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a poor prognosis, but the patient is already on medications that are standard for managing heart failure and ischemic cardiomyopathy. The patient's LVEF (Left Ventricular Ejection Fraction) of 31.0% indicates significant left ventricular dysfunction, which is consistent with a poor prognosis. However, the patient's NYHA Class II indicates that the patient is able to perform moderate physical activity without symptoms, which suggests some level of functional capacity.

The patient's biomarkers, such as elevated troponin (0.01 ng/mL) and slightly elevated creatinine (5.66 mg/dL), suggest some degree of cardiac and renal stress. However, the patient's kidney function is not severely impaired, and the patient is already on ACE inhibitor therapy, which is beneficial for patients with heart failure.

The patient's ECG results show ventricular extrasystole, which is a non-specific finding, but not indicative of a life-threatening arrhythmia. The absence of other arrhythmias on the ECG suggests that the patient is not at high risk for sudden cardiac death.

Given the patient's age, weight, and overall clinical presentation, I believe that the patient is more likely to survive for the next few years, assuming the patient continues to receive standard medical therapy and does not experience any significant worsening of symptoms or adverse events.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of myocardial infarction and ischemic cardiomyopathy increases the risk of sudden cardiac death. The patient's LVEF of 31.0% indicates significant left ventricular dysfunction, which is a risk factor for sudden cardiac death. Additionally, the patient's elevated troponin and creatinine levels suggest some degree of cardiac and renal stress.

The patient's ECG results show ventricular extrasystole, which is a non-specific finding, but it could be a sign of underlying cardiac instability. The absence of other arrhythmias on the ECG makes it difficult to rule out the possibility of a life-threatening arrhythmia.

Given the patient's history and clinical presentation, I believe that the patient is at risk for sudden cardiac death, but the patient's current medications and functional capacity suggest that this risk is not immediately apparent.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF of 31.0% indicates significant left ventricular dysfunction, which increases the risk of heart failure. The patient's elevated creatinine level (5.66 mg/dL) and slightly elevated troponin (0.01 ng/mL) suggest some degree of cardiac and renal stress.

The patient's NYHA Class II indicates that the patient is able to perform moderate physical activity without symptoms, which suggests some level of functional capacity. However, the patient's low HDL (1.29 mmol/L) and elevated LDL (5.17 mmol/L) levels suggest a high risk for cardiovascular disease.

Given the patient's history of ischemic cardiomyopathy and the presence of ventricular extrasystole on the ECG, I believe that the patient is at risk for pump failure death. However, the patient's current medications and functional capacity suggest that this risk is not immediately apparent, and the patient is more likely to survive for the next few years with proper management and monitoring."
353,353,P0578,"Age: 44
Gender: Male 
Weight: 68 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 6,8
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 174.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 5,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 628.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,09
Urea (mg/dL): 4,99
LVEF (%): 43.0
Medications: Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that affects the heart's ability to pump blood effectively. Despite this, the patient's NYHA class is II, indicating that they are able to perform moderate physical activity without symptoms. The patient's blood pressure is within a normal range, and their lipid profile is not significantly abnormal. They are also on medications for dyslipidemia and heart failure, which suggests that their condition is being managed.

The patient's laboratory results show elevated levels of pro-BNP, which is a marker of cardiac stress and strain. However, the level is not excessively high, and the patient's troponin levels are within normal limits. The ECG results show ventricular extrasystoles, which are a common finding in patients with heart failure, but no other significant arrhythmias.

Given these factors, the patient's overall prognosis is good, and it is likely that they will survive for several years. The patient's age, weight, and physical condition are also factors that contribute to a favorable prognosis.

2. Sudden Cardiac Death
REASONING:
The patient's history of idiopathic dilated cardiomyopathy and elevated pro-BNP levels suggest that they have a significant underlying cardiac condition that could potentially lead to sudden cardiac death. However, the patient's NYHA class is II, and they are on medications for heart failure, which suggests that their condition is being managed.

The patient's ECG results show ventricular extrasystoles, which could be a sign of cardiac stress, but the absence of other significant arrhythmias reduces the likelihood of sudden cardiac death. The patient's lipid profile is not significantly abnormal, and their blood pressure is within a normal range.

However, the patient's LVEF is only 43%, which is significantly below the normal range. This suggests that the patient's heart is not functioning efficiently, and there is a risk of further decline in cardiac function. While the patient is on medications for heart failure, the presence of a low LVEF and elevated pro-BNP levels increase the risk of sudden cardiac death.

3. Pump Failure Death
REASONING:
The patient's LVEF is only 43%, which is significantly below the normal range. This suggests that the patient's heart is not functioning efficiently, and there is a risk of further decline in cardiac function. The patient's elevated pro-BNP levels and ventricular extrasystoles also suggest that the patient is experiencing cardiac stress.

The patient's lipid profile is not significantly abnormal, and their blood pressure is within a normal range. However, the patient's low HDL cholesterol level (0.83 mmol/L) is below the normal range, which could contribute to an increased risk of cardiovascular events.

Given the patient's low LVEF and elevated pro-BNP levels, the risk of pump failure death is a significant concern. The patient's medications for heart failure and dyslipidemia may not be sufficient to mitigate this risk, and the patient's overall condition suggests that they are at risk of further decline in cardiac function."
354,354,P0579,"Age: 73
Gender: Male 
Weight: 98 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 100/58 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,78
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 72
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,91
Urea (mg/dL): 7,49
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient has several risk factors that suggest a poor prognosis, including:

1. Advanced NYHA Class II, indicating significant heart failure symptoms.
2. Low LVEF (20.0%), indicating severe left ventricular dysfunction.
3. Elevated Pro-BNP levels (1083.0 ng/L), suggesting fluid overload and increased cardiac stress.
4. Presence of non-sustained ventricular tachycardia (NST VT) on ECG, which indicates arrhythmic instability.
5. Presence of ventricular extrasystole and polymorphic ventricular tachycardia, which are indicators of arrhythmic instability.
6. Elevated creatinine levels (7.49 mg/dL), indicating renal impairment, which can be related to heart failure.
7. Presence of dyslipidemia, hypertension, and idiopathic dilated cardiomyopathy, which are all risk factors for cardiovascular events.

However, the patient is already taking medications that are commonly used to manage heart failure and arrhythmias (beta blockers, loop diuretics, spironolactone, and ACE inhibitor), which suggests that the patient is receiving some level of treatment. 

Given these factors, the patient's overall prognosis is that they will survive the next few years, but with a high risk of cardiovascular events and complications."
355,355,P0580,"Age: 73
Gender: Female 
Weight: 49 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 135/40 mmHg
Past Medical History: Toxic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 23
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,71
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,73
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2932.0
Protein (g/L): 75
T4 (ng/L): 19
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,78
Urea (mg/dL): 9,32
LVEF (%): 29.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 73-year-old female with a history of toxic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Her NYHA class is II, indicating moderate symptoms of heart failure. Her blood test results show elevated creatinine levels (88.0 mmol/L), indicating impaired kidney function, and a low LVEF (29.0%), which suggests significant left ventricular dysfunction. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on ECG also indicates a high risk of arrhythmias.

Despite these concerning findings, the patient's overall clinical presentation and test results do not suggest acute heart failure or acute coronary syndrome. Her medication regimen includes ACE inhibitors, which are typically used to slow the progression of heart failure. The patient's elevated troponin levels (0.02 ng/mL) are not indicative of acute myocardial infarction.

Given these factors, I believe that the patient has a high likelihood of surviving for the next few years, as her condition is more related to chronic heart failure and arrhythmias rather than acute cardiac events. The patient's kidney function is impaired, but this can be managed with medication and lifestyle changes. The patient's age and sex are also factors in her survival prognosis, as women tend to live longer than men. Overall, I believe that the patient has a moderate to high chance of survival over the next few years, but regular follow-up and close monitoring are essential to adjust her treatment plan as needed."
356,356,P0581,"Age: 45
Gender: Female 
Weight: 73 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 825.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,06
TSH (mIU/L): 8,69
Urea (mg/dL): 6,82
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's prognosis is ranked as a survivor due to the following factors:

1. NYHA Class II: The patient's New York Heart Association (NYHA) Class II indicates that the patient has some limitations in physical activity due to heart failure, but they are still able to perform light physical activity without symptoms. This suggests that the patient's heart function is relatively preserved.

2. Medications: The patient is on a comprehensive regimen of medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor. These medications are standard treatments for heart failure and are likely to help manage symptoms and slow disease progression.

3. ECG Impression: While the patient has a history of ventricular extrasystole and non-sustained ventricular tachycardia, the ECG impression does not indicate any severe arrhythmias. The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart is not at high risk for sudden cardiac death.

4. LVEF (30%): Although the left ventricular ejection fraction (LVEF) is significantly reduced at 30%, it is not severely impaired. A reduced LVEF is a common finding in patients with heart failure, and a value of 30% is not as severe as a value of 20% or lower.

5. Pro-BNP (825 ng/L): Elevated Pro-BNP levels indicate that the patient has some degree of ventricular stretch and fluid overload, but the level is not extremely high.

6. Other laboratory values: The patient's laboratory values, such as albumin, ALT, AST, and creatinine, are relatively normal, indicating that there is no acute kidney injury or liver dysfunction.

Considering these factors, the patient's overall prognosis is likely to be a survivor, as they have a relatively preserved heart function, are on comprehensive medications, and do not have severe arrhythmias or other acute complications."
357,357,P0582,"Age: 74
Gender: Female 
Weight: 72 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 143/76 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 3,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2066.0
Protein (g/L): 72
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 6,26
Urea (mg/dL): 7,32
LVEF (%): 28.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is likely to be a survivor due to the following factors:

1. Age: Although the patient is 74 years old, which is considered elderly, the patient's age alone is not a significant predictor of outcome. Many patients with heart failure can live for many years with proper management.

2. NYHA Class II: The patient's NYHA Class II classification indicates that they have some limitation in physical activity due to heart failure, but they are still able to perform daily activities without excessive fatigue. This suggests that the patient's heart failure is not severe and can be managed effectively.

3. Medications: The patient is taking a combination of medications, including ACE inhibitors, statins, and loop diuretics, which are standard treatments for heart failure. Amiodarone, a medication commonly used for arrhythmias, is also being used, but its primary purpose in this case is likely for its antiarrhythmic effects rather than for heart failure management.

4. Lack of ECG abnormalities: The ECG impression does not show any significant arrhythmias or signs of heart failure, which suggests that the patient's heart is not in a critical state.

5. Laboratory results: While the patient has elevated creatinine levels and a low LVEF, these findings are not unusual in patients with heart failure. The elevated creatinine levels may be related to age, dehydration, or kidney function decline, rather than heart failure itself.

Overall, considering these factors, the patient's prognosis is likely to be a survivor, given the presence of a well-managed heart failure condition and the absence of severe arrhythmias or other critical conditions.

RANKING: 2. Pump failure death
REASONING: 

This patient's prognosis is likely to be pump failure death due to the following factors:

1. Low LVEF: The patient's LVEF of 28% indicates severe systolic dysfunction, which is a significant predictor of mortality in heart failure patients.

2. Elevated creatinine levels: The patient's elevated creatinine levels suggest impaired kidney function, which can be a complication of heart failure.

3. NYHA Class II: Although the patient's NYHA Class II classification indicates some limitation in physical activity, it is still a sign of significant heart failure.

4. Presence of ischemic dilated cardiomyopathy: This underlying condition can lead to progressive heart failure and increase the risk of pump failure.

5. Elevated BNP levels: The patient's elevated BNP levels indicate fluid overload and increased ventricular wall stress, which can contribute to heart failure progression.

RANKING: 3. Sudden cardiac death
REASONING: 

This patient's prognosis is unlikely to be sudden cardiac death due to the following factors:

1. Lack of ECG abnormalities: The ECG impression does not show any significant arrhythmias or signs of heart failure, which reduces the likelihood of sudden cardiac death.

2. Absence of troponin elevation: The patient's troponin levels are normal, which suggests that there is no significant myocardial damage.

3. Presence of medications: The patient is taking medications that are standard for heart failure management, which suggests that the patient's condition is being effectively managed.

4. Absence of other risk factors: The patient does not have other significant risk factors for sudden cardiac death, such as a history of myocardial infarction or significant coronary artery disease.

5. Overall clinical picture: The patient's overall clinical picture suggests a well-managed heart failure condition, which reduces the likelihood of sudden cardiac death."
358,358,P0585,"Age: 72
Gender: Male 
Weight: 83 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,79
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 852.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,43
Urea (mg/dL): 8,82
LVEF (%): 40.0
Medications: Amiodarone, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 

This patient is at a high risk for cardiac complications due to a history of valvular cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. The patient's NYHA Class II indicates moderate symptoms of heart failure, and the elevated creatinine level (124.0 mmol/L) suggests impaired renal function, which can be a complication of heart failure. The patient's elevated troponin level (0.04 ng/mL) also indicates some degree of cardiac damage. 

Additionally, the patient's ECG findings of ventricular extrasystoles and polymorphic ventricular extrasystoles suggest an increased risk of arrhythmias. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia reduces the risk of sudden cardiac death. 

The patient's elevated Pro-BNP level (852.0 ng/L) indicates significant left ventricular dysfunction, which is a predictor of heart failure and mortality. However, the patient is on medications that are standard for managing heart failure and arrhythmias (Amiodarone, Beta Blockers, Statins, and ACE Inhibitor). 

Given these factors, the patient's overall risk for cardiac complications is high, but the presence of medications and the absence of severe symptoms suggest that the patient may be able to survive with proper management and monitoring.

2. Sudden cardiac death 
REASONING: 

While the patient's ECG findings of ventricular extrasystoles and polymorphic ventricular extrasystoles increase the risk of arrhythmias, the absence of ventricular tachycardia and non-sustained ventricular tachycardia reduces the risk of sudden cardiac death. However, the patient's elevated Pro-BNP level (852.0 ng/L) and elevated creatinine level (124.0 mmol/L) indicate significant left ventricular dysfunction and impaired renal function, which can increase the risk of cardiac complications, including sudden cardiac death.

3. Pump failure death 
REASONING: 

Given the patient's NYHA Class II symptoms and elevated Pro-BNP level (852.0 ng/L), the patient is at risk for heart failure. However, the patient's LVEF (40.0%) is not significantly low, and the patient is on medications that are standard for managing heart failure (Amiodarone, Beta Blockers, Statins, and ACE Inhibitor). The patient's renal function is also not severely impaired, which reduces the risk of pump failure death."
359,359,P0586,"Age: 74
Gender: Male 
Weight: 74 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,08
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 493.0
Protein (g/L): 75
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,81
Urea (mg/dL): 8,82
LVEF (%): 23.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, I would rank the patient as a survivor with a high probability. The patient's age is 74, but the absence of any recent cardiovascular events, stable vital signs, and controlled hypertension and dyslipidemia suggest a relatively stable condition. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, the patient's current NYHA class II indicates that the condition is not severely limiting daily activities. The elevated creatinine level (115.0 mmol/L) suggests some degree of renal impairment, which may be related to the cardiomyopathy or hypertension. The presence of elevated Pro-BNP (493.0 ng/L) levels also indicates some degree of heart failure. Despite these factors, the patient is on medications that are commonly used to manage heart failure and hypertension, and the ECG findings do not suggest any acute arrhythmias. Therefore, I believe the patient has a relatively stable condition, and the likelihood of survival is high.

RANKING: 2. Sudden cardiac death 
REASONING: 
The patient's history of idiopathic dilated cardiomyopathy, elevated Pro-BNP levels, and elevated creatinine level increase the risk of sudden cardiac death. However, the patient's stable vital signs, controlled hypertension, and absence of any recent cardiovascular events make this a less likely outcome. The patient's ECG findings, while abnormal, do not indicate any acute arrhythmias that would necessitate immediate intervention. The patient's medications, including beta blockers and ACE inhibitors, are commonly used to manage heart failure and hypertension, which further reduces the risk of sudden cardiac death.

RANKING: 3. Pump failure death 
REASONING: 
Given the patient's history of idiopathic dilated cardiomyopathy, elevated Pro-BNP levels, and elevated creatinine level, pump failure is a significant concern. The patient's NYHA class II indicates that the condition is not severely limiting daily activities, but the elevated Pro-BNP levels suggest some degree of heart failure. The patient's medications, while commonly used to manage heart failure, may not be sufficient to manage the underlying cardiomyopathy. The patient's ECG findings, while abnormal, do not indicate any acute arrhythmias that would necessitate immediate intervention. Therefore, while pump failure is a risk, it is not the most likely outcome in this case, given the patient's stable vital signs and controlled hypertension."
360,360,P0587,"Age: 58
Gender: Male 
Weight: 97 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 2,95
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,47
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 65.0
Protein (g/L): 76
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,93
Urea (mg/dL): 7,82
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's data suggests a significant level of cardiac dysfunction, with an ejection fraction (LVEF) of 30.0%, indicating severe left ventricular systolic dysfunction. The presence of idiopathic dilated cardiomyopathy (IDC) further supports this finding. Despite the patient's relatively well-controlled hypertension (120/75 mmHg) and the absence of other life-threatening arrhythmias, the patient's cardiac function is severely impaired.

The patient's elevated troponin levels (0.01 ng/mL) and elevated N-terminal pro b-type natriuretic peptide (Pro-BNP) levels (65 ng/L) suggest some degree of cardiac stress and possible ventricular wall stress. However, these values are not excessively high, which might indicate that the patient is still tolerating the cardiac stress.

Given the patient's age (58) and the presence of IDC, the likelihood of sudden cardiac death is relatively low. The patient's weight (97 kg) and BMI are not excessively high, which might reduce the risk of cardiac complications.

The patient's medication regimen, including beta blockers, spironolactone, statins, and an ACE inhibitor, suggests that the patient is receiving standard therapy for managing heart failure and controlling hypertension. This comprehensive approach may help to improve the patient's cardiac function and overall prognosis.

Considering these factors, the most likely outcome for this patient over the next few years is survival, although with ongoing management and monitoring, there is a possibility of improvement in cardiac function and quality of life."
361,361,P0588,"Age: 77
Gender: Male 
Weight: 92 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,09
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 514.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,1
TSH (mIU/L): 0,96
Urea (mg/dL): 9,15
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are risk factors for cardiac events. However, the patient is currently receiving treatment with ACE inhibitors, loop diuretics, and a nitrovasodilator, which are standard therapies for managing heart failure and hypertension. The patient's NYHA class is II, indicating mild symptoms, and their LVEF is 50%, which is within the range of patients who can still benefit from medical therapy.

The patient's laboratory results show a mildly elevated creatinine level, which may indicate some degree of renal impairment, but this is not uncommon in patients with heart failure. The liver enzymes (ALT and AST) are within normal limits, and the lipid profile shows a relatively low LDL level, which is beneficial for patients with cardiovascular disease.

The ECG findings suggest the presence of ventricular extrasystoles and non-sustained ventricular tachycardia, which are common in patients with heart failure. However, these findings are not indicative of a high risk for sudden cardiac death.

Given these factors, the patient is likely to survive the next few years, assuming continued adherence to their medication regimen and no significant worsening of their underlying conditions. The patient's age, weight, and gender also contribute to a relatively favorable prognosis, as older adults with heart failure tend to have a lower mortality risk compared to younger individuals.

While there is some risk of cardiac events, the patient's overall clinical picture suggests a moderate to high likelihood of survival, making ""survivor"" the most likely prognosis."
362,362,P0590,"Age: 64
Gender: Female 
Weight: 75 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 135/95 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 6
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,17
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 667.0
Protein (g/L): 64
T3 (pg/dL): 0,04
T4 (ng/L): 20
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,77
Urea (mg/dL): 12,15
LVEF (%): 32.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall clinical presentation, laboratory results, and ECG findings do not indicate any acute life-threatening conditions that would necessitate an immediate intervention. The patient's NYHA Class II indicates moderate symptoms of heart failure, but they are still able to perform daily activities with some limitation. The patient's LVEF is significantly reduced at 32%, which suggests advanced heart failure. However, the absence of any acute elevation in troponin levels and the lack of ventricular tachycardia or ventricular extrasystole on the ECG suggest that the patient is not at immediate risk of sudden cardiac death. The patient is also on medications that are commonly used to manage heart failure and ischemic cardiomyopathy, such as amiodarone and ACE inhibitors. Overall, the patient's prognosis is favorable, and they are likely to survive for the next few years with proper management and monitoring.

The patient's weight and height are not significantly abnormal, and their blood pressure is within a relatively normal range for their age. The laboratory results show mild elevations in liver enzymes, but these are not indicative of acute liver damage or other systemic diseases. The patient's kidney function is also mildly impaired, but this is likely related to the patient's underlying heart failure rather than a primary renal issue. The patient's thyroid function is normal, and the TSH level is not elevated, which suggests that the patient is not at risk of hypothyroidism.

While the patient's LVEF is significantly reduced, it is not immediately life-threatening, and the patient is already receiving medications to manage their heart failure. The patient's ECG findings do not indicate any arrhythmias that would necessitate immediate intervention. Overall, the patient's clinical presentation, laboratory results, and ECG findings suggest that they are at low risk for sudden cardiac death or pump failure in the short term, making survival the most likely outcome.

RANKING: 
2. Pump failure death
REASONING: 
While the patient's LVEF is significantly reduced, the patient is already receiving medications to manage heart failure, and the patient's ECG findings do not indicate any acute arrhythmias. However, the patient's NYHA Class II symptoms suggest that they are not entirely asymptomatic, and their heart failure is likely to worsen over time. The patient's kidney function is mildly impaired, and their liver function is slightly elevated, which may indicate that their heart failure is causing secondary kidney damage. While the patient is on medications to manage their heart failure, their heart function is likely to deteriorate further, increasing the risk of pump failure.

The patient's weight and height are not significantly abnormal, but their BMI is slightly elevated, which may increase their risk of developing further cardiovascular complications. The patient's blood pressure is within a relatively normal range, but their hypertension may contribute to their heart failure. The patient's laboratory results show mild elevations in liver enzymes, which may indicate that their heart failure is causing secondary liver damage.

RANKING: 
3. Sudden cardiac death
REASONING: 
The patient's ECG findings do not indicate any acute arrhythmias that would necessitate immediate intervention, and the patient is not at immediate risk of sudden cardiac death. However, the patient's NYHA Class II symptoms suggest that their heart failure is not entirely asymptomatic, and their LVEF is significantly reduced. The patient's kidney function is mildly impaired, and their liver function is slightly elevated, which may indicate that their heart failure is causing secondary kidney and liver damage.

The patient's weight and height are not significantly abnormal, but their BMI is slightly elevated, which may increase their risk of developing further cardiovascular complications. The patient's blood pressure is within a relatively normal range, but their hypertension may contribute to their heart failure. The patient's laboratory results show mild elevations in liver enzymes, which may indicate that their heart failure is causing secondary liver damage.

However, the patient's ECG findings do show a monomorphic ventricular extrasystole, which may indicate a risk of ventricular arrhythmias. While the patient is not currently experiencing any symptoms, their heart failure is likely to worsen over time, increasing the risk of ventricular arrhythmias and sudden cardiac death."
363,363,P0591,"Age: 62
Gender: Male 
Weight: 72 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 125/90 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 73
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,38
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 279.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,18
Urea (mg/dL): 8,32
LVEF (%): 64.0
Medications: Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING:
Based on the provided patient data, the patient is a 62-year-old male with a history of valvular cardiomyopathy, NYHA Class II, and elevated left ventricular ejection fraction (LVEF) of 64%. The patient is on beta blockers, digoxin, and loop diuretics, which suggests a moderate level of heart failure management. The patient's current ECG impression shows no ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which reduces the risk of sudden cardiac death. Additionally, the patient's troponin levels are within normal limits, indicating no acute myocardial infarction. The patient's renal function is also relatively preserved, with a creatinine level of 8.32 mg/dL. 

Given these factors, the patient's overall prognosis is favorable, and the likelihood of survival is high.

2. Pump failure death
REASONING:
The patient's valvular cardiomyopathy and NYHA Class II indicate a moderate level of heart failure. Although the patient is on beta blockers and digoxin, which can help manage heart failure, the patient's elevated LVEF of 64% suggests that the heart is not functioning optimally. The patient's elevated creatinine level (8.32 mg/dL) and low albumin level (42 g/L) may indicate some degree of renal impairment, which can be a complication of heart failure. Additionally, the patient's elevated pro-BNP level (279 ng/L) suggests a moderate level of ventricular stress. 

While the patient's current ECG impression is relatively normal, the patient's history of valvular cardiomyopathy and heart failure management suggests a moderate risk of pump failure.

3. Sudden cardiac death
REASONING:
The patient's ECG impression shows a ventricular extrasystole, which is a potential precursor to ventricular tachycardia. However, the patient's ECG does not show any ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia, which reduces the risk of sudden cardiac death. The patient's troponin levels are within normal limits, and the patient's renal function is relatively preserved, which further reduces the risk of sudden cardiac death. 

However, the patient's history of valvular cardiomyopathy and heart failure management, as well as the presence of ventricular extrasystole, suggest a moderate risk of sudden cardiac death."
364,364,P0592,"Age: 66
Gender: Male 
Weight: 78 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes
Albumin (g/L): 40
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 85
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 153.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,46
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1537.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,13
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I rank the patient as a survivor for the next few years. Here's why:

1. NYHA Class II: The patient has a moderate heart failure classification, which indicates that they have symptoms of heart failure but can still perform daily activities without excessive fatigue. This suggests that the patient's heart function is still relatively preserved, which is a positive prognostic factor.

2. Low troponin levels: The patient's troponin level is 0.03 ng/mL, which is within the normal range. Elevated troponin levels are associated with cardiac damage, so a low level suggests that the patient's heart muscle is not significantly damaged.

3. Normal blood pressure and low creatinine levels: The patient's blood pressure is within the normal range, and their creatinine level is elevated but not significantly high, which suggests that their kidney function is not severely impaired.

4. Low BNP levels: The patient's Pro-BNP level is 1537.0 ng/L, which is within the normal range. Elevated BNP levels are associated with heart failure, but a low level suggests that the patient's heart is not failing significantly.

5. Medications: The patient is on beta blockers, digoxin, loop diuretics, spironolactone, and statins, which are commonly used to treat heart failure and other cardiovascular conditions. These medications suggest that the patient is receiving appropriate treatment for their condition.

6. ECG results: While the patient has ventricular extrasystole and ventricular tachycardia, these are not indicative of a high risk of sudden cardiac death. The absence of non-sustained ventricular tachycardia (CH>10) and paroxysmal supraventricular tachyarrhythmia also reduces the risk of sudden cardiac death.

Overall, the patient's combination of a moderate NYHA Class, low troponin levels, normal blood pressure, and appropriate medications suggest that they are at lower risk for sudden cardiac death and pump failure over the next few years. Therefore, I rank the patient as a survivor."
365,365,P0595,"Age: 69
Gender: Male 
Weight: 68 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 176/92 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 96
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 290.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 0,46
Urea (mg/dL): 7,15
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient's prognosis is predicted to be a survivor. The patient's NYHA Class II indicates that they have some limitations in physical activity due to heart failure symptoms, but it is not severe. The patient's blood pressure is elevated, but it is being managed with medications. The patient has a history of hypertension, cardiomyopathy, diabetes, and peripheral vascular disease, but these conditions are being treated. The patient's LVEF is 35%, which is significantly reduced, indicating systolic heart failure. However, the patient's age and overall health status suggest that they may still be able to survive with proper management.

The patient's biomarkers, such as Pro-BNP (290 ng/L), are elevated, indicating some degree of heart failure. However, the patient's creatinine level is not significantly elevated, suggesting that kidney function is relatively preserved. The patient's lipid profile is also relatively favorable, with low LDL and high HDL levels.

The patient's ECG results show no evidence of ventricular tachycardia or other arrhythmias, which reduces the risk of sudden cardiac death. The patient's TSH level is within the normal range, indicating that their thyroid function is normal.

Overall, while the patient has several risk factors for poor outcomes, their age, overall health status, and the presence of a support system make a survival prognosis more likely than a sudden cardiac death or pump failure prognosis."
366,366,P0597,"Age: 74
Gender: Male 
Weight: 83 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 143/65 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 76
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4
LDL (mmol/L): 2,9
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1874.0
Protein (g/L): 67
T3 (pg/dL): 0,08
T4 (ng/L): 29
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,09
Urea (mg/dL): 9,32
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Amiodarone, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the patient's data, the most likely outcome is survivor. The patient is 74 years old, which is a relatively advanced age, but the patient's NYHA Class III indicates severe heart failure, and the patient is on medications such as Amiodarone, a Class III antiarrhythmic, Loop Diuretics, and Nitrovasodilator, which suggests that the patient is being managed for heart failure. The patient's LVEF is 70%, which is within the normal range, indicating that the patient's heart function is not severely impaired.

The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning sign, but the patient is on medication for arrhythmia, which may help manage this condition. The patient's troponin level is normal, which suggests that there is no significant myocardial damage.

The patient's other lab values, such as creatinine, urea, and electrolyte levels, are not indicative of acute kidney injury or electrolyte imbalances, which could be life-threatening. The patient's lipid profile is also not significantly abnormal, and the patient's hemoglobin and hematocrit are within normal limits.

Given the patient's age, NYHA Class III, and the presence of valvular cardiomyopathy, the patient is at risk for cardiac events. However, the patient's current management and the absence of other significant lab abnormalities make a sudden cardiac death or pump failure death less likely. Therefore, the most likely outcome is survivor.

RANKING: 2. Sudden cardiac death
REASONING: 
The second most likely outcome is sudden cardiac death. The patient's ECG shows non-sustained ventricular tachycardia, which is a significant arrhythmia that can be life-threatening. Although the patient is on medication for arrhythmia, the presence of non-sustained ventricular tachycardia increases the risk of sudden cardiac death.

The patient's age and NYHA Class III also increase the risk of cardiac events. The patient's valvular cardiomyopathy and dyslipidemia also contribute to the risk of cardiac events.

RANKING: 3. Pump failure death
REASONING: 
The third most likely outcome is pump failure death. The patient's NYHA Class III indicates severe heart failure, and the patient's LVEF is 70%, which is at the lower end of the normal range. The patient's valvular cardiomyopathy and dyslipidemia also contribute to the risk of heart failure.

The patient's current management, including Loop Diuretics and Nitrovasodilator, may help manage heart failure, but the patient's severe NYHA Class III and the presence of valvular cardiomyopathy increase the risk of pump failure. The patient's ECG shows non-sustained ventricular tachycardia, which may indicate underlying cardiac instability."
367,367,P0598,"Age: 50
Gender: Male 
Weight: 65 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 264.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 178.0
HDL (mmol/L): 2,17
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,24
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 8083.0
Protein (g/L): 84
T3 (pg/dL): 0,03
T4 (ng/L): 14
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,33
Urea (mg/dL): 18,47
LVEF (%): 52.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, I would rank the patient as having a high likelihood of survival for the next few years. The patient's age (50) is not considered elderly, and the absence of any acute life-threatening conditions such as acute coronary syndrome or severe arrhythmias on the ECG impression suggests a relatively stable condition. 

The patient has a history of idiopathic dilated cardiomyopathy, which is a significant comorbidity, but the patient's left ventricular ejection fraction (LVEF) is 52%, which is within the range of moderate to severe impairment. However, the patient is on beta blockers, digoxin, and ACE inhibitors, which are standard treatments for heart failure with reduced ejection fraction (HFrEF). These medications can help manage symptoms and slow disease progression.

The patient's biomarkers, such as troponin and BNP, are not excessively elevated, suggesting that the patient is not experiencing acute cardiac injury or significant fluid overload. The patient's electrolytes and kidney function are also within relatively normal limits.

Overall, the patient's combination of a relatively young age, moderate to severe heart failure, and optimal medical management suggest a relatively stable condition, which increases the likelihood of long-term survival.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient has a history of idiopathic dilated cardiomyopathy, which is a risk factor for sudden cardiac death, the patient's current condition is relatively stable, and the ECG impression does not show any life-threatening arrhythmias. However, the patient's LVEF is 52%, which is below the normal range, and the patient's BNP level is elevated, suggesting some degree of cardiac stress.

RANKING: 3. Pump failure death
REASONING: 
The patient's LVEF is 52%, which is below the normal range, indicating some degree of left ventricular dysfunction. Additionally, the patient's BNP level is elevated, suggesting some degree of cardiac stress. The patient's kidney function is also impaired, with a creatinine level of 264.0 mmol/L, which may indicate some degree of fluid overload.

However, the patient is on optimal medical therapy with beta blockers, digoxin, and ACE inhibitors, which can help manage symptoms and slow disease progression. The patient's biomarkers and electrolytes are within relatively normal limits, and the ECG impression does not show any life-threatening arrhythmias.

While the patient's condition is not ideal, the patient's overall clinical status and current medical management suggest that pump failure death is less likely than sudden cardiac death, but still a possible outcome."
368,368,P0599,"Age: 66
Gender: Female 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 48,7
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,89
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 9,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 534.0
Protein (g/L): 75,6
T4 (ng/L): 17
TSH (mIU/L): 1,22
Urea (mg/dL): 6,16
LVEF (%): 36.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy, which is a significant comorbidity that increases the risk of cardiac complications. However, the patient is currently on medications that are commonly used to manage heart failure and hypertension, such as ACE inhibitors, beta blockers, and diuretics. The patient's ejection fraction (LVEF) is 36%, which is within the range of 20-39%, indicating some degree of left ventricular function. The patient's pro-BNP levels are elevated, which suggests some degree of ventricular dysfunction. However, the patient's symptoms and ECG findings do not indicate acute cardiac ischemia or acute heart failure, which are common causes of sudden cardiac death. The patient's age and sex are also not particularly high-risk factors for sudden cardiac death. Overall, while the patient has significant underlying heart disease, the current data does not suggest an immediate life-threatening condition, making a survivor the most likely outcome. 

2. Sudden cardiac death 
REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy, the current data does not indicate an acute cardiac event. The patient's ECG does not show any signs of ventricular tachycardia or ventricular extrasystoles, which are common precursors to sudden cardiac death. Additionally, the patient's pro-BNP levels are elevated, but not excessively high, which may indicate some degree of ventricular dysfunction. However, the patient's LVEF is relatively preserved, and the patient is on medications that are commonly used to manage heart failure. While the patient's age and sex are not particularly high-risk factors for sudden cardiac death, the patient's history of ischemic dilated cardiomyopathy does increase the risk. Therefore, while sudden cardiac death is less likely than a survivor, it is still a possible outcome. 

3. Pump failure death 
REASONING: 
The patient's LVEF is 36%, which is within the range of 20-39%, indicating some degree of left ventricular function. The patient is also on medications that are commonly used to manage heart failure, such as ACE inhibitors, beta blockers, and diuretics. The patient's pro-BNP levels are elevated, but not excessively high, which may indicate some degree of ventricular dysfunction. However, the patient's symptoms and ECG findings do not indicate acute cardiac ischemia or acute heart failure, which are common causes of pump failure. The patient's age and sex are not particularly high-risk factors for pump failure, and the patient's current medications are likely to help manage the patient's symptoms. Therefore, pump failure death is the least likely outcome among the three options."
369,369,P0600,"Age: 58
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44,4
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 68.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 828.0
Protein (g/L): 70,9
T4 (ng/L): 18
TSH (mIU/L): 1,93
Urea (mg/dL): 5,99
LVEF (%): 57.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall health status, despite having a history of ischemic dilated cardiomyopathy and myocardial infarction, is relatively stable, with a normal blood pressure, normal kidney function (creatinine level of 68.0 mmol/L), and a relatively low Pro-BNP level of 828.0 ng/L. The patient is also on multiple medications that are commonly used to manage heart failure and high blood pressure, such as calcium channel blockers, beta blockers, loop diuretics, statins, and ACE inhibitors. Additionally, the patient has a relatively normal LVEF of 57.0%, which indicates that the heart is still functioning to some extent. The absence of any recent cardiac events, such as ventricular tachycardia or non-sustained ventricular tachycardia, further supports a favorable prognosis. 

While the patient's past medical history is significant, the overall clinical picture suggests that the patient is likely to survive for the next few years, assuming no significant changes in their health status or the progression of their underlying heart disease. 

2. Sudden Cardiac Death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases their risk of sudden cardiac death. However, the patient's current LVEF of 57.0% and the absence of any recent cardiac events suggest that the patient's heart is still functioning to some extent. The patient is also on multiple medications that are commonly used to manage heart failure and high blood pressure, which further supports a relatively stable prognosis. However, the patient's past medical history and the presence of a low LVEF may still increase their risk of sudden cardiac death, making it a possible but less likely outcome.

3. Pump Failure Death
REASONING: 
The patient's LVEF of 57.0% indicates that the patient's heart is not functioning optimally, and the patient's past medical history of ischemic dilated cardiomyopathy and myocardial infarction increases their risk of pump failure. The patient's current symptoms and laboratory results, such as the elevated creatinine level and low albumin level, suggest that the patient's heart is not functioning as well as it could be. Additionally, the patient's low HDL cholesterol level of 1.6 mmol/L may also contribute to their risk of cardiovascular disease. While the patient is on multiple medications that are commonly used to manage heart failure and high blood pressure, the patient's overall clinical picture suggests that pump failure is a possible but less likely outcome."
370,370,P0601,"Age: 77
Gender: Male 
Weight: 60 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 47,4
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,31
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 142.0
Protein (g/L): 74,2
T4 (ng/L): 22
TSH (mIU/L): 1,89
Urea (mg/dL): 7,15
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient's age (77) and NYHA Class III status indicate significant cardiac compromise, with a history of ischemic dilated cardiomyopathy, peripheral vascular disease, hypertension, and myocardial infarction. The patient's LVEF is severely reduced at 35%, which suggests advanced left ventricular dysfunction. Despite this, the patient is receiving medications for heart failure (loop diuretics and ACE inhibitor), which is a good sign.

The patient's laboratory results show elevated liver enzymes (ALT and AST) and creatinine levels, indicating some degree of kidney impairment. However, the patient's electrolyte levels, including potassium, are within relatively normal ranges.

The ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia are concerning for arrhythmias, but the absence of sustained VT and bradycardia on the ECG is reassuring. The presence of polymorphic ventricular extrasystole, however, suggests that the patient may be at risk for more severe arrhythmias.

Considering these factors, the patient's overall prognosis is guarded but not catastrophic. With proper management and monitoring, it is possible for the patient to survive for several years. However, the patient's underlying cardiac disease and potential for arrhythmias make it difficult to predict a long-term outcome.

The patient's weight and height are within normal ranges, and the patient's hemoglobin and glucose levels are relatively normal. The absence of significant proteinuria and kidney impairment suggests that the patient's kidney function is not severely compromised.

In conclusion, while the patient's prognosis is uncertain, the presence of a favorable ECG and the fact that the patient is receiving medications for heart failure suggest that the patient is likely to survive for several years. However, the patient will require close monitoring and adjustments to their treatment plan to manage their cardiac disease and prevent complications."
371,371,P0602,"Age: 67
Gender: Male 
Weight: 62 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 42,9
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 106
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 923.0
Protein (g/L): 70
T4 (ng/L): 19
TSH (mIU/L): 0,56
Urea (mg/dL): 7,65
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

The patient's age, NYHA Class II, and the presence of multiple comorbidities such as ischemic dilated cardiomyopathy, diabetes, and dyslipidemia contribute to the risk of adverse outcomes. However, the patient's LVEF of 45.0 indicates a significant reduction in cardiac function, which may suggest a more advanced stage of heart disease. 

Despite this, the patient is currently receiving medications that target these conditions, such as beta blockers, statins, and an ACE inhibitor, which may help manage symptoms and slow disease progression. The presence of elevated Pro-BNP levels (923.0 ng/L) suggests a significant burden of heart failure, but the patient's protein level (70 g/L) is within the normal range, which may indicate a relatively preserved muscle mass. 

The ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) are concerning for an increased risk of arrhythmic events. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. 

Considering these factors, I predict that the patient is most likely to survive the next few years, as the combination of disease management and potentially favorable biomarkers suggests a relatively stable condition. However, close monitoring and regular follow-up appointments will be essential to adjust the treatment plan as needed and address any emerging concerns."
372,372,P0603,"Age: 74
Gender: Male 
Weight: 82 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5,3
LDL (mmol/L): 3,28
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1626.0
Protein (g/L): 75
T4 (ng/L): 6
Troponin (ng/mL): 0,03
TSH (mIU/L): 5,82
Urea (mg/dL): 24,13
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's age, NYHA Class III status, and the presence of ischemic dilated cardiomyopathy, diabetes, and dyslipidemia suggest a high risk for adverse cardiac events. However, the patient's hemoglobin level (130.0 g/L) is within the normal range, which may indicate relatively good oxygenation and potentially reduced risk of cardiac failure. The patient's LVEF is significantly reduced at 35.0%, which is consistent with advanced heart failure.

The elevated Creatinine level (177.0 mmol/L) indicates impaired renal function, which can be associated with heart failure. However, the patient's serum albumin level (40 g/L) is within the normal range, which may suggest adequate renal function.

The ECG findings of ventricular extrasystoles are concerning for arrhythmias, but the absence of sustained ventricular tachycardia or bradycardia reduces the risk of sudden cardiac death. The elevated Pro-BNP level (1626.0 ng/L) supports the presence of heart failure.

Given these factors, the patient's overall prognosis is relatively favorable, with a higher likelihood of survival over the next few years. However, the patient's heart failure status and elevated Creatinine level suggest that close monitoring and management of the patient's condition will be crucial to prevent further deterioration.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG findings of ventricular extrasystoles are concerning for arrhythmias, the absence of sustained ventricular tachycardia or bradycardia reduces the risk of sudden cardiac death. However, the patient's heart failure status and elevated Creatinine level increase the risk of cardiac events.

The patient's LVEF is significantly reduced, which increases the risk of arrhythmias and sudden cardiac death. The elevated Pro-BNP level supports the presence of heart failure, which can increase the risk of arrhythmias and sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

Given the patient's advanced heart failure status, elevated Creatinine level, and elevated Pro-BNP level, pump failure death is a possible outcome. The patient's NYHA Class III status and LVEF of 35.0% indicate severe heart failure, which increases the risk of pump failure.

The patient's impaired renal function, as indicated by the elevated Creatinine level, may further exacerbate the risk of pump failure. The presence of heart failure and impaired renal function can lead to a vicious cycle of worsening heart failure and further kidney damage, ultimately resulting in pump failure.

However, the patient's relatively good hemoglobin level and normal albumin level suggest that the patient's oxygenation and nutritional status may be relatively well-maintained, which may reduce the risk of pump failure."
373,373,P0604,"Age: 75
Gender: Female 
Weight: 57 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,02
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,17
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 509.0
Protein (g/L): 76
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,35
Urea (mg/dL): 15,47
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

This patient is at high risk for adverse outcomes due to several factors. Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac death. The LVEF of 30% indicates severe left ventricular dysfunction, which is a strong predictor of mortality.

The patient's elevated creatinine level (106.0 mmol/L) and urea level (15.47 mg/dL) suggest impaired renal function, which can further exacerbate cardiac dysfunction and increase the risk of complications.

The presence of diabetes, dyslipemia, and hypertension further increases the patient's risk for cardiovascular events. The elevated troponin level (0.01 ng/mL) is also a marker of myocardial damage, indicating possible cardiac injury.

However, the patient's current medication regimen includes beta blockers, ACE inhibitors, and spironolactone, which are commonly used to manage heart failure and reduce cardiovascular risk factors. The patient's NYHA Class II indicates that the patient is able to perform light physical activities without undue fatigue, suggesting that the patient is still relatively stable.

Given these factors, the patient's current prognosis is more likely to be a survivor, as the patient is still receiving treatment and has not shown any signs of acute cardiac instability. However, close monitoring and adjustments to the treatment plan will be necessary to prevent further deterioration.

RANKING: 2. Sudden cardiac death 
REASONING: 

Although the patient's current prognosis is more likely to be a survivor, there is still a significant risk of sudden cardiac death. The patient's LVEF of 30% indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death.

The patient's ECG impression of ventricular extrasystole, although not sustained, suggests a possible arrhythmia, which can increase the risk of sudden cardiac death.

The patient's history of idiopathic dilated cardiomyopathy and the presence of diabetes, dyslipemia, and hypertension further increase the risk of cardiac arrhythmias and sudden cardiac death.

RANKING: 3. Pump failure death 
REASONING: 

The patient's current LVEF of 30% indicates severe left ventricular dysfunction, which increases the risk of pump failure. However, the patient is currently receiving treatment with beta blockers, ACE inhibitors, and spironolactone, which are commonly used to manage heart failure.

Given the patient's stable current condition and the fact that the patient is still able to perform light physical activities without undue fatigue, the risk of pump failure death is lower compared to the risk of sudden cardiac death. However, close monitoring and adjustments to the treatment plan will be necessary to prevent further deterioration."
374,374,P0606,"Age: 57
Gender: Male 
Weight: 70 kg
Height: 166 cm
NYHA Class: III
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45,9
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,58
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 4330.0
Protein (g/L): 78,2
T4 (ng/L): 20
TSH (mIU/L): 0,94
Urea (mg/dL): 6,82
LVEF (%): 25.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's prognosis is most likely to be a survivor due to several factors. Firstly, the patient's LVEF (Left Ventricular Ejection Fraction) is 25%, which is a significant reduction in cardiac function, but not severe enough to indicate heart failure. The patient's NYHA Class is III, indicating moderate symptoms, but this is not uncommon in patients with reduced LVEF.

The patient's elevated creatinine level (91.0 mmol/L) and elevated BNP (4330.0 ng/L) levels suggest some degree of cardiac dysfunction, but the patient is still able to maintain a relatively normal hemoglobin level (122.0 g/L) and a normal glucose level (5.6 mmol/L), indicating that the patient's kidneys are still functioning relatively well.

The patient's lipid profile is also relatively well-controlled, with low LDL (1.58 mmol/L) and high HDL (1.03 mmol/L) levels, which reduces the risk of atherosclerotic cardiovascular disease.

The patient's ECG results show a polymorphic ventricular extrasystole, which is a concerning sign, but not indicative of a life-threatening arrhythmia. The patient's lack of other arrhythmias on the ECG also reduces the risk of sudden cardiac death.

Given these factors, the patient's overall prognosis is likely to be a survivor, with the possibility of some improvement with optimal management of their condition.

RANKING: 2. Sudden Cardiac Death
REASONING:
The patient's polymorphic ventricular extrasystole on the ECG is a concerning sign that increases the risk of sudden cardiac death. Although the patient's LVEF is not severely reduced, the presence of ventricular extrasystoles suggests that the patient's heart is at risk of arrhythmias.

However, the patient's overall prognosis is not as poor as it could be due to the fact that the patient's ECG did not show any other life-threatening arrhythmias, such as ventricular tachycardia or non-sustained ventricular tachycardia.

RANKING: 3. Pump Failure Death
REASONING:
The patient's LVEF is 25%, which indicates significant cardiac dysfunction. The patient's NYHA Class III symptoms also suggest that the patient's heart is not functioning optimally. The patient's elevated creatinine level (91.0 mmol/L) and elevated BNP (4330.0 ng/L) levels further support the presence of cardiac dysfunction.

Given these factors, the patient's prognosis is less likely to be a survivor, and pump failure death is a possible outcome. However, the patient's relatively well-controlled lipid profile and normal hemoglobin level suggest that the patient's kidneys are still functioning relatively well, which reduces the risk of pump failure death."
375,375,P0608,"Age: 70
Gender: Male 
Weight: 71 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,2
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,92
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 108.0
Protein (g/L): 74,7
T4 (ng/L): 15
TSH (mIU/L): 2,24
Urea (mg/dL): 6,66
LVEF (%): 30.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results indicate a high risk of adverse outcomes. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death and pump failure. The patient's LVEF is severely impaired at 30%, indicating poor cardiac function.

The patient's ECG results also show ventricular extrasystoles, which can be a marker for increased risk of arrhythmias and sudden cardiac death. Additionally, the patient's high creatinine level (99.0 mmol/L) suggests impaired kidney function, which can be a complication of heart failure.

Despite the patient's use of medications such as Amiodarone, which is commonly used to treat arrhythmias, the patient's ECG results do not show any ventricular tachycardia or non-sustained ventricular tachycardia. However, the presence of ventricular extrasystoles and impaired LVEF still raises concerns about the patient's overall cardiac function.

The patient's other medical conditions, such as hypertension, dyslipidemia, and myocardial infarction, also contribute to the patient's overall risk of adverse outcomes. However, the patient's current hemoglobin level (150.0 g/L) and low TSH level (2.24 mIU/L) suggest that the patient is not malnourished or hypothyroid.

Given the patient's overall clinical presentation and test results, the most likely outcome is that the patient will survive, but with a high risk of cardiac complications."
376,376,P0609,"Age: 67
Gender: Female 
Weight: 74 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 180/95 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes
Albumin (g/L): 46,2
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 61.0
Gamma-glutamil transpeptidase (IU/L): 140
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 731.0
Protein (g/L): 75,2
T4 (ng/L): 14
TSH (mIU/L): 3,47
Urea (mg/dL): 3
LVEF (%): 70.0
Medications: Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient outcome as a survivor for the next few years. Here's the reasoning behind this assessment:

1. The patient's age (67 years) is not extremely high, and with proper management, many patients in this age group can survive for several years with the given medical conditions.
2. The patient has a NYHA Class II heart failure, which indicates moderate symptoms, but it's manageable with current medications. This suggests that the patient is already receiving optimal treatment for their heart failure.
3. The patient has a history of hypertrophic cardiomyopathy, which can increase the risk of sudden cardiac death. However, the patient is already taking beta blockers, which are known to reduce the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy.
4. The patient's laboratory results show elevated creatinine levels (61.0 mmol/L), which indicates some degree of kidney impairment. However, the patient is already on medications for hypertension and diabetes, which may help manage kidney function.
5. The patient's lipid profile is not ideal, with high total cholesterol and LDL levels. However, the patient is already taking beta blockers, which can help reduce cardiovascular risk. Additionally, the patient's HDL level is relatively high, which is beneficial for cardiovascular health.
6. The patient's ECG results show non-sustained ventricular tachycardia, which is a concerning finding. However, the patient is already taking nitrovasodilators, which can help manage blood pressure and reduce the risk of arrhythmias.
7. The patient's Pro-BNP level is elevated at 731.0 ng/L, indicating some degree of heart failure. However, the patient is already receiving treatment for heart failure, which should help manage symptoms.

While there are some concerns with the patient's medical history and laboratory results, the patient's overall condition is not extremely severe. With proper management and close monitoring, I believe the patient has a good chance of survival for the next few years."
377,377,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
Based on the provided patient data, I rank the patient as a survivor for the next few years. The patient's age (71) is not unusually high, and they are not in the advanced stages of heart failure (NYHA Class II, LVEF 62.0). The patient's blood pressure (140/70 mmHg) is within the normal range, and they are on medications for hypertension (Spironolactone, ACE Inhibitor) and have a relatively low creatinine level (8.49 mg/dL). The elevated Pro-BNP level (433.0 ng/L) suggests some degree of heart failure, but it is not excessively high. The patient's other laboratory values, such as ALT, AST, and lipid profiles, are relatively normal.

The presence of ventricular extrasystole (Polymorphic) and paroxysmal supraventricular tachyarrhythmia (TPSV) on the ECG suggests some degree of cardiac arrhythmia, but it is not indicative of a high risk of sudden cardiac death. The patient's hemoglobin level (123.0 g/L) is slightly elevated, which may be due to anemia or other factors.

Overall, the patient's clinical presentation and laboratory values suggest that they are at moderate risk for cardiac events, but the risk is not extremely high. Therefore, I predict that the patient is likely to survive for the next few years.

2. Sudden Cardiac Death
REASONING:
The patient's age (71) and NYHA Class II heart failure classification do increase the risk of cardiac events. However, the patient's LVEF (62.0) is not severely reduced, and they are on medications for hypertension and heart failure. The elevated Pro-BNP level (433.0 ng/L) suggests some degree of heart failure, but it is not excessively high.

The presence of ventricular extrasystole (Polymorphic) on the ECG is a concern, as it may indicate a higher risk of ventricular arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia (CH>10) reduces the risk of sudden cardiac death.

The patient's hemoglobin level (123.0 g/L) is slightly elevated, which may be due to anemia or other factors. The presence of anemia may increase the risk of cardiac events, but it is not a significant risk factor in this case.

Overall, while the patient has some risk factors for cardiac events, the risk is not extremely high. However, the presence of ventricular extrasystole on the ECG makes it slightly more likely that the patient may experience a cardiac event.

3. Pump Failure Death
REASONING:
The patient's NYHA Class II heart failure classification and elevated Pro-BNP level (433.0 ng/L) suggest that they have some degree of heart failure. However, the patient's LVEF (62.0) is not severely reduced, and they are on medications for hypertension and heart failure.

The patient's creatinine level (8.49 mg/dL) is elevated, which may indicate some degree of kidney impairment. However, the patient is on medications for hypertension, which may be contributing to the elevated creatinine level.

The presence of ventricular extrasystole (Polymorphic) on the ECG is a concern, as it may indicate a higher risk of ventricular arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia (CH>10) reduces the risk of pump failure death.

Overall, while the patient has some risk factors for cardiac events, the risk of pump failure death is not the highest. The patient's age, NYHA Class II heart failure classification, and elevated Pro-BNP level do increase the risk, but the presence of ventricular extrasystole on the ECG and the patient's relatively preserved LVEF reduce the risk."
378,378,P0611,"Age: 66
Gender: Male 
Weight: 72 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 105/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,39
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2919.0
Protein (g/L): 68,1
T4 (ng/L): 18
TSH (mIU/L): 0,38
Urea (mg/dL): 8,65
LVEF (%): 23.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation, laboratory results, and ECG findings suggest a high likelihood of survival for the next few years. The patient's age is 66, which is considered advanced for many cardiac conditions, but the presence of ischemic dilated cardiomyopathy, dyslipidemia, and a history of myocardial infarction indicate a significant cardiovascular burden. However, the patient's current NYHA Class II indicates that they are still able to perform daily activities with some limitation.

The patient's laboratory results show a mild elevation in creatinine (99.0 mol/L), which may indicate some degree of kidney impairment, but this is not uncommon in patients with heart failure. The presence of elevated Pro-BNP (2919.0 ng/L) suggests that the patient has significant left ventricular dysfunction, but the LVEF (23.0%) is still relatively preserved.

The ECG findings are notable for ventricular extrasystoles, which are a common finding in patients with heart failure. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and a nitrovasodilator, which is commonly used to manage heart failure and reduce cardiovascular risk factors. These medications are generally effective in managing heart failure and reducing cardiovascular risk.

Given the patient's overall clinical presentation, laboratory results, and ECG findings, I would rank the three possible prognoses as follows:

1. Survivor: The patient's relatively preserved LVEF, the presence of a NYHA Class II classification, and the effectiveness of their medication regimen suggest that they are likely to survive for the next few years with proper management.
2. Pump failure death: While the patient has significant left ventricular dysfunction, the presence of a preserved LVEF and the effectiveness of their medication regimen reduce the risk of pump failure death.
3. Sudden cardiac death: The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG, and the patient's overall clinical presentation, reduce the risk of sudden cardiac death. However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy still pose a risk for arrhythmic events, making this outcome less likely."
379,379,P0612,"Age: 67
Gender: Female 
Weight: 93 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 159/62 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 2,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 233.0
Protein (g/L): 67
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,5
Urea (mg/dL): 11,82
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, Hydralazine, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a poor prognosis. Key factors contributing to this include:

1. Low LVEF of 30%, indicating severe left ventricular dysfunction.
2. Elevated creatinine level of 141.0 mmol/L, suggesting impaired kidney function.
3. Presence of other medical conditions such as diabetes, dyslipidemia, and hypertension, which can further compromise cardiac function.
4. Elevated Pro-BNP level of 233.0 ng/L, indicating increased ventricular wall stress and potential heart failure.
5. The presence of ventricular extrasystoles on ECG, which may indicate electrical instability.

Despite these concerning factors, the patient's current medication regimen, including beta blockers, ACE inhibitors, and spironolactone, suggests that the patient is receiving appropriate management for heart failure and hypertension. However, the combination of these factors still points towards a higher risk of adverse outcomes.

Given the patient's age and overall clinical presentation, a survival prognosis of ""survivor"" is more likely than sudden cardiac death or pump failure death. However, the patient's long-term outlook remains uncertain and requires close monitoring and ongoing management to optimize their condition."
380,380,P0613,"Age: 65
Gender: Male 
Weight: 54 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,54
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2740.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 1,96
Urea (mg/dL): 9,32
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient's age, NYHA Class II, and the presence of enolic dilated cardiomyopathy, dyslipemia, and hypertension indicate that the patient has a significant underlying cardiac condition that has led to reduced left ventricular function, as evidenced by the LVEF of 30.0%. The patient's elevated creatinine level (104.0 mmol/L) and elevated Pro-BNP level (2740.0 ng/L) suggest that the patient has a significant burden of cardiac stress, which is likely contributing to the patient's reduced LVEF. The patient's medication regimen includes ACE inhibitors, which are known to improve outcomes in patients with heart failure. Additionally, the patient's electrolyte levels (e.g., potassium, sodium) are within normal limits, and the patient's hemoglobin level is elevated, which suggests that the patient is not experiencing significant anemia. 

While the patient has a history of ventricular extrasystoles and TPSV, these are not indicative of a high risk for sudden cardiac death. The patient's ECG impression does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are common causes of sudden cardiac death. Therefore, based on the available data, the patient's prognosis is that they will survive for the next few years."
381,381,P0614,"Age: 58
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 41,2
ALT or GPT (IU/L): 42.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 5,78
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 9,3
Hemoglobin (g/L): 110.0
HDL (mmol/L): 2,69
Potassium (mEq/L): 3,75
LDL (mmol/L): 2,52
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 4446.0
Protein (g/L): 68,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 11,4
LVEF (%): 18.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at a high risk for adverse cardiac events, but the presence of a patent outcome of ""survivor"" suggests that the patient has survived a recent cardiac event or has a history of cardiac disease. The patient's NYHA Class II indicates that they have some limitations in their physical activity due to heart failure symptoms, but they are still able to perform daily activities.

The patient's LVEF of 18.0 is significantly reduced, indicating severe left ventricular dysfunction. The elevated Troponin level (0.01 ng/mL) suggests some degree of cardiac damage. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG also indicate an increased risk for arrhythmias.

However, the patient's low level of BNP (4446 ng/L) suggests that the patient's heart is not under significant strain, which may indicate that the patient is not in a state of acute heart failure. The patient's medication regimen, which includes beta blockers, ACE inhibitors, and calcium channel blockers, is typical for managing heart failure and hypertension.

Given these factors, the patient is likely to survive, but their cardiac disease is likely to progress, and they may require further medical intervention to manage their condition.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's severe left ventricular dysfunction (LVEF of 18.0) and history of idiopathic dilated cardiomyopathy increase their risk for sudden cardiac death. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG also increase the risk for arrhythmias, which can lead to sudden cardiac death.

Additionally, the patient's low level of HDL (2.69 mmol/L) and high level of LDL (2.52 mmol/L) increase their risk for cardiovascular disease. The patient's elevated creatinine level (113.0 mmol/L) also suggests some degree of kidney dysfunction, which can increase the risk for cardiovascular disease.

While the patient is taking medications to manage their heart failure and hypertension, their underlying cardiac disease may still pose a significant risk for sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

While the patient's LVEF of 18.0 indicates severe left ventricular dysfunction, the patient's BNP level (4446 ng/L) is not extremely elevated, suggesting that the patient's heart is not under significant strain. The patient's medication regimen is also typical for managing heart failure, which suggests that the patient is receiving adequate treatment.

However, the patient's low level of HDL (2.69 mmol/L) and high level of LDL (2.52 mmol/L) increase their risk for cardiovascular disease, and the patient's elevated creatinine level (113.0 mmol/L) suggests some degree of kidney dysfunction. These factors may increase the risk for pump failure, but the patient's overall prognosis is still uncertain and may not be as severe as sudden cardiac death."
382,382,P0615,"Age: 61
Gender: Male 
Weight: 103 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,42
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 12,2
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,87
Potassium (mEq/L): 3,91
LDL (mmol/L): 1,47
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 86.0
Protein (g/L): 67,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,91
Urea (mg/dL): 6,9
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient has a complex medical history with multiple comorbid conditions such as ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction. However, the patient has been taking a comprehensive set of medications including beta blockers, angiotensin II receptor blockers, statins, and a nitrovasodilator, which suggests a good level of cardiovascular management. The patient's current NYHA class is II, indicating some limitations in physical activity, but not severe. 

The patient's renal function is impaired, as indicated by elevated creatinine levels, but this is not uncommon in patients with heart failure. The patient's LVEF is significantly reduced at 35%, which is a strong indicator of poor cardiac function.

The patient's troponin levels are within the normal range, which suggests that there is no significant myocardial infarction in the recent past. The patient's BNP levels are elevated, indicating some level of cardiac stress.

Despite the patient's poor cardiac function, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests a relatively stable cardiac rhythm. The presence of ventricular extrasystoles is a common finding in patients with cardiac disease, but it is not a cause for concern in this case.

Considering the patient's overall medical history, medication regimen, and the absence of any acute cardiac events on the ECG, the most likely outcome is a survivor. However, close monitoring and follow-up are essential to adjust the medication regimen and address any potential issues that may arise."
383,383,P0617,"Age: 50
Gender: Male 
Weight: 88 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 90/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 46.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,61
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 8,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,53
LDL (mmol/L): 2,82
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3172.0
Protein (g/L): 78,9
T4 (ng/L): 17,3
Troponin (ng/mL): 0,45
TSH (mIU/L): 6
Urea (mg/dL): 7,6
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a high likelihood of survival for the next few years. Key factors contributing to this assessment include:

1. Age: While the patient is 50 years old, this is not considered old for a patient with cardiomyopathy.
2. NYHA Class II: The patient's functional capacity is moderate, indicating that they are able to perform light physical activity without significant limitations, which is a good prognostic indicator.
3. Low Blood Pressure: The patient's blood pressure is within a relatively normal range, which suggests that their cardiovascular system is functioning adequately.
4. Low Pro-BNP levels: Elevated B-type natriuretic peptide (BNP) levels are often associated with heart failure, but the patient's level of 3172.0 ng/L is actually within the normal range. This suggests that the patient's heart is not failing at the moment.
5. Low Troponin levels: Elevated troponin levels are often associated with myocardial infarction or myocardial damage, but the patient's level of 0.45 ng/mL is within the normal range, indicating that the patient's heart muscle is not currently under significant stress.
6. Low Creatinine levels: Elevated creatinine levels are often associated with kidney dysfunction, but the patient's level of 7.6 mg/dL is within the normal range, indicating that their kidneys are functioning adequately.
7. Presence of Medications: The patient is taking medications for their condition, including ACE inhibitors, which are known to improve outcomes in patients with heart failure.
8. Absence of other concerning features: The patient does not have any other concerning features, such as significant kidney dysfunction, elevated liver enzymes, or other signs of heart failure.

Overall, based on the patient's clinical presentation and test results, I believe that the patient has a high likelihood of survival for the next few years."
384,384,P0620,"Age: 50
Gender: Male 
Weight: 85 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 100/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41,5
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,94
Potassium (mEq/L): 4,22
LDL (mmol/L): 3,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 233.0
Protein (g/L): 68,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 4,7
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's data indicates a severe heart condition with a left ventricular ejection fraction (LVEF) of 39%, which is significantly below the normal range. The presence of ventricular extrasystoles on the ECG is also concerning. However, the patient is currently on optimal medical therapy with beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF) and cardiomyopathy. The patient's blood pressure is well-controlled at 100/65 mmHg, and their kidney function is preserved, as evidenced by a creatinine level of 4.7 mg/dL.

While the patient's symptoms and lab results indicate a high risk of adverse outcomes, the fact that they are currently on optimal therapy and have not experienced any recent decompensation or hospitalizations suggests that they may be able to tolerate these treatments and potentially survive for the next few years. The Pro-BNP level of 233 ng/L is elevated, but this is not significantly higher than the normal range, and the patient's troponin level is within normal limits. Overall, the patient's current clinical status and treatment plan suggest that they are at high risk for cardiac events, but the possibility of survival for the next few years cannot be ruled out.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's severe heart failure with a LVEF of 39% and ventricular extrasystoles on the ECG increase the risk of sudden cardiac death. However, the fact that the patient is on optimal medical therapy and has not experienced any recent decompensation or hospitalizations suggests that they may be able to tolerate these treatments and potentially survive for a longer period.

RANKING: 3. Pump failure death
REASONING: 

The patient's severe heart failure with a LVEF of 39% and elevated Pro-BNP level of 233 ng/L indicate a high risk of pump failure. The fact that the patient's kidney function is preserved suggests that they may be able to tolerate diuretics and other medications, but the presence of ventricular extrasystoles on the ECG and the patient's overall clinical status suggest that pump failure is a possible outcome. However, the patient's current treatment plan and clinical status make it less likely than sudden cardiac death, but more likely than survivorship."
385,385,P0621,"Age: 56
Gender: Male 
Weight: 78 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 120/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 33,7
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 3,46
Creatinine (mmol/L): 148.0
Gamma-glutamil transpeptidase (IU/L): 103
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 156.0
HDL (mmol/L): 0,73
Potassium (mEq/L): 2,94
LDL (mmol/L): 2,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 16094.0
Protein (g/L): 60,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,55
Urea (mg/dL): 11,8
LVEF (%): 16.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, I would rank the patient as having a high likelihood of survival over the next few years. Several factors contribute to this assessment:

1. Age: The patient is 56 years old, which is relatively young for advanced heart failure, and therefore, the likelihood of mortality is lower compared to older patients.
2. NYHA Class III: The patient's NYHA class indicates moderate symptoms of heart failure, but it is still possible to manage the condition with optimal treatment.
3. Medications: The patient is on beta blockers, loop diuretics, spironolactone, and ACE inhibitors, which are standard treatments for heart failure and hypertension. This suggests that the patient is receiving appropriate therapy.
4. Pro-BNP levels: While the Pro-BNP level is elevated, indicating some degree of heart failure, it is not excessively high, suggesting that the patient is not in a severely decompensated state.
5. ECG findings: The presence of non-sustained ventricular tachycardia and ventricular extrasystole suggests that the patient has some level of cardiac electrical instability, but it is not immediately life-threatening.
6. Troponin levels: The troponin level is within normal limits, indicating no acute myocardial infarction.

However, there are some concerns that may impact the patient's long-term prognosis:

1. Idiopathic dilated cardiomyopathy: This condition can be unpredictable, and there is a risk of progression to more severe heart failure.
2. Elevated creatinine levels: The patient has elevated creatinine levels, which may indicate some degree of kidney impairment.
3. Elevated LVEF: The left ventricular ejection fraction (LVEF) is significantly reduced, indicating poor heart function.

Overall, while there are some concerns, the patient's overall condition, treatment, and age suggest a higher likelihood of survival over the next few years."
386,386,P0623,"Age: 52
Gender: Female 
Weight: 73 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45,9
ALT or GPT (IU/L): 104.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 5,81
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 5
Hemoglobin (g/L): 144.0
Potassium (mEq/L): 4,4
Sodium (mEq/L): 145.0
Protein (g/L): 75,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,17
Urea (mg/dL): 7,6
LVEF (%): 28.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I rank the patient as having the highest likelihood of being a survivor over the next few years. 

The patient's age, NYHA Class II, and LVEF of 28% indicate a significant degree of left ventricular dysfunction, which is a common complication of ischemic dilated cardiomyopathy. However, the patient is currently receiving medications for heart failure (Angiotensin II Receptor Blocker, Beta Blockers, and Loop Diuretics), which are known to improve symptoms and reduce mortality in patients with heart failure.

The patient's laboratory results, including normal blood pressure, normal liver enzymes, and normal troponin levels, suggest that there is no acute cardiac event or inflammation. The patient's electrolyte and kidney function are also within normal limits, indicating no acute kidney injury or electrolyte imbalances.

The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG also suggests that the patient is not at high risk for arrhythmic events.

While the patient has a history of myocardial infarction and dyslipidemia, the patient is currently receiving statins, which can help to reduce cardiovascular risk factors.

Overall, considering the patient's current clinical status, medication regimen, and laboratory results, I believe that the patient has the highest likelihood of being a survivor over the next few years."
387,387,P0625,"Age: 57
Gender: Female 
Weight: 70 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 37,6
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 19,7
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,39
Potassium (mEq/L): 4,35
LDL (mmol/L): 3,73
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1935.0
Protein (g/L): 70,2
T4 (ng/L): 9,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 7,15
Urea (mg/dL): 8,6
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient is at high risk for cardiac-related complications due to their NYHA Class III status, indicating severe heart failure symptoms. Their past medical history of hypertensive cardiomyopathy, myocardial infarction, diabetes, and dyslipemia further exacerbates their cardiovascular risk. The elevated Troponin level (0.01 ng/mL) suggests some degree of myocardial damage, but it is not significantly elevated. The elevated Pro-BNP level (1935 ng/L) also supports this diagnosis. However, the patient's LVEF (48.0%) is relatively preserved, which may indicate that the patient has some residual cardiac function. The patient's medication regimen, including ACE inhibitors, beta blockers, and statins, suggests that they are receiving optimal management for their cardiovascular conditions. 

The absence of significant ECG abnormalities, such as ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, reduces the risk of sudden cardiac death. Therefore, based on the patient's clinical presentation and medication regimen, the most likely outcome is that the patient will survive in the next few years.

2. Pump failure death
REASONING: 
Although the patient's LVEF (48.0%) is preserved, their NYHA Class III status and elevated Pro-BNP level (1935 ng/L) suggest that the patient is at risk for cardiac failure exacerbation. The patient's past medical history of hypertension, diabetes, and dyslipemia also increases the risk of cardiovascular events. The elevated creatinine level (94.0 mmol/L) and urea level (8.6 mg/dL) may indicate some degree of renal impairment, which can be a complication of heart failure.

The patient's medication regimen, while comprehensive, may not be fully addressing the patient's cardiovascular needs, particularly with regards to their diabetes and dyslipemia. The absence of significant ECG abnormalities does not rule out the possibility of pump failure death, as this can occur without overt arrhythmic events.

3. Sudden cardiac death
REASONING: 
The patient's ECG impression does not show any significant arrhythmias, including ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia. The absence of these arrhythmias reduces the risk of sudden cardiac death. However, the patient's NYHA Class III status and elevated Pro-BNP level suggest that the patient is at risk for cardiac-related complications. The patient's past medical history of myocardial infarction and hypertensive cardiomyopathy also increases the risk of cardiac events.

While the patient's LVEF (48.0%) is preserved, this may not be sufficient to completely rule out the possibility of sudden cardiac death, particularly if the patient experiences a significant cardiac event or has a sudden change in their cardiovascular status. However, based on the available information, the risk of sudden cardiac death is lower compared to pump failure death."
388,388,P0627,"Age: 74
Gender: Male 
Weight: 67 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,67
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1312.0
Protein (g/L): 64
T3 (pg/dL): 0,04
T4 (ng/L): 13
TSH (mIU/L): 2,56
Urea (mg/dL): 5,49
LVEF (%): 37.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient's prognosis as a survivor for the next few years. Here's the reasoning behind this ranking:

1. The patient's age of 74 is not particularly old for someone with cardiomyopathy, and their NYHA Class II indicates that they have some symptoms but are not severely limited in their physical activity.

2. The patient's LVEF (Left Ventricular Ejection Fraction) of 37% is significantly reduced, indicating poor heart function. However, this is not uncommon in patients with idiopathic dilated cardiomyopathy. Despite this, the patient's symptoms and medication regimen suggest that they are being managed effectively.

3. The patient's elevated creatinine level (118.0 mol/L) and urea level (5.49 mg/dL) indicate some degree of kidney impairment, which can be associated with heart failure. However, this is not immediately life-threatening and can be managed with their current medication regimen.

4. The patient's elevated Pro-BNP level (1312.0 ng/L) suggests that they are experiencing some degree of heart failure, but the level is not extremely high, indicating that their symptoms are not severely debilitating.

5. The patient's ECG findings show a polymorphic ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia. These arrhythmias are concerning, but the fact that they are non-sustained suggests that they are not immediately life-threatening.

6. The patient's medication regimen includes beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are all standard treatments for heart failure and arrhythmias. This suggests that the patient is receiving appropriate management for their condition.

Considering these factors, I believe that the patient's prognosis is most likely to be a survivor, as they are receiving effective management for their condition, and their symptoms are not immediately life-threatening. However, close monitoring and regular follow-up will be necessary to ensure that their condition does not deteriorate.

While the patient's ECG findings and elevated Pro-BNP level are concerning, the patient's overall condition is stable, and their medication regimen suggests that they are receiving appropriate management. Therefore, I would rank survivor as the most likely prognosis."
389,389,P0628,"Age: 68
Gender: Female 
Weight: 94 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,25
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1747.0
Protein (g/L): 75
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 5,66
LVEF (%): 50.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with multiple comorbidities, including hypertension, myocardial infarction, and cardiomyopathy, which indicates a high risk for cardiac events. However, the patient is currently on multiple medications that are commonly used to manage these conditions, such as beta blockers, digoxin, and ACE inhibitors, which can help reduce the risk of cardiac events.

The patient's laboratory results also show elevated troponin levels, which is a marker of cardiac damage, but the troponin level is within the normal range (0.01 ng/mL). This suggests that there is no acute myocardial infarction at the time of the test.

The patient's LVEF is 50%, which is within the normal range, indicating that the patient's left ventricle is functioning adequately. The patient's ECG results show ventricular extrasystoles, which can be a sign of ventricular arrhythmias, but there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia.

Considering these factors, the patient's overall prognosis is likely to be a survivor. The patient's multiple comorbidities and elevated troponin levels suggest a high risk for cardiac events, but the patient's current medical management and the absence of acute cardiac damage or arrhythmias suggest that the patient can be managed conservatively with close monitoring.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's multiple comorbidities and elevated troponin levels increase the risk for cardiac events, the patient's current medical management and the absence of acute cardiac damage or arrhythmias make sudden cardiac death less likely. However, the patient's elevated Pro-BNP levels (1747 ng/L) suggest that the patient has some degree of heart failure, which can increase the risk for cardiac events.

Additionally, the patient's age (68 years) and weight (94 kg) are also risk factors for cardiac events. However, the patient's NYHA Class II indicates that the patient has some symptoms of heart failure, but the patient is still able to perform daily activities without significant limitation.

Considering these factors, while the patient is at risk for cardiac events, the patient's overall prognosis is not as poor as sudden cardiac death. The patient's current medical management and the absence of acute cardiac damage or arrhythmias suggest that the patient can be managed conservatively with close monitoring.

RANKING: 3. Pump Failure Death
REASONING: 

Given the patient's elevated Pro-BNP levels, NYHA Class II, and elevated creatinine levels, it is possible that the patient has some degree of heart failure. However, the patient's LVEF is 50%, which is within the normal range, indicating that the patient's left ventricle is functioning adequately.

The patient's elevated troponin levels and elevated creatinine levels suggest that the patient has some degree of cardiac damage and renal impairment, but the patient's current medical management and the absence of acute cardiac damage or arrhythmias suggest that the patient can be managed conservatively with close monitoring.

Considering these factors, while the patient has some degree of heart failure and cardiac damage, the patient's overall prognosis is not as poor as pump failure death. The patient's current medical management and the absence of acute cardiac damage or arrhythmias suggest that the patient can be managed conservatively with close monitoring.

It's worth noting that the patient's Pro-BNP levels are elevated, which suggests that the patient may benefit from further evaluation and management of heart failure, such as ACE inhibitors, beta blockers, and diuretics. However, based on the current information, pump failure death is less likely than sudden cardiac death or survivor."
390,390,P0630,"Age: 61
Gender: Male 
Weight: 90 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,66
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 848.0
Protein (g/L): 71
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,98
Urea (mg/dL): 6,99
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has several factors that suggest a high likelihood of survival, despite their significant cardiovascular history. 

Firstly, the patient's NYHA Class II classification indicates that they have moderate symptoms, but they are still able to perform daily activities with some limitation. This suggests that their cardiac function is not severely impaired, which is a good prognostic sign.

Secondly, the patient's ejection fraction (LVEF) is 35%, which is relatively preserved compared to the average LVEF for patients with ischemic dilated cardiomyopathy. A lower LVEF is associated with a higher risk of heart failure and mortality, but in this case, the LVEF is still within a range that suggests the patient may be able to tolerate some level of physical stress.

Thirdly, the patient's medications include beta blockers, statins, and an ACE inhibitor, which are all evidence-based treatments for cardiovascular disease. These medications can help to slow the progression of heart failure, lower blood pressure, and reduce the risk of cardiovascular events.

Finally, the patient's biomarkers, such as troponin and BNP, are not excessively elevated, suggesting that there is no acute myocardial infarction or significant heart failure. The absence of ventricular tachycardia or ventricular extrasystoles on the ECG also suggests that the patient's heart is not experiencing any acute arrhythmias that could be life-threatening.

Overall, considering the patient's NYHA Class II classification, preserved LVEF, and treatment with evidence-based medications, the most likely outcome is that the patient will survive."
391,391,P0631,"Age: 39
Gender: Male 
Weight: 123 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,86
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 37.0
Protein (g/L): 76
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,81
Urea (mg/dL): 5,49
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. However, the patient's current NYHA Class II classification indicates that they are not currently experiencing severe symptoms. The presence of ventricular extrasystole on the ECG, but no ventricular tachycardia or non-sustained ventricular tachycardia, suggests that the patient is not at high risk for sudden cardiac death. The patient's LVEF of 25% indicates significant left ventricular dysfunction, but the patient is currently on multiple medications that are known to improve heart function and reduce symptoms. The patient's lipid profile, blood pressure, and renal function are also within acceptable limits. Given these factors, the patient is at high risk for heart failure, but the presence of multiple medications and the absence of severe symptoms suggest that the patient is likely to survive in the short term.

RANKING: 2. Pump failure death
REASONING: 
While the patient's LVEF of 25% indicates significant left ventricular dysfunction, the patient is currently on multiple medications that are known to improve heart function and reduce symptoms. The patient's NYHA Class II classification suggests that they are not currently experiencing severe symptoms, and the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces the risk of sudden cardiac death. However, the patient's LVEF is still significantly reduced, and the patient's idiopathic dilated cardiomyopathy is a chronic condition that can lead to progressive heart failure. If the patient's heart function does not improve with medication, pump failure death is a possible outcome.

RANKING: 3. Sudden cardiac death
REASONING: 
The patient's ECG shows ventricular extrasystole, which is a risk factor for ventricular arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces the risk of sudden cardiac death. The patient's LVEF is significantly reduced, which increases the risk of arrhythmias and sudden cardiac death. However, the patient's NYHA Class II classification and the presence of multiple medications that are known to improve heart function and reduce symptoms reduce the risk of sudden cardiac death. Given the patient's complex medical history and the presence of ventricular extrasystole, sudden cardiac death is the least likely outcome."
392,392,P0632,"Age: 73
Gender: Male 
Weight: 81 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Other HF etiology, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,92
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1395.0
Protein (g/L): 70
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,28
Urea (mg/dL): 7,99
LVEF (%): 35.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's age, NYHA Class II, and the presence of a past medical history of heart failure (HF) etiology, hypertension, and other comorbidities, such as elevated creatinine levels, indicate a high risk of cardiovascular complications. However, the patient's current hemoglobin level (162.0 g/L) is within the normal range, and the absence of severe anemia is a positive prognostic factor.

The patient's LVEF of 35.0% is significantly reduced, indicating severe left ventricular dysfunction, which is a strong predictor of adverse outcomes. However, the presence of beta blockers and ACE inhibitors, which are standard treatments for HF, suggests that the patient is receiving optimal medical therapy.

The patient's ECG findings, including ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, indicate a high risk of arrhythmic events. However, the absence of more severe arrhythmic abnormalities, such as ventricular fibrillation or sustained ventricular tachycardia, reduces the likelihood of sudden cardiac death.

The patient's Pro-BNP level of 1395.0 ng/L is elevated, indicating some degree of heart failure, but it is not excessively high, which might suggest that the patient is not in a state of acute decompensated heart failure.

Considering these factors, the patient's overall prognosis is more favorable than the other two options. The patient is likely to survive, but the presence of severe left ventricular dysfunction and arrhythmic events requires close monitoring and optimization of medical therapy to minimize the risk of adverse outcomes.

RANKING: Sudden cardiac death (less likely)
REASONING:
The patient's age, NYHA Class II, and the presence of a past medical history of HF etiology, hypertension, and other comorbidities increase the risk of sudden cardiac death. However, the patient's current hemoglobin level and LVEF are not as severely impaired as in the survivor prognosis, which reduces the likelihood of sudden cardiac death.

The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, indicate a high risk of arrhythmic events, but the absence of more severe arrhythmic abnormalities reduces the likelihood of sudden cardiac death.

RANKING: Pump failure death (least likely)
REASONING:
The patient's elevated creatinine level (88.0 mmol/L) and LVEF of 35.0% indicate significant kidney dysfunction and left ventricular dysfunction, respectively. These factors increase the risk of pump failure. However, the patient is receiving beta blockers and ACE inhibitors, which are standard treatments for HF, and the absence of more severe symptoms or signs of acute decompensated heart failure reduces the likelihood of pump failure death.

The patient's Pro-BNP level is elevated, but not excessively high, which might suggest that the patient is not in a state of acute decompensated heart failure. Additionally, the patient's hemoglobin level is within the normal range, which reduces the likelihood of anemia-related complications.

Considering these factors, the patient's overall prognosis is less favorable than the survivor prognosis, and pump failure death is the least likely outcome."
393,393,P0633,"Age: 51
Gender: Male 
Weight: 97 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 58.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 168.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4
LDL (mmol/L): 2,2
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 193.0
Protein (g/L): 74
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2
Urea (mg/dL): 5,66
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's data, I rank the patient as having the highest likelihood of being a survivor. The patient's age (51) is not considered elderly, and the presence of a past medical history of ischemic dilated cardiomyopathy, dyslipidemia, and myocardial infarction suggests a chronic condition that has been managed with beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and coronary artery disease. The patient's current NYHA class is II, indicating mild symptoms, which is a relatively stable condition.

The patient's laboratory results show elevated creatinine levels (97.0 mmol/L) and slightly elevated liver enzymes (ALT 58.0, AST 35.0), which could indicate some degree of kidney and liver dysfunction. However, these findings are not uncommon in patients with chronic heart failure and do not necessarily indicate a poor prognosis.

The ECG results show ventricular extrasystole (polymorphic) and non-sustained ventricular tachycardia, which are concerning signs of arrhythmia. However, the absence of sustained ventricular tachycardia (CH>10) and paroxysmal supraventricular tachyarrhythmia suggests that the patient is not at high risk of sudden cardiac death.

The patient's LVEF (20.0%) is significantly reduced, indicating poor cardiac function. However, this finding is consistent with the patient's history of ischemic dilated cardiomyopathy and is not an isolated finding.

Overall, while the patient has several risk factors and concerning ECG findings, the combination of a stable NYHA class, management with standard medications, and the absence of other severe findings suggest that the patient is at high risk of being a survivor."
394,394,P0634,"Age: 76
Gender: Male 
Weight: 72 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 114/77 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,67
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,66
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 716.0
Protein (g/L): 76
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,67
Urea (mg/dL): 10,48
LVEF (%): 38.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I rank the patient as having a high likelihood of survival over the next few years. The key factors contributing to this assessment are:

1. Age: Although the patient is 76 years old, their age alone is not a contraindication for survival. Many patients with advanced heart disease live for several years with proper management.

2. NYHA Class II: This indicates that the patient's symptoms are moderate, but not severe. This classification suggests that the patient can still perform daily activities with some limitation, which is a positive prognostic sign.

3. Medications: The patient is taking a combination of medications that are commonly used to manage heart failure, diabetes, and hypertension. This suggests that the patient is receiving comprehensive care, which can help manage their conditions.

4. Pro-BNP levels: Although the patient's Pro-BNP levels are elevated, which can indicate fluid overload and heart failure, this can be managed with medication and lifestyle changes.

5. ECG Impression: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac rhythm is relatively stable.

6. LVEF: Although the patient's left ventricular ejection fraction (LVEF) is low at 38%, this can be improved with medication and lifestyle modifications.

7. Other lab results: The patient's laboratory results, such as creatinine and urea levels, are not significantly abnormal, which suggests that the patient's kidney function is not severely compromised.

While the patient has several comorbidities, including ischemic dilated cardiomyopathy, diabetes, and hypertension, these conditions can be managed with medication and lifestyle changes. Overall, the combination of a moderate NYHA Class, comprehensive medication regimen, and stable cardiac rhythm suggests that the patient is likely to survive for several years with proper management."
395,395,P0636,"Age: 39
Gender: Male 
Weight: 79 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 115/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 47
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 7,01
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 162
Glucose (mmol/L): 5
Hemoglobin (g/L): 167.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 5,1
LDL (mmol/L): 4,5
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 114.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,701
Urea (mg/dL): 6,82
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's prognosis is ranked as a survivor due to the following factors:

1. Age: The patient is 39 years old, which is considered relatively young for heart failure, and therefore, a good prognosis is expected.
2. NYHA Class II: The patient's New York Heart Association (NYHA) class is II, indicating mild symptoms, which suggests that the patient is still relatively active and has not developed severe symptoms of heart failure.
3. Blood Pressure: The patient's blood pressure is within a relatively normal range (115/85 mmHg), which is not a significant risk factor for cardiovascular events.
4. Past Medical History: While the patient has idiopathic dilated cardiomyopathy, which is a significant underlying condition, the fact that it is idiopathic suggests that the disease may be less aggressive.
5. Medications: The patient is on beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy.
6. ECG Impression: The ECG shows ventricular extrasystoles and polymorphic ventricular tachycardia, but no ventricular tachycardia or bradycardia. This suggests that the patient has some arrhythmia issues, but they are not severe enough to be a significant concern.
7. Pro-BNP: The patient's pro-b-type natriuretic peptide (Pro-BNP) level is elevated at 114.0 ng/L, which is a marker of heart failure. However, the level is not extremely high, which suggests that the patient is not in severe heart failure.
8. LVEF: The left ventricular ejection fraction (LVEF) is 29.0%, which is significantly reduced, indicating that the patient has significant left ventricular dysfunction.

Overall, considering the patient's age, NYHA class, blood pressure, past medical history, medications, ECG impression, Pro-BNP level, and LVEF, the patient is likely to survive for several years with proper management and treatment. However, it is essential to closely monitor the patient's condition and adjust the treatment plan as needed to prevent complications.

It is essential to note that the patient's prognosis is still uncertain and can change over time. Regular follow-up appointments and monitoring of the patient's condition are crucial to adjust the treatment plan and prevent complications."
396,396,P0637,"Age: 58
Gender: Male 
Weight: 75 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 6,85
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 163.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,8
LDL (mmol/L): 4,84
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 269.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,83
Urea (mg/dL): 6,16
LVEF (%): 25.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1

REASONING:

Based on the patient's data, I predict that the patient is most likely to be a survivor in the next few years. The primary reasons for this prediction are:

1. The patient's New York Heart Association (NYHA) class is II, indicating mild heart failure symptoms, which suggests that the patient's heart is still functioning relatively well, despite the presence of dilated cardiomyopathy.
2. The patient's left ventricular ejection fraction (LVEF) is 25%, which is within the normal range for a 58-year-old male. Although the LVEF is lower than the average value, it is still within the range that would allow the patient to survive for an extended period.
3. The patient's creatinine level is elevated, indicating impaired kidney function, but it is not severely elevated, which may suggest that the patient's kidneys are still functioning to some extent.
4. The patient's troponin level is normal, which suggests that there is no significant myocardial damage or necrosis.
5. The patient's ECG impression shows no signs of ventricular tachycardia, which is a significant risk factor for sudden cardiac death.
6. The patient is on an ACE inhibitor, which is a standard treatment for heart failure and can help to slow the progression of heart failure.

While the patient's past medical history of dilated cardiomyopathy and dyslipidemia are concerning, the patient's current clinical status and medication regimen suggest that they are unlikely to experience a sudden cardiac death or pump failure in the near future. Therefore, I predict that the patient is most likely to be a survivor in the next few years."
397,397,P0638,"Age: 55
Gender: Male 
Weight: 82 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 48
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 12,5
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,71
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 775.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,18
Urea (mg/dL): 8,15
LVEF (%): 31.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipidemia, hypertension, and a history of myocardial infarction. The elevated creatinine level (99.0 mmol/L) suggests some degree of renal impairment, which can be a contributing factor to cardiac disease progression. The patient's low LVEF (31.0%) is also a significant concern, indicating reduced cardiac function.

Despite the presence of these comorbidities and reduced LVEF, the patient is currently taking beta blockers, spironolactone, statins, and an ACE inhibitor, which are all evidence-based treatments for managing heart failure and reducing cardiovascular risk. The patient's troponin level is within normal limits (0.005 ng/mL), which suggests that there is no acute myocardial infarction.

The patient's ECG findings, including ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, indicate a high risk of arrhythmias, but the fact that these are non-sustained suggests that they may not be life-threatening. The patient's Pro-BNP level is elevated at 775.0 ng/L, which is consistent with heart failure.

Overall, given the patient's current treatment regimen, medical history, and ECG findings, the most likely outcome is that the patient will survive for the next few years, although with a high risk of cardiovascular events. Regular monitoring and adjustments to the treatment plan may be necessary to manage the patient's cardiovascular risk.

2. Sudden cardiac death
REASONING: 
While the patient has a high risk of cardiovascular events, the fact that the patient is currently taking evidence-based treatments and has no acute myocardial infarction on troponin levels suggests that sudden cardiac death is less likely. However, the patient's complex medical history, reduced LVEF, and ECG findings of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia do increase the risk of arrhythmias.

Additionally, the patient's age (55) and sex (male) also increase the risk of sudden cardiac death. However, the patient's current ECG findings and troponin levels do not suggest an immediate life-threatening arrhythmia.

3. Pump failure death
REASONING: 
Given the patient's reduced LVEF (31.0%) and elevated Pro-BNP level (775.0 ng/L), pump failure is a significant concern. However, the patient is currently taking evidence-based treatments for heart failure, including beta blockers, spironolactone, statins, and an ACE inhibitor, which can help manage symptoms and slow disease progression.

The patient's ECG findings, while concerning for arrhythmias, do not suggest acute heart failure or pump failure. Therefore, pump failure death is the least likely outcome, although regular monitoring and adjustments to the treatment plan may be necessary to manage the patient's heart failure risk."
398,398,P0639,"Age: 49
Gender: Male 
Weight: 90 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 59.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,742
Urea (mg/dL): 6,49
LVEF (%): 50.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's data suggests that they are at a higher risk for adverse cardiac events, but the patient has a history of idiopathic dilated cardiomyopathy and hypertension, which are contributing factors to their heart condition. The patient is already taking medications for these conditions, including beta blockers and ACE inhibitors, which are commonly used to manage symptoms and slow disease progression. 

The patient's LVEF of 50% indicates a significant impairment of cardiac function, which is a risk factor for adverse outcomes. However, the patient's NYHA class II classification suggests that they are still able to perform moderate physical activity without significant symptoms. 

The absence of elevated troponin levels and no history of ventricular tachycardia or arrhythmias on ECG suggests that the patient is not at high risk for sudden cardiac death. 

Additionally, the patient's renal function is slightly impaired, but not severely compromised. 

Taking into account these factors, the patient is likely to survive for the next few years, assuming they continue to adhere to their treatment plan and do not experience any significant changes in their underlying conditions."
399,399,P0640,"Age: 69
Gender: Male 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41,2
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,82
Creatinine (mmol/L): 166.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,33
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1660.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,97
Urea (mg/dL): 10,91
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 69-year-old male with a history of idiopathic dilated cardiomyopathy, which is a condition that weakens the heart muscle and can lead to heart failure. The patient's left ventricular ejection fraction (LVEF) is 30%, indicating significant impairment of the heart's pumping function.

The patient's current medications, including digoxin, loop diuretics, spironolactone, and an ACE inhibitor, suggest that the patient is being managed for heart failure and possibly for arrhythmias. The presence of ventricular extrasystole and non-sustained ventricular tachycardia (VT) on the ECG is concerning for a high risk of sudden cardiac death.

However, the patient's NYHA class is II, indicating mild symptoms of heart failure, and the patient's blood pressure is relatively well-controlled. The patient's kidney function is also relatively preserved, with a creatinine level of 10.91 mg/dL.

Considering these factors, the patient's overall prognosis is likely to be a survivor, with a reasonable chance of survival for the next few years with appropriate management and monitoring.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG shows signs of ventricular arrhythmias, the patient's overall clinical presentation is not as severe as would be expected for a high-risk patient for sudden cardiac death. The patient's LVEF is significantly impaired, and the patient's NYHA class is II, indicating some degree of heart failure symptoms.

However, the patient's ECG shows non-sustained VT, which is a significant finding, but the patient's medications and current clinical presentation suggest that the patient is being managed for arrhythmias and heart failure.

Given the patient's history of idiopathic dilated cardiomyopathy and the presence of ventricular arrhythmias, there is a moderate risk of sudden cardiac death, but it is not the most likely outcome.

RANKING: 3. Pump failure death
REASONING: 

While the patient's LVEF is significantly impaired at 30%, the patient's NYHA class is II, indicating mild symptoms of heart failure, and the patient is receiving medications to manage heart failure and arrhythmias.

However, the patient's creatinine level is elevated at 10.91 mg/dL, indicating some degree of kidney dysfunction. The patient's albumin level is also low, at 41.2 g/L, which can be associated with heart failure and kidney disease.

Given these factors, there is a moderate risk of pump failure death, but it is not the most likely outcome, as the patient is currently being managed for heart failure and arrhythmias, and the patient's kidney function and albumin level are not severely impaired."
400,400,P0641,"Age: 68
Gender: Male 
Weight: 98 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 155/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 35,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,02
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,08
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 718.0
Protein (g/L): 71
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,71
Urea (mg/dL): 9,35
LVEF (%): 64.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING:

Based on the provided patient data, the patient has several factors that suggest a relatively favorable prognosis. 

1. Age: The patient is 68 years old, which is considered advanced age, but not extremely high-risk. However, age itself is not a strong predictor of outcome.

2. NYHA Class II: The patient has a mild heart failure classification, which indicates that the heart is still relatively functional, but not severely compromised.

3. Medications: The patient is on a combination of medications that are commonly used to treat heart failure, hypertension, and arrhythmias. This suggests that the patient is receiving adequate medical therapy.

4. Pro-BNP: The patient's Pro-BNP level is elevated, indicating some degree of heart failure. However, the level is not extremely high, which may suggest that the heart is not severely failing.

5. LVEF: The patient's LVEF is 64%, which is within the normal range for a male patient of this age group. This suggests that the patient's heart is still relatively functional.

6. ECG findings: The patient has a few abnormal ECG findings, including ventricular extrasystoles and TPSV, but no signs of severe arrhythmias or ventricular tachycardia.

Given these factors, I predict that the patient is most likely to survive for the next few years, with a reasonable quality of life. However, it is essential to monitor the patient closely and adjust the treatment plan as needed to ensure optimal outcomes.

The other two options, sudden cardiac death and pump failure death, are less likely because:

- Sudden cardiac death is less likely due to the patient's relatively stable ECG findings and the fact that the patient is on medications that can help manage arrhythmias.
- Pump failure death is less likely due to the patient's mild heart failure classification, relatively high LVEF, and the presence of medications that can help manage heart failure symptoms."
401,401,P0642,"Age: 72
Gender: Male 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 37,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,51
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 413.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,44
Urea (mg/dL): 5,13
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient has a significant history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to reduced heart function. This condition is often associated with a poor prognosis. However, the patient's NYHA Class II indicates that the symptoms are manageable with current medical therapy.

The patient's current medications, including beta blockers, loop diuretics, and statins, are commonly used to manage symptoms and slow disease progression in patients with heart failure. The presence of a calcium channel blocker and nitrovasodilator suggests that the patient is being treated to manage symptoms and reduce the workload on the heart.

The patient's LVEF of 30.0% is significantly reduced, indicating severe systolic dysfunction. However, the patient's age, weight, and other vital signs are not overly indicative of acute decompensation. 

The patient's laboratory results show elevated creatinine and urea levels, indicating impaired kidney function. However, this is not uncommon in patients with heart failure and may be related to the patient's age and other comorbid conditions.

The ECG impression is largely unremarkable, with no signs of acute arrhythmias or significant ischemia. The presence of ventricular extrasystoles may be a concern, but they are not severe enough to indicate a high risk of sudden cardiac death.

Considering these factors, the patient's overall prognosis is more favorable than the other options, and it is likely that the patient will survive the next few years with proper management and monitoring.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's history of ischemic dilated cardiomyopathy and reduced LVEF increase the risk of sudden cardiac death, the patient's current symptoms and laboratory results do not suggest acute decompensation or significant arrhythmias. However, the patient's age and comorbidities, such as diabetes and peripheral vascular disease, may increase the risk of cardiac events.

The patient's ECG impression shows ventricular extrasystoles, which may be a precursor to more severe arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the likelihood of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's reduced LVEF and impaired kidney function increase the risk of pump failure, which is a common cause of mortality in patients with heart failure. However, the patient's current symptoms and laboratory results do not suggest acute decompensation, and the patient is receiving optimal medical therapy.

The patient's age and comorbidities also increase the risk of pump failure. However, the patient's NYHA Class II symptoms suggest that the patient is relatively stable, and the presence of a calcium channel blocker and nitrovasodilator may help reduce the workload on the heart.

Overall, while pump failure is a potential risk, it is not the most likely outcome based on the provided information."
402,402,P0644,"Age: 72
Gender: Male 
Weight: 85 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia
Albumin (g/L): 43,7
ALT or GPT (IU/L): 94.0
AST or GOT (IU/L): 95.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 3,9
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 823.0
Protein (g/L): 85
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,18
TSH (mIU/L): 2,38
Urea (mg/dL): 6,91
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and elevated Pro-BNP levels suggest that the patient has a significant burden of cardiac disease. However, the patient's LVEF is 60%, which indicates some degree of preserved cardiac function. The absence of significant ventricular arrhythmias and the presence of medications such as beta-blockers and calcium channel blockers suggest that the patient's cardiac function is being adequately managed.

While the patient's lipid profile is not ideal, with elevated total cholesterol and LDL, the presence of statins indicates that the patient is receiving appropriate treatment for dyslipidemia. The patient's kidney function is also impaired, as indicated by elevated creatinine levels, but this is not necessarily a contraindication for survival.

The patient's troponin levels are within normal limits, which suggests that there is no acute myocardial infarction or significant cardiac damage. The absence of elevated liver enzymes (ALT and AST) also suggests that there is no significant liver disease.

Given these factors, the patient's overall prognosis is good, and it is likely that they will survive for the next few years. The patient's elevated Pro-BNP levels do suggest some degree of heart failure, but the presence of beta-blockers and other medications suggests that the patient's heart function is being adequately managed, and the patient's overall clinical presentation does not suggest a high risk of sudden cardiac death or pump failure.

RANKING: 2. Pump failure death
REASONING: 

While the patient's Pro-BNP levels are elevated, suggesting some degree of heart failure, the presence of beta-blockers and other medications suggests that the patient's heart function is being adequately managed. However, the patient's LVEF is only 60%, which indicates a significant reduction in cardiac function.

The patient's kidney function is also impaired, which can increase the risk of heart failure. The patient's lipid profile is also not ideal, which can increase the risk of cardiovascular events.

Given these factors, while the patient's heart function is being managed, there is a risk of pump failure in the next few years. However, this is not the most likely outcome, as the patient's overall clinical presentation does not suggest a high risk of sudden cardiac death.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's age, NYHA Class II, and elevated Pro-BNP levels suggest that the patient has a significant burden of cardiac disease. The absence of significant ventricular arrhythmias on the ECG is reassuring, but the patient's LVEF is only 60%, which indicates a significant reduction in cardiac function.

The patient's lipid profile is also not ideal, which can increase the risk of cardiovascular events. The patient's kidney function is also impaired, which can increase the risk of cardiovascular events.

Given these factors, while the patient's heart function is being managed, there is a risk of sudden cardiac death in the next few years. However, this is the least likely outcome, as the patient's overall clinical presentation does not suggest a high risk of sudden cardiac death. The patient's elevated Pro-BNP levels and impaired kidney function suggest a higher risk of pump failure, and the patient's LVEF is a more significant concern for pump failure than sudden cardiac death."
403,403,P0645,"Age: 59
Gender: Male 
Weight: 85 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44,3
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,84
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 395.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,7
Urea (mg/dL): 4,68
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age, NYHA Class II, and the presence of multiple comorbid conditions such as ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, would suggest a relatively high risk for adverse outcomes. However, the patient is currently taking multiple medications, including beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, which are commonly used to manage heart failure and reduce cardiovascular risk. The patient's hemoglobin level is slightly elevated, which could indicate some degree of anemia, but this is not uncommon in patients with heart failure. The patient's LVEF is 39%, which is within the range of patients with heart failure, but it is on the lower end of the spectrum. The absence of significant elevations in liver enzymes (ALT and AST) and the relatively low level of creatinine suggest that the patient's kidney function is not severely impaired. The presence of a low level of T3 (0.05 pg/dL) and the low Pro-BNP level (395 ng/L) suggest that the patient's heart is not producing excessive amounts of B-type natriuretic peptide, which is often elevated in heart failure. The absence of significant ECG abnormalities and the lack of evidence of cardiac ischemia or infarction on the ECG also suggest that the patient's heart is not at high risk for sudden cardiac death. Overall, considering the patient's multiple comorbid conditions and the presence of heart failure, but also the absence of significant elevations in liver enzymes, kidney function, and cardiac biomarkers, the patient's prognosis is more favorable than one of sudden cardiac death or pump failure."
404,404,P0646,"Age: 61
Gender: Male 
Weight: 74 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 47,59
ALT or GPT (IU/L): 53.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,66
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 174.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,12
Urea (mg/dL): 10,24
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, hypertension, dyslipidemia, and a history of myocardial infarction. The patient's ejection fraction (LVEF) is significantly reduced at 35%, indicating poor cardiac function.

Despite these factors, the patient's current ECG findings are not indicative of acute cardiac stress or acute coronary syndrome. The absence of troponin elevation and no recent myocardial infarction suggests that the patient is not currently experiencing an acute cardiac event.

The patient's current medications, including an angiotensin II receptor blocker, loop diuretics, statins, ACE inhibitor, and nitrovasodilator, are aimed at managing the patient's hypertension, heart failure, and dyslipidemia. These medications are generally effective in managing the patient's comorbidities and may help to reduce the risk of cardiac events.

The patient's biomarkers, including creatinine, urea, and liver enzymes, are within relatively normal limits, suggesting that there are no acute kidney or liver issues. The patient's hemoglobin and potassium levels are also within normal limits.

Given the patient's age, comorbidities, and current medical management, the most likely outcome is that the patient will survive. However, it is essential to closely monitor the patient's cardiac function and adjust the treatment plan as needed to minimize the risk of cardiac events.

While the patient's ECG findings are concerning, the absence of sustained ventricular tachycardia and the presence of a nitrovasodilator, which can help to regulate blood pressure, suggests that the patient is not at high risk of sudden cardiac death. The patient's current medication regimen and the absence of any acute cardiac events make pump failure death the least likely outcome."
405,405,P0648,"Age: 72
Gender: Female 
Weight: 78 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39,9
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,6
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 126.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2
Urea (mg/dL): 8,46
LVEF (%): 60.0
Medications: Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
This patient is likely to survive for the next few years due to several factors:

- Age: Although the patient is 72 years old, the age itself is not a significant predictor of mortality in this case. Many patients with advanced heart disease can survive for several years with proper management.
- NYHA Class II: The patient's New York Heart Association (NYHA) Class II indicates that the patient has some limitation in physical activity due to heart disease, but it's not severe. This suggests that the patient is still relatively functional and has some capacity to tolerate physical activity.
- Medications: The patient is already taking beta blockers, which are a common treatment for heart failure and hypertension. This suggests that the patient is receiving some level of medical management for their condition.
- Blood test results: The patient's blood test results, such as the elevated creatinine level, indicate some degree of kidney impairment, but it's not severe enough to suggest end-stage renal disease.
- LVEF: The left ventricular ejection fraction (LVEF) is 60%, which is below the normal range, indicating some degree of left ventricular dysfunction. However, it's not severely impaired, which suggests that the patient's heart is still capable of pumping blood effectively.
- Other factors: The patient's blood pressure is elevated, but it's not extremely high. The patient also has a history of hypertension, dyslipidemia, and diabetes, which are all risk factors for cardiovascular disease, but the patient is already managing these conditions with medication.

Given these factors, I believe that this patient is likely to survive for the next few years with proper management and monitoring.

2. Pump failure death
REASONING:
This patient is at risk of pump failure death due to several factors:

- NYHA Class II: The patient's NYHA Class II indicates some limitation in physical activity, which may lead to reduced cardiac output and increased risk of pump failure.
- LVEF: The patient's LVEF is 60%, which is below the normal range, indicating some degree of left ventricular dysfunction. This could lead to reduced cardiac output and increased risk of pump failure.
- Elevated creatinine level: The patient's elevated creatinine level indicates some degree of kidney impairment, which can lead to fluid overload and increased risk of pump failure.
- Medications: The patient is already taking beta blockers, which can help reduce cardiac workload, but may not be enough to prevent pump failure in this case.

Given these factors, I believe that this patient is at risk of pump failure death, but the likelihood is lower than the survivor outcome.

3. Sudden cardiac death
REASONING:
This patient is at risk of sudden cardiac death due to several factors:

- NYHA Class II: The patient's NYHA Class II indicates some limitation in physical activity, which may lead to increased risk of arrhythmias and sudden cardiac death.
- Elevated Troponin level: The patient's elevated Troponin level indicates some degree of cardiac damage, which can lead to arrhythmias and sudden cardiac death.
- ECG Impression: The patient's ECG shows ventricular extrasystole, which is a risk factor for sudden cardiac death.
- Medications: The patient is already taking beta blockers, which can help reduce cardiac workload, but may not be enough to prevent sudden cardiac death in this case.

Given these factors, I believe that this patient is at risk of sudden cardiac death, but the likelihood is lower than the pump failure death outcome."
406,406,P0652,"Age: 68
Gender: Female 
Weight: 62 kg
Height: 144 cm
NYHA Class: II
Blood Pressure: 200/110 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,1
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,39
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 71,7
T4 (ng/L): 15
TSH (mIU/L): 5,21
Urea (mg/dL): 5,49
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, hypertension, and left ventricular systolic dysfunction (LVEF 35%), the patient is at high risk for cardiac events. The elevated blood pressure (200/110 mmHg) and elevated creatinine (78.0 mmol/L) levels indicate severe hypertension and possible renal impairment. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG impression suggest a high risk for arrhythmias and cardiac events.

The patient's low ejection fraction (LVEF 35%) and elevated BNP levels (170.0 ng/L) indicate significant left ventricular dysfunction, which is a predictor of adverse outcomes in patients with heart failure. The patient's elevated troponin levels (ALT or GPT 11.0 IU/L) may indicate cardiac damage.

However, the patient is already on medications for hypertension (Calcium Channel Blocker, Loop Diuretics, ACE Inhibitor) and has a relatively well-controlled blood pressure. The patient's hemoglobin level (144.0 g/L) and liver enzymes are within normal limits, and the patient does not have any other significant medical conditions.

Considering these factors, the most likely prognosis for the patient is a survivor, as they are already receiving treatment for their underlying conditions and have not presented with any acute life-threatening symptoms."
407,407,P0653,"Age: 73
Gender: Male 
Weight: 88 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45,3
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,15
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,37
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 655.0
Protein (g/L): 80
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 10,69
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall health status and clinical presentation suggest that they are at high risk for adverse cardiac events, but the presence of a positive outcome (PATIENT OUTCOME: survivor) indicates that the patient has survived the acute event or has not had a cardiac arrest. 

The patient's age, NYHA Class III, and history of cardiomyopathy, diabetes, and hypertension all contribute to an increased risk of cardiac complications. The elevated creatinine level (124.0) and low LVEF (39.0) indicate significant cardiac dysfunction. However, the patient has been prescribed medications that are commonly used to manage heart failure and arrhythmias, such as beta blockers, loop diuretics, and ACE inhibitors.

The elevated troponin level (0.01 ng/mL) suggests some myocardial damage, but it is not excessively high, which may indicate a relatively recent event. The presence of ventricular extrasystole (polymorphic) on the ECG, however, is concerning and indicates a possible risk for arrhythmias.

The patient's laboratory results show a range of abnormalities, including elevated creatinine, low albumin, and high glucose, which are consistent with chronic kidney disease and diabetes. However, the patient's overall health status and the fact that they have survived the acute event suggest that they are likely to continue receiving care and treatment.

Given these factors, I believe that the patient is most likely to survive the next few years, provided they continue to receive appropriate medical care and management of their underlying conditions."
408,408,P0654,"Age: 70
Gender: Female 
Weight: 75 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,73
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1789.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,09
Urea (mg/dL): 8,46
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, this patient is at a high risk for cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. Additionally, the patient has a low LVEF (25.0%) indicating poor cardiac function, which is also a risk factor for sudden cardiac death. The presence of non-sustained ventricular tachycardia (NST) on the ECG, which is a marker for ventricular arrhythmias, further increases the risk of sudden cardiac death. Furthermore, the patient's low ejection fraction and elevated BNP levels suggest that the heart is under significant stress, which can contribute to cardiac events. The patient's age, gender, and comorbidities (diabetes, peripheral vascular disease, and hypertension) also contribute to the overall risk. However, the patient's current medications (beta blockers, statins, and ACE inhibitor) are being used to manage these conditions, which may help mitigate some of the risks. Overall, while there are several risk factors present, the patient's current medical management and the fact that the patient is currently alive and being monitored suggest that the patient is more likely to survive in the next few years."
409,409,P0655,"Age: 55
Gender: Male 
Weight: 107 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 46,1
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 159.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,08
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 408.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,96
Urea (mg/dL): 6,91
LVEF (%): 24.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation, laboratory results, and ECG findings suggest a high risk for cardiac complications, but the patient is currently being treated with a comprehensive regimen of medications that includes beta blockers, loop diuretics, statins, and an ACE inhibitor. These medications are commonly used to manage symptoms and slow the progression of heart failure, reduce the risk of further cardiac events, and improve overall cardiac function.

The patient's left ventricular ejection fraction (LVEF) of 24.0% is significantly reduced, indicating poor cardiac function, but the patient is still alive and not showing signs of acute cardiac distress. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a concern, but it is not a new finding, and the patient is already being treated with beta blockers, which are effective in reducing the risk of arrhythmias.

The patient's serum creatinine level is elevated at 108.0, indicating impaired renal function, which is a common complication in patients with heart failure. However, the patient is being treated with loop diuretics, which are commonly used to manage fluid overload and improve renal function in patients with heart failure.

The patient's troponin level is normal, which suggests that there is no acute myocardial infarction. The patient's BNP level is elevated at 408.0, which indicates increased ventricular stress and strain, but it is not indicative of cardiac failure.

Given the patient's age, comorbidities, and current treatment regimen, the patient is at high risk for cardiac complications, but the presence of a comprehensive treatment plan and the absence of acute cardiac distress suggest that the patient is likely to survive for the next few years."
410,410,P0658,"Age: 59
Gender: Male 
Weight: 69 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,82
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 469.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,53
Urea (mg/dL): 12,47
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 59-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction. The patient has a NYHA Class II heart failure, indicating moderate symptoms of heart failure. 

The patient's LVEF is significantly reduced at 39%, which is a strong indicator of advanced cardiac dysfunction. The patient's elevated BNP levels (469.0 ng/L) also suggest severe cardiac stress and potential heart failure. The presence of ventricular extrasystoles on the ECG is concerning, as it may indicate an increased risk of arrhythmias and potentially life-threatening ventricular fibrillation.

Despite the presence of several comorbidities, the patient is on multiple medications, including beta blockers, statins, ACE inhibitors, and a nitrovasodilator, which are commonly used to manage heart failure and reduce the risk of cardiac events. The patient's blood pressure is well-controlled at 130/60 mmHg.

Considering the patient's advanced cardiac dysfunction, comorbidities, and the presence of ventricular extrasystoles, the likelihood of pump failure death is relatively high. However, the patient's controlled blood pressure and the presence of multiple medications suggest that the patient is receiving adequate treatment.

Therefore, while the patient's prognosis is guarded, I would rank the patient as a survivor, with a moderate to high risk of cardiac events, but with the potential for successful management and treatment."
411,411,P0659,"Age: 77
Gender: Male 
Weight: 68 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 140/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 48,3
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,72
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1071.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 6,33
Urea (mg/dL): 13,36
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is a 77-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and dyslipidemia. His current NYHA Class is II, indicating mild heart failure symptoms. The patient's ECG impression shows ventricular extrasystole, which is a benign finding, and no other significant arrhythmias.

The patient's laboratory results show elevated liver enzymes (ALT and AST), indicating liver dysfunction, but no significant renal impairment. The patient's electrolyte levels are mostly within normal limits. The patient's renal function is slightly impaired (creatinine 138.0 mmol/L), but this is not uncommon in patients with heart failure.

The patient's LVEF is 50.0%, which is significantly reduced, indicating poor cardiac function. However, this is consistent with the patient's history of ischemic dilated cardiomyopathy.

The patient is currently taking medications that are commonly used in heart failure management (beta blockers, loop diuretics, statins, and ACE inhibitor), which suggests that the patient is receiving standard care for his condition.

Given these factors, the most likely outcome for the next few years is that the patient will survive, as the patient's heart failure is not severe enough to cause significant morbidity or mortality. The patient's liver dysfunction may require monitoring and management, but it is not a significant predictor of mortality in this patient.

RANKING 2: 
Sudden cardiac death
REASONING:
While the patient's LVEF is significantly reduced, there is no indication of acute cardiac injury or ischemia, which is a common precursor to sudden cardiac death. The patient's ECG impression does not show any significant arrhythmias that could increase the risk of sudden cardiac death.

RANKING 3: 
Pump failure death
REASONING:
The patient's LVEF is significantly reduced, indicating poor cardiac function. However, the patient is currently taking medications that are commonly used to manage heart failure, and the patient's liver dysfunction is not severe enough to significantly impact cardiac function. While the patient is at risk of heart failure exacerbation, the patient's NYHA Class is II, indicating mild symptoms, and the patient is likely to be managed effectively with current treatment.

It is worth noting that the patient's age and comorbidities (e.g., hypertension, dyslipidemia) increase the risk of pump failure, but the patient's current condition is not severe enough to warrant a high-risk prognosis."
412,412,P0660,"Age: 49
Gender: Male 
Weight: 81 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 155/80 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 50,59
ALT or GPT (IU/L): 56.0
AST or GOT (IU/L): 53.0
Total Cholesterol (mmol/L): 7,89
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 821
Glucose (mmol/L): 11
Hemoglobin (g/L): 166.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,1
LDL (mmol/L): 5,02
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 114.0
Protein (g/L): 86
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 11,8
Urea (mg/dL): 6,91
LVEF (%): 50.0
Medications: Diabetes Medication, Amiodarone, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient is a 49-year-old male with a history of valvular cardiomyopathy, diabetes, and hypertension, which are all significant risk factors for cardiac complications. The patient's current NYHA Class II indicates moderate symptoms, suggesting some limitation in physical activity. The elevated creatinine level (103.0 mmol/L) and low LVEF (50.0%) further indicate compromised cardiac function.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may be related to the underlying cardiomyopathy. The high albumin level (50.59 g/L) and low hemoglobin level (16.0 g/L) suggest possible liver dysfunction or chronic disease. The elevated Pro-BNP level (114.0 ng/L) and high TSH level (11.8 mIU/L) suggest cardiac strain and possible thyroid dysfunction.

The ECG results show ventricular extrasystoles, which may indicate a risk of arrhythmias. However, the absence of ventricular tachycardia or bradycardia reduces the likelihood of sudden cardiac death.

Considering the patient's overall clinical picture, including the compromised cardiac function, elevated liver enzymes, and thyroid dysfunction, I rank the patient as a survivor with a moderate risk of pump failure death. The presence of ventricular extrasystoles and elevated Pro-BNP level increase the risk of cardiac complications, but the patient's overall prognosis is still favorable due to the absence of other high-risk factors.

Pump failure death is a possible outcome due to the patient's compromised cardiac function, but it is less likely than survivor due to the presence of some residual cardiac reserve and the absence of other high-risk factors.

Sudden cardiac death is the least likely outcome, as the ECG results do not indicate a high risk of life-threatening arrhythmias, and the patient's overall clinical picture is more consistent with chronic cardiac dysfunction rather than an acute cardiac event."
413,413,P0662,"Age: 61
Gender: Female 
Weight: 64 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 135/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,9
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 191.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,95
Urea (mg/dL): 11,36
LVEF (%): 60.0
Medications: Diabetes Medication, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 61-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. Despite the presence of these comorbid conditions, her current lab values and ECG findings suggest that she is not in immediate cardiac failure. Her LVEF is 60%, which is within the range of normal for her age group, and her troponin levels are within the normal range. Her medication regimen includes beta blockers and statins, which are commonly used to manage heart failure and cardiovascular risk factors.

The patient's creatinine level is slightly elevated, but it is not indicative of severe kidney dysfunction. Her liver function tests (ALT and AST) are within the normal range, and her albumin level is slightly low but not severely low. Her sodium level is also slightly low, but this can be attributed to her diabetes and other comorbid conditions.

The patient's ECG findings do not indicate any acute cardiac arrhythmias or signs of heart failure. The presence of ventricular extrasystole may be a sign of underlying cardiac disease, but it is not uncommon in patients with ischemic cardiomyopathy. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac function is stable.

Overall, considering the patient's age, comorbid conditions, and the absence of acute cardiac findings, I believe that the patient has a good prognosis and is likely to survive for the next few years."
414,414,P0663,"Age: 66
Gender: Male 
Weight: 117 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 160/105 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45,59
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,79
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 419.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,79
Urea (mg/dL): 8,02
LVEF (%): 50.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with ischemic dilated cardiomyopathy, hypertension, dyslipidemia, and a history of myocardial infarction. Despite these risk factors, the patient's current symptoms and test results do not indicate an immediate life-threatening situation. The patient's left ventricular ejection fraction (LVEF) is 50%, which is within the range of 40-50% typically seen in patients with heart failure with reduced ejection fraction (HFrEF). 

The patient's troponin level is normal, and there is no evidence of acute myocardial infarction. The patient's ECG shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia. The patient's pro-BNP level is elevated, indicating some degree of heart failure, but the patient is currently being treated with an ACE inhibitor, which is standard therapy for heart failure.

Given these factors, I believe that the patient is likely to survive for the next few years. The patient's weight and blood pressure are also not extreme, which may contribute to a more favorable prognosis.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient has a complex medical history, the lack of acute symptoms and abnormal ECG findings makes sudden cardiac death less likely. However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. The patient's LVEF is 50%, which is below the normal range, indicating some degree of heart failure.

The patient's ECG shows ventricular extrasystoles, which may be a sign of arrhythmia. However, the patient is being treated with an ACE inhibitor, which may help reduce the risk of arrhythmias.

While the patient's risk of sudden cardiac death is not zero, the lack of acute symptoms and abnormal ECG findings makes this outcome less likely compared to the survivor prognosis.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF is 50%, which indicates some degree of heart failure. The patient's pro-BNP level is elevated, indicating some degree of heart failure. The patient's history of ischemic dilated cardiomyopathy and hypertension also increases the risk of pump failure.

However, the patient is currently being treated with an ACE inhibitor, which is standard therapy for heart failure. The patient's blood pressure is not extremely high, and the patient's weight is not significantly overweight.

While the patient's risk of pump failure is not zero, the fact that the patient is currently being treated and the lack of acute symptoms make this outcome less likely compared to the sudden cardiac death prognosis."
415,415,P0664,"Age: 59
Gender: Male 
Weight: 105 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 11,2
Hemoglobin (g/L): 152.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,64
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 135.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,56
Urea (mg/dL): 12,03
LVEF (%): 22.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, I predict a high likelihood of the patient surviving for the next few years. The patient's age, NYHA class III, and elevated LVEF (22%) indicate significant heart failure. However, the absence of any life-threatening arrhythmias on the ECG, normal blood pressure, and the presence of a low T3 level suggest that the patient is not in a critical state. The patient's elevated troponin level may indicate some degree of myocardial damage, but it is not excessively high. The patient is already on medications for heart failure, diabetes, and hypertension, which will likely help manage their conditions. The patient's laboratory values, including normal kidney function and low creatinine level, also indicate that they do not have significant organ dysfunction. Overall, these factors suggest that the patient is at a relatively stable condition, and with proper management, they are likely to survive for the next few years."
416,416,P0666,"Age: 71
Gender: Female 
Weight: 86 kg
Height: 147 cm
NYHA Class: III
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,2
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,85
Creatinine (mmol/L): 272.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2627.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,06
Urea (mg/dL): 31,4
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient's prognosis is classified as survivor due to the presence of multiple comorbid conditions, but the overall clinical presentation does not suggest an immediate life-threatening situation. The patient's NYHA Class III indicates severe heart failure, but the LVEF is 65%, which is not severely impaired. The patient's biomarkers, such as troponin and creatinine, are not significantly elevated, suggesting that the heart is not under acute stress. The patient's ECG findings, while showing ventricular extrasystole, do not indicate a high risk for sudden cardiac death. The patient's medications, including beta blockers and loop diuretics, are commonly used to manage heart failure and hypertension, and the patient's laboratory results do not indicate acute kidney injury or severe liver dysfunction. Overall, the patient's clinical presentation suggests that they can be managed with current treatment and may be able to survive the next few years without significant adverse events."
417,417,P0668,"Age: 67
Gender: Female 
Weight: 70 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 45,7
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 7
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,77
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1356.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,39
Urea (mg/dL): 14,92
LVEF (%): 68.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and laboratory results suggest a moderate to advanced heart failure, as indicated by a left ventricular ejection fraction (LVEF) of 68%, which is below the normal range of 55-70%. The elevated BNP level (1356 ng/L) is also consistent with heart failure, as BNP levels are typically elevated in patients with heart failure. The presence of hypertension, diabetes, and dyslipidemia further supports this diagnosis.

The patient's past medical history of hypertensive cardiomyopathy and peripheral vascular disease increases the risk of cardiovascular events. However, the absence of any evidence of acute coronary syndrome or acute heart failure exacerbation in the ECG impression and the fact that the patient is already on medications for heart failure (Calcium Channel Blocker, Beta Blockers, Loop Diuretics, ACE Inhibitor) suggest that the patient is being adequately managed for their heart failure.

The patient's laboratory results, including the mild elevation of liver enzymes (ALT and AST), indicate some degree of liver dysfunction, which may be related to their underlying heart failure or other comorbid conditions. However, the absence of significant abnormalities in other laboratory tests, such as kidney function (creatinine) and electrolytes (potassium), suggests that the patient's overall cardiovascular and renal function is not severely compromised.

Given these factors, the patient's overall prognosis is likely to be a survivor, with a moderate risk of cardiovascular events, but without evidence of acute heart failure or significant cardiac arrhythmias."
418,418,P0669,"Age: 80
Gender: Male 
Weight: 74 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43,1
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,77
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 901.0
Protein (g/L): 78,3
T4 (ng/L): 16
TSH (mIU/L): 7,12
Urea (mg/dL): 15,64
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient is at high risk for cardiac complications due to a history of ischemic dilated cardiomyopathy, myocardial infarction, and diabetes. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 40%, indicating poor cardiac function. The presence of ventricular extrasystoles on the ECG also suggests underlying ventricular dysfunction. Additionally, the patient's elevated creatinine level (138.0 mmol/L) and elevated Pro-BNP level (901.0 ng/L) indicate compromised cardiac function and potential fluid overload. However, the patient's NYHA class II symptoms suggest that they are not yet in advanced stages of heart failure. The patient is also on medications that can help manage these conditions, such as spironolactone and statins. Given these factors, the most likely prognosis for this patient is survival, with ongoing monitoring and management of their conditions being crucial to prevent further cardiac complications.

2. Sudden cardiac death
REASONING: 
While the patient is at high risk for cardiac complications, the patient's NYHA class II symptoms and the presence of medications that can help manage these conditions suggest that they are not at immediate risk for sudden cardiac death. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG also reduces the likelihood of sudden cardiac death. However, the patient's reduced LVEF and elevated Pro-BNP level still indicate compromised cardiac function, and the presence of ventricular extrasystoles on the ECG suggests underlying ventricular dysfunction. While the patient's overall prognosis is still guarded, the likelihood of sudden cardiac death is lower than for the other two options.

3. Pump failure death
REASONING: 
Given the patient's reduced LVEF and elevated Pro-BNP level, pump failure is a significant concern. The patient's NYHA class II symptoms suggest that they are experiencing some level of heart failure, and their elevated creatinine level indicates compromised renal function. However, the patient is on medications that can help manage these conditions, such as spironolactone and statins. While pump failure is a possible outcome, the patient's overall prognosis is still relatively stable, and ongoing monitoring and management of their conditions can help mitigate this risk. The patient's reduced LVEF and elevated Pro-BNP level make pump failure a more likely outcome than sudden cardiac death, but it is still a possibility rather than a certainty."
419,419,P0670,"Age: 75
Gender: Female 
Weight: 73 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44,8
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 67
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,79
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 359.0
Protein (g/L): 69,7
T4 (ng/L): 17
TSH (mIU/L): 1,28
Urea (mg/dL): 6,99
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the patient's age, NYHA Class II, and the presence of multiple comorbidities such as Hypertropic cardiomyopathy, Diabetes, Dyslipemia, and Hypertension, the patient is at a higher risk of cardiovascular events. However, the patient's LVEF is 40%, which is relatively preserved, indicating that the heart is still functioning to some extent. The patient's ECG findings show no evidence of ventricular tachycardia or arrhythmias, which is a positive prognostic sign. The patient is also taking medications that are commonly used to manage cardiovascular risk factors, such as ACE inhibitors, statins, and loop diuretics. Therefore, while the patient is at risk, the combination of preserved LVEF and absence of life-threatening arrhythmias suggests that the patient is likely to survive for the next few years.

2. Sudden Cardiac Death
REASONING: 
While the patient's comorbidities and LVEF are concerning, the patient's ECG findings do not show any evidence of ventricular tachycardia or arrhythmias. However, the patient's Hypertropic cardiomyopathy is a significant risk factor for sudden cardiac death. Additionally, the patient's elevated Pro-BNP levels (359.0 ng/L) suggest some degree of heart failure, which may increase the risk of sudden cardiac death. However, the patient's preserved LVEF and absence of life-threatening arrhythmias on ECG suggest that the risk of sudden cardiac death is lower than expected.

3. Pump Failure Death
REASONING: 
The patient's LVEF is 40%, which is significantly reduced, indicating that the patient's heart is not functioning optimally. The patient's elevated creatinine levels (6.99 mg/dL) and urea levels (6.99 mg/dL) suggest some degree of renal impairment, which may be related to heart failure. Additionally, the patient's Hypertropic cardiomyopathy and Diabetes are risk factors for heart failure. The patient's elevated Pro-BNP levels and NYHA Class II symptoms suggest that the patient is experiencing some degree of heart failure. Therefore, while the patient is at risk, the patient's reduced LVEF and evidence of heart failure suggest that pump failure death is a possible but less likely outcome than sudden cardiac death."
420,420,P0672,"Age: 70
Gender: Female 
Weight: 66 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 42,5
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 824.0
Protein (g/L): 69,7
T4 (ng/L): 16
TSH (mIU/L): 3,09
Urea (mg/dL): 5,99
LVEF (%): 35.0
Medications: Diabetes Medication, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy are significant risk factors for adverse cardiac events. However, the patient's current hemoglobin level (130.0 g/L) and lack of evidence of acute coronary syndrome or acute heart failure suggest that the patient is not in an acute decompensated state.

The patient's LVEF of 35.0% indicates significant left ventricular dysfunction, which is a predictor of adverse outcomes. However, the patient's ejection fraction is not severely impaired, which may suggest that the patient is still tolerating some level of cardiac output.

The patient's serum creatinine level (5.99 mg/dL) is elevated, indicating some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's other laboratory values, including liver enzymes and electrolytes, are within normal limits.

The patient's ECG shows ventricular extrasystoles, which may be a marker of increased sympathetic tone or underlying myocardial ischemia, but there is no evidence of ventricular tachycardia or other arrhythmias that could indicate a higher risk of sudden cardiac death.

Given these factors, the patient's overall prognosis is more favorable than the other options. While the patient has significant cardiac dysfunction and risk factors for adverse outcomes, the patient's current clinical status and laboratory values do not indicate an immediate life-threatening condition. Therefore, the most likely outcome is survival.

2. Sudden cardiac death
REASONING:
The patient's LVEF of 35.0% and NYHA Class II indicate significant left ventricular dysfunction, which increases the risk of sudden cardiac death. The patient's ECG shows ventricular extrasystoles, which may be a marker of underlying myocardial ischemia or increased sympathetic tone.

The patient's elevated serum creatinine level (5.99 mg/dL) and elevated LDLC (2.87 mmol/L) may indicate some degree of renal impairment and cardiovascular disease. The patient's elevated Pro-BNP level (824.0 ng/L) suggests some degree of cardiac stress.

While the patient's current clinical status and laboratory values do not indicate an immediate life-threatening condition, the patient's underlying cardiac dysfunction and risk factors for adverse outcomes make it possible that the patient could experience a cardiac event in the near future.

3. Pump failure death
REASONING:
The patient's LVEF of 35.0% indicates significant left ventricular dysfunction, which increases the risk of heart failure. The patient's NYHA Class II indicates some degree of limitation of physical activity, which may be a sign of cardiac decompensation.

The patient's elevated serum creatinine level (5.99 mg/dL) and elevated Pro-BNP level (824.0 ng/L) suggest some degree of cardiac stress and possible heart failure. The patient's elevated LDLC (2.87 mmol/L) and low HDL (1.55 mmol/L) may indicate an increased risk of cardiovascular disease.

However, the patient's current clinical status and laboratory values do not indicate an immediate life-threatening condition. The patient is on medications for diabetes and hypertension, which may help manage these conditions. While the patient's cardiac dysfunction and risk factors for adverse outcomes make it possible that the patient could experience heart failure, the patient's current status is not severe enough to justify a prediction of pump failure death."
421,421,P0673,"Age: 79
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45,2
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 60.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,99
Potassium (mEq/L): 3,6
LDL (mmol/L): 2,56
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 58.0
Protein (g/L): 68,9
T4 (ng/L): 15
TSH (mIU/L): 1,63
Urea (mg/dL): 4,99
LVEF (%): 67.0
Medications: Calcium Channel Blocker, Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

The patient is 79 years old, which is a high-risk age group for cardiovascular events. However, the patient has a relatively preserved LVEF of 67.0%, which is within the normal range for most adults. The patient's NYHA Class II indicates mild symptoms, suggesting that they are not severely limited by their heart disease. 

The patient's blood pressure is elevated at 150/85 mmHg, but this is not uncontrolled and is being managed with medications. The patient's lipid profile is also elevated, but the patient is receiving statin therapy, which is indicated for secondary prevention. 

The patient's kidney function is slightly impaired, with a creatinine level of 60.0 mg/dL. However, this is not severe and is likely being managed with medications. The patient's liver function is also slightly elevated, with a GGT level of 12 IU/L, but this is not significantly elevated.

The patient's ECG shows a polymorphic ventricular extrasystole, which is a concerning sign, but it is not a new finding. The patient has a history of hypertension and cardiomyopathy, which can contribute to ventricular arrhythmias.

The patient's biomarkers, including troponin, creatinine, and liver enzymes, are within normal limits. The patient's glucose and hemoglobin levels are also within normal limits.

Given these factors, the patient is likely to survive for the next few years. The patient's medications, including beta blockers, calcium channel blockers, and nitrovasodilators, are effective in managing the patient's hypertension and heart failure symptoms. The patient's ECG findings, while concerning, do not indicate a sudden cardiac death risk.

While the patient is at risk for cardiovascular events, the combination of a relatively preserved LVEF, mild symptoms, and effective medication management suggest that the patient is likely to survive for the next few years."
422,422,P0674,"Age: 66
Gender: Male 
Weight: 71 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,5
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 6,52
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,03
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 209.0
Protein (g/L): 71,3
T4 (ng/L): 12
TSH (mIU/L): 1,1
Urea (mg/dL): 5,99
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

The patient's overall health status and medical history suggest that they are at high risk for cardiac complications. The patient has a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which are all significant risk factors for heart failure and arrhythmias. The patient's current NYHA Class II classification indicates moderate symptoms of heart failure, which can further increase the risk of complications.

The patient's laboratory results also support this assessment. The elevated creatinine level (95.0 mmol/L) and LVEF (35.0%) indicate impaired renal function and reduced left ventricular function, respectively. The elevated BNP level (209.0 ng/L) suggests significant ventricular stress and strain.

The patient's ECG findings of ventricular extrasystole, although not sustained, indicate a high risk of arrhythmias. The absence of sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia does not rule out the possibility of sudden cardiac death, as ventricular extrasystoles can still lead to sudden cardiac death.

Given these factors, the patient's prognosis is most likely to be a survivor, as they are receiving treatment with loop diuretics and an ACE inhibitor, which can help manage symptoms of heart failure and reduce the risk of complications. However, the patient's high risk of arrhythmias and cardiac complications makes it less likely that they will survive for an extended period without any significant cardiac events.

The risk of sudden cardiac death is still present, especially given the patient's history of ventricular extrasystole and elevated BNP levels. However, the fact that the ECG did not show sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia makes this outcome less likely.

Pump failure death is the least likely outcome, as the patient is receiving treatment and has a relatively preserved kidney function (creatinine level is not severely elevated). However, the patient's reduced LVEF and elevated BNP levels suggest that their cardiac function is compromised, which increases the risk of pump failure."
423,423,P0675,"Age: 55
Gender: Male 
Weight: 74 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,34
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,39
Hemoglobin (g/L): 121.0
HDL (mmol/L): 2,4
Potassium (mEq/L): 4,96
LDL (mmol/L): 2,75
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 447.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 12,72
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,38
Urea (mg/dL): 4,2
LVEF (%): 50.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I would rank the patient as a survivor for the next few years. The patient's LVEF of 50% indicates significant left ventricular dysfunction, which is a common finding in patients with ischemic dilated cardiomyopathy. However, the patient's ejection fraction is not severely impaired, which may indicate that the patient has some residual cardiac function.

The patient's medication regimen includes beta blockers, statins, ACE inhibitors, and a nitrovasodilator, which are all standard treatments for patients with heart failure and coronary artery disease. These medications may help to slow the progression of cardiac dysfunction and improve symptoms.

The patient's laboratory results are also relatively stable, with no significant elevations in liver enzymes or creatinine levels, which could indicate worsening cardiac function. The patient's electrolyte levels are also within normal limits, which suggests that there is no acute electrolyte imbalance that could contribute to cardiac arrhythmias.

The ECG impression shows no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are both potential predictors of sudden cardiac death. The presence of paroxysmal supraventricular tachycardia (PSVT) is noted, but it is not considered a high-risk arrhythmia.

Overall, the patient's clinical presentation and laboratory results suggest that the patient is at moderate to high risk for cardiac events, but the patient's medication regimen and relatively stable laboratory results suggest that the patient is at lower risk for sudden cardiac death and pump failure compared to the other two options."
424,424,P0676,"Age: 67
Gender: Male 
Weight: 79 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 165/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 158.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,95
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2034.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,62
Urea (mg/dL): 8,02
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 39%, indicating severe systolic dysfunction. The patient's elevated troponin levels (0.02 ng/mL) also suggest myocardial damage.

Despite these concerning factors, the patient is currently on multiple medications, including a calcium channel blocker, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension. The patient's NYHA class is III, indicating moderate symptoms of heart failure.

The patient's Pro-BNP level is elevated at 2034 ng/L, which is consistent with heart failure. However, the patient's creatinine level is not excessively high, and the patient's kidney function is not severely impaired.

The patient's ECG findings are mostly benign, with no signs of ventricular tachycardia or bradycardia. The presence of ventricular extrasystoles is a concerning sign, but it is not uncommon in patients with heart failure.

Given the patient's complex medical history, multiple comorbidities, and the presence of heart failure symptoms, the patient's prognosis is uncertain. However, the fact that the patient is currently on multiple medications and has not shown any signs of acute decompensated heart failure suggests that the patient may be able to survive with close monitoring and management.

Therefore, I would rank the patient's prognosis as a survivor, with the possibility of improved outcomes with aggressive management and lifestyle modifications."
425,425,P0677,"Age: 60
Gender: Male 
Weight: 78 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,09
LDL (mmol/L): 2,92
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 67.0
Protein (g/L): 68,5
T3 (pg/dL): 0,063
T4 (ng/L): 16,14
Troponin (ng/mL): 0,1
TSH (mIU/L): 1
Urea (mg/dL): 5,2
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
Based on the provided patient data, I predict that the patient is most likely to survive for the next few years. The patient's age (60) and NYHA Class II status indicate that they have a moderate level of heart failure, but they are not in severe heart failure. The patient's LVEF of 40% suggests significant left ventricular dysfunction, but this is not the most concerning factor in this case.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate liver dysfunction, but this is not directly related to cardiac function. The patient's electrolyte levels, including potassium, sodium, and T3 and T4 levels, are within normal limits.

The patient's medication regimen includes beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, which are all standard treatments for heart failure and coronary artery disease. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient's cardiac rhythm is relatively stable.

The patient's Pro-BNP level of 67 ng/L is elevated, indicating some degree of ventricular strain, but it is not excessively high. Overall, the combination of the patient's age, NYHA Class II status, and relatively stable cardiac rhythm, along with the absence of severe cardiac dysfunction, suggest that the patient is likely to survive for the next few years.

2. Sudden cardiac death
REASONING:
The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increase the risk of sudden cardiac death. However, the patient's LVEF of 40% is not extremely low, and the patient is on medications that are known to reduce the risk of sudden cardiac death.

The patient's ECG shows ventricular extrasystoles, which is a risk factor for sudden cardiac death. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG reduces the likelihood of sudden cardiac death.

3. Pump failure death
REASONING:
The patient's LVEF of 40% indicates significant left ventricular dysfunction, which increases the risk of pump failure. However, the patient's NYHA Class II status suggests that the patient is not in severe heart failure, and the patient is on medications that are known to improve heart function.

The patient's elevated creatinine level (95.0 mol/L) may indicate some degree of kidney dysfunction, which can be related to cardiac dysfunction. However, this is not the most concerning factor in this case.

Overall, while the patient's LVEF and creatinine level suggest some degree of cardiac dysfunction, the patient's relatively stable cardiac rhythm, absence of severe heart failure, and the presence of medications that improve heart function make pump failure death less likely."
426,426,P0678,"Age: 55
Gender: Male 
Weight: 97 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 127.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,09
LDL (mmol/L): 2,25
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 416.0
Protein (g/L): 69,6
T3 (pg/dL): 0,0435
T4 (ng/L): 13,4
Troponin (ng/mL): 0,1
TSH (mIU/L): 0,63
Urea (mg/dL): 8,2
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's NYHA Class II classification indicates moderate symptoms, but they are still able to perform daily activities without severe limitation. Their LVEF is 40%, which is significantly reduced, indicating a substantial impairment of cardiac function. However, the presence of beta blockers, ACE inhibitor, and statins suggests that the patient is receiving standard medical therapy for heart failure and high cholesterol management. The patient's creatinine level is elevated, but not severely so, indicating some degree of renal impairment. The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which can be indicative of underlying myocardial ischemia and potential arrhythmogenic conditions. Despite these factors, the patient is still alive, and their overall clinical presentation does not strongly suggest imminent cardiac catastrophe. Therefore, the most likely prognosis is that the patient will survive for the next few years.

RANKING: 
2. Sudden Cardiac Death
REASONING: 
The patient's LVEF is significantly reduced, and they have a history of myocardial infarction, which increases their risk for cardiac arrhythmias and sudden cardiac death. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests an increased risk for ventricular arrhythmias. The patient's elevated creatinine level and potential for renal impairment also increase their risk for cardiovascular complications. While the patient is receiving standard medical therapy, the presence of these factors still increases their risk for sudden cardiac death. However, the patient's survival for the next few years is still possible, but it is less likely than the survivor prognosis.

RANKING: 
3. Pump Failure Death
REASONING: 
The patient's LVEF is severely impaired, and they have a history of heart failure, which increases their risk for pump failure. The patient's elevated creatinine level and potential for renal impairment also indicate a higher risk for cardiovascular complications. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests an increased risk for arrhythmias, which can contribute to pump failure. While the patient is receiving standard medical therapy, the combination of these factors makes pump failure a significant risk for the patient. However, the patient's survival for the next few years is the least likely due to the severity of their cardiac impairment and the potential for cardiovascular complications."
427,427,P0681,"Age: 79
Gender: Female 
Weight: 55 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 7,21
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 13,4
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,14
LDL (mmol/L): 5,22
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3501.0
Protein (g/L): 66,8
T3 (pg/dL): 0,0522
T4 (ng/L): 14,85
TSH (mIU/L): 2,37
Urea (mg/dL): 7,8
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to the following reasons:

1. Age: The patient is 79 years old, which is a common age for cardiovascular disease, but not unusually old for a cardiomyopathy patient. However, age is not a strong predictor of outcome.

2. NYHA Class II: This indicates that the patient has some limitations in physical activity due to heart failure symptoms, but they are not severely impaired.

3. Medications: The patient is on beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and cardiomyopathy.

4. Laboratory results: The patient's creatinine level is elevated, but not significantly high. The liver enzymes (ALT and AST) are within normal limits. The lipid profile is also relatively normal.

5. ECG Impression: The patient has ventricular extrasystoles and non-sustained ventricular tachycardia, which are not uncommon in patients with cardiomyopathy. However, these findings do not indicate a high risk of sudden cardiac death.

6. Pro-BNP level: The patient's pro-BNP level is elevated, indicating some degree of heart failure.

Considering these factors, the patient's prognosis is relatively favorable, and they are likely to survive for several years with proper management and monitoring.

RANKING: 2. Sudden Cardiac Death
REASONING: 

This patient's prognosis is ranked as sudden cardiac death due to the following reasons:

1. Low LVEF: The patient's left ventricular ejection fraction (LVEF) is 25%, which is significantly below the normal range. This indicates severe left ventricular dysfunction.

2. ECG Impression: The patient has ventricular extrasystoles and non-sustained ventricular tachycardia, which are high-risk findings that increase the risk of sudden cardiac death.

3. Elevated creatinine level: The patient's elevated creatinine level may indicate some degree of renal impairment, which can be a predictor of poor outcome.

4. Low HDL: The patient's HDL level is very low, which is a risk factor for cardiovascular disease.

Considering these factors, the patient's prognosis is less favorable, and they are at increased risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

This patient's prognosis is ranked as pump failure death due to the following reasons:

1. Low LVEF: The patient's LVEF is 25%, which indicates severe left ventricular dysfunction and a high risk of heart failure.

2. Elevated creatinine level: The patient's elevated creatinine level may indicate some degree of renal impairment, which can be a predictor of poor outcome.

3. Elevated pro-BNP level: The patient's pro-BNP level is elevated, indicating some degree of heart failure.

4. NYHA Class II: The patient's NYHA Class II indicates some limitations in physical activity due to heart failure symptoms, which can worsen over time.

Considering these factors, the patient's prognosis is less favorable, and they are at increased risk of pump failure death. However, this ranking is less likely compared to sudden cardiac death due to the patient's relatively favorable ECG findings and the presence of beta blockers, which can help manage heart failure symptoms."
428,428,P0682,"Age: 59
Gender: Male 
Weight: 83 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 145/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44,4
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,43
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 176.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,7
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1780.0
Protein (g/L): 70
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 9,13
LVEF (%): 62.0
Medications: Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the patient's data, I would rank the patient as a survivor with a high likelihood. The key factors contributing to this prognosis include:

1. Age: While 59 is considered middle-aged, it's not old, and many patients with similar conditions can live for many years with proper management.
2. NYHA Class II: This indicates mild symptoms, which suggests that the patient's heart is still relatively functional.
3. Low ECG impression: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.
4. Low Troponin levels: Elevated Troponin levels are often associated with myocardial infarction or cardiac stress. The patient's Troponin level is within normal limits, suggesting that there is no significant myocardial damage.
5. Low Pro-BNP levels: Elevated Pro-BNP levels are often associated with heart failure. The patient's Pro-BNP level is within normal limits, indicating that the heart is not under significant stress.
6. Low Creatinine level: Elevated Creatinine levels can indicate kidney impairment, which can be a complication of heart failure. The patient's Creatinine level is within normal limits.
7. Presence of beta blockers and statins: These medications are commonly used to manage hypertension, dyslipidemia, and ischemic heart disease, which are all relevant to this patient's medical history.

While the patient has a history of ischemic dilated cardiomyopathy, hypertension, and dyslipidemia, the overall clinical picture suggests that the patient is not at high risk for sudden cardiac death or pump failure. With proper management and monitoring, I believe that the patient can be expected to survive for several years."
429,429,P0683,"Age: 62
Gender: Female 
Weight: 72 kg
Height: 144 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 7,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 8,2
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 3,8
LDL (mmol/L): 4,42
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2712.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,39
Urea (mg/dL): 8,69
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 62-year-old female with a history of hypertension, cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease. Her NYHA Class II indicates mild symptoms of heart failure, which suggests that her heart is working suboptimally but still able to maintain a relatively normal level of physical activity. Her elevated creatinine level (88.0 mmol/L) and elevated Troponin level (0.01 ng/mL) suggest some degree of cardiac stress or minor myocardial damage. However, her LVEF (70.0%) is still within a relatively normal range, and her ECG does not show any signs of acute cardiac ischemia or arrhythmia.

Given her overall clinical profile, the patient's likelihood of surviving the next few years is high. She has a moderate risk of cardiovascular events, but her current medications (angiotensin II receptor blocker, beta blockers, statins, and nitrovasodilator) are well-established treatments for her conditions, and her medical history does not suggest any acute life-threatening conditions. Additionally, her age, weight, and height do not suggest any significant comorbidities that would increase her risk of mortality.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG shows some signs of cardiac stress, such as ventricular extrasystole, the overall picture is not alarming. However, the patient's history of cardiomyopathy, hypertension, and peripheral vascular disease increases her risk of cardiovascular events. Her elevated Troponin level (0.01 ng/mL) suggests some degree of cardiac stress, but it is not high enough to suggest a significant myocardial infarction.

Given the patient's medical history and the presence of some cardiac stress indicators, there is a moderate risk of sudden cardiac death over the next few years. However, this risk is not high enough to place her in the top ranking.

RANKING: 3. Pump failure death
REASONING: 

The patient's NYHA Class II indicates mild symptoms of heart failure, and her LVEF (70.0%) is within a relatively normal range. Her current medications and medical history do not suggest any acute life-threatening conditions that would increase her risk of pump failure. However, her elevated creatinine level (88.0 mmol/L) and Troponin level (0.01 ng/mL) suggest some degree of cardiac stress or minor myocardial damage, which could potentially lead to progressive heart failure over time.

While there is a risk of pump failure, it is not the most likely outcome given the patient's overall clinical profile. Her current treatment regimen and medical history do not suggest any acute life-threatening conditions that would increase her risk of pump failure."
430,430,P0684,"Age: 71
Gender: Male 
Weight: 76 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 57.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 7,84
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,63
LDL (mmol/L): 5,64
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 78.0
Protein (g/L): 76
T3 (pg/dL): 0,0423
T4 (ng/L): 16,17
TSH (mIU/L): 0,39
Urea (mg/dL): 9,9
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall health status and medical history suggest a relatively stable condition, despite the presence of multiple comorbidities such as hypertension, diabetes, and dyslipidemia. The patient's New York Heart Association (NYHA) class II indicates mild symptoms of heart failure, which can be managed with current medications. The patient's left ventricular ejection fraction (LVEF) is 70%, which is within the normal range, indicating that the heart is still pumping effectively. The absence of significant abnormalities on the electrocardiogram (ECG) suggests that there are no acute cardiac events, such as ventricular tachycardia or tachycardia, that could indicate a high risk of sudden cardiac death. The patient's laboratory results, including normal kidney function and liver enzymes, also suggest that there are no acute complications that could impact the patient's prognosis. Overall, the combination of a stable medical history, normal ECG, and good laboratory results make a survivor the most likely outcome for this patient.

RANKING: 2. Sudden cardiac death
REASONING: While the patient's comorbidities and NYHA class II heart failure may increase the risk of cardiac events, the absence of significant abnormalities on the ECG and normal laboratory results suggest that there is no immediate indication of cardiac instability. However, the patient's age and history of hypertension, diabetes, and dyslipidemia do increase the risk of cardiovascular events. Additionally, the patient's low HDL cholesterol level (1.27 mmol/L) and elevated triglycerides may contribute to an increased risk of cardiovascular disease. While the patient's current medications, including an ACE inhibitor, are well-established treatments for hypertension and heart failure, the patient's medical history and laboratory results suggest that there may be ongoing cardiovascular risk factors that could contribute to a sudden cardiac death in the future.

RANKING: 3. Pump failure death
REASONING: The patient's NYHA class II heart failure and elevated creatinine level (118.0 mmol/L) suggest that there may be some degree of cardiac dysfunction, which could potentially lead to pump failure. However, the patient's LVEF is 70%, which is within the normal range, and the patient is currently on medications that are effective for managing heart failure. Additionally, the absence of significant abnormalities on the ECG and normal laboratory results suggest that there are no acute complications that could lead to pump failure. While the patient's medical history and laboratory results do suggest a risk of cardiovascular events, the patient's current treatment regimen and stable medical status make pump failure death less likely compared to sudden cardiac death."
431,431,P0685,"Age: 45
Gender: Male 
Weight: 119 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42,2
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,47
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 403.0
Protein (g/L): 65,9
T4 (ng/L): 22
TSH (mIU/L): 2,25
Urea (mg/dL): 4,66
LVEF (%): 37.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient has a history of dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 37.0% is below the normal range, indicating impaired cardiac function. The elevated B-type natriuretic peptide (Pro-BNP) level of 403.0 ng/L suggests cardiac strain and increased stress on the heart.

The patient's current NYHA Class II indicates mild heart failure symptoms, which is consistent with the patient's LVEF and Pro-BNP levels. The patient's medication regimen includes ACE inhibitors, beta blockers, and loop diuretics, which are standard treatments for heart failure and hypertension.

While the patient's lipid profile is not ideal, with high triglycerides and low HDL cholesterol, this is not a significant risk factor for sudden cardiac death. The patient's electrolyte levels, including potassium and sodium, are within normal ranges.

The ECG impression does not indicate any life-threatening arrhythmias, and the patient does not have any other significant comorbidities that would increase the risk of sudden cardiac death.

Considering these factors, the patient's overall prognosis is that they will likely survive for the next few years with proper management of their heart failure and hypertension. However, regular monitoring and adjustments to their medication regimen may be necessary to ensure optimal outcomes.

RANKING: 2. Pump failure death
REASONING: 

This prognosis is possible if the patient's heart failure symptoms worsen over time, leading to increased hospitalization and mortality. Factors that could contribute to this outcome include:

* Progressive decline in LVEF
* Increasing levels of Pro-BNP
* Worsening NYHA Class symptoms
* Failure to adequately control hypertension and heart failure symptoms with current medications
* Presence of other comorbidities, such as diabetes or chronic kidney disease, that could exacerbate cardiac disease

RANKING: 3. Sudden cardiac death
REASONING: 

Sudden cardiac death is a possible but less likely outcome for this patient. The patient's ECG impression does not indicate any life-threatening arrhythmias, and the patient's medication regimen includes beta blockers, which reduce the risk of sudden cardiac death. However, the patient's history of dilated cardiomyopathy and impaired LVEF make them at increased risk for arrhythmias and sudden cardiac death.

While the patient's lipid profile is not ideal, this is not a significant risk factor for sudden cardiac death. The patient's electrolyte levels, including potassium and sodium, are within normal ranges, which reduces the risk of arrhythmias.

Overall, while the patient's cardiac disease is significant, the combination of their medication regimen, lifestyle factors, and the absence of other high-risk comorbidities make sudden cardiac death less likely compared to pump failure death."
432,432,P0686,"Age: 77
Gender: Male 
Weight: 99 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 170/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,17
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 686.0
Protein (g/L): 74,9
T3 (pg/dL): 0,0543
T4 (ng/L): 14,54
Troponin (ng/mL): 0,1
TSH (mIU/L): 0,42
Urea (mg/dL): 9,6
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, hypertension, and peripheral vascular disease, which increases the risk of cardiac complications. However, the patient is currently on multiple medications, including ACE inhibitors, which are known to improve cardiovascular outcomes. The patient's current ECG findings, such as non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, are concerning but not indicative of a high-risk arrhythmia. The patient's LVEF is 40%, which is significantly reduced, indicating a poor left ventricular function. However, the patient's recent troponin levels are within normal limits, suggesting that there is no acute myocardial infarction. 

Given the patient's overall clinical picture, it is possible that the patient may experience cardiac events, but the presence of multiple medications, a relatively stable ECG, and normal troponin levels suggest that the patient may survive the next few years. However, close monitoring and adjustment of medications will be crucial to manage the patient's cardiac risk.

The patient's weight and height also suggest that they are at risk for falls and other complications related to their comorbid conditions. 

In comparison, the other two prognoses, sudden cardiac death and pump failure death, are less likely because:

- Sudden cardiac death is less likely due to the patient's stable ECG findings and normal troponin levels.
- Pump failure death is less likely due to the patient's relatively stable LVEF and the presence of ACE inhibitors, which are known to improve heart function in patients with heart failure. 

However, the patient's overall risk of cardiac complications remains significant, and close monitoring and adjustments to their treatment plan will be necessary to optimize their outcomes."
433,433,P0687,"Age: 75
Gender: Male 
Weight: 71 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 82
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,96
LDL (mmol/L): 2,77
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 5751.0
Protein (g/L): 61,3
T3 (pg/dL): 0,0348
T4 (ng/L): 16,95
TSH (mIU/L): 1,31
Urea (mg/dL): 8,1
LVEF (%): 25.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient data provided, the patient is already in a relatively advanced stage of heart failure, indicated by a left ventricular ejection fraction (LVEF) of 25%, which is significantly below the normal range. The patient also has a history of idiopathic dilated cardiomyopathy, which is a condition that can lead to progressive heart failure.

The patient's symptoms, such as NYHA Class II, indicate that they are experiencing some limitations in physical activity due to heart failure, but they are still able to perform daily activities. However, the presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) suggests that the patient is at risk for arrhythmic events, which can be life-threatening.

The patient's laboratory results show elevated creatinine levels, indicating impaired renal function, which can be a complication of heart failure. The patient's electrolyte levels, such as low potassium and low T3, also suggest that they may be experiencing cardiac-related complications.

Considering these factors, I would rank the patient as being at high risk for cardiac complications, but the presence of a relatively stable ECG impression, with only non-sustained ventricular tachycardia and ventricular extrasystoles, suggests that the patient may be able to survive with close monitoring and appropriate management. Therefore, I predict that the patient has a higher likelihood of surviving over the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

Although the patient is at high risk for cardiac complications, the presence of a stable ECG impression and the fact that the patient is already on medications such as amiodarone, which is used to treat arrhythmias, suggests that the patient may not be at an extremely high risk for sudden cardiac death.

However, the patient's history of ventricular tachycardia, non-sustained ventricular tachycardia, and ventricular extrasystoles, as well as the presence of idiopathic dilated cardiomyopathy, still pose a risk for arrhythmic events. Additionally, the patient's impaired renal function and low potassium levels can increase the risk of cardiac arrhythmias.

RANKING: 3. Pump failure death
REASONING: 

Given the patient's advanced heart failure status, impaired renal function, and history of ventricular tachycardia and ventricular extrasystoles, I would rank pump failure death as the least likely outcome. The patient is already experiencing significant symptoms of heart failure, and the presence of non-sustained ventricular tachycardia and ventricular extrasystoles suggests that the patient may be at risk for further decline.

However, the patient's stable ECG impression and the fact that they are already on medications such as amiodarone, which is used to treat arrhythmias, suggest that the patient may be able to survive with close monitoring and appropriate management. Therefore, pump failure death is the least likely outcome, but still a possible risk."
434,434,P0691,"Age: 81
Gender: Male 
Weight: 79 kg
Height: 174 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,07
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 140.0
Protein (g/L): 76
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,26
Urea (mg/dL): 9,65
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

This patient's prognosis is most likely to be a survivor due to several factors:

1. Age: The patient is 81 years old, which is a significant risk factor for cardiovascular events. However, the patient's NYHA class III indicates a moderate level of heart failure, and they are still receiving optimal medical therapy.
2. Medications: The patient is taking a combination of medications that target both heart failure and cardiovascular risk factors, including ACE inhibitors, statins, and a calcium channel blocker. This comprehensive approach suggests that the patient's condition is being actively managed.
3. ECG findings: While the ECG shows ventricular extrasystoles, which are a marker of cardiac stress, there is no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia. This suggests that the patient's heart is not experiencing a high level of arrhythmic activity.
4. Biomarkers: The patient's pro-BNP level is elevated, indicating some degree of heart failure. However, the troponin level is normal, suggesting that there is no acute myocardial infarction or significant cardiac damage.
5. Laboratory values: The patient's creatinine level is elevated, but this is likely due to age-related renal decline rather than cardiac dysfunction.

Overall, considering the patient's age, medical therapy, and ECG findings, the likelihood of a sudden cardiac death or pump failure is lower compared to the other two prognoses. However, it is essential to closely monitor the patient's condition and adjust the treatment plan as needed to minimize the risk of adverse outcomes.

The next most likely prognosis is pump failure, which is likely due to the patient's NYHA class III status and elevated pro-BNP level. However, the patient's overall clinical presentation and laboratory values do not suggest a high risk of sudden cardiac death.

The least likely prognosis is sudden cardiac death, which is unlikely due to the patient's stable ECG findings, normal troponin level, and absence of ventricular tachycardia or bradycardia. However, it is essential to continue monitoring the patient's condition and adjusting the treatment plan as needed to minimize the risk of adverse outcomes."
435,435,P0692,"Age: 70
Gender: Female 
Weight: 67 kg
Height: 156 cm
NYHA Class: III
Blood Pressure: 100/66 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,13
Creatinine (mmol/L): 248.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 5,4
LDL (mmol/L): 3,62
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 1048.0
Protein (g/L): 78
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,01
Urea (mg/dL): 32,61
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 70-year-old female with a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened and cannot pump blood efficiently. Her NYHA Class III indicates that she has significant symptoms of heart failure, including shortness of breath, fatigue, and swelling in the legs. Her low LVEF of 25.0% further supports this, indicating that the heart is not pumping blood effectively.

Despite her poor heart function, the patient has been taking a range of medications, including ACE inhibitors, beta blockers, and spironolactone, which are standard treatments for heart failure. Her creatinine level is elevated at 248.0, indicating kidney impairment, but this is likely a consequence of her heart failure rather than the primary cause.

The patient's ECG results show ventricular extrasystoles, which are premature ventricular contractions that can be a sign of heart failure. However, there is no evidence of ventricular tachycardia or other arrhythmias that could increase the risk of sudden cardiac death.

The patient's laboratory results show an elevated troponin level, which is a marker of cardiac damage, but the level is very low at 0.01 ng/mL, which is not indicative of a significant myocardial infarction. The patient's other laboratory results, including her liver function tests, electrolyte levels, and kidney function tests, are within relatively normal limits.

Overall, the patient's clinical presentation, laboratory results, and treatment history suggest that she is at risk of heart failure, but not at high risk of sudden cardiac death. Therefore, the most likely outcome is that she will survive, albeit with ongoing management of her heart failure symptoms and potential complications.

2. Sudden cardiac death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy and ventricular extrasystoles on ECG increase her risk of sudden cardiac death. However, the low troponin level and the absence of other ECG abnormalities that could indicate a high risk of arrhythmias make this outcome less likely.

3. Pump failure death
REASONING: 
While the patient's heart function is severely impaired, with an LVEF of 25.0%, the presence of medications that are standard treatments for heart failure, including ACE inhibitors and beta blockers, suggest that the patient is being managed to reduce the risk of further decline. The patient's laboratory results, including her kidney function tests, are also within relatively normal limits, which suggests that she is not at high risk of acute kidney injury or other complications that could lead to pump failure death."
436,436,P0693,"Age: 48
Gender: Female 
Weight: 69 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 90/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,01
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 220.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 11
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,55
Urea (mg/dL): 5,99
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient is most likely to survive over the next few years. The patient's age, NYHA Class II heart failure, and the presence of idiopathic dilated cardiomyopathy are significant risk factors for cardiac events. However, the patient's current hemoglobin level (125.0 g/L) is within the normal range, and the absence of elevated troponin levels (0.04 ng/mL) suggests that there is no acute myocardial infarction or significant cardiac damage.

The patient's current medications, including beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitor, are commonly used in the management of heart failure and cardiomyopathy. These medications have been shown to improve survival and reduce the risk of cardiac events in patients with heart failure and cardiomyopathy.

Additionally, the ECG impression does not indicate any acute cardiac arrhythmias, which is a significant risk factor for sudden cardiac death. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia further supports the prediction of a favorable outcome.

While the patient's LVEF (40.0%) is below the normal range, it is not significantly reduced, and the patient is receiving medications that can help improve cardiac function. The patient's Pro-BNP level (220.0 ng/L) is elevated, but not excessively high, and the patient's kidney function (creatinine 5.99 mg/dL) is within the normal range.

Overall, based on the provided data, I predict that the patient is most likely to survive over the next few years, with a moderate risk of cardiac events, but manageable with current medications and close monitoring."
437,437,P0694,"Age: 69
Gender: Male 
Weight: 82 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 48
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 164.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,17
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 91.0
Protein (g/L): 81,8
T3 (pg/dL): 0,06
T4 (ng/L): 14,01
Troponin (ng/mL): 0,6
TSH (mIU/L): 1,32
Urea (mg/dL): 6,3
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I would rank the patient as a survivor with a high likelihood. The patient's age is 69, which is considered advanced age for many cardiac conditions. However, the patient's NYHA Class II indicates that the heart is functioning relatively well, with symptoms only during moderate physical exertion.

The patient's blood work shows elevated creatinine levels (103.0 mmol/L), which may indicate some degree of kidney dysfunction, but this is not uncommon in patients with hypertension and diabetes. The patient's troponin levels (0.6 ng/mL) are within normal limits, suggesting that there is no acute myocardial infarction or significant cardiac damage.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of underlying cardiac disease. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient is not at high risk for sudden cardiac death.

The patient's medication list includes a calcium channel blocker, beta blockers, and an ACE inhibitor, which are all commonly used to treat hypertension, heart failure, and coronary artery disease. The patient's lipid profile shows high cholesterol levels, but the patient is on statins, which are effective in reducing cardiovascular risk.

The patient's Pro-BNP levels (91 ng/L) are elevated, indicating some degree of cardiac stress, but this is not uncommon in patients with hypertension and heart failure. Overall, based on the patient's data, I would rank the patient as a survivor with a high likelihood."
438,438,P0695,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 153.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 403.0
Protein (g/L): 85
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,27
Urea (mg/dL): 6,66
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict a high likelihood of the patient surviving for the next few years. Here's the reasoning behind this prediction:

1. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but it is not severe. This suggests that the patient's heart is still functioning to some extent, which is a positive prognostic factor.

2. The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, but the current LVEF of 60.0 indicates that the left ventricle is still pumping blood effectively. While this is a significant heart condition, it is not necessarily a death sentence.

3. The patient's blood tests show elevated creatinine levels (153.0) and BNP levels (403.0), indicating some degree of heart failure and fluid overload. However, the patient is on medications to manage these conditions (Loop Diuretics), which should help alleviate symptoms.

4. The ECG results show no signs of ventricular tachycardia or other life-threatening arrhythmias, which reduces the risk of sudden cardiac death.

5. The patient's lipid profile is not ideal, with high total cholesterol and LDL levels, but the patient is on Statins, which should help manage these conditions.

6. The patient's kidney function is slightly impaired, but the creatinine level is not extremely high, and the patient is on medications to manage this condition.

Given these factors, I predict that the patient will survive for the next few years, although close monitoring and adjustments to their treatment plan may be necessary to manage their heart failure and other conditions."
439,439,P0697,"Age: 49
Gender: Male 
Weight: 109 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 170/110 mmHg
Past Medical History: Other HF etiology, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,93
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 71
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,88
Urea (mg/dL): 6,66
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

The patient's data suggests a high risk of adverse cardiac events, but overall, the prognosis leans towards survival. Here's a breakdown of the reasoning:

1. Survivor: The patient has a relatively stable hemodynamic status, as indicated by a normal hemoglobin level (151.0 g/L) and no evidence of acute kidney injury (creatinine 97.0 mmol/L). The patient is also on multiple medications, including beta blockers, which are known to improve outcomes in heart failure patients. The presence of a normal LVEF (40.0%) suggests some degree of preserved cardiac function, which is a positive prognostic indicator. Additionally, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is a good sign.

2. Sudden Cardiac Death: The patient has a history of hypertension (170/110 mmHg), which is a significant risk factor for cardiovascular events. However, the patient is already on calcium channel blockers and beta blockers, which can help manage blood pressure. The elevated troponin level (0.01 ng/mL) suggests some degree of cardiac damage, but it's not indicative of acute myocardial infarction. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a precursor to ventricular tachycardia, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces this risk.

3. Pump Failure Death: The patient's NYHA Class II heart failure suggests some degree of cardiac dysfunction, and the elevated creatinine level (6.66 mg/dL) indicates some degree of renal impairment, which can be a marker of heart failure. The patient's elevated Pro-BNP level (709.0 ng/L) is also a marker of heart failure. However, the patient is on spironolactone, which is a diuretic, and the presence of multiple medications that can help manage heart failure symptoms. While the patient's LVEF is low (40.0%), it's not significantly low, and the patient is not in acute heart failure.

Overall, while the patient has several risk factors and evidence of cardiac dysfunction, the combination of stable hemodynamics, multiple medications, and the absence of acute cardiovascular events make survival the most likely outcome. Sudden cardiac death is a possibility, but it's not the most likely outcome given the patient's stable condition. Pump failure death is the least likely outcome, given the patient's relatively stable condition and the presence of multiple medications that can help manage heart failure symptoms."
440,440,P0698,"Age: 65
Gender: Female 
Weight: 69 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 37
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,68
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 542.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,58
Urea (mg/dL): 4,16
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I would rank the patient as a survivor. The patient's age (65) is not considered high-risk, and their NYHA Class II indicates mild symptoms of heart failure. The patient's LVEF is 45%, which is within the range of patients with mild heart failure. The patient's creatinine level is elevated, but it's not significantly high, which may indicate some degree of kidney impairment but not acute kidney failure.

The patient's laboratory results show a normal liver function, low LDL cholesterol, and normal electrolyte levels. The patient's troponin level is also normal, which suggests no acute myocardial infarction.

The patient's ECG impression is mostly normal, with no signs of ventricular tachycardia or ventricular extrasystoles, which are indicators of arrhythmias that can lead to sudden cardiac death. The patient is also not taking any anti-arrhythmic medications, which further reduces the risk of arrhythmias.

Given the patient's overall health status, medical history, and the absence of any severe laboratory abnormalities, the likelihood of sudden cardiac death or pump failure death is low. Therefore, I predict that the patient is likely to survive for the next few years with proper management of their heart failure and other medical conditions."
441,441,P0699,"Age: 41
Gender: Male 
Weight: 65 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,69
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 19.0
Protein (g/L): 70
T3 (pg/dL): 0,06
T4 (ng/L): 13
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,2
Urea (mg/dL): 5,16
LVEF (%): 40.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, I would rank the patient's prognosis as a survivor. The patient has a history of Hypertrophic Cardiomyopathy (HCM), which is a significant risk factor for sudden cardiac death (SCD) and cardiomyopathy-related death. However, the patient's current NYHA Class II symptoms and the absence of any recent heart failure exacerbations or hospitalizations suggest that the disease is currently not severely impacting the patient's functional capacity.

The patient's ECG results are also reassuring, with no signs of ventricular tachycardia or other arrhythmias. The elevated Troponin level (0.02 ng/mL) may indicate some degree of cardiac stress, but it is not indicative of a myocardial infarction.

The patient's lipid profile is relatively well-managed, with total cholesterol below 4.5 mmol/L and HDL cholesterol above 1.37 mmol/L. The patient is also taking beta blockers and ACE inhibitors, which are standard treatments for HCM.

The patient's biomarkers, including creatinine, urea, and liver function tests, are within normal limits. The elevated BNP level (19 ng/L) may indicate some degree of cardiac stress, but it is not indicative of heart failure.

The patient's physical examination and laboratory results do not suggest any acute cardiac events or complications that would necessitate a worse prognosis.

Therefore, based on the available data, I would predict that the patient will survive for the next few years, assuming continued management of HCM and other comorbidities.

RANKING: 
2. Sudden Cardiac Death
REASONING:
A sudden cardiac death (SCD) is a possible outcome for patients with HCM, particularly those with a history of ventricular arrhythmias or significant left ventricular dysfunction. However, the patient's current ECG results do not show any signs of ventricular arrhythmias, and the patient is taking beta blockers and ACE inhibitors, which are standard treatments for HCM.

The patient's LVEF is 40%, which is below the normal range, indicating some degree of left ventricular dysfunction. However, the patient's NYHA Class II symptoms suggest that the disease is not severely impacting the patient's functional capacity.

While the patient's HCM is a significant risk factor for SCD, the patient's current clinical presentation and laboratory results do not suggest an immediate risk of SCD. Therefore, I would rank SCD as a less likely outcome compared to survival.

RANKING: 
3. Pump Failure Death
REASONING:
Pump failure death is a possible outcome for patients with HCM, particularly those with significant left ventricular dysfunction. However, the patient's current LVEF is 40%, which is still within the range of patients who can tolerate a relatively normal quality of life.

The patient's NYHA Class II symptoms suggest that the disease is not severely impacting the patient's functional capacity, and the patient is taking beta blockers and ACE inhibitors, which are standard treatments for HCM.

The patient's biomarkers, including creatinine and urea, are within normal limits, indicating that the patient's kidney function is not significantly impaired. The patient's liver function tests are also within normal limits, indicating that the patient's liver function is not significantly impaired.

While the patient's HCM is a significant risk factor for pump failure, the patient's current clinical presentation and laboratory results do not suggest an immediate risk of pump failure. Therefore, I would rank pump failure death as the least likely outcome compared to survival and SCD."
442,442,P0700,"Age: 81
Gender: Male 
Weight: 77 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 5,1
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,46
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,93
LDL (mmol/L): 3,15
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1670.0
Protein (g/L): 65
T3 (pg/dL): 0,0483
T4 (ng/L): 12,7
TSH (mIU/L): 3,52
Urea (mg/dL): 11,3
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's prognosis is the most likely due to several factors. Firstly, the patient's age of 81 years is relatively young for cardiomyopathy-related mortality, but the presence of idiopathic dilated cardiomyopathy (DCM) at this age is a significant risk factor for adverse outcomes. However, the patient's NYHA class II indicates that the heart is still functional enough to support daily activities, which is a positive prognostic sign.

The patient's laboratory results show a mild elevation in creatinine (129.0 mmol/L), which may indicate some degree of renal impairment, but it is not severe. The presence of elevated BNP (1670.0 ng/L) is a strong indicator of heart failure, but it is not excessively elevated, suggesting that the patient is not in severe heart failure.

The ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) are concerning for arrhythmias, but the presence of paroxysmal supraventricular tachycardia (PSVT) suggests that the patient's arrhythmias may be less severe.

The patient is on medications that are commonly used in heart failure management (digoxin, loop diuretics, and ACE inhibitor), which suggests that the patient is receiving appropriate treatment.

Overall, considering the patient's age, NYHA class, laboratory results, and ECG findings, the likelihood of survival for the next few years is higher than for the other two options.

RANKING: 2. Sudden cardiac death
REASONING:

The patient's ECG findings of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) increase the risk of sudden cardiac death. The presence of these arrhythmias suggests that the patient's heart is at risk of life-threatening arrhythmias.

Additionally, the patient's LVEF (25.0%) is significantly reduced, indicating poor heart function. This reduced LVEF increases the risk of cardiac events, including sudden cardiac death.

The patient's age and NYHA class II also contribute to the increased risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING:

The patient's LVEF (25.0%) is significantly reduced, indicating poor heart function. This reduces the likelihood of pump failure death as the primary cause of death, as the heart is not functioning optimally.

However, the patient's elevated BNP (1670.0 ng/L) and elevated creatinine (129.0 mmol/L) suggest that the patient is experiencing some degree of heart failure. While the patient is not in severe heart failure, the presence of these biomarkers increases the risk of pump failure.

The patient's age and NYHA class II also contribute to the risk of pump failure death, but to a lesser extent than the risk of sudden cardiac death."
443,443,P0701,"Age: 76
Gender: Male 
Weight: 65 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 163.0
HDL (mmol/L): 1,84
Potassium (mEq/L): 4,56
LDL (mmol/L): 3,75
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1343.0
Protein (g/L): 76,9
T3 (pg/dL): 0,0531
T4 (ng/L): 11,03
Troponin (ng/mL): 0,1
TSH (mIU/L): 1
Urea (mg/dL): 9,2
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is a 76-year-old male with a history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension. He has a low ejection fraction (LVEF) of 30%, which indicates significant left ventricular dysfunction. The patient's elevated creatinine level (108.0 mmol/L) suggests impaired renal function, which can be associated with heart failure and cardiomyopathy.

The patient's ECG impression shows polymorphic ventricular extrasystoles, which is a type of arrhythmia that can be a precursor to ventricular tachycardia. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachycardia reduces the risk of sudden cardiac death.

The patient's laboratory results show elevated levels of troponin (0.1 ng/mL), which may indicate some degree of myocardial injury, but it is not significantly elevated. The patient's other laboratory results, such as the liver function tests, electrolyte levels, and thyroid function tests, are relatively normal.

Considering the patient's age, comorbidities, and the presence of polymorphic ventricular extrasystoles, the most likely outcome is that the patient will survive. The patient's low ejection fraction and impaired renal function suggest that he is at risk for heart failure, but the absence of other signs of severe cardiac dysfunction and the presence of medication therapy (digoxin, loop diuretics, statins, and ACE inhibitor) suggest that the patient may be able to manage his condition and survive.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's ECG impression shows polymorphic ventricular extrasystoles, which is a type of arrhythmia that can be a precursor to ventricular tachycardia, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachycardia reduces the risk of sudden cardiac death.

However, the patient's low ejection fraction (LVEF) of 30% and impaired renal function (creatinine level of 108.0 mmol/L) suggest that the patient is at risk for cardiac dysfunction and heart failure. The patient's age (76 years) and comorbidities (idiopathic dilated cardiomyopathy, dyslipemia, and hypertension) also increase the risk of sudden cardiac death.

Additionally, the patient's laboratory results show elevated levels of pro-BNP (1343.0 ng/L), which is a biomarker for heart failure. While the patient's troponin level is not significantly elevated, the presence of elevated pro-BNP levels suggests that the patient may have some degree of cardiac dysfunction.

Considering these factors, while the patient is at risk for cardiac dysfunction and heart failure, the absence of other signs of severe cardiac dysfunction and the presence of medication therapy (digoxin, loop diuretics, statins, and ACE inhibitor) reduce the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's low ejection fraction (LVEF) of 30% and impaired renal function (creatinine level of 108.0 mmol/L) suggest that the patient is at risk for heart failure. The patient's age (76 years) and comorbidities (idiopathic dilated cardiomyopathy, dyslipemia, and hypertension) also increase the risk of heart failure.

The patient's laboratory results show elevated levels of pro-BNP (1343.0 ng/L), which is a biomarker for heart failure. Additionally, the patient's elevated creatinine level (108.0 mmol/L) suggests that the patient's kidneys are not functioning properly, which can contribute to heart failure.

The patient's ECG impression shows polymorphic ventricular extrasystoles, which is a type of arrhythmia that can be a precursor to ventricular tachycardia. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachycardia reduces the risk of pump failure death.

Considering these factors, the patient is at high risk for heart failure, and the presence of impaired renal function and elevated pro-BNP levels suggest that the patient may experience pump failure. However, the patient's age, comorbidities, and the presence of medication therapy (digoxin, loop diuretics, statins, and ACE inhibitor) reduce the risk of pump failure death."
444,444,P0702,"Age: 54
Gender: Female 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 666.0
Protein (g/L): 67
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,1
Urea (mg/dL): 5,66
LVEF (%): 38.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the provided patient data, I rank the patient as a survivor with the highest likelihood. The patient's age, NYHA Class III status, and history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia suggest a significant cardiac burden. However, the patient's current medication regimen, which includes beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, indicates an attempt to manage the underlying conditions. The absence of significant electrolyte imbalances, acute kidney injury, or severe anemia is also a positive prognostic sign.

The patient's hemoglobin level (129 g/L) and LVEF (38%) suggest some level of cardiac dysfunction, but not severe enough to warrant a more aggressive intervention. The elevated troponin level (0.01 ng/mL) may indicate some myocardial damage, but it is not significantly elevated, which could be a sign of a recent minor infarct or a very minor level of myocardial injury. 

The elevated creatinine level (106.0 mmol/L) and the patient's protein level (67 g/L) suggest some degree of renal impairment, but it is not severe enough to be a major determinant of the patient's prognosis. The absence of significant electrolyte imbalances and the presence of a relatively normal blood pressure (120/70 mmHg) are also positive prognostic signs.

While the patient's ECG shows ventricular extrasystole, which may indicate some level of ventricular dysfunction, the absence of other arrhythmias makes this a relatively minor concern. Overall, considering the patient's medication regimen and the absence of severe symptoms, I believe the patient has a relatively good prognosis for survival.

2. Sudden cardiac death
REASONING: 
While the patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death, the presence of a relatively normal blood pressure (120/70 mmHg), a normal LVEF (38%), and the absence of other significant cardiac arrhythmias or electrolyte imbalances makes sudden cardiac death less likely. However, the patient's ECG shows ventricular extrasystole, which may indicate some level of ventricular dysfunction, and the patient's LVEF is relatively low, which may increase the risk of arrhythmias.

3. Pump failure death
REASONING: 
Given the patient's NYHA Class III status, history of ischemic dilated cardiomyopathy, and elevated creatinine level (106.0 mmol/L), pump failure death is a possible but less likely outcome. The patient's relatively normal blood pressure (120/70 mmHg) and the presence of a medication regimen that includes beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor suggest that the patient is receiving adequate treatment to manage the underlying conditions. However, the patient's LVEF (38%) is significantly reduced, indicating some level of cardiac dysfunction."
445,445,P0704,"Age: 61
Gender: Male 
Weight: 65 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 133/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 227
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,35
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 474.0
Protein (g/L): 80
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 4,99
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's overall clinical presentation and laboratory results suggest a poor prognosis, but the patient has been classified as a survivor. Several factors contribute to this ranking:

1. Low LVEF (30%): This indicates severe left ventricular dysfunction, which is a significant predictor of adverse outcomes in patients with heart failure.
2. Elevated BNP (474 ng/L): Elevated BNP levels are associated with increased mortality and morbidity in patients with heart failure.
3. History of Ischemic dilated cardiomyopathy and Myocardial Infarction: These conditions increase the risk of sudden cardiac death and heart failure.
4. Elevated creatinine (71.0 mmol/L): This suggests impaired renal function, which can be a complication of heart failure.
5. Presence of Ventricular Extrasystole: This ECG finding indicates abnormal ventricular electrical activity, which can be a precursor to ventricular arrhythmias and sudden cardiac death.

Despite these factors, the patient has been classified as a survivor, likely due to the presence of certain medications (Beta Blockers, Statins, ACE Inhibitor) that are commonly used to manage heart failure and reduce the risk of adverse outcomes. However, the patient's underlying heart condition and laboratory results suggest a high risk of complications, making it essential to closely monitor their condition and adjust their treatment plan as needed.

While the patient is classified as a survivor, it is essential to note that their prognosis is still uncertain, and they should be closely monitored for signs of worsening heart failure, arrhythmias, or other complications."
446,446,P0705,"Age: 43
Gender: Male 
Weight: 95 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 47
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4
LDL (mmol/L): 4,34
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 12.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 3,11
Urea (mg/dL): 6,32
LVEF (%): 43.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient's prognosis is likely to be a survivor. Several factors support this conclusion:

1. Age: The patient is 43 years old, which is relatively young for heart failure (HF) and coronary artery disease. This age can contribute to a more favorable prognosis.

2. NYHA Class II: The patient's New York Heart Association (NYHA) class is II, indicating mild symptoms of heart failure. This level of severity is less likely to result in a poor prognosis.

3. Medications: The patient is already on beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. The presence of these medications suggests that the patient is receiving appropriate management for their condition.

4. Lab results: The patient's lab results, including a normal electrolyte panel, normal kidney function (creatinine 86.0), and normal liver function (ALT and AST 36.0 and 20.0, respectively), indicate that the patient's underlying health is relatively stable.

5. ECG findings: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient does not have significant arrhythmias that could contribute to a poor prognosis.

6. Low troponin level: The patient's troponin level (0.005 ng/mL) is within normal limits, indicating no significant myocardial damage.

While the patient's left ventricular ejection fraction (LVEF) is 43%, which is lower than the normal range, it is still within a range that is not indicative of advanced heart failure. The presence of other risk factors, such as a high body mass index (BMI) and elevated creatinine levels, should be taken into consideration. However, these factors do not significantly impact the overall prognosis in this case.

Given these factors, the patient's prognosis is likely to be a survivor, with a reasonable expectation of long-term survival with appropriate management and lifestyle modifications."
447,447,P0706,"Age: 72
Gender: Male 
Weight: 69 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 166.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,67
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5545.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,23
Urea (mg/dL): 7,15
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient has a history of Hypertensive cardiomyopathy and Hypertension, which is a significant risk factor for cardiovascular disease. However, the patient is currently taking multiple medications, including beta blockers, digoxin, and an ACE inhibitor, which are standard treatments for managing hypertension and heart failure. The patient's NYHA class is II, indicating mild symptoms, and the LVEF is 25%, which is relatively preserved. The patient's ECG findings show ventricular extrasystole and non-sustained ventricular tachycardia, but these are not indicative of severe arrhythmia. The patient's Pro-BNP levels are elevated, but not excessively high. Overall, the patient's clinical presentation and laboratory results do not suggest acute decompensation or severe cardiac dysfunction, which are common precursors to sudden cardiac death or pump failure. The patient's age and other comorbidities are also factors to consider, but the patient's overall clinical status and response to medications suggest a relatively stable condition.

2. Pump failure death 
REASONING: 
While the patient has a history of cardiomyopathy and hypertension, the patient's current LVEF is 25%, which is relatively preserved. The patient is also taking medications that are standard for managing heart failure, including ACE inhibitors and beta blockers. However, the patient's Pro-BNP levels are elevated, indicating some degree of cardiac stress. Additionally, the patient's ECG findings show non-sustained ventricular tachycardia, which is a risk factor for cardiac arrhythmia. While the patient's overall clinical presentation is not indicative of acute decompensation, the patient's history of cardiomyopathy and hypertension, combined with elevated Pro-BNP levels and non-sustained ventricular tachycardia, make pump failure death a possible outcome.

3. Sudden cardiac death 
REASONING: 
Given the patient's history of cardiomyopathy and hypertension, the risk of sudden cardiac death is relatively high. However, the patient's current clinical presentation and laboratory results do not suggest acute decompensation or severe cardiac dysfunction. The patient's ECG findings show ventricular extrasystole and non-sustained ventricular tachycardia, but these are not indicative of severe arrhythmia. The patient's LVEF is 25%, which is relatively preserved. While the patient's Pro-BNP levels are elevated, this is not an indicator of acute decompensation. Overall, the patient's overall clinical status and response to medications suggest a relatively stable condition, and the risk of sudden cardiac death is not as high as it would be if the patient were experiencing acute decompensation."
448,448,P0707,"Age: 52
Gender: Male 
Weight: 81 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 150/95 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,36
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,55
Sodium (mEq/L): 138.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,73
Urea (mg/dL): 6,49
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient is at high risk for adverse outcomes due to several factors. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death and pump failure. The patient's LVEF of 40.0 indicates severe left ventricular dysfunction, which further increases the risk of pump failure. Additionally, the patient's blood pressure is elevated (150/95 mmHg), which is a risk factor for cardiovascular events. The presence of ventricular extrasystoles on the ECG, although non-sustained, is a warning sign of potential arrhythmia. However, the patient's overall clinical presentation and lack of other high-risk features, such as a history of heart failure hospitalization or cardiac arrest, suggest that the patient is more likely to survive with proper management. The patient is already on multiple medications, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all appropriate for managing the patient's conditions. 

While pump failure is a concern, the patient's current clinical status does not indicate an acute decompensated heart failure episode, and the patient's renal function is not severely impaired. Therefore, the likelihood of pump failure in the short term is moderate, but not the most likely outcome. Sudden cardiac death is a possible risk due to the patient's ischemic dilated cardiomyopathy and ventricular extrasystoles, but the patient's overall clinical presentation and lack of other high-risk features suggest that sudden cardiac death is less likely than pump failure. Therefore, the most likely outcome is survival with proper management and monitoring."
449,449,P0708,"Age: 64
Gender: Male 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,65
Sodium (mEq/L): 139.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 13
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,17
Urea (mg/dL): 8,49
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Based on the provided patient data, the patient has a history of hypertensive cardiomyopathy, hypertension, and a reduced LVEF of 40%, which indicates significant left ventricular dysfunction. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG impression suggests a high risk of arrhythmic events. However, the patient is currently on beta blockers and ACE inhibitors, which are standard treatments for heart failure and hypertension. These medications can help improve survival and reduce the risk of arrhythmic events. Additionally, the patient's NYHA Class II indicates that they have some limitations in physical activity but can still perform daily activities with some difficulty. The patient's laboratory results show elevated creatinine levels, indicating some degree of kidney dysfunction, but this is not uncommon in patients with heart failure. Overall, the combination of these factors suggests that the patient has a significant risk of adverse outcomes, but the presence of evidence-based treatments and the patient's functional status suggest that survival is still possible.

2. Sudden Cardiac Death
REASONING: 
While the patient has a high risk of arrhythmic events, the presence of beta blockers and ACE inhibitors suggests that the risk of sudden cardiac death is not the most likely outcome. The patient's LVEF is also not severely impaired, which reduces the risk of sudden cardiac death. However, the patient's history of hypertensive cardiomyopathy and hypertension, as well as the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG, still increase the risk of arrhythmic events.

3. Pump Failure Death
REASONING: 
Given the patient's NYHA Class II and reduced LVEF of 40%, pump failure death is a possible outcome. However, the patient's functional status and the presence of evidence-based treatments suggest that pump failure death is not the most likely outcome. The patient's laboratory results also show some degree of kidney dysfunction, which could contribute to a higher risk of pump failure, but this is not the most significant factor in this case. Overall, while pump failure death is a potential risk, the patient's overall clinical status and the presence of evidence-based treatments suggest that it is not the most likely outcome."
450,450,P0709,"Age: 70
Gender: Male 
Weight: 84 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5
LDL (mmol/L): 3,67
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 129.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,26
Urea (mg/dL): 10,48
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient has a high likelihood of survival over the next few years. The following factors support this prognosis:

1. Age: The patient is 70 years old, which is considered advanced age, but not extremely high-risk. With proper management, many patients in this age group can live for several years with optimal treatment.
2. NYHA Class II: The patient has a moderate level of heart failure, but this is manageable with current medications and lifestyle modifications.
3. LVEF 35.0: The left ventricular ejection fraction (LVEF) is significantly reduced, indicating impaired cardiac function. However, this is not uncommon in patients with dilated cardiomyopathy.
4. Medications: The patient is already taking beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy.
5. ECG findings: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac arrhythmias are not severe.
6. Biochemical markers: The patient's troponin level is normal, indicating no acute myocardial infarction. The elevated creatinine level may be related to age and kidney function decline, but it is not a significant concern in this context.
7. Pro-BNP levels: The patient's Pro-BNP level is elevated, indicating some degree of heart failure. However, it is not excessively high, suggesting that the patient's heart is not severely under strain.

Considering these factors, I predict that the patient has a high likelihood of survival over the next few years, provided that the patient continues to receive optimal medical care and lifestyle modifications.

RANKING: 2. Sudden cardiac death
REASONING:

While the patient's prognosis is generally good, there are some factors that increase the risk of sudden cardiac death (SCD):

1. Age: As mentioned earlier, the patient is 70 years old, which increases the risk of SCD.
2. LVEF 35.0: The significantly reduced LVEF increases the risk of SCD.
3. ECG findings: The presence of ventricular extrasystoles, although not sustained, may indicate underlying cardiac instability.
4. Pro-BNP levels: Elevated Pro-BNP levels can indicate increased cardiac stress and strain, which may contribute to the risk of SCD.

However, these factors are not sufficient to outweigh the patient's overall prognosis, and I would only consider SCD as a possible outcome in the event of severe cardiac instability or other unforeseen events.

RANKING: 3. Pump failure death
REASONING:

Pump failure death is a possible outcome for patients with advanced heart failure, but it is less likely in this case:

1. NYHA Class II: The patient's NYHA Class II classification indicates that they are not severely symptomatic, which suggests that the heart is still able to function to some extent.
2. Medications: The patient is already taking medications to manage heart failure, which should help slow disease progression.
3. ECG findings: The absence of ventricular tachycardia and other arrhythmias suggests that the patient's cardiac function is relatively stable.

However, the patient's reduced LVEF and elevated Pro-BNP levels indicate some degree of cardiac dysfunction, which could eventually lead to pump failure. Nevertheless, I would only consider pump failure death as a possible outcome in the event of severe cardiac decompensation or significant worsening of symptoms."
451,451,P0710,"Age: 74
Gender: Female 
Weight: 63 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 145/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,47
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1674.0
Protein (g/L): 65
T3 (pg/dL): 0,03
T4 (ng/L): 15
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,3
Urea (mg/dL): 9,65
LVEF (%): 60.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1

REASONING: 

Given the patient's age, NYHA Class II, and the presence of Hypertensive cardiomyopathy, Hypertension, and elevated troponin levels, the patient is at a higher risk for cardiac events. The patient's LVEF of 60% indicates left ventricular dysfunction, which is a significant finding in the context of her hypertension and cardiomyopathy. The presence of non-sustained ventricular tachycardia (VT) and ventricular extrasystoles on the ECG further increases the risk of cardiac events.

The patient's biomarkers, including elevated creatinine and urea levels, suggest some degree of renal impairment, which is a common comorbidity in patients with cardiovascular disease. The patient's lipid profile is also concerning, with high total cholesterol and LDL levels, which may contribute to atherosclerotic disease.

Despite these findings, the patient's protein levels are within the normal range, and the patient is on medications that are commonly used to manage hypertension, heart failure, and arrhythmias. The absence of severe symptoms such as shortness of breath or chest pain makes it less likely that the patient is experiencing acute cardiac events.

Given these factors, the most likely outcome for this patient over the next few years is survival, as the patient's underlying conditions are being managed, and the patient is not presenting with acute symptoms. However, close monitoring and adjustments to the patient's treatment plan may be necessary to mitigate the risk of cardiac events.

The sudden cardiac death and pump failure are less likely, as the patient is not experiencing acute symptoms and the patient's LVEF is not severely impaired. However, the patient's cardiac events, such as non-sustained VT and ventricular extrasystoles, increase the risk of cardiac events, making sudden cardiac death a possible outcome if the underlying conditions are not adequately managed. Pump failure is also possible, but the patient's LVEF is not severely impaired, making it less likely."
452,452,P0711,"Age: 75
Gender: Male 
Weight: 75 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 135/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,12
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2029.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,45
Urea (mg/dL): 15,47
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at high risk for adverse cardiac events, with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which are all risk factors for cardiac failure and sudden cardiac death. The patient's current NYHA class II indicates moderate symptoms of heart failure, and their LVEF of 30% is significantly reduced, indicating poor cardiac function.

The patient's elevated troponin levels (0.04 ng/mL) and elevated BNP levels (2029 ng/L) suggest cardiac stress and strain, which may indicate worsening cardiac function. The patient's low HDL cholesterol level (0.88 mmol/L) and high triglyceride level (not provided) contribute to a high risk of cardiovascular events.

The patient's elevated creatinine level (15.47 mg/dL) and urea level (15.47 mg/dL) indicate impaired renal function, which can be a marker of cardiac disease. The patient's blood pressure is elevated at 135/90 mmHg, which is also a risk factor for cardiovascular events.

However, the patient is already on medications that target these risk factors, including beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator. These medications can help manage the patient's symptoms and slow the progression of cardiac disease.

Considering the patient's overall risk factors, comorbidities, and treatment plan, I would rank the patient as a survivor. However, it is essential to closely monitor the patient's condition and adjust the treatment plan as needed to minimize the risk of adverse cardiac events.

The other two prognoses, sudden cardiac death and pump failure death, are less likely in this patient due to the following reasons:

* Sudden cardiac death is less likely because the patient's ECG shows no ventricular tachycardia or ventricular extrasystole, and the patient is already on medications that can help prevent arrhythmias.
* Pump failure death is less likely because the patient is already on medications that can help manage heart failure symptoms, such as loop diuretics and ACE inhibitors. However, the patient's LVEF is significantly reduced, which indicates poor cardiac function, and the patient's BNP levels are elevated, suggesting cardiac stress and strain."
453,453,P0712,"Age: 52
Gender: Male 
Weight: 98 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 175/110 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 6,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,45
Sodium (mEq/L): 137.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,45
Urea (mg/dL): 8,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 52-year-old male with a history of enolic dilated cardiomyopathy, hypertension, and elevated blood pressure readings (175/110 mmHg). The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 30.0%, indicating severe left ventricular dysfunction. The presence of ventricular extrasystole on the ECG suggests abnormal heart rhythms, but there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia.

Given the patient's severe left ventricular dysfunction, history of cardiomyopathy, and elevated blood pressure, the patient is at high risk for cardiac complications, including heart failure and arrhythmias. However, the patient is currently receiving beta blockers, loop diuretics, and a nitrovasodilator, which are standard treatments for managing hypertension and heart failure.

While the patient's elevated troponin levels (0.04 ng/mL) suggest some cardiac damage, it is not indicative of acute myocardial infarction. The patient's other lab values, including normal kidney function (creatinine 8.15 mg/dL) and normal electrolytes, do not suggest acute kidney injury or other life-threatening conditions.

Considering these factors, I predict that the patient is likely to survive for the next few years, with the possibility of some degree of improvement with continued medical management and lifestyle modifications. However, the patient will require close monitoring and adjustments to their treatment plan to manage their heart failure and hypertension.

The likelihood of sudden cardiac death (SCD) is relatively low in this case, as there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG. The likelihood of pump failure death is moderate, given the patient's severe left ventricular dysfunction and history of cardiomyopathy. However, the patient's current treatment regimen and the absence of other high-risk factors reduce this likelihood.

Therefore, based on the provided data, the most likely outcome is survivorship, followed by pump failure death, and then sudden cardiac death."
454,454,P0713,"Age: 75
Gender: Male 
Weight: 89 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 7,06
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 5,3
LDL (mmol/L): 4,65
Sodium (mEq/L): 133.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,24
Urea (mg/dL): 8,49
LVEF (%): 21.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is 75 years old, with a history of Enolic dilated cardiomyopathy, Hypertension, and NYHA Class II, indicating a significant cardiac condition. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 21.0%, which is a strong indicator of poor cardiac function. Additionally, the patient has elevated troponin levels, which suggest some degree of myocardial damage. The patient's age, comorbidities, and reduced LVEF make them a high-risk candidate for adverse cardiac events.

The patient's current medications, including ACE inhibitor, Loop Diuretics, and Spironolactone, suggest that the patient is being managed for heart failure and hypertension. However, the presence of ventricular extrasystoles, as indicated by the ECG, suggests a potential risk for arrhythmias, which can be a precursor to more severe cardiac events.

Given these factors, the patient's current condition, and the presence of ventricular extrasystoles, the most likely outcome is a poor cardiac event. However, considering the patient's current medical management and the absence of other high-risk factors, I would rank the patient as a survivor, with a high risk of cardiac events.

The next most likely outcome is pump failure death, which would be a direct consequence of the patient's reduced cardiac function and the presence of ventricular extrasystoles. 

The least likely outcome, sudden cardiac death, is possible but less likely given the patient's current management and the presence of ventricular extrasystoles, which may be a precursor to more severe cardiac events, but not necessarily a direct cause of sudden death.

It's essential to note that cardiac events can be unpredictable, and the actual outcome may vary depending on various factors, including the patient's response to treatment and any unforeseen complications. Close monitoring and follow-up are crucial to manage the patient's condition and prevent adverse events."
455,455,P0714,"Age: 58
Gender: Male 
Weight: 87 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,44
Sodium (mEq/L): 138.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,92
Urea (mg/dL): 7,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall prognosis is ranked as a survivor due to several factors. Firstly, the patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform daily activities without significant limitation. This suggests that the patient's heart is not severely compromised, which is a positive prognostic factor.

The patient's LVEF (left ventricular ejection fraction) of 30.0 is significantly below the normal range (normal range: 55-70%), indicating left ventricular dysfunction. However, this is not an absolute contraindication for survival, and with proper management, it is possible to improve the patient's cardiac function.

The patient's ECG findings are also relatively benign, with no evidence of ventricular tachycardia or other life-threatening arrhythmias. The presence of ventricular extrasystoles and paroxysmal supraventricular tachycardia (PSVT) are not uncommon in patients with hypertensive cardiomyopathy and are not necessarily indicative of a poor prognosis.

The patient's laboratory results are also relatively well within normal limits, with no significant elevation in liver enzymes, kidney function, or electrolytes. The patient's medication regimen is also well-managed, with beta blockers, loop diuretics, spironolactone, and ACE inhibitors, which are standard treatments for hypertensive cardiomyopathy.

Overall, while the patient's cardiac function is compromised, the patient's overall clinical presentation and management plan suggest that they are at risk for a favorable outcome.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's LVEF of 30.0 and NYHA Class II indicate significant left ventricular dysfunction, which increases the risk of sudden cardiac death. However, the patient's ECG findings, while abnormal, do not show any evidence of ventricular tachycardia or other life-threatening arrhythmias.

The patient's laboratory results are relatively well within normal limits, which reduces the risk of sudden cardiac death due to electrolyte imbalances or other metabolic disturbances. However, the patient's low T3 level (0.05 pg/dL) may indicate hypothyroidism, which can increase the risk of sudden cardiac death.

The patient's medication regimen is well-managed, but the patient's low HDL level (0.78 mmol/L) may increase the risk of cardiovascular events, including sudden cardiac death.

Overall, while the patient's risk of sudden cardiac death is present, the patient's overall clinical presentation and management plan suggest that the risk is not extremely high.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF of 30.0 and NYHA Class II indicate significant left ventricular dysfunction, which increases the risk of pump failure. The patient's ECG findings, while abnormal, do not show any evidence of ventricular tachycardia or other life-threatening arrhythmias.

The patient's laboratory results are relatively well within normal limits, which reduces the risk of pump failure due to electrolyte imbalances or other metabolic disturbances. However, the patient's low T3 level (0.05 pg/dL) may indicate hypothyroidism, which can increase the risk of pump failure.

The patient's medication regimen is well-managed, but the patient's low HDL level (0.78 mmol/L) may increase the risk of cardiovascular events, including pump failure.

Overall, the patient's risk of pump failure is significant, but the patient's overall clinical presentation and management plan suggest that the risk is not extremely high. However, the patient's low T3 level and low HDL level may increase the risk of pump failure, making this a more likely outcome than sudden cardiac death."
456,456,P0715,"Age: 73
Gender: Male 
Weight: 72 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 131/87 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,57
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5
LDL (mmol/L): 1,86
Sodium (mEq/L): 135.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,92
Urea (mg/dL): 18,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results suggest that they are at risk for cardiac complications, but the absence of any severe symptoms and the presence of a favorable LVEF value (45.0%) indicate that they are unlikely to experience sudden cardiac death in the near future. The patient's NYHA Class II classification indicates that they have some limitations in their physical activity, but they are still able to perform daily activities without significant symptoms. The absence of any signs of acute myocardial infarction (normal Troponin levels) and the presence of a normal ECG impression also suggest that the patient's cardiac function is relatively preserved. Additionally, the patient's medication regimen, which includes ACE inhibitors and beta blockers, is standard for managing heart failure and reducing cardiovascular risk. Therefore, based on the available information, the most likely outcome for the patient is a favorable one, with a high likelihood of survival over the next few years.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF value of 45.0% indicates that their cardiac function is compromised, and they are at risk for heart failure exacerbation. The presence of NYHA Class II symptoms and the use of loop diuretics and spironolactone suggest that the patient is already experiencing some degree of heart failure. While the patient's medication regimen is standard for managing heart failure, the presence of dyslipemia and hypertension may contribute to further cardiac stress. The patient's elevated creatinine level (141.0) may also indicate some degree of renal impairment, which can be a risk factor for heart failure exacerbation. While the patient's ECG impression does not show any signs of acute myocardial infarction, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia is concerning. Therefore, while the patient is unlikely to experience sudden cardiac death, they are at risk for heart failure exacerbation, which could lead to pump failure.

RANKING: 3. Sudden cardiac death
REASONING: The patient's ECG impression shows signs of ventricular extrasystoles and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. However, the patient's LVEF value is 45.0%, which is relatively preserved, and the patient's medication regimen includes beta blockers, which can reduce the risk of sudden cardiac death. Additionally, the patient's absence of any acute myocardial infarction symptoms and normal Troponin levels suggest that the patient's cardiac function is relatively preserved. However, the patient's ECG impression is concerning, and the presence of ventricular extrasystoles and non-sustained ventricular tachycardia increases the risk of sudden cardiac death. Therefore, while the patient is unlikely to experience sudden cardiac death, the presence of these ECG findings makes it a more likely outcome than pump failure death."
457,457,P0720,"Age: 69
Gender: Male 
Weight: 91 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 21
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 2,82
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,39
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,84
Sodium (mEq/L): 136.0
Protein (g/L): 66
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,12
Urea (mg/dL): 7,99
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and test results suggest that they are at high risk for adverse cardiac events, but the absence of any overt signs of heart failure, acute coronary syndrome, or significant arrhythmias (such as ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia) suggests that the patient's cardiac function may still be somewhat preserved. The presence of a low LVEF (30%) indicates significant left ventricular dysfunction, but the patient's NYHA Class III symptoms and stable hemodynamics (BP 120/80 mmHg) suggest that they are not currently in acute decompensated heart failure. The patient's troponin level is within normal limits, which further supports this assessment. Additionally, the patient's medication regimen includes ACE inhibitors, which are known to improve cardiac function and reduce mortality in patients with heart failure. While the patient's ECG shows polymorphic ventricular extrasystoles, this finding is not uncommon in patients with heart failure and is often a benign finding. Overall, the combination of these factors suggests that the patient is at high risk for cardiac events, but the current clinical presentation is not indicative of an immediate life-threatening situation, making a survivor prognosis the most likely outcome."
458,458,P0721,"Age: 39
Gender: Male 
Weight: 70 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,65
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,83
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 486.0
Protein (g/L): 72
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,76
Urea (mg/dL): 8,15
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 39-year-old male with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is compromised due to an enlarged left ventricle. The patient's NYHA Class II indicates mild symptoms, which suggests that the condition is not severely impacting the patient's daily life. 

The patient's laboratory results show elevated creatinine levels (88.0 mmol/L), indicating impaired kidney function, which is a common complication of heart failure. However, the patient is on medications that are commonly used to manage heart failure, such as beta blockers, spironolactone, and an ACE inhibitor, which may help alleviate symptoms and slow disease progression.

The patient's troponin level (0.03 ng/mL) is within the normal range, which suggests that there is no significant myocardial infarction (heart attack) at this time. The ECG findings of ventricular extrasystole (polymorphic) are concerning, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient is not at high risk for sudden cardiac death.

Given these factors, the patient's overall prognosis is more likely to be a survivor, as the patient's condition is manageable with current treatment, and there are no red flags indicating a high risk of sudden cardiac death or pump failure. However, regular monitoring and follow-up appointments will be necessary to adjust treatment and prevent potential complications.

RANKING: 
2. Sudden cardiac death
REASONING: 
The patient's ECG findings of ventricular extrasystole (polymorphic) are concerning and could potentially increase the risk of sudden cardiac death. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces the likelihood of sudden cardiac death. 

Additionally, the patient's elevated creatinine levels and impaired kidney function could increase the risk of cardiac complications, including sudden cardiac death. However, the patient is on medications that are commonly used to manage heart failure and kidney function, which may help mitigate these risks.

RANKING: 
3. Pump failure death
REASONING: 
The patient's left ventricular ejection fraction (LVEF) is 30.0%, which is significantly below the normal range (50-70%). This indicates that the patient's heart is not pumping efficiently, which increases the risk of pump failure.

Additionally, the patient's elevated creatinine levels and impaired kidney function could increase the risk of complications such as heart failure exacerbation, which could lead to pump failure. However, the patient's NYHA Class II symptoms and response to current treatment suggest that the patient's heart is still functional, and pump failure is less likely in the short term."
459,459,P0723,"Age: 64
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/85 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,97
Sodium (mEq/L): 140.0
Protein (g/L): 63
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,92
Urea (mg/dL): 9,32
LVEF (%): 31.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's overall prognosis is considered favorable due to the following reasons:
- The patient's NYHA Class II indicates mild symptoms, which suggests that the patient is still relatively active and able to perform daily activities without significant limitations.
- The patient's LVEF (Left Ventricular Ejection Fraction) of 31.0 is within the normal range, indicating that the left ventricle is still functioning relatively well.
- The absence of significant elevations in troponin levels suggests that there is no acute myocardial infarction or significant cardiac injury.
- The patient's medication regimen, which includes loop diuretics, statins, and an ACE inhibitor, is standard for managing heart failure and reducing cardiovascular risk factors.
- The ECG findings do not indicate any life-threatening arrhythmias, which further supports a favorable prognosis.
- The patient's laboratory values, including electrolyte levels and liver function tests, are relatively normal, indicating that there are no significant underlying metabolic or liver disorders that could impact cardiac function.

While the patient's past medical history of dilated cardiomyopathy is a significant concern, the patient's current clinical status and medication regimen suggest that they are well-managed and at risk for a favorable outcome."
460,460,P0724,"Age: 86
Gender: Male 
Weight: 80 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 139/93 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,46
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1329.0
Protein (g/L): 70
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 0,63
Urea (mg/dL): 9,48
LVEF (%): 33.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

The patient's overall clinical presentation and lab results suggest a high risk for adverse cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. The patient's NYHA Class II indicates moderate symptoms of heart failure, and the elevated LVEF of 33.0 suggests a significant reduction in cardiac function.

The patient's ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) are concerning for arrhythmias, which can lead to sudden cardiac death. The presence of ventricular tachycardia, in particular, is a significant risk factor for sudden cardiac death.

The patient's elevated troponin level (0.05 ng/mL) is also a marker of myocardial injury, which may indicate ongoing cardiac damage. The patient's creatinine level (80.0 mmol/L) is elevated, which may indicate impaired renal function, which can contribute to fluid overload and worsen heart failure.

While the patient is currently on medications that may help manage heart failure and hypertension, the presence of multiple comorbidities (diabetes, peripheral vascular disease, and hypertension) and the patient's poor cardiac function (LVEF 33.0) make it challenging to predict a long-term outcome. However, given the patient's age (86) and the presence of multiple risk factors, I would rank the patient as a survivor, with a moderate risk of sudden cardiac death and pump failure death.

The patient's low T3 level (0.06 pg/dL) and normal TSH level (0.63 mIU/L) suggest that the patient is euthyroid, which is good news. However, the patient's low HDL cholesterol level (1.78 mmol/L) and high triglyceride level (not provided) may contribute to atherosclerosis and further cardiac risk.

In conclusion, while the patient is currently on medications that may help manage their condition, the combination of their cardiac history, ECG findings, and laboratory results make it challenging to predict a long-term outcome. However, given the patient's age and multiple risk factors, I would rank the patient as a survivor with a moderate risk of sudden cardiac death and pump failure death."
461,461,P0726,"Age: 85
Gender: Male 
Weight: 69 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,31
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 31,5
Glucose (mmol/L): 5,71
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,82
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 407.0
Protein (g/L): 72,3
T3 (pg/dL): 0,0507
T4 (ng/L): 11,37
TSH (mIU/L): 3,67
Urea (mg/dL): 6
LVEF (%): 30.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and LVEF of 30.0, which indicates severe left ventricular dysfunction, the patient is at high risk for adverse cardiac events. However, the patient is taking an ACE inhibitor, which is a standard treatment for heart failure. The presence of ventricular extrasystoles and ventricular tachycardia on the ECG suggests some degree of ventricular instability, but it is not immediately life-threatening. The patient's laboratory values, including elevated creatinine and urea, indicate some degree of renal impairment, but this is not directly related to the cardiac condition. The patient's hemoglobin and liver enzymes are within normal limits. The patient's prognosis for survival is still relatively good due to the presence of ACE inhibitor therapy, which can help to improve cardiac function and reduce mortality. 

2. Sudden cardiac death
REASONING: 
The patient's severe left ventricular dysfunction (LVEF 30.0) and the presence of ventricular extrasystoles and ventricular tachycardia on the ECG make him at high risk for sudden cardiac death. However, the patient's age, NYHA Class II, and the presence of ACE inhibitor therapy may mitigate this risk. Sudden cardiac death is still a possible outcome, but it is less likely compared to the patient's overall survival.

3. Pump failure death
REASONING: 
Pump failure death is a possible outcome for patients with severe left ventricular dysfunction (LVEF 30.0) and NYHA Class II. However, the patient is taking an ACE inhibitor, which can help to improve cardiac function. The patient's renal impairment (elevated creatinine and urea) may increase the risk of pump failure, but this is not the primary concern. Given the patient's overall condition and the presence of ACE inhibitor therapy, pump failure death is the least likely outcome compared to sudden cardiac death."
462,462,P0727,"Age: 75
Gender: Male 
Weight: 78 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 155/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 163.0
Gamma-glutamil transpeptidase (IU/L): 144
Glucose (mmol/L): 6,73
Hemoglobin (g/L): 114.0
HDL (mmol/L): 2,23
Potassium (mEq/L): 5,38
LDL (mmol/L): 2,88
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1364.0
Protein (g/L): 72,4
T3 (pg/dL): 0,0435
T4 (ng/L): 8,18
Troponin (ng/mL): 0,3
TSH (mIU/L): 5,83
Urea (mg/dL): 10,3
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's prognosis can be assessed based on the provided data. Here's the reasoning behind the ranking:

1. The patient's LVEF (Left Ventricular Ejection Fraction) is 30.0%, which indicates severe left ventricular dysfunction, a hallmark of heart failure. This suggests that the patient has advanced cardiomyopathy and is at high risk for cardiac events.

2. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH > 10) on the ECG indicates significant arrhythmia burden, which can lead to sudden cardiac death.

3. The patient's NYHA Class II classification indicates moderate symptoms of heart failure, which may limit physical activity and increase the risk of complications.

4. The patient's electrolyte and renal function are relatively well-maintained, which suggests that they are not experiencing severe kidney dysfunction or electrolyte imbalances that could contribute to cardiac complications.

5. The patient's medication regimen includes ACE inhibitors, which are generally recommended for patients with heart failure and hypertension. However, the presence of severe left ventricular dysfunction and arrhythmias may require more aggressive management.

Considering these factors, the most likely outcome for the patient is a poor prognosis, with a high risk of cardiac events. However, the patient is currently classified as a survivor, which suggests that they may still be able to manage their condition with optimal medical therapy.

The next most likely outcome is pump failure death, which is a possible consequence of the patient's severe left ventricular dysfunction and arrhythmias. The patient's LVEF is severely impaired, and the presence of non-sustained ventricular tachycardia increases the risk of cardiac events.

The least likely outcome is sudden cardiac death, although the patient's ECG findings suggest a high risk of arrhythmias. However, the patient's overall clinical presentation and management plan may mitigate this risk, and they may be able to survive with close monitoring and aggressive management."
463,463,P0729,"Age: 74
Gender: Female 
Weight: 76 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,52
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,27
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 3,8
LDL (mmol/L): 4,57
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2397.0
Protein (g/L): 81,3
T3 (pg/dL): 0,0369
T4 (ng/L): 18,09
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,71
Urea (mg/dL): 8,1
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 74-year-old female with a history of hypertensive cardiomyopathy, hypertension, and NYHA Class II. She has elevated blood pressure (180/90 mmHg), which is a significant risk factor for cardiovascular disease. Her eGFR (estimated from creatinine) is 75 mL/min/1.73m, indicating mild renal impairment. The patient's LVEF is 50.0%, which is below the normal range, indicating left ventricular dysfunction.

Although the patient has elevated troponin levels (0.4 ng/mL), which may indicate some degree of cardiac damage, her overall clinical presentation does not suggest acute myocardial infarction. The patient's ECG shows ventricular extrasystole, which is a benign finding in many patients. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia makes it less likely that the patient will experience sudden cardiac death.

The patient's medications, including digoxin, loop diuretics, and an ACE inhibitor, are standard treatments for managing heart failure and hypertension. The patient's biomarkers, such as elevated BNP (2397 ng/L), indicate some degree of cardiac stress and strain, but do not suggest acute heart failure.

Considering the patient's age, comorbidities, and medication regimen, the most likely outcome for the next few years is that she will survive. However, it is essential to closely monitor her condition and adjust her treatment plan as needed to manage her cardiovascular risk factors and prevent potential complications."
464,464,P0731,"Age: 82
Gender: Female 
Weight: 73 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,28
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,73
Sodium (mEq/L): 142.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,67
Urea (mg/dL): 10,48
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is 82 years old with a history of ischemic dilated cardiomyopathy, which is a significant comorbidity that increases the risk of adverse outcomes. However, the patient's LVEF is 39.0%, which indicates that the heart is still pumping moderately well. The patient's current medications, including beta blockers, statins, and an ACE inhibitor, are standard treatments for heart failure and ischemic heart disease. Additionally, the patient's blood pressure is well-controlled at 130/100 mmHg. The patient's troponin level is 0.03 ng/mL, which is within the normal range, suggesting that there is no acute myocardial infarction. The patient's ECG shows non-sustained ventricular tachycardia, but this is not a contraindication to survival. The patient's kidney function is also within the normal range, and the patient's hemoglobin and electrolyte levels are also within normal limits. Overall, while the patient has significant comorbidities, the patient's current clinical status and treatment plan suggest a favorable prognosis.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a significant finding that increases the risk of sudden cardiac death. Additionally, the patient's LVEF is only 39.0%, which indicates that the heart is not pumping efficiently. The patient's age and history of ischemic dilated cardiomyopathy also increase the risk of sudden cardiac death. While the patient is on beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and ischemic heart disease, the patient's medications may not be sufficient to prevent sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: While the patient's LVEF is 39.0%, which indicates that the heart is not pumping efficiently, the patient's current medications and clinical status suggest that the patient is still able to manage their symptoms. The patient's blood pressure is well-controlled, and the patient's kidney function and electrolyte levels are within normal limits. However, the patient's ECG shows non-sustained ventricular tachycardia, which increases the risk of heart failure exacerbation and pump failure. Additionally, the patient's age and history of ischemic dilated cardiomyopathy increase the risk of pump failure. Therefore, while the patient is not at immediate risk of sudden cardiac death, the patient is at increased risk of pump failure in the next few years."
465,465,P0732,"Age: 48
Gender: Male 
Weight: 93 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 160/100 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 7,89
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 110
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 5,2
LDL (mmol/L): 5,84
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 11.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,19
Urea (mg/dL): 5,32
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient is a 48-year-old male with a history of hypertension, cardiomyopathy, and dyslipidemia. His current NYHA Class II indicates moderate symptoms of heart failure. The patient's high blood pressure, elevated creatinine levels, and low LVEF (25%) suggest significant cardiac dysfunction. However, the patient is currently taking medications that are standard for managing hypertension, heart failure, and cardiomyopathy, such as beta blockers, loop diuretics, spironolactone, and an ACE inhibitor.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate some degree of liver dysfunction, but this is not directly related to cardiac function. The patient's lipid profile is also abnormal, with high total cholesterol and LDL levels, but this is not a primary concern given the patient's cardiac status.

The ECG results show ventricular extrasystole, which is a benign finding but may indicate some degree of cardiac stress. However, there is no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all potential indicators of more severe cardiac dysfunction.

Given the patient's current symptoms, medical history, and laboratory results, the most likely outcome is that the patient will survive. The patient's LVEF is low, but the patient is already taking medications to manage heart failure, and the patient's ECG results do not indicate any life-threatening arrhythmias. With proper management and monitoring, it is possible that the patient's cardiac function may improve, and the patient may be able to tolerate medications and lifestyle changes to reduce the risk of cardiac events.

2. Sudden cardiac death
REASONING: 
While the patient's cardiac function is compromised, the patient's ECG results do not show any life-threatening arrhythmias. The patient's ventricular extrasystole is a benign finding, and there is no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia. Additionally, the patient is already taking medications to manage hypertension, heart failure, and cardiomyopathy.

However, the patient's low LVEF (25%) and elevated creatinine levels suggest significant cardiac dysfunction, which increases the risk of cardiac events. The patient's high blood pressure (160/100 mmHg) also increases the risk of cardiac events. While the patient is taking medications to manage these conditions, the patient's current medication regimen may not be adequate to prevent cardiac events.

3. Pump failure death
REASONING: 
Pump failure death is a possible outcome for this patient, given the patient's low LVEF (25%) and elevated creatinine levels, which indicate significant cardiac dysfunction. However, this outcome is less likely than sudden cardiac death, given the patient's current ECG results and medication regimen.

While the patient's cardiac function is compromised, the patient is already taking medications to manage heart failure, hypertension, and cardiomyopathy. The patient's ventricular extrasystole is a benign finding, and there is no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia. With proper management and monitoring, it is possible that the patient's cardiac function may improve, and the patient may be able to tolerate medications and lifestyle changes to reduce the risk of cardiac events."
466,466,P0736,"Age: 51
Gender: Male 
Weight: 80 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 53,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4
LDL (mmol/L): 2,74
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1780.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,12
Urea (mg/dL): 9,13
LVEF (%): 63.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I would rank the patient as having the highest likelihood of survival for the next few years. This is due to the following reasons:

- The patient's NYHA class is II, indicating mild heart failure symptoms, which is a relatively mild stage of heart failure.
- The patient's LVEF (left ventricular ejection fraction) is 63.0%, which is within the normal range, indicating that the left ventricle is still pumping effectively.
- The patient has been taking beta blockers and statins, which are commonly used to manage heart failure and dyslipidemia, respectively.
- The patient's laboratory results show no significant elevations in liver enzymes (ALT and AST), which suggests that liver function is relatively preserved.
- The patient's creatinine level is elevated, but it is still within the normal range, indicating that kidney function is not severely impaired.
- The patient's BNP level is elevated, which is a marker of heart failure, but it is not extremely high, suggesting that the patient's heart is still pumping effectively.
- The patient's ECG impression shows no ventricular tachycardia or non-sustained ventricular tachycardia, which are potential indicators of arrhythmias that can lead to sudden cardiac death.

While the patient has a history of ischemic dilated cardiomyopathy, hypertension, and dyslipidemia, the patient's current clinical presentation and laboratory results suggest that the condition is relatively well-managed, and the patient is at lower risk for sudden cardiac death and pump failure."
467,467,P0738,"Age: 70
Gender: Female 
Weight: 74 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 91
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 2,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,93
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 623.0
Protein (g/L): 69
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,94
Urea (mg/dL): 3,33
LVEF (%): 38.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is 70 years old, with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction. The patient's left ventricular ejection fraction (LVEF) is 38%, which indicates significant left ventricular dysfunction. The patient's ejection fraction is one of the most critical factors in determining prognosis in heart failure patients.

The patient's current medication regimen includes beta blockers, ACE inhibitors, and statins, which are standard treatments for heart failure and hypertension. The patient's blood pressure is 140/80 mmHg, which is slightly elevated but within a relatively normal range.

The patient's troponin level is 0.01 ng/mL, which is within the normal range. The patient's pro-BNP level is elevated at 623 ng/L, which indicates some degree of heart failure. However, the patient's pro-BNP level is not extremely elevated, which may suggest that the patient's heart failure is not as severe.

Given the patient's age, medical history, and current medical condition, the patient is likely to survive the next few years. The patient's NYHA class is III, indicating severe heart failure, but the patient's medication regimen and relatively normal blood pressure suggest that the patient may be able to tolerate some level of stress and physical activity.

While the patient's LVEF is significantly reduced, the patient's age and relatively normal blood pressure suggest that the patient may be able to tolerate some level of stress and physical activity. Therefore, the most likely outcome is that the patient will survive the next few years.

Sudden cardiac death and pump failure death are less likely outcomes given the patient's current medical condition and medication regimen. While the patient's LVEF is significantly reduced, the patient's elevated pro-BNP level and relatively normal blood pressure suggest that the patient's heart failure is not as severe as it could be. Sudden cardiac death and pump failure death are more likely outcomes in patients with more severe heart failure or those with more significant left ventricular dysfunction."
468,468,P0739,"Age: 47
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 83.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 2,53
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5
LDL (mmol/L): 1,45
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3200.0
Protein (g/L): 70
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,05
Urea (mg/dL): 11,98
LVEF (%): 32.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient's prognosis is primarily influenced by the combination of their underlying heart condition, laboratory results, and the presence of certain risk factors. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which significantly increases their risk for cardiac events. The left ventricular ejection fraction (LVEF) is severely impaired at 32%, indicating poor cardiac function. This low LVEF is a strong predictor of adverse outcomes.

Secondly, the patient's elevated creatinine level (177.0 mmol/L) suggests impaired renal function, which is often seen in advanced heart failure. This can lead to further complications such as fluid overload, electrolyte imbalances, and increased risk of kidney failure.

Thirdly, the patient's elevated troponin level (0.01 ng/mL) indicates some degree of myocardial damage, which can be a sign of ongoing cardiac stress.

The patient's ECG shows ventricular extrasystoles, which are a type of abnormal heart rhythm that can increase the risk of cardiac events. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the likelihood of sudden cardiac death.

In contrast, the patient is on beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic cardiomyopathy. These medications can help manage symptoms, slow disease progression, and reduce the risk of adverse events.

Given these factors, the most likely outcome is that the patient will survive, although with ongoing management and monitoring, there is a risk of pump failure death or sudden cardiac death. However, the combination of the patient's current treatment and the presence of certain risk factors make pump failure death the second most likely outcome, and sudden cardiac death the least likely."
469,469,P0740,"Age: 52
Gender: Male 
Weight: 77 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 135/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes
Albumin (g/L): 43
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,43
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 610.0
Protein (g/L): 70
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,51
Urea (mg/dL): 6,99
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient has a complex medical history, with a significant history of ischemic dilated cardiomyopathy, which is a condition that can lead to heart failure. However, the patient is currently on medications for diabetes, beta blockers, spironolactone, statins, and ACE inhibitors, which are commonly used to manage heart failure and ischemic heart disease. The patient's NYHA class II indicates that they have some limitations in physical activity, but they are still able to perform daily activities without severe symptoms. 

The patient's laboratory results show elevated levels of troponin, which can indicate cardiac damage, but the level is very low (0.01 ng/mL), which suggests that the damage is minimal. The patient's LVEF is 30%, which is significantly reduced, indicating poor heart function. However, the patient is currently asymptomatic and has no signs of acute heart failure.

The patient's ECG results are normal, with no signs of ventricular arrhythmias or other cardiac abnormalities. The patient's Pro-BNP level is elevated, but not excessively high, which may indicate some level of cardiac stress. 

Overall, considering the patient's age, medical history, and current symptoms, I would rank the patient as a survivor. The patient's heart failure is likely stable, and with continued medical management, the patient can likely survive for the next few years without significant progression of their condition. However, close monitoring and regular follow-up appointments will be necessary to ensure that the patient's condition does not worsen.

The other two prognoses, sudden cardiac death and pump failure death, are less likely because the patient's current symptoms and test results do not indicate a high risk of sudden cardiac death or acute heart failure. While the patient has a significant medical history, the patient's current condition is stable, and with proper management, the patient can likely survive for the next few years."
470,470,P0741,"Age: 63
Gender: Female 
Weight: 85 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,45
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 347.0
Protein (g/L): 68,4
T4 (ng/L): 14
TSH (mIU/L): 1,32
Urea (mg/dL): 5,32
LVEF (%): 68.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 63-year-old female with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction. The patient's current NYHA Class II indicates moderate symptoms of heart failure, but the patient is still able to perform daily activities with some limitation. The patient's LVEF of 68.0 is slightly below the normal range, indicating some degree of left ventricular dysfunction.

The patient's laboratory results show elevated creatinine levels (78.0 mmol/L), which may indicate some degree of renal impairment. However, the patient is not on dialysis, and the creatinine level is not extremely high.

The ECG impression shows a history of ventricular extrasystole, which may indicate some degree of ventricular dysfunction. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

The patient is on beta blockers and statins, which are standard treatments for heart failure and hyperlipidemia, respectively. The patient's hemoglobin level is slightly elevated at 124.0 g/L, which is within the normal range.

Considering these factors, the patient's overall condition is stable, and the patient is likely to survive for the next few years without any significant adverse events. The patient's heart failure symptoms are moderate, but the patient is still able to manage with current medications, and the patient's renal function is not severely impaired.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death. The patient's LVEF of 68.0 is slightly below the normal range, which may indicate some degree of left ventricular dysfunction.

The patient's ECG impression shows a history of ventricular extrasystole, which may indicate some degree of ventricular dysfunction. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death, but does not eliminate it.

The patient's elevated creatinine level (78.0 mmol/L) and slightly elevated liver enzymes (ALT and AST) may indicate some degree of renal and liver impairment, which may increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's NYHA Class II indicates moderate symptoms of heart failure, which may increase the risk of pump failure. The patient's LVEF of 68.0 is slightly below the normal range, which may indicate some degree of left ventricular dysfunction.

The patient's elevated creatinine level (78.0 mmol/L) and slightly elevated liver enzymes (ALT and AST) may indicate some degree of renal and liver impairment, which may increase the risk of pump failure.

The patient's ECG impression shows a history of ventricular extrasystole, which may indicate some degree of ventricular dysfunction. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death, but does not eliminate the risk of pump failure.

The patient's current medications, beta blockers and statins, are standard treatments for heart failure and hyperlipidemia, respectively. However, the patient's symptoms and laboratory results suggest that the patient may require additional treatment to manage heart failure and prevent pump failure."
471,471,P0744,"Age: 49
Gender: Male 
Weight: 92 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,6
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 7,4
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 171.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,47
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5.0
Protein (g/L): 80,1
T4 (ng/L): 17
TSH (mIU/L): 0,64
Urea (mg/dL): 3,5
LVEF (%): 57.0
Medications: Amiodarone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient's NYHA Class II indicates that they have moderate symptoms of heart failure, but they are still able to perform daily activities without severe limitations. Their LVEF of 57.0 is within the normal range for an adult, and their creatinine level of 3.5 mg/dL is slightly elevated but not indicative of acute kidney injury. The patient's ECG impression shows no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all risk factors for sudden cardiac death. Additionally, the patient's medication regimen includes Amiodarone, which is used to treat various arrhythmias. The patient's laboratory values, including their hemoglobin, potassium, and electrolytes, are relatively stable, suggesting that the patient is not experiencing acute electrolyte imbalances or anemia. Overall, these factors suggest that the patient is likely to survive for the next few years.

2. Pump failure death
REASONING: 
The patient's LVEF of 57.0 is slightly below the normal range, indicating some degree of left ventricular dysfunction. Their NYHA Class II classification also suggests that they have some symptoms of heart failure. While their creatinine level is slightly elevated, it is not indicative of acute kidney injury. However, the patient's hypertension and hypertensive cardiomyopathy may still pose a risk for cardiac pump failure in the future. The patient's medication regimen includes Amiodarone, which may help manage arrhythmias but may not address the underlying cardiac dysfunction.

3. Sudden cardiac death
REASONING: 
The patient's ECG impression shows a monomorphic ventricular extrasystole, which is a type of arrhythmia that can increase the risk of sudden cardiac death. The patient's NYHA Class II classification and LVEF of 57.0 suggest that they have some degree of cardiac dysfunction, which may increase the risk of sudden cardiac death. The patient's past medical history of hypertensive cardiomyopathy and hypertension also increases their risk for cardiac arrhythmias. However, the patient's stable laboratory values and the absence of other risk factors for sudden cardiac death, such as non-sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia, make this prognosis less likely."
472,472,P0745,"Age: 75
Gender: Female 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 38,7
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 108.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,28
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1143.0
Protein (g/L): 64,9
T4 (ng/L): 11
TSH (mIU/L): 13,15
Urea (mg/dL): 16,31
LVEF (%): 34.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
The patient is 75 years old and has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. However, the patient is currently on medications that are commonly used to manage heart failure and arrhythmias, including beta blockers, angiotensin II receptor blockers, and spironolactone. The patient's left ventricular ejection fraction (LVEF) is 34%, which is significantly reduced, indicating poor cardiac function.

Despite these factors, the patient's current ECG impression does not show any life-threatening arrhythmias, and the patient has a relatively stable hemodynamic status. The patient's medications and the lack of any recent adverse cardiac events suggest that the patient is currently stable. Additionally, the patient's age and weight are not extremely high, which reduces the risk of sudden cardiac death.

Therefore, based on the available information, I would predict that the patient is likely to survive the next few years, with a reasonable quality of life and minimal risk of sudden cardiac death or pump failure.

2. Sudden Cardiac Death 
REASONING: 
While the patient's age and medical history increase the risk of sudden cardiac death, the patient's current ECG impression does not show any life-threatening arrhythmias, and the patient is on medications that are commonly used to manage arrhythmias. However, the patient's LVEF is significantly reduced, indicating poor cardiac function, which increases the risk of arrhythmias and sudden cardiac death.

Additionally, the patient has a history of myocardial infarction, which is a significant risk factor for sudden cardiac death. However, the patient is currently on medications that are commonly used to manage heart failure and arrhythmias, which reduces the risk of sudden cardiac death.

3. Pump Failure Death 
REASONING: 
Given the patient's significantly reduced LVEF (34%), poor cardiac function, and history of ischemic dilated cardiomyopathy, pump failure is a significant concern. The patient's current medications, including beta blockers and spironolactone, are commonly used to manage heart failure, but the patient's LVEF is still significantly reduced, indicating poor cardiac function.

Additionally, the patient's elevated creatinine levels (113.0 mmol/L) suggest some degree of renal impairment, which can be a complication of heart failure. While the patient is on medications that are commonly used to manage heart failure, the patient's overall clinical picture suggests that pump failure is a significant risk, and the patient may require close monitoring and adjustment of their medications to manage their cardiac function."
473,473,P0746,"Age: 71
Gender: Female 
Weight: 85 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 38,7
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,51
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 292.0
Protein (g/L): 64,9
T4 (ng/L): 16
TSH (mIU/L): 1,02
Urea (mg/dL): 7,15
LVEF (%): 58.0
Medications: Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

Based on the provided patient data, the patient's prognosis can be determined as follows:

1. The patient is 71 years old, which is an advanced age for a significant portion of the population. However, the patient's NYHA Class II indicates that the patient has some limitations in physical activity due to heart failure, but they are not in a New York Heart Association Class III or IV. This suggests that the patient's heart function is not severely compromised.

2. The patient has a history of hypertension, which is a significant risk factor for cardiovascular disease. However, the patient's blood pressure is controlled with medications, which reduces this risk.

3. The patient's LVEF (Left Ventricular Ejection Fraction) is 58.0%, which is below the normal range (50-70%). This indicates that the patient's heart is not pumping efficiently, which increases the risk of heart failure.

4. The patient's elevated creatinine level (87.0 mol/L) suggests that the patient may have some degree of renal impairment, which can be a complication of heart failure.

5. The patient's elevated Pro-BNP (pro-brain natriuretic peptide) level (292.0 ng/L) is indicative of heart failure. Elevated BNP levels are associated with increased mortality and morbidity in patients with heart failure.

6. The patient's ECG shows ventricular extrasystoles, which can be a sign of ventricular arrhythmias. While the patient does not have ventricular tachycardia, the presence of ventricular extrasystoles increases the risk of arrhythmias, which can lead to sudden cardiac death.

Considering these factors, the most likely outcome for the patient is survival. The patient's heart function is compromised, but they are not in a severe state of heart failure, and their blood pressure is controlled. The patient's elevated creatinine level and Pro-BNP level suggest that the patient may require close monitoring and possibly additional treatment to manage their heart failure. However, the patient's overall condition is not as severe as to predict a high risk of sudden cardiac death.

In comparison, pump failure death is a possible outcome, given the patient's compromised LVEF and elevated Pro-BNP level. However, the patient's controlled blood pressure and absence of severe heart failure symptoms suggest that pump failure death is less likely.

Sudden cardiac death is the least likely outcome, given the patient's controlled blood pressure, absence of ventricular tachycardia, and ventricular extrasystoles. However, the patient's elevated Pro-BNP level and ventricular extrasystoles do increase the risk of arrhythmias, which can lead to sudden cardiac death."
474,474,P0747,"Age: 58
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 3,8
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,35
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 158.0
Protein (g/L): 68
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1
Urea (mg/dL): 6,66
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1

REASONING: 

Based on the provided patient data, the patient's prognosis is likely to be a survivor. The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 30.0%, indicating severe left ventricular dysfunction, which is a hallmark of advanced heart failure. However, the patient is currently on medications for heart failure management, including Angiotensin II Receptor Blocker, Beta Blockers, and Statins, which are standard treatments for heart failure.

Although the patient has a high creatinine level (53.0 mmol/L), which may indicate some degree of renal impairment, it is not severe enough to significantly impact the patient's overall prognosis. The patient's ECG findings, including ventricular extrasystoles, suggest some degree of ventricular dysfunction, but there is no evidence of acute ventricular tachycardia or other life-threatening arrhythmias.

The patient's troponin level is within normal limits, and the TSH level is also normal, indicating no acute myocardial infarction or thyroid dysfunction. The patient's electrolytes and renal function tests are also relatively stable.

Given these factors, the patient's prognosis is more likely to be a survivor, as they are receiving optimal medical management for their heart failure and do not have any acute life-threatening conditions. However, it is essential to monitor the patient closely for any signs of worsening heart failure or arrhythmias, and adjust their treatment plan as needed."
475,475,P0748,"Age: 69
Gender: Male 
Weight: 59 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 122/68 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,43
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 15272.0
Protein (g/L): 59
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 8,49
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and presence of hypertensive cardiomyopathy and dyslipidemia suggest that the patient has a significant underlying cardiac condition. However, the patient is currently being treated with beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for managing hypertension and heart failure. The patient's LVEF is 15%, which is a relatively preserved ejection fraction, suggesting that the patient may still have some residual cardiac function.

The patient's Pro-BNP level is elevated at 15,272 ng/L, which indicates some degree of ventricular stress and potential heart failure. However, the patient is also being treated with an ACE inhibitor, which can help to reduce BNP levels. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests that the patient has an increased risk of arrhythmias, but these are not necessarily indicative of an immediate life-threatening condition.

Given the patient's overall clinical presentation and treatment plan, I would rank the patient as a survivor, with a moderate to high likelihood of long-term survival. The patient's elevated creatinine level (8.49 mg/dL) suggests some degree of renal impairment, but this can be managed with medication and lifestyle modifications.

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the patient's current treatment plan and the fact that the patient's LVEF is relatively preserved. Sudden cardiac death is unlikely due to the patient's absence of symptoms and the presence of beta blockers, which can help to reduce the risk of arrhythmias. Pump failure death is also less likely due to the patient's preserved LVEF and the presence of ACE inhibitors, which can help to reduce ventricular stress.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient has an increased risk of arrhythmias due to the presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, the patient's current treatment plan and overall clinical presentation suggest that the risk of sudden cardiac death is moderate.

RANKING: 3. Pump failure death
REASONING: 

The patient's elevated creatinine level and Pro-BNP level suggest that the patient has some degree of ventricular stress and potential heart failure. However, the patient's LVEF is relatively preserved, and the patient is being treated with ACE inhibitors, which can help to reduce ventricular stress. Additionally, the patient's NYHA Class II suggests that the patient has some degree of functional capacity, which reduces the likelihood of pump failure death. Therefore, while pump failure death is a possible outcome, it is the least likely of the three prognoses."
476,476,P0749,"Age: 75
Gender: Male 
Weight: 64 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,72
Sodium (mEq/L): 137.0
Protein (g/L): 68
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,44
Urea (mg/dL): 8,65
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

Based on the provided patient data, I rank the patient's prognosis as follows:

1. Survivor: The patient's overall health status, despite having multiple comorbidities, is relatively stable. The patient's NYHA Class II indicates moderate symptoms, but they are still able to perform daily activities without severe limitation. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient's heart rhythm is relatively stable. The patient's LVEF is 40%, which is significantly reduced but not severely impaired, indicating that the patient may still have some residual cardiac function. The patient's hemoglobin and liver function tests are within normal limits, and the patient is on medications that are commonly used to manage heart failure and hypertension. Given these factors, I believe that the patient is likely to survive for the next few years.

2. Sudden Cardiac Death: While the patient has a history of ischemic dilated cardiomyopathy, which is a risk factor for sudden cardiac death, the patient's current ECG does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia. The patient's LVEF is significantly reduced, but not severely impaired, and the patient is on medications that are commonly used to manage heart failure. However, the patient's age and comorbidities do increase the risk of sudden cardiac death. I would estimate that the risk of sudden cardiac death is moderate, but it is not the most likely outcome.

3. Pump Failure Death: Pump failure death is a possible outcome for patients with severe heart failure, and the patient's LVEF is significantly reduced. However, the patient is on medications that are commonly used to manage heart failure, including ACE inhibitors, spironolactone, and statins. The patient's NYHA Class II symptoms suggest that they are able to perform daily activities without severe limitation, which is a good indicator of cardiac function. Additionally, the patient's hemoglobin and liver function tests are within normal limits. Given these factors, I believe that the risk of pump failure death is lower than sudden cardiac death, but still a possible outcome.

It is essential to note that this is a subjective interpretation of the patient's data, and a more accurate prognosis can only be made by a comprehensive evaluation and discussion with the patient."
477,477,P0750,"Age: 62
Gender: Male 
Weight: 107 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 108
Glucose (mmol/L): 12,2
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 134.0
Protein (g/L): 69
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,5
Urea (mg/dL): 8,65
LVEF (%): 47.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, hypertension, and a previous myocardial infarction. The patient's current NYHA Class II indicates that they have some limitation in physical activity due to their heart condition, but they are still able to perform daily activities without severe symptoms.

The patient's laboratory results show elevated creatinine levels, which may indicate some degree of renal impairment. However, the patient is on medications that are commonly used to treat patients with heart failure and renal impairment, such as loop diuretics and ACE inhibitors.

The ECG results show non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia, which are concerning signs of arrhythmia. However, the patient is on beta blockers, which are commonly used to treat arrhythmias and reduce the risk of sudden cardiac death.

The patient's LVEF is 47%, which is lower than the normal range, indicating some degree of left ventricular dysfunction. However, the patient is on medications that are commonly used to treat heart failure, including spironolactone, which is an aldosterone antagonist that can help improve LVEF.

Considering the patient's complex medical history, comorbidities, and the presence of arrhythmias, I believe that the patient is at high risk of adverse outcomes. However, the patient's laboratory results and medication regimen suggest that they are receiving optimal treatment for their heart condition. Therefore, I rank the patient as having a moderate to high risk of adverse outcomes, but I do not predict a high risk of sudden cardiac death or pump failure death in the short term. The patient's overall prognosis is more likely to be a survivor, given their stable laboratory results and the effectiveness of their treatment regimen."
478,478,P0751,"Age: 51
Gender: Male 
Weight: 61 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40,5
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 7,28
Creatinine (mmol/L): 121.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,77
LDL (mmol/L): 5,17
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 4168.0
Protein (g/L): 72,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,03
Urea (mg/dL): 7,7
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 51-year-old male with a history of idiopathic dilated cardiomyopathy, which is a condition characterized by the enlargement of the heart's chambers, leading to reduced cardiac function. The patient's NYHA Class II indicates moderate symptoms of heart failure, such as fatigue, shortness of breath, and swelling in the legs.

The patient's elevated Pro-BNP levels (4168.0 ng/L) suggest significant cardiac stress and strain, which is consistent with the diagnosis of heart failure. The patient's LVEF (20.0%) is also severely impaired, indicating a significant reduction in cardiac function.

Despite the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG, these findings are not indicative of a high risk of sudden cardiac death. The patient is also on medications, including beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure and are expected to improve symptoms and cardiac function.

The patient's electrolyte levels, liver function tests, and other laboratory values are generally within normal limits, with the exception of slightly elevated creatinine levels, which may indicate some degree of kidney impairment. However, this is not uncommon in patients with heart failure.

Considering these factors, the patient's overall prognosis is good, and the likelihood of sudden cardiac death is relatively low. The patient's heart failure symptoms are manageable with current medications, and the patient's cardiac function is likely to improve with continued medical therapy. Therefore, the most likely outcome for the next few years is a survivor."
479,479,P0753,"Age: 56
Gender: Male 
Weight: 88 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 145/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40,5
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 5,99
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 120
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 148.0
Potassium (mEq/L): 4,17
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 906.0
Protein (g/L): 78,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,46
Urea (mg/dL): 7,5
LVEF (%): 20.0
Medications: Amiodarone, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is likely to be a survivor for the next few years due to several factors. Firstly, the patient's age (56) is not extremely high, and with proper management, many patients with idiopathic dilated cardiomyopathy can survive for several years. The patient's NYHA Class II indicates that they have some limitation in physical activity, but they are not severely limited. 

The patient's elevated troponin level (0.01 ng/mL) may indicate some degree of cardiac damage, but it is not significantly elevated, suggesting that the patient's heart is not in a state of acute damage or acute infarction. The patient's creatinine level (7.5 mg/dL) is elevated, indicating some degree of renal impairment, which can be managed with proper medication and lifestyle changes. The patient's ECG findings, including ventricular extrasystole and polymorphic ventricular extrasystole, suggest that the patient is at risk of arrhythmias, but this can be managed with medication.

The patient's medication regimen includes ACE inhibitors, loop diuretics, and amiodarone, which can help manage hypertension, heart failure, and arrhythmias. The patient's low LVEF (20.0%) indicates severe left ventricular dysfunction, but with proper management, this can be improved over time.

Overall, while this patient has several comorbidities and risk factors, the patient's age, NYHA Class II, and relatively mild cardiac dysfunction make a survivorship prognosis more likely. However, close monitoring and follow-up are necessary to adjust the treatment plan as needed.

RANKING: 2. Sudden cardiac death
REASONING: 

This patient is at increased risk of sudden cardiac death due to several factors. The patient's LVEF (20.0%) is severely impaired, indicating a high risk of arrhythmias and sudden cardiac death. The patient's ECG findings, including ventricular extrasystole and polymorphic ventricular extrasystole, suggest a high risk of arrhythmias. The patient's elevated troponin level (0.01 ng/mL) may indicate some degree of cardiac damage, which can increase the risk of arrhythmias.

The patient's comorbidities, including hypertension, diabetes, and dyslipemia, also increase the risk of sudden cardiac death. The patient's medication regimen, including amiodarone, can help manage arrhythmias, but it is not a guarantee against sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

This patient is at risk of pump failure death due to several factors. The patient's LVEF (20.0%) is severely impaired, indicating a high risk of heart failure. The patient's NYHA Class II indicates that they have some limitation in physical activity, which can lead to deconditioning and increased risk of pump failure.

The patient's elevated creatinine level (7.5 mg/dL) indicates some degree of renal impairment, which can lead to fluid overload and increased risk of pump failure. The patient's low albumin level (40.5 g/L) may indicate some degree of malnutrition, which can increase the risk of pump failure.

The patient's comorbidities, including hypertension, diabetes, and dyslipemia, also increase the risk of pump failure. The patient's medication regimen, including loop diuretics, can help manage fluid overload, but it is not a guarantee against pump failure."
480,480,P0755,"Age: 75
Gender: Female 
Weight: 69 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41,3
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,35
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5
Hemoglobin (g/L): 125.0
HDL (mmol/L): 2,1
Potassium (mEq/L): 4,78
LDL (mmol/L): 1,82
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 285.0
Protein (g/L): 70,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,78
Urea (mg/dL): 8
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient's age, NYHA Class II, and the absence of any acute cardiac events (e.g., ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia) on the ECG impression suggest a relatively stable cardiac condition. The patient's left ventricular ejection fraction (LVEF) is 70%, which is within the normal range, indicating that the patient's heart is functioning relatively well. The patient's medications, including beta blockers, loop diuretics, spironolactone, and ACE inhibitor, are standard treatments for managing heart failure and valvular cardiomyopathy. The patient's laboratory results, such as the elevated creatinine level, may indicate some degree of renal impairment, but it is not immediately life-threatening.

2. Sudden Cardiac Death
REASONING:
While the patient's ECG shows ventricular extrasystole, which may indicate an increased risk of arrhythmias, the absence of any sustained ventricular tachycardia or other high-risk arrhythmias on the ECG impression makes this prognosis less likely. However, the patient's age, valvular cardiomyopathy, and elevated creatinine level do increase the risk of sudden cardiac death. The patient's NYHA Class II also suggests that the patient has some degree of heart failure, which may increase the risk of arrhythmias.

3. Pump Failure Death
REASONING:
The patient's LVEF is 70%, which is within the normal range, and the patient is taking medications that are standard for managing heart failure. The patient's laboratory results, such as the elevated creatinine level, may indicate some degree of renal impairment, but it is not immediately life-threatening. The absence of any acute cardiac events on the ECG impression makes this prognosis less likely. However, the patient's age and valvular cardiomyopathy do increase the risk of pump failure, and the patient's NYHA Class II suggests that the patient has some degree of heart failure."
481,481,P0756,"Age: 74
Gender: Male 
Weight: 72 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 175/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 38,9
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 3,83
LDL (mmol/L): 3,2
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 373.0
Protein (g/L): 64,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,68
Urea (mg/dL): 8,8
LVEF (%): 41.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor

REASONING: 

Based on the provided patient data, the patient has a history of hypertensive cardiomyopathy and hypertension, which suggests a chronic cardiac condition that has likely led to left ventricular dysfunction. The patient's left ventricular ejection fraction (LVEF) is 41%, which is significantly reduced, indicating impaired cardiac function. The presence of elevated troponin levels (0.01 ng/mL) also suggests some degree of cardiac damage.

The patient's electrocardiogram (ECG) shows ventricular extrasystole, which may be a sign of ventricular arrhythmias. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the likelihood of an acute cardiac event.

The patient's medication regimen, including amiodarone and spironolactone, suggests that the patient is being managed for arrhythmias and fluid overload, respectively. The presence of spironolactone also suggests that the patient has some degree of heart failure.

Given these factors, the patient's overall prognosis is more favorable, and it is likely that the patient will survive the next few years with proper management and treatment of their underlying conditions. While there is a risk of cardiac events, the patient's current condition and management plan suggest that a survivor outcome is the most likely."
482,482,P0757,"Age: 59
Gender: Male 
Weight: 91 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43,1
ALT or GPT (IU/L): 148.0
AST or GOT (IU/L): 85.0
Total Cholesterol (mmol/L): 3,74
Creatinine (mmol/L): 121.0
Gamma-glutamil transpeptidase (IU/L): 187
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,6
Potassium (mEq/L): 4,09
LDL (mmol/L): 2,43
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 182.0
Protein (g/L): 79,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,7
Urea (mg/dL): 8
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the patient's data, I would rank the patient as a survivor for the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a significant comorbidity, but the patient is currently being managed with medications that are standard for heart failure and arrhythmias. The patient's LVEF is 35%, which is significantly reduced, but the patient is not experiencing acute decompensated heart failure symptoms at the time of evaluation. The patient's NT-proBNP levels are elevated, which may indicate some degree of heart failure, but the patient's clinical status is stable.

The patient's ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning for arrhythmias, but the patient is not experiencing symptoms or complications from these arrhythmias. The patient is also not experiencing any acute coronary syndromes or acute decompensated heart failure.

While the patient's creatinine level is elevated, which may indicate some degree of kidney dysfunction, the patient's hemoglobin and potassium levels are within normal limits, and the patient is not experiencing any acute kidney injury symptoms. The patient's lipid profile is also not significantly abnormal, and the patient is on statins, which is standard for cardiovascular disease prevention.

Overall, the patient's clinical status is stable, and the patient is receiving standard management for heart failure and arrhythmias. Therefore, I would rank the patient as a survivor for the next few years."
483,483,P0758,"Age: 55
Gender: Male 
Weight: 81 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44,5
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,33
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,08
Potassium (mEq/L): 4,76
LDL (mmol/L): 2,78
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 5004.0
Protein (g/L): 70,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,29
Urea (mg/dL): 10,8
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient is at high risk for a poor outcome due to the presence of severe left ventricular dysfunction (LVEF 20.0), which indicates significant cardiomyopathy. The patient's NYHA Class II classification suggests moderate symptoms, but the LVEF is a more critical factor in determining the prognosis. The patient's elevated creatinine level (110.0 mmol/L) and elevated Pro-BNP levels (5004.0 ng/L) also indicate a high risk of adverse cardiac events.

The patient's lipid profile is not ideal, with high LDL and low HDL levels, which can contribute to atherosclerosis and cardiac events. However, the patient is on statins, which should help to manage this risk.

The presence of ventricular extrasystoles on the ECG is a concerning sign, indicating potential electrical instability in the heart. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is a positive sign.

Given the patient's severe cardiomyopathy, elevated biomarkers, and the presence of ventricular extrasystoles, the likelihood of a sudden cardiac death or pump failure is high. However, the patient is already receiving medications that should help to manage their condition, and the absence of other high-risk features (e.g., severe hypertension, atrial fibrillation) suggests that the patient is at lower risk for a sudden cardiac death compared to pump failure.

Therefore, based on the available data, the most likely outcome is that the patient will survive, but with a high risk of adverse cardiac events."
484,484,P0759,"Age: 69
Gender: Male 
Weight: 73 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 40,1
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,94
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 173.0
HDL (mmol/L): 0,79
Potassium (mEq/L): 3,48
LDL (mmol/L): 3,82
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1837.0
Protein (g/L): 71,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,2
Urea (mg/dL): 10,1
LVEF (%): 18.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is 69 years old with a history of idiopathic dilated cardiomyopathy and hypertension, which are risk factors for heart failure and arrhythmias. The patient's current NYHA Class II indicates moderate symptoms of heart failure, which suggests that the patient is still relatively functional despite the disease. The patient's LVEF of 18.0 is significantly reduced, indicating poor cardiac function.

The patient's biomarkers, such as elevated troponin and BNP levels, also suggest cardiac stress and strain. However, the patient's hemoglobin level is within a relatively normal range, which could indicate some level of compensation. The patient's medication regimen includes beta blockers, which are known to improve survival and reduce symptoms in patients with heart failure.

The ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning, but the patient's overall clinical presentation and medication regimen suggest that these findings are not immediately life-threatening. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia also suggests that the patient is not at high risk for sudden cardiac death.

Given the patient's age, comorbidities, and medication regimen, the most likely outcome is that the patient will survive for the next few years, although with ongoing management and monitoring, the patient may require adjustments to their treatment plan to manage their symptoms and prevent further decline.

RANKING: 
2. Sudden cardiac death
REASONING: 
The patient's ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning for an increased risk of sudden cardiac death. The patient's history of idiopathic dilated cardiomyopathy and hypertension also increases the risk of sudden cardiac death. However, the patient's age, hemoglobin level, and medication regimen suggest that the patient is not at extremely high risk for sudden cardiac death.

RANKING: 
3. Pump failure death
REASONING: 
The patient's LVEF of 18.0 is significantly reduced, indicating poor cardiac function. The patient's elevated BNP and troponin levels also suggest that the patient is experiencing cardiac stress and strain. While the patient is currently on beta blockers and other medications to manage their symptoms, the patient's NYHA Class II indicates that their heart failure is not well-controlled, and the patient may require further medical intervention to improve their symptoms and function.

However, given the patient's overall clinical presentation and medication regimen, pump failure death is less likely than sudden cardiac death. The patient's hemoglobin level and ECG findings suggest that the patient is not at immediate risk for cardiac arrest, and the patient's medication regimen is likely to provide some level of protection against sudden cardiac death."
485,485,P0763,"Age: 60
Gender: Male 
Weight: 74 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 95/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,18
LDL (mmol/L): 4,2
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2774.0
Protein (g/L): 65,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,76
Urea (mg/dL): 7,6
LVEF (%): 21.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the patient's data, I would rank the patient as a survivor with a high likelihood of survival for the next few years. The key factors contributing to this assessment are:

- NYHA Class II: The patient has a moderate level of heart failure symptoms, but it's not severe enough to indicate advanced heart failure.
- LVEF 21.0: The left ventricular ejection fraction is significantly reduced, indicating impaired cardiac function, but it's not completely collapsed, which is a good sign.
- Medications: The patient is taking beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy.
- Pro-BNP level: The elevated Pro-BNP level indicates some degree of heart failure, but it's not extremely high, suggesting that the patient is not in acute decompensated heart failure.
- No acute arrhythmias: The ECG impression shows no signs of acute arrhythmias, which reduces the risk of sudden cardiac death.

However, the patient's age (60), low LVEF (21%), and elevated creatinine level (100.0) do raise some concerns about the patient's long-term prognosis.

RANKING: 2. Sudden cardiac death
REASONING:
While the patient is unlikely to die suddenly, I would rank sudden cardiac death as a possibility due to the presence of:
- Idiopathic dilated cardiomyopathy: This condition increases the risk of sudden cardiac death.
- Non-sustained ventricular tachycardia: The ECG impression shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death.
- Low LVEF: The patient's low LVEF increases the risk of arrhythmias and sudden cardiac death.
- Age: The patient's age (60) is also a risk factor for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING:
Pump failure death is a possibility, but I would rank it as the least likely due to the patient's:
- NYHA Class II: The patient's symptoms are not severe enough to indicate advanced heart failure.
- Medications: The patient is taking standard treatments for heart failure, which should help manage symptoms.
- Pro-BNP level: While elevated, it's not extremely high, suggesting that the patient is not in acute decompensated heart failure.
- No acute arrhythmias: The ECG impression shows no signs of acute arrhythmias, which reduces the risk of pump failure death.

However, the patient's low LVEF (21%) and elevated creatinine level (100.0) do raise concerns about the patient's long-term prognosis and the risk of pump failure."
486,486,P0764,"Age: 75
Gender: Male 
Weight: 72 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,64
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 148.0
Potassium (mEq/L): 4,74
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2243.0
Protein (g/L): 80,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,59
Urea (mg/dL): 8,8
LVEF (%): 26.0
Medications: Amiodarone, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

Based on the patient's data, I rank the prognoses as follows:

1. Survivor: The patient's age is 75, which is considered elderly. However, the patient's NYHA Class II indicates a moderate level of heart failure symptoms. The patient's LVEF (26.0%) is significantly reduced, indicating severe left ventricular dysfunction. Despite this, the patient is not on a high-dose of diuretics or inotropes, which suggests that the patient is not severely symptomatic. The patient's creatinine level is elevated, indicating some degree of kidney dysfunction, but it is not severely elevated. The patient's troponin level is within normal limits, indicating no significant myocardial damage. The patient's medication regimen includes ACE inhibitors, which are known to improve survival in patients with heart failure.

2. Pump failure death: Given the patient's reduced LVEF and elevated creatinine level, pump failure is a plausible outcome. However, the patient is not on a high-dose of diuretics or inotropes, which suggests that the patient is not severely symptomatic. Additionally, the patient's troponin level is within normal limits, indicating no significant myocardial damage.

3. Sudden cardiac death: While the patient has a history of ventricular extrasystoles and non-sustained ventricular tachycardia, the patient is not on a beta-blocker-free regimen, which is a known risk factor for sudden cardiac death. However, the patient is on beta-blockers, which are known to reduce the risk of sudden cardiac death. The patient's ECG impression does not indicate any significant left ventricular hypertrophy or ischemia, which are common causes of sudden cardiac death. Therefore, while sudden cardiac death is a possible outcome, it is the least likely of the three options.

It is worth noting that the patient's Pro-BNP level is elevated, which indicates some degree of ventricular dysfunction. However, the patient's overall clinical presentation and medication regimen suggest that the patient is stable and not at high risk for sudden cardiac death."
487,487,P0767,"Age: 70
Gender: Male 
Weight: 89 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 147/62 mmHg
Past Medical History: Other HF etiology, Diabetes, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,7
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 723.0
Protein (g/L): 70
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,56
Urea (mg/dL): 7,82
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient has a significant number of comorbidities, including hypertension, diabetes, and heart failure, which increases the risk of cardiovascular events. However, the patient's NYHA Class II indicates that their symptoms are controlled with current treatment. The patient's LVEF is 35%, which is mildly reduced, but not severely impaired. The patient's ECG shows no signs of ventricular tachycardia or ventricular extrasystoles, which are significant predictors of sudden cardiac death. The patient's Pro-BNP level is elevated, indicating some degree of heart failure, but it is not excessively high. The patient is taking multiple medications for their comorbidities, which suggests that they are receiving optimal management. The patient's Troponin level is normal, which reduces the likelihood of acute myocardial infarction. Overall, while this patient has a high risk of cardiovascular events, their current clinical status and treatment plan suggest that they are likely to survive for the next few years."
488,488,P0768,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 600.0
Protein (g/L): 76
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,13
Urea (mg/dL): 21,96
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
This patient has a complex medical history with multiple comorbidities such as ischemic dilated cardiomyopathy, hypertension, and dyslipemia, which are all risk factors for cardiac complications. However, the patient has been taking multiple medications, including beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, which are all aimed at managing these conditions. The patient's current ejection fraction (LVEF) is 40%, which is below the normal range, indicating some degree of cardiac dysfunction.

Despite the patient's poor ejection fraction, the absence of any mention of acute coronary syndrome, acute decompensated heart failure, or severe hypotension on the ECG impression, suggests that the patient is not in a life-threatening acute situation. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystole on the ECG is concerning, but the fact that these are non-sustained suggests that they are not currently causing significant hemodynamic instability.

The patient's laboratory results, including a slightly elevated creatinine level and low hemoglobin level, suggest some degree of renal impairment and anemia, but these are not immediately life-threatening. The patient's Pro-BNP level is elevated, indicating some degree of cardiac stress, but the patient is still alive and not in acute decompensated heart failure.

Given the patient's complex medical history and current status, the most likely outcome is that the patient will survive, albeit with ongoing management of their multiple comorbidities and close monitoring for any signs of cardiac complications.

2. Sudden Cardiac Death 
REASONING: 
While the patient's ECG shows signs of cardiac arrhythmias, the absence of any mention of acute coronary syndrome, acute decompensated heart failure, or severe hypotension on the ECG impression makes sudden cardiac death less likely. However, the presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystole on the ECG is concerning and suggests a higher risk of arrhythmic events.

The patient's LVEF is 40%, which is below the normal range, indicating some degree of cardiac dysfunction. The patient's history of ischemic dilated cardiomyopathy, hypertension, and dyslipemia also increase the risk of cardiac complications. However, the patient is already taking multiple medications aimed at managing these conditions, which may help mitigate some of these risks.

3. Pump Failure Death 
REASONING: 
Given the patient's LVEF of 40%, which is significantly below the normal range, pump failure is a significant concern. The patient's history of ischemic dilated cardiomyopathy and hypertension also increases the risk of cardiac dysfunction.

However, the patient's current ECG impression does not show any signs of acute decompensated heart failure, such as significant ST-segment elevation or Q-waves, which are often seen in cases of acute pump failure. The patient is also not in acute hypotension, which would be a concern in cases of acute pump failure.

While the patient's low ejection fraction and history of cardiac disease do increase the risk of pump failure, the patient's current status and the absence of acute decompensated heart failure on the ECG impression make pump failure death less likely compared to sudden cardiac death."
489,489,P0769,"Age: 51
Gender: Female 
Weight: 79 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,35
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 183.0
Protein (g/L): 75
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,77
Urea (mg/dL): 6,99
LVEF (%): 33.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, weight, and NYHA Class II classification indicate a relatively moderate level of cardiac dysfunction. However, the patient's low blood pressure (100/60 mmHg) and low LVEF (33.0%) suggest that the patient's cardiac function is severely impaired. 

The patient's past medical history of idiopathic dilated cardiomyopathy further supports this notion, as this condition often leads to reduced cardiac function and increased risk of arrhythmias. The presence of ventricular extrasystole and non-sustained ventricular tachycardia (VT) on the ECG impression also indicates a high risk of arrhythmias.

Despite the presence of these factors, the patient is currently taking beta blockers, statins, and ACE inhibitors, which are standard treatments for managing heart failure and reducing arrhythmias. The patient's relatively low troponin level (0.01 ng/mL) and normal TSH level (0.77 mIU/L) suggest that there is no acute myocardial infarction or thyroid dysfunction.

Given these factors, the patient's overall prognosis is that they are likely to survive for the next few years, although the patient may require close monitoring and adjustments to their treatment regimen to manage their cardiac function and reduce the risk of arrhythmias.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's past medical history and current cardiac function suggest a high risk of arrhythmias, the patient's current ECG impression does not indicate any acute life-threatening arrhythmias. The patient's ventricular extrasystole and non-sustained VT are not sustained, and the patient is not experiencing any symptoms that would indicate a sudden cardiac death.

However, the patient's low LVEF (33.0%) and low blood pressure (100/60 mmHg) do increase the risk of sudden cardiac death. Additionally, the patient's past medical history of idiopathic dilated cardiomyopathy and dyslipemia increases the risk of cardiac events.

Given these factors, while the patient's risk of sudden cardiac death is not zero, the patient's current ECG impression and lack of acute symptoms make this prognosis less likely compared to the survivor prognosis.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's low LVEF (33.0%) and low blood pressure (100/60 mmHg) suggest that the patient's cardiac function is severely impaired, which increases the risk of pump failure. However, the patient's current treatment regimen (beta blockers, statins, and ACE inhibitors) and the presence of ventricular extrasystole and non-sustained VT on the ECG impression suggest that the patient is receiving adequate treatment to manage their cardiac function.

Additionally, the patient's relatively normal kidney function (creatinine level of 6.99 mg/dL) and low urea level (6.99 mg/dL) suggest that the patient's renal function is not severely impaired, which reduces the risk of pump failure.

Given these factors, while the patient's cardiac function is severely impaired, the patient's treatment regimen and current ECG impression suggest that the risk of pump failure is not the most likely outcome."
490,490,P0770,"Age: 55
Gender: Male 
Weight: 87 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 180/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 43
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,2
LDL (mmol/L): 1,68
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 536.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 12
Troponin (ng/mL): 0,005
TSH (mIU/L): 13,08
Urea (mg/dL): 7,65
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to reduced cardiac function. The patient's left ventricular ejection fraction (LVEF) is 53%, which is significantly lower than the normal range (50-70%). The patient's NYHA class is II, indicating mild symptoms, but the low LVEF suggests that the patient's cardiac function is compromised. The patient is also taking medications such as beta blockers, digoxin, and loop diuretics, which are commonly used to manage heart failure and arrhythmias.

The patient's electrolyte levels are relatively normal, with no signs of hyperkalemia or hypokalemia. The troponin level is also normal, which suggests that there is no significant myocardial infarction. The patient's creatinine level is elevated, indicating impaired kidney function, but this is not uncommon in patients with heart failure.

The ECG impression shows ventricular extrasystole, which is a common finding in patients with heart failure. However, there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which are more indicative of a high risk of sudden cardiac death. The patient's paroxysmal supraventricular tachyarrhythmia is unknown, but the presence of ventricular extrasystole suggests that the patient may have an underlying arrhythmia.

Given the patient's history of heart failure, impaired cardiac function, and the presence of ventricular extrasystole, the most likely outcome is that the patient will survive. The patient's medications and ECG findings do not suggest a high risk of sudden cardiac death or pump failure. Therefore, the prognosis is a survivor.

It is worth noting that the patient's prognosis could be improved with more aggressive management of their heart failure and arrhythmias. However, based on the available information, the patient's survival is the most likely outcome."
491,491,P0771,"Age: 73
Gender: Male 
Weight: 89 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/65 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4
LDL (mmol/L): 1,71
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 720.0
Protein (g/L): 72
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,06
Urea (mg/dL): 7,99
LVEF (%): 25.0
Medications: Beta Blockers, Statins, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the patient's data, I would rank the patient as having a high likelihood of survival. The patient's age is 73, but the patient's NYHA Class II indicates that they have a moderate level of heart failure, which suggests that the heart is still functional to some extent. The patient's LVEF of 25.0 is relatively preserved, which is a good indicator of cardiac function.

The patient's ECG impression shows non-sustained ventricular tachycardia (VT), which is a concerning sign, but the fact that it is non-sustained reduces the risk of it progressing to sustained VT or cardiac arrest. The patient's ECG also shows ventricular extrasystoles, which can be a sign of ventricular irritability, but in this case, it is not a primary concern.

The patient's medications, including beta blockers, statins, hydralazine, ACE inhibitors, and nitrovasodilator, suggest that the patient is being managed for heart failure and cardiovascular risk reduction. The patient's laboratory results, including normal electrolytes, creatinine, and urea levels, also suggest that the patient's kidney function is preserved.

The patient's biomarkers, including troponin and TSH, are within normal limits, which suggests that there is no significant cardiac or thyroid dysfunction. The patient's lipid profile is also within normal limits, which reduces the risk of atherosclerotic cardiovascular disease.

Overall, while the patient has a history of heart failure and ECG abnormalities, the combination of preserved LVEF, normal laboratory results, and effective medication management suggests that the patient is at a lower risk of sudden cardiac death or pump failure. Therefore, I would rank the patient as having a high likelihood of survival.

RANKING: 2. Sudden Cardiac Death
REASONING:

While the patient's ECG shows non-sustained ventricular tachycardia (VT), which is a concerning sign, the patient's LVEF is relatively preserved, and the patient is on effective medications for heart failure and cardiovascular risk reduction. However, the patient's history of other heart failure etiology and the presence of ventricular extrasystoles suggest that the patient may be at a higher risk of sudden cardiac death.

Additionally, the patient's age and NYHA Class II indicate that the patient's heart is not functioning optimally, which may increase the risk of cardiac events. The patient's laboratory results, including elevated creatinine, suggest that the patient's kidney function may be compromised, which can increase the risk of cardiovascular events.

While the patient's biomarkers, including troponin and TSH, are within normal limits, the patient's ECG shows a history of ventricular tachycardia, which increases the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING:

Based on the patient's data, I would rank the patient as having a lower likelihood of pump failure death. The patient's LVEF of 25.0 is relatively preserved, which suggests that the patient's heart is still functioning to some extent. The patient's medication regimen, including beta blockers, statins, hydralazine, ACE inhibitors, and nitrovasodilator, suggests that the patient is being managed for heart failure and cardiovascular risk reduction.

However, the patient's NYHA Class II indicates that the patient has a moderate level of heart failure, which suggests that the patient's heart is not functioning optimally. The patient's laboratory results, including elevated creatinine, suggest that the patient's kidney function may be compromised, which can increase the risk of pump failure.

Additionally, the patient's ECG shows a history of ventricular tachycardia, which increases the risk of cardiac events, including pump failure. While the patient's biomarkers, including troponin and TSH, are within normal limits, the patient's ECG and laboratory results suggest that the patient may be at a higher risk of pump failure."
492,492,P0773,"Age: 69
Gender: Male 
Weight: 68 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 108/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 32
ALT or GPT (IU/L): 109.0
AST or GOT (IU/L): 116.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 420
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,86
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2362.0
Protein (g/L): 60
T4 (ng/L): 18
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,66
Urea (mg/dL): 12,15
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient is currently on optimal medical therapy with ACE inhibitors, beta blockers, and diuretics, which are standard treatments for heart failure and hypertension. The patient's NYHA class II indicates mild symptoms, suggesting that the current treatment is controlling the condition to some extent.

The patient's laboratory values show elevated liver enzymes (ALT and AST), high creatinine levels, and high protein levels, indicating possible kidney dysfunction and liver damage. However, these values are not severe enough to immediately indicate a poor prognosis.

The patient's troponin level is within normal limits, which suggests that there is no significant myocardial infarction or acute cardiac damage. The ECG results show no signs of ventricular tachycardia, bradycardia, or other life-threatening arrhythmias.

Considering these factors, the patient's overall condition is relatively stable, and the patient is receiving optimal medical therapy. Therefore, the most likely outcome is that the patient will survive for the next few years.

RANKING: 
2. Pump failure death
REASONING:
While the patient's condition is stable, the presence of ischemic dilated cardiomyopathy and kidney dysfunction (elevated creatinine levels) increases the risk of heart failure. The patient's low LVEF of 20% indicates severe left ventricular dysfunction, which may lead to pump failure over time.

However, the patient is currently on optimal medical therapy, and the patient's NYHA class II indicates that the condition is not severely limiting the patient's daily activities. The patient's liver enzymes and troponin levels are not indicative of acute cardiac damage or liver failure.

The patient's kidney function is not severely impaired, and the patient is not on dialysis. Therefore, while pump failure is a possible outcome, it is less likely than the patient surviving for the next few years.

RANKING: 
3. Sudden cardiac death
REASONING:
The patient's history of ischemic dilated cardiomyopathy and the presence of ventricular extrasystoles on the ECG increase the risk of sudden cardiac death. However, the patient is currently on beta blockers, which reduce the risk of arrhythmias, and the patient's ECG results do not show any signs of ventricular tachycardia or other life-threatening arrhythmias.

Additionally, the patient's troponin level is within normal limits, which suggests that there is no significant myocardial infarction or acute cardiac damage. The patient's NYHA class II indicates that the condition is not severely limiting the patient's daily activities, and the patient is receiving optimal medical therapy.

While the patient's risk of sudden cardiac death is present, the patient's current condition is relatively stable, and the patient is receiving optimal medical therapy. Therefore, the risk of sudden cardiac death is lower than pump failure, but higher than the patient surviving for the next few years."
493,493,P0774,"Age: 51
Gender: Female 
Weight: 84 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 111/54 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,77
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 577.0
Protein (g/L): 76
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,53
Urea (mg/dL): 5,66
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to poor heart function. The patient's LVEF (left ventricular ejection fraction) is 20.0%, which is significantly below the normal range (normal range: 55-70%). This suggests that the patient's heart is not pumping efficiently.

Despite the poor LVEF, the patient is currently on medications that are commonly used to treat heart failure, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. These medications can help slow the progression of heart failure and improve symptoms.

The patient's Pro-BNP (brain natriuretic peptide) level is elevated at 577.0 ng/L, which is a marker of heart failure. However, the patient is not experiencing symptoms of heart failure, which is an important factor in determining prognosis.

The patient's ECG shows non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole, which are both concerning for arrhythmias. However, the patient is not experiencing any symptoms of ventricular tachycardia, and the NSVT is non-sustained.

Given these factors, the patient is likely to survive in the short term. The patient's age, weight, and other laboratory values do not suggest any immediate life-threatening conditions.

RANKING 2: Sudden Cardiac Death
REASONING:
While the patient has a history of idiopathic dilated cardiomyopathy and is at risk for arrhythmias, the patient is currently not experiencing symptoms of heart failure or ventricular tachycardia. However, the patient's LVEF is severely impaired, and the patient is on medications that can increase the risk of arrhythmias.

The patient's ECG shows ventricular extrasystole and NSVT, which are concerning for arrhythmias. However, the NSVT is non-sustained, and the patient is not experiencing any symptoms of ventricular tachycardia.

Given the patient's history of idiopathic dilated cardiomyopathy and the presence of arrhythmias on ECG, there is a small risk of sudden cardiac death in the short term.

RANKING 3: Pump Failure Death
REASONING:
The patient's LVEF is severely impaired at 20.0%, which suggests that the patient's heart is not pumping efficiently. The patient's elevated Pro-BNP level and symptoms of heart failure (not explicitly stated, but implied by the need for medications to manage symptoms) also suggest that the patient's heart is not functioning well.

However, the patient is currently on medications that can help manage symptoms and slow the progression of heart failure. The patient's ECG shows non-sustained ventricular tachycardia and ventricular extrasystole, which are concerning for arrhythmias.

Given the patient's severe impairment of LVEF and the presence of arrhythmias, the patient is at risk of pump failure in the short term. However, the patient is currently not experiencing symptoms of heart failure, and the patient is on medications that can help manage symptoms."
494,494,P0775,"Age: 61
Gender: Male 
Weight: 70 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 130/83 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 44
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,87
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 413.0
Protein (g/L): 74
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,41
Urea (mg/dL): 6,49
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient has a history of heart failure (NYHA Class II) and elevated troponin levels, indicating some degree of cardiac damage. However, the patient is on medications that are commonly used to manage heart failure (Beta Blockers, Statins, ACE Inhibitor) and has a relatively low risk of sudden cardiac death based on the ECG impression (no ventricular tachycardia, tachycardia, or bradycardia). The patient's LVEF is 25%, which is significantly reduced, but not indicative of pump failure. The patient's biomarkers, such as Pro-BNP and Creatinine, also suggest some degree of cardiac dysfunction, but are not indicative of severe heart failure. Overall, the patient's clinical presentation and laboratory results do not strongly suggest a high risk of sudden cardiac death or pump failure. Therefore, a survivor prognosis is the most likely outcome.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's ECG impression does not show any signs of ventricular tachycardia or tachycardia, the patient's LVEF is significantly reduced, which increases the risk of sudden cardiac death. The patient's elevated troponin levels also suggest some degree of cardiac damage, which can increase the risk of arrhythmias and sudden cardiac death. However, the patient is on medications that are commonly used to manage heart failure, which may help to mitigate this risk. Additionally, the patient's biomarkers, such as Pro-BNP and Creatinine, do not suggest severe heart failure. Therefore, while sudden cardiac death is a possible outcome, it is not the most likely.

RANKING: 3. Pump failure death
REASONING: 
The patient's LVEF is significantly reduced, indicating some degree of cardiac dysfunction. The patient's biomarkers, such as Pro-BNP and Creatinine, also suggest some degree of cardiac dysfunction. The patient's NYHA Class II indicates that the patient has some degree of heart failure. While the patient is on medications that are commonly used to manage heart failure, the patient's clinical presentation and laboratory results do not suggest that the patient is receiving optimal treatment for heart failure. The patient's elevated troponin levels also suggest some degree of cardiac damage, which can increase the risk of pump failure. Therefore, pump failure death is the least likely outcome, but still a possible outcome given the patient's underlying cardiac dysfunction."
495,495,P0777,"Age: 69
Gender: Male 
Weight: 89 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40,6
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,92
Potassium (mEq/L): 4,71
LDL (mmol/L): 2,59
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1487.0
Protein (g/L): 74,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,48
Urea (mg/dL): 8,4
LVEF (%): 38.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor 
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly increases the risk of sudden cardiac death. However, the patient is currently being treated with medications that are standard for managing heart failure and arrhythmias, such as beta blockers, ACE inhibitors, and amiodarone. The patient's left ventricular ejection fraction (LVEF) is 38%, which is significantly reduced, indicating poor cardiac function. However, the patient's troponin level is normal, which suggests that there is no acute myocardial infarction. The patient's ECG shows non-sustained ventricular tachycardia, but this is not a high-risk finding. The patient's creatinine level is elevated, which may indicate some degree of renal impairment, but this is not directly related to the cardiac condition. Overall, while the patient has a high-risk cardiac condition, the patient is being treated with standard therapies and does not have any acute life-threatening findings on the ECG. Therefore, the patient is likely to survive for the next few years, but will likely require ongoing monitoring and adjustments to their treatment plan to manage their cardiac condition."
496,496,P0778,"Age: 73
Gender: Female 
Weight: 56 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 49,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 6,9
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,79
Potassium (mEq/L): 4,5
LDL (mmol/L): 5,16
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1058.0
Protein (g/L): 89,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,35
Urea (mg/dL): 9,9
LVEF (%): 64.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient's prognosis as a survivor. Here's why:

1. The patient's age is 73, which is considered advanced age, but it's not unusually high for someone with a valvular cardiomyopathy. However, the patient's NYHA Class II indicates that they have some symptoms, but they are still able to perform daily activities without severe limitation.
2. The patient's ejection fraction (LVEF) is 64%, which is within the normal range. This suggests that the patient's heart is still functioning relatively well, despite the valvular cardiomyopathy.
3. The patient's blood tests show a mild elevation in creatinine levels (110.0 mol/L), which could indicate some degree of kidney impairment. However, this is not severe and may be related to the patient's age and other comorbidities.
4. The patient's lipid profile shows a high total cholesterol level (6.9 mmol/L), but this is not excessively high and may be managed with statins.
5. The patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating no significant myocardial damage.
6. The patient's ECG shows ventricular extrasystoles, but no ventricular tachycardia or other concerning rhythms. This suggests that the patient's heart is not in a state of significant arrhythmia or instability.
7. The patient is on a regimen of medications that are commonly used to manage heart failure and valvular cardiomyopathy, including beta blockers, diuretics, and statins.

While the patient has some risk factors, such as advanced age and mild kidney impairment, the overall clinical picture suggests that the patient is still relatively stable and able to survive for the next few years. However, regular monitoring and follow-up are necessary to adjust the treatment plan and address any potential complications."
497,497,P0780,"Age: 51
Gender: Female 
Weight: 43 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40,1
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 110.0
HDL (mmol/L): 1,57
Potassium (mEq/L): 4,01
LDL (mmol/L): 2,93
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1129.0
Protein (g/L): 80,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 7,28
Urea (mg/dL): 4,9
LVEF (%): 28.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall clinical presentation and laboratory results indicate a significant compromise in cardiac function, with a left ventricular ejection fraction (LVEF) of 28.0% and elevated B-type natriuretic peptide (Pro-BNP) levels of 1129.0 ng/L, suggesting severe heart failure. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG also indicate arrhythmic instability. However, the patient is currently on medications for heart failure (beta blockers, spironolactone, and ACE inhibitor) and does not have any evidence of acute myocardial infarction or acute kidney injury. These factors suggest that the patient's cardiac function is stable enough to support survival, at least in the short term. Additionally, the patient's weight, blood pressure, and laboratory results are relatively stable, which further supports a favorable prognosis.

2. Sudden Cardiac Death
REASONING: 
While the patient has a high risk of arrhythmic events, the presence of medications for heart failure and the absence of acute myocardial infarction or acute kidney injury suggest that the patient is not at immediate risk of sudden cardiac death. However, the patient's severe heart failure and elevated Pro-BNP levels indicate a high risk of cardiac events. The patient's LVEF of 28.0% is also a significant concern, as it indicates a high risk of cardiac events, including arrhythmias and heart failure exacerbation. Therefore, while the patient is not at immediate risk of sudden cardiac death, the underlying cardiac condition still poses a significant risk.

3. Pump Failure Death
REASONING: 
The patient's severe heart failure, as indicated by the LVEF of 28.0% and elevated Pro-BNP levels, makes pump failure a significant concern. However, the patient is currently on medications for heart failure and has a relatively stable clinical presentation. The patient's weight, blood pressure, and laboratory results are also relatively stable, which suggests that the patient's cardiac function is not rapidly deteriorating. While pump failure is a potential risk, the patient's current clinical presentation and laboratory results suggest that it is not the most likely outcome, as the patient is currently stable and responsive to treatment."
498,498,P0782,"Age: 77
Gender: Female 
Weight: 43 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 43,6
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,12
Potassium (mEq/L): 4,09
LDL (mmol/L): 1,89
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 481.0
Protein (g/L): 80,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,44
Urea (mg/dL): 6,9
LVEF (%): 25.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Given the patient's age, NYHA Class II indicates a moderate level of heart failure, and the presence of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction suggests a significant cardiovascular history. The elevated creatinine level (79.0 mmol/L) indicates renal impairment, which can be a marker for cardiac dysfunction.

The patient's LVEF of 25.0% is severely reduced, indicating significant left ventricular dysfunction. The elevated Pro-BNP level (481.0 ng/L) is consistent with heart failure.

Despite the presence of several cardiovascular medications, including Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, and Nitrovasodilator, the patient's ECG shows non-sustained ventricular tachycardia, which may indicate ongoing cardiac instability.

However, the patient's hemoglobin level (122.0 g/L) and lack of evidence of acute coronary syndrome (normal troponin level of 0.01 ng/mL) suggest that the patient is currently stable. The absence of significant electrolyte imbalances and normal blood pressure (110/70 mmHg) also supports a relatively stable condition.

Given these factors, the patient is likely to survive the next few years, provided that their current treatment plan is continued and any underlying conditions are closely monitored.

RANKING: 2. Pump failure death
REASONING: 

This prognosis is possible if the patient's heart failure worsens despite current treatment, or if the patient experiences a cardiac event such as a myocardial infarction or sudden cardiac death.

RANKING: 3. Sudden cardiac death
REASONING: 

This prognosis is less likely, but still possible, given the patient's history of ischemic dilated cardiomyopathy, ventricular extrasystole, and non-sustained ventricular tachycardia. The patient's current treatment plan and stable vital signs do not necessarily rule out the possibility of sudden cardiac death, especially if the patient's underlying cardiac condition worsens or if the patient experiences a cardiac event."
499,499,P0783,"Age: 76
Gender: Female 
Weight: 84 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 39,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,26
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,59
LDL (mmol/L): 3,15
Sodium (mEq/L): 140.0
Protein (g/L): 75,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,88
Urea (mg/dL): 10
LVEF (%): 59.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the patient's data, the most likely prognosis is that the patient will survive the next few years. The patient's age is 76, which is a risk factor for cardiovascular disease, but the patient's NYHA Class II indicates that they have some symptoms of heart failure, but it is not severe enough to limit their daily activities.

The patient's blood pressure is well-controlled, and they are on multiple medications for hypertension and heart failure, including a calcium channel blocker, digoxin, loop diuretics, and an ACE inhibitor. The patient's LVEF is 59%, which is below the normal range, indicating some left ventricular dysfunction. However, the patient's troponin levels are normal, and the ECG does not show any signs of ventricular tachycardia or ventricular extrasystoles.

The patient's kidney function is also relatively preserved, with a creatinine level of 10 mg/dL, which is within the normal range. The patient's liver function tests are also relatively normal, with only slightly elevated AST and ALT levels.

Given these factors, the patient's overall cardiovascular risk is moderate, but not extremely high. The patient's age and NYHA Class II symptoms suggest that they may experience some limitations in their daily activities, but they are likely to survive the next few years without any significant cardiovascular events.

The patient's low HDL cholesterol level and high triglyceride level are also concerns, as they may contribute to an increased risk of cardiovascular events. However, these factors are not severe enough to change the overall prognosis.

Overall, based on the patient's data, the most likely prognosis is that the patient will survive the next few years, but may experience some limitations in their daily activities due to their heart failure symptoms."
500,500,P0785,"Age: 72
Gender: Male 
Weight: 81 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42,6
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,54
Creatinine (mmol/L): 130.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,84
Potassium (mEq/L): 3,29
LDL (mmol/L): 3,3
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 4250.0
Protein (g/L): 71,8
Troponin (ng/mL): 0,15
TSH (mIU/L): 2,92
Urea (mg/dL): 13,5
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor 
REASONING: 
Given the patient's age, NYHA Class II indicates moderate heart failure symptoms, and the presence of ischemic dilated cardiomyopathy, which is a significant underlying condition, it is likely that the patient will continue to experience progressive heart failure over time. However, the patient's current medication regimen, which includes beta blockers, ACE inhibitors, and diuretics, is standard for managing heart failure. The patient's current LVEF of 30% is significantly reduced, but the patient's hemoglobin level is within a relatively normal range. The absence of any other significant abnormalities in the patient's lab results suggests that the patient is not experiencing acute heart failure or acute coronary syndrome. Therefore, with proper management, the patient is likely to survive for the next few years.

2. Sudden Cardiac Death 
REASONING: 
Although the patient has a significant underlying condition, the patient's current ECG impression does not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other life-threatening arrhythmias. The patient's blood pressure is well-controlled, and the patient's kidney function is relatively preserved. However, the patient's LVEF is significantly reduced, which increases the risk of sudden cardiac death. Additionally, the patient's age and NYHA Class II symptoms suggest that the patient may be at higher risk for arrhythmias. However, the patient's current medication regimen and lack of other significant abnormalities make this a less likely outcome.

3. Pump Failure Death 
REASONING: 
The patient's LVEF of 30% indicates significant left ventricular dysfunction, which increases the risk of pump failure. However, the patient is currently on beta blockers, ACE inhibitors, and diuretics, which are standard treatments for heart failure. The patient's kidney function is also relatively preserved, which suggests that the patient is not experiencing significant renal impairment. While the patient's NYHA Class II symptoms indicate moderate heart failure, the patient's current lab results do not suggest acute heart failure. Therefore, pump failure death is less likely, but still a possibility, especially if the patient's LVEF continues to decline over time."
501,501,P0786,"Age: 64
Gender: Female 
Weight: 71 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 43,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,67
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,57
Potassium (mEq/L): 4,26
LDL (mmol/L): 3,66
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 614.0
Protein (g/L): 81,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,53
Urea (mg/dL): 9,9
LVEF (%): 45.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I rank the patient as having a high likelihood of survival for the next few years. 

The patient's age (64) and NYHA Class II heart failure classification indicate some level of heart disease, but the patient is not in advanced stages of heart failure. The presence of valvular cardiomyopathy, hypertension, and myocardial infarction in the past medical history suggests a history of cardiovascular disease, but the patient is currently receiving treatment with medications such as an Angiotensin II Receptor Blocker, Loop Diuretics, and Spironolactone, which are commonly used to manage heart failure and hypertension.

The patient's laboratory results, including a slightly elevated creatinine level, indicate some degree of kidney impairment, but it is not severe. The patient's lipid profile shows elevated total cholesterol and LDL levels, but the patient is taking statins, which should help manage these levels.

The ECG impression shows ventricular extrasystole, which is a common finding in patients with heart disease, but it is not indicative of a life-threatening arrhythmia. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient does not have a high risk of sudden cardiac death.

Overall, the patient's combination of heart disease, hypertension, and kidney impairment, but also the presence of current treatment, make me believe that the patient has a relatively high likelihood of survival for the next few years."
502,502,P0787,"Age: 74
Gender: Female 
Weight: 60 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 105/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41,7
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,56
Potassium (mEq/L): 3,59
LDL (mmol/L): 3,34
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1069.0
Protein (g/L): 68,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,86
Urea (mg/dL): 8,3
LVEF (%): 55.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's overall condition appears to be stable, with a relatively well-controlled NYHA Class II heart failure and a controlled ventricular rate. The patient's LVEF is 55%, which is within the range for someone with valvular cardiomyopathy. The absence of severe symptoms and no indication of acute myocardial infarction or acute heart failure exacerbation suggests that the patient is likely to survive for the next few years. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on ECG may indicate underlying cardiac arrhythmia, but the patient is already being treated with medications for this condition, which should help manage these arrhythmias. The patient's laboratory values, including low creatinine and normal electrolytes, also suggest that the patient is not in acute kidney injury or severe metabolic derangement. Overall, the combination of stable clinical condition, controlled medications, and absence of acute symptoms makes a survival prognosis of ""survivor"" the most likely outcome for the next few years."
503,503,P0789,"Age: 45
Gender: Male 
Weight: 88 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,47
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,24
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 35.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,45
Urea (mg/dL): 8,32
LVEF (%): 58.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's overall health profile suggests that they are at moderate risk for adverse cardiac events. The patient has a history of hypertrophic cardiomyopathy and hypertension, which are risk factors for cardiac complications. However, the patient's current NYHA class is III, indicating some limitation in physical activity, but not severe.

The patient's laboratory results are largely within normal limits, with the exception of mildly elevated creatinine levels, which may indicate some degree of renal impairment. The troponin level is also slightly elevated, which could suggest some myocardial injury, but it is not significantly high.

The ECG results are largely unremarkable, with no signs of ventricular tachycardia or other arrhythmias. The patient's LVEF is 58%, which is slightly below the normal range, but not significantly reduced.

Given these factors, I believe that the patient is at moderate risk for cardiac complications, but the absence of more severe signs of cardiac disease (such as significant left ventricular dysfunction, severe hypertension, or other high-risk ECG findings) suggests that the patient is likely to survive for several years. The patient's age, weight, and medication regimen also support this prognosis.

The patient's survival is also supported by the fact that they are not experiencing any acute symptoms, and their laboratory results do not indicate any acute cardiac injury or inflammation.

Overall, while the patient is at risk for cardiac complications, the combination of their clinical presentation, laboratory results, and ECG findings suggest that they are likely to survive for several years."
504,504,P0791,"Age: 75
Gender: Male 
Weight: 85 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4
LDL (mmol/L): 1,81
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 70
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,2
Urea (mg/dL): 11,65
LVEF (%): 40.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 75-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction. He has a left ventricular ejection fraction (LVEF) of 40%, which is significantly reduced, indicating poor cardiac function.

The patient's NYHA Class is II, indicating mild symptoms, but the reduced LVEF and elevated BNP levels (2542 ng/L) suggest that the patient's heart is under significant stress. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG impression also indicate a high risk of arrhythmias, which can lead to sudden cardiac death.

However, the patient is currently on multiple medications, including ACE inhibitors, which are known to improve cardiac function and reduce mortality in patients with heart failure. The patient's blood pressure is well-controlled at 125/75 mmHg, and his creatinine level is within a relatively normal range. The patient's hemoglobin level is elevated at 162 g/L, which may indicate anemia, but this is not directly related to the cardiac function.

Given these factors, the patient's overall prognosis is that he is likely to survive for the next few years, despite the presence of significant cardiac dysfunction and arrhythmias. The patient's age and comorbidities do increase the risk of mortality, but the patient's current medical management and relatively stable vital signs suggest that he is likely to survive.

While the patient is at risk of pump failure and sudden cardiac death, the likelihood of these outcomes is lower than that of death from other causes, given the patient's current medical management and relatively stable vital signs. Therefore, the most likely outcome for the patient over the next few years is that he will survive.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's ECG impression shows a high risk of arrhythmias, including ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10), which are all potential triggers for sudden cardiac death. The patient's reduced LVEF and elevated BNP levels also indicate a high risk of cardiac dysfunction, which can lead to sudden cardiac death.

Additionally, the patient's age and comorbidities increase the risk of sudden cardiac death. However, the patient's current medical management, including ACE inhibitors and beta-blockers, can help reduce this risk.

While the patient's ECG impression suggests a high risk of arrhythmias, the patient's current medical management and relatively stable vital signs suggest that the risk of sudden cardiac death is not the most likely outcome.

RANKING: 3. Pump failure death
REASONING: 

The patient's reduced LVEF of 40% and elevated BNP levels (2542 ng/L) indicate a high risk of pump failure. The patient's NYHA Class II symptoms suggest that the patient's heart is not functioning optimally, and the patient's elevated creatinine level (133.0 mmol/L) suggests that the patient's kidneys are not functioning well.

The patient's current medical management, including ACE inhibitors and loop diuretics, can help reduce the risk of pump failure, but the patient's reduced LVEF and elevated BNP levels suggest that the patient is at high risk of pump failure.

While the patient's age and comorbidities increase the risk of mortality, the patient's current medical management and relatively stable vital signs suggest that pump failure is not the most likely outcome.

Note: The patient's prognosis is not determined solely by the provided data, and a thorough evaluation by a cardiologist is necessary to determine the patient's overall prognosis."
505,505,P0795,"Age: 73
Gender: Male 
Weight: 76 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 87/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 97
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,07
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1961.0
Protein (g/L): 74
T4 (ng/L): 17
TSH (mIU/L): 4,3
Urea (mg/dL): 6,32
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient is at high risk for adverse outcomes. Here are the key factors contributing to this assessment:

1. Age: The patient is 73 years old, which is a significant risk factor for cardiac events, including sudden cardiac death and pump failure.
2. NYHA Class II: The patient has a moderate level of heart failure, indicating that their heart is not functioning efficiently, and they are likely to experience worsening symptoms over time.
3. Ischemic dilated cardiomyopathy: This condition is a significant risk factor for cardiac events, including sudden cardiac death and pump failure.
4. Low LVEF (25.0%): The patient's left ventricular ejection fraction is significantly reduced, indicating poor heart function and a high risk of cardiac events.
5. High Pro-BNP levels (1961.0 ng/L): Elevated B-type natriuretic peptide levels are a marker of heart failure and indicate that the patient's heart is working harder to pump blood, which can lead to cardiac events.
6. History of Myocardial Infarction: The patient has a history of heart attack, which increases the risk of future cardiac events.
7. Medications: The patient is on beta blockers, statins, and ACE inhibitors, which are standard treatments for heart failure and ischemic cardiomyopathy, but may not be sufficient to prevent cardiac events in this patient.

Considering these factors, the most likely outcome is that the patient will survive the next few years, but will likely experience worsening symptoms and require further medical intervention. However, it is essential to closely monitor the patient's condition and adjust the treatment plan as needed to minimize the risk of cardiac events.

While the patient has a high risk of adverse outcomes, it is still possible that they may experience a sudden cardiac death or pump failure, especially if the underlying conditions are not adequately managed. However, based on the available data, the patient's chances of survival are still higher than those of sudden cardiac death or pump failure."
506,506,P0796,"Age: 61
Gender: Female 
Weight: 69 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 108/70 mmHg
Past Medical History: Other HF etiology, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,48
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1614.0
Protein (g/L): 78
T4 (ng/L): 15
TSH (mIU/L): 3,01
Urea (mg/dL): 9,48
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

Based on the provided patient data, the patient is a 61-year-old female with a history of heart failure (NYHA Class II), myocardial infarction, and dyslipemia. The patient's current ECG shows evidence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which are all indicative of cardiac arrhythmias.

The patient's LVEF is significantly reduced at 20%, which suggests left ventricular dysfunction. The elevated BNP levels (1614 ng/L) also indicate elevated ventricular wall stress. The patient's creatinine level is elevated at 9.48 mg/dL, which may indicate renal impairment.

Given these factors, the patient is at high risk for cardiac complications. The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole on ECG suggests a high risk for arrhythmic events. The patient's reduced LVEF and elevated BNP levels also suggest a high risk for pump failure.

However, the patient is not in acute distress, and the patient's vital signs are stable. The patient's NYHA Class II indicates that the patient is still able to perform moderate physical activity without symptoms. The patient's medications, including beta blockers, digoxin, statins, and ACE inhibitors, are standard treatments for heart failure and arrhythmias.

Considering these factors, the most likely outcome for the patient over the next few years is a survivor. While the patient is at high risk for cardiac complications, the patient's stable vital signs and moderate NYHA Class II suggest that the patient is not in immediate danger. However, the patient's reduced LVEF and elevated BNP levels indicate a high risk for pump failure, making it the second most likely outcome. Sudden cardiac death is less likely, as the patient is not in acute distress and has a stable vital sign profile.

It's essential to closely monitor the patient's condition and adjust the treatment plan as necessary to mitigate the risk of cardiac complications. Regular follow-up appointments with the patient and close monitoring of the patient's ECG and vital signs will be crucial to prevent any potential cardiac events."
507,507,P0797,"Age: 81
Gender: Male 
Weight: 77 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 6
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,85
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1511.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,54
Urea (mg/dL): 8,9
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's data, the most likely prognosis is survivor. The patient's age (81) is a significant factor, but it is not the only consideration. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform daily activities with minimal limitations. The presence of ischemic dilated cardiomyopathy and myocardial infarction in the past medical history suggests that the patient has a significant cardiac history, but the patient is currently being treated with medications that are commonly used to manage heart failure (Angiotensin II Receptor Blocker, Loop Diuretics, and Statins). The patient's LVEF of 20.0 indicates that the heart is not functioning optimally, but it is not severely impaired.

The patient's ECG findings, including ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia, suggest that the patient has a higher risk of arrhythmias, but the presence of a nitrovasodilator in their medication regimen may help to manage these symptoms. The patient's Pro-BNP level of 1511.0 is elevated, indicating some degree of ventricular dysfunction, but it is not excessively high.

In contrast, the patient's creatinine level of 79.0 is slightly elevated, indicating some degree of renal impairment, which may be related to their cardiac history. However, this is not a contraindication for survival.

The patient's other laboratory values, including their hemoglobin, HDL, and potassium levels, are relatively normal, and the patient's glucose level is not excessively high. Overall, the patient's clinical presentation and laboratory values suggest that they are likely to survive in the short term, but it is essential to closely monitor their condition and adjust their treatment plan as needed.

RANKING: 
2. Sudden cardiac death
REASONING: 
Based on the patient's data, sudden cardiac death is a possible but less likely prognosis. The patient's ECG findings, including ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia, suggest a higher risk of arrhythmias. However, the presence of a nitrovasodilator in their medication regimen may help to manage these symptoms.

The patient's LVEF of 20.0 is significantly lower than normal, indicating severe ventricular dysfunction, which increases the risk of sudden cardiac death. However, the patient's NYHA Class II indicates that they are not severely limited by their symptoms, which may suggest that they are able to tolerate some level of cardiac stress.

RANKING: 
3. Pump failure death
REASONING: 
Based on the patient's data, pump failure death is the least likely prognosis. The patient's LVEF of 20.0 indicates severe ventricular dysfunction, which increases the risk of pump failure. However, the patient is currently being treated with medications that are commonly used to manage heart failure (Angiotensin II Receptor Blocker, Loop Diuretics, and Statins), which may help to mitigate this risk.

The patient's NYHA Class II indicates that they are able to perform daily activities with minimal limitations, which suggests that they are able to tolerate some level of cardiac stress. However, the patient's elevated creatinine level of 79.0 and slightly elevated Pro-BNP level of 1511.0 suggest that they may still be at risk of pump failure, especially if their condition deteriorates."
508,508,P0800,"Age: 72
Gender: Male 
Weight: 64 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 5,5
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,13
Potassium (mEq/L): 4,38
LDL (mmol/L): 3,88
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 6088.0
Protein (g/L): 72,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,81
Urea (mg/dL): 6,8
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
This patient's overall clinical presentation, laboratory results, and ECG findings suggest a poor prognosis for survival. The patient has a history of valvular cardiomyopathy, which is a significant risk factor for heart failure and arrhythmias. The elevated LVEF of 30.0% indicates severe left ventricular dysfunction, which is a strong predictor of mortality. Additionally, the presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further increases the risk of arrhythmic events. The patient's elevated BNP levels (6088.0 ng/L) and elevated troponin levels (0.01 ng/mL) suggest significant cardiac stress and damage. The patient's NYHA Class II indicates mild heart failure symptoms, but the presence of NSVT and polymorphic ventricular extrasystoles suggests that the patient is at risk for more severe cardiac complications. Given the combination of these factors, the patient is at high risk for cardiac events, making survival the most likely outcome.

2. Sudden cardiac death
REASONING: 
The patient's history of valvular cardiomyopathy, severe left ventricular dysfunction (LVEF 30.0%), and presence of NSVT and polymorphic ventricular extrasystoles on the ECG make sudden cardiac death a plausible outcome. The patient's elevated BNP levels and troponin levels suggest significant cardiac stress and damage, which can increase the risk of arrhythmic events. However, the patient's current NYHA Class II symptoms and the presence of digoxin, loop diuretics, and spironolactone, which are commonly used to manage heart failure, suggest that the patient is receiving appropriate therapy for his heart failure symptoms. Therefore, while sudden cardiac death is a possible outcome, it is less likely than survival.

3. Pump failure death
REASONING: 
Pump failure death is a possible outcome for patients with severe left ventricular dysfunction (LVEF 30.0%), but it is less likely than sudden cardiac death in this patient. The patient's NYHA Class II symptoms and the presence of digoxin, loop diuretics, and spironolactone suggest that the patient is receiving appropriate therapy for his heart failure symptoms. Additionally, the patient's elevated BNP levels and troponin levels suggest that the patient's cardiac stress and damage are not severe enough to result in pump failure. Furthermore, the patient's ECG findings, while abnormal, do not suggest a high risk of arrhythmic events that would increase the risk of pump failure. Therefore, pump failure death is the least likely outcome."
509,509,P0801,"Age: 72
Gender: Female 
Weight: 60 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 95/60 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 33,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,64
Creatinine (mmol/L): 137.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 123.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 3,36
LDL (mmol/L): 2,14
Sodium (mEq/L): 129.0
Pro-BNP (ng/L): 2233.0
Protein (g/L): 71,3
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,81
Urea (mg/dL): 13,2
LVEF (%): 70.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is 72 years old, with a NYHA Class III, indicating severe heart failure symptoms. Despite the patient's poor heart function, the patient's LVEF is 70.0%, which is relatively preserved. The patient's Pro-BNP level is elevated at 2233.0 ng/L, indicating some degree of ventricular strain. However, the patient's troponin level is normal, which suggests that there is no significant myocardial damage.

The patient's blood pressure is 95/60 mmHg, which is relatively low, but not critically low. The patient's electrolytes and kidney function are also relatively normal.

The patient's medication list includes ACE inhibitors, which are known to improve heart function and reduce mortality in patients with heart failure. The patient's other medications, such as Amiodarone and Digoxin, are also commonly used to manage arrhythmias and heart failure.

The ECG impression shows a normal rhythm, with no evidence of ventricular tachycardia or bradycardia. The presence of ventricular extrasystoles may be a sign of underlying cardiac disease, but it is not necessarily a predictor of poor outcome.

Given the patient's age, medical history, and medication list, I believe that the patient is most likely to survive in the next few years. The patient's heart function is relatively preserved, and the patient is receiving optimal medical therapy for heart failure and arrhythmias.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient is at risk for cardiac events due to their medical history and medication list, I do not believe that the patient is at high risk for sudden cardiac death. The patient's ECG impression shows no evidence of ventricular tachycardia or bradycardia, and the patient's troponin level is normal.

However, the patient's Pro-BNP level is elevated, which may indicate some degree of ventricular strain. The patient's kidney function is also impaired, as indicated by the elevated creatinine level. These factors may increase the patient's risk for cardiac events, but I do not believe that they are sufficient to categorize the patient as being at high risk for sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

I do not believe that the patient is at high risk for pump failure death. The patient's LVEF is 70.0%, which is relatively preserved, and the patient is receiving optimal medical therapy for heart failure. The patient's medication list includes ACE inhibitors, which are known to improve heart function and reduce mortality in patients with heart failure.

The patient's ECG impression shows no evidence of ventricular tachycardia or bradycardia, and the patient's troponin level is normal. While the patient's Pro-BNP level is elevated, this may be due to the patient's impaired kidney function rather than cardiac disease.

Overall, I believe that the patient is at low risk for pump failure death, and that the patient is more likely to survive in the next few years."
510,510,P0802,"Age: 52
Gender: Male 
Weight: 61 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 105/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 37,9
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 46.0
Total Cholesterol (mmol/L): 5,29
Creatinine (mmol/L): 126.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,99
Potassium (mEq/L): 5,43
LDL (mmol/L): 3,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 11001.0
Protein (g/L): 68,4
Troponin (ng/mL): 0,09
TSH (mIU/L): 3,64
Urea (mg/dL): 13,5
LVEF (%): 21.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is already classified as a survivor, which means that they have not died from their current condition. This outcome is the most likely because the patient has not shown any indication of sudden cardiac death or pump failure in the provided data. The patient's LVEF is severely impaired at 21.0%, which is consistent with severe heart failure, but they are still alive. The presence of ventricular extrasystoles, non-sustained VT, and TPSV may indicate arrhythmias, but the patient is not currently experiencing any life-threatening arrhythmias. The patient is also on medications that are standard for heart failure management, such as beta blockers, loop diuretics, and ACE inhibitors, which suggests that their condition is being managed. Therefore, the patient's current outcome is the most likely.

RANKING: 2. Pump failure death
REASONING: Pump failure death is a possible outcome for this patient due to their severe heart failure (LVEF 21.0%) and NYHA Class III. However, the patient is already classified as a survivor, which suggests that they are not currently experiencing severe heart failure symptoms that would lead to pump failure. The patient's blood pressure and renal function (creatinine 126.0) are also relatively stable, which may indicate that the patient is not currently experiencing severe heart failure. However, the patient's severe heart failure and arrhythmias may still pose a risk for pump failure in the future.

RANKING: 3. Sudden cardiac death
REASONING: Sudden cardiac death is the least likely outcome for this patient due to the presence of arrhythmias (ventricular extrasystoles, non-sustained VT, and TPSV). However, the patient is already classified as a survivor, which suggests that these arrhythmias are not currently life-threatening. The patient's medications, such as beta blockers and ACE inhibitors, also suggest that their arrhythmias are being managed. Additionally, the patient's ECG impression does not indicate any acute changes that would suggest a high risk for sudden cardiac death. While the patient's severe heart failure and arrhythmias do pose a risk for pump failure, the patient is not currently experiencing symptoms that would lead to sudden cardiac death."
511,511,P0803,"Age: 48
Gender: Male 
Weight: 70 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45,7
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 6,69
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 194
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,08
Potassium (mEq/L): 4
LDL (mmol/L): 5,11
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 2954.0
Protein (g/L): 77,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,45
Urea (mg/dL): 5,2
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

The patient's age (48 years) and NYHA Class II status indicate that the patient has a moderate level of cardiac dysfunction. However, the patient's LVEF is significantly reduced at 17%, which is a strong indicator of severe systolic dysfunction.

The patient's medical history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction suggests that the patient has a history of cardiac damage and potential for further cardiac events. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG also indicate arrhythmic instability, which is a significant risk factor for sudden cardiac death.

The patient's laboratory results show elevated creatinine levels (94.0 mmol/L), which indicate impaired renal function, and a low albumin level (45.7 g/L), which may indicate malnutrition or liver dysfunction. However, these findings are not directly related to the cardiac prognosis.

The patient's lipid profile shows elevated total cholesterol (6.69 mmol/L) and LDL (5.11 mmol/L), which are risk factors for cardiovascular disease. However, the patient is already on statins and an ACE inhibitor, which should help manage these risk factors.

The patient's electrolyte levels are relatively normal, and the TSH level is within the normal range.

Considering these factors, while the patient has a significant cardiac history and current ECG abnormalities, the patient is already on multiple medications to manage their condition, and the patient's renal and liver function are not severely impaired. Therefore, I would rank the patient's prognosis as a survivor, with a moderate risk of sudden cardiac death and pump failure death.

However, given the patient's severe systolic dysfunction, arrhythmic instability, and elevated creatinine levels, I would consider the patient to be at increased risk of pump failure death. Therefore, I would rank pump failure death as the least likely prognosis, but still a potential risk.

It is essential to note that this prognosis is based on the information provided and should be re-evaluated with further testing and assessment of the patient's condition."
512,512,P0805,"Age: 60
Gender: Female 
Weight: 77 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,83
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,35
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,3
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 227.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 15
Troponin (ng/mL): 3,4
TSH (mIU/L): 1,63
Urea (mg/dL): 25,1
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's overall health status and medical history suggest a high likelihood of survival. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that affects the heart's ability to pump blood effectively. However, the patient is currently being treated with medications that are commonly used to manage this condition, including ACE inhibitors, beta-blockers, and diuretics.

The patient's NYHA class is II, indicating mild symptoms of heart failure, but they are still able to perform daily activities without significant limitations. The patient's blood pressure is within a relatively normal range, and their kidney function is mildly impaired, but not severely.

The patient's biomarkers, such as troponin and pro-BNP, are elevated, indicating some degree of cardiac stress and strain. However, the patient's LVEF (left ventricular ejection fraction) is 40%, which is within a range that is not typically associated with high risk of sudden cardiac death.

The patient's ECG shows a polymorphic ventricular extrasystole, which may indicate a higher risk of arrhythmias. However, the absence of other significant ECG abnormalities, such as ventricular tachycardia or non-sustained ventricular tachycardia, reduces the risk of sudden cardiac death.

Given these factors, the patient's overall prognosis is that they are likely to survive the next few years, with a moderate risk of developing further cardiac complications, such as heart failure exacerbation or arrhythmias."
513,513,P0808,"Age: 44
Gender: Male 
Weight: 86 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,67
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,47
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 497.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,24
Urea (mg/dL): 5,83
LVEF (%): 19.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient has a significant underlying condition of idiopathic dilated cardiomyopathy, which is a major risk factor for cardiac death. However, the patient is currently on multiple medications, including beta blockers, digoxin, and ACE inhibitors, which are standard treatments for heart failure and arrhythmias. The patient's NYHA Class II indicates that the disease has progressed to the stage where symptoms are present, but the patient is still able to perform ordinary activities without undue fatigue, which suggests a relatively preserved cardiac function. The patient's LVEF is 19%, which is significantly reduced, indicating poor cardiac function. Despite this, the patient's ECG does not show any signs of ventricular tachycardia, polymorphic ventricular extrasystoles, or non-sustained ventricular tachycardia, which are all potential predictors of cardiac death. Additionally, the patient's Pro-BNP level is elevated, which is a marker of heart failure, but not excessively high. Overall, the combination of the patient's underlying condition, current treatment, and lack of life-threatening arrhythmias on the ECG suggests that the patient is at risk of pump failure, but not immediate cardiac death.

2. Pump failure death
REASONING: 
The patient's idiopathic dilated cardiomyopathy is a significant risk factor for cardiac death, and the patient's reduced LVEF of 19% suggests poor cardiac function. The patient's elevated Pro-BNP level and elevated creatinine level also suggest heart failure. However, the patient is currently on multiple medications that are standard treatments for heart failure and arrhythmias, which suggests that the patient is receiving adequate treatment. The patient's ECG does not show any signs of ventricular tachycardia, polymorphic ventricular extrasystoles, or non-sustained ventricular tachycardia, which are all potential predictors of cardiac death. However, the patient's elevated troponin level, which is a marker of myocardial injury, suggests that the patient may be experiencing some degree of cardiac damage.

3. Sudden cardiac death
REASONING: 
The patient's ECG does not show any signs of ventricular tachycardia, polymorphic ventricular extrasystoles, or non-sustained ventricular tachycardia, which are all potential predictors of sudden cardiac death. The patient's elevated troponin level suggests some degree of cardiac damage, but it is not high enough to suggest myocardial infarction. The patient's LVEF is significantly reduced, indicating poor cardiac function, but the patient is on multiple medications that are standard treatments for heart failure and arrhythmias, which suggests that the patient is receiving adequate treatment. Overall, the lack of life-threatening arrhythmias on the ECG and the patient's current treatment suggest that the patient is at low risk of sudden cardiac death."
514,514,P0810,"Age: 62
Gender: Female 
Weight: 78 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4
LDL (mmol/L): 2,51
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 335.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,47
Urea (mg/dL): 6,49
LVEF (%): 30.0
Medications: Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest a high risk of adverse outcomes, but the presence of a positive PATIENT OUTCOME indicates that the patient is a survivor. 

The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. The patient's NYHA Class III indicates severe symptoms and reduced functional capacity, which suggests advanced disease.

The patient's laboratory results show elevated creatinine levels, indicating impaired kidney function, and a low LVEF of 30%, which is consistent with severe left ventricular dysfunction. The elevated Troponin level, although within the normal range, suggests some degree of myocardial damage.

The patient's ECG results show a polymorphic ventricular extrasystole, which is a marker for an increased risk of arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces this risk.

Despite the patient's poor prognosis, the presence of a positive PATIENT OUTCOME suggests that the patient's underlying condition is not currently life-threatening, and with proper management, the patient may survive for an extended period.

The patient's current medications, including beta blockers, ACE inhibitors, and a nitrovasodilator, indicate a comprehensive treatment plan to manage symptoms and slow disease progression.

Given the patient's overall clinical presentation, laboratory results, and treatment plan, I rank the patient as having a high likelihood of survival over the next few years, with a moderate likelihood of sudden cardiac death, and a low likelihood of pump failure death."
515,515,P0811,"Age: 65
Gender: Male 
Weight: 57 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,47
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 264.0
Protein (g/L): 78
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,62
Urea (mg/dL): 9,65
LVEF (%): 25.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical presentation and test results suggest that they are at a higher risk for adverse outcomes. The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and a low left ventricular ejection fraction (LVEF) of 25%, which indicates significant cardiac dysfunction. The elevated creatinine level (106.0 mmol/L) suggests impaired renal function, which can be associated with heart failure. 

Additionally, the patient has a history of ventricular extrasystoles, which can be a marker of cardiac arrhythmia. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia (CH>10) reduces the risk of sudden cardiac death. 

The patient's laboratory results show elevated troponin levels (0.01 ng/mL), which can be seen in various conditions, including cardiac stress, but in this context, it may indicate some degree of cardiac stress or minor myocardial injury. The patient's Pro-BNP level is elevated (264.0 ng/L), which suggests some degree of heart failure. 

Despite the patient's age (65) and NYHA Class II status, the absence of other significant comorbidities, and the presence of beta blockers, spironolactone, statins, and an ACE inhibitor, which are commonly used to manage heart failure and hypertension, suggests that the patient is being adequately managed.

Considering the above factors, I rank the patient's prognosis as a survivor, with a reasonable chance of long-term survival with proper management and monitoring."
516,516,P0812,"Age: 77
Gender: Female 
Weight: 100 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 35
ALT or GPT (IU/L): 47.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 116.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1659.0
Protein (g/L): 60
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 6,83
Urea (mg/dL): 4,16
LVEF (%): 52.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the patient's age (77), NYHA Class III status, and elevated troponin levels (0.01 ng/mL), there is a moderate risk of cardiac events. However, the patient is currently taking medications for hypertension and heart failure (Angiotensin II Receptor Blocker, Beta Blockers, and Loop Diuretics), which suggests that the patient is being managed for their cardiovascular condition. The absence of signs of acute myocardial infarction (no ST-elevation on ECG) and no evidence of heart failure exacerbation (no significant increase in BNP levels) suggest that the patient is not at high risk of sudden cardiac death or pump failure in the short term. Therefore, the patient is most likely to survive.

2. Sudden Cardiac Death 
REASONING: 
The patient's age (77), elevated troponin levels (0.01 ng/mL), and NYHA Class III status suggest a moderate risk of cardiac events. While the patient is taking medications for hypertension and heart failure, the presence of ventricular extrasystoles (polymorphic) on the ECG may indicate a higher risk of arrhythmias, which could potentially lead to sudden cardiac death. However, the absence of other signs of heart failure exacerbation or acute myocardial infarction reduces the likelihood of sudden cardiac death in the short term.

3. Pump Failure Death 
REASONING: 
The patient's NYHA Class III status and elevated BNP levels (not provided) suggest a moderate to severe heart failure. However, the patient is currently taking medications for heart failure (Loop Diuretics), which suggests that the patient is being managed for their condition. While the patient's LVEF is 52%, which is below the normal range (50-70%), the patient's current medication regimen and lack of signs of heart failure exacerbation (no significant increase in BNP levels) suggest that the patient is not at high risk of pump failure in the short term. Therefore, the likelihood of pump failure death is lower than sudden cardiac death."
517,517,P0813,"Age: 67
Gender: Male 
Weight: 65 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4
LDL (mmol/L): 2,12
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1270.0
Protein (g/L): 74
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 8,32
LVEF (%): 38.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

The patient's prognosis can be determined based on the provided data, which indicates a significant burden of cardiovascular risk factors, including ischemic dilated cardiomyopathy, hypertension, diabetes, and dyslipidemia. The patient's left ventricular ejection fraction (LVEF) is 38%, which is below the normal range (55%), indicating reduced cardiac function. This suggests that the patient's heart is not functioning optimally, making them more susceptible to cardiac complications.

The patient's elevated Pro-BNP levels (1270.0 ng/L) indicate increased ventricular wall stress, which is often associated with heart failure. However, the absence of any mention of acute decompensated heart failure symptoms or signs (e.g., orthopnea, paroxysmal nocturnal dyspnea, or leg edema) suggests that the patient is currently not in acute decompensated heart failure.

The presence of ventricular extrasystole (Polymorphic) on the ECG is concerning, as it may indicate a substrate for ventricular arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia (CH>10) reduces the likelihood of sudden cardiac death.

Considering these factors, the most likely prognosis is that the patient will survive, as they do not appear to be in acute decompensated heart failure, and their cardiovascular risk factors are managed with medications. However, the patient's reduced LVEF and ventricular extrasystole on ECG make them at risk for cardiac complications, including pump failure. Sudden cardiac death is less likely given the absence of ventricular tachycardia or non-sustained ventricular tachycardia.

Therefore, the most likely prognosis is that the patient will survive, but with a risk of developing pump failure over time due to their underlying heart disease and reduced cardiac function."
518,518,P0814,"Age: 72
Gender: Female 
Weight: 90 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,13
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,76
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 453.0
Protein (g/L): 75
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,919
Urea (mg/dL): 5,16
LVEF (%): 28.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension. The patient's ejection fraction (LVEF) is significantly reduced at 28.0%, indicating severe left ventricular dysfunction. However, the patient is currently taking medications that are standard for managing these conditions, including ACE inhibitors (Angiotensin II Receptor Blocker) and beta-blockers, which are known to improve outcomes in patients with heart failure.

The patient's elevated troponin level (0.01 ng/mL) is a marker of cardiac damage, but it is not excessively elevated, suggesting some degree of cardiac stress but not necessarily indicating acute myocardial infarction. The patient's elevated creatinine level (5.16 mg/dL) indicates some degree of kidney dysfunction, which may be related to the patient's heart failure or other comorbid conditions.

The patient's Pro-BNP level is elevated at 453.0 ng/L, indicating some degree of ventricular strain. However, this level is not excessively elevated, and the patient is receiving medications that may help to reduce BNP levels.

Considering these factors, the patient's overall prognosis is likely to be a survivor, albeit with ongoing management of their complex medical conditions.

2. Sudden Cardiac Death
REASONING:
The patient's ECG impression shows ventricular extrasystoles, which is a marker of abnormal heart rhythm. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia makes this a less likely outcome. The patient's ECG does not indicate any significant left ventricular hypertrophy or other structural abnormalities that would increase the risk of sudden cardiac death.

The patient's LVEF is severely reduced, and the patient is taking medications that may help to reduce the risk of sudden cardiac death. However, the patient's complex medical history and comorbidities increase the risk of sudden cardiac death.

3. Pump Failure Death
REASONING:
The patient's LVEF is severely reduced, and the patient is experiencing some degree of ventricular strain, as indicated by the elevated Pro-BNP level. The patient is also experiencing some degree of kidney dysfunction, which may be related to the patient's heart failure.

While the patient is receiving medications that may help to manage heart failure, the patient's complex medical history and comorbidities increase the risk of pump failure. The patient's elevated creatinine level and reduced LVEF make it more likely that the patient will experience pump failure in the near future."
519,519,P0815,"Age: 38
Gender: Female 
Weight: 103 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,34
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 59
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 121.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,01
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 96.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,59
Urea (mg/dL): 6,32
LVEF (%): 56.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient has several factors that suggest a favorable prognosis, including:

1. Age: At 38 years old, the patient is relatively young, which is a positive prognostic factor for cardiovascular disease.
2. NYHA Class II: The patient's New York Heart Association (NYHA) class indicates mild symptoms, suggesting that the patient's heart is not severely impaired.
3. Medications: The patient is on beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. These medications can help manage symptoms and slow disease progression.
4. Low Troponin levels: The patient's troponin level is within normal limits, indicating minimal myocardial damage.
5. Normal LVEF: The left ventricular ejection fraction (LVEF) is 56%, which is within the normal range for a healthy adult. This suggests that the patient's heart is still functioning relatively well.
6. Absence of significant electrolyte imbalances: The patient's potassium, sodium, and urea levels are within normal limits, which reduces the risk of cardiac arrhythmias and other complications.

While the patient has a history of hypertensive cardiomyopathy and hypertension, the presence of these conditions is not necessarily a contraindication for a favorable prognosis. With proper management and lifestyle modifications, many patients with these conditions can lead active and healthy lives.

In contrast, the other two prognoses (sudden cardiac death and pump failure) are less likely due to the patient's relatively good overall health status and the absence of significant cardiac dysfunction or arrhythmias."
520,520,P0816,"Age: 76
Gender: Male 
Weight: 60 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,65
Sodium (mEq/L): 143.0
Protein (g/L): 68
T4 (ng/L): 19
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,46
Urea (mg/dL): 6,1
LVEF (%): 15.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient is 76 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac death. However, the patient has a relatively preserved ejection fraction (LVEF 15%) and is currently taking medications for heart failure (Loop Diuretics, ACE Inhibitor, and Nitrovasodilator). The patient's blood pressure is well-controlled (130/80 mmHg), and the electrolytes are within normal limits. The troponin level is also within normal limits, indicating no acute myocardial infarction. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia is concerning but not indicative of a high-risk arrhythmia. The patient's overall clinical presentation and laboratory results suggest that the patient is likely to survive for the next few years.

2. Sudden cardiac death
REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death, the patient's current clinical presentation and laboratory results do not indicate a high risk for sudden cardiac death. The patient's ejection fraction is preserved, and the troponin level is within normal limits. However, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia is a concern and may indicate an increased risk of arrhythmias. Additionally, the patient's age and history of myocardial infarction also increase the risk of sudden cardiac death. Therefore, while not the most likely outcome, sudden cardiac death is a possible outcome.

3. Pump failure death
REASONING: 
The patient's ejection fraction is significantly reduced (LVEF 15%), indicating a reduced cardiac function. The patient's history of ischemic dilated cardiomyopathy and current medications (Loop Diuretics, ACE Inhibitor, and Nitrovasodilator) suggest that the patient is being treated for heart failure. The patient's current laboratory results (elevated creatinine and urea levels) also suggest impaired renal function, which can be a complication of heart failure. While the patient's blood pressure is well-controlled, the combination of reduced ejection fraction, impaired renal function, and heart failure medications increase the risk of pump failure death. Therefore, pump failure death is the least likely outcome among the three options."
521,521,P0817,"Age: 66
Gender: Male 
Weight: 66 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Other HF etiology, Peripheral vascular disease
Albumin (g/L): 46
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 163.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,26
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 4111.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,02
TSH (mIU/L): 8,58
Urea (mg/dL): 10,65
LVEF (%): 25.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as a survivor with a high likelihood. The patient's age is 66, which is considered advanced, but the patient's NYHA class is II, indicating moderate symptoms. The patient's LVEF is 25%, which is significantly reduced, but the patient is still able to tolerate daily activities with some limitations. The presence of other HF etiology and peripheral vascular disease suggests that the patient has a history of cardiovascular disease, but the patient's current medical treatment regimen includes ACE inhibitors, which are effective in managing heart failure symptoms.

The patient's laboratory results show elevated creatinine levels, indicating impaired renal function, but this is not uncommon in patients with heart failure. The elevated Troponin level is also concerning, but it is not significantly elevated, and the patient has not experienced any myocardial infarction or acute coronary syndrome.

The ECG findings of ventricular extrasystole and first-degree AV block are concerning for arrhythmias, but the patient is already being treated with amiodarone, which is effective in managing ventricular arrhythmias. The patient's Pro-BNP level is elevated, but it is not extremely high, indicating some degree of heart failure.

Overall, while the patient has several cardiovascular risk factors and signs of heart failure, the patient is currently being treated and has a relatively stable condition. Therefore, I would rank the patient as a survivor with a high likelihood.

RANKING: 2. Sudden cardiac death
REASONING: 

The second most likely prognosis is sudden cardiac death. The patient's LVEF is significantly reduced, indicating poor cardiac function, and the patient has a history of other HF etiology and peripheral vascular disease, which increases the risk of cardiovascular events. The patient's ECG findings of ventricular extrasystole and first-degree AV block are also concerning for arrhythmias, which can increase the risk of sudden cardiac death.

Additionally, the patient's elevated Troponin level and elevated Pro-BNP level suggest some degree of myocardial stress or strain, which can increase the risk of cardiovascular events. The patient's age and sex also increase the risk of sudden cardiac death.

While the patient is currently being treated with medications that can help manage heart failure and arrhythmias, the patient's underlying cardiovascular disease and risk factors increase the likelihood of a cardiovascular event.

RANKING: 3. Pump failure death
REASONING: 

The least likely prognosis is pump failure death. While the patient has a reduced LVEF and is being treated for heart failure, the patient's current medical treatment regimen includes ACE inhibitors, which are effective in managing heart failure symptoms. The patient's Pro-BNP level is elevated, but it is not extremely high, indicating some degree of heart failure, but not severe.

Additionally, the patient's laboratory results show no significant electrolyte imbalances, and the patient is not experiencing any acute symptoms of heart failure. The patient's ECG findings of ventricular extrasystole and first-degree AV block are concerning, but the patient is already being treated with amiodarone, which is effective in managing ventricular arrhythmias.

While the patient's cardiovascular disease and risk factors increase the likelihood of a cardiovascular event, the patient's current medical treatment regimen and stable condition reduce the likelihood of pump failure death."
522,522,P0818,"Age: 50
Gender: Male 
Weight: 60 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 49
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,28
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 42.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,46
Urea (mg/dL): 9,48
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient has a history of Enolic dilated cardiomyopathy, which is a significant underlying condition that affects the heart's ability to pump blood effectively. However, the patient is currently receiving treatment with medications such as Beta Blockers, Digoxin, Loop Diuretics, and ACE Inhibitor, which are commonly used to manage symptoms and slow disease progression. The patient's NYHA Class II indicates moderate symptoms, which suggests that the patient is still relatively mobile and able to perform daily activities with some limitations.

The patient's laboratory results show a relatively stable level of liver enzymes, low levels of creatinine, and a normal blood pressure. The ECG results indicate the presence of ventricular extrasystole and non-sustained ventricular tachycardia, but these are not indicative of severe arrhythmia or significant cardiac dysfunction. The patient's Pro-BNP level is elevated, but not excessively high, suggesting some degree of heart failure.

Given the patient's relatively stable condition, moderate symptoms, and the effectiveness of current treatment, the most likely outcome is that the patient will survive the next few years. However, it is essential to closely monitor the patient's condition and adjust treatment as needed to prevent complications and progression of the disease.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient has a history of Enolic dilated cardiomyopathy, which increases the risk of sudden cardiac death, the patient is currently receiving treatment with medications that can help manage symptoms and slow disease progression. The patient's laboratory results and ECG results do not indicate any acute cardiac events or significant arrhythmia.

However, the patient's low LVEF (35%) and elevated Pro-BNP level suggest that the patient's heart is not functioning optimally. The patient's NYHA Class II symptoms also indicate some degree of cardiac dysfunction. Although the patient is receiving treatment, the risk of sudden cardiac death cannot be entirely ruled out, especially if the patient's condition worsens or if the treatment is not effective.

RANKING: 3. Pump failure death
REASONING: 
The patient's low LVEF (35%) and elevated Pro-BNP level suggest that the patient's heart is not functioning optimally, which increases the risk of heart failure. The patient's NYHA Class II symptoms also indicate some degree of cardiac dysfunction. While the patient is receiving treatment with medications that can help manage symptoms, the risk of pump failure death is higher than the risk of sudden cardiac death due to the patient's underlying condition.

The patient's elevated creatinine level and low albumin level also suggest that the patient may have some degree of kidney dysfunction, which can contribute to the development of heart failure. Additionally, the patient's low HDL level and elevated LDL level increase the risk of atherosclerosis, which can contribute to cardiac dysfunction.

Overall, while the patient is receiving treatment, the combination of the patient's underlying condition, laboratory results, and ECG results make pump failure death a possible outcome."
523,523,P0819,"Age: 65
Gender: Male 
Weight: 76 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 68.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,13
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 6
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,84
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 199.0
Protein (g/L): 64
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,69
Urea (mg/dL): 5,49
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is most likely to survive due to the following reasons:

1. Age: The patient is 65 years old, which is considered middle-aged. While age is a significant risk factor for cardiac events, it's not the only factor in this case.
2. NYHA Class II: The patient has a mild heart failure, which indicates that their heart is not severely impaired. This suggests that they are still able to tolerate physical activity and may have a relatively preserved cardiac function.
3. Medications: The patient is taking beta blockers, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension. These medications are likely to have a positive impact on the patient's cardiac health.
4. Electrocardiogram (ECG) findings: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart is not at high risk for arrhythmias.
5. Laboratory values: The patient's creatinine level is slightly elevated, but this is not uncommon in patients with heart failure. The troponin level is normal, which suggests that there is no significant myocardial damage.

While the patient's LVEF (left ventricular ejection fraction) is low at 35%, this can be improved with optimal treatment. The patient's weight, blood pressure, and other laboratory values are also within relatively normal ranges.

Considering these factors, the patient is likely to survive with appropriate treatment and management of their underlying conditions.

RANKING: 2. Sudden cardiac death
REASONING: 

This patient is at risk for sudden cardiac death due to the following reasons:

1. Hypertensive cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which can lead to cardiac arrhythmias and sudden cardiac death.
2. Low LVEF: The patient's LVEF is low at 35%, which suggests that their heart is not functioning efficiently.
3. ECG findings: The presence of ventricular extrasystoles on the ECG suggests that the patient's heart is at risk for arrhythmias.
4. Elevated creatinine level: The patient's creatinine level is slightly elevated, which may indicate kidney dysfunction and increased risk for cardiac complications.

While the patient is taking medications that are standard for heart failure and hypertension, their underlying cardiac condition and laboratory values suggest that they are at risk for cardiac complications, including sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

This patient is at risk for pump failure death due to the following reasons:

1. Low LVEF: The patient's LVEF is low at 35%, which suggests that their heart is not functioning efficiently.
2. NYHA Class II: The patient has a mild heart failure, which indicates that their heart is not functioning optimally.
3. Elevated creatinine level: The patient's creatinine level is slightly elevated, which may indicate kidney dysfunction and increased risk for cardiac complications.
4. Hypertension: The patient has a history of hypertension, which can lead to cardiac complications, including heart failure.

However, the patient is taking medications that are standard for heart failure and hypertension, which may help mitigate these risks. Additionally, the patient's ECG findings and laboratory values are not as concerning as those in the sudden cardiac death category. Therefore, while pump failure is a risk, it is not the most likely outcome for this patient."
524,524,P0820,"Age: 70
Gender: Male 
Weight: 75 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 134/61 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1017.0
Protein (g/L): 73
T4 (ng/L): 18
Troponin (ng/mL): 0,04
TSH (mIU/L): 4,22
Urea (mg/dL): 11,82
LVEF (%): 15.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

Based on the provided patient data, I predict that the patient has a high likelihood of survival over the next few years. The key factors contributing to this prediction include:

1. The patient's NYHA Class III classification indicates that they have significant heart failure symptoms, but they are still able to maintain some level of physical activity. This suggests that the heart is still functioning to some extent, and with proper management, the patient may be able to tolerate treatment and reduce symptoms.
2. The patient's LVEF of 15.0 is significantly reduced, indicating severe left ventricular dysfunction, but it is not completely collapsed. This suggests that the heart is still capable of pumping some blood, albeit inefficiently.
3. The patient's medication regimen includes ACE inhibitors, Angiotensin II Receptor Blockers, and Hydralazine, which are all standard treatments for heart failure. These medications can help reduce symptoms and slow disease progression.
4. The patient's laboratory results, including elevated creatinine levels, indicate some degree of renal impairment, but this is not uncommon in patients with heart failure.
5. The ECG impression does not show any life-threatening arrhythmias, which is a positive sign.

However, there are some potential risks and concerns:

1. The patient's low LVEF and NYHA Class III classification indicate a high risk of heart failure exacerbation and potential hospitalization.
2. The patient's dyslipidemia and elevated total cholesterol levels increase the risk of cardiovascular events.
3. The patient's elevated Pro-BNP levels indicate some degree of cardiac stress and potential for further decline.

Overall, while there are some concerns, the patient's overall clinical presentation and treatment plan suggest a high likelihood of survival over the next few years. Regular monitoring and follow-up with the patient's cardiologist will be crucial to manage the patient's condition and prevent complications.

RANKING: 2. Sudden Cardiac Death 
REASONING: 

Based on the provided patient data, I predict a lower likelihood of sudden cardiac death over the next few years. The key factors contributing to this prediction include:

1. The patient's ECG impression does not show any life-threatening arrhythmias, which is a significant risk factor for sudden cardiac death.
2. The patient's medication regimen includes anti-arrhythmic medications, such as Amiodarone, which can help prevent arrhythmias.
3. The patient's laboratory results, including normal troponin levels and normal TSH, do not indicate any acute cardiac injury or inflammation.
4. The patient's LVEF is severely reduced, but this is not a direct indicator of sudden cardiac death risk.

However, there are some potential risks and concerns:

1. The patient's NYHA Class III classification indicates a high risk of heart failure exacerbation and potential for cardiac complications.
2. The patient's dyslipidemia and elevated total cholesterol levels increase the risk of cardiovascular events.
3. The patient's low HDL levels indicate a high risk of cardiovascular disease.

RANKING: 3. Pump Failure Death 
REASONING: 

Based on the provided patient data, I predict a lower likelihood of pump failure death over the next few years. The key factors contributing to this prediction include:

1. The patient's LVEF of 15.0 is severely reduced, but it is not completely collapsed, indicating some degree of cardiac function.
2. The patient's medication regimen includes ACE inhibitors, Angiotensin II Receptor Blockers, and Hydralazine, which can help reduce symptoms and slow disease progression.
3. The patient's laboratory results, including normal creatinine levels, indicate some degree of renal function, which is important for overall health.
4. The patient's ECG impression does not show any life-threatening arrhythmias, which is a significant risk factor for pump failure death.

However, there are some potential risks and concerns:

1. The patient's NYHA Class III classification indicates a high risk of heart failure exacerbation and potential for cardiac complications.
2. The patient's dyslipidemia and elevated total cholesterol levels increase the risk of cardiovascular events.
3. The patient's low HDL levels indicate a high risk of cardiovascular disease.

It is essential to monitor the patient closely and adjust the treatment plan as needed to manage the patient's condition and prevent complications. Regular follow-up with the patient's cardiologist will be crucial to ensure the best possible outcomes."
525,525,P0821,"Age: 75
Gender: Male 
Weight: 66 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 114.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,45
Sodium (mEq/L): 142.0
Protein (g/L): 67
T3 (pg/dL): 0,0363
T4 (ng/L): 12,28
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,11
Urea (mg/dL): 10,9
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient's prognosis is ranked as a survivor due to several factors:

1. Age: Although the patient is 75 years old, the age alone is not a significant predictor of outcome in patients with cardiomyopathy. However, the patient's age is not extremely high, and the presence of idiopathic dilated cardiomyopathy may be contributing to the overall poor prognosis.

2. NYHA Class II: The patient's NYHA class is II, indicating some limitation in physical activity due to symptoms, but not severe. This suggests that the patient has some residual cardiac function, which can contribute to a better prognosis.

3. Medications: The patient is on beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and cardiomyopathy. These medications can help manage symptoms and slow disease progression.

4. ECG findings: While the patient has several arrhythmias, including ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, the absence of sustained ventricular tachycardia or other life-threatening arrhythmias is a positive sign.

5. Laboratory values: The patient's creatinine level is elevated, indicating some degree of kidney impairment, but the patient is not on dialysis. The patient's electrolytes and liver enzymes are relatively normal, which suggests that the patient's kidney and liver function are not severely compromised.

6. Hemoglobin and TSH levels: The patient's hemoglobin is slightly low, but not significantly so. The TSH level is within the normal range, which suggests that the patient's thyroid function is normal.

7. LVEF: The patient's LVEF is significantly reduced, indicating severe left ventricular dysfunction. However, the patient is still alive and has a relatively preserved NYHA class, which suggests that the patient's heart is still functioning to some extent.

Given these factors, the patient's prognosis is ranked as a survivor, with a reasonable expectation of survival for several years with proper management and monitoring.

RANKING: 2. Sudden cardiac death
REASONING:

This patient's prognosis is ranked as sudden cardiac death due to the following factors:

1. Severe LVEF: The patient's LVEF is significantly reduced, indicating severe left ventricular dysfunction. This increases the risk of sudden cardiac death.

2. Presence of ventricular tachycardia: The patient has non-sustained ventricular tachycardia, which increases the risk of sudden cardiac death.

3. Elevated creatinine level: The patient's creatinine level is elevated, indicating some degree of kidney impairment. This can contribute to the development of electrolyte imbalances and cardiac arrhythmias, which increase the risk of sudden cardiac death.

4. Presence of arrhythmias: The patient has several arrhythmias, including ventricular extrasystole and non-sustained ventricular tachycardia, which increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING:

This patient's prognosis is ranked as pump failure death due to the following factors:

1. Severe LVEF: The patient's LVEF is significantly reduced, indicating severe left ventricular dysfunction. This increases the risk of heart failure.

2. Elevated creatinine level: The patient's creatinine level is elevated, indicating some degree of kidney impairment. This can contribute to the development of fluid overload and electrolyte imbalances, which can exacerbate heart failure.

3. NYHA Class II: The patient's NYHA class is II, indicating some limitation in physical activity due to symptoms. This suggests that the patient's heart is not functioning optimally, increasing the risk of pump failure.

4. Presence of arrhythmias: The patient has several arrhythmias, including ventricular extrasystole and non-sustained ventricular tachycardia, which can contribute to the development of heart failure.

While the patient's prognosis is ranked as pump failure death, the patient's survival is still possible with proper management and monitoring. However, the risk of sudden cardiac death and pump failure is significant, and the patient should be closely monitored and managed to minimize these risks."
526,526,P0822,"Age: 51
Gender: Male 
Weight: 82 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,92
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 11,8
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,65
Sodium (mEq/L): 140.0
Protein (g/L): 61
T3 (pg/dL): 0,0474
T4 (ng/L): 13,8
Troponin (ng/mL): 0,4
TSH (mIU/L): 3,85
Urea (mg/dL): 6,7
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient as having the highest likelihood of being a survivor over the next few years. The patient has a relatively well-controlled blood pressure (120/80 mmHg) and is on medications for diabetes, hypertension, and heart failure (Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator). The patient's LVEF (Left Ventricular Ejection Fraction) is 30.0, which is a relatively preserved value, indicating that the patient's heart is still pumping effectively.

Additionally, the patient's ECG findings do not show any signs of severe arrhythmias, such as ventricular tachycardia or ventricular extrasystoles. The absence of non-sustained ventricular tachycardia (CH>10) and paroxysmal supraventricular tachyarrhythmia is also a positive sign.

However, the patient has a significant history of idiopathic dilated cardiomyopathy, which is a condition that can lead to progressive heart failure and increased risk of arrhythmias and sudden cardiac death. Despite this, the patient's current condition and the fact that they are receiving treatment for their heart failure suggest that they may be able to manage their condition effectively.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's heart failure status and idiopathic dilated cardiomyopathy increase their risk of sudden cardiac death, the patient's current condition and treatment plan reduce this risk. However, the patient's LVEF is only 30.0, which is a relatively low value, indicating that the patient's heart is not pumping efficiently. This may increase the risk of sudden cardiac death, particularly if the patient experiences a cardiac event such as a heart attack or severe arrhythmia.

Additionally, the patient's elevated creatinine level (100.0) may indicate some degree of renal impairment, which can increase the risk of cardiac complications.

RANKING: 3. Pump Failure Death
REASONING: 

While the patient's LVEF is 30.0, which is a relatively low value, the patient is currently receiving treatment for heart failure, including medications such as Digoxin, Loop Diuretics, and Spironolactone, which can help manage symptoms and slow disease progression. However, the patient's LVEF is still relatively low, and the patient's history of idiopathic dilated cardiomyopathy suggests that the patient may be at risk of progressive heart failure.

Additionally, the patient's elevated creatinine level (100.0) and elevated blood urea (6.7) may indicate some degree of renal impairment, which can increase the risk of pump failure."
527,527,P0823,"Age: 64
Gender: Male 
Weight: 74 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,1
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,8
Sodium (mEq/L): 138.0
Protein (g/L): 65
T3 (pg/dL): 0,0504
T4 (ng/L): 21
TSH (mIU/L): 2,62
Urea (mg/dL): 8
LVEF (%): 20.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall health status, despite having multiple comorbid conditions such as ischemic dilated cardiomyopathy, diabetes, and hypertension, suggests that the patient is likely to survive for the next few years. The patient's LVEF of 20% indicates severe left ventricular dysfunction, but the presence of medications such as Amiodarone, Beta Blockers, and ACE Inhibitor, which are commonly used to manage heart failure and arrhythmias, further supports the likelihood of survival.

Additionally, the patient's current ECG impression shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other life-threatening arrhythmias, which reduces the risk of sudden cardiac death.

While the patient's kidney function (Creatinine 124.0) and liver function (ALT 17.0, AST 20.0) are mildly elevated, these are not immediately life-threatening and can be managed with the current medications.

However, the patient's low HDL cholesterol level (1.03 mmol/L) and elevated triglycerides (not provided) suggest a high risk of cardiovascular events, which may increase the risk of cardiac events. Nevertheless, the overall clinical picture suggests that the patient is likely to survive for the next few years, but close monitoring and further evaluation are necessary to manage the patient's cardiovascular risk factors.

RANKING: 2. Pump failure death
REASONING: 

Given the patient's severe left ventricular dysfunction (LVEF 20%), pump failure is a significant concern. The patient's kidney function (Creatinine 124.0) and liver function (ALT 17.0, AST 20.0) are mildly elevated, which may indicate some degree of cardiac dysfunction.

The patient's medications, including Amiodarone, Beta Blockers, and ACE Inhibitor, are aimed at managing heart failure and arrhythmias, but may not be sufficient to reverse the severe left ventricular dysfunction.

The patient's NYHA Class II indicates that they experience some symptoms of heart failure, which may worsen over time. Therefore, pump failure is a possible outcome in the next few years.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's severe left ventricular dysfunction (LVEF 20%) and history of myocardial infarction increase the risk of sudden cardiac death. The patient's ECG impression shows a monomorphic ventricular extrasystole, which is a concerning sign of ventricular arrhythmias.

However, the patient's current medications, including Amiodarone, Beta Blockers, and ACE Inhibitor, are aimed at managing arrhythmias and reducing the risk of sudden cardiac death.

The patient's low HDL cholesterol level (1.03 mmol/L) and elevated triglycerides (not provided) increase the risk of cardiovascular events, which may contribute to the risk of sudden cardiac death.

While the patient's overall clinical picture is concerning, the presence of medications aimed at managing arrhythmias and heart failure reduces the likelihood of sudden cardiac death compared to pump failure. However, close monitoring and further evaluation are necessary to manage the patient's cardiovascular risk factors."
528,528,P0824,"Age: 42
Gender: Male 
Weight: 86 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 33,5
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 124
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,64
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 226.0
Protein (g/L): 66,6
T4 (ng/L): 17
TSH (mIU/L): 1,63
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has several factors that suggest a relatively good prognosis, despite the presence of several comorbidities. The patient's NYHA Class II indicates that they have some limitations in physical activity, but it is not severe. The patient's LVEF of 40% is below normal, but it is not significantly low. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is also a positive sign. The patient is on beta blockers and loop diuretics, which are standard treatments for heart failure and hypertension. 

However, the patient's elevated creatinine level (72.0 mmol/L) and high blood pressure (150/90 mmHg) suggest some degree of kidney and cardiovascular strain. The patient's high LDL cholesterol (2.64 mmol/L) also increases the risk of cardiovascular events. 

Despite these factors, the patient's overall clinical presentation and the absence of more severe symptoms or signs of heart failure suggest that they are likely to survive for the next few years. The patient's elevated BNP level (226.0 ng/L) suggests some degree of heart strain, but it is not extremely high.

It is worth noting that the patient's age (42) and gender (male) also contribute to their relatively good prognosis, as men generally have a better survival rate than women for cardiovascular events.

Overall, while the patient has several comorbidities and risk factors, the combination of their clinical presentation and the absence of more severe symptoms or signs of heart failure suggest that they are likely to survive for the next few years."
529,529,P0825,"Age: 51
Gender: Male 
Weight: 99 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,24
Sodium (mEq/L): 149.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 77
T3 (pg/dL): 0,06
T4 (ng/L): 23
Troponin (ng/mL): 0,005
TSH (mIU/L): 0,316
Urea (mg/dL): 7,65
LVEF (%): 32.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the patient's data, I would rank the patient as a survivor for the next few years. The patient has a history of heart failure (HF etiology), which is the underlying condition that led to the current NYHA Class II classification. The patient's LVEF (Left Ventricular Ejection Fraction) is 32.0%, which is a significant reduction in cardiac function, but it is still above the threshold for HF (typically considered <30%). The patient's biomarkers, such as Troponin (0.005 ng/mL) and Pro-BNP (320 ng/L), are not excessively elevated, indicating some degree of cardiac stress but not severe. The patient's medications, including ACE inhibitors, beta-blockers, and digoxin, are being used to manage HF and other comorbid conditions.

The patient's laboratory values, such as creatinine (129 mmol/L), urea (7.65 mg/dL), and potassium (4.4 mEq/L), are elevated, indicating some degree of renal impairment and possible electrolyte imbalance. However, these values are not drastically abnormal and can be managed with the patient's current medications.

The patient's ECG impression shows ventricular extrasystoles, which may indicate arrhythmia, but there is no evidence of ventricular tachycardia or other life-threatening arrhythmias. The presence of paroxysmal supraventricular tachycardia (PSVT) is a concern, but it is not a contraindication for survival.

Considering the patient's overall clinical presentation, medical history, and laboratory values, I believe that the patient is likely to survive for the next few years with proper management of their conditions and close monitoring."
530,530,P0826,"Age: 45
Gender: Male 
Weight: 74 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Toxic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5
LDL (mmol/L): 3,28
Sodium (mEq/L): 148.0
Pro-BNP (ng/L): 53.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,62
Urea (mg/dL): 5,16
LVEF (%): 48.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 45-year-old male with a history of toxic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. However, the patient's current ECG impression shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, but no sustained ventricular tachycardia or other life-threatening arrhythmias. Additionally, the patient's LVEF is 48%, which is slightly below the normal range, but not severely impaired.

The patient's current medications, including beta blockers, digoxin, and an ACE inhibitor, are standard treatments for heart failure and arrhythmias, and are likely effective in managing the patient's symptoms.

The patient's laboratory results show a mildly elevated creatinine level, which may indicate some degree of kidney dysfunction, but this is not uncommon in patients with heart failure. The patient's liver function tests are also mildly elevated, but not significantly abnormal.

The patient's electrolyte levels are within normal limits, and the patient's blood pressure is well-controlled.

Considering these factors, the patient's overall prognosis is likely to be a survivor. The patient's toxic dilated cardiomyopathy is a significant risk factor for sudden cardiac death, but the absence of life-threatening arrhythmias and the effectiveness of current medications suggest that the patient is likely to survive the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

Although the patient's toxic dilated cardiomyopathy is a significant risk factor for sudden cardiac death, the absence of sustained ventricular tachycardia or other life-threatening arrhythmias on the ECG impression makes this outcome less likely. However, the patient's mildly elevated creatinine level and mildly elevated liver function tests may indicate some degree of cardiac dysfunction, which could increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

Given the patient's mildly elevated creatinine level and mildly elevated liver function tests, there is a possibility that the patient's cardiac dysfunction may progress to pump failure. However, the patient's current medications and ECG impression do not suggest a high risk of sudden cardiac death or life-threatening arrhythmias. Additionally, the patient's LVEF is only 48%, which is slightly below the normal range, but not severely impaired.

Overall, while there is a possibility that the patient's cardiac dysfunction may progress to pump failure, the patient's current clinical status and ECG impression suggest that this outcome is less likely than sudden cardiac death."
531,531,P0827,"Age: 41
Gender: Male 
Weight: 54 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 97.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,13
Urea (mg/dL): 3,83
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient is likely to survive for the next few years. Here's the reasoning behind this ranking:

1. The patient has a relatively stable hemodynamic status, with a normal blood pressure (130/70 mmHg) and a low creatinine level (84.0 mol/L), indicating a relatively preserved renal function. This suggests that the patient's cardiac function is not severely impaired.

2. The patient's LVEF (Left Ventricular Ejection Fraction) is 26.0%, which is lower than the normal range (55%). However, in the context of idiopathic dilated cardiomyopathy, an LVEF of 26.0% is not considered severely impaired. With proper management and treatment, many patients with such an LVEF can survive for an extended period.

3. The patient has a low level of troponin (0.005 ng/mL), which suggests that there is minimal myocardial damage. Elevated troponin levels are often associated with acute myocardial infarction or cardiac rupture.

4. The patient is on medications that are commonly used to manage heart failure and arrhythmias, including beta blockers, digoxin, loop diuretics, and an ACE inhibitor. These medications can help slow the progression of heart failure and reduce the risk of arrhythmias.

5. The patient does not have any other significant risk factors for sudden cardiac death or pump failure, such as a history of myocardial infarction, coronary artery disease, or significant valvular disease.

While the patient's ECG shows non-sustained ventricular tachycardia (NSVT) and ventricular extrasystoles, these are relatively common in patients with idiopathic dilated cardiomyopathy. With proper management and monitoring, the risk of sudden cardiac death can be reduced.

Overall, based on the provided patient data, the patient is likely to survive for the next few years with proper management and treatment."
532,532,P0828,"Age: 70
Gender: Male 
Weight: 94 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 175.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,03
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1603.0
Protein (g/L): 69
T3 (pg/dL): 0,07
T4 (ng/L): 20
TSH (mIU/L): 0,495
Urea (mg/dL): 11,98
LVEF (%): 55.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's data, the most likely prognosis is survivor. The patient's age, NYHA Class II, and the presence of valvular cardiomyopathy, dyslipidemia, and hypertension are significant risk factors for cardiac complications. However, the patient's hemoglobin level (153.0 g/L) and lack of severe anemia are favorable. The patient is also on multiple medications, including beta blockers, digoxin, and statins, which are standard treatments for heart failure and high cholesterol.

The patient's LVEF (55.0%) is significantly reduced, indicating some degree of left ventricular dysfunction. However, the patient's ejection fraction is not severely impaired, which suggests that the patient may still have some residual cardiac function. The presence of elevated creatinine (175.0 mmol/L) and urea (11.98 mg/dL) levels indicates some degree of renal impairment, which can be associated with heart failure.

The patient's ECG findings are concerning for ventricular extrasystoles, which can be a marker for underlying cardiac arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia (CH>10) reduces the risk of sudden cardiac death. The presence of paroxysmal supraventricular tachyarrhythmia is unknown, which makes it difficult to assess the risk of arrhythmias.

Overall, while the patient has several risk factors and concerning ECG findings, the patient's overall clinical presentation and the presence of multiple medications suggest that the patient is likely to survive for the next few years. However, close monitoring and regular follow-up are necessary to assess the patient's cardiac function and adjust treatment as needed.

Prognosis: 5-year survival rate: 70-80%
10-year survival rate: 40-50%"
533,533,P0829,"Age: 60
Gender: Female 
Weight: 97 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Other HF etiology, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 27.0
Protein (g/L): 72
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 5
Urea (mg/dL): 5,16
LVEF (%): 50.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is a 60-year-old female with a history of heart failure (HF) due to other etiology, hypertension, and elevated creatinine levels, indicating potential kidney impairment. However, the patient's current NYHA Class II symptoms suggest that the heart failure is not severe. The patient's LVEF (left ventricular ejection fraction) is 50%, which is within the normal range, and the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient does not have a high risk of sudden cardiac death. The patient's medication regimen, which includes an Angiotensin II Receptor Blocker (ARB) and Digoxin, is standard treatment for heart failure. The patient's laboratory results, including normal troponin levels, indicate that there is no evidence of acute myocardial infarction. 

Given these factors, the patient is likely to survive for the next few years without significant cardiovascular events. The patient's weight, blood pressure, and electrolyte levels are also within relatively normal ranges, which further supports a favorable prognosis. Therefore, the most likely outcome for this patient over the next few years is a survivor.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's current ECG results do not show any evidence of ventricular tachycardia or non-sustained ventricular tachycardia, the patient's history of heart failure and elevated creatinine levels indicate a potential risk of cardiovascular events. The patient's LVEF is slightly below normal, which may indicate some degree of left ventricular dysfunction. Additionally, the patient's Pro-BNP levels are elevated, which may indicate some degree of ventricular strain. While the patient is currently taking standard treatment for heart failure, the presence of these factors may increase the risk of sudden cardiac death in the future.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's current NYHA Class II symptoms and elevated creatinine levels suggest that the patient has some degree of heart failure. The patient's LVEF is also below normal, which may indicate some degree of left ventricular dysfunction. However, the patient is currently taking standard treatment for heart failure, and the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient does not have a high risk of sudden cardiac death. While the patient's Pro-BNP levels are elevated, this may be a response to the patient's current heart failure rather than a sign of impending pump failure. Therefore, while there is a risk of pump failure, the patient's current treatment regimen and relatively normal LVEF make this outcome less likely compared to sudden cardiac death."
534,534,P0831,"Age: 66
Gender: Female 
Weight: 103 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 65.0
Protein (g/L): 70
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 4,99
LVEF (%): 58.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the patient's age, NYHA Class II, and the presence of multiple comorbid conditions such as hypertension, diabetes, and dyslipidemia, the patient is at risk for cardiac complications. However, the patient's current ECG impression does not show any life-threatening arrhythmias, and the troponin level is within normal limits. The patient's LVEF is 58.0%, which is slightly below the normal range, but not significantly reduced.

The patient's creatinine level is elevated, which may indicate some degree of renal impairment, but it is not severe. The patient is on medications such as spironolactone and ACE inhibitor, which are commonly used to manage conditions like hypertension and heart failure.

Considering these factors, I would rank the patient as a survivor, as the likelihood of sudden cardiac death or pump failure is relatively low. The patient's comorbid conditions and elevated creatinine level do pose a risk, but the absence of life-threatening arrhythmias and relatively preserved LVEF suggest that the patient may be able to manage their condition with current treatment.

The patient's past medical history of myocardial infarction and hypertension also suggests that the patient has had some cardiac damage, but the fact that the patient is currently on medications and has a relatively preserved LVEF suggests that the patient's cardiac function is not severely impaired.

In contrast, pump failure death is less likely because the patient's LVEF is not severely reduced, and the patient is on medications that can help manage heart failure. Sudden cardiac death is also less likely due to the absence of life-threatening arrhythmias and the patient's relatively preserved cardiac function."
535,535,P0832,"Age: 56
Gender: Male 
Weight: 94 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 145/85 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5
LDL (mmol/L): 1,42
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 217.0
Protein (g/L): 74
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 7,49
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient is at high risk for adverse cardiac events due to the presence of several comorbid conditions such as dilated cardiomyopathy, hypertension, diabetes, and dyslipidemia. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 35%, indicating poor cardiac function. The elevated B-type natriuretic peptide (Pro-BNP) level of 217 ng/L suggests cardiac strain and possible heart failure. However, the patient is currently being treated with medications for these conditions, including beta-blockers, loop diuretics, and an ACE inhibitor, which can help manage symptoms and slow disease progression. The patient's ECG impression shows ventricular extrasystoles, which may be related to the underlying cardiomyopathy, but does not indicate a high risk for sudden cardiac death or ventricular tachycardia. Therefore, based on the available information, the patient is most likely to survive for the next few years with proper management and monitoring."
536,536,P0833,"Age: 68
Gender: Female 
Weight: 66 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,96
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 10,4
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,36
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 588.0
Protein (g/L): 73
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,36
Urea (mg/dL): 9,82
LVEF (%): 55.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and the presence of hypertension, diabetes, dyslipemia, and peripheral vascular disease suggest that the patient has a history of cardiovascular risk factors that could contribute to cardiac disease. However, the patient's current blood pressure is well-controlled (140/70 mmHg), and the patient is taking medications for hypertension, diabetes, and dyslipemia, which indicates that the patient is actively managing their conditions.

The patient's LVEF is 55.0%, which is slightly below the normal range, indicating some degree of left ventricular dysfunction. However, the patient's Troponin levels are normal, and there is no evidence of acute myocardial infarction or cardiac rupture.

The ECG impression shows ventricular extrasystole, which is a benign finding and does not necessarily indicate a significant cardiac problem. The absence of other arrhythmias and no evidence of cardiac ischemia or infarction further supports a favorable prognosis.

The patient's renal function is also preserved, with a creatinine level of 9.82 mg/dL, which is within the normal range. The patient's electrolyte levels, including potassium, sodium, and TSH, are also within normal limits.

Considering these factors, the patient's overall cardiovascular risk profile suggests that they are at moderate risk for cardiac events, but the absence of acute cardiac problems and the patient's good blood pressure control and renal function suggest that they are likely to survive for the next few years without significant cardiac events."
537,537,P0834,"Age: 58
Gender: Male 
Weight: 76 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 90/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 181.0
Gamma-glutamil transpeptidase (IU/L): 76
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,18
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,48
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 6433.0
Protein (g/L): 74
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,17
Urea (mg/dL): 17,8
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 58-year-old male with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death and heart failure. The patient's left ventricular ejection fraction (LVEF) of 26.0% indicates severe systolic dysfunction, which is a hallmark of heart failure. However, the patient's current New York Heart Association (NYHA) class is II, indicating mild symptoms, which suggests that the patient is still relatively asymptomatic despite the severe underlying pathology.

The patient's biomarkers, such as elevated troponin (0.01 ng/mL), elevated creatinine (1.81 mmol/L), and elevated BNP (6433 ng/L), indicate ongoing cardiac stress and potential heart failure. However, the patient's hemoglobin level is normal, and the patient is not experiencing any acute symptoms.

The patient's medication regimen includes digoxin, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. The patient's blood pressure is well-controlled at 90/70 mmHg, and the ECG findings are not indicative of any acute arrhythmias.

Given the patient's severe underlying heart disease, ongoing biomarkers of cardiac stress, and controlled blood pressure, the most likely outcome is that the patient will survive for the next few years. However, the patient will likely require close monitoring and adjustments to their medication regimen to manage their heart failure symptoms and prevent further decline.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's severe heart disease and ongoing biomarkers of cardiac stress make them at risk for sudden cardiac death, the patient's controlled blood pressure, lack of acute symptoms, and normal hemoglobin level reduce this risk. The patient's ECG findings are not indicative of any acute arrhythmias, and the patient is not experiencing any symptoms that would suggest an acute cardiac event.

However, the patient's severe underlying heart disease and ongoing biomarkers of cardiac stress make it possible that the patient could experience a sudden cardiac event. The patient's left ventricular ejection fraction of 26.0% is a significant risk factor for sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's severe heart failure, as indicated by their LVEF of 26.0%, makes pump failure a significant risk. However, the patient's controlled blood pressure, lack of acute symptoms, and normal hemoglobin level reduce this risk. The patient's ongoing biomarkers of cardiac stress, such as elevated troponin and BNP, suggest that the patient's heart is still under significant stress, but the patient is not currently experiencing any acute symptoms.

Given the patient's severe underlying heart disease and ongoing biomarkers of cardiac stress, it is possible that the patient could experience a decline in cardiac function and require hospitalization for heart failure. However, the patient's controlled blood pressure and lack of acute symptoms reduce the likelihood of pump failure death.

It's worth noting that the patient's overall prognosis is influenced by their age, comorbidities, and the presence of ongoing biomarkers of cardiac stress. A cardiologist would need to carefully monitor the patient's condition and adjust their treatment plan as needed to minimize the risk of adverse outcomes."
538,538,P0836,"Age: 53
Gender: Male 
Weight: 67 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44,1
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,41
LDL (mmol/L): 3,48
Sodium (mEq/L): 135.0
Protein (g/L): 78,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,89
Urea (mg/dL): 8,7
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a significant amount of comorbidities, including idiopathic dilated cardiomyopathy, which is a condition that affects the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is 30%, which is well below the normal range, indicating severe left ventricular dysfunction.

The patient's medication regimen includes beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and arrhythmias. However, the presence of non-sustained ventricular tachycardia (VT) on the ECG suggests a high risk of arrhythmic events.

Despite these factors, the patient's Troponin levels are normal, which suggests that there is no acute myocardial infarction. The patient's creatinine level is elevated, which may indicate some degree of kidney impairment, but this is not directly related to cardiac function.

Given the patient's age, comorbidities, and medication regimen, the likelihood of sudden cardiac death is relatively low. The patient's ECG findings suggest a high risk of arrhythmic events, but the absence of a clear indication of severe cardiac dysfunction or acute myocardial infarction reduces this risk.

Therefore, based on the available data, the most likely outcome for this patient over the next few years is survival, although the patient will likely require close monitoring and adjustments to their medication regimen to manage their arrhythmias and heart failure symptoms.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's idiopathic dilated cardiomyopathy and LVEF of 30% increase the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia (VT) on the ECG is a significant risk factor for sudden cardiac death.

Additionally, the patient's elevated creatinine level may indicate some degree of kidney impairment, which can increase the risk of arrhythmic events. The patient's medication regimen includes beta blockers, which can increase the risk of hypotension and bradycardia, which may increase the risk of cardiac arrest.

While the patient's Troponin levels are normal, the presence of ventricular extrasystoles and non-sustained VT on the ECG suggests a high risk of arrhythmic events. However, the patient's overall clinical profile is not as severe as the survivor outcome.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF of 30% and NYHA Class II symptoms indicate significant left ventricular dysfunction and heart failure. The patient's elevated creatinine level and elevated blood urea nitrogen (BUN) level may indicate some degree of kidney impairment, which can increase the risk of pump failure.

The patient's medication regimen includes loop diuretics, which can help manage heart failure symptoms, but the presence of non-sustained VT on the ECG suggests a high risk of arrhythmic events. The patient's elevated troponin level is also a risk factor for cardiac damage.

While the patient's Troponin levels are not elevated, the patient's overall clinical profile suggests a high risk of pump failure. The patient's ECG findings and medication regimen suggest that the patient is at high risk for arrhythmic events and cardiac dysfunction, which can increase the risk of pump failure.

However, the patient's overall clinical profile is not as severe as the sudden cardiac death outcome, and the patient's medication regimen includes beta blockers, which can help manage heart failure symptoms."
539,539,P0837,"Age: 84
Gender: Male 
Weight: 54 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 36,2
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,85
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 15
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,54
Potassium (mEq/L): 4,62
LDL (mmol/L): 2,81
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2619.0
Protein (g/L): 73,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,54
Urea (mg/dL): 12,7
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is 84 years old, with a history of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction, which are all risk factors for cardiac complications. However, the patient's current NYHA Class II indicates that the patient has some symptoms, but they are not severely limited in their physical activities.

The patient's laboratory results show a slightly elevated creatinine level (86.0 mmol/L) and a mildly elevated troponin level (0.01 ng/mL), which may indicate some cardiac strain. However, the troponin level is not significantly elevated, and the LVEF (Left Ventricular Ejection Fraction) is 25.0%, which is within the normal range.

The ECG findings show ventricular extrasystoles, which are a common finding in patients with cardiac disease, but there is no evidence of ventricular tachycardia or bradycardia. The patient is also taking medications that are commonly used to manage heart failure and arrhythmias, such as digoxin, loop diuretics, spironolactone, ACE inhibitors, and nitrovasodilator.

Considering these factors, the patient's overall condition appears to be stable, and the patient is likely to survive for the next few years with proper management and monitoring. The patient's age is a significant risk factor, but the patient's current condition and laboratory results suggest that the patient is not at high risk of sudden cardiac death or pump failure in the near future.

The patient's Pro-BNP level (2619.0 ng/L) is elevated, which suggests some degree of cardiac stress, but it is not significantly elevated. The patient's potassium level (4.62 mEq/L) is within the normal range, which reduces the risk of arrhythmias.

Overall, based on the provided data, the patient's prognosis is most likely to be a survivor, with a moderate risk of cardiac complications, but manageable with proper medical care."
540,540,P0840,"Age: 55
Gender: Female 
Weight: 55 kg
Height: 145 cm
NYHA Class: III
Blood Pressure: 80/40 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 44,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,44
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,15
LDL (mmol/L): 3,71
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 991.0
Protein (g/L): 77,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,87
Urea (mg/dL): 7,8
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a history of valvular cardiomyopathy, which is a significant risk factor for cardiac complications. However, the patient is currently on medications for heart failure management, including Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, and Spironolactone, which are standard treatments for heart failure. The patient's NYHA Class III indicates severe symptoms, but the fact that they are already on medications for heart failure suggests that the condition is being managed. The patient's LVEF (40.0) is low, indicating reduced heart function, but not critically low. The ECG impression does not indicate any acute cardiac events, and the patient's troponin levels are normal. The patient's Pro-BNP levels are elevated, which can be a marker for heart failure, but it is not an indicator of a poor outcome. Considering these factors, the patient is likely to survive for the next few years.

2. Sudden Cardiac Death
REASONING: 
The patient's history of valvular cardiomyopathy increases the risk of sudden cardiac death. However, the patient is already on medications for heart failure, which reduces the risk of sudden cardiac death. The patient's LVEF is low, which increases the risk of sudden cardiac death. The elevated Pro-BNP levels also suggest that the patient may have some degree of heart failure, which increases the risk of sudden cardiac death. However, the patient's normal troponin levels and lack of acute cardiac events on the ECG impression reduce the likelihood of sudden cardiac death.

3. Pump Failure Death
REASONING: 
The patient's LVEF is low (40.0), which indicates reduced heart function. The patient's NYHA Class III indicates severe symptoms, which suggests that the patient's heart is not functioning optimally. The patient's Pro-BNP levels are elevated, which can be a marker for heart failure. However, the patient is already on medications for heart failure, which suggests that the condition is being managed. The patient's Creatinine levels are elevated, which can indicate kidney dysfunction, but it is not directly related to pump failure. The patient's ECG impression does not indicate any acute cardiac events, which reduces the likelihood of pump failure death. Considering these factors, pump failure death is the least likely outcome."
541,541,P0841,"Age: 54
Gender: Male 
Weight: 75 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,18
LDL (mmol/L): 2,75
Sodium (mEq/L): 139.0
Protein (g/L): 67,9
T3 (pg/dL): 0,0648
T4 (ng/L): 12,24
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,77
Urea (mg/dL): 5,5
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient has a significant history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which are risk factors for cardiac events. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 25%, indicating poor cardiac function. However, the patient's current ECG impression does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are common precursors to sudden cardiac death. The patient is also on medications that are commonly used to manage heart failure and hypertension, which suggests that the patient is receiving appropriate treatment for their underlying conditions.

While the patient's Troponin level is elevated, which may indicate some myocardial damage, it is not significantly elevated, suggesting that the patient may not be experiencing an acute myocardial infarction at the moment. The patient's other lab results, such as creatinine and urea levels, are within normal limits, which suggests that the patient's kidney function is not severely impaired.

Given these factors, I believe that the patient is at high risk of cardiac events, but the absence of any immediate signs of acute cardiac damage or arrhythmias suggests that the patient may survive for the next few years with proper management and treatment. Therefore, I rank the patient as having a high chance of survival."
542,542,P0842,"Age: 57
Gender: Male 
Weight: 84 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 125/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,21
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 690.0
Protein (g/L): 74
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,83
Urea (mg/dL): 5,16
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the patient's data, I would rank the patient as a survivor for the next few years. Here's the reasoning behind this assessment:

1. LVEF of 20.0%: A left ventricular ejection fraction (LVEF) of 20% is a significant indicator of advanced left ventricular dysfunction, which is a major predictor of poor prognosis in heart failure patients. However, the patient is already on medications that are indicated for heart failure management, which suggests that the clinician is actively managing the condition.

2. Presence of Ventricular Extrasystole and Non-sustained Ventricular Tachycardia (NSVT): While these arrhythmias are concerning, the fact that they are non-sustained (less than 30 seconds) may indicate that the patient's heart is still functioning to some extent. The presence of these arrhythmias, however, may require closer monitoring and adjustments to the patient's medication regimen.

3. NYHA Class III: The patient's New York Heart Association (NYHA) class III classification indicates severe symptoms of heart failure, which may limit physical activity and overall quality of life. However, the fact that the patient is still able to walk and perform daily activities suggests that the heart is still functional enough to support daily life.

4. Other factors: The patient's blood pressure, electrolytes, liver function tests, and renal function are within relatively normal limits, which suggests that there are no acute complications that would immediately threaten the patient's life.

5. Pro-BNP levels: The patient's Pro-BNP level is elevated, indicating some degree of heart failure. However, the level is not extremely high, which may suggest that the patient is not in acute decompensated heart failure.

Considering these factors, I believe that the patient is likely to survive for the next few years with proper management and monitoring. However, it is essential to closely monitor the patient's condition, adjust the medication regimen as needed, and consider further interventions if the patient's symptoms worsen or if there are signs of worsening heart failure."
543,543,P0844,"Age: 73
Gender: Male 
Weight: 66 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/88 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 3,1
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 10,6
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1713.0
Protein (g/L): 78
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,86
Urea (mg/dL): 7,15
LVEF (%): 20.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. The patient's current NYHA Class II indicates a moderate level of heart failure symptoms. The patient's LVEF (Left Ventricular Ejection Fraction) is severely impaired at 20%, which is a significant indicator of poor cardiac function.

The patient's biomarkers, such as elevated Troponin levels (0.01 ng/mL) and Pro-BNP levels (1713 ng/L), suggest some degree of cardiac stress and strain. However, the absence of elevated creatine kinase or other signs of myocardial damage reduces the likelihood of acute myocardial infarction.

The patient's medication regimen includes beta-blockers, ACE inhibitors, and spironolactone, which are standard treatments for heart failure and hypertension. The patient's electrolyte levels are mostly within normal ranges, with the exception of slightly elevated potassium levels (4.5 mEq/L), which may require monitoring.

The ECG impression shows ventricular extrasystoles, which are benign and not indicative of a life-threatening arrhythmia. The absence of other arrhythmias or signs of ventricular tachycardia reduces the risk of sudden cardiac death.

Considering the patient's age, medical history, and current condition, the likelihood of sudden cardiac death or pump failure death is relatively low. Therefore, the most likely outcome is that the patient will survive, although close monitoring and follow-up are essential to adjust the treatment plan and manage any potential complications."
544,544,P0847,"Age: 65
Gender: Male 
Weight: 67 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 100/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 47
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 15,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 6,3
LDL (mmol/L): 3,49
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 564.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,96
Urea (mg/dL): 9,82
LVEF (%): 50.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood efficiently is compromised. The patient's left ventricular ejection fraction (LVEF) is 50%, which is below the normal range (55%), indicating reduced cardiac function.

The patient's NYHA class is II, which suggests mild symptoms of heart failure, such as fatigue and shortness of breath, but the patient is still able to perform daily activities without significant limitations. The patient's blood pressure is 100/50 mmHg, which is slightly low but not severely hypotensive.

The patient's laboratory results show elevated liver enzymes (ALT and AST), indicating possible liver damage or stress. However, the patient's renal function is normal, and the creatinine level is within the normal range.

The patient's medication regimen includes beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, which are standard treatments for heart failure and cardiomyopathy.

The ECG impression does not show any significant arrhythmias, and the patient does not have evidence of acute coronary syndrome or severe cardiac ischemia.

Given these factors, I believe the patient is at moderate risk for cardiac complications, but the overall prognosis is still favorable due to the patient's relatively preserved cardiac function and the absence of severe arrhythmias or acute coronary syndromes. Therefore, I predict the patient will survive for the next few years with appropriate management and monitoring.

RANKING: 2. Pump failure death
REASONING: 

While the patient has a history of idiopathic dilated cardiomyopathy and reduced LVEF, the patient's cardiac function is still relatively preserved, and the patient is not in acute heart failure. However, the patient's elevated liver enzymes and slightly low blood pressure may indicate some degree of cardiac stress or damage.

If the patient's cardiac function continues to decline, the patient may experience worsening heart failure symptoms, leading to pump failure. However, this is a more speculative prognosis, and the patient's current cardiac function is still relatively preserved.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's ECG impression does show ventricular extrasystole, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. However, the ventricular extrasystole was described as monomorphic, which suggests that it may not be as high-risk as other types of arrhythmias.

Additionally, the patient's LVEF is still relatively preserved, and the patient does not have evidence of acute coronary syndrome or severe cardiac ischemia. While the patient's elevated liver enzymes and slightly low blood pressure may indicate some degree of cardiac stress or damage, these factors do not necessarily increase the risk of sudden cardiac death.

Overall, while the patient has some risk factors for cardiac complications, the patient's current cardiac function and ECG results do not suggest an extremely high risk for sudden cardiac death."
545,545,P0849,"Age: 81
Gender: Female 
Weight: 76 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 47
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 122.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,8
LDL (mmol/L): 3,52
Sodium (mEq/L): 153.0
Pro-BNP (ng/L): 1494.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 15
TSH (mIU/L): 3,52
Urea (mg/dL): 20,63
LVEF (%): 60.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a relatively stable clinical presentation with a normal blood pressure, no acute symptoms, and no evidence of acute coronary syndrome or acute heart failure. The presence of a ventricular extrasystole on ECG is noted, but it is not sustained, which is a good sign. The patient's NYHA class is III, indicating moderate symptoms of heart failure, but the patient is still ambulatory and not in acute distress. The patient's medications are well-managed, with no signs of under or over-medication. The patient's laboratory values, including creatinine and electrolytes, are within relatively normal limits. The presence of a high Pro-BNP level (1494.0 ng/L) is concerning for heart failure, but it is not an absolute predictor of poor outcome. Overall, the patient's clinical presentation and laboratory values suggest that the patient is likely to survive for the next few years with proper management and monitoring."
546,546,P0850,"Age: 48
Gender: Male 
Weight: 60 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,81
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2429.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,11
TSH (mIU/L): 3,28
Urea (mg/dL): 4,66
LVEF (%): 12.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 48-year-old male with a history of heart failure (HF) and multiple comorbidities. The patient has a NYHA Class II heart failure classification, indicating mild symptoms, but still significant enough to warrant treatment. The patient's vital signs are relatively stable, with a blood pressure of 120/60 mmHg and an oxygen saturation of 100%. The patient's laboratory results show elevated creatinine levels (80.0 mmol/L) and a low LVEF (12.0%), indicating significant cardiac dysfunction. However, the patient is already on a regimen of medications for HF, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor.

The ECG results show ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia, which are all concerning for arrhythmias. However, the patient is not in cardiac arrest or showing signs of imminent cardiac death. The patient's Pro-BNP levels are elevated (2429.0 ng/L), indicating fluid overload and possible worsening heart failure.

Given the patient's relatively stable vital signs, mild symptoms, and the presence of multiple comorbidities, the likelihood of sudden cardiac death is lower compared to pump failure death. The patient's ECG results, while concerning, do not indicate an immediate life-threatening arrhythmia. Therefore, the most likely outcome for the next few years is survival, assuming the patient adheres to their treatment regimen and receives regular follow-up care.

Sudden cardiac death is the second most likely outcome, as the patient has a history of ventricular tachycardia and polymorphic ventricular tachycardia, which can increase the risk of sudden cardiac death. However, the patient's current ECG results do not show any signs of imminent cardiac arrest.

Pump failure death is the least likely outcome, given the patient's current medication regimen and stable vital signs. While the patient has significant cardiac dysfunction, the patient is already receiving treatment for HF, and the patient's LVEF is not severely impaired.

It is essential for the patient to continue monitoring their condition closely and adjust their treatment plan as needed to prevent worsening heart failure and arrhythmias. Regular follow-up appointments with the cardiologist and close monitoring of the patient's vital signs and ECG results will help identify any potential issues early, reducing the risk of sudden cardiac death and pump failure."
547,547,P0852,"Age: 68
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5
LDL (mmol/L): 2,51
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 457.0
Protein (g/L): 70
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,4
Urea (mg/dL): 4,99
LVEF (%): 60.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

Based on the patient's data, the patient is 68 years old with a history of hypertensive cardiomyopathy and hypertension, which is a significant risk factor for cardiovascular disease. The patient's NYHA Class II indicates moderate heart failure, but the patient's ejection fraction (LVEF) is still within the normal range at 60%. The patient's lipid profile is also relatively well-controlled, with low total cholesterol and low LDL levels. The patient's medication regimen includes beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, which is standard treatment for heart failure and hypertension.

The patient's biomarkers, such as troponin and creatinine, are not significantly elevated, indicating no acute myocardial infarction or significant kidney damage. The patient's electrolytes, including potassium and sodium levels, are within the normal range. The patient's ECG shows ventricular extrasystole, but it is polymorphic and not sustained, which may indicate a benign arrhythmia.

Considering these factors, the patient's overall condition appears stable, and the patient is likely to survive for the next few years. The patient's age, NYHA Class II, and controlled hypertension are risk factors for cardiovascular disease, but the patient's current medication regimen and relatively well-controlled lipid profile suggest that the patient is at moderate risk for cardiovascular events. Therefore, I predict that the patient will survive for the next few years with careful management and monitoring.

The patient's Pro-BNP levels are elevated, which may indicate some degree of heart failure, but the patient's LVEF is still within the normal range. The patient's kidney function is also relatively well-preserved, given the creatinine level of 80.0 mmol/L. The patient's medication regimen is comprehensive, and the patient's ECG shows no signs of significant arrhythmias.

In summary, while the patient has some risk factors for cardiovascular disease, the patient's current condition appears stable, and the patient is likely to survive for the next few years with careful management and monitoring."
548,548,P0854,"Age: 71
Gender: Male 
Weight: 72 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 100/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 156.0
AST or GOT (IU/L): 130.0
Total Cholesterol (mmol/L): 3,05
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,29
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1551.0
Protein (g/L): 73
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,33
Urea (mg/dL): 12,48
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a complex medical history with multiple comorbid conditions such as ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which increase the risk of cardiac events. However, the patient is currently on medications that are standard for managing these conditions, including beta blockers, statins, and an ACE inhibitor. The presence of elevated troponin levels (0.01 ng/mL) indicates some myocardial damage, but the level is within a relatively normal range for a post-myocardial infarction patient. 

The patient's NYHA class II indicates mild symptoms, which is a good prognostic sign. The LVEF of 30% is significantly reduced, but not severely impaired, which may indicate some residual cardiac function. The patient's biomarkers, including elevated liver enzymes (ALT and AST) and creatinine, may indicate some degree of kidney dysfunction. However, the patient's creatinine level is not excessively elevated.

The patient's ECG findings, including ventricular extrasystole and paroxysmal supraventricular tachycardia (PSVT), may indicate some degree of arrhythmia, but the presence of ventricular tachycardia and non-sustained ventricular tachycardia are not present. 

Considering these factors, the patient's overall prognosis is favorable, and they are likely to survive for the next few years. However, close monitoring and adjustments to their treatment plan may be necessary to manage their cardiac and kidney function.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's prognosis is favorable, there are some risk factors that increase the likelihood of sudden cardiac death. The patient's LVEF of 30% is significantly reduced, indicating severe cardiac dysfunction. The presence of ventricular extrasystole on the ECG may indicate some degree of ventricular arrhythmia, which can increase the risk of sudden cardiac death. 

Additionally, the patient's elevated troponin levels (0.01 ng/mL) may indicate some degree of myocardial damage, which can increase the risk of arrhythmias and sudden cardiac death. The patient's kidney function is also compromised, which may increase the risk of arrhythmias and sudden cardiac death.

However, the patient's overall prognosis is still relatively favorable, and the risk of sudden cardiac death is not extremely high. The patient's NYHA class II symptoms and the presence of beta blockers and ACE inhibitor may help to mitigate some of these risks.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF of 30% is significantly reduced, indicating severe cardiac dysfunction. The patient's kidney function is also compromised, with a creatinine level of 141.0 mmol/L, which may indicate some degree of cardiac-kidney interaction. The patient's elevated liver enzymes (ALT and AST) and creatinine may indicate some degree of liver and kidney dysfunction, which can increase the risk of pump failure.

The patient's ECG findings, including ventricular extrasystole, may indicate some degree of ventricular arrhythmia, which can increase the risk of pump failure. The patient's elevated troponin levels (0.01 ng/mL) may indicate some degree of myocardial damage, which can increase the risk of pump failure.

However, the patient's overall prognosis is not extremely poor, and the patient's NYHA class II symptoms and the presence of beta blockers and ACE inhibitor may help to mitigate some of these risks. Close monitoring and adjustments to their treatment plan may be necessary to manage their cardiac and kidney function."
549,549,P0855,"Age: 71
Gender: Male 
Weight: 70 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 135/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 2,14
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 110.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,6
LDL (mmol/L): 0,97
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 17984.0
Protein (g/L): 71
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,65
Urea (mg/dL): 7,15
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is at high risk for cardiac events, with a history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 18%, indicating poor cardiac function. The elevated N-terminal pro-b-type natriuretic peptide (Pro-BNP) level of 17,984 ng/L suggests heart failure. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG further increases the risk of cardiac arrhythmias.

Despite the presence of multiple comorbidities, the patient is currently on beta blockers, digoxin, and ACE inhibitors, which are standard treatments for heart failure and hypertension. However, the patient's NYHA class is II, indicating mild symptoms, which may suggest that the current treatment regimen is effective in managing symptoms.

Given the patient's overall clinical presentation, I would predict that the patient is most likely to survive for the next few years, with ongoing monitoring and adjustments to their treatment plan as needed to manage their cardiac conditions.

RANKING 2: Sudden cardiac death
REASONING: 
While the patient is at high risk for cardiac events, the presence of a NYHA class II and the fact that the patient is currently on standard treatments for heart failure and hypertension, suggest that sudden cardiac death is less likely. However, the patient's LVEF is significantly reduced, and the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG increases the risk of arrhythmias.

RANKING 3: Pump failure death
REASONING: 
Pump failure death is a possible outcome for this patient, given their history of ischemic dilated cardiomyopathy and reduced LVEF. However, the patient is currently on treatment for heart failure and hypertension, which suggests that the patient's cardiac function is being managed. The patient's NYHA class is also II, indicating mild symptoms, which may suggest that the patient's cardiac function is not severely impaired.

Overall, while pump failure death is a possible outcome, I would rank it as the least likely given the patient's current treatment regimen and symptom level."
550,550,P0856,"Age: 63
Gender: Male 
Weight: 88 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 169.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4
LDL (mmol/L): 2,46
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 406.0
Protein (g/L): 70
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,02
Urea (mg/dL): 4,99
LVEF (%): 44.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 

1. Survivor
REASONING: 

The patient is a 63-year-old male with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac events. However, the patient has been receiving a comprehensive treatment regimen of medications, including ACE inhibitors, beta blockers, loop diuretics, and statins, which are commonly used to manage heart failure and prevent further cardiac damage. The patient's current NYHA Class II classification indicates a moderate level of functional impairment, but it is not severe. The patient's LVEF is 44%, which is lower than the normal range, indicating some degree of left ventricular dysfunction. 

The patient's ECG shows ventricular extrasystole, but it is monomorphic and not sustained, which suggests that it is not a high-risk arrhythmia. The absence of other arrhythmias on the ECG is also reassuring. The patient's creatinine level is elevated, but it is not significantly high, and the patient is not showing signs of acute kidney injury. 

Given these factors, the patient is likely to survive the next few years, and the prognosis is favorable. The patient's treatment regimen and the absence of high-risk features on the ECG and laboratory tests suggest that the patient is likely to continue to manage his condition effectively and avoid major adverse cardiac events.

2. Sudden Cardiac Death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy and the presence of ventricular extrasystole on the ECG are risk factors for sudden cardiac death. While the patient is receiving treatment, the risk of sudden cardiac death is still present, especially if the ventricular extrasystole is not adequately managed. The patient's LVEF is also lower than normal, which can increase the risk of arrhythmias and sudden cardiac death.

However, the patient's ECG does not show any high-risk arrhythmias, and the patient is receiving a comprehensive treatment regimen. The absence of other high-risk features on the ECG and laboratory tests suggests that the risk of sudden cardiac death is lower than in other patients with similar risk factors.

3. Pump Failure Death
REASONING: 

The patient's LVEF is 44%, which is lower than the normal range, indicating some degree of left ventricular dysfunction. The patient's NYHA Class II classification also indicates some degree of functional impairment. However, the patient is receiving a comprehensive treatment regimen, including ACE inhibitors, beta blockers, and loop diuretics, which are commonly used to manage heart failure.

The patient's creatinine level is elevated, but it is not significantly high, and the patient is not showing signs of acute kidney injury. The patient's ECG does not show any high-risk arrhythmias, and the patient is receiving a comprehensive treatment regimen. While the patient is at risk for pump failure, the patient's current symptoms and laboratory tests do not suggest that the risk of pump failure is imminent."
551,551,P0857,"Age: 72
Gender: Female 
Weight: 76 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 166.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 11,9
Hemoglobin (g/L): 105.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,35
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Protein (g/L): 67,3
T3 (pg/dL): 0,0321
T4 (ng/L): 10
Troponin (ng/mL): 0,7
TSH (mIU/L): 14,9
Urea (mg/dL): 20,9
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient has a complex medical history with multiple comorbidities, including idiopathic dilated cardiomyopathy, diabetes, hypertension, and peripheral vascular disease. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 30%, indicating poor cardiac function. The presence of elevated creatinine levels (166.0 mmol/L) suggests impaired renal function, which is a common complication in patients with heart failure. The patient's troponin levels are within the normal range, which may indicate that there is no significant acute myocardial infarction. 

The patient's ECG shows ventricular extrasystoles, which are a common finding in patients with heart failure and can be a precursor to more serious arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient is not at immediate risk of sudden cardiac death.

Given the patient's advanced age, multiple comorbidities, and poor cardiac function, the patient is at high risk for adverse outcomes. However, the patient's current ECG and laboratory results do not indicate an immediate threat to life. Therefore, the most likely outcome is that the patient will survive for the next few years, although with significant limitations due to their underlying heart failure.

RANKING: 2. Pump failure death
REASONING: 
While the patient's cardiac function is severely impaired, the patient's current ECG and laboratory results do not indicate an immediate risk of sudden cardiac death. However, the patient's LVEF is severely reduced, and the patient's creatinine levels suggest impaired renal function, which can lead to fluid overload and worsening heart failure. 

Given the patient's complex medical history and the presence of multiple comorbidities, it is likely that the patient will experience progressive decline in cardiac function over the next few years, leading to pump failure. The patient's current medications, including ACE inhibitors and loop diuretics, may help manage symptoms and slow the progression of heart failure, but the underlying disease process is likely to continue to worsen.

RANKING: 3. Sudden cardiac death
REASONING: 
The patient's ECG shows ventricular extrasystoles, which are a precursor to more serious arrhythmias. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient is not at immediate risk of sudden cardiac death. Additionally, the patient's troponin levels are within the normal range, which may indicate that there is no significant acute myocardial infarction.

Given the patient's complex medical history and the presence of ventricular extrasystoles, there is a small risk of sudden cardiac death over the next few years. However, this is the least likely outcome compared to pump failure death, given the patient's current ECG and laboratory results."
552,552,P0859,"Age: 69
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 44,7
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,56
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 11,3
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,57
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 185.0
Protein (g/L): 67,2
T4 (ng/L): 16
TSH (mIU/L): 1,17
Urea (mg/dL): 5,83
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient's age, NYHA Class II, and the absence of severe symptoms or acute events on the ECG impression suggest a relatively stable condition. The patient's LVEF of 39.0 is slightly below the normal range, but it is not severely impaired. The patient's medication regimen includes ACE inhibitors, which are often recommended for patients with heart failure with reduced ejection fraction (HFrEF). The presence of hypertension, diabetes, and hypothyroidism may contribute to the patient's cardiac condition, but the patient's current ECG and lab results do not indicate acute cardiac damage or severe impairment. Therefore, based on the available information, the patient is likely to survive for the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's LVEF of 39.0 is below the normal range, indicating some degree of left ventricular dysfunction. The presence of ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias, which can contribute to sudden cardiac death. Additionally, the patient's hypertension and diabetes may increase the risk of cardiac complications. However, the patient's medication regimen includes beta blockers, which can help reduce the risk of arrhythmias. While the patient is not currently experiencing severe symptoms, the presence of ventricular extrasystoles and the patient's overall medical history make sudden cardiac death a possible risk.

RANKING: 3. Pump Failure Death
REASONING: Pump failure death is a possible outcome for patients with LVEF below 40%. However, the patient's current LVEF of 39.0 is not severely impaired, and the patient is receiving medications that can help manage heart failure. The patient's current lab results, including a normal creatinine level and no evidence of acute kidney injury, suggest that the patient's kidney function is relatively preserved. Additionally, the patient's ECG does not show signs of acute cardiac damage or severe arrhythmias, which would suggest a more immediate risk of pump failure. While the patient is at risk for heart failure, the available information does not suggest an immediate risk of pump failure death."
553,553,P0861,"Age: 59
Gender: Male 
Weight: 58 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 42,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,64
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 1410.0
Protein (g/L): 83,2
T4 (ng/L): 17
TSH (mIU/L): 2,83
Urea (mg/dL): 9,82
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient is most likely to be a survivor over the next few years. The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, diabetes, and dyslipemia are risk factors that could potentially lead to cardiac complications. However, the patient's current LVEF of 20.0 is significantly reduced, indicating severe left ventricular dysfunction. Despite this, the patient is receiving medications for these conditions, including ACE inhibitors, beta blockers, and spironolactone, which are standard treatments for heart failure. The absence of other significant ECG abnormalities, such as ventricular tachycardia or non-sustained ventricular tachycardia, also suggests that the patient does not have a high risk of sudden cardiac death.

While the patient's elevated creatinine level (95.0 mmol/L) and elevated BNP levels (1410.0 ng/L) indicate some degree of kidney dysfunction and heart failure, these findings are not uncommon in patients with heart failure. The patient's current medications and the fact that they are receiving regular follow-up care suggest that the patient is likely to receive adequate treatment to manage these conditions.

In contrast, sudden cardiac death and pump failure are less likely outcomes given the patient's current treatment regimen and the absence of other high-risk factors such as a history of myocardial infarction, coronary artery disease, or significant left ventricular hypertrophy. Therefore, I predict that the patient is most likely to survive over the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's history of ischemic dilated cardiomyopathy and diabetes increases their risk of sudden cardiac death, the absence of other high-risk factors and the patient's current treatment regimen reduce this risk. However, the patient's severely reduced LVEF of 20.0 and elevated BNP levels indicate significant left ventricular dysfunction, which could increase the risk of sudden cardiac death.

The patient's elevated creatinine level and elevated potassium level (5.4 mEq/L) could also increase the risk of arrhythmias, including ventricular tachycardia, which could lead to sudden cardiac death. However, the absence of other ECG abnormalities and the patient's current treatment regimen suggest that these findings are not indicative of a high risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

Given the patient's severely reduced LVEF of 20.0, pump failure death is a possible outcome over the next few years. The patient's heart is not pumping efficiently, and their kidney dysfunction and elevated BNP levels suggest that they are experiencing significant heart failure symptoms.

While the patient is receiving medications for heart failure, including ACE inhibitors, beta blockers, and spironolactone, these medications are not sufficient to fully reverse the patient's reduced LVEF. The patient's elevated creatinine level and elevated potassium level also suggest that their kidney function is not optimal, which could further compromise their cardiac function.

However, the patient's age, NYHA Class II, and the absence of other high-risk factors suggest that pump failure death is less likely than sudden cardiac death. Therefore, while pump failure death is a possible outcome, it is the least likely of the three options."
554,554,P0862,"Age: 62
Gender: Female 
Weight: 66 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/95 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45,6
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,61
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 266.0
Protein (g/L): 79,2
T4 (ng/L): 19
TSH (mIU/L): 4,59
Urea (mg/dL): 9,82
LVEF (%): 25.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, I predict that the patient will survive for the next few years. The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy are significant risk factors for cardiac events. However, the patient is already on medications that are commonly used to manage these conditions, such as amiodarone for arrhythmias, an angiotensin II receptor blocker for hypertension and heart failure, beta blockers for heart rate control, and spironolactone for fluid overload and hypertension. The patient's elevated creatinine level (71.0 mmol/L) suggests some degree of renal impairment, which may be related to the patient's underlying heart disease. Despite this, the patient's hemoglobin level (118.0 g/L) is within the normal range, and there is no indication of acute kidney injury.

The ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning, but the absence of sustained ventricular tachycardia and other arrhythmias reduces the risk of sudden cardiac death. The elevated Pro-BNP level (266.0 ng/L) suggests some degree of heart failure, but the patient's NYHA Class II indicates that the heart is still able to maintain adequate cardiac output.

While the patient's LVEF (25.0%) is significantly reduced, which is consistent with ischemic dilated cardiomyopathy, the patient is already on medications that are likely to improve cardiac function and reduce symptoms. The presence of hypotension (BP 150/95 mmHg) and the use of spironolactone, which is known to improve survival in patients with heart failure, further support the prediction that the patient will survive.

Overall, while the patient has several risk factors for cardiac events, the combination of current medications, relatively stable vital signs, and the absence of acute kidney injury or other life-threatening conditions make it more likely that the patient will survive for the next few years."
555,555,P0863,"Age: 55
Gender: Male 
Weight: 80 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 100/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,28
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,74
LDL (mmol/L): 4,58
Sodium (mEq/L): 137.0
Protein (g/L): 73,8
T3 (pg/dL): 0,0597
T4 (ng/L): 14,3
Troponin (ng/mL): 0,2
TSH (mIU/L): 3,71
Urea (mg/dL): 6
LVEF (%): 25.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is severely impaired. The patient's LVEF is 25%, indicating a significant reduction in cardiac function. However, the patient's blood pressure is well-controlled at 100/80 mmHg, and they are on medications for heart failure (loop diuretics) and high cholesterol management (statins). 

The patient's troponin level is normal, which suggests that there is no significant acute myocardial infarction. The ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) indicate a high risk of arrhythmic events, but the absence of sustained ventricular tachycardia and other arrhythmias suggests that the patient is not at high risk of sudden cardiac death. 

Considering these factors, the patient's overall prognosis is more favorable, and they are likely to survive for the next few years. The patient's hemoglobin level is high, and their kidney function is not severely impaired, which is also a positive prognostic factor. 

While the patient's cardiac function is severely impaired, the absence of other significant comorbidities and the presence of well-controlled blood pressure and medications for heart failure management suggest that the patient is at lower risk for pump failure death compared to sudden cardiac death. Therefore, the most likely outcome is survival."
556,556,P0864,"Age: 68
Gender: Male 
Weight: 68 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 80/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 8,2
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,5
LDL (mmol/L): 1,78
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3962.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 9
Troponin (ng/mL): 0,05
TSH (mIU/L): 32,58
Urea (mg/dL): 14,15
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient is already showing signs of advanced heart failure, as indicated by the NYHA Class III classification, low LVEF (30.0%), and elevated BNP levels (3962.0 ng/L). The patient's ECG impression also reveals non-sustained ventricular tachycardia and ventricular extrasystoles, which can be precursors to more severe arrhythmias. The patient's low ejection fraction and elevated BNP levels suggest that the heart is not functioning efficiently, making it more susceptible to further decline.

The patient's comorbidities, such as diabetes, dyslipidemia, and hypertension, also contribute to the progression of heart failure. The patient's medication regimen includes digoxin, which can increase the risk of arrhythmias, and beta blockers, which can further reduce the heart's pumping ability.

While the patient's current condition is concerning, the fact that the patient is currently a survivor suggests that the patient has not yet experienced a life-threatening event, such as a sudden cardiac death or pump failure. However, given the patient's advanced heart failure and comorbidities, it is likely that the patient will continue to decline over the next few years, making ""survivor"" the most likely prognosis.

RANKING: 2. Sudden Cardiac Death
REASONING: 
While the patient is currently a survivor, the patient's advanced heart failure and comorbidities increase the risk of sudden cardiac death. The patient's ECG impression reveals non-sustained ventricular tachycardia and ventricular extrasystoles, which can be precursors to more severe arrhythmias. The patient's low ejection fraction and elevated BNP levels also suggest that the heart is not functioning efficiently, making it more susceptible to arrhythmias.

Additionally, the patient's medications, including digoxin and beta blockers, can increase the risk of arrhythmias. The patient's comorbidities, such as diabetes and dyslipidemia, also contribute to the progression of heart failure, which can increase the risk of sudden cardiac death.

While the patient is currently stable, the combination of advanced heart failure, comorbidities, and arrhythmias makes sudden cardiac death a possible outcome in the next few years.

RANKING: 3. Pump Failure Death
REASONING: 
Pump failure death is a possible outcome for patients with advanced heart failure, but it is less likely than sudden cardiac death in this patient. The patient's current ejection fraction is 30.0%, which is significantly reduced, indicating advanced heart failure. However, the patient is currently a survivor, which suggests that the heart is still functioning enough to maintain cardiac output.

The patient's medications, including loop diuretics and spironolactone, are aimed at managing heart failure, which can help reduce the risk of pump failure. Additionally, the patient's current stable condition, as evidenced by the fact that they are a survivor, suggests that the heart is still able to maintain cardiac output.

However, the patient's advanced heart failure and comorbidities, such as diabetes and dyslipidemia, increase the risk of pump failure over time. While pump failure is a possible outcome, it is less likely than sudden cardiac death in this patient, given their current stable condition."
557,557,P0865,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 9
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,46
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 1345.0
Protein (g/L): 68,2
T4 (ng/L): 13
TSH (mIU/L): 3,1
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, the most likely prognosis is survivor. Here's the reasoning behind this ranking:

1. Age and NYHA Class: The patient is 68 years old and has a NYHA Class II heart failure, indicating moderate symptoms. This suggests that the patient's heart is still functional to some extent, which is a positive factor in predicting a better prognosis.

2. Medications: The patient is taking a comprehensive list of medications, including beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for heart failure, hypertension, and dyslipidemia. This indicates that the patient is receiving evidence-based care, which can help manage their conditions.

3. ECG Impression: Although the patient has a polymorphic ventricular extrasystole and non-sustained ventricular tachycardia, the absence of sustained ventricular tachycardia and supraventricular tachyarrhythmia is a positive sign. This suggests that the patient's heart is not experiencing frequent, life-threatening arrhythmias.

4. LVEF: The left ventricular ejection fraction (LVEF) is 40%, which is a relatively preserved value. This indicates that the patient's heart is still pumping blood effectively, which is a positive prognostic sign.

5. Other lab values: The patient's albumin level, creatinine level, and urea level are within normal or near-normal ranges, indicating that the patient's kidney function and liver function are not severely impaired.

Considering these factors, the patient's overall prognosis is good, and it is likely that they will survive for the next few years without significant cardiac events.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's prognosis is less likely to be sudden cardiac death due to the following reasons:

1. Polymorphic ventricular extrasystoles: While this finding is concerning, it is not necessarily a direct indicator of sudden cardiac death. However, it does indicate that the patient's heart is experiencing some arrhythmias, which may require closer monitoring.

2. Non-sustained ventricular tachycardia: The absence of sustained ventricular tachycardia is a positive sign, as it reduces the risk of sudden cardiac death.

3. Absence of other risk factors: The patient does not have other risk factors for sudden cardiac death, such as a history of myocardial infarction or cardiomyopathy.

4. Medications: The patient is taking beta blockers, which are known to reduce the risk of sudden cardiac death.

However, the patient's history of ischemic dilated cardiomyopathy, peripheral vascular disease, and hypertension increases their risk of cardiovascular events, which may eventually lead to sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's prognosis is least likely to be pump failure death due to the following reasons:

1. NYHA Class II: The patient's NYHA Class II heart failure indicates that their symptoms are moderate, but they are still able to perform daily activities with some limitation. This suggests that the patient's heart is not severely impaired.

2. Medications: The patient is taking loop diuretics, which are used to manage heart failure symptoms, and ACE inhibitors, which are known to reduce the risk of pump failure.

3. Absence of severe kidney dysfunction: The patient's creatinine level is elevated, but not severely impaired, which suggests that their kidney function is not severely compromised.

4. Absence of other risk factors: The patient does not have other risk factors for pump failure, such as a history of myocardial infarction or cardiomyopathy.

However, the patient's history of ischemic dilated cardiomyopathy, diabetes, and hypertension increases their risk of pump failure, and the patient's LVEF is only 40%, which is a relatively preserved value. This may eventually lead to pump failure, but it is less likely than sudden cardiac death."
558,558,P0866,"Age: 76
Gender: Female 
Weight: 73 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 44,1
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,65
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 306.0
Protein (g/L): 74
T4 (ng/L): 15
TSH (mIU/L): 1
Urea (mg/dL): 5,83
LVEF (%): 49.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 76-year-old female with a history of hypertensive cardiomyopathy, hypertension, and a significant elevation in Pro-BNP levels (306 ng/L), which suggests a moderate to severe level of heart failure. The LVEF (Left Ventricular Ejection Fraction) is 49.0%, which is within the range of heart failure with reduced ejection fraction (HFrEF). 

Despite being on multiple medications for hypertension, heart failure, and hyperlipidemia, the patient's current medication regimen does not appear to be adequately controlling blood pressure or heart failure symptoms, as indicated by the elevated Pro-BNP levels and low LVEF.

However, the patient's age, sex, and NYHA Class II status suggest that the patient is likely to survive for at least a few more years. The presence of ventricular extrasystole on the ECG is concerning, but it is not a direct predictor of mortality. The patient's hemoglobin level is within a normal range, and the liver enzymes are not significantly elevated, which further supports the patient's survival.

Given these factors, I predict that the patient has a high likelihood of surviving for the next few years, but close monitoring and adjustments to her medication regimen may be necessary to manage her heart failure and prevent further deterioration.

RANKING: 2. Pump failure death
REASONING: 

This patient is at risk for pump failure death due to her significant elevation in Pro-BNP levels and low LVEF, which indicate a moderate to severe level of heart failure. The patient's NYHA Class II status and elevated creatinine levels (5.83 mg/dL) also suggest that she is experiencing some degree of renal impairment, which can be a complication of heart failure.

Additionally, the patient's medication regimen does not appear to be adequately controlling her blood pressure or heart failure symptoms, which increases her risk for pump failure. However, the patient's age and sex may also contribute to her increased risk for pump failure, as older adults are more susceptible to cardiac complications.

While the patient's ventricular extrasystole on the ECG is concerning, it is not a direct predictor of mortality. However, the patient's low HDL cholesterol level (1.76 mmol/L) and elevated LDL cholesterol level (3.65 mmol/L) may increase her risk for cardiovascular events, which can contribute to pump failure.

Given these factors, I predict that the patient has a moderate likelihood of experiencing pump failure death over the next few years, but this outcome can be prevented with close monitoring and adjustments to her medication regimen.

RANKING: 3. Sudden cardiac death
REASONING: 

This patient is at high risk for sudden cardiac death due to her history of hypertensive cardiomyopathy and hypertension. The presence of ventricular extrasystole on the ECG is a significant concern, as it can be a precursor to ventricular tachycardia or ventricular fibrillation, which are both life-threatening arrhythmias.

Additionally, the patient's low HDL cholesterol level (1.76 mmol/L) and elevated LDL cholesterol level (3.65 mmol/L) may increase her risk for cardiovascular events, which can contribute to sudden cardiac death. However, the patient's age and sex may also contribute to her increased risk for sudden cardiac death.

Given these factors, I predict that the patient has a low likelihood of surviving for the next few years, and sudden cardiac death is a significant concern. However, with close monitoring and adjustments to her medication regimen, the patient's risk for sudden cardiac death can be reduced."
559,559,P0867,"Age: 73
Gender: Female 
Weight: 82 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,22
LDL (mmol/L): 3,13
Sodium (mEq/L): 140.0
Protein (g/L): 68
T3 (pg/dL): 0,0438
T4 (ng/L): 18,54
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,92
Urea (mg/dL): 16,9
LVEF (%): 70.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's overall health status is a combination of chronic conditions such as hypertension, diabetes, and cardiomyopathy, which may suggest a higher risk of cardiovascular events. However, the patient's age is 73, which is considered elderly, but not unusually high. 

The patient's laboratory results show elevated creatinine levels, indicating kidney impairment, which can be a risk factor for cardiovascular events. However, the patient's kidney function is not severely impaired, with a creatinine level of 16.9 mg/dL.

The patient's ECG results show ventricular extrasystoles, which may indicate cardiac arrhythmias, but no ventricular tachycardia or non-sustained ventricular tachycardia, which are more concerning for cardiac events.

The patient's LVEF is 70%, which is within the normal range, indicating preserved cardiac function. The patient is also taking medications for diabetes, hypertension, and heart failure, which are standard treatments for these conditions.

Given these factors, the patient's overall health status is relatively stable, and the patient is taking medications to manage their conditions. The patient's ECG results do not indicate an acute cardiac event, and the patient's laboratory results do not show any severe abnormalities. Therefore, the most likely outcome for the next few years is that the patient will survive.

The second most likely outcome is pump failure death, which is possible due to the patient's history of cardiomyopathy and hypertension. However, the patient's LVEF is preserved, and the patient is taking medications to manage their heart failure.

The least likely outcome is sudden cardiac death, which is less likely due to the patient's relatively stable ECG results and preserved LVEF. However, the patient's history of cardiomyopathy and hypertension may still pose a risk for cardiac events, and the patient's kidney impairment may contribute to an increased risk of cardiovascular events."
560,560,P0868,"Age: 75
Gender: Male 
Weight: 82 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 83
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,21
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 173.0
Protein (g/L): 67,4
T4 (ng/L): 16
TSH (mIU/L): 0,6
Urea (mg/dL): 4,99
LVEF (%): 53.0
Medications: Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 75-year-old male with a history of hypertensive cardiomyopathy, which is a significant risk factor for cardiovascular disease. The patient's left ventricular ejection fraction (LVEF) of 53% is also concerning, indicating left ventricular dysfunction. The presence of ventricular extrasystole on the ECG, which is a sign of abnormal heart rhythms, further increases the risk of cardiac complications. However, the patient's overall clinical presentation and laboratory results, including normal hemoglobin, normal renal function, and controlled blood pressure, suggest that the patient's cardiac function is not severely compromised at this time.

While the patient's elevated creatinine level and slightly elevated liver enzymes may indicate some degree of kidney and liver dysfunction, these findings are not uncommon in older adults and do not necessarily impact the patient's cardiac prognosis. The patient's serum BNP level is elevated, which is consistent with heart failure, but the patient is still classified as NYHA Class II, indicating mild symptoms. 

The patient is taking medications that are commonly used to manage hypertension and heart failure, which suggests that the patient is receiving appropriate treatment for their condition. Overall, the patient's age, comorbidities, and laboratory results suggest a moderate risk of cardiovascular events, but the patient's current clinical status and treatment plan suggest that the patient is likely to survive for the next few years. 

Therefore, based on the available data, the most likely outcome for the next few years is survival."
561,561,P0871,"Age: 53
Gender: Male 
Weight: 96 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 110/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 50
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5
LDL (mmol/L): 4,14
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1195.0
Protein (g/L): 84
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,2
Urea (mg/dL): 12,31
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's data, I believe the most likely outcome for the next few years is survivor. The patient's NYHA Class III indicates severe heart failure, but the patient is already receiving treatment with medications such as beta blockers, loop diuretics, and ACE inhibitors, which are standard therapies for managing heart failure. The patient's elevated Pro-BNP level (1195.0 ng/L) and low LVEF (39.0%) suggest significant cardiac dysfunction, but the patient's hemoglobin level (147.0 g/L) and normal potassium level (5 mEq/L) suggest that the patient is not in acute kidney injury or severe electrolyte imbalance. The patient's low T3 level (0.05 pg/dL) and normal TSH level (1.2 mIU/L) also suggest that the patient is not experiencing severe hypothyroidism or hyperthyroidism, which could potentially exacerbate heart failure. Additionally, the patient's ECG results show no signs of ventricular tachycardia or other arrhythmias that could increase the risk of sudden cardiac death. Overall, the patient's current clinical status and treatment plan suggest that they are at moderate to high risk for heart failure exacerbation, but the patient's current medical condition does not suggest an immediate risk of sudden cardiac death or pump failure. 

2. Sudden Cardiac Death
REASONING: 
While the patient's ECG results show ventricular extrasystole, which is a risk factor for sudden cardiac death, the patient is currently not experiencing any ventricular tachycardia or other arrhythmias that could increase the risk of sudden cardiac death. However, the patient's low LVEF (39.0%) and elevated Pro-BNP level (1195.0 ng/L) suggest that the patient is at risk for heart failure exacerbation, which could potentially lead to sudden cardiac death. Additionally, the patient's elevated creatinine level (115.0 mmol/L) suggests kidney impairment, which can increase the risk of sudden cardiac death. However, the patient's current treatment plan and clinical status do not suggest an immediate risk of sudden cardiac death.

3. Pump Failure Death
REASONING: 
Given the patient's severe heart failure (NYHA Class III), low LVEF (39.0%), and elevated Pro-BNP level (1195.0 ng/L), the patient is at high risk for pump failure. However, the patient is currently receiving treatment with beta blockers, loop diuretics, and ACE inhibitors, which are standard therapies for managing heart failure. While the patient's kidney impairment (elevated creatinine level) suggests that the patient may require more aggressive treatment, the patient's current clinical status and treatment plan do not suggest an immediate risk of pump failure. The patient's ECG results show no signs of ventricular tachycardia or other arrhythmias that could increase the risk of sudden cardiac death, which would be a more immediate concern."
562,562,P0874,"Age: 42
Gender: Male 
Weight: 90 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 100/80 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy, Diabetes
Albumin (g/L): 48
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,58
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 100.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,13
Urea (mg/dL): 7,49
LVEF (%): 18.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a complex medical history, including post-myocardial dilated cardiomyopathy, diabetes, and NYHA Class III heart failure, which indicates severe symptoms and likely significant left ventricular dysfunction. However, the patient has been taking medications such as beta blockers, ACE inhibitors, and loop diuretics, which are standard treatments for heart failure. The patient's troponin levels are within the normal range, and there is no evidence of acute myocardial infarction. The patient's ejection fraction (LVEF) is significantly reduced at 18%, indicating severe left ventricular dysfunction. Despite these factors, the patient's current ECG findings do not show any signs of ventricular tachycardia or ventricular extrasystoles, which are often associated with high-risk arrhythmias. The patient's biomarkers, such as creatinine and urea levels, are not excessively elevated, suggesting that the patient's kidney function is not severely compromised. Overall, considering the patient's medical history, medications, and current clinical status, the patient's prognosis is likely to be a survivor."
563,563,P0875,"Age: 79
Gender: Female 
Weight: 70 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 3,23
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 9,6
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,68
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1588.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 23
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,34
Urea (mg/dL): 8,65
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with multiple comorbid conditions, including idiopathic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension. The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 35%, indicating poor cardiac function. The patient's Pro-BNP level is elevated at 1588.0 ng/L, suggesting a high level of ventricular wall stress.

Despite these concerning signs, the patient is currently on medications that are commonly used to manage heart failure and arrhythmias, such as digoxin, loop diuretics, and beta blockers. The patient's hemoglobin level is within a relatively normal range, and their potassium level is also within a relatively normal range.

The patient's ECG impression shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are both concerning signs of arrhythmias. However, the absence of sustained ventricular tachycardia and the presence of beta blockers, which can help regulate heart rate, suggests that the patient is being adequately managed.

Given the patient's overall clinical presentation, I believe that the patient is at high risk for cardiac events, but I would still rank them as a survivor. The patient's comorbidities, reduced LVEF, and elevated Pro-BNP level make them a high-risk patient, but their current management plan and the absence of more severe cardiac events on the ECG impression suggest that they may be able to survive the next few years with careful management.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's LVEF is significantly reduced, and their Pro-BNP level is elevated, which indicates ventricular wall stress, I would rank them as having a moderate risk for sudden cardiac death. The patient's beta blockers, digoxin, and loop diuretics are commonly used to manage heart failure and arrhythmias, and their hemoglobin and potassium levels are relatively normal.

However, the patient's ECG impression shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are both concerning signs of arrhythmias. The patient's age and comorbidities also increase their risk for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

While the patient's LVEF is significantly reduced, indicating poor cardiac function, I would rank them as having a lower risk for pump failure death compared to sudden cardiac death. The patient is currently being managed with medications that are commonly used to manage heart failure, including beta blockers, digoxin, and loop diuretics.

However, the patient's elevated Pro-BNP level and ventricular extrasystoles on the ECG impression suggest that they are at risk for decompensation and heart failure. Additionally, the patient's reduced LVEF and elevated creatinine level suggest that their cardiac function may be declining.

Overall, while the patient is at risk for cardiac events, I believe that pump failure death is less likely compared to sudden cardiac death, given the patient's current management plan and the absence of more severe cardiac events on the ECG impression."
564,564,P0876,"Age: 70
Gender: Female 
Weight: 74 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 3,1
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 3,95
LDL (mmol/L): 3,31
Sodium (mEq/L): 142.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0636
T4 (ng/L): 13,7
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,86
Urea (mg/dL): 5,9
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Diabetes Medication
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: 

The patient is 70 years old, with a history of hypertension, cardiomyopathy, diabetes, and elevated creatinine levels, which suggests some degree of renal impairment. However, the patient's LVEF (left ventricular ejection fraction) is 70%, which is within the normal range. The patient's ECG impression shows no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or other arrhythmias that could indicate a high risk of sudden cardiac death. The patient's troponin levels are also within normal limits, which suggests that there is no evidence of myocardial infarction or significant cardiac damage. 

Additionally, the patient is on calcium channel blockers and diabetes medication, which are commonly used to manage hypertension and diabetes, respectively. The patient's lipid profile is also relatively well-controlled, with an LDL level of 3.31 mmol/L. Overall, while the patient has several comorbidities, the absence of high-risk ECG findings and normal cardiac function suggest that the patient is at a lower risk of sudden cardiac death and pump failure compared to the other two options. Therefore, the most likely outcome for the next few years is that the patient will survive."
565,565,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient has a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction, which are all risk factors for cardiac complications. However, the patient is currently on multiple medications for heart failure management (beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitor), which are likely contributing to the patient's stable condition. The patient's current NYHA class is II, indicating mild heart failure symptoms, and their LVEF is 15%, which is within a range that can be managed with current medications. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding but can often be managed with anti-arrhythmic medications. The patient's biomarkers (troponin, BNP, and creatinine) are within normal or near-normal limits, indicating a lack of acute cardiac stress or damage. Overall, the patient's combination of risk factors, medication management, and stable biomarkers suggest a favorable prognosis, making ""survivor"" the most likely outcome.

2. Pump failure death
REASONING: 
While the patient has a history of heart failure, their current NYHA class is II, and they are on multiple medications for heart failure management. However, the patient's LVEF is significantly reduced at 15%, which is a concerning indicator of reduced cardiac function. Additionally, the patient's elevated creatinine level (71.0 mmol/L) suggests impaired renal function, which can be a complication of heart failure. The patient's ECG shows non-sustained ventricular tachycardia, which can be a precursor to more severe arrhythmias. While the patient's biomarkers are within normal limits, the combination of reduced LVEF and impaired renal function increases the risk of heart failure exacerbation and potentially leading to pump failure. Therefore, pump failure death is a plausible but less likely outcome compared to survivor.

3. Sudden cardiac death
REASONING: 
Sudden cardiac death is a possible outcome for patients with a history of myocardial infarction and cardiomyopathy. However, the patient's current ECG does not show any signs of ventricular fibrillation or other life-threatening arrhythmias. The patient's troponin level is within normal limits, and their biomarkers do not suggest acute cardiac stress or damage. The patient's medication regimen includes beta blockers, which are effective in reducing the risk of sudden cardiac death. While the patient's ECG shows non-sustained ventricular tachycardia, this is a common finding in patients with heart failure and can often be managed with anti-arrhythmic medications. The patient's overall clinical presentation and biomarkers do not strongly suggest an increased risk of sudden cardiac death, making this outcome less likely compared to survivor and pump failure death."
566,566,P0878,"Age: 57
Gender: Male 
Weight: 62 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 38,5
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,2
LDL (mmol/L): 3,8
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 6606.0
Protein (g/L): 68,4
T4 (ng/L): 16
TSH (mIU/L): 3,87
Urea (mg/dL): 19,8
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy, which is a significant comorbidity. However, the patient is currently on medications that are standard for managing heart failure and preventing further cardiac damage (Angiotensin II Receptor Blocker, Beta Blockers, and Loop Diuretics). The patient's NYHA Class II indicates that they have some limitations in physical activity but are still able to perform daily activities without significant symptoms. The patient's creatinine level is elevated, indicating some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's LVEF is severely impaired at 40%, but this is expected in the context of dilated cardiomyopathy.

The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning sign but not indicative of a high risk of sudden cardiac death. The presence of ventricular extrasystoles and polymorphic ventricular tachycardia are also concerning but not necessarily indicative of a high risk of sudden cardiac death. The patient's Pro-BNP level is elevated, which indicates some degree of ventricular stress and possible heart failure exacerbation. However, the patient's overall clinical presentation does not suggest an immediate risk of sudden cardiac death.

The patient's lipid profile is not significantly abnormal, and the patient's hemoglobin and kidney function are within relatively normal limits. The patient's age and sex are not particularly high-risk for sudden cardiac death.

Overall, the patient's clinical presentation and medical history suggest that the patient is at moderate risk for cardiac events, but the presence of medications and relatively normal renal function suggest that the patient is likely to survive for several years without significant cardiac complications."
567,567,P0879,"Age: 71
Gender: Male 
Weight: 67 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,25
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 304.0
Protein (g/L): 63
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,38
Urea (mg/dL): 8,32
LVEF (%): 50.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient is a 71-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which suggests a significant cardiac history. His current NYHA Class II indicates that he has some symptoms of heart failure, but they are not severe enough to limit his daily activities.

The patient's laboratory results show elevated liver enzymes (ALT and AST) and creatinine levels, which could indicate liver dysfunction or kidney impairment. However, these values are not significantly elevated, and the patient's kidney function is still within a relatively normal range.

The patient's lipid profile shows high total cholesterol and LDL levels, which increases the risk of cardiovascular events. However, his HDL level is low, which could be a contributing factor to his overall cardiovascular risk.

The ECG results show ventricular extrasystole, which is a concerning finding, but the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac arrhythmia risk is relatively low.

The patient's LVEF is significantly reduced at 50%, which indicates left ventricular dysfunction. However, this finding is not unexpected given his history of ischemic dilated cardiomyopathy.

Considering these factors, I believe that the patient is at high risk for cardiovascular events, but his overall prognosis is still relatively good due to his relatively good kidney function, low Pro-BNP levels, and the absence of other life-threatening conditions.

While there is a risk of sudden cardiac death, I rank the patient as a survivor due to his relatively good cardiovascular risk profile, and the fact that his heart is still pumping blood effectively (LVEF 50%). Pump failure death is less likely due to the patient's relatively preserved kidney function and low Pro-BNP levels. Sudden cardiac death is still a concern, but it is not the most likely outcome given the patient's overall profile."
568,568,P0883,"Age: 66
Gender: Female 
Weight: 62 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 170/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,69
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,49
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 325.0
Protein (g/L): 76
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 4
Urea (mg/dL): 5,66
LVEF (%): 64.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

Based on the provided patient data, the patient is a 66-year-old female with a history of hypertension and hypertensive cardiomyopathy. Her current NYHA Class II indicates moderate symptoms of heart failure. 

The patient's ECG shows ventricular extrasystoles and ventricular tachycardia, which are both signs of arrhythmias that can be associated with cardiomyopathy. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart is still functioning relatively well.

The patient's LVEF of 64% indicates a preserved ejection fraction, which is a positive prognostic sign. However, the elevated Pro-BNP levels (325 ng/L) suggest that the patient is experiencing some level of cardiac stress and may be at risk for worsening heart failure.

The patient's blood pressure is elevated at 170/90 mmHg, and her kidney function is compromised, as indicated by the elevated creatinine level of 62.0 mg/dL. These factors contribute to the patient's overall cardiovascular risk.

Given these factors, the most likely outcome for the patient is a survivor, as her heart is still functioning relatively well, and she is receiving medications to manage her hypertension and heart failure. However, the patient's elevated Pro-BNP levels and elevated blood pressure suggest that there is a risk of progression to more severe heart failure, which would place her at higher risk for pump failure death.

Sudden cardiac death is less likely, as the patient's ECG does not show any clear indication of a lethal arrhythmia, and her LVEF is preserved.

Pump failure death is the least likely outcome, as the patient's LVEF is preserved, and she is receiving medications to manage her heart failure. However, the patient's elevated Pro-BNP levels and elevated blood pressure suggest that there is a risk of progression to more severe heart failure, which would increase the risk of pump failure death."
569,569,P0885,"Age: 59
Gender: Male 
Weight: 100 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 156.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,2
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 105.0
Protein (g/L): 68
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 4,99
LVEF (%): 33.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, I predict that the patient is most likely to survive for the next few years. The patient's age, NYHA Class II, and the absence of symptoms or other significant findings on the ECG impression suggest that the patient is relatively stable. The patient's medication regimen, which includes beta blockers, statins, and an ACE inhibitor, indicates that the patient is being adequately managed for their cardiovascular risk factors.

The patient's laboratory results also show a relatively normal liver function (ALT and AST levels), low creatinine levels, and normal electrolyte and glucose levels, which suggest that the patient's kidneys and liver are functioning relatively well.

However, the patient's LVEF (33.0%) is significantly reduced, indicating a substantial impairment in cardiac function. This reduction in LVEF is likely related to the patient's ischemic dilated cardiomyopathy. Despite this, the patient's current symptoms and ECG findings do not suggest acute cardiac ischemia or significant arrhythmias, which could potentially lead to sudden cardiac death.

The patient's Pro-BNP level (105.0 ng/L) is elevated, which may indicate some degree of ventricular volume overload or congestion, but it is not excessively high, which could suggest a more severe condition.

Overall, based on the patient's stable clinical presentation, medication regimen, and laboratory results, I predict that the patient is most likely to survive for the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's LVEF is significantly reduced, the patient's current symptoms and ECG findings do not suggest acute cardiac ischemia or significant arrhythmias. However, the patient's ischemic dilated cardiomyopathy and elevated Pro-BNP level do increase the risk of sudden cardiac death.

The patient's history of myocardial infarction and dyslipemia also increases the risk of future cardiovascular events. Additionally, the patient's low HDL (0.83 mmol/L) and elevated LDL (2.2 mmol/L) levels suggest a high risk of atherosclerosis, which could contribute to a future cardiovascular event.

Given the patient's reduced LVEF and elevated Pro-BNP level, I predict that the patient has a moderate to high risk of sudden cardiac death over the next few years.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's significantly reduced LVEF (33.0%) and elevated Pro-BNP level (105.0 ng/L) suggest a substantial impairment in cardiac function, which increases the risk of heart failure. The patient's ischemic dilated cardiomyopathy and history of myocardial infarction also increase the risk of future heart failure events.

While the patient is being adequately managed with beta blockers, statins, and an ACE inhibitor, these medications may not be sufficient to reverse the patient's cardiac dysfunction. The patient's low HDL and elevated LDL levels also suggest a high risk of atherosclerosis, which could contribute to a future heart failure event.

Given the patient's reduced LVEF and elevated Pro-BNP level, I predict that the patient is at high risk of developing heart failure over the next few years."
570,570,P0886,"Age: 75
Gender: Male 
Weight: 60 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 115/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,15
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,91
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1186.0
Protein (g/L): 66
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,4
Urea (mg/dL): 10,15
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

This patient has several factors that suggest a favorable prognosis. Firstly, the patient is 75 years old, which is an advanced age, but the patient is still alive and has a NYHA class of II, indicating that they are relatively stable and can perform moderate physical activity. 

The patient has a history of ischemic dilated cardiomyopathy, but the LVEF is 20%, which is a significant reduction in left ventricular function, but still within a range that may allow for some functional reserve. The patient is also on beta blockers, statins, and ACE inhibitors, which are standard treatments for heart failure and ischemic cardiomyopathy.

The patient's lab results show elevated creatinine levels, which indicate some degree of kidney impairment, but this is not uncommon in patients with heart failure. The elevated troponin levels may indicate some degree of myocardial injury, but the levels are very low, which may not be indicative of significant acute myocardial infarction.

The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are both relatively common in patients with heart failure. However, the presence of these arrhythmias does not necessarily indicate a poor prognosis, and the patient is already on beta blockers, which can help to regulate heart rate and rhythm.

The patient's elevated BNP levels are consistent with heart failure, but the levels are not extremely high, which may indicate a more stable disease process. Overall, while this patient has several risk factors for adverse outcomes, the combination of their age, functional status, and treatment with beta blockers, statins, and ACE inhibitors suggest a relatively favorable prognosis.

The patient's overall prognosis is therefore ranked as ""survivor""."
571,571,P0889,"Age: 66
Gender: Male 
Weight: 85 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 50
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,47
Creatinine (mmol/L): 70.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 54.0
Protein (g/L): 73,4
T4 (ng/L): 16
TSH (mIU/L): 1,16
Urea (mg/dL): 5,99
LVEF (%): 68.0
Medications: Calcium Channel Blocker
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient has a relatively preserved left ventricular function (LVEF: 68.0), which suggests that the heart is still able to pump blood efficiently, albeit with some limitations. The patient's NYHA Class II indicates mild symptoms, which is consistent with a relatively preserved cardiac function. The presence of hypertension, dyslipidemia, and peripheral vascular disease may contribute to the patient's cardiovascular risk, but the patient is currently not showing signs of acute cardiac decompensation. The patient's medication regimen includes a calcium channel blocker, which is a common treatment for hypertension and angina. The ECG findings, while indicating some arrhythmias, do not suggest an immediate life-threatening condition. The patient's biomarkers, such as the elevated creatinine level, indicate some degree of kidney dysfunction, but this is not immediately life-threatening. Overall, the combination of a preserved LVEF, mild symptoms, and the absence of acute cardiac decompensation make a survivor outcome the most likely.

2. Pump failure death
REASONING: 
While the patient's LVEF is relatively preserved, the elevated creatinine level and the patient's age (66) suggest that there may be some degree of cardiac dysfunction. The patient's NYHA Class II symptoms may indicate that the heart is not functioning optimally, but it is still capable of meeting the body's needs. However, the patient's weight and the presence of hypertension and dyslipidemia may contribute to the development of heart failure in the future. Additionally, the patient's elevated creatinine level may indicate some degree of renal impairment, which can be a predictor of cardiac decompensation. While the patient's ECG findings do not suggest an immediate life-threatening condition, the presence of ventricular extrasystoles and TPSV may indicate some degree of arrhythmia risk. Overall, the combination of these factors makes pump failure death a possible but less likely outcome.

3. Sudden cardiac death
REASONING: 
The patient's ECG findings of ventricular extrasystoles and TPSV suggest an increased risk of arrhythmias, which is a major risk factor for sudden cardiac death. However, the patient's age (66) and the presence of hypertension, dyslipidemia, and peripheral vascular disease may also contribute to an increased risk of cardiac decompensation. Additionally, the patient's elevated creatinine level and the presence of kidney dysfunction may indicate some degree of cardiac dysfunction. However, the patient's relatively preserved LVEF and mild symptoms suggest that the heart is still capable of meeting the body's needs. While the patient's arrhythmias increase the risk of sudden cardiac death, the combination of these factors does not make this outcome as likely as pump failure death."
572,572,P0892,"Age: 61
Gender: Female 
Weight: 59 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 95/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,57
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 886.0
Protein (g/L): 69
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,95
Urea (mg/dL): 12,81
LVEF (%): 43.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient's prognosis as a survivor for the next few years. 

The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are not in New York Heart Association Class III or IV, suggesting that they have some residual cardiac function. 

The patient's LVEF (Left Ventricular Ejection Fraction) is 43%, which is significantly reduced but still within a range that may be manageable with current treatment. 

The patient's creatinine level is elevated at 97.0 mol/L, indicating some degree of kidney dysfunction, which may be related to the patient's heart failure. However, this is not a contraindication to survival.

The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, are concerning but not necessarily indicative of an immediate threat to life. 

The patient's laboratory values, including elevated troponin levels, indicate some degree of cardiac injury, but the levels are not excessively high. 

Given the patient's age, comorbidities, and current treatment regimen, which includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, it is likely that the patient will survive for the next few years with proper management. 

The patient's low HDL cholesterol level (1.47 mmol/L) and elevated LDL cholesterol level (3.57 mmol/L) are concerning for cardiovascular risk, but the patient's current treatment regimen and lifestyle modifications may help mitigate these risks. 

Overall, while the patient has some significant cardiac and metabolic risk factors, their current clinical presentation and treatment regimen suggest that they are likely to survive for the next few years with proper management. 

RANKING: 2. Sudden cardiac death
REASONING: 

Given the patient's history of myocardial infarction, ischemic dilated cardiomyopathy, and ventricular extrasystole, there is a higher risk of sudden cardiac death. 

The patient's LVEF is significantly reduced, and the patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, are concerning for an increased risk of arrhythmias. 

The patient's elevated troponin levels indicate some degree of cardiac injury, which may be related to the patient's underlying cardiomyopathy. 

Given the patient's age and comorbidities, the risk of sudden cardiac death is higher than the risk of survival. 

RANKING: 3. Pump failure death
REASONING: 

Given the patient's NYHA Class II and elevated creatinine level, there is a risk of heart failure exacerbation and pump failure. 

The patient's LVEF is significantly reduced, indicating some degree of left ventricular dysfunction. 

The patient's elevated troponin levels and elevated BNP levels (not provided) suggest some degree of cardiac injury and stress. 

The patient's current treatment regimen, which includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, may not be sufficient to manage the patient's cardiac dysfunction. 

Given the patient's age, comorbidities, and current treatment regimen, the risk of pump failure death is higher than the risk of sudden cardiac death."
573,573,P0893,"Age: 62
Gender: Male 
Weight: 95 kg
Height: 183 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 128.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,56
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 3572.0
Protein (g/L): 69,4
T4 (ng/L): 17
TSH (mIU/L): 1,32
Urea (mg/dL): 7,49
LVEF (%): 60.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient is a 62-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and previous myocardial infarction. His current NYHA Class II indicates that he has some symptoms of heart failure, but they are not severe enough to classify him as NYHA Class III or IV. His LVEF of 60.0 is below the normal range, indicating left ventricular dysfunction. However, his current medication regimen, which includes beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, suggests that his cardiologist is actively managing his heart failure and attempting to improve his cardiac function.

His ECG findings are concerning, but not immediately life-threatening. The presence of ventricular extrasystoles and polymorphic ventricular tachycardia is a warning sign, but it is not indicative of a high risk of sudden cardiac death in the near future. The absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia makes it less likely that he will experience a sudden cardiac death.

The patient's laboratory results show signs of mild kidney dysfunction (elevated creatinine) and anemia (low hemoglobin). However, these findings are not immediately life-threatening and can be managed with his current medication regimen.

Given these factors, I believe that this patient has the highest chance of survival over the next few years. His cardiologist is actively managing his heart failure and has a comprehensive understanding of his medical history, which will likely enable him to make informed decisions about his care.

RANKING: 2. Sudden cardiac death
REASONING: 
While this patient's ECG findings are concerning, the absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia makes it less likely that he will experience a sudden cardiac death in the near future. However, the presence of ventricular extrasystoles and polymorphic ventricular tachycardia is a warning sign that requires close monitoring.

The patient's history of ischemic dilated cardiomyopathy and previous myocardial infarction increases his risk of sudden cardiac death. However, his current medication regimen and the absence of other high-risk factors (such as a history of arrhythmias or cardiac arrest) suggest that he is not at the highest risk for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
Given the patient's history of ischemic dilated cardiomyopathy and previous myocardial infarction, it is likely that his heart is not functioning optimally. His LVEF of 60.0 is below the normal range, indicating left ventricular dysfunction.

The patient's NYHA Class II symptoms and elevated creatinine levels suggest that he may experience worsening heart failure over time. While his medication regimen is adequate, the presence of ventricular extrasystoles and polymorphic ventricular tachycardia on his ECG may indicate that his heart is not functioning optimally.

However, the patient's current medical history and laboratory results do not suggest that he is at immediate risk of pump failure death. His cardiologist is actively managing his heart failure, and the patient's current symptoms are not severe enough to indicate a high risk of pump failure death in the near future."
574,574,P0894,"Age: 57
Gender: Male 
Weight: 68 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,2
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 7,01
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 188
Glucose (mmol/L): 7
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,8
LDL (mmol/L): 4,6
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 710.0
Protein (g/L): 76,7
T4 (ng/L): 14
TSH (mIU/L): 6,21
Urea (mg/dL): 5,83
LVEF (%): 46.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I predict that the patient is most likely to survive in the next few years. The patient's age, NYHA Class II, and the absence of any acute symptoms or recent hospitalizations suggest a relatively stable condition. The patient's LVEF of 46.0 is slightly below the normal range, but it is not severely impaired, and the patient is currently receiving treatment with medications that are effective for managing heart failure and arrhythmias. The patient's laboratory values, including the elevated creatinine level, suggest some degree of kidney impairment, which is a common comorbidity in patients with heart failure.

The patient's ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, indicate a high risk of arrhythmic events. However, the absence of sustained ventricular tachycardia and the presence of digoxin, a medication that can help regulate heart rhythm, suggest that the patient's arrhythmias are not currently severe enough to pose an immediate threat. Overall, while the patient's heart failure and arrhythmias are significant concerns, the patient's overall clinical status and treatment plan suggest that they are likely to survive in the next few years.

The patient's Pro-BNP level of 710.0 ng/L is elevated, indicating some degree of cardiac stress, but it is not excessively high, and the patient is receiving treatment to manage symptoms. The patient's kidney function is impaired, which may require close monitoring and adjustment of medications.

While there is a risk of sudden cardiac death, the patient's overall clinical status and treatment plan suggest that this is the least likely outcome in the next few years. The patient's ECG findings and medication regimen suggest that arrhythmias are being adequately managed, and the patient's heart failure symptoms are being controlled. Overall, I predict that the patient is most likely to survive in the next few years."
575,575,P0895,"Age: 77
Gender: Male 
Weight: 66 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 154/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,2
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,79
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 126.0
Protein (g/L): 66,3
T4 (ng/L): 15
TSH (mIU/L): 0,85
Urea (mg/dL): 8,99
LVEF (%): 63.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is currently classified as a survivor, and the provided data suggests that they have a relatively stable condition. The patient's LVEF (Left Ventricular Ejection Fraction) is 63%, which is within the normal range for a 77-year-old male. The patient's NYHA Class is II, indicating mild symptoms of heart failure. The absence of any acute symptoms or signs of decompensated heart failure, such as acute kidney injury (elevated creatinine) or severe dyspnea, also supports this prognosis.

The patient's ECG findings indicate the presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia, but these findings are not indicative of a life-threatening arrhythmia. The patient is also taking an ACE inhibitor, which is a standard treatment for hypertension and heart failure.

The patient's laboratory results show a slightly elevated creatinine level (95.0 mol/L) but are otherwise within normal limits. The patient's lipid profile is also relatively well-controlled, with low total cholesterol and low LDL levels. The absence of any acute elevation in liver enzymes (ALT or AST) or significant electrolyte imbalances (e.g., hyperkalemia) further supports this prognosis.

Given the patient's stable condition, lack of acute symptoms, and controlled comorbidities, I predict that the patient will survive for the next few years without significant progression of their heart disease."
576,576,P0896,"Age: 47
Gender: Male 
Weight: 100 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 100/63 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 48
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,61
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 226.0
Protein (g/L): 72
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,77
Urea (mg/dL): 7,65
LVEF (%): 20.0
Medications: Beta Blockers, Statins, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's prognosis is ranked as a survivor due to the following factors:

1. Age: Although the patient is 47 years old, which is considered middle-aged, the age itself is not a significant predictor of outcome in this case. However, the patient's relatively young age compared to those with advanced heart failure or significant coronary artery disease may contribute to a better prognosis.

2. NYHA Class II: The patient's NYHA Class II classification indicates mild symptoms of heart failure, which suggests that the patient's heart is still functioning relatively well, and with proper management, the patient may be able to maintain a relatively normal quality of life.

3. Medications: The patient is on multiple medications, including beta blockers, statins, hydralazine, and ACE inhibitors, which are standard treatments for heart failure and coronary artery disease. These medications will help control symptoms, slow disease progression, and reduce the risk of adverse outcomes.

4. Pro-BNP levels: Although the patient's Pro-BNP levels are elevated, which indicates some level of heart failure, the level is not extremely high, suggesting that the patient's heart is still functioning relatively well.

5. Troponin levels: The patient's troponin levels are normal, indicating no significant myocardial damage or infarction.

6. ECG Impression: The patient's ECG shows no signs of significant arrhythmias, which reduces the risk of sudden cardiac death.

7. Hemoglobin and kidney function: The patient's hemoglobin and kidney function are relatively normal, indicating that there is no significant anemia or kidney disease.

8. Low albumin: The patient's low albumin level may indicate malnutrition or liver disease, but it is not a significant predictor of outcome in this case.

9. Other laboratory values: The patient's other laboratory values, such as creatinine, potassium, and glucose levels, are relatively normal.

Given these factors, the patient's prognosis is ranked as a survivor, with a relatively good chance of maintaining their current quality of life with proper management and treatment.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's prognosis is ranked as sudden cardiac death due to the following factors:

1. LVEF: The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 20%, indicating severe heart failure.

2. NYHA Class II: The patient's NYHA Class II classification indicates mild symptoms of heart failure, but the severity of symptoms is still significant.

3. Pro-BNP levels: The patient's Pro-BNP levels are elevated, indicating some level of heart failure.

4. Low HDL: The patient's low HDL cholesterol level may contribute to an increased risk of cardiovascular events.

5. Presence of ventricular extrasystole: The patient's ECG shows ventricular extrasystole, which increases the risk of arrhythmias and sudden cardiac death.

6. Family history of idiopathic dilated cardiomyopathy: The patient's family history of idiopathic dilated cardiomyopathy may increase the risk of sudden cardiac death.

7. Medications: Although the patient is on multiple medications, the patient's medications do not adequately control the patient's heart failure symptoms.

8. Low albumin: The patient's low albumin level may indicate malnutrition or liver disease, which can contribute to an increased risk of cardiovascular events.

9. Elevated creatinine: The patient's elevated creatinine level may indicate kidney disease, which can contribute to an increased risk of cardiovascular events.

Given these factors, the patient's prognosis is ranked as sudden cardiac death, with a relatively high risk of cardiovascular events.

RANKING: 3. Pump failure death
REASONING: 

The patient's prognosis is ranked as pump failure death due to the following factors:

1. Severe LVEF: The patient's LVEF is significantly reduced at 20%, indicating severe heart failure.

2. Severe heart failure symptoms: The patient's NYHA Class II classification indicates mild symptoms of heart failure, but the severity of symptoms is still significant.

3. Pro-BNP levels: The patient's Pro-BNP levels are elevated, indicating some level of heart failure.

4. Ventricular extrasystole: The patient's ECG shows ventricular extrasystole, which increases the risk of arrhythmias and sudden cardiac death.

5. Family history of idiopathic dilated cardiomyopathy: The patient's family history of idiopathic dilated cardiomyopathy may increase the risk of pump failure.

6. Elevated creatinine: The patient's elevated creatinine level may indicate kidney disease, which can contribute to an increased risk of pump failure.

7. Low albumin: The patient's low albumin level may indicate malnutrition or liver disease, which can contribute to an increased risk of pump failure."
577,577,P0900,"Age: 67
Gender: Male 
Weight: 74 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/53 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42,1
ALT or GPT (IU/L): 46.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 3,05
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 93
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,34
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 3611.0
Protein (g/L): 66,9
T4 (ng/L): 19
TSH (mIU/L): 2,15
Urea (mg/dL): 5,99
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
This patient's prognosis is ranked as a survivor due to several factors. Firstly, the patient's LVEF is 40%, which is significantly lower than the normal range, indicating a substantial reduction in cardiac function. However, the patient is already on medications for heart failure, including an ACE inhibitor, which is a standard treatment for heart failure. The patient's NYHA class is II, indicating mild symptoms, and they are not experiencing severe shortness of breath or fatigue.

The patient's laboratory results show elevated creatinine levels, indicating some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's lipid profile is also not ideal, with high triglycerides and low HDL, but they are already on statins, which will help manage their cholesterol levels.

The ECG findings of ventricular extrasystoles and non-sustained ventricular tachycardia are concerning, but the fact that they are non-sustained suggests that the patient is not experiencing frequent arrhythmias that could lead to sudden cardiac death. The absence of paroxysmal supraventricular tachyarrhythmias and bradycardia reduces the risk of arrhythmia-related complications.

Given the patient's age, comorbidities, and current treatment regimen, the risk of sudden cardiac death is moderate, but not the highest. The patient's renal impairment and elevated creatinine levels do increase the risk of pump failure, but the fact that they are on ACE inhibitors and have a relatively mild NYHA class reduces this risk.

Therefore, based on the available information, the patient's prognosis is ranked as a survivor, with a moderate risk of pump failure and arrhythmias. However, with proper management and monitoring, it is possible for the patient to improve their condition and reduce their risk of adverse outcomes.

RANKING: 
2. Pump failure death
REASONING:
This patient's prognosis is ranked as pump failure death due to the significant reduction in LVEF and the presence of renal impairment. The patient's elevated creatinine levels indicate some degree of kidney damage, which can lead to fluid overload and exacerbate heart failure. The patient's NYHA class is II, but the fact that they are not experiencing severe symptoms does not necessarily mean that they are not at risk of pump failure.

The patient's elevated BNP levels (3611.0 ng/L) are also concerning, as this is a marker of ventricular stress and can indicate increased strain on the heart. The fact that the patient is not on diuretics or other medications to manage fluid overload increases the risk of pump failure.

While the patient is on ACE inhibitors, which can help reduce blood pressure and fluid overload, the fact that their blood pressure is still elevated (120/53 mmHg) and they have a high creatinine level (87.0) suggests that their renal function is not optimal. This combination of factors increases the risk of pump failure.

RANKING: 
3. Sudden cardiac death
REASONING:
This patient's prognosis is ranked as sudden cardiac death due to the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG. The fact that the patient has a history of myocardial infarction and is on beta blockers, which can increase the risk of arrhythmias, further increases the risk of sudden cardiac death.

The patient's LVEF is significantly reduced, which can increase the risk of arrhythmias and sudden cardiac death. The fact that the patient is not on anti-arrhythmic medications or implantable cardioverter-defibrillator (ICD) therapy increases the risk of sudden cardiac death.

While the patient's age and comorbidities do increase the risk of pump failure, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests that the patient is at high risk of sudden cardiac death. Therefore, this patient's prognosis is ranked as sudden cardiac death, with a high risk of adverse outcomes."
578,578,P0901,"Age: 52
Gender: Male 
Weight: 78 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 115/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 48
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 64
Glucose (mmol/L): 8,2
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5
LDL (mmol/L): 4,01
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1558.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,56
Urea (mg/dL): 8,32
LVEF (%): 26.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, I would rank the patient's prognosis as a survivor. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. However, the patient's left ventricular ejection fraction (LVEF) is 26%, which indicates severe left ventricular dysfunction, but it's not the lowest value I've seen. The patient is also taking multiple medications for heart failure, including diuretics, spironolactone, and beta blockers, which suggests a well-managed condition.

The patient's laboratory results show elevated levels of BNP (1558 ng/L), which is a biomarker for heart failure. However, the troponin level is within normal limits, which suggests that the patient is not experiencing acute myocardial infarction. The patient's creatinine level is elevated (95.0 mmol/L), which may indicate some degree of kidney dysfunction, but it's not excessively high.

The ECG impression shows ventricular extrasystoles, which can be a marker for cardiac disease, but it's not a specific indicator of poor prognosis. The patient's ECG also shows a TPSV (paroxysmal supraventricular tachycardia), which can be a sign of underlying cardiac disease, but it's not a contraindication for survival.

Considering the patient's overall condition, I believe that the patient's prognosis is more likely to be a survivor, given their well-managed heart failure and the absence of other significant risk factors. However, close monitoring and follow-up are still necessary to ensure the patient's condition does not deteriorate."
579,579,P0902,"Age: 44
Gender: Male 
Weight: 75 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 140/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 41.0
Total Cholesterol (mmol/L): 7,55
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 151
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 173.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,27
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 147.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,06
TSH (mIU/L): 0,753
Urea (mg/dL): 5,83
LVEF (%): 39.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that affects the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is 39%, which is significantly below the normal range (50-70%). This indicates that the patient's heart is not pumping efficiently, and this is a significant concern.

The patient is also taking an ACE inhibitor, which is a common medication used to treat heart failure and hypertension. However, the patient's blood pressure is still elevated at 140/100 mmHg, which may indicate that the medication is not effective.

The patient's troponin levels are normal, which suggests that there is no significant myocardial damage. However, the patient's Pro-BNP levels are elevated, which indicates that the patient's heart is working harder to pump blood, and this may be a sign of heart failure.

The patient's other lab results are relatively normal, but the patient's creatinine level is elevated, which may indicate some degree of kidney impairment.

Considering these factors, the most likely outcome for the patient is a survival of the next few years. However, it is essential to monitor the patient's condition closely and adjust the treatment plan as needed.

The other two options, sudden cardiac death and pump failure death, are less likely because the patient's troponin levels are normal, and the patient is taking an ACE inhibitor, which is a common medication used to treat heart failure. However, the patient's LVEF is significantly below the normal range, and the patient's Pro-BNP levels are elevated, which suggests that the patient is at risk of developing heart failure.

Sudden cardiac death is also less likely because the patient's ECG impression does not show any ventricular tachycardia or ventricular extrasystoles, which are common causes of sudden cardiac death.

Pump failure death is also less likely because the patient is taking an ACE inhibitor, which is a common medication used to treat heart failure. However, the patient's LVEF is significantly below the normal range, and the patient's Pro-BNP levels are elevated, which suggests that the patient is at risk of developing heart failure."
580,580,P0903,"Age: 63
Gender: Male 
Weight: 59 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 9,46
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 170
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,93
Potassium (mEq/L): 5,07
LDL (mmol/L): 6,65
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1975.0
Protein (g/L): 76,4
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,84
Urea (mg/dL): 11,7
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to the presence of several factors that suggest a relatively stable cardiovascular condition. The patient's NYHA Class II indicates that they have some limitations in physical activity, but they are still able to perform daily tasks without severe shortness of breath. The patient's LVEF of 20.0 is significantly reduced, but it is not indicative of severe heart failure. The absence of any evidence of acute myocardial infarction, heart failure exacerbation, or other critical conditions in the recent past suggests that the patient's heart function is stable.

The patient's lipid profile and renal function are also relatively well-controlled, with total cholesterol and LDL levels below average, and creatinine levels within a relatively normal range. The presence of elevated BNP levels suggests some degree of cardiac stress, but it is not indicative of heart failure.

The patient's ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, are concerning for cardiac arrhythmias, but they are not indicative of a life-threatening condition. The patient is already on beta blockers, which are effective in managing ventricular arrhythmias, and spironolactone, which may help with heart failure symptoms.

Overall, while this patient has several cardiovascular risk factors and some cardiac dysfunction, their current clinical presentation and laboratory results suggest that they are likely to survive for the next few years without significant cardiovascular complications."
581,581,P0904,"Age: 74
Gender: Female 
Weight: 64 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 105/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,91
Creatinine (mmol/L): 137.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 111.0
HDL (mmol/L): 1,18
Potassium (mEq/L): 3,81
LDL (mmol/L): 2,12
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 694.0
Protein (g/L): 68,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,28
Urea (mg/dL): 12,7
LVEF (%): 31.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient is 74 years old, with a history of ischemic dilated cardiomyopathy, diabetes, dyslipidemia, hypertension, and myocardial infarction. The patient's NYHA class is III, indicating severe heart failure symptoms. The patient's LVEF is significantly reduced at 31%, which is consistent with the patient's history of cardiomyopathy.

The patient's biomarkers, such as elevated creatinine and urea levels, suggest renal impairment, which is a common comorbidity in patients with heart failure. The patient's Pro-BNP level is elevated, indicating increased ventricular wall stress. However, the patient is on medications that are commonly used to manage heart failure, such as beta blockers, loop diuretics, statins, and ACE inhibitors.

The ECG impression shows sinus node dysfunction, which is consistent with the patient's age and history of heart failure. The absence of ventricular extrasystoles, ventricular tachycardia, and non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

Given the patient's overall clinical profile, with a history of heart failure, renal impairment, and elevated biomarkers, the patient is at high risk for pump failure death. However, the patient's current ECG impression and the absence of severe arrhythmias suggest that the patient is at lower risk for sudden cardiac death. Therefore, the most likely outcome for the patient over the next few years is survival.

2. Sudden cardiac death
REASONING:
The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death. The patient's ECG impression shows sinus node dysfunction, which can increase the risk of arrhythmias. The patient's elevated Pro-BNP level and elevated creatinine and urea levels suggest that the patient's heart is under significant stress, which can increase the risk of arrhythmias.

However, the patient's current ECG impression does not show any ventricular extrasystoles, ventricular tachycardia, or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death. Additionally, the patient is on medications that are commonly used to manage heart failure and arrhythmias.

3. Pump failure death
REASONING:
The patient's LVEF is significantly reduced at 31%, which indicates that the patient's heart is not functioning efficiently. The patient's history of heart failure and elevated biomarkers, such as creatinine and urea, suggest that the patient is at high risk for pump failure.

However, the patient is on medications that are commonly used to manage heart failure, such as beta blockers, loop diuretics, statins, and ACE inhibitors. The patient's current ECG impression does not show any severe arrhythmias, which reduces the risk of sudden cardiac death. While the patient's pump function is impaired, the patient's current clinical profile suggests that the patient is more likely to survive over the next few years, rather than experiencing pump failure death."
582,582,P0905,"Age: 46
Gender: Male 
Weight: 69 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 47,3
ALT or GPT (IU/L): 50.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 4,83
Creatinine (mmol/L): 92.0
Gamma-glutamil transpeptidase (IU/L): 96
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,02
Potassium (mEq/L): 5,25
LDL (mmol/L): 2,83
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2470.0
Protein (g/L): 75,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 6,5
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is currently in a relatively stable condition, with a past medical history of idiopathic dilated cardiomyopathy, which is the primary underlying cause of their cardiac dysfunction. The patient's left ventricular ejection fraction (LVEF) is 25%, which is significantly reduced, but not critically low. The presence of ventricular extrasystoles on the ECG, although concerning, is not indicative of a high risk of sudden cardiac death. The patient's current blood pressure is within a relatively normal range for their age and height. The patient's serum creatinine level is elevated, but it is not indicative of severe kidney dysfunction.

The patient is currently receiving medications that are commonly used to manage heart failure and arrhythmias, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. The patient's troponin level is within normal limits, which suggests that there is no evidence of acute myocardial infarction or significant myocardial damage.

Given these factors, the patient's overall prognosis is relatively good, and they are likely to survive for the next few years. The patient's elevated creatinine level and reduced LVEF suggest that they may require ongoing management of their heart failure, but with the right treatment and monitoring, they can be expected to live a relatively normal life.

2. Sudden cardiac death
REASONING:
The patient's reduced LVEF of 25% is a significant indicator of poor cardiac function, and their past medical history of idiopathic dilated cardiomyopathy increases their risk of sudden cardiac death. The presence of ventricular extrasystoles on the ECG also increases the risk of arrhythmias, which can lead to sudden cardiac death.

However, the patient's current blood pressure, troponin level, and lack of evidence of acute myocardial infarction or significant myocardial damage reduce the likelihood of sudden cardiac death. The patient's serum creatinine level is also not indicative of severe kidney dysfunction, which can contribute to the development of arrhythmias.

3. Pump failure death
REASONING:
The patient's reduced LVEF of 25% and elevated serum creatinine level suggest that their heart is not functioning optimally, increasing the risk of pump failure. The patient's elevated BNP level (2470 ng/L) also suggests that their heart is under significant strain, which can lead to pump failure.

However, the patient's current medications and the absence of evidence of acute myocardial infarction or significant myocardial damage reduce the likelihood of pump failure. The patient's ventricular extrasystoles on the ECG are concerning, but not indicative of a high risk of pump failure. Overall, while the patient's cardiac function is compromised, the presence of ongoing management with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor suggests that they can be expected to survive for the next few years, albeit with ongoing monitoring and management of their heart failure."
583,583,P0906,"Age: 82
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,39
Creatinine (mmol/L): 185.0
Gamma-glutamil transpeptidase (IU/L): 52
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,15
Potassium (mEq/L): 4,02
LDL (mmol/L): 2,91
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 28179.0
Protein (g/L): 80,2
Troponin (ng/mL): 0,07
TSH (mIU/L): 1,92
Urea (mg/dL): 17,2
LVEF (%): 15.0
Medications: Calcium Channel Blocker, Diabetes Medication, Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, the patient's NYHA Class III indicates that they are experiencing significant symptoms despite their medication regimen. The elevated Pro-BNP levels (28179.0 ng/L) suggest a high burden of ventricular stress, but the patient's hemoglobin level (135.0 g/L) and lack of anemia-related symptoms suggest that anemia is not a contributing factor to their symptoms.

The patient's LVEF (15.0%) is severely impaired, indicating a high risk of heart failure. However, the patient's renal function is preserved (Creatinine 17.2 mg/dL), which suggests that they are not experiencing significant kidney dysfunction. The absence of troponin elevation (0.07 ng/mL) suggests that there is no significant myocardial injury.

The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, suggest that they have a high risk of arrhythmias. However, the absence of sustained ventricular tachycardia (CH>10) and paroxysmal supraventricular tachyarrhythmia code suggests that the patient's arrhythmia burden is not excessively high.

Given these factors, the patient's overall risk of adverse outcomes appears to be moderate to high. However, the patient's age (82), weight (80 kg), and relatively preserved renal function suggest that they may be more likely to survive with optimal management. Therefore, I predict that the patient has a high likelihood of survival.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The patient's history of ischemic dilated cardiomyopathy, elevated Pro-BNP levels, and LVEF (15.0%) indicate a high risk of adverse outcomes. The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, also suggest a high risk of arrhythmias. However, the absence of sustained ventricular tachycardia (CH>10) and paroxysmal supraventricular tachyarrhythmia code suggests that the patient's arrhythmia burden is not excessively high.

The patient's age (82) and weight (80 kg) are also risk factors for sudden cardiac death. However, the patient's relatively preserved renal function (Creatinine 17.2 mg/dL) and lack of anemia-related symptoms suggest that they are not experiencing significant kidney dysfunction.

Given these factors, the patient's overall risk of sudden cardiac death appears to be moderate to high. However, the patient's relatively preserved renal function and lack of anemia-related symptoms suggest that they may be more likely to survive with optimal management. Therefore, I predict that the patient has a moderate likelihood of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's severely impaired LVEF (15.0%) and elevated Pro-BNP levels (28179.0 ng/L) indicate a high risk of heart failure. The patient's NYHA Class III indicates that they are experiencing significant symptoms despite their medication regimen.

The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, also suggest a high risk of arrhythmias. The absence of sustained ventricular tachycardia (CH>10) and paroxysmal supraventricular tachyarrhythmia code suggests that the patient's arrhythmia burden is not excessively high.

The patient's age (82) and weight (80 kg) are also risk factors for pump failure death. However, the patient's relatively preserved renal function (Creatinine 17.2 mg/dL) and lack of anemia-related symptoms suggest that they are not experiencing significant kidney dysfunction.

Given these factors, the patient's overall risk of pump failure death appears to be high. The patient's severely impaired LVEF and elevated Pro-BNP levels suggest that they are at high risk of developing heart failure. Therefore, I predict that the patient has a high likelihood of pump failure death."
584,584,P0909,"Age: 40
Gender: Female 
Weight: 125 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42,9
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,26
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 12.0
Protein (g/L): 74,8
T4 (ng/L): 15
TSH (mIU/L): 1,49
Urea (mg/dL): 6,82
LVEF (%): 49.0
Medications: Diabetes Medication, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient's prognosis is ranked as a survivor due to the following factors:

- Age: The patient is 40 years old, which is considered relatively young for heart failure.
- NYHA Class: The patient has a NYHA Class II, indicating mild heart failure symptoms, which is less severe compared to Class III or IV.
- Blood Pressure: The patient's blood pressure is well-controlled at 140/80 mmHg, which reduces the risk of further cardiovascular events.
- Medications: The patient is on Diabetes Medication, Beta Blockers, and ACE Inhibitor, which are commonly used to manage heart failure, hypertension, and diabetes.
- LVEF: The patient's left ventricular ejection fraction (LVEF) is 49.0%, which is relatively preserved, indicating that the heart is still pumping effectively.
- ECG Impression: The ECG shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which reduces the risk of sudden cardiac death.
- Other lab values: The patient's liver enzymes (ALT and AST) are within normal limits, and the albumin level is slightly low, which may indicate some degree of malnutrition or dehydration.
- Creatinine level: The patient's creatinine level is elevated at 66.0, which may indicate some degree of renal impairment, but it is not significantly high.
- Pro-BNP: The patient's pro-B-type natriuretic peptide (Pro-BNP) level is within the normal range, which suggests that the heart is not under significant stress.

While the patient has a history of idiopathic dilated cardiomyopathy, hypertension, and dyslipidemia, their overall clinical profile and lab values suggest that they are likely to survive in the short term. However, long-term prognosis remains uncertain and would require further monitoring and management."
585,585,P0910,"Age: 73
Gender: Female 
Weight: 74 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 46,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 11,1
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,1
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 614.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 0,67
Urea (mg/dL): 4,49
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is likely to survive for the next few years. Here's the reasoning behind this ranking:

1. Age and NYHA Class II: The patient is 73 years old and has a New York Heart Association (NYHA) Class II, indicating that she has mild symptoms of heart failure, but she is still able to perform daily activities with some limitation. This suggests that her heart function is relatively preserved, which is a positive prognostic factor.

2. Low risk of sudden cardiac death: The ECG results do not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other life-threatening arrhythmias. The absence of these conditions reduces the risk of sudden cardiac death.

3. Moderate renal impairment: The patient has elevated creatinine levels (66.0 mmol/L), indicating moderate renal impairment. However, the patient is on medications for diabetes and hypertension, which may help manage her renal function. Additionally, the LVEF (70.0) is relatively preserved, which suggests that the patient's heart function is not severely compromised.

4. Hypertension and cardiomyopathy: The patient has a history of hypertension and cardiomyopathy, which are risk factors for heart failure and cardiovascular events. However, the patient is on medications for these conditions, and the NYHA Class II classification indicates that her symptoms are well-managed.

5. Low albumin levels: The patient has low albumin levels (46.6 g/L), which may indicate malnutrition or liver dysfunction. However, this finding is not directly related to cardiovascular outcomes.

6. Pro-BNP levels: The patient has elevated Pro-BNP levels (614.0 ng/L), which is a marker of heart failure. However, the patient's LVEF is relatively preserved, and the NYHA Class II classification suggests that her symptoms are mild, which may indicate that her heart is not severely overloaded.

In conclusion, based on the provided data, the patient is likely to survive for the next few years due to her relatively preserved heart function, well-managed hypertension and cardiomyopathy, and the absence of life-threatening arrhythmias. However, close monitoring and follow-up with the patient's cardiologist are essential to ensure that her condition does not deteriorate over time."
586,586,P0911,"Age: 64
Gender: Female 
Weight: 67 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 5,95
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 2,54
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,26
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1114.0
Protein (g/L): 72,5
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 5,22
Urea (mg/dL): 6,49
LVEF (%): 65.0
Medications: Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient has a history of Hypertensive cardiomyopathy, which is a significant risk factor for heart failure. However, the patient's LVEF is 65%, which indicates some degree of preserved left ventricular function. The patient is also taking Beta Blockers, which can help reduce the strain on the heart. Additionally, the patient's ECG results do not show any signs of arrhythmias, which are a common cause of sudden cardiac death.

While the patient has several comorbidities, including hypertension, dyslipidemia, and elevated creatinine levels, these can be managed with medication and lifestyle changes. The patient's current treatment regimen and lifestyle adjustments may be sufficient to prevent further deterioration of the heart function.

2. Sudden cardiac death
REASONING: 
The patient's history of Hypertensive cardiomyopathy and elevated creatinine levels increase the risk of sudden cardiac death. However, the patient's LVEF is 65%, which suggests that the heart is still functioning to some extent. The patient's ECG results do not show any signs of arrhythmias, which reduces the risk of sudden cardiac death.

The patient's elevated Pro-BNP levels (1114.0 ng/L) indicate some degree of heart failure, but this can be managed with treatment. The patient's age and sex are also factors that can influence the risk of sudden cardiac death.

3. Pump failure death
REASONING: 
While the patient's LVEF is 65%, which is lower than the normal range (55%), it is still within the range that can be managed with treatment. The patient's ECG results do not show any signs of arrhythmias, and the patient is taking Beta Blockers, which can help reduce the strain on the heart.

However, the patient's elevated creatinine levels (87.0 mmol/L) indicate some degree of kidney dysfunction, which can increase the risk of pump failure. Additionally, the patient's age and sex are also factors that can influence the risk of pump failure. Overall, while the patient's prognosis is not the best, the patient is likely to survive for several years with proper treatment and management of their comorbidities."
587,587,P0912,"Age: 75
Gender: Female 
Weight: 57 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 50,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,28
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,11
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1619.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 4,68
LVEF (%): 68.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's overall prognosis is ranked as a survivor. The patient's age of 75 is not particularly high, but the presence of NYHA Class III heart failure and Hypertensive cardiomyopathy indicates a significant cardiac burden. However, the patient's ejection fraction (LVEF) is 68%, which suggests that the heart is still pumping effectively to some extent.

The patient's laboratory results show elevated creatinine levels (79.0 mmol/L), which may indicate some degree of kidney impairment. However, the patient is on medications such as Loop Diuretics and ACE Inhibitor, which are commonly used to manage heart failure and hypertension. The patient's electrolyte levels, including potassium and sodium, are also within relatively normal ranges.

The patient's ECG findings are also not concerning, with no evidence of ventricular tachycardia or bradycardia. The presence of polymorphic ventricular extrasystoles is a concern, but it is not necessarily a predictor of sudden cardiac death.

Overall, considering the patient's age, NYHA Class III heart failure, and the presence of Hypertensive cardiomyopathy, the patient's prognosis is ranked as a survivor, but with a high risk of adverse cardiac events. Regular monitoring and close follow-up are essential to manage the patient's condition and prevent potential complications.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient's ECG findings show polymorphic ventricular extrasystoles, which is a concern, the overall prognosis is not ranked as sudden cardiac death. The patient's LVEF is 68%, and the patient is on medications that are commonly used to manage heart failure and hypertension.

However, the patient's age of 75, NYHA Class III heart failure, and Hypertensive cardiomyopathy do increase the risk of sudden cardiac death. Additionally, the patient's elevated creatinine levels and kidney impairment may contribute to a higher risk of cardiac events.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's LVEF is 68%, which is lower than the normal range (50-70%). This suggests that the patient's heart is not pumping as effectively as it should be. The patient's NYHA Class III heart failure classification indicates that the patient's symptoms are severe, and the patient is experiencing significant limitations in daily activities.

The patient's elevated creatinine levels and kidney impairment may also contribute to a higher risk of pump failure death. The patient's medications, including Loop Diuretics and ACE Inhibitor, are used to manage heart failure, but these medications may not be sufficient to reverse the underlying cardiac dysfunction.

Overall, the patient's LVEF and NYHA Class III heart failure classification suggest that the patient is at a higher risk of pump failure death, making this the least likely prognosis among the three options."
588,588,P0914,"Age: 54
Gender: Male 
Weight: 93 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45,2
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,51
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 464.0
Protein (g/L): 72,8
T3 (pg/dL): 0,05
T4 (ng/L): 14
TSH (mIU/L): 1,21
Urea (mg/dL): 7,32
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is a 54-year-old male with a complex medical history, including ischemic dilated cardiomyopathy, hypertension, and a history of myocardial infarction. Despite these comorbidities, the patient's current NYHA Class II classification indicates that they are still relatively functional and able to perform daily activities without significant limitation. The patient's LVEF of 20.0 is significantly reduced, indicating severe left ventricular dysfunction, which is a common complication of ischemic dilated cardiomyopathy. However, the patient's current medication regimen includes an Angiotensin II Receptor Blocker, Beta Blockers, and Statins, which are standard treatments for heart failure and hypertension.

The patient's laboratory results show elevated creatinine levels (103.0 mmol/L), which indicate impaired renal function, but this is not uncommon in patients with heart failure. The patient's electrolyte panel, including potassium levels (4.7 mEq/L), is relatively normal. The Pro-BNP level of 464.0 ng/L is elevated, which is consistent with heart failure.

The ECG findings of ventricular extrasystole and sinus node dysfunction may indicate underlying cardiac conduction abnormalities, but these are not immediately life-threatening. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient is not at high risk for sudden cardiac death.

Considering these factors, the patient's overall prognosis is that they are likely to survive for the next few years, albeit with ongoing management of their heart failure and comorbid conditions. With proper medication adherence and lifestyle modifications, it is possible that the patient's condition may stabilize or even improve over time.

The other two prognoses (sudden cardiac death and pump failure death) are less likely because:

* Sudden cardiac death is unlikely due to the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG.
* Pump failure death is unlikely because the patient is already receiving standard treatments for heart failure and has a relatively preserved renal function.

However, it is essential to closely monitor the patient's condition and adjust the treatment plan as needed to minimize the risk of complications and optimize their overall prognosis."
589,589,P0915,"Age: 78
Gender: Male 
Weight: 103 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 36,4
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,16
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2390.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,65
Urea (mg/dL): 8,69
LVEF (%): 38.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 
Given the patient's age, NYHA Class II, and LVEF of 38%, the patient is at a high risk for cardiac complications. However, the patient's current ECG findings, including ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, suggest that the patient is experiencing significant cardiac arrhythmias. The presence of these arrhythmias, despite being non-sustained, may indicate underlying cardiac instability. 

Although the patient has a history of ischemic dilated cardiomyopathy, the absence of significant elevations in troponin levels and the relatively preserved LVEF suggest that the patient's cardiac function is not severely impaired at this time. Additionally, the patient is on multiple medications, including beta blockers, loop diuretics, spironolactone, ACE inhibitors, and nitrovasodilators, which are standard treatments for managing heart failure and hypertension.

Given these factors, it is possible that the patient's cardiac function can be managed with current treatment, and the patient can survive the next few years. However, it is essential to closely monitor the patient's cardiac function, arrhythmias, and overall health to prevent potential cardiac complications. 

The patient's weight and high blood pressure also suggest that there is a risk of further cardiac complications, but the patient's current medical treatment and the presence of a favorable ECG profile suggest that the patient can survive the next few years."
590,590,P0922,"Age: 65
Gender: Male 
Weight: 81 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,34
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 86.0
Protein (g/L): 72
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,99
LVEF (%): 58.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 65-year-old male with a history of hypertension, cardiomyopathy, and diabetes, which are all risk factors for cardiovascular disease. However, the patient's NYHA Class II indicates that they have some symptoms of heart failure but are still able to perform daily activities without severe limitation. The patient's ejection fraction (LVEF) is 58%, which is within the normal range, suggesting that the patient's heart is still functioning relatively well. The patient's medication regimen includes ACE inhibitors, beta blockers, and loop diuretics, which are standard treatments for heart failure and hypertension.

The patient's ECG impression shows a TPSV, which is a type of supraventricular tachycardia that is often associated with a good prognosis. There is no evidence of ventricular tachycardia or ventricular extrasystole, which are more ominous signs. The patient's troponin levels are within normal limits, and the patient's creatinine levels are elevated, but this is likely due to the patient's age and other comorbidities rather than cardiac disease.

Overall, based on the patient's age, medical history, and current clinical status, I would predict that the patient has a good prognosis and is likely to survive for the next few years without significant cardiovascular events. The patient's current treatment regimen and the absence of severe cardiac symptoms suggest that the patient is being well-managed, and the patient's cardiac function is relatively preserved.

RANKING: 
2. Sudden Cardiac Death
REASONING: 
The patient's history of hypertension and cardiomyopathy increases their risk of sudden cardiac death, but the patient's current medical history and ECG impression do not suggest an immediate risk for sudden cardiac death. The patient's LVEF is 58%, which is within the normal range, and the patient's troponin levels are within normal limits, which suggests that the patient's cardiac muscle is not experiencing significant damage.

However, the patient's elevated creatinine levels and elevated blood pressure may indicate some degree of cardiac strain, and the patient's diabetes and hypertension may contribute to a higher risk of cardiovascular events in the long term. Additionally, the patient's low HDL cholesterol level may also contribute to an increased risk of cardiovascular events.

While the patient's current treatment regimen includes beta blockers, which can help reduce the risk of sudden cardiac death, the patient's ECG impression shows a TPSV, which may increase the risk of arrhythmias in the future.

RANKING: 
3. Pump Failure Death
REASONING: 
The patient's LVEF is 58%, which is below the normal range, and the patient's ejection fraction is within the range for pump failure. The patient's elevated creatinine levels and elevated blood pressure may indicate some degree of cardiac strain, and the patient's diabetes and hypertension may contribute to a higher risk of cardiovascular events in the long term.

The patient's current treatment regimen includes loop diuretics, which can help manage fluid overload and reduce the risk of pump failure. However, the patient's NYHA Class II indicates that they have some symptoms of heart failure, which may suggest that the patient is already experiencing some degree of cardiac dysfunction.

The patient's elevated albumin level (40 g/L) may also indicate some degree of liver dysfunction or fluid overload, which can contribute to pump failure. Overall, while the patient is being well-managed with their current treatment regimen, the patient's cardiac function is not as strong as it could be, and the patient's risk of pump failure is higher than that of sudden cardiac death or survivor."
591,591,P0923,"Age: 78
Gender: Male 
Weight: 61 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 72.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 5
LDL (mmol/L): 2,56
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 487.0
Protein (g/L): 73
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,75
Urea (mg/dL): 11,48
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient is 78 years old, with a history of ischemic dilated cardiomyopathy, which indicates a pre-existing heart condition that can lead to heart failure. However, the patient is currently taking medications such as Beta Blockers, Loop Diuretics, Spironolactone, and ACE Inhibitor, which are commonly used to manage heart failure and prevent further complications. The patient's NYHA Class II indicates that they have some symptoms of heart failure, but they are still able to perform moderate physical activity without symptoms.

The patient's ejection fraction (LVEF) is 35%, which is significantly reduced, indicating severe left ventricular dysfunction. However, the patient's Pro-BNP levels are elevated, which suggests that the patient's heart is under strain. Despite this, the patient's troponin levels are within normal limits, indicating no recent myocardial infarction.

The patient's ECG shows a polymorphic ventricular extrasystole, which can be a sign of arrhythmia, but there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia. The patient also has a mild bradycardia, which can be a sign of heart failure.

Overall, considering the patient's age, medical history, and current medication regimen, the most likely outcome is that the patient will survive the next few years, provided that their current treatment plan is continued and any underlying conditions are managed effectively. 

2. Sudden cardiac death
REASONING: 
While the patient's heart condition is severe, with a reduced ejection fraction and elevated Pro-BNP levels, the patient is currently receiving medications to manage heart failure and prevent further complications. The absence of recent myocardial infarction and normal troponin levels reduce the likelihood of sudden cardiac death.

However, the patient's age and pre-existing conditions, such as ischemic dilated cardiomyopathy and peripheral vascular disease, increase the risk of sudden cardiac death. The patient's polymorphic ventricular extrasystole on the ECG also increases the risk of arrhythmia, which can lead to sudden cardiac death.

3. Pump failure death
REASONING: 
Given the patient's severe left ventricular dysfunction (LVEF 35%), it is likely that the patient will experience heart failure exacerbation in the near future. However, the patient is currently receiving medications to manage heart failure, which reduces the likelihood of pump failure death.

The patient's elevated Pro-BNP levels and reduced ejection fraction suggest that the patient's heart is under strain, but the patient's troponin levels are normal, indicating no recent myocardial infarction. The patient's age and pre-existing conditions also increase the risk of heart failure exacerbation.

However, considering the patient's current treatment plan and the absence of any recent changes in the patient's condition, the likelihood of pump failure death is lower compared to sudden cardiac death."
592,592,P0924,"Age: 72
Gender: Female 
Weight: 65 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 5,6
LDL (mmol/L): 2,43
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 2235.0
Protein (g/L): 70
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 8,15
LVEF (%): 55.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's overall health status appears to be relatively stable. The patient's age (72) is a significant risk factor for cardiac events, but the patient's NYHA class II indicates that they are still able to perform daily activities with some limitation. The patient's blood pressure is well-controlled, and their medications, including Amiodarone and Angiotensin II Receptor Blocker, suggest that they are receiving adequate treatment for their hypertensive cardiomyopathy and hypertension.

The patient's laboratory results show no significant elevations in liver enzymes, which suggests that the patient's liver function is relatively preserved. The patient's electrolyte levels are also within normal ranges, which is important for maintaining proper cardiac function.

The ECG results show ventricular extrasystoles, but no other significant arrhythmias or signs of cardiac ischemia. This suggests that the patient's cardiac function is not severely compromised at this time.

The patient's LVEF (Left Ventricular Ejection Fraction) is 55%, which is below the normal range, indicating some degree of left ventricular dysfunction. However, this is not a contraindication for survival, and the patient's overall health status suggests that they are likely to survive for the next few years.

Overall, based on the patient's stable health status, well-controlled blood pressure, and adequate treatment, I predict that the patient is most likely to survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's LVEF is below the normal range, the patient's overall health status and treatment suggest that they are not at high risk for sudden cardiac death. The patient's ECG results do show ventricular extrasystoles, but these are not indicative of a high risk for sudden cardiac death.

The patient's laboratory results are relatively normal, which suggests that the patient's liver and kidney function are preserved. The patient's electrolyte levels are also within normal ranges, which is important for maintaining proper cardiac function.

The patient's medication regimen, including Amiodarone, suggests that the patient is receiving adequate treatment for their hypertensive cardiomyopathy and arrhythmias. However, the patient's Pro-BNP levels are elevated, which suggests that the patient may have some degree of heart failure. While this is a risk factor for sudden cardiac death, it is not a contraindication for survival.

Overall, while the patient's LVEF is below the normal range, the patient's overall health status and treatment suggest that they are not at high risk for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF is below the normal range, which suggests that the patient may have some degree of left ventricular dysfunction. The patient's Pro-BNP levels are also elevated, which suggests that the patient may have some degree of heart failure.

The patient's ECG results show ventricular extrasystoles, which may be indicative of a high risk for pump failure. However, the patient's overall health status and treatment suggest that they are not at high risk for pump failure.

The patient's laboratory results show some elevations in liver enzymes and creatinine, which may suggest some degree of liver and kidney dysfunction. However, these elevations are not severe, and the patient's overall health status suggests that they are not at high risk for pump failure.

Overall, while the patient's LVEF is below the normal range and the patient's Pro-BNP levels are elevated, the patient's overall health status and treatment suggest that they are not at high risk for pump failure. However, the patient's elevated LVEF and Pro-BNP levels do increase the risk for pump failure, making it a more likely outcome compared to sudden cardiac death."
593,593,P0925,"Age: 77
Gender: Male 
Weight: 82 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,36
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 424.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,33
Urea (mg/dL): 6,66
LVEF (%): 57.0
Medications: Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient's overall health status is compromised due to the presence of Hypertrophic Cardiomyopathy (HCM), which is a condition that can lead to heart failure and arrhythmias. However, the patient is currently being treated with beta blockers, which are commonly used to manage symptoms of HCM and reduce the risk of sudden cardiac death. The patient's ejection fraction (LVEF) is 57.0%, which is lower than the normal range, indicating some degree of left ventricular dysfunction. 

Although the patient has elevated troponin levels, which can indicate some degree of myocardial damage, the levels are very low (0.01 ng/mL). The patient's other laboratory values, including liver function tests, kidney function, and electrolyte levels, are relatively normal.

Additionally, the patient's ECG impression does not show any signs of ventricular tachycardia or ventricular fibrillation, which are common causes of sudden cardiac death. The presence of paroxysmal supraventricular tachycardia (PSVT) is noted, but it is not a life-threatening arrhythmia.

Considering these factors, I believe that the patient is most likely to survive for the next few years, as the patient's condition is being managed with medication and the patient's overall health status, while compromised, is not immediately life-threatening. 

2. Sudden cardiac death
REASONING: 
The patient's history of Hypertrophic Cardiomyopathy (HCM) increases the risk of sudden cardiac death. Although the patient is being treated with beta blockers, which can reduce this risk, the patient's ejection fraction is lower than normal, and the presence of some degree of myocardial damage (indicated by elevated troponin levels) may increase the risk of arrhythmias.

Additionally, the patient's age (77 years) and elevated creatinine levels (106.0 mmol/L) may also increase the risk of sudden cardiac death.

3. Pump failure death
REASONING: 
The patient's ejection fraction is 57.0%, which is lower than the normal range, indicating some degree of left ventricular dysfunction. This could potentially lead to heart failure, but the patient is currently being treated with loop diuretics, which are commonly used to manage symptoms of heart failure.

However, the patient's overall health status, including the presence of Hypertrophic Cardiomyopathy, elevated troponin levels, and elevated creatinine levels, makes pump failure death a less likely outcome compared to sudden cardiac death."
594,594,P0926,"Age: 81
Gender: Male 
Weight: 68 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 36
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,67
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,11
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 779.0
Protein (g/L): 68
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,1
Urea (mg/dL): 14,81
LVEF (%): 42.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 81-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. The patient's ejection fraction (LVEF) is 42%, which is below the normal range, indicating some degree of left ventricular dysfunction. The patient's current NYHA class is II, indicating some limitation in physical activity due to heart failure symptoms.

The patient's biomarkers, such as elevated Troponin and Pro-BNP levels, suggest some degree of cardiac stress and strain. However, the patient's troponin level is within the normal range, and the Pro-BNP level is not excessively high. The patient's potassium level is slightly elevated, but not significantly high.

The patient's medications, including beta blockers, statins, and calcium channel blockers, are commonly used to manage heart failure and coronary artery disease. The patient's ECG findings do not indicate any significant arrhythmias or conduction abnormalities.

Given these factors, the patient's overall clinical picture suggests that he is likely to survive the next few years with careful management of his medications and lifestyle modifications. The patient's age and comorbidities do pose some risks, but the patient's current condition does not appear to be in an acute crisis, and the patient's cardiac function is not severely compromised.

While there is always some risk of cardiac events, the patient's current condition and management plan suggest that he is more likely to survive the next few years compared to the other two options. Therefore, the most likely prognosis is survival."
595,595,P0928,"Age: 62
Gender: Female 
Weight: 55 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 32
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,51
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,67
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 712.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,67
Urea (mg/dL): 9,15
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor 
REASONING: 
Based on the provided patient data, the patient is classified as having a moderate to severe cardiac dysfunction with an LVEF of 32%, which is significantly below the normal range. The presence of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction indicate a high risk of adverse cardiac events. However, the patient's current NYHA Class II classification suggests that they are still able to perform moderate physical activity without symptoms. The presence of elevated Pro-BNP levels (712 ng/L) also indicates a high level of ventricular stress, but it is not an immediate indication of cardiac failure. The patient's blood pressure and medication regimen are well-controlled, with no evidence of acute coronary syndrome or acute heart failure. 

The patient's ECG results show ventricular extrasystole, which is a common finding in patients with cardiomyopathy, but it is not indicative of an acute cardiac event. Overall, the combination of the patient's cardiac dysfunction, hypertension, and controlled blood pressure, along with the absence of acute cardiac events, suggest that the patient is at high risk for cardiac events but is not currently experiencing an acute cardiac emergency. Therefore, the most likely outcome is that the patient will survive the next few years. 

The patient's weight and height are within normal limits, and the absence of other significant comorbidities (such as severe pulmonary disease or renal failure) further supports the likelihood of survival. The patient's laboratory results are also largely within normal limits, with the exception of mildly elevated liver enzymes and a slightly elevated creatinine level, which may indicate mild kidney impairment but are not life-threatening.

While the patient is at risk for cardiac events, the combination of well-controlled hypertension, absence of acute cardiac events, and current NYHA Class II classification suggest that the patient is likely to survive the next few years without a significant cardiac event."
596,596,P0930,"Age: 56
Gender: Male 
Weight: 79 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 105/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 120
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 157.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,5
LDL (mmol/L): 2,28
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 7066.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 27
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,72
Urea (mg/dL): 10,65
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
Given the patient's NYHA Class III status and LVEF of 25%, it indicates severe left ventricular dysfunction. The presence of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension further exacerbates the patient's cardiac condition. However, the patient's current blood pressure is within a relatively normal range (105/75 mmHg). The patient's creatinine level is slightly elevated, which may indicate some degree of kidney impairment, but it is not severe. The patient's troponin level is also within a relatively normal range, indicating no significant myocardial infarction. The presence of a TSH level of 2.72 mIU/L is within the normal range, indicating that the patient's thyroid function is normal. The patient is on medications that are commonly used to manage heart failure and control blood pressure. The patient's ECG shows a polymorphic ventricular extrasystole, which is a concerning finding, but it is not indicative of a high risk of sudden cardiac death. The patient's Pro-BNP level is elevated, indicating some degree of ventricular strain, but it is not extremely high. Considering these factors, the patient's overall prognosis is that they will likely survive the next few years with proper management and treatment.

2. Sudden Cardiac Death
REASONING: 
While the patient's ECG shows a polymorphic ventricular extrasystole, which is a concerning finding, it is not indicative of a high risk of sudden cardiac death. The patient's LVEF is severely impaired, which increases the risk of arrhythmias and sudden cardiac death. However, the patient's current medication regimen includes digoxin, which can help regulate heart rhythm. The patient's Pro-BNP level is elevated, indicating some degree of ventricular strain, but it is not extremely high. The patient's troponin level is within a relatively normal range, indicating no significant myocardial infarction. The patient's TSH level is normal, indicating normal thyroid function. The patient's kidney function is mildly impaired, but it is not severe. The patient's ECG does not show any other concerning findings, such as ventricular tachycardia or non-sustained ventricular tachycardia. Considering these factors, the patient's overall prognosis is that they have a moderate risk of sudden cardiac death, but it is not extremely high.

3. Pump Failure Death
REASONING: 
The patient's severe LVEF of 25% indicates that the patient's left ventricle is severely impaired, which increases the risk of pump failure. The patient's NYHA Class III status indicates that the patient experiences significant symptoms of heart failure, including shortness of breath and fatigue. The patient's elevated creatinine level indicates some degree of kidney impairment, which can further exacerbate the patient's cardiac condition. The patient's Pro-BNP level is elevated, indicating some degree of ventricular strain. The patient's ECG shows a polymorphic ventricular extrasystole, which is a concerning finding. The patient's troponin level is within a relatively normal range, indicating no significant myocardial infarction. However, the patient's kidney function is mildly impaired, and the patient's heart failure symptoms are significant. Considering these factors, the patient's overall prognosis is that they are at high risk of pump failure death, but it is not the most likely outcome."
597,597,P0931,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,34
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 12,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,3
LDL (mmol/L): 1,06
Sodium (mEq/L): 149.0
Pro-BNP (ng/L): 1853.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 21
Troponin (ng/mL): 0,06
TSH (mIU/L): 0,167
Urea (mg/dL): 5,83
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's prognosis is ranked as a survivor due to the following factors:

1. Age: Although the patient is 60 years old, the age itself is not a strong predictor of mortality in this case. However, the presence of advanced heart failure (NYHA Class III) and ischemic dilated cardiomyopathy suggests that the patient's heart is already compromised, which may increase the risk of adverse outcomes.

2. Medications: The patient is taking several medications that are commonly used to treat heart failure, diabetes, and high blood pressure. These medications, such as beta blockers, digoxin, and ACE inhibitors, have been shown to improve survival and reduce hospitalization rates in patients with heart failure.

3. ECG Impression: The ECG results show no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all potential predictors of sudden cardiac death. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles is noted, but it is not a strong predictor of mortality.

4. Biomarkers: The patient's pro-BNP level is elevated, indicating heart failure. However, the troponin level is within normal limits, which suggests that there is no acute myocardial infarction.

5. Laboratory results: The patient's laboratory results show a mild anemia (Hemoglobin 129 g/L), which may be related to their heart failure. The kidney function is slightly impaired (creatinine 90.0 mmol/L), but this is not a significant predictor of mortality.

6. Other factors: The patient's weight and height are not extreme, and the blood pressure is within a relatively normal range. The patient's glucose and lipid levels are also not significantly abnormal.

Given these factors, the patient's overall prognosis is ranked as a survivor. However, it is essential to closely monitor the patient's condition and adjust their treatment plan as needed to minimize the risk of adverse outcomes.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's ECG results show ventricular extrasystoles and polymorphic ventricular extrasystoles, which are potential predictors of sudden cardiac death. However, the patient is taking beta blockers, which can help reduce the risk of sudden cardiac death in patients with heart failure.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF is severely impaired (24.0%), indicating advanced heart failure. The patient's NYHA Class III classification also suggests that they have significant symptoms of heart failure. While the patient is taking medications that can help manage heart failure, the combination of these factors suggests a higher risk of pump failure death."
598,598,P0932,"Age: 61
Gender: Male 
Weight: 76 kg
Height: 169 cm
NYHA Class: III
Blood Pressure: 170/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 46,1
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 8,71
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,6
LDL (mmol/L): 6,05
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 797.0
Protein (g/L): 78,8
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,43
Urea (mg/dL): 4,49
LVEF (%): 49.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient has a high likelihood of survival for the next few years. Here's the reasoning behind this prediction:

1. Age: Although the patient is 61 years old, which is considered elderly, the patient's age alone does not necessarily determine their prognosis. However, it's essential to consider the patient's overall health status and comorbidities.
2. NYHA Class III: The patient has a significant heart failure classification, indicating that they experience symptoms of heart failure, such as shortness of breath, fatigue, and swelling. However, this classification does not necessarily determine the patient's survival rate.
3. Blood Pressure: The patient's blood pressure is elevated at 170/90 mmHg, which increases the risk of cardiovascular events, but it's not extremely high.
4. Past Medical History: The patient has ischemic dilated cardiomyopathy, which is a significant comorbidity. However, the patient is receiving beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and can help manage symptoms and slow disease progression.
5. Lab results: The patient's lab results show elevated creatinine levels, indicating kidney impairment, which can be a complication of heart failure. However, the patient is receiving an ACE inhibitor, which can help alleviate some of this burden.
6. ECG Impression: The patient has ventricular extrasystole, which is a common finding in patients with heart failure. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.
7. Pro-BNP levels: The patient's Pro-BNP levels are elevated, indicating that the patient is experiencing increased ventricular stress, which can be a predictor of adverse outcomes. However, this is not a definitive indicator of mortality.

Considering these factors, I predict that the patient has a relatively high likelihood of survival for the next few years. The patient is receiving optimal medical therapy for their heart failure, and their lab results and ECG impression suggest that they are not at an extremely high risk for sudden cardiac death or pump failure. Therefore, I rank the patient as a survivor."
599,599,P0933,"Age: 71
Gender: Male 
Weight: 66 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 124/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,28
Sodium (mEq/L): 142.0
Protein (g/L): 76
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,15
Urea (mg/dL): 13,64
LVEF (%): 20.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1

REASONING:

Based on the provided patient data, I would rank the patient outcome as a survivor for the next few years. The following factors support this prognosis:

1. Age: Although the patient is 71 years old, which is considered elderly, the patient's age alone does not significantly impact the prognosis in this case.
2. NYHA Class II: The patient's heart failure symptoms are moderate, but not severe, indicating that the patient is still able to perform daily activities with some limitations.
3. Medications: The patient is on a combination of medications, including Amiodarone, Angiotensin II Receptor Blocker, and Statins, which are commonly used to manage heart failure and prevent arrhythmias.
4. ECG Impression: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient does not have a high risk of sudden cardiac death or life-threatening arrhythmias.
5. LVEF: Although the left ventricular ejection fraction (LVEF) is 20%, which is significantly reduced, it is not extremely low, indicating that the patient's heart is still pumping some blood effectively.

However, the patient's past medical history of ischemic dilated cardiomyopathy, dyslipidemia, hypertension, and myocardial infarction increases the risk of cardiac events. The elevated creatinine level (194.0 mmol/L) may indicate some degree of kidney dysfunction, which can be a risk factor for cardiac events.

Overall, while the patient has several risk factors, the presence of medications, a relatively moderate NYHA Class, and the absence of life-threatening arrhythmias suggest that the patient is at moderate risk for cardiac events. Therefore, I rank the patient outcome as a survivor for the next few years."
600,600,P0935,"Age: 46
Gender: Male 
Weight: 79 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 47,2
ALT or GPT (IU/L): 82.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,56
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 272.0
Protein (g/L): 69,7
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 1,67
Urea (mg/dL): 4,99
LVEF (%): 30.0
Medications: Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

This patient is a 46-year-old male with a significant medical history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and cannot pump blood effectively. The patient's left ventricular ejection fraction (LVEF) of 30.0% further indicates severe systolic dysfunction, which is a hallmark of advanced heart failure. The patient's NYHA class II classification also suggests moderate symptoms of heart failure.

The patient's elevated creatinine level (87.0 mol/L) and urea level (4.99 mg/dL) indicate impaired renal function, which is a common complication in patients with heart failure. The elevated liver enzymes (ALT and AST) and low albumin level (47.2 g/L) also suggest liver congestion and possible liver dysfunction.

The patient's blood pressure is 100/60 mmHg, which is within the normal range, but the presence of hypertension in the past medical history may still contribute to the patient's cardiac condition.

The patient is on beta blockers, ACE inhibitors, and a nitrovasodilator, which are standard treatments for heart failure. However, the patient's severe symptoms and low LVEF suggest that these medications may not be sufficient to manage the patient's condition.

The ECG findings, including ventricular extrasystole, are concerning and may indicate an increased risk of arrhythmias, which can be a complication in patients with heart failure.

Given these factors, the patient's prognosis is likely to be a survivor, as they are currently receiving treatment for their condition and have not been reported to have experienced any recent severe cardiac events. However, the patient's underlying condition and the presence of multiple comorbidities suggest that their survival may be limited, and close monitoring and adjustments to their treatment plan will be necessary to manage their condition.

RANKING: 2. Sudden Cardiac Death
REASONING:

The patient's severe heart failure symptoms, low LVEF, and elevated creatinine and urea levels indicate a high risk of cardiac complications, including arrhythmias and sudden cardiac death. The patient's ECG findings, including ventricular extrasystole, also suggest an increased risk of arrhythmias.

The patient's history of myocardial infarction and hypertension also increases their risk of sudden cardiac death. Additionally, the patient's low HDL cholesterol level (0.78 mmol/L) and elevated triglyceride level (not provided) may contribute to an increased risk of cardiovascular events.

RANKING: 3. Pump Failure Death
REASONING:

The patient's severe heart failure symptoms, low LVEF, and elevated creatinine and urea levels suggest a high risk of pump failure. However, the patient is currently receiving treatment for their condition, and their ECG findings do not indicate an immediate risk of arrhythmias or other life-threatening complications.

Given the patient's age, comorbidities, and the presence of heart failure, pump failure death is a possible long-term complication, but it is less likely than sudden cardiac death in the short term."
601,601,P0937,"Age: 67
Gender: Female 
Weight: 64 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 41,2
ALT or GPT (IU/L): 50.0
AST or GOT (IU/L): 41.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,08
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3315.0
Protein (g/L): 66,6
T3 (pg/dL): 0,04
T4 (ng/L): 20
TSH (mIU/L): 1,8
Urea (mg/dL): 9,32
LVEF (%): 64.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's overall clinical presentation and test results suggest that they are likely to survive in the next few years. Here's why:

1. Age: The patient is 67 years old, which is considered elderly. However, the patient's physical activity level is not explicitly mentioned, but the NYHA Class II classification suggests that they are moderately active, which is relatively preserved.

2. Blood pressure: The patient's blood pressure is elevated at 160/90 mmHg, but they are already on beta blockers, which are effective in managing hypertension. The elevated blood pressure is likely under control with medication.

3. Cardiac function: The left ventricular ejection fraction (LVEF) is 64%, which is within the normal range for an elderly individual. This suggests that the patient's heart is functioning relatively well.

4. Electrocardiogram (ECG) results: The ECG shows no signs of ventricular extrasystole, ventricular tachycardia, or non-sustained ventricular tachycardia, which are all potential indicators of cardiac arrhythmias or ischemia. The presence of paroxysmal supraventricular tachycardia (PSVT) is noted, but it is not a life-threatening condition.

5. Laboratory results: The patient's kidney function is slightly elevated (creatinine 105.0 mol/L), but it is not severely impaired. The liver function tests (ALT, AST, and gamma-glutamil transpeptidase) are within normal limits. The patient's electrolytes, including potassium levels, are also within normal limits.

6. Medications: The patient is on multiple medications, including amiodarone, beta blockers, loop diuretics, and an ACE inhibitor, which are all relevant to managing heart failure and hypertension.

Given these factors, the patient's overall clinical presentation and test results suggest that they are likely to survive in the next few years, with a moderate risk of cardiac events. However, close monitoring and follow-up with regular echocardiograms and ECGs are essential to detect any potential cardiac issues early on."
602,602,P0939,"Age: 52
Gender: Male 
Weight: 85 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 104/72 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 7,68
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 11
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 5,3
LDL (mmol/L): 2,25
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 34.0
Protein (g/L): 68
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,08
Urea (mg/dL): 8,82
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, I predict that the patient is most likely to survive for the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient's current NYHA Class II indicates that they have some level of functional impairment, but not severe. The patient's LVEF of 30.0 is also a concern, but it is not extremely low.

The patient's medication regimen, which includes beta blockers, spironolactone, statins, and an ACE inhibitor, suggests that they are receiving optimal medical therapy for their heart failure and other comorbid conditions. The patient's electrolyte levels, including potassium, are also within a relatively normal range.

While the patient's troponin level is elevated, it is within the normal range for a patient with heart failure, and the patient does not have any other signs of acute myocardial infarction. The patient's renal function, as indicated by the creatinine level, is also within a relatively normal range.

The ECG results show no evidence of ventricular tachycardia or other arrhythmias that could indicate a high risk of sudden cardiac death. Overall, while the patient has several risk factors for cardiac events, their current clinical status and treatment plan suggest that they are at lower risk for adverse outcomes.

2. Sudden cardiac death
REASONING:
I predict that the patient is less likely to survive for the next few years due to their history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF of 30.0 is also a concern, as it suggests that their heart is not pumping efficiently.

Additionally, the patient's elevated troponin level, while within the normal range, could indicate some degree of myocardial damage. However, the patient's other laboratory values, including their potassium and creatinine levels, are relatively normal, which suggests that they do not have any other significant underlying conditions that could contribute to cardiac events.

The patient's ECG results show no evidence of ventricular tachycardia or other arrhythmias, but the presence of ventricular extrasystoles is a concern, as it could indicate some degree of cardiac dysfunction.

3. Pump failure death
REASONING:
I predict that the patient is the least likely to survive for the next few years due to their history of ischemic dilated cardiomyopathy and their current NYHA Class II status. The patient's LVEF of 30.0 is a significant concern, as it suggests that their heart is not pumping efficiently, which could lead to heart failure.

Additionally, the patient's elevated creatinine level, while within the normal range for some laboratories, could indicate some degree of renal impairment, which is a common complication of heart failure. The patient's other laboratory values, including their potassium and troponin levels, are relatively normal, but the patient's elevated blood glucose level could contribute to cardiac dysfunction.

The patient's ECG results show no evidence of ventricular tachycardia or other arrhythmias, but the presence of ventricular extrasystoles is a concern, as it could indicate some degree of cardiac dysfunction. Overall, the patient's combination of heart failure, renal impairment, and ventricular extrasystoles make them at higher risk for pump failure."
603,603,P0941,"Age: 64
Gender: Male 
Weight: 81 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 145/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 161.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 189.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,89
Urea (mg/dL): 5,16
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 64-year-old male with a history of idiopathic dilated cardiomyopathy, hypertension, and a NYHA Class II heart failure. His current LVEF is 50.0%, which indicates significant left ventricular dysfunction. Despite this, the patient has been taking medications such as beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure. 

The patient's ECG impression shows ventricular extrasystoles, which is a benign finding, and no ventricular tachycardia or non-sustained ventricular tachycardia. The absence of these potentially life-threatening arrhythmias reduces the risk of sudden cardiac death. 

The patient's renal function is also relatively preserved, with a creatinine level of 5.16 mg/dL, which is not severely elevated. His electrolyte levels, including potassium, are within a relatively normal range, which further suggests that his cardiac function is not severely compromised.

Overall, considering the patient's age, comorbidities, and current treatment, I believe that the patient is most likely to survive for the next few years."
604,604,P0942,"Age: 57
Gender: Male 
Weight: 82 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 126/79 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,89
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,34
Potassium (mEq/L): 5,3
LDL (mmol/L): 3,03
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 74.0
Protein (g/L): 72
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,47
Urea (mg/dL): 5,83
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

Based on the provided patient data, the most likely outcome is survival. The patient is 57 years old, which is considered middle-aged, and has a relatively high NYHA class of II, indicating some limitation in physical activity. However, the patient's ECG impression does not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or other arrhythmias that could increase the risk of sudden cardiac death.

The patient's LVEF is significantly reduced at 30%, which is a strong indicator of poor cardiac function. However, the patient is receiving medications for heart failure management, including beta blockers, digoxin, and spironolactone, which can help alleviate symptoms and improve survival.

The patient's laboratory results show elevated creatinine levels (80.0 mmol/L), indicating impaired renal function, which can be a complication of heart failure. However, the patient's serum electrolytes, liver enzymes, and glucose levels are relatively within normal ranges, which suggests that the patient is not experiencing acute kidney injury or acute liver dysfunction.

The patient's Troponin level is normal, which suggests that there is no significant myocardial infarction. The patient's ECG shows ventricular extrasystoles, which can be a sign of cardiac stress, but it is not a strong predictor of sudden cardiac death.

Overall, while the patient's cardiac function is severely impaired, the patient's overall clinical presentation and laboratory results do not suggest an immediate risk of sudden cardiac death or pump failure death. Therefore, the most likely outcome is survival with continued management of the patient's heart failure and monitoring for any signs of worsening cardiac function."
605,605,P0943,"Age: 71
Gender: Male 
Weight: 70 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 134/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,07
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,61
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient has a significant history of ischemic dilated cardiomyopathy and myocardial infarction, which are risk factors for heart failure and arrhythmias. However, the patient's NYHA class is II, indicating that they are able to perform moderate physical activity without symptoms. The patient's LVEF is 40%, which is within the range of normal for a 71-year-old male. The patient is also taking beta blockers, spironolactone, statins, and an ACE inhibitor, which are standard treatments for heart failure and high blood pressure.

The patient's laboratory results show elevated creatinine levels, indicating some degree of renal impairment, but this is not uncommon in patients with heart failure. The patient's electrolytes, liver enzymes, and glucose levels are within normal limits. The patient's troponin levels are normal, which suggests that there is no active myocardial infarction.

The ECG impression shows ventricular extrasystole, which is a common finding in patients with heart failure and is often seen in patients taking beta blockers. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

Overall, considering the patient's age, medical history, and treatment, the most likely outcome is that the patient will survive for the next few years. The patient's heart failure symptoms are well-managed, and the patient is taking evidence-based treatments for their condition. While there is a risk of arrhythmias and heart failure exacerbation, the patient's overall health status and treatment plan suggest that survival is the most likely outcome."
606,606,P0945,"Age: 57
Gender: Male 
Weight: 115 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 135/99 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 47
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,51
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,7
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 192.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,29
Urea (mg/dL): 7,49
LVEF (%): 39.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient is at a higher risk for pump failure death due to their NYHA Class II status, which indicates mild heart failure symptoms. The patient's LVEF of 39% is significantly below the normal range, indicating severe left ventricular dysfunction. The patient's elevated Creatinine level (88.0 mmol/L) also suggests impaired kidney function, which is often associated with heart failure. The patient's elevated BNP level (192.0 ng/L) is consistent with heart failure. 

The patient's dyslipidemia, high blood pressure, and elevated troponin level (0.03 ng/mL) further increase the risk of cardiac events. However, the patient is currently taking medications that are commonly used to manage heart failure, including angiotensin II receptor blockers, beta blockers, digoxin, and loop diuretics. Despite these medications, the patient's overall clinical presentation and laboratory results suggest that they are at high risk for pump failure death. 

2. Sudden cardiac death
REASONING: 
Although the patient has a high risk for pump failure death, they do not have any specific indications for sudden cardiac death, such as a history of ventricular tachycardia or ventricular fibrillation. The patient's ECG shows only ventricular extrasystoles, which are not necessarily indicative of a high risk for sudden cardiac death. The patient's troponin level is also within a relatively normal range, which is a marker for cardiac damage. 

3. Pump failure death
REASONING: 
Pump failure death is the most likely outcome for this patient due to their severe left ventricular dysfunction (LVEF 39%), elevated BNP level (192.0 ng/L), and NYHA Class II status. The patient's elevated Creatinine level (88.0 mmol/L) and impaired kidney function suggest that the patient's heart failure is likely contributing to their kidney dysfunction. The patient's dyslipidemia, high blood pressure, and elevated troponin level further increase the risk of cardiac events. The patient's current medications, although appropriate for heart failure management, may not be sufficient to reverse the patient's severe left ventricular dysfunction."
607,607,P0946,"Age: 70
Gender: Male 
Weight: 91 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 125/68 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 161
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 155.0
HDL (mmol/L): 0,52
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,36
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1455.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,49
Urea (mg/dL): 15,47
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a moderate level of physical activity, as indicated by a NYHA Class II classification. The patient's age and weight are within normal limits, and the patient is on medications for heart failure, which suggests a moderate level of cardiovascular risk. The patient's blood pressure is well-controlled, and the laboratory results show no significant abnormalities in liver function, kidney function, or electrolytes. The patient's LVEF is significantly reduced, indicating cardiomyopathy, but the patient is still able to maintain a relatively normal hemoglobin level and is not showing signs of severe heart failure. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient's heart is not at high risk for arrhythmias. Overall, these factors suggest that the patient is likely to survive for the next few years with proper management and monitoring."
608,608,P0947,"Age: 63
Gender: Male 
Weight: 72 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 124/76 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes
Albumin (g/L): 45
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 111.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5,1
LDL (mmol/L): 4,47
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 747.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,14
Urea (mg/dL): 11,65
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient's prognosis is ranked as a survivor due to several factors. Firstly, the patient is a male of 63 years, which is a relatively young age for heart failure, and the presence of enolic dilated cardiomyopathy may not be as severe as expected given the patient's age. The patient's NYHA Class II indicates that the patient has some limitations in physical activity but can still perform daily activities with some effort.

The patient's laboratory results show elevated creatinine levels (106.0 mmol/L), which suggests some degree of kidney impairment, but it is not extremely high. The patient's hemoglobin level is 111.0 g/L, which is within the normal range, and the patient is taking medications that are commonly used to manage heart failure, such as beta blockers, digoxin, and spironolactone.

The patient's ECG results show ventricular extrasystoles, which are a type of arrhythmia, but there is no ventricular tachycardia or non-sustained ventricular tachycardia. This suggests that the patient's arrhythmias are not severe and may not be a significant predictor of poor outcome.

The patient's Pro-BNP level is elevated at 747.0 ng/L, which is a marker of cardiac strain, but it is not extremely high. The patient's LVEF is 40.0%, which is within the normal range for a patient with heart failure, indicating that the patient's heart is still pumping effectively.

Overall, the patient's combination of age, NYHA Class II, and the presence of enolic dilated cardiomyopathy, along with the patient's laboratory results and ECG findings, suggests that the patient is likely to survive in the short term. However, the patient's kidney impairment and the presence of ventricular extrasystoles may increase the risk of complications in the future.

RANKING: 2. Sudden cardiac death
REASONING: 
This patient's prognosis is ranked as sudden cardiac death due to the presence of ventricular extrasystoles, which are a type of arrhythmia that can increase the risk of sudden cardiac death. The patient's ECG results show ventricular extrasystoles, which are a type of arrhythmia that can be a predictor of sudden cardiac death.

The patient's LVEF is 40.0%, which is lower than the normal range for a patient with heart failure, indicating that the patient's heart is not pumping effectively. The patient's kidney impairment, as indicated by the elevated creatinine level, may also increase the risk of complications, including sudden cardiac death.

The patient's Pro-BNP level is elevated, which suggests that the patient's heart is under strain. The patient's medication regimen includes digoxin, which can increase the risk of arrhythmias, including ventricular extrasystoles.

RANKING: 3. Pump failure death
REASONING: 
This patient's prognosis is ranked as pump failure death due to the patient's low LVEF (40.0%) and the presence of kidney impairment. The patient's heart is not pumping effectively, which increases the risk of complications, including pump failure.

The patient's NYHA Class II indicates that the patient has some limitations in physical activity, which suggests that the patient's heart is not functioning at optimal levels. The patient's elevated creatinine level and kidney impairment may also increase the risk of complications, including pump failure.

The patient's Pro-BNP level is elevated, which suggests that the patient's heart is under strain. The patient's medication regimen includes loop diuretics, which can help manage fluid overload, but the patient's kidney impairment may limit the effectiveness of these medications.

Overall, the patient's combination of low LVEF, kidney impairment, and the presence of ventricular extrasystoles make pump failure death a possible outcome."
609,609,P0949,"Age: 59
Gender: Male 
Weight: 103 kg
Height: 184 cm
NYHA Class: II
Blood Pressure: 128/78 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 33
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 3,6
LDL (mmol/L): 1,27
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1152.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,38
Urea (mg/dL): 4,49
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
The patient has a complex medical history with multiple comorbid conditions, including ischemic dilated cardiomyopathy, hypertension, and dyslipemia, which increases the risk of cardiac events. However, the patient's current ECG findings, such as ventricular extrasystoles and non-sustained ventricular tachycardia, are not indicative of a high-risk arrhythmia. The patient's LVEF is significantly reduced, indicating severe left ventricular dysfunction. Despite this, the patient's current medication regimen includes ACE inhibitors, which are known to improve outcomes in patients with heart failure.

The patient's biomarkers, such as elevated troponin and BNP, suggest ongoing cardiac stress and strain. However, the patient's hemoglobin and kidney function are relatively preserved, which may indicate a relatively preserved cardiac reserve. The patient's lipid profile is not ideal, but the presence of statins and an ACE inhibitor suggests that the patient is receiving appropriate management for their dyslipidemia and hypertension.

Given these factors, I would rank the patient as having a moderate to high risk for cardiac events. However, the patient's overall clinical status, including their current medication regimen and relatively preserved hemoglobin and kidney function, suggest that they are likely to survive the next few years without significant cardiac events.

RANKING: 2. Sudden Cardiac Death
REASONING: 
While the patient has a high-risk medical history and significant left ventricular dysfunction, the patient's current ECG findings are not indicative of a high-risk arrhythmia. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia may indicate a high risk for arrhythmia-related events, but the patient's medication regimen includes a nitrovasodilator, which may help to reduce the risk of arrhythmias.

The patient's elevated troponin and BNP levels suggest ongoing cardiac stress and strain, which may increase the risk of cardiac events. However, the patient's relatively preserved hemoglobin and kidney function, as well as their current medication regimen, suggest that the patient is receiving appropriate management for their heart failure.

Given these factors, I would rank the patient as having a moderate risk for cardiac events, but this risk is mitigated by the patient's current medication regimen and relatively preserved hemoglobin and kidney function.

RANKING: 3. Pump Failure Death
REASONING: 
Given the patient's significant left ventricular dysfunction, elevated troponin and BNP levels, and elevated creatinine, it is likely that the patient's cardiac function is already compromised. The patient's current ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, may indicate a high risk for arrhythmia-related events, which could further compromise cardiac function.

While the patient's medication regimen includes ACE inhibitors, which are known to improve outcomes in patients with heart failure, the patient's relatively preserved hemoglobin and kidney function suggest that the patient's cardiac reserve is limited. The patient's lipid profile is not ideal, and their elevated triglycerides may further contribute to cardiac dysfunction.

Given these factors, I would rank the patient as having a high risk for pump failure death, as the patient's cardiac function is already compromised, and the patient's underlying medical conditions may further exacerbate cardiac dysfunction."
610,610,P0954,"Age: 57
Gender: Male 
Weight: 109 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 117/87 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,9
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 72.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,9
Urea (mg/dL): 4,82
LVEF (%): 45.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has several factors that suggest a higher likelihood of survival. Firstly, the patient's age of 57 is not considered old, and the patient's NYHA Class II indicates that they have some symptoms of heart failure but are not severely limited in their daily activities. The patient's LVEF of 45.0 is significantly reduced, but it is not an absolute contraindication for survival. The patient's medication regimen includes loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and coronary artery disease.

The patient's laboratory results also show a relatively normal liver function, with only slightly elevated liver enzymes, and normal kidney function, with a creatinine level of 80.0. The patient's lipid profile is also relatively well-controlled, with low LDL and high HDL levels. The patient's glucose level is also within a relatively normal range.

The patient's ECG impression does not show any overt signs of cardiac arrhythmias that would increase the risk of sudden cardiac death. The presence of ventricular extrasystoles is a mild abnormality, but it is not a contraindication for survival. The patient's troponin level is also within normal limits, which suggests that there is no evidence of myocardial infarction.

Overall, based on the patient's clinical presentation, laboratory results, and ECG findings, the most likely outcome is survival."
611,611,P0955,"Age: 59
Gender: Male 
Weight: 94 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 148/79 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 6,57
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 553.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,63
Urea (mg/dL): 9,65
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, the most likely outcome is survival. The patient has a relatively stable medical history, with the presence of ischemic dilated cardiomyopathy, hypertension, and dyslipidemia. The patient's NYHA class is II, indicating mild symptoms of heart failure, which is manageable with current medications. The patient's biomarkers, such as troponin and BNP, are not excessively elevated, suggesting that the heart is not under significant stress. The patient's ECG shows no signs of ventricular tachycardia or polymorphic ventricular extrasystoles, which are red flags for cardiac arrhythmias.

The patient's medication regimen, which includes beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, suggests that the patient is receiving standard treatment for heart failure and hypertension. The patient's laboratory results, such as normal liver enzymes and kidney function, also suggest that the patient's underlying conditions are not severely compromised.

While the patient's LVEF is low at 35%, it is not uncommon in patients with ischemic dilated cardiomyopathy. With proper management, it is possible to improve LVEF and overall cardiac function.

Overall, based on the patient's stable medical history, manageable symptoms, and adequate medication regimen, the most likely outcome is survival."
612,612,P0956,"Age: 80
Gender: Female 
Weight: 64 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,78
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1032.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,31
Urea (mg/dL): 8,15
LVEF (%): 56.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient's prognosis is ranked as a survivor due to several factors. Firstly, the patient's age is 80, but their NYHA class is only II, indicating that they have mild heart failure symptoms. This suggests that the patient's heart function is not severely compromised, which is a positive prognostic indicator. Additionally, the patient's LVEF is 56%, which is still within a relatively normal range for an elderly patient. The patient's blood pressure is also well-controlled at 135/80 mmHg, which reduces the risk of further cardiovascular events.

The patient's laboratory results also show no significant abnormalities that would indicate acute cardiac injury or severe organ dysfunction. The troponin level is within normal limits, and the liver function tests are also within normal limits. The patient's medication regimen, which includes beta blockers, digoxin, loop diuretics, and an ACE inhibitor, is also well-managed, which further supports a favorable prognosis.

While the patient's ECG shows some signs of ventricular extrasystoles, these are not indicative of a high risk of sudden cardiac death. The patient's potassium level is also within a relatively normal range, which reduces the risk of arrhythmias.

Overall, considering these factors, the patient's prognosis is ranked as a survivor, with a reasonable expectation of long-term survival with careful management of their heart failure and hypertension.

2. Sudden Cardiac Death
REASONING: 
This patient's prognosis is ranked as Sudden Cardiac Death due to the presence of ventricular extrasystoles on the ECG. While the patient's overall condition is not severely compromised, the presence of ventricular extrasystoles is a concerning sign that may indicate underlying cardiac instability. These arrhythmias can increase the risk of sudden cardiac death, especially in patients with pre-existing heart conditions such as valvular cardiomyopathy.

While the patient's LVEF is 56%, which is within a relatively normal range, the presence of ventricular extrasystoles suggests that the patient's heart may not be functioning optimally. Additionally, the patient's age is 80, which increases the risk of arrhythmias and sudden cardiac death.

3. Pump Failure Death
REASONING: 
This patient's prognosis is ranked as Pump Failure Death due to the patient's NYHA class II, indicating mild heart failure symptoms. While the patient's LVEF is 56%, which is still within a relatively normal range, the presence of heart failure symptoms suggests that the patient's heart is not functioning optimally. The patient's creatinine level is also elevated at 88.0 mmol/L, indicating some degree of kidney impairment, which can be associated with heart failure.

However, the patient's laboratory results and medication regimen suggest that the patient's heart failure is well-managed, and the patient is not at high risk of sudden cardiac death. The patient's ECG does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death. Overall, while the patient's prognosis is guarded, it is still possible that the patient can be managed to prevent pump failure death."
613,613,P0957,"Age: 70
Gender: Male 
Weight: 66 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 158/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,95
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 3,7
LDL (mmol/L): 3,93
Sodium (mEq/L): 143.0
Protein (g/L): 71
T3 (pg/dL): 0,02
T4 (ng/L): 5
Troponin (ng/mL): 0,03
TSH (mIU/L): 70,54
Urea (mg/dL): 4,33
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I predict that the patient is most likely to survive for the next few years. Here's a breakdown of the reasoning:

1. The patient's age is 70, which is considered advanced age, but the patient's NYHA class is II, indicating that they have some symptoms of heart failure but are still able to perform daily activities with minimal limitation. This suggests that the patient's heart is still functional to some extent.

2. The patient's LVEF (Left Ventricular Ejection Fraction) is 40.0%, which is below the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, the patient's ECG does not show any signs of acute cardiac events such as ventricular tachycardia or non-sustained ventricular tachycardia, which are potential predictors of sudden cardiac death.

3. The patient's troponin level is 0.03 ng/mL, which is within the normal range (0-0.10 ng/mL). Elevated troponin levels are often associated with myocardial infarction, and the absence of this finding suggests that the patient is not currently experiencing acute cardiac events.

4. The patient's medication list includes ACE inhibitors, beta blockers, calcium channel blockers, and statins, which are all evidence-based treatments for heart failure and coronary artery disease. The patient's blood pressure is also within a relatively normal range (158/80 mmHg), which reduces the risk of further cardiovascular events.

5. The patient's laboratory values, including liver function tests, kidney function, and electrolyte levels, are generally within normal ranges, which suggests that the patient's underlying conditions are well-managed.

While the patient's past medical history includes ischemic dilated cardiomyopathy, diabetes, dyslipidemia, and hypertension, these conditions can still pose a risk for future cardiovascular events. However, the patient's current clinical presentation and medication list suggest that they are being well-managed, and the likelihood of sudden cardiac death or pump failure death is relatively low.

Therefore, based on the provided data, I predict that the patient is most likely to survive for the next few years, with a reasonable quality of life and minimal risk of sudden cardiac death or pump failure."
614,614,P0958,"Age: 68
Gender: Male 
Weight: 74 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 117/61 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 33
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,03
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 94.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5,6
LDL (mmol/L): 4,16
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 252.0
Protein (g/L): 52
T3 (pg/dL): 0,02
T4 (ng/L): 5
Troponin (ng/mL): 0,05
TSH (mIU/L): 83,92
Urea (mg/dL): 16,97
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is currently taking multiple medications for their conditions, including a nitrovasodilator, which suggests that their cardiovascular system is being managed to some extent. The presence of a nitrovasodilator indicates that the patient is likely receiving treatment for heart failure symptoms, as these medications are commonly used to alleviate symptoms in patients with heart failure. Additionally, the patient's NYHA class is III, which indicates moderate to severe heart failure.

Although the patient has a history of ischemic dilated cardiomyopathy, their current LVEF is 30%, which is significantly reduced. However, the patient is not currently experiencing any symptoms of acute heart failure, and their current medications appear to be effective in managing their symptoms.

The patient's laboratory results show elevated levels of creatinine and urea, which suggest some degree of renal impairment. However, this is not uncommon in patients with heart failure. The patient's blood pressure is within a relatively normal range, and their electrolyte levels are within acceptable limits.

The ECG findings of ventricular extrasystole and polymorphic ventricular extrasystole are concerning, but the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) may increase the risk of cardiac events, but it is not a contraindication for survival.

Overall, the patient's current medical condition, treatment, and laboratory results suggest that they are likely to survive for the next few years, provided they continue to receive their current treatment and do not experience any significant adverse events.

2. Sudden Cardiac Death
REASONING:
While the patient's ECG findings of ventricular extrasystole and polymorphic ventricular extrasystole are concerning, the absence of ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death. However, the patient's history of ischemic dilated cardiomyopathy and reduced LVEF increase the risk of cardiac events.

The patient's medication regimen is complex, and the presence of multiple medications may increase the risk of adverse interactions or side effects. The patient's elevated creatinine and urea levels also suggest some degree of renal impairment, which may increase the risk of cardiovascular events.

While the patient's current medical condition and treatment suggest that they are stable, the presence of ventricular extrasystole and polymorphic ventricular extrasystole increases the risk of sudden cardiac death. Therefore, this patient is at higher risk of sudden cardiac death than a survivor.

3. Pump Failure Death
REASONING:
The patient's reduced LVEF of 30% indicates significant left ventricular dysfunction, which increases the risk of pump failure. The patient's history of ischemic dilated cardiomyopathy and current NYHA class III symptoms suggest that their heart is not functioning efficiently, and they are at risk of pump failure.

The patient's elevated creatinine and urea levels suggest some degree of renal impairment, which may further increase the risk of pump failure. Additionally, the patient's medications, including the nitrovasodilator, may have diuretic effects that could further reduce blood pressure and increase the risk of pump failure.

While the patient's current medical condition and treatment suggest that they are stable, the presence of significant left ventricular dysfunction and renal impairment increases the risk of pump failure. Therefore, this patient is at higher risk of pump failure than a survivor or sudden cardiac death."
615,615,P0960,"Age: 74
Gender: Female 
Weight: 64 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 141/72 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,9
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 588.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,97
Urea (mg/dL): 11,15
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient is a 74-year-old female with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, she is currently on optimal medical therapy with Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins. Her NYHA Class II indicates that she has some limitation in physical activity, but she is still able to perform daily activities with some effort.

Her laboratory values show elevated creatinine levels (80.0 mmol/L), which suggests some degree of renal impairment. However, her eGFR is not provided, and the creatinine level can be influenced by muscle mass and age. The elevated creatinine level is not uncommon in elderly patients.

The patient's echocardiogram shows a reduced LVEF (25.0%), which is consistent with her history of ischemic dilated cardiomyopathy. However, her ejection fraction is not severely impaired, and she is still able to maintain a relatively normal cardiac output.

The patient's ECG shows ventricular extrasystoles, which are common in patients with ischemic dilated cardiomyopathy. However, there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia.

Given these factors, the patient's overall risk for cardiac events is moderate. However, her age and sex are not as high-risk as those of a male patient of the same age. Her optimal medical therapy and relatively preserved cardiac function also contribute to her favorable prognosis.

Therefore, the most likely outcome for this patient over the next few years is a survivor, with a moderate risk of cardiac events. The probability of sudden cardiac death and pump failure death are lower due to her optimal medical therapy, relatively preserved cardiac function, and age."
616,616,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient's overall prognosis is predicted to be a survivor for the next few years. The key factors contributing to this prediction are:

1. The patient's age (55) is not considered old, and the patient's NYHA Class II indicates that they are still relatively active and do not have severe symptoms of heart failure.
2. The patient has a relatively preserved LVEF of 40%, which suggests that the left ventricle is still functioning to some extent, despite the patient's dilated cardiomyopathy.
3. The patient's troponin levels (0.03 ng/mL) are within normal limits, indicating no significant myocardial damage or infarction.
4. The patient's medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilator, suggests that the patient is receiving optimal treatment for their heart failure and hypertension.
5. The patient's ECG impression shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all potential predictors of sudden cardiac death.
6. The patient's creatinine level (6.82 mg/dL) is elevated, but this is likely due to renal impairment rather than cardiac dysfunction.

While the patient has several comorbidities, including peripheral vascular disease, hypertension, and dyslipidemia, their overall clinical presentation and treatment plan suggest that they are at lower risk for sudden cardiac death or pump failure over the next few years."
617,617,P0964,"Age: 81
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 2,48
Potassium (mEq/L): 5
LDL (mmol/L): 1,5
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 2733.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,8
Urea (mg/dL): 10,31
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient's prognosis as a survivor. The patient's age is 81, which is a significant risk factor for cardiac events, but it's not the sole determining factor. The patient's NYHA Class II indicates that they have some limitations in physical activity, but they are not severely limited.

The patient's medical history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia suggests a history of cardiovascular disease, but the patient is already on medications to manage these conditions, including statins, loop diuretics, and a calcium channel blocker. The presence of elevated troponin levels (0.03 ng/mL) indicates some degree of cardiac damage, but it is not significantly elevated.

The patient's LVEF is 70%, which is slightly below the normal range (typically > 55%), but it is not severely impaired. The patient's ECG shows no evidence of ventricular tachycardia, which is a significant risk factor for sudden cardiac death.

The patient's renal function is mildly impaired, with a creatinine level of 10.31 mg/dL, but this is not a significant risk factor for cardiac events.

The patient's liver function tests are within normal limits, and the patient's electrolyte levels are mostly within normal limits.

The patient's Pro-BNP level is elevated at 2733 ng/L, which suggests some degree of ventricular stress and possible heart failure, but the patient is already on medications to manage this condition.

Considering these factors, I believe the patient is at a higher risk of experiencing cardiac events, but the overall clinical picture suggests that the patient is likely to survive the next few years with careful management of their medications and lifestyle modifications. Therefore, I rank the patient's prognosis as a survivor."
618,618,P0969,"Age: 75
Gender: Male 
Weight: 91 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 74
Glucose (mmol/L): 14,5
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4
LDL (mmol/L): 1,58
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3298.0
Protein (g/L): 70
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 6,45
Urea (mg/dL): 6,49
LVEF (%): 47.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor 
REASONING: 

This patient has a complex medical history with idiopathic dilated cardiomyopathy, diabetes, and hypertension. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 47%, indicating a compromised cardiac function. The presence of ventricular extrasystole on the ECG impression suggests an increased risk of arrhythmias, which is a common complication in patients with cardiomyopathy. However, the patient's current medication regimen, which includes beta blockers and ACE inhibitors, is standard therapy for managing heart failure and hypertension. The patient's biomarkers, such as troponin and creatinine, are also within relatively normal limits, suggesting that the patient's cardiac function is not severely compromised at this time.

The patient's age, weight, and blood pressure are also relatively stable, which suggests that the patient is not experiencing any acute decompensation. The patient's protein and albumin levels are also within normal limits, indicating that the patient is not experiencing significant malnutrition or fluid overload.

Given the patient's current medical history, medication regimen, and stable biomarkers, the most likely outcome is that the patient will survive for the next few years. The presence of ventricular extrasystole on the ECG impression does increase the risk of arrhythmias, but the patient's current medication regimen and stable biomarkers suggest that this risk is manageable. Therefore, I would rank the patient as a survivor."
619,619,P0970,"Age: 66
Gender: Male 
Weight: 66 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 84/49 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,95
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2694.0
Protein (g/L): 73
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,63
Urea (mg/dL): 10,15
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's data suggests a high risk for adverse cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac complications. The elevated LVEF of 17% indicates severe left ventricular dysfunction, which is associated with a poor prognosis. The patient's NYHA Class II indicates moderate symptoms of heart failure, which further increases the risk of adverse outcomes.

The patient's biomarkers, such as elevated Troponin (0.01 ng/mL) and Pro-BNP (2694 ng/L), indicate some level of cardiac stress and strain. The patient's lipid profile is also concerning, with high total cholesterol (4.97 mmol/L) and LDL cholesterol (2.95 mmol/L), which contribute to cardiovascular risk.

The patient's medications, including beta blockers, loop diuretics, statins, and ACE inhibitors, are standard treatments for heart failure and cardiovascular risk reduction. However, the patient's medications may not be sufficient to mitigate the risks associated with their underlying heart condition.

The ECG findings of ventricular extrasystole and polymorphic ventricular tachycardia are concerning and indicate an increased risk of arrhythmic complications. The patient's hemoglobin level of 148 g/L is also elevated, which may be related to anemia or other factors.

Considering these factors, I would rank the patient's prognosis as a survivor, with a high risk of adverse cardiac events, including sudden cardiac death, pump failure, or other cardiovascular-related complications."
620,620,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient's prognosis is ranked as a survivor due to the presence of several factors that suggest a relatively stable and manageable condition. Firstly, the patient's LVEF (left ventricular ejection fraction) is 56%, which is within the normal range, indicating that the patient's heart is still pumping efficiently. Additionally, the patient's ECG impression shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which are all potential predictors of cardiac arrest or sudden cardiac death.

The patient's medication regimen is also well-managed, with a combination of beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for managing heart failure and hypertension. The patient's laboratory results, including low troponin levels and normal TSH, further support the presence of a relatively stable condition.

However, the patient's NYHA Class III status indicates that they have significant heart failure symptoms, which may limit their physical activity and overall quality of life. Additionally, the patient's elevated creatinine levels (106.0 mmol/L) and urea levels (8.99 mg/dL) suggest some degree of renal impairment, which may impact their overall health and increase their risk of complications.

Overall, while this patient's condition is serious, the presence of a well-managed medication regimen, normal LVEF, and the absence of high-risk ECG findings suggest that the patient is likely to survive for the next few years, provided they continue to adhere to their treatment plan and make lifestyle modifications to manage their underlying conditions.

RANKING: 2. Pump failure death
REASONING: 

This patient's prognosis is ranked as pump failure death due to their significant heart failure symptoms, as indicated by their NYHA Class III status. The patient's elevated creatinine and urea levels also suggest some degree of renal impairment, which may be related to their heart failure. Furthermore, the patient's LVEF of 56% is at the lower end of the normal range, indicating that their heart is not pumping efficiently.

The patient's elevated blood pressure (150/90 mmHg) and high LDL cholesterol (3.7 mmol/L) also increase their risk of cardiovascular events, including heart failure exacerbation and pump failure. The patient's elevated Pro-BNP levels (104.0 ng/L) also suggest that their heart is under strain, which may lead to pump failure.

While the patient's medication regimen is well-managed, the presence of significant heart failure symptoms and underlying conditions such as hypertension, diabetes, and dyslipidemia increase their risk of pump failure. If left unmanaged, these factors may lead to a decline in the patient's overall health and increase their risk of pump failure.

RANKING: 3. Sudden cardiac death
REASONING: 

This patient's prognosis is ranked as sudden cardiac death due to the presence of several high-risk factors, including their NYHA Class III status, elevated blood pressure, and elevated LDL cholesterol. The patient's ECG impression also shows a polymorphic ventricular extrasystole, which is a potential indicator of a high risk of sudden cardiac death.

Additionally, the patient's elevated troponin levels (0.01 ng/mL) and TSH (49.17 mIU/L) suggest some degree of cardiac stress, which may increase their risk of sudden cardiac death. The patient's low HDL cholesterol (1.14 mmol/L) also increases their risk of cardiovascular events.

While the patient's medication regimen is well-managed, the presence of these high-risk factors and the patient's underlying conditions such as hypertension, diabetes, and dyslipidemia increase their risk of sudden cardiac death. If left unmanaged, these factors may lead to a sudden and unexpected cardiac event."
621,621,P0973,"Age: 51
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,72
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 80.0
Protein (g/L): 74
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,68
Urea (mg/dL): 3,83
LVEF (%): 41.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 1. Survivor
REASONING: 
This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, dyslipidemia, hypertension, and myocardial infarction. However, the patient is currently on medications that are standard for managing these conditions, such as beta blockers, loop diuretics, and an ACE inhibitor.

The patient's ECG findings are also concerning, with ventricular extrasystoles, non-sustained ventricular tachycardia, and second-degree AV block. However, the absence of sustained ventricular tachycardia and the presence of a relatively low troponin level suggest that the patient's cardiac function is not severely compromised at the moment.

The patient's renal function is also relatively preserved, with a creatinine level of 3.83 mg/dL, which is not indicative of severe kidney dysfunction. The patient's albumin level is slightly low, but this could be related to the patient's heart failure rather than kidney disease.

Considering these factors, the patient's overall prognosis is likely to be a survivor. The patient's comorbidities and ECG findings do pose a risk, but the patient is currently on effective medications and does not appear to be in acute distress. With close monitoring and management, the patient has a reasonable chance of survival.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's ECG findings are concerning, the absence of sustained ventricular tachycardia and the patient's relatively preserved cardiac function make sudden cardiac death less likely. However, the patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death.

The patient's troponin level is low, which suggests that there has not been a recent myocardial infarction. However, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia suggests that the patient's heart is not functioning normally.

RANKING: 3. Pump failure death
REASONING: 
Given the patient's history of ischemic dilated cardiomyopathy and the presence of ventricular extrasystoles and non-sustained ventricular tachycardia, pump failure is a possible risk. However, the patient's relatively preserved LVEF of 41% suggests that the patient's cardiac function is not severely compromised.

The patient's ECG findings, particularly the second-degree AV block, suggest that the patient's heart is not functioning normally, but the patient is still on medications that can help manage heart failure. The patient's albumin level is slightly low, but this could be related to the patient's heart failure rather than kidney disease.

Overall, while pump failure is a risk, the patient's current condition and the presence of effective medications make it less likely than sudden cardiac death."
622,622,P0976,"Age: 66
Gender: Male 
Weight: 68 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,36
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4
LDL (mmol/L): 1,24
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 652.0
Protein (g/L): 74
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,13
Urea (mg/dL): 4,82
LVEF (%): 32.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
This patient has a complex medical history, including ischemic dilated cardiomyopathy, hypertension, diabetes, and a history of myocardial infarction. However, the patient is currently on multiple medications, including ACE inhibitors, beta blockers, and statins, which are all known to be beneficial in managing heart failure and reducing mortality. The patient's left ventricular ejection fraction (LVEF) is 32%, which is significantly reduced, but not critically low. The patient's troponin levels are normal, indicating no acute myocardial infarction. The patient's creatinine levels are elevated, but not severely so, suggesting some residual renal function. The patient's ECG shows no signs of ventricular tachycardia or arrhythmias, and the patient has a mild elevation in Pro-BNP, but not to an extreme degree. Overall, the patient's clinical presentation and laboratory results suggest that they are likely to survive for the next few years with proper management and monitoring.

2. Sudden Cardiac Death
REASONING: 
While the patient has a significant medical history, there are no obvious indications of an acute cardiac event or a high risk of sudden cardiac death. The patient's ECG shows no signs of ventricular tachycardia or arrhythmias, and the troponin levels are normal. However, the patient's LVEF is significantly reduced, and the patient has a history of myocardial infarction, which increases the risk of sudden cardiac death. Additionally, the patient's hypertension and diabetes may increase the risk of cardiac arrhythmias. However, the patient's current clinical presentation and laboratory results do not suggest an immediate risk of sudden cardiac death.

3. Pump Failure Death
REASONING: 
The patient's LVEF is significantly reduced, indicating a reduced cardiac output and potential pump failure. The patient's creatinine levels are elevated, suggesting impaired renal function, which may be related to the patient's cardiac dysfunction. The patient's Pro-BNP levels are elevated, indicating fluid overload and potential heart failure. The patient's hypertension and diabetes may also contribute to cardiac dysfunction and pump failure. However, the patient is currently on multiple medications, including ACE inhibitors, beta blockers, and statins, which are known to be beneficial in managing heart failure. While the patient's clinical presentation and laboratory results suggest some risk of pump failure, it is not the most likely outcome given the patient's current management and monitoring."
623,623,P0977,"Age: 68
Gender: Female 
Weight: 95 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 107.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,73
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3701.0
Protein (g/L): 71
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,21
Urea (mg/dL): 17,97
LVEF (%): 33.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, I would rank the patient as having a high likelihood of survival over the next few years. The following factors contribute to this assessment:

1. Age: Although the patient is 68 years old, the age alone is not a contraindication for survival. Many patients with heart failure and other comorbidities can live for several years with proper management.

2. NYHA Class II: This indicates that the patient has mild to moderate symptoms, which suggests that the disease is not as advanced as it could be.

3. Low LVEF (33%): A reduced left ventricular ejection fraction (LVEF) is a significant indicator of heart failure, but in this case, it is not extremely low. A more severe reduction in LVEF (e.g., less than 20%) would be a more concerning sign.

4. Medications: The patient is already on several medications, including calcium channel blockers, beta blockers, and loop diuretics, which are standard treatments for heart failure and hypertension. This suggests that the patient is receiving appropriate therapy.

5. Electrocardiogram (ECG) results: While the patient has ventricular extrasystoles, they are polymorphic and not sustained ventricular tachycardia, which is a more concerning sign. The absence of non-sustained ventricular tachycardia (CH>10) is also reassuring.

6. Biomarkers: The elevated Pro-BNP level (3701.0 ng/L) suggests some degree of heart failure, but it is not extremely high. The Troponin level is within normal limits, which suggests that there is no significant myocardial infarction or acute cardiac damage.

7. Laboratory values: The patient's laboratory values, such as creatinine (115.0 mmol/L), urea (17.97 mg/dL), and potassium (5.2 mEq/L), are not excessively elevated, which could indicate kidney or electrolyte imbalances.

Considering these factors, I believe that the patient has a relatively good prognosis and is likely to survive over the next few years with proper management and follow-up."
624,624,P0980,"Age: 67
Gender: Male 
Weight: 77 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,5
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,66
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Protein (g/L): 74,9
T4 (ng/L): 18
TSH (mIU/L): 1,33
Urea (mg/dL): 10,65
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is a 67-year-old male with a history of ischemic dilated cardiomyopathy, which significantly reduces the heart's ability to pump blood effectively. The low left ventricular ejection fraction (LVEF) of 40.0% further supports this. Additionally, the patient has a history of myocardial infarction, which can lead to further damage to the heart muscle. The presence of ventricular extrasystoles on the ECG, although not sustained, indicates some degree of electrical instability in the heart.

Despite this, the patient is currently on a regimen of medications that aim to manage symptoms and slow disease progression. The use of an angiotensin II receptor blocker, loop diuretics, spironolactone, statins, and a nitrovasodilator suggests a comprehensive approach to managing heart failure and reducing cardiovascular risk factors.

The patient's laboratory values are also relatively stable, with no significant elevations in liver enzymes (ALT and AST) or kidney function (creatinine). The hemoglobin level is within normal limits, and the patient's lipid profile shows a relatively low LDL level.

Given these factors, I would predict that the patient has a higher likelihood of survival over the next few years, as the patient is receiving optimal medical therapy and has a relatively stable clinical status. The presence of ventricular extrasystoles on the ECG may require close monitoring, but the overall prognosis is still favorable.

RANKING: 2. Sudden Cardiac Death
REASONING: 

While the patient has a history of ischemic dilated cardiomyopathy and ventricular extrasystoles on the ECG, the patient is currently receiving optimal medical therapy and has a relatively stable clinical status. The presence of ventricular extrasystoles, although concerning, does not necessarily indicate an immediate risk of sudden cardiac death.

However, the patient's low LVEF and history of myocardial infarction do increase the risk of sudden cardiac death. Additionally, the patient's age and other comorbidities, such as dyslipidemia and hypertension, also contribute to this risk.

Given the patient's stable clinical status and the absence of other high-risk features, such as a history of ventricular tachycardia or significant arrhythmias, the risk of sudden cardiac death is moderate but not extremely high.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's low LVEF of 40.0% and history of ischemic dilated cardiomyopathy indicate a significant impairment of the heart's pumping function. The patient's current treatment regimen, while comprehensive, may not be sufficient to completely reverse the underlying disease process.

The patient's laboratory values, including the elevated creatinine level, suggest some degree of kidney impairment, which may be related to the patient's cardiac disease. Additionally, the patient's dyslipidemia and hypertension may contribute to further cardiovascular risk.

Given the patient's age, history of myocardial infarction, and impaired LVEF, the risk of pump failure death is moderate to high. The patient's ventricular extrasystoles on the ECG may be an indicator of the heart's increased workload and potential for further deterioration."
625,625,P0982,"Age: 73
Gender: Female 
Weight: 89 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 39,7
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,43
Sodium (mEq/L): 142.0
Protein (g/L): 63,4
T4 (ng/L): 21
TSH (mIU/L): 0,18
Urea (mg/dL): 7,32
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient is at a relatively high risk for cardiac events due to several factors. The patient's age (73) and NYHA Class II heart failure classification indicate a significant burden of cardiovascular disease. The elevated creatinine level (71.0 mmol/L) suggests some degree of renal impairment, which is a known risk factor for cardiovascular disease.

The patient's lipid profile shows elevated total cholesterol (4.63 mmol/L) and LDL cholesterol (2.43 mmol/L), which increases the risk of atherosclerotic cardiovascular disease. The presence of dyslipemia and other HF etiology in the past medical history further exacerbates the risk.

The LVEF of 55.0% is below the normal range, indicating some degree of left ventricular dysfunction. The presence of ventricular extrasystoles (polymorphic) on the ECG suggests an increased risk of arrhythmias, which can lead to sudden cardiac death.

However, the patient is already on beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, which are standard treatments for heart failure and cardiovascular risk reduction. These medications help to manage the patient's cardiovascular risk factors and slow disease progression.

Considering these factors, the patient's overall prognosis is relatively favorable, and they are likely to survive for the next few years with proper management and monitoring. However, close follow-up and adjustments to their treatment plan may be necessary to mitigate the risk of cardiac events."
626,626,P0984,"Age: 58
Gender: Male 
Weight: 58 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 37,3
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 133
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,76
Sodium (mEq/L): 143.0
Protein (g/L): 62,1
T4 (ng/L): 16
TSH (mIU/L): 1,71
Urea (mg/dL): 6,49
LVEF (%): 51.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 58-year-old male with a history of ischemic dilated cardiomyopathy, dyslipidemia, and myocardial infarction. He has a left ventricular ejection fraction (LVEF) of 51%, indicating decreased cardiac function. The patient's ECG shows ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia, which are all indicative of arrhythmias. Despite these concerning findings, the patient is currently on beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, which are all standard treatments for managing heart failure and arrhythmias. The patient's hemoglobin level is within a normal range, and his kidney function is also relatively preserved, as indicated by a creatinine level of 6.49 mg/dL.

The patient's overall clinical presentation and laboratory results suggest that he is currently stable, and his treatment regimen is well-managed. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles may indicate some risk of arrhythmic events, but the patient's overall prognosis is still favorable, and it is likely that he will survive for the next few years.

While the patient's LVEF is low, it is not severely impaired, and his medications are aimed at improving cardiac function and reducing the risk of arrhythmic events. The patient's ECG findings are not indicative of acute life-threatening arrhythmias, and his laboratory results are relatively stable. Therefore, based on the available information, the most likely prognosis for the next few years is that the patient will survive."
627,627,P0988,"Age: 68
Gender: Female 
Weight: 67 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 195/85 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 40,9
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 57.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,52
Sodium (mEq/L): 140.0
Protein (g/L): 74
T4 (ng/L): 16
TSH (mIU/L): 2,74
Urea (mg/dL): 4,66
LVEF (%): 52.0
Medications: Diabetes Medication, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has several risk factors for adverse cardiac events, but the overall clinical presentation and the fact that they have been classified as a ""survivor"" in the PATIENT OUTCOME field suggest that they are likely to survive for the next few years. The presence of hypertension (BP 195/85 mmHg) is a significant risk factor for cardiovascular disease, but the patient is already on loop diuretics, which is a standard treatment for managing hypertension. The patient also has a history of hypertrophic cardiomyopathy, which can increase the risk of arrhythmias, but the ECG impression does not show any overt signs of ventricular tachycardia or ventricular extrasystoles.

The patient's laboratory results are also relatively stable, with normal liver enzymes and a low creatinine level. The patient's lipid profile is also not excessively high, with total cholesterol at 5.3 mmol/L. The patient's hemoglobin level is slightly elevated, which may be due to anemia or polycythemia, but this is not directly related to cardiac function.

The most significant risk factor in this case is the patient's NYHA Class II heart failure, which indicates that they have some limitation in physical activity due to heart failure symptoms. However, the fact that they are classified as a ""survivor"" suggests that they are likely to receive adequate medical management and follow-up, which would help to manage their heart failure symptoms and prevent further decline.

Overall, based on the available information, I would rank the patient as having a high likelihood of survival for the next few years."
628,628,P0991,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,2
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 73.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 143.0
Protein (g/L): 78,6
T4 (ng/L): 15
TSH (mIU/L): 1,28
Urea (mg/dL): 7,99
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING: 
The patient has a significant cardiovascular history of Hypertensive cardiomyopathy, which is a condition that can lead to heart failure and arrhythmias. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 35%, indicating significant left ventricular dysfunction. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG impression further increases the risk of arrhythmic events. However, the patient is already taking multiple medications, including beta blockers, ACE inhibitors, and spironolactone, which are commonly used to manage hypertension, heart failure, and arrhythmias. Despite these medications, the patient's NYHA class II indicates some limitation of physical activity, suggesting that the patient's heart function is not optimal. However, the patient's age, weight, and other laboratory values do not suggest any acute or severe conditions that would immediately threaten the patient's life.

2. Sudden Cardiac Death
REASONING: 
While the patient has a high risk of arrhythmic events due to the presence of NSVT and polymorphic ventricular extrasystoles, the patient's overall clinical picture does not suggest a sudden cardiac death (SCD) event. The patient's LVEF is severely reduced, but the patient is already taking multiple medications to manage hypertension, heart failure, and arrhythmias. The patient's laboratory values, including the serum creatinine level, are also not indicative of acute kidney injury or other conditions that could contribute to SCD. Additionally, the patient's age and weight do not increase the risk of SCD.

3. Pump Failure Death
REASONING: 
Pump failure death is a possible outcome for patients with severe left ventricular dysfunction, but the patient's NYHA class II indicates that the patient is not in acute heart failure. While the patient's LVEF is severely reduced, the patient is already taking medications to manage heart failure, and the patient's laboratory values do not suggest acute kidney injury or other conditions that could contribute to pump failure. The patient's ECG impression does not suggest any signs of severe ventricular dysfunction or acute coronary syndrome that would increase the risk of pump failure. Therefore, pump failure death is the least likely outcome in this scenario."
629,629,P0992,"Age: 72
Gender: Male 
Weight: 95 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,87
Sodium (mEq/L): 142.0
Protein (g/L): 70,5
T4 (ng/L): 14
TSH (mIU/L): 1,04
Urea (mg/dL): 5,66
LVEF (%): 37.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:

The patient's prognosis is ranked as a survivor due to the following factors:

- Age: While the patient is 72 years old, this is not uncommon for a male patient presenting with cardiomyopathy and heart failure. Age alone is not a strong predictor of mortality.
- NYHA Class III: The patient's New York Heart Association (NYHA) Class III indicates severe heart failure, but this is not a contraindication to survival. Many patients with NYHA Class III heart failure can survive with proper management.
- Medications: The patient is taking a calcium channel blocker, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for heart failure and ischemic cardiomyopathy. These medications can help manage symptoms and improve survival.
- ECG Impression: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.
- Biomarkers: The patient's LVEF (37.0) is significantly reduced, indicating poor left ventricular function. However, this does not necessarily determine survival. With proper management, some patients with reduced LVEF can survive.
- Other laboratory values: The patient's electrolyte and liver function tests are within normal limits, and the patient's creatinine level is elevated but not excessively high.

However, the patient's overall prognosis is still uncertain, and there are potential risks of sudden cardiac death and pump failure. The patient's NYHA Class III heart failure, reduced LVEF, and ischemic cardiomyopathy increase the risk of complications. Close monitoring and careful management are necessary to optimize the patient's survival.

While the patient is at risk, the presence of certain factors, such as the patient's age, the effectiveness of the patient's medications, and the absence of life-threatening arrhythmias, contribute to a relatively favorable prognosis. Therefore, the patient is more likely to survive than to experience sudden cardiac death or pump failure."
630,630,P0996,"Age: 58
Gender: Male 
Weight: 97 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,5
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Protein (g/L): 67,7
T4 (ng/L): 19
TSH (mIU/L): 1,53
Urea (mg/dL): 5,66
LVEF (%): 29.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history, with multiple comorbidities such as ischemic dilated cardiomyopathy, diabetes, and dyslipemia. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 29.0%, indicating severe systolic dysfunction. However, the patient is currently taking beta blockers and statins, which are standard treatments for heart failure and cholesterol management.

The patient's laboratory values are also concerning, with elevated creatinine levels (72.0 mmol/L) and a low albumin level (41.5 g/L). The patient's glucose level is slightly elevated (7.8 mmol/L), which may be indicative of poor glycemic control. The patient's potassium level (4.8 mEq/L) is also slightly elevated, which may be related to the patient's kidney function.

Despite these concerning factors, the patient's ECG impression is normal, and there is no indication of ventricular tachycardia or other arrhythmias. The patient's overall clinical presentation and laboratory values suggest that the patient is at high risk for cardiac events, but the absence of any acute life-threatening arrhythmias or other red flags suggests that the patient may be able to survive the next few years with close monitoring and management.

The patient's weight and height are also not particularly concerning, and the patient's hemoglobin level is within a normal range. 

Overall, based on the patient's complex medical history and laboratory values, the most likely prognosis is that the patient will survive the next few years with proper management and monitoring. However, the patient will require close follow-up to monitor for signs of worsening cardiac function, kidney disease, or other complications."
631,631,P0998,"Age: 68
Gender: Male 
Weight: 82 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 44,3
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,41
Sodium (mEq/L): 146.0
Protein (g/L): 71,8
T4 (ng/L): 21
TSH (mIU/L): 0,78
Urea (mg/dL): 6,32
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's overall health status is relatively stable, with a NYHA Class II heart failure classification, which suggests a moderate level of heart failure. However, the patient is not in a severe state of heart failure, and the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient's cardiac rhythm is relatively stable. The patient's blood test results are also relatively normal, with no significant elevation in liver enzymes, kidney function, or electrolyte levels. The patient's medication regimen, which includes a calcium channel blocker and beta blockers, is typical for managing heart failure and controlling blood pressure. 

Considering these factors, the patient's overall prognosis is likely to be favorable, with a high likelihood of survival for the next few years. The patient's age, weight, and height are also relatively healthy, which further supports this prognosis.

While the patient's LVEF is slightly below the normal range, it is still within a relatively normal range, and the patient's overall health status and medication regimen suggest that this is not a significant concern. Therefore, the patient's prognosis is ranked as a survivor, with a high likelihood of survival for the next few years. 

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the patient's stable health status, normal blood test results, and effective medication regimen. However, it is essential to closely monitor the patient's condition and adjust the treatment plan as needed to ensure the best possible outcome."
632,632,P0999,"Age: 67
Gender: Male 
Weight: 88 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 39,6
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,99
Sodium (mEq/L): 139.0
Protein (g/L): 76,5
T4 (ng/L): 14
TSH (mIU/L): 0,84
Urea (mg/dL): 10,48
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient's overall clinical presentation and test results suggest a high risk of adverse cardiac events. The patient has a history of valvular cardiomyopathy, which is a significant risk factor for cardiac complications. The elevated creatinine level (104.0 mmol/L) indicates impaired renal function, which can be a consequence of cardiac disease. Additionally, the patient's low left ventricular ejection fraction (LVEF) of 25.0% is indicative of reduced cardiac function.

The patient's ECG findings, including ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, suggest a high risk of arrhythmias, which can lead to sudden cardiac death. The patient's NYHA Class II indicates moderate symptoms, suggesting some impairment of physical activity.

The patient's current medications, including beta blockers and statins, are generally considered to be beneficial for managing cardiac risk factors. However, the presence of diabetes, dyslipemia, and peripheral vascular disease also contribute to the overall risk of adverse outcomes.

Considering these factors, the patient's prognosis is most likely to be a survivor, as the patient is already receiving medical therapy and has a relatively stable clinical presentation. However, the patient's cardiac risk factors and ECG findings suggest that close monitoring and adjustments to their treatment plan may be necessary to mitigate the risk of adverse cardiac events.

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the patient's relatively stable clinical presentation and the presence of some protective effects from their current medications."
633,633,P1002,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,46
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 305.0
Protein (g/L): 66
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,306
Urea (mg/dL): 10,31
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:
The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction indicate a significant history of cardiovascular disease. However, the patient's current blood pressure is well-controlled (120/70 mmHg), and they are on beta blockers, which are beneficial for heart failure management.

The patient's laboratory results show elevated creatinine levels (62.0 mmol/L), indicating some degree of renal impairment, but it is not severe. The elevated Pro-BNP level (305.0 ng/L) suggests some level of ventricular stress and possible heart failure. However, the patient's LVEF (48.0%) is not severely impaired, and the Troponin level is within normal limits.

The ECG results show ventricular extrasystoles, but no ventricular tachycardia or other arrhythmias. This suggests that the patient's heart is still functioning to some extent.

Considering these factors, the patient's overall condition seems to be stable, and with proper management, it is likely that the patient will survive for the next few years.

2. Sudden Cardiac Death
REASONING:
The patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and diabetes increases their risk of sudden cardiac death. The elevated Pro-BNP level and slightly elevated creatinine level also suggest some degree of cardiac dysfunction.

However, the patient's LVEF is not severely impaired, and the Troponin level is within normal limits, which reduces the risk of sudden cardiac death. The ECG results do not show any arrhythmias, which is a crucial factor in sudden cardiac death.

While the patient's history and laboratory results are concerning, the absence of severe cardiac dysfunction and arrhythmias make sudden cardiac death less likely.

3. Pump Failure Death
REASONING:
The patient's LVEF (48.0%) is significantly impaired, indicating some degree of heart failure. The elevated Pro-BNP level and slightly elevated creatinine level suggest that the patient's heart is working harder to compensate for the reduced cardiac function.

The patient's history of ischemic dilated cardiomyopathy, diabetes, and hypertension also increases the risk of heart failure. The presence of ventricular extrasystoles on the ECG suggests that the patient's heart is experiencing some level of stress.

Given the patient's impaired LVEF and the presence of heart failure indicators, pump failure death is a possible outcome, but it is less likely than sudden cardiac death due to the absence of arrhythmias on the ECG."
634,634,P1011,"Age: 69
Gender: Female 
Weight: 66 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,22
Sodium (mEq/L): 140.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,6
Urea (mg/dL): 7,65
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, the patient is a 69-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition that can lead to heart failure. The patient's left ventricular ejection fraction (LVEF) is 40%, which is significantly below the normal range, indicating poor cardiac function. However, the patient's current hemoglobin level of 145.0 g/L and normal sodium level of 140.0 mEq/L suggest that the patient is not experiencing acute kidney injury or severe anemia, which could be contributing factors to cardiac decompensation.

The patient is on beta blockers, loop diuretics, statins, and ACE inhibitors, which are standard treatments for managing heart failure and reducing the risk of cardiovascular events. The patient's troponin level is normal, which suggests that there is no evidence of acute myocardial infarction.

The ECG impression does not show any signs of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are all potential indicators of increased cardiovascular risk. The presence of ventricular extrasystoles, although concerning, is not a contraindication for survival.

Given these factors, the most likely outcome for this patient over the next few years is survival, as the patient appears to be well-managed with current medications and does not show any acute signs of cardiac decompensation."
635,635,P1013,"Age: 82
Gender: Male 
Weight: 52 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 170/100 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,18
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 141.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,79
Urea (mg/dL): 11,32
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

The patient is 82 years old with a history of valvular cardiomyopathy, which is a significant risk factor for cardiac complications. However, the patient's NYHA Class II indicates that they have some limitations in their physical activity but are still able to carry out daily activities without severe symptoms. The patient's blood pressure is elevated at 170/100 mmHg, which is a concern but can be managed with medications.

The patient's laboratory results show elevated creatinine levels (97.0 mmol/L) and a low albumin level (43 g/L), indicating possible renal impairment. The patient's lipid profile is not ideal, with high total cholesterol (6.18 mmol/L) and low HDL (1.91 mmol/L). The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG suggests cardiac arrhythmias, which can be a concern.

Despite these concerns, the patient has been classified as a survivor, indicating that they are currently stable and not showing any immediate signs of cardiac failure or significant arrhythmias. The patient is also on medications that are commonly used to manage cardiovascular risk factors, such as calcium channel blockers, digoxin, loop diuretics, statins, and nitrovasodilators.

The patient's left ventricular ejection fraction (LVEF) is 50.0%, which is within the normal range for an 82-year-old patient. The patient's troponin levels are normal, and the TSH level is within the normal range.

Overall, while the patient has several cardiovascular risk factors and cardiac complications, they are currently stable and not showing any immediate signs of cardiac failure or significant arrhythmias. Therefore, I believe that the patient is most likely to survive in the next few years.

RANKING: 2. Sudden cardiac death
REASONING:

While the patient has several cardiovascular risk factors, the patient's current clinical status and laboratory results do not suggest an immediate risk of sudden cardiac death. The patient's LVEF is within the normal range, and the troponin levels are normal. However, the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG is a concern, as these can be precursors to more serious arrhythmias.

Additionally, the patient's age and NYHA Class II classification increase the risk of cardiac complications, including sudden cardiac death. However, the patient is currently stable, and the patient's medications are managing the risk factors.

RANKING: 3. Pump failure death
REASONING:

The patient's elevated creatinine levels (97.0 mmol/L) and low albumin level (43 g/L) suggest possible renal impairment, which can increase the risk of cardiac pump failure. Additionally, the patient's high blood pressure (170/100 mmHg) and elevated total cholesterol (6.18 mmol/L) can also contribute to cardiac pump failure.

Furthermore, the patient's valvular cardiomyopathy and NYHA Class II classification increase the risk of cardiac pump failure. While the patient is currently stable, the patient's cardiac medications are managing the risk factors, but the patient's underlying cardiac condition may still lead to pump failure in the future.

However, considering the patient's current clinical status and laboratory results, I believe that pump failure death is the least likely outcome in the next few years, as the patient is currently stable, and the patient's medications are managing the risk factors."
636,636,P1016,"Age: 68
Gender: Male 
Weight: 62 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 138/88 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 159.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4
LDL (mmol/L): 2,74
Sodium (mEq/L): 140.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,17
TSH (mIU/L): 2,16
Urea (mg/dL): 5,66
LVEF (%): 55.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient's current clinical presentation and laboratory results suggest that they are likely to survive for the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events, but the patient is currently being treated with medications (Beta Blockers, Statins, ACE Inhibitor) that are standard for managing this condition. The patient's left ventricular ejection fraction (LVEF) is 55%, which is within the range for a patient with a history of ischemic dilated cardiomyopathy, but not severely impaired. The patient's troponin level is also within normal limits, suggesting that there is no acute myocardial infarction. Additionally, the patient's ECG shows no evidence of ventricular tachycardia or bradycardia, which are both potential predictors of sudden cardiac death. Overall, the patient's clinical presentation and laboratory results suggest that they are at moderate risk for cardiac events, but the treatment is likely to mitigate this risk.

The patient's age (68) and NYHA class II (moderate symptoms) also support the likelihood of survival. However, the patient's low albumin level (43 g/L) and elevated creatinine level (88.0 mmol/L) suggest some degree of renal impairment, which may increase the risk of cardiac events.

While the patient is at risk, the combination of current treatment, normal troponin levels, and the absence of other concerning ECG findings make a sudden cardiac death less likely. The patient's prognosis is therefore classified as survivor.

2. Sudden cardiac death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy, low LVEF, and elevated creatinine level increase the risk of cardiac events, including sudden cardiac death. However, the patient is currently being treated with medications that are standard for managing this condition, which may help mitigate this risk. The absence of ventricular tachycardia on the ECG is a positive sign, but the presence of ventricular extrasystoles (polymorphic) is a concern, as they can be a precursor to ventricular arrhythmias. Additionally, the patient's low albumin level and elevated creatinine level suggest some degree of renal impairment, which may increase the risk of cardiac events.

While the patient's current treatment and ECG results do not rule out sudden cardiac death, the combination of these risk factors and the patient's age (68) increase the likelihood of this outcome.

3. Pump failure death
REASONING: 
The patient's history of ischemic dilated cardiomyopathy, low LVEF, and elevated creatinine level increase the risk of pump failure. The patient's NYHA class II symptoms suggest that the patient has some degree of heart failure, which can lead to pump failure. However, the patient is currently being treated with medications that are standard for managing heart failure, which may help mitigate this risk.

The patient's ECG results show no evidence of ventricular tachycardia or bradycardia, which are both predictors of pump failure. However, the presence of ventricular extrasystoles (polymorphic) and the patient's low albumin level and elevated creatinine level suggest that the patient is at risk of cardiac events, including pump failure.

Overall, while the patient's current treatment and ECG results do not rule out pump failure, the combination of these risk factors and the patient's age (68) make this outcome less likely compared to sudden cardiac death."
637,637,P1017,"Age: 53
Gender: Male 
Weight: 81 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/69 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,74
Sodium (mEq/L): 134.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,07
TSH (mIU/L): 1,26
Urea (mg/dL): 5,49
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 

1. Survivor
REASONING:

The patient's age (53 years) and NYHA Class II heart failure classification suggest a moderate level of cardiac dysfunction. However, the patient's left ventricular ejection fraction (LVEF) of 40% indicates that the heart is still pumping blood effectively, albeit with some impairment. The presence of ischemic dilated cardiomyopathy and hypertension, as well as the use of beta blockers and ACE inhibitor, suggest that the patient is receiving appropriate treatment for heart failure.

The patient's laboratory results, including normal blood pressure, normal liver enzymes, and normal kidney function, do not indicate any acute or severe metabolic disturbances. The absence of significant electrolyte imbalances, anemia, or other systemic diseases also supports a favorable prognosis.

The ECG findings, including non-sustained ventricular tachycardia, are concerning but not indicative of a high risk of sudden cardiac death. The patient's troponin levels are within normal limits, which suggests that there is no acute myocardial infarction.

Given these factors, the patient's overall clinical presentation and management suggest a moderate risk of cardiac events, but not an extremely high risk. Therefore, a survivor outcome is the most likely.

2. Sudden cardiac death
REASONING:

The patient's history of ischemic dilated cardiomyopathy and hypertension increases the risk of cardiac arrhythmias, including ventricular tachycardia. The presence of non-sustained ventricular tachycardia on the ECG is a concern, but the fact that it is non-sustained (less than 10 beats) reduces the risk of sudden cardiac death. However, the patient's LVEF of 40% and the presence of ventricular extrasystoles on the ECG suggest that the heart is still at risk of arrhythmias.

Additionally, the patient's age and NYHA Class II heart failure classification increase the risk of cardiac events. However, the patient is receiving beta blockers and ACE inhibitor, which can help reduce the risk of arrhythmias and cardiac events.

3. Pump failure death
REASONING:

The patient's LVEF of 40% indicates significant cardiac dysfunction, which increases the risk of pump failure. The patient's NYHA Class II classification also suggests that the heart is not functioning optimally, but the patient is receiving treatment with beta blockers and ACE inhibitor, which can help improve cardiac function.

However, the patient's laboratory results, including elevated creatinine levels, suggest some degree of kidney impairment, which can be a complication of heart failure. Additionally, the patient's age and history of hypertension increase the risk of cardiovascular events.

While the patient's current clinical presentation does not suggest acute cardiac failure, the presence of ischemic dilated cardiomyopathy and hypertension increases the risk of pump failure over time. However, the patient's current management and laboratory results do not indicate a high risk of immediate pump failure."
638,638,P1019,"Age: 54
Gender: Male 
Weight: 87 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 110/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 11,2
Hemoglobin (g/L): 164.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,8
Sodium (mEq/L): 139.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 3,27
Urea (mg/dL): 8,65
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient has several factors that suggest a relatively better prognosis. Firstly, the patient's age is 54, which is still considered relatively young for a patient with ischemic dilated cardiomyopathy. The patient's NYHA Class II indicates that they are able to perform moderate physical activity without symptoms, which suggests that the disease is not severely limiting their daily activities.

The patient's laboratory results are also relatively stable, with normal liver enzymes and a normal kidney function (creatinine level). The patient's lipid profile is also relatively good, with a low LDL cholesterol level.

The patient is currently on medications that are standard of care for patients with heart failure and coronary artery disease, including beta blockers, statins, and an angiotensin II receptor blocker. These medications are known to improve survival and reduce morbidity in patients with heart failure.

The ECG impression is also reassuring, with no evidence of ventricular tachycardia or other arrhythmias that could indicate a high risk of sudden cardiac death.

Overall, based on the patient's age, physical condition, laboratory results, and treatment, the patient is at relatively low risk for sudden cardiac death or pump failure in the next few years. Therefore, the most likely outcome is that the patient will survive."
639,639,P1020,"Age: 73
Gender: Male 
Weight: 82 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 116/67 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,92
Sodium (mEq/L): 133.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,95
Urea (mg/dL): 4,82
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING: 
The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient's current LVEF is 45%, which indicates a moderate reduction in left ventricular function. The patient's NYHA Class is II, suggesting a moderate level of symptoms, but not severe. 

The patient's biomarkers, such as troponin and creatinine, are not excessively elevated, which may indicate some degree of cardiac muscle damage but not severe enough to suggest acute myocardial infarction or significant kidney dysfunction. The patient's lipid profile is also not excessively high, with total cholesterol at 4.29 mmol/L and LDL at 2.92 mmol/L. 

The patient is also on multiple medications, including beta blockers, statins, and an ACE inhibitor, which are standard treatments for patients with heart failure and high blood pressure. The calcium channel blocker is likely used to control ventricular extrasystoles, which are a common arrhythmia in patients with heart failure.

Considering these factors, the patient's overall prognosis is favorable, and the patient is likely to survive for the next few years without significant cardiac events. 

2. Sudden cardiac death
REASONING: 
While the patient's history of ischemic dilated cardiomyopathy is a significant risk factor for cardiac events, the patient's current LVEF is 45%, which is not as severely reduced as in some other patients with similar histories. The patient's NYHA Class is also II, suggesting some level of symptoms, but not severe.

However, the patient's age (73) and the presence of ventricular extrasystoles (ECG impression) are risk factors for sudden cardiac death. The patient's biomarkers, such as troponin and creatinine, are not excessively elevated, but the patient's potassium level is slightly low (4.8 mEq/L), which may be a risk factor for arrhythmias.

3. Pump failure death
REASONING: 
Given the patient's current LVEF of 45%, the patient is at risk of progressive heart failure, which can lead to pump failure. The patient's NYHA Class is II, suggesting some level of symptoms, and the patient's biomarkers, such as creatinine and troponin, are not excessively elevated.

However, the patient's age (73) and the presence of ventricular extrasystoles (ECG impression) make pump failure death a more likely outcome than sudden cardiac death. The patient's kidney function is also slightly impaired, as indicated by the elevated creatinine level (97.0 mmol/L), which may further exacerbate heart failure.

Overall, while the patient's prognosis is still favorable, pump failure death is a possible outcome, especially considering the patient's age and the presence of ventricular extrasystoles."
640,640,P1021,"Age: 58
Gender: Female 
Weight: 82 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 160/94 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 64
Glucose (mmol/L): 12,6
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,48
Sodium (mEq/L): 138.0
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,42
Urea (mg/dL): 7,32
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, I would rank the patient as having a high likelihood of survival for the next few years. The patient's age, NYHA Class II heart failure, and the presence of ischemic dilated cardiomyopathy, diabetes, and hypertension are significant risk factors for adverse cardiac events. However, the patient's current LVEF of 30.0 is not severely impaired, and the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests a lower risk of sudden cardiac death.

The patient is also receiving optimal medical therapy with beta blockers, spironolactone, statins, and an ACE inhibitor, which is standard of care for managing heart failure and hypertension. The presence of elevated troponin levels may indicate some degree of cardiac damage, but it is not significantly elevated, which is a positive prognostic sign.

The patient's electrolyte and liver function tests are also within relatively normal limits, and the absence of significant hyperkalemia or hypokalemia is a good sign. The patient's hemoglobin and TSH levels are also within normal limits.

Overall, while the patient has significant comorbidities, the absence of severe cardiac dysfunction, arrhythmias, and the presence of optimal medical therapy suggest a relatively favorable prognosis.

2. Sudden cardiac death
REASONING:
While the patient has several risk factors for cardiac events, including ischemic dilated cardiomyopathy, hypertension, and diabetes, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG reduces the likelihood of sudden cardiac death. However, the patient's LVEF of 30.0 is significantly impaired, and the patient's NYHA Class II heart failure suggests that the patient may be at risk of progressive cardiac decline.

The patient's elevated troponin levels and elevated creatinine levels may indicate some degree of cardiac and renal impairment, which could increase the risk of cardiac events. However, the patient is receiving optimal medical therapy, and the absence of significant electrolyte imbalances is a positive prognostic sign.

3. Pump failure death
REASONING:
Given the patient's significant impairment of LVEF (30.0), NYHA Class II heart failure, and the presence of ischemic dilated cardiomyopathy, pump failure death is a significant risk. The patient's elevated creatinine levels and elevated troponin levels suggest some degree of cardiac and renal impairment, which could lead to progressive heart failure.

While the patient is receiving optimal medical therapy, the patient's NYHA Class II heart failure suggests that the patient may not be receiving the most aggressive treatment for heart failure, and the patient's LVEF is significantly impaired, which increases the risk of pump failure. The absence of significant arrhythmias on the ECG reduces the likelihood of sudden cardiac death, but the patient's impaired cardiac function still makes pump failure a significant risk."
641,641,P1027,"Age: 69
Gender: Male 
Weight: 66 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 127/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 48
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,71
Creatinine (mmol/L): 106.0
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,39
Sodium (mEq/L): 140.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 24
Troponin (ng/mL): 0,05
TSH (mIU/L): 3,74
Urea (mg/dL): 10,15
LVEF (%): 30.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

This patient is at high risk for adverse outcomes due to the presence of idiopathic dilated cardiomyopathy, which is a condition that significantly impairs the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is only 30%, indicating severe systolic dysfunction. This, combined with the patient's NYHA Class II status, suggests that the patient experiences moderate symptoms of heart failure, such as fatigue, shortness of breath, and swelling. The patient's elevated creatinine level (106.0 mmol/L) also indicates impaired kidney function, which can be a complication of advanced heart failure.

The patient's electrolyte levels, including low potassium (4.6 mEq/L) and low T3 (0.04 pg/dL), also suggest that the patient may be experiencing hypokalemia and hypothyroidism, respectively. These conditions can further exacerbate the patient's heart failure symptoms and increase the risk of arrhythmias.

The patient's ECG results show ventricular extrasystoles, which are abnormal heart rhythms that can increase the risk of sudden cardiac death. The presence of sinus node dysfunction on the ECG also suggests that the patient's heart is having trouble regulating its rhythm, which can lead to arrhythmias.

Given the patient's severe heart failure, impaired kidney function, and presence of arrhythmias, I believe that the most likely outcome for this patient over the next few years is survivor. The patient's current treatment regimen, which includes medications to manage heart failure, arrhythmias, and hypertension, will likely be adjusted to better manage the patient's symptoms and reduce the risk of complications.

The patient's prognosis is less likely to be sudden cardiac death due to the fact that the patient's ECG results do not show any signs of ventricular tachycardia or other life-threatening arrhythmias. While the patient's heart failure is severe, the patient's medications and current treatment regimen should help to manage the condition and prevent sudden cardiac death.

The patient's prognosis is less likely to be pump failure death due to the fact that the patient is currently receiving medications to manage heart failure and the patient's LVEF is not as severely impaired as it could be. Additionally, the patient's kidney function is impaired, but the patient's creatinine level is not extremely high, which may indicate that the patient's kidney function is not as severely compromised as it could be.

It's worth noting that the patient's age and sex also play a role in the patient's prognosis. The patient is 69 years old, which puts them in an age group where the risk of complications and mortality from heart failure and arrhythmias is higher. However, the patient's overall health status and treatment regimen will play a significant role in determining the patient's prognosis."
642,642,P1029,"Age: 69
Gender: Male 
Weight: 68 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 88/58 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,08
Sodium (mEq/L): 140.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,81
Urea (mg/dL): 7,65
LVEF (%): 35.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient is a 69-year-old male with a history of ischemic dilated cardiomyopathy, which is a significant underlying condition that affects the heart's ability to pump blood effectively. Despite this, the patient has a relatively good ejection fraction (LVEF) of 35%, which indicates that the heart is still able to pump some blood. The patient is also on medications that are standard for managing heart failure and arrhythmias.

The patient's laboratory results show mild elevations in liver enzymes (ALT and AST), which could be related to the underlying cardiomyopathy. However, these values are not excessively high, and the patient's kidney function (creatinine) is within a relatively normal range.

The ECG findings show polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are concerning signs of arrhythmias. However, the absence of sustained ventricular tachycardia and other arrhythmias suggests that the patient is not in immediate danger.

Given these factors, I believe that the patient is likely to survive for the next few years, provided that the patient adheres to their medication regimen and makes lifestyle changes to manage their condition. The patient's age and weight are also relatively favorable, as they are not considered high-risk for sudden cardiac death.

While the patient's LVEF is low, it is not severely impaired, and the patient is on medications that can help improve heart function. Overall, the patient's prognosis is guarded but not catastrophic, making ""survivor"" the most likely outcome.

RANKING: Survivor
REASONING (in case of a sudden cardiac death):
If the patient were to experience a sudden cardiac death, it would be more likely due to a life-threatening arrhythmia, such as a ventricular fibrillation or pulseless ventricular tachycardia, rather than a non-sustained arrhythmia. The patient's ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia are concerning, but not necessarily indicative of a life-threatening arrhythmia.

RANKING: Sudden cardiac death
REASONING:
In this scenario, the patient's ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia are more concerning, and the patient's LVEF is significantly impaired. The patient's age and weight are also risk factors for sudden cardiac death.

RANKING: Pump failure death
REASONING:
While the patient's LVEF is low, it is not severely impaired, and the patient is on medications that can help improve heart function. However, the patient's kidney function is slightly elevated, and the patient's liver enzymes are mildly elevated, which could indicate some degree of cardiac dysfunction. Additionally, the patient's age and weight are not ideal for optimal heart function.

Given these factors, while the patient is at risk for pump failure, I believe that it is less likely than sudden cardiac death, as the patient is on medications that can help manage heart failure, and the patient's ECG findings are not indicative of a life-threatening arrhythmia."
643,643,P1030,"Age: 69
Gender: Male 
Weight: 100 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 124/67 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 158.0
AST or GOT (IU/L): 105.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,16
Sodium (mEq/L): 140.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,72
Urea (mg/dL): 8,49
LVEF (%): 53.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING:

Based on the provided patient data, the patient is a 69-year-old male with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is weakened due to an enlarged heart. The patient's left ventricular ejection fraction (LVEF) is 53%, which is below the normal range (typically above 55%). This suggests that the patient's heart is not functioning optimally, increasing the risk of complications.

The patient's NYHA Class II indicates that they experience some limitations in physical activity due to their heart condition, but they can still carry out their daily activities without severe shortness of breath.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate liver damage or inflammation, but are not directly related to the heart condition. The patient's lipid profile shows high cholesterol levels, but this is not uncommon in patients with heart disease.

The patient's ECG findings are notable for ventricular extrasystoles, which are abnormal heart rhythms that can increase the risk of cardiac arrhythmias and sudden cardiac death. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient does not have a high risk of sudden cardiac death at this time.

Given the patient's overall clinical presentation, I believe that the patient is at higher risk of experiencing pump failure death due to their dilated cardiomyopathy. However, the patient is already taking medications to manage their condition, including beta blockers, loop diuretics, and an ACE inhibitor, which can help reduce the risk of complications.

Therefore, I rank the patient's prognosis as a survivor, with a moderate risk of pump failure death over the next few years, but with the possibility of sudden cardiac death."
644,644,P1031,"Age: 78
Gender: Male 
Weight: 65 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 114/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,97
Sodium (mEq/L): 135.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 22
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,86
Urea (mg/dL): 10,15
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"RANKING: 
1. Survivor
REASONING:
Based on the provided patient data, the patient is 78 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death and pump failure. However, the patient's current NYHA class is II, indicating moderate symptoms, but not severe. The patient's LVEF is 25%, which is within the range of expected for someone with dilated cardiomyopathy.

The patient's ECG impression shows ventricular extrasystole, which is a concerning finding, but it is not a direct indicator of sudden cardiac death. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. The presence of first-degree atrioventricular block (AVB) is a sign of cardiac conduction system disease, but it is not a direct indicator of sudden cardiac death.

The patient's biomarkers, including troponin and TSH, are within normal limits, which suggests that the patient does not have significant acute myocardial infarction or thyroid dysfunction. The patient's creatinine level is elevated, but it is not significantly high, and the patient is on medications that are commonly used in patients with heart failure.

Considering these factors, the patient's overall risk for sudden cardiac death and pump failure appears to be moderate. The patient's age, NYHA class, and LVEF suggest that the patient is at risk for pump failure, but the absence of significant biomarkers, the presence of AVB, and the patient's current medication regimen reduce the risk of sudden cardiac death. Therefore, the most likely outcome for the patient over the next few years is survivor."
645,645,P1054,"Age: 58
Gender: Male 
Weight: 91 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,7
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,08
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 4492.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,45
Urea (mg/dL): 12,03
LVEF (%): 20.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 
1. Survivor
REASONING:
The patient has a complex medical history with ischemic dilated cardiomyopathy, hypertension, and a history of myocardial infarction. The current ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning for an increased risk of arrhythmias. However, the patient is already on medications for these conditions, including Amiodarone, which is effective for treating ventricular arrhythmias.

The patient's elevated troponin level (0.01 ng/mL) is not significantly elevated, and the LVEF is only 20%, which is significantly reduced. However, the patient's current medications, including ACE inhibitors and beta-blockers, are aimed at improving cardiac function and reducing the risk of further cardiac events.

The patient's lab values are also concerning, with elevated creatinine (95.0 mmol/L) and BNP (4492.0 ng/L), indicating impaired renal function and increased ventricular stress. However, the patient is already on loop diuretics, which are intended to reduce fluid overload and alleviate symptoms.

The patient's weight and height are within normal limits, and the blood pressure is well-controlled. The lipid profile shows elevated total cholesterol and LDL levels, but the patient is on statins, which are effective in lowering cholesterol levels.

Given the patient's complex medical history, current medications, and lab values, the most likely outcome is that the patient will survive. While the patient has several risk factors for adverse cardiac events, the patient is already on multiple medications that target these risk factors, and the patient's current condition does not indicate an immediate life-threatening situation.

The other two prognoses are less likely because:

- Sudden cardiac death is unlikely due to the patient's current medications and the fact that the ECG findings are not indicative of a life-threatening arrhythmia.
- Pump failure death is possible, but the patient's current medications and lab values do not indicate a severe reduction in cardiac function or a significant increase in symptoms."
646,646,P1056,"Age: 79
Gender: Male 
Weight: 78 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 111/76 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,65
Sodium (mEq/L): 137.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,62
Urea (mg/dL): 9,82
LVEF (%): 39.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 79-year-old male with a history of hypertensive cardiomyopathy and hypertension. His NYHA Class is II, indicating mild symptoms of heart failure. The patient's LVEF is 39.0%, which is significantly below the normal range, indicating severe left ventricular dysfunction.

The patient's ECG shows polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and sinus node dysfunction, all of which are concerning signs of cardiac arrhythmias. The presence of non-sustained ventricular tachycardia (CH>10) further increases the risk of cardiac complications.

However, the patient's hemoglobin level is slightly elevated, which could be indicative of anemia or other conditions that may affect cardiac function. The patient's renal function is also mildly impaired, with elevated creatinine levels.

Despite these concerns, the patient's age, weight, and blood pressure are not particularly high-risk factors for cardiac complications. The patient's ECG findings and LVEF suggest that the patient is at risk for cardiac complications, but the overall clinical picture is not as severe as it could be.

Therefore, I would rank the patient's prognosis as a survivor, with a reasonable chance of managing their symptoms and complications with appropriate medical therapy.

2. Sudden Cardiac Death
REASONING: 

While the patient's ECG findings and LVEF are concerning, the patient's age and overall clinical presentation do not necessarily indicate a high risk for sudden cardiac death. However, the presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia increases the risk of cardiac arrhythmias.

The patient's LVEF is significantly below normal, which increases the risk of cardiac complications, including sudden cardiac death. However, the patient's age and other risk factors do not make this outcome particularly likely.

3. Pump Failure Death
REASONING: 

Given the patient's severe LVEF and NYHA Class II symptoms, pump failure is a significant concern. The patient's elevated creatinine levels also suggest some degree of renal impairment, which may be related to cardiac dysfunction.

However, the patient's ECG findings and other clinical markers do not suggest a high risk for sudden cardiac death or cardiac arrhythmias. While pump failure is a concern, the patient's overall clinical presentation and risk factors do not make this outcome as likely as cardiac arrhythmias."
647,647,P1057,"Age: 72
Gender: Female 
Weight: 72 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 104/62 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 44
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 10,7
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,59
Sodium (mEq/L): 139.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,33
TSH (mIU/L): 0,76
Urea (mg/dL): 12,31
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's overall health status, despite having a NYHA Class II heart failure, suggests that the patient has a relatively preserved functional capacity for daily activities. The patient's ejection fraction (LVEF) of 35.0% indicates significant left ventricular dysfunction, but it is not extremely low, which may indicate a possible potential for recovery or stabilization of cardiac function. 

The patient's lipid profile and laboratory values, such as low HDL and high LDL levels, are concerning but do not appear to be significantly impacting the patient's overall prognosis at this point. The patient's medication regimen includes ACE inhibitors, which are typically used to manage heart failure and hypertension, and beta blockers, which are often used to reduce the risk of arrhythmias and improve survival in patients with heart failure.

The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG is concerning, but the fact that they are non-sustained suggests that the patient may not be at immediate risk of life-threatening arrhythmias. The patient's lack of other concerning ECG findings, such as wide QRS complexes or signs of ischemia, further reduces the risk of sudden cardiac death.

Given these factors, I would rank the patient as having a relatively high likelihood of survival, likely due to the patient's relatively preserved functional capacity, controlled blood pressure, and the presence of evidence-based medications for heart failure and hypertension. However, it is essential to continue monitoring the patient closely to ensure that any potential cardiac issues do not worsen over time."
648,648,P1058,"Age: 77
Gender: Male 
Weight: 63 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 131/60 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 40
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,9
Sodium (mEq/L): 140.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,58
Urea (mg/dL): 9,98
LVEF (%): 19.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient has a history of valvular cardiomyopathy, which can lead to heart failure and arrhythmias. However, the patient is currently taking medications for heart failure (Loop Diuretics) and has a relatively stable blood pressure. The patient's LVEF is 19.0, which is within the normal range for an elderly patient. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on ECG is concerning, but the patient's heart rate is not excessively high, and the medications are being managed. The patient's troponin levels are within normal limits, and the TSH is within normal limits, indicating no acute myocardial infarction or thyroid dysfunction. The patient's overall clinical presentation is stable, and the patient is receiving optimal medical therapy. Therefore, the most likely outcome for this patient over the next few years is survival.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient has a history of valvular cardiomyopathy, which increases the risk of arrhythmias, the patient's current ECG findings are not indicative of a high risk for sudden cardiac death. The presence of ventricular tachycardia on ECG is concerning, but the patient is taking medications to manage this condition. The patient's LVEF is within normal limits, and the patient's troponin levels are normal, indicating no acute myocardial infarction. However, the patient's age and history of valvular cardiomyopathy increase the risk of sudden cardiac death. The patient's ECG findings and clinical presentation do not indicate an immediate risk for sudden cardiac death, but the patient's overall risk is still elevated.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 19.0, which is significantly below the normal range for an elderly patient. This indicates that the patient's heart is not functioning optimally, and there is a risk of heart failure. The patient's history of valvular cardiomyopathy and dyslipemia further increases the risk of heart failure. The patient's current medications are aimed at managing heart failure, but the patient's LVEF is still significantly below normal. While the patient is receiving optimal medical therapy, the risk of pump failure death is elevated due to the patient's underlying heart condition and the patient's suboptimal LVEF."
649,649,P1064,"Age: 63
Gender: Female 
Weight: 67 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 163/94 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,28
Sodium (mEq/L): 141.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,35
Urea (mg/dL): 6,32
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class II, and LVEF of 30.0 indicate a significant impairment of cardiac function, which is a risk factor for heart failure and cardiac death. However, the patient is currently taking medications that are known to improve heart failure symptoms and reduce mortality risk (e.g., Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics). 

The patient's ECG results show no evidence of ventricular tachycardia, which is a significant risk factor for sudden cardiac death. The absence of ventricular tachycardia and non-sustained ventricular tachycardia also suggests that the patient's cardiac arrhythmias are not severe enough to pose an immediate threat.

The patient's laboratory results show elevated creatinine levels, indicating some degree of kidney dysfunction, but this is not directly related to cardiac function. The patient's electrolyte levels are relatively normal, and the troponin level is within normal limits, indicating no acute myocardial infarction.

Considering these factors, the patient's overall prognosis is most likely to be a survivor. The patient's cardiac function is impaired, but the patient is taking medications that can help manage this condition, and the ECG results do not indicate an immediate threat to cardiac function."
650,650,P1065,"Age: 80
Gender: Male 
Weight: 79 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 146/83 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 14,9
Hemoglobin (g/L): 179.0
HDL (mmol/L): 0,83
LDL (mmol/L): 3,21
Sodium (mEq/L): 135.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,06
Urea (mg/dL): 13,98
LVEF (%): 56.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Based on the patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, the patient is already in a compromised state. However, the patient's current medical condition is stable, as indicated by the ""survivor"" patient outcome. 

The patient's LVEF is 56.0%, which is a relatively preserved ejection fraction, but still below the normal range. This suggests that the patient's heart is functioning adequately to some extent, but not optimally. 

The patient's medications, including digoxin, loop diuretics, and an ACE inhibitor, are standard treatments for managing heart failure and arrhythmias. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG is also reassuring. 

The patient's laboratory results, including normal troponin levels and a low T3 level, suggest that the patient is not experiencing acute myocardial injury or inflammation. The patient's hemoglobin level is within the normal range, indicating adequate oxygenation. 

Considering these factors, the patient's overall prognosis is that they will survive in the short-term. However, the patient's long-term prognosis is uncertain and will depend on the progression of their idiopathic dilated cardiomyopathy and the effectiveness of their current treatment regimen."
651,651,P1066,"Age: 72
Gender: Female 
Weight: 81 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 164/79 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,62
Sodium (mEq/L): 139.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 11
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,38
Urea (mg/dL): 8,32
LVEF (%): 42.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 
1. Survivor
REASONING: 

The patient's overall health status is relatively stable, with a NYHA Class II classification indicating moderate symptoms of heart failure. The patient's LVEF is 42%, which is below the normal range, indicating some degree of left ventricular dysfunction. However, the patient is not in acute heart failure, as there is no mention of acute symptoms such as shortness of breath, fatigue, or swelling. The patient is also on medications for hypertension and heart failure, which suggests that the condition is being managed.

The patient's laboratory results show a mild elevation in creatinine levels, which may indicate some degree of renal impairment. However, the patient's electrolyte levels are within normal limits, and there is no evidence of acute kidney injury.

The ECG results show a history of ventricular extrasystoles and polymorphic ventricular tachycardia, but no evidence of sustained ventricular tachycardia or bradycardia. The presence of TPSV (paroxysmal supraventricular tachycardia) may indicate a risk for arrhythmias, but it is not a contraindication for a good outcome.

Considering these factors, the patient's overall prognosis is good, with a high likelihood of survival over the next few years. The patient's age is 72, which is advanced, but the patient's health status is relatively stable, and the patient is on medications for hypertension and heart failure. With proper management, the patient can be expected to survive for several years."
652,652,P1073,"Age: 70
Gender: Female 
Weight: 63 kg
Height: 144 cm
NYHA Class: II
Blood Pressure: 134/86 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,23
Sodium (mEq/L): 141.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 12
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,43
Urea (mg/dL): 8,82
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of idiopathic dilated cardiomyopathy, the patient is already at an increased risk for cardiac events. However, the patient's current LVEF of 40.0 is relatively preserved, which suggests that the patient's heart is still capable of pumping blood effectively, albeit with some compromise. The absence of elevated troponin levels and no indication of acute myocardial infarction or significant cardiac ischemia further supports this assessment.

The patient's blood pressure is within a relatively normal range, and the presence of beta blockers and ACE inhibitor medications suggests that the patient is being adequately managed for their heart condition. The patient's electrolyte levels, including potassium, are also within a relatively normal range.

While the patient's LVEF is not ideal, it is not severely compromised, and the patient's overall clinical presentation does not suggest a high risk for sudden cardiac death or pump failure. Therefore, the most likely prognosis for this patient over the next few years is a survivor.

RANKING: 2. Pump failure death
REASONING: 
While the patient's LVEF is 40.0, which is below the normal range, the patient is still able to pump blood effectively, and the patient's current medications suggest that they are being managed for their heart condition. However, the patient's NYHA Class II indicates some symptoms of heart failure, which may indicate a higher risk for pump failure.

Given the patient's age and the presence of idiopathic dilated cardiomyopathy, the patient is already at an increased risk for cardiac events. If the patient's condition worsens, the risk for pump failure increases. However, without more information on the patient's functional capacity and the presence of any other risk factors, it is difficult to predict when or if pump failure will occur.

RANKING: 3. Sudden cardiac death
REASONING: 
The patient's ECG findings of ventricular extrasystole and the presence of idiopathic dilated cardiomyopathy increase the risk for sudden cardiac death. However, the absence of any indication of ventricular tachycardia or other life-threatening arrhythmias reduces this risk.

Given the patient's age and the presence of a NYHA Class II, the patient is already at an increased risk for cardiac events. However, the patient's relatively preserved LVEF and the absence of elevated troponin levels suggest that the patient's heart is still capable of pumping blood effectively. Therefore, while the patient is at risk for sudden cardiac death, the likelihood of this occurring in the next few years is lower compared to pump failure."
653,653,P0008,"Age: 44
Gender: Male 
Weight: 114 kg
Height: 179 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42,19
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 12,3
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,77
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 623.0
Protein (g/L): 76
T3 (pg/dL): 0,02
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 9,8
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: The patient has a significant medical history of ischemic dilated cardiomyopathy, which is a condition that significantly increases the risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is also severely impaired at 30.0%, indicating poor cardiac function. Additionally, the patient has a history of hypertension, diabetes, and dyslipemia, all of which are risk factors for cardiovascular disease. The presence of elevated troponin levels (0.01 ng/mL) suggests myocardial injury, which may indicate ongoing cardiac stress. The patient's ECG impression shows ventricular extrasystole, which is a sign of abnormal heart rhythm. Given these factors, the patient is at high risk for sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: The patient's severely impaired LVEF (30.0%) and history of ischemic dilated cardiomyopathy make pump failure a significant concern. The patient's elevated creatinine levels (9.8 mg/dL) also suggest impaired renal function, which can be a complication of heart failure. The patient's NYHA Class II indicates moderate symptoms of heart failure, which can lead to pump failure. While the patient is on medications for heart failure (Loop Diuretics), the severity of their condition and the presence of other risk factors make pump failure a plausible outcome.

RANKING: 3. Survivor
REASONING: While the patient has a significant medical history and multiple risk factors for cardiovascular disease, their current medical treatment and management plan (including medications for diabetes, hypertension, and heart failure) suggest that they are being actively managed. The patient's elevated troponin levels and ventricular extrasystole on ECG do indicate some level of cardiac stress, but the absence of other concerning findings (e.g., high troponin levels, ventricular tachycardia) and the presence of beta blockers, which are standard therapy for heart failure, suggest that the patient is being adequately managed. However, the patient's severely impaired LVEF and history of ischemic dilated cardiomyopathy still make pump failure a possible outcome, making survival less likely than sudden cardiac death."
654,654,P0012,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,3
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 3,1
LDL (mmol/L): 2,43
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 958.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,51
Urea (mg/dL): 8,02
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

This patient has a high-risk profile for heart failure, with a history of ischemic dilated cardiomyopathy, hypertension, and previous myocardial infarction. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 35%, indicating significant left ventricular dysfunction. The patient's elevated creatinine level (120.0 mmol/L) also suggests impaired renal function, which is a common complication of heart failure.

The patient's NYHA class III classification indicates severe symptoms of heart failure, and the presence of ventricular extrasystoles (Polymorphic) and paroxysmal supraventricular tachycardia (PSVT) on the ECG suggest an increased risk of arrhythmias, which can precipitate cardiac arrest or sudden cardiac death.

While the patient's current ECG does not show any signs of ventricular tachycardia, the presence of ventricular extrasystoles and PSVT increases the risk of sudden cardiac death. However, the patient's ECG impression does not indicate any other life-threatening arrhythmias.

In contrast, pump failure death is a more likely outcome due to the patient's severe left ventricular dysfunction and impaired renal function, which can lead to acute decompensated heart failure and death.

Sudden cardiac death is the least likely outcome in this scenario, as the patient's current ECG does not show any signs of ventricular tachycardia or other life-threatening arrhythmias. However, the patient's overall high-risk profile and the presence of ventricular extrasystoles and PSVT still increase the risk of sudden cardiac death.

It's worth noting that this patient is already on medications that are commonly used to manage heart failure and arrhythmias, but the severity of their condition and the presence of ventricular extrasystoles and PSVT may still pose a risk for sudden cardiac death. Close monitoring and adjustment of medications may be necessary to mitigate this risk."
655,655,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 
The patient's ECG impression reveals multiple concerning findings, including ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which are all indicative of significant cardiac arrhythmias. The presence of ventricular extrasystole and non-sustained ventricular tachycardia, in particular, suggests that the patient is at high risk of experiencing a life-threatening arrhythmic event. The patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and NYHA Class III heart failure also increases the risk of sudden cardiac death. The patient's low LVEF of 18% further supports this, as it indicates severe left ventricular dysfunction, which can contribute to arrhythmic events. Additionally, the patient's elevated Pro-BNP levels and elevated creatinine levels suggest significant cardiac and renal impairment, which can also contribute to an increased risk of sudden cardiac death. Given these findings, it is reasonable to predict that the patient is at high risk of sudden cardiac death in the next few years.

RANKING: 2. Pump Failure Death
REASONING: 
The patient's NYHA Class III heart failure classification and elevated Pro-BNP levels suggest that the patient has significant left ventricular dysfunction and fluid overload, which can lead to pump failure. The patient's elevated creatinine levels also suggest impaired renal function, which can contribute to fluid overload and electrolyte imbalances. While the patient is on medications to manage heart failure, including diuretics and spironolactone, the patient's elevated sodium levels and low potassium levels suggest that these medications may not be adequately controlling fluid overload and electrolyte imbalances. Additionally, the patient's low LVEF of 18% suggests that the patient's left ventricle is not functioning efficiently, which can contribute to pump failure. Given these findings, it is reasonable to predict that the patient is at risk of pump failure in the next few years.

RANKING: 3. Survivor
REASONING: 
While the patient has a significant medical history, including ischemic dilated cardiomyopathy and myocardial infarction, the patient's current medications and ECG findings do not suggest an immediate and high risk of sudden cardiac death or pump failure. The patient's blood pressure is within a relatively normal range, and the patient's hemoglobin and potassium levels are within normal limits. Additionally, the patient's troponin levels are normal, which suggests that the patient does not have significant myocardial damage. While the patient's LVEF is low, it is not as severe as in the pump failure ranking, and the patient is on medications to manage heart failure, which suggests that the patient's heart function is being managed. Given these findings, it is reasonable to predict that the patient has a moderate risk of mortality in the next few years, but it is less likely than pump failure or sudden cardiac death."
656,656,P0018,"Age: 57
Gender: Male 
Weight: 88 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 48
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,78
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 110.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,21
Urea (mg/dL): 9,35
LVEF (%): 58.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

Based on the patient's medical history, physical examination, and diagnostic test results, the most likely prognosis for the next few years is sudden cardiac death. 

The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is compromised due to scarring and enlargement of the heart muscle. This condition is a significant risk factor for sudden cardiac death. Additionally, the patient's left ventricular ejection fraction (LVEF) is 58%, which is below the normal range, indicating poor heart function.

The patient's elevated troponin levels (0.01 ng/mL) also suggest some degree of myocardial injury, which can be a precursor to arrhythmias and sudden cardiac death.

Furthermore, the patient's ECG findings of ventricular extrasystole (monomorphic) suggest an abnormal heart rhythm, which can increase the risk of sudden cardiac death.

Given the patient's history of myocardial infarction, dyslipidemia, and hypertension, it is likely that the patient has a compromised cardiac function, which increases the risk of sudden cardiac death.

While the patient is on medications, including beta blockers, statins, ACE inhibitors, and a nitrovasodilator, these medications may not be sufficient to completely mitigate the risk of sudden cardiac death, especially given the patient's underlying cardiac conditions.

Overall, the combination of the patient's medical history, physical examination, and diagnostic test results make sudden cardiac death the most likely prognosis for the next few years."
657,657,P0028,"Age: 76
Gender: Male 
Weight: 72 kg
Height: 187 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 41,5
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 130.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 10,2
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5
LDL (mmol/L): 2,9
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 7822.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,29
Urea (mg/dL): 10,91
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the patient's data, the most likely prognosis is sudden cardiac death. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly increases the risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 35%, which is a marker of poor cardiac function and further supports this prognosis. Additionally, the patient has a history of ventricular extrasystoles on the ECG, which can be a precursor to more severe arrhythmias.

The patient's ECG also shows signs of ventricular dysfunction, including a low LVEF and a high level of B-type natriuretic peptide (BNP) (7822.0 ng/L), which indicates increased ventricular wall stress. The patient's high blood pressure and low HDL cholesterol levels also contribute to the increased risk of cardiovascular events.

Pump failure death is the second most likely prognosis due to the patient's poor cardiac function (LVEF 35%) and history of heart failure. The patient is also taking medications that can exacerbate heart failure, such as beta blockers and loop diuretics.

Survivor is the least likely prognosis due to the patient's severe cardiac dysfunction and history of cardiovascular disease. However, it is still possible that the patient may survive with optimal management of their condition and treatment of their underlying heart failure."
658,658,P0043,"Age: 63
Gender: Male 
Weight: 87 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 115/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 636.0
Protein (g/L): 81
T3 (pg/dL): 0,07
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,57
Urea (mg/dL): 4,9
LVEF (%): 26.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 
This patient has a high risk of pump failure death due to the presence of severe left ventricular dysfunction (LVEF 26.0), which is a well-established predictor of adverse outcomes in patients with heart failure. Additionally, the patient has a history of myocardial infarction, which can further compromise cardiac function. The patient's elevated troponin levels (0.01 ng/mL) also indicate some degree of myocardial damage. However, the patient is receiving medications such as ACE inhibitors and beta blockers, which can help alleviate symptoms and improve cardiac function. Furthermore, the patient's NYHA Class II symptoms suggest that they are still relatively asymptomatic compared to a higher class. Therefore, while the patient has several risk factors, the presence of current treatment and relatively mild symptoms suggest a higher likelihood of survival.

RANKING: 2. Pump failure death
REASONING: 
This patient is at high risk of pump failure death due to the presence of severe left ventricular dysfunction (LVEF 26.0), a history of myocardial infarction, and elevated troponin levels (0.01 ng/mL). The patient's elevated creatinine levels (102.0 mmol/L) also indicate some degree of renal impairment, which can further exacerbate cardiac function. The patient's elevated Pro-BNP levels (636.0 ng/L) suggest a high level of ventricular stress, indicating that the heart is working hard to pump blood effectively. However, the patient is receiving medications such as ACE inhibitors and beta blockers, which can help alleviate symptoms and improve cardiac function. Despite these factors, the patient's severe left ventricular dysfunction and elevated troponin levels make pump failure death a significant concern.

RANKING: 3. Sudden cardiac death
REASONING: 
While the patient has a history of ventricular extrasystoles and non-sustained ventricular tachycardia (CH>10), the patient's ECG impression does not indicate any ongoing arrhythmic events. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia is a concern, but the patient's current ECG impression does not suggest an ongoing arrhythmic event. Additionally, the patient is receiving medications such as beta blockers, which can help regulate heart rate and reduce the risk of arrhythmias. The patient's mild symptoms and the presence of current treatment suggest that sudden cardiac death is less likely, but cannot be ruled out entirely."
659,659,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Survivor
2. Pump failure death
3. Sudden cardiac death

REASONING:

Based on the provided patient data, the patient is at high risk for cardiac-related complications due to a history of ischemic dilated cardiomyopathy, diabetes, dyslipidemia, and myocardial infarction. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 25%, indicating poor cardiac function.

The patient's elevated creatinine level (118.0 mmol/L) and urea level (8.91 mg/dL) suggest impaired renal function, which can be a contributing factor to cardiac complications.

The presence of ventricular extrasystole and non-sustained ventricular tachycardia (NSVT) on the ECG impression suggests a high risk of arrhythmias, which can lead to sudden cardiac death.

However, the patient is not currently on anti-arrhythmic medications for ventricular arrhythmias, which might suggest a lower risk for sudden cardiac death due to arrhythmias.

The patient is also taking medications that are commonly used to manage heart failure and hypertension, such as beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are likely contributing to the patient's survival.

Considering these factors, the patient is more likely to experience pump failure death due to the underlying cardiac condition and the presence of renal impairment, rather than sudden cardiac death. Therefore, the prognosis is ranked as survivor, followed by pump failure death, and finally, sudden cardiac death."
660,660,P0051,"Age: 52
Gender: Male 
Weight: 74 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 2,74
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5
LDL (mmol/L): 1,4
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 693.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,55
Urea (mg/dL): 8,91
LVEF (%): 26.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 
The patient's overall clinical presentation, laboratory results, and ECG findings suggest that the patient is at high risk for cardiac events, but the presence of idiopathic dilated cardiomyopathy and severe left ventricular dysfunction (LVEF 26.0) indicates that the patient's cardiac function is severely compromised. However, the patient is on multiple medications for heart failure and arrhythmias, which may help manage symptoms and prevent sudden cardiac death. The patient's low troponin levels (0.01 ng/mL) and normal ECG findings for ventricular tachycardia or non-sustained ventricular tachycardia also suggest that the patient is not currently experiencing a cardiac event. 

Given these factors, the patient is likely to survive for the next few years, but will require close monitoring and ongoing management to prevent cardiac decompensation and arrhythmias.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's severe left ventricular dysfunction and history of idiopathic dilated cardiomyopathy increase the risk for sudden cardiac death, the patient's low troponin levels and normal ECG findings suggest that the patient is not currently experiencing a cardiac event. However, the patient's history of ventricular extrasystole and polymorphic ventricular extrasystole on ECG may indicate an increased risk for arrhythmias, which can lead to sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
Given the patient's severe left ventricular dysfunction (LVEF 26.0) and history of idiopathic dilated cardiomyopathy, it is likely that the patient will experience cardiac decompensation and pump failure in the near future. The patient's elevated creatinine levels (118.0 mmol/L) and low albumin levels (39 g/L) also suggest that the patient's renal function is compromised, which can exacerbate cardiac decompensation. While the patient is on multiple medications for heart failure and arrhythmias, the patient's severe cardiac dysfunction may ultimately lead to pump failure, which can be fatal."
661,661,P0053,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,15
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 2234.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,11
Urea (mg/dL): 9,57
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Diabetes Medication, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death 
REASONING: 

This patient has several high-risk factors for cardiac complications, which make sudden cardiac death the most likely outcome. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that can lead to arrhythmias and decreased cardiac function. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 39%, indicating poor cardiac function. The presence of ventricular extrasystoles on the ECG also suggests an increased risk of arrhythmias, which can lead to sudden cardiac death.

Additionally, the patient's high creatinine level (112.0 mmol/L) may indicate impaired renal function, which can be a risk factor for cardiac complications. The patient's high troponin level (0.01 ng/mL) also suggests some degree of cardiac damage, which can contribute to an increased risk of sudden cardiac death.

The patient's NYHA Class II heart failure classification indicates that the patient has some limitation in physical activity, which may increase the risk of cardiac complications. The patient's medications, including a nitrovasodilator, may also contribute to the risk of arrhythmias and cardiac complications.

While the patient's age (68) is not unusually high, the combination of these factors makes sudden cardiac death the most likely outcome.

RANKING: 2. Pump failure death 
REASONING: 

Pump failure death is a possible outcome for this patient, given the patient's history of ischemic dilated cardiomyopathy and reduced LVEF. The patient's NYHA Class II heart failure classification indicates that the patient has some limitation in physical activity, which may contribute to the risk of pump failure.

However, the patient's medications, including a calcium channel blocker and statins, may help to manage the patient's heart failure symptoms and reduce the risk of pump failure. The patient's creatinine level is also relatively high, which may indicate some degree of kidney impairment, but this does not necessarily increase the risk of pump failure.

RANKING: 3. Survivor 
REASONING: 

While the patient's history of ischemic dilated cardiomyopathy and reduced LVEF may increase the risk of cardiac complications, the patient's age (68) is not unusually high, and the patient's medications may help to manage the patient's heart failure symptoms. The patient's creatinine level is also relatively high, which may indicate some degree of kidney impairment, but this does not necessarily increase the risk of pump failure.

The patient's troponin level is relatively low, which suggests that the patient's cardiac damage is not severe. The patient's ECG findings are not suggestive of any significant arrhythmias, which may reduce the risk of sudden cardiac death. Overall, while the patient's history and medications do increase the risk of cardiac complications, the patient's age and ECG findings suggest that the patient is at lower risk for sudden cardiac death and pump failure."
662,662,P0057,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,7
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 155.0
Gamma-glutamil transpeptidase (IU/L): 168
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5
LDL (mmol/L): 2,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3996.0
Protein (g/L): 81
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 8,79
Urea (mg/dL): 15,15
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, and hypertension, which can increase the risk of cardiovascular events. The patient's current NYHA Class III indicates severe heart failure, and the elevated LVEF of 29.0 suggests significant left ventricular dysfunction. The presence of elevated troponin levels, despite being below the threshold for acute myocardial infarction, may indicate ongoing cardiac damage.

The patient's laboratory results show elevated creatinine levels, indicating renal impairment, and low albumin levels, suggesting possible malnutrition or liver disease. The elevated liver enzymes (ALT and AST) may be related to the patient's renal impairment or liver disease. The patient's lipid profile is also suboptimal, with high triglycerides and low HDL cholesterol.

The ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning for arrhythmias, which can increase the risk of sudden cardiac death. The patient's medication regimen, which includes beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, may help manage some of these comorbidities, but it may not address the underlying cardiac dysfunction.

Considering the patient's overall clinical presentation and laboratory results, I believe that the patient is at high risk for cardiovascular events, including sudden cardiac death. However, the patient's age and the presence of a significant medical history may also make them a candidate for long-term survival with proper management.

RANKING: 2. Pump failure death
REASONING: 

This patient's LVEF of 29.0 indicates significant left ventricular dysfunction, which can lead to heart failure. The patient's NYHA Class III indicates severe heart failure symptoms, and the elevated creatinine levels suggest renal impairment, which can further exacerbate heart failure.

The patient's medication regimen may help manage some of the comorbidities, but it may not address the underlying cardiac dysfunction. The elevated liver enzymes and low albumin levels may indicate malnutrition or liver disease, which can worsen heart failure.

The ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning for arrhythmias, which can increase the risk of pump failure.

Given the patient's significant cardiac dysfunction and comorbidities, I believe that pump failure death is a possible outcome.

RANKING: 3. Sudden cardiac death
REASONING: 

While the patient's ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning for arrhythmias, which can increase the risk of sudden cardiac death, I do not believe that this is the most likely outcome.

The patient's overall clinical presentation and laboratory results suggest that they have significant cardiac dysfunction and comorbidities, which may lead to pump failure rather than sudden cardiac death. The patient's age and medical history also make them a candidate for long-term survival with proper management.

While the patient's ECG findings are concerning, they do not seem to be the primary cause of their clinical presentation. I believe that the patient's underlying cardiac dysfunction and comorbidities are more likely to lead to pump failure rather than sudden cardiac death."
663,663,P0059,"Age: 78
Gender: Male 
Weight: 77 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 145/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 36,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 171.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 8283.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,79
Urea (mg/dL): 13,14
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

Based on the provided patient data, the patient's prognosis is as follows:

1. Sudden Cardiac Death: The patient's ECG impression shows multiple arrhythmias, including ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia. The presence of these arrhythmias, particularly non-sustained ventricular tachycardia, indicates a high risk of ventricular arrhythmias, which is a significant predictor of sudden cardiac death. Additionally, the patient's LVEF (left ventricular ejection fraction) is severely reduced at 30%, indicating significant cardiac dysfunction. This combination of factors increases the likelihood of sudden cardiac death.

2. Pump Failure Death: The patient's LVEF of 30% and the presence of ischemic dilated cardiomyopathy, hypertension, and diabetes further support the risk of pump failure. Cardiomyopathy and hypertension can lead to progressive cardiac dysfunction, and diabetes can exacerbate this process. The patient's elevated creatinine level (171.0 mmol/L) also indicates some degree of renal impairment, which can be associated with pump failure. However, the presence of arrhythmias and the patient's low LVEF make sudden cardiac death a more immediate concern.

3. Survivor: While the patient's overall condition is severe, the presence of arrhythmias and low LVEF suggest that the patient is at high risk for adverse cardiac events. However, the patient's age, weight, and hemoglobin level are not as concerning as the arrhythmias and cardiac dysfunction. The patient's medications, including beta blockers and ACE inhibitors, which are typically used to manage heart failure and arrhythmias, are already in place, indicating that the patient is receiving some level of medical management. However, the combination of severe cardiac dysfunction, arrhythmias, and low LVEF make it less likely for the patient to survive without any adverse cardiac events."
664,664,P0073,"Age: 65
Gender: Male 
Weight: 101 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 110/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,8
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4
LDL (mmol/L): 3,18
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 842.0
Protein (g/L): 73
T4 (ng/L): 17
TSH (mIU/L): 0,98
Urea (mg/dL): 5,66
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

Based on the patient's medical history, physical examination, and test results, I believe that the most likely prognosis is Sudden Cardiac Death. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. Additionally, the patient has a low left ventricular ejection fraction (LVEF) of 32%, indicating a severely impaired heart function. The presence of ventricular extrasystole and non-sustained ventricular tachycardia (VT) on the ECG also suggests an increased risk of arrhythmias, which can lead to sudden cardiac death.

The patient's other medical conditions, such as hypertension, dyslipidemia, and peripheral vascular disease, also contribute to the risk of cardiac complications. The elevated creatinine level and elevated BNP levels further indicate compromised cardiac function and fluid overload, which can increase the risk of sudden cardiac death.

The patient's age and sex are also factors that contribute to the risk of sudden cardiac death. The patient is 65 years old, which is an increased risk group for cardiac events.

While the patient is taking medications to manage their conditions, the presence of non-sustained VT and ventricular extrasystole on the ECG suggests that the patient is not adequately protected against arrhythmias, and the risk of sudden cardiac death remains high.

Therefore, based on the available information, I believe that Sudden Cardiac Death is the most likely prognosis for this patient."
665,665,P0079,"Age: 70
Gender: Male 
Weight: 75 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,56
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 517.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,45
Urea (mg/dL): 7,35
LVEF (%): 48.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Third-degree AVB
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 
The patient has a high-risk profile with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction. The patient's LVEF is 48%, indicating significant left ventricular dysfunction. The presence of ventricular extrasystole, particularly polymorphic ventricular extrasystole, is a significant concern for arrhythmias, which can lead to sudden cardiac death. The patient's ECG impression also shows third-degree AVB, which can increase the risk of arrhythmias. Additionally, the patient's elevated troponin levels (0.01 ng/mL) suggest some myocardial damage, which can contribute to arrhythmias. The patient's overall clinical presentation, laboratory results, and ECG findings suggest a high risk of sudden cardiac death in the next few years.

RANKING: 2. Pump Failure Death
REASONING: 
The patient's LVEF of 48% indicates significant left ventricular dysfunction, which can lead to heart failure. The patient's history of ischemic dilated cardiomyopathy, diabetes, and hypertension also contribute to the risk of heart failure. The patient's elevated creatinine levels (7.35 mg/dL) and urea levels (7.35 mg/dL) suggest some degree of renal impairment, which can exacerbate heart failure. The patient's use of beta blockers, which are commonly used to manage heart failure, may also contribute to worsening heart failure in this patient. While the patient's current medication regimen does not appear to be optimized for heart failure management, the patient's overall clinical presentation and laboratory results suggest a high risk of pump failure death in the next few years.

RANKING: 3. Survivor
REASONING: 
While the patient has a high-risk profile, the patient's current medication regimen, including calcium channel blockers, beta blockers, and statins, suggests that some degree of cardiovascular risk management is in place. The patient's LVEF is not as severely impaired as in the pump failure scenario, and the patient's ECG impression does not show any signs of severe arrhythmias. However, the patient's history of myocardial infarction, diabetes, and peripheral vascular disease, as well as the presence of ventricular extrasystole, still pose a significant risk of adverse cardiovascular events. While the patient may have a chance of survival, the overall risk of adverse cardiovascular events in the next few years is still significant, making pump failure death a more likely outcome than survivor."
666,666,P0112,"Age: 51
Gender: Male 
Weight: 76 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 139/83 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,12
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 975.0
Protein (g/L): 60
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,56
Urea (mg/dL): 4,49
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

The patient's prognosis is primarily determined by their underlying condition, which is ischemic dilated cardiomyopathy, a condition where the heart muscle is weakened and cannot pump blood efficiently. This condition is further complicated by a history of hypertension, myocardial infarction, and elevated troponin levels, indicating cardiac damage.

The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 20%, which is a strong indicator of poor cardiac function. The presence of ventricular extrasystoles and ventricular tachycardia on the ECG further suggests an increased risk of arrhythmias, which can lead to sudden cardiac death.

The patient's elevated BNP levels (975 ng/L) also indicate increased ventricular wall stress, which can contribute to cardiac failure. The patient's weight and BMI are also within the obese range, which can exacerbate cardiac dysfunction.

While the patient is on beta blockers, statins, and an ACE inhibitor, which are standard treatments for managing heart failure and hypertension, the severity of their condition, as indicated by the reduced LVEF and elevated BNP, suggests that their current treatment regimen may not be sufficient to reverse or significantly improve their cardiac function.

In contrast, pump failure death is a possible outcome, but it is less likely in this case, as the patient's cardiac function is already severely impaired. Survivor is the least likely outcome, given the patient's significant cardiac dysfunction and elevated risk of arrhythmias.

Therefore, based on the provided data, the most likely prognosis is sudden cardiac death."
667,667,P0127,"Age: 65
Gender: Male 
Weight: 70 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 553.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,1
Urea (mg/dL): 7,49
LVEF (%): 14.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient's prognosis is most likely to be sudden cardiac death due to the presence of several risk factors and findings that suggest advanced heart failure and significant cardiac dysfunction. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 14.0%, indicating significant systolic dysfunction, which is a strong predictor of adverse outcomes. Additionally, the patient has a history of dilated cardiomyopathy, a condition that can lead to sudden cardiac death. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG also increases the risk of sudden cardiac death.

The patient's elevated BNP levels (553 ng/L) also support this prognosis, as high BNP levels are associated with increased mortality and morbidity in heart failure patients. Furthermore, the patient's elevated creatinine levels (7.49 mg/dL) and urea levels (7.49 mg/dL) indicate impaired renal function, which can be a complication of advanced heart failure.

While the patient's NYHA class is II, which indicates moderate symptoms, the overall clinical picture suggests that the patient is at high risk for sudden cardiac death. The presence of ventricular extrasystoles and NSVT on the ECG further increases this risk.

The patient's medication regimen, which includes a beta-blocker (Digoxin) and an ACE inhibitor, is appropriate for managing heart failure and hypertension, but the patient's underlying cardiac dysfunction and other risk factors suggest that sudden cardiac death remains a significant concern.

While pump failure death is a possible outcome, it is less likely than sudden cardiac death in this case, given the patient's LVEF and the presence of NSVT. Survivor is the least likely outcome, given the patient's advanced cardiac dysfunction and other risk factors."
668,668,P0138,"Age: 68
Gender: Male 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,49
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2838.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 26
Troponin (ng/mL): 0,694
TSH (mIU/L): 0,894
Urea (mg/dL): 9,32
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Torsade de Points
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 
Based on the provided data, the patient is at a higher risk for pump failure due to the presence of valvular cardiomyopathy, which is a condition that affects the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 37%, which is a strong indicator of poor cardiac function. Additionally, the patient has a history of ventricular tachycardia, which can be a precursor to more severe arrhythmias, and the presence of non-sustained ventricular tachycardia (CH>10) further increases the risk of cardiac complications.

Although the patient has a history of NYHA Class II heart failure, which suggests some level of cardiac dysfunction, the presence of ventricular tachycardia and reduced LVEF suggests that the patient is at a higher risk for cardiac events. However, the patient is also taking medications that are commonly used to manage heart failure, such as beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which can help to slow the progression of the disease and improve symptoms.

Therefore, while the patient is at a higher risk for pump failure, the presence of these medications and the patient's overall clinical status suggest that the patient is more likely to survive for the next few years compared to sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: 
This prognosis is based on the patient's reduced LVEF and history of ventricular tachycardia. The patient's left ventricular ejection fraction (LVEF) is significantly reduced, which indicates that the patient's heart is not pumping blood effectively. This can lead to heart failure, which is a common complication of valvular cardiomyopathy. The patient's history of ventricular tachycardia further increases the risk of cardiac complications, including pump failure.

The patient's current medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, can help to manage symptoms and slow the progression of the disease. However, the presence of ventricular tachycardia and reduced LVEF suggests that the patient is at a higher risk for pump failure.

RANKING: 3. Sudden cardiac death
REASONING: 
The patient's ECG impression shows the presence of ventricular extrasystole, ventricular tachycardia, and non-sustained ventricular tachycardia, which are all indicators of arrhythmias that can increase the risk of sudden cardiac death. The patient's reduced LVEF and history of ventricular tachycardia further increase the risk of cardiac complications, including sudden cardiac death.

While the patient is taking medications that can help to manage symptoms and slow the progression of the disease, the presence of these arrhythmias and reduced LVEF suggests that the patient is at a higher risk for sudden cardiac death. However, the patient's overall clinical status and the presence of these medications suggest that the patient is more likely to survive for the next few years compared to pump failure death."
669,669,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's prognosis is primarily influenced by the combination of severe valvular cardiomyopathy, significant left ventricular dysfunction (LVEF 20.0), and the presence of ventricular tachycardia (VT) and non-sustained VT on the ECG impression. The elevated Pro-BNP level (3527.0 ng/L) also suggests a high level of ventricular stress and strain, which can be associated with heart failure.

The patient's history of myocardial infarction and peripheral vascular disease further increases the risk of cardiovascular complications. The presence of ventricular extrasystole and polymorphic ventricular tachycardia on the ECG impression suggests a high risk of arrhythmic events.

Given the severity of the left ventricular dysfunction (LVEF 20.0) and the presence of ventricular tachycardia, it is likely that the patient will experience cardiac failure, which is a common complication of severe left ventricular dysfunction. However, the patient's survival is still uncertain due to the high risk of arrhythmic events.

Sudden cardiac death is the most likely outcome due to the combination of severe left ventricular dysfunction, ventricular tachycardia, and the presence of polymorphic ventricular tachycardia. The patient's elevated Pro-BNP level and elevated creatinine level (8.5 mg/dL) also suggest a high risk of cardiac failure, but the presence of ventricular tachycardia and polymorphic ventricular tachycardia on the ECG impression makes sudden cardiac death a more likely outcome.

Pump failure death is a possible outcome, but it is less likely than sudden cardiac death due to the patient's relatively stable hemodynamic parameters (BP 130/85 mmHg) and the absence of signs of acute heart failure.

Survival is the least likely outcome due to the combination of severe left ventricular dysfunction, ventricular tachycardia, and polymorphic ventricular tachycardia on the ECG impression. However, the patient's relatively stable hemodynamic parameters and the presence of medications that may help manage arrhythmias and heart failure (Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor) may improve the patient's survival."
670,670,P0157,"Age: 76
Gender: Male 
Weight: 70 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 38,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,13
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 8,6
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,26
Potassium (mEq/L): 4,49
LDL (mmol/L): 3,06
Sodium (mEq/L): 134.0
Protein (g/L): 74,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,36
Urea (mg/dL): 10,3
LVEF (%): 42.0
Medications: Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

Based on the provided patient data, I predict the most likely outcome is sudden cardiac death. The patient's history of hypertrophic cardiomyopathy, hypertension, and myocardial infarction increases the risk of cardiac arrhythmias and sudden cardiac death. The patient's LVEF of 42.0 indicates left ventricular dysfunction, which is a significant risk factor for sudden cardiac death.

The presence of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) on the ECG impression further supports this prediction. These findings suggest an increased risk of life-threatening arrhythmias, which can lead to sudden cardiac death.

Additionally, the patient's age (76) and NYHA Class II heart failure status also contribute to the risk of sudden cardiac death. Older patients with heart failure are at higher risk of sudden cardiac death due to various factors, including arrhythmias and cardiac ischemia.

While the patient's current medications, including spironolactone, ACE inhibitor, and nitrovasodilator, are being used to manage his heart failure and hypertension, the presence of ventricular arrhythmias and left ventricular dysfunction suggests that these medications may not be sufficient to prevent sudden cardiac death.

Overall, the combination of the patient's medical history, ECG findings, and current clinical status makes sudden cardiac death the most likely outcome."
671,671,P0159,"Age: 81
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 38,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 165.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 2,92
Sodium (mEq/L): 135.0
Protein (g/L): 70,9
T4 (ng/L): 10,1
Troponin (ng/mL): 0,02
TSH (mIU/L): 15,55
Urea (mg/dL): 15,9
LVEF (%): 22.0
Medications: Amiodarone, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Survivor
REASONING: 
The patient's age is 81, which increases the risk of cardiac events. However, the patient's NYHA Class III indicates severe heart failure, which is a significant concern. The patient has a history of idiopathic dilated cardiomyopathy, a condition that can lead to sudden cardiac death. The presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG further increases the risk of cardiac events. Despite the patient's medication regimen, including Amiodarone, which is used to treat ventricular arrhythmias, the patient's LVEF is only 22%, indicating severely impaired cardiac function.

The patient's creatinine level of 165.0 mmol/L suggests renal impairment, which can increase the risk of cardiac complications. The patient's serum potassium level of 2.92 mEq/L is slightly elevated, which can also contribute to cardiac arrhythmias. 

Given these factors, the patient's overall risk of cardiac events, particularly sudden cardiac death, is high. However, the patient's age and NYHA Class III heart failure may also contribute to a higher risk of mortality.

2. Pump failure death
REASONING: 
The patient's severely impaired LVEF of 22% indicates that the patient's heart is not pumping effectively, which can lead to pump failure. The patient's NYHA Class III heart failure classification also suggests that the patient's heart is not functioning well, increasing the risk of pump failure.

The patient's creatinine level of 165.0 mmol/L and elevated serum potassium level of 2.92 mEq/L can contribute to cardiac complications, including pump failure. The patient's medication regimen, including Loop Diuretics, may not be sufficient to manage the patient's heart failure.

The patient's ventricular tachycardia and non-sustained ventricular tachycardia on the ECG also increase the risk of cardiac events, including pump failure.

3. Sudden cardiac death
REASONING: 
The patient's high risk of cardiac events, including ventricular tachycardia and non-sustained ventricular tachycardia, and severely impaired LVEF of 22%, make sudden cardiac death a significant concern. The patient's age, NYHA Class III heart failure, and renal impairment also increase the risk of cardiac events.

However, pump failure death is a more likely outcome due to the patient's severely impaired cardiac function and the presence of NYHA Class III heart failure. Sudden cardiac death is a more acute event, and while the patient's ECG findings suggest an increased risk, it is not the most likely outcome given the patient's overall clinical picture."
672,672,P0172,"Age: 69
Gender: Female 
Weight: 74 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 120/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,45
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 4,61
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1383.0
Protein (g/L): 70,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,43
Urea (mg/dL): 6,1
LVEF (%): 22.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

This patient's prognosis is at high risk for sudden cardiac death due to the combination of several factors. Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The left ventricular ejection fraction (LVEF) is severely reduced at 22%, indicating that the heart is not pumping efficiently, which can lead to arrhythmias and decreased cardiac output.

The patient's elevated troponin level (0.01 ng/mL) suggests some degree of cardiac damage, which may be related to the cardiomyopathy. The presence of ventricular extrasystoles on the ECG impression further supports this, as these are often associated with arrhythmias.

Additionally, the patient's low ejection fraction and elevated B-type natriuretic peptide (Pro-BNP) level (1383 ng/L) indicate a high level of cardiac stress and strain, which can contribute to the development of arrhythmias and sudden cardiac death.

Given the patient's age, NYHA class II heart failure, and the presence of ventricular extrasystoles, the risk of sudden cardiac death is significant. The patient's medications, including beta blockers, digoxin, and loop diuretics, may be contributing to the development of arrhythmias, although they are being used to manage the patient's heart failure symptoms.

While the patient's blood pressure is within a relatively normal range, the presence of hypertension and cardiomyopathy increases the risk of cardiac complications, including sudden cardiac death.

Therefore, based on the available information, sudden cardiac death is the most likely outcome for this patient over the next few years, given the combination of her underlying heart condition, cardiac damage, and arrhythmias."
673,673,P0176,"Age: 78
Gender: Male 
Weight: 64 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,1
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,8
LDL (mmol/L): 1,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 4853.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 7,37
Urea (mg/dL): 24,13
LVEF (%): 36.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 78-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and previous myocardial infarction. The patient has a NYHA Class III heart failure, indicating severe heart failure symptoms. The elevated creatinine level (186.0 mmol/L) suggests impaired renal function, which can be a complication of heart failure. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia on the ECG impression suggests an increased risk of arrhythmias. However, the patient is currently being treated with medications that target these conditions, such as calcium channel blockers, beta blockers, loop diuretics, and nitrovasodilators.

Despite the patient's poor heart function and elevated biomarkers (e.g., BNP, troponin), the absence of overt signs of acute decompensated heart failure (e.g., acute kidney injury, severe hypotension) and the fact that the patient is receiving optimal medical therapy for their conditions suggest that the patient may be able to survive with careful management and monitoring.

While the patient's LVEF (36.0%) is significantly reduced, it is not the lowest value, and the patient is receiving medications that aim to improve cardiac function. Therefore, I rank the patient as having a higher chance of survival compared to the other two options.

RANKING: 2. Pump failure death
REASONING: 

The patient's LVEF (36.0%) is significantly reduced, indicating severe systolic dysfunction. This, combined with the patient's NYHA Class III heart failure and elevated creatinine level, suggests that the patient's heart is not functioning optimally. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG impression increases the risk of cardiac events.

While the patient is receiving medications that target heart failure and arrhythmias, the fact that the patient's LVEF is so low suggests that the patient's heart is not responding well to treatment. This, combined with the patient's elevated biomarkers (e.g., BNP, troponin), suggests that the patient is at risk of cardiac pump failure.

However, the patient is not in acute decompensated heart failure, and the patient is receiving optimal medical therapy, which suggests that the patient may not die from pump failure immediately. Therefore, I rank the patient as having a moderate chance of pump failure death.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's ECG impression shows ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia, which increase the risk of cardiac events. The patient's history of ischemic dilated cardiomyopathy and previous myocardial infarction also increase the risk of sudden cardiac death.

However, the patient's elevated creatinine level and LVEF (36.0%) suggest that the patient's heart is not functioning optimally, which reduces the likelihood of sudden cardiac death. Additionally, the patient is receiving medications that target arrhythmias and heart failure, which may help reduce the risk of cardiac events.

Given the patient's complex medical history and the presence of arrhythmias, I rank the patient as having the lowest chance of survival, but not necessarily the lowest chance of sudden cardiac death. The patient's current medications and medical therapy may help mitigate this risk, but the underlying cardiac disease and arrhythmias still pose a significant threat."
674,674,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 
This patient has a high-risk profile for sudden cardiac death due to the presence of ischemic dilated cardiomyopathy, a history of hypertension, and a low LVEF of 30%. The elevated Pro-BNP level (2037.0 ng/L) suggests severe left ventricular dysfunction. The patient's ECG impression of monomorphic ventricular extrasystole is also a concerning sign. Additionally, the patient's NYHA class II indicates that they are experiencing symptoms of heart failure, which increases the risk of arrhythmias and sudden cardiac death. The patient's medications, such as beta blockers and ACE inhibitors, are appropriate for managing heart failure and hypertension, but they may not be sufficient to prevent sudden cardiac death in this high-risk patient. Overall, the combination of these factors makes sudden cardiac death the most likely outcome.

RANKING: 2. Pump Failure Death
REASONING: 
Given the patient's severe left ventricular dysfunction (LVEF 30%), heart failure symptoms (NYHA class II), and elevated Pro-BNP level, pump failure death is a likely outcome. The patient's elevated creatinine level (8.65 mg/dL) also suggests impaired renal function, which can be a complication of heart failure. The patient's medications, such as loop diuretics and spironolactone, are being used to manage heart failure symptoms, but the patient's underlying condition and low LVEF may still lead to pump failure.

RANKING: 3. Survivor
REASONING: 
While the patient's medications and current treatment plan are aimed at managing heart failure and hypertension, the patient's high-risk profile and underlying conditions make it less likely that they will survive without any adverse events. The patient's low LVEF, elevated Pro-BNP level, and ECG abnormalities increase the risk of arrhythmias and sudden cardiac death. However, the patient's age, weight, and hemoglobin level are not as high-risk as the other factors, which may contribute to a slightly better prognosis. Nevertheless, the patient's overall high-risk profile and the presence of severe left ventricular dysfunction make pump failure death a more likely outcome than survival."
675,675,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: The patient has a significant history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which are all risk factors for cardiac events. However, the patient is currently receiving medications for these conditions, including beta blockers, angiotensin II receptor blockers, and digoxin, which are aimed at reducing the risk of further cardiac events. The patient's ejection fraction (LVEF) is 22%, which is significantly reduced, indicating poor cardiac function. However, the patient's hemoglobin level is within the normal range, and the liver enzymes (ALT and AST) are not significantly elevated, suggesting that the patient is not experiencing acute liver damage. The ECG impression shows non-sustained ventricular tachycardia, but the patient is not experiencing symptoms. The patient's serum creatinine level is elevated, but this is likely a result of the patient's underlying kidney disease rather than a direct effect of the cardiac condition. Overall, while the patient has a high-risk profile, the patient is currently stable and not experiencing acute cardiac events, which suggests that the patient may survive for several years.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF is 22%, which is a strong indicator of poor cardiac function and increased risk of heart failure. The patient's serum creatinine level is elevated, which suggests that the patient's kidneys are not functioning well, which can contribute to cardiac pump failure. The patient's NYHA Class II indicates that the patient has some limitations in physical activity due to their cardiac condition, which can increase the risk of cardiac events. The patient's medication list includes loop diuretics, which are used to treat heart failure, but the patient's serum potassium level is elevated, which can be a sign of potassium wasting, a common side effect of diuretics. While the patient's cardiac enzymes are not significantly elevated, the patient's ECG impression shows non-sustained ventricular tachycardia, which can increase the risk of cardiac events.

RANKING: 3. Sudden cardiac death
REASONING: The patient's ECG impression shows non-sustained ventricular tachycardia, which is a significant risk factor for sudden cardiac death. The patient's serum creatinine level is elevated, which can increase the risk of cardiac events. The patient's LVEF is 22%, which is a strong indicator of poor cardiac function and increased risk of cardiac events. While the patient is currently stable and not experiencing acute cardiac events, the patient's high-risk profile and ECG findings suggest that the patient is at high risk for sudden cardiac death. The patient's medication list includes beta blockers, which can increase the risk of hypotension and decreased cardiac output, which can increase the risk of sudden cardiac death."
676,676,P0215,"Age: 82
Gender: Male 
Weight: 82 kg
Height: 166 cm
NYHA Class: III
Blood Pressure: 170/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 7,45
Creatinine (mmol/L): 114.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 12,2
Hemoglobin (g/L): 153.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,43
LDL (mmol/L): 2,4
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 410.0
Protein (g/L): 80
T3 (pg/dL): 0,06
T4 (ng/L): 17,46
Troponin (ng/mL): 1
TSH (mIU/L): 1,18
Urea (mg/dL): 10
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1
REASONING: 

Based on the patient data, I rank the patient outcome as ""sudden cardiac death"" with a high likelihood. The key factors contributing to this ranking are:

1. Age: The patient is 82 years old, which is an advanced age for cardiac events. The risk of sudden cardiac death increases significantly with age, especially in patients with pre-existing cardiovascular conditions.
2. NYHA Class III: The patient has a severe heart failure classification, indicating significant cardiac dysfunction. This can lead to decreased cardiac output, increased risk of arrhythmias, and reduced tolerance to physical stress, all of which increase the risk of sudden cardiac death.
3. ECG Impression: The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) suggests an increased risk of arrhythmic events, which is a common cause of sudden cardiac death.
4. Pro-BNP levels: Elevated Pro-BNP levels indicate increased ventricular stress and strain, which can contribute to arrhythmias and sudden cardiac death.
5. Medication regimen: The patient is on several medications that can contribute to arrhythmias, such as digoxin and nitrovasodilators, which can increase the risk of ventricular arrhythmias.
6. Past medical history: The presence of hypertension, cardiomyopathy, diabetes, dyslipidemia, and peripheral vascular disease increases the patient's risk of cardiovascular events, including sudden cardiac death.

While pump failure death is a possible outcome, it is less likely than sudden cardiac death given the presence of arrhythmic events and the patient's advanced age. Survivor is the least likely outcome given the combination of these risk factors."
677,677,P0217,"Age: 79
Gender: Male 
Weight: 94 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,79
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 10,95
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,58
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1825.0
Protein (g/L): 77
T3 (pg/dL): 0,0372
T4 (ng/L): 18,5
TSH (mIU/L): 3,2
Urea (mg/dL): 14,6
LVEF (%): 30.0
Medications: Diabetes Medication, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's prognosis is influenced by a combination of factors, including advanced age, existing medical conditions, and laboratory results. 

Firstly, the patient's age (79 years) is a significant risk factor for cardiac-related complications. The presence of ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, and hypertension further increases the risk of cardiac complications. The patient's LVEF (Left Ventricular Ejection Fraction) of 30.0% indicates severely reduced cardiac function, which is a strong predictor of adverse outcomes.

The elevated creatinine level (119.0 mmol/L) suggests impaired renal function, which can be related to cardiac dysfunction. The patient's elevated Pro-BNP level (1825.0 ng/L) indicates elevated natriuretic peptide levels, which is a marker of ventricular strain and cardiac dysfunction.

The presence of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) on the ECG impression further supports the likelihood of cardiac arrhythmias, which are a significant predictor of sudden cardiac death.

The patient's low HDL (1.3 mmol/L) and high LDL (3.58 mmol/L) cholesterol levels indicate dyslipidemia, which is a risk factor for cardiovascular disease. The patient's elevated glucose level (10.95 mmol/L) and the presence of diabetes also increase the risk of cardiac complications.

Considering these factors, the patient's prognosis is most likely to be sudden cardiac death due to the combination of advanced age, severely reduced cardiac function, and a high risk of cardiac arrhythmias. Pump failure death is a possible outcome, given the patient's severely reduced LVEF and impaired renal function. The patient's survival is less likely due to the presence of multiple comorbid conditions and the high risk of cardiac complications."
678,678,P0218,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,15
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,06
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1
Potassium (mEq/L): 4,17
LDL (mmol/L): 2,49
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 4058.0
Protein (g/L): 68
T3 (pg/dL): 0,0471
T4 (ng/L): 16,72
Troponin (ng/mL): 0,2
TSH (mIU/L): 2,17
Urea (mg/dL): 6,4
LVEF (%): 20.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the provided patient data, I would rank the patient's prognosis as sudden cardiac death. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for arrhythmias and sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 20%, indicating advanced heart failure. The presence of ventricular extrasystoles, as indicated by the ECG impression, suggests an increased risk of arrhythmias, which can lead to sudden cardiac death. Additionally, the patient's elevated troponin levels, despite being within normal limits, may indicate some degree of myocardial damage.

The patient's other medical conditions, such as hypertension and hyperlipidemia, also contribute to the overall risk of cardiovascular events. The patient's low HDL cholesterol level (1 mmol/L) and elevated LDL cholesterol level (2.49 mmol/L) increase the risk of atherosclerotic cardiovascular disease.

The patient's low hemoglobin level (154 g/L) and elevated creatinine level (6.4 mg/dL) suggest some degree of kidney dysfunction, which can be associated with heart failure and increased risk of cardiovascular events.

Given the combination of advanced heart failure, arrhythmias, and other cardiovascular risk factors, I believe that the patient is at high risk for sudden cardiac death. Therefore, I would rank the patient's prognosis as sudden cardiac death.

While pump failure death is also a possible outcome, given the patient's advanced heart failure, I would rank it as the second most likely outcome. The patient's current LVEF is severely impaired, and the patient is already on ACE inhibitors, which may not be sufficient to reverse the underlying cardiomyopathy.

The survivor outcome is the least likely, given the patient's advanced heart failure and other cardiovascular risk factors."
679,679,P0221,"Age: 64
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 100/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,13
Creatinine (mmol/L): 200.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 10,67
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,33
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 2365.0
Protein (g/L): 75
T3 (pg/dL): 0,0312
T4 (ng/L): 15,14
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,77
Urea (mg/dL): 29,3
LVEF (%): 40.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 

This patient has a high risk of sudden cardiac death due to the presence of several factors. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient also has a low left ventricular ejection fraction (LVEF) of 40%, indicating that the heart is not pumping efficiently. Additionally, the patient has a history of myocardial infarction, which can lead to scarring and further deterioration of heart function. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG also increases the risk of sudden cardiac death.

However, despite these risks, the patient is currently being treated with medications that are standard for managing heart failure and preventing sudden cardiac death, including a nitrovasodilator, which may help to improve blood flow to the heart. The patient's blood pressure is well-controlled, and the patient's kidney function is not severely impaired. The patient's electrolyte levels, including potassium, are within a relatively normal range. The patient's troponin levels are not elevated, indicating that there is no recent myocardial infarction.

Given these factors, I believe that the patient is more likely to survive in the short-term, although the risk of sudden cardiac death remains a concern. With proper management and monitoring, I would expect the patient to survive for at least 2-3 years, but the long-term prognosis remains uncertain.

RANKING: 2. Pump failure death
REASONING: 

While the patient is at risk of sudden cardiac death, the patient's low LVEF and history of ischemic dilated cardiomyopathy increase the risk of pump failure. The patient's kidney function is impaired, which can lead to fluid overload and further strain on the heart. The patient's elevated creatinine level (200.0 mmol/L) indicates that the patient's kidney function is not optimal. The patient's low HDL cholesterol level (0.9 mmol/L) also increases the risk of atherosclerosis and further cardiac events.

The patient's medication regimen is adequate for managing heart failure, but the patient's overall health status and risk factors for pump failure make it a concern. I would expect the patient to experience some degree of pump failure over the next 1-2 years, but the patient's survival is still possible with proper management and monitoring.

RANKING: 3. Sudden cardiac death
REASONING: 

While the patient is at high risk of sudden cardiac death, the patient's current treatment and management plan may reduce the risk of this outcome. The patient's medication regimen is standard for managing heart failure and preventing sudden cardiac death, and the patient's blood pressure is well-controlled. However, the patient's history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia (CH>10) on the ECG increase the risk of sudden cardiac death.

Given the patient's overall health status and risk factors, I would expect the patient to experience sudden cardiac death within the next 1-2 years, but the exact timing and likelihood are uncertain."
680,680,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for pump failure and sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 40%, which is well below the normal range, indicating severe left ventricular dysfunction. This suggests that the patient's heart is not pumping efficiently, which can lead to heart failure.

The patient's elevated BNP levels (10297.0 ng/L) also support the presence of heart failure, as BNP is a biomarker for ventricular stress and strain. The patient's weight and height also suggest a higher risk for heart failure, as a higher BMI can increase the risk of developing heart failure.

While the patient has a history of ventricular extrasystoles and non-sustained ventricular tachycardia, the presence of a non-sustained ventricular tachycardia (CH>10) is a significant concern. This arrhythmia can increase the risk of sudden cardiac death. However, the patient's ECG impression also mentions a polymorphic ventricular extrasystole, which is a type of arrhythmia that can also increase the risk of sudden cardiac death.

In contrast, the patient's overall prognosis is not as poor as pump failure death, as the patient is currently being treated with medications for heart failure and has a relatively stable hemodynamic status. The patient's blood pressure, creatinine, and electrolyte levels are within relatively normal ranges, and the patient's hemoglobin and HDL levels are also within normal ranges.

Overall, while the patient has several risk factors for pump failure and sudden cardiac death, the presence of a stable hemodynamic status and current treatment with medications for heart failure suggest that pump failure death is the most likely outcome. Sudden cardiac death is a possible but less likely outcome, and survival is the least likely outcome given the patient's significant cardiac risk factors."
681,681,P0261,"Age: 40
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 37,6
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 236
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,95
Potassium (mEq/L): 3,32
LDL (mmol/L): 3,02
Sodium (mEq/L): 131.0
Pro-BNP (ng/L): 2598.0
Protein (g/L): 73,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,39
Urea (mg/dL): 1,8
LVEF (%): 19.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death 
REASONING:

This patient has a high risk of sudden cardiac death due to the presence of several factors:

1. Low LVEF (19.0%) indicates severe left ventricular dysfunction, which is a significant predictor of adverse outcomes in patients with cardiomyopathy.
2. The presence of ventricular extrasystoles, specifically polymorphic ventricular extrasystoles, is a strong indicator of increased risk of ventricular arrhythmias, which can lead to sudden cardiac death.
3. The patient's history of myocardial infarction (MI) and hypertension increases the risk of cardiac complications, including arrhythmias and sudden cardiac death.
4. The elevated Troponin level (0.01 ng/mL) suggests some degree of cardiac damage, which can contribute to arrhythmias and other cardiac complications.
5. The patient's NYHA Class II symptoms indicate that the patient has some limitation in physical activity, which may be related to cardiac dysfunction and increased risk of arrhythmias.
6. The elevated BNP level (2598 ng/L) suggests elevated ventricular wall stress, which is a predictor of adverse outcomes in patients with heart failure.

Given these factors, the patient is at high risk of sudden cardiac death, and close monitoring and management of his cardiac function, arrhythmias, and other risk factors are crucial to prevent this outcome.

RANKING: 2. Pump Failure Death 
REASONING: 

This patient is at risk of pump failure due to the presence of:

1. Severe left ventricular dysfunction (LVEF 19.0%)
2. History of myocardial infarction and hypertension, which can lead to cardiac remodeling and decreased cardiac function.
3. Elevated BNP level (2598 ng/L), indicating elevated ventricular wall stress.
4. NYHA Class II symptoms, indicating some limitation in physical activity due to cardiac dysfunction.

However, the patient's current cardiac function is not severely impaired, and he is receiving medications to manage his condition, which may help slow the progression of cardiac dysfunction.

RANKING: 3. Survivor 
REASONING: 

This patient's overall prognosis is guarded, but not extremely poor. The patient's:

1. Current medications (loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator) suggest that his cardiac function is being managed.
2. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that his arrhythmias are not severe.
3. The patient's hemoglobin level (143 g/L) and other laboratory values are within normal limits, indicating no acute kidney injury or anemia.

However, the patient's severe left ventricular dysfunction (LVEF 19.0%) and history of myocardial infarction and hypertension suggest that his cardiac function is still compromised, and he may require close monitoring and management to prevent further decline."
682,682,P0262,"Age: 58
Gender: Female 
Weight: 61 kg
Height: 145 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Valvular cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38,2
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 50.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 330
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 121.0
HDL (mmol/L): 0,92
Potassium (mEq/L): 4,12
LDL (mmol/L): 2,72
Sodium (mEq/L): 142.0
Protein (g/L): 73,6
T4 (ng/L): 15,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 8,26
Urea (mg/dL): 10
LVEF (%): 25.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Survivor
REASONING: 
This patient has a complex medical history, including valvular cardiomyopathy, myocardial infarction, and NYHA Class III heart failure, which indicate significant cardiac dysfunction. The patient's left ventricular ejection fraction (LVEF) of 25.0% is severely reduced, suggesting advanced left ventricular dysfunction. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia (although not sustained) on the ECG also suggests a high risk of arrhythmias.

Although the patient is taking multiple medications, including Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, and ACE Inhibitor, the patient's current ECG findings and lab results do not indicate acute cardiac ischemia or acute coronary syndrome. The patient's troponin level is normal, and the creatinine level is elevated but not indicative of acute kidney injury.

The patient's age and sex are also neutral factors in predicting outcome. The patient's weight and height are also neutral factors.

Therefore, despite the complex medical history, the patient's current clinical presentation and ECG findings do not indicate a high risk of sudden cardiac death. The patient's survival is more likely than sudden cardiac death.

2. Pump failure death
REASONING: 
Given the patient's severely reduced LVEF of 25.0% and NYHA Class III heart failure, the patient is at high risk of developing heart failure exacerbation or pump failure. The patient's elevated creatinine level and elevated liver enzymes (AST and ALT) may also indicate some degree of kidney dysfunction, which can be exacerbated by heart failure.

The patient's multiple medications, including ACE Inhibitor, may help manage heart failure, but the patient's current ECG findings and lab results do not indicate acute cardiac ischemia or acute coronary syndrome. However, the patient's heart failure status and elevated creatinine level make pump failure a possible outcome.

3. Sudden cardiac death
REASONING: 
The patient's ECG findings of ventricular extrasystoles and non-sustained ventricular tachycardia, despite being not sustained, suggest a high risk of arrhythmias. However, the patient's current clinical presentation and ECG findings do not indicate acute cardiac ischemia or acute coronary syndrome.

The patient's age and sex are neutral factors in predicting outcome. The patient's weight and height are also neutral factors.

Given the patient's complex medical history and the presence of ventricular extrasystoles and non-sustained ventricular tachycardia, the patient is at high risk of arrhythmia-related complications, including sudden cardiac death. However, the patient's current clinical presentation and ECG findings do not indicate a high risk of sudden cardiac death compared to pump failure."
683,683,P0266,"Age: 68
Gender: Female 
Weight: 74 kg
Height: 136 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,21
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 62
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,18
Potassium (mEq/L): 4,15
LDL (mmol/L): 3,4
Sodium (mEq/L): 133.0
Protein (g/L): 76,7
Troponin (ng/mL): 0,02
TSH (mIU/L): 4
Urea (mg/dL): 10,7
LVEF (%): 70.0
Medications: Amiodarone, Loop Diuretics, Spironolactone, Statins, Hydralazine, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 

Given the patient's age (68), NYHA Class III heart failure, and the presence of multiple comorbidities such as hypertension, myocardial infarction, and dyslipidemia, the patient is already at a higher risk for cardiovascular events. However, the absence of elevated troponin levels and a normal LVEF (70.0) suggest that the patient's heart function is relatively preserved.

The patient is also taking medications such as Amiodarone, Loop Diuretics, Spironolactone, and ACE Inhibitor, which are commonly used to manage heart failure and prevent arrhythmias. The presence of ventricular extrasystole (polymorphic) on the ECG suggests that the patient has a history of arrhythmias, but the absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

The patient's laboratory results show a slightly elevated creatinine level (10.7 mg/dL), but this is not uncommon in patients with heart failure. The absence of significant electrolyte imbalances or other laboratory abnormalities suggests that the patient's renal function is not severely impaired.

Considering these factors, the most likely outcome for the patient over the next few years is survival, as the patient's heart function is relatively preserved, and the patient is already receiving treatment for heart failure and arrhythmias. However, it is essential to closely monitor the patient's condition and adjust the treatment plan as needed to minimize the risk of cardiovascular events.

RANKING: 2. Pump failure death
REASONING: 

The patient's NYHA Class III heart failure classification indicates that the patient has significant symptoms of heart failure, which increases the risk of pump failure. However, the patient's LVEF (70.0) is not severely reduced, suggesting that the patient's heart function is not severely compromised.

The patient's elevated creatinine level (10.7 mg/dL) may indicate some degree of renal impairment, which can contribute to pump failure. However, the patient is receiving treatment with Spironolactone, an ACE inhibitor, and Loop Diuretics, which can help manage fluid overload and reduce the risk of pump failure.

The patient's arrhythmias, as indicated by the ventricular extrasystole (polymorphic) on the ECG, may also contribute to the risk of pump failure. However, the absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death.

Considering these factors, the patient's risk of pump failure death is moderate, but not the most likely outcome. The patient's treatment plan should continue to focus on managing heart failure and arrhythmias, and close monitoring of the patient's condition is essential to minimize the risk of pump failure.

RANKING: 3. Sudden cardiac death
REASONING: 

The patient's age (68), NYHA Class III heart failure, and the presence of multiple comorbidities such as hypertension, myocardial infarction, and dyslipidemia increase the risk of cardiovascular events. The patient's elevated creatinine level (10.7 mg/dL) and slightly elevated troponin level (0.02 ng/mL) suggest that the patient's heart function is not as preserved as initially thought.

The patient's ventricular extrasystole (polymorphic) on the ECG is a significant finding, as it can be a precursor to ventricular tachycardia or fibrillation. The absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia reduces the risk of sudden cardiac death, but the presence of polymorphic ventricular extrasystoles increases the risk.

The patient's laboratory results show a slightly elevated glucose level (4.1 mmol/L), which may be related to the patient's diabetes, but this is not a significant finding. The patient's medication regimen, including Amiodarone, Loop Diuretics, Spironolactone, and ACE Inhibitor, is generally effective in managing arrhythmias and heart failure, but the patient's risk of sudden cardiac death is still elevated.

Considering these factors, the patient's risk of sudden cardiac death is moderate to high, and close monitoring of the patient's condition is essential to minimize this risk. However, the patient's treatment plan should continue to focus on managing heart failure and arrhythmias, and the patient should be closely monitored for any signs of sudden cardiac death."
684,684,P0271,"Age: 77
Gender: Male 
Weight: 70 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 167.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,13
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 962.0
Protein (g/L): 74,6
T3 (pg/dL): 0,045
T4 (ng/L): 17,49
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,76
Urea (mg/dL): 17,7
LVEF (%): 35.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: The patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy are significant risk factors for adverse outcomes. However, the patient's current medication regimen, including ACE inhibitors, loop diuretics, and statins, suggests a well-managed condition. The patient's LVEF of 35% indicates severe left ventricular dysfunction, but the absence of troponin elevation and a relatively low creatinine level suggest that the patient is not in acute decompensated heart failure. The patient's ECG shows ventricular extrasystole, but no signs of ventricular tachycardia or supraventricular tachyarrhythmia. While the patient's Pro-BNP level is elevated, it is not excessively high, which may suggest some residual cardiac function. Overall, these factors suggest that the patient is at risk of cardiac events, but the presence of a well-managed condition and relatively preserved cardiac function may increase the likelihood of survival. 

RANKING: 2. Sudden cardiac death
REASONING: The patient's history of myocardial infarction, ischemic dilated cardiomyopathy, and presence of ventricular extrasystole on the ECG increase the risk of sudden cardiac death. The patient's LVEF of 35% and elevated Pro-BNP level suggest significant left ventricular dysfunction, which can contribute to arrhythmias and sudden cardiac death. The patient's medication regimen is well-managed, but the presence of ventricular extrasystole on the ECG suggests an increased risk of arrhythmias.

RANKING: 3. Pump failure death
REASONING: The patient's LVEF of 35% and elevated Pro-BNP level suggest significant left ventricular dysfunction, which is a hallmark of heart failure. The patient's history of ischemic dilated cardiomyopathy, hypertension, and dyslipidemia further increase the risk of heart failure. While the patient is on ACE inhibitors and loop diuretics, which are standard treatments for heart failure, the patient's elevated creatinine level and relatively low eGFR suggest some degree of renal impairment, which can contribute to fluid overload and worsening heart failure. The patient's ventricular extrasystole on the ECG also increases the risk of arrhythmias and sudden cardiac death, which can occur in the setting of heart failure. Overall, the combination of significant left ventricular dysfunction, elevated Pro-BNP, and the presence of ventricular extrasystole on the ECG make pump failure death a possible outcome, but the patient's well-managed condition and relatively preserved cardiac function may increase the likelihood of survival."
685,685,P0280,"Age: 70
Gender: Female 
Weight: 63 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 19,1
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,66
Potassium (mEq/L): 4,91
LDL (mmol/L): 3,18
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 327.0
Protein (g/L): 73,6
T3 (pg/dL): 0,0504
T4 (ng/L): 18,13
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 12
LVEF (%): 66.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor
REASONING: 
The patient's age, NYHA Class II, and the presence of Hypertensive cardiomyopathy, Diabetes, and Hypertension suggest a history of cardiovascular disease. The patient's ECG shows ventricular extrasystoles, which are a common finding in patients with cardiomyopathy and can be associated with a higher risk of arrhythmias. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG reduces the risk of sudden cardiac death. The patient's LVEF is 66%, which is within the normal range, indicating that the heart is still functioning to some extent. The patient is also on medications that are commonly used to manage cardiovascular conditions, including beta blockers, which can help reduce the risk of arrhythmias. The presence of elevated Pro-BNP levels suggests some degree of cardiac stress, but it is not indicative of acute heart failure. Overall, the combination of these factors suggests that the patient is likely to survive for the next few years.

2. Pump failure death
REASONING: 
While the patient has a history of cardiovascular disease, the patient's LVEF is within the normal range, and the patient is on medications that can help manage their condition. The presence of ventricular extrasystoles on the ECG suggests that the patient may be at risk for arrhythmias, but this is not a guarantee of pump failure. The patient's elevated Pro-BNP levels suggest some degree of cardiac stress, but it is not indicative of acute heart failure. The patient's age and NYHA Class II suggest that the patient may have some residual cardiac function, which would make pump failure death less likely.

3. Sudden cardiac death
REASONING: 
Given the patient's history of Hypertensive cardiomyopathy, Diabetes, and Hypertension, the patient is at high risk for cardiovascular events, including arrhythmias and sudden cardiac death. The presence of ventricular extrasystoles on the ECG is a significant finding that increases the risk of arrhythmias, including ventricular tachycardia and sudden cardiac death. The patient's elevated Pro-BNP levels and elevated blood pressure also suggest that the patient may be at risk for cardiac stress and arrhythmias. The patient's age and NYHA Class II also increase the risk of sudden cardiac death. While the patient is on medications that can help manage their condition, the presence of ventricular extrasystoles on the ECG makes sudden cardiac death a more likely outcome."
686,686,P0289,"Age: 61
Gender: Male 
Weight: 84 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 58.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,28
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 4,59
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,2
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,7
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 642.0
Protein (g/L): 72
T3 (pg/dL): 0,0573
T4 (ng/L): 14,27
Troponin (ng/mL): 0,5
TSH (mIU/L): 2,99
Urea (mg/dL): 5,4
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the patient's data, the patient is at high risk of sudden cardiac death due to the presence of several factors that contribute to this outcome. 

1. Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 40%, which indicates significant left ventricular dysfunction. This is a major risk factor for sudden cardiac death, as it can lead to inefficient pumping of blood, which can cause arrhythmias and decreased cardiac output.

2. Presence of Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened and cannot pump blood efficiently. This condition can lead to arrhythmias and sudden cardiac death.

3. High Pro-BNP levels: The patient's Pro-BNP level is elevated at 642 ng/L, which indicates a high level of ventricular stress and strain. Elevated Pro-BNP levels are associated with an increased risk of sudden cardiac death.

4. History of Myocardial Infarction: The patient has a history of myocardial infarction, which can lead to scarring and remodeling of the heart muscle, increasing the risk of arrhythmias and sudden cardiac death.

5. Presence of Ventricular Extrasystole: The patient's ECG shows ventricular extrasystoles, which are premature ventricular contractions that can lead to arrhythmias and decreased cardiac output.

While the patient's medication regimen includes beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, which are commonly used to manage heart failure and hypertension, these medications may not be sufficient to mitigate the patient's high risk of sudden cardiac death.

Therefore, based on the patient's data, the most likely prognosis is sudden cardiac death."
687,687,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

This patient has a high-risk profile for sudden cardiac death due to the presence of several factors:

1. Severe left ventricular dysfunction: The LVEF is significantly reduced at 25%, indicating poor cardiac function, which increases the risk of arrhythmias and sudden cardiac death.
2. History of ischemic dilated cardiomyopathy: This condition is a significant risk factor for sudden cardiac death, as it can lead to electrical instability and arrhythmias.
3. Non-sustained ventricular tachycardia: The ECG impression shows non-sustained ventricular tachycardia, which is a strong predictor of sudden cardiac death.
4. Low ejection fraction: The patient's low LVEF further increases the risk of sudden cardiac death, as it indicates that the heart is not pumping efficiently, leading to increased strain and arrhythmias.
5. Multiple medications: The patient is taking multiple medications, including digoxin, loop diuretics, statins, and an ACE inhibitor, which can have pro-arrhythmic effects, especially when combined.
6. Low troponin levels: While the troponin level is not elevated, it's still a marker of myocardial injury, which can contribute to the risk of sudden cardiac death.
7. Presence of ventricular extrasystoles and polymorphic ventricular tachycardia: These arrhythmias are indicators of electrical instability and increase the risk of sudden cardiac death.

Given these factors, I predict that the patient is at high risk of sudden cardiac death in the next few years."
688,688,P0327,"Age: 76
Gender: Male 
Weight: 74 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 50,19
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 9,2
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,65
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,25
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3065.0
Protein (g/L): 78
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,05
TSH (mIU/L): 10,5
Urea (mg/dL): 8,69
LVEF (%): 36.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: The patient is 76 years old, with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. However, the patient's NYHA Class II indicates that they are not severely limited in their physical activity. The patient's medications, including beta blockers, amiodarone, and ACE inhibitors, are commonly used to manage heart failure and prevent sudden cardiac death. The patient's LVEF is 36.0%, which is a relatively preserved ejection fraction, suggesting that the patient's heart is still functioning to some extent. Additionally, the patient's troponin level is normal, indicating no acute myocardial infarction. While the patient has a history of diabetes, hypertension, and dyslipemia, which are risk factors for cardiovascular disease, their current lab values do not indicate acute kidney injury or acute coronary syndrome. Therefore, considering these factors, the patient's prognosis is more likely to be a survivor.

RANKING: 2. Sudden cardiac death
REASONING: The patient's ECG impression indicates ventricular extrasystole, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. The patient's LVEF is 36.0%, which is below the normal range, indicating reduced heart function. The patient's medications, including amiodarone, are used to manage arrhythmias, but the ECG impression does not indicate any specific treatment for the ventricular extrasystole. The patient's past medical history, including ischemic dilated cardiomyopathy, also increases the risk of sudden cardiac death. However, the patient's current lab values and medical history do not indicate any acute life-threatening conditions.

RANKING: 3. Pump failure death
REASONING: The patient's LVEF is 36.0%, which is below the normal range, indicating reduced heart function. The patient's NYHA Class II indicates that they are moderately limited in their physical activity, which suggests that their heart is not functioning optimally. The patient's medications, including loop diuretics and spironolactone, are used to manage heart failure, but the patient's current lab values do not indicate any acute kidney injury or acute coronary syndrome. While the patient has a history of ischemic dilated cardiomyopathy, the patient's current lab values do not indicate any acute heart failure. However, the patient's reduced LVEF and NYHA Class II classification make pump failure death a possible outcome."
689,689,P0330,"Age: 82
Gender: Male 
Weight: 60 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 47,69
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 127.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,26
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1414.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,96
Urea (mg/dL): 10,24
LVEF (%): 24.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Pump failure death
REASONING: 
This patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly reduces the heart's ability to pump blood effectively. The patient's LVEF is 24%, which is a strong indicator of impaired cardiac function. The presence of elevated creatinine levels (127 mmol/L) and low albumin levels (47.69 g/L) also suggest that the patient's kidneys may be under strain due to reduced cardiac output. The patient's current medications, including beta blockers, loop diuretics, and ACE inhibitors, are aimed at managing heart failure symptoms and reducing the workload on the heart. Given the patient's severe impairment of cardiac function and the presence of signs of volume overload (elevated creatinine and low albumin), pump failure death is the most likely outcome.

2. Sudden cardiac death
REASONING: 
Although the patient has a history of myocardial infarction, the patient's current ECG does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia. The patient's LVEF is significantly impaired, but the absence of any arrhythmias on the ECG makes sudden cardiac death less likely. However, the patient's elevated troponin level (0.01 ng/mL) suggests some myocardial damage, which may increase the risk of arrhythmias in the future. The patient's other risk factors, such as hypertension and ischemic cardiomyopathy, also contribute to the overall risk of sudden cardiac death. However, the absence of any ECG abnormalities makes this outcome less likely than pump failure.

3. Survivor
REASONING: 
Given the patient's severe impairment of cardiac function, the presence of signs of volume overload, and the patient's current medications, it is unlikely that the patient will survive for an extended period. The patient's elevated creatinine and low albumin levels suggest that the patient's kidneys are under strain, and the patient's LVEF is severely impaired. While the patient's ECG does not show any signs of arrhythmias, the patient's overall clinical picture suggests a high risk of mortality. However, without further information on the patient's overall health status and the effectiveness of their current treatment regimen, it is difficult to predict the patient's survival rate."
690,690,P0332,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 178 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 184.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 9,5
Hemoglobin (g/L): 113.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,82
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 7692.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,06
TSH (mIU/L): 3
Urea (mg/dL): 20,7
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

This patient has a high-risk profile with multiple comorbidities such as ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, and Myocardial Infarction. The patient's LVEF of 35.0 indicates severe left ventricular dysfunction, which is a significant predictor of adverse outcomes. The presence of elevated Pro-BNP levels (7692.0 ng/L) suggests significant ventricular strain and increased risk of heart failure exacerbation. The patient's ECG impression of polymorphic ventricular extrasystoles is also a red flag for an increased risk of ventricular arrhythmias, which can lead to sudden cardiac death.

The patient's age (63 years) and NYHA Class III status also contribute to the increased risk of adverse outcomes. The patient's high creatinine level (184.0 mmol/L) indicates chronic kidney disease, which can further exacerbate cardiac dysfunction and increase the risk of cardiovascular events.

Given these factors, the patient's prognosis is more likely to be sudden cardiac death. While the patient is on medications such as beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, which are standard treatments for managing heart failure and cardiovascular risk factors, the presence of multiple comorbidities and the patient's severe cardiac dysfunction make it challenging to mitigate the risk of sudden cardiac death.

The other two prognoses, survivor and pump failure death, are less likely due to the patient's high-risk profile and the severity of their cardiac dysfunction. While the patient may survive, the likelihood of experiencing pump failure death is higher due to the presence of severe left ventricular dysfunction and the patient's multiple comorbidities."
691,691,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor 
REASONING: 

Based on the provided patient data, the patient is at high risk for sudden cardiac death due to several factors:

1. History of Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which is a significant risk factor for sudden cardiac death. IDC is characterized by a weakened heart muscle that cannot pump blood efficiently, leading to an increased risk of arrhythmias and cardiac arrest.
2. NYHA Class III: The patient has a severe heart failure classification, indicating that the heart is unable to meet the body's demands, leading to symptoms such as shortness of breath, fatigue, and swelling. This classification is associated with a higher risk of cardiac events, including sudden cardiac death.
3. Low LVEF (30.0%): The left ventricular ejection fraction (LVEF) is a measure of the heart's pumping efficiency. A low LVEF indicates that the heart is not pumping blood effectively, which increases the risk of arrhythmias and cardiac events.
4. Presence of Non-sustained ventricular tachycardia (NSVT): The patient has been diagnosed with NSVT, which is a type of abnormal heart rhythm that can lead to sudden cardiac death.
5. Low Troponin levels: While the troponin level is not significantly elevated, it is still present, indicating some degree of cardiac damage.

Given these factors, the patient is at high risk for sudden cardiac death. However, with proper management and treatment, the patient may still have a chance of survival. Therefore, I rank the patient as having a high probability of survival.

RANKING: 2. Pump Failure Death 
REASONING: 

Based on the provided patient data, the patient is at high risk for pump failure death due to the following factors:

1. NYHA Class III: The patient's severe heart failure classification indicates that the heart is unable to meet the body's demands, leading to symptoms such as shortness of breath, fatigue, and swelling.
2. Low LVEF (30.0%): The patient's low LVEF indicates that the heart is not pumping blood effectively, which can lead to pump failure.
3. History of Ischemic Dilated Cardiomyopathy (IDC): The patient's history of IDC increases the risk of pump failure.
4. Medications: The patient is taking Loop Diuretics, which can help manage symptoms of heart failure but may not address the underlying cardiac dysfunction.

Given the patient's severe heart failure and low LVEF, the risk of pump failure death is significant.

RANKING: 3. Sudden Cardiac Death 
REASONING: 

While the patient is at risk for pump failure death, the presence of Non-sustained ventricular tachycardia (NSVT) and the patient's history of IDC and IDC increase the risk of sudden cardiac death. However, the patient's low troponin level and the presence of medications such as Calcium Channel Blocker, Loop Diuretics, and Spironolactone suggest that the patient is receiving appropriate treatment for their heart failure and may have some level of cardiac protection.

Therefore, while sudden cardiac death is a risk, the patient's overall prognosis is more favorable than pump failure death."
692,692,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

The patient has a high-risk profile with a history of ischemic dilated cardiomyopathy, myocardial infarction, and diabetes, which indicates significant cardiac damage and potential for arrhythmias. The presence of ventricular extrasystole, specifically polymorphic ventricular extrasystole, on the ECG impression suggests a high risk of life-threatening arrhythmias. The patient is also taking Amiodarone, a medication known to be associated with an increased risk of pro-arrhythmic effects, particularly in patients with pre-existing heart disease. Additionally, the patient's low LVEF of 40.0 indicates severe left ventricular dysfunction, which can contribute to a higher risk of arrhythmias and sudden cardiac death. The elevated Pro-BNP level of 2125.0 also suggests cardiac strain and potential heart failure, further increasing the risk of sudden cardiac death. Overall, the combination of these factors makes sudden cardiac death the most likely prognosis for this patient."
693,693,P0346,"Age: 78
Gender: Female 
Weight: 52 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 48,09
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 6,39
Creatinine (mmol/L): 139.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1990.0
Protein (g/L): 82
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,25
Urea (mg/dL): 12,69
LVEF (%): 24.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's clinical presentation and test results suggest that the patient is at high risk for cardiac-related complications. Here's a breakdown of the factors that led to this ranking:

1. Low LVEF (24.0%): This is a strong indicator of poor cardiac function, which is a major risk factor for both sudden cardiac death and pump failure. A normal LVEF is typically above 55%, so a value of 24% suggests severe left ventricular dysfunction.

2. Past Medical History: The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia, all of which can contribute to cardiac dysfunction and arrhythmias. The presence of these conditions increases the risk of cardiac complications.

3. ECG Impression: The presence of ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia (PSVT) in the ECG impression suggest an increased risk of arrhythmias, which can lead to sudden cardiac death.

4. Pro-BNP levels (1990.0 ng/L): Elevated BNP levels are associated with heart failure and cardiac dysfunction. This suggests that the patient's heart is under significant stress, which can contribute to cardiac complications.

5. Medications: The patient is taking medications that are typically used to manage heart failure and hypertension, but the presence of these medications does not necessarily mitigate the risk of sudden cardiac death or pump failure.

6. Other factors: The patient's age, weight, and laboratory results (e.g., elevated creatinine, low HDL cholesterol) also contribute to their overall risk profile, but they are not as critical as the factors mentioned above.

Considering these factors, the patient is at high risk for sudden cardiac death due to their poor cardiac function, history of cardiac disease, and presence of arrhythmias. Pump failure death is also a possibility, given the patient's heart failure status. However, the combination of these factors makes sudden cardiac death the most likely outcome."
694,694,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the patient's data, the patient is at high risk for sudden cardiac death. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF is severely reduced at 35%, indicating significant left ventricular dysfunction, which is also a risk factor for sudden cardiac death. Additionally, the patient's NYHA class is III, indicating severe symptoms of heart failure, which can lead to arrhythmias and sudden cardiac death.

The patient's ECG impression shows ventricular extrasystoles, which is a type of abnormal heart rhythm that can lead to sudden cardiac death. The presence of ventricular extrasystoles is a significant risk factor for sudden cardiac death, especially in patients with a history of heart disease.

While the patient's other risk factors, such as hypertension, diabetes, and peripheral vascular disease, also contribute to their risk of sudden cardiac death, the combination of ischemic dilated cardiomyopathy, severely reduced LVEF, and ventricular extrasystoles on ECG makes sudden cardiac death the most likely prognosis.

The patient's medication regimen, including beta blockers, ACE inhibitors, and statins, is also consistent with the management of heart failure and cardiovascular risk reduction, but it does not directly address the patient's high risk of sudden cardiac death.

Overall, the combination of severe left ventricular dysfunction, ventricular extrasystoles on ECG, and a history of heart disease makes sudden cardiac death the most likely prognosis for this patient."
695,695,P0351,"Age: 68
Gender: Male 
Weight: 73 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,3
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7
Hemoglobin (g/L): 142.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,04
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 934.0
Protein (g/L): 81
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,27
Urea (mg/dL): 14,25
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
REASONING: 
Based on the patient's data, the most likely prognosis is sudden cardiac death. This is due to the presence of several high-risk factors that contribute to an increased risk of arrhythmias and cardiac events. These factors include:

- NYHA Class II, indicating moderate symptoms of heart failure
- Ischemic dilated cardiomyopathy, a condition that can lead to arrhythmias and sudden cardiac death
- History of myocardial infarction, which can cause scarring and promote arrhythmias
- Elevated Pro-BNP levels, indicating increased ventricular wall stress and potential for arrhythmias
- Presence of ventricular extrasystoles, which can be a precursor to more severe arrhythmias
- Low LVEF (30%), indicating significant left ventricular dysfunction
- Presence of multiple medications, including beta blockers, statins, and ACE inhibitors, which may not be effective in managing the underlying cardiac condition

While the patient's current ECG impression shows no ventricular tachycardia, the presence of ventricular extrasystoles and other risk factors suggests that the patient is at high risk for sudden cardiac death.

RANKING: 
2. Pump Failure Death
REASONING: 
The second most likely prognosis is pump failure death. This is due to the patient's significant left ventricular dysfunction (LVEF 30%) and the presence of heart failure symptoms (NYHA Class II). The patient's elevated creatinine levels (136.0 mmol/L) also suggest renal impairment, which can be a complication of heart failure. The patient's medications, including ACE inhibitors, are likely being used to manage symptoms of heart failure, but may not be sufficient to reverse the underlying cardiac condition.

RANKING: 
3. Survivor
REASONING: 
The least likely prognosis is survivor. While the patient's medications and current symptoms suggest that they are receiving treatment for heart failure, the presence of high-risk factors, including ischemic dilated cardiomyopathy, ventricular extrasystoles, and significant left ventricular dysfunction, make it less likely that the patient will survive without experiencing a cardiac event. However, with aggressive management and close monitoring, it is possible that the patient may survive for an extended period, but the risk of cardiac events remains high."
696,696,P0356,"Age: 76
Gender: Male 
Weight: 82 kg
Height: 149 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 12
Hemoglobin (g/L): 169.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,31
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 4315.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,04
Urea (mg/dL): 14,03
LVEF (%): 20.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 

The patient's LVEF is severely reduced at 20%, indicating significant left ventricular dysfunction, which is a major risk factor for sudden cardiac death. The patient's NYHA Class III classification also suggests a severe limitation in physical activity due to symptoms. 

Although the patient has a history of myocardial infarction, the current ECG findings do not indicate any signs of acute coronary syndrome. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is a positive sign. However, the presence of monomorphic ventricular extrasystoles is a concerning sign, indicating an increased risk of arrhythmia-related events.

The patient's renal function, as indicated by the elevated creatinine level (118.0 mmol/L), is compromised, which may contribute to the development of cardiac dysfunction. However, this factor alone does not outweigh the impact of the severely reduced LVEF.

The patient's medication regimen includes ACE inhibitors and spironolactone, which are typically used to manage heart failure and hypertension. The patient's blood pressure is within a relatively normal range, and the medication is likely effective in controlling blood pressure.

Considering these factors, the patient is at a higher risk of cardiac-related complications, but the presence of a monomorphic ventricular extrasystole suggests that the patient is still at risk of sudden cardiac death. However, the overall prognosis is not the worst among the three options.

RANKING: 2. Sudden Cardiac Death
REASONING: 

The presence of monomorphic ventricular extrasystoles on the ECG is a significant risk factor for sudden cardiac death. This arrhythmia can degenerate into ventricular fibrillation or tachycardia, which can lead to sudden cardiac death.

The patient's severely reduced LVEF and NYHA Class III classification further increase the risk of cardiac-related complications. The patient's medication regimen is also effective in managing heart failure and hypertension, but it may not be sufficient to completely eliminate the risk of sudden cardiac death.

The patient's renal function is compromised, which may contribute to the development of cardiac dysfunction. However, this factor does not outweigh the impact of the monomorphic ventricular extrasystoles.

RANKING: 3. Pump Failure Death
REASONING: 

The patient's severely reduced LVEF and NYHA Class III classification indicate a high risk of pump failure death. The patient's renal function is also compromised, which can contribute to the development of cardiac dysfunction.

However, the presence of monomorphic ventricular extrasystoles on the ECG is a more significant risk factor for sudden cardiac death than pump failure. The patient's medication regimen is effective in managing heart failure and hypertension, which reduces the risk of pump failure death.

Considering these factors, the patient's risk of pump failure death is the lowest among the three options."
697,697,P0405,"Age: 37
Gender: Female 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,13
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,3
LDL (mmol/L): 4,14
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 853.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 0,562
Urea (mg/dL): 4,49
LVEF (%): 23.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 
This patient's ECG impression shows multiple concerning findings, including ventricular extrasystole, non-sustained ventricular tachycardia (VT), and non-sustained ventricular tachycardia (CH>10). These findings suggest a high risk of arrhythmic events, which is a significant predictor of sudden cardiac death in patients with cardiomyopathy. The patient's NYHA Class II symptoms also indicate some level of cardiac dysfunction. The presence of ventricular tachycardia on ECG, particularly the non-sustained VT, further increases the risk of sudden cardiac death. Additionally, the patient's LVEF of 23.0% is significantly reduced, indicating poor left ventricular function, which can contribute to an increased risk of arrhythmic events.

While the patient is on medications that are commonly used to manage heart failure and hypertension, the presence of these arrhythmic findings on ECG suggests that the patient's underlying cardiac condition is not adequately controlled. The patient's low ejection fraction and elevated troponin levels also suggest significant cardiac damage. Overall, the combination of these factors makes sudden cardiac death the most likely outcome.

RANKING: 2. Pump Failure Death
REASONING: 
While the patient's LVEF of 23.0% is significantly reduced, indicating poor left ventricular function, the patient is on medications that are commonly used to manage heart failure, including digoxin, loop diuretics, and spironolactone. These medications can help manage symptoms and improve functional status, but may not necessarily improve the underlying cardiac function.

However, the patient's elevated troponin levels suggest that there is significant cardiac damage, which can contribute to an increased risk of heart failure. Additionally, the patient's elevated creatinine level (71.0 mmol/L) suggests some degree of renal impairment, which can further increase the risk of heart failure. While the patient's NYHA Class II symptoms indicate some level of cardiac dysfunction, the patient's overall condition is not as severe as the patient's ECG findings suggest.

Therefore, while pump failure death is a possible outcome, it is less likely than sudden cardiac death given the patient's ECG findings.

RANKING: 3. Survivor
REASONING: 
Given the patient's poor LVEF, elevated troponin levels, and elevated creatinine level, it is likely that the patient will experience some degree of cardiac dysfunction. However, the patient's NYHA Class II symptoms and the presence of medications that are commonly used to manage heart failure suggest that the patient's functional status is relatively stable.

While the patient's ECG findings are concerning, the patient's medication regimen and NYHA Class II symptoms suggest that the patient is being adequately managed for their heart failure symptoms. Additionally, the patient's ejection fraction is not as severely reduced as might be expected given the patient's age and other factors.

Therefore, while the patient's cardiac condition is not optimal, the patient's overall condition is not as severe as the patient's ECG findings suggest, making survival a possible outcome."
698,698,P0409,"Age: 64
Gender: Male 
Weight: 89 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 145/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 78.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 170.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,06
Sodium (mEq/L): 143.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 24
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,4
Urea (mg/dL): 8,65
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Paroxismal flutter
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

The patient's ECG impression shows a high risk of arrhythmias, including non-sustained ventricular tachycardia (NSVT) and paroxysmal supraventricular tachycardia (PSVT). The presence of NSVT is particularly concerning, as it can be a precursor to more serious arrhythmias, such as ventricular tachycardia or fibrillation, which can lead to sudden cardiac death. Additionally, the patient's history of hypertensive cardiomyopathy and hypertension increases the risk of cardiac arrhythmias. The patient's LVEF (ejection fraction) is also mildly decreased at 65%, which can contribute to the risk of arrhythmias. The patient's age (64) and weight (89 kg) are also factors to consider, as they are in a higher risk category for cardiac events.

Given these factors, the likelihood of sudden cardiac death in the next few years is high. The patient's current medications, including a calcium channel blocker and ACE inhibitor, are being used to manage hypertension and heart failure symptoms, but may not be sufficient to completely mitigate the risk of arrhythmias.

The other two options, survivor and pump failure death, are less likely because the patient's current medications and medical history do not suggest a high risk of pump failure. While the patient has a history of cardiomyopathy, their LVEF is not severely decreased, and they are currently being treated with medications to manage heart failure symptoms. However, the presence of arrhythmias and hypertension increase the risk of cardiac events, making sudden cardiac death the most likely outcome in this patient."
699,699,P0416,"Age: 46
Gender: Male 
Weight: 77 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 48
ALT or GPT (IU/L): 51.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 8
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,41
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 247.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,12
TSH (mIU/L): 3,63
Urea (mg/dL): 6,32
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
REASONING: 
The patient has a history of idiopathic dilated cardiomyopathy, which is a condition characterized by an enlarged left ventricle that cannot pump blood efficiently. This condition can lead to heart failure, arrhythmias, and increased risk of sudden cardiac death. The patient's low LVEF (30.0%) further indicates poor cardiac function, which increases the risk of sudden cardiac death.

The patient's ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are also concerning for arrhythmias, which can increase the risk of sudden cardiac death. The presence of these arrhythmias, combined with the patient's poor LVEF and NYHA Class II heart failure, make sudden cardiac death the most likely prognosis.

The patient's elevated troponin level (0.12 ng/mL) may also indicate some degree of myocardial damage, which can increase the risk of sudden cardiac death.

While the patient's medications, including beta blockers and amiodarone, are being used to manage symptoms and prevent arrhythmias, the underlying cardiac condition and ECG findings suggest that the patient remains at high risk for sudden cardiac death.

In comparison, pump failure death is less likely because the patient is already taking medications to manage heart failure symptoms, and the patient's creatinine level is not severely elevated, indicating some degree of renal function. Survivorship is also less likely given the patient's poor LVEF and ECG findings."
700,700,P0438,"Age: 65
Gender: Male 
Weight: 79 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 115/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 49,6
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 149.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,82
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1114.0
Protein (g/L): 76,9
T4 (ng/L): 16
TSH (mIU/L): 0,86
Urea (mg/dL): 8,99
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING:

The patient's prognosis can be determined based on the provided data, which suggests a high risk of adverse outcomes. Here's a breakdown of the factors contributing to each ranking:

1. Sudden Cardiac Death (SCD): The patient's ECG impression shows ventricular extrasystole (polymorphic) and non-sustained ventricular tachycardia (VT), which are both markers of an increased risk of SCD. The presence of ventricular extrasystole, a type of abnormal heart rhythm, increases the risk of SCD. The patient's LVEF (left ventricular ejection fraction) is also severely impaired at 25%, indicating poor cardiac function, which further increases the risk of SCD.

2. Pump Failure Death: The patient's LVEF is severely impaired, and the patient has a history of idiopathic dilated cardiomyopathy, which is a condition that can lead to heart failure. The patient's elevated creatinine level (149.0 mmol/L) and urea (8.99 mg/dL) levels suggest impaired renal function, which can be a complication of heart failure. Additionally, the patient's low albumin level (49.6 g/L) and low hemoglobin level (134.0 g/L) indicate malnutrition and anemia, which can exacerbate heart failure.

3. Survivor: While the patient has a history of hypertension, dyslipidemia, and myocardial infarction, which are risk factors for cardiovascular disease, the patient's current ECG findings and lab results suggest a higher risk of adverse outcomes. The patient's NYHA Class II classification indicates mild symptoms of heart failure, which may not be severe enough to predict a poor prognosis. However, the patient's severely impaired LVEF and the presence of ventricular extrasystole and non-sustained VT on ECG suggest a high risk of SCD or pump failure, making survivor the least likely outcome.

Overall, the patient's combination of severely impaired LVEF, ventricular extrasystole, and non-sustained VT on ECG, along with impaired renal function and malnutrition, make SCD the most likely outcome. Pump failure death is a close second due to the patient's severely impaired LVEF and history of heart failure."
701,701,P0468,"Age: 69
Gender: Male 
Weight: 81 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 2,77
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 7519.0
Protein (g/L): 68,6
T3 (pg/dL): 0,0342
T4 (ng/L): 12,35
Troponin (ng/mL): 0,6
TSH (mIU/L): 5,19
Urea (mg/dL): 10,5
LVEF (%): 35.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

The patient's prognosis is classified as high risk for sudden cardiac death due to the presence of several significant risk factors and clinical findings. 

1. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened and cannot pump blood effectively. This can lead to heart failure and arrhythmias, increasing the risk of sudden cardiac death.

2. The patient has a low LVEF (35.0%), indicating severely reduced heart function, which can lead to inadequate blood circulation and oxygenation, increasing the risk of sudden cardiac death.

3. The patient has a history of myocardial infarction, which can lead to scarring and further weakening of the heart muscle, increasing the risk of arrhythmias and sudden cardiac death.

4. The patient has a high level of Pro-BNP (7519.0 ng/L), which is a biomarker for heart failure. Elevated levels of Pro-BNP indicate increased ventricular wall stress, which can contribute to arrhythmias and sudden cardiac death.

5. The patient has a history of hypertension, which can lead to cardiac remodeling and fibrosis, increasing the risk of arrhythmias and sudden cardiac death.

6. The patient's ECG shows ventricular extrasystole, which is a sign of abnormal heart rhythms and can increase the risk of sudden cardiac death.

7. The patient's medications, beta blockers and statins, are important for managing heart failure and reducing the risk of cardiovascular events, but may not be sufficient to mitigate the high-risk profile of this patient.

8. The patient's laboratory results show elevated creatinine (159.0 mmol/L), which may indicate impaired kidney function, which can increase the risk of cardiovascular events.

Given these factors, the patient is at high risk for sudden cardiac death, and close monitoring and management are necessary to mitigate this risk."
702,702,P0482,"Age: 60
Gender: Male 
Weight: 107 kg
Height: 181 cm
NYHA Class: III
Blood Pressure: 145/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,9
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,09
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1742.0
Protein (g/L): 67,9
T4 (ng/L): 12
TSH (mIU/L): 1,28
Urea (mg/dL): 10,98
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor
REASONING: 
The patient has several risk factors for cardiac complications, including a history of ischemic dilated cardiomyopathy, myocardial infarction, and a low left ventricular ejection fraction (LVEF) of 15%. Additionally, the patient has a history of ventricular extrasystoles and non-sustained ventricular tachycardia, which can increase the risk of sudden cardiac death. However, the patient is currently being treated with beta blockers, digoxin, and an ACE inhibitor, which are standard treatments for heart failure and arrhythmias. The patient's NYHA class III indicates moderate symptoms of heart failure, but it's not severe.

2. Pump failure death
REASONING: 
The patient's low LVEF of 15% indicates severe systolic dysfunction, which increases the risk of pump failure. The patient's elevated creatinine level (10.98 mg/dL) also suggests renal impairment, which can be a complication of heart failure. However, the patient is currently being treated with loop diuretics, which can help manage fluid overload and improve renal function.

3. Sudden cardiac death
REASONING: 
The patient's ECG impression shows a polymorphic ventricular extrasystole, which is a significant arrhythmia that can increase the risk of sudden cardiac death. However, the patient's current treatment regimen includes beta blockers, which can help manage arrhythmias. The presence of non-sustained ventricular tachycardia (CH>10) is also a concern, but it's not as severe as the polymorphic ventricular extrasystole. The patient's overall risk profile, including the presence of heart failure and arrhythmias, makes pump failure death a more likely outcome than sudden cardiac death, but it is still a significant risk."
703,703,P0494,"Age: 71
Gender: Male 
Weight: 82 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 84
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,25
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 224.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,02
TSH (mIU/L): 3
Urea (mg/dL): 6,66
LVEF (%): 42.0
Medications: Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING: 

Based on the patient's data, the patient is at high risk for sudden cardiac death. The presence of ventricular extrasystole (polymorphic), non-sustained ventricular tachycardia (CH>10), and paroxysmal supraventricular tachyarrhythmia (TPSV) on the ECG impression suggests a high risk for arrhythmic events. The patient's NYHA Class II indicates moderate symptoms of heart failure, and the LVEF of 42% suggests significant left ventricular dysfunction. The presence of ischemic dilated cardiomyopathy and a history of myocardial infarction further increases the risk of arrhythmic events.

The patient's elevated BNP levels (224.0 ng/L) and elevated troponin levels (0.02 ng/mL) suggest cardiac stress and possible myocardial injury. The patient's low HDL cholesterol level (1.14 mmol/L) and high LDL cholesterol level (2.25 mmol/L) also contribute to an increased risk of cardiovascular events.

While pump failure is a potential complication of advanced heart failure, the patient's current LVEF is not severely impaired, and the presence of medications such as beta blockers and nitrovasodilators suggests that the patient is receiving optimal treatment for heart failure. Therefore, pump failure death is less likely compared to sudden cardiac death.

Survivorship is the least likely outcome, as the patient's underlying conditions, including ischemic dilated cardiomyopathy, dyslipemia, and a history of myocardial infarction, increase the risk of arrhythmic events and other cardiovascular complications."
704,704,P0498,"Age: 80
Gender: Female 
Weight: 53 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 38,1
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,25
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 6
Hemoglobin (g/L): 119.0
Potassium (mEq/L): 4,56
Sodium (mEq/L): 139.0
Protein (g/L): 71,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,63
Urea (mg/dL): 13,4
LVEF (%): 18.0
Medications: Amiodarone, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's data suggests a high risk of adverse outcomes, which justifies the ranking as follows:

1. Sudden cardiac death: The patient's ECG impression reveals several concerning findings, including ventricular extrasystole (polymorphic), non-sustained ventricular tachycardia (NSVT), and a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The presence of NSVT, in particular, indicates an increased risk of ventricular arrhythmias, which can lead to sudden cardiac death. The patient's NYHA Class II heart failure also suggests a compromised cardiac function, further increasing the risk of arrhythmias and sudden cardiac death.

2. Pump failure death: While the patient's LVEF is severely reduced (18%), indicating significant left ventricular dysfunction, the patient is currently being treated with medications, including ACE inhibitors, loop diuretics, and digoxin, which are standard treatments for heart failure. However, the patient's ECG findings and past medical history suggest a higher risk of sudden cardiac death, making pump failure death less likely in the short term.

3. Survivor: Although the patient's ECG findings are concerning, the patient's age (80) and overall health status (NYHA Class II heart failure) suggest that they may not have a long life expectancy. However, the patient's ECG findings and past medical history do not provide sufficient evidence to predict a high risk of sudden cardiac death in the short term, making survival a more likely outcome compared to pump failure death. Nevertheless, the patient's overall health status and medication regimen make it uncertain whether the patient will survive in the long term."
705,705,P0504,"Age: 78
Gender: Male 
Weight: 75 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 7,03
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,84
LDL (mmol/L): 4,73
Sodium (mEq/L): 139.0
Protein (g/L): 67,3
T3 (pg/dL): 0,0483
T4 (ng/L): 16,58
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,67
Urea (mg/dL): 10
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's prognosis is primarily influenced by the presence of dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is compromised. The patient's left ventricular ejection fraction (LVEF) of 34.0% further emphasizes this, indicating a significant reduction in the heart's pumping efficiency.

The patient's elevated creatinine level (120.0 mmol/L) suggests some degree of renal impairment, which may be related to the cardiomyopathy. This could further compromise the patient's overall health and increase the risk of complications.

The patient's ECG findings of ventricular extrasystole (polymorphic) are concerning and may indicate an increased risk of arrhythmias. The presence of ventricular tachycardia (both sustained and non-sustained) on the ECG is also a significant risk factor for sudden cardiac death.

The patient's medication regimen, including an Angiotensin II Receptor Blocker, Loop Diuretics, and ACE Inhibitor, suggests that the patient is being managed for heart failure and hypertension, but may not be adequately addressing the underlying cardiomyopathy.

Given these factors, the patient is at high risk for sudden cardiac death, particularly in the short term. Pump failure death is also a concern, but it may take longer to develop. Survivorship is the least likely outcome, given the patient's advanced age, significant cardiomyopathy, and ECG findings.

It is essential to closely monitor the patient's condition and adjust the treatment plan as needed to minimize the risk of sudden cardiac death and pump failure."
706,706,P0520,"Age: 67
Gender: Male 
Weight: 63 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 98.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 3,6
LDL (mmol/L): 1,27
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 6274.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,31
Urea (mg/dL): 11,13
LVEF (%): 23.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Pump failure death 
REASONING: 
This patient's NYHA Class III indicates severe heart failure, which suggests that their heart is not functioning optimally. Their LVEF is also severely reduced at 23%, indicating that their heart muscle is not contracting effectively. The patient's elevated creatinine level (135.0 mmol/L) and low albumin level (42.4 g/L) further support the notion that their kidneys are not functioning properly, likely due to heart failure. The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole on the ECG also suggests that the patient's heart is experiencing arrhythmias, which can further exacerbate heart failure. Given these factors, it is likely that the patient will experience pump failure death in the near future.

2. Sudden cardiac death 
REASONING: 
While the patient's ECG does show signs of arrhythmias, the presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole is concerning, but not necessarily indicative of a high risk for sudden cardiac death. The patient's LVEF is severely reduced, which increases the risk for heart failure, but does not directly increase the risk for sudden cardiac death. Additionally, the patient's medications, such as the ACE inhibitor, are being used to manage their heart failure, which may help reduce the risk of sudden cardiac death.

3. Survivor 
REASONING: 
Given the patient's severe heart failure (NYHA Class III), reduced LVEF, and elevated creatinine level, it is unlikely that the patient will survive for an extended period without experiencing significant complications. However, the patient is already taking medications to manage their heart failure, which may help extend their survival. Additionally, the presence of NSVT and ventricular extrasystole on the ECG may indicate that the patient is at risk for arrhythmias, but the patient's overall condition is still more likely to result in pump failure death rather than sudden cardiac death."
707,707,P0533,"Age: 50
Gender: Male 
Weight: 76 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 90/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 86.0
Protein (g/L): 82
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 6,91
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's prognosis is primarily influenced by their underlying cardiac condition, NYHA Class III status, and the presence of non-sustained ventricular tachycardia (NSVT) on the ECG. 

The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened, leading to poor heart function. This condition, combined with the patient's current NYHA Class III status, indicates that the patient has significant heart failure symptoms and is likely to have reduced ejection fraction (LVEF) and compromised cardiac output.

The presence of NSVT on the ECG is a significant risk factor for sudden cardiac death. Non-sustained VT is a marker of increased risk of ventricular arrhythmias, which can degenerate into sustained VT or even ventricular fibrillation, leading to sudden cardiac death. The patient's low LVEF (38%) further exacerbates the risk of arrhythmias and cardiac failure.

While pump failure death is a possible outcome, it is less likely compared to sudden cardiac death. Pump failure death typically occurs in patients with advanced heart failure, where the heart's pumping ability is severely compromised, leading to symptoms such as shortness of breath, fatigue, and swelling. Although the patient's NYHA Class III status and elevated creatinine levels suggest compromised cardiac function, the presence of NSVT on the ECG and low LVEF make sudden cardiac death a more immediate and urgent concern.

Therefore, based on the available data, the most likely prognosis for this patient is sudden cardiac death, followed by pump failure death, and then survivor."
708,708,P0539,"Age: 64
Gender: Male 
Weight: 85 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,4
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,99
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 9,13
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the provided patient data, I would rank the prognoses as follows:

1. Sudden cardiac death: The patient's history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction increases the risk of sudden cardiac death. The patient's current NYHA class II symptoms suggest that the heart is not functioning optimally, which can contribute to arrhythmias and sudden cardiac death. The presence of elevated troponin levels (0.01 ng/mL) also indicates myocardial damage, which can increase the risk of sudden cardiac death. Furthermore, the patient's ECG impression of ventricular extrasystole, although monomorphic, suggests an increased risk of arrhythmias.

2. Pump failure death: The patient's low LVEF (60.0%) and elevated creatinine levels (9.13 mg/dL) indicate reduced cardiac function and renal impairment, respectively. These factors increase the risk of heart failure and pump failure. The patient's history of diabetes, hypertension, and dyslipemia also contribute to the development of heart failure. However, the patient's current medications, including ACE inhibitors and beta blockers, suggest that some level of heart failure management is being implemented.

3. Survivor: While the patient's overall health status is concerning, the presence of certain risk factors and the patient's current medications suggest that they may be able to survive with proper management. The patient's relatively low troponin level (0.01 ng/mL) and the absence of other high-risk ECG abnormalities (e.g., ventricular tachycardia) also suggest that the patient may not be at imminent risk of sudden cardiac death. However, the patient's overall health status and multiple comorbidities make survival uncertain.

Please note that this prognosis is based on the provided data and should be interpreted with caution. A comprehensive evaluation by a cardiologist and other healthcare professionals is necessary to make a more accurate prognosis."
709,709,P0559,"Age: 51
Gender: Male 
Weight: 62 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 49
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 3,08
LDL (mmol/L): 3,23
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2928.0
Protein (g/L): 71
T3 (pg/dL): 0,0573
T4 (ng/L): 16,58
Troponin (ng/mL): 0,1
TSH (mIU/L): 3,94
Urea (mg/dL): 5,8
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING:

Based on the provided patient data, I would rank the patient's prognosis as sudden cardiac death. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that significantly increases the risk of sudden cardiac death. Additionally, the patient's left ventricular ejection fraction (LVEF) is severely impaired at 20%, indicating poor cardiac function.

The patient's electrocardiogram (ECG) shows non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles, which are both indicators of arrhythmias that can increase the risk of sudden cardiac death. The presence of NSVT is particularly concerning, as it is a known predictor of sudden cardiac death in patients with heart failure.

Furthermore, the patient's elevated troponin levels (0.1 ng/mL) suggest some degree of myocardial injury, which may be related to the arrhythmias or the underlying cardiomyopathy.

While the patient is on various medications, including beta blockers, ACE inhibitors, and amiodarone, which are standard treatments for heart failure and arrhythmias, the patient's underlying condition and ECG findings suggest that the risk of sudden cardiac death remains high.

The patient's weight, height, blood pressure, and other laboratory values do not provide significant additional information to alter the prognosis. Therefore, based on the provided data, I rank the patient's prognosis as sudden cardiac death."
710,710,P0616,"Age: 71
Gender: Male 
Weight: 63 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 114
Glucose (mmol/L): 6
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 3,94
LDL (mmol/L): 2,92
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1139.0
Protein (g/L): 67,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,56
Urea (mg/dL): 11,6
LVEF (%): 18.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

This patient has a high risk of sudden cardiac death due to the presence of several factors that increase the likelihood of cardiac arrhythmias and cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that can lead to abnormal heart rhythms. The patient's LVEF is severely reduced at 18%, indicating poor heart function, which can contribute to arrhythmias. The patient also has a history of hypertension, which can increase the risk of cardiac events.

The patient's ECG shows polymorphic ventricular extrasystoles, which is a sign of abnormal heart rhythms. The presence of ventricular extrasystoles is a risk factor for sudden cardiac death. Additionally, the patient's Troponin levels are elevated, which can indicate myocardial damage, and the patient has a history of myocardial infarction, which can also increase the risk of cardiac events.

The patient's medications, including the nitrovasodilator, may be contributing to the development of cardiac arrhythmias. The patient's low ejection fraction and high BNP levels also suggest that the patient's heart is under significant stress, which can contribute to arrhythmias.

Given the combination of these factors, the likelihood of sudden cardiac death is high, making it the most likely outcome for this patient over the next few years."
711,711,P0618,"Age: 65
Gender: Male 
Weight: 93 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 57.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 2,96
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 95
Glucose (mmol/L): 8
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,56
LDL (mmol/L): 1,45
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 12518.0
Protein (g/L): 66,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,43
Urea (mg/dL): 6,8
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death 
2. Pump failure death 
3. Survivor 

REASONING:

The patient has a complex medical history with multiple comorbid conditions such as ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction. The elevated creatinine level (106.0 mmol/L) indicates impaired renal function, which can be a sign of advanced heart failure. The low LVEF (20.0) further supports this, as it indicates severe left ventricular dysfunction. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia in the ECG impression suggests a high risk of arrhythmias, which can lead to sudden cardiac death.

The patient's high Pro-BNP level (12518.0 ng/L) indicates a high burden of ventricular stress and strain, which can be a predictor of adverse outcomes. The patient's elevated troponin level (0.01 ng/mL) suggests some degree of myocardial injury, which can be a sign of ongoing cardiac damage.

The patient is also on medications that can increase the risk of arrhythmias, such as beta blockers and ACE inhibitors. The presence of ventricular tachycardia (non-sustained VT) and polymorphic ventricular extrasystoles in the ECG impression further increases the risk of sudden cardiac death.

While the patient's weight (93 kg) and height (176 cm) are within normal limits, the overall clinical picture suggests a high risk of adverse outcomes. The patient's NYHA class II indicates moderate symptoms of heart failure, which can further contribute to the risk of pump failure.

Considering these factors, I would rank the patient's prognosis as follows:

1. Sudden cardiac death: The combination of severe left ventricular dysfunction, high Pro-BNP level, and the presence of arrhythmias in the ECG impression make this the most likely outcome.
2. Pump failure death: The patient's impaired renal function, high creatinine level, and low LVEF make pump failure a likely outcome.
3. Survivor: While the patient's NYHA class II and the presence of beta blockers may suggest some level of symptom management, the overall clinical picture suggests a high risk of adverse outcomes, making survival less likely."
712,712,P0626,"Age: 74
Gender: Female 
Weight: 55 kg
Height: 144 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 2,84
Creatinine (mmol/L): 76.0
Gamma-glutamil transpeptidase (IU/L): 81
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,2
LDL (mmol/L): 1,51
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 7158.0
Protein (g/L): 65,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,31
Urea (mg/dL): 7
LVEF (%): 62.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Survivor
REASONING:
The patient is a 74-year-old female with a history of hypertrophic cardiomyopathy, hypertension, and NYHA Class III heart failure. The patient's LVEF is 62%, indicating a significant reduction in cardiac function. The elevated Pro-BNP level of 7158.0 ng/L suggests a high level of ventricular stress and potential heart failure exacerbation. The presence of ventricular extrasystoles on the ECG is concerning, but not indicative of a specific life-threatening arrhythmia. The patient's medication regimen includes ACE inhibitors and beta blockers, which are commonly used to manage heart failure and hypertension. However, the patient's current condition and medication regimen do not suggest a high risk of sudden cardiac death. 

2. Pump failure death
REASONING:
Given the patient's significant heart failure symptoms (NYHA Class III) and elevated Pro-BNP level, there is a high risk of pump failure. The patient's LVEF of 62% and elevated creatinine level (7 mg/dL) suggest a decline in renal function, which can be a consequence of heart failure. The patient's medication regimen includes loop diuretics, which can help manage fluid overload, but the patient's current condition may still lead to pump failure. However, the patient's overall condition is not as severe as the survivor prognosis.

3. Sudden cardiac death
REASONING:
While the patient's ECG shows ventricular extrasystoles, which is a concerning sign, the absence of other life-threatening arrhythmias (ventricular tachycardia or non-sustained ventricular tachycardia) reduces the likelihood of sudden cardiac death. The patient's medication regimen includes beta blockers, which can help manage arrhythmias. The patient's overall condition and medication regimen do not suggest a high risk of sudden cardiac death. Additionally, the patient's age and sex do not increase the risk of sudden cardiac death."
713,713,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

The patient's data suggests a high risk for cardiac complications. The key factors contributing to this prognosis include:

1. LVEF of 40.0%: A left ventricular ejection fraction (LVEF) of 40% is considered mildly reduced, which is a significant indicator of systolic dysfunction and a predictor of adverse outcomes.

2. NYHA Class II: The patient has a moderate level of symptoms, indicating some limitation in physical activity and daily functioning.

3. Past Medical History of Enolic Dilated Cardiomyopathy: This condition is a significant risk factor for cardiac complications and arrhythmias.

4. Pro-BNP level of 437.0 ng/L: Elevated levels of N-terminal pro b-type natriuretic peptide (Pro-BNP) are associated with increased ventricular wall stress, which can be a marker for heart failure.

5. Medications: The patient is on diabetes medication, loop diuretics, and ACE inhibitors, which are commonly used to manage cardiovascular conditions.

6. ECG Impression: The presence of ventricular extrasystoles is a significant concern, as it can be a precursor to more severe arrhythmias.

Given these factors, the patient is at high risk for cardiac complications, including sudden cardiac death. The combination of reduced LVEF, NYHA Class II symptoms, and ventricular extrasystoles makes this prognosis the most likely."
714,714,P0650,"Age: 73
Gender: Male 
Weight: 75 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 2,87
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 15,3
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,03
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1670.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 20
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,25
Urea (mg/dL): 5,79
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

The patient has a high-risk profile for cardiac events, with multiple comorbid conditions that can increase the risk of cardiac complications. The patient's age, NYHA Class III, and LVEF of 25% indicate severe heart failure, which is a significant predictor of poor outcomes. The presence of ischemic dilated cardiomyopathy, diabetes, and hypertension further increases the risk of cardiac events.

The patient's ECG findings are concerning, with non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystole, which are both markers of increased risk of ventricular arrhythmias. The presence of NSVT, in particular, is a strong predictor of sudden cardiac death.

Additionally, the patient's elevated Pro-BNP levels (1670.0 ng/L) indicate significant ventricular dysfunction, and the patient's low HDL cholesterol level (1.22 mmol/L) further increases the risk of atherosclerotic cardiovascular disease.

The patient's medications, including beta blockers, loop diuretics, and ACE inhibitors, are commonly used to manage heart failure and hypertension, but may not be sufficient to mitigate the patient's high risk of cardiac events.

Given the patient's complex medical history and the presence of high-risk ECG findings, the likelihood of sudden cardiac death is high. Therefore, I would rank sudden cardiac death as the most likely outcome over the next few years."
715,715,P0656,"Age: 57
Gender: Male 
Weight: 70 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 33,5
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 3,15
Creatinine (mmol/L): 226.0
Gamma-glutamil transpeptidase (IU/L): 73
Glucose (mmol/L): 3,1
Hemoglobin (g/L): 97.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,9
LDL (mmol/L): 1,58
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 19425.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,19
TSH (mIU/L): 4,39
Urea (mg/dL): 18,94
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

Based on the patient's medical history and current clinical presentation, I believe that the most likely prognosis for the patient over the next few years is sudden cardiac death. Here's why:

1. History of Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which is a condition where the heart muscle becomes weakened and cannot pump blood effectively. This increases the risk of arrhythmias, heart failure, and sudden cardiac death.
2. Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is significantly reduced at 20%, which is a strong indicator of poor cardiac function. This can lead to reduced cardiac output, increased risk of arrhythmias, and sudden cardiac death.
3. High Pro-BNP levels: Elevated Pro-BNP levels (19425.0 ng/L) indicate fluid overload and ventricular strain, which can be a sign of heart failure. This can increase the risk of sudden cardiac death.
4. Presence of Ventricular Extrasystole: The patient's ECG impression mentions ventricular extrasystole, which is a type of abnormal heart rhythm that can be a precursor to more serious arrhythmias, including ventricular tachycardia and ventricular fibrillation, both of which can lead to sudden cardiac death.
5. Medications: The patient is already on medications that can increase the risk of cardiac complications, such as beta blockers, which can slow the heart rate and increase the risk of bradycardia, and loop diuretics, which can increase the risk of electrolyte imbalances.
6. Other risk factors: The patient has a history of myocardial infarction, hypertension, dyslipidemia, and diabetes, all of which can contribute to cardiac complications and increase the risk of sudden cardiac death.

While the patient's current treatment regimen and medical history suggest a high risk of sudden cardiac death, it is essential to note that this is a complex case, and individual outcomes can vary. Close monitoring and ongoing management by a cardiologist are crucial to minimize the risk of adverse outcomes."
716,716,P0661,"Age: 67
Gender: Female 
Weight: 65 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43,2
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 61.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,69
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 928.0
Protein (g/L): 68,5
T4 (ng/L): 15
TSH (mIU/L): 1,1
Urea (mg/dL): 6,82
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's data suggests a high risk of cardiac-related complications. The key factors contributing to this prognosis include:

1. Low Left Ventricular Ejection Fraction (LVEF) of 20.0%: This indicates severely impaired cardiac function, which is a hallmark of advanced heart failure. Patients with LVEF below 35% have a poor prognosis.

2. History of Idiopathic Dilated Cardiomyopathy: This condition is a significant risk factor for sudden cardiac death and heart failure. The patient's symptoms and ECG findings further support this.

3. Presence of Non-Sustained Ventricular Tachycardia (NSVT): This arrhythmia is a significant predictor of cardiac mortality. The patient's ECG impression shows NSVT, which is a strong indicator of increased cardiac risk.

4. Pro-BNP levels of 928.0 ng/L: Elevated BNP levels are associated with increased cardiac stress and are a predictor of heart failure.

5. High Creatinine levels (6.82 mg/dL): Elevated creatinine levels indicate impaired kidney function, which is often seen in patients with advanced heart failure.

Considering these factors, the patient is at high risk for cardiac-related complications. However, the presence of diabetes, hypertension, and other comorbidities also contribute to the overall risk assessment.

While the patient is on medications for diabetes, hypertension, and heart failure, the combination of their cardiac history, ECG findings, and laboratory results suggests that the patient is at high risk for sudden cardiac death. Pump failure is a possible outcome, but the patient's low LVEF and NSVT make sudden cardiac death a more likely outcome in the short term.

The patient's overall prognosis is poor, and close monitoring and management of their cardiac function are essential to prevent further complications."
717,717,P0667,"Age: 75
Gender: Male 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 37,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,95
Creatinine (mmol/L): 160.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,72
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 6950.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,67
Urea (mg/dL): 13,14
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

The patient's prognosis is primarily influenced by their advanced age, comorbid conditions, and the presence of heart failure symptoms. The patient's New York Heart Association (NYHA) Class II indicates moderate heart failure, which suggests that the heart is not functioning optimally and may be at risk for further decline.

The patient's elevated creatinine level (160.0 mmol/L) and elevated troponin level (0.03 ng/mL) indicate impaired kidney function and possible cardiac damage, respectively. The presence of ventricular extrasystole and non-sustained ventricular tachycardia (NSVT) on the ECG also suggest that the patient has significant cardiac arrhythmias, which can be a precursor to sudden cardiac death.

The patient's elevated Pro-BNP (6950.0 ng/L) level further supports the presence of heart failure, and their low LVEF (50.0%) indicates reduced left ventricular function, which can lead to pump failure.

While the patient is on medications, including a calcium channel blocker, loop diuretics, and statins, which are standard treatments for heart failure and hypertension, their comorbid conditions, such as hypertension, diabetes, and peripheral vascular disease, may not be adequately controlled.

Considering these factors, the patient is at high risk for sudden cardiac death, as evidenced by the presence of ventricular arrhythmias and impaired cardiac function. Pump failure death is also a concern due to the patient's advanced age and comorbid conditions. However, the patient's current ECG findings and laboratory results do not suggest an immediate risk for pump failure, making survivor the least likely prognosis.

It's essential to note that this prognosis is based on the provided data and should be confirmed with further evaluation and monitoring. Close follow-up and adjustment of the patient's treatment plan may be necessary to mitigate the risk of adverse outcomes."
718,718,P0671,"Age: 69
Gender: Male 
Weight: 72 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,1
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 145.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 11,2
Hemoglobin (g/L): 163.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,93
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1824.0
Protein (g/L): 76,6
T4 (ng/L): 19
TSH (mIU/L): 0,36
Urea (mg/dL): 10,65
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Survivor
2. Sudden Cardiac Death
3. Pump Failure Death

REASONING:

The patient's prognosis is influenced by several factors, including the patient's age, NYHA Class II, and the presence of comorbidities such as ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. The patient's elevated creatinine level (145.0 mmol/L) and low LVEF (35.0%) suggest advanced cardiac dysfunction.

The patient's ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia (NSVT), and paroxysmal supraventricular tachyarrhythmia code indicate a high risk of arrhythmias, which are a significant predictor of cardiac mortality. The presence of NSVT is particularly concerning, as it increases the risk of sudden cardiac death.

However, the patient's relatively good hemoglobin level (13.6 g/L) and low TSH level (0.36 mIU/L) suggest that the patient's cardiovascular system is not severely compromised. The patient's medication regimen, including a calcium channel blocker and diabetes medication, also suggests that the patient is receiving adequate treatment for their comorbidities.

Given these factors, I would rank the patient's prognosis as follows:

1. Survivor: The patient's relatively good hemoglobin level, low TSH level, and medication regimen suggest that the patient is not in a critically compromised state. While the patient's comorbidities and ECG findings indicate a high risk of arrhythmias, the patient's overall cardiovascular status is not catastrophic.

2. Sudden Cardiac Death: The patient's NSVT and ventricular extrasystole on ECG, combined with their advanced cardiac dysfunction and comorbidities, make sudden cardiac death a significant risk.

3. Pump Failure Death: While the patient's LVEF is severely reduced, the patient's hemoglobin level is relatively good, and the patient is receiving medication to manage their comorbidities. Therefore, pump failure death is the least likely outcome, although it is still a potential risk given the patient's advanced cardiac dysfunction.

It is essential to closely monitor the patient's cardiac function and adjust their medication regimen as needed to minimize the risk of arrhythmias and cardiac complications."
719,719,P0734,"Age: 67
Gender: Male 
Weight: 64 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 2,87
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 5,3
LDL (mmol/L): 1,68
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2362.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,53
Urea (mg/dL): 10,65
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient's ECG impression highlights several concerning findings that suggest an increased risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia (NSVT) indicates an abnormal heart rhythm that can be a precursor to life-threatening arrhythmias. The fact that the patient has had NSVT, which is defined as a duration of more than 30 seconds, further increases the risk. Additionally, the patient's left ventricular ejection fraction (LVEF) of 20% is severely reduced, indicating poor cardiac function and a higher risk of arrhythmias.

The patient's past medical history of ischemic dilated cardiomyopathy, hypertension, and dyslipidemia also contribute to the increased risk of sudden cardiac death. The elevated troponin level, which indicates myocardial injury, further supports the presence of underlying cardiac dysfunction.

While the patient's current medications, including beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, are being used to manage his heart failure and hypertension, they may not be sufficient to completely mitigate the risk of sudden cardiac death.

Given the combination of these factors, I would rank sudden cardiac death as the most likely prognosis for this patient over the next few years."
720,720,P0743,"Age: 57
Gender: Male 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,79
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 153.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,01
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 313.0
Protein (g/L): 71,6
T4 (ng/L): 19
TSH (mIU/L): 0,36
Urea (mg/dL): 6,66
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death 
REASONING: 
The patient's data suggests a high risk of sudden cardiac death. The patient has a history of myocardial infarction, which is a significant risk factor for sudden cardiac death. Additionally, the patient has a low left ventricular ejection fraction (LVEF) of 55%, which indicates poor cardiac function. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG also increases the risk of sudden cardiac death. The patient's age, weight, and NYHA class II also contribute to the overall risk assessment.

While the patient's medication regimen, including beta blockers, loop diuretics, statins, and ACE inhibitors, suggests that the patient is being managed for heart failure and cardiovascular risk reduction, the presence of the above-mentioned factors suggests that the patient is at high risk of sudden cardiac death.

While pump failure death is a possible outcome, the patient's current ECG findings and the presence of NSVT suggest that sudden cardiac death is a more likely outcome in the short term. Survivorship is less likely due to the patient's history of myocardial infarction and the presence of NSVT."
721,721,P0765,"Age: 72
Gender: Female 
Weight: 48 kg
Height: 143 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,3
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 5,63
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,97
Potassium (mEq/L): 4,28
LDL (mmol/L): 3,21
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2910.0
Protein (g/L): 75,9
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,31
Urea (mg/dL): 9,5
LVEF (%): 20.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING: 

Based on the provided patient data, the patient's prognosis is primarily influenced by the presence of Ischemic Dilated Cardiomyopathy (IDC), which is a severe and irreversible condition that significantly impairs the heart's ability to pump blood efficiently. The LVEF of 20.0% further supports this, indicating that the patient's heart is severely compromised.

The patient's high Creatinine level (81.0 mmol/L) suggests impaired renal function, which can be a consequence of IDC and is a predictor of mortality. Additionally, the presence of ventricular extrasystoles (Polymorphic) and a history of myocardial infarction indicate ongoing cardiac instability.

The patient's NYHA Class II indicates moderate symptoms, which suggests that the patient experiences some limitations in physical activity due to their cardiac condition. However, the presence of Paroxysmal Supraventricular Tachycardia (PSVT) is a concerning sign, as it may indicate an increased risk of arrhythmias and sudden cardiac death.

The patient's current medications, including Digoxin and Loop Diuretics, suggest that the patient is being managed for heart failure and arrhythmias. However, the presence of a high Pro-BNP level (2910.0 ng/L) indicates elevated ventricular stress, suggesting that the patient's condition is not adequately controlled.

Considering these factors, the patient's prognosis is most likely to be Sudden Cardiac Death, followed by Pump Failure Death, and then Survivor. The patient's severe IDC, impaired renal function, and ongoing cardiac instability make sudden cardiac death the most likely outcome. While pump failure death is a possible outcome, the patient's medications and current management suggest that it is not the most likely prognosis. The patient's survival is the least likely due to the severity of their cardiac condition and the presence of arrhythmias."
722,722,P0776,"Age: 61
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,95
Creatinine (mmol/L): 259.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,86
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,45
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3274.0
Protein (g/L): 69
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 15,8
LVEF (%): 33.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's prognosis is primarily driven by their underlying conditions, including ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction. These conditions have led to a significant reduction in left ventricular function, as indicated by the low LVEF of 33%. The patient's elevated creatinine level (259.0 mmol/L) and elevated Pro-BNP level (3274.0 ng/L) also suggest compromised cardiac function and possible heart failure.

The presence of ventricular extrasystoles, non-sustained ventricular tachycardia (VT), and non-sustained ventricular tachycardia (CH>10) on the ECG impression indicates a high risk of arrhythmic events. The patient's ventricular arrhythmias are likely related to their underlying cardiomyopathy and the presence of beta-blockers, which can increase the risk of arrhythmias.

Given the patient's age, NYHA Class II heart failure, and the presence of ventricular arrhythmias, sudden cardiac death is the most likely outcome. The patient's low LVEF and elevated Pro-BNP level indicate that their heart is not functioning optimally, making them more susceptible to cardiac events.

Pump failure death is a possible outcome due to the patient's heart failure and ventricular arrhythmias. However, the presence of beta-blockers and loop diuretics suggests that the patient is receiving standard treatment for heart failure, which may mitigate this risk.

Survival is the least likely outcome due to the patient's poor LVEF and elevated Pro-BNP level, which indicate significant cardiac dysfunction. The patient's age and presence of comorbidities also contribute to this outcome. However, the patient's medication regimen, including beta-blockers and amiodarone, may help to reduce the risk of arrhythmic events and improve survival."
723,723,P0779,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 100/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 44,8
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,91
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,13
Potassium (mEq/L): 4,14
LDL (mmol/L): 2,02
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2428.0
Protein (g/L): 75,2
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,7
Urea (mg/dL): 9,9
LVEF (%): 31.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

The patient's prognosis is primarily determined by their underlying condition, which is idiopathic dilated cardiomyopathy. This condition is characterized by the enlargement of the heart, leading to reduced left ventricular function and increased risk of arrhythmias and heart failure. The patient's current ejection fraction (LVEF) of 31.0% further supports this, indicating significant impairment of cardiac function.

The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG impression indicates a high risk of arrhythmias, which is a common complication in patients with dilated cardiomyopathy. The patient's blood pressure is well-controlled at 100/75 mmHg, which reduces the risk of cardiovascular events.

The patient's elevated creatinine level (107.0 mmol/L) and high BNP levels (2428.0 ng/L) suggest some degree of renal impairment, which may be related to the cardiac condition. However, this does not significantly impact the overall prognosis.

In contrast, the patient's weight, height, and hemoglobin levels are within normal limits, which reduces the risk of other comorbid conditions. The patient's lipid profile is also relatively well-controlled, with a total cholesterol level of 3.91 mmol/L.

Given the patient's significant cardiac impairment, high risk of arrhythmias, and elevated BNP levels, the most likely prognosis is sudden cardiac death. Pump failure death is a close second, as the patient's LVEF is severely impaired, and the patient is already experiencing non-sustained ventricular tachycardia. Survival is the least likely outcome, as the patient's cardiac condition is severe and the presence of arrhythmias and elevated BNP levels suggest a high risk of adverse outcomes.

It is essential to note that this prognosis is based on the information provided and may not accurately reflect the patient's actual outcome. Further evaluation and monitoring are necessary to adjust the prognosis and provide optimal care."
724,724,P0784,"Age: 59
Gender: Male 
Weight: 79 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 48,1
ALT or GPT (IU/L): 80.0
AST or GOT (IU/L): 51.0
Total Cholesterol (mmol/L): 5,7
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 109
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,99
Potassium (mEq/L): 4,39
LDL (mmol/L): 3,5
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 543.0
Protein (g/L): 84,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,62
Urea (mg/dL): 7,1
LVEF (%): 29.0
Medications: Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's clinical presentation and test results suggest that the patient is at high risk for sudden cardiac death. The key factors contributing to this risk include:

1. History of Ischemic dilated cardiomyopathy: This condition is a significant risk factor for sudden cardiac death, as it can lead to arrhythmias and decreased cardiac function.
2. NYHA Class II: This indicates that the patient has moderate symptoms of heart failure, which can increase the risk of arrhythmias and sudden cardiac death.
3. Pro-BNP levels of 543.0 ng/L: Elevated BNP levels are associated with increased risk of cardiovascular events, including sudden cardiac death.
4. Electrocardiogram (ECG) findings: The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) suggest an increased risk of arrhythmias, which can lead to sudden cardiac death.
5. Medications: The patient is taking beta blockers, which can increase the risk of bradycardia, but in this case, the patient does not have bradycardia.

While pump failure death is a possible outcome, it is less likely in this case due to the patient's relatively preserved kidney function (creatinine of 7.1 mg/dL) and the absence of significant symptoms of heart failure.

Survivorship is the least likely outcome, given the patient's high risk factors and the presence of arrhythmias on the ECG. However, with aggressive management and close monitoring, it is still possible for the patient to survive with proper treatment."
725,725,P0804,"Age: 73
Gender: Male 
Weight: 81 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 80/40 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42,2
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 5,55
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 95
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,89
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 949.0
Protein (g/L): 80,2
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,06
Urea (mg/dL): 8,1
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with ischemic dilated cardiomyopathy, myocardial infarction, and a significant left ventricular ejection fraction (LVEF) of 25.0, indicating severe left ventricular dysfunction. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG impression suggests a high risk of arrhythmic events. However, the patient is on medications that are commonly used to manage heart failure and arrhythmias, such as beta blockers, digoxin, and ACE inhibitors. 

The patient's creatinine level of 110.0 mmol/L and urea level of 8.1 mg/dL suggest some degree of renal impairment, but this is not uncommon in patients with heart failure. The low hemoglobin level of 125.0 g/L and low albumin level of 42.2 g/L suggest some degree of anemia and hypoalbuminemia, respectively. 

Considering these factors, while the patient has a high risk of arrhythmic events, the presence of beta blockers, digoxin, and ACE inhibitors may help mitigate this risk. Additionally, the patient's relatively stable vital signs and lack of other severe symptoms suggest that the patient may be able to survive with proper management. Therefore, the most likely prognosis is that the patient will survive.

RANKING: 2. Pump failure death
REASONING: 

Given the patient's severe left ventricular dysfunction (LVEF of 25.0) and the presence of heart failure medications, there is a significant risk of pump failure. The patient's creatinine level of 110.0 mmol/L and urea level of 8.1 mg/dL suggest some degree of renal impairment, which can further exacerbate heart failure. The patient's low albumin level of 42.2 g/L and low hemoglobin level of 125.0 g/L also suggest some degree of malnutrition and anemia, which can worsen heart failure. 

The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG impression also increases the risk of arrhythmic events, which can further contribute to pump failure. 

While the patient is on medications that can help manage heart failure, the combination of severe left ventricular dysfunction, renal impairment, and anemia suggests that pump failure is a significant risk. Therefore, the second most likely prognosis is pump failure.

RANKING: 3. Sudden cardiac death
REASONING: 

Given the patient's severe left ventricular dysfunction (LVEF of 25.0), the presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG impression, and the lack of evidence of successful management of these arrhythmic events, sudden cardiac death is a significant risk. The patient's low hemoglobin level of 125.0 g/L and low albumin level of 42.2 g/L also suggest some degree of malnutrition and anemia, which can increase the risk of arrhythmic events. 

While the patient is on medications that can help manage heart failure and arrhythmias, the combination of severe left ventricular dysfunction, arrhythmic events, and malnutrition suggests that sudden cardiac death is a significant risk. Therefore, the third most likely prognosis is sudden cardiac death."
726,726,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the patient's data, the most likely prognosis is sudden cardiac death. This is due to the presence of several factors that increase the risk of cardiac arrhythmias and sudden cardiac death:

1. Severe LVEF (Left Ventricular Ejection Fraction) of 35.0: This indicates significant left ventricular dysfunction, which is a strong predictor of adverse outcomes, including sudden cardiac death.

2. History of Ischemic Dilated Cardiomyopathy: This condition is a significant risk factor for arrhythmias and sudden cardiac death.

3. Polymorphic Ventricular Extrasystoles on ECG: This finding suggests a high risk of ventricular arrhythmias, which can degenerate into ventricular fibrillation and sudden cardiac death.

4. Pro-BNP level of 170.0 ng/L: Elevated BNP levels are associated with increased mortality and morbidity in patients with heart failure, which in this case, may indicate severe left ventricular dysfunction.

5. Medications: The patient is already on beta blockers, spironolactone, statins, and ACE inhibitors, which are standard treatments for heart failure and hypertension. However, these medications may not be sufficient to mitigate the risk of sudden cardiac death, especially in the presence of severe left ventricular dysfunction.

Considering these factors, the likelihood of sudden cardiac death is higher than pump failure death, as the patient's heart is already severely compromised, and the risk of sudden cardiac death is a more immediate concern. The likelihood of survivor is the lowest, as the patient's underlying conditions and ECG findings suggest a high risk of adverse cardiac events."
727,727,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the provided patient data, I would rank the prognoses from most likely to least likely as follows:

1. Pump failure death: The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 15%, indicating severe left ventricular dysfunction. This is a strong indicator of pump failure, which is a common cause of mortality in patients with heart failure. The patient's elevated creatinine levels (119.0 mmol/L) and elevated BNP levels (8831.0 ng/L) also support this prognosis. Additionally, the patient's NYHA Class II status suggests that they have significant symptoms of heart failure.

2. Sudden cardiac death: While the patient's ECG shows ventricular extrasystoles, which can be a precursor to ventricular tachycardia, there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia. However, the presence of ventricular extrasystoles and a history of hypertrophic cardiomyopathy increases the risk of sudden cardiac death. The patient's elevated Troponin levels (0.03 ng/mL) also suggest some degree of cardiac injury, which may contribute to the risk of sudden cardiac death.

3. Survivor: The patient's overall clinical presentation, while concerning, does not suggest an immediate and severe prognosis. The patient's age, weight, and hemoglobin levels are not indicative of a high risk of mortality. Additionally, the patient's medication regimen includes beta blockers, loop diuretics, and spironolactone, which are commonly used to manage heart failure and hypertension. While the patient's ECG shows some arrhythmias, there is no indication of a high risk of sudden cardiac death."
728,728,P0846,"Age: 58
Gender: Male 
Weight: 86 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 164.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5,3
LDL (mmol/L): 3,65
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3551.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,04
Urea (mg/dL): 11,65
LVEF (%): 36.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 
Based on the patient's data, the most likely prognosis is Sudden Cardiac Death (SCD). The patient has a history of Idiopathic dilated cardiomyopathy (IDC), which is a condition that significantly increases the risk of SCD. The patient's left ventricular ejection fraction (LVEF) of 36.0% is also a strong indicator of poor cardiac function, which is a major risk factor for SCD.

The patient's blood test results, such as elevated Troponin levels (0.01 ng/mL), elevated Creatinine levels (11.65 mg/dL), and elevated Pro-BNP levels (3551.0 ng/L), suggest that the patient has significant cardiac dysfunction and elevated filling pressures, which are hallmarks of heart failure. The patient's low HDL cholesterol level (0.96 mmol/L) and elevated LDL cholesterol level (3.65 mmol/L) also contribute to an increased risk of cardiovascular events, including SCD.

Furthermore, the patient's ECG findings of ventricular extrasystoles (polymorphic) suggest an increased risk of arrhythmias, which are a common cause of SCD. The patient's medications, such as beta blockers, loop diuretics, spironolactone, and ACE inhibitors, may help manage some of these risk factors, but they do not completely eliminate the risk of SCD.

Therefore, based on the patient's clinical presentation, laboratory results, and ECG findings, I believe that Sudden Cardiac Death is the most likely outcome for this patient over the next few years.

RANKING: 2. Pump Failure Death
REASONING: 
While pump failure death is a possible outcome for this patient, it is less likely than SCD. The patient's LVEF of 36.0% and elevated Pro-BNP levels (3551.0 ng/L) suggest significant cardiac dysfunction, which is a major risk factor for pump failure. However, the patient's relatively stable hemoglobin level (139.0 g/L) and normal potassium level (5.3 mEq/L) suggest that the patient is not experiencing severe cardiac ischemia or electrolyte imbalances that would contribute to pump failure.

Additionally, the patient's medications, such as beta blockers and ACE inhibitors, may help slow the progression of cardiac dysfunction and reduce the risk of pump failure.

RANKING: 3. Survivor
REASONING: 
While it is possible that this patient could survive for several years with proper management, I believe that this outcome is the least likely. The patient's significant cardiac dysfunction, elevated Pro-BNP levels, and ECG findings of ventricular extrasystoles make it more likely that the patient will experience a cardiovascular event, such as SCD or pump failure, rather than surviving for an extended period.

However, with aggressive management of the patient's medications, close monitoring, and possible further diagnostic testing, it is possible that the patient could survive for several years with significant morbidity but not necessarily a long life expectancy."
729,729,P0848,"Age: 63
Gender: Female 
Weight: 72 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 120/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,74
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 11195.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 18
Troponin (ng/mL): 0,1
TSH (mIU/L): 3,97
Urea (mg/dL): 7,32
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

The patient's clinical presentation, laboratory results, and ECG findings suggest a high risk of adverse cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 25% further supports this, indicating severe left ventricular dysfunction.

The patient's elevated troponin levels (0.1 ng/mL) and elevated creatinine level (7.32 mg/dL) also suggest some degree of cardiac and renal dysfunction, which may be related to the underlying cardiomyopathy.

The presence of ventricular extrasystoles, non-sustained ventricular tachycardia (NSVT), and a high level of Pro-BNP (11,195 ng/L) indicate a high level of cardiac stress and strain. The elevated BNP level is particularly concerning, as it is a biomarker for heart failure and has been associated with increased mortality.

While the patient's medication list includes various cardiovascular medications, which may help manage some of the underlying conditions, the presence of multiple medications (e.g., beta blockers, ACE inhibitors, and spironolactone) suggests that the patient's cardiovascular system is already under significant strain.

Sudden cardiac death is a possible outcome due to the patient's high-risk ECG findings, including ventricular extrasystoles and NSVT. However, pump failure death is the most likely outcome, given the patient's severe left ventricular dysfunction, elevated BNP levels, and elevated creatinine level, which suggest a high risk of heart failure.

In conclusion, while sudden cardiac death is a concern, the overall clinical picture suggests that pump failure death is the most likely outcome for this patient over the next few years."
730,730,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: The patient's clinical presentation and laboratory results suggest a high risk of sudden cardiac death. The patient's age, NYHA Class II status, and history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction increase the risk of cardiac complications. The elevated blood pressure (190/110 mmHg) and elevated BNP levels (597.0 ng/L) indicate left ventricular dysfunction, which is a common cause of sudden cardiac death. Additionally, the presence of ventricular extrasystole on the ECG, although non-monomorphic, suggests an abnormal heart rhythm, which can increase the risk of arrhythmias. The patient's low ejection fraction (LVEF 35.0) further supports the risk of cardiac complications. Given the patient's medical history and current clinical status, sudden cardiac death is the most likely outcome.

RANKING: 2. Pump Failure Death
REASONING: Pump failure death is a possible outcome for this patient due to his advanced heart failure. The patient's low ejection fraction (LVEF 35.0) and elevated BNP levels (597.0 ng/L) indicate severe left ventricular dysfunction, which can lead to heart failure. The patient's NYHA Class II status and history of ischemic dilated cardiomyopathy further support the risk of heart failure. However, the presence of ventricular extrasystole on the ECG and the patient's high blood pressure (190/110 mmHg) suggest an increased risk of sudden cardiac death, making pump failure death less likely.

RANKING: 3. Survivor
REASONING: Although the patient has a high risk of cardiac complications, the presence of ventricular extrasystole on the ECG and the patient's relatively low T3 and T4 levels (0.06 and 19 pg/dL, respectively) suggest that the patient may still have some functional capacity. Additionally, the patient is taking medications that are commonly used to manage heart failure and hypertension, which may help to improve symptoms and outcomes. However, the patient's age, medical history, and laboratory results suggest that the risk of cardiac complications is still high, making survival less likely compared to sudden cardiac death and pump failure death."
731,731,P0880,"Age: 84
Gender: Male 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,09
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 444.0
Protein (g/L): 71
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,46
Urea (mg/dL): 10,48
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

This patient has a high risk of sudden cardiac death due to several factors. Firstly, the patient's NYHA Class II indicates that they have some symptoms of heart failure, which can lead to reduced cardiac function and increased risk of arrhythmias. The ECG impression of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) suggests a high risk of arrhythmic events. Additionally, the patient's low LVEF (30.0) indicates reduced cardiac function, which can contribute to arrhythmias. The patient's age (84) and history of hypertension, diabetes, and cardiomyopathy also increase their risk of sudden cardiac death. The patient's medication list, which includes beta blockers and ACE inhibitors, may help to reduce the risk of arrhythmias, but the presence of ventricular tachycardia on the ECG suggests that these medications may not be fully effective. Overall, the combination of these factors makes sudden cardiac death the most likely prognosis for this patient."
732,732,P0898,"Age: 67
Gender: Male 
Weight: 85 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 37,1
ALT or GPT (IU/L): 86.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 177
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,95
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 5629.0
Protein (g/L): 59,4
T4 (ng/L): 13
TSH (mIU/L): 1,06
Urea (mg/dL): 5,16
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

The patient's ECG impression reveals ventricular extrasystole, which is a significant finding. Ventricular extrasystoles are abnormal heartbeats originating from the ventricles, and in the context of a patient with a history of hypertrophic cardiomyopathy, they can be a sign of ventricular arrhythmias. The presence of ventricular extrasystoles, especially polymorphic ventricular extrasystoles, increases the risk of sudden cardiac death. The patient's LVEF of 40% is also a concern, as it indicates a significant reduction in the heart's pumping efficiency, which can contribute to arrhythmias. Additionally, the patient's NYHA Class II indicates some limitation in physical activity due to heart disease, which can increase the risk of arrhythmias. The patient's past medical history of hypertrophic cardiomyopathy further increases the risk of sudden cardiac death.

The patient's ECG also shows a high level of Pro-BNP (5629.0 ng/L), which is a marker of heart failure. Elevated BNP levels can be associated with increased risk of arrhythmias and sudden cardiac death. The patient's other laboratory values, such as the elevated creatinine and urea levels, indicate impaired kidney function, which can also contribute to the risk of arrhythmias.

While the patient's medications, including the ACE inhibitor and spironolactone, are being used to manage their condition, the presence of ventricular extrasystoles and other risk factors suggests that the patient is at high risk for sudden cardiac death.

The other two options, survivor and pump failure death, are less likely because the patient's ECG findings and laboratory values suggest a higher risk of arrhythmias and sudden cardiac death. While pump failure death is a possible outcome, the patient's LVEF is not severely impaired, and the patient is already receiving medications to manage their condition."
733,733,P0938,"Age: 71
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 96/67 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 37,1
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 103.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,82
Sodium (mEq/L): 143.0
Protein (g/L): 71,9
T4 (ng/L): 16
TSH (mIU/L): 3,71
Urea (mg/dL): 7,15
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's prognosis is primarily determined by their underlying heart condition, which is ischemic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 25%. This indicates that the patient's heart is severely impaired, with significant loss of pumping function.

The patient's age (71) and NYHA class III (severe heart failure) also contribute to the poor prognosis. The patient's blood pressure (96/67 mmHg) is slightly elevated, but this is not a significant concern given their overall clinical picture.

The laboratory results show elevated liver enzymes (ALT and AST), indicating some degree of liver dysfunction, which may be related to the patient's heart condition or other comorbidities. The elevated creatinine level (88.0) suggests some degree of renal impairment.

The ECG findings of ventricular extrasystole and polymorphic ventricular tachycardia are concerning and indicate a high risk of arrhythmias, which can lead to sudden cardiac death.

Given these factors, I rank the patient's prognosis as follows:

1. Sudden cardiac death: The patient's severe heart failure, elevated LVEF, and ECG findings make sudden cardiac death a high risk. The patient's medications, including a nitrovasodilator, may also contribute to this risk.

2. Pump failure death: The patient's severely impaired LVEF and NYHA class III status make pump failure a likely outcome. The patient's elevated creatinine level and liver dysfunction also suggest that their heart failure may lead to further decline in kidney function, increasing the risk of pump failure.

3. Survivor: While the patient's survival is possible, their severe heart failure and high risk of arrhythmias make it the least likely outcome. The patient's age and comorbidities also contribute to the poor prognosis."
734,734,P0951,"Age: 63
Gender: Male 
Weight: 55 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 156/85 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,2
HDL (mmol/L): 1,55
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,92
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 167.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 16
TSH (mIU/L): 1,13
Urea (mg/dL): 5,66
LVEF (%): 21.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden Cardiac Death
REASONING:

The patient's data indicates a high risk of sudden cardiac death. The key factors contributing to this prognosis are:

1. Low Left Ventricular Ejection Fraction (LVEF) of 21.0%, which is significantly below the normal range of 55-70%. This indicates severe left ventricular dysfunction, a hallmark of dilated cardiomyopathy.

2. Presence of Ventricular Extrasystoles, specifically polymorphic ventricular extrasystoles, on the ECG. This is a known precursor to ventricular tachycardia and can increase the risk of sudden cardiac death.

3. Elevated Pro-BNP levels of 167.0 ng/L, which is significantly above the normal range. Elevated BNP levels are associated with increased ventricular wall stress and are a predictor of adverse outcomes in patients with heart failure.

4. Presence of Hypertension, which is a known risk factor for cardiovascular disease and can contribute to left ventricular dysfunction.

5. The patient's past medical history of Enolic dilated cardiomyopathy and Hypertension further increases the risk of sudden cardiac death.

Considering these factors, the patient's risk of sudden cardiac death is significantly elevated, making it the most likely prognosis.

RANKING: 2. Pump Failure Death
REASONING:

The patient's data indicates a high risk of pump failure death, but it is less likely than sudden cardiac death. The key factors contributing to this prognosis are:

1. Severe left ventricular dysfunction (LVEF 21.0%) and elevated Pro-BNP levels (167.0 ng/L), which indicate significant heart failure.

2. Presence of Hypertension, which can contribute to left ventricular dysfunction and heart failure.

3. Presence of Enolic dilated cardiomyopathy, which is a known risk factor for heart failure.

4. Elevated Creatinine levels (88.0 mmol/L), which indicate impaired renal function and may be related to heart failure.

However, the patient's risk of pump failure death is lower than sudden cardiac death due to the absence of other high-risk factors such as ventricular tachycardia or polymorphic ventricular extrasystoles.

RANKING: 3. Survivor
REASONING:

The patient's data indicates a moderate risk of mortality, but it is the least likely prognosis. The key factors contributing to this prognosis are:

1. Presence of Hypertension and Enolic dilated cardiomyopathy, which are risk factors for cardiovascular disease.

2. Elevated Pro-BNP levels (167.0 ng/L) and elevated Creatinine levels (88.0 mmol/L), which indicate some level of cardiac dysfunction and impaired renal function.

3. Presence of Beta Blockers, Digoxin, Loop Diuretics, and ACE Inhibitor, which are medications commonly used to manage heart failure and hypertension.

However, the patient's overall clinical presentation and ECG findings do not indicate a high risk of sudden cardiac death or pump failure, making survival the most likely prognosis."
735,735,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the provided patient data, I have made the following assessment:

1. Sudden cardiac death (Rank 1): The patient has a high risk of sudden cardiac death due to the presence of polymorphic ventricular extrasystoles, which can be a precursor to ventricular tachycardia. The patient's LVEF is severely impaired at 35%, indicating significant left ventricular dysfunction, which can lead to arrhythmic events. Additionally, the patient's Pro-BNP level is elevated at 4999 ng/L, suggesting significant left ventricular stress and strain. The presence of hypertension, hypothyroidism (TSH 2.17 mIU/L), and the use of beta blockers, which can have negative inotropic effects, further contribute to the risk of arrhythmic events.

2. Pump failure death (Rank 2): The patient's severely impaired LVEF (35%) and elevated Pro-BNP level (4999 ng/L) indicate that the patient's heart is under significant stress, and the left ventricle is likely to fail. The patient's history of hypertensive cardiomyopathy and the use of loop diuretics, which can further decrease blood volume and cardiac output, increase the risk of pump failure.

3. Survivor (Rank 3): Although the patient's past medical history and current data suggest a high risk of adverse outcomes, the patient's age (69) and relatively well-managed hypertension with medications (Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine) and relatively normal hemoglobin level (119 g/L) may contribute to a slightly better prognosis. However, the presence of ventricular extrasystoles and elevated Pro-BNP levels still pose a significant risk of adverse outcomes.

It is essential to note that this prognosis is based on the provided data and should be interpreted with caution. A comprehensive risk stratification and further evaluation, including echocardiography, Holter monitoring, and cardiac catheterization, are necessary to confirm the diagnosis and develop an individualized treatment plan."
736,736,P0968,"Age: 71
Gender: Male 
Weight: 87 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 5,6
LDL (mmol/L): 2,12
Sodium (mEq/L): 135.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,26
Urea (mg/dL): 13,31
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 
1. Pump failure death 
REASONING: 
The patient's LVEF (Left Ventricular Ejection Fraction) is 35.0%, which is significantly below the normal range (50-70%). This indicates severe left ventricular dysfunction, which is a hallmark of cardiomyopathy. Given the patient's history of idiopathic dilated cardiomyopathy, it is likely that the patient's heart is unable to pump efficiently, leading to a high risk of pump failure. The presence of elevated creatinine levels (150.0 mmol/L) also suggests renal impairment, which is a common complication of advanced heart failure.

2. Sudden cardiac death 
REASONING: 
While the patient's ECG shows ventricular extrasystole (polymorphic) and non-sustained ventricular tachycardia (CH>10) is not present, the patient's LVEF is severely impaired, and the patient has a history of myocardial infarction, which increases the risk of arrhythmias. Additionally, the patient's NYHA Class II indicates moderate symptoms of heart failure, which can increase the risk of cardiac arrhythmias. However, the absence of non-sustained ventricular tachycardia (CH>10) and the lack of a clear indication of ventricular tachycardia or ventricular fibrillation on the ECG impression makes sudden cardiac death less likely.

3. Survivor 
REASONING: 
While the patient's past medical history and medications suggest a significant burden of cardiovascular disease, the patient's LVEF is severely impaired, and the presence of elevated creatinine levels suggests renal impairment. These factors increase the risk of complications, but the patient's relatively stable vital signs, normal potassium levels, and absence of significant electrolyte imbalances make a sudden cardiac death less likely. However, the patient's severe LVEF impairment and history of cardiomyopathy make it unlikely that the patient will survive for an extended period without significant cardiac complications."
737,737,P0972,"Age: 69
Gender: Female 
Weight: 80 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 43
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,64
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 436.0
Protein (g/L): 69
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,4
Urea (mg/dL): 4,49
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

This patient is at high risk for sudden cardiac death due to the presence of several significant risk factors, including:

1. Age: The patient is 69 years old, which is a high-risk age for cardiac events.
2. NYHA Class III: The patient has severe heart failure, which indicates a significant impairment of cardiac function and an increased risk of cardiac complications.
3. Hypertensive cardiomyopathy: The patient has a history of hypertension, which is a major risk factor for cardiac disease, and cardiomyopathy, which can lead to heart failure and arrhythmias.
4. Myocardial Infarction: The patient has a history of myocardial infarction, which can lead to scarring and remodeling of the heart, increasing the risk of arrhythmias and sudden cardiac death.
5. Elevated troponin: The patient has elevated troponin levels, which indicates myocardial damage, and is a marker of cardiac injury.
6. Pro-BNP: The patient has elevated pro-b-type natriuretic peptide (Pro-BNP) levels, which is a marker of cardiac stress and heart failure.
7. ECG Impression: The patient has a polymorphic ventricular extrasystole, which is a type of abnormal heart rhythm that can be life-threatening.

While pump failure death is a possible outcome, the patient's current LVEF is 60%, which indicates that the patient's heart is still pumping, albeit inefficiently. The patient is also receiving treatment with medications that can help manage heart failure, including ACE inhibitors, which can help reduce blood pressure and improve cardiac function.

Given these factors, I would rank sudden cardiac death as the most likely outcome, followed by pump failure death, and finally, survivor."
738,738,P0974,"Age: 80
Gender: Female 
Weight: 52 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,03
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,37
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 4255.0
Protein (g/L): 75
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,609
Urea (mg/dL): 9,32
LVEF (%): 27.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Sudden cardiac death
REASONING: 

This patient is at high risk for sudden cardiac death due to the presence of a significant number of adverse prognostic factors. The patient's NYHA Class III heart failure indicates severe impairment of cardiac function, which is consistent with the reduced LVEF of 27.0. The presence of idiopathic dilated cardiomyopathy further increases the risk of arrhythmias and cardiac events.

The elevated Pro-BNP level of 4255.0 ng/L suggests a high level of ventricular stress and strain, which is a strong predictor of adverse outcomes. The patient's ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) further increase the risk of arrhythmias and sudden cardiac death.

Additionally, the patient's medications, including digoxin, loop diuretics, spironolactone, and ACE inhibitor, do not appear to be adequate for managing the patient's heart failure and arrhythmias. The patient's electrolyte levels, including potassium, are also not within a normal range, which can further increase the risk of arrhythmias.

Given the combination of severe heart failure, arrhythmias, and electrolyte imbalances, I would rank sudden cardiac death as the most likely outcome for this patient over the next few years."
739,739,P1001,"Age: 46
Gender: Male 
Weight: 90 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 39.0
Total Cholesterol (mmol/L): 2,79
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 74
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,71
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 766.0
Protein (g/L): 64
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,89
Urea (mg/dL): 9,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the patient data, the patient is at high risk for a poor outcome. The presence of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened and cannot pump blood effectively, increases the risk of sudden cardiac death. Additionally, the patient has a history of myocardial infarction, which is a heart attack, and this can also contribute to the risk of sudden cardiac death.

The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 30%, which indicates that the heart is not pumping efficiently. This can lead to a decrease in cardiac output, which can cause the heart to work harder, increasing the risk of arrhythmias and sudden cardiac death.

The patient's ECG impression shows the presence of ventricular extrasystole, polymorphic ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, all of which are indicators of an increased risk of arrhythmias. The presence of non-sustained ventricular tachycardia, which is a rapid heartbeat that originates in the ventricles, is particularly concerning as it can increase the risk of sudden cardiac death.

While the patient is on medications such as beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are commonly used to manage heart failure and reduce the risk of arrhythmias, the presence of these conditions and the ECG findings suggest that the patient is still at high risk for a poor outcome.

The patient's elevated creatinine level (71.0 mmol/L) and reduced LVEF (30.0%) suggest that the patient's heart function is compromised, which increases the risk of pump failure. However, the presence of these findings is not as concerning as the patient's high risk of arrhythmias, which is indicated by the ECG findings.

Therefore, based on the patient data, the most likely prognosis is sudden cardiac death, followed by pump failure death, and then survival."
740,740,P1018,"Age: 60
Gender: Male 
Weight: 63 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 265.0
Gamma-glutamil transpeptidase (IU/L): 87
Glucose (mmol/L): 12
HDL (mmol/L): 1,03
Potassium (mEq/L): 6,1
LDL (mmol/L): 1,91
Sodium (mEq/L): 131.0
Protein (g/L): 87
T3 (pg/dL): 0,04
T4 (ng/L): 15
TSH (mIU/L): 3,73
Urea (mg/dL): 25,29
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 
1. Survivor 
REASONING: 
This patient has a significant number of risk factors for adverse cardiac outcomes, including a history of ischemic dilated cardiomyopathy, hypertension, diabetes, and elevated creatinine levels. However, the patient's NYHA class is II, indicating mild symptoms, and they are receiving evidence-based medications for their conditions. The patient's low LVEF of 25.0 is a significant concern, but the patient's age and sex may still allow for potential improvement with optimal medical therapy and lifestyle modifications. 

2. Pump failure death 
REASONING: 
Given the patient's low LVEF and elevated creatinine levels, pump failure is a plausible outcome. The patient's diabetes and hypertension may also contribute to worsening cardiac function over time. However, the patient's NYHA class II symptoms suggest that they are still able to tolerate some physical activity, which may mitigate the risk of pump failure.

3. Sudden cardiac death 
REASONING: 
While the patient's ECG showed ventricular extrasystole, which is a marker for increased risk of arrhythmias, the lack of other indicators of high-risk arrhythmias (e.g., ventricular tachycardia, non-sustained ventricular tachycardia) and the absence of other factors that would increase the risk of sudden cardiac death (e.g., high blood pressure, low ejection fraction) makes this outcome less likely. The patient's medications and NYHA class II symptoms also suggest that they are receiving adequate management for their conditions, which may reduce the risk of sudden cardiac death."
741,741,P0011,"Age: 59
Gender: Male 
Weight: 85 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 9
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,03
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2382.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,66
Urea (mg/dL): 9,8
LVEF (%): 22.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Survivor
REASONING: 
Based on the provided patient data, this patient has a complex medical history with ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, which are all risk factors for cardiac events. However, the patient's current LVEF (22.0%) is significantly reduced, indicating a compromised cardiac function. Despite this, the patient's NYHA class is III, suggesting a moderate level of symptoms, and the patient is on medications for diabetes, hypertension, and heart failure (Loop Diuretics). The elevated Pro-BNP level (2382.0 ng/L) and the presence of ventricular extrasystoles on ECG suggest that the patient is experiencing some degree of cardiac stress. However, the absence of other concerning features such as severe hypotension, acute coronary syndrome, or significant electrolyte imbalances may suggest that the patient is not in immediate danger of a sudden cardiac death.

2. Sudden cardiac death
REASONING: 
While the patient's LVEF is significantly reduced, the absence of any signs of acute coronary syndrome, and the presence of ventricular extrasystoles on ECG, which may indicate an underlying cardiac electrical instability, make it less likely that the patient is at high risk for sudden cardiac death. However, the patient's complex medical history and elevated Pro-BNP level suggest that there may be ongoing cardiac stress and potential for cardiac events. 

3. Pump failure death
REASONING: 
Given the patient's reduced LVEF, elevated Pro-BNP level, and presence of ventricular extrasystoles on ECG, it is possible that the patient is at risk for pump failure. However, the patient's NYHA class is III, suggesting that they are able to manage their symptoms with current treatment, and the absence of any signs of severe hypotension or acute kidney injury may suggest that the patient is not at immediate risk for pump failure."
742,742,P0027,"Age: 79
Gender: Male 
Weight: 74 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 115/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,1
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,2
LDL (mmol/L): 1,6
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 990.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,5
Urea (mg/dL): 6,24
LVEF (%): 27.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history with multiple comorbidities such as ischemic dilated cardiomyopathy, diabetes, dyslipidemia, peripheral vascular disease, and myocardial infarction. However, the patient is currently on multiple medications, including beta blockers, ACE inhibitors, and statins, which are commonly used to manage these conditions. The patient's ejection fraction (LVEF) is 27%, which is significantly reduced, indicating advanced heart failure.

Despite these factors, the patient's current ECG impression does not show any signs of acute myocardial infarction or ventricular rupture, and the patient's biomarkers (Troponin, BNP) are not elevated. The patient's renal function is also preserved, as indicated by a normal creatinine level.

While the patient has a high risk of cardiac events, the patient's overall clinical presentation and laboratory results do not suggest an immediate life-threatening situation. Therefore, I would predict that the patient has a higher chance of survival over the next few years, assuming continued adherence to current medications and management of comorbid conditions.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's ECG impression shows non-sustained ventricular tachycardia, which is a significant risk factor for sudden cardiac death. Additionally, the patient has a history of ischemic dilated cardiomyopathy, which can increase the risk of ventricular arrhythmias. However, the patient is already on beta blockers, which are known to reduce the risk of arrhythmias.

While the patient's LVEF is significantly reduced, the patient is also on ACE inhibitors, which can help to reduce the risk of sudden cardiac death by reducing afterload and improving cardiac function. However, the patient's history of myocardial infarction and peripheral vascular disease may still increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

While the patient's LVEF is significantly reduced, indicating advanced heart failure, the patient is currently on multiple medications that can help to manage symptoms and improve cardiac function. However, the patient's renal function is compromised, as indicated by a high creatinine level, which can increase the risk of fluid overload and pump failure.

Additionally, the patient's ECG impression shows ventricular extrasystole and non-sustained ventricular tachycardia, which can increase the risk of pump failure. While the patient is on ACE inhibitors, which can help to reduce afterload, the patient's renal function may limit the effectiveness of these medications.

Overall, while pump failure is a risk for this patient, the patient's current clinical presentation and laboratory results suggest that sudden cardiac death may be a more immediate risk, given the presence of ventricular arrhythmias."
743,743,P0030,"Age: 77
Gender: Female 
Weight: 60 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 95/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 42,9
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 9,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,03
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2118.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,71
Urea (mg/dL): 10,02
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING:
The patient's clinical presentation and test results suggest a high risk of cardiac dysfunction. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that affects the heart's ability to pump blood effectively. The LVEF (Left Ventricular Ejection Fraction) of 20.0% is significantly below the normal range, indicating severe left ventricular dysfunction. This, combined with the patient's NYHA Class II symptoms, suggests that the patient is experiencing significant symptoms related to cardiac dysfunction.

The patient's elevated creatinine level (100.0 mmol/L) and BNP (Pro-BNP) level (2118.0 ng/L) also indicate cardiac strain and potential heart failure. The presence of ventricular extrasystoles on the ECG, although not sustained, may indicate underlying cardiac instability.

Given these factors, the patient is at high risk of experiencing pump failure, which is a life-threatening complication of heart failure. The patient's age, diabetes, and existing medications (e.g., beta blockers and ACE inhibitors) also contribute to this risk.

While the patient's blood pressure is within a relatively normal range, the presence of ventricular extrasystoles and the patient's overall clinical presentation suggest that the patient is at high risk of cardiac complications, including pump failure. Therefore, pump failure death is the most likely outcome for this patient over the next few years."
744,744,P0031,"Age: 76
Gender: Male 
Weight: 81 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,2
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 7,14
Creatinine (mmol/L): 195.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 138.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 310.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 23,82
LVEF (%): 33.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death 
2. Sudden cardiac death 
3. Survivor

REASONING:

The patient's data indicates a high risk of adverse cardiac events. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly impairs the heart's ability to pump blood effectively. This condition is a major risk factor for heart failure, which is confirmed by the patient's low left ventricular ejection fraction (LVEF) of 33%. The patient's elevated creatinine level (195.0 mmol/L) and urea level (23.82 mg/dL) also suggest impaired renal function, which can be a complication of heart failure.

The patient's ECG findings, including non-sustained ventricular tachycardia (NSVT) and ventricular extrasystoles, further increase the risk of cardiac arrhythmias and sudden cardiac death. The presence of NSVT is a significant predictor of arrhythmic events.

The patient's medication list includes a beta blocker, digoxin, and loop diuretics, which are commonly used to manage heart failure. However, the patient's elevated troponin level (0.01 ng/mL) suggests some degree of cardiac damage, which may indicate underlying myocardial ischemia or infarction.

While the patient's NYHA class II suggests that they are experiencing some limitation in physical activity due to heart failure, the presence of diabetes, dyslipidemia, and other comorbidities further increases the risk of adverse cardiac events.

In comparison to sudden cardiac death, pump failure death is a more likely outcome due to the patient's established heart failure and impaired cardiac function. Sudden cardiac death is a possible outcome, but the patient's ECG findings and other factors suggest that pump failure is a more probable event.

Therefore, based on the patient's clinical presentation and risk factors, pump failure death is the most likely outcome."
745,745,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the provided patient data, I would rank the prognoses as follows:

1. Sudden cardiac death: The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 26%, indicating severe left ventricular dysfunction. This is a strong predictor of sudden cardiac death in patients with ischemic dilated cardiomyopathy. Additionally, the patient's high BNP levels (32552 ng/L) and elevated Troponin levels (0.05 ng/mL) suggest significant cardiac stress and damage. The presence of ventricular extrasystoles on the ECG impression also increases the risk of arrhythmias, which can lead to sudden cardiac death.

2. Pump failure death: Given the patient's severely reduced LVEF and elevated BNP levels, it is likely that the patient will experience heart failure symptoms, including shortness of breath, fatigue, and swelling. The patient's current NYHA Class III classification indicates severe heart failure symptoms, and the use of loop diuretics suggests that the patient is already experiencing fluid overload. The patient's elevated creatinine levels (10.24 mg/dL) also indicate impaired renal function, which is often seen in advanced heart failure.

3. Survivor: While the patient's age, weight, and other factors such as hypertension and dyslipidemia may increase their risk of cardiovascular events, the patient's severe left ventricular dysfunction and elevated BNP levels suggest a high risk of cardiac complications. However, the patient's relatively stable vital signs, normal potassium levels, and the absence of other high-risk factors for sudden cardiac death make a ""survivor"" outcome less likely compared to pump failure death."
746,746,P0035,"Age: 73
Gender: Male 
Weight: 83 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 33,19
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,9
LDL (mmol/L): 1,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 752.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,29
Urea (mg/dL): 7,8
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient's ECG impression shows a high risk of arrhythmias, with ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia. The presence of these arrhythmias, particularly non-sustained ventricular tachycardia, indicates a high risk of sudden cardiac death. Additionally, the patient's LVEF of 39.0% indicates significant left ventricular dysfunction, which is a common precursor to ventricular arrhythmias. The patient's history of ischemic dilated cardiomyopathy, which is a common cause of ventricular arrhythmias, further supports this prognosis.

The patient's medications, including beta blockers and nitrovasodilators, are often used to manage arrhythmias and heart failure symptoms. However, the presence of non-sustained ventricular tachycardia and ventricular extrasystoles suggests that these medications may not be fully effective in managing the patient's cardiac rhythm disturbances.

While pump failure death is a possible outcome for this patient, the presence of arrhythmias and ventricular dysfunction make sudden cardiac death a more likely prognosis in the short term. However, pump failure death is still a potential risk in the long term, particularly if the patient's heart function continues to deteriorate.

RANKING: 2. Pump failure death
REASONING: 

As mentioned earlier, the patient's LVEF of 39.0% indicates significant left ventricular dysfunction, which is a common precursor to heart failure. The patient's NYHA Class II symptoms suggest that the patient is experiencing some limitations in physical activity due to heart failure, but not severe symptoms.

The patient's medications, including beta blockers and nitrovasodilators, are often used to manage heart failure symptoms. However, the presence of non-sustained ventricular tachycardia and ventricular extrasystoles suggests that the patient's heart function may be deteriorating, increasing the risk of pump failure.

The patient's creatinine level of 93.0 mmol/L is slightly elevated, which may indicate some degree of renal impairment, which can be a complication of heart failure. The patient's albumin level of 33.19 g/L is low, which may indicate some degree of malnutrition or liver dysfunction, which can also be a complication of heart failure.

While pump failure death is a possible outcome for this patient, the presence of arrhythmias and ventricular dysfunction make sudden cardiac death a more likely prognosis in the short term.

RANKING: 3. Survivor
REASONING: 

While the patient's prognosis is uncertain, the patient's medications and medical history suggest that they may be able to manage their condition with proper treatment. The patient's NYHA Class II symptoms suggest that they are not experiencing severe heart failure symptoms, and their LVEF of 39.0% is not extremely low.

The patient's creatinine level of 93.0 mmol/L is slightly elevated, but this may not be a significant concern in the short term. The patient's albumin level of 33.19 g/L is low, but this may not be a significant concern in the short term.

The patient's arrhythmias and ventricular dysfunction are concerning, but the presence of beta blockers and nitrovasodilators suggests that the patient is receiving appropriate treatment for these conditions. With proper management, the patient may be able to manage their condition and avoid severe complications.

However, the patient's age (73 years) and medical history (ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction) make them more susceptible to cardiac complications, which may increase the risk of mortality."
747,747,P0040,"Age: 83
Gender: Male 
Weight: 88 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 7
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,84
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1184.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,8
Urea (mg/dL): 10,91
LVEF (%): 40.0
Medications: Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING: 
The patient's clinical presentation and test results suggest a high risk of pump failure death. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure. The patient's LVEF of 40.0 is severely reduced, indicating significant left ventricular dysfunction. Additionally, the patient has a history of myocardial infarction, which can further compromise cardiac function. The patient's elevated BNP levels (1184.0 ng/L) and elevated troponin levels (0.01 ng/mL) also suggest cardiac stress and potential myocardial injury. Furthermore, the patient's NYHA Class II classification indicates moderate symptoms of heart failure. The patient's elevated creatinine level (10.91 mg/dL) and urea level (10.91 mg/dL) may also indicate renal impairment, which can be a complication of heart failure. Given these factors, the patient is at high risk of pump failure death.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's ECG impression of ventricular extrasystole and non-sustained ventricular tachycardia (VT) increases the risk of sudden cardiac death. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also increases the risk of ventricular arrhythmias. However, the patient's low LVEF and elevated BNP levels suggest a more compromised cardiac function, which may increase the risk of pump failure death.

RANKING: 3. Survivor
REASONING: 
While the patient's ECG impression of first-degree atrioventricular block (AVB) is concerning, it does not necessarily indicate a high risk of sudden cardiac death. Additionally, the patient's low LVEF and elevated BNP levels suggest a more compromised cardiac function, which may increase the risk of pump failure death. The patient's medications, including statins, ACE inhibitor, and nitrovasodilator, may also help manage cardiac function and reduce the risk of complications. However, the patient's overall clinical presentation and test results suggest a higher risk of pump failure death compared to sudden cardiac death or survival."
748,748,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the patient's data, I would rank sudden cardiac death as the most likely outcome for the next few years. The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF of 30.0% is also a strong indicator of poor cardiac function, which can lead to arrhythmias and sudden cardiac death. The presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG further supports this risk. Additionally, the patient's elevated Troponin level (0.01 ng/mL) suggests some degree of cardiac injury, which may increase the risk of sudden cardiac death.

The patient's age (71) and NYHA Class II also contribute to the risk of sudden cardiac death. While the patient is on medications such as Amiodarone and ACE Inhibitor, which are commonly used to manage heart failure and arrhythmias, the underlying cardiac condition and the presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggest that the patient remains at high risk for sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: 

Pump failure death is a likely outcome for this patient in the next few years. The patient's LVEF of 30.0% indicates severe left ventricular dysfunction, which can lead to heart failure. The patient's NYHA Class II suggests that they have some symptoms of heart failure, such as shortness of breath or fatigue. The patient's elevated creatinine level (10.02 mg/dL) and urea level (10.02 mg/dL) also suggest impaired renal function, which is often seen in patients with advanced heart failure.

The patient's elevated BNP level (475.0 ng/L) is also a strong indicator of heart failure. While the patient is on medications such as Spironolactone and ACE Inhibitor, which are commonly used to manage heart failure, the patient's underlying cardiac condition and the presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggest that the patient remains at risk for pump failure.

RANKING: 3. Survivor
REASONING: 

The patient's overall prognosis is guarded, but survival is still possible. The patient's elevated creatinine level and urea level suggest some degree of renal impairment, which can increase the risk of complications. However, the patient is on medications such as ACE Inhibitor, which can help to slow the progression of heart failure.

The patient's elevated BNP level and NYHA Class II suggest that they have some degree of heart failure, but the patient's LVEF of 30.0% suggests that the patient's cardiac function is severely impaired. The presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG also increases the risk of sudden cardiac death.

Overall, while the patient's prognosis is guarded, the patient's age and underlying cardiac condition suggest that survival is unlikely, and pump failure death is the most likely outcome in the next few years."
749,749,P0054,"Age: 55
Gender: Male 
Weight: 72 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 47
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3
Creatinine (mmol/L): 147.0
Gamma-glutamil transpeptidase (IU/L): 246
Glucose (mmol/L): 9,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,66
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3765.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,46
Urea (mg/dL): 16,26
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

The patient's prognosis is dominated by their severe heart failure symptoms, as indicated by their New York Heart Association (NYHA) Class III classification. This classification indicates that the patient has significant limitations in physical activity and experiences symptoms such as shortness of breath, fatigue, and swelling in the legs.

The patient's left ventricular ejection fraction (LVEF) of 25% is also a significant concern, as it indicates that the left ventricle is severely impaired in pumping blood efficiently. This, combined with their history of ischemic dilated cardiomyopathy, makes it likely that the patient's heart is unable to meet the body's oxygen demands, leading to pump failure.

The patient's elevated BNP levels (3765 ng/L) further support this conclusion, as BNP is a marker of ventricular stress and strain. Elevated BNP levels are associated with an increased risk of heart failure exacerbation and death.

In contrast, while the patient's ECG shows ventricular extrasystole, this is not a significant finding, as it is a benign condition that does not necessarily indicate a high risk of sudden cardiac death. The patient's troponin levels are also within normal limits, which suggests that there is no significant myocardial damage.

Sudden cardiac death is also less likely, as the patient's ECG does not show any signs of ventricular tachycardia or other arrhythmias that would increase the risk of sudden cardiac death.

Therefore, based on the patient's clinical presentation, laboratory results, and ECG findings, the most likely prognosis is pump failure death."
750,750,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the provided patient data, the patient is at high risk for pump failure death. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened and cannot pump blood effectively. The left ventricular ejection fraction (LVEF) is 25%, which is significantly below the normal range, indicating severe left ventricular dysfunction.

Additionally, the patient has a history of myocardial infarction, which can lead to further damage to the heart muscle and exacerbate the condition. The patient's elevated creatinine levels (124.0 mmol/L) may indicate kidney dysfunction, which can be related to cardiac dysfunction.

The patient's elevated BNP levels (3258.0 ng/L) also suggest heart failure, and the presence of edema and possible fluid overload (not directly measured but inferred from the elevated albumin level and the need for loop diuretics) further supports this diagnosis.

While the patient's medications, including ACE inhibitors and beta blockers, are typical for managing heart failure, the patient's symptoms and lab results indicate a high risk for pump failure.

Sudden cardiac death is less likely due to the absence of any signs of arrhythmias on the ECG, and the patient's medications are not primarily aimed at preventing arrhythmias.

Survivor is the least likely outcome, as the patient's underlying condition and lab results suggest a high risk for cardiac failure and pump failure."
751,751,P0065,"Age: 66
Gender: Male 
Weight: 106 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43,3
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,9
LDL (mmol/L): 3
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 114.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,17
TSH (mIU/L): 0,85
Urea (mg/dL): 16,7
LVEF (%): 40.0
Medications: Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING:

Based on the provided patient data, the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are significant risk factors for heart failure. The current NYHA Class II classification indicates that the patient experiences symptoms of heart failure, such as shortness of breath, fatigue, or swelling, which can lead to pump failure. The LVEF (Left Ventricular Ejection Fraction) of 40.0% is also a strong indicator of reduced cardiac function.

The patient's elevated creatinine level (143.0 mmol/L) and urea level (16.7 mg/dL) suggest impaired renal function, which can be a consequence of heart failure. Additionally, the patient's elevated troponin level (0.17 ng/mL) indicates some degree of cardiac muscle damage, which can contribute to pump failure.

The patient's current medication regimen, including a nitrovasodilator, may not be sufficient to adequately manage the patient's heart failure symptoms. The presence of ventricular extrasystole on the ECG impression suggests that the patient is at risk of arrhythmias, which can further exacerbate heart failure.

Considering these factors, the most likely prognosis for the patient is pump failure death within the next few years."
752,752,P0066,"Age: 47
Gender: Male 
Weight: 95 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 110/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 33,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 167.0
Gamma-glutamil transpeptidase (IU/L): 121
Glucose (mmol/L): 10,6
Hemoglobin (g/L): 125.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 5,3
LDL (mmol/L): 3
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 4797.0
Protein (g/L): 85
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,06
TSH (mIU/L): 4,36
Urea (mg/dL): 15,15
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING: 
Given the patient's severe left ventricular dysfunction (LVEF: 35.0) and the presence of ischemic dilated cardiomyopathy, it is highly likely that the patient will experience pump failure death in the next few years. The patient's NYHA Class III indicates severe heart failure, and their LVEF is significantly below the normal range, suggesting that their heart is not pumping efficiently. Additionally, the patient's elevated creatinine level (167.0) and elevated BNP level (4797.0) indicate that their heart is under significant strain, which increases the risk of pump failure. The patient's age (47) and other comorbidities (diabetes, dyslipemia, and peripheral vascular disease) also contribute to their high risk of pump failure. 

2. Sudden cardiac death
REASONING: 
While the patient's ECG shows ventricular extrasystole (polymorphic) and a high BNP level, these findings alone do not necessarily indicate a high risk of sudden cardiac death. However, the patient's history of ischemic dilated cardiomyopathy and the presence of ventricular extrasystoles suggest that they may have underlying cardiac arrhythmias that could increase their risk of sudden cardiac death. Nevertheless, the patient's medications (Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, and Statins) and their relatively stable ECG impression make this prognosis less likely than pump failure.

3. Survivor
REASONING: 
Given the patient's severe heart failure and significant left ventricular dysfunction, it is unlikely that they will survive for an extended period without experiencing pump failure. However, their age (47) and the presence of certain comorbidities (diabetes and peripheral vascular disease) may contribute to their overall mortality risk. While the patient's BNP level is elevated, this finding alone is not sufficient to rule out a favorable outcome. Additionally, the patient's relatively stable ECG impression and the presence of certain medications (e.g., Spironolactone) suggest that they may be receiving adequate treatment to manage their heart failure symptoms. Therefore, while the patient's prognosis is guarded, it is still possible that they may survive for an extended period without experiencing pump failure."
753,753,P0078,"Age: 75
Gender: Male 
Weight: 59 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 215.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,5
LDL (mmol/L): 1,99
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 7468.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,16
TSH (mIU/L): 4,97
Urea (mg/dL): 15,82
LVEF (%): 25.0
Medications: Amiodarone, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death 
2. Sudden cardiac death 
3. Survivor

REASONING:

Based on the patient's data, the most likely outcome is pump failure death. This is due to the patient's advanced age, severe left ventricular dysfunction (LVEF 25%), and history of idiopathic dilated cardiomyopathy, which significantly increases the risk of heart failure. The patient's elevated creatinine level (215.0 mmol/L) and elevated BNP levels (7468.0 ng/L) also suggest advanced heart failure. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG further supports this prognosis.

The second most likely outcome is sudden cardiac death, which is a common complication of advanced heart failure, particularly in patients with a history of ventricular arrhythmias. The patient's elevated Troponin level (0.16 ng/mL) and the presence of non-sustained ventricular tachycardia on the ECG also increase the risk of sudden cardiac death.

The least likely outcome is survivor, as the patient's severe heart failure and advanced age make it unlikely that they will survive without significant complications. However, it's worth noting that survival rates for patients with advanced heart failure can vary depending on various factors, including the effectiveness of treatment and the presence of any underlying comorbidities."
754,754,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

This patient's prognosis is unfavorable due to a combination of factors. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is only 35%, indicating severely impaired cardiac function, which increases the risk of heart failure and arrhythmias. The presence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG further supports this risk.

The patient's elevated creatinine level (207.0 mmol/L) and elevated BNP level (428.0 ng/L) also suggest significant cardiac dysfunction and fluid overload, which are common in heart failure.

The patient's age (81 years) and NYHA class III status (indicating severe heart failure symptoms) also contribute to the risk of pump failure death.

In contrast, while the patient's troponin level is slightly elevated, which may indicate some myocardial injury, it is not significantly elevated, and the patient is not experiencing acute myocardial infarction symptoms.

Therefore, based on the available data, sudden cardiac death is the most likely outcome, followed by pump failure death, and the patient is least likely to survive."
755,755,P0099,"Age: 68
Gender: Male 
Weight: 81 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 44,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 16,5
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,87
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 103.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,89
Urea (mg/dL): 6,45
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 
The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. Additionally, the patient's LVEF is severely impaired at 25%, indicating advanced heart failure. The presence of ventricular extrasystole on the ECG impression suggests a high risk of arrhythmias, which can lead to sudden cardiac death. The patient's age, NYHA class II, and multiple comorbidities (diabetes, hypertension, peripheral vascular disease) also contribute to the risk of sudden cardiac death. The patient's low HDL cholesterol level (0.93 mmol/L) further increases the risk of cardiovascular events.

RANKING: 2. Pump failure death
REASONING: 
Given the patient's severely impaired LVEF and NYHA class II heart failure, pump failure is a likely outcome. The patient's elevated creatinine level (95.0 mmol/L) and elevated blood urea level (6.45 mg/dL) suggest impaired renal function, which is common in advanced heart failure. The patient's low albumin level (44.3 g/L) and elevated liver enzymes (ALT and AST) may indicate malnutrition and liver dysfunction, which can exacerbate heart failure. The patient's multiple comorbidities and medications (diabetes medication, angiotensin II receptor blocker, beta blockers, and statins) further support the likelihood of pump failure.

RANKING: 3. Survivor
REASONING: 
While the patient's prognosis is guarded, there is still a possibility of survival with proper management and treatment. The patient's age and comorbidities are significant risk factors, but the patient's relatively low troponin level (0.01 ng/mL) and absence of ventricular tachycardia on the ECG impression suggest that the patient may not be in an acute cardiac crisis. With proper medical management, including optimization of medications, dietary changes, and possibly additional treatments such as ACE inhibitors or beta blockers, the patient may be able to manage their heart failure symptoms and survive for an extended period. However, the patient's underlying heart disease and comorbidities will likely continue to pose a risk for cardiovascular events and mortality."
756,756,P0107,"Age: 53
Gender: Male 
Weight: 74 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 127/76 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,87
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 670.0
Protein (g/L): 74,1
T3 (pg/dL): 0,01
T4 (ng/L): 11
TSH (mIU/L): 2,3
Urea (mg/dL): 8,32
LVEF (%): 27.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

The patient's prognosis is determined by analyzing the provided data, which suggests a severe and advanced stage of heart failure. Here's a breakdown of the key points:

1. Left Ventricular Ejection Fraction (LVEF) of 27%: This indicates severe systolic dysfunction, which is a hallmark of heart failure. A low LVEF is a strong predictor of poor prognosis.

2. NYHA Class III: This classification indicates severe heart failure symptoms, which is consistent with a poor prognosis.

3. Pro-BNP levels of 670 ng/L: Elevated BNP levels are associated with increased mortality and morbidity in heart failure patients.

4. History of Ischemic Dilated Cardiomyopathy: This condition is a significant risk factor for sudden cardiac death and heart failure.

5. Presence of Ventricular Tachycardia (VT): Non-sustained VT is a significant risk factor for sudden cardiac death, as it can degenerate into sustained VT, which is a leading cause of cardiac arrest.

6. Medication list: While the patient is on medications for heart failure and hypertension, the presence of a loop diuretic, spironolactone, statins, and an ACE inhibitor indicates that the patient is receiving standard treatment for heart failure, but may not be addressing the underlying cause of the heart failure.

Given these factors, the most likely outcome is Survivor. The patient's severe heart failure and history of ischemic dilated cardiomyopathy put them at high risk for pump failure death, but the fact that they are on standard medications and do not have evidence of severe hypertension or hyperkalemia (potassium level is within normal limits) suggests that they may be able to manage their condition and avoid pump failure death.

While sudden cardiac death is a possible outcome, the patient's LVEF is not severely impaired, and they are on medications that should help manage their heart failure symptoms. Therefore, sudden cardiac death is less likely.

Pump failure death is the most likely outcome, given the patient's severe heart failure and history of ischemic dilated cardiomyopathy. However, as mentioned earlier, the patient's management plan, including their medications, may help mitigate this risk, making survivor the most likely outcome."
757,757,P0129,"Age: 86
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,82
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 2036.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5
Urea (mg/dL): 19,8
LVEF (%): 50.0
Medications: Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient is at high risk of sudden cardiac death. The patient's age (86) is a significant risk factor for cardiac events. The patient's NYHA Class II indicates some limitation of physical activity, which may be related to cardiac symptoms. The patient's LVEF (50.0) is significantly reduced, indicating left ventricular dysfunction. The presence of non-sustained ventricular tachycardia (CH>10) on the ECG is a significant risk factor for sudden cardiac death.

The patient's past medical history of hypertensive cardiomyopathy and hypertension further increases the risk of cardiac events. The elevated creatinine level (212.0) suggests impaired renal function, which can be related to cardiac disease. The patient's elevated Troponin level (0.01 ng/mL) is a marker of cardiac injury.

Given these factors, the patient is at high risk of sudden cardiac death. While the patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, the patient's overall clinical presentation and history make sudden cardiac death the most likely prognosis.

RANKING: 2. Pump failure death
REASONING: 

Pump failure death is a possible prognosis for this patient, given the patient's reduced LVEF (50.0) and impaired renal function (elevated creatinine level). The patient's NYHA Class II symptoms may be related to cardiac dysfunction, and the patient's medications (loop diuretics, spironolactone, hydralazine, and nitrovasodilator) are commonly used to manage heart failure.

However, the presence of non-sustained ventricular tachycardia (CH>10) on the ECG suggests that the patient is at risk for cardiac events, which may increase the risk of pump failure death.

RANKING: 3. Survivor
REASONING: 

While the patient's age (86) and reduced LVEF (50.0) suggest a poor prognosis, the patient's current clinical presentation and ECG findings do not indicate an immediate risk of cardiac events. The patient's medications and medical history suggest that the patient is being managed for heart failure, and the patient's electrolyte levels (potassium 4.5 mEq/L) are within normal limits.

Additionally, the patient's recent ECG does not show any significant arrhythmias that would indicate an immediate risk of cardiac events. Therefore, while the patient's prognosis is guarded, the patient's current clinical presentation and ECG findings suggest that the patient may survive for a longer period."
758,758,P0134,"Age: 62
Gender: Male 
Weight: 84 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,1
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1528.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,34
Urea (mg/dL): 7,65
LVEF (%): 41.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

This patient has a complex medical history, with multiple comorbid conditions such as idiopathic dilated cardiomyopathy, diabetes, and hypertension. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 41%, indicating poor cardiac function. The presence of ventricular tachycardia (non-sustained VT) and polymorphic ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias. However, the patient is currently on medications that are commonly used to manage these conditions, including beta blockers, ACE inhibitors, and digoxin.

The patient's kidney function is also impaired, with an elevated creatinine level of 7.65 mg/dL, which may indicate a need for closer monitoring and potential adjustment of medications to avoid further kidney damage. The elevated liver enzymes (ALT and AST) may also suggest some degree of liver dysfunction, but this is not directly related to the cardiac condition.

Considering these factors, the patient's overall prognosis is more likely to be a survival outcome, as the patient is receiving optimal medical therapy for their cardiac conditions and the severity of their cardiac dysfunction is not immediately life-threatening. However, close monitoring and regular follow-up appointments will be necessary to adjust medications and manage any potential complications.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient has a high risk of arrhythmias, the presence of ventricular tachycardia (non-sustained VT) and polymorphic ventricular extrasystoles on the ECG suggests an increased risk of sudden cardiac death. However, the patient is currently on medications that are commonly used to manage these conditions, and the patient's cardiac function is not severely impaired.

The patient's age, weight, and kidney function also contribute to an increased risk of sudden cardiac death. The patient is 62 years old, which places them in a higher risk category for cardiac-related mortality. Additionally, the patient's kidney function is impaired, which may increase the risk of arrhythmias and sudden cardiac death.

However, the patient's LVEF is not severely impaired, and the patient is receiving optimal medical therapy, which reduces the likelihood of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

The patient's LVEF is significantly reduced at 41%, indicating poor cardiac function. This, combined with the patient's idiopathic dilated cardiomyopathy, makes pump failure death a significant concern. The patient's kidney function is also impaired, which may further increase the risk of pump failure.

The patient's medications, including ACE inhibitors and beta blockers, are commonly used to manage heart failure, but the patient's LVEF is not well-compensated, and the patient's cardiac function is not being adequately supported. The patient's elevated creatinine level also suggests that the patient's kidney function is not well-supported, which may further increase the risk of pump failure.

The patient's age and comorbid conditions also contribute to an increased risk of pump failure death. The patient is 62 years old, which places them in a higher risk category for cardiac-related mortality."
759,759,P0139,"Age: 83
Gender: Female 
Weight: 53 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 110/80 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,51
Creatinine (mmol/L): 137.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 115.0
Potassium (mEq/L): 3,79
Sodium (mEq/L): 138.0
Protein (g/L): 73,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,55
Urea (mg/dL): 8,9
LVEF (%): 68.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

This patient is an 83-year-old female with a history of valvular cardiomyopathy, hypertension, and NYHA Class III heart failure. Her current LVEF is 68%, indicating a moderate level of left ventricular dysfunction. Her blood tests show elevated creatinine levels (137.0 mmol/L) and urea levels (8.9 mg/dL), suggesting impaired kidney function. Her electrolyte levels, including potassium (3.79 mEq/L) and sodium (138.0 mEq/L), are within normal limits. Her troponin level is within the normal range (0.01 ng/mL), indicating no significant myocardial injury.

Given her medical history and current laboratory results, the patient's prognosis is more favorable than pump failure death. The fact that her ECG does not show signs of ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which are common precursors to sudden cardiac death, further supports this prognosis. The patient's current medication regimen, which includes an angiotensin II receptor blocker, digoxin, loop diuretics, spironolactone, and a nitrovasodilator, suggests that her cardiovascular system is being adequately managed.

RANKING: 2. Sudden cardiac death
REASONING: 

Although the patient's ECG does not show any life-threatening arrhythmias, her history of valvular cardiomyopathy and hypertension may increase her risk of sudden cardiac death. Her elevated creatinine levels and urea levels suggest impaired kidney function, which can contribute to cardiac dysfunction and arrhythmias. Additionally, her low hemoglobin level (115.0 g/L) may indicate anemia, which can also increase the risk of sudden cardiac death.

However, the patient's current LVEF is 68%, which is relatively preserved, and her troponin level is within the normal range, indicating no significant myocardial injury. The absence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG also reduces the likelihood of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 

Given the patient's impaired kidney function (elevated creatinine and urea levels) and her current LVEF of 68%, pump failure death is a possible but less likely outcome. The patient's NYHA Class III heart failure indicates that her heart is not functioning optimally, and her elevated troponin level suggests some degree of myocardial injury.

However, the fact that her ECG does not show any life-threatening arrhythmias and her medication regimen is well-managed reduces the likelihood of pump failure death. Additionally, her elevated potassium level (3.79 mEq/L) may be a sign of hyperkalemia, which can be managed with her current medication regimen.

Overall, while pump failure death is a possible outcome, it is less likely given the patient's current medical status and the absence of any life-threatening arrhythmias."
760,760,P0141,"Age: 76
Gender: Female 
Weight: 70 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 39,9
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,05
Creatinine (mmol/L): 167.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 123.0
Potassium (mEq/L): 3,15
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 5387.0
Protein (g/L): 71,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 17,69
Urea (mg/dL): 25
LVEF (%): 25.0
Medications: Loop Diuretics, Spironolactone, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Survivor
REASONING: 
Given the patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, the patient is at a high risk for adverse outcomes. However, the patient's LVEF is 25%, which is within the range of acceptable for a patient with heart failure. The patient is also on medications that are commonly used to manage heart failure, such as loop diuretics, spironolactone, statins, hydralazine, and nitrovasodilator. 

The patient's creatinine level is elevated at 167.0 mmol/L, which may indicate some degree of renal impairment. However, this is not uncommon in patients with heart failure. The presence of ventricular extrasystoles, non-sustained VT, and paroxysmal supraventricular tachycardia may indicate underlying arrhythmia issues, but these are not uncommon in patients with heart failure.

Given these factors, the patient is likely to survive for the next few years. 

2. Sudden Cardiac Death
REASONING: 
While the patient is at a high risk for adverse outcomes, the presence of LVEF 25% is a significant concern. A low LVEF is a strong predictor of increased risk of sudden cardiac death. However, the patient is also on medications that are commonly used to manage heart failure, which may help reduce the risk of sudden cardiac death.

The patient's ECG findings of ventricular extrasystoles, non-sustained VT, and paroxysmal supraventricular tachycardia may increase the risk of sudden cardiac death. However, these findings are not unique to this patient and can be seen in patients with heart failure.

Given these factors, the patient is at increased risk for sudden cardiac death, but the likelihood is lower than the patient's overall risk of dying from pump failure.

3. Pump Failure Death
REASONING: 
The patient's LVEF is 25%, which is a significant concern for pump failure. The patient's NYHA Class II indicates that the patient is experiencing some symptoms of heart failure, which may indicate that the patient is at risk for pump failure.

The patient's creatinine level is elevated at 167.0 mmol/L, which may indicate some degree of renal impairment. This can increase the risk of pump failure. The patient's ECG findings of ventricular extrasystoles, non-sustained VT, and paroxysmal supraventricular tachycardia may also increase the risk of pump failure.

Given these factors, the patient is at high risk for pump failure death."
761,761,P0143,"Age: 56
Gender: Female 
Weight: 83 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 110/65 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 38,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,66
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 86.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 3,39
LDL (mmol/L): 3,86
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1036.0
Protein (g/L): 68,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 8,4
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden Cardiac Death
REASONING: The patient's history of valvular cardiomyopathy, myocardial infarction, and peripheral vascular disease increases the risk of sudden cardiac death. The patient's LVEF is severely impaired at 40%, indicating significant left ventricular dysfunction, which can lead to arrhythmias and sudden cardiac death. The presence of ventricular extrasystoles and ventricular tachycardia on the ECG further supports this risk. Additionally, the patient's high troponin level (0.01 ng/mL) suggests some degree of myocardial damage, which can contribute to arrhythmias. The patient's age and NYHA class III status also increase the risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
REASONING: Pump failure death is a likely outcome for this patient due to their severe left ventricular dysfunction (LVEF 40%) and history of valvular cardiomyopathy. The patient's NYHA class III status indicates that they have significant symptoms of heart failure, which can lead to pump failure. The patient's elevated creatinine level (110.0 mmol/L) suggests impaired renal function, which can be a complication of heart failure.

RANKING: 3. Survivor
REASONING: While the patient's prognosis is concerning, there is still a possibility that they may survive for a few years. The patient's age and NYHA class III status do increase the risk of mortality, but the fact that they are not currently experiencing symptoms and are receiving medication for their condition may improve their chances of survival. However, the presence of ventricular extrasystoles and ventricular tachycardia on the ECG, as well as the patient's severely impaired LVEF, make this outcome less likely compared to pump failure death."
762,762,P0151,"Age: 74
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 43,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 162
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 123.0
Potassium (mEq/L): 3,85
Sodium (mEq/L): 133.0
Protein (g/L): 84,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,31
Urea (mg/dL): 8
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 
The patient's age (74) and NYHA Class III heart failure status indicate a high risk of cardiovascular events. The patient's LVEF of 70% is also a concerning factor, as it suggests reduced left ventricular function. The patient's creatinine level of 105.0 (elevated) and elevated Gamma-glutamil transpeptidase (162) levels may indicate kidney impairment, which can be a complication of heart failure. 

Additionally, the patient's low blood pressure (90/60 mmHg) and low hemoglobin (123.0) levels may indicate poor perfusion of vital organs, increasing the risk of cardiac events. The patient's troponin level of 0.01 ng/mL is within the normal range, but the patient's past medical history of valvular cardiomyopathy increases the risk of arrhythmias and cardiac events.

Given these factors, the patient is at high risk for sudden cardiac death. The presence of ventricular extrasystole on the ECG is a significant concern, as it can be a precursor to more serious arrhythmias.

RANKING: 2. Pump failure death
REASONING: 
The patient's NYHA Class III heart failure status and reduced LVEF of 70% indicate a high risk of pump failure. The patient's elevated creatinine level (105.0) and elevated Gamma-glutamil transpeptidase (162) levels further support this risk. The patient's low blood pressure (90/60 mmHg) and low hemoglobin (123.0) levels also contribute to the risk of pump failure.

RANKING: 3. Survivor
REASONING: 
While the patient's past medical history of valvular cardiomyopathy and current medications (Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, and Nitrovasodilator) suggest a treatment plan to manage heart failure, the patient's high risk factors (age, NYHA Class III status, reduced LVEF, elevated creatinine, and Gamma-glutamil transpeptidase) suggest that the patient may not survive without further complications. However, given the patient's stable vital signs and normal troponin level, there is a possibility that the patient may survive for an extended period with proper management and monitoring."
763,763,P0155,"Age: 59
Gender: Male 
Weight: 81 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 35,5
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,52
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,6
Hemoglobin (g/L): 133.0
Potassium (mEq/L): 4,75
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 10534.0
Protein (g/L): 66,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,82
Urea (mg/dL): 20,8
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: The patient's overall clinical presentation and laboratory results do not indicate an immediate high risk for sudden cardiac death or pump failure. The patient has a history of ischemic dilated cardiomyopathy, which is the underlying cause of the current NYHA Class II heart failure. The patient's elevated BNP levels (10534 ng/L) suggest some degree of heart failure, but the patient is still able to maintain a relatively stable hemodynamic status (blood pressure 90/60 mmHg). The patient's kidney function is also relatively preserved (creatinine 141.0 mmol/L), which suggests that the patient is not in acute kidney injury or failure. The patient is on multiple medications for heart failure, diabetes, and hypertension, which indicates a good level of cardiovascular management. The absence of ventricular tachycardia, ventricular extrasystole, and paroxysmal supraventricular tachyarrhythmia on the ECG impression suggests that the patient is not at high risk for arrhythmic events. Therefore, based on the available information, the most likely outcome for the patient over the next few years is survival. 

RANKING: 2. Sudden cardiac death
REASONING: While the patient has a history of ischemic dilated cardiomyopathy, the patient's current clinical presentation and laboratory results do not indicate an immediate high risk for sudden cardiac death. The patient's elevated BNP levels suggest some degree of heart failure, but the patient is still able to maintain a relatively stable hemodynamic status. However, the patient's elevated creatinine level (141.0 mmol/L) suggests some degree of renal impairment, which can be a risk factor for sudden cardiac death. Additionally, the patient's dyslipidemia and peripheral vascular disease may also contribute to an increased risk of sudden cardiac death. However, the patient is on multiple medications for heart failure, diabetes, and hypertension, which indicates a good level of cardiovascular management.

RANKING: 3. Pump failure death
REASONING: The patient's current clinical presentation and laboratory results do not indicate an immediate high risk for pump failure. The patient's elevated BNP levels (10534 ng/L) suggest some degree of heart failure, but the patient is still able to maintain a relatively stable hemodynamic status. The patient's kidney function is also relatively preserved (creatinine 141.0 mmol/L), which suggests that the patient is not in acute kidney injury or failure. However, the patient's history of ischemic dilated cardiomyopathy and current NYHA Class II heart failure suggest that the patient may be at risk for progressive heart failure. The patient's elevated creatinine level (141.0 mmol/L) and elevated troponin level (0.01 ng/mL) suggest some degree of cardiac stress, but the patient is still able to maintain a relatively stable hemodynamic status. Therefore, while the patient is at risk for pump failure, the patient's current clinical presentation and laboratory results do not indicate an immediate high risk for pump failure."
764,764,P0160,"Age: 71
Gender: Male 
Weight: 62 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 107
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 123.0
Potassium (mEq/L): 4,59
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 27357.0
Protein (g/L): 74,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,15
Urea (mg/dL): 19,2
LVEF (%): 13.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden Cardiac Death
REASONING:

This patient has a high-risk profile for sudden cardiac death (SCD) due to the presence of several factors:

1. Age: The patient is 71 years old, which increases the risk of cardiac arrhythmias and SCD.
2. NYHA Class III: This indicates severe heart failure, which can lead to cardiac remodeling and increased risk of arrhythmias.
3. Valvular cardiomyopathy: This underlying condition can lead to electrical and structural changes in the heart, increasing the risk of arrhythmias.
4. ECG findings: The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia code indicate a high risk of arrhythmias.
5. Pro-BNP levels: Elevated levels of Brain Natriuretic Peptide (BNP) are associated with increased risk of cardiac events, including SCD.
6. Low LVEF: A left ventricular ejection fraction (LVEF) of 13% indicates significant left ventricular dysfunction, which can lead to arrhythmias and SCD.

Given these factors, the patient is at high risk for sudden cardiac death. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG further increases this risk.

RANKING: 2. Pump Failure Death
REASONING:

The patient's low LVEF (13%) and NYHA Class III heart failure indicate that the heart is not pumping efficiently, which can lead to pump failure. The presence of medications such as Spironolactone, Hydralazine, and Nitrovasodilator suggests that the patient is being treated for heart failure. However, the patient's high risk of SCD due to the factors mentioned above takes precedence over the risk of pump failure.

RANKING: 3. Survivor
REASONING:

While the patient has a high risk of SCD, the presence of medications such as Beta Blockers, Digoxin, and Loop Diuretics indicates that the patient is receiving treatment for heart failure and arrhythmias. Additionally, the patient's relatively stable vital signs and laboratory values suggest that the patient may not be in acute distress. However, the patient's underlying heart condition and risk of SCD make it less likely that the patient will survive for an extended period without a cardiac event."
765,765,P0186,"Age: 57
Gender: Male 
Weight: 65 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 90/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 2,84
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 59
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,68
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5098.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,07
TSH (mIU/L): 5,32
Urea (mg/dL): 8,49
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's data suggests a high risk of cardiac complications. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is severely impaired, leading to heart failure. The patient's NYHA Class III indicates severe symptoms of heart failure, which requires optimal medical therapy and close monitoring.

The patient's elevated troponin levels (0.07 ng/mL) suggest myocardial injury, which may be related to the cardiomyopathy. The presence of ventricular tachycardia (non-sustained VT) and polymorphic ventricular extrasystole on the ECG indicates arrhythmia, which can be a life-threatening complication in patients with heart failure.

The patient's low ejection fraction (LVEF) of 27.0% further supports the presence of heart failure. The elevated creatinine level (8.49 mg/dL) suggests renal impairment, which is common in patients with heart failure.

Considering the patient's severe heart failure symptoms, arrhythmias, and elevated troponin levels, the most likely prognosis is sudden cardiac death, which is a sudden and unexpected death caused by a cardiac event. This is a common complication in patients with severe heart failure, especially those with a history of cardiomyopathy.

While pump failure death (option 2) is also a possible outcome, it is less likely in the short term, as the patient is already receiving medications to manage heart failure (beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitor). These medications can help alleviate symptoms and improve survival.

The patient's overall prognosis is guarded, and close monitoring and optimization of their medications and lifestyle are crucial to prevent further cardiac events."
766,766,P0188,"Age: 59
Gender: Female 
Weight: 49 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 33,9
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 66.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 334
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 3,93
LDL (mmol/L): 3,44
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 7574.0
Protein (g/L): 65
T3 (pg/dL): 0,0306
T4 (ng/L): 9,59
Troponin (ng/mL): 0,1
TSH (mIU/L): 26,88
Urea (mg/dL): 14,4
LVEF (%): 70.0
Medications: Amiodarone, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death 
REASONING: 
The patient has a history of valvular cardiomyopathy, which is a condition that affects the heart's ability to pump blood efficiently. This condition is already causing the patient to have a reduced ejection fraction (LVEF) of 70%, indicating that the heart is not pumping effectively. The patient also has elevated creatinine levels (143.0 mmol/L), which suggests impaired kidney function, likely due to the heart's reduced pumping ability. The patient is also taking medications such as Loop Diuretics and Spironolactone, which are typically used to manage fluid overload and heart failure. The presence of elevated troponin levels (0.1 ng/mL) also suggests some degree of cardiac damage, further supporting the likelihood of heart failure. The patient's elevated BNP levels (7574.0 ng/L) also indicate a high level of stress on the heart, which is consistent with heart failure. Considering these factors, pump failure death is the most likely outcome for this patient over the next few years.

2. Sudden cardiac death 
REASONING: 
While the patient has a history of valvular cardiomyopathy, which is a risk factor for sudden cardiac death, the patient's current LVEF is 70%, which is not severely impaired. The patient is also not taking any medications that are known to increase the risk of sudden cardiac death, such as beta blockers. The patient's ejection fraction is not significantly reduced, and the patient does not have any other risk factors for sudden cardiac death, such as a family history of sudden cardiac death or a previous event. Therefore, while sudden cardiac death cannot be ruled out entirely, it is less likely than pump failure death.

3. Survivor 
REASONING: 
Given the patient's history of valvular cardiomyopathy, elevated creatinine levels, and elevated BNP levels, the patient is at high risk for heart failure. However, the patient is currently taking medications to manage fluid overload and heart failure, which should help to slow the progression of the disease. The patient's LVEF is 70%, which is not severely impaired, and the patient does not have any other risk factors for sudden cardiac death. While the patient's ejection fraction is not ideal, it is not significantly reduced, which suggests that the patient may be able to tolerate some level of stress without experiencing a catastrophic event. Therefore, while the patient is at risk for heart failure, the likelihood of survival is moderate, and the patient may be able to manage their condition with close monitoring and treatment."
767,767,P0192,"Age: 83
Gender: Female 
Weight: 69 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,47
Creatinine (mmol/L): 122.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,25
LDL (mmol/L): 4,24
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5541.0
Protein (g/L): 72
T3 (pg/dL): 0,0237
T4 (ng/L): 18,93
TSH (mIU/L): 0,92
Urea (mg/dL): 19,3
LVEF (%): 65.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING:
This patient has a high risk of pump failure death due to several factors. Firstly, the patient's NYHA Class III indicates severe heart failure, which is a strong predictor of mortality and morbidity. The patient's LVEF of 65.0% is also below the normal range, indicating reduced cardiac function. The presence of Hypertensive cardiomyopathy, Diabetes, and Hypertension in the patient's past medical history suggests chronic stress on the heart, further exacerbating the condition. The patient's elevated creatinine level (122.0 mmol/L) and urea level (19.3 mg/dL) indicate impaired renal function, which is often seen in heart failure patients. The patient's high Pro-BNP level (5541.0 ng/L) also suggests elevated ventricular stretch and wall tension, a common cause of heart failure. Additionally, the patient's medications, including ACE inhibitors and loop diuretics, are standard treatments for heart failure, but in this case, the patient's elevated sodium level (142.0 mEq/L) may indicate fluid overload, which can worsen heart failure. 

The ECG findings of ventricular extrasystoles and polymorphic ventricular tachycardia are concerning for arrhythmias, which can further increase the risk of cardiac events. While the patient does not have sustained ventricular tachycardia, the presence of non-sustained ventricular tachycardia (CH>10) is still a significant concern. The patient's low HDL level (1.32 mmol/L) and high LDL level (4.24 mmol/L) may also contribute to cardiovascular disease progression. Overall, the combination of these factors makes pump failure death the most likely outcome for this patient. 

2. Sudden cardiac death
REASONING:
While the patient's ECG findings of ventricular extrasystoles and polymorphic ventricular tachycardia are concerning for arrhythmias, the absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia (CH>10) makes sudden cardiac death less likely. However, the patient's high Pro-BNP level and elevated creatinine and urea levels suggest a high risk of cardiac events, including arrhythmias. The patient's low ejection fraction and NYHA Class III also increase the risk of sudden cardiac death. Additionally, the patient's medications, including ACE inhibitors and loop diuretics, may contribute to electrolyte imbalances that can increase the risk of arrhythmias.

3. Survivor
REASONING:
While the patient's age and medical history are against them, the patient's current medications and the absence of severe arrhythmias on the ECG make survival possible. However, the patient's elevated Pro-BNP level, impaired renal function, and low ejection fraction indicate a high risk of cardiac events. The patient's low hemoglobin level (11.7 g/L) may also be a concern, as anemia can exacerbate heart failure. Overall, while survival is possible, the patient's high-risk profile makes it less likely."
768,768,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 
The patient's age (89) and NYHA Class III status indicate severe heart failure, which increases the risk of sudden cardiac death. The patient's LVEF is 70%, which is below the normal range, suggesting impaired cardiac function. The presence of ventricular extrasystoles, non-sustained VT, and non-sustained ventricular tachycardia on the ECG also increase the risk of sudden cardiac death.

The patient's medications, including a nitrovasodilator, suggest that they are receiving treatment for heart failure and hypertension. However, the patient's elevated troponin levels (1.2 ng/mL) and elevated creatinine levels (8.2 mg/dL) suggest that the patient's heart is not functioning optimally, which increases the risk of pump failure.

The patient's elevated BNP levels (3179 ng/L) also suggest that the patient is experiencing significant cardiac stress, which increases the risk of sudden cardiac death.

Overall, while pump failure is a concern, the patient's risk of sudden cardiac death is higher due to the presence of life-threatening arrhythmias and impaired cardiac function.

RANKING: 2. Pump failure death
REASONING: 
The patient's impaired LVEF (70%) and elevated creatinine levels (8.2 mg/dL) suggest that the patient's heart is not functioning optimally, which increases the risk of pump failure. The patient's elevated troponin levels (1.2 ng/mL) also suggest that the patient's heart is experiencing cardiac stress, which increases the risk of pump failure.

The patient's medications, including a nitrovasodilator, suggest that they are receiving treatment for heart failure. However, the patient's NYHA Class III status indicates that the patient's heart failure is severe, which increases the risk of pump failure.

The patient's elevated BNP levels (3179 ng/L) also suggest that the patient is experiencing significant cardiac stress, which increases the risk of pump failure.

Overall, while pump failure is a concern, the patient's risk of sudden cardiac death is higher due to the presence of life-threatening arrhythmias and impaired cardiac function.

RANKING: 3. Survivor
REASONING: 
The patient's age (89) and NYHA Class III status indicate severe heart failure, which increases the risk of pump failure and sudden cardiac death. However, the patient's elevated BNP levels (3179 ng/L) and elevated creatinine levels (8.2 mg/dL) suggest that the patient is experiencing significant cardiac stress, which may indicate that the patient's heart is still functioning to some extent.

The patient's medications, including a nitrovasodilator, suggest that they are receiving treatment for heart failure. While the patient's LVEF is 70%, which is below the normal range, it is still within the range for a patient with severe heart failure.

The patient's elevated troponin levels (1.2 ng/mL) and elevated potassium levels (4.4 mEq/L) suggest that the patient's heart is experiencing some degree of stress, but the patient's hemoglobin level (143 g/L) is within the normal range, which suggests that the patient is not experiencing significant anemia.

Overall, while the patient's risk of pump failure and sudden cardiac death is high, the patient's elevated BNP levels and elevated creatinine levels suggest that the patient's heart is still functioning to some extent, which increases the likelihood of survival."
769,769,P0200,"Age: 80
Gender: Male 
Weight: 69 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 119.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2129.0
Protein (g/L): 67
T3 (pg/dL): 0,0429
T4 (ng/L): 15,56
Troponin (ng/mL): 0,2
TSH (mIU/L): 0,58
Urea (mg/dL): 13,9
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",pump failure death,"RANKING: 
1. Survivor 
REASONING: 
The patient's current clinical presentation and laboratory results indicate a high risk of adverse outcomes. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. The patient's LVEF is severely impaired at 39%, indicating poor cardiac function. The presence of ventricular extrasystoles on the ECG is also concerning, as it suggests an increased risk of arrhythmias. Additionally, the patient's low ejection fraction and elevated BNP levels suggest that the heart is working under significant stress, which can lead to heart failure. However, the patient is currently on medications that are commonly used to manage heart failure and prevent arrhythmias, such as beta blockers, loop diuretics, and an ACE inhibitor. 

While the patient's current condition is concerning, the fact that the patient is not experiencing any symptoms of acute heart failure or acute coronary syndrome suggests that the patient may be able to survive for the next few years without significant deterioration. The patient's age and comorbidities also suggest that the patient's life expectancy is limited, but the patient's current condition is not necessarily fatal. Therefore, I would rank the patient as having a high likelihood of survival.

2. Sudden cardiac death 
REASONING: 
The patient's history of ischemic dilated cardiomyopathy and ventricular extrasystoles on the ECG make it likely that the patient is at risk for sudden cardiac death. The patient's low ejection fraction and elevated BNP levels also suggest that the heart is under significant stress, which can lead to sudden cardiac death. However, the patient is currently on medications that are commonly used to prevent arrhythmias and heart failure, which reduces the risk of sudden cardiac death. Additionally, the patient's age and comorbidities suggest that the patient's life expectancy is limited, which may reduce the likelihood of sudden cardiac death.

3. Pump failure death 
REASONING: 
The patient's current clinical presentation and laboratory results suggest that the patient is at risk for heart failure, which can lead to pump failure death. The patient's low ejection fraction and elevated BNP levels suggest that the heart is under significant stress, and the patient's history of ischemic dilated cardiomyopathy increases the risk of heart failure. However, the patient is currently on medications that are commonly used to manage heart failure, which reduces the risk of pump failure death. Additionally, the patient's age and comorbidities suggest that the patient's life expectancy is limited, which may reduce the likelihood of pump failure death. While the patient is at risk for heart failure, the fact that the patient is not currently experiencing symptoms of acute heart failure suggests that the patient may be able to survive for the next few years without significant deterioration."
770,770,P0212,"Age: 65
Gender: Male 
Weight: 79 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 44.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 688
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,08
LDL (mmol/L): 2,22
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 79
T3 (pg/dL): 0,0492
T4 (ng/L): 16,35
Troponin (ng/mL): 3,1
TSH (mIU/L): 0,79
Urea (mg/dL): 10
LVEF (%): 70.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

The patient's age, weight, and NYHA class indicate that they have a moderate level of heart disease, but are still relatively active and have not reached the advanced stages of heart failure. The patient's LVEF is 70%, which is within the normal range, suggesting that the heart is still functioning relatively well. The patient's ejection fraction and lack of ventricular tachycardia or other arrhythmias on the ECG also support this.

While the patient has multiple comorbidities, such as hypertension, diabetes, and dyslipidemia, these conditions can be managed with medications and lifestyle changes. The patient is already on medications for these conditions, and the patient's blood work shows that they are not in acute distress.

The patient's Pro-BNP level is elevated at 709 ng/L, which is a marker of heart failure. However, this can be a normal finding in patients with mild to moderate heart failure. The patient's kidney function is also slightly elevated, but this is not unusual for someone with heart failure.

Given these factors, I believe that the patient is at high risk for heart failure exacerbation, but I do not believe that the patient is at high risk for sudden cardiac death or pump failure death. Therefore, I rank the patient as having the best prognosis.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's ECG shows ventricular extrasystoles, which can be a marker of cardiac stress and may indicate an increased risk for arrhythmias. The patient's elevated Pro-BNP level and slightly elevated kidney function also suggest that the patient may be at risk for heart failure exacerbation.

However, the patient's LVEF is still within the normal range, and the patient is on medications for their comorbid conditions, which suggests that the patient is being managed effectively. The patient's ECG does not show any other concerning findings, such as ventricular tachycardia or non-sustained ventricular tachycardia.

Given these factors, I believe that the patient is at moderate risk for sudden cardiac death, but the risk is not as high as it would be if the patient had other concerning ECG findings or more severe symptoms.

RANKING: 3. Pump failure death
REASONING: 

The patient's Pro-BNP level is elevated, which suggests that the patient may be at risk for heart failure exacerbation. The patient's kidney function is slightly elevated, which can be a sign of fluid overload, a common complication of heart failure.

The patient's LVEF is slightly below the normal range, which may indicate some degree of cardiac dysfunction. The patient's ECG shows ventricular extrasystoles, which can be a marker of cardiac stress and may indicate an increased risk for arrhythmias.

Given these factors, I believe that the patient is at moderate to high risk for pump failure death. However, the patient's overall clinical picture is not as concerning as it would be if the patient had other concerning ECG findings or more severe symptoms.

It's worth noting that the patient's prognosis is still relatively good compared to patients with more severe symptoms and ECG findings. However, close monitoring and follow-up are necessary to ensure that the patient's condition does not worsen."
771,771,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death 
REASONING: 

Based on the patient's clinical presentation, the following factors contribute to a high risk of sudden cardiac death:

1. Low LVEF of 30%: This indicates severe left ventricular dysfunction, which increases the risk of arrhythmias and sudden cardiac death.
2. NYHA Class III: This classification suggests significant heart failure symptoms, which may indicate a more advanced stage of the disease.
3. Pro-BNP levels of 1100 ng/L: Elevated B-type natriuretic peptide (BNP) levels are associated with increased ventricular wall stress and a higher risk of cardiac events, including sudden cardiac death.
4. History of idiopathic dilated cardiomyopathy: This condition can lead to arrhythmias, heart failure, and sudden cardiac death.
5. Presence of ventricular extrasystoles on ECG: Polymorphic ventricular extrasystoles are a marker of abnormal heart rhythm and can increase the risk of sudden cardiac death.

Given these factors, the patient's risk of sudden cardiac death is relatively high.

RANKING: 2. Pump failure death 
REASONING: 

Based on the patient's clinical presentation, the following factors contribute to a high risk of pump failure death:

1. Low LVEF of 30%: This indicates severe left ventricular dysfunction, which can lead to heart failure and pump failure.
2. NYHA Class III: This classification suggests significant heart failure symptoms, which may indicate a more advanced stage of the disease.
3. History of idiopathic dilated cardiomyopathy: This condition can lead to heart failure and pump failure.
4. Pro-BNP levels of 1100 ng/L: Elevated BNP levels are associated with increased ventricular wall stress and a higher risk of cardiac events, including pump failure.

Given these factors, the patient's risk of pump failure death is significant.

RANKING: 3. Survivor 
REASONING: 

While the patient has a high risk of cardiac events, the following factors suggest a relatively better prognosis:

1. Controlled hypertension: The patient's blood pressure is well-controlled at 115/70 mmHg.
2. Medications: The patient is taking medications for diabetes, heart failure, and hypertension, which can help manage symptoms and slow disease progression.
3. Normal electrolytes and renal function: The patient's electrolyte levels and renal function are within normal limits, which suggests good overall cardiovascular health.

However, the patient's severe left ventricular dysfunction, high BNP levels, and history of idiopathic dilated cardiomyopathy outweigh these positive factors, making survival less likely."
772,772,P0223,"Age: 64
Gender: Male 
Weight: 64 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,2
Creatinine (mmol/L): 254.0
Gamma-glutamil transpeptidase (IU/L): 175
Glucose (mmol/L): 15,78
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,71
LDL (mmol/L): 2,29
Sodium (mEq/L): 127.0
Pro-BNP (ng/L): 12746.0
Protein (g/L): 81
T3 (pg/dL): 0,0114
T4 (ng/L): 17,74
Troponin (ng/mL): 1,5
TSH (mIU/L): 2,65
Urea (mg/dL): 20,37
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

The patient's data suggests a high risk of sudden cardiac death due to several factors:

1. Low LVEF (30.0%): This is a significant indicator of left ventricular dysfunction, which increases the risk of sudden cardiac death.
2. ECG Impression: The presence of ventricular extrasystole and non-sustained ventricular tachycardia (VT) suggests an increased risk of arrhythmic events.
3. Past Medical History: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death.
4. NYHA Class III: This indicates severe heart failure, which can lead to arrhythmias and sudden cardiac death.
5. Medications: The patient is on beta blockers, which can increase the risk of bradycardia, but the patient does not have bradycardia, however, the presence of beta blockers can still contribute to the risk of ventricular arrhythmias.

Given these factors, the patient is at a high risk of sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: 

The patient's data suggests a high risk of pump failure death due to:

1. Low LVEF (30.0%): This indicates significant left ventricular dysfunction, which can lead to heart failure.
2. NYHA Class III: This indicates severe heart failure, which can lead to pump failure.
3. Past Medical History: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for pump failure.
4. Medications: The patient is on loop diuretics, which can help manage fluid overload, but the patient's LVEF is still severely impaired.

Given these factors, the patient is at a high risk of pump failure death.

RANKING: 3. Survivor
REASONING: 

The patient's data suggests that the patient is at risk of complications, but the patient's overall condition is not as severe as the other two options.

1. Low LVEF (30.0%): While this indicates significant left ventricular dysfunction, the patient's NYHA Class III and past medical history suggest that the patient is already experiencing significant heart failure symptoms.
2. ECG Impression: The patient has ventricular extrasystole and non-sustained VT, which increases the risk of arrhythmic events.
3. Past Medical History: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death.

However, the patient is on beta blockers, which can help manage heart rate and reduce the risk of arrhythmias. Additionally, the patient's medications, such as spironolactone and hydralazine, can help manage heart failure symptoms.

Given these factors, the patient is at risk of complications, but the patient's overall condition is not as severe as the other two options."
773,773,P0239,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,35
Potassium (mEq/L): 5,2
LDL (mmol/L): 3,7
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 9992.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,42
TSH (mIU/L): 7,83
Urea (mg/dL): 24,79
LVEF (%): 10.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING:

Based on the patient's ECG impression, which shows sustained ventricular tachycardia (VT), I would rank sudden cardiac death as the most likely prognosis for the next few years. The presence of sustained VT is a significant risk factor for sudden cardiac death, especially in a patient with a history of ischemic dilated cardiomyopathy and other comorbid conditions such as hypertension, diabetes, and peripheral vascular disease.

The patient's left ventricular ejection fraction (LVEF) is severely impaired at 10%, which is a hallmark of advanced heart failure. The presence of sustained VT further increases the risk of sudden cardiac death due to the potential for life-threatening arrhythmias.

While pump failure death is a concern given the patient's NYHA class III status and elevated creatinine levels, the immediate risk of sudden cardiac death due to sustained VT takes precedence. The patient's elevated troponin levels and LVEF also suggest ongoing myocardial damage and reduced cardiac function, which can contribute to the risk of sudden cardiac death.

Sudden cardiac death is the most likely prognosis for the next few years due to the combination of the patient's underlying heart condition, comorbidities, and ECG findings."
774,774,P0242,"Age: 69
Gender: Female 
Weight: 57 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 34
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 285.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 12,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,4
LDL (mmol/L): 1,71
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 656.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,05
TSH (mIU/L): 6,87
Urea (mg/dL): 23,46
LVEF (%): 21.0
Medications: Diabetes Medication, Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: The patient has a severe heart failure with a left ventricular ejection fraction (LVEF) of 21.0%, which indicates advanced heart failure. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) suggests significant arrhythmic instability. However, the patient's blood pressure is well-controlled (110/70 mmHg), and they are on medications for diabetes, hypertension, and heart failure, which are all effective in managing these conditions. Additionally, the patient's hemoglobin level is within the normal range, and their liver enzymes and kidney function tests are relatively normal. While the patient's creatinine level is elevated, it is not significantly elevated, and the patient is on an ACE inhibitor, which can help reduce proteinuria and slow kidney disease progression. Overall, the patient's condition is severe but not immediately life-threatening, and with proper management, it is possible for the patient to survive for several years.

RANKING: 2. Sudden cardiac death
REASONING: The patient's LVEF is very low (21.0%), which indicates advanced heart failure. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) increases the risk of sudden cardiac death. Additionally, the patient's elevated creatinine level and proteinuria suggest kidney disease, which can contribute to an increased risk of sudden cardiac death. However, the patient's blood pressure is well-controlled, and they are on medications for diabetes, hypertension, and heart failure, which can help reduce this risk. While the patient's ECG impression suggests arrhythmias, the patient's overall condition is not as unstable as it would be if the patient had a significantly elevated creatinine level or a more severe arrhythmia.

RANKING: 3. Pump failure death
REASONING: Pump failure death is a likely outcome for this patient due to their severe heart failure (LVEF 21.0%) and significant arrhythmic instability. The patient's elevated creatinine level and proteinuria suggest kidney disease, which can contribute to pump failure. The patient's ECG impression also suggests significant arrhythmias, which can further exacerbate heart failure. Additionally, the patient's low HDL cholesterol level (1.32 mmol/L) and elevated triglyceride level (not provided) suggest dyslipidemia, which can contribute to cardiovascular disease progression. While the patient's blood pressure is well-controlled, the patient's overall condition is severe, and pump failure is a likely outcome."
775,775,P0248,"Age: 43
Gender: Female 
Weight: 50 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,79
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 996.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 18
Troponin (ng/mL): 0,09
TSH (mIU/L): 1,34
Urea (mg/dL): 3,66
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING:
The patient's current clinical presentation, laboratory results, and ECG findings suggest a high risk of pump failure death. 

The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is compromised due to scarring and enlargement of the heart muscle. This condition is further exacerbated by the patient's low left ventricular ejection fraction (LVEF) of 37.0%, indicating poor cardiac function.

The patient's elevated B-type natriuretic peptide (Pro-BNP) level of 996.0 ng/L is also indicative of heart failure, as it is a marker of cardiac stress and strain. The patient's symptoms of NYHA Class II, which represents mild to moderate heart failure, further support this finding.

Additionally, the patient's elevated creatinine level of 3.66 mg/dL indicates impaired renal function, which can be associated with heart failure. The patient's elevated troponin level of 0.09 ng/mL, although within the normal range, may indicate some degree of myocardial injury, which can be a risk factor for cardiac events.

Given the patient's medical history, laboratory results, and ECG findings, the likelihood of pump failure death is high.

RANKING: 
2. Sudden cardiac death
REASONING:
While the patient's ECG findings do not show any ventricular tachycardia or ventricular extrasystoles, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death.

The patient's low LVEF of 37.0% and elevated Pro-BNP level of 996.0 ng/L suggest that the patient's heart is under significant stress, which can lead to arrhythmias and sudden cardiac death.

However, the patient's absence of any specific ECG findings that would indicate a high risk of sudden cardiac death (such as ventricular tachycardia or ventricular extrasystoles) makes this prognosis less likely.

RANKING: 
3. Survivor
REASONING:
Given the patient's poor LVEF of 37.0% and elevated Pro-BNP level of 996.0 ng/L, the patient is at high risk of cardiac events. However, the patient's NYHA Class II symptoms and absence of any ECG findings that would indicate a high risk of sudden cardiac death make this prognosis less likely.

While the patient's medical history and laboratory results suggest a high risk of pump failure, the patient's overall clinical presentation and ECG findings do not support a high risk of sudden cardiac death. Therefore, the likelihood of the patient surviving is lower compared to pump failure death, but higher than sudden cardiac death.

Note: The prognosis is subjective and based on the provided data. A more accurate prognosis can only be made after a thorough evaluation by a cardiologist, taking into account additional factors such as the patient's overall health, lifestyle, and medical history."
776,776,P0256,"Age: 72
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 150/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 33
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 267
Glucose (mmol/L): 9,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1475.0
Protein (g/L): 64
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,13
Urea (mg/dL): 5,83
LVEF (%): 48.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death 
REASONING: 

Based on the provided patient data, the patient has a high-risk profile for cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 48%, which is below the normal range, indicating significant left ventricular dysfunction. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and polymorphic ventricular extrasystoles on the ECG further increase the risk of arrhythmic events.

Additionally, the patient has a history of myocardial infarction, hypertension, and diabetes, which are all risk factors for cardiac events. The patient's elevated troponin levels (0.01 ng/mL) also suggest some degree of cardiac damage.

The patient's age (72 years) and NYHA class III status also contribute to the overall risk assessment. The patient's elevated BNP levels (1475 ng/L) indicate a high level of ventricular strain, which is consistent with heart failure.

Given these factors, the most likely outcome for the patient in the next few years is sudden cardiac death. The patient's cardiac events, ventricular dysfunction, and elevated BNP levels make it likely that the patient will experience a cardiac event, which could be life-threatening.

RANKING: 2. Pump failure death 
REASONING: 

The second most likely outcome for the patient is pump failure death. The patient's LVEF is 48%, indicating significant left ventricular dysfunction, which is a risk factor for heart failure. The patient's elevated BNP levels (1475 ng/L) and NYHA class III status also suggest that the patient has heart failure.

The patient's history of ischemic dilated cardiomyopathy, hypertension, and diabetes also contribute to the risk of heart failure. The patient's elevated creatinine levels (88.0 mmol/L) and urea levels (5.83 mg/dL) suggest some degree of renal impairment, which can be a complication of heart failure.

The patient's medications, including loop diuretics, ACE inhibitors, and statins, are standard treatments for heart failure and hypertension, which suggests that the patient is receiving appropriate management for their conditions.

RANKING: 3. Survivor 
REASONING: 

The least likely outcome for the patient is survivor. While the patient is receiving standard treatments for their conditions, the patient's high-risk profile and cardiac events make it less likely that they will survive in the next few years. The patient's ventricular dysfunction, elevated BNP levels, and history of cardiac events make it more likely that the patient will experience a cardiac event, which could be life-threatening.

However, it's worth noting that the patient is receiving medications that are standard treatments for heart failure and hypertension, which suggests that the patient is receiving appropriate management for their conditions. Additionally, the patient's age (72 years) is also a risk factor for mortality, but it's not the only factor to consider.

In conclusion, while the patient has a high-risk profile, the patient is receiving standard treatments for their conditions, and the patient's age is also a factor to consider. However, the patient's cardiac events, ventricular dysfunction, and elevated BNP levels make sudden cardiac death and pump failure death more likely outcomes in the next few years."
777,777,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

Based on the provided patient data, the patient is a 63-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which suggests a significant underlying cardiac pathology. However, the patient's current ejection fraction (LVEF) is 15.0%, which is actually higher than the normal range (typically considered <55%), indicating some degree of preserved cardiac function. Additionally, the patient's NYHA Class II classification suggests mild symptoms, which may indicate a more preserved cardiac reserve.

Furthermore, the patient's laboratory results show a slightly elevated creatinine level (154.0 mol/L), but this is not excessively high and could be attributed to various factors, including dehydration or other non-cardiac causes. The patient's troponin level is within normal limits (0.01 ng/mL), which suggests no acute myocardial infarction.

The patient's medication regimen, which includes amiodarone, digoxin, loop diuretics, hydralazine, and a nitrovasodilator, is relatively standard for managing heart failure and arrhythmias in patients with cardiomyopathy.

Given these factors, the patient's overall prognosis is relatively favorable, and I would rank the patient as a survivor. However, it is essential to continue monitoring the patient's condition and adjusting the treatment plan as necessary to ensure optimal management of their underlying cardiac disease.

RANKING: 2. Sudden cardiac death
REASONING: 

Although the patient's ejection fraction is slightly elevated, the patient's NYHA Class II classification and mildly elevated creatinine level suggest some level of cardiac dysfunction. The patient's ECG results show ventricular extrasystoles, which could be indicative of underlying cardiac disease.

However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG makes it less likely for the patient to experience sudden cardiac death. Additionally, the patient's troponin level is within normal limits, which reduces the risk of acute myocardial infarction.

Considering these factors, I would rank the patient as having a lower risk of sudden cardiac death compared to the patient who is expected to survive.

RANKING: 3. Pump failure death
REASONING: 

Given the patient's history of ischemic dilated cardiomyopathy and myocardial infarction, the patient is at risk for developing heart failure. The patient's mildly elevated creatinine level and slightly elevated troponin level suggest some degree of cardiac dysfunction.

The patient's ejection fraction is 15.0%, which is lower than the normal range, indicating some degree of left ventricular dysfunction. Additionally, the patient's NYHA Class II classification suggests some level of symptoms, which may indicate a higher risk of pump failure.

Considering these factors, I would rank the patient as having a moderate to high risk of pump failure death, although the patient's current ejection fraction is slightly elevated, and the patient's medication regimen is standard for managing heart failure.

In summary, the patient's overall prognosis is most likely to be survival, followed by a lower risk of sudden cardiac death, and a moderate to high risk of pump failure death."
778,778,P0265,"Age: 83
Gender: Female 
Weight: 77 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 155/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,99
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 8,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 3,66
LDL (mmol/L): 2,03
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 984.0
Protein (g/L): 67
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,29
Urea (mg/dL): 9,7
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death 
REASONING: 

Based on the patient's age, NYHA Class II status, and the presence of ventricular extrasystoles on the ECG impression, I would rank the patient's prognosis as sudden cardiac death. The patient's age of 83 puts them at a higher risk for arrhythmic events, and the presence of ventricular extrasystoles on the ECG impression indicates an increased risk of life-threatening arrhythmias. The patient's LVEF of 70% also suggests some degree of left ventricular dysfunction, which can contribute to the risk of sudden cardiac death. Additionally, the patient's history of myocardial infarction and hypertension further increases their risk for cardiac complications.

While pump failure death is a possible outcome, the patient's current LVEF is not severely impaired, and they are on medications that are generally used to manage heart failure. The presence of ventricular extrasystoles, however, suggests a higher risk for sudden cardiac death.

RANKING: 2. Pump failure death 
REASONING: 

Given the patient's NYHA Class II status, the patient is already experiencing some degree of heart failure, and their LVEF is 70%. However, the patient's current medications, including beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator, are generally used to manage heart failure and reduce the risk of further decline. The patient's creatinine level is slightly elevated, which may indicate some degree of kidney dysfunction, but it is not severe. 

The patient's ventricular extrasystoles on the ECG impression also suggest a higher risk for cardiac complications, but the presence of these arrhythmias is not as concerning as the ventricular extrasystoles. 

Therefore, while pump failure death is a possible outcome, it is less likely than sudden cardiac death.

RANKING: 3. Survivor 
REASONING: 

The patient's overall health status, including their age, NYHA Class II status, and current medications, suggest that they are likely to survive for several years. The patient's LVEF is not severely impaired, and they are on medications that are generally used to manage heart failure. The patient's creatinine level is not severely elevated, and their kidney function appears to be relatively preserved.

The presence of ventricular extrasystoles on the ECG impression is a concern, but the patient is on medications that can help manage arrhythmias. The patient's blood pressure is elevated, but it is not excessively high, and they are on medications to manage hypertension.

Overall, while the patient's prognosis is uncertain, the presence of several risk factors for cardiac complications does not necessarily mean that they will not survive. With proper management and monitoring, it is possible for the patient to survive for several years."
779,779,P0269,"Age: 79
Gender: Male 
Weight: 62 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 45,5
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 184.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,82
Potassium (mEq/L): 5,12
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Protein (g/L): 71,1
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,31
Urea (mg/dL): 20,1
LVEF (%): 22.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

The patient's prognosis is primarily influenced by their NYHA Class II status, indicating moderate heart failure symptoms. This classification suggests that the patient has some limitation in physical activity due to heart failure, but they can still perform daily activities without severe symptoms. However, the presence of valvular cardiomyopathy, peripheral vascular disease, and myocardial infarction increases the risk of cardiac complications.

The patient's low ejection fraction (LVEF) of 22.0% is a significant indicator of systolic heart failure. This value is below the normal range (50-70%), which may lead to reduced cardiac output and increased risk of heart failure exacerbation.

The patient's elevated creatinine level (184.0 mol/L) suggests impaired renal function, which can be a complication of heart failure. The patient is also taking Loop Diuretics, which are commonly used to manage fluid overload in heart failure patients. However, the elevated creatinine level may indicate inadequate diuresis or worsening renal function.

The patient's ECG findings of ventricular extrasystole (polymorphic) and the absence of ventricular tachycardia or non-sustained ventricular tachycardia may suggest an increased risk of arrhythmias, which can contribute to sudden cardiac death.

Considering these factors, the most likely outcome for the patient is pump failure death, as their heart failure symptoms and impaired renal function increase the risk of cardiac complications. Sudden cardiac death is a possible outcome due to arrhythmias or other cardiac events, but it is less likely than pump failure death. Survivor is the least likely outcome, given the patient's advanced age, multiple comorbidities, and evidence of heart failure."
780,780,P0285,"Age: 69
Gender: Female 
Weight: 76 kg
Height: 147 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 163.0
Gamma-glutamil transpeptidase (IU/L): 48,4
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,56
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2365.0
Protein (g/L): 75
T3 (pg/dL): 0,0294
T4 (ng/L): 16,92
Troponin (ng/mL): 1,4
TSH (mIU/L): 0,56
Urea (mg/dL): 21,2
LVEF (%): 25.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

The patient's ECG findings, particularly the presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole, indicate a high risk of arrhythmias. However, the patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 25%, which suggests a severe impairment of cardiac function. This, combined with the patient's history of ischemic dilated cardiomyopathy, indicates a high risk of heart failure.

Although the patient's NYHA Class is III, indicating severe heart failure, the presence of NSVT and ventricular extrasystole suggests that the patient's heart is still experiencing arrhythmias, which can lead to sudden cardiac death. However, the patient's pump failure is already a significant concern due to their reduced LVEF.

In contrast, sudden cardiac death is a more likely outcome than pump failure death, as the patient's heart is already compromised due to the severe arrhythmias and reduced LVEF. While pump failure death is a significant concern, it is likely that the patient's heart will continue to deteriorate due to the arrhythmias and reduced cardiac function, leading to a higher risk of sudden cardiac death.

Therefore, based on the patient's ECG findings and medical history, I would rank the possible outcomes as follows: sudden cardiac death is the most likely outcome, followed by pump failure death, and finally survivor."
781,781,P0287,"Age: 70
Gender: Female 
Weight: 80 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4
LDL (mmol/L): 3,13
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1537.0
Protein (g/L): 72
T3 (pg/dL): 0,027
T4 (ng/L): 21,25
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,93
Urea (mg/dL): 5,5
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Amiodarone, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

This patient's prognosis is at a high risk for sudden cardiac death due to several factors:

1. Elevated Pro-BNP levels: The patient's Pro-BNP level is significantly elevated at 1537.0 ng/L, indicating a high level of ventricular stress and potential cardiac strain. Elevated BNP levels are often associated with heart failure and increased risk of arrhythmias, which can lead to sudden cardiac death.

2. History of Hypertensive cardiomyopathy: The patient's history of hypertensive cardiomyopathy increases the risk of cardiac arrhythmias and sudden cardiac death. Hypertensive cardiomyopathy can lead to left ventricular remodeling and fibrosis, which can disrupt normal electrical conduction pathways in the heart, increasing the risk of arrhythmias.

3. Age and NYHA Class II: The patient's age (70 years) and NYHA Class II status indicate a moderate level of heart failure, which increases the risk of arrhythmias and sudden cardiac death.

4. Medications: The patient is taking Amiodarone, a medication commonly used to treat arrhythmias, which may indicate an underlying arrhythmic disorder.

5. ECG Impression: The patient's ECG shows ventricular extrasystoles, which are premature ventricular contractions that can increase the risk of arrhythmias.

While pump failure death is a possible outcome, the presence of these risk factors makes sudden cardiac death a more likely prognosis in this patient."
782,782,P0293,"Age: 74
Gender: Male 
Weight: 90 kg
Height: 184 cm
NYHA Class: III
Blood Pressure: 125/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40,5
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,61
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 3,19
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,7
Potassium (mEq/L): 5,11
LDL (mmol/L): 1,73
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1081.0
Protein (g/L): 68
T3 (pg/dL): 0,024
T4 (ng/L): 16,52
Troponin (ng/mL): 0,2
TSH (mIU/L): 0,62
Urea (mg/dL): 10,3
LVEF (%): 28.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

Based on the patient's data, the patient is at high risk for sudden cardiac death due to the presence of ventricular extrasystoles, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia. The ECG impression highlights the presence of these arrhythmias, which are indicative of a high risk of cardiac events. The patient's NYHA Class III status and history of idiopathic dilated cardiomyopathy also contribute to the increased risk of sudden cardiac death. The elevated Pro-BNP levels (1081.0 ng/L) further supports this prognosis.

RANKING: 2. Pump Failure Death
REASONING: 

The patient's LVEF of 28.0% indicates significant left ventricular dysfunction, which is consistent with the patient's NYHA Class III status. The elevated creatinine level (93.0 mmol/L) and elevated urea level (10.3 mg/dL) also suggest impaired renal function, which can be associated with pump failure. The patient's history of idiopathic dilated cardiomyopathy and the presence of ventricular arrhythmias further support the risk of pump failure.

RANKING: 3. Survivor
REASONING: 

While the patient's past medical history and current data suggest a high risk of cardiac events, the patient's age (74) and the presence of certain medications (e.g., beta blockers, digoxin, and spironolactone) that are commonly used to manage heart failure and arrhythmias may mitigate some of the risks. However, the patient's overall prognosis is still uncertain due to the presence of underlying conditions that can contribute to cardiac events."
783,783,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

The patient's LVEF is significantly reduced at 25%, which indicates severe left ventricular dysfunction, a common complication in patients with idiopathic dilated cardiomyopathy. However, the patient is receiving optimal medical therapy with medications such as Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone, which are standard treatments for heart failure and hypertension. 

Although the patient has a high level of Pro-BNP (1693 ng/L), which is indicative of heart failure, the patient's hemoglobin level is relatively high (138 g/L), and there is no evidence of acute coronary syndrome (Troponin level of 0.3 ng/mL). 

Given the patient's age, comorbid conditions, and the presence of a ventricular arrhythmia (Non-sustained ventricular tachycardia), there is a concern for the risk of sudden cardiac death. However, the patient's ECG findings do not indicate a high risk for sudden cardiac death. 

Therefore, considering the patient's medical therapy and the severity of heart failure, the most likely outcome is that the patient will survive with the current treatment regimen."
784,784,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the provided patient data, I would rank the possible prognoses from most likely to least likely as follows:

1. Pump failure death: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure. The patient's LVEF (Left Ventricular Ejection Fraction) of 42.0 is also low, indicating reduced cardiac function. Additionally, the patient is on medications such as Loop Diuretics and Spironolactone, which are commonly used to manage heart failure. The patient's elevated creatinine level (106.0 mmol/L) may also suggest some degree of renal impairment, which can be a complication of heart failure. The elevated Pro-BNP level (1160.0 ng/L) further supports the likelihood of heart failure.

2. Sudden cardiac death: The patient's ECG shows ventricular extrasystoles, which are a type of abnormal heart rhythm. However, the patient does not have any other significant arrhythmias such as ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. While the presence of ventricular extrasystoles is a risk factor for sudden cardiac death, it is not as strong a predictor as the patient's underlying heart failure.

3. Survivor: While the patient's overall health status and medical history suggest a significant risk of adverse outcomes, the patient's age (71 years) and relatively good hemoglobin level (113.0 g/L) and normal TSH level (4.34 mIU/L) may contribute to a slightly better prognosis. However, the patient's history of ischemic dilated cardiomyopathy and elevated creatinine level make it less likely for the patient to survive without any major complications."
785,785,P0317,"Age: 63
Gender: Male 
Weight: 72 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 95/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,64
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 325.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 6,37
Urea (mg/dL): 13,14
LVEF (%): 24.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death 
REASONING: 

This patient has a high-risk profile for sudden cardiac death (SCD) due to the presence of several risk factors, including:

1. Ischemic dilated cardiomyopathy, which is a significant cause of SCD.
2. History of myocardial infarction, which can lead to ventricular arrhythmias.
3. NYHA Class III heart failure, indicating severe symptoms and reduced functional capacity.
4. Elevated Pro-BNP levels (325 ng/L), which indicate increased ventricular stress and strain.
5. Low LVEF (24.0%), indicating poor ventricular function.
6. Presence of ventricular extrasystoles, which can be a precursor to ventricular tachycardia or fibrillation.
7. Presence of multiple medications, including beta-blockers and ACE inhibitors, which can be pro-arrhythmic.
8. Presence of diabetes, dyslipidemia, and peripheral vascular disease, which can contribute to cardiovascular disease.

Given these risk factors, the patient is at high risk for sudden cardiac death, which is a major concern in patients with advanced heart failure.

RANKING: 2. Pump failure death 
REASONING: 

This patient is at high risk for pump failure death due to:

1. Severe NYHA Class III heart failure, indicating significant symptoms and reduced functional capacity.
2. Low LVEF (24.0%), indicating poor ventricular function.
3. Elevated Pro-BNP levels (325 ng/L), indicating increased ventricular stress and strain.
4. Presence of ventricular extrasystoles, which can lead to further ventricular dysfunction.
5. Presence of multiple medications, including beta-blockers and ACE inhibitors, which can contribute to reduced cardiac output.

Given these factors, the patient is at high risk for pump failure death, which is a common cause of death in patients with advanced heart failure.

RANKING: 3. Survivor 
REASONING: 

While this patient has several risk factors for SCD and pump failure death, the patient's overall clinical presentation and laboratory results do not indicate an immediate risk for sudden cardiac death or pump failure. The patient is on multiple medications, including beta-blockers and ACE inhibitors, which can help reduce cardiovascular risk. The patient's NYHA Class III heart failure is managed with loop diuretics, which can help reduce symptoms and improve functional capacity. The patient's laboratory results, including normal troponin levels and normal potassium levels, do not indicate acute myocardial injury or electrolyte imbalances. Therefore, while the patient is at risk for cardiovascular events, the patient is likely to survive for the next few years with proper management and monitoring."
786,786,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the provided patient data, I would rank the prognoses as follows:

1. Sudden cardiac death: The patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and low LVEF (36.0%) suggest a high risk of arrhythmic events, including ventricular tachycardia and sudden cardiac death. The presence of a monomorphic ventricular extrasystole on the ECG impression also increases the risk of ventricular arrhythmias. The patient's age (69) and low LVEF also contribute to this risk. Although the patient is currently on medications that are typically used to manage heart failure and prevent arrhythmias, the patient's overall clinical profile suggests a high risk of sudden cardiac death.

2. Pump failure death: The patient's LVEF of 36.0% indicates a significant reduction in cardiac function, which is a major risk factor for heart failure. The patient's NYHA Class II status and history of myocardial infarction also suggest a high risk of heart failure exacerbation. The patient's elevated creatinine levels (98.0) and low albumin levels (43.8) may indicate renal dysfunction, which can contribute to heart failure. While the patient is currently on medications that are typically used to manage heart failure, the patient's overall clinical profile suggests a high risk of pump failure death.

3. Survivor: Although the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, the patient's current ECG impression does not show any signs of acute arrhythmias. The patient's medications and low troponin levels (0.01 ng/mL) suggest that the patient's cardiac function is currently stable. The patient's age (69) and low HDL cholesterol (1.27 mmol/L) may also contribute to an increased risk of cardiovascular events, but the patient's overall clinical profile is not as concerning as it is for sudden cardiac death or pump failure death.

It is essential to note that this prognosis is based on the information provided and may not accurately reflect the patient's actual outcome. A thorough evaluation and further testing may be necessary to determine the patient's true prognosis."
787,787,P0321,"Age: 67
Gender: Female 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,6
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 2,87
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,45
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 4636.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,43
Urea (mg/dL): 6,01
LVEF (%): 18.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the provided patient data, the patient is at high risk for sudden cardiac death due to the presence of several comorbid conditions that can increase the risk of arrhythmias and cardiac events. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. Additionally, the patient has a low LVEF of 18%, indicating severe left ventricular dysfunction, which can lead to arrhythmias and cardiac events.

The patient also has a history of ventricular extrasystoles, which are abnormal heart rhythms that can increase the risk of sudden cardiac death. The presence of ventricular extrasystoles on the ECG impression further supports this risk.

The patient's medications, including beta blockers and digoxin, may also contribute to the risk of sudden cardiac death, as these medications can slow the heart rate and increase the risk of arrhythmias.

While pump failure death is a possible outcome, the patient's current ECG findings and medical history suggest that sudden cardiac death is a more immediate and likely risk. 

The patient's low LVEF and elevated troponin levels suggest that the patient is at risk for cardiac events, but the presence of ventricular extrasystoles and other comorbid conditions make sudden cardiac death a more likely outcome."
788,788,P0329,"Age: 61
Gender: Female 
Weight: 95 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,2
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 17,2
Hemoglobin (g/L): 165.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,78
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 10340.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,44
Urea (mg/dL): 7,35
LVEF (%): 24.0
Medications: Diabetes Medication, Digoxin, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING: 
The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 24.0%, which is a clear indicator of impaired cardiac function. This is consistent with the patient's history of ischemic dilated cardiomyopathy. The patient's NYHA Class II classification also supports this, indicating moderate symptoms of heart failure. Additionally, the elevated BNP (Brain Natriuretic Peptide) level of 10340.0 ng/L is a strong predictor of pump failure. The presence of elevated BNP levels indicates increased ventricular wall stress and increased cardiac workload, which can lead to pump failure. Furthermore, the patient's elevated creatinine level (99.0 mmol/L) and elevated glucose level (17.2 mmol/L) also suggest impaired renal function, which can exacerbate cardiac dysfunction and increase the risk of pump failure. The patient's treatment with ACE inhibitors, digoxin, and spironolactone also supports the likelihood of pump failure, as these medications are commonly used to manage heart failure.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's ECG findings show ventricular extrasystole, the presence of monomorphic ventricular extrasystoles is not a direct indicator of an increased risk of sudden cardiac death. The patient's LVEF is significantly reduced, and the elevated BNP level suggests impaired cardiac function, but these factors do not directly increase the risk of sudden cardiac death. However, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of arrhythmias, which can lead to sudden cardiac death.

RANKING: 3. Survivor
REASONING: 
The patient's LVEF is significantly reduced, and the elevated BNP level suggests impaired cardiac function. However, the patient's NYHA Class II classification indicates moderate symptoms of heart failure, which may be managed with current treatment. The patient's elevated creatinine level and glucose level also suggest impaired renal function, but these factors can be managed with current treatment. The patient's treatment with ACE inhibitors, digoxin, and spironolactone also supports the likelihood of managing the patient's heart failure symptoms. While the patient's ECG findings show ventricular extrasystoles, the presence of monomorphic ventricular extrasystoles is not a direct indicator of an increased risk of sudden cardiac death. Overall, the patient's current treatment and clinical status suggest that the patient may survive with proper management."
789,789,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the patient's data, the most likely prognosis is sudden cardiac death. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that can lead to heart failure and arrhythmias. The presence of a low left ventricular ejection fraction (LVEF) of 22.0 indicates significant left ventricular dysfunction, which is a major risk factor for sudden cardiac death.

The patient's elevated Pro-BNP levels (3311.0 ng/L) also suggest a high risk of heart failure, which can lead to sudden cardiac death. Additionally, the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG impression indicates an increased risk of arrhythmias, which can contribute to sudden cardiac death.

The patient's medical history of diabetes and dyslipemia also increases the risk of cardiovascular events, including sudden cardiac death.

While pump failure death is a possible outcome, it is less likely than sudden cardiac death in this case. The patient is already on medications for heart failure (Digoxin), and the patient's NYHA Class II indicates that they are not severely limited in their physical activities. However, the patient's low LVEF and elevated Pro-BNP levels suggest that they are at risk of developing more severe heart failure, which could ultimately lead to pump failure.

Therefore, while pump failure death is a possible outcome, the patient's immediate risk of sudden cardiac death is higher due to the presence of significant left ventricular dysfunction, arrhythmias, and other risk factors."
790,790,P0339,"Age: 77
Gender: Male 
Weight: 64 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 37,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,49
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3307.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,37
Urea (mg/dL): 16,03
LVEF (%): 33.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING: The patient has a significant history of ischemic dilated cardiomyopathy, which is a condition that can lead to left ventricular dysfunction and heart failure. The patient's LVEF is severely impaired at 33%, indicating a significant reduction in the heart's pumping ability. Additionally, the patient has a history of hypertension, diabetes, and peripheral vascular disease, which can further exacerbate cardiac strain. The patient's elevated creatinine level (135.0 mmol/L) and elevated BNP level (3307.0 ng/L) suggest impaired cardiac function and fluid overload, respectively. The patient's age and weight also contribute to the risk of pump failure. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG also indicate an increased risk of arrhythmias, which can further compromise cardiac function.

While the patient's current medications, including ACE inhibitors and loop diuretics, are standard treatments for heart failure, the patient's underlying cardiac condition and other comorbidities suggest that pump failure is a likely outcome in the near future. The patient's ECG findings and laboratory results further support this prognosis, indicating a high risk of cardiac dysfunction and arrhythmias.

Given the patient's history, physical characteristics, and laboratory results, pump failure death is the most likely outcome in the next few years."
791,791,P0363,"Age: 83
Gender: Male 
Weight: 55 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 41,1
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 13,6
Glucose (mmol/L): 4,59
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,2
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1469.0
Protein (g/L): 73
T3 (pg/dL): 0,0468
T4 (ng/L): 13,29
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,04
Urea (mg/dL): 5,6
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which indicates significant cardiac damage and potential for arrhythmias. The presence of ventricular extrasystole on the ECG impression, specifically polymorphic ventricular extrasystole, is a concerning sign that can be a precursor to more serious arrhythmias. Additionally, the patient's low left ventricular ejection fraction (LVEF) of 25.0 indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death. The patient's medications, including an ACE inhibitor and a nitrovasodilator, are aimed at managing heart failure and hypertension, but the underlying cardiac damage and arrhythmias may still pose a significant risk of sudden cardiac death. Given the patient's age, comorbidities, and ECG findings, sudden cardiac death is the most likely outcome.

RANKING: 2. Pump failure death
REASONING: The patient's severe left ventricular dysfunction (LVEF 25.0) and history of heart failure (NYHA Class III) increase the risk of pump failure. The patient's medications, including loop diuretics and spironolactone, are aimed at managing symptoms of heart failure, but the underlying cardiac damage may still lead to decompensation and pump failure. The patient's elevated creatinine level (82.0) and low albumin level (41.1) may also indicate kidney dysfunction, which can be a complication of heart failure.

RANKING: 3. Survivor
REASONING: While the patient's severe cardiac damage and arrhythmias increase the risk of adverse outcomes, the patient's age (83) and the presence of medications aimed at managing heart failure and hypertension suggest that they may survive for an extended period. However, the patient's LVEF of 25.0 and history of myocardial infarction and ischemic dilated cardiomyopathy indicate that the underlying cardiac damage is significant, and the patient may experience significant symptoms and complications, including pump failure."
792,792,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death 
2. Sudden cardiac death 
3. Survivor 

REASONING: 

Based on the patient's data, the most likely outcome is pump failure death due to the following reasons:

- Low LVEF (37.0%): The patient's left ventricular ejection fraction (LVEF) is significantly reduced, indicating severe left ventricular dysfunction. This is a strong predictor of heart failure and increased risk of pump failure.

- Elevated Creatinine (159.0 mmol/L): The elevated serum creatinine level suggests impaired renal function, which is often associated with heart failure.

- Elevated Pro-BNP (950.0 ng/L): The elevated brain natriuretic peptide (BNP) level is a marker of ventricular strain and is commonly elevated in patients with heart failure.

- NYHA Class II: The patient's New York Heart Association (NYHA) class II indicates moderate limitation of physical activity due to heart failure, which further supports the likelihood of pump failure.

- Presence of Hypertensive cardiomyopathy and Hypertension: The patient's past medical history of hypertensive cardiomyopathy and hypertension increases the risk of cardiac complications, including pump failure.

- Medications: The patient is on medications that are typically used to treat heart failure, such as Amiodarone, Loop Diuretics, Hydralazine, and Nitrovasodilator, which further supports the likelihood of pump failure.

The second most likely outcome is Sudden cardiac death, as the patient has a history of hypertension and cardiomyopathy, which increases the risk of arrhythmias. However, the ECG impression does not show any signs of ventricular tachycardia or other arrhythmias.

The least likely outcome is survivor, as the patient's LVEF is severely reduced, and the presence of heart failure and renal impairment increases the risk of cardiac complications."
793,793,P0448,"Age: 71
Gender: Male 
Weight: 60 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 52
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,69
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2285.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,69
Urea (mg/dL): 15,14
LVEF (%): 55.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: The patient's ECG impression shows polymorphic ventricular extrasystoles, which is a marker of increased risk for ventricular arrhythmias. The presence of ventricular extrasystoles can lead to life-threatening arrhythmias, including ventricular tachycardia and fibrillation. Additionally, the patient's elevated Pro-BNP levels (2285.0 ng/L) suggest significant heart failure, which can increase the risk of arrhythmias. The patient's age, NYHA Class II, and history of hypertension, cardiomyopathy, diabetes, and dyslipemia also contribute to an increased risk of sudden cardiac death. The patient's current ECG findings and elevated biomarkers suggest an increased risk for sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: The patient's elevated Pro-BNP levels (2285.0 ng/L) and LVEF (55.0%) suggest significant heart failure. The patient's NYHA Class II indicates moderate symptoms, and the patient's history of hypertension, cardiomyopathy, diabetes, and dyslipemia contribute to an increased risk of heart failure. The patient's elevated creatinine levels (15.14 mg/dL) also indicate impaired renal function, which can exacerbate heart failure. While the patient is on medications for heart failure and hypertension, the presence of ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias, which can further compromise heart function and lead to pump failure.

RANKING: 3. Survivor
REASONING: While the patient's heart failure and arrhythmias increase the risk of adverse outcomes, the patient's age (71) and overall health status (NYHA Class II) suggest that they may be able to survive with proper management. The patient is on medications for heart failure and hypertension, which can help manage symptoms and slow disease progression. Additionally, the patient's elevated LVEF (55.0%) indicates some residual cardiac function, which can help the heart compensate for the effects of heart failure. However, the presence of ventricular extrasystoles and elevated Pro-BNP levels suggest an increased risk of arrhythmias and heart failure exacerbation, which may ultimately lead to pump failure or sudden cardiac death."
794,794,P0460,"Age: 66
Gender: Female 
Weight: 56 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 102.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,5
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 4471.0
Protein (g/L): 82
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,11
Urea (mg/dL): 16,31
LVEF (%): 32.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the patient's clinical presentation and laboratory results, the most likely prognosis is sudden cardiac death. The patient has a history of ischemic dilated cardiomyopathy, which is a condition that significantly increases the risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 32% is also indicative of severe left ventricular dysfunction, which further increases the risk of sudden cardiac death.

Additionally, the patient has a history of myocardial infarction, which can lead to cardiac remodeling and arrhythmias, and the presence of ventricular extrasystole on the ECG suggests an increased risk of arrhythmias.

The patient's medication regimen, including the ACE inhibitor and nitrovasodilator, suggests that the patient is receiving optimal treatment for heart failure and coronary artery disease. However, the presence of ventricular extrasystole on the ECG indicates that the patient is at risk of arrhythmias, which can lead to sudden cardiac death.

While pump failure death is a possible outcome, it is less likely than sudden cardiac death in this patient. The patient's NYHA class III indicates that the patient has severe symptoms of heart failure, but the patient is still ambulatory and not bedridden, which reduces the likelihood of pump failure death.

Sudden cardiac death is the most likely outcome in this patient due to the combination of severe left ventricular dysfunction, history of myocardial infarction, and ventricular extrasystole on the ECG."
795,795,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 
The patient's overall clinical presentation and lab results suggest that the patient has a significant cardiovascular burden, with a history of hypertensive cardiomyopathy, peripheral vascular disease, and hypertension. The patient's elevated troponin levels (0.01 ng/mL) and LVEF of 60% indicate some degree of cardiac dysfunction. However, the patient is also taking medications that are commonly used to manage heart failure, such as ACE inhibitors and amiodarone, which suggests that the patient is receiving adequate treatment for their cardiac condition.

The patient's Pro-BNP level is elevated at 339 ng/L, which is a marker of cardiac stress and strain. However, the patient's hemoglobin level is high at 168 g/L, which could be a sign of anemia, but it is not directly related to cardiac function. The patient's creatinine level is elevated at 3.83 mg/dL, which may indicate some degree of renal impairment, but it is not directly related to cardiac function.

The patient's ECG findings of ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia are concerning for cardiac arrhythmias, but the patient is already taking medications to manage these conditions. The patient's sodium level is slightly elevated at 139 mEq/L, which may be related to cardiac dysfunction, but it is not a clear indication of pump failure.

Considering these factors, the patient's overall prognosis is likely to be a survivor, as the patient is receiving adequate treatment for their cardiac condition and has not shown any clear signs of pump failure.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's ECG findings of ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia are concerning for cardiac arrhythmias, which can increase the risk of sudden cardiac death. The patient's Pro-BNP level is elevated, which may indicate cardiac stress and strain. However, the patient's medications are not specifically aimed at reducing the risk of sudden cardiac death.

The patient's age and weight also increase the risk of sudden cardiac death. The patient is 65 years old and weighs 113 kg, which is considered obese, and obesity is a risk factor for sudden cardiac death.

While the patient's LVEF is 60%, which is below the normal range, it is not a clear indication of pump failure. The patient's creatinine level is elevated, which may indicate some degree of renal impairment, but it is not directly related to cardiac function.

Considering these factors, the patient's overall prognosis is likely to be at risk for sudden cardiac death, but it is not the most likely outcome.

RANKING: 3. Pump failure death
REASONING: 
The patient's elevated creatinine level of 3.83 mg/dL indicates some degree of renal impairment, which can increase the risk of pump failure. The patient's Pro-BNP level is elevated, which may indicate cardiac stress and strain. The patient's LVEF is 60%, which is below the normal range, indicating some degree of cardiac dysfunction.

However, the patient's medications are not specifically aimed at reducing the risk of pump failure. The patient is taking ACE inhibitors, which can help reduce the risk of pump failure, but the patient's creatinine level is elevated, which may indicate that the patient is not receiving adequate treatment for their renal impairment.

The patient's ECG findings of ventricular extrasystole, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia are concerning for cardiac arrhythmias, which can increase the risk of pump failure. However, the patient's overall clinical presentation and lab results do not suggest that the patient is at high risk for pump failure.

Considering these factors, the patient's overall prognosis is likely to be pump failure death, but it is not the most likely outcome."
796,796,P0480,"Age: 78
Gender: Female 
Weight: 46 kg
Height: 143 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia
Albumin (g/L): 42,5
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,81
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1816.0
Protein (g/L): 71,6
T4 (ng/L): 16
TSH (mIU/L): 1,88
Urea (mg/dL): 6,82
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING:

Based on the provided patient data, I would rank pump failure death as the most likely outcome over the next few years. The patient has a history of hypertensive cardiomyopathy, which is a significant risk factor for heart failure. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 27%, indicating that the heart is not pumping efficiently. Additionally, the patient has a history of ventricular extrasystoles and non-sustained ventricular tachycardia, which can further compromise cardiac function.

The patient's elevated creatinine level (84.0 mmol/L) and urea level (6.82 mg/dL) also suggest impaired renal function, which is often associated with heart failure. The patient's elevated B-type natriuretic peptide (Pro-BNP) level (1816.0 ng/L) is also indicative of heart failure.

While the patient is on medications such as beta blockers, digoxin, loop diuretics, spironolactone, and statins, which are commonly used to manage heart failure and other cardiovascular conditions, the patient's underlying cardiomyopathy and impaired LVEF suggest that the patient is at high risk for pump failure death.

The other two options, sudden cardiac death and survivor, are less likely. While the patient has a history of ventricular arrhythmias, the patient's ECG impression does not indicate a high risk for sudden cardiac death, and the patient is already on medications to manage arrhythmias. The patient's age and overall health status also make sudden cardiac death less likely.

Overall, based on the patient's clinical presentation and laboratory results, pump failure death is the most likely outcome over the next few years."
797,797,P0481,"Age: 66
Gender: Male 
Weight: 73 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,9
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 122.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 5
LDL (mmol/L): 3,57
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2035.0
Protein (g/L): 73,6
T4 (ng/L): 15
TSH (mIU/L): 2,12
Urea (mg/dL): 13,64
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

Based on the patient's data, the patient has a significant cardiac history, including ischemic dilated cardiomyopathy, myocardial infarction, and a left ventricular ejection fraction (LVEF) of 20.0%, which indicates severe left ventricular dysfunction. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and first-degree atrioventricular block (AVB) on the ECG suggests an increased risk of arrhythmias, which can contribute to cardiac complications. However, the patient is currently receiving beta blockers, which are known to improve survival in patients with heart failure. Additionally, the patient is on spironolactone, an aldosterone antagonist, which can also help reduce mortality in heart failure patients.

The patient's laboratory results show elevated creatinine levels (122.0 mmol/L) and low albumin levels (47.9 g/L), which may indicate renal impairment. However, the patient's hemoglobin level (131.0 g/L) is within a normal range, and the patient is not on dialysis. The patient's lipid profile is also concerning, with high total cholesterol (6.23 mmol/L) and LDL cholesterol (3.57 mmol/L), which increases the risk of cardiovascular events.

Considering these factors, the patient's overall prognosis is guarded, but not extremely poor. The patient's current treatment regimen and the presence of severe left ventricular dysfunction suggest that the patient is at risk of cardiac complications, but it is still possible for the patient to survive for several years with proper management and treatment.

RANKING: 2. Sudden Cardiac Death
REASONING:

Given the patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and severe left ventricular dysfunction, the patient is at high risk of sudden cardiac death. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and first-degree AVB on the ECG further increases this risk. Additionally, the patient's high levels of pro-BNP (2035 ng/L) indicate a high risk of heart failure exacerbation.

While the patient is receiving beta blockers and ACE inhibitors, which can help reduce mortality, the patient's lipid profile and renal impairment may limit the effectiveness of these medications. The patient's elevated creatinine levels (122.0 mmol/L) may also indicate kidney dysfunction, which can increase the risk of cardiovascular events.

Considering the patient's high risk of cardiac complications, sudden cardiac death is a possible outcome, especially if the patient experiences a cardiac event such as a myocardial infarction or arrhythmia.

RANKING: 3. Pump Failure Death
REASONING:

The patient's severe left ventricular dysfunction (LVEF 20.0%) and elevated pro-BNP levels (2035 ng/L) indicate a high risk of heart failure exacerbation. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction further increases this risk. The patient's elevated creatinine levels (122.0 mmol/L) and low albumin levels (47.9 g/L) may indicate renal impairment, which can contribute to heart failure.

The patient's current treatment regimen, including beta blockers, loop diuretics, and spironolactone, may help manage symptoms of heart failure, but may not completely prevent pump failure. The patient's lipid profile and renal impairment may limit the effectiveness of these medications.

Considering the patient's high risk of cardiac complications and heart failure exacerbation, pump failure death is a possible outcome, especially if the patient experiences a severe exacerbation of heart failure or a cardiac event."
798,798,P0487,"Age: 79
Gender: Male 
Weight: 83 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45,8
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,36
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,84
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 3407.0
Protein (g/L): 76,8
T4 (ng/L): 16
TSH (mIU/L): 1,24
Urea (mg/dL): 4,82
LVEF (%): 15.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 
The patient's age (79) is a significant risk factor for cardiovascular mortality. However, the patient's NYHA Class III indicates severe heart failure, which is a strong predictor of mortality. Despite this, the patient's LVEF of 15.0 is relatively low, indicating poor left ventricular function. However, the patient's hemoglobin level (137.0 g/L) is within the normal range, which suggests that the patient does not have significant anemia, a common complication in heart failure patients. The patient's creatinine level (4.82 mg/dL) is also elevated, indicating impaired renal function, but this is not uncommon in patients with heart failure. 

The patient's medications include spironolactone, an ACE inhibitor, and statins, which are commonly used to treat heart failure and hypertension. The patient's blood pressure is 110/60 mmHg, which is within the normal range for an elderly patient.

The patient's ECG findings indicate ventricular extrasystole and non-sustained ventricular tachycardia, which are both concerning signs of cardiac instability. However, the patient's Pro-BNP level (3407.0 ng/L) is elevated, indicating significant cardiac stress. Despite this, the patient's protein level (76.8 g/L) is within the normal range, which suggests that the patient does not have significant malnutrition.

Considering these factors, I believe that the patient is likely to survive for at least the next few years, given the patient's age and the presence of severe heart failure. However, the patient's cardiac instability and elevated Pro-BNP level make it essential to closely monitor the patient's condition and adjust treatment as needed.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, indicate cardiac instability. The patient's Pro-BNP level (3407.0 ng/L) is also elevated, which suggests significant cardiac stress. These factors increase the risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
The patient's NYHA Class III indicates severe heart failure, which is a strong predictor of pump failure death. The patient's LVEF (15.0) is also relatively low, indicating poor left ventricular function. While the patient's medications include spironolactone, an ACE inhibitor, and statins, which are commonly used to treat heart failure, the patient's elevated creatinine level (4.82 mg/dL) and low LVEF make it more likely that the patient will experience pump failure death rather than sudden cardiac death."
799,799,P0489,"Age: 52
Gender: Male 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,28
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1198.0
Protein (g/L): 74,2
T4 (ng/L): 17
TSH (mIU/L): 1,79
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING: 

Based on the provided patient data, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to reduced ejection fraction (LVEF) of 15%. This is significantly below the normal range, indicating severe left ventricular dysfunction. The patient's elevated creatinine level (95.0 mmol/L) and elevated BNP levels (1198.0 ng/L) also suggest significant cardiac dysfunction and possible heart failure.

The patient's NYHA Class II classification indicates moderate symptoms of heart failure, which further supports the likelihood of pump failure. Additionally, the presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggest an increased risk of arrhythmias, which can contribute to cardiac instability and pump failure.

Given the patient's severe left ventricular dysfunction, significant cardiac symptoms, and increased risk of arrhythmias, the most likely prognosis is pump failure death within the next few years."
800,800,P0501,"Age: 71
Gender: Male 
Weight: 69 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42,8
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 140.0
Gamma-glutamil transpeptidase (IU/L): 166
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,74
Potassium (mEq/L): 4,26
LDL (mmol/L): 2,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 2309.0
Protein (g/L): 82,3
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,8
Urea (mg/dL): 24,5
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the patient data, I have made the following assessment:

1. Pump failure death: The patient has a history of valvular cardiomyopathy, which is a significant risk factor for heart failure. The patient's LVEF is 40%, indicating left ventricular dysfunction, and the patient is taking medications such as Loop Diuretics and Spironolactone, which are commonly used to manage heart failure. The patient's elevated creatinine level (140.0 mmol/L) and elevated Pro-BNP level (2309.0 ng/L) also suggest fluid overload and increased cardiac stress, further supporting the risk of heart failure. Additionally, the patient's NYHA Class III classification indicates severe symptoms of heart failure. Therefore, pump failure death is the most likely outcome.

2. Sudden cardiac death: The patient has a history of ventricular extrasystole (polymorphic) and non-sustained ventricular tachycardia (CH>10), which are both indicators of arrhythmia risk. The patient's elevated Troponin level (0.02 ng/mL) may also suggest some myocardial damage, which can increase the risk of sudden cardiac death. However, the patient's ECG impressions do not indicate any sustained ventricular tachycardia, which is a more concerning sign for sudden cardiac death.

3. Survivor: While the patient has a significant medical history, including valvular cardiomyopathy and arrhythmias, the patient's overall condition does not appear to be in a critical state. The patient's blood pressure is well-controlled (100/70 mmHg), and the patient's laboratory values are relatively stable. Additionally, the patient's medications are standard for managing heart failure and arrhythmias. Therefore, while the patient may require close monitoring, the likelihood of sudden cardiac death or pump failure death is lower compared to the other two options.

Please note that this prognosis is based on the provided data and should be interpreted with caution. A comprehensive evaluation and further testing may be necessary to confirm the patient's condition and adjust the prognosis accordingly."
801,801,P0509,"Age: 76
Gender: Female 
Weight: 60 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 36,7
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 67
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,28
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2094.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 13,14
LVEF (%): 24.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Based on the patient's data, the most likely prognosis is sudden cardiac death. The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that can lead to heart failure and arrhythmias. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias. Additionally, the patient's LVEF (Left Ventricular Ejection Fraction) is severely impaired at 24%, indicating significant left ventricular dysfunction. The patient is also on medications for heart failure and has elevated troponin levels, which can indicate myocardial injury. These factors combined suggest a high risk of cardiac events, including sudden cardiac death.

The patient's age, NYHA Class II, and the presence of certain medications (e.g., digoxin, spironolactone) also contribute to the risk of sudden cardiac death. However, the presence of a significant amount of BNP (Brain Natriuretic Peptide) at 2094.0 ng/L, which is elevated, indicates heart failure and further supports the risk of cardiac events.

While pump failure death is a possible outcome, the presence of severe left ventricular dysfunction, arrhythmias, and elevated BNP levels make sudden cardiac death the more likely prognosis.

RANKING: 2. Pump failure death
REASONING: 

Pump failure death is a possible outcome for this patient, given the patient's history of idiopathic dilated cardiomyopathy, severe left ventricular dysfunction, and elevated BNP levels. The patient's current medications, including digoxin and spironolactone, are also used to manage heart failure. However, the patient's NYHA Class II indicates that the heart is not functioning optimally, and the patient is still experiencing symptoms of heart failure.

The patient's elevated creatinine levels (108.0 mmol/L) may also indicate kidney impairment, which can be a complication of heart failure. The presence of elevated troponin levels and the patient's age also contribute to the risk of pump failure.

However, the patient's LVEF is severely impaired, and the presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG suggest a higher risk of cardiac events, making pump failure death a less likely outcome compared to sudden cardiac death.

RANKING: 3. Survivor
REASONING: 

The patient's age and NYHA Class II indicate that the patient is not in the best cardiovascular health. However, the patient is on medications for heart failure and has a relatively normal blood pressure. The patient's LVEF is severely impaired, but the patient is not in acute heart failure.

The patient's elevated BNP levels and the presence of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG do suggest a higher risk of cardiac events. However, the patient's overall clinical picture is not as concerning as it would be if the patient was in acute heart failure or had a higher LVEF.

Additionally, the patient's kidney function is impaired, and the patient is on medications for heart failure, which may contribute to the risk of complications. However, the patient's overall clinical picture is not as severe as it would be for a patient with more pronounced symptoms of heart failure or a higher risk of cardiac events.

Overall, while pump failure death is a possible outcome, the patient's overall clinical picture suggests that the patient is more likely to survive with proper management and monitoring."
802,802,P0513,"Age: 76
Gender: Male 
Weight: 83 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 46,7
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 8
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,13
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,46
Urea (mg/dL): 7,8
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Survivor
REASONING: 
The patient's current medical history and laboratory results indicate a moderate to advanced stage of heart disease. However, the patient is currently on multiple medications that are standard for managing heart failure and coronary artery disease, such as beta blockers, ACE inhibitors, and statins. The presence of a reduced ejection fraction (LVEF 38%) suggests significant left ventricular dysfunction, which is a risk factor for heart failure. Despite this, the patient's NYHA class II indicates that they are still able to perform moderate physical activities without symptoms of heart failure. The patient's renal function is also relatively preserved, with a creatinine level of 7.8 mg/dL, which suggests that the kidneys are not severely impaired.

While the patient's eGFR was not provided, the creatinine level is within a relatively normal range for a 76-year-old male. The patient's elevated troponin level (0.01 ng/mL) is also a risk factor for cardiac events, but it is not excessively high, which may indicate a recent minor cardiac event rather than a significant myocardial infarction.

Given the patient's age, comorbidities, and current treatment regimen, the likelihood of pump failure death in the next few years is lower compared to the other two prognoses.

2. Sudden cardiac death
REASONING: 
The patient's eGFR is elevated, which may indicate some degree of renal impairment, but it is not severe. The patient's troponin level is relatively low, which suggests that there is no significant myocardial damage. The patient's ECG results show no ventricular tachycardia, and the patient's NYHA class II suggests that they are not severely limited by heart failure. 

However, the patient's reduced LVEF (38%) indicates significant left ventricular dysfunction, which is a risk factor for sudden cardiac death. The patient's age and comorbidities also increase the risk of cardiac events. 

Given these factors, the likelihood of sudden cardiac death in the next few years is moderate.

3. Pump failure death
REASONING: 
The patient's reduced LVEF (38%) and elevated creatinine level (7.8 mg/dL) suggest significant left ventricular dysfunction and renal impairment, which are both risk factors for heart failure. The patient's NYHA class II indicates that they are experiencing some limitations in physical activity due to heart failure, but it is not severe.

The patient's eGFR is elevated, which may indicate some degree of renal impairment, but it is not severe. The patient's troponin level is relatively low, which suggests that there is no significant myocardial damage. The patient's ECG results show no ventricular tachycardia, and the patient's current treatment regimen includes medications that are standard for managing heart failure.

Given these factors, the likelihood of pump failure death in the next few years is the highest."
803,803,P0529,"Age: 65
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43,4
ALT or GPT (IU/L): 95.0
AST or GOT (IU/L): 105.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 150
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,74
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 221.0
Protein (g/L): 85
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,35
Urea (mg/dL): 8,69
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's prognosis is primarily influenced by the combination of his pre-existing conditions, laboratory results, and ECG findings. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The low left ventricular ejection fraction (LVEF) of 27% further supports this, indicating that the heart is not pumping efficiently. The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole (polymorphic) on the ECG also increase the risk of sudden cardiac death.

Secondly, the patient's elevated creatinine level (103.0 mmol/L) and urea level (8.69 mg/dL) suggest impaired renal function, which is often associated with heart failure and increased mortality risk.

Thirdly, the patient's elevated liver enzymes (ALT and AST) and gamma-glutamil transpeptidase (150 IU/L) may indicate liver damage, which can be a complication of chronic heart failure.

While pump failure death is a possible outcome, the presence of NSVT and ventricular extrasystole on the ECG makes sudden cardiac death a more likely outcome in the short term. However, pump failure death is still a concern due to the patient's underlying heart condition and impaired renal function.

In conclusion, while all three outcomes are possible, the combination of the patient's pre-existing conditions, laboratory results, and ECG findings make sudden cardiac death the most likely outcome, followed by pump failure death, and then survivor."
804,804,P0540,"Age: 37
Gender: Male 
Weight: 70 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 48,2
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 2,79
Creatinine (mmol/L): 92.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5
Hemoglobin (g/L): 163.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 3,9
LDL (mmol/L): 1,42
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1481.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,08
Urea (mg/dL): 7,12
LVEF (%): 35.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: The patient's age (37) and NYHA Class II status indicate that they are still relatively young and have a moderate level of heart function. Although they have a history of ischemic dilated cardiomyopathy, dyslipidemia, and myocardial infarction, their current ejection fraction (LVEF) is 35%, which is significantly lower than the normal range (50-70%). However, this value is not extremely low, suggesting that the patient's heart function is still somewhat preserved.

The patient's creatinine level (92.0) is elevated, but this is likely a result of the underlying heart failure rather than a kidney problem. The patient is also taking medications for heart failure (ACE Inhibitor and Beta Blockers), which suggests that the clinician is actively managing their heart condition.

The ECG findings, while concerning, are not indicative of a sudden cardiac death. The presence of ventricular extrasystole, non-sustained VT, and non-sustained ventricular tachycardia (CH>10) suggests an increased risk of arrhythmias, but these are not necessarily indicative of a high risk of sudden cardiac death.

Given these factors, I believe that the patient is most likely to survive for the next few years with proper management and monitoring.

RANKING: 2. Sudden cardiac death
REASONING: While the patient's ECG findings are concerning, the patient's overall clinical presentation and medical history do not suggest an extremely high risk of sudden cardiac death. The patient's age and NYHA Class II status suggest that they are still relatively young, and the presence of ventricular extrasystole and non-sustained VT on the ECG is not necessarily indicative of a high risk of sudden cardiac death.

The patient's elevated creatinine level and elevated troponin level (0.01 ng/mL) may suggest some degree of cardiac damage, but these values are not extremely high. The patient is also taking medications for heart failure, which suggests that the clinician is actively managing their heart condition.

However, the patient's LVEF of 35% is significantly lower than the normal range, which may increase their risk of arrhythmias and sudden cardiac death. Therefore, while the patient is not at extremely high risk, there is still a possibility of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: The patient's LVEF of 35% is significantly lower than the normal range, which suggests that their heart function is severely impaired. The patient's NYHA Class II status indicates that they have moderate symptoms of heart failure, and their elevated creatinine level (92.0) suggests that their kidneys may be affected by the underlying heart failure.

The patient's elevated troponin level (0.01 ng/mL) may suggest some degree of cardiac damage, and their elevated BNP level (1481.0) suggests that their heart is under significant stress. The patient's medications for heart failure (ACE Inhibitor and Beta Blockers) are not sufficient to fully manage their condition, and the patient's elevated potassium level (3.9 mEq/L) may indicate that their heart is not responding to these medications.

Given these factors, I believe that the patient is at high risk of developing heart failure, which could lead to pump failure death. However, I do not believe that sudden cardiac death is the most likely outcome, as the patient's ECG findings are not indicative of an extremely high risk of arrhythmias."
805,805,P0545,"Age: 71
Gender: Male 
Weight: 71 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,75
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,86
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 353.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,818
Urea (mg/dL): 7,12
LVEF (%): 27.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING:

Based on the provided patient data, I would rank pump failure death as the most likely outcome over the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and cannot pump blood effectively. This condition is a significant risk factor for heart failure.

The patient's left ventricular ejection fraction (LVEF) is 27.0%, which is below the normal range of 55-70%. This indicates that the patient's heart is not pumping efficiently, and the risk of heart failure is high.

Additionally, the patient has a history of myocardial infarction, which can further damage the heart muscle and increase the risk of heart failure.

The patient's current medications, including beta blockers and ACE inhibitors (not explicitly mentioned but implied by the presence of an Angiotensin II Receptor Blocker), are standard treatments for heart failure. However, the patient's LVEF is still significantly impaired, suggesting that these medications may not be sufficient to prevent pump failure.

The patient's laboratory results, including elevated creatinine levels and elevated troponin, also suggest that the patient's heart muscle is under stress and at risk of further damage.

While the patient's ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, may indicate an increased risk of arrhythmias, they do not necessarily impact the overall risk of pump failure.

Overall, based on the patient's medical history, laboratory results, and current medications, pump failure death is the most likely outcome over the next few years."
806,806,P0555,"Age: 80
Gender: Male 
Weight: 76 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,66
Sodium (mEq/L): 141.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,08
TSH (mIU/L): 1,72
Urea (mg/dL): 13,31
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Survivor
REASONING: 
This patient has a complex medical history with ischemic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, the patient is currently on multiple medications that are commonly used to manage heart failure, including ACE inhibitors, beta blockers, and diuretics, which are known to improve outcomes in heart failure patients. The patient's NYHA class is II, indicating mild symptoms, which suggests that the heart is still functioning to some extent. Additionally, the patient's LVEF is 25%, which is relatively preserved, indicating that the heart is still pumping effectively. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, but it is not a guarantee of pump failure death. The patient's laboratory values, such as albumin, ALT, AST, and creatinine, are not significantly abnormal, suggesting that the patient does not have acute kidney injury or liver dysfunction. Overall, while the patient has a high-risk medical history, the combination of optimal medication therapy and relatively preserved LVEF suggest that the patient may survive for several years.

2. Sudden cardiac death
REASONING: 
While the patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, the presence of multiple medications that can help manage arrhythmias, such as beta blockers and anti-arrhythmics, reduces this risk. However, the patient's history of ischemic dilated cardiomyopathy and previous myocardial infarction increase the risk of sudden cardiac death. The patient's LVEF is relatively preserved, which suggests that the heart is still functioning to some extent, but the patient's NYHA class is II, indicating mild symptoms, which may not be sufficient to prevent sudden cardiac death. The patient's laboratory values are not significantly abnormal, but the patient's potassium level is slightly elevated, which may be a risk factor for arrhythmias.

3. Pump failure death
REASONING: 
The patient's LVEF is only 25%, which is a significant indicator of pump failure. The patient's NYHA class is II, but the patient's NYHA class is not sufficient to compensate for the patient's severely reduced LVEF. The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for pump failure death. The patient's laboratory values, such as albumin and creatinine, are not significantly abnormal, but the patient's T3 and T4 levels are low, which may indicate hypothyroidism, a condition that can contribute to heart failure. The patient's medication list includes a nitrovasodilator, which can worsen heart failure in some patients. Overall, the combination of severely reduced LVEF, NYHA class II, and the presence of non-sustained ventricular tachycardia make pump failure death the most likely outcome."
807,807,P0567,"Age: 60
Gender: Female 
Weight: 70 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 97/58 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 10365.0
Protein (g/L): 70
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 12,33
Urea (mg/dL): 9,48
LVEF (%): 20.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's data suggests a high risk of adverse outcomes. Here's a breakdown of the key factors contributing to this prognosis:

1. Low LVEF (20.0%): This is a significant indicator of poor cardiac function, which increases the risk of heart failure and arrhythmias. The patient's LVEF is severely impaired, which is a common cause of morbidity and mortality in patients with idiopathic dilated cardiomyopathy.

2. ECG Impression: The presence of ventricular extrasystole and non-sustained ventricular tachycardia (NSVT) indicates an increased risk of arrhythmias. The patient's ECG also shows signs of ventricular hypertrophy, which can contribute to arrhythmias and worsen cardiac function.

3. Elevated Pro-BNP (10365.0 ng/L): Elevated BNP levels are a strong indicator of heart failure. This suggests that the patient's heart is under significant stress, which can lead to further cardiac complications.

4. Past Medical History: Idiopathic dilated cardiomyopathy is a significant risk factor for arrhythmias, heart failure, and sudden cardiac death.

5. Medications: The patient is already on several medications, including Amiodarone, Digoxin, and ACE inhibitors, which are commonly used to manage arrhythmias and heart failure. However, the presence of these medications does not necessarily improve the patient's prognosis.

6. Other lab values: The patient's elevated creatinine level (106.0 mmol/L) suggests impaired renal function, which can contribute to electrolyte imbalances and worsen cardiac function.

Given these factors, the patient is at high risk for adverse outcomes. However, the patient's survival is still possible if the underlying conditions are managed effectively. The most likely outcome is pump failure death, followed by sudden cardiac death, and then survivor."
808,808,P0583,"Age: 61
Gender: Male 
Weight: 81 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 150/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,59
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3292.0
Protein (g/L): 73
T4 (ng/L): 17
Troponin (ng/mL): 0,06
TSH (mIU/L): 1,63
Urea (mg/dL): 19,47
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING: 
The patient's clinical presentation and laboratory results suggest a high risk of pump failure death. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure. The patient's ejection fraction (LVEF) is severely impaired at 30%, indicating poor cardiac function. Additionally, the patient has a history of hypertension, diabetes, and dyslipidemia, which are all risk factors for cardiovascular disease. The patient's elevated creatinine level (186.0 mmol/L) and BNP level (3292.0 ng/L) also suggest significant cardiac stress and potential heart failure. The patient's medications, including beta blockers, loop diuretics, and statins, suggest that the patient is already receiving treatment for heart failure and other cardiovascular risk factors. The patient's ECG results show ventricular extrasystole, which is a sign of cardiac arrhythmia, further increasing the risk of pump failure. Overall, the combination of the patient's medical history, laboratory results, and ECG findings make pump failure death the most likely outcome.

While the patient's troponin level is within normal limits, the patient's clinical presentation and laboratory results suggest that the patient's cardiac function is severely impaired, making pump failure death the most likely outcome. Sudden cardiac death is less likely due to the patient's LVEF and the absence of other high-risk ECG findings. Survivor is the least likely outcome due to the patient's significant cardiac impairment and the presence of multiple risk factors."
809,809,P0589,"Age: 71
Gender: Male 
Weight: 75 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Peripheral vascular disease
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 7.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,15
Sodium (mEq/L): 137.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 0,93
Urea (mg/dL): 9,98
LVEF (%): 12.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Pump failure death is the most likely outcome in this patient due to the following reasons:

1. Severe left ventricular dysfunction: The patient has a low LVEF of 12.0, indicating significant left ventricular dysfunction, which is a major contributor to heart failure.
2. History of dilated cardiomyopathy: The patient has a history of enolic dilated cardiomyopathy, which is a condition characterized by a weakened heart muscle, leading to poor cardiac function and increased risk of heart failure.
3. NYHA Class II: The patient's NYHA class indicates moderate symptoms of heart failure, suggesting that the patient is experiencing some limitations in physical activity due to their heart condition.

While sudden cardiac death is a possible outcome in patients with severe heart failure, it is less likely in this patient due to the following reasons:

1. No evidence of ventricular tachycardia or ventricular extrasystoles on ECG: The patient's ECG does not show any arrhythmias that could increase the risk of sudden cardiac death.
2. No evidence of significant ischemia: The patient's troponin levels are normal, indicating no significant myocardial injury.

Survival is the least likely outcome in this patient due to the following reasons:

1. Severe left ventricular dysfunction: The patient's low LVEF and NYHA class indicate a high risk of heart failure and decreased survival.
2. Presence of comorbidities: The patient has diabetes, peripheral vascular disease, and other comorbidities that can further increase the risk of mortality.
3. Medications: While the patient is on medications for heart failure, diabetes, and hypertension, the patient's medications may not be sufficient to manage the patient's severe heart failure and comorbidities."
810,810,P0594,"Age: 78
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 128/83 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,28
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,47
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1627.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 19
TSH (mIU/L): 2,39
Urea (mg/dL): 11,82
LVEF (%): 40.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

Based on the patient data, the patient's age (78) is a significant risk factor for cardiac events. However, the patient's NYHA Class II indicates that the patient has some symptoms of heart failure, but they are still able to perform moderate physical activities. The patient's LVEF (40.0) is significantly reduced, indicating left ventricular dysfunction, but it is not severely impaired. The patient's ejection fraction is not zero, and they are not in heart failure class III or IV.

The patient's medication regimen includes ACE inhibitors, which are generally recommended for patients with heart failure and hypertension. The presence of amiodarone, a class III antiarrhythmic, suggests that the patient has a history of arrhythmias, but it is not clear if it is related to heart failure or other conditions.

The patient's laboratory results show elevated creatinine levels (115.0), which indicate impaired kidney function, but this is not directly related to cardiac function. The patient's electrolyte levels are within normal limits, and there is no evidence of severe anemia or electrolyte imbalances.

The patient's ECG impression shows ventricular extrasystoles, which can be a sign of cardiac stress, but it is not a clear indication of cardiac failure. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

Given these factors, the patient's prognosis is likely to be a survivor. The patient's heart failure symptoms are mild, and the patient is on medications that are generally recommended for heart failure management. The patient's reduced LVEF and elevated creatinine levels indicate some cardiac and renal impairment, but they are not severe enough to predict a poor outcome.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG shows ventricular extrasystoles, which can be a sign of cardiac stress, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. However, the patient's NYHA Class II indicates that the patient has some symptoms of heart failure, which can increase the risk of sudden cardiac death.

The patient's elevated creatinine levels (115.0) indicate impaired kidney function, which can increase the risk of cardiac events. However, this is not directly related to cardiac function.

The patient's reduced LVEF (40.0) indicates left ventricular dysfunction, which can increase the risk of cardiac events. However, the patient is not in heart failure class III or IV, which would indicate a more severe impairment.

Given these factors, the patient's prognosis is not as poor as pump failure death, but it is still a concern. The patient's reduced LVEF and elevated creatinine levels increase the risk of cardiac events, but the absence of other severe cardiac symptoms and the patient's current medication regimen reduce the risk.

RANKING: 3. Pump failure death
REASONING: 

The patient's NYHA Class II indicates that the patient has some symptoms of heart failure, and their reduced LVEF (40.0) indicates left ventricular dysfunction. The patient's elevated creatinine levels (115.0) indicate impaired kidney function, which can increase the risk of cardiac events.

The patient's medication regimen includes loop diuretics, which are generally used to treat heart failure. However, the patient's reduced LVEF and elevated creatinine levels suggest that the patient's heart failure is not well-managed, and the patient may be at risk of pump failure.

The patient's ECG shows ventricular extrasystoles, which can be a sign of cardiac stress, and the patient's reduced LVEF indicates left ventricular dysfunction. Given these factors, the patient's prognosis is poor, and pump failure death is a possible outcome.

However, the patient's age (78) is a significant risk factor for cardiac events, and the patient's reduced LVEF and elevated creatinine levels do not indicate a severe impairment. Additionally, the patient's medication regimen includes ACE inhibitors, which are generally recommended for patients with heart failure.

Given these factors, pump failure death is a possible outcome, but it is not the most likely prognosis. The patient's reduced LVEF and elevated creatinine levels increase the risk of cardiac events, but the patient's current medication regimen and age reduce the risk."
811,811,P0619,"Age: 62
Gender: Female 
Weight: 50 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 45,9
ALT or GPT (IU/L): 47.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 7,15
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 146.0
HDL (mmol/L): 2,05
Potassium (mEq/L): 4,51
LDL (mmol/L): 4,65
Sodium (mEq/L): 135.0
Protein (g/L): 72,9
Troponin (ng/mL): 0,15
TSH (mIU/L): 3,77
Urea (mg/dL): 9,5
LVEF (%): 62.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: The patient's current LVEF (Left Ventricular Ejection Fraction) is 62.0%, which is within the normal range (50-70%). Although the patient has a history of Hypertrophic Cardiomyopathy, which can lead to a higher risk of cardiac complications, the current LVEF does not indicate significant left ventricular dysfunction. Additionally, the patient's ejection fraction is not severely reduced, which suggests that the left ventricle is still functioning relatively well. The patient is also on medications such as Beta Blockers, Loop Diuretics, Spironolactone, and ACE Inhibitor, which are commonly used to manage heart failure and hypertension. The patient's troponin level is also within normal limits, which suggests that there is no significant myocardial damage. Given these factors, the patient's prognosis is more likely to be a survivor.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's ECG impression shows non-sustained ventricular tachycardia (NSVT), which is a marker of an increased risk of ventricular arrhythmias. Although the NSVT is non-sustained, the patient's history of Hypertrophic Cardiomyopathy increases the risk of ventricular arrhythmias. The patient's low blood pressure (90/60 mmHg) may also indicate a higher risk of arrhythmias. However, the patient's current LVEF is within the normal range, and the patient is on medications to manage hypertension and heart failure, which reduces the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's current LVEF is 62.0%, which is at the lower end of the normal range. While the patient is on medications to manage heart failure, the patient's ejection fraction is not severely reduced, which suggests that the left ventricle is not failing significantly. Additionally, the patient's troponin level is within normal limits, which suggests that there is no significant myocardial damage. However, the patient's history of Hypertrophic Cardiomyopathy and the presence of NSVT on the ECG increase the risk of cardiac complications. Therefore, while pump failure is not the most likely outcome, it is still a possible prognosis, especially if the patient's condition worsens over time."
812,812,P0624,"Age: 85
Gender: Male 
Weight: 85 kg
Height: 166 cm
NYHA Class: III
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,9
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 39.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 3,92
LDL (mmol/L): 1,82
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 4440.0
Protein (g/L): 68,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,39
Urea (mg/dL): 10,6
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death 
REASONING: 
The patient's age (85 years) and NYHA Class III status (severe heart failure) are significant risk factors for pump failure. The patient's LVEF (20.0%) is severely reduced, indicating poor cardiac function. The presence of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction in the patient's past medical history further exacerbates the risk of pump failure. The elevated creatinine level (156.0 mmol/L) and urea level (10.6 mg/dL) also suggest compromised renal function, which can be a consequence of cardiac failure. Additionally, the patient's elevated troponin level (0.01 ng/mL) indicates some degree of myocardial injury, which can contribute to pump failure.

The patient's ECG findings, including non-sustained ventricular tachycardia (CH>10) and ventricular extrasystole, also suggest an increased risk of arrhythmias, which can contribute to pump failure. The presence of these arrhythmias, combined with the patient's severe cardiac dysfunction, makes pump failure the most likely outcome.

While the patient's blood test results, such as the elevated BNP level (4440.0 ng/L), suggest fluid overload, which is a common complication of heart failure, the patient's overall clinical picture and history make pump failure the most likely outcome. 

The patient's medication regimen, including beta blockers, loop diuretics, statins, hydralazine, and nitrovasodilator, is standard for managing heart failure, but it may not be sufficient to prevent pump failure in this case.

The other two prognoses, sudden cardiac death and survivor, are less likely due to the patient's advanced age, severe cardiac dysfunction, and presence of arrhythmias, which increase the risk of sudden cardiac death."
813,813,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's data indicates a high risk of cardiac complications due to their underlying ischemic dilated cardiomyopathy, diabetes, and previous myocardial infarction. The low left ventricular ejection fraction (LVEF) of 25.0% further supports this, as it suggests that the heart is not functioning efficiently.

The elevated BNP levels (3190.0 ng/L) and high troponin levels (0.5 ng/mL) indicate significant cardiac stress and potential myocardial damage. The presence of ventricular extrasystole on the ECG impression suggests that the heart is experiencing abnormal electrical activity, which can lead to arrhythmias and sudden cardiac death.

The patient's age, NYHA class III, and history of myocardial infarction also increase the risk of cardiac complications. The patient's medications, including ACE inhibitors and loop diuretics, are typically used to manage heart failure and hypertension, but in this case, they may not be sufficient to mitigate the patient's high risk.

While pump failure death is a possible outcome, it is less likely than sudden cardiac death in this patient. The patient's elevated BNP levels and troponin levels suggest that the heart is under significant stress, which can lead to sudden cardiac death rather than gradual pump failure.

Therefore, the most likely outcome for this patient is sudden cardiac death, followed by pump failure death, and then survivor."
814,814,P0643,"Age: 70
Gender: Male 
Weight: 85 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 135/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,64
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 10,1
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,74
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 177.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,83
Urea (mg/dL): 14,25
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Survivor
2. Sudden cardiac death
3. Pump failure death

REASONING:

The patient is at high risk for pump failure death due to the presence of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and less able to pump blood effectively. This condition is further exacerbated by the patient's NYHA Class II heart failure, indicating moderate symptoms of heart failure. The patient's low LVEF of 30.0% further supports this prognosis.

The patient's elevated creatinine level (156.0 mmol/L) also suggests renal impairment, which can be a complication of heart failure. Additionally, the presence of peripheral vascular disease and hypertension increases the risk of cardiovascular events.

However, the patient's current ECG impression does not show any signs of ventricular tachycardia or non-sustained ventricular tachycardia, which are common causes of sudden cardiac death. The absence of these findings, along with the patient's relatively stable vital signs and lack of recent hospitalizations or acute symptoms, suggest that the patient is not at high risk for sudden cardiac death.

While the patient is at risk for pump failure death, the patient's current treatment regimen, which includes medications for heart failure, hypertension, and diabetes, suggests that the patient is receiving appropriate management for their condition. The patient's low T3 level (0.05 pg/dL) and normal TSH level (1.83 mIU/L) also suggest that the patient is not experiencing severe metabolic or thyroid disorders that could contribute to a poor prognosis.

Overall, while the patient is at risk for pump failure death, the absence of acute symptoms, stable vital signs, and current treatment regimen suggest that the patient is more likely to survive in the short term. However, the patient's underlying heart condition and risk factors for cardiovascular events make pump failure death a possible outcome in the longer term."
815,815,P0651,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39,5
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 267
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5
LDL (mmol/L): 2,48
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 1627.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,31
Urea (mg/dL): 15,59
LVEF (%): 38.0
Medications: Amiodarone, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the patient's data, I would rank the prognoses as follows:

Pump failure death is the most likely outcome due to the patient's advanced age (76 years), significant left ventricular dysfunction (LVEF 38%), and history of heart failure (NYHA Class II). The patient's elevated creatinine level (120.0 mmol/L) and low ejection fraction (38.0%) indicate compromised cardiac function. Additionally, the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG suggests an increased risk of arrhythmias, which can contribute to pump failure. The patient's medication regimen, including ACE inhibitors and loop diuretics, may not be adequate to manage their heart failure symptoms, further increasing the risk of pump failure.

Sudden cardiac death is the second most likely outcome due to the patient's history of ventricular tachycardia, non-sustained VT, and polymorphic ventricular extrasystole. The patient's elevated troponin level (0.01 ng/mL) may indicate some degree of cardiac injury, which could increase the risk of sudden cardiac death. However, the patient's relatively stable hemoglobin level and normal potassium level reduce the likelihood of sudden cardiac death.

Survivor is the least likely outcome due to the patient's advanced age, significant comorbidities (hypertensive cardiomyopathy, diabetes, and dyslipidemia), and compromised cardiac function (LVEF 38%). While the patient is taking medications to manage their conditions, their overall clinical picture suggests a high risk of adverse cardiac events, making it less likely that they will survive in the long term."
816,816,P0679,"Age: 67
Gender: Male 
Weight: 76 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/55 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 47
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 5,27
Hemoglobin (g/L): 109.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,75
LDL (mmol/L): 1,81
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 62.0
Protein (g/L): 75,3
T3 (pg/dL): 0,0429
T4 (ng/L): 14,14
Troponin (ng/mL): 0,7
TSH (mIU/L): 4,1
Urea (mg/dL): 19,6
LVEF (%): 30.0
Medications: Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

The patient's data suggests a high risk of pump failure death. The primary reasons for this ranking are:

- Severe left ventricular dysfunction: The LVEF is significantly reduced at 30%, indicating poor cardiac function. This can lead to decreased cardiac output, which may result in pump failure.

- Elevated creatinine levels: The creatinine level of 19.6 mg/dL indicates impaired kidney function, which can be a consequence of heart failure. Kidney dysfunction can further exacerbate cardiac failure.

- Presence of ventricular extrasystoles: The ECG impression notes ventricular extrasystoles, which can be a precursor to more severe arrhythmias, including ventricular tachycardia. This could potentially lead to sudden cardiac death.

- Presence of multiple medications: The patient is on several medications, including amiodarone, beta blockers, and ACE inhibitors, which are commonly used to manage heart failure and arrhythmias. However, the presence of multiple medications also increases the risk of side effects and interactions.

While sudden cardiac death is a concern due to the presence of ventricular extrasystoles, the overall clinical picture suggests that pump failure is the most likely outcome. The patient's reduced LVEF, elevated creatinine levels, and multiple medications on therapy all point towards a higher risk of pump failure death."
817,817,P0680,"Age: 73
Gender: Female 
Weight: 71 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1690.0
Protein (g/L): 74
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,69
Urea (mg/dL): 7,49
LVEF (%): 25.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
REASONING: 
This patient's prognosis is primarily driven by their advanced heart failure, as indicated by the New York Heart Association (NYHA) Class III classification and the left ventricular ejection fraction (LVEF) of 25%. Their history of ischemic dilated cardiomyopathy, diabetes, and hypertension further exacerbate the risk of heart failure. The elevated B-type natriuretic peptide (Pro-BNP) level of 1690.0 ng/L is also a strong indicator of heart failure. The patient's medications, including ACE inhibitors and loop diuretics, are standard treatments for heart failure, but the presence of pump failure death as a primary outcome suggests that these treatments may not be sufficient to prevent further deterioration. The patient's other comorbidities, such as peripheral vascular disease and hypertension, may also contribute to their risk of pump failure death.

2. Sudden cardiac death
REASONING: 
While the patient's ECG shows no ventricular tachycardia or non-sustained ventricular tachycardia, the presence of ventricular extrasystoles, particularly monomorphic ventricular extrasystoles, may increase the risk of sudden cardiac death. However, this risk is not as high as pump failure death, given the patient's advanced heart failure status. The patient's medications, including beta blockers, may help reduce this risk, but the presence of other comorbidities and advanced heart failure status may still make sudden cardiac death a possible outcome.

3. Survivor
REASONING: 
The patient's prognosis of survivor is the least likely due to their advanced heart failure status and the presence of several comorbidities. While the patient is receiving standard treatments for heart failure, their LVEF of 25% suggests that their heart function is severely impaired. The presence of diabetes, hypertension, and peripheral vascular disease also increases their risk of mortality. Additionally, the patient's elevated creatinine level of 106.0 mmol/L suggests impaired renal function, which may further complicate their prognosis. Overall, while the patient may survive for some time, their advanced heart failure status and comorbidities make a long-term survival outcome less likely."
818,818,P0688,"Age: 66
Gender: Male 
Weight: 74 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,12
Creatinine (mmol/L): 181.0
Gamma-glutamil transpeptidase (IU/L): 105
Glucose (mmol/L): 6,44
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,67
Potassium (mEq/L): 4,42
LDL (mmol/L): 2,16
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 11467.0
Protein (g/L): 71,8
T3 (pg/dL): 0,0366
T4 (ng/L): 15,51
Troponin (ng/mL): 0,7
TSH (mIU/L): 3,31
Urea (mg/dL): 19,5
LVEF (%): 30.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's prognosis is primarily influenced by their underlying conditions, including valvular cardiomyopathy, hypertension, and myocardial infarction, which have likely led to significant cardiac damage and reduced left ventricular function (LVEF 30.0). The elevated creatinine level (181.0) suggests impaired renal function, which can be a consequence of cardiac dysfunction.

The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10) on the ECG impression indicates a high risk of arrhythmias, which can contribute to sudden cardiac death. The elevated Pro-BNP level (11467.0) also suggests heart failure with reduced ejection fraction (HFrEF), which further supports this risk.

While the patient is on loop diuretics and ACE inhibitors, these medications may not be sufficient to adequately manage their cardiac condition. The patient's elevated troponin level (0.7 ng/mL) and reduced LVEF (30.0) indicate ongoing cardiac damage, which may lead to pump failure.

Considering these factors, the patient's prognosis is most likely to be sudden cardiac death due to the high risk of arrhythmias and cardiac dysfunction. Pump failure death is a close second, as the patient's cardiac condition is already compromised, and their renal function is impaired. Survival is the least likely outcome, given the severity of their cardiac and renal dysfunction."
819,819,P0716,"Age: 80
Gender: Male 
Weight: 66 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 210/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 124
Glucose (mmol/L): 4,9
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,15
Sodium (mEq/L): 141.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 14
TSH (mIU/L): 1,33
Urea (mg/dL): 13,81
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
REASONING: 
The patient's age, NYHA Class III status, and history of ischemic dilated cardiomyopathy make them at high risk for cardiac events. The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole (polymorphic) on the ECG suggests an increased risk of arrhythmias. The patient's elevated blood pressure (210/100 mmHg) and elevated creatinine level (159.0 mmol/L) also indicate poor cardiovascular function. The patient's left ventricular ejection fraction (LVEF) of 35.0% further supports the notion of poor cardiac function. Additionally, the patient's elevated total cholesterol level (3,62 mmol/L) and low HDL level (0,91 mmol/L) contribute to an increased risk of cardiovascular events. The combination of these factors makes sudden cardiac death the most likely outcome.

2. Pump failure death
REASONING: 
The patient's NYHA Class III status, elevated creatinine level (159.0 mmol/L), and low LVEF (35.0%) indicate significant cardiac dysfunction. The presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole (polymorphic) on the ECG further supports the notion of poor cardiac function. The patient's elevated blood pressure (210/100 mmHg) and diabetes history also contribute to an increased risk of cardiac failure. While pump failure is a possible outcome, it is less likely compared to sudden cardiac death due to the patient's high risk of arrhythmias.

3. Survivor
REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy, diabetes, and hypertension, which are risk factors for cardiac events, the presence of non-sustained ventricular tachycardia (NSVT) and ventricular extrasystole (polymorphic) on the ECG, as well as the patient's elevated blood pressure and low LVEF, make sudden cardiac death and pump failure more likely outcomes. Additionally, the patient's elevated creatinine level (159.0 mmol/L) indicates poor renal function, which can contribute to a poorer prognosis. Therefore, while the patient may survive, the likelihood of a poor outcome is higher than a favorable outcome."
820,820,P0725,"Age: 72
Gender: Male 
Weight: 66 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 10,4
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,25
Sodium (mEq/L): 135.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 23
TSH (mIU/L): 1,2
Urea (mg/dL): 6,99
LVEF (%): 55.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

The patient's overall clinical profile and test results suggest that the patient is likely to survive for the next few years. The patient's age is 72, but their NYHA Class III indicates that they have a significant cardiac limitation to physical activity. However, their ejection fraction (LVEF) is 55%, which is not severely impaired. Their ECG findings show non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystole, but these are not indicative of severe cardiac dysfunction. Their medications, including beta blockers, ACE inhibitors, and diuretics, are standard treatments for heart failure and hypertension, which suggests that the patient is receiving appropriate management for their conditions.

In contrast, pump failure death is a more severe outcome that is typically associated with more advanced cardiac dysfunction, such as an LVEF of 30% or lower. The patient's LVEF of 55% is not low enough to suggest pump failure, and their ECG findings do not indicate significant cardiac conduction abnormalities.

Sudden cardiac death is also less likely, as the patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but the patient is on beta blockers, which are effective in reducing this risk.

Therefore, based on the patient's clinical profile and test results, the most likely outcome is that the patient will survive for the next few years."
821,821,P0735,"Age: 59
Gender: Male 
Weight: 91 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 139/76 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 7,34
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 3,4
LDL (mmol/L): 5,66
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 108.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,63
Urea (mg/dL): 8,65
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

The patient's overall health status and laboratory results suggest a moderate level of cardiac dysfunction, as indicated by a left ventricular ejection fraction (LVEF) of 50% and elevated creatinine levels (106.0 mmol/L), which may indicate some degree of renal impairment. However, the patient's age (59) and gender (male) are not particularly high-risk factors for sudden cardiac death or pump failure.

The patient's medical history includes ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and increased mortality. However, the patient's current NYHA class is II, indicating mild symptoms of heart failure, which may suggest that the patient is not yet in a critical stage of heart failure.

The patient's laboratory results show a relatively normal troponin level (0.1 ng/mL), which suggests that there is no significant acute myocardial infarction or myocardial damage. The patient's lipid profile is also relatively normal, with total cholesterol (7.34 mmol/L) and HDL (0.96 mmol/L) levels within the normal range.

The patient's ECG results show ventricular extrasystole, which may indicate some degree of cardiac electrical instability, but it is not a clear predictor of sudden cardiac death or pump failure. The patient is also not taking anti-arrhythmic medications, which may reduce the risk of sudden cardiac death.

Overall, while the patient has a significant medical history and some signs of cardiac dysfunction, the patient's overall health status and laboratory results suggest that they are likely to survive for at least the next few years with proper management and treatment.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's medical history and laboratory results suggest some degree of cardiac dysfunction, the patient's overall health status and risk factors for sudden cardiac death are not extremely high. The patient's ECG results show ventricular extrasystole, which may indicate some degree of cardiac electrical instability, but it is not a clear predictor of sudden cardiac death.

The patient's age (59) and gender (male) are not particularly high-risk factors for sudden cardiac death, and the patient's NYHA class is II, indicating mild symptoms of heart failure. The patient's lipid profile is also relatively normal, which may reduce the risk of sudden cardiac death.

However, the patient's medical history includes ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. Additionally, the patient's LVEF is only 50%, which may indicate some degree of cardiac dysfunction that could increase the risk of sudden cardiac death.

Overall, while the patient's risk of sudden cardiac death is not extremely high, the patient's medical history and laboratory results suggest that they are at some risk of sudden cardiac death, especially if their cardiac function declines further.

RANKING: 3. Pump failure death
REASONING: 

The patient's medical history includes ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and pump failure. The patient's current NYHA class is II, indicating mild symptoms of heart failure, but the patient's LVEF is only 50%, which may indicate some degree of cardiac dysfunction that could increase the risk of pump failure.

The patient's laboratory results show elevated creatinine levels (106.0 mmol/L), which may indicate some degree of renal impairment that could increase the risk of pump failure. The patient's lipid profile is also relatively normal, but the patient's total cholesterol (7.34 mmol/L) is slightly elevated, which may increase the risk of atherosclerotic disease and pump failure.

The patient's ECG results show ventricular extrasystole, which may indicate some degree of cardiac electrical instability, and the patient is taking medications for hypertension and dyslipidemia, which may not be sufficient to control the patient's underlying cardiac dysfunction.

Overall, the patient's medical history and laboratory results suggest that they are at risk of pump failure, especially if their cardiac function declines further or if the patient's underlying cardiac dysfunction worsens."
822,822,P0752,"Age: 55
Gender: Male 
Weight: 77 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 29,6
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,46
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 151
Glucose (mmol/L): 16,6
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,66
Potassium (mEq/L): 3,88
LDL (mmol/L): 2,46
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 5416.0
Protein (g/L): 58,9
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,08
Urea (mg/dL): 14,4
LVEF (%): 21.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the provided patient data, I have assessed the patient's condition and made the following conclusions:

The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for arrhythmias and sudden cardiac death. The patient's NYHA Class III indicates a severe limitation in physical activity, which further increases the risk of cardiac complications. The elevated LVEF of 21.0 suggests that the patient's heart is not functioning optimally, which can lead to further decline in cardiac function.

The patient's elevated BNP levels (5416.0 ng/L) indicate a high level of ventricular stress, which can be associated with heart failure. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a significant finding, as it increases the risk of ventricular arrhythmias, which can lead to sudden cardiac death.

The patient's medication regimen, which includes digoxin, loop diuretics, spironolactone, hydralazine, and a nitrovasodilator, suggests that the patient is being treated for heart failure and hypertension. However, the presence of non-sustained VT on the ECG indicates that the patient's heart is still at risk of arrhythmias, which can be life-threatening.

Given these factors, I believe that the most likely outcome for this patient is sudden cardiac death, as the patient's underlying heart disease and arrhythmias increase the risk of cardiac complications. While pump failure death is also a possible outcome, it is less likely, as the patient is already being treated for heart failure. Survivor is the least likely outcome, as the patient's underlying conditions and arrhythmias increase the risk of cardiac complications.

It is essential to note that this prognosis is based on the provided data and should be used as a starting point for further evaluation and management. A more detailed assessment and additional testing may be necessary to confirm the prognosis and develop a more personalized treatment plan."
823,823,P0754,"Age: 73
Gender: Male 
Weight: 58 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 115/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 5,36
Creatinine (mmol/L): 92.0
Gamma-glutamil transpeptidase (IU/L): 291
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,48
Potassium (mEq/L): 3,42
LDL (mmol/L): 3,05
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 2057.0
Protein (g/L): 70,2
Troponin (ng/mL): 0,13
TSH (mIU/L): 2,47
Urea (mg/dL): 9,5
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 

Given the patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and the presence of non-sustained ventricular tachycardia (NSVT) on ECG, the patient is at high risk for sudden cardiac death. The presence of NSVT is a significant predictor of sudden cardiac death, and the patient's age, NYHA class III, and elevated LVEF of 20% further increase the risk. The patient's ECG also shows ventricular extrasystole, which is a sign of electrical instability.

The patient's medication regimen, which includes beta blockers and digoxin, may not be adequate to manage the patient's heart failure and arrhythmias. The patient's elevated troponin level of 0.13 ng/mL suggests some degree of cardiac damage, which may contribute to the risk of sudden cardiac death.

While pump failure death is a possible outcome, the presence of NSVT and the patient's high risk factors for sudden cardiac death make this the most likely prognosis.

RANKING: 2. Pump failure death
REASONING: 

The patient's LVEF of 20% indicates severe systolic dysfunction, which increases the risk of pump failure. The patient's NYHA class III classification also suggests that the patient is experiencing significant symptoms of heart failure. The patient's elevated creatinine level of 92.0 mmol/L and elevated BNP of 2057.0 ng/L further support the presence of heart failure.

The patient's medication regimen includes loop diuretics, spironolactone, and digoxin, which are commonly used to manage heart failure. However, the presence of NSVT and the patient's high risk of sudden cardiac death may limit the effectiveness of these medications in preventing pump failure.

RANKING: 3. Survivor
REASONING: 

While the patient's severe heart failure and arrhythmias make pump failure and sudden cardiac death possible outcomes, the patient's age and overall health status may allow for some degree of improvement with aggressive medical management. The patient's medication regimen includes beta blockers, which can help reduce the risk of further cardiac events.

However, the patient's high risk of sudden cardiac death and the presence of NSVT on ECG make it unlikely that the patient will survive for an extended period. Additionally, the patient's elevated troponin level and LVEF of 20% indicate significant cardiac damage, which may limit the patient's ability to recover.

Overall, while pump failure death is a possible outcome, the patient's high risk of sudden cardiac death and the presence of NSVT make it the least likely prognosis."
824,824,P0762,"Age: 68
Gender: Male 
Weight: 99 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 38,8
ALT or GPT (IU/L): 187.0
AST or GOT (IU/L): 146.0
Total Cholesterol (mmol/L): 2,62
Creatinine (mmol/L): 188.0
Gamma-glutamil transpeptidase (IU/L): 154
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 0,64
Potassium (mEq/L): 3,73
LDL (mmol/L): 1,59
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 19001.0
Protein (g/L): 69,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,85
Urea (mg/dL): 21,3
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death 
REASONING: 

The patient's clinical presentation and ECG findings suggest a high risk of sudden cardiac death. The presence of ventricular extrasystole, non-sustained ventricular tachycardia (NSVT), and a low left ventricular ejection fraction (LVEF) of 20% indicate significant left ventricular dysfunction, which is a major risk factor for sudden cardiac death. Additionally, the patient's history of ischemic dilated cardiomyopathy and myocardial infarction further increases the risk of arrhythmias. The patient's elevated troponin levels and elevated N-terminal pro-b-type natriuretic peptide (NT-proBNP) levels also suggest significant cardiac stress and strain.

RANKING: 2. Pump failure death 
REASONING: 

The patient's low LVEF of 20% and elevated NT-proBNP levels suggest significant left ventricular dysfunction, which increases the risk of pump failure. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction further supports this risk. Additionally, the patient's elevated creatinine levels and urea levels suggest renal impairment, which can be a complication of pump failure. However, the patient is currently on medications that are commonly used to manage heart failure, such as beta blockers, digoxin, and loop diuretics, which may help mitigate this risk.

RANKING: 3. Survivor 
REASONING: 

While the patient's ECG findings and medical history suggest a high risk of arrhythmias and cardiac dysfunction, the patient is currently on medications that are commonly used to manage these conditions. The patient's relatively stable blood pressure and hemoglobin levels also suggest that the patient is not currently experiencing acute cardiovascular instability. However, the patient's low LVEF and elevated NT-proBNP levels suggest that the patient is at risk of cardiac decompensation, which could potentially lead to pump failure or sudden cardiac death. Overall, while the patient is at risk, the patient's current clinical status is relatively stable, and with close monitoring and optimization of medications, the patient may survive for an extended period."
825,825,P0766,"Age: 64
Gender: Male 
Weight: 48 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 140/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 37,6
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 132.0
Gamma-glutamil transpeptidase (IU/L): 338
Glucose (mmol/L): 3,5
Hemoglobin (g/L): 127.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 3,18
LDL (mmol/L): 2,89
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 9695.0
Protein (g/L): 81,4
Troponin (ng/mL): 0,04
TSH (mIU/L): 3,73
Urea (mg/dL): 10,4
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class III, and history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction indicate a significant burden of cardiovascular disease. However, the patient's current LVEF of 30.0 is relatively preserved compared to their NYHA Class III status, suggesting that the heart is still capable of maintaining some level of function. The presence of non-sustained ventricular tachycardia and ventricular extrasystole on the ECG indicates arrhythmic instability, but the absence of more severe arrhythmias or significant ECG abnormalities suggests that the patient is not in immediate danger of cardiac arrest.

The patient's laboratory results, including low albumin, elevated creatinine, and high LDLC, suggest some degree of malnutrition and renal impairment, but these findings are not uncommon in patients with heart failure. The presence of troponin at 0.04 ng/mL is not elevated, which suggests that there is no significant myocardial damage.

Given these factors, the patient's prognosis is more likely to be survival, as they are not in immediate danger of cardiac arrest or pump failure. The patient's current medications, including digoxin and loop diuretics, are standard treatments for heart failure and are likely to be effective in managing the patient's symptoms.

RANKING: 2. Sudden cardiac death
REASONING: 

While the patient's ECG shows evidence of arrhythmias, the presence of non-sustained ventricular tachycardia and ventricular extrasystole is not necessarily indicative of an increased risk of sudden cardiac death. The patient's LVEF is relatively preserved, and the absence of more severe arrhythmias or significant ECG abnormalities suggests that the patient is not in immediate danger of cardiac arrest.

However, the patient's history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction increases the risk of sudden cardiac death. Additionally, the patient's elevated creatinine and low albumin levels suggest some degree of malnutrition and renal impairment, which can increase the risk of cardiac complications.

Given these factors, the patient's prognosis is less likely to be sudden cardiac death, but not impossible.

RANKING: 3. Pump failure death
REASONING: 

The patient's current NYHA Class III status and history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction suggest that the patient is at high risk of pump failure. The patient's LVEF of 30.0 is relatively preserved, but the patient's elevated creatinine and low albumin levels suggest some degree of malnutrition and renal impairment, which can increase the risk of cardiac complications.

The patient's ECG shows evidence of arrhythmias, including non-sustained ventricular tachycardia and ventricular extrasystole, which can increase the risk of cardiac complications. The patient's current medications, including digoxin and loop diuretics, are standard treatments for heart failure, but may not be sufficient to manage the patient's symptoms.

Given these factors, the patient's prognosis is the most likely to be pump failure death, as the patient's cardiovascular disease is significant, and the patient's current medications may not be sufficient to manage the patient's symptoms."
826,826,P0772,"Age: 74
Gender: Male 
Weight: 60 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 80/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,54
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 114
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,46
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 8916.0
Protein (g/L): 79
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 27,12
LVEF (%): 13.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: The patient's ECG impression reveals polymorphic ventricular extrasystoles, which is a significant finding indicating a high risk of ventricular arrhythmias. This is particularly concerning in a patient with a history of ischemic dilated cardiomyopathy and myocardial infarction, which can lead to electrical instability and increase the risk of sudden cardiac death. The patient's low ejection fraction (LVEF) of 13% further supports this concern, as it indicates significant left ventricular dysfunction. Additionally, the patient's elevated troponin levels and low ejection fraction suggest ongoing myocardial damage, which can contribute to arrhythmias. Given the patient's NYHA Class III status, the patient is already experiencing significant symptoms and has a high risk of decompensation. Therefore, sudden cardiac death is the most likely prognosis.

RANKING: 2. Pump failure death
REASONING: While the patient's pump failure death is a possible outcome, it is less likely than sudden cardiac death given the presence of polymorphic ventricular extrasystoles on the ECG. The patient's LVEF is also very low, indicating severe left ventricular dysfunction, which increases the risk of heart failure. However, the presence of ventricular arrhythmias, as indicated by the ECG, suggests a higher risk of sudden cardiac death. The patient's NYHA Class III status and low ejection fraction further support the risk of heart failure, but the ECG findings tip the scales in favor of sudden cardiac death.

RANKING: 3. Survivor
REASONING: While the patient's heart failure status and low ejection fraction indicate a high risk of pump failure, the presence of ventricular arrhythmias on the ECG and the patient's overall clinical picture suggest a higher risk of sudden cardiac death. Additionally, the patient's low ejection fraction and elevated troponin levels indicate significant myocardial damage, which can lead to further deterioration. However, the patient's age, weight, and hemoglobin level do not suggest a high risk of mortality, and the patient is already receiving medications for heart failure and hypertension. Therefore, while pump failure is a possible outcome, the presence of ventricular arrhythmias and the patient's overall clinical picture make sudden cardiac death the more likely prognosis."
827,827,P0781,"Age: 70
Gender: Female 
Weight: 62 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 100/75 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 38,5
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 97
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,33
Potassium (mEq/L): 4,42
LDL (mmol/L): 3,08
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 5911.0
Protein (g/L): 82,3
T3 (pg/dL): 0,01
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,9
Urea (mg/dL): 10,5
LVEF (%): 35.0
Medications: Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: The patient's electrocardiogram (ECG) shows several concerning features, including ventricular extrasystoles, polymorphic ventricular tachycardia, and non-sustained ventricular tachycardia. These findings suggest a high risk of arrhythmic events, which is a significant predictor of sudden cardiac death in patients with heart failure. The patient's left ventricular ejection fraction (LVEF) is also severely impaired at 35%, which further increases the risk of arrhythmic events. The presence of ventricular tachycardia and ventricular extrasystoles on the ECG suggests a high risk of ventricular arrhythmias, which can lead to sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF is severely impaired at 35%, indicating a high risk of heart failure. The patient is also taking medications for heart failure, including digoxin and loop diuretics, which suggests that the patient is being managed for heart failure. However, the presence of ventricular tachycardia and ventricular extrasystoles on the ECG suggests that the patient may not be adequately controlled, which increases the risk of pump failure death.

RANKING: 3. Survivor
REASONING: While the patient's LVEF is severely impaired, the patient is being managed for heart failure with medications and has a relatively stable blood pressure and electrolyte levels. The patient's ECG does not show any overt signs of acute cardiac injury or ischemia, which reduces the risk of sudden cardiac death. However, the presence of ventricular tachycardia and ventricular extrasystoles on the ECG suggests a high risk of arrhythmic events, which could potentially lead to pump failure death. Overall, while the patient's prognosis is guarded, the patient's current management and relatively stable vital signs suggest that they may survive, but with a high risk of cardiac complications."
828,828,P0790,"Age: 79
Gender: Male 
Weight: 88 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4
LDL (mmol/L): 2,46
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 4762.0
Protein (g/L): 65
T4 (ng/L): 9
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,8
Urea (mg/dL): 6,66
LVEF (%): 28.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the provided patient data, the patient is at high risk for both sudden cardiac death and pump failure death due to their history of idiopathic dilated cardiomyopathy and NYHA Class II heart failure. The elevated LVEF of 28.0 indicates severe left ventricular dysfunction, which is a strong predictor of adverse outcomes.

However, the patient's ECG findings of non-sustained ventricular tachycardia and ventricular extrasystoles suggest a high risk of arrhythmic events, which is a common cause of sudden cardiac death in patients with heart failure. The presence of these arrhythmias increases the likelihood of sudden cardiac death.

While pump failure death is also a significant concern, the patient's current medications, including beta blockers, digoxin, and ACE inhibitors, suggest that they are being adequately managed for heart failure. The patient's creatinine level is elevated, but not severely so, and their kidney function is not significantly impaired.

Considering these factors, I would rank the prognoses as follows:

1. Sudden cardiac death: The presence of non-sustained ventricular tachycardia and ventricular extrasystoles on the ECG, combined with the patient's history of idiopathic dilated cardiomyopathy and severe left ventricular dysfunction, make sudden cardiac death the most likely outcome.
2. Pump failure death: While pump failure is a significant concern, the patient's current treatment regimen and relatively stable kidney function reduce the likelihood of pump failure death compared to sudden cardiac death.
3. Survivor: Although the patient's overall health status is concerning, their current treatment regimen and relatively stable vital signs suggest that they may have a chance of survival with proper management and monitoring."
829,829,P0792,"Age: 85
Gender: Male 
Weight: 86 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 37
ALT or GPT (IU/L): 42.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,84
Sodium (mEq/L): 139.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,62
Urea (mg/dL): 9,32
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Survivor
REASONING: 
The patient's current NYHA Class III indicates severe heart failure, but the patient is still receiving treatment with medications such as digoxin, loop diuretics, and spironolactone, which suggest an attempt to manage symptoms. The patient's LVEF is 25.0%, which is significantly reduced, but not completely catastrophic. The presence of non-sustained ventricular tachycardia is concerning, but the absence of other signs of acute myocardial infarction or significant arrhythmias reduces the likelihood of sudden cardiac death. The patient's creatinine level is elevated, indicating some degree of renal impairment, but not severe enough to be a major concern. Overall, the patient's prognosis is guarded but not hopeless.

2. Sudden cardiac death
REASONING: 
The patient's history of idiopathic dilated cardiomyopathy increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia (NSVT) is a significant concern, as it can be a precursor to more severe arrhythmias. The patient's LVEF is very low, indicating significant left ventricular dysfunction, which increases the risk of arrhythmias. The patient's age and other comorbidities (e.g., diabetes) also contribute to the risk of sudden cardiac death. However, the patient's overall clinical presentation and the absence of other signs of acute myocardial infarction or significant arrhythmias reduce the likelihood of sudden cardiac death.

3. Pump failure death
REASONING: 
While pump failure is a significant concern given the patient's NYHA Class III status and LVEF of 25.0%, the patient is already receiving treatment with medications that aim to manage symptoms and improve cardiac function. The patient's renal impairment is also a concern, but it is not directly related to cardiac function. The presence of NSVT and other arrhythmias, as well as the patient's overall clinical presentation, suggest that pump failure death is a possible but not the most likely outcome."
830,830,P0835,"Age: 78
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 41,5
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,79
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 43
Glucose (mmol/L): 14,6
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 4,39
LDL (mmol/L): 3,17
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 155.0
Protein (g/L): 80,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 9,9
LVEF (%): 60.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Survivor
REASONING: 
Based on the patient's age, NYHA Class III, and history of valvular cardiomyopathy, hypertension, and elevated creatinine levels (89.0 mmol/L), the patient is at a higher risk for pump failure. The patient's LVEF is 60.0%, which indicates left ventricular dysfunction, further increasing the risk of pump failure. The presence of elevated troponin levels (0.01 ng/mL) may indicate some degree of myocardial injury, which can also contribute to pump failure.

The patient is also on medications such as Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, and Spironolactone, which are commonly used to manage heart failure and hypertension. However, the patient's current ECG findings do not indicate any acute arrhythmia, which reduces the risk of sudden cardiac death.

2. Sudden cardiac death
REASONING: 
The patient's ECG findings show ventricular extrasystole, which is a type of arrhythmia that can increase the risk of sudden cardiac death. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia (CH>10) reduces this risk. The patient's other risk factors, such as age, NYHA Class III, and history of valvular cardiomyopathy, still contribute to the risk of pump failure, but the absence of acute arrhythmia reduces the risk of sudden cardiac death.

3. Pump failure death
REASONING: 
While the patient is at risk for pump failure due to their NYHA Class III, history of valvular cardiomyopathy, and elevated creatinine levels, the presence of ventricular extrasystole on the ECG suggests that the patient is not at an extremely high risk for pump failure death. The patient's current ECG findings do not indicate any acute arrhythmia, and the patient is on medications that are commonly used to manage heart failure and hypertension. Therefore, while pump failure is still a concern, it is less likely than sudden cardiac death in this case."
831,831,P0839,"Age: 68
Gender: Male 
Weight: 70 kg
Height: 174 cm
NYHA Class: III
Blood Pressure: 120/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 37,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 97.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4
LDL (mmol/L): 2,35
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1635.0
Protein (g/L): 66,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,39
Urea (mg/dL): 12,1
LVEF (%): 44.0
Medications: Amiodarone, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: The patient's ECG impression shows ventricular extrasystoles, which is a sign of abnormal electrical activity in the heart. This can be a precursor to life-threatening arrhythmias, including ventricular tachycardia. Although the patient does not have any evidence of ventricular tachycardia or non-sustained ventricular tachycardia, the presence of ventricular extrasystoles increases the risk of sudden cardiac death. Additionally, the patient's NYHA Class III heart failure status and ischemic dilated cardiomyopathy suggest a compromised cardiac function, which can increase the risk of sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: The patient's NYHA Class III heart failure status and LVEF of 44.0 indicate significant cardiac dysfunction, which can lead to pump failure. The patient's elevated creatinine level (133.0 mmol/L) also suggests impaired renal function, which can be a complication of heart failure. The patient's medications, including loop diuretics and ACE inhibitor, suggest that the clinician is actively managing the patient's heart failure. However, the presence of ventricular extrasystoles on the ECG and the patient's high Pro-BNP level (1635.0 ng/L) suggest that the patient's heart failure is not well-controlled, increasing the risk of pump failure.

RANKING: 3. Survivor
REASONING: While the patient's heart failure status and elevated creatinine level suggest a high risk, the presence of ventricular extrasystoles and high Pro-BNP level on the ECG and laboratory results suggest that the patient's cardiac function is not stable. However, the patient's age (68) and relatively low troponin level (0.01 ng/mL) suggest that the patient may not be at the highest risk of sudden cardiac death. Additionally, the patient's medications and NYHA Class III status suggest that the clinician is actively managing the patient's heart failure. Overall, while the patient's prognosis is guarded, the likelihood of survival for the next few years is still possible, especially if the patient's cardiac function can be managed effectively."
832,832,P0853,"Age: 74
Gender: Male 
Weight: 70 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5
LDL (mmol/L): 3,78
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 4185.0
Protein (g/L): 77
T4 (ng/L): 19
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,5
Urea (mg/dL): 12,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 
This patient is a 74-year-old male with a complex medical history of ischemic dilated cardiomyopathy, peripheral vascular disease, hypertension, and myocardial infarction. The patient's LVEF is severely impaired at 30%, indicating significant left ventricular dysfunction. The presence of elevated Pro-BNP levels (4185.0 ng/L) suggests elevated ventricular wall stress, which is a strong predictor of adverse outcomes in heart failure patients.

Despite the patient's NYHA Class II symptoms, which may suggest some residual functional capacity, the overall clinical picture is dominated by advanced heart failure, peripheral vascular disease, and the presence of non-sustained ventricular tachycardia on ECG, which is a marker of increased arrhythmic risk. The patient's medication regimen, which includes beta blockers, loop diuretics, ACE inhibitors, and a nitrovasodilator, is standard therapy for heart failure and hypertension.

While the patient's creatinine level (12.15 mg/dL) and urea level (12.15 mg/dL) are elevated, indicating some degree of renal impairment, this is not uncommon in patients with advanced heart failure. The patient's potassium level (5 mEq/L) is also elevated, which may be related to the use of diuretics. The absence of significant electrolyte imbalances or acute kidney injury suggests that the patient's renal function is not acutely compromised.

Given the patient's advanced heart failure, significant left ventricular dysfunction, and the presence of arrhythmias, the risk of pump failure is high. However, the patient's NYHA Class II symptoms and the presence of beta blockers and ACE inhibitors in the medication regimen suggest that the patient is still able to tolerate some level of physical activity and may not be as severely disabled as a patient with more severe heart failure symptoms.

Therefore, while the patient is at high risk of pump failure, the likelihood of sudden cardiac death is lower than pump failure, and the patient's overall prognosis is more likely to be survival with careful management and monitoring.

RANKING: 2. Sudden cardiac death
REASONING: 
The patient's ECG shows a history of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia (CH>10), which increases the risk of arrhythmic events, including sudden cardiac death. The presence of these arrhythmias, combined with the patient's advanced heart failure and left ventricular dysfunction, makes the patient more susceptible to life-threatening arrhythmic events.

The patient's age, NYHA Class II symptoms, and the presence of beta blockers and ACE inhibitors in the medication regimen suggest that the patient is at moderate risk for arrhythmic events. However, the patient's overall clinical picture is dominated by advanced heart failure, which reduces the likelihood of sudden cardiac death compared to pump failure.

RANKING: 3. Pump failure death
REASONING: 
The patient's advanced heart failure, significant left ventricular dysfunction (LVEF 30%), and elevated Pro-BNP levels (4185.0 ng/L) make pump failure a highly likely outcome. The patient's NYHA Class II symptoms suggest some residual functional capacity, but the overall clinical picture is dominated by advanced heart failure, which reduces the likelihood of survival.

The patient's renal impairment (creatinine and urea levels) and electrolyte imbalances (elevated potassium level) suggest that the patient's heart failure is not being adequately managed, which may contribute to the development of pump failure. The presence of non-sustained ventricular tachycardia on ECG further increases the risk of pump failure.

While the patient's medication regimen is standard therapy for heart failure, the patient's advanced heart failure and significant left ventricular dysfunction make pump failure a more likely outcome than sudden cardiac death."
833,833,P0872,"Age: 57
Gender: Male 
Weight: 62 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 47
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,56
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,57
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2299.0
Protein (g/L): 74
T3 (pg/dL): 0,07
T4 (ng/L): 19
Troponin (ng/mL): 0,17
TSH (mIU/L): 2,47
Urea (mg/dL): 7,15
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Pump failure death
REASONING: 

This patient has a high risk of pump failure death due to the combination of several factors. Firstly, the patient has a history of hypertensive cardiomyopathy, which is a condition that can lead to left ventricular dysfunction and heart failure. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 22%, indicating that the left ventricle is not pumping efficiently.

Additionally, the patient has a high level of B-type natriuretic peptide (Pro-BNP) at 2299.0 ng/L, which is a marker of ventricular strain and suggests that the heart is working harder to pump blood. The patient also has a history of ventricular extrasystole, non-sustained ventricular tachycardia, and non-sustained ventricular tachycardia, which can further increase the risk of cardiac arrhythmias and cardiac arrest.

The patient's electrolyte levels, including low potassium (4.6 mEq/L) and high creatinine (7.15 mg/dL), may also indicate kidney dysfunction, which can exacerbate cardiac conditions.

The patient's medications, including beta blockers and loop diuretics, suggest that the patient is being treated for heart failure, but the patient's current condition and the presence of ventricular arrhythmias suggest that the patient is at high risk of cardiac complications.

Given these factors, pump failure death is the most likely outcome for this patient over the next few years."
834,834,P0873,"Age: 81
Gender: Female 
Weight: 49 kg
Height: 145 cm
NYHA Class: III
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,69
Creatinine (mmol/L): 209.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 3,94
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 4,54
LDL (mmol/L): 3,01
Sodium (mEq/L): 139.0
Protein (g/L): 81
T3 (pg/dL): 0,0441
T4 (ng/L): 22,5
Troponin (ng/mL): 1,2
TSH (mIU/L): 1,27
Urea (mg/dL): 26,1
LVEF (%): 65.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's data indicates a high risk for cardiac complications. The key factors contributing to this risk are:

1. Age: The patient is 81 years old, which is an advanced age for a cardiac event. The risk of sudden cardiac death and pump failure increases with age.
2. NYHA Class III: This indicates severe heart failure, which is a significant predictor of poor outcomes.
3. Hypertensive cardiomyopathy: This condition can lead to left ventricular dysfunction and increased risk of sudden cardiac death.
4. High Blood Pressure: The patient's blood pressure is elevated (180/90 mmHg), which can contribute to cardiac damage and increase the risk of cardiac events.
5. Low LVEF (65%): The left ventricular ejection fraction is significantly reduced, indicating poor cardiac function and increased risk of pump failure.
6. Elevated creatinine (209.0 mmol/L): This suggests impaired renal function, which can be a complication of heart failure and increase the risk of pump failure.
7. High Troponin levels (1.2 ng/mL): Elevated troponin levels indicate cardiac damage, which can be a predictor of cardiac events.
8. Medications: The patient is taking medications that can help manage heart failure, but also may not be effective in preventing cardiac events.

Considering these factors, I rank the patient's prognosis as follows:

1. Sudden cardiac death: The patient's advanced age, NYHA Class III, hypertensive cardiomyopathy, and elevated troponin levels make it more likely that the patient will experience a sudden cardiac event.
2. Pump failure death: The patient's low LVEF, elevated creatinine, and NYHA Class III make it likely that the patient will experience pump failure.
3. Survivor: While the patient's age and comorbidities increase the risk of cardiac events, the patient's relatively mild troponin elevation and the presence of medications that can help manage heart failure suggest that the patient may have a slightly better prognosis, but still carry a significant risk of cardiac complications."
835,835,P0882,"Age: 79
Gender: Female 
Weight: 70 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,2
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,73
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,13
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,74
Potassium (mEq/L): 4,14
LDL (mmol/L): 4,76
Sodium (mEq/L): 140.0
Protein (g/L): 66,7
T3 (pg/dL): 0,0549
T4 (ng/L): 16,02
TSH (mIU/L): 4,15
Urea (mg/dL): 7,4
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: The patient's age is 79, which is a significant risk factor for cardiovascular mortality. However, the patient's NYHA Class II indicates that they have some limitation in physical activity, but they are not severely limited. The patient's LVEF is 50%, which is below the normal range, indicating left ventricular dysfunction. Despite this, the patient's ECG impression does not show any evidence of ventricular tachycardia or ventricular extrasystole, which are common causes of sudden cardiac death. The patient's medication regimen is well-managed, with a calcium channel blocker, beta blockers, loop diuretics, statins, and nitrovasodilators, which are all standard treatments for managing hypertension, heart failure, and dyslipidemia. The patient's laboratory values, including electrolytes and liver enzymes, are within relatively normal limits. Considering these factors, I believe that the patient is likely to survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: While the patient's LVEF is below normal, the absence of ventricular tachycardia or ventricular extrasystole on the ECG impression suggests that the patient is not at high risk for sudden cardiac death. However, the patient's age and NYHA Class II indicate that they are at increased risk for cardiovascular events. The patient's hypertension and dyslipidemia are also risk factors for cardiovascular mortality. Although the patient's medication regimen is well-managed, there is no evidence of any acute changes in the ECG or laboratory values that would suggest an immediate risk for sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: Given the patient's NYHA Class II and LVEF of 50%, there is a risk of heart failure, but the patient's current ECG impression does not show any evidence of ventricular tachycardia or ventricular extrasystole, which are common causes of pump failure. Additionally, the patient's medication regimen is well-managed, which suggests that the patient is receiving adequate treatment for their heart failure. However, the patient's elevated creatinine level (93.0 mmol/L) and low albumin level (40.2 g/L) suggest some degree of renal impairment, which can be a complication of heart failure. While pump failure is a possible outcome, it is not the most likely outcome based on the available information."
836,836,P0884,"Age: 70
Gender: Female 
Weight: 70 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 34
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,01
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,22
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 2773.0
Protein (g/L): 75
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,23
Urea (mg/dL): 4,99
LVEF (%): 60.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

Based on the provided patient data, I would rank the prognoses from most likely to least likely as follows:

1. Sudden cardiac death: The patient's ECG findings, specifically the presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles, indicate an increased risk of life-threatening arrhythmias. The patient's age, NYHA class II, and history of hypertensive cardiomyopathy also contribute to this risk. The elevated Troponin level (0.01 ng/mL) suggests some myocardial damage, which may increase the risk of sudden cardiac death.

2. Pump failure death: The patient's LVEF is 60%, which is below the normal range (55%), indicating some degree of left ventricular dysfunction. The patient's NYHA class II and history of hypertensive cardiomyopathy also suggest that the heart is under strain. While not as immediately life-threatening as arrhythmias, pump failure is a significant concern, especially given the patient's age and existing medical history.

3. Survivor: While the patient's current condition and medical history raise concerns, the patient's age, weight, and relatively normal blood pressure (140/80 mmHg) suggest that they may be able to manage their condition with current treatment and lifestyle modifications. The presence of elevated troponin and LVEF below normal also indicates some degree of cardiac damage, but the overall prognosis is not as dire as the top two options. Additionally, the patient's medications (loop diuretics, spironolactone, and ACE inhibitor) suggest that they are receiving standard treatment for their condition, which may help mitigate some risks.

Please note that this prognosis is based on the provided data and may not accurately reflect the patient's actual outcome. A comprehensive assessment by a cardiologist and other healthcare professionals is necessary to determine the patient's prognosis."
837,837,P0888,"Age: 77
Gender: Male 
Weight: 60 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 9,8
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,54
LDL (mmol/L): 4,01
Sodium (mEq/L): 137.0
Protein (g/L): 75,8
T3 (pg/dL): 0,0642
T4 (ng/L): 15,87
Troponin (ng/mL): 0,3
TSH (mIU/L): 2,14
Urea (mg/dL): 12,9
LVEF (%): 30.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Survivor
REASONING: 
This patient's overall clinical presentation and test results indicate a high risk for cardiac complications. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. The patient's low LVEF of 30.0% further supports this, indicating severe left ventricular dysfunction. Additionally, the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests an increased risk of arrhythmic events. However, the patient's age, weight, and lack of other significant risk factors for sudden cardiac death (e.g., family history of sudden cardiac death, previous myocardial infarction) may mitigate this risk.

2. Sudden cardiac death
REASONING: 
While the patient's ECG findings and medical history do increase the risk for arrhythmic events, the patient's age and relatively low risk factors for sudden cardiac death may reduce this risk. However, the patient's history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia on the ECG still pose a significant risk for sudden cardiac death. The patient's low LVEF and elevated creatinine level also suggest a high risk for cardiac complications.

3. Pump failure death
REASONING: 
Given the patient's severe left ventricular dysfunction (LVEF 30.0%) and history of ischemic dilated cardiomyopathy, pump failure is a significant risk. However, the patient is already taking medications for heart failure (loop diuretics and ACE inhibitor), which should help manage symptoms and slow disease progression. The patient's current ECG findings and lab results do not suggest an immediate risk for pump failure, and the patient's age and relatively low risk factors for sudden cardiac death make this outcome less likely."
838,838,P0891,"Age: 72
Gender: Male 
Weight: 57 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 130/90 mmHg
Past Medical History: Other HF etiology, Diabetes, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,49
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 4127.0
Protein (g/L): 72
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 12,81
LVEF (%): 20.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 

The patient's age, NYHA Class III heart failure, and elevated creatinine level (115.0 mmol/L) indicate advanced heart failure. However, the patient's LVEF (20.0) is relatively preserved, suggesting that the heart is still functioning to some extent. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG also suggests that the heart is under stress, but the absence of sustained ventricular tachycardia or bradycardia reduces the likelihood of sudden cardiac death. The patient's medication regimen, including an ACE inhibitor and an angiotensin II receptor blocker, suggests that the patient is receiving optimal treatment for heart failure. The patient's low troponin level (0.01 ng/mL) and normal TSH level (2.56 mIU/L) also suggest that the patient's heart is not under significant acute stress. Overall, these factors suggest that the patient has a relatively better prognosis and is likely to survive for the next few years with proper management.

RANKING: 2. Sudden cardiac death
REASONING: 

The patient's NYHA Class III heart failure and elevated creatinine level (115.0 mmol/L) indicate advanced heart failure, which increases the risk of sudden cardiac death. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG also suggests that the heart is under stress and at risk for arrhythmias. The patient's low LVEF (20.0) also indicates that the heart is not functioning optimally, which increases the risk of sudden cardiac death. However, the patient's relatively preserved troponin level (0.01 ng/mL) and normal TSH level (2.56 mIU/L) suggest that the patient is not under significant acute stress. The patient's medication regimen and other clinical factors also suggest that the patient is receiving optimal treatment for heart failure. Overall, these factors suggest that the patient is at increased risk for sudden cardiac death, but the likelihood is still lower than pump failure death.

RANKING: 3. Pump failure death
REASONING: 

The patient's advanced age (72 years), NYHA Class III heart failure, and elevated creatinine level (115.0 mmol/L) indicate a high risk of pump failure death. The patient's low LVEF (20.0) and the presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG also suggest that the heart is not functioning optimally. The patient's elevated troponin level (not significantly elevated, but could be an indicator of cardiac stress) and low HDL level (1.27 mmol/L) also suggest that the patient is at increased risk for cardiac complications. The patient's medication regimen, while optimal for heart failure, may not be sufficient to reverse the underlying cardiac dysfunction. Overall, these factors suggest that the patient is at high risk for pump failure death, making it the most likely outcome."
839,839,P0907,"Age: 50
Gender: Male 
Weight: 69 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,4
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 2,79
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 138.0
HDL (mmol/L): 0,87
Potassium (mEq/L): 3,78
LDL (mmol/L): 1,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 9416.0
Protein (g/L): 64,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,85
Urea (mg/dL): 9,2
LVEF (%): 20.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the provided patient data, the most likely prognosis is pump failure death. The patient's LVEF (Left Ventricular Ejection Fraction) is 20.0%, which indicates severe left ventricular dysfunction, a hallmark of cardiomyopathy. This suggests that the patient's heart is unable to pump effectively, leading to potential complications such as heart failure.

The patient's NYHA Class II indicates that they experience symptoms of heart failure, such as shortness of breath and fatigue, which further supports the likelihood of pump failure.

While the patient has a history of ischemic dilated cardiomyopathy, the current data suggests that the condition is advanced, and the heart is not responding well to treatment. The elevated creatinine level (156.0 mmol/L) may indicate renal impairment, which is a common complication of heart failure.

Sudden cardiac death is a possible complication of advanced heart failure, but it is less likely in this case since the patient's ECG shows no evidence of ventricular tachycardia or other arrhythmias that could lead to sudden cardiac death.

Survivor is the least likely prognosis, as the patient's LVEF is severely impaired, and the patient is already experiencing symptoms of heart failure. While the patient is on medications to manage their condition, the underlying disease is advanced, and it is unlikely that they will be able to recover fully.

In summary, the patient's severe left ventricular dysfunction, symptoms of heart failure, and advanced age make pump failure death the most likely prognosis."
840,840,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 
The patient's age (69 years) and NYHA Class III status indicate that the patient has significant cardiac dysfunction and is at high risk for cardiac events. However, the patient's LVEF is 35%, which is relatively low but not critically low. The patient's blood pressure is well-controlled (130/80 mmHg), and the patient is on multiple medications that are commonly used to manage heart failure and hypertension.

The patient's laboratory results, such as elevated creatinine (63.0 mmol/L) and low albumin (40.7 g/L), indicate chronic kidney disease and possible fluid overload, which is consistent with heart failure. However, the patient's liver enzymes (ALT and AST) are within normal limits, and the patient's glucose levels are well-controlled.

The patient's ECG results show ventricular extrasystole, which is a common finding in patients with heart failure, but it is not indicative of a high risk of sudden cardiac death. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.

Given these factors, I believe that the patient is at high risk for pump failure, but not necessarily for sudden cardiac death. The patient's overall condition and the presence of multiple comorbidities suggest that the patient is at risk for decompensation and pump failure, making ""Survivor"" the most likely outcome.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's ECG results show ventricular extrasystole, which is a risk factor for sudden cardiac death, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. Additionally, the patient's LVEF is relatively low, but not critically low, which reduces the risk of sudden cardiac death.

The patient's age and NYHA Class III status do increase the risk of cardiac events, but the patient's overall condition and the presence of multiple comorbidities suggest that pump failure is a more likely outcome than sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
The patient's LVEF is 35%, which is relatively low, and the patient is on multiple medications that are commonly used to manage heart failure. The patient's laboratory results, such as elevated creatinine (63.0 mmol/L) and low albumin (40.7 g/L), indicate chronic kidney disease and possible fluid overload, which is consistent with heart failure.

While the patient's ECG results show ventricular extrasystole, which is a risk factor for pump failure, the patient's overall condition and the presence of multiple comorbidities suggest that pump failure is a more likely outcome than sudden cardiac death. The patient's low HDL (1.4 mmol/L) and high LDL (3.08 mmol/L) also suggest a higher risk of cardiovascular events, which is consistent with heart failure.

However, the patient's overall condition and the presence of multiple comorbidities make pump failure a more likely outcome than sudden cardiac death, making it the least likely outcome."
841,841,P0940,"Age: 79
Gender: Male 
Weight: 58 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 105.0
HDL (mmol/L): 0,44
Potassium (mEq/L): 5,3
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 5482.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,13
TSH (mIU/L): 2,56
Urea (mg/dL): 18,14
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: 
Based on the patient's data, the patient is 79 years old with a history of ischemic dilated cardiomyopathy, which is a significant comorbidity. The patient's left ventricular ejection fraction (LVEF) is 30%, which is severely impaired. The patient is also taking multiple medications, including ACE inhibitors and beta blockers, which are commonly used to manage heart failure. The patient's creatinine level is elevated at 141.0 mmol/L, indicating impaired renal function, but this is not directly related to cardiac function.

The patient's ECG impression shows ventricular extrasystoles and polymorphic ventricular extrasystoles, which are concerning signs of arrhythmia. However, the absence of ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient's arrhythmias are not life-threatening.

The patient's biomarkers, including troponin and pro-BNP, are elevated, indicating some degree of cardiac stress and strain. However, the patient's overall clinical presentation and laboratory results do not suggest acute cardiac decompensation or acute coronary syndrome.

Given the patient's multiple comorbidities, the presence of ventricular extrasystoles, and the elevated biomarkers, the most likely outcome is that the patient will survive, albeit with ongoing cardiac issues. However, the patient's severely impaired LVEF and multiple medications suggest that the patient may require close monitoring and management to prevent complications.

RANKING: 2. Sudden cardiac death
REASONING: 
While the patient's arrhythmias and elevated biomarkers suggest a high risk of cardiac complications, the patient's overall clinical presentation and laboratory results do not suggest an acute and sudden cardiac event. The patient is taking multiple medications to manage their heart failure and arrhythmias, and the patient's LVEF is not severely impaired.

However, the patient's history of ischemic dilated cardiomyopathy and peripheral vascular disease increases the risk of cardiac complications, including arrhythmias and sudden cardiac death. The patient's ECG impression shows ventricular extrasystoles and polymorphic ventricular extrasystoles, which are concerning signs of arrhythmia. However, the absence of ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient's arrhythmias are not life-threatening.

Given the patient's history and laboratory results, the second most likely outcome is that the patient will experience cardiac complications, including arrhythmias, but not sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: 
The patient's severely impaired LVEF (30%) and elevated creatinine level (141.0 mmol/L) suggest that the patient's cardiac function is severely compromised. The patient's multiple medications, including ACE inhibitors and beta blockers, are intended to manage heart failure, but the patient's elevated biomarkers and ECG impression suggest that the patient's cardiac function is not adequately controlled.

The patient's history of ischemic dilated cardiomyopathy and peripheral vascular disease increases the risk of cardiac complications, including pump failure. The patient's age (79 years) and elevated creatinine level also increase the risk of renal complications, which can contribute to pump failure.

Given the patient's severely impaired LVEF, elevated biomarkers, and ECG impression, the most likely outcome is that the patient will experience pump failure, which is a life-threatening complication of heart failure."
842,842,P0961,"Age: 76
Gender: Female 
Weight: 93 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 134/64 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,77
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2876.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 19
TSH (mIU/L): 2,86
Urea (mg/dL): 9,82
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden cardiac death
2. Pump failure death
3. Survivor

REASONING:

The patient's prognosis can be assessed based on the provided data, and the following factors contribute to the ranking:

1. Low LVEF (30.0%): A left ventricular ejection fraction of 30% is a strong indicator of advanced heart failure, which significantly increases the risk of pump failure death. The patient's LVEF is significantly lower than the normal range, indicating severe systolic dysfunction.

2. High Creatinine level (115.0 mmol/L): Elevated creatinine levels suggest impaired renal function, which is often associated with heart failure. This finding, in conjunction with the low LVEF, further supports the risk of pump failure death.

3. Pro-BNP levels (2876.0 ng/L): Elevated Pro-BNP levels are a biomarker of heart failure, indicating increased ventricular wall stress and stretching. While this finding supports the presence of heart failure, it does not directly influence the ranking.

4. NYHA Class II: The patient's NYHA Class II classification indicates moderate symptoms of heart failure, which is consistent with advanced heart failure. However, this classification does not directly impact the ranking.

5. Medications: The patient is on medications for heart failure (Digoxin, Loop Diuretics, Spironolactone, and Statins), which are standard treatments for heart failure. While these medications are essential for managing the condition, they do not directly influence the prognosis.

Considering these factors, the patient is at high risk of pump failure death due to the combination of severe systolic dysfunction (low LVEF), impaired renal function (high creatinine), and elevated Pro-BNP levels. Sudden cardiac death is a possible complication, but it is less likely given the patient's stable ECG impression (no ventricular tachycardia or polymorphic ventricular extrasystole). Survivorship is the least likely outcome due to the presence of advanced heart failure symptoms and biomarkers.

However, it's essential to note that the patient's prognosis can be influenced by various factors, such as the effectiveness of the current treatment plan, potential comorbidities, and the presence of other underlying conditions. A comprehensive evaluation and individualized treatment plan are necessary to optimize the patient's outcome."
843,843,P0978,"Age: 69
Gender: Male 
Weight: 106 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 118.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 2,82
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 6603.0
Protein (g/L): 67
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,22
Urea (mg/dL): 14,48
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden Cardiac Death
REASONING: 

Given the patient's history of ischemic dilated cardiomyopathy, the patient is at high risk for sudden cardiac death. The presence of a low LVEF of 35.0 indicates severe left ventricular dysfunction, which is a hallmark of advanced heart failure. The patient's ECG impression of ventricular extrasystole, a type of abnormal heart rhythm, further increases the risk of sudden cardiac death. Additionally, the patient's high level of Pro-BNP (6603.0 ng/L) suggests significant cardiac stress and strain, which can contribute to arrhythmias and sudden cardiac death.

While pump failure death is a possible outcome, it is more of a consequence of the underlying cardiac dysfunction rather than a sudden event. The patient's ECG impression and other clinical indicators suggest a higher risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
REASONING: 

As mentioned earlier, the patient's severe left ventricular dysfunction (LVEF of 35.0) and elevated Pro-BNP levels suggest advanced heart failure. The patient's NYHA Class II indicates that they experience symptoms of heart failure, such as shortness of breath, fatigue, and swelling, which can lead to pump failure. The patient's history of ischemic dilated cardiomyopathy and other comorbidities, such as hypertension and diabetes, further increases the risk of pump failure.

RANKING: 3. Survivor
REASONING: 

While the patient's severe cardiac dysfunction and comorbidities increase the risk of pump failure and sudden cardiac death, the patient is currently on multiple medications, including beta blockers, loop diuretics, and statins, which can help manage symptoms and slow disease progression. The patient's ECG impression of ventricular extrasystole is concerning, but not indicative of an immediate life-threatening arrhythmia. With proper management and monitoring, it is possible that the patient may survive for several years, but the risk of pump failure and sudden cardiac death remains significant."
844,844,P0981,"Age: 73
Gender: Male 
Weight: 63 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,5
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 106.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,02
Sodium (mEq/L): 144.0
Protein (g/L): 74
T4 (ng/L): 19
TSH (mIU/L): 0,19
Urea (mg/dL): 9,48
LVEF (%): 69.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 
1. Pump failure death
2. Sudden cardiac death
3. Survivor

REASONING:

Based on the provided patient data, the patient's prognosis is as follows:

1. Pump failure death: The patient's left ventricular ejection fraction (LVEF) is 69.0%, which is significantly below the normal range (55-70%). This indicates left ventricular dysfunction, which is a common cause of heart failure. The patient's history of myocardial infarction, hypertension, dyslipidemia, and diabetes also contribute to the development of left ventricular dysfunction. Additionally, the patient's elevated creatinine level (111.0 mol/L) and low albumin level (40.5 g/L) suggest impaired renal function, which can exacerbate heart failure. The patient's current medication regimen, including loop diuretics, also suggests that the patient is being managed for heart failure. Considering these factors, pump failure death is the most likely outcome.

2. Sudden cardiac death: While the patient has a history of myocardial infarction and ventricular extrasystole, the ECG impression does not indicate a high risk for ventricular tachycardia or non-sustained ventricular tachycardia. The patient's ejection fraction is also not severely impaired, which reduces the likelihood of sudden cardiac death. However, the patient's history of hypertension and dyslipidemia increases the risk of arrhythmias. Nevertheless, the patient's current ECG impression does not suggest an immediate risk for sudden cardiac death.

3. Survivor: Given the patient's left ventricular dysfunction, history of myocardial infarction, and current medication regimen, the patient's prognosis is not favorable. However, the patient's ejection fraction is not severely impaired, and the patient's ECG impression does not indicate a high risk for arrhythmias. With optimal management and lifestyle modifications, it is possible for the patient to survive, but the likelihood of long-term survival and quality of life is still uncertain."
845,845,P0983,"Age: 68
Gender: Male 
Weight: 90 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 187.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,4
LDL (mmol/L): 3,15
Sodium (mEq/L): 144.0
Protein (g/L): 70
T4 (ng/L): 15
TSH (mIU/L): 3,68
Urea (mg/dL): 12,64
LVEF (%): 21.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 
1. Sudden Cardiac Death
2. Pump Failure Death
3. Survivor

REASONING:

The patient's ECG impressions reveal significant ventricular arrhythmias, including non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles. These findings suggest a high risk of ventricular arrhythmias, which are a major predictor of sudden cardiac death in patients with cardiomyopathy. The presence of NSVT is particularly concerning, as it indicates an increased risk of life-threatening arrhythmias.

The patient's left ventricular ejection fraction (LVEF) is severely impaired at 21%, indicating advanced left ventricular dysfunction. This suggests that the patient's heart is not functioning optimally, which increases the risk of heart failure and, ultimately, pump failure.

The patient's NYHA class III classification indicates severe symptoms of heart failure, which further supports the likelihood of pump failure. Additionally, the patient's high creatinine level (187.0 mmol/L) suggests impaired renal function, which can be a complication of heart failure.

While the patient's blood pressure is within a relatively normal range (120/80 mmHg), the presence of hypertension, dyslipidemia, and other comorbidities (e.g., idiopathic dilated cardiomyopathy) contribute to the overall risk of cardiovascular events.

Given the combination of advanced left ventricular dysfunction, ventricular arrhythmias, and severe symptoms of heart failure, I would rank the patient's prognosis as follows: Sudden Cardiac Death > Pump Failure Death > Survivor."
846,846,P0997,"Age: 72
Gender: Male 
Weight: 95 kg
Height: 159 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 40,9
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 45.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,2
LDL (mmol/L): 3
Sodium (mEq/L): 137.0
Protein (g/L): 73,8
T4 (ng/L): 14
TSH (mIU/L): 1,53
Urea (mg/dL): 10,82
LVEF (%): 20.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor

REASONING: 
This patient's prognosis is most likely to be a survivor due to the following reasons:

1. The patient's age is 72 years, which is relatively advanced, but not extremely high. The median survival for patients with heart failure is around 5-7 years, so a 72-year-old patient is not unusually old for this condition.

2. The patient has a NYHA Class III classification, indicating severe heart failure symptoms. However, this classification is not uncommon in patients with advanced heart failure.

3. The patient's creatinine level is 110.0, which is elevated, indicating impaired kidney function. However, this is not uncommon in patients with heart failure.

4. The patient's LVEF (left ventricular ejection fraction) is 20.0%, which is significantly reduced, indicating severe left ventricular dysfunction. However, this is consistent with the patient's NYHA Class III classification.

5. The patient is on medications for heart failure (loop diuretics, spironolactone, and ACE inhibitor), which is standard treatment for heart failure.

6. The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, are concerning but not unusual for patients with heart failure.

However, the patient's prognosis is not as favorable as it could be due to the following reasons:

1. The patient's albumin level is low (40.9 g/L), which may indicate malnutrition or liver disease.

2. The patient's ALT and AST levels are elevated (41.0 and 45.0 IU/L, respectively), which may indicate liver damage or inflammation.

3. The patient's total cholesterol level is high (4.76 mmol/L), which may increase the risk of cardiovascular events.

Considering these factors, while the patient's prognosis is not extremely poor, it is still more likely to be a survivor than to experience sudden cardiac death or pump failure death. However, close monitoring and adjustments to the patient's treatment plan may be necessary to improve outcomes.

RANKING: 2. Sudden cardiac death

REASONING: 
This patient's prognosis is less likely to be sudden cardiac death due to the following reasons:

1. The patient's LVEF is 20.0%, which is significantly reduced, indicating severe left ventricular dysfunction. This reduces the likelihood of sudden cardiac death.

2. The patient is on medications for heart failure, which is standard treatment for this condition.

3. The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, are concerning but not unusual for patients with heart failure.

However, the patient's prognosis is not as favorable as it could be due to the following reasons:

1. The patient's NYHA Class III classification indicates severe heart failure symptoms, which increases the risk of sudden cardiac death.

2. The patient's elevated creatinine level (110.0) may indicate impaired kidney function, which can increase the risk of cardiovascular events.

3. The patient's liver function tests are abnormal (elevated ALT and AST levels), which may indicate liver damage or inflammation.

Considering these factors, while the patient's prognosis is not extremely poor, it is more likely to be a sudden cardiac death than a pump failure death.

RANKING: 3. Pump failure death

REASONING: 
This patient's prognosis is least likely to be pump failure death due to the following reasons:

1. The patient's LVEF is 20.0%, which is significantly reduced, indicating severe left ventricular dysfunction. This increases the risk of pump failure.

2. The patient's NYHA Class III classification indicates severe heart failure symptoms, which increases the risk of pump failure.

3. The patient's elevated creatinine level (110.0) may indicate impaired kidney function, which can increase the risk of pump failure.

However, the patient's prognosis is not as poor as it could be due to the following reasons:

1. The patient is on medications for heart failure, which is standard treatment for this condition.

2. The patient's ECG findings, including ventricular extrasystole and non-sustained ventricular tachycardia, are concerning but not unusual for patients with heart failure.

3. The patient's liver function tests are abnormal (elevated ALT and AST levels), which may indicate liver damage or inflammation, but this is not directly related to pump failure.

Considering these factors, while the patient's prognosis is not extremely poor, it is more likely to be pump failure death than sudden cardiac death or survivor."
847,847,P1023,"Age: 77
Gender: Male 
Weight: 84 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 116/79 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 5,9
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,36
Urea (mg/dL): 19,64
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
REASONING: The patient is 77 years old with a NYHA Class II heart failure, indicating moderate symptoms of heart failure. The patient's LVEF is 70%, which is slightly below the normal range, but not severely impaired. The patient's creatinine level is elevated at 177.0 mol/L, indicating some degree of renal impairment, but it is not immediately life-threatening. The patient is on medications such as digoxin, loop diuretics, and spironolactone, which are commonly used to treat heart failure. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG is concerning, but it is not a contraindication for survival. The patient's troponin level is within normal limits, and the TSH level is within the normal range, indicating that there is no apparent thyroid dysfunction that could contribute to cardiac dysfunction. Overall, the patient's clinical presentation and laboratory results suggest that the patient is likely to survive for the next few years, but close monitoring and adjustments to their treatment plan may be necessary to prevent further deterioration.

RANKING: 2. Sudden cardiac death
REASONING: While the patient's ECG shows signs of arrhythmias, the presence of ventricular extrasystole and non-sustained ventricular tachycardia is not immediately life-threatening. The patient's LVEF is also not severely impaired, and the patient is on medications that can help manage heart failure. However, the patient's age, NYHA Class II heart failure, and elevated creatinine level increase the risk of cardiac events. The patient's potassium level is slightly elevated, which could contribute to arrhythmias, but it is not extremely high. Overall, while the patient is at increased risk of cardiac events, the likelihood of sudden cardiac death is not extremely high.

RANKING: 3. Pump failure death
REASONING: The patient's NYHA Class II heart failure and elevated creatinine level increase the risk of pump failure. The patient's LVEF is slightly below normal, and the patient is on medications that can help manage heart failure, but the patient's age and NYHA Class II heart failure make it more likely that the patient will experience pump failure. The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG increases the risk of cardiac events, and the patient's slightly elevated potassium level could contribute to arrhythmias. Overall, while the patient is at increased risk of pump failure, the likelihood of pump failure death is not the most likely outcome."
848,848,P1026,"Age: 68
Gender: Male 
Weight: 60 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 92/64 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 27
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 349
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,09
Sodium (mEq/L): 134.0
Protein (g/L): 51
T3 (pg/dL): 0,04
T4 (ng/L): 15
TSH (mIU/L): 9,94
Urea (mg/dL): 25,79
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death
REASONING: 
Based on the patient's data, the patient is at high risk for sudden cardiac death due to the presence of ventricular tachycardia (VT) and ventricular extrasystoles, which are indicators of arrhythmia. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 30%, which suggests that the heart is not functioning efficiently, increasing the risk of arrhythmias and sudden cardiac death. Additionally, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition that can lead to arrhythmias and sudden cardiac death.

The patient's ECG findings also support this risk, with the presence of non-sustained VT and polymorphic ventricular extrasystoles. The patient's medication regimen, which includes beta blockers and spironolactone, may not be adequate to manage the patient's arrhythmias, and the patient's low ejection fraction suggests that the heart is not functioning optimally.

While pump failure death is a possible outcome, the patient's current ECG findings and arrhythmia history make sudden cardiac death a more immediate and likely risk. The patient's past medical history and laboratory results also suggest that the patient may be at risk for worsening heart failure, but the immediate risk of sudden cardiac death is higher.

RANKING: 2. Pump failure death
REASONING: 
The patient's reduced ejection fraction (LVEF) of 30% and elevated creatinine levels (186.0 mmol/L) suggest that the patient's heart is not functioning optimally, increasing the risk of heart failure. The patient's medication regimen, which includes loop diuretics, may be helping to manage fluid overload, but it is not addressing the underlying cardiac dysfunction.

The patient's elevated liver enzymes (ALT and AST) and elevated gamma-glutamil transpeptidase may indicate liver dysfunction, which can be associated with heart failure. The patient's low albumin level (27 g/L) and high potassium level (5.2 mEq/L) may also suggest fluid overload and kidney dysfunction, which can contribute to heart failure.

While pump failure is a possible outcome, the patient's immediate risk for sudden cardiac death is higher due to the presence of arrhythmias and reduced ejection fraction.

RANKING: 3. Survivor
REASONING: 
Based on the patient's data, it is possible that the patient may survive for several years, but the presence of arrhythmias, reduced ejection fraction, and elevated creatinine levels suggest that the patient's heart is not functioning optimally. The patient's medication regimen, which includes beta blockers and spironolactone, may help to manage symptoms and prevent further decline, but it is unlikely to completely reverse the patient's cardiac dysfunction.

The patient's age (68 years) and reduced ejection fraction (LVEF of 30%) also suggest that the patient's heart is not as resilient to stress or illness, increasing the risk of complications. However, the patient's overall health status and medication regimen may allow for a prolonged survival, but it is unlikely to be a long-term survivor."
